Volume 3

CONTENTS

Monographs on Drug Substances, Dosage Forms and Pharmaceutical Aids
   Monographs to Z ....

Monographs on Vaccines and Immunosera for Human Use ....
Monographs on Herbs and Herbal Products ....
Monographs on Blood and Blood-related Products ....
Monographs on Biotechnology Products ....
Monographs on Veterinary Products ....

Index ....
GENERAL NOTICES

General Statements

Name

Official and Official Articles

Official Standards

Added Substances

Alternative Methods

Meanings of Terms

Provisions Applicable to Monographs and Test Methods

Expression of Contents

Expression of Concentrations

Abbreviated Statements

Weights and Measures

Monographs

General Monographs

Production

Manufacture of Drug Products

Excipients

Individual Monographs

Titles

Chemical Formulae

Atomic and Molecular Weights

Definitions

Statement of Contents

Descriptions

Identification

Tests and Assay

Tests

Other tests

Limits

Quantities
Apparatus ....
Reagents and Solutions ....
Indicators ....
Reference Substances ....
Tests Animals ....
Calculation of Results ....
Storage ....
Storage Containers ....
Labelling ....
General Notices

General Statements

The General Notices provide the basic guidelines for the interpretation and application of the standards, tests, assays, and other specifications of the Indian Pharmacopoeia (IP), as well as to the statements made in the monographs and other texts of the Pharmacopoeia.

A monograph is to be constructed in accordance with any general monograph or notice or any appendix, note or other explanatory material that is contained in this Pharmacopoeia and that is applicable to that monograph. All statements contained in the monograph, except where a specific general notice indicates otherwise and with the exceptions given hereafter, constitute standards for the official articles. An article is not of pharmacopoeial quality unless it complies with all of the requirements stated.

Exceptions to the General Notices do exist, and where they do, the wording in the individual monograph or an appendix takes precedence and specifically indicates directions or the intent. Thus, the specific wording of standards, tests, assays and other specifications is binding wherever deviations from the General Notices exist. Likewise, where there is no specific mention to the contrary, the General Notices apply.

Name. The full name or title of this book, including addenda thereto, is Indian Pharmacopoeia 2007, abbreviated to IP 2007. In the texts, the term “Pharmacopoeia” or “IP” without qualification means the Indian Pharmacopoeia 2007 and any addenda thereto.

Official and Official Articles. The word ‘official’ wherever used in this Pharmacopoeia or with reference thereto, is synonymous with ‘pharmacopoeial’, with ‘IP’ and with ‘compendial’. The designation IP in conjunction with the official title on the label of an article is an indication that the article purports to comply with IP standards.

The following terms are used where the articles for which monographs are provided are to be distinguished.

An official substance is a single drug or a drug entity or a pharmaceutical aid for which the monograph title includes no indication of the nature of a dosage form.

An official preparation is a drug product (dosage form) and is the finished or partially finished preparation or product of one or more official substances formulated for use on the patient.

An article is an item for which a monograph is provided, whether an official substance or an official preparation.

Official Standards. The requirements stated in the monographs apply to articles that are intended for medicinal use but not necessarily to articles that may be sold under the same name for other purposes.

The active pharmaceutical ingredients (drug substances), excipients (pharmaceutical aids), pharmaceutical preparations (dosage forms) and other articles described in the monographs are intended for human and veterinary use (unless explicitly restricted to one of these uses).

The requirements given in the monographs are not framed to provide against all possible impurities, contaminants or adulterants; they provide appropriate limitation of potential impurities only.

A preparation must comply throughout the shelf-life assigned to it by the manufacturer; for opened or broached containers the maximum period of validity for use may sometimes be stated in the individual monograph. Nevertheless, the responsibility for assigning the period of validity shall be with the manufacturer.

Added Substances. An official substance, as distinguished from an official preparation, contains no added substances except when specifically permitted in the individual monograph. Unless otherwise specified in the individual monograph, or elsewhere in the General Notices, suitable substances may be added to an official preparation to enhance its stability, usefulness or elegance, or to facilitate its preparation. Such auxiliary substances shall be harmless in the amounts used, shall not exceed the minimum quantity required to provide their intended effect, shall not impair the therapeutic efficacy or the bioavailability or safety of the preparation and shall not interfere with the tests and assays prescribed for determining compliance with the official standards. Particular care should be taken to ensure that such substances are free from harmful organisms. The freedom to the manufacturers to add auxiliary substances imposes on them the responsibility of satisfying the licensing authorities on the purpose of the addition and the innocuity of such substances.

Alternative Methods. The tests and assays described are the official methods upon which the standards of the Pharmacopoeia are based. Alternative methods of analysis may be used for control purposes, provided that the methods used are shown to give results of equivalent accuracy and enable an unequivocal decision to be made as to whether compliance with the standards of the monographs would be achieved if the official methods were used. Automated procedures utilising the same basic chemistry as the test procedures given in the monograph may also be used to determine compliance. Such alternative or automated procedures must be validated.

In the event of doubt or dispute, the methods of analysis of the Pharmacopoeia are alone authoritative and only the result obtained by the procedure given in this Pharmacopoeia is conclusive.
Meanings of Terms

Alcohol. The term “alcohol” without qualification means ethanol (95 per cent). Other dilutions of ethanol are indicated by the term “alcohol” or “alcohol” followed by a statement of the percentage by volume of ethanol (C₂H₆O) required.

Desiccator. A tightly-closed container of suitable size and design that maintains an atmosphere of low moisture content by means of silica gel or phosphorus pentoxide or other suitable desiccant.

Drying and ignition to constant weight. Two consecutive weighings after the drying or igniting operations do not differ by more than 0.5 mg, the second weighing following an additional period of drying or of ignition respectively appropriate to the nature and quantity of the residue.

Ethanol. The term “ethanol” without qualification means anhydrous ethanol or absolute alcohol.

Filtration. Unless otherwise stated, filtration is the passing of a liquid through a suitable filter paper or equivalent device until the filtrate is clear.

Freshly prepared. Made not more than 24 hours before it is issued for use.

Label. Any printed packing material, including package inserts that provide information on the article.

Negligible. A quantity not exceeding 0.50 mg.

Solution. Where the name of the solvent is not stated, “solution” implies a solution in water. The water used complies with the requirements of the monograph on Purified Water. The term ‘distilled water’ indicates Purified Water prepared by distillation.

Temperature. The symbol º used without qualification indicates the use of the Celsius thermometric scale.

Water. If the term is used without qualification it means Purified Water of the Pharmacopoeia. The term ‘distilled water’ indicates Purified Water prepared by distillation.

Water-bath. A bath of boiling water unless water at another temperature is indicated. Other methods of heating may be used provided the required temperature is approximately maintained but not exceeded.

Provisions Applicable To Monographs and Test Methods

Expression of Content. Where the content of a substance is defined, the expression “per cent” is used according to circumstances with one of two meanings:

— per cent w/w (percentage, weight in weight) expressing the number of grams of substance in 100 grams of final product.

The expression “parts per million” refers to the weight in weight, unless otherwise stated.

Where the content of a substance is expressed in terms of the chemical formula for that substance an upper limit exceeding 100 per cent may be stated. Such an upper limit applies to the result of the assay calculated in terms of the equivalent content of the specified chemical formula. For example, the statement ‘contains not less than 99.0 per cent and not more than 101.0 per cent of C₇H₆O₂ implies that the result of the assay is not less than 99.0 per cent and not more than 101.0 per cent, calculated in terms of the equivalent content of C₇H₆O₂.

Where the result of an assay or test is required to be calculated with reference to the dried, anhydrous, ignited substance, or the substance free from solvent, the determination of loss on drying, water content, loss on ignition, content of the specified solvent, respectively is carried out by the method prescribed in the relevant test in the monograph.

Expression of Concentrations. The following expressions in addition to the ones given under Expression of Content are also used:

— per cent w/v (percentage, weight in volume) expressing the number of grams of substance in 100 millilitres of product

— per cent v/w (percentage, volume in weight) expressing the number of millilitres of substance in 100 grams of product.

Usually, the strength of solutions of solids in liquids is expressed as percentage weight in volume, of liquids in liquids as percentage volume in volume, of solids in semi-solid bases (e.g. creams) and of gases in liquids as percentage weight in weight.

When the concentration of a solution is expressed as parts of dissolved substance in parts of solution, it means parts by weight (g) of a solid in parts by volume (ml) of the final solution; as parts by weight (g) of a gas in parts by weight (g) of the final solution.

When the concentration of a solution is expressed in molarity designated by the symbol M preceded by a number, it denotes the number of moles of the stated solute contained in sufficient Purified Water (unless otherwise stated) to produce 1 litre of solution.

Abbreviated Statements. Incomplete sentences are employed in parts of the monographs for directness and brevity (for example, Iodine Value. Not more than ……; Relative Density. ……..to……..) Where the tests are abbreviated, it is to be understood that the test method referred to in brackets
provides the method to be followed and that the values specified are the applicable limits.

**Weights and Measures.** The metric system of weights and measures is employed in the Pharmacopoeia. All measures are required to be graduated at 25º and all measurements in tests and assays, unless otherwise stated, are to be made at that temperature. Graduated glass apparatus used in analytical operations shall comply with the requirements stated in Chapter 2.1.6

**Monographs**

**General Monographs**

General monographs on dosage forms include requirements of general application and apply to all preparations within the scope of the Introduction section of the general monograph, except where a preamble limits the application. The requirements are not necessarily comprehensive for a given specific preparation; additional requirements may sometimes be given in the individual monograph for it.

**Production.** Statements given under the heading Production relate to particular aspects of the manufacturing process and are not necessarily comprehensive. However, they are mandatory instructions to manufacturers. They may relate, for example, to source materials, to the manufacturing process and its validation and control, to any in-process testing that is to be carried out by the manufacturer on the final product either on selected batches or on each batch prior to release. All this cannot be verified on a sample of the final product by an independent analyst. It is for the licensing authority to verify that the instructions have been followed.

The absence of a section on Production does not imply that attention to features such as those given above is not required. An article described in a monograph of the Pharmacopoeia is to be manufactured in accordance with the principles of good manufacturing practice and in accordance with the requirements of the Drugs and Cosmetics Rules, 1945. The general principles applicable to the manufacture and quality assurance of drugs and preparations meant for human use apply equally to veterinary products as well.

**Manufacture of Drug Products.** The opening definitive statement in certain monographs for drug products is given in terms of the active ingredient(s) only. Any ingredient(s) other than those included in the statement, must comply with the general notice on Excipients and the product must conform to the Pharmacopoeial requirements.

Official preparations are prepared only from ingredients that comply with the requirements of the pharmacopoeial monographs for those individual ingredients for which monographs are provided.

**Excipients.** Any substance added in preparing an official preparation shall be innocuous, shall have no adverse influence in the therapeutic efficacy of the active ingredients and shall not interfere with the tests and assays of the Pharmacopoeia. Care should be taken to ensure that such substances are free from harmful organisms.

**Individual Monographs**

Drug products that are the subject of an individual monograph are also required to comply with the tests given in the general monographs.

**Titles.** The main title for a drug substance is the International Non-proprietary Name (INN) approved by the World Health Organization. Subsidiary names and synonyms have also been given in some cases; where included, they have the same significance as the main title.

The main titles of drug products are the ones commonly recognised in practice. Synonyms drawn from the full non-proprietary name of the active ingredient or ingredients have also been given. Where, however, a product contains one or the other of different salts of an active molecule, the main title is based on the full name of the active ingredient. For example, Chloroquine Phosphate Tablets and Chloroquine Sulphate Tablets.

**Chemical Formulae.** When the chemical structure of an official substance is known or generally accepted, the graphic and molecular formulae are normally given at the beginning of the monograph for information. This information refers to the chemically pure substance and is not to be regarded as an indication of the purity of the official material. Elsewhere, in statement of purity and strength and in descriptions of processes of assay, it will be evident from the context that the formulae denote the chemically pure substances.

Where the absolute stereochemical configuration is specified, the International Union of Pure and Applied Chemistry (IUPAC) R/S and E/Z systems of designation have been used. If the substance is an enantiomer of unknown absolute stereochemistry, the sign of the optical rotation, as determined in the solvent and under the conditions specified in the monograph, has been attached to the systematic name. An indication of sign of rotation has also been given where this is incorporated in a trivial name that appears on an IUPAC preferred list.

**Atomic and Molecular Weights.** The atomic weight or molecular weight is shown, as and when appropriate at the top right hand corner of the monograph. The atomic and molecular weights and graphic formulae do not constitute analytical standards for the substances described.

**Definition.** The opening statement of a monograph is one that constitutes an official definition of the substance,
preparation or other article that is the subject of the monograph. In certain monographs for pharmaceutical preparations the statement is given in terms of the principal ingredient(s).

In monographs on vegetable drugs, the definition indicates whether the subject of the monograph is, for example, the whole drug or the drug in powdered form.

Certain pharmaceutical substances and other articles are defined by reference to a particular method of manufacture. A statement that a substance or article is prepared or obtained by a certain method constitutes part of the official definition and implies that other methods are not permitted. A statement that a substance *may* be prepared or obtained by a certain method, however, indicates that this is one possible method and does not imply that other methods are not permissible.

**Statement of content.** The limits of content stated are those determined by the method described under Assay.

**Description.** The statements under the heading Description are not to be interpreted in a strict sense and are not to be regarded as official requirements.

**Solubility.** Statements on solubility are given in Chapter 2.4.26 and are intended as information on the approximate solubility at a temperature between 15º and 30º, unless otherwise stated, and are not to be considered as official requirements. However, a test for solubility stated in a monograph constitutes part of the standards for the substance that is the subject of that monograph.

**Test Methods**

References to general methods of testing are indicated by test method numbers in brackets immediately after the heading of the test or at the end of the text.

**Identification.** The tests given under the heading Identification are not necessarily sufficient to establish absolute proof of identity. They provide a means of verifying that the identity of the material under examination is in accordance with the label on the container.

In certain monographs alternative series of identification tests are given; compliance with either one or the other set of tests is adequate to verify the identity of the article.

When tests for infrared absorption are applied to material extracted from formulated preparations, strict concordance with the specified reference spectrum may not always be possible, but nevertheless a close resemblance between the spectrum of the extracted material and the specified reference spectrum should be achieved.

**Tests and Assays**

The tests and assays are the official methods upon which the standards of the Pharmacopoeia depend. The requirements are not framed to take into account all possible impurities. It is not to be presumed, for example, that an impurity that is not detectable by means of the prescribed tests is tolerated. Material found to contain such an impurity is not of pharmacopoeial quality if the nature or amount of the impurity found is incompatible with good pharmaceutical practice.

Pharmacopoeial methods and limits should be used merely as compliance requirements and not as requirements to guarantee total quality assurance. Tests and assays are prescribed for the minimum sample available on which the attributes of the article should be measured. Assurance of quality must be ensured by the manufacturer by the use of statistically valid sampling and testing programmes.

**Tests.** Unless otherwise stated, the assays and tests are carried out at a temperature between 20º and 30º.

Where it is directed that an analytical operation is to be carried out ‘in subdued light’, precautions should be taken to avoid exposure to direct sunlight or other strong light. Where a procedure is directed to be performed ‘protected from light’ precautions should be taken to exclude actinic light by the use of low-actinic glassware, working in a dark room or similar procedures.

For preparations other than those of fixed strength, the quantity to be taken for a test or an assay is usually expressed in terms of the active ingredient. This means that the quantity of the active ingredient expected to be present and the quantity of the preparation to be taken are calculated from the strength stated on the label.

**Other Tests.** In the monographs on dosage forms and certain preparations, under the sub-heading ‘Other tests’ it is stated that the article complies with the tests stated under the general monograph of the relevant dosage form or preparation. Details of such tests are provided in the general monographs.

**Limits.** The limits given are based on data obtained in normal analytical practice. They take into account normal analytical errors, of acceptable variations in manufacture and of deterioration to an extent that is acceptable. No further tolerances are to be applied to the limits for determining whether or not the article under examination complies with the requirements of the monograph.

**Quantities.** Unless otherwise stated, the quantities to be taken for assays, limit tests and other tests are of the substance under examination.

In tests with numerical limits and assays, the quantity stated on the label.

In tests with numerical limits and assays, the quantity stated on the label.
Reagents and Solutions. The reagents required for the tests and assays of the Pharmacopoeia are defined in the various chapters showing their nature, degree of purity and the strengths of the solutions to be made from them. The requirements set out are not intended to imply that the materials are suitable for use in medicine; regents not covered by monographs in the pharmacopoeia shall not be claimed to be of IP quality.

The term ‘analytical reagent grade of commerce’ implies that the chemical is of a high degree of purity wherein the limits of various impurities are known. Where it is directed to use a ‘general laboratory reagent grade of commerce’ it is intended that a chemically pure grade material, not necessarily required to be tested for limiting or absence of certain impurities, is to be used.

Indicators. Where the use of an indicator solution is mentioned in an assay or test, approximately 0.1 ml of the solution shall be added, unless otherwise directed.

Reference Substances. Certain monographs require the use of a chemical reference substance or a biological reference preparation or a reference spectrum. These are authentic specimens chosen and verified on the basis of their suitability for intended use as prescribed in the Pharmacopoeia and are not necessarily suitable in other circumstances.

IP Reference Substances, abbreviated to IPRS (and referred to as RS in the individual monographs) are issued by the Indian Pharmacopoeia Commission (IPC). They are the official standards to be used in cases of arbitration. Secondary Standards (Working Standards) may be used for routine analysis, provided they are standardized at regular intervals against the Reference Substances.

Biological Reference Substances, also abbreviated to IPRS and Standard Preparations of antibiotics are issued by agencies authorised by the IPC. They are standardized against the International Standards and Reference Preparations established by the World Health Organization (WHO). The potency of these preparations is expressed in International Units.

Reference spectra are published by the IPC and they are accompanied by information concerning the conditions used for sample preparation and recording of the spectra.

Test animals. Unless otherwise directed, animals used in a test or an assay shall be healthy and are drawn from a uniform stock, and have not previously been treated with any material that will interfere with the test or the assay.

Calculation of results. In determining compliance with a numerical limit in assay or test, the result should be calculated to one decimal place more than the significant figures stated and then rounded up or down as follows: if the last figure calculated is 5 to 9, the preceding figure is increased by 1; if it is 4 or less, the preceding figure is left unchanged.

Storage. Statements under the side-heading Storage constitute non-mandatory advice. The articles of the Pharmacopoeia are to be stored under conditions that prevent contamination and, as far as possible, deterioration. Precautions that should be taken in relation to the effects of the atmosphere, moisture, heat and light are indicated, where appropriate, in the individual monograph.

Specific directions are given in some monographs with respect to the temperatures at which Pharmacopeial articles should be stored, where it is considered that usage at a lower or higher temperature may produce undesirable results. The storage conditions are defined by the following terms:

— Store in a dry, well-ventilated place at a temperature not exceeding 30º
— Store in a refrigerator (2º to 8º). Do not freeze
— Store in a freezer (-2º to -18º)
— Store in a deep freezer (Below -18º)

Storage conditions not related to temperature are indicated in the following terms:

— Store protected from light
— Store protected from light and moisture

Where no specific storage directions or limitations are given in the monograph or by the manufacturer, it is to be understood...
that the storage conditions include protection from moisture, freezing and excessive heat (any temperature above 40º).

**Storage Containers.** The requirements, guidance and information on containers for pharmaceutical use are given in the chapter entitled Containers (6.1)

In general, an article should be packed in a well-closed container i.e. one that protects the contents from contamination by extraneous solids, liquids or vapours and from loss of the article under normal conditions of handling and storage.

Where, additionally, loss or deterioration of the article from effervescence, deliquescence or evaporation under normal conditions of storage is likely, the container must be capable of being tightly closed, and re-closed after use.

In certain cases, special requirements of pack have been indicated in some monographs under Storage, using expressions that have been defined in chapter 6.1.

**Labelling.** The labelling of drugs and pharmaceuticals is governed by the Drugs and Cosmetics Rules, 1945. The statements that are given in the monographs under the side-heading ‘Labelling’ are not comprehensive. Only those that are necessary to demonstrate compliance or otherwise with the monograph have been given and they are mandatory. For example, in the monograph on Betamethasone Sodium Tablets the labelling statement is “The label states the strength in terms of the equivalent amount of betamethasone”. Any other statements are included as recommendations.
DRUG SUBSTANCES, DOSAGE FORMS
AND
PHARMACEUTICAL AIDS

N to Z .................................................................................................................
N

Nalidixic Acid
Nalidixic Acid Tablets
Nalorphine Hydrochloride
Nalorphine Injection
Nandrolone Decanoate
Nandrolone Decanoate Injection
Nandrolone Phenylpropionate
Nandrolone Phenylpropionate Injection
Naphazoline Nitrate
Nelfinavir Mesylate
Nelfinavir Mesylate Oral Powder
Nelfinavir Tablets
Neomycin Sulphate
Neomycin Eye Drops
Neomycin Eye Ointment
Neostigmine Bromide
Neostigmine Tablets
Neostigmine Methylsulphate
Neostigmine Injection
Nevirapine
Nevirapine Oral Suspension
Nevirapine Tablets
Niclosamide
Niclosamide Tablets
Nicotinamide
Nicotinamide Tablets
Nicotinic Acid
Nicotinic Tablets
Nicoumalone
Nicoumalone Tablets
<table>
<thead>
<tr>
<th>Medicine</th>
<th>Format</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nifedipine</td>
<td></td>
</tr>
<tr>
<td>Nifedipine Capsules</td>
<td></td>
</tr>
<tr>
<td>Nifedipine Sustained release-Tablets</td>
<td></td>
</tr>
<tr>
<td>Nifedipine Tablets</td>
<td></td>
</tr>
<tr>
<td>Nikethamide</td>
<td></td>
</tr>
<tr>
<td>Nikethamide Injection</td>
<td></td>
</tr>
<tr>
<td>Nitrazepam</td>
<td></td>
</tr>
<tr>
<td>Nitrazepam Tablets</td>
<td></td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td></td>
</tr>
<tr>
<td>Nitrofurantoin Tablets</td>
<td></td>
</tr>
<tr>
<td>Nitrofurazone</td>
<td></td>
</tr>
<tr>
<td>Nitrous Oxide</td>
<td></td>
</tr>
<tr>
<td>Noradrenaline Bitartrate</td>
<td></td>
</tr>
<tr>
<td>Noradrenaline Bitartrate Injection</td>
<td></td>
</tr>
<tr>
<td>Norethisterone</td>
<td></td>
</tr>
<tr>
<td>Norethisterone Tablets</td>
<td></td>
</tr>
<tr>
<td>Norfloxacin</td>
<td></td>
</tr>
<tr>
<td>Norfloxacin Eye Drops</td>
<td></td>
</tr>
<tr>
<td>Norfloxacin Tablets</td>
<td></td>
</tr>
<tr>
<td>Norgestrel</td>
<td></td>
</tr>
<tr>
<td>Norgestrel And Ethinyloestradiol Tablets</td>
<td></td>
</tr>
<tr>
<td>Nortriptyline Hydrochloride</td>
<td></td>
</tr>
<tr>
<td>Nortriptyline Tablets</td>
<td></td>
</tr>
<tr>
<td>Noscapine</td>
<td></td>
</tr>
<tr>
<td>Noscapine Linctus</td>
<td></td>
</tr>
<tr>
<td>Novobiocin Sodium</td>
<td></td>
</tr>
<tr>
<td>Nystatin</td>
<td></td>
</tr>
<tr>
<td>Nystatin Ointment</td>
<td></td>
</tr>
<tr>
<td>Nystatin Pessaries</td>
<td></td>
</tr>
<tr>
<td>Nystatin Tablets</td>
<td></td>
</tr>
</tbody>
</table>
Nalidixic Acid

\[
\text{Nalidixic Acid is } 1\text{-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid.}
\]

Nalidixic Acid contains not less than 99.0 per cent and not more than 101.0 per cent of C\textsubscript{12}H\textsubscript{12}N\textsubscript{2}O\textsubscript{3}, calculated on the dried basis.

_description_. A white to slightly yellow, crystalline powder.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nalidixic acid RS or with the reference spectrum of nalidixic acid.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.0005 per cent w/v solution in 0.1 M sodium hydroxide shows absorption maxima at about 258 nm and 334 nm; ratio of the absorbance at about 258 nm to that at about 334 nm, 2.2 to 2.4.

C. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (c).

D. Dissolve 0.1 g in 2 ml of hydrochloric acid and add 0.5 ml of a 10 per cent w/v solution of 2-naphthol in ethanol (95 per cent); an orange-red colour develops.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 70 volumes of ethanol (95 per cent), 20 volumes of dichloromethane and 10 volumes of 5 M ammonia.

Test solution (a). Dissolve 0.2 g of the substance under examination in 10 ml of dichloromethane.

Test solution (b). A 0.1 per cent w/v solution of the substance under examination in dichloromethane.

Reference solution (a). A 0.002 per cent w/v solution of the substance under examination in dichloromethane.

Reference solution (b). A 0.0008 per cent w/v solution of the substance under examination in dichloromethane.

Reference solution (c). A 0.1 per cent w/v solution of nalidixic acid RS in dichloromethane.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Sulphated ash (2.3.18) Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°.

Assay. Weigh accurately about 0.15 g, dissolve in 10 ml of dichloromethane, add 30 ml of 2-propanol and 10 ml of carbon dioxide-free water and titrate with 0.1 M ethanolic sodium hydroxide, determining the end-point potentiometrically (2.4.25) and using a glass electrode as the indicator electrode and a silver-silver chloride reference electrode with a sleeve diaphragm or a capillary tip filled with a saturated solution of lithium chloride in ethanol. Throughout the titration keep the temperature of the solution at 15° to 20° and pass a current of nitrogen through the solution.

1 ml of 0.1 M ethanolic sodium hydroxide is equivalent to 0.02322 g of C\textsubscript{12}H\textsubscript{12}N\textsubscript{2}O\textsubscript{3}.

Storage. Store protected from light and moisture.

Nalidixic Acid Tablets

Nalidixic Acid Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of nalidixic acid, C\textsubscript{12}H\textsubscript{12}N\textsubscript{2}O\textsubscript{3}.

Identification

To a quantity of the powdered tablets containing 1 g of Nalidixic Acid add 50 ml of chloroform, shake for 15 minutes, filter and evaporate the filtrate to dryness. The residue, after drying at 105°, complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nalidixic acid RS or with the reference spectrum of nalidixic acid.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.0005 per cent w/v solution in 0.1 M sodium hydroxide shows...
absorption maxima at about 258 nm and 334 nm; ratio of the absorbance at about 258 nm to that at about 334 nm, 2.2 to 2.4.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 70 volumes of ethanol (95 per cent), 20 volumes of dichloromethane and 10 volumes of 5 M ammonia.

Test solution. Shake a quantity of the powdered tablets containing 0.1 g of Nalidixic Acid with 50 ml of chloroform for 15 minutes, filter, evaporate the filtrate to dryness and dissolve the residue in 5 ml of chloroform.

Reference solution. Dilute 1 volume of the test solution to 200 volumes with chloroform.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Other Tests. Complies with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.1 g of Nalidixic Acid, add 150 ml of 0.1 M sodium hydroxide, shake for 3 minutes, dilute to 200.0 ml with 0.1 M sodium hydroxide, mix and allow to stand for 15 minutes. Dilute 2.0 ml of the solution to 100.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 334 nm (2.4.7), using 0.1 M sodium hydroxide as the blank. Calculate the content of C₁₂H₁₂N₂O₃ taking 494 as the specific absorbance at 334 nm.

Storage. Store protected from light and moisture.

Nalorphine Hydrochloride

Nalorphine Hydrochloride contains not less than 97.0 per cent and not more than 103.0 per cent of C₁₉H₂₁NO₃.HCl, calculated on the dried basis.

Description. A white or almost white, crystalline powder; odourless. It slowly darkens on exposure to air and light.

Identification

Test A may be omitted if tests B, C, D and E are carried out. Tests C and D may be omitted if tests A, B and E are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nalorphine hydrochloride RS.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.01 per cent w/v solution in 0.1 M sodium hydroxide shows an absorption maximum only at about 298 nm; absorbance at about 298 nm, about 0.6.

C. To 10 ml of a 2 per cent w/v solution add 0.05 ml of dilute ammonia solution; a white precipitate soluble in sodium hydroxide solution is produced.

D. Dissolve 2 mg in 2 ml of water, add 0.15 ml of potassium ferricyanide solution containing, in each ml, 0.05 ml of ferric chloride solution; a deep bluish green colour is produced immediately.

E. Gives reaction A of chlorides (2.3.1).

Tests

Melting range (2.4.21). 260° to 263°.

Acidity. Dissolve 0.2 g in 10 ml of freshly boiled and cooled water and titrate with 0.02 M sodium hydroxide using methyl red solution as indicator; not more than 0.2 ml of 0.02 M sodium hydroxide is required to change the colour of the solution.

Specific optical rotation (2.4.22). –122° to –125°, determined in a 2.0 per cent w/v solution.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 100° at a pressure not exceeding 0.7 kPa for 2 hours.

Assay. Weigh accurately about 25 mg and dissolve in sufficient water to produce 250 ml. Measure the absorbance of the resulting solution at the maximum at about 285 nm (2.4.7). Calculate the content of C₁₉H₂₁NO₃.HCl from the absorbance obtained by repeating the operation with nalorphine hydrochloride RS in place of the substance under examination.
Storage. Store protected from light and moisture.

Nalorphine Injection

Nalorphine Hydrochloride Injection

Nalorphine Injection is a sterile solution of Nalorphine Hydrochloride in Water for Injections containing suitablebuffering agents.

Nalorphine Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nalorphine hydrochloride, C_{19}H_{21}NO_3.HCl.

Identification

A. To a volume containing 50 mg of Nalorphine Hydrochloride add dilute ammonia solution until the solution is alkaline and extract with 25 ml of a mixture of 1 volume of ethanol (95 per cent) and 3 volumes of chloroform and evaporate the extract to dryness. Dry the residue at a pressure not exceeding 2 kPa. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nalorphine hydrochloride RS.

B. To a volume containing 0.1 g of Nalorphine Hydrochloride add 0.05 ml of dilute ammonia solution; a white precipitate soluble in sodium hydroxide solution is produced.

C. Gives reaction A of chlorides (2.3.1).

Tests

pH (2.4.24). 6.0 to 7.5.

Other Tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. Transfer an accurately measured volume containing about 10 mg of Nalorphine Hydrochloride to a separating funnel, add 1 ml of dilute hydrochloric acid and dilute to 10 ml with water. Extract with five successive quantities, each of 5 ml, of chloroform, allowing the layers to separate before drawing off each chloroform extract and discard the chloroform extracts. Transfer the aqueous layer to a 100-ml volumetric flask with the aid of small quantities of water and dilute to volume with water. Measure the absorbance of the resulting solution at the maximum at about 285 nm (2.4.7). Calculate the content of C_{19}H_{21}NO_3.HCl from the absorbance obtained by repeating the operation with nalorphine hydrochloride RS.

Storage. Store protected from light.

Nandrolone Decanoate

C_{28}H_{44}O_3 Mol. Wt. 428.7

Nandrolone Decanoate is 3-oxo-4-estren-17β-yl decanoate.

Nandrolone Decanoate contains not less than 97.0 per cent and not more than 103.0 per cent of C_{28}H_{44}O_3, calculated on the dried basis.

Description. A white to creamy-off white, crystalline powder; odour, faint and characteristic.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nandrolone decanoate RS or with the reference spectrum of nandrolone decanoate.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in ethanol (95 per cent) shows an absorption maximum only at about 239 nm; absorbance at about 239 nm, about 0.41.

C. Dissolve 25 mg in 1 ml of methanol, add 2 ml of semicarbazide acetate solution, heat under a reflux condenser for 30 minutes and cool; the precipitate, after recrystallisation from ethanol (95 per cent), melts at about 175° (2.4.21).

Tests

Specific optical rotation (2.4.22). +32.0° to +36.0°, determined in a 2.0 per cent w/v solution in dioxan.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 70 volumes of heptane and 30 volumes of acetone.

Test solution. Dissolve 0.1 g of the substance under examination in 10 ml of chloroform.

Reference solution (a). A 0.005 per cent w/v solution of the substance under examination in chloroform.

Reference solution (b). A 0.01 per cent w/v solution of nandrolone RS in chloroform.
Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. In the chromatogram obtained with the test solution any spot corresponding to nandrolone is not more intense than the spot in the chromatogram obtained with reference solution (b) and any other secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (a).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 4 hours.

Assay. Weigh accurately about 10 mg and dissolve in sufficient ethanol (95 per cent) to produce 100.0 ml. Dilute 5.0 ml to 50.0 ml with ethanol (95 per cent) and measure the absorbance of the resulting solution at the maximum at about 239 nm (2.4.7). Calculate the content of C₂₈H₄₄O₃ taking 407 as the specific absorbance at 239 nm.

Storage. Store protected from light and moisture.

Nandrolone Decanoate Injection

Nandrolone Decanoate Injection is a sterile solution of Nandrolone Decanoate in Ethyl Oleate or other suitable ester, in a suitable fixed oil or in any mixture of these.

Nandrolone Decanoate Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nandrolone decanoate, C₂₈H₄₄O₃.

Identification

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 70 volumes of heptane and 30 volumes of acetone.

Test solution. Dilute a suitable volume of the injection with carbon tetrachloride to give a solution containing 0.5 per cent w/v solution of Nandrolone Decanoate.

Reference solution. A 0.5 per cent w/v solution of nandrolone decanoate RS in carbon tetrachloride.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution. Ignore any subsidiary spots due to the vehicle.

Tests

Other Tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. To an accurately measured volume containing about 0.1 g of Nandrolone Decanoate add sufficient chloroform to produce 100.0 ml. Dilute 3.0 ml of the solution to 50.0 ml with chloroform. To 5.0 ml of this solution add 10 ml of isoniazid solution and sufficient methanol to produce 20.0 ml. Allow to stand for 45 minutes and measure the absorbance of the resulting solution at the maximum at about 380 nm (2.4.7), using as the blank 5 ml of chloroform treated in the same manner. Calculate the content of C₂₈H₄₄O₃ from the absorbance obtained by repeating the operation using a suitable quantity of nandrolone RS.

1 mg of C₁₈H₂₆O₂ is equivalent to 1.562 mg of C₂₈H₄₄O₃.

Storage. Store protected from light.

Nandrolone Phenylpropionate

Nandrolone Phenylpropionate

C₇H₁₄O₃

Mol.Wt. 406.6

Nandrolone Phenylpropionate is 3-oxo-4-estren-17β-yl 3-phenylpropionate.

Nandrolone Phenylpropionate contains not less than 97.0 per cent and not more than 103.0 per cent of C₂₇H₃₄O₃, calculated on the dried basis.

Description. A white to creamy-white, crystalline powder; odour, characteristic.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nandrolone phenylpropionate RS or with the reference spectrum of nandrolone phenylpropionate.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in ethanol (95 per cent) shows an absorption maximum only at about 240 nm; absorbance at about 240 nm, about 0.43.
C. Dissolve 25 mg in 1 ml of methanol, add 2 ml of semicarbazide acetate solution, heat under a reflux condenser for 30 minutes and cool; the precipitate, after recrystallisation from ethanol (95 per cent) melts at about 182° (2.4.21).

Tests

Specific optical rotation (2.4.22). +48.0° to +51.0°, determined in a 1.0 per cent w/v solution in dioxan.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 70 volumes of heptane and 30 volumes of acetone.

Test solution. Dissolve 0.1 g of the substance under examination in 100 ml of chloroform.

Reference solution (a). A 0.005 per cent w/v solution of the substance under examination in chloroform.

Reference solution (b). A 0.01 per cent w/v solution of nandrolone RS in chloroform.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. In the chromatogram obtained with the test solution any spot corresponding to nandrolone is not more intense than the spot in the chromatogram obtained with reference solution (b) and any other secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (a).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 4 hours.

Assay. Weigh accurately about 10 mg, dissolve in sufficient ethanol to produce 100.0 ml, dilute 5.0 ml to 50.0 ml with ethanol and measure the absorbance of the resulting solution at the maximum at about 240 nm (2.4.7). Calculate the content of C_{27}H_{34}O_{3} taking 430 as the specific absorbance at 240 nm.

Storage. Store protected from light.

Nandrolone Phenylpropionate Injection

Nandrolone Phenylpropionate Injection is a sterile solution of Nandrolone Phenylpropionate in Ethyl Oleate or other suitable ester, in a suitable fixed oil or in a mixture of these.

Nandrolone Phenylpropionate Injection contains not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of nandrolone phenylpropionate, C_{27}H_{34}O_{3}.

Identification

Dissolve a volume of the injection containing 50 mg of Nandrolone Phenylpropionate in 8 ml of light petroleum (40° to 60°) and extract with three 8-ml quantities of a mixture of 7 volumes of glacial acetic acid and 3 volumes of water. Wash the combined extracts with 10 ml of light petroleum (40° to 60°), dilute with water until the solution becomes turbid, allow to stand for 2 hours in ice and filter. The precipitate, after washing with water and drying over phosphorus pentoxide at a pressure not exceeding 0.7 kPa, complies with the following test.

Determine by thin-layer chromatography (2.4.17), using a silica gel GF254 precoated plate the surface of which has been modified by chemically-bonded octadecysilyl groups.

Mobile phase. A mixture of 20 volumes of water, 40 volumes of acetonitrile and 60 volumes of propan-2-ol.

Test solution. A 0.5 per cent w/v solution of the dried precipitate in chloroform.

Reference solution (a). A 0.5 per cent w/v solution of nandrolone phenylpropionate RS in chloroform.

Reference solution (b). A mixture of equal volumes of the test solution and the reference solution.

Apply to the plate 5 µl of each solution. After development, dry the plate in air until the solvent has evaporated and heat it at 100° for 10 minutes. Allow to cool and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single spot.

Tests

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. To an accurately measured volume containing about 0.1 g of Nandrolone Phenylpropionate add sufficient chloroform to produce 100.0 ml. Dilute 3.0 ml of this solution to 50.0 ml with chloroform. To 5.0 ml of the resulting solution add 10 ml of isoniazid solution and sufficient methanol to produce 20.0 ml. Allow to stand for 45 minutes and measure the absorbance of the solution at the maximum at about 380 nm (2.4.7), using as blank 5 ml of chloroform treated in the same manner. Calculate the content of C_{27}H_{34}O_{3} from the absorbance obtained from a 0.006 per cent w/v solution of nandrolone phenylpropionate RS treated in the same manner.

Storage. Store protected from light.

Labelling. The label states that the preparation is for intramuscular injection only.
Naphazoline Nitrate

\[
\text{C}_7\text{H}_8\text{N}_2\text{HNO}_3 \quad \text{Mol. Wt. 273.3}
\]

Naphazoline Nitrate is 2-(1-naphthylmethyl)-2-imidazoline nitrate.

Naphazoline Nitrate contains not less than 99.0 per cent and not more than 101.0 per cent of \(\text{C}_7\text{H}_8\text{N}_2\text{HNO}_3\) calculated on the dried basis.

Description. A white or almost white, crystalline powder.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with naphazoline nitrate RS.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in 0.01 M hydrochloric acid shows absorption maxima at about 270 nm, 280 nm, 287 nm and 291 nm; absorbances at these maxima are about 0.43, 0.50, 0.35 and 0.34 respectively.

C. Dissolve about 0.5 mg in 1 ml of methanol, add 0.5 ml of a freshly prepared 5 per cent w/v solution of sodium nitroprusside and 0.5 ml of a 2 per cent w/v solution of sodium hydroxide, allow to stand for 10 minutes and add 1 ml of a 8 per cent w/v solution of sodium bicarbonate; a violet colour is produced.

D. Dissolve about 10 mg in 5 ml of water, add 0.2 g of magnesium oxide, shake mechanically for 30 minutes. Add 10 ml of chloroform and shake vigorously. Allow to stand, separate the chloroform layer, filter and evaporate the aqueous layer to dryness. The residue gives reaction A for nitrates (2.3.1).

Tests

Appearance of solution. A 1.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1) and colourless (2.4.1).

\(\text{pH}\) (2.4.24). 5.0 to 6.5, determined in a 1.0 per cent w/v solution.

Naphthylacetyldihylenediamine. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel \(G\).

Mobile phase. A mixture of 100 volumes of methanol and 1.5 volumes of strong ammonia solution.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of methanol.

Reference solution. A solution containing 2 per cent w/v of naphazoline nitrate RS and 0.01 per cent w/v of naphthylacetyldihylenediamine hydrochloride RS.

Apply to the plate 10 \(\mu\)l of each solution. After development, dry the plate at 105\(^\circ\) for 5 minutes, spray with a 0.5 per cent w/v solution of ninhydrin in methanol and heat at 105\(^\circ\) for 10 minutes. Any spot corresponding to naphthylacetyldihylenediamine hydrochloride in the chromatogram obtained with the test solution is not more intense than the corresponding spot in the chromatogram obtained with the reference solution. The test is not valid unless the chromatogram obtained with the reference solution shows two clearly separated spots.

Chlorides (2.3.12). 15.0 ml of 1.0 per cent w/v solution in carbon dioxide-free water complies with the limit test for chlorides (375 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105\(^\circ\) for 3 hours.

Assay. Weigh accurately about 0.2 g, dissolve in 30 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02733 g of \(\text{C}_7\text{H}_8\text{N}_2\text{HNO}_3\).

Storage. Store protected from light.

Nelfinavir Mesylate

\[
\text{C}_{32}\text{H}_{45}\text{N}_{3}\text{O}_{4}\text{S,CH}_3\text{SO}_3\text{H} \quad \text{Mol. Wt. 663.9}
\]

Nelfinavir Mesylate is (3S,4aS,8aS)-N-(tert-butyldecahydro-2,3,3a]-[(2R,3R)-3-hydroxy-o-toluamido]-hydroxy-4-(phenylthio)butyl]-isoquinoline-3-carboxamide methyl sulphonate.
Nelfinavir Mesylate contains not less than 98.0 per cent and not more than 101.0 per cent of C$_{32}$H$_{45}$N$_3$O$_4$S, CH$_3$O$_3$S, calculated on the anhydrous basis.

**Description.** A white or almost white powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nelfinavir mesylate RS or with the reference spectrum of nelfinavir mesylate.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Specific optical rotation** (2.4.22). –105° to –120°, determined in a 1.0 per cent w/v solution in methanol.

**Related substances.** Determine by liquid chromatography (2.4.14), using the chromatographic system described in the Assay.

**Test solution.** A 0.1 per cent w/v solution of the substance under examination in the mobile phase.

**Reference solution (a).** A 0.001 per cent w/v solution of the substance under examination in the mobile phase.

**Reference solution (b).** A 0.01 per cent w/v solution of methanesulphonic acid in the mobile phase.

Inject reference solution (a). The test is not valid unless the column efficiency determined from the nelfinavir peak is not less than 4000 theoretical plates and the tailing factor is not more than 2.0.

Separately inject reference solution (b) and record the chromatograms. Separately inject the test solution and continue the chromatography for at least three times the retention time of the principal peak. In the chromatogram obtained with the test solution, the area of any peak other than the principal peak is not greater than half of the area of the principal peak in the chromatogram obtained with reference solution (a) (0.5 per cent) and the sum of the areas of all such peaks is not greater than the area of the principal peak in the chromatogram obtained with reference solution (a) (1.0 per cent). Ignore any peak due to methanesulphonic acid corresponding to the retention time of the principal peak in the chromatogram obtained with reference solution (b).

**Methanesulphonic acid.** 13.5 per cent to 15.5 per cent w/w, calculated on the anhydrous basis, determined by the following method. Weigh accurately about 0.6 g, dissolve in 50 ml of dimethylformamide and titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.00961 g of CH$_3$SO$_3$H.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Water** (2.3.43). Not more than 3.0 per cent, determined on 0.5 g.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** A 0.01 per cent w/v solution of the substance under examination in the mobile phase.

**Reference solution.** A 0.01 per cent w/v solution of nelfinavir mesylate RS in the mobile phase.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 μm),
- mobile phase: a filtered and degassed mixture of 45 volumes of acetonitrile, 20 volumes of methanol and 35 volumes of a buffer prepared by dissolving 4.0 g of sodium dihydrogen phosphate in 1000 ml of water, to which 1 ml of dimethylamine solution and 1 g of sodium octanesulphonate are added and mixed to dissolve,
- flow rate. 1 ml per minute,
- spectrophotometer set at 215 nm,
- a 20 μl loop injector.

Inject the test solution. The test is not valid unless the column efficiency determined from the nelfinavir peak is not less than 5000 theoretical plates, the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Separately inject the test solution and the reference solution and measure the responses for the principal peak. Calculate the content of C$_{32}$H$_{45}$N$_3$O$_4$S, CH$_3$O$_3$S.

**Storage.** Store protected from light.

**Nelfinavir Mesylate Oral Powder**

Nelfinavir Mesylate Oral Powder contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nelfinavir, C$_{32}$H$_{45}$N$_3$O$_4$S.

**Identification**

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.
Tests

Dissolution (2.5.2).

Apparatus. No 1
Medium. 900 ml of 0.1 M hydrochloric acid.
Speed and time. 75 rpm and 45 minutes.
Withdraw a suitable volume of the medium and filter.
Determine by liquid chromatography (2.4.14).

Test solution. Use the filtrate and, if necessary, dilute with the dissolution medium.

Reference solution. A 0.065 per cent w/v solution of nelfinavir mesylate RS in methanol. Dilute 10 ml of the solution to 100 ml with the dissolution medium.

Use the chromatographic system described under Assay.

Assay. Determine by liquid chromatography (2.4.14).

Solvent mixture. 30 volumes of water and 70 volumes of methanol.

Test solution. Weigh accurately a quantity of the powder containing 50 mg of Nelfinavir Mesylate, disperse in 50 ml of 0.1 M hydrochloric acid, dilute to 250.0 ml with the solvent mixture and filter.

Reference solution (a). Dissolve 10 mg of nelfinavir mesylate RS in 2 ml of methanol and dilute to 10 ml with the mobile phase.

Reference solution (b). Dilute 1 ml of reference solution (a) to 100 ml with the mobile phase.

Chromatographic system
– a stainless steel column 15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
– column temperature 40º,
– mobile phase: a mixture of 35 volumes of a buffer solution prepared by dissolving 4 g of sodium dihydrogen phosphate dihydrate and 1 g of 1-octane sulphonic acid sodium salt into 1000 ml of water, adding 1 ml of dimethylamine and filtering, 45 volumes acetonitrile and 20 volumes of methanol,
– flow rate. 2 ml per minute,
– spectrophotometer set at 220 nm,
– a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency in not less than 2000 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C32H45N3O4S in the oral powder.

Storage. Store protected from moisture, at a temperature not exceeding 30º.

Labelling. The label states the strength in terms of the equivalent amount of nelfinavir.

Nelfinavir Tablets

Nelfinavir Mesylate Tablets

Nelfinavir Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nelfinavir mesylate, C32H45N3O4S,CH4O3S.

Identification
A. Shake a quantity of the powdered tablets containing about 0.1 g of Nelfinavir Mesylate with 80 ml of methanol for
10 minutes, add sufficient methanol to produce 100 ml, mix and filter. Dilute 5 ml of the filtrate to 100 ml with methanol.

When examined in the range 200 nm to 300 nm the resulting solution shows an absorption maximum only at about 254 nm (2.4.7).

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Dissolution** (2.5.2).

**Apparatus.** No 1

**Medium.** 900 ml of 0.01 M hydrochloric acid.

**Speed and time.** 50 rpm and 30 minutes.

Withdraw a suitable volume of the medium and filter promptly through a membrane filter disc with an average pore diameter not greater than 1.0 µm. Reject the first few ml of the filtrate and dilute a suitable volume of the filtrate with the same solvent. Measure the absorbance of the resulting solution at the maximum at about 250 nm (2.4.7). Calculate the content of C$_{32}$H$_{45}$N$_3$O$_4$S, CH$_4$O$_3$S from the absorbance of a solution of known concentration of nelfinavir mesylate RS.

D. Not less than 75 per cent of the stated amount of C$_{32}$H$_{45}$N$_3$O$_4$S, CH$_4$O$_3$S.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh accurately a quantity of the powdered tablets containing about 100 mg of Nelfinavir Mesylate, add about 20 ml of methanol, mix with the aid of ultrasound for 10 minutes and dilute to 100 ml with the mobile phase.

**Reference solution.** Weigh accurately about 10 mg of nelfinavir mesylate RS, add about 10 ml of methanol, shake for 10 minutes and dilute to 50 ml with the mobile phase.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica particles or ceramic microparticles (5 µm),
- mobile phase: a filtered and degassed mixture of 45 volumes of acetonitrile, 20 volumes of methanol and 35 volumes of a buffer prepared by dissolving 4.0 g of sodium dihydrogen phosphate in 1000 ml of water, to which are added 1 ml of dimethylamine solution and 1 g of sodium octanesulphonate and mixing to dissolve,
- flow rate. 1 ml per minute,
- spectrophotometer set at 215 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the column efficiency determined from the nelfinavir mesylate peak is not less than 4000 theoretical plates and the tailing factor is not more than 2.0.

Inject separately the diluent (10 ml of methanol diluted to 50 ml with the mobile phase) and the test solution and continue the chromatography for 4 times the retention time of the principal peak. Examine the diluent chromatogram for any extraneous peaks and ignore the corresponding peaks observed in the chromatogram obtained with the test solution.

Any secondary peak observed in the chromatogram obtained with the test solution should not be more than 1.0 per cent and the sum of the areas of all the secondary peaks should not be more than 2.0 per cent when calculated by percentage area normalisation. Inhibit integration of peak due to methanesulphonic acid.

**Other tests.** Complies with the tests stated under Tablets.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh accurately a quantity of the powdered tablets containing about 200 mg of Nelfinavir Mesylate, add about 20 ml of methanol, mix with the aid of ultrasound for 10 minutes and dilute to 100.0 ml with the mobile phase. Filter through a membrane filter disc with an average pore diameter not greater than 1.0 µm, rejecting the first few ml of the filtrate. Further dilute 5.0 ml of the filtrate to 100.0 ml with the mobile phase.

**Reference solution.** Weigh accurately about 50 mg of nelfinavir mesylate RS, add about 10 ml of methanol, mix with the aid of ultrasound to dissolve and dilute to 50.0 ml with the mobile phase. Dilute 5.0 ml of this solution to 50.0 ml with the mobile phase.

Use the chromatographic system described in the test for Related substances.

Inject the reference solution. The test is not valid unless the column efficiency determined from the nelfinavir mesylate peak is not less than 5000 theoretical plates, the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject separately the test solution and the reference solution and measure the responses for the major peak. Calculate the content of C$_{32}$H$_{45}$N$_3$O$_4$S, CH$_4$O$_3$S in the tablets.

**Storage.** Store protected from light.

**Neomycin Sulphate**

Neomycin Sulphate is a mixture of the sulphates of substances obtained by the growth of certain selected strains of *Streptomyces fradiae*.

Neomycin Sulphate has a potency of not less than 600 Units per mg, calculated on the dried basis.

**Description.** A white or yellowish-white powder; odourless or almost odourless; hygroscopic.
Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H.

Mobile phase. A freshly prepared 3.85 per cent w/v solution of ammonium acetate.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of water.

Reference solution. A 2.0 per cent w/v solution of neomycin sulphate RS in water.

Apply to the plate 1 µl of each solution. After development, dry the plate in air for 10 minutes, heat at 100° for 1 hour and spray with a 0.1 per cent w/v solution of ninhydrin in $\text{1-butanol}$ saturated with water. Heat again at 100° for 5 minutes. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

B. Dissolve about 10 mg in 5 ml of water, add 0.1 ml of pyridine and 2 ml of a 0.1 per cent w/v solution of ninhydrin and heat on a water-bath at a temperature of about 70° for 10 minutes; a deep violet colour is produced.

C. A 5 per cent w/v solution gives the reactions of sulphates (2.3.1).

Tests

pH (2.4.24). 5.0 to 7.5, determined in a 1.0 per cent w/v solution.

Specific optical rotation (2.4.22). +53.5° to +59.0°, determined in a 10.0 per cent w/v solution.

Neamine. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H.

Mobile phase. A mixture of 30 volumes of methanol, 20 volumes of strong ammonia solution and 10 volumes of dichloromethane.

Test solution. Dissolve 0.25 g of the substance under examination in 10 ml of water.

Reference solution. A 0.05 per cent w/v solution of neamine RS in water.

Apply to the plate as 5-mm bands 5 µl of each solution. Dry the bands; allow the mobile phase to rise at least 8 cm. Dry the plate at 100° to 105° for 10 minutes. Spray the plate with ethanolic ninhydrin solution and heat at 100° to 105° for 10 minutes. In the chromatogram obtained with the test solution the principal band corresponds to the principal band in the chromatogram obtained with reference solution (c) and the band due to neomycin C with an Rf value slightly less than that of the principal band is not more intense than the band obtained with reference solution (a) (15 per cent) but is more intense than the band in the chromatogram obtained with reference solution (b) (3 per cent). The test is not valid unless in the chromatogram obtained with reference solution (c) a band appears with an Rf value slightly less than that of the principal band.

Sulphated ash (2.3.18). Not more than 1.0 per cent.

Loss on drying (2.4.19). Not more than 8.0 per cent, determined on 0.5 g by drying in an oven at 60° over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 3 hours.

Assay. Determine by the microbiological assay of antibiotics, Method A (2.2.10).

Storage. Store protected from light and moisture.

Labelling. The label states the strength in terms of Units of neomycin per mg.

Neomycin Eye Drops

Neomycin Sulphate Eye Drops

Neomycin Sulphate Eye Drops are a sterile solution of Neomycin Sulphate in Purified Water.

Neomycin Sulphate Eye Drops contain not less than 90.0 per cent and not more than 115.0 per cent w/v of the stated amount of neomycin sulphate.

Identification

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel.
Mobile phase. A mixture of 60 volumes of methanol, 40 volumes of strong ammonia solution and 20 volumes of chloroform.

Test solution. Dilute if necessary a volume of the eye drops to produce a solution containing 0.5 per cent w/v of Neomycin Sulphate in water.

Reference solution (a). A 0.5 per cent w/v solution of neomycin sulphate RS in water.

Reference solution (b). A mixture of equal volumes of the eye drops and reference solution (a).

Apply to the plate 1 µl of each solution. After development, dry the plate in air, spray with a 1 per cent w/v solution of ninhydrin in 1-butanol and heat at 105° for 2 minutes. The principal red spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a) and the principal red spot in the chromatogram obtained with reference solution (b) appears as a single spot.

Tests

Neamine. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H.

Mobile phase. A mixture of 30 volumes of methanol, 20 volumes of strong ammonia solution and 10 volumes of dichloromethane.

Test solution. A volume of the eye drops containing 5 µg (3.5 Units).

Reference solution. The same volume of water containing 0.1 µg of neamine RS.

Apply to the plate each solution. After development, dry the plate with in a current of warm air, heat at 110° for 10 minutes, spray with a 1 per cent w/v solution of ninhydrin and stannous chloride reagent and heat at 110° for 15 minutes. The chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and the principal red spot in the chromatogram obtained with reference solution (b) appears as a single spot.

Neomycin C. Determine by liquid chromatography (2.4.14).

Test solution. Dilute the eye drops with 0.02 M borax to contain 1 mg (700 Units) per ml. To 0.5 ml of the diluted solution add 1.5 ml of a freshly prepared 2 per cent w/v solution of 1-fluoro-2,4-dinitrobenzene in methanol, dilute to 25 ml with the mobile phase, allow to stand and use the clear lower layer.

Reference solution. Add 1.5 ml of the 1-fluoro-2,4-dinitrobenzene solution to 0.5 ml of a 0.1 per cent w/v solution of neomycin sulphate RS in 0.02 M borax, heat in a water-bath at 60° for 1 hour and cool; dilute the solution to 25 ml with the mobile phase, allow to stand and use the clear lower layer.

Chromatographic system

– a stainless steel column 20 cm x 4.6 mm, packed with porous silica particles (5 µm),
– mobile phase: a mixture of 97 ml of tetrahydrofuran, 1.0 ml of water and 0.5 ml of glacial acetic acid diluted with sufficient of a 2.0 per cent v/v solution of ethanol in ethanol-free chloroform to produce 250 ml,
– flow rate. 1.6 ml per minute,
– spectrophotometer set at 350 nm,
– a 10 µl loop injector.

If necessary the tetrahydrofuran and water content of the mobile phase may be adjusted so that the chromatogram obtained with the reference solution shows resolution similar to that in the specimen chromatogram supplied with framycetin sulphate RS. The mobile phase should be passed through the column for several hours before the solutions are injected. Continue the chromatography for 1.4 times the retention time of the peak due to neomycin B.

The column efficiency, determined using the peak due to Neomycin B in the chromatogram obtained with the test solution, should be not less than 13,000 theoretical plates.

In the chromatogram obtained with the test solution the area of the peak corresponding to neomycin C is not less than 3.0 per cent and not more than 15.0 per cent of sum of the areas of the peaks corresponding to Neomycin B and Neomycin C.

Other Tests. Complies with the tests stated under Eye Drops.

Assay. Measure accurately a quantity containing 5 mg of Neomycin Sulphate and dilute to 50.0 ml with sterile phosphate buffer pH 8.0 and mix. Dilute 10.0 ml of the resulting solution to 100.0 ml with the same solvent.

Determine by the microbiological assay of antibiotics, Method A (2.2.10).

The upper fiducial limit of error is not less than 90.0 per cent and the lower fiducial limit of error is not more than 115.0 per cent of the stated number of Units per ml.

Storage. Store protected from light.

Labelling. The strength is stated in terms of percentage w/v as well as the number of Units per ml.

Neomycin Eye Ointment

Neomycin Sulphate Eye Ointment

Neomycin Sulphate Eye Ointment is a sterile preparation containing Neomycin Sulphate in a suitable basis.

Neomycin Sulphate Eye Ointment contains not less than 90.0 per cent and not more than 115.0 per cent of the stated amount of neomycin sulphate.
NEOMYCIN EYE OINTMENT

Identification

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel.

Mobile phase. A mixture of 60 volumes of methanol, 40 volumes of strong ammonia solution and 20 volumes of chloroform.

Test solution. Disperse a quantity of the eye ointment containing 20 mg of Neomycin Sulphate in 20 ml of chloroform, extract with 5 ml of water and use the aqueous extract.

Reference solution (a). A 0.4 per cent w/v solution of neomycin sulphate RS in water.

Reference solution (b). A mixture of equal volumes of test solution and reference solution (a).

Apply to the plate 1 µl of each solution. After development, dry the plate in air, spray with a 1 per cent w/v solution of ninhydrin in 1-butanol and heat at 105° for 2 minutes. The principal red spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a) and the principal red spot in the chromatogram obtained with reference solution (b) appears as a single spot.

Tests

Neamine. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H.

Mobile phase. A mixture of 30 volumes of methanol, 20 volumes of strong ammonia solution and 10 volumes of dichloromethane.

Test solution. Disperse a quantity of the eye ointment containing 20 mg of Neomycin Sulphate in 20 ml of chloroform, shake gently with 8 ml of water, allow the layers to separate and use the aqueous layer.

Reference solution. A 0.005 per cent w/v solution of neamine RS in water.

Apply to the plate 2 µl of each solution. After development, dry the plate in a current of warm air, heat at 110° for 10 minutes, spray with ninhydrin and stannous chloride reagent and heat at 110° for 15 minutes. The area of the peak corresponding to Neomycin B and Neomycin C is not more than 3.0 per cent and not more than 15.0 per cent of the sum of the areas of the peaks corresponding to Neomycin B and Neomycin C.

Neomycin C. Determine by liquid chromatography (2.4.17)

Test solution. Disperse a quantity of the eye ointment containing 5 mg of Neomycin Sulphate in 20 ml of light petroleum (120° to 160°), add 5 ml of 0.02 M borax, shake, separate the aqueous layer and centrifuge. To 0.5 ml of the separated aqueous layer add 1.5 ml of a freshly prepared 2 per cent w/v solution of 1-fluoro-2,4-dinitrobenzene in methanol, heat on a water-bath at 60° for 1 hour and cool. Dilute the resulting solution to 25 ml with the mobile phase, allow to stand and use the clear lower layer.

Reference solution. Add 1.5 ml of the 1-fluoro-2,4-dinitrobenzene solution to 0.5 ml of a 0.1 per cent w/v solution of neomycin sulphate RS in 0.02 M borax and proceed as for the test solution.

Chromatographic system

– a stainless steel column 20 cm x 4.6 mm, packed with porous silica particles (5 µm),
– mobile phase: 97 ml of tetrahydrofuran, 1.0 ml of water and 0.5 ml of glacial acetic acid with sufficient of a 2.0 per cent v/v solution of ethanol in ethanol-free chloroform to produce 250 ml,
– flow rate. 1.6 ml per minute,
– spectrophotometer set at 350 nm,
– a 10 µl loop injector.

If necessary the tetrahydrofuran and water content of the mobile phase may be adjusted so that the chromatogram obtained with reference solution shows resolution similar to that in the specimen chromatogram supplied with framycetin sulphate RS. The mobile phase should be passed through the column for several hours before the solutions are injected. Continue the chromatography for 1.4 times the retention time of the peak due to neomycin B.

The column efficiency, determined using the peak due to Neomycin B in the chromatogram obtained with the test solution, should be not less than 13,000 theoretical plates.

In the chromatogram obtained with the test solution the area of the peak corresponding to neomycin C is not less than 3.0 per cent and not more than 15.0 per cent of the sum of the areas of the peaks corresponding to Neomycin B and Neomycin C.

Other Tests. Complies with the tests stated under Eye Ointments.

Assay. Weigh accurately a quantity containing 5 mg of Neomycin Sulphate, dissolve in 25 ml of chloroform, extract with four quantities, each of 20 ml, of sterile phosphate buffer pH 8.0, combine the extracts and add sufficient of the buffer solution to produce 100.0 ml.

Carry out the microbiological assay of antibiotics, Method A (2.2.10).

The upper fiducial limit of error is not less than 90.0 per cent and the lower fiducial limit of error is not more than 115.0 per cent of the stated number of Units per g.

Storage. Store protected from light.

Labelling. The strength is stated in terms of percentage w/v as well as the number of Units per ml.
Neostigmine Bromide

\[ \text{C}_{12}\text{H}_{19}\text{BrN}_{2}\text{O}_{2} \]  
Mol. Wt. 303.2

Neostigmine Bromide is \( 3\)-(dimethylcarbamoyloxy) trimethylanilinium bromide.

Neostigmine Bromide contains not less than 98.0 per cent and not more than 101.0 per cent of \( \text{C}_{12}\text{H}_{19}\text{BrN}_{2}\text{O}_{2} \), calculated on the dried basis.

**Description.** Colourless crystals or a white, crystalline powder; odourless; hygroscopic.

**Identification**

*Test A* may be omitted if *tests B, C, D and E* are carried out. *Tests B, C and D* may be omitted if *tests A* and *E* are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *neostigmine bromide RS*.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.02 per cent w/v solution in 0.5 M sulphuric acid shows absorption maxima at about 260 nm and 266 nm.

C. Warm about 50 mg with 1 ml of *dilute sodium hydroxide solution*; an odour of dimethylamine develops slowly.

D. Warm about 50 mg with 0.4 g of potassium hydroxide and 2 ml of ethanol (95 per cent) on a water-bath for 3 minutes, replacing the evaporated ethanol. Cool, add 2 ml of *dilute diazobenzenesulphonic acid solution*; an orange-red colour is produced.

E. Gives the reactions of bromides (2.3.1).

**Tests**

**Appearance of solution.** A 0.5 per cent w/v solution is clear (2.4.1), and colourless (2.4.1).

**Acidity.** Dissolve 0.2 g in 20 ml of carbon dioxide-free water and titrate to pH 7.0 with 0.02 M sodium hydroxide (carbonate-free); not more than 0.1 ml is required.

**3-Hydroxytrimethylanilinium bromide.** Dissolve 50 mg in a mixture of 1 ml of sodium carbonate solution and 9 ml of water. Absorbance of the resulting solution at about 294 nm, measured immediately after preparation, not more than 0.25 (2.4.7).

**Sulphates** (2.3.17). 0.75 g complies with the limit test for sulphates (200 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105°.

**Assay.** Weigh accurately about 0.5 g, dissolve in 20 ml of anhydrous glacial acetic acid, add 5 ml of acetic anhydride. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.03032 g of \( \text{C}_{12}\text{H}_{19}\text{BrN}_{2}\text{O}_{2} \).

**Storage.** Store protected from light and moisture.

Neostigmine Tablets

Neostigmine Bromide Tablets

Neostigmine Bromide Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of neostigmine bromide, \( \text{C}_{12}\text{H}_{19}\text{BrN}_{2}\text{O}_{2} \).

**Identification**

Triturate a quantity of the powdered tablets containing about 0.3 g of Neostigmine Bromide with three quantities, each of 5 ml of ether and discard the ether. Macerate the residue with several quantities, each of 10 ml of ethanol (95 per cent), filtering after each maceration. Evaporate the combined filtrates on a water-bath and dry the residue at 105° for 1 hour. The residue melts at about 167°, with decomposition. The residue complies with the following tests.

A. Warm about 50 mg with 0.4 g of potassium hydroxide and 2 ml of ethanol (95 per cent) on a water-bath for 3 minutes, replacing the evaporated ethanol. Cool, add 2 ml of *dilute diazobenzenesulphonic acid solution*; an orange-red colour is produced.

B. Gives the reactions of bromides (2.3.1).

**Tests**

**Other Tests.** Complies with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.15 g of Neostigmine Bromide, transfer to a semi-micro ammonia-distillation apparatus, add 20 ml of a 50 per cent w/v solution of sodium hydroxide and 0.5 ml of a 2 per cent w/v solution of 2-octanol in liquid paraffin. Pass a current of steam through the mixture, collect the distillate in 50 ml of 0.01 M sulphuric acid until the
volume is about 200 ml and titrate the excess of acid with 0.02 M sodium hydroxide using methyl red solution as indicator. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of sulphuric acid required to neutralise the dimethylamine produced.

1 ml of 0.01 M sulphuric acid is equivalent to 0.006064 g of C₁₃H₂₂N₂O₂S.

Storage. Store protected from light and moisture.

**Neostigmine Methylsulphate**

C₁₃H₂₂N₂O₆S  Mol. Wt. 334.4

Neostigmine Methylsulphate is 3-(dimethylcarbamoyloxy)-trimethylanilinium methyl sulphate.

Neostigmine Methylsulphate contains not less than 98.5 per cent and not more than 101.0 per cent of C₁₃H₂₂N₂O₆S, calculated on the dried basis.

**Description.** Colourless crystals or a white, crystalline powder; hygroscopic.

**Identification**

Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with neostigmine methylsulphate RS or with the reference spectrum of neostigmine methylsulphate.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.05 per cent w/v solution in 0.5 M sulphuric acid shows absorption maxima at about 261 nm and 267 nm. The ratio of the absorbance at the maximum at about 267 nm to that at the maximum at 261 nm is 0.84 to 0.87.

C. Dissolve 0.1 g in 5 ml of distilled water and add 1 ml of a 6 per cent w/v solution of barium chloride; no precipitate is produced. Add 2 ml of hydrochloric acid and heat in a water-bath for 10 minutes; a white precipitate is produced.

D. Warm about 50 mg with 0.4 g of potassium hydroxide and 2 ml of ethanol (95 per cent) on a water-bath for 3 minutes, replacing the evaporated ethanol. Cool, add 2 ml of dilute diazobenzenesulphonic acid solution; an orange-red colour is produced.

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution in distilled water is clear (2.4.1), and colourless (2.4.1).

**Acidity or alkalinity.** To 4.0 ml of a 5.0 per cent w/v solution in distilled water add 6.0 ml of water and 0.1 ml of phenol-phthalein solution; the solution is colourless. Add 0.3 ml of 0.01 M sodium hydroxide; the solution becomes red. Add 0.4 ml of 0.01 M hydrochloric acid; the solution becomes colourless. Add 0.1 ml of methyl red solution; the solution becomes red or yellowish-red.

**3-Hydroxytrimethylanilinium methyl sulphate.** Dissolve 50 mg in a mixture of 1 ml of sodium carbonate solution and 9 ml of water. Absorbance of the resulting solution at about 294 nm, measured immediately after preparation, not more than 0.20 (2.4.7).

**Chlorides** (2.3.12). 1.0 g complies with the limit test for chlorides (250 ppm).

**Sulphates** (2.3.17). 0.75 g complies with the limit test for sulphates (200 ppm).

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105°.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Assay.** Weigh accurately about 0.3 g and dissolve in 150 ml of water. Add 100 ml of 2 M sodium hydroxide, distill and collect the distillate in 50 ml of a 4 per cent w/v solution of boric acid until a total volume of 250 ml is reached. Titrate the distillate with 0.1 M hydrochloric acid using 0.25 ml of methyl red-methylene blue solution as indicator. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of hydrochloric acid required.

1 ml of 0.1 M hydrochloric acid is equivalent to 0.03344 g of C₁₃H₂₂N₂O₆S.

Storage. Store protected from light and moisture.

**Neostigmine Injection**

Neostigmine Methylsulphate Injection

Neostigmine Injection is a sterile solution of Neostigmine Methylsulphate in Water for Injections.

Neostigmine Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of neostigmine methylsulphate, C₁₃H₂₂N₂O₆S.

**Identification**

A. Dilute, if necessary, a volume of the injection containing 2.5 mg of Neostigmine Methylsulphate to 5 ml with water, shake with three quantities, each of 10 ml, of ether and discard the ether extracts.

When examined in the range 230 nm to 360 nm (2.4.7), a 2 cm layer of the resulting solution shows absorption maxima at about 260 nm and 267 nm.
B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 50 volumes of chloroform, 35 volumes of methanol, 10 volumes of formic acid and 5 volumes of water.

**Test solution.** Dilute the injection under examination, if necessary, with water to produce a solution containing 0.05 per cent w/v of Neostigmine Methylsulphate.

**Reference solution (a).** A 0.05 per cent w/v solution of neostigmine methylsulphate RS in water.

**Reference solution (b).** A mixture of equal volumes of the test solution and reference solution (a).

Apply to the plate 10 µl of each solution. After development, dry the plate in air, spray with dilute potassium iobismuthate solution. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

C. To 1 ml add 0.5 ml of sodium hydroxide solution and evaporate to dryness on a water-bath. Heat quickly in an oil-bath to about 250° and maintain at this temperature for about 30 seconds. Cool, dissolve the residue in 1 ml of water, cool in ice water and add 1 ml of diazobenzenesulphonic acid solution; an orange-red colour is produced.

**Tests**

**pH.** (2.4.24) 4.5 to 6.5.

**3-Hydroxy trimethylanilinium methyl sulphate.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dilute the injection if necessary, with water to contain a 0.05 per cent w/v solution of Neostigmine Methylsulphate.

**Reference solution (a).** Dilute 1 volume of the test solution to 100 volumes with water.

**Reference solution (b).** Add 0.05 ml of 5 M sodium hydroxide to 1 ml of the test solution and allow to stand for 5 minutes. Add 0.1 ml of 5 M hydrochloric acid and use immediately.

**Chromatographic system**

- a stainless steel column 25 cm × 4.6 mm packed with octadecylsilane chemically bonded to porous silica particles (5 µm) (such as Lichrosphere 60 RP-select B),
- mobile phase: 0.0015 M solution of sodium heptanesulphonate in a mixture of 15 volumes of acetonitrile and 85 volumes of 0.05 M potassium dihydrogen orthophosphate adjusted to pH 3.0 with orthophosphoric acid,
- flow rate of 1.1 ml per minute,
- spectrophotometer set at 215 nm,
- a 10 µl loop injector.

In the chromatogram obtained with reference solution (b) the principal peak has a retention time of about 6.8 minutes (neostigmine methylsulphate) and there is a peak with a relative retention time of about 0.5 (3-hydroxy trimethylanilinium methylsulphate). In the chromatogram obtained with the test solution, the area of any secondary peak with a retention time corresponding to that of the peak due to (3-hydroxy)trimethylanilinium methylsulphate in the chromatogram obtained with reference solution (b) is not greater than the area of the principal peak in the chromatogram obtained with reference solution (a) (1 per cent).

**Other Tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Dilute an accurately measured volume containing about 25 mg of Neostigmine Methylsulphate to 50.0 ml with water. Measure the absorbance of the resulting solution at the maximum at about 260 nm (2.4.7). Calculate the content of C₁₃H₂₂N₂O₆S taking 14.35 as the specific absorbance at 260 nm.

**Storage.** Store protected from light.

---

**Nevirapine**

\[
\text{C}_{15}\text{H}_{14}\text{N}_{4}\text{O} \quad \text{Mol. Wt. 266.3}
\]

Nevirapine is 11-cyclopropyl-5,11-dihydro-4-methy-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one.

Nevirapine contains not less than 98.0 per cent and not more than 102.0 per cent of C₁₅H₁₄N₄O, calculated on the dried basis.

**Description.** A white or almost white crystalline powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nevirapine RS or with the reference spectrum of nevirapine.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.
Tests

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 0.1 g of the substance under examination in 100 ml of methanol.

Reference solution. Dilute 1 ml of the test solution to 100 ml with methanol.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica or ceramic microparticles (5 µm),
- mobile phase: a filtered and degassed mixture of 20 volumes of methanol, 20 volumes of acetonitrile and 60 volumes of a buffer prepared by dissolving 12.0 g of sodium dihydrogen phosphate in about 800 ml of water, adjusting the pH to 3.0 with phosphoric acid and diluting to 1000.0 ml with water;
- flow rate. 1.2 ml per minute,
- spectrophotometer set at 230 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the column efficiency determined from the nevirapine peak is not less than 3000 theoretical plates, the tailing factor is not more than 2.0 and the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Separately inject the test solution and the reference solution and measure the responses for the principal peak. Calculate the content of C_{15}H_{14}N_{4}O.

Storage. Store protected from moisture.

Nevirapine Tablets

Nevirapine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nevirapine, C_{15}H_{14}N_{4}O.

Identification

A. When examined in the range 250 nm to 450 nm (2.4.7) a 0.001 per cent w/v solution in the mobile phase described under Assay, shows an absorption maximum at about 230 nm.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

Dissolution (2.5.2).

Apparatus. No 1.

Medium. 900 ml of 0.1 M hydrochloric acid.

Speed and time. 50 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter through a membrane filter disc with an average pore diameter not greater than 1.0 µm, rejecting the first few ml of the filtrate. Measure the absorbance of the resulting solution, at the maximum at about 313 nm (2.4.7).

Calculate the content of C_{15}H_{14}N_{4}O from the absorbance obtained from a solution of known concentration of nevirapine RS in 0.1 M hydrochloric acid.

D. Not less than 70 per cent of the stated amount of C_{15}H_{14}N_{4}O.

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Shake a quantity of the powdered tablets with a suitable quantity of the mobile phase to obtain a mixture...
containing 0.05 per cent w/v of Nevirapine and filter through a membrane filter disc with an average diameter not exceeding 1.0 µm, rejecting the first few ml of the filtrate.

Reference solution. A 0.05 per cent w/v solution of nevirapine RS in the mobile phase.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica or ceramic microparticles (5 µm),
- mobile phase: a filtered and degassed mixture of 20 volumes of methanol, 20 volumes of acetonitrile and 60 volumes of a buffer prepared by dissolving 12.0 g of sodium dihydrogen phosphate in about 800 ml of water, adjusting the pH to 3.0 with orthophosphoric acid and diluting to 1000.0 ml with water,
- flow rate. 1.2 ml per minute,
- spectrophotometer set at 230 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the column efficiency determined from the nevirapine peak is not less than 7500 theoretical plates, the tailing factor is not more than 1.5 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and continue the chromatography for at least five times the retention time of the principal peak. Determine the amount of related substances by the area normalisation method. Any individual impurity is not more than 1.0 per cent and the sum of all impurities is not more than 2.0 per cent.

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh and powder 20 tablets. Shake a quantity of powder containing about 100 mg of Nevirapine with sufficient of the mobile phase to obtain a mixture containing 0.05 per cent w/v of Nevirapine. Mix and filter through a membrane filter disc with an average pore diameter not greater than 1.0 µm, rejecting the first few ml of the filtrate.

Reference solution. A 0.05 per cent w/v solution of nevirapine RS in the mobile phase.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica or ceramic microparticles (5 µm),
- mobile phase: a filtered and degassed mixture of 20 volumes of methanol, 20 volumes of acetonitrile and 60 volumes of a buffer prepared by dissolving 12.0 g of sodium dihydrogen phosphate in about 800 ml of water, adjusting the pH to 3.0 with phosphoric acid and diluting to 1000.0 ml with water;
- flow rate. 1.2 ml per minute,
- spectrophotometer set at 230 nm,
- a 20 µl loop injector.

Nevirapine Oral Suspension
Nevirapine Oral Suspension is a suspension of Nevirapine in a suitable flavoured vehicle.

Nevirapine Oral Suspension contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nevirapine, C_{15}H_{14}N_{4}O.

Identification
A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 40 volumes of 1-butanol, 30 volumes of heptane, 30 volumes of acetone and 10 volumes of strong ammonia solution.

Test solution. Dilute the preparation under examination with methanol to obtain a solution containing 1 mg of Nevirapine per ml.

Reference solution. A 0.1 per cent w/v solution of nevirapine RS in a mixture of 75 volumes of methanol and 25 volumes of water.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

Tests
pH (2.4.24). 5.0 to 7.0.

Related substances. Determine by liquid chromatography (2.4.14).
**Test solution.** To an accurately measured volume of the preparation under examination containing about 25 mg of Nevirapine add about 10 ml of methanol, mix with the aid of ultrasound for 10 minutes, dilute to 50 ml with water, mix and filter.

**Reference solution.** Weigh accurately about 25 mg of nevirapine RS, add about 10 ml of methanol, mix with the aid of ultrasound to dissolve and dilute to 50 ml with water.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octylsilyl silica gel for chromatography (5 µm)(such as Hypersil C8),
- mobile phase: filtered and degassed gradient mixtures of methanol and 0.1 M ammonium acetate,
- flow rate. 1 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 270 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>0.1 M ammonium acetate (per cent v/v)</th>
<th>Methanol (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>25</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>30</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>31</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>40</td>
<td>95</td>
<td>5</td>
</tr>
</tbody>
</table>

Inject the reference solution. The test is not valid unless the column efficiency determined from the nevirapine peak is not less than 3000 theoretical plates and the tailing factor is not more than 2.0.

Inject separately the diluent (dilute 10 ml of methanol to 50 ml with water) and the test solution. Examine the diluent chromatogram for any extraneous peaks and ignore the corresponding peaks observed in the chromatogram obtained with the test solution. Ignore any peaks due to preservatives also.

Any secondary peak observed in the chromatogram obtained with the test solution should not be more than 1.0 per cent and the sum of the areas of all the secondary peaks should not be more than 2.0 per cent when calculated by percentage area normalisation.

**Other tests.** Comply with the tests stated under Oral Liquids.

**Assay.** Determine by liquid chromatography (2.4.14)

**Test solution.** Weigh accurately a quantity of the preparation under examination containing 25 mg of Nevirapine, add about 10 ml of methanol, mix with the aid of ultrasound for 10 minutes, dilute to 50.0 ml with water, mix and filter. Further dilute 10.0 ml of the filtrate to 25.0 ml with water.

**Reference solution.** Weigh accurately about 50 mg of nevirapine RS, add about 20 ml of methanol, mix with the aid of ultrasound to dissolve and dilute to 100.0 ml with water. Dilute 10.0 ml of this solution to 25.0 ml with water.

Use the chromatographic system described under the test for Related substances.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject separately the test solution and the reference solution and measure the responses for the principal peak.

Determine the weight per ml of the oral suspension (2.4.29) and calculate the content of C_{15}H_{14}N_{4}O weight in volume.

**Storage.** Store protected from light.

**Niclosamide**

Anhydrous Niclosamide

![Niclosamide structure]

C_{13}H_{8}Cl_{2}N_{2}O_{4}  
Mol. Wt. 327.1

Niclosamide is 2’,5-dichloro-4’-nitrosalicylanilide.

Niclosamide contains not less than 98.0 per cent and not more than 101.0 per cent of C_{13}H_{8}Cl_{2}N_{2}O_{4}, calculated on the dried basis.

**Description.** A yellowish white to yellowish, fine crystals or powder; odourless.

**Identification**

*Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with niclosamide RS or with the reference spectrum of niclosamide.

B. Heat 50 mg with 5 ml of 1 M hydrochloric acid and 0.1 g of zinc powder in a water-bath for 10 minutes, cool and filter. To the filtrate add 1 ml of a 0.5 per cent w/v solution of sodium nitrite and allow to stand for 3 minutes. Add 2 ml of a 2 per cent w/v solution of ammonium sulphamate, shake, allow to

822
stand for 3 minutes and add 2 ml of a 0.5 per cent w/v solution of N- (1-naphthyl) ethylenediamine dihydrochloride; a violet colour is produced.

C. Heat the substance under examination on a copper wire in a non-luminous flame; a green colour is imparted to the flame.

Tests

Chlorides (2.3.12). To 2.0 g add a mixture of 40 ml of water and 1.2 ml of 5 M acetic acid, boil for 2 minutes, cool and filter; 10 ml of the filtrate diluted to 15 ml with water complies with the limit test for chlorides (500 ppm).

2-Chloro-4-nitroaniline. Not more than 100 ppm, determined by the following method. Boil 0.25 g with 5 ml of methanol, cool, add 45 ml of 1 M hydrochloric acid, heat to boiling, cool, filter and dilute the filtrate to 50.0 ml with 1 M hydrochloric acid. To 10.0 ml of this solution add 0.5 ml of a 0.5 per cent w/v solution of sodium nitrite and allow to stand for 3 minutes. Add 1.0 ml of a 2 per cent w/v solution of ammonium sulphamate, shake, allow to stand for 3 minutes and add 1.0 ml of a 0.5 per cent w/v solution of N- (1-naphthyl) ethylenediamine dihydrochloride. Any pinkish violet colour produced is not more intense than that obtained in a solution prepared at the same time and in the same manner using 10.0 ml of a solution prepared by diluting 2.0 ml of a 0.00050 per cent w/v solution of 2-chloro-4-nitroaniline in methanol to 20 ml with 1 M hydrochloric acid and beginning at the words “add 0.5 ml of a 0.5 per cent w/v solution of sodium nitrite.....”.

5-Chlorosalicylic acid. Not more than 60 ppm, determined by the following method. Boil 1.0 g with 15 ml of water for 2 minutes, cool, filter through a membrane filter (pore size 0.45 µm), wash the filter and dilute the combined filtrate and washings to 20 ml with water (solution A). Dissolve 30 mg of 5-chlorosalicylic acid in 20 ml of methanol and add sufficient water to produce 100.0 ml. Dilute 1.0 ml of this solution to 100.0 ml with water (solution B). To 10.0 ml of each of solutions A and B add separately 0.1 ml of ferric chloride solution; any violet colour produced in solution A is not more intense than that obtained in solution B.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105° for 4 hours.

Assay. Weigh accurately about 0.3 g, dissolve in 80 ml of a mixture of equal volumes of acetone and methanol. Titrate with 0.1 M tetrabutylammonium hydroxide, determining the end-point potentiometrically (2.4.25). Carry out a blank titration. 1 ml of 0.1 M tetrabutylammonium hydroxide is equivalent to 0.03271 g of C₇H₅Cl₂N₂O₄.

Storage. Store protected from light and moisture.

Niclosamide Tablets

Niclosamide Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of niclosamide, C₁₃H₁₂Cl₂N₂O₄. The tablets may contain sweetening and flavouring agents.

Identification

Heat a quantity of the powdered tablets containing 0.5 g of Niclosamide with 25 ml of hot ethanol (95 per cent), filter while hot and evaporate the filtrate to dryness on a water-bath. The residue complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with niclosamide RS or with the reference spectrum of niclosamide.

B. Heat 50 mg with 5 ml of 1 M hydrochloric acid and 0.1 g of zinc powder in a water-bath for 10 minutes, cool and filter. To the filtrate add 1 ml of a 0.5 per cent w/v solution of sodium nitrite and allow to stand for 3 minutes. Add 2 ml of a 2 per cent w/v solution of ammonium sulphamate, shake, allow to stand for 3 minutes and add 2 ml of a 0.5 per cent w/v solution of N- (1-naphthyl) ethylenediamine dihydrochloride; a violet colour is produced.

Tests

2-Chloro-4-nitroaniline. Not more than 100 ppm, Boil a quantity of the powdered tablets containing 0.1 g of Niclosamide with 20 ml of methanol and 20 ml of a solution in methanol containing 10 µg of 2-chloro-4-nitroaniline, cool, add 45 ml of 1 M hydrochloric acid, heat to boiling, cool, filter and dilute the filtrate to 50.0 ml with 1 M hydrochloric acid. To 10.0 ml of this solution add 0.5 ml of a 0.5 per cent w/v solution of sodium nitrite and allow to stand for 3 minutes. Add 1.0 ml of a 2 per cent w/v solution of ammonium sulphamate, shake, allow to stand for 3 minutes and add 1.0 ml of a 0.5 per cent w/v solution of N- (1-naphthyl) ethylenediamine dihydrochloride. Any pinkish violet colour produced is not more intense than that obtained in a solution prepared at the same time and in the same manner using 10.0 ml of a solution prepared by diluting 2.0 ml of a 0.00050 per cent w/v solution of 2-chloro-4-nitroaniline in methanol to 20 ml with 1 M hydrochloric acid and beginning at the words “add 0.5 ml of a 0.5 per cent w/v solution of sodium nitrite.....”.

5-Chlorosalicylic acid. Boil a quantity of the powdered tablets containing 0.5 g of Niclosamide with 10 ml of water for 2 minutes, cool, filter and to the filtrate add 0.2 ml of ferric chloride solution; no red or violet colour is produced.

Disintegration. The test does not apply.

Other Tests. Comply with the tests stated under Tablets.
**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powdered tablets containing about 0.3 g of Niclosamide dissolved in 60 ml of dimethylformamide. Titrate with 0.1 M tetrabutylammonium hydroxide, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M tetrabutylammonium hydroxide is equivalent to 0.03271 g of C₁₃H₈Cl₂N₂O₄.

**Storage.** Store protected from light and moisture.

**Labelling.** The label states that the tablets should be chewed thoroughly before swallowing.

---

**Nicotinamide**

Niacinamide

\[
\text{C}_6\text{H}_6\text{N}_2\text{O} \quad \text{Mol. Wt. 122.1}
\]

Nicotinamide is pyridine-3-carboxamide.

Nicotinamide contains not less than 99.0 per cent and not more than 101.0 per cent of C₆H₆N₂O, calculated on the dried basis.

**Description.** Colourless crystals or a white, crystalline powder; odour, faint and characteristic.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nicotinamide RS or with the reference spectrum of nicotinamide.

B. Heat about 5 mg in a dry tube; pyridine is evolved.

C. Boil 0.1 g with 1 ml of dilute sodium hydroxide solution; ammonia is evolved.

D. To 2 ml of a 0.1 per cent w/v solution add 6 ml of cyanogen bromide solution and 1 ml of a 2.5 per cent w/v solution of aniline; a golden yellow colour develops.

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and not more intensely coloured than reference solution BYS7 (2.4.1).

**pH** (2.4.24). 6.0 to 7.5, determined in a 5.0 per cent w/v solution.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

---

**Mobile phase.** A mixture of 48 volumes of chloroform, 45 volumes of ethanol and 4 volumes of water.

**Test solution.** Dissolve 0.8 g of the substance under examination in 10 ml of ethanol (50 per cent).

**Reference solution.** A 0.02 per cent w/v solution of the substance under examination in ethanol (50 per cent).

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 10 cm. Dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Heavy metals (2.3.13).** Dissolve 0.67 g in 10 ml of water, 7.5 ml of 1 M hydrochloric acid and sufficient water to produce 25 ml. The solution complies with the limit test for heavy metals, Method A (30 ppm).

**Chlorides (2.3.12).** 1.0 g complies with the limit test for chlorides (250 ppm).

**Sulphates (2.3.17).** 1.2 g complies with the limit test for sulphates (125 ppm).

**Sulphated ash (2.3.18).** Not more than 0.1 per cent.

**Loss on drying (2.4.19).** Not more than 0.5 per cent, determined on 1.0 g by drying over phosphorus pentoxide at a pressure of 1.5 to 2.7 kPa for 18 hours.

**Assay.** Weigh accurately about 0.25 g, dissolve in 20 ml of anhydrous glacial acetic acid, heating slightly if necessary. Add 5 ml of acetic anhydride. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01221 g of C₆H₆N₂O.

**Storage.** Store protected from moisture.

---

**Nicotinamide Tablets**

Niacinamide Tablets

Niacinamide Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of nicotinamide, C₆H₆N₂O.

**Identification**

Shake a quantity of the powdered tablets containing 0.2 g of Nicotinamide with 50 ml of ethanol for 15 minutes, filter and evaporate the filtrate to dryness on a water-bath. The residue complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nicotinamide RS or with the reference spectrum of nicotinamide.
B. Boil 0.1 g with 1 ml of dilute sodium hydroxide solution; ammonia is evolved.

C. To 2 ml of a 0.1 per cent w/v solution add 6 ml of cyanogen bromide solution and 1 ml of a 2.5 per cent w/v solution of aniline; a golden yellow colour develops.

D. When examined in the range 230 nm to 360 nm (2.4.7), the solution obtained in the Assay shows an absorption maximum only at about 262 nm and two shoulders at about 258 nm and 269 nm.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 48 volumes of chloroform, 45 volumes of ethanol and 4 volumes of water.

Test solution. Shake a quantity of the powdered tablets containing 0.1 g of Nicotinamide with 15 ml of ethanol for 15 minutes, filter, evaporate to dryness on a water-bath and dissolve the residue as completely as possible in 1 ml of ethanol.

Reference solution. Dilute 1 volume of the test solution to 400 volumes with ethanol.

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 10 cm. Dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Other Tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 50 mg of Nicotinamide, shake with 50 ml of ethanol (95 per cent) for 15 minutes and dilute to 100.0 ml with ethanol (95 per cent). Mix, filter, dilute 5.0 ml of the filtrate to 100.0 ml with ethanol (95 per cent) and measure the absorbance of the resulting solution at the maximum at about 262 nm (2.4.7). Calculate the content of C₆H₅NO₂ taking 241 as the specific absorbance at 262 nm.

Storage. Store protected from light and moisture.

Nicotinic Acid

Niacin

\[ \text{C₆H₅NO₂} \quad \text{Mol. Wt. 123.1} \]

Nicotinic Acid is pyridine-3-carboxylic acid.

Nicotinic Acid contains not less than 99.5 per cent and not more than 100.5 per cent of C₆H₅NO₂, calculated on the dried basis.

Description. A white or creamy-white, crystalline powder.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nicotinic acid RS or with the reference spectrum of nicotinic acid.

B. Heat a small quantity with twice its weight of soda lime; pyridine is evolved.

C. Dissolve about 50 mg in 20 ml of water, neutralise to litmus paper with 0.1 M sodium hydroxide, add 3 ml of copper sulphate solution; a blue precipitate is gradually produced.

D. To 2 ml of a 0.1 per cent w/v solution add 6 ml of cyanogen bromide solution and 1 ml of a 2.5 per cent w/v solution of aniline; a golden yellow colour is produced.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 85 volumes of 1-propanol, 10 volumes of anhydrous formic acid and 5 volumes of water.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of water. Warm slightly, if necessary.

Reference solution. A 0.01 per cent w/v solution of the substance under examination in water.

Apply to the plate 5 µl of each solution. After development, dry the plate at 105° for 10 minutes and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Heavy metals (2.3.13). Mix 1.0 g with 1.5 ml of dilute hydrochloric acid and sufficient water to produce 25 ml, heat gently and cool to room temperature. The resulting solution complies with the limit test for heavy metals, Method B (20 ppm).

Chlorides (2.3.12). 1.0 g complies with the limit test for chlorides (250 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105° for 1 hour.

Assay. Weigh accurately about 0.25 g, dissolve in 50 ml of carbon dioxide-free water and titrate with 0.1 M sodium hydroxide.
hydroxide using phenol red solution as indicator. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of sodium hydroxide required.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.01231 g of C₆H₅NO₂.

**Storage.** Store protected from light and moisture.

---

**Nicotinic Tablets**

Niacin Acid Tablets

Nicotinic Acid Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of nicotinic acid, C₆H₅NO₂.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 48 volumes of chloroform, 45 volumes of ethanol (95 per cent) and 8 volumes of water.

**Test solution.** Shake a quantity of the powdered tablets containing 50 mg of Nicotinic Acid with 50 ml of hot ethanol (95 per cent), filter and allow the filtrate to cool.

**Reference solution.** A 0.1 per cent w/v solution of nicotinic acid RS in ethanol (95 per cent).

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

B. Triturate a quantity of the powdered tablets containing 50 mg of Nicotinic Acid with 10 ml of water and filter. To 2 ml of the filtrate add 6 ml of cyanogen bromide solution and 1 ml of a 2.5 per cent w/v solution of aniline; a golden yellow precipitate is produced.

C. Shake a quantity of the powdered tablets containing 0.1 g of Nicotinic Acid with ethanol (95 per cent), filter and evaporate the filtrate to dryness. Add to the residue 10 mg of citric acid and 0.15 ml of acetic anhydride and heat on a water-bath; a reddish-violet colour is produced.

**Tests**

**Other Tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.25 g of Nicotinic Acid, add 40 ml of hot ethanol (95 per cent), previously neutralised to phenolphthalein solution, and shake. Allow to stand for 15 minutes, swirling occasionally, and then shake for 10 minutes. Filter through a plug of cotton and wash the filter with ethanol (95 per cent). Add 50 ml of carbon dioxide-free water and titrate with 0.1 M sodium hydroxide using phenol red solution as indicator.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.01231 g of C₆H₅NO₂.

**Storage.** Store protected from light and moisture.

---

**Nicoumalone**

Acenocoumarol

![](image)

C₁₉H₁₅NO₆  
Mol. Wt. 353.3

Nicoumalone is (RS)-4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]coumarin.

Nicoumalone contains not less than 98.5 per cent and not more than 100.5 per cent of C₁₉H₁₅NO₆, calculated on the dried basis.

**Description.** A white to brownish-white powder; odourless or almost odourless.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nicoumalone RS or with the reference spectrum of nicoumalone.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in a mixture of 9 volumes of methanol and 1 volume of 1 M hydrochloric acid shows absorption maxima at about 283 nm and 306 nm; absorbances at the maxima, about 0.65 and about 0.52, respectively.

C. Heat 50 mg with 2.5 ml of glacial acetic acid, 0.5 ml of hydrochloric acid and 0.2 g of zinc powder on a water-bath for 5 minutes, cool and filter. To the filtrate add 0.05 ml of sodium nitrite solution and add the mixture to 10 ml of a 1 per cent w/v solution of 2-naphthol containing 3 ml of 5 M sodium hydroxide; a bright red precipitate is produced.

**Tests**

**Appearance of solution.** A 2.0 per cent w/v solution in acetone is clear (2.4.1).
B. A 2.0 per cent w/v solution in 0.1 M sodium hydroxide is clear (2.4.1), and yellow.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with **silica gel GF254**.

**Mobile phase.** A mixture of 50 volumes of **chloroform**, 50 volumes of **cyclohexane** and 20 volumes of **glacial acetic acid**.

**Test solution.** Dissolve 0.2 g of the substance under examination in 10 ml of **acetone**.

**Reference solution.** A 0.002 per cent w/v solution of the substance under examination in 10 ml of **acetone**.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and immediately examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°C.

**Assay.** Weigh accurately about 0.75 g, dissolve in 50 ml of **acetone** and titrate with 0.1 M sodium hydroxide using **bromothymol blue solution** as indicator. Repeat the operation without the substance under examination. The difference between the tetrations represents the amount of sodium hydroxide required.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.03533 g of C19H15NO6.

**Storage.** Store protected from light.

**Nicoumalone Tablets**

**Acenocoumarol Tablets**

Nicoumalone Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nicoumalone, C19H15NO6.

**Identification**

A. Heat a quantity of the powdered tablets containing 50 mg of Nicoumalone with 30 ml of **acetone** under a reflux condenser for 5 minutes, filter and wash the residue with two quantities, each of 10 ml, of **acetone**. Evaporate the combined filtrate and washings to 5 ml, and add **water** dropwise until the solution becomes turbid, heat on a water-bath until the solution is clear and allow to stand. Filter, wash the crystals with a mixture of equal volumes of **acetone** and **water** and dry at 100° at a pressure of 2 kPa for 30 minutes.

On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nicoumalone RS or with the reference spectrum of nicoumalone.

B. When examined in the range 230 nm to 360 nm (2.4.7), the final solution obtained in the Assay shows absorption maxima at about 283 nm and 306 nm.

C. Heat 50 mg of the residue obtained in test A, with 2.5 ml of glacial acetic acid, 0.5 ml of hydrochloric acid and 0.2 g of zinc powder on a water-bath for 5 minutes, cool and filter. To the filtrate add 0.05 ml of sodium nitrite solution and add the mixture to 10 ml of a 1 per cent w/v solution of 2-naphthol containing 3 ml of 5 M sodium hydroxide; a bright red precipitate is produced.

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with **silica gel GF254**.

**Mobile phase.** A mixture of 50 volumes of **chloroform**, 50 volumes of **cyclohexane** and 20 volumes of **glacial acetic acid**.

**Test solution.** Shake a quantity of the powdered tablets containing 20 mg of Nicoumalone with 5 ml of **acetone**, centrifuge and use the supernatant liquid.

**Reference solution.** Dilute 1 volume of the test solution to 200 volumes with **acetone**.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and immediately examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Uniformity of content.** Comply with the test stated under Tablets.

Finely crush one tablet, add 30 ml of **methanol**, stir the mixture for 30 minutes and filter through sintered glass, washing the residue with three quantities, each of 15 ml, of **methanol**. To the combined filtrate and washings add 10 ml of 1 M **hydrochloric acid** and sufficient **methanol** to produce 100.0 ml. If necessary, dilute further with a solvent prepared by diluting 1 volume of 1 M hydrochloric acid to 10 volumes with **methanol** to produce a solution containing about 0.001 per cent w/v solution of Nicoumalone. Measure the absorbance of the resulting solution at the maximum at about 306 nm (2.4.7). Calculate the content of C19H15NO6 taking 521 as the specific absorbance at 306 nm.

**Other Tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 10 mg of
Nicoumalone, add 30 ml of methanol, stir the mixture for 30 minutes and filter through sintered-glass, washing the residue with three quantities, each of 15 ml, of methanol. To the combined filtrate and washings add 10 ml of 1 M hydrochloric acid and sufficient methanol to produce 100.0 ml. Dilute 5.0 ml of this solution to 50.0 ml with a solvent prepared by diluting 1 volume of 1 M hydrochloric acid to 10 volumes with methanol and measure the absorbance of the resulting solution at the maximum at about 306 nm (2.4.7). Calculate the content of C₁₉H₁₅NO₆ taking 521 as the specific absorbance at 306 nm.

Storage. Store protected from light and moisture.

Nifedipine

\[
\text{C}_{17}\text{H}_{18}\text{N}_{2}\text{O}_{6} \quad \text{Mol. Wt. 346.3}
\]

Nifedipine is dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylate.

Nifedipine contains not less than 98.0 per cent and not more than 102.0 per cent of C₁₇H₁₈N₂O₆, calculated on the dried basis.

Description. A yellow, crystalline powder; readily affected by exposure to light.

NOTE — Nifedipine, when exposed to daylight and certain wavelengths of artificial light, readily converts to a nitrosophenyl derivative. Exposure to ultraviolet light leads to the formation of a nitrophenyl derivative. Perform the tests and assay in the dark or under long-wavelength light (greater than 420 nm). Use low-actinic glassware.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nifedipine RS or with the reference spectrum of nifedipine.

B. In the test for Related substances, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to nifedipine in the chromatogram obtained with the reference solution.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 60 volumes of cyclohexane and 40 volumes of ethyl acetate.

Test solution. Dissolve 0.1 g of the substance under examination in 100 ml of methanol.

Reference solution. A 0.1 per cent w/v solution of nifedipine RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

D. To 25 mg add 10 ml of a mixture of 5 volumes of ethanol (95 per cent), 3.5 volumes of water and 1.5 volumes of hydrochloric acid and dissolve with gentle heating. Add 0.5 g of granulated zinc and allow to stand for 5 minutes, swirling occasionally. Filter, add 5 ml of a 1 per cent w/v solution of sodium nitrite to the filtrate and allow to stand for 2 minutes. Add 2 ml of a 0.5 per cent w/v solution of ammonium sulphamate, shake vigorously with care and add 2 ml of a 0.5 per cent w/v solution of N-(1-naphthyl) ethylenediamine dihydrochloride; an intense red colour develops which persists for more than 5 minutes.

Tests

Related substances. Determine by liquid chromatography (2.4.14)

Test solution. Dissolve 0.2 g of the substance under examination in 20 ml of methanol and dilute to 50 ml with the mobile phase.

Reference solution (a). Dissolve an accurately weighed quantity of nifedipine RS in sufficient methanol to produce a 1.0 per cent w/v solution and dilute quantitatively with the mobile phase to obtain a 0.4 per cent w/v solution.

Reference solution (b). A 0.04 per cent w/v solution of dimethyl-2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylate RS (nitrophenylpyridine analogue) in methanol.

Reference solution (c). A 0.04 per cent w/v solution of dimethyl-2,6-dimethyl-4-(2-nitrosophenyl)pyridine-3,5-dicarboxylate RS (nitroso-phenylpyridine analogue) in methanol.

Reference solution (d). Mix 1 volume of each of reference solutions (b) and (c) and 0.1 volume of the test solution, dilute to 10 volumes with the mobile phase and then dilute 2 volumes of the resulting solution to 10 volumes with the mobile phase.
Chromatographic system

- a stainless steel column 15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 55 volumes of water, 36 volumes of methanol and 9 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 235 nm,
- a 20 µl loop injector.

Inject reference solution (d). The peaks appear in the order nitrophenylpyridine analogue, nitrosophenylpyridine analogue and nifedipine, which has a retention time of about 15.5 minutes. The test is not valid unless, in the chromatogram obtained with reference solution (d), (a) the resolution factor between the peaks due to the nitrophenylpyridine analogue and the nitrosophenylpyridine analogue is greater than 1.5, (b) the resolution between the peaks due to the nitrophenylpyridine analogue and nifedipine is greater than 1.5, and (c) the height of the peak due to the nitrophenylpyridine analogue is at least 20 per cent of the full-scale deflection.

Inject the test solution and reference solutions (a) and (d) and record the chromatograms for twice the retention time of nifedipine. In the chromatogram obtained with the test solution no secondary peak other than any peaks corresponding to the nitrophenylpyridine analogue and the nitrosophenylpyridine analogue has an area greater than that of the peak due to nifedipine in the chromatogram obtained with reference solution (d) and the areas of any peaks corresponding to the nitrophenylpyridine analogue and the nitrosophenylpyridine analogue are not greater than the areas of the corresponding peaks in the chromatogram obtained with reference solution (d). The total amount of related substances is not greater than 0.3 per cent. Ignore any peak with an area less than 10 per cent of the area of the peak due to nifedipine in the chromatogram obtained with reference solution (d).

**Heavy metals** (2.3.13). 2.0 g complies with limit test for heavy metals, Method B (10 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°C for 2 hours.

**Assay.** Weigh accurately about 0.13 g, dissolve in a mixture of 25 ml of 2-methyl-2-propanol and 25 ml of 1 M perchloric acid and titrate with 0.1 M ceric ammonium sulphate, using 0.1 ml of ferroin solution as indicator until the pink colour is discharged, titrating slowly towards the end-point. Carry out a blank titration.

1 ml of 0.1 M ceric ammonium sulphate is equivalent to 0.01732 g of C_{17}H_{18}N_{2}O_{6}.

**Storage.** Store protected from light.

Nifedipine Capsules

Nifedipine Capsules contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nifedipine, C_{17}H_{18}N_{2}O_{6}.

**NOTE —** Nifedipine, when exposed to daylight and certain wavelengths of artificial light, readily converts to a nitrosophenyl derivative. Exposure to ultraviolet light leads to the formation of a nitrophenyl derivative. Perform the tests and assay in the dark or under long-wavelength light (greater than 420 nm). Use low-actinic glassware.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of equal volumes of ethyl acetate and cyclohexane.

**Test solution.** Transfer a quantity of the contents of the capsules containing 30 mg of Nifedipine into a centrifuge tube containing 0.1 M sodium hydroxide, add 25 ml of dichloromethane, stopper the tube and shake gently for 1 hour. Centrifuge for 10 minutes at 2000 to 2500 rpm. Remove the supernatant aqueous layer by aspiration with a syringe and transfer 5 ml of the clarified lower layer to a suitable vial.

**Reference solution (a).** A 0.12 per cent w/v solution of nifedipine RS in dichloromethane.

**Reference solution (b).** A mixture of equal volumes of test solution and reference solution (a).

Apply to the plate 500 µl of each solution as bands 20 mm by 3 mm. After development, dry the plate in air until the solvent is not detectable and immediately examine in ultraviolet light at 254 nm. The principal band, appearing as a dark blue band, in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution. Spray with a solution prepared in the following manner. Dissolve 3 g of bismuth subnitrate and 30 g of potassium iodide in 10 ml of 3 M hydrochloric acid and dilute with water to 100 ml; dilute 10 ml to 100 ml with 0.3 M hydrochloric acid. In the chromatogram obtained with test solution the principal band, appearing as a compact light orange band against a yellow background, corresponds to that in the chromatogram obtained with reference solution (a). The band obtained with reference solution (b) appears as a single band under both visualisation procedures.

**Tests**

**Uniformity of content.** Comply with the test stated under Capsules.

Transfer the contents of a capsule quantitatively to a 200-ml volumetric flask with the aid of methanol, dilute to volume
with methanol and mix. Complete the Assay beginning at the words “Measure the absorbance...” and calculate the content of C₁₇H₁₈N₂O₆ in the capsule.

**Other Tests.** Comply with the tests stated under Capsules.

**Assay.** Transfer the contents of 5 capsules containing about 50 mg of Nifedipine quantitatively to a 200-ml volumetric flask with the aid of small quantities of methanol. Dilute to volume with methanol and mix. To 20.0 ml add sufficient methanol to produce 100.0 ml and mix. Measure the absorbance of the resulting solution at the maximum at about 350 nm (2.4.7). Calculate the content of C₁₇H₁₈N₂O₆ in the capsules from the absorbance obtained by repeating the operation with a 0.005 per cent w/v solution of nifedipine RS in methanol.

**Storage.** Store protected from light.

---

**Nifedipine Sustained-release Tablets**

Nifedipine Sustained-release Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nifedipine, C₁₇H₁₈N₂O₆.

**NOTE -** Nifedipine, when exposed to daylight and certain wavelengths of artificial light, readily converts to a nitrophenyl derivative. Exposure to ultraviolet light leads to the formation of a nitrophenyl derivative. Perform the tests and the assay in the dark or under long-wavelength light (greater than 420 nm). Use low-actinic glassware.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of equal volumes of ethyl acetate and cyclohexane.

**Test solution.** Transfer a quantity of the contents of the capsules containing 30 mg of Nifedipine into a centrifuge tube containing 0.1 M sodium hydroxide, add 25 ml of dichloromethane, stopper the tube and shake gently for 1 hour. Centrifuge for 10 minutes at 2000 rpm to 2500 rpm. Remove the supernatant aqueous layer by aspiration with a syringe and use 5 ml of the clarified lower layer.

**Reference solution.** A 0.12 per cent w/v solution of nifedipine RS in dichloromethane.

Apply to the plate 500 µl of each solution as bands 20 mm by 3 mm. After development, dry the plate in air until the odour of the solvent is not detectable and immediately examine in ultraviolet light at 254 nm. The principal band, appearing as a dark blue band, in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution. Spray with a solution prepared in the following manner. Dissolve 3 g of bismuth subnitrate and 30 g of potassium iodide in 10 ml of 3 M hydrochloric acid and dilute to 100 ml with water; dilute 10 ml of this solution to 100 ml with 0.3 M hydrochloric acid. In the chromatogram obtained with the test solution the principal band, appearing as a compact light orange band against a yellow background, corresponds to that in the chromatogram obtained with reference solution.

**Tests**

**Dissolution (2.5.2)**

A. Apparatus No. 1

Medium. 900 ml of 0.1 M hydrochloric acid

Speed and time. 150 rpm and 120 minutes.

Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate, suitably diluted with the dissolution medium, if necessary, at the maximum at about 340 nm (2.4.7).

Calculate the content of C₁₇H₁₈N₂O₆ in the medium from the absorbance obtained from a solution of known concentration of nifedipine RS in the same medium.

D. Not less than 25 per cent and not more than 45 per cent of the stated amount of C₁₇H₁₈N₂O₆.

B. Apparatus No. 1

Medium. 900 ml of phosphate buffer pH 6.8

Speed and time. 150 rpm and 6 hours.

Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate, suitably diluted with the dissolution medium, if necessary, at the maximum at about 340 nm (2.4.7).

Calculate the content of C₁₇H₁₈N₂O₆ in the medium from the absorbance obtained from a solution of known concentration of nifedipine RS in the same medium.

D. Not less than 60 per cent of the stated amount of C₁₇H₁₈N₂O₆.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 25 mg of Nifedipine, disperse in methanol, shake and dilute to 100.0 ml with methanol, filter. Dilute 20.0 ml of the filtrate to 100.0 ml with methanol. Measure the absorbance of the resulting solution at the maximum at about 350 nm (2.4.7). Calculate the content of C₁₇H₁₈N₂O₆ from the absorbance obtained with a 0.005 per cent w/v solution of nifedipine RS in methanol.

**Storage.** Store protected from light and moisture.
Nifedipine Tablets

Nifedipine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nifedipine, C_{17}H_{18}N_{2}O_{6}. The tablets may be coated.

**NOTE —** Nifedipine, when exposed to daylight and certain wavelengths of artificial light, readily converts to a nitrosophenyl derivative. Exposure to ultraviolet light leads to the formation of a nitrophenyl derivative. Perform the tests and assay in the dark or under long-wavelength light (greater than 420 nm). Use low-actinic glassware.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of equal volumes of ethyl acetate and cyclohexane.

**Test solution.** Transfer a quantity of the powdered tablets containing 30 mg of Nifedipine to a centrifuge tube containing 20 ml of 0.1 M sodium hydroxide, add 25 ml of dichloromethane, stopper the tube and shake gently for 1 hour. Centrifuge for 10 minutes at 2000 to 2500 rpm. Remove the supernatant aqueous layer by aspiration with a syringe and transfer 5.0 ml of the clarified lower layer to a suitable vial.

**Reference solution (a).** A 0.12 per cent w/v solution of nifedipine RS in dichloromethane.

**Reference solution (b).** A mixture of equal volumes of the test solution and reference solution (a).

Apply to the plate 500 µl of each solution as bands 20 mm by 3 mm. After development, dry the plate in air until the solvent is not detectable and immediately examine in ultraviolet light at 254 nm. The principal band, appearing as a dark blue band, in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). Spray with a solution prepared in the following manner. Dissolve 3 g of bismuth subnitrate and 30 g of potassium iodide in 10 ml of 3 M hydrochloric acid and dilute with water to 100 ml; dilute 10 ml to 100 ml with 0.3 M hydrochloric acid. In the chromatogram obtained with the test solution the principal band, appearing as a compact light orange band against a yellow background, corresponds to that in the chromatogram obtained with reference solution (a). The band obtained with reference solution (b) appears as a single band under both visualisation procedures.

**Tests**

**Uniformity of content.** Comply with the test stated under Tablets.

Shake one tablet with methanol in a 200-ml volumetric flask, dilute to volume with methanol, mix and filter. Complete the Assay beginning at the words “Measure the absorbance....” and calculate the content of C_{17}H_{18}N_{2}O_{6} in the tablet.

**Other Tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 50 mg of Nifedipine into a 200-ml volumetric flask. Dissolve with the aid of 50 ml of methanol. Dilute to volume with methanol, mix and filter. Dilute 20 ml of the filtrate to 100 ml with methanol and mix. Measure the absorbance of the resulting solution at the maximum at about 350 nm (2.4.7). Calculate the content of C_{17}H_{18}N_{2}O_{6} from the absorbance obtained by repeating the operation with a 0.005 per cent w/v solution of nifedipine RS in methanol.

**Storage.** Store protected from light and moisture.

**Nikethamide**

Nikethamide is N,N-diethylpyridine-3-carboxamide.

Nikethamide contains not less than 99.0 per cent and not more than 101.0 per cent of C_{10}H_{14}N_{2}O, calculated on the anhydrous basis.

**Description.** A colourless or slightly yellowish, oily liquid or crystalline mass; odour, slight and characteristic.

**Identification**

**Test A may be omitted if tests B, C and D are carried out. Tests C and D may be omitted if tests A and B are carried out.**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nikethamide RS or with the reference spectrum of nikethamide.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution shows an absorption maximum only at about 263 nm; absorbance at about 263 nm, about 0.57.

C. Heat 0.1 g with 1 ml of 2 M sodium hydroxide; diethylamine, recognisable by its odour, is evolved progressively; the fumes turn red litmus paper blue.

D. To 2 ml of a 0.1 per cent w/v solution add 2 ml of cyanogen bromide solution and 3 ml of a 2.5 per cent w/v solution of aniline and mix; a yellow colour is produced.
Tests

**Appearance of solution.** The substance, in liquid form or liquefied by gentle heating, is clear (2.4.1), and not more intensely coloured than reference solution YS5 (2.4.1).

**pH (2.4.24).** 6.0 to 7.8, determined in a 25.0 per cent w/v solution.

**Congealing temperature (2.4.10).** 23° to 24.5°.

**Refractive index (2.4.27).** 1.522 to 1.526.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 75 volumes of chloroform and 25 volumes of 1-propanol.

**Test solution.** Dissolve 0.4 g of the substance under examination in 10 ml of methanol.

**Reference solution (a).** A 0.04 per cent w/v solution of ethylnicotinamide RS in methanol.

**Reference solution (b).** A 0.004 per cent w/v solution of ethylnicotinamide RS in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any spot corresponding to ethylnicotinamide in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and any other secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (b).

**Heavy metals (2.3.13).** 2.0 g complies with limit test for heavy metals, Method B (10 ppm).

**Sulphated ash (2.3.18).** Not more than 0.1 per cent.

**Water (2.3.43).** Not more than 0.3 per cent, determined on 2.0 g.

**Assay.** Weigh accurately about 0.15 g, dissolve in 20 ml of anhydrous glacial acetic acid and 5 ml of acetic anhydride. Titratre with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01782 g of C_{10}H_{14}N_{2}O.

**Storage.** Store protected from light.

Nikethamide Injection

Nikethamide Injection is a sterile solution containing 25 per cent w/v solution of Nikethamide in Water for Injections.

Nikethamide Injection contains not less than 24.0 per cent and not more than 26.0 per cent w/v solution of nikethamide, C_{10}H_{14}N_{2}O.

Identification

A. Make 1 ml alkaline with 5 M sodium hydroxide, extract with 5 ml of dichloromethane and evaporate the solvent.

On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nikethamide RS or with the reference spectrum of nikethamide.

B. Gives a voluminous precipitate with alkaline potassium mercuri-iodide solution and a greyish-brown flocculent precipitate with tannic acid solution. Gives no precipitate with iodine solution or with potassium mercuri-iodide solution.

C. Heat 1 ml with 0.2 g of sodium hydroxide; diethylamine, recognisable by its odour, is evolved.

Tests

**pH (2.4.24).** 6.0 to 8.0.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 75 volumes of chloroform and 25 volumes of 1-propanol.

**Test solution.** Dilute 1 ml of the injection to 5 ml with methanol.

**Reference solution (a).** A 0.05 per cent w/v solution of ethylnicotinamide RS in methanol.

**Reference solution (b).** A 0.005 per cent w/v solution of ethylnicotinamide RS in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any spot corresponding to ethylnicotinamide in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and any other secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (b).

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Dilute 5.0 ml to 500.0 ml with water. To 5.0 ml of the solution add 5 ml of 1 M hydrochloric acid and sufficient water to produce 500.0 ml. Measure the absorbance of the resulting solution at the maximum at about 263 nm (2.4.7). Calculate the content of C_{10}H_{14}N_{2}O taking 282 as the specific absorbance at 263 nm.

**Storage.** Store protected from light, in single dose containers.
Nitrazepam

\[ \text{C}_{15}\text{H}_{11}\text{N}_{3}\text{O}_{3} \quad \text{Mol. Wt. 281.3} \]

Nitrazepam is 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one.

Nitrazepam contains not less than 99.0 per cent and not more than 101.0 per cent of \( \text{C}_{15}\text{H}_{11}\text{N}_{3}\text{O}_{3} \), calculated on the dried basis.

**Description.** A yellow, crystalline powder; odourless or almost odourless.

**Identification.**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nitrazepam RS or with the reference spectrum of nitrazepam.

B. Carry out the following procedure in subdued light.

When examined in the range 230 nm to 360 nm (2.4.7), a freshly prepared 0.0005 per cent w/v solution in a 0.5 per cent w/v solution of sulphuric acid in methanol shows an absorption maximum only at about 280 nm; absorbance at about 280 nm, about 0.45.

C. Dissolve 10 mg in 1 ml of methanol, warming if necessary, and add 0.05 ml of 2 M sodium hydroxide; an intense yellow colour is produced.

D. Dissolve 20 mg in a mixture of 5 ml of hydrochloric acid and 10 ml of water, boil for 5 minutes, cool and add 2 ml of a 0.1 per cent w/v solution of sodium nitrite. Allow to stand for 1 minute, add 1 ml of a 0.5 per cent w/v solution of sulphamic acid, mix, allow to stand for 1 minute, add 1 ml of a 0.1 per cent w/v solution of \( \text{N-(1-naphthyl)ethylenediamine dihydrochloride} \); a red colour is produced.

**Tests.**

**Related substances and decomposition products.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 85 volumes of nitromethane and 15 volumes of ethyl acetate.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of acetone.

Reference solution. A 0.002 per cent w/v solution of the substance under examination in acetone.

Apply to the plate 10 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Heavy metals (2.3.13).** 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash (2.3.18).** Not more than 0.1 per cent.

**Loss on drying (2.4.19).** Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105° for 4 hours.

**Assay.** Weigh accurately about 0.25 g, dissolve in 50 ml of acetic anhydride. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02813 g of \( \text{C}_{15}\text{H}_{11}\text{N}_{3}\text{O}_{3} \).

**Storage.** Store protected from light and moisture.

Nitrazepam Tablets

Nitrazepam Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nitrazepam, \( \text{C}_{15}\text{H}_{11}\text{N}_{3}\text{O}_{3} \).

**Identification.**

Carry out the following procedure in subdued light.

A. When examined in the range 230 nm to 360 nm (2.4.7), the final solution obtained in the Assay shows an absorption maximum only at about 280 nm.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 100 volumes of chloroform and 10 volumes of methanol.

Test solution. Shake a quantity of the powdered tablets with sufficient methanol to produce a solution containing 5 mg of Nitrazepam per ml, allow to settle and decant the supernatant liquid.

Reference solution. A 0.5 per cent w/v solution of nitrazepam RS in methanol.

Apply to the plate 2 µl of each solution. After development, dry the plate in air, spray it with ethanolic sulphuric acid (10 per cent w/v), heat at 105° for 10 minutes and examine in
ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

C. To a quantity of the powdered tablets containing 5 mg of Nitrazepam add 5 ml of hydrochloric acid and 10 ml of water, heat on a water-bath for 15 minutes, filter and cool. To the clear filtrate add 1 ml of a 0.1 per cent w/v solution of sodium nitrite, allow to stand for 3 minutes and add 1 ml of a 0.5 per cent w/v solution of sulphamic acid. Allow to stand for 3 minutes and add 1 ml of a 0.1 per cent w/v solution of N-(1-naphthyl) ethylenediamine dihydrochloride; a red colour is produced.

Tests

Related substances and decomposition products. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 40 volumes of nitromethane, 40 volumes of toluene and 20 volumes of chloroform.

Test solution. Shake a quantity of the powdered tablets containing 40 mg of Nitrazepam with 25 ml of chloroform, filter, carefully evaporate the filtrate to dryness and dissolve the residue in 2 ml of chloroform.

Reference solution. Dilute 1 volume of the test solution to 200 volumes with chloroform.

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Uniformity of content. Comply with the test stated under Tablets.

NOTE — Carry out the following procedure in subdued light.

Powder 1 tablet, add 5 ml of water, mix and allow to stand for 15 minutes protected from light. Add 70 ml of a 0.5 per cent v/v solution of hydrochloric acid in methanol, shake for 15 minutes protected from light, add sufficient of the hydrochloric acid solution to produce 100.0 ml and filter. Dilute 10.0 ml of the filtrate to 100.0 ml with the same solvent and measure the absorbance of the resulting solution immediately at the maximum at about 280 nm (2.4.7). Calculate the content of C₁₅H₁₁N₃O₃ taking 910 as the specific absorbance at 280 nm.

Storage. Store protected from light and moisture.

Nitrofurantoin

\[
\begin{align*}
\text{O}_2\text{N} & \quad \text{O} \\
\text{C}_8\text{H}_6\text{N}_4\text{O}_5 & \quad \text{Mol. Wt. 238.2 (anhydrous)} \\
\text{C}_8\text{H}_6\text{N}_4\text{O}_5\cdot\text{H}_2\text{O} & \quad \text{Mol. Wt. 256.2 (hydrous)}
\end{align*}
\]

Nitrofurantoin is 1-(5-nitrofurfurylideneamino)imidazolidine-2,4-dione. It is anhydrous or contains one molecule of water of hydration.

Nitrofurantoin contains not less than 98.0 per cent and not more than 102.0 per cent of C₈H₆N₄O₅, calculated on the dried basis.

Description. Lemon yellow crystals or a crystalline powder; odourless or almost odourless.

Identification

Carry out the following test in subdued light.

A. When examined in the range 230 nm to 400 nm (2.4.7), the final solution obtained in the Assay shows absorption maxima at about 266 nm and 367 nm; the ratio of the absorbance at the maximum at about 367 nm to that at the maximum at about 266 nm is 1.36 to 1.42.

B. To 1 ml of a 0.1 per cent w/v solution in dimethylformamide add 0.1 ml of 0.5 M ethanolic potassium hydroxide; a brown colour develops.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 90 volumes of nitromethane and 10 volumes of methanol.

Test solution. Dissolve 0.25 g of the substance under examination in minimum volume of dimethylformamide and dilute to 10 ml with acetone.
Nitrofurantoin Tablets

Nitrofurantoin Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nitrofurantoin, C₈H₆N₄O₅.

Identification

Carry out the following procedure in subdued light.

A. When examined in the range 230 nm to 400 nm (2.4.7), the final solution obtained in the Assay shows absorption maxima at about 266 nm and 367 nm.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 90 volumes of nitromethane and 10 volumes of methanol.

Test solution. Shake a quantity of the powdered tablets containing 0.1 g of Nitrofurantoin with 10 ml of a mixture of 9 volumes of acetone and 1 volume of dimethylformamide and filter.

Nitrofurazone

Nitofural

C₈H₆N₄O₄ Mol. Wt. 198.1

Nitrofurazone is 5-nitro-2-furaldehyde semicarbazone.

Nitrofurazone contains not less than 97.0 per cent and not more than 103.0 per cent of C₈H₆N₄O₄, calculated on the dried basis.

Description. A yellow to brownish-yellow, crystalline powder; odourless or almost odourless.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nitrofurazone RS or with the reference spectrum of nitrofurazone.

B. Dissolve 1 mg in 1 ml of dimethylformamide and add 0.05 ml of 1 M ethanolic potassium hydroxide; a ruby red colour is produced.
Tests

**pH** (2.4.24). 5.0 to 7.0, determined in the filtrate obtained by shaking 1.0 g with 100 ml of carbon dioxide-free water and filtering.

**Related substances.** Carry out the following procedure in subdued light.

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 95 volumes of toluene and 5 volumes of dioxan.

**Test solution.** Dissolve 0.1 g of the substance under examination in 10 ml of a mixture of equal volumes of acetone and dimethylformamide.

**Reference solution (a).** A 0.002 per cent w/v solution of 5-nitrofurfurylidene azine RS in a mixture of equal volumes of acetone and dimethylformamide.

**Reference solution (b).** A 0.01 per cent w/v solution of nitrofurfural diacetate RS in a mixture of equal volumes of acetone and dimethylformamide.

Apply to the plate 10 µl of each solution. After development, dry the plate in air, heat it at 105° for 5 minutes and spray with phenylhydrazine hydrochloride solution. In the chromatogram obtained with the test solution any spots corresponding to 5-nitrofurfurylidene azine and nitrofurfural diacetate are not more intense than the spots in the chromatograms obtained with reference solutions (a) and (b) respectively.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°.

**Assay.** Carry out the following procedure in subdued light.

Weigh accurately about 60 mg, add 20.0 ml of dimethylformamide, swirl to dissolve and add sufficient water to produce 500.0 ml. Dilute 5.0 ml of the solution to 100.0 ml with water and mix. Measure the absorbance of the resulting solution at the maximum at about 375 nm (2.4.7). Calculate the content of \( \text{C}_3\text{H}_6\text{N}_4\text{O}_4 \) taking 822 as the specific absorbance at 375 nm.

**Storage.** Store protected from light and moisture.

**Nitrous Oxide**

\( \text{N}_2\text{O} \)  

Mol. Wt. 44.0

Nitrous Oxide contains not less than 98.0 per cent v/v of \( \text{N}_2\text{O} \).

**NOTE —** Carry out the following tests on a full cylinder from which no gas has been withdrawn. The cylinder from which the gas is taken should be kept at room temperature for not less than 6 hours before carrying out the tests. Keep the cylinder in the vertical position with the outlet valve uppermost and deliver the gas at a rate of 4 litres per hour, unless otherwise directed. The test for carbon monoxide should be carried out on the first portion of gas drawn from the cylinder and that for nitric oxide and nitrogen dioxide immediately thereafter.

**Description.** A colourless gas; odourless.

**Identification**

A. A glowing splinter of wood bursts into flame on contact with the gas.

B. Shake with alkaline pyrogallol solution; the gas being examined is not absorbed and the solution does not become brown.

**Tests**

**Acidity or alkalinity.** Use hermetically-closed, flat-bottomed, glass cylinders with dimensions such that 50 ml of liquid reaches a height of 12 to 14 cm, fitted with an outlet tube and with an inlet tube with an orifice of 1 mm in internal diameter reaching to within 2 mm of the bottom of the cylinder. For solution (1) pass 2.0 litres of the gas under examination through a mixture of 0.1 ml of 0.01 M hydrochloric acid and 50 ml of carbon dioxide-free water. For solution (2) use 50 ml of carbon dioxide-free water. For solution (3) add 0.2 ml of 0.01 M hydrochloric acid to 50 ml of carbon dioxide-free water. To each solution add 0.1 ml of a 0.02 per cent w/v solution of methyl red in ethanol (70 per cent). The intensity of the colour of solution (1) is between those of solutions (2) and (3).

**Arsine and phosphine.** Through a mercuric chloride paper attached to a glass tube as in the limit test for arsenic (2.3.10), pass 2.0 litres of the gas; no visible stain is produced.

**Carbon dioxide.** Not more than 300 ppm v/v determined by the following method. Use the apparatus described in the test for Acidity or alkalinity. Pass 1.0 litre through 50 ml of clear barium hydroxide solution. Any turbidity produced in the resulting solution is not more than that obtained in a reference solution prepared at the same time by adding 1 ml of a 0.11 per cent w/v solution of sodium bicarbonate in carbon dioxide-free water to 50 ml of barium hydroxide solution.

**Carbon monoxide.** Not more than 10 ppm v/v, determined by the following method. Connect in series a U-tube containing silica gel impregnated with chromium trioxide, a drechsel bottle containing 100 ml of a 40 per cent w/v solution of potassium hydroxide, a U-tube containing pellets of potassium hydroxide, a U-tube containing phosphorus pentoxide dispersed on previously granulated, fused pumice, a tube containing iodine pentoxide in granules, previously dried at 200° and kept at a temperature of 120°, packed in 1-cm...
columns separated by 1-cm columns of glass wool giving an effective length of 5 cm, and a flask containing 2.0 ml of 1 M potassium iodide and 0.15 ml of starch solution.

Flush the apparatus with 5.0 litres of carbon dioxide-free air and, if necessary, discharge the blue colour in the iodide solution by adding a small quantity of freshly prepared 0.002 M sodium thiosulphate. Continue flushing until not more than 0.045 ml of 0.002 M sodium thiosulphate is required after passing 5.0 litres of carbon dioxide-free air. Pass 5.0 litres of the gas under examination through the apparatus and flush the last traces of liberated iodine into the reaction flask by passing through the apparatus 1.0 litre of carbon monoxide-free air. Titrate the liberated iodine with 0.002 M sodium thiosulphate. Carry out a blank titration under the same conditions, using 5.0 litres of carbon dioxide-free air. The difference between the volumes of 0.002 M sodium thiosulphate used in the two titrations is not greater than 1.0 ml.

Halogens and hydrogen sulphide. Pass a volume containing 1.0 litre measured at 25° and at 101.3 kPa through a mixture of 100 ml of water and 1 ml of silver nitrate solution; neither opalescence nor darkening is produced.

Nitric oxide and nitrogen dioxide. Not more than 2 ppm v/v in both the liquid and gaseous phases, determined by the following method. Use two of the cylinders described in the test for Acidity or alkalinity connected in series. Examine separately both the liquid and gaseous phases of the gas under examination. To obtain the liquid phase invert the cylinder. The liquid vaporises on leaving the valve.

For solution A dissolve 1 g of sulphanilic acid in a mixture of 10 ml of glacial acetic acid and 180 ml of water. For solution B dissolve 0.2 g of N-(1-naphthyl) ethylenediamine dihydrochloride in 10 ml of a 50 per cent v/v solution of glacial acetic acid, heating gently, and dilute to 200 ml with water. Mix 9 volumes of solution A with 1 volume of solution B (reagent A).

In the first cylinder place 15 ml of a solution containing 2.5 per cent w/v solution of potassium permanganate and 1.2 per cent v/v of sulphuric acid (96 per cent). Place 20 ml of reagent A in the second cylinder and connect the outlet tube of the first cylinder to the inlet tube of the second cylinder. Pass 2.5 litres of the gas under examination through the reagents at a rate of 15 litres per hour. Prepare a reference solution by adding 0.25 ml of a 0.00616 per cent v/v solution of sodium nitrite to 20 ml of reagent A. Allow both the sample and reference solutions to stand for 10 minutes. For both liquid and gaseous phases, any red colour in the sample solution is not more intense than that in the reference solution.

Oxidising substances. Pass a volume containing 2.0 litres measured at 25° and at 101.3 kPa through a freshly prepared solution of 0.5 g of soluble starch and 0.5 g of potassium iodide in 100 ml of water containing 0.05 ml of glacial acetic acid; the colour of the liquid is not changed.

Water. Pass a measured quantity at a rate of 6 litres per hour through an absorption tube containing magnesium perchlorate; the increase in weight of the tube does not exceed 2 mg per litre of gas, the initial and final weighings of the tube being made when the air in it has been displaced by the nitrous oxide.

Assay. Carry out the assay of nitrous oxide (2.3.32), using 100 ml of the gas under examination. Use a cylinder of the gas under examination from which at least 1 per cent w/w of the contents have been removed.

Storage. Store under pressure in metal cylinders of the type conforming to the appropriate safety regulations and at a temperature not exceeding 37°.

Labelling. The cylinder is painted blue and carries a label stating “Nitrous Oxide”. In addition, “Nitrous Oxide” or the symbol “N₂O” should be stencilled in paint on the shoulder of the cylinder.

Noradrenaline Bitartrate
Noradrenaline Acid Tartrate; Levarterenol Bitartrate; Norepinephrine Bitartrate

C₈H₁₁NO₃·C₄H₆O₆·H₂O Mol. Wt. 337.3
Noradrenaline Bitartrate is (R)-2-amino-1-(3,4-dihydroxyphenyl)ethanol hydrogen (2R,3R)-tartrate monohydrate.
Noradrenaline Bitartrate contains not less than 98.5 per cent and not more than 101.0 per cent of C₈H₁₁NO₃·C₄H₆O₆, calculated on the anhydrous basis.

Description. A white or almost white, crystalline powder; odourless. It gradually darkens on exposure to air and light.

Identification
Test A may be omitted if tests B, C, D, E and F are carried out. Tests C, D, E may be omitted if tests A, B and F are carried out.
A. Dissolve 0.2 g in 2 ml of water containing about 10 mg of sodium sulphite and add sufficient dilute ammonia solution to give an alkaline reaction. Keep the mixture at about 4° for 1 hour and filter.
On the residue (residue R) determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with noradrenaline acid tartrate RS treated in the same manner.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.005 per cent w/v solution in 0.01 M hydrochloric acid shows an absorption maximum at about 279 nm; absorbance at about 279 nm, about 0.40.

C. Wash residue R obtained in test A with three quantities, each of 2 ml, of water, followed by 5 ml of ethanol (95 per cent) and 5 ml of ether and dry the precipitate under pressure of 1.5 to 2.5 kPa for 3 hours. The specific optical rotation (2.4.22), determined in a 2.0 per cent w/v solution of the dried precipitate in 0.5 M hydrochloric acid is –44° to –48°.

D. To 1 ml of a 1 per cent w/v solution, add 0.05 ml of ferric chloride solution; an intense green colour is produced. Add, drop by drop, sodium bicarbonate solution; the colour changes to blue and then red.

E. To 1 ml of a 0.1 per cent w/v solution add 10 ml of phthalate buffer pH 3.6, add 1 ml of 0.05 M iodine, set aside for 5 minutes and add 2 ml of 0.1 M sodium thiosulphate; not more than a faint red colour is produced. Repeat the test using buffer solution pH 6.6 instead of phthalate buffer pH 3.6; a strong reddish violet colour is produced (distinction from adrenaline and isoprenaline).

F. The filtrate obtained in test A gives the reactions of tartrates (2.3.1).

**Tests**

**Appearance of solution.** A freshly prepared 2.0 per cent w/v solution is clear (2.4.1), and not more intensely coloured than reference solution BYS5 (2.4.1).

**pH** (2.4.24). 3.5 to 5.0, determined in a 1.0 per cent w/v solution.

**Melting range** (2.4.21). 100° to 106°, with decomposition.

**Adrenaline.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 50 volumes of acetone, 50 volumes of dichloromethane and 0.5 volume of anhydrous formic acid.

**Prepare the following solutions immediately before use.**

**Test solution.** Dissolve 0.25 g of the substance under examination in 10 ml of water.

**Reference solution (a).** A 0.125 per cent w/v solution of adrenaline tartrate RS in water.

**Reference solution (b).** A 0.025 per cent w/v solution of adrenaline tartrate RS in water.

**Reference solution (c).** A mixture of equal volumes of the test solution and reference solution (b).

Apply to the plate 6 µl of each of test solution, reference solutions (a) and (b) and 12 µl of reference solution (c) as bands 20 mm by 2 mm. Allow the applied bands to dry in air, spray them with a saturated solution of sodium bicarbonate, allow to dry in air and spray the bands twice with acetic anhydride, drying between the two sprayings. Heat the plate at 50° for 90 minutes and develop the chromatograms. After removal of the plate, allow it to dry in air and spray with a freshly prepared mixture of 8 volumes of methanol, 2 volumes of ethylenediamine and 2 volumes of a 0.5 per cent w/v solution of potassium ferricyanide. Dry the plate at 60° for 10 minutes and examine in ultraviolet light at 254 and 365 nm. In the chromatogram obtained with the test solution any band with a slightly higher Rf value than the principal band is not more intense than the corresponding band in the chromatogram obtained with reference solution (b). The chromatogram obtained with reference solution (c) shows a clearly separated band corresponding to the most intense band in the chromatogram obtained with reference solution (a) at a higher Rf value than the most intense band.

**Noradrenaline.** Absorbance of a 0.2 per cent w/v solution in 0.01 M hydrochloric acid at 310 nm, not more than 0.40 (2.4.7).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Water** (2.3.43). 4.5 to 5.8 per cent, determined on 0.5 g.

**Assay.** Weigh accurately about 0.6 g, dissolve in 50 ml of anhydrous glacial acetic acid, warming if necessary. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator, until a bluish green colour is obtained. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.03193 g of C9H11NO3.C4H6O6.

**Storage.** Store protected from moisture.

**Noradrenaline Bitartrate Injection**

Noradrenaline Acid Tartrate Injection; Noradrenaline Injection; Levarterenol Bitartrate Injection; Norepinephrine Bitartrate Injection

Noradrenaline Bitartrate Injection is a sterile solution of Noradrenaline Bitartrate. It is prepared by diluting Sterile Noradrenaline Concentrate to 250 times its volume with Sodium Chloride and Dextrose Injection or with Dextrose Injection (5 per cent w/v) immediately before use.

Noradrenaline Bitartrate Injection contains in 1 ml 8 µg of Noradrenaline Bitartrate equivalent to approximately 4 µg of noradrenaline.

**Tests**

**Other Tests.** Complies with the tests stated under Parenteral Preparations (Injections).
Sterile Noradrenaline Concentrate

Sterile Noradrenaline Concentrate is a sterile, isotonic solution containing 0.2 per cent w/v of Noradrenaline Bitartrate in Water for Injections.

Sterile Noradrenaline Concentrate contains not less than 0.18 per cent and not more than 0.23 per cent w/v of noradrenaline bitartrate, C₈H₁₁NO₃.C₄H₆O₆.H₂O.

Identification

Mix 0.5 ml with 10 ml of phthalate buffer pH 3.6, add 1 ml of 0.05 M iodine, allow to stand for 5 minutes and add 2 ml of 0.1 M sodium thiosulphate; not more than a very faint red colour is produced. Repeat the test using phosphate buffer pH 6.6 instead of phthalate buffer pH 3.6; a strong reddish violet colour is produced.

Tests

pH (2.4.24). 3.0 to 4.6.

Other Tests. Complies with the tests stated under Parenteral Preparations (Concentrated Solutions for Injection).

Assay. Dilute 5.0 ml to 200.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 279 nm (2.4.7). Calculate the content of C₈H₁₁NO₃.C₄H₆O₆.H₂O taking 80 as the specific absorbance at 279 nm.

Storage. Store protected from light, in single dose containers.

Labelling. The label states (1) “Sterile Noradrenaline Concentrate”; (2) that 1 volume of the solution diluted to 250 volumes with Sodium Chloride and Dextrose Injection or with Dextrose Injection (5 per cent w/v) produces Noradrenaline Bitartrate Injection, which must be used immediately after preparation; (3) that if the solution is brown it should not be used.

Norethisterone

Norethindrone

Norethisterone is 17β-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one.

Norethisterone contains not less than 98.0 per cent and not more than 102.0 per cent of C₂₀H₂₆O₂, calculated on the dried basis.

Description. A white or yellowish-white, crystalline powder; odourless.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with norethisterone RS or with the reference spectrum of norethisterone.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Solvent mixture. A mixture of 90 volumes of acetone and 10 volumes of formamide.

Mobile phase. A mixture of 40 volumes of hexane and 10 volumes of dioxan.

Test solution. Dissolve 10 mg of the substance under examination in 10 ml of chloroform.

Reference solution. Dissolve 10 mg of norethisterone RS in 10 ml of chloroform.

Place the dry plate in a tank containing a shallow layer of the solvent mixture, allow the solvent mixture to ascend to the top, remove the plate from the tank and allow the solvent to evaporate. Use within 2 hours, with the flow of the mobile phase in the direction in which the aforementioned treatment was done.

Apply to the plate 2 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air, allow the solvent to evaporate, heat at 120° for 15 minutes and spray the hot plate with ethanolic sulphuric acid (20 per cent v/v). Heat at 120° for a further 10 minutes, allow to cool and examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to and exhibits fluorescence similar to that in the chromatogram obtained with the reference solution.

C. Dissolve about 2 mg in 2 ml of ethanol (95 per cent) and add 1 ml of a 1 per cent w/v solution of butylated hydroxytoluene in ethanol (95 per cent) and 2 ml of 1 M sodium hydroxide. Heat in a water-bath for 30 minutes and cool; a yellowish pink colour is produced.

Tests

Appearance of solution. Dissolve 0.2 g in sufficient dioxan to produce 10 ml (solution A). The solution is clear (2.4.1), and not more intensely coloured than reference solution YS6 (2.4.1).

Specific optical rotation (2.4.22). –33.0° to –37.0°, determined in a solution prepared by diluting 5.0 ml of solution A to 10.0 ml with dioxan.

Light absorption. Dissolve 10 mg in sufficient ethanol (95 per cent) to produce 100 ml, dilute 10 ml of the solution to 100 ml with methanol (98 per cent). Absorbance of the
resulting solution at the maximum at about 240 nm, 0.55 to 0.59 (2.4.7).

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 90 volumes of chloroform and 10 volumes of acetone.

**Test solution.** Dissolve 0.5 g of the substance under examination in 100 ml of the mobile phase.

**Reference solution (a).** A 0.0025 per cent w/v solution of the substance under examination in the mobile phase.

**Reference solution (b).** A solution containing 0.025 per cent w/v each of the substance under examination and ethisterone RS in the mobile phase.

Apply to the plate 10 µl of each solution. After development, dry the plate in air, spray with ethanolic sulphuric acid (20 per cent v/v), heat at 105° for 5 minutes and examine in ultraviolet light at 365 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a). The chromatogram obtained with reference solution (b) shows two clearly separated spots of equal intensities.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105° for 3 hours.

**Assay.** Weigh accurately about 0.4 g, dissolve in 40 ml of tetrahydrofuran, add 10 ml of a 10 per cent w/v solution of silver nitrate and titrate with 0.1 M sodium hydroxide using 2 ml of bromocresol green solution as indicator. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of sodium hydroxide required.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.02984 g of C₂₀H₂₆O₂.

**Storage.** Store protected from light and moisture.

---

**Norethisterone Tablets**

Norethindrone Tablets

Norethisterone Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of norethisterone, C₂₀H₂₆O₂.

**Identification**

Place a quantity of the powdered tablets containing 25 mg of Norethisterone on a small filter, wash with three quantities, each of 5 ml, of light petroleum (60° to 80°) and discard the washings. Extract the residue with 15 ml of chloroform, evaporate the extract to dryness and recrystallise from aqueous methanol. The residue complies with the following test.

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Solvent mixture.** A mixture of 90 volumes of acetone and 10 volumes of 1,2-propanediol.

**Mobile phase.** A mixture of 40 volumes of cyclohexane and 10 volumes of toluene.

**Test solution.** Dissolve 25 mg of the substance under examination in 10 ml of the solvent mixture.

**Reference solution (a).** Dissolve 25 mg of norethisterone RS in 10 ml of the solvent mixture.

**Reference solution (b).** Mix equal volumes of the test solution and reference solution (a).

Place the dry plate in a tank containing a shallow layer of the solvent mixture, allow the solvent mixture to ascend to the top, remove the plate from the tank and allow the solvent to evaporate. Use within 2 hours, with the flow of the mobile phase in the direction in which the aforementioned treatment was done.

Apply to the plate 2 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air, spray with ethanolic sulphuric acid (20 per cent v/v), heat at 120° for a further 10 minutes, allow to cool and examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

**Tests**

**Uniformity of content.** Comply with the test stated under Tablets.

Powder one tablet and warm with about 75 ml of ethanol (95 per cent) with stirring. Cool, transfer to a 100-ml volumetric flask and dilute to volume with ethanol (95 per cent). Centrifuge a few ml of the mixture until a clear supernatant liquid is obtained. Dilute 10.0 ml of the supernatant liquid to 50.0 ml with ethanol (95 per cent) and mix. Measure the absorbance of the resulting solution at the maximum at about 240 nm (2.4.7). Calculate the content of C₂₀H₂₆O₂ in the tablet taking 570 as the specific absorbance at 240 nm.

**Other Tests.** Comply with the tests stated under Tablets.
Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.2 g of Norethisterone and transfer to a glass column closed at the bottom with a small piece of absorbent cotton. The glass column consists of a piece of glass tubing (150 mm x 10 mm) tapered at the bottom and sealed at the top to another piece of glass tubing (150 mm x 25 mm). Place a small piece of absorbent cotton on top of the powder, pass 200 ml of light petroleum (60° to 80°) through the column and discard the effluent. Extract the residue with 200 ml of chloroform, evaporate the chloroform from the extract and dry the residue at 105° for 2 hours. Allow to cool, dissolve in 40 ml of tetrahydrofuran, add 10 ml of a 10 per cent w/v solution of silver nitrate. Titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.4.25). Repeat the operation without the substance under examination. The difference between the titrations represents the amount of sodium hydroxide required.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.02984 g of C₂₀H₂₆O₂.

Storage. Store protected from light and moisture.

Norfloxacin

Norfloxacin is 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid.

Norfloxacin contains not less than 99.0 per cent and not more than 101.0 per cent of C₁₆H₁₈FN₃O₃, calculated on the dried basis.

Description. A white to pale yellow, crystalline powder.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with norfloxacin RS or with the reference spectrum of norfloxacin.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.0005 per cent w/v solution in 0.1 M sodium hydroxide shows an absorption maximum at about 273 nm.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G, previously washed with methanol and dried.

Mobile phase. A mixture of 40 volumes of dichloromethane, 40 volumes of methanol, 20 volumes of toluene, 14 volumes of diethylamine and 8 volumes of water.

Test solution. Dissolve 0.8 g of the substance under examination in 100 ml of a mixture of equal volumes of methanol and dichloromethane.

Reference solution. Dissolve 4.0 mg of norfloxacin RS in 1 ml of glacial acetic acid, add 4 ml of methanol and mix; dilute 1 ml of the solution with 9 ml of a mixture of equal volumes of methanol and dichloromethane (reference solution A). Dilute a portion of reference solution A with an equal volume of the methanol-dichloromethane mixture (reference solution B).

Apply separately to the plate spots of the three solutions in quantities indicated below. For spot 1 use 5 µl of the test solution; for spots 2, 3 and 4 use 1 µl, 1.5 µl and 2 µl respectively of reference solution A; for spot 5 use 5 µl of reference solution B. Place the plate in a paper-lined chamber previously equilibrated with the mobile phase and allow the solvent front to move about nine-tenths of the length of the plate. After development, dry the plate in air and examine in ultraviolet light at 254 nm and 365 nm. Compare the intensities of any secondary spots in the chromatogram obtained with the test solution with those of the principal spots (2), (3), (4) and (5). The sum of the intensities of secondary spots obtained with the test solution is not more than 0.5 per cent of impurities. (The spots (2) (3) (4) and (5) represent 0.2 per cent, 0.3 per cent, 0.4 per cent and 0.5 per cent respectively of impurities).

Heavy metals (2.3.13). 1.33 g complies with the limit test for heavy metals, Method B (15 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent, determined on 1.0 g in a platinum crucible.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 0.5 g by drying in an oven at 100° at a pressure not exceeding 0.7 kPa.

Assay. Weigh accurately about 0.3 g and dissolve in 100 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25) and using a suitable anhydrous electrode system. (The electrode system may be rendered anhydrous by filling the electrode with 0.1 M lithium perchlorate in acetic anhydride after removing any aqueous solution contained in it). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.03193 g of C₁₆H₁₈FN₃O₅.
**Storage.** Store protected from light and moisture.

**Norfloxacin Eye Drops**

Norfloxacin Eye Drops are a sterile solution of Norfloxacin in Purified water.

Norfloxacin Eye Drops contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of norfloxacin, C\textsubscript{16}H\textsubscript{18}FN\textsubscript{3}O\textsubscript{3}.

**Identification**

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**pH** (2.4.24). 4.6 to 5.5.

**Other tests.** Comply with the tests stated under Eye Drops.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dilute a suitable volume of the eye drops with a 0.1 per cent v/v solution of orthophosphoric acid to produce a solution containing 0.005 per cent w/v of Norfloxacin.

**Reference solution.** A 0.005 per cent w/v solution of norfloxacin RS in 0.1 per cent v/v solution of orthophosphoric acid.

**Chromatographic system**

- a stainless steel column 30 cm x 3.9 mm, packed with octadecylsilyl silica gel (10 µm) (such as Bondapack C18),
- column temperature 50°,
- mobile phase: a mixture of 300 volumes of methanol and 700 volumes of 0.1 per cent v/v orthophosphoric acid,
- flow rate. 2 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 µl loop injector.

Precondition the column using 0.01 M anhydrous sodium dihydrogen orthophosphate, adjusted to pH 4.0 with orthophosphoric acid, at a flow rate of 0.5 ml per minute for 8 hours. Equilibrate the column with the mobile phase for about 30 minutes before starting the chromatography.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0. The relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution.

Calculate the content of C\textsubscript{16}H\textsubscript{18}FN\textsubscript{3}O\textsubscript{3} in the eye drops.

**Storage.** Store protected from light.

---

**Norfloxacin Tablets**

Norfloxacin Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of norfloxacin, C\textsubscript{16}H\textsubscript{18}FN\textsubscript{3}O\textsubscript{3}. The tablets may be coated.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 40 volumes of chloroform, 40 volumes of methanol, 20 volumes of toluene, 14 volumes of diethylamine and 8 volumes of water.

**Test solution.** Shake a quantity of the finely powdered tablets containing 75 mg of Norfloxacin with 50 ml of a mixture of equal volumes of acidified methanol (containing 0.9 per cent v/v of hydrochloric acid) and dichloromethane, centrifuge and use the clear supernatant solution.

**Reference solution.** A 0.15 per cent w/v solution of norfloxacin RS in the same solvent mixture.

Precondition the column using 0.01 M anhydrous sodium dihydrogen orthophosphate, adjusted to pH 4.0 with orthophosphoric acid, at a flow rate of 0.5 ml per minute for 8 hours. Equilibrate the column with the mobile phase for about 30 minutes before starting the chromatography.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0. The relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution.

Calculate the content of C\textsubscript{16}H\textsubscript{18}FN\textsubscript{3}O\textsubscript{3} in the tablets.

**Tests**

**Dissolution** (2.5.2).

**Apparatus.** No 1

Medium. 750 ml of acetate buffer pH 4.0.

Speed and time. 50 rpm and 30 minutes.

Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate, suitably diluted with acetate buffer pH 4.0, if necessary, at the maximum at about 278 nm (2.4.7). Concomitantly measure the absorbance of a solution of known concentration of norfloxacin RS in the same medium. Calculate the total content of C\textsubscript{16}H\textsubscript{18}FN\textsubscript{3}O\textsubscript{3} in the medium.

D. Not less than 70 per cent of the stated amount of C\textsubscript{16}H\textsubscript{18}FN\textsubscript{3}O\textsubscript{3}.

**Other Tests.** Comply with the tests stated under Tablets.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh and powder 20 tablets. Add 80 ml of the mobile phase to an accurately weighed quantity of the powdered tablets containing about 100 mg of Norfloxacin, mix with the aid of ultrasound for 10 minutes, dilute with a 0.1 per
cent v/v solution of phosphoric acid to 200.0 ml and mix. Dilute 10.0 ml of this solution to 25.0 ml with the mobile phase, mix and use the resulting solution after filtration through a filter with porosity of not more than 0.1 µm.

Reference solution. A 0.02 per cent w/v solution of norfloxacin RS in the mobile phase.

Chromatographic system
- a stainless steel column 30 cm x 3.9 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 85 volumes of a 0.1 per cent v/v solution of phosphoric acid and 15 volumes of acetonitrile,
- temperature. column 40° ± 1°, after preconditioning with degassed 0.01 M sodium dihydrogen phosphate adjusted to pH 4.0 with phosphoric acid flowing at a rate of 0.5 ml per minute for 8 hours,
- flow rate. 2 ml per minute,
- spectrophotometer set at 275 nm,
- a 20 µl loop injector.

Inject the test solution and the reference solution. The assay is not valid unless the capacity factor is not less than 2, the column efficiency is not less than 1500 theoretical plates, the tailing factor for the norfloxacin peak is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Calculate the content of C_{16}H_{18}FN_{3}O_{3} in the tablets.

Storage. Store protected from light and moisture.

Norgestrel

C_{21}H_{28}O_{2}  Mol. Wt. 312.5

Norgestrel is rac-13-ethyl-17-hydroxy-18,19-dinor-17α-pregn-4-en-20-yn-3-one.

Description. A white or almost white, crystalline powder; practically odourless.

Identification
A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with norgestrel RS.

B. When examined in the range 220 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in methanol shows an absorption maximum only at about 240 nm.

C. Melting range (2.4.21). 205° to 212°, but the range between beginning and end of melting does not exceed 4°.

Tests
Specific optical rotation (2.4.22). –0.1° to +0.1°, determined in a 5.0 per cent w/v solution in chloroform.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 80 volumes of dichloromethane and 20 volumes of ethyl acetate.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of chloroform.

Reference solution (a). A 0.01 per cent w/v solution of the substance under examination in chloroform.

Reference solution (b). A 0.004 per cent w/v solution of the substance under examination in chloroform.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and spray with phosphomolybdic acid solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than two such spots are more intense than the spot in the chromatogram obtained with reference solution (b).

Sulphated ash. (2.3.18) Not more than 0.3 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105° for 5 hours.

Assay. Weigh accurately about 0.1 g, dissolve in sufficient ethanol (95 per cent) to produce 100.0 ml, dilute stepwise with ethanol (95 per cent) to obtain a solution containing 0.001 per cent w/v of Levonorgestrel and measure the absorbance of the resulting solution at the maximum at about 241 nm, (2.4.7). Calculate the content of C_{21}H_{28}O_{2} from the absorbance obtained with a 0.001 per cent w/v solution of norgestrel RS in ethanol (95 per cent).

Storage. Store protected from moisture.

Norgestrel and Ethinyloestradiol Tablets

Norgestrel and Ethinyloestradiol Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of norgestrel, C_{21}H_{28}O_{2} and ethinyloestradiol, C_{20}H_{24}O_{2}. The tablets may be film-coated.

Identification
Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.
Mobile phase. A mixture of 96 volumes of dichloromethane and 4 volumes of ethanol (95 per cent).

Test solution. Powder 20 tablets finely, triturate with 20 ml of dichloromethane, allow the solids to sediment and use the clear supernatant liquid.

Reference solution. A solution containing 0.06 per cent w/v solution of norgestrel RS and 0.006 per cent w/v solution of ethinyloestradiol RS.

Apply to the plate 40 µl of each solution. After development, dry the plate in air, spray with ethanolic sulphuric acid (80 per cent v/v), heat at 110° for 10 minutes and examine in ultraviolet light at 365 nm. The principal spots in the chromatogram obtained with the test solution correspond to the spots for norgestrel (red fluorescence) and ethinyloestradiol (orange-yellow fluorescence) in the chromatogram obtained with the reference solution.

Tests

Uniformity of content. Comply with the test stated under Tablets.

Carry out the procedure described under Assay but using the following test solution.

Test solution. Add 2.0 ml of methanol (70 per cent) and 2.0 ml of a 0.00002 per cent w/v solution of diphenyl in methanol (70 per cent) (internal standard solution) to one tablet, shake for 20 minutes, centrifuge, filter the supernatant liquid through a membrane filter with a pore size of not more than 0.2 mm and use the filtrate.

Calculate the contents of norgestrel C21H29O2, and ethinyloestradiol, C20H24O2, in the tablet.

Other Tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14) using the chromatographic system described under Uniformity of content.

Test solution. Weigh and powder 20 tablets. To a quantity of the powder equivalent to one tablet add 2.0 ml of methanol (70 per cent) and 2.0 ml of a 0.00002 per cent w/v solution of diphenyl in methanol (70 per cent) (internal standard solution), shake for 20 minutes, centrifuge, filter the supernatant liquid through a membrane filter with a pore size of not more than 0.2 mm and use the filtrate.

Reference solution. A solution in methanol (70 per cent) containing 0.15 mg per ml of norgestrel RS and 0.015 mg per ml of ethinyloestradiol RS. Take 2.0 ml of this solution and add 2.0 ml of a 0.00002 per cent w/v solution of diphenyl in methanol (70 per cent) and use the resulting solution.

Chromatographic system
- a stainless steel column 15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 to 7 µm),
  - mobile phase: a mixture of 35 volumes of acetonitrile, 15 volumes of methanol and 45 volumes of water,
  - flow rate. 1 to 1.5 ml per minute,
  - spectrophotometer set at 215 nm,
  - a 20 µl loop injector.

Inject the reference solution. The resolution between the two major peaks is not less 2.5 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution. The relative retention times are about 0.7 for ethinyloestradiol and about 1.0 for norgestrel.

Calculate the contents of norgestrel, C21H29O2, and ethinyloestradiol, C20H24O2, in the tablets.

Storage. Store protected from light.

Nortriptyline Hydrochloride

\[
\begin{align*}
\text{N} & \quad \text{CH}_3 \\
\text{H} & \\
\text{C}_{19}\text{H}_{21}\text{N}\text{HCl} & \quad \text{Mol. Wt. 299.8}
\end{align*}
\]

Nortriptyline Hydrochloride is 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohept-5-ylidene)propyl(methyl)amine hydrochloride.

Nortriptyline Hydrochloride contains not less than 98.0 per cent and not more than 101.5 per cent of C19H21N,HCl, calculated on the dried basis.

Description. A white to off-white powder; odour slight and characteristic.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and, D are carried out.

A. Dissolve 0.1 g in 10 ml of water, make alkaline with 1 M sodium hydroxide, extract with 5 ml of chloroform and evaporate to dryness using a current of nitrogen.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nortriptyline hydrochloride RS treated in the same manner or with the reference spectrum of nortriptyline.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in methanol shows an absorption maximum only at about 239 nm; absorbance at about 239 nm, about 0.48.

844
C. To about 50 mg dissolved in 3 ml of warm water, add 1 drop of a 2.5 per cent w/v solution of quinhydrone in methanol; a red colour is produced after a few minutes (distinction from amitriptyline).

D. Gives the reactions of chlorides (2.3.1).

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 85 volumes of cyclohexane, 15 volumes of ethyl acetate and 3 volumes of diethylamine.

**Test solution.** Dissolve 0.2 g of the substance under examination in 10 ml of ethanol (95 per cent) prepared in subdued light.

**Reference solution.** A 0.001 per cent w/v solution of dibenzosuberone RS in ethanol (95 per cent) prepared in subdued light.

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 14 cm in an unsaturated tank protected from light. Dry the plate in air, spray with a freshly prepared solution of sulphuric acid containing 4 per cent v/v of formaldehyde solution and examine immediately in ultraviolet light at 365 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Heavy metals** (2.3.13). 2.0 g complies with the limit test for heavy metals, Method B (10 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°C for 3 hours.

**Assay.** Weigh accurately about 0.25 g and dissolve in 25 ml of anhydrous glacial acetic acid, warm slightly, if necessary, to effect solution. Cool, add 5 ml of mercuric acetate solution. Titrate with 0.1M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02998 g of C\textsubscript{19}H\textsubscript{21}N.HCl.

**Storage.** Store protected from light and moisture.

**Nortriptyline Tablets**

Nortriptyline Hydrochloride Tablets

Nortriptyline Tablets contain less than 90.0 per cent and not more than 110.0 per cent of the stated amount of nortriptyline, C\textsubscript{19}H\textsubscript{21}N. The tablets are coated.

**Identification**

A. Shake a quantity of the powdered tablets containing about 5 mg of nortriptyline with 20 ml of methanol and filter. To 1 ml of the filtrate add 1 ml of a 2.5 per cent w/v solution of sodium bicarbonate, 1 ml of a 2 per cent w/v solution of sodium periodate and 1 ml of a 0.3 per cent w/v solution of potassium permanganate. Allow to stand for 15 minutes, acidify with 1 M sulphuric acid and extract with 10 ml of 2,2,4-trimethylpentane.

When examined in the range 230 nm to 360 nm (2.4.7), the resulting trimethylpentane solution shows an absorption maximum only at about 265 nm.

B. Triturate a quantity of the powdered tablets containing 0.1 g of nortriptyline with 10 ml of chloroform, filter and evaporate the filtrate to a low volume. Add ether until a turbidity is produced and allow to stand. Dissolve 50 mg of the precipitate in 3 ml of warm water, cool and add 1 drop of a 2.5 per cent w/v solution of quinhydrone in methanol; a red colour is produced after a few minutes (distinction from amitriptyline).

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 85 volumes of cyclohexane, 15 volumes of ethyl acetate and 3 volumes of diethylamine.

**Test solution.** Extract a quantity of the powdered tablets containing 20 mg of nortriptyline with 5 ml of a mixture of 9 volumes of ethanol (95 per cent) and 1 volume of 2 M hydrochloric acid, centrifuge and use the supernatant liquid.

**Reference solution.** A 0.001 per cent w/v solution of dibenzosuberone RS in ethanol (95 per cent) prepared in subdued light.

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 14 cm in an unsaturated tank protected from light. Dry the plate in air, spray with a freshly prepared solution of sulphuric acid containing 4 per cent v/v of formaldehyde solution and examine immediately in ultraviolet light at 365 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Uniformity of content** (For tablets containing 10 mg or less). Comply with the test stated under Tablets.

Determine by liquid chromatography (2.4.14)

**Test solution.** Powder one tablet, add 2.5 ml of water, shake vigorously to completely disperse the tablet, add 5 ml of methanol and shake for 30 minutes. Add sufficient water to produce 10 ml, centrifuge and use the clear supernatant liquid.
**Reference solution.** A 0.01 per cent w/v solution of nortriptyline hydrochloride RS in methanol (50 per cent).

Follow the procedure given in the Assay. Calculate the content of C_{20}H_{23}N in the tablet.

**Other Tests.** Comply with the tests stated under Tablets.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Shake vigorously 20 tablets with 50 ml of water until the tablets disintegrate completely, add 100.0 ml of methanol and shake for 30 minutes. Add sufficient water to produce 200.0 ml, filter and dilute a volume of the filtrate containing about 25 mg of nortriptyline to 100.0 ml with methanol (50 per cent).

**Reference solution.** A 0.025 per cent w/v solution of nortriptyline hydrochloride RS in methanol (50 per cent).

**Chromatographic system**
- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (10 µm),
- mobile phase: a 0.56 per cent w/v solution of sodium hexanesulphonate in a mixture of equal volumes of water and acetonitrile adjusted to pH 4.5 with glacial acetic acid,
- flow rate. 2 ml per minute,
- spectrophotometer set at 239 nm,
- a 20 µl loop injector.

Inject the test solution and the reference solution. Calculate the content of C_{20}H_{23}N in the tablets.

**Storage.** Store protected from light and moisture.

**Noscapine**

Narcotine

[Chemical structure of Noscapine]

C_{22}H_{23}NO_{7}  Mol. Wt. 413.4

Noscapine contains not less than 98.5 per cent and not more than 100.5 per cent of C_{22}H_{23}NO_{7}, calculated on the dried basis.

**Description.** Colourless crystals or a white crystalline powder.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with noscapine RS or with the reference spectrum of noscapine.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.005 per cent w/v solution in methanol shows absorption maxima at about 291 nm and 310 nm; ratio of absorbance at the maximum at about 310 nm to that at the maximum at about 291 nm, 1.2 to 1.3.

C. To 0.1 g in a porcelain dish add a few drops of sulphuric acid and stir; a greenish-yellow solution is formed which on warming becomes red and finally violet.

D. Dissolve 50 mg in 5 ml of 5 M hydrochloric acid, add 10 ml of a mixture of equal volumes of ethanol (95 per cent) and a saturated solution of sodium acetate, mix and allow to stand for about 3 minutes; shining crystals separate.

**Tests**

**Appearance of solution.** A 2.0 per cent w/v solution in acetone examined immediately after preparation is clear (2.4.1), and not more intensely coloured than reference solution YS6 (2.4.1).

**Specific optical rotation** (2.4.22). +42.0° to +48.0°, determined at 20° in a solution prepared by dissolving 0.5 g in sufficient 0.1 M hydrochloric acid to produce 25.0 ml.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 60 volumes of acetone, 60 volumes of toluene, 9 volumes of ethanol (95 per cent) and 3 volumes of strong ammonia solution.

**Test solution.** Dissolve 0.25 g of the substance under examination in 10 ml of acetone.

**Reference solution.** A 0.0125 per cent w/v solution of the substance under examination in acetone.

Apply to the plate 10 µl of each solution. After development, dry the plate in air, spray with dilute potassium iodosobismuthate solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Morphine.** Dissolve 0.1 g in 10 ml of 0.1 M hydrochloric acid. To 1 ml of the resulting solution add a mixture of 1 ml of
potassium ferricyanide solution, 0.05 ml of ferric chloride test solution and 4 ml of water; no blue or dark green colour develops within 1 minute.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105°C.

**Assay.** Weigh accurately about 0.35 g, dissolve in 40 ml of anhydrous glacial acetic acid, warming gently. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.04134 g of C$_{22}$H$_{23}$NO$_7$.

**Storage.** Store protected from light and moisture.

---

**Noscapine Linctus**

Narcotine Linctus

Noscapine Linctus is a solution of Noscapine in a suitable flavoured vehicle. It may contain up to 1 per cent w/v solution of Citric Acid.

Noscapine Linctus contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of noscapine, C$_{22}$H$_{23}$NO$_7$.

**Identification**

To a quantity containing 60 mg of Noscapine add 20 ml of water, 2 g of sodium chloride and 2 ml of 5 M sodium hydroxide. Extract with successive quantities of 50, 50, 25 and 25 ml of ether. Combine the extracts, wash with three quantities, each of 5 ml, of water and evaporate to dryness. Dissolve the residue in 20 ml of chloroform. Wash with three quantities, each of 20 ml, of water, dry the chloroform layer with anhydrous sodium sulphate, filter and evaporate the solvent. If necessary, induce crystallisation by scratching with a glass rod. The crystals comply with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with noscapine RS or with the reference spectrum of noscapine.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.005 per cent w/v solution in methanol shows absorption maxima at about 291 nm and 310 nm; ratio of absorbance at the maximum at about 310 nm to that at the maximum at about 291 nm, 1.2 to 1.3.

**Tests**

**Other tests.** Complies with the tests stated under Oral Liquids.

---

**Novobiocin Sodium**

Novobiocin Sodium is the monosodium salt of novobiocin, N-[7-{3-O-(aminocarbonyl)-6-deoxy-5-C-methyl-4-O-methyl-β-L-lyxo-hexopyranosyl}-4-hydroxy-8-methyl-2-oxo-2H-1-benzopyran-3-yl]-4-hydroxy-3-(3-methyl-2-butaryl)benzamide, an antimicrobial substance produced by the growth of certain strains of Streptomyces niveus or related organisms or by other means.

Novobiocin Sodium contains the equivalent of not less than 850 µg of novobiocin per mg, calculated on the dried basis.

**Description.** A white or yellowish white, crystalline powder.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 75 volumes of chloroform, 25 volumes of methanol and 1 volume of strong ammonia solution.

**Test solution.** Dissolve a quantity of the substance under examination in methanol so as to obtain a solution containing 0.1 per cent w/v solution of novobiocin.

**Reference solution.** A 0.1 per cent w/v solution of novobiocin RS in methanol.
Apply to the plate 1 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in a 0.4 per cent w/v solution of potassium hydroxide shows an absorption maximum only at about 307 nm.

C. The residue obtained by igniting it gives the tests for sodium salts (2.3.1).

**Tests**

**pH** (2.4.24). 6.6 to 8.5, determined in a 2.5 per cent w/v solution.

**Specific optical rotation** (2.4.22). −50.0° to −58.0°, determined in a 5.0 per cent w/v solution in methanol containing 1 per cent v/v of hydrochloric acid.

**Loss on drying** (2.4.19). Not more than 6 per cent, determined on 0.2 g by drying in an oven at 60° over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 3 hours.

**Assay.** Determine by the microbiological assay of antibiotics, Method A (2.2.10), and express the results in µg of novobiocin per mg.

Novobiocin Sodium intended for use in the manufacture of Parenteral Preparations complies with the following additional requirements.

**Bacterial endotoxins** (2.2.3). Not more than 0.7 Endotoxin units per mg.

**Sterility.** Complies with the test for sterility (2.2.11).

**Storage.** Store protected from light and moisture at a temperature not exceeding 30°. If it is intended for use in the manufacture of parenteral preparations, the container should be sterile and sealed so as to exclude micro-organisms.

**Labelling.** The label states whether or not the contents are intended for use in the manufacture of parenteral preparations.

**Nystatin**

Nystatin is an antifungal substance produced by the growth of certain strains of Streptomyces noursei or by any other means. It consists mainly of polyenes, the principal component being nystatin A1.

Nystatin has a potency of not less than 4400 Units per mg, calculated on the dried basis.

**Description.** A yellow to slightly brown powder; odour, characteristic; hygroscopic.

---

NYSTATIN

Identify the item being used in the document.
Nystatin intended for oral administration complies with the following additional requirement.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity, using a quantity containing not less than 600 Units suspended in not more than 0.5 ml of a 0.5 per cent w/v solution of *acacia* and injecting the suspension intraperitoneally.

**Storage.** Store protected from light and moisture.

**Labelling.** The label states the strength in terms of the number of Units of Nystatin per mg.

### Nystatin Ointment

Nystatin Ointment is a dispersion of Nystatin in microfine powder in a suitable ointment basis.

Nystatin Ointment contains not less than 90.0 per cent and not more than 130.0 per cent of the stated number of Units of nystatin.

**Identification**

Disperse a quantity containing 25,000 Units in 10 ml of chloroform, add 40 ml of methanol and shake. Filter and dilute 1 ml of the filtrate to 25 ml with methanol.

When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows absorption maxima at about 291 nm, 305 nm and 319 nm. The ratios of the absorbances at the maxima at about 291 nm and about 319 nm to the absorbance at the maximum at about 305 nm are 0.61 to 0.73 and 0.83 to 0.96, respectively. Use as the blank a solution prepared exactly in the same manner without the substance under examination.

**Tests**

**Other tests.** Complies with the tests stated under Ointments.

**Assay.** Protect the solution from light throughout the assay.

Weigh accurately a quantity containing 400,000 Units, disperse in 20 ml of *ether* in a stoppered flask, add 70 ml of *dimethylformamide*, shake for a few minutes, add 10 ml of *water*, shake vigorously for a few minutes and add sufficient *dimethylformamide* to produce 100.0 ml. Mix well, filter and dilute 10.0 ml of the filtrate to 100.0 ml with *buffer solution No 4* (2.2.10).

Determine by the microbiological assay of antibiotics (2.2.10).

**Storage.** Store protected from moisture.

**Labelling.** The label states the strength in terms of the number of Units of Nystatin per g.

### Nystatin Pessaries

Nystatin Vaginal Tablets

Nystatin Pessaries contain not less than 90.0 per cent and not more than 130.0 per cent of the stated number of Units of nystatin.

**Identification**

Extract a quantity of the powdered pessaries containing 300,000 Units with a mixture of 50 ml of *methanol* and 5 ml of *glacial acetic acid*, add sufficient *methanol* to produce 100 ml and filter. Dilute 1 ml of the filtrate to 100 ml with *methanol*. The resulting solution complies with the following test.

Disperse a quantity containing 25,000 Units in 10 ml of chloroform, add 40 ml of methanol and shake. Filter and dilute 1 ml of the filtrate to 25 ml with methanol.

When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows absorption maxima at about 291 nm, 305 nm and 319 nm. The ratios of the absorbances at the maxima at about 291 nm and about 319 nm to the absorbance at the maximum at about 305 nm are 0.61 to 0.73 and 0.83 to 0.96, respectively. Use as the blank a solution prepared exactly in the same manner without the substance under examination.

**Tests**

**Other Tests.** Comply with the tests stated under Pessaries.

**Loss on drying** (2.4.19). Not more than 5 per cent, determined on 1.0 g of the powdered pessaries by drying in an oven at 60° at a pressure not exceeding 0.7 kPa for 3 hours.

**Assay.** Protect the solution from light throughout the assay.

Weigh and powder 20 pessaries. Weigh accurately a quantity of the powder containing 200,000 Units and shake with 50.0 ml of *dimethylformamide* for 1 hour. Centrifuge, dilute 10.0 ml of the clear, supernatant liquid to 200.0 ml with *buffer solution No 4* (2.2.10).

Determine by the microbiological assay of antibiotics (2.2.10).

**Storage.** Store protected from light and moisture.

**Labelling.** The label states the strength in terms of the number of Units of Nystatin.

### Nystatin Tablets

Nystatin Tablets contain not less than 90.0 per cent and not more than 130.0 per cent of the stated number of Units of nystatin. The tablets are coated.
Identification

Extract a quantity of the powdered tablets containing 300,000 Units with a mixture of 50 ml of methanol and 5 ml of glacial acetic acid, add sufficient methanol to produce 100 ml and filter. Dilute 1 ml of the filtrate to 100 ml with methanol. The resulting solution complies with the following test.

When examined in the range 230 nm to 360 nm (2.4.7), the solution shows absorption maxima at about 291 nm, 305 nm and 319 nm. The ratios of the absorbances at the maxima at about 291 nm and about 319 nm to the absorbance at the maximum at about 305 nm are 0.61 to 0.73 and 0.83 to 0.96, respectively. Use as the blank a solution prepared exactly in the same manner without the substance under examination.

Tests

Disintegration (2.5.1). 30 minutes, but using a 0.6 per cent v/v solution of hydrochloric acid in place of water. If the tablets fail to disintegrate, wash them rapidly by immersion in water and continue the test using phosphate buffer pH 6.8; the tablets then disintegrate within a further 30 minutes.

Loss on drying (2.4.19). Not more than 5.0 per cent, determined on 1.0 g of the powdered tablets by drying in an oven at 60° at a pressure not exceeding 0.7 kPa for 3 hours.

Other Tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 200,000 Units and shake with 50.0 ml of dimethylformamide for 1 hour. Centrifuge, dilute 10.0 ml of the clear, supernatant liquid to 200.0 ml with buffer solution No 4 (2.2.10).

Determine by the microbiological assay of antibiotics (2.2.10).

Storage. Store protected from moisture.

Labelling. The label states the strength in terms of the number of Units of Nystatin.
O

Oestradiol Benzoate ....
Oestradiol Injection ....
Ofloxacin ....
Ofloxacin Infusion ....
Ofloxacin Ophthalmic Solution ....
Ofloxacin Tablets ....
Olanzapine ....
Olanzapine Tablets ....
Oleic Acid ....
Omeprazole ....
Omeprazole Capsules ....
Oral Rehydration Salts ....
Ormeloxifen Hydrochloride ....
Ormeloxifen Hydrochloride Tablets ....
Orphenadrine Citrate ....
Orphenadrine Hydrochloride ....
Orphenadrine Tablets ....
Oseltamivir Phosphate ....
Oseltamivir Capsules ....
Oseltamivir Oral Suspension ....
Oxazepam ....
Oxazepam Tablets ....
Oxprenolol Hydrochloride ....
Oxprenolol Tablets ....
Oxyn 
Oxygen ....
Oxygen 93 Per Cent ....
Oxyphenbutazone ....
Oxyphenbutazone Tablets ....
Oxytetracycline Dihydrate ....
Oxytetracycline Injection ....
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxytetracycline Hydrochloride</td>
<td>....</td>
</tr>
<tr>
<td>Oxytetracycline Capsules</td>
<td>....</td>
</tr>
<tr>
<td>Oxytetracycline Eye Ointment</td>
<td>....</td>
</tr>
<tr>
<td>Oxytetracycline Hydrochloride Injection</td>
<td>....</td>
</tr>
<tr>
<td>Oxytocin</td>
<td>....</td>
</tr>
<tr>
<td>Oxytocin Injection</td>
<td>....</td>
</tr>
<tr>
<td>Oxytocin Nasal Solution</td>
<td>....</td>
</tr>
</tbody>
</table>
Oestradiol Benzoate

\[ \text{C_{25}H_{28}O}_3 \] \hspace{1cm} \text{Mol. Wt. 376.5}

Oestradiol Benzoate is 17\(\beta\)-hydroxyestra-1,3,5(10)-trien-3-yl benzoate.

Oestradiol Benzoate contains not less than 97.0 per cent and not more than 103.0 per cent of \(\text{C}_{25}\text{H}_{28}\text{O}_3\), calculated on the dried basis.

**Description.** Colourless crystals or a white, crystalline powder; odourless.

**Identification**

Test A may be omitted if tests B and C are carried out. Test C may be omitted if tests A and B are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with oestradiol benzoate \(\text{RS}\) or with the reference spectrum of oestradiol benzoate.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b) when examined in daylight and in ultraviolet light at 365 nm.

C. To about 1 mg add 0.5 ml of a 5 per cent w/v solution of ammonium molybdate in sulphuric acid; a yellowish green colour develops which exhibits an intense green fluorescence when examined in ultraviolet light at 365 nm. Add 1 ml of sulphuric acid and 9 ml of water; the solution becomes pink with a yellowish fluorescence.

**Tests**

**Specific optical rotation** (2.4.22). +57.0° to +63.0°, determined in a 1.0 per cent w/v solution in dioxan.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel \(\text{G}\).

**Mobile phase.** A mixture of 90 volumes of toluene and 10 volumes of ethanol (95 per cent).

**Test solution (a).** Dissolve 0.2 g of the substance under examination in 10 ml of a mixture of 90 volumes of chloroform and 10 volumes of methanol.

Test solution (b). Dissolve 0.1 g of the substance under examination in 100 ml of the same solvent mixture.

**Reference solution (a).** A 0.02 per cent w/v solution of the substance under examination in the same solvent mixture.

**Reference solution (b).** A 0.1 per cent w/v solution of oestradiol benzoate \(\text{RS}\) in the same solvent mixture.

Apply to the plate 5 \(\mu\)l of each solution. After development, dry the plate in air until the odour of the solvent is no longer detectable, heat at 110° for 10 minutes, spray the plate while hot with ethanolic sulphuric acid (20 per cent), heat again at 110° for 10 minutes and examine in ultraviolet light at 365 nm. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Sulphated ash** (2.3.18). Not more than 0.2 per cent, determined on 0.5 g.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 0.5 g by drying in an oven at 105° for 3 hours.

**Assay.** Weigh accurately about 25 mg, dissolve in sufficient ethanol (95 per cent) to produce 250.0 ml. Dilute 10.0 ml to 100.0 ml with ethanol (95 per cent) and measure the absorbance of the resulting solution at the maximum at about 231 nm (2.4.7). Calculate the content of \(\text{C}_{25}\text{H}_{28}\text{O}_3\) taking 500 as the specific absorbance at 231 nm.

**Storage.** Store protected from light and moisture.

Oestradiol Injection

Oestradiol Benzoate Injection

Oestradiol Injection is a sterile solution of Oestradiol Benzoate in Ethyl Oleate or other suitable ester, in a suitable fixed oil or in any mixture of these. It may contain suitable alcohols.

Oestradiol Benzoate Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of oestradiol benzoate, \(\text{C}_{25}\text{H}_{28}\text{O}_3\).

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel \(\text{G}\).

**Mobile phase.** A mixture of 80 volumes of toluene and 20 volumes of ethyl acetate.

**Test solution.** Add 10 ml of 2,2,4-trimethylpentane to a volume of the injection containing 2 mg of Oestradiol Benzoate and extract with three quantities, each of 10 ml, of ethanol (70 per cent). Wash the combined extracts with 15 ml of 2,2,4-trimethylpentane, evaporate the ethanolic extract to dryness.
using a rotary evaporator and dissolve the residue in 2 ml of chloroform.

**Reference solution.** A 0.1 per cent w/v solution of oestradiol benzoate RS in chloroform.

Apply to the plate 5 µl of each solution. After development, dry the plate in air, spray with ethanolic sulphuric acid (20 per cent), heat at 105º for 10 minutes and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

**Tests**

**Other Tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution (a).** Dilute an accurately measured quantity of the injection containing about 1 mg of Oestradiol Benzoate to 10.0 ml with a mixture of 90 volumes of cyclohexane and 10 volumes of dioxan.

**Test solution (b).** Add 1 ml of a solution prepared by dissolving 15 mg of 4-hydroxybenzaldehyde (internal standard) in 10.0 ml of dioxan, adding sufficient cyclohexane to produce 100.0 ml (solution A), to an accurately measured quantity of the injection containing about 1 mg of Oestradiol Benzoate and dilute to 10.0 ml with sufficient of a mixture of 90 volumes of cyclohexane and 10 volumes of dioxan.

**Reference solution.** Add 10 ml of solution A to 10 mg of oestradiol benzoate RS, accurately weighed, and dilute to 100.0 ml with the same solvent mixture.

**Chromatographic system**
- a stainless steel column 30 cm x 4 mm, packed with porous silica particles (10 µm),
- mobile phase: 90 volumes of cyclohexane and 10 volumes of dioxan,
- flow rate. 2 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject test solutions (a), (b) and the reference solution. The assay is not valid unless the resolution between the peaks due to benzyl alcohol (if present) and oestradiol benzoate and between the peaks due to oestradiol benzoate and the internal standard is more than 1.5.

Calculate the content of C_{21}H_{28}O_{3} in the injection.

**Storage.** Store protected from light.

**Labelling.** The label states (1) the nature and composition of the solvent; (2) that it is meant for intramuscular injection only; (3) that any solid matter that may have separated on standing should be redissolved by warming before use.
chromatogram obtained with the test solution, the area of any secondary peak is not more than 0.5 times the area of the peak in the chromatogram obtained with reference solution (b) (0.5 per cent) and the sum of areas of all the secondary peaks is not more than the area of the peak in the chromatogram obtained with the reference solution (b) (1.0 per cent).

**Heavy Metals** (2.3.13). 2.0 g complies with the limit test for heavy metals, Method C (10 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.2 per cent, determined on 1.0 g by drying in an oven at 105° for 4 hours.

**Assay.** Weigh accurately about 0.3 g, dissolve in 100 ml anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml 0.1 M perchloric acid is equivalent of 0.03614 g of $\text{C}_{18}\text{H}_{20}\text{FN}_{3}\text{O}_{4}$.

**Storage.** Store protected from light and moisture.

### Ofloxacin Infusion

Ofloxacin Infusion contain Ofloxacin in water for injection.

Ofloxacin Infusion contain not less than 90.0 per cent and not more than 120.0 per cent of the stated amount of ofloxacin, $\text{C}_{18}\text{H}_{20}\text{FN}_{3}\text{O}_{4}$.

**Identification**

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**pH** (2.4.24). 3.8 to 5.8

**Other tests.** Complies with the tests stated under Parenteral Preparation (Infusions).

**Assay.** Determine by liquid chromatography (2.4.14).

**NOTE** — Protect the solutions from the light.

**Test solution.** Measure accurately a volume containing 50 mg of Ofloxacin in 100.0 ml with mobile phase. Dilute 5.0 ml of the solution to 50.0 ml with mobile phase.

**Reference solution.** A 0.005 per cent w/v solution of ofloxacin RS in mobile phase.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 μm),
- mobile phase: a mixture of 80 volumes of buffer solution prepared by dissolving 6.8 g of potassium dihydrogen orthophosphate and 0.47 g sodium 1-hexane sulphonate in 1000 ml of water, add 1 ml of triethylamine and adjust the pH to 3.0 with orthophosphoric acid and 20 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 294 nm,
- a 20 μl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of $\text{C}_{18}\text{H}_{20}\text{FN}_{3}\text{O}_{4}$ in infusion.

### Ofloxacin Ophthalmic Solution

Ofloxacin Ophthalmic Solution is a sterile aqueous solution of Ofloxacin.

Ofloxacin Ophthalmic Solution contain not less than 90.0 per cent and more than 110.0 per cent of the stated amount of ofloxacin, $\text{C}_{18}\text{H}_{20}\text{FN}_{3}\text{O}_{4}$.

**Identification**

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**pH** (2.4.24). 6.0 to 7.2.

**Sterility** (2.2.11). Comply with the test for sterility.

**Assay.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** Phosphate buffer pH 7.25 prepared by dissolving 3.56 g of disodium hydrogen phosphate in 1000 ml water, adjusted pH to 7.25 using orthophosphoric acid or sodium hydroxide solution.

**Test solution.** Measure accurately a volume of Ophthalmic Solution containing 30 mg of Ofloxacin in 100.0 ml of solvent mixture. Dilute 1.0 ml of the solution to 10.0 with solvent mixture.

**Reference solution.** A 0.003 per cent w/v solution of ofloxacin RS in solvent mixture.

**Chromatographic system**

- a stainless steel column 15 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 μm) (such as TSK GEL),
- mobile phase: a mixture of 20 volumes of acetonitrile, 80 volumes of phosphate buffer pH 7.25 prepared by
dissolving 2.54 g of *tetrabutyl ammonium hydrogen sulphate* and 3.56 g of *disodium hydrogen phosphate* in 1000 ml water,
- flow rate 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C₁₈H₂₀FN₃O₄.

**Storage.** Store protected from light.

---

**Ofloxacin Tablets**

Ofloxacin Tablets contain Ofloxacin.

Ofloxacin Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of ofloxacin, C₁₈H₂₀FN₃O₄.

**Identification**

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution (a).

**Tests**

**Dissolution (2.5.2).**

Apparatus. No 1
Medium. 900 ml of *0.1 M hydrochloride acid*.
Speed and time. 50 rpm for 30 minutes.

Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate, suitably diluted with the medium if necessary, at the maximum at about 294 nm (2.4.7). Calculate the content of C₁₈H₂₀FN₃O₄ in the medium from the absorbance obtained from a solution of known concentration of ofloxacin RS in the same medium.

D. Not less than 75 per cent of the stated amount of C₁₈H₂₀FN₃O₄.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh and powder 20 tablets. Weigh accurately a quantity of powdered tablet containing 25 mg of Ofloxacin, disperse in 60 ml of *methanol* and dilute to 100 ml with *methanol* and filter.

**Reference solution (a).** A 0.1 per cent w/v solution of ofloxacin RS in methanol.

**Chromatographic system**
- a stainless steel column 15 cm x 4.6 mm packed with octadecysilanol silica gel for chromatography (5 µm),
- mobile phase: a mixture of 92 volumes of *potassium dihydrogen phosphate* in 1000 ml of *water* and adjust the pH to 2.4 with *orthophosphoric acid*.
- flow rate. 2 ml per minute,
- spectrophotometer set at 294 nm,
- a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C₁₈H₂₀FN₃O₄.

**Storage.** Store protected from light and moisture.
Olanzapine

\[
\begin{align*}
\text{C}_{17}\text{H}_{20}\text{N}_{4}\text{S} & \quad \text{Mol. Wt. 312.4} \\
\text{Olanzapine is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno}[2,3-b][1,5]\text{benzodiazepine} \\
\text{Olanzapine contains not less than 98.0 per cent and not more than 102.0 per cent of C}_{17}\text{H}_{20}\text{N}_{4}\text{S}, \text{calculated on the anhydrous basis.} \\
\text{Description.} \text{ A yellow crystalline powder.} \\
\text{Identification} \\
\text{Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with olanzapine RS or with the reference spectrum of olanzapine.} \\
\text{Tests} \\
\text{Related substances.} \text{ Determine by liquid chromatography (2.4.14).} \\
\text{Solvent mixture.} \text{ 40 volumes of water and 60 volumes of acetonitrile.} \\
\text{Test solution.} \text{ Dissolve 50 mg of the substance under examination in 25 ml of solvent mixture.} \\
\text{Reference solution (a).} \text{ A 0.2 per cent w/v solution of olanzapine RS in solvent mixture.} \\
\text{Reference solution (b).} \text{ Dilute 1 ml of reference solution (a) to 100 ml with solvent mixture.} \\
\text{Chromatographic system} \\
- \text{a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),} \\
- \text{column temperature 40º,} \\
- \text{mobile phase: A. a mixture of 80 volumes of buffer solution pH 6.8 prepared by dissolving 4.825 g of sodium dihydrogen orthophosphate monohydrate in 1000 ml of water, adjust pH to 6.8 with 10 per cent w/v of sodium hydroxide and 20 volumes of acetonitrile,} \\
- \text{B. acetonitrile,} \\
- \text{flow rate. 1.2 ml per minute,} \\
\begin{array}{c|c|c}
\text{Time} & \text{Mobile phase A} & \text{Mobile phase B} \\
\text{(in min.)} & \text{(per cent v/v)} & \text{(per cent v/v)} \\
0 & 100 & 0 \\
20 & 63 & 37 \\
30 & 45 & 55 \\
32 & 100 & 0 \\
38 & 100 & 0 \\
\end{array}
\]

Inject reference solution (b). The test is not valid unless the tailing factor is not more than 2.0 and the column efficiency in not less than 2000 theoretical plates.

Inject the test solution and reference solution (b). Run the chromatogram for three times, the principal peak due to olanzapine. In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 0.5 times the area of the peak in the chromatogram obtained with reference solution (b) (0.5 per cent) and the sum of areas of all the secondary peaks is not more than twice the area of the peak in the chromatogram obtained with the reference solution (b) (2.0 per cent).

\text{Heavy metals (2.3.13).} \text{ 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).} \\
\text{Sulphated ash (2.3.18).} \text{ Not more than 0.1 per cent.} \\
\text{Water (2.3.43).} \text{ Not more than 1.0 per cent, determined on 1.0 g.} \\
\text{Assay.} \text{ Weigh accurately about 0.2 g, dissolve in 40 ml of glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.} \\
1 \text{ ml of 0.1 M perchloric acid is equivalent to 0.01562 g of C}_{17}\text{H}_{20}\text{N}_{4}\text{S.} \\
\text{Storage.} \text{ Store protected from light and moisture, at a temperature not exceeding 30º.} \\

\text{Olanzapine Tablets} \\
\text{Olanzapine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of olanzapine, C}_{17}\text{H}_{20}\text{N}_{4}\text{S.} \\
\text{Identification} \\
\text{In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.}
Tests

Dissolution (2.5.2).

Apparatus. No 1

Medium. 900 ml of 0.01 M hydrochloric acid.

Speed and time. 50 rpm for 45 minutes.

Withdraw a suitable volume of the medium and filter. Determine by liquid chromatography (2.4.14).

NOTE – Protect all the solutions from light.

Test solution. Use the filtrate, if necessary dilute with dissolution medium.

Reference solution. Weigh 16 mg of olanzapine RS, dissolve in about 2.5 ml of acetonitrile and dilute to 25 ml with 0.01 M hydrochloric acid. Dilute suitably to get 0.0016 per cent w/v in dissolution medium.

Chromatographic system as described under Assay, using 50 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0. The column efficiency in not less than 2500 theoretical plates.

Inject the test solution and the reference solution.

Calculate the content of C17H20N4S.

D. Not less than 70 per cent of the stated amount of C17H20N4S.

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Take 10 intact tablets to a suitable volumetric flask, disperse in acetonitrile and dilute with 0.01 M hydrochloric acid to get final concentration of 0.01 per cent w/v of Olanzapine.

Reference solution. Weigh 10 mg of olanzapine RS, dissolve in about 25 ml of acetonitrile and dilute to 100 ml with 0.01 M hydrochloric acid.

Chromatographic system

– a stainless steel column 25 cm x 4.6 mm packed with packed with octadecylsilyl silica gel for chromatography (5 µm),

– mobile phase: a mixture of 70 volumes of buffer solution prepared by dissolving 3 g of ammonium dihydrogen orthophosphate in 900 ml water, add 2 ml of triethylamine and dilute to 1000 ml with water. Adjust pH to 2.5 with orthophosphoric acid and 30 volumes of methanol,

– flow rate. 1 ml per minute,

– spectrophotometer set at 220 nm,

– a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency in not less than 2500 theoretical plates. The relative standard deviation for replicate injections is not more than 2 per cent.

Inject the test solution and the reference solution.

Calculate the content of C17H20N4S.

Storage. Store protected from light and moisture, at a temperature not exceeding 25º.

Oleic Acid

Oleic Acid consists mainly of (Z)-octadec-9-enoic acid, C18H34O2, together with varying amounts of saturated and other unsaturated fatty acids and is obtained by the hydrolysis of fats or fixed oils and separation of the liquid acids by expression or other suitable means. It may contain a suitable antioxidant.

Description. A clear, yellowish to pale brown, oily liquid; odour, characteristic. On exposure to air it darkens in colour and the odour becomes more pronounced.

Identification

A. To 1 ml add 1 ml of ethanol (95 per cent); the solution is clear. It turns orange or red on addition of 0.1 ml of methyl orange solution.

B. Take a mixture of 1 ml of nitric acid and 1 ml of water in a test-tube with an internal diameter of about 12.5 mm and add 1 ml of the substance under examination on the surface of the mixture. Introduce 0.5 g of copper turnings into the lower layer and allow to stand under a hood for 4 hours; the upper layer solidifies.

C. Complies with the test for Iodine value (2.3.28).

Tests

Weight per ml (2.4.29). 0.889 g to 0.895 g.

Peroxide value (2.3.35). Not more than 10.0.

Acid value (2.3.23). 195 to 202, determined on 0.5 g.

Iodine value (2.3.28). 85 to 95, determined by Method A.

Water-soluble acids. Shake 5 ml with 5 ml of water for 2 minutes, allow the liquids to separate and filter the aqueous layer through paper moistened with water. To the filtrate add 0.05 ml of methyl orange solution; the liquid does not become red.

Neutral fats and mineral oils. Boil 1 ml with 5 ml of 0.5 M sodium carbonate and 25 ml of water in a large flask. The solution, while still hot, is not more opalescent than opalescence standard OS2 (2.4.1).
Congealing point. Dry about 10 ml by heating to 110° with frequent stirring, transfer to a test-tube about 20 mm in diameter, cool and when at 15° immerse the tube in a suitable water-bath so that the cooling takes place at the rate of 2° per minute. Stir the sample with a thermometer; it does not become cloudy until the temperature has fallen to 10°. On further cooling it congeals to a white solid or semi-solid mass at about 4°.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Storage. Store protected from light and moisture in a refrigerator (8° to 15°).

Labelling. The label states (1) where applicable, that it is used for external use only; (2) the name and concentration of any added antioxidant.

Omeprazole

\[
\text{C}_{17}\text{H}_{19}\text{N}_{3}\text{O}_{3}\text{S}, \quad \text{Mol. Wt. 345.4}
\]

Omeprazole is 5-methoxy-2-[[4-(methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl] -1H-benzimidazole.

Omeprazole contains not less than 99.0 per cent and not more than 101.0 per cent of C\text{17}H\text{19}N\text{3}O\text{3}S, calculated on the dried basis.

NOTE — Perform the tests and assay in subdued light and use low-actinic glassware.

Description. A white or almost white powder.

Identification

Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with omeprazole RS or with the reference spectrum of omeprazole.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in 0.1 M sodium hydroxide shows absorption maxima at about 276 nm and 305 nm; the ratio of the absorbance at about 305 nm to that at about 276 nm, 1.6 to 1.8.

C. In the test for Related substances, the principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a).

Tests

Appearance of solution. A 2.0 per cent w/v solution in dichloromethane is clear (2.4.1).

Light absorption (2.4.7). Absorbances of a freshly prepared 2.0 per cent w/v solution in dichloromethane at 400 nm, 500 nm and 600 nm are not more than 0.25, 0.10 and 0.10 respectively.

Related substances. A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 50 volumes of benzene, 30 volumes of ethyl acetate and 10 volumes of methanol.

Test solution. Dissolve 0.4 g of the substance under examination in 100 ml of ethanol.

Reference solution (a). A 0.4 per cent w/v solution of omeprazole RS in ethanol.

Reference solution (b). A 0.004 per cent w/v solution of omeprazole RS in ethanol.

Reference solution (c). A 0.002 per cent w/v solution of omeprazole RS in ethanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm immediately. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (c) and the total intensity of all such spots in the chromatogram obtained with the test solution is not more than the intensity of the spot obtained with reference solution (b).

B. In the Assay, the sum of the areas of all the secondary peaks is not greater than 1.5 per cent of the total area of all peaks.

Heavy metals (2.3.13). The residue obtained in the test for Sulphated ash, complies with the limit test for heavy metals, Method B (20 ppm).

Sulphated ash (2.3.18). Not more than 0.2 per cent.

Loss on drying (2.4.19). Not more than 0.2 per cent, determined on 1.0 g by drying in an oven at 60° at a pressure not exceeding 0.7 kPa for 4 hours.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. A 0.005 per cent w/v solution of the substance under examination in the mobile phase.

Reference solution. A 0.005 per cent w/v solution of omeprazole RS in the mobile phase.

Chromatographic system

– a stainless steel column 30 cm x 3.9 mm, packed with octadecylsilane bonded to porous silica (5 µm),
– mobile phase: a mixture of 65 volumes of phosphate buffer pH 7.4 and 35 volumes of acetonitrile,
Inject the reference solution. Repeat the procedure at least five times and measure the peak responses of the peak due to omeprazole. The relative standard deviation of the replicate injections is not more than 2.0 per cent. Calculate the content of $C_{17}H_{19}N_{3}O_{3}S$.

Storage. Store protected from light and moisture in a refrigerator (2º to 8º).

NOTE — A combination of elevated temperatures (37º-50º) and high humidity degrades Omeprazole. It rapidly degrades under acidic conditions.

Omeprazole Capsules

Omeprazole Capsules contain enteric-coated granules of Omeprazole.

Omeprazole Capsules contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of omeprazole, $C_{17}H_{19}N_{3}O_{3}S$.

NOTE — Perform the tests and assay in subdued light and use low-actinic glassware.

Identification

A. To a quantity of the contents of the capsules containing 50 mg of Omeprazole in a 100-ml volumetric flask add about 70 ml of 0.1 $M$ sodium hydroxide. Mix in an ultrasonic bath for about 5 minutes and heat on a water-bath for 10 minutes. Cool, make up to volume with 0.1 $M$ sodium hydroxide and filter. Dilute 2 ml of the filtrate to 100 ml with 0.1 $M$ sodium hydroxide.

When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows absorption maxima at about 276 nm and 305 nm.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to omeprazole in the chromatogram obtained with the reference solution.

Tests

Dissolution (2.5.2).

A. Apparatus. No 1

Medium. 900 ml of 0.1 $M$ hydrochloric acid,

Speed and time. 100 rpm and 2 hours.

Tap the granules from a capsule slightly with a glass rod to make them settle to the bottom. Rotate the paddle at 100 rpm for 2 hours, drain the solution slowly without losing any granules. Transfer them quantitatively to a 100-ml volumetric flask, add 20 ml of 0.1 $M$ sodium hydroxide and mix with the aid of ultrasound. Dilute to volume with 0.1 $M$ sodium hydroxide, centrifuge about 15 ml for 5 minutes and dilute 5.0 ml of the clear supernatant liquid to 50.0 ml with the mobile phase. Using the resulting solution as the test solution, carry out the determination as described in the Assay. Calculate the content of $C_{17}H_{19}N_{3}O_{3}S$ in the supernatant liquid. Calculate the percentage of omeprazole released in the acid medium by subtracting the content of $C_{17}H_{19}N_{3}O_{3}S$ in the test solution from the total content of omeprazole determined in the Assay. Not more than 15 per cent of the stated amount of $C_{17}H_{19}N_{3}O_{3}S$ is dissolved in 2 hours.

B. Apparatus. No 1

Medium. 900 ml of phosphate buffer pH 6.8,

Speed and time. 100 rpm and 45 minutes.

Tap the granules from a capsule slightly with a glass rod to make them settle to the bottom. Rotate the paddle at 100 rpm for 45 minutes and filter the solution. Using the filtered medium as the test solution, carry out the determination as described in the Assay. Calculate the content of $C_{17}H_{19}N_{3}O_{3}S$ in the medium.

D. Not less than 70 per cent of the stated amount of $C_{17}H_{19}N_{3}O_{3}S$.

Other Tests. Comply with the tests stated under Capsules.

Loss on drying (2.4.19). Not more than 3.0 per cent, determined on 0.5 g of the contents of the capsules by drying in an oven at 60º at a pressure not exceeding 0.7 kPa for 4 hours.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Mix the contents of 20 capsules. Weigh and transfer the granules containing about 20 mg of Omeprazole to a 100-ml volumetric flask, add 20 ml of 0.1 $M$ sodium hydroxide, mix with the aid of ultrasound and dilute to volume with 0.1 $M$ sodium hydroxide. Centrifuge for 5 minutes and dilute 5.0 ml of the clear supernatant liquid to 50.0 ml with the mobile phase.

Reference solution. Take 20 mg of omeprazole RS in a dry, stoppered test-tube, add 20.0 ml of 0.1 $M$ sodium hydroxide, shake vigorously for 5 minutes and dilute 1.0 ml of the solution with the mobile phase to produce 50.0 ml.

Chromatographic system

- a stainless steel column 30 cm x 3.9 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 65 volumes of phosphate buffer pH 7.4 and 35 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 302 nm,
- a 20 µl loop injector.
Inject the reference solution. Repeat the procedure at least five times and measure the peak responses of the peak due to omeprazole. The relative standard deviation of the replicate injections is not more than 2.0 per cent.

Calculate the content of C₁₇H₁₉N₃O₃S in the capsules.

**Storage.** Store protected from light and moisture.

---

**Oral Rehydration Salts**

**ORS Powder**

Oral Rehydration Salts are dry, homogeneously mixed powders containing Dextrose, Sodium Chloride, Potassium Chloride and either Sodium Bicarbonate or Sodium Citrate for use in oral rehydration therapy after being dissolved in the requisite amount of water.

They may contain suitable flavouring agents and, where necessary, suitable flow agents in the minimum quantity required to achieve a satisfactory product but may not contain artificial sweetening agents like mono- and/or polysaccharides. If saccharin/saccharin sodium or aspartame is used in preparations meant for paediatric use, the concentration of saccharin should be such that its daily intake is not more than 5 mg/kg of body weight and that of aspartame should be such that its daily intake is not more than 40 mg/kg of body weight.

**Strength.** A formulation of reduced osmolarity (given below) recommended by the World Health Organization (WHO) for the Diarrhoeal Diseases Control Programme, and of the United Nations Children’s Fund (UNICEF).

Composition of the formulation in terms of the amount, in g, to be dissolved in sufficient water to produce 1000 ml.

- Sodium Chloride 2.6
- Dextrose (anhydrous) 13.5
- or Dextrose Monohydrate 14.85
- Potassium Chloride 1.5
- Sodium Citrate 2.9

The molar concentrations of sodium, potassium, chloride and citrate ions in terms of millimoles per litre are given below:

<table>
<thead>
<tr>
<th>Ion</th>
<th>mmol/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium</td>
<td>75</td>
</tr>
<tr>
<td>Potassium</td>
<td>20</td>
</tr>
<tr>
<td>Chloride</td>
<td>65</td>
</tr>
<tr>
<td>Citrate</td>
<td>10</td>
</tr>
<tr>
<td>Dextrose</td>
<td>75</td>
</tr>
</tbody>
</table>

The total osmolar concentration of the solution in terms of mOsmol per litre is 245.

Oral Rehydration Salts contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of Dextrose (anhydrous) or Dextrose Monohydrate (as appropriate) and of the requisite amounts of sodium, Na, potassium, K, chloride, Cl, and citrate, C₆H₅O₇, calculated from the stated amounts of the relevant constituents.

**Description.** A white to creamy-white, amorphous or crystalline powder; odourless.

**Identification**

A. When heated, melting and charring occurs and an odour of burnt sugar is produced.

B. Add a few drops of the solution prepared as directed in the label to 5 ml of potassium cupri-tartrate solution; a copious red precipitate is produced on boiling.

C. Gives reaction A of sodium salts, reaction A of potassium salts and reaction A of chlorides (2.3.1).

D. A quantity containing about 50 mg of citric acid gives the reactions of citrates (2.3.1).

**Tests**

**Uniformity of weight.** Comply with the test for contents of packaged dosage forms (2.5.6).

**Seal test (only for sachets).** Loosely bundle 10 sachets with a rubber band and submerge the bundle under water in a vacuum desiccator maintained at a pressure not exceeding 18 kPa for one minute. Examine the bundle for any fine stream of bubbles. Re-establish normal pressure and open the bundle. No penetration of water is observed in any sachet.

**Other Tests.** Comply with the tests stated under Oral Powders.

**Assay.** Carry out the following assays on the well-mixed contents of an individual sachet or on a suitable sample from the well-mixed contents of a bulk container. Where the amount in an individual sachet is insufficient to carry out all the assays, take a separate sachet for the Assay for citrate and for the Assay for dextrose. For the Assays for total sodium, for potassium and for total chloride weigh accurately about 8.0 g and dissolve in sufficient water to produce 500.0 ml (solution A).

For total sodium — Dilute a suitable volume of solution A with a sufficient volume of a solution of strontium chloride such that the final solution contains a 1500- to 2000-fold excess of strontium ions and determine by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 589 nm and using sodium solution AAS, suitably diluted with the strontium chloride solution, for the standard solutions or, alternately by Method A for flame photometry (2.4.4). 1 g of Sodium Chloride, and of Sodium Citrate is equivalent to 0.3934 and 0.2345 g of Na respectively.
For potassium — Dilute a suitable volume of solution A with a sufficient volume of solution of strontium chloride such that the final solution contains a 1500- to 2000-fold excess of strontium ions and determine by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 767 nm and using potassium solution AAS, suitably diluted with the strontium chloride solution, for the standard solutions or, alternatively by Method A for flame photometry (2.4.4).

1 g of Potassium Chloride is equivalent to 0.5245 g of K.

For total chloride — Titrate 50 ml of solution A with 0.1 M silver nitrate using potassium chromate solution as indicator.

1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of Cl.

1 g of Sodium Chloride, and of Potassium Chloride is equivalent to 0.6066 and 0.4756 g of Cl respectively.

For citrate — Weigh accurately about 2.0 g and dissolve in 50 ml of anhydrous glacial acetic acid by heating at about 50º. Cool, allow to stand for 10 minutes. Titrate with 0.1 M perchloric acid, using 1-naphtholbenzein solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.006303 g of C₆H₅O₇.

1 g of Sodium Citrate is equivalent to 0.6430 g of C₆H₅O₇.

For dextrose — Weigh accurately about 7.5 g, dissolve in 40 ml of water, add 0.5 ml of dilute ammonia solution, and dilute to 50 ml with water. Mix well, allow to stand for 30 minutes, filter the solution, if turbid, and measure the optical rotation in a 2-dm tube (2.4.22). The observed rotation, in degrees, multiplied by 0.9477 and 1.0424 represents the weight in g of C₆H₁₂O₆ and C₆H₁₂O₆·H₂O respectively, as appropriate, in the weight taken for the Assay.

Storage. Store protected from moisture in sachets, preferably made of aluminum foil, containing sufficient powder for a single dose or for a day’s treatment or for use in hospitals, in bulk containers containing sufficient quantity to produce a volume of solution appropriate to the daily requirements of the hospital concerned.

Labelling. The label states (1) for sachets, the total weights, in g, of each constituent; (2) for bulk containers, the weights, in g, of each constituent in a stated quantity, in g, of the oral powder; (3) the molar concentration in millimoles per litre of sodium, potassium, chloride and citrate ions, and of dextrose as well as the total osmolar concentration in mOsmol per litre of the solution prepared from the oral powder; (4) the total weight of the contents of the container; (5) the directions for use; (6) that any portion of the solution prepared from the oral powder that remains unused for 24 hours after preparation should be discarded; (7) the storage conditions. g, of the oral powder.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ormeloxifen hydrochloride RS or with the reference spectrum of ormeloxifen.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.01 per cent w/v solution in methanol shows absorption maxima at about 278 and 282 nm.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 90 volumes of chloroform and 10 volumes of methanol.

Test solution. Dissolve 0.25 g of the substance under examination in 100 ml of chloroform.

Reference solution. A 0.25 per cent w/v solution of ormeloxifen hydrochloride RS in chloroform.

Apply to the plate 2 µl of each solution. After development, dry the plate in air, until the odour of the solvents is no longer detectable and spray with a 0.3 per cent w/v solution of potassium permanganate. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

D. To 1 ml of a 2 per cent w/v solution in ethanol (95 per cent) add 1 ml of a saturated solution of picric acid in water, stir
well and set aside for 5 minutes. The yellow precipitate obtained after washing with water and drying at 60°C for 4 hours melts at 212° to 218° (2.4.21).

**Tests**

**Total basic substances.** Weigh accurately 0.5 g, dissolve in 25 ml of anhydrous glacial acetic acid, add 10 ml of a 5 per cent w/v solution of mercuric acetate in anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator to a bluish green end-point. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.04935 g of C$_{30}$H$_{35}$NO$_3$.HCl.

**cis-Isomer.** Not more than 1.5 per cent of the total content of hydrochlorides of trans- and cis-isomers determined in the Assay.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 3.5 per cent, determined on 1.0 g by drying in an oven at 105°C for 4 hours.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** A 0.004 per cent w/v solution of the substance under examination in the mobile phase.

**Reference solution.** A solution containing 0.004 per cent w/v of trans-ormeloxifen hydrochloride RS and 0.0006 per cent w/v of cis-ormeloxifen hydrochloride RS in the mobile phase.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 80 volumes of acetonitrile and 20 volumes of water containing 0.04 per cent w/v solution of tetramethylammonium hydroxide adjusted to pH 7.6 with phosphoric acid,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 µl loop injector.

Inject the reference solution and use an attenuation such that the response for the principal peak due to trans-ormeloxifen hydrochloride is more than 50 per cent of the full-scale deflection of the recorder. Make a total of six injections. When the chromatograms are recorded under the conditions described above, trans-ormeloxifen hydrochloride is eluted before cis-ormeloxifen hydrochloride. The test is not valid unless the relative standard deviation of six replicate injections is not greater than 6 per cent and the resolution between the peaks due to cis-ormeloxifen hydrochloride and trans-ormeloxifen hydrochloride is greater than 1. If necessary, adjust the proportions and the flow rate of the mobile phase to obtain proper resolution. Inject a suitable volume of test solution and record the response. From the average peak areas of the six replicate analyses calculate the content of trans-ormeloxifen hydrochloride and cis-ormeloxifen hydrochloride in the substance under examination by comparing with the peak responses for trans-ormeloxifen hydrochloride and cis-ormeloxifen hydrochloride respectively obtained with reference solution.

**Storage.** Store protected from moisture.

**Ormeloxifen Hydrochloride Tablets**

**Centchroman Hydrochloride Tablets; Centchroman Tablets**

Ormeloxifen Hydrochloride Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of Ormeloxifen hydrochloride, C$_{30}$H$_{35}$NO$_3$.HCl.

**Identification**

Shake a quantity of the powdered tablets containing 0.1 g of Ormeloxifen Hydrochloride with 10 ml of chloroform, filter and evaporate the filtrate to dryness at a pressure not exceeding 0.7 kPa. The residue complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ormeloxifen hydrochloride RS or with the reference spectrum of ormeloxifen.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.01 per cent w/v solution in methanol shows absorption maxima at about 278 and 282 nm.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 90 volumes of chloroform and 10 volumes of methanol.

**Test solution.** Dissolve 0.25 g of the substance under examination in 100 ml of chloroform.

**Reference solution.** A 0.25 per cent w/v solution of ormeloxifen hydrochloride RS in chloroform.

Apply to the plate 2 µl of each solution. After development, dry the plate in air, until the odour of the solvents is no longer detectable and spray with a 0.3 per cent w/v solution of potassium permanganate. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

**Tests**

**Dissolution** (2.5.2).

**Apparatus.** No 2

**Medium.** 900 ml of water.
Speed and time. 100 rpm and 45 minutes.
Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate, suitably diluted if necessary, at the maximum at about 278 nm (2.4.7). Calculate the content of C₃₀H₃₅NO₃.HCl in the medium from the absorbance obtained from a solution of known concentration of Ormeloxifen hydrochloride RS in water.

D. Not less than 70 per cent of the stated amount of C₃₀H₃₅NO₃.HCl.

cis-Isomer. Not more than 1.5 per cent of the total content of hydrochlorides of trans-and cis-isomers determined in the Assay.

Other Tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.17).

Test solution. Weigh and powder 20 tablets. Shake a quantity of the powder containing 0.1 g of Ormeloxifen Hydrochloride with three quantities, each of 5 ml, of methanol, centrifuge each extract, dilute the combined extracts to 25 ml with methanol and then dilute 250 µl of the resulting solution to 25 ml with the mobile phase.

Reference solution. A solution containing 0.004 per cent w/v of trans-ormeloxifen hydrochloride RS and 0.0006 per cent w/v of cis-ormeloxifen hydrochloride RS in the mobile phase.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 80 volumes of acetonitrile and 20 volumes of water containing 0.04 per cent w/v solution of tetramethylammonium hydroxide adjusted to pH 7.6 with phosphoric acid,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 µl loop injector.

Inject the reference solution and use an attenuation such that the response for the principal peak due to trans-ormeloxifen hydrochloride is more than 50 per cent of full-scale deflection of the recorder. Make a total of six injections. When the chromatograms are recorded under the conditions described above, trans-ormeloxifen hydrochloride is eluted before cis-ormeloxifen hydrochloride. The test is not valid unless the relative standard deviation of six replicate injections is not greater than 6 per cent and the resolution between the peaks due to cis-ormeloxifen hydrochloride and trans-ormeloxifen hydrochloride is greater than 1. If necessary, adjust the proportions and the flow rate of the mobile phase to obtain proper resolution. Inject a suitable volume of test solution and record the response. From the average peak areas of the six replicate analyses calculate the content of trans-ormeloxifen hydrochloride and cis-ormeloxifen hydrochloride in the substance under examination.

Storage. Store protected from moisture.

Orphenadrine Citrate

\[
\text{Orphenadrine Citrate is (RS)-dimethyl[2-(2-methylbenzhydryloxy)ethyl]amine dihydrogen citrate.}
\]

Orphenadrine Citrate contains not less than 98.5 per cent and not more than 101.0 per cent of C₁₈H₂₃NO₃C₆H₈O₇, calculated on the dried basis.

Description. A white or almost white, crystalline powder; odourless or almost odourless.

Identification

Test A may be omitted if tests B, C, D and E are carried out. Tests B, C and D may be omitted if tests A and E are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with orphenadrine citrate RS.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.06 per cent w/v solution in ethanol (95 per cent) shows absorption maxima at 258 nm, 264 nm and 271 nm; absorbances at the maxima are about 0.68, 0.72 and 0.47 respectively.

C. Dissolve 50 mg in 10 ml of ethanol (50 per cent), add 10 ml of picric acid solution and allow to stand. The precipitate, after recrystallisation from ethanol (95 per cent), melts at about 89º or at about 107º (2.4.21).

D. Dissolve 5 mg in 2 ml of sulphuric acid; an orange-red colour is produced.

E. To 1 g add 10 ml water and 2 ml of 5 M sodium hydroxide, shake with two quantities, each of 10 ml, of chloroform and discard the chloroform. Heat the aqueous solution to boiling with an excess of mercuric sulphate solution, filter if necessary and boil the resulting solution with 0.2 ml of dilute potassium permanganate solution; the solution is decolorised and a white precipitate is produced.
Orphenadrine Hydrochloride

**C_{15}H_{25}NO.HCl**

Orphenadrine Hydrochloride is (RS)-dimethyl [2-(2-methylbenzhydryloxy) ethyl]amine hydrochloride.

Orphenadrine Hydrochloride contains not less than 98.5 per cent and not more than 101.0 per cent of C_{15}H_{25}NO.HCl calculated on the dried basis.

**Description.** A white or almost white, crystalline powder; odourless or almost odourless.

**Tests**

**Quaternary ammonium salt.** Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel G*.

**Mobile phase.** A mixture of 50 volumes of 2-propanol, 30 volumes of *butyl acetate*. 15 volumes of water and 5 volumes of *strong ammonia solution*.

**Test solution.** Dissolve 0.1 g of the substance under examination in 10 ml methanol.

**Reference solution.** A 0.005 per cent *w/v* solution of ethyldimethyl [2-(2-methylbenzhydryloxy)ethyl] ammonium chloride RS.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and spray with *dilute potassium iodobismuthate solution*. Any spot corresponding to ethyldimethyl [2-(2-methylbenzhydryloxy) ethyl] ammonium chloride in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Secondary amine.** Determine by thin-layer chromatography (2.4.17) coating the plate with *silica gel GF254*.

**Mobile phase.** A mixture of 96 volumes of 1-butanol and 4 volumes of *strong ammonia solution*.

**Test solution.** Dissolve 0.4 g of the substance under examination in 10 ml methanol.

**Reference solution.** A 0.02 per cent *w/v* solution of methyl [2-(2-methylbenzhydryloxy)ethyl]amine hydrochloride RS.

Apply to the plate 10 µl of each solution. After development, dry in air and examine in ultra-violet light at 254 nm. Spray the plate with *dilute potassium iodobismuthate solution* and examine again. By each method of visualisation any spot corresponding to methyl [2-(2-methylbenzhydryloxy)ethyl]amine hydrochloride in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Heavy Metals** (2.3.13). 2.0 g complies with the limit test for heavy metals, Method B (10 ppm). Use 2 ml of lead standard solution (10 ppm Pb) to prepare the standard.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.3.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º for 3 hours.

**Assay.** Weigh accurately about 1.0 g dissolve in 30 ml of anhydrous glacial acetic acid. Titrate with 0.1 *M perchloric acid*, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 *M perchloric acid* is equivalent to 0.04615 g of C_{15}H_{25}NO, C_{6}H_{8}O_{7}.

**Storage.** Store protected from light.
Secondary amine. Determine by thin-layer chromatography (2.4.17) coating the plate with silica gel GF254.

Mobile phase. A mixture of 96 volumes of l-butanol and 4 volumes of strong ammonia solution.

Test solution. Dissolve 0.4 g of the substance under examination in 10 ml methanol.

Reference solution. A 0.02 per cent w/v solution of methyl [2-(2-methylbenzhydryloxy)ethyl]amine hydrochloride RS.

Apply to the plate 10 µl of each solution. After development, dry in air and examine in ultra-violet light at 254 nm. Spray the plate with dilute potassium iodobismuthate solution and examine again. By each method of visualisation any spot corresponding to methyl [2-(2-methylbenzhydryloxy)ethyl]amine hydrochloride in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Heavy Metals (2.3.13). 2.0 g complies with the limit test for heavy metals, Method B (10 ppm). Use 2 ml of lead standard solution (10 ppm Pb) to prepare the standard.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.3.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105° for 3 hours.

Assay. Weigh accurately about 1.0 g, dissolve in 20 ml of anhydrous glacial acetic acid, add 20 ml of mercuric acetate solution and titrate with 0.1 M perchloric acid using 1-naphtholbenzein solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.03058 g of C18H23NO, HCl.

Storage. Store protected from light.

Orphenadrine Tablets

Orphenadrine Hydrochloride Tablets

Orphenadrine Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of orphenadrine hydrochloride, C18H23NO.HCl.

Identification

Extract a quantity of the powdered tablets containing about 0.15 g of Orphenadrine Hydrochloride with chloroform, filter and evaporate the filtrate to dryness. The residue complies with the following tests.

A. Dissolve 5 mg in 2 ml of sulphuric acid; an orange-red colour is produced.

B. Dissolve 50 mg in 10 ml of ethanol (50 per cent), add 10 ml of picric acid solution and allow to stand. The precipitate, after recrystallisation from ethanol (95 per cent), melts at about 89° or at about 107° (2.4.21).

C. A 5 per cent w/v solution gives reaction A of chlorides (2.3.1).

Tests

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 70 mg Orphenadrine Hydrochloride and dissolve as completely as possible in a mixture of 5 ml of water and 5 ml of 2 M hydrochloric acid. Without delay extract with four quantities, each of 15 ml, of chloroform, filter the combined extracts and evaporate to about 20 ml. Add 30 ml of anhydrous glacial acetic and 2 ml of mercuric acetate solution and titrate with 0.02 M perchloric acid determining the end point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.02 M perchloric acid is equivalent to 0.006117 g of C18H23NO.HCl.

Storage. Store protected from light and moisture.

Oseltamivir Phosphate

Oseltamivir Phosphate is phosphoric acid salt of ethyl (3R,4R,5S)-4-(acetylamino)-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate.

Oseltamivir Phosphate contain not less than 98.0 per cent and not more than 102.0 per cent of C16H28N2O4 .H3PO4, calculated on the dried basis.

Description. A white to off-white powder.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with oseltamivir phosphate RS.
B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Specific optical rotation** (2.4.22). -42.0° to -48.0°, determined in a 1.0 per cent w/v solution in methanol.

**Related substances.** Determine by liquid chromatography (2.4.14).

*NOTE — Prepare the solutions immediately before use.*

**Test solution.** Dissolve 25 mg of the substance under examination in 25 ml of the mobile phase.

**Reference solution (a).** A 0.1 per cent w/v solution of oseltamivir phosphate RS in the mobile phase.

**Reference solution (b).** Dilute 1 ml of reference solution (a) to 100 ml with the mobile phase.

**Chromatographic system**
- a stainless steel column 15 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm) (such as YMC pack PRO C8),
- column temperature 50º,
- mobile phase: a mixture of 66 volumes of buffer solution prepared by dissolving 6.8 g of anhydrous monobasic potassium phosphate in 1000 ml of water and adjusting the pH to 6.0 with dilute sodium hydroxide, 24.5 volumes of methanol and 23.5 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 207 nm,
- a 20 µl loop injector.

Inject reference solution (a). The test is not valid unless the column efficiency is not less than 2000 theoretical plates and the tailing factor is not more than 2.0.

Inject the test solution and reference solution (b). Calculate the content of C₁₆H₂₈N₂O₄·H₃PO₄.

**Phosphoric acid.** 23.4 to 24.4 per cent, calculated on a dried basis.

Weigh accurately about 0.2 g and dissolve in 40 ml of distilled water. Titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.0049 g of phosphoric acid.

**Heavy metals** (2.3.13). 1 g complies with the limit test for heavy metals, Method A (20 ppm).

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1 g by drying in an oven at 105º.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 50 mg of the substance under examination in 50.0 ml of the mobile phase. Dilute 10.0 ml of the solution to 50.0 ml with the mobile phase.

**Reference solution.** A 0.02 per cent w/v solution of oseltamivir phosphate RS in the mobile phase.

**Chromatographic system**
- a stainless steel column 15 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm) (such as YMC pack PRO C8),
- column temperature 50º,
- mobile phase: a mixture of 66 volumes of buffer solution prepared by dissolving 6.8 g of anhydrous monobasic potassium phosphate in 1000 ml of water and adjusting the pH to 6.0 with dilute sodium hydroxide, 24.5 volumes of methanol and 23.5 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 207 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency in not less than 2000 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution. Calculate the content of C₁₀H₂₃N₂O₅·H₃PO₄.

**Storage.** Store protected from light and moisture.

**Oseltamivir Capsules**

Oseltamivir Phosphate Capsules

Oseltamivir Capsules contain Oseltamivir Phosphate.

Oseltamivir Capsules contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of oseltamivir, C₁₀H₂₃N₂O₅.

**Identification**

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Dissolution** (2.5.2).

Apparatus. No. 1

Medium. 900 ml of 0.1 M hydrochloric acid.

Speed and time. 50 rpm and 45 minutes
Withdraw a suitable volume of the medium and filter. Determine by liquid chromatography (2.4.14).

Test solution. Use the filtrate.

Reference solution. Dissolve 50 mg of oseltamivir phosphate RS in 20 ml of the mobile phase and dilute to 100 ml with the dissolution medium. Dilute 5 ml of the solution to 25 ml with the dissolution medium.

Test solution. Weigh accurately a quantity of the mixed contents of 20 capsules containing about 50 mg of oseltamivir, disperse in 50 ml of mobile phase and filter.

Reference solution (a). A 0.1 per cent w/v solution of oseltamivir phosphate RS in the mobile phase.

Reference solution (b). Dilute 1 ml of reference solution to 100 ml with the mobile phase.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm) (such as YMC pack PRO C8),
- mobile phase: a mixture of 66 volumes of a buffer solution prepared by dissolving 6.8 g of anhydrous monobasic potassium phosphate in 1000 ml of water, adjusting the pH to 6.0 with dilute sodium hydroxide, 24.5 volumes of methanol and 23.5 volumes of acetonitrile,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 207 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the column efficiency is not less than 2000 theoretical plates and the tailing factor is not more than 2.0, the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution. Calculate the content of C₁₆H₂₈N₂O₄.

Storage. Store protected from moisture, at a temperature not exceeding 30º.

Labelling. The label states the strength in terms of the equivalent amount of oseltamivir.

Oseltamivir Oral Suspension

Oseltamivir Phosphate Oral Suspension

Oseltamivir Oral Suspension is a mixture consisting of Oseltamivir Phosphate with buffering agents and other excipients. It contains a suitable flavouring agent. It is filled in a sealed container.

The suspension is constituted by dispersing the contents of the sealed container in the specified volume of water just before issue.

Oseltamivir Oral Suspension contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of oseltamivir C₁₆H₂₈N₂O₄.

The contents of the sealed container comply with the following requirement.

Water (2.3.43). Not more than 2.5 per cent, determined on 1.0 g.

The constituted suspension complies with the requirements stated under Oral liquids and with the following requirements.
Identification

A. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with reference solution (b).

B. To 2 ml of the reconstituted suspension, add 2 ml of dilute nitric acid and 4 ml of a 10 per cent w/v solution of ammonium molybdate and warm the solution. A bright yellow precipitate is formed.

Tests

pH (2.4.24). 3.0 to 5.0.

Related substances. Determine by liquid chromatography (2.4.14).

NOTE — Prepare the solutions immediately before use.

Test solution. Weigh accurately a quantity of the suspension containing 25 mg of oseltamivir, dissolve in 25 ml of the mobile phase and filter.

Reference solution (a). A 0.1 per cent w/v solution of oseltamivir phosphate RS in the mobile phase.

Reference solution (b). Dilute 1 ml of reference solution (a) to 100 ml with the mobile phase.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),
- column temperature 35º,
- mobile phase: 70 volumes of a buffer solution prepared by dissolving 6.8 g of potassium dihydrogen phosphate in 1000 ml of water and adjusting the pH to 6.0 with dilute sodium hydroxide, 15 volumes of methanol and 15 volumes of acetonitrile,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 207 nm,
- a 20 µl loop injector.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than the area of the peak in the chromatogram obtained with the reference solution (b) (1.0 per cent) and the sum of areas of all the secondary peaks is not more than 3 times the area of the peak in the chromatogram obtained with the reference solution (b) (3.0 per cent).

Other tests. Complies with the tests stated under Oral liquids.

Assay. Determine by liquid chromatography (2.4.14).

NOTE — Prepare the solutions immediately before use.

Test solution. Weigh accurately a quantity of the suspension containing 60 mg of oseltamivir, dissolve in 250.0 ml of the mobile phase and filter. Dilute 10.0 ml of the solution to 25.0 ml with the mobile phase and filter.

Reference solution. A 0.0125 per cent w/v solution of oseltamivir phosphate RS in the mobile phase.

Chromatographic system

- a stainless steel column 15 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 60 volumes of a buffer solution prepared by dissolving 6.8 g of potassium dihydrogen phosphate in 1000 ml of water and adjusting the pH to 6.0 with dilute sodium hydroxide, 24.5 volumes of methanol and 23.5 volumes of acetonitrile,
- flow rate. 1.2 ml per minute,
- spectrophotometer set at 207 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency in not less than 2000 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C₁₆H₂₈N₂O₄.

Storage. Store protected from moisture, at a temperature not exceeding 30°.

Labelling. The label states (1) the quantity of active ingredient in terms of the equivalent amount of oseltamivir; (b) the temperature of storage and the period during which the constituted suspension may be expected to be satisfactory for use.

Oxazepam

![Oxazepam](image)

C₁₅H₁₁ClIN₂O₂ Mol. Wt. 286.7

Oxazepam is 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one.

Oxazepam contains not less than 98.5 per cent and not more than 101.0 per cent of C₁₅H₁₁ClIN₂O₂, calculated on the dried basis.
Description. A white or almost white, crystalline powder.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and D may be omitted if tests A and C are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with oxazepam RS.

B. Prepare the solutions immediately before use, protected from light.

Dissolve about 20 mg in sufficient ethanol (95 per cent) to produce 100 ml. Dilute 10 ml of the solution to 50 ml with ethanol (95 per cent) (solution A). Dilute 10 ml of solution A to 100 ml with ethanol (95 per cent) (solution B).

When examined in the range 230 nm to 360 nm (2.4.7), solution A shows an absorption maximum at about 316 nm. When examined in the range 220 nm to 250 nm, solution B shows an absorption maximum at about 229 nm; absorbance at about 229 nm, 1.220 to 1.300.

C. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).

D. Dissolve about 20 mg in a mixture of 5 ml of hydrochloric acid and 10 ml of water. Heat to boiling for 5 minutes and cool. Add 2 ml of a 0.1 per cent w/v solution of sodium nitrite and allow to stand for 1 minute. Add 1 ml of a 0.5 per cent w/v solution of sulphamic acid, mix and allow to stand for 1 minute. Add 1 ml of 0.1 per cent w/v solution of a N- (1-naphthyl) ethylenediamine dihydrochloride; a red colour is produced.

Tests

Related substances: Carry out the test protected from light.

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Wash the plate with methanol before use.

Mobile phase. A mixture of 100 volumes of dichloromethane and 10 volumes of methanol.

Test solution (a). Dissolve 50 mg of the substance under examination in sufficient acetone to produce 10 ml.

Test solution (b). Dilute 2 ml of test solution (a) to 10 ml with acetone.

Reference solution (a). Dissolve 10 mg of oxazepam RS in sufficient acetone to produce 10 ml.

Reference solution (b). Dissolve 10 mg each of oxazepam RS and bromazepam RS in sufficient acetone to produce 10 ml.

Reference solution (c). Dilute 1 ml of reference solution (a) to 100 ml with acetone.

Reference solution (d). Dilute 5 ml of solution (d) to 10 ml with acetone.

Apply to the plate 20 µl of each solution. Allow the mobile phase to rise 17 cm in the same direction as the washing with methanol. Dry in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (c) and at most one such spot is more intense than the spot in the chromatogram obtained with reference solution (d). The test is not valid unless the chromatogram obtained with reference solution (b) shows two clearly separated spots.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.3.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105° at a pressure not exceeding 0.7 kPa.

Assay. Weigh accurately about 0.25 g and dissolve in a mixture of 10 ml of anhydrous glacial acetic acid and 90 ml of acetic anhydride and titrate with 0.1 M perchloric acid determining the end point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02867 g of C₅H₅ClIN₂O₂.

Storage. Store protected from light and moisture.

Oxazepam Tablets

Oxazepam Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of oxazepam, C₅H₃ClIN₂O₂.

Identification

A. Extract a quantity of the powdered tablets containing 20 mg of Oxazepam with 25 ml of chloroform, filter, evaporate to dryness and dry the residue at 60° at a pressure not exceeding 0.7 kPa.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with oxazepam RS or with the reference spectrum of oxazepam.

B. When examined in the range 210 nm to 360 nm (2.4.7), the solution obtained in the Assay shows absorption maxima at about 230 nm and 316 nm.

Tests

Related substances. Carry out the test protected from light.
Determine by thin-layer chromatography (2.4.17) coating the plate with silica gel GF 254. Wash the plate with methanol before use.

**Mobile phase.** A mixture of 100 volumes of dichloromethane and 10 volumes of methanol.

**Test solution.** Shake a quantity of powdered tablets containing 30 mg of Oxazepam with 6 ml of acetone and centrifuge.

**Reference solution (a).** Dilute 1 volume of the test solution to 100 volumes with acetone.

**Reference solution (b).** Dilute 1 volume of the test solution to 500 volumes with acetone.

**Reference solution (c).** A solution containing 0.1 per cent w/v each of oxazepam RS and bromazepam RS.

Apply to the plate 20 µl of each of the solutions. Allow the mobile phase to rise 17 cm in the same direction as in the washing with methanol. Dry in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) (1 per cent) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b) (0.2 per cent). The test is not valid unless the chromatogram obtained with reference solution (c) shows two clearly separated spots.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 25 mg of Oxazepam and shake with 150 ml of ethanol (95 per cent) for 30 minutes. Add sufficient ethanol (95 per cent) to produce 250.0 ml and centrifuge. Dilute 5.0 ml of the supernatant liquid to 100.0 ml with the same solvent and measure the absorbance of the resulting solution at the maximum at about 230 nm (2.4.7). Calculate the content of C_{15}H_{23}NO_{3},HCl taking 1250 as the specific absorbance at 230 nm.

**Storage.** Store protected from light at a temperature not exceeding 30°C.

---

Oxprenolol Hydrochloride contains not less than 98.5 per cent and not more than 101.5 per cent of C_{15}H_{23}NO_{3},HCl, calculated on the dried basis.

**Description.** A white or almost white, crystalline powder.

**Identification**

**Test A may be omitted if tests B and C are carried out. Test B may be omitted if tests A and C are carried out.**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with oxprenolol RS or with the reference spectrum of oxprenolol.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (c). C. Gives reaction A of chlorides (2.3.1).

**Tests**

**Appearance of solution.** A 10.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and not more intensely coloured than reference solution GYS6 (2.4.1).

**pH (2.4.24).** 4.5 to 6.0, determined in a freshly prepared 10.0 per cent w/v solution.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 88 volumes of chloroform, 12 volumes of methanol and 2 volumes of strong ammonia solution.

**Test solution (a).** Dissolve 0.5 g of the substance under examination in 10 ml of a mixture of 90 volumes of chloroform and 10 volumes of methanol.

**Test solution (b).** Dissolve 0.5 g of the substance under examination in 100 ml of a mixture of 90 volumes of chloroform and 10 volumes of methanol.

**Reference solution (a).** A 0.02 per cent w/v solution of the substance under examination in a mixture of 90 volumes of chloroform and 10 volumes of methanol.

**Reference solution (b).** A 0.01 per cent w/v solution of the substance under examination in a mixture of 90 volumes of chloroform and 10 volumes of methanol.

**Reference solution (c).** A 0.5 per cent w/v solution of oxprenolol hydrochloride RS in a mixture of 90 volumes of chloroform and 10 volumes of methanol.

Apply to the plate 2 µl of each solution. Allow the mobile phase to rise 13 cm. Dry the plate in warm air for 10 minutes, allow to cool, spray with anisaldehyde solution, heat at 105°C for 10 minutes and examine in daylight. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained.
with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 60º over phosphorus pentoxide at a pressure of 1.5 to 2.5 kPa for 6 hours.

**Assay.** Weigh accurately about 0.25 g, dissolve in 60 ml of anhydrous glacial acetic acid, add 5 ml of mercuric acetate solution. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.03018 g of C₁₅H₂₃NO₃.HCl.

**Storage.** Store protected from light and moisture.

---

**Oxprenolol Tablets**

Oxprenolol Hydrochloride Tablets

Oxprenolol Hydrochloride Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of oxprenolol hydrochloride, C₁₅H₂₃NO₃.HCl. The tablets are coated.

**Identification**

A. To a quantity of the powdered tablets containing 50 mg of Oxprenolol Hydrochloride add 10 ml of water and 2 ml of dilute sodium hydroxide solution, extract with 10 ml of chloroform and reserve the aqueous layer for test C. Dry the chloroform extract over anhydrous sodium sulphate, filter and evaporate the filtrate to dryness.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with oxprenolol hydrochloride RS or with the reference spectrum of oxprenolol hydrochloride.

B. When examined in the range 230 nm to 360 nm (2.4.7), the solution obtained in the Assay shows an absorption maximum only at about 273 nm.

C. The aqueous layer obtained in test A gives reaction A of chlorides (2.3.1).

D. The residue obtained in test A melts at about 76º (2.4.21).

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 88 volumes of chloroform, 12 volumes of methanol and 2 volumes of strong ammonia solution.

**Test solution.** Extract a quantity of the powdered tablets containing 0.25 g of Oxprenolol Hydrochloride with 5 ml of water, centrifuge and use the supernatant liquid.

**Reference solution.** Dilute 1 volume of the test solution to 200 volumes with water.

Apply to the plate 2 μl of each solution. Allow the mobile phase to rise 13 cm. Dry the plate in warm air for 10 minutes, allow to cool, spray with anisaldehyde solution, heat at 105º for 10 minutes and examine in daylight. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Other Tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 20 mg of Oxprenolol Hydrochloride, add 25 ml of 0.1 M hydrochloric acid and sufficient water to produce 250.0 ml. Mix with the aid of ultrasound for 5 minutes, shake for 15 minutes and filter. Measure the absorbance of the resulting solution at the maximum at about 273 nm (2.4.7). Calculate the content of C₁₅H₂₃NO₃.HCl taking 74.5 as the specific absorbance at 273 nm.

**Storage.** Store protected from moisture.

---

**Oxygen**

O₂

Mol. Wt. 32.0

Oxygen contains not less than 99.0 per cent v/v of O₂.

This monograph applies to oxygen for medicinal use only.

**Description.** A colourless gas; odourless.

**Identification**

A. A glowing splinter of wood bursts into flame on contact with the gas.

B. Shake with alkaline pyrogallol solution; the gas under examination is absorbed and the solution becoming dark brown.

C. When tested as described under Assay, not more than 1.0 ml of gas remains.

**Tests**

**Carbon dioxide.** Not more than 300 ppm v/v, determined by using a carbon dioxide detector tube (2.1.1).
Carbon monoxide. Not more than 5 ppm v/v, determined by using a carbon monoxide detector tube (2.1.1).

Water vapour. Not more than 67 ppm v/v, determined by using a water vapour detector tube (2.1.1).

Assay (2.3.3). Use 100 ml of the gas under examination and place spirals of freshly cleaned copper wire and 125 ml of ammonia buffer pH 10.9 in the pipette. The volume of the residual gas in the burette is not more than 1.0 ml.

Storage. Store under pressure in metal cylinders of the type conforming to the appropriate safety regulations. Valves and taps should not be lubricated with oil or grease.

Labelling. The shoulder of the metal cylinder should be painted white and the remainder should be painted black. The cylinder should carry a label stating “Oxygen”. In addition, “Oxygen” or the symbol “O2” should be stencilled in paint on the shoulder of the cylinder.

Oxygen 93 Per Cent

Oxygen 93 Per Cent contains not less than 90.0 per cent and not more than 96.0 per cent, v/v of O2, the remainder consisting mostly of argon and nitrogen. It is produced from air by the molecular sieve process.

Description. A colourless gas; odourless.

Identification

A. A glowing splinter of wood bursts into flame on contact with the gas.

B. Shake with alkaline pyrogallol solution; the gas under examination is absorbed and the solution becomes dark brown.

C. When tested as described under Assay, not more than 10.0 ml and not less than 4.0 ml of gas remain.

Tests

Carbon dioxide. Not more than 300 ppm v/v, determined by using a carbon dioxide detector tube (2.1.1).

Carbon monoxide. Not more than 5 ppm v/v, determined by using a carbon monoxide detector tube (2.1.1).

Assay (2.3.3). Use 100 ml of the gas under examination and place spirals of freshly cleaned copper wire and 125 ml of ammonia buffer pH 10.9 in the pipette. The volume of the residual gas in the burette is not more than 10.0 ml and not less than 4.0 ml.

Storage. Store in cylinders or in a low pressure collecting tank. Containers used for Oxygen 93 Per Cent must not be treated with any toxic, sleep-inducing or narcosis-producing compounds and must not be treated with any compound that will be irritating to the respiratory tract when the Oxygen 93 Per Cent is used.

Labelling. Label each outlet “Oxygen 93 Per Cent”, when it is piped directly from the collecting tank to the point of use. If it is stored in cylinders, reduce the pressure by means of a regulator. Measure the gases with a gas volume meter downstream from the detector tube in order to minimise contamination or change of the specimens. The shoulder of the cylinder should be painted white and the remainder should be painted black. The cylinder should carry a label stating “Oxygen 93 Per Cent” and “For medicinal use”.

Oxyphenbutazone

C_{19}H_{20}N_{2}O_{3},H_{2}O Mol. Wt. 342.4

Oxyphenbutazone is (RS)-4-butyl-1-(4-hydroxyphenyl)-2-phenylpyrazolidine-3,5-dione monohydrate.

Oxyphenbutazone contains not less than 98.0 per cent and not more than 101.0 per cent of C_{19}H_{20}N_{2}O_{3}, calculated on the anhydrous basis.

Description. A white to yellowish white, crystalline powder; almost odourless.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and D may be omitted if tests A and C are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with oxyphenbutazone RS or with the reference spectrum of oxyphenbutazone.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.01 M sodium hydroxide shows an absorption maximum at about 254 nm; absorbance at about 254 nm, 0.71 to 0.77.

C. To 2 ml of a 1 per cent w/v solution in ethanol (95 per cent) add 2 ml of a 0.1 per cent w/v solution of 2,6-dichloroquinone-
4-chlorimide in ethanol (95 per cent) and 1 ml of sodium carbonate solution; an intense green colour is produced.

D. To 0.1 g add 1 ml of glacial acetic acid and 2 ml of hydrochloric acid and boil under a reflux condenser for 30 minutes. Cool, add 10 ml of water and filter. To the filtrate add 3 ml of a 0.7 per cent w/v solution of sodium nitrite; a yellow colour develops. To 1 ml of the resulting solution add a solution of 10 mg of 2-naphthol in 5 ml of sodium carbonate solution; an orange-red precipitate is produced.

Tests

**Appearance of solution.** To 0.5 g add a mixture of 12 ml of 1 M sodium hydroxide and 8 ml of a 7.5 per cent w/v solution of glycine, shake for 1 minute and maintain at 25º for exactly 60 minutes. The solution is clear (2.4.1).

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

**Mobile phase.** A 0.02 per cent w/v solution of butylated hydroxytoluene in a mixture of 80 volumes of chloroform and 20 volumes of glacial acetic acid.

**Test solution.** Dissolve 0.1 g of the substance under examination in 5 ml of a solution containing 0.02 per cent w/v of butylated hydroxytoluene in ethanol.

**Reference solution.** Dilute 1 ml of the test solution to 200 ml with the ethanolic butylated hydroxytoluene solution.

To prepare the plate, allow the mobile phase to rise 4 cm. Dry the plate in a current of cold air for 1 minute. Without delay and under a current of nitrogen, apply separately to the plate 5 µl of each solution prepared immediately before use. Develop immediately, allowing the mobile phase to rise 10 cm. Dry the plate in a current of cold air for 15 minutes and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Water** (2.3.43). 5.0 to 6.0 per cent, determined on 0.5 g.

**Assay.** Weigh accurately about 0.5 g, dissolve in 50 ml of acetone and titrate with 0.1 M sodium hydroxide, using bromothymol blue solution as indicator and continuing the titration until the blue colour persists for at least 15 seconds. Carry out a blank titration.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.03244 g of C19H20N2O3.

**Storage.** Store protected from light.

--

**Oxyphenbutazone Tablets**

Oxyphenbutazone Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of oxyphenbutazone, C19H20N2O3,H2O. The tablets are coated.

**Identification**

Extract a quantity of the powdered tablets containing 0.3 g of Oxyphenbutazone with 60 ml of acetone, filter and evaporate the filtrate to dryness. The residue complies with the following tests.

A. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.01 M sodium hydroxide shows an absorption maximum at about 254 nm; absorbance at about 254 nm, 0.71 to 0.77.

B. To 2 ml of a 1 per cent w/v solution in ethanol (95 per cent) add 2 ml of a 0.1 per cent w/v solution of 2,6-dichloroquinone-4-chlorimide in ethanol (95 per cent) and 1 ml of sodium carbonate solution; an intense green colour is produced.

C. To 0.1 g add 1 ml of glacial acetic acid and 2 ml of hydrochloric acid and boil under a reflux condenser for 30 minutes. Cool, add 10 ml of water and filter. To the filtrate add 3 ml of a 0.7 per cent w/v solution of sodium nitrite; a yellow colour develops. To 1 ml of the resulting solution add a solution of 10 mg of 2-naphthol in 5 ml of sodium carbonate solution; an orange-red precipitate is produced.

Tests

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

**Mobile phase.** A 0.02 per cent w/v solution of butylated hydroxytoluene in a mixture of 80 volumes of chloroform and 20 volumes of glacial acetic acid.

**Test solution.** Shake a quantity of the powdered tablets containing 0.2 g of Oxyphenbutazone with 10 ml of a solution containing 0.02 per cent w/v of butylated hydroxytoluene in ethanol for 15 minutes and centrifuge. Use the supernatant liquid.

**Reference solution.** Dilute 1 ml of the test solution to 200 ml with the ethanolic butylated hydroxytoluene solution.

To prepare the plate, allow the mobile phase to rise 4 cm. Dry the plate in a current of cold air for 1 minute. Without delay and under a current of nitrogen, apply separately to the plate 5 µl of each solution prepared immediately before use. Develop immediately, allowing the mobile phase to rise 10 cm. Dry the plate in a current of cold air for 15 minutes and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.
**Dissolution (2.5.2).**

Apparatus. No 1

Medium. 900 ml of phosphate buffer pH 7.6.

Speed and time. 100 rpm and 30 minutes.

Withdraw a suitable volume of the medium and filter promptly through a membrane filter disc with an average pore diameter not greater than 1.0 µm. Reject the first few ml of the filtrate and dilute a suitable volume of the filtrate with the same solvent. Measure the absorbance of the resulting solution at the maximum at about 262 nm (2.4.7). Calculate the content of C_{19}H_{20}N_{2}O_{3},H_{2}O in the medium from the absorbance obtained from a solution of known concentration of oxyphenbutazone RS in the same medium.

D. Not less than 60 per cent of the stated amount of C_{19}H_{20}N_{2}O_{3},H_{2}O.

**Other Tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh 20 tablets and reduce to a fine powder. Weigh accurately a quantity of the powder containing about 0.5 g of Oxyphenbutazone and extract successively with 30, 10 and 10 ml of warm acetone. Filter the combined extracts, cool. Titrate with 0.1 M sodium hydroxide, using bromothymol blue solution as indicator and continuing the titration until the blue colour persists for at least 15 seconds. Carry out a blank titration.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.03424 g of C_{19}H_{20}N_{2}O_{3},H_{2}O.

**Storage.** Store protected from moisture.

---

**Oxytetracycline Dihydrate**

Oxytetracycline

\[
\begin{align*}
\text{C}_{22}\text{H}_{24}\text{N}_{2}\text{O}_{9}2\text{H}_{2}\text{O} & \quad \text{Mol. Wt. 496.5} \\
\text{Oxytetracycline is (4S,4aR,5S,5aR,6S,12aS)-4-dimethyl amino-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide, a substance produced by the growth of certain strains of Streptomyces rimosus or obtained by any other means. It contains a variable quantity of water.}
\end{align*}
\]

Oxytetracycline has a potency not less than 900 µg of C_{22}H_{24}N_{2}O_{9}, per mg, calculated on the anhydrous basis.

**Description.** A tan yellow or light yellow (with or without a greenish tinge), crystalline powder; odourless.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), coating the plate with the substance prepared by mixing 25 g of silica gel G with 50 ml of a mixture of 2.5 ml of glycerin and 47.5 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution. After spreading the plate, allow it to stand at room temperature till it is dry (70 to 90 minutes).

**Mobile phase.** The lower layer formed after shaking 200 ml of a mixture of 2 volumes of ethyl acetate, 2 volumes of chloroform and 1 volume of acetone with 25 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution.

**Test solution.** Dissolve 0.05 g of the substance under examination in 100 ml of methanol.

**Reference solution (a).** A 0.05 per cent w/v solution of oxytetracycline RS in methanol.

**Reference solution (b).** A solution containing 0.05 per cent w/v each of demethylchlortetracycline hydrochloride RS, oxytetracycline hydrochloride RS and tetracycline hydrochloride RS in methanol.

Apply to the plate 1 µl of each solution, freshly prepared. After development, dry the plate in air, expose to the vapours of ammonia and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

B. To about 0.5 mg add 2 ml of sulphuric acid; a red colour is produced. Add the solution to 1 ml of water; the colour changes to yellow.

C. Dissolve about 2 mg in 5 ml of a 1 per cent w/v solution of sodium carbonate and add 2 ml of diazotised sulphanilic acid solution; an orange-red to brownish-red colour is produced.

**Tests**

**pH (2.4.24).** 4.5 to 7.5, determined in a 1.0 per cent w/v suspension in freshly boiled and cooled water.

**Specific optical rotation (2.4.22).** –203° to –216°, determined at 20° in a 1.0 per cent w/v solution in 0.1 M hydrochloric acid, after allowing the solution to stand protected from light for 30 minutes before measurement.
Light absorption. Absorbance of a 0.002 per cent w/v solution in buffer solution pH 2.0 at the maximum at about 353 nm, 0.58 to 0.62 (2.4.7).

Light-absorbing impurities. A. Dissolve 20 mg in sufficient of a mixture of 1 volume of 1 M hydrochloric acid and 99 volumes of methanol to produce 10 ml. Absorbance of the resulting solution at about 430 nm, when measured within 1 hour of preparing the solution, not more than 0.25, calculated on the anhydrous basis (2.4.7).

B. Dissolve 0.1 g in sufficient of a mixture of 1 volume of 1 M hydrochloric acid and 99 volumes of methanol to produce 10 ml. Absorbance of the resulting solution at about 490 nm, when measured within 1 hour of preparing the solution, not more than 0.20, calculated on the anhydrous basis (2.4.7).

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 20 mg of the substance under examination in 25 ml of 0.01 M hydrochloric acid.

Reference solution (a). Dissolve 20 mg of oxytetracycline RS in 25 ml of 0.01 M hydrochloric acid.

Reference solution (b). Dissolve 20 mg of 4-epi-oxytetra-cycline RS in 25 ml of 0.01 M hydrochloric acid.

Reference solution (c). Dissolve 20 mg of tetracycline hydrochloride RS in 25 ml of 0.01 M hydrochloric acid.

Reference solution (d). Dilute a mixture of 1.5 ml of reference solution (a), 1.0 ml of reference solution (b) and 3.0 ml of reference solution (c) to 25 ml with 0.01 M hydrochloric acid.

Reference solution (e). Dilute a mixture of 1.0 ml of reference solution (b) and 4.0 ml of reference solution (c) to 200 ml with 0.01 M hydrochloric acid.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with styrene-divinylbenzene co-polymer (8 to 10 µm),
- column. temperature 60º,
- mobile phase: add 60 g of 2-methyl-2-propanol to a volumetric flask with the aid of 200 ml of water, add 60 ml of 0.33 M phosphate buffer pH 7.5, 50 ml of a 1.0 per cent w/v solution of tetrabutylammonium hydrogen sulphate previously adjusted to pH 7.5 with 2 M sodium hydroxide and 10 ml of a 0.04 per cent w/v solution of disodium edetate previously adjusted to pH 7.5 with 2 M sodium hydroxide and dilute to 1000.0 ml with water;
- flow rate. 1 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Adjust the sensitivity so that the heights of the peaks in the chromatogram obtained with reference solution (d) are at least 50 per cent of the full-scale deflection of the recorder.

The test is not valid unless (a) the resolution between the first peak (4-epi-oxytetracycline) and the second peak (oxytetracycline) is at least 4.0 (b) the resolution between the second peak and the third peak (tetracycline) is at least 5.0 (the content of 2-methyl-2-propanol in the mobile phase may be adjusted if necessary) and (c) the symmetry factor for the second peak is at most 1.25.

Inject reference solution (a) six times. The test is not valid unless the relative standard deviation of the area of the peak due to oxytetracycline is not greater than 1.0 per cent.

Inject the test solution and reference solution (e). In the chromatogram obtained with the test solution the area of any peak corresponding to 4-epi-oxytetracycline or tetracycline is not greater than the area of the corresponding peak in the chromatogram obtained with reference solution (e). In the chromatogram obtained with the test solution the area of any peak appearing on the tail of the principal peak is not greater than 4.0 times that of the peak due to 4-epi-oxytetracycline in the chromatogram obtained with reference solution (e).

Heavy metals (2.3.13). 0.4 g complies with limit the test for heavy metals, Method B (50 ppm).

Sulphated ash (2.3.18). Not more than 0.5 per cent.

Water (2.3.43). 4.0 to 9.0 per cent, determined on 0.5 g.

Assay. Determine by the microbiological assay of antibiotics, Method A or B (2.2.10), and express the results in µg of oxytetracycline, C_{22}H_{24}N_{2}O_{9}, per mg.

Oxytetracycline intended for use in the manufacture of parenteral preparations without a further procedure for the removal of bacterial endotoxins complies with the following additional requirement.

Bacterial endotoxins (2.2.3). Not more than 0.4 Endotoxin Unit per mg of Oxytetracycline.

Oxytetracycline intended for use in the manufacture of parenteral preparations without a further sterilisation procedure complies with the following additional requirement.

Sterility. Complies with the test for sterility (2.2.11).

Storage. Store protected from light and moisture. If it is intended for use in the manufacture of parenteral preparations, the container should be sterile and sealed so as to exclude micro-organisms.

Labelling. The label states whether or not the contents are intended for use in the manufacture of parenteral preparations.
**Oxytetracycline Injection**

Oxytetracycline Injection is a sterile solution of oxytetracycline with or without one or more suitable buffering agents, anaesthetics, preservatives, antioxidants, complexing agents and solvents.

Oxytetracycline Injection contains not less than 90.0 per cent and not more than 120.0 per cent of the stated amount of anhydrous oxytetracycline, C\(_{22}\)H\(_{24}\)N\(_2\)O\(_9\).

**Description.** A clear, yellow to tan yellow solution. It may have a greenish tinge.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), coating the plate with the substance prepared by mixing 25 g of silica gel G with 50 ml of a mixture of 2.5 ml of glycerin and 47.5 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution. After spreading the plate, allow it to stand at room temperature till it is dry (70 to 90 minutes).

**Mobile phase.** The lower layer formed after shaking 200 ml of a mixture of 2 volumes of ethyl acetate, 2 volumes of chloroform and 1 volume of acetone with 25 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution.

**Test solution.** Shake a quantity containing 10 mg of anhydrous oxytetracycline with 20 ml of methanol, centrifuging if necessary and use the clear supernatant liquid.

**Reference solution (a).** A 0.05 per cent w/v solution of oxytetracycline hydrochloride RS in methanol.

**Reference solution (b).** A solution containing 0.05 per cent w/v each of demethylchlortetracycline hydrochloride RS, oxytetracycline hydrochloride RS and tetracycline hydrochloride RS in methanol.

Apply to the plate 1 µl of each solution, freshly prepared. After development, dry the plate in air, expose to the vapours of ammonia and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

B. Add 0.1 ml to 2 ml of sulphuric acid; a red colour is produced. Add the solution to 1 ml of water; the colour changes to yellow.

**Tests**

**pH (2.4.24).** 8.0 to 9.0.

**Bacterial endotoxins (2.2.3).** Not more than 0.4 Endotoxin Unit per mg of Oxytetracycline.

**Other Tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Determine by the microbiological assay of antibiotics, Method A or B (2.2.10), and express the result in mg of oxytetracycline, C\(_{22}\)H\(_{24}\)N\(_2\)O\(_9\), per ml.

**Storage.** Store protected from light.

**Labelling.** The label states (1) the strength in mg of anhydrous oxytetracycline per ml; (2) that the contents are to be used for intramuscular use only; (3) the names of any preservatives used.

**Oxytetracycline Hydrochloride**

C\(_{22}\)H\(_{24}\)N\(_2\)O\(_9\),HCl  Mol. Wt. 496.9

Oxytetracycline Hydrochloride is (4S,4aR,5S,5aR,6S,12aS)-4-dimethylamino-1,4,4a,5,5a,6,11,12a-octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide hydrochloride, a substance produced by the growth of certain strains of *Streptomyces rimosus* or obtained by any other means.

**Description.** A pale yellow, crystalline powder; odourless; hygroscopic.

Oxytetracycline Hydrochloride has a potency not less than 835 μg of C\(_{22}\)H\(_{24}\)N\(_2\)O\(_9\), per mg, calculated on the anhydrous basis.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), coating the plate with the substance prepared by mixing 25 g of silica gel G with 50 ml of a mixture of 2.5 ml of glycerin and 47.5 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution. After spreading the plate, allow it to stand at room temperature till it is dry (70 to 90 minutes).

**Mobile phase.** The lower layer formed after shaking 200 ml of a mixture of 2 volumes of ethyl acetate, 2 volumes of chloroform and 1 volume of acetone with 25 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution.

**Test solution.** Dissolve 0.05 g of the substance under examination in 100 ml of methanol.

**Reference solution (a).** A 0.05 per cent w/v solution of oxytetracycline hydrochloride RS in methanol.

**Reference solution (b).** A solution containing 0.05 per cent w/v each of demethylchlortetracycline hydrochloride RS, oxytetracycline hydrochloride RS and tetracycline hydrochloride RS in methanol.

Apply to the plate 1 µl of each solution, freshly prepared. After development, dry the plate in air, expose to the vapours
of ammonia and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

B. To about 0.5 mg add 2 ml of sulphuric acid; a red colour is produced. Add the solution to 1 ml of water; the colour changes to yellow.

C. Dissolve about 2 mg in 5 ml of a 1 per cent w/v solution of sodium carbonate and add 2 ml of diazotised sulphanal acid solution; an orange-red to brownish-red colour is produced.

D. A 5 per cent w/v solution gives the reactions of chlorides (2.3.1).

Tests

pH (2.4.24). 2.0 to 3.0, determined in a 1.0 per cent w/v solution.

Specific optical rotation (2.4.22). –188° to –200°, determined at 20° in a 1 per cent w/v solution in 0.1 M hydrochloric acid.

Light absorption (2.4.7). Absorbance of a 0.002 per cent w/v solution in chloride buffer solution pH 2.0 at the maximum at about 353 nm, 0.54 to 0.58.

Light-absorbing impurities. A. Dissolve 20 mg in sufficient of a mixture of 1 volume of 1 M hydrochloric acid and 99 volumes of methanol to produce 10 ml. Absorbance of the resulting solution at about 430 nm, when measured within 1 hour of preparing the solution, not more than 0.50, calculated on the anhydrous basis (2.4.7).

B. Dissolve 0.1 g in sufficient of a mixture of 1 volume of 1 M hydrochloric acid and 99 volumes of methanol to produce 10 ml. Absorbance of the resulting solution at about 490 nm, when measured within 1 hour of preparing the solution, not more than 0.20, calculated on the anhydrous basis (2.4.7).

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 20 mg of the substance under examination in 25 ml of 0.01 M hydrochloric acid.

Reference solution (a). Dissolve 20 mg of oxytetracycline RS in 25 ml of 0.01 M hydrochloric acid.

Reference solution (b). Dissolve 20 mg of 4-epioxytetracycline RS in 25 ml of 0.01 M hydrochloric acid.

Reference solution (c). Dissolve 20 mg of tetracycline hydrochloride RS in 25 ml of 0.01 M hydrochloric acid.

Reference solution (d). Dissolve 20 mg of a-apo-oxytetracycline RS in 20 ml of 0.01 M sodium hydroxide and dilute to 250 ml with 0.01 M hydrochloric acid.

Reference solution (e). Dissolve 20 mg of b-apo-oxytetracycline RS in 20 ml of 0.01 M sodium hydroxide and dilute to 250 ml with 0.01 M hydrochloric acid.

Reference solution (f). Dilute a mixture of 1.5 ml of reference solution (a), 1.0 ml of reference solution (b), 3.0 ml each of reference solutions (c) (d) and (e) to 25 ml with 0.01 M hydrochloric acid.

Reference solution (g). Dilute a mixture of 1.0 ml of reference solution (b), 4.0 ml of reference solution (c) and 40.0 ml of reference solution (e) to 200 ml with 0.01 M hydrochloric acid.

Chromatographic system

– a stainless steel column 25 cm x 4.6 mm, packed with styrene-divinylbenzene co-polymer (8 to 10 µm),
– column. temperature 60°,
– mobile phase: transfer separately 30 g (for mobile phase A) or 100 g (for mobile phase B) of 2-methyl-2-propanol to volumetric flasks with the aid of 200 ml of water; to each flask add 60 ml of 0.33 M phosphate buffer pH 7.5, 50 ml of a 1.0 per cent w/v solution of tetrabutyl-ammonium hydrogen sulphate previously adjusted to pH 7.5 with 2 M sodium hydroxide and 10 ml of a 0.04 per cent w/v solution of disodium edetate previously adjusted to pH 7.5 with 2 M sodium hydroxide and dilute each solution to 1000.0 ml with water.,
– flow rate. 1 ml per minute,
– spectrophotometer set at 254 nm,
– a 20 µl loop injector.

Carry out a one-step gradient elution in the following manner. Pump a mixture containing 30 volumes of mobile phase B and 70 volumes of mobile phase A for 15 minutes, then pump a mixture containing 30 volumes of mobile phase A and 70 volumes of mobile phase B for 15 minutes and finally equilibrate with the first mixture. Adjust the sensitivity so that the heights of the peaks in the chromatogram obtained with reference solution (f) are at least 50 per cent of full-scale deflection of the recorder.

The test is not valid unless, in the chromatogram obtained with reference solution (f), (a) the resolution between the first peak (4-epioxytetracycline) and the second peak (oxytetracycline) is at least 4.0, (b) the resolution between the second peak and the third peak (tetracycline) is at least 5.0, (c) the resolution between the fourth peak (a-apo-oxytetracycline) and the fifth peak (b-apo-oxytetracycline) is at least 3.5, and (d) the symmetry factor of the second peak is at most 1.25. If necessary adjust the proportions of the mobile phases used to produce the one-step gradient elution. Adjust the time-programme for the one-step gradient elution if necessary.

Inject reference solution (a) six times. The test is not valid if the relative standard deviation of the area of the peak due to
oxtetracycline is greater than 1.0 per cent. If necessary, adjust the integrator parameters.

Inject the test solution and reference solution (g). In the chromatogram obtained with the test solution the area of any peak corresponding to 4-epi oxytetracycline or tetracycline is not greater than the area of the corresponding peak in the chromatogram obtained with reference solution (g) and the total area of the peaks corresponding to a -apo-oxytetracycline and to b -apo-oxytetracycline and any peak between the latter two is not greater than the area of the peak due to b -apo-oxytetracycline in the chromatogram obtained with reference solution (g). In the chromatogram obtained with the test solution the area of any peak appearing on the tail of the principal peak is not greater than 4.0 times that of the peak due to 4-epi oxytetracycline in the chromatogram obtained with reference solution (g).

Heavy metals (2.3.13). 0.4 g complies with the limit test for heavy metals, Method B (50 ppm).

Sulphated ash (2.3.18). Not more than 0.5 per cent.

Water (2.3.43). Not more than 2.0 per cent w/w, determined on 0.5 g.

Assay. Determine by the microbiological assay of antibiotics, Method A or B (2.2.10), and express the result in µg of oxytetracycline, C₂₂H₂₄N₂O₉, per mg.

Oxytetracycline Hydrochloride intended for use in the manufacture of parenteral preparations without a further procedure for the removal of bacterial endotoxins complies with the following additional requirement.

Bacterial endotoxins (2.2.3). Not more than 0.4 Endotoxin Unit per mg.

Oxytetracycline Hydrochloride intended for use in the manufacture of parenteral preparations without a further sterilisation procedure complies with the following additional requirement.

Sterility. Complies with test for sterility (2.2.11).

Storage. Store protected from light and moisture. If it is intended for use in the manufacture of parenteral preparations, the container should be sterile and sealed so as to exclude micro-organisms.

Labelling. The label states whether or not the contents are intended for use in the manufacture of parenteral preparations.

Oxytetracycline Capsules

Oxytetracycline Hydrochloride Capsules

Oxytetracycline Capsules contain not less than 95.0 per cent and not more than 110.0 per cent of the stated amount of oxytetracycline hydrochloride, C₂₂H₂₄N₂O₉.HCl.

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with the substance prepared by mixing 25 g of silica gel G with 50 ml of a mixture of 2.5 ml of glycerin and 47.5 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution. After spreading the plate, allow it to stand at room temperature till it is dry (70 to 90 minutes).

Mobile phase. The lower layer formed after shaking 200 ml of a mixture of 2 volumes of ethyl acetate, 2 volumes of chloroform and 1 volume of acetone with 25 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution.

Test solution. Extract a quantity of the contents of the capsules containing 10 mg of Oxytetracycline Hydrochloride with 20 ml methanol, centrifuge and use the supernatant liquid.

Reference solution (a). A 0.05 per cent w/v solution of oxytetracycline hydrochloride RS in methanol.

Reference solution (b). A solution containing 0.05 per cent w/v each of demethylchlortetracycline hydrochloride RS, oxytetracycline hydrochloride RS and tetracycline hydrochloride RS in methanol.

Apply to the plate 1 µl of each solution, freshly prepared. After development, dry the plate in air, expose to the vapours of ammonia and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

B. To 0.5 mg of the contents of the capsules add 2 ml of sulphuric acid; a red colour is produced. Add the solution to 1 ml of water; the colour changes to yellow.

C. Dissolve about 2 mg of the contents of the capsules in 5 ml of a 1 per cent w/v solution of sodium carbonate and add 2 ml of diazotised sulphanilic acid solution; a light brown colour is produced.

D. The contents of the capsules give the reactions of chlorides (2.3.1).

Tests

Light-absorbing impurities. Dissolve a portion of the mixed contents of five capsules as completely as possible in sufficient of a mixture of 1 volume of 1 M hydrochloric acid and 99 volumes of methanol to produce two solutions of Oxytetracycline Hydrochloride containing (1) 0.2 per cent w/v and (2) 1.0 per cent w/v and filter each solution. Absorbance of the filtrate obtained from solution (1) at about 430 nm, when measured within 1 hour of preparing the solution, not greater
than 0.75 and of the filtrate obtained from solution (2) at about 490 nm, not more than 0.40 (2.4.7).

**Dissolution (2.5.2).**

**Apparatus.** No 1

**Medium.** 900 ml of 0.1 M hydrochloric acid.

**Speed and time.** 100 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter through a membrane filter disc with an average pore diameter not greater than 1.0 µm. Measure the absorbance of the filtrate, suitably diluted if necessary, at the maximum at about 353 nm (2.4.7). Calculate the content of C₂₂H₂₄N₂O₉.HCl in the medium taking 282 as the specific absorbance at 353 nm.

D. Not less than 75 per cent of the stated amount of C₂₂H₂₄N₂O₉.HCl.

**Loss on drying (2.4.19).** Not more than 5.0 per cent, determined on 1.0 g of the mixed contents of the capsules by drying in an oven at 60º at a pressure not exceeding 0.7 kPa for 3 hours.

**Other Tests.** Comply with the tests stated under Capsules.

**Assay.** Weigh accurately a quantity of the mixed contents of 20 capsules containing about 0.25 g of Oxytetracycline Hydrochloride, add 250.0 ml of water, shake, filter.

Determine by the microbiological assay of antibiotics, Method A or B (2.2.10), and express the results in mg of oxytetracycline hydrochloride per capsule taking each mg of oxytetracycline to be equivalent to 1.079 mg of oxytetracycline hydrochloride, C₂₂H₂₄N₂O₉.HCl.

**Storage.** Store protected from light and moisture.

**Oxytetracycline Eye Ointment**

Oxytetracycline Hydrochloride Eye Ointment

Oxytetracycline Eye Ointment contains not less than 90.0 per cent and not more than 115.0 per cent of the stated amount of oxytetracycline hydrochloride, C₂₂H₂₄N₂O₉.HCl.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with the substance prepared by mixing 25 g of silica gel G with 50 ml of a mixture of 2.5 ml of glycerin and 47.5 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution. After spreading the plate, allow it to stand at room temperature till it is dry (70 to 90 minutes).

**Mobile phase.** The lower layer formed after shaking 200 ml of a mixture of 2 volumes of ethyl acetate, 2 volumes of chloroform and 1 volume of acetone with 25 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution.

**Test solution.** A solution prepared by heating a quantity containing 20 mg of Oxytetracycline Hydrochloride with 20 ml of methanol for 20 minutes, cooling in ice, filtering, carefully evaporating the filtrate to dryness and dissolving the residue in 20 ml of methanol.

**Reference solution (a).** A 0.05 per cent w/v solution of oxytetracycline hydrochloride RS in methanol.

**Reference solution (b).** A solution containing 0.05 per cent w/v each of demethylchlortetracycline hydrochloride RS, oxytetracycline hydrochloride RS and tetracycline hydrochloride RS in methanol.

Apply to the plate 1 µl of each solution, freshly prepared. After development, dry the plate in air, expose to the vapours of ammonia and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

**Tests**

**Water (2.3.43).** Not more than 1.0 per cent, determined on 0.5 g.

**Other Tests.** Complies with the tests stated under Eye Ointments.

**Assay.** Weigh accurately about 1.0 g and transfer to a separating funnel. Add 25 ml of peroxide-free ether, shake well and extract with five quantities, each of 20 ml, of 0.1 M hydrochloric acid. Combine the extracts and dilute to 200.0 ml with 0.1 M hydrochloric acid. Dilute a suitable volume of the resulting solution with buffer solution No 3 (2.2.10), to produce a solution containing 1 µg of oxytetracycline per ml.

Determine by the microbiological assay of antibiotics, Method B (2.2.10), and express the results as a percentage of oxytetracycline hydrochloride taking each mg of oxytetracycline to be equivalent to 1.079 mg of oxytetracycline hydrochloride, C₂₂H₂₄N₂O₉.HCl.

**Storage.** Store protected from light and moisture.

**Oxytetracycline Hydrochloride Injection**

Oxytetracycline Hydrochloride Injection is a sterile material consisting of Oxytetracycline Hydrochloride with or without buffering agents and other excipients. It is filled in a sealed container.

The injection is constituted by dissolving the contents of the sealed container in the requisite amount of sterile Water for Injections, immediately before use.
The constituted solution complies with the requirements for Clarity of solution and Particulate matter stated under Parenteral Preparations (Injections).

Storage. The constituted solution may be used within three days of preparation when stored in a refrigerator (2º to 8º).

Oxytetracycline Hydrochloride Injection contains not less than 90.0 per cent and not more than 115.0 per cent of the stated amount of oxytetracycline, \( \text{C}_{22}\text{H}_{24}\text{N}_{2}\text{O}_{9} \).

The contents of the sealed container comply with the requirements stated under Parenteral Preparations (Powders for Injection) and with the following requirements.

Description. A pale yellow, crystalline powder.

Identification
A. Determine by thin-layer chromatography (2.4.17), coating the plate with the substance prepared by mixing 25 g of silica gel G with 50 ml of a mixture of 2.5 ml of glycerin and 47.5 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution. After spreading the plate, allow it to stand at room temperature till it is dry (70 to 90 minutes).

Mobile phase. The lower layer formed after shaking 200 ml of a mixture of 2 volumes of ethyl acetate, 2 volumes of chloroform and 1 volume of acetone with 25 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution.

Test solution. Dissolve 0.05 g of the substance under examination in 100 ml of methanol.

Reference solution (a). A 0.05 per cent w/v solution of oxytetracycline hydrochloride RS in methanol.

Reference solution (b). A solution containing 0.05 per cent w/v each of demethylchlortetracycline hydrochloride RS, oxytetracycline hydrochloride RS and tetracycline hydrochloride RS in methanol.

Apply to the plate 1 µl of each solution, freshly prepared. After development, dry the plate in air, expose to the vapours of ammonia and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

B. To about 0.5 mg add 2 ml of sulphuric acid; a red colour is produced. Add the solution to 1 ml of water; the colour changes to yellow.

C. Dissolve about 2 mg in 5 ml of a 1 per cent w/v solution of sodium carbonate and add 2 ml of diazotised sulphanilic acid solution; an orange-red to brownish-red colour is produced.

Tests

Appearance of solution. A 10.0 per cent w/v solution is clear (2.4.1) and yellow.

pH (2.4.24). 2.0 to 3.0, determined in a 1.0 per cent w/v solution.

Light-absorbing impurities. A. Dissolve 20 mg in sufficient of a mixture of 1 volume of 1 M hydrochloric acid and 99 volumes of methanol to produce 10 ml. Absorbance of the resulting solution at about 430 nm, when measured within 1 hour of preparing the solution, not more than 0.50, calculated on the anhydrous basis (2.4.7).

B. Dissolve 0.1 g in sufficient of a mixture of 1 volume of 1 M hydrochloric acid and 99 volumes of methanol to produce 10 ml. Absorbance of the resulting solution at about 490 nm, when measured within 1 hour of preparing the solution, not more than 0.20, calculated on the anhydrous basis (2.4.7).

Assay. Determine by the microbiological assay of antibiotics, method A or B (2.2.10), and express the result in µg of oxytetracycline, \( \text{C}_{22}\text{H}_{24}\text{N}_{2}\text{O}_{9} \), per mg.

Bacterial endotoxins (2.2.3). Not more than 0.4 Endotoxin Unit per mg.

Storage. Store protected from light and moisture.

Labelling. The label states (1) the quantity of Oxytetracycline Hydrochloride contained in it in terms of the equivalent amount of oxytetracycline; (2) that the contents are to be used for intravenous injection only; (3) the names of the buffering agents used.

Oxytocin

\[
\text{Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-GlyNH}_2
\]

\( \text{C}_{8}\text{H}_{8}\text{N}_{12}\text{O}_{12}\text{S}_2 \) Mol. Wt. 1007.2

Oxytocin is a cyclic nonapeptide hormone obtained by a process of fractionation from the posterior lobe of the pituitary gland of healthy oxen or other mammals or by synthesis that has the property of stimulating contraction of the uterus and milk ejection in receptive animals. It may be presented as a solid or as a solution in a solvent containing an appropriate antimicrobial preservative such as 0.2 per cent w/v solution of chlorbutol.

If it is derived from animal species, Oxytocin contains not less than 90.0 per cent and not more than 111.0 per cent of the stated number of Units of oxytocic activity. If it is a synthetic product presented as a solid, it contains not less than 560 Units per mg, calculated with reference to the peptide content and when presented as a liquid, it contains not less than 150 Units per ml.
**Description.** When presented as a solid, a white or almost white powder. When presented as a liquid, a clear colourless liquid.

**Identification**

Gives rise to an appropriate response when administered as directed under one of the methods described for Assay.

**Tests**

**Peptide.** 90.0 to 110.0 per cent of the stated amount of oxytocin, \( C_{43}H_{66}N_{12}O_{12}S_{2} \) expressed per mg for the solid, and in mg per ml for the liquid.

Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 3.5 mg of the substance under examination in sufficient of a 1.56 per cent w/v solution of sodium dihydrogen phosphate to produce 10.0 ml or use the liquid preparation as appropriate.

**Reference solution.** Dissolve 3.5 mg of oxytocin RS in sufficient of a 1.56 per cent w/v solution of sodium dihydrogen phosphate to produce 10.0 ml.

**Chromatographic system**

- a stainless steel column 12 cm x 4.6 mm, packed with octadecysilane bonded to porous silica (5 µm),
- mobile phase: appropriate proportions of a 1.56 per cent w/v solution of sodium dihydrogen phosphate (mobile phase A) and a mixture of equal volumes of acetonitrile and water (mobile phase B),
- flow rate. 1 ml per minute,
- spectrophotometer set at 220 nm,
- a 20 µl loop injector.

Equilibrate the column with a mixture of 70 volumes of mobile phase A and 30 volumes of mobile phase B and record the chromatograms as follows. Operate by gradient elution increasing continuously and linearly the proportion of mobile phase B by 1.0 per cent v/v per minute for 30 minutes. Finally elute using the same mixture for 15 minutes to re-equilibrate the column.

Calculate the content of the peptide, \( C_{43}H_{66}N_{12}O_{12}S_{2} \).

**Assay.** The potency of oxytocin is determined by comparing its activity with that of the Standard Preparation of oxytocin under the conditions of a suitable method of assay.

**Standard Preparation**

The Standard Preparation is the 4th International Standard for Oxytocin, established in 1978, consisting of freeze-dried synthetic oxytocin peptide with human albumin and citric acid (supplied in ampoules containing 12.5 Units), or any other suitable preparation the potency of which has been determined in relation to the International Standard.

**NOTE — Any of the following methods may be followed.**

**Method A. By depression of the blood pressure in chicken —** Anaesthetise a young healthy adult cockerel weighing 1.2 to 2.3 kg with an anaesthetic that will maintain a prolonged and constant high blood pressure. Expose the glutaeus primus muscle in one thigh and cut and retract it to reveal the popliteal artery and crural vein. Cannulate the popliteal artery and record the blood pressure on a suitable recorder calibrated for use over a linear range. Cannulate the crural or brachial vein.

Immediately before use prepare a solution of the Standard Preparation in saline solution so that the volume to be injected is between 0.1 ml and 0.5 ml. Record the blood pressure responses to the injection into the cannulated vein of two doses of this solution; the doses should be such as to produce clearly discriminated, precipitous, submaximal decreases in blood pressure; the required doses normally lie between 20 and 100 milliUnits. The interval between injections should be constant and lie between 3 and 10 minutes depending on the rate at which the blood pressure returns to normal. Immediately before use dilute the preparation being examined with saline solution so as to obtain responses similar to those obtained with the Standard Preparation. The ratio between the two doses of the preparation under examination should be the same as that between the two doses of the Standard Preparation and this ratio should be kept constant throughout the assay.

The two doses of the Standard Preparation and the two doses of the preparation under examination should be given according to a randomised block or a Latin square design and at least six responses to each should be recorded.

If the animal rapidly becomes insensitive to the repeated injections of the solutions another animal must be used. Measure all the responses and calculate the result of the assay by standard statistical methods.

**Method B. By contraction of the rat uterus —** Inject 100 µg of oestradiol benzoate intramuscularly into a female rat weighing 120 to 200 g 18 to 24 hours before the assay. Immediately before the assay confirm by vaginal smear that the rat is in oestrus or preoestrus. Kill the rat and suspend one horn of the uterus in a bath containing a solution of the following composition.

<table>
<thead>
<tr>
<th>Composition (per cent w/v)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride</td>
<td>0.662</td>
</tr>
<tr>
<td>Potassium chloride</td>
<td>0.045</td>
</tr>
<tr>
<td>Calcium chloride</td>
<td>0.007</td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
<td>0.256</td>
</tr>
<tr>
<td>Disodium hydrogen phosphate</td>
<td>0.029</td>
</tr>
<tr>
<td>Sodium dihydrogen phosphate</td>
<td>0.003</td>
</tr>
<tr>
<td>Magnesium chloride</td>
<td>0.010</td>
</tr>
<tr>
<td>Dextrose</td>
<td>0.050</td>
</tr>
</tbody>
</table>
Maintain the bath at a temperature of 32°C or at some other suitable temperature at which spontaneous contractions of the uterus are abolished and the preparation maintains its sensitivity. Oxygenate the solution with a mixture of 95 per cent of oxygen and 5 per cent of carbon dioxide and record the contractions of the muscle using a suitable instrument giving a linear response (for example an isotonic lever with a load not exceeding 2 g). Record the contractions produced by the addition to the bath of two doses of the Standard Preparation suitably diluted with the above solution. The doses should be such as to produce clearly discriminated, submaximal contractions; the required doses normally lie between 10 and 50 micro Units per ml of bath liquid. When maximal contraction has been reached, replace the bath liquid by a fresh solution. The doses should be added at regular intervals of 3 to 5 minutes depending upon the rate of recovery of the muscle. Dilute the preparation under examination so as to obtain responses on the addition of two doses similar to those obtained with the Standard Preparation. The ratio between the two doses of the preparation under examination should be the same as that between the two doses of the Standard Preparation and this ratio should be kept constant throughout the assay.

The two doses of Standard Preparation and the two doses of the preparation under examination should be given according to a randomised block or a Latin square design and at least six responses to each should be recorded.

Measure all the responses and calculate the result of the assay by standard statistical methods.

Method C. By measurement of milk-ejection pressure in a lactating rat—Select a lactating rat, in the third to twenty-first day after parturition and weighing about 300 g, separate it from the litter and 30 to 60 minutes later anaesthetise (for example, by the intraperitoneal injection of a solution of Pentobarbitone Sodium). Tie the rat to an operating table, maintained at 37°C, by its hind legs leaving the front legs free. Cannulate the trachea with a short polyethylene tube of internal diameter about 2.5 mm in such a manner so as to ensure a free airway; apply artificial respiration only if necessary. Cannulate an external jugular or femoral vein with a polyethylene tube of internal diameter about 0.4 mm which is filled with saline solution and closed with a pin.

Shave the skin surrounding the inguinal and abdominal teats and excise the tip of one teat, preferably the lower inguinal teat. Insert a polyethylene tube of internal diameter about 0.3 mm and external diameter about 0.6 mm, to a depth sufficient to obtain appropriate measurement of pressure (3 to 10 mm depth), into the primary teat duct which opens onto the cut surface and tie firmly in place with a ligature. Connect this cannula with a suitable strain gauge transducer (such as that used for recording arterial blood pressure in the rat) and fill the whole system with a 3.8 per cent w/v solution of sodium citrate or saline solution containing 50 Units of heparin sodium per ml to prevent clotting of milk. After cannulation, inject a small volume (0.05 to 0.2 ml) of this solution into the teat duct through the transducer to clear the milk from the tip of the cannula. (This procedure may be repeated during the assay should obstruction arise from milk ejected into the cannula). Clamp the strain gauge so that a slight tension is applied to the teat and its natural alignment is preserved and connect the gauge to a potentiometric recorder adjusted to give full-scale deflection for an increase in milk-ejection pressure of about 5.3 kPa. Inject all solutions through the venous cannula using a 1-ml syringe graduated in 0.01 ml and wash them in with 0.2 ml of saline solution.

Prepare a solution of the Standard Preparation and a solution of the preparation under examination in saline solution so that the volume to be injected is between 0.1 ml and 0.4 ml. Choose two doses of the Standard Preparation such that the increase in milk-ejection pressure is about 1.35 kPa for the lower dose and about 2.7 kPa for the higher dose. As an initial approximation, a lower dose of between 0.1 and 0.4 milliUnit and an upper dose of 1.5 to 2 times this amount may be tried. Choose two doses of the preparation under examination with the same inter-dose ratio, matching the effects of the doses of the Standard Preparation as closely as possible. Inject the four doses (two doses of the Standard Preparation and two doses of the preparation being examined) at intervals of 3 to 5 minutes. The two doses of Standard Preparation and the two doses of the preparation under examination should be given according to a randomised block or a Latin square design and at least four responses to each should be recorded.

Measure all the responses and calculate the result of the assay by standard statistical methods.

The estimated potency is not less than 90 per cent and not more than 111 per cent of the stated potency. The fiducial limits of error are not less than 80 per cent and not more than 125 per cent of the stated potency. Oxytocin of natural origin obtained by extraction and purification complies with the following additional requirement.

Vasopressor activity. Not more than 0.5 Unit per 20 Units of oxytocic activity, when assayed by the biological assay for vasopressor activity described below.

The vasopressor activity is estimated by comparing the activity of the preparation under examination with that of the Standard Preparation of arginine vasopressin under the conditions of a suitable method of assay.

Standard Preparation

The Standard Preparation is the 1st International Standard for Arginine vasopressin, established in 1978, consisting of
freeze-dried synthetic arginine vasopressin peptide acetate with human albumin and citric acid (supplied in ampoules containing 8.20 Units), or another suitable preparation the potency of which has been determined in relation to that of the International Standard.

Inject slowly into the tail vein of a male albino rat weighing about 300 g a solution of a suitable α-adrenoceptor blocking agent, for example 10 ml per kg of body weight of a solution prepared by dissolving 5 mg of phenoxybenzamine hydrochloride in 0.1 ml of ethanol (95 per cent), adding 0.05 ml of 1 M hydrochloric acid and diluting to 5 ml with saline solution. After 18 hours, anaesthetise the rat with an anaesthetic that will maintain a prolonged and uniform blood pressure. After 45 to 60 minutes, tie the rat on its back to the operating table by its hind legs. Cannulate the trachea with a short polyethylene tube of external diameter about 2.5 mm and dissect a carotid artery ready for cannulation. Then cannulate the femoral vein close to the inguinal ligament. Retract the abdominal muscles to expose the inguinal ligament. Retract the superficial pudendal vein to one side and dissect the femoral vein towards the inguinal ligament from the corresponding artery. When dissecting, a deep branch reaching the femoral vein must be found and tied off to prevent bleeding during cannulation. Tie a short polyethylene cannula of external diameter about 1 mm into the femoral vein by two ligatures and join by a short piece of flexible tubing to a 1-ml burette with an attached thistle funnel containing saline solution at about 37º. Firmly fix a wet absorbent cotton swab to the thigh so as to cover the incision and cannula. At this stage inject through the venous cannula 200 Units of heparin, dissolved in saline solution, per 100 g of body weight. Then tie in a carotid cannula of external diameter about 1 mm and connect by a column of saline solution containing heparin with a suitable pressure measuring device such as a mercury manometer of internal diameter about 2 to 3 mm.

The central and peripheral nervous system including both vagus and associated sympathetic nerves is left intact. No artificial respiration is necessary. Taking care that no air is injected, inject all solutions through the venous cannula by means of a 1-ml syringe graduated in 0.01 ml and wash in with 0.2 ml of saline solution from the burette.

Dilute the extract of the Standard Preparation and the preparation under examination with saline solution so that the volume to be injected is between 0.1 ml and 0.5 ml.

Choose two doses of the Standard Preparation such that the elevation of the blood pressure is about 4 kPa for the lower dose and about 7 kPa but always submaximal for the higher dose, the ratio of low to high dose being determined by the response and usually being 3 to 5. As an initial approximation doses of 3 and 5 milliUnits may be tried. Choose two doses of the preparation under examination with the same inter-dose ratio, matching the effects of the dose of the Standard Preparation as closely as possible. Inject doses at intervals of 10 to 15 minutes.

The two doses of the Standard Preparation and the two doses of the preparation under examination should be given in a randomised block or a Latin square design and four to five responses to each should be recorded.

Measure all the responses and calculate the result of the assay by standard statistical methods.

Oxytocin intended for use in the manufacture of parenteral preparations without a further procedure for the removal of bacterial endotoxins complies with the following additional requirement.

Bacterial endotoxins (2.2.3). Not more than 100 Endotoxin Units per 200 Units of oxytocin.

Oxytocin intended for use in the manufacture of parenteral preparations without a further sterilisation procedure complies with the following additional requirement.

Sterility (2.2.11). Complies with the test for sterility.

Storage. Store protected from moisture. If the substance is intended for use in the manufacture of parenteral preparations, the container should be sterile, tamper-evident and sealed so as to exclude micro-organisms.

Labelling. The label states (1) the number of Units of oxytocic activity per mg (for solid) or per ml (for liquid); (2) either the animal species from which it is obtained or whether it is synthetic, as appropriate; (3) whether or not the contents are intended for use in the manufacture of parenteral preparations.

Oxytocin Injection

Oxytocin Injection is a sterile solution of Oxytocin in Water for Injections.

Oxytocin Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated number of Units of oxytocin activity.

Description. A clear, colourless liquid.

Identification

Gives rise to an appropriate response when administered as directed under one of the methods described for Assay.

Tests

pH (2.4.24). 3.5 to 4.5.

Other Tests. Complies with the tests stated under Parenteral Preparations (Injections).
Bacterial endotoxins (2.2.3). Not more than 100 Endotoxin Units per 200 Units of oxytocin.

Assay. The potency of oxytocin is determined by comparing its activity with that of the Standard Preparation of oxytocin under the conditions of a suitable method of assay.

Standard Preparation

The Standard Preparation is the 4th International Standard for Oxytocin, established in 1978, consisting of freeze-dried synthetic oxytocin peptide with human albumin and citric acid (supplied in ampoules containing 12.5 Units), or any other suitable preparation the potency of which has been determined in relation to the International Standard.

NOTE — Any of the following methods may be followed.

Method A. By depression of the blood pressure in chicken — Anaesthetise a young healthy adult cockerel weighing 1.2 to 2.3 kg with an anaesthetic that will maintain a prolonged and constant high blood pressure. Expose the glutus primus muscle in one thigh and cut and retract it to reveal the popliteal artery and crural vein. Cannulate the popliteal artery and record the blood pressure on a suitable recorder calibrated for use over a linear range. Cannulate the crural or brachial vein.

Immediately before use prepare a solution of the Standard Preparation in saline solution so that the volume to be injected is between 0.1 ml and 0.5 ml. Record the blood pressure responses to the injection into the cannulated vein of two doses of this solution; the doses should be such as to produce clearly discriminated, precipitous, submaximal decreases in blood pressure; the required doses normally lie between 20 and 100 milliUnits. The interval between injections should be constant and lie between 3 and 10 minutes depending on the rate at which the blood pressure returns to normal. Immediately before use dilute the preparation being examined with saline solution so as to obtain responses similar to those obtained with the Standard Preparation. The ratio between the two doses of the preparation under examination should be the same as that between the two doses of the Standard Preparation and this ratio should be kept constant throughout the assay.

The two doses of the Standard Preparation and the two doses of the preparation under examination should be given according to a randomised block or a Latin square design and at least six responses to each should be recorded.

If the animal rapidly becomes insensitive to the repeated injections of the solutions another animal must be used. Measure all the responses and calculate the result of the assay by standard statistical methods.

Method B. By contraction of the rat uterus — Inject 100 µg of oestradiol benzoate intramuscularly into a female rat weighing 120 to 200 g 18 to 24 hours before the assay. Immediately before the assay confirm by vaginal smear that the rat is in oestrus or preoestrus. Kill the rat and suspend one horn of the uterus in a bath containing a solution of the following composition.

Maintain the bath at a temperature of 32º or at some other suitable temperature at which spontaneous contractions of the uterus are abolished and the preparation maintains its sensitivity. Oxygenate the solution with a mixture of 95 per cent of oxygen and 5 per cent of carbon dioxide and record the contractions of the muscle using a suitable instrument giving a linear response (for example an isotonic lever with a load not exceeding 2 g). Record the contractions produced by the addition to the bath of two doses of the Standard Preparation suitably diluted with the above solution. The doses should be such as to produce clearly discriminated, submaximal contractions; the required doses normally lie between 10 and 50 micro Units per ml of bath liquid. When maximal contraction has been reached, replace the bath liquid by a fresh solution. The doses should be added at regular intervals of 3 to 5 minutes depending upon the rate of recovery of the muscle. Dilute the preparation being examined so as to obtain responses on the addition of two doses similar to those obtained with the Standard Preparation. The ratio between the two doses of the preparation under examination should be the same as that between the two doses of the Standard Preparation and this ratio should be kept constant throughout the assay.

The two doses of Standard Preparation and the two doses of the preparation under examination should be given according to a randomised block or a Latin square design and at least six responses to each should be recorded.

Measure all the responses and calculate the result of the assay by standard statistical methods.

Method C. By measurement of milk-ejection pressure in a lactating rat — Select a lactating rat, in the third to twenty-first day after parturition and weighing about 300 g, separate it from the litter and 30 to 60 minutes later anaesthetise (for example, by the intraperitoneal injection of a solution of Pentobarbitone Sodium). Tie the rat to an operating table, maintained at 37º, by its hind legs leaving the front legs free. Cannulate the trachea with a short polyethylene tube of
internal diameter about 2.5 mm in such a manner so as to ensure a free airway; apply artificial respiration only if necessary. Cannulate an external jugular or femoral vein with a polyethylene tube of internal diameter about 0.4 mm which is filled with saline solution and closed with a pin.

Shave the skin surrounding the inguinal and abdominal teats and excise the tip of one teat, preferably the lower inguinal teat. Insert a polyethylene tube of internal diameter about 0.3 mm and external diameter about 0.6 mm, to a depth sufficient to obtain appropriate measurement of pressure (3 to 10 mm depth), into the primary teat duct which opens onto the cut surface and tie firmly in place with a ligature. Connect this cannula with a suitable strain gauge transducer (such as that used for recording arterial blood pressure in the rat) and fill the whole system with a 3.8 per cent w/v solution of sodium citrate or saline solution containing 50 Units of heparin sodium per ml to prevent clotting of milk. After cannulation, inject a small volume (0.05 to 0.2 ml) of this solution into the teat duct through the transducer to clear the milk from the tip of the cannula. (This procedure may be repeated during the assay should obstruction arise from milk ejected into the cannula.) Clamp the strain gauge so that a slight tension is applied to the teat and its natural alignment is preserved and connect the gauge to a potentiometric recorder adjusted to give full-scale deflection for an increase in milk-ejection pressure of about 5.3 kPa. Inject all solutions through the venous cannula using a 1-ml syringe graduated in 0.01 ml and wash them in with 0.2 ml of saline solution.

Prepare a solution of the Standard Preparation and a solution of the preparation under examination in saline solution so that the volume to be injected is between 0.1 ml and 0.4 ml. Choose two doses of the Standard Preparation such that the increase in milk-ejection pressure is about 1.35 kPa for the lower dose and about 2.7 kPa for the higher dose. As an initial approximation, a lower dose of between 0.1 and 0.4 milliUnit and an upper dose of 1.5 to 2 times this amount may be tried. Choose two doses of the preparation under examination with the same inter-dose ratio, matching the effects of the doses of the Standard Preparation as closely as possible. Inject the four doses (two doses of the Standard Preparation and two doses of the preparation under examination at intervals of 3 to 5 minutes. The two doses of Standard Preparation and the two doses of the preparation under examination should be given according to a randomised block or a Latin square design and at least four responses to each should be recorded.

Measure all the responses and calculate the result of the assay by standard statistical methods.

The estimated potency is not less than 90 per cent and not more than 111 per cent of the stated potency. The fiducial limits of error are not less than 80 per cent and not more than 125 per cent of the stated potency.

Oxytocin Injection containing Oxytocin of natural origin obtained by extraction and purification complies with the following additional requirement.

**Vaspressor activity.** Not more than 0.5 Unit per 20 Units of oxytocic activity, when assayed by the biological assay for vaspressor activity described below.

The vaspressor activity is estimated by comparing the activity of the preparation under examination with that of the Standard Preparation of arginine vasopressin under the conditions of a suitable method of assay.

**Standard Preparation**

The Standard Preparation is the 1st International Standard for Arginine vasopressin, established in 1978, consisting of freeze-dried synthetic arginine vasopressin peptide acetate with human albumin and citric acid (supplied in ampoules containing 8.20 Units), or any other suitable preparation the potency of which has been determined in relation to that of the International Standard.

Inject slowly into the tail vein of a male albino rat weighing about 300 g a solution of a suitable a-adrenoceptor blocking agent, for example 10 ml per kg of body weight of a solution prepared by dissolving 5 mg of phenoxybenzamine hydrochloride in 0.1 ml of ethanol (95 per cent), adding 0.05 ml of 1 M hydrochloric acid and diluting to 5 ml with saline solution. After 18 hours, anaesthetise the rat with an anaesthetic that will maintain a prolonged and uniform blood pressure. After 45 to 60 minutes, tie the rat on its back to the operating table by its hind legs. Cannulate the trachea with a short polyethylene tube of external diameter about 2.5 mm and dissect a carotid artery ready for cannulation. Then cannulate the femoral vein close to the inguinal ligament. Retract the abdominal muscles to expose the inguinal ligament. Retract the superficial pudendal vein to one side and dissect the femoral vein towards the inguinal ligament from the corresponding artery. When dissecting, a deep branch reaching the femoral vein must be found and tied off to prevent bleeding during cannulation. Tie a short polyethylene cannula of external diameter about 1 mm into the femoral vein by two ligatures and join by a short piece of flexible tubing to a 1-ml burette with an attached thistle funnel containing saline solution at about 37º. Firmly fix a wet absorbent cotton swab to the thigh so as to cover the incision and cannula. At this stage inject through the venous cannula 200 Units of heparin, dissolved in saline solution, per 100 g of body weight. Then tie in a carotid cannula of external diameter about 1 mm and connect by a column of saline solution containing heparin with a suitable pressure measuring device such as a mercury manometer of internal diameter about 2 to 3 mm.

The central and peripheral nervous system including both vagus and associated sympathetic nerves is left intact. No
artificial respiration is necessary. Taking care that no air is injected, inject all solutions through the venous cannula by means of a 1-ml syringe graduated in 0.01 ml and wash in with 0.2 ml of saline solution from the burette.

Dilute the extract of the Standard Preparation and the preparation under examination with saline solution so that the volume to be injected is between 0.1 ml and 0.5 ml.

Choose two doses of the Standard Preparation such that the elevation of the blood pressure is about 4 kPa for the lower dose and about 7 kPa but always submaximal for the higher dose, the ratio of low to high dose being determined by the response and usually being 3 to 5. As an initial approximation doses of 3 and 5 milliUnits may be tried. Choose two doses of the preparation under examination with the same inter-dose ratio, matching the effects of the dose of the Standard Preparation as closely as possible. Inject doses at intervals of 10 to 15 minutes.

The two doses of the Standard Preparation and the two doses of the preparation under examination should be given in a randomised block or a Latin square design and four to five responses to each should be recorded.

Measure all the responses and calculate the result of the assay by standard statistical methods.

**Storage.** Store at temperature not exceeding 30º. Do not freeze.

**Labelling.** The label states (1) the number of Units of oxytocin activity per ml; (2) either the animal species from which it is obtained or whether it is synthetic, as appropriate.

**Oxytocin Nasal Solution**

Oxytocin Nasal Solution is a solution of Oxytocin in a suitable solvent containing an appropriate antimicrobial preservative.

Oxytocin Nasal Solution contains not less than 85.0 per cent and not more than 120.0 per cent of the stated number of Units of oxytocic activity.

**Description.** A clear, colourless solution.

**Tests**

**pH** (2.4.24). 3.5 to 4.5.

**Other Tests.** Complies with the tests stated under Nasal Preparations.

**Assay.** The potency of oxytocin is determined by comparing its activity with that of the Standard Preparation of oxytocin under the conditions of a suitable method of assay.

**Standard Preparation**

The Standard Preparation is the 4th International Standard for Oxytocin, established in 1978, consisting of freeze-dried synthetic oxytocin peptide with human albumin and citric acid (supplied in ampoules containing 12.5 Units), or any other suitable preparation the potency of which has been determined in relation to the International Standard.

**NOTE — Any of the following methods may be followed.**

**Method A. By depression of the blood pressure in chicken —** Anaesthetise a young healthy adult cockerel weighing 1.2 to 2.3 kg with an anaesthetic that will maintain a prolonged and constant high blood pressure. Expose the gluteus primus muscle in one thigh and cut and retract it to reveal the popliteal artery and crural vein. Cannulate the popliteal artery and record the blood pressure on a suitable recorder calibrated for use over a linear range. Cannulate the crural or brachial vein. Immediately before use dilute the preparation being examined with saline solution so as to obtain responses similar to those obtained with the Standard Preparation. The ratio between the two doses of the preparation under examination should be the same as that between the two doses of the Standard Preparation and this ratio should be kept constant throughout the assay.

Immediately before use dilute the preparation being examined with saline solution so as to obtain responses similar to those obtained with the Standard Preparation. The ratio between the two doses of the Standard Preparation and the two doses of the preparation under examination should be given according to a randomised block or a Latin square design and at least six responses to each should be recorded.

If the animal rapidly becomes insensitive to the repeated injections of the solutions another animal must be used. Measure all the responses and calculate the result of the assay by standard statistical methods.

**Method B. By contraction of the rat uterus —** Inject 100 µg of oestradiol benzoate intramuscularly into a female rat weighing 120 to 200 g 18 to 24 hours before the assay. Immediately before the assay confirm by vaginal smear that the rat is in oestrus or preoestrus. Kill the rat and suspend one horn of the uterus in a bath containing a solution of the following composition.

<table>
<thead>
<tr>
<th>Composition (per cent w/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride</td>
</tr>
<tr>
<td>Potassium chloride</td>
</tr>
<tr>
<td>Calcium chloride</td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
</tr>
</tbody>
</table>
OXYTOCIN NASAL SOLUTION

By measurement of milk-ejection pressure in a lactating rat — Select a lactating rat, in the third to twenty-first day after parturition and weighing about 300 g, separate it from the litter and 30 to 60 minutes later anaesthetise (for example, by the intraperitoneal injection of a solution of Pentobarbitone Sodium). Tie the rat to an operating table, maintained at 37º, by its hind legs leaving the front legs free. Cannulate the trachea with a short polyethylene tube of internal diameter about 2.5 mm in such a manner so as to ensure a free airway; apply artificial respiration only if necessary. Cannulate an external jugular or femoral vein with a polyethylene tube of internal diameter about 0.4 mm which is filled with saline solution and closed with a pin.

Shave the skin surrounding the inguinal and abdominal teats and excise the tip of one teat, preferably the lower inguinal teat. Insert a polyethylene tube of internal diameter about 0.3 mm and external diameter about 0.6 mm, to a depth sufficient to obtain appropriate measurement of pressure (3 to 10 mm depth), into the primary teat duct which opens onto the cut surface and tie firmly in place with a ligature. Connect this cannula with a suitable strain gauge transducer (such as that used for recording arterial blood pressure in the rat) and fill the whole system with a 3.8 per cent w/v solution of sodium citrate or saline solution containing 50 Units of heparin sodium per ml to prevent clotting of milk. After cannulation, inject a small volume (0.05 to 0.2 ml) of this solution into the teat duct through the transducer to clear the milk from the tip of the cannula. (This procedure may be repeated during the assay should obstruction arise from milk ejected into the cannula). Clamp the strain gauge so that a slight tension is applied to the teat and its natural alignment is preserved and connect the gauge to a potentiometric recorder adjusted to give full-scale deflection for an increase in milk-ejection pressure of about 5.3 kPa. Inject all solutions through the venous cannula using a 1-ml syringe graduated in 0.01 ml and wash them in with 0.2 ml of saline solution.

Prepare a solution of the Standard Preparation and a solution of the preparation under examination in saline solution so that the volume to be injected is between 0.1 ml and 0.4 ml. Choose two doses of the Standard Preparation such that the increase in milk-ejection pressure is about 1.35 kPa for the lower dose and about 2.7 kPa for the higher dose. As an initial approximation, a lower dose of between 0.1 and 0.4 milliUnit and an upper dose of 1.5 to 2 times this amount may be tried. Choose two doses of the preparation under examination with the same inter-dose ratio, matching the effects of the doses of the Standard Preparation as closely as possible. Inject the four doses (two doses of the Standard Preparation and two doses of the preparation under examination) at intervals of 3 to 5 minutes. The two doses of Standard Preparation and the two doses of the preparation under examination should be given according to a randomised block or a Latin square design and at least four responses to each should be recorded.

Measure all the responses and calculate the result of the assay by standard statistical methods.

Method C. By measurement of milk-ejection pressure in a lactating rat — Select a lactating rat, in the third to twenty-first day after parturition and weighing about 300 g, separate it from the litter and 30 to 60 minutes later anaesthetise (for example, by the intraperitoneal injection of a solution of Pentobarbitone Sodium). Tie the rat to an operating table, maintained at 37º, by its hind legs leaving the front legs free. Cannulate the trachea with a short polyethylene tube of internal diameter about 2.5 mm in such a manner so as to ensure a free airway; apply artificial respiration only if necessary. Cannulate an external jugular or femoral vein with a polyethylene tube of internal diameter about 0.4 mm which is filled with saline solution and closed with a pin.

Shave the skin surrounding the inguinal and abdominal teats and excise the tip of one teat, preferably the lower inguinal teat. Insert a polyethylene tube of internal diameter about 0.3 mm and external diameter about 0.6 mm, to a depth sufficient to obtain appropriate measurement of pressure (3 to 10 mm depth), into the primary teat duct which opens onto the cut surface and tie firmly in place with a ligature. Connect this cannula with a suitable strain gauge transducer (such as that used for recording arterial blood pressure in the rat) and fill the whole system with a 3.8 per cent w/v solution of sodium citrate or saline solution containing 50 Units of heparin sodium per ml to prevent clotting of milk. After cannulation, inject a small volume (0.05 to 0.2 ml) of this solution into the teat duct through the transducer to clear the milk from the tip of the cannula. (This procedure may be repeated during the assay should obstruction arise from milk ejected into the cannula). Clamp the strain gauge so that a slight tension is applied to the teat and its natural alignment is preserved and connect the gauge to a potentiometric recorder adjusted to give full-scale deflection for an increase in milk-ejection pressure of about 5.3 kPa. Inject all solutions through the venous cannula using a 1-ml syringe graduated in 0.01 ml and wash them in with 0.2 ml of saline solution.

Prepare a solution of the Standard Preparation and a solution of the preparation under examination in saline solution so that the volume to be injected is between 0.1 ml and 0.4 ml. Choose two doses of the Standard Preparation such that the increase in milk-ejection pressure is about 1.35 kPa for the lower dose and about 2.7 kPa for the higher dose. As an initial approximation, a lower dose of between 0.1 and 0.4 milliUnit and an upper dose of 1.5 to 2 times this amount may be tried. Choose two doses of the preparation under examination with the same inter-dose ratio, matching the effects of the doses of the Standard Preparation as closely as possible. Inject the four doses (two doses of the Standard Preparation and two doses of the preparation under examination) at intervals of 3 to 5 minutes. The two doses of Standard Preparation and the two doses of the preparation under examination should be given according to a randomised block or a Latin square design and at least four responses to each should be recorded.

Measure all the responses and calculate the result of the assay by standard statistical methods.

The estimated potency is not less than 90 per cent and not more than 111 per cent of the stated potency. The fiducial limits of error are not less than 80 per cent and not more than 125 per cent of the stated potency.

Oxytocin Nasal Solution containing Oxytocin of natural origin obtained by extraction and purification complies with the following additional requirement.

**Vasopressor activity.** Not more than 0.5 Unit per 20 Units of oxytocic activity, when assayed by the biological assay for vasopressor activity described below.

The vasopressor activity is estimated by comparing the activity of the preparation under examination with that of the Standard
Preparation of arginine vasopressin under the conditions of a suitable method of assay.

**Standard Preparation**

The Standard Preparation is the 1st International Standard for Arginine vasopressin, established in 1978, consisting of freeze-dried synthetic arginine vasopressin peptide acetate with human albumin and citric acid (supplied in ampoules containing 8.20 Units), or any other suitable preparation the potency of which has been determined in relation to that of the International Standard.

Inject slowly into the tail vein of a male albino rat weighing about 300 g a solution of a suitable a-adrenoceptor blocking agent, for example 10 ml per kg of body weight of a solution prepared by dissolving 5 mg of phenoxybenzamine hydrochloride in 0.1 ml of ethanol (95 per cent), adding 0.05 ml of 1 M hydrochloric acid and diluting to 5 ml with saline solution. After 18 hours, anaesthetise the rat with an anaesthetic that will maintain a prolonged and uniform blood pressure. After 45 to 60 minutes, tie the rat on its back to the operating table by its hind legs. Cannulate the trachea with a short polyethylene tube of external diameter about 2.5 mm and dissect a carotid artery ready for cannulation. Then cannulate the femoral vein close to the inguinal ligament. Retract the abdominal muscles to expose the inguinal ligament. Retract the superficial pudendal vein to one side and dissect the femoral vein towards the inguinal ligament from the corresponding artery. When dissecting, a deep branch reaching the femoral vein must be found and tied off to prevent bleeding during cannulation. Tie a short polyethylene cannula of external diameter about 1 mm into the femoral vein by two ligatures and join by a short piece of flexible tubing to a 1-ml burette with an attached thistle funnel containing saline solution at about 37º. Firmly fix a wet absorbent cotton swab to the thigh so as to cover the incision and cannula. At this stage inject through the venous cannula 200 Units of heparin, dissolved in saline solution, per 100 g of body weight. Then dilute the extract of the Standard Preparation and the preparation under examination with saline solution so that the volume to be injected is between 0.1 ml and 0.5 ml.

Choose two doses of the Standard Preparation such that the elevation of the blood pressure is about 4 kPa for the lower dose and about 7 kPa but always submaximal for the higher dose, the ratio of low to high dose being determined by the response and usually being 3 to 5. As an initial approximation doses of 3 and 5 milliUnits may be tried. Choose two doses of the preparation under examination with the same inter-dose ratio, matching the effects of the dose of the Standard Preparation as closely as possible. Inject doses at intervals of 10 to 15 minutes.

The two doses of the Standard Preparation and the two doses of the preparation under examination should be given in a randomised block or a Latin square design and four to five responses to each should be recorded.

Measure all the responses and calculate the result of the assay by standard statistical methods.

**Storage.** Store at a temperature not exceeding 30º.

**Labelling.** The label states (1) the number of Units of oxytocic activity per ml; (2) either the animal species from which it is obtained or whether it is synthetic, as appropriate; (3) that the preparation is intended for intranasal administration only.
P

Paclitaxel
Paclitaxel Injection
Pancreatin
D-Panthenol
Paracetamol
Paracetamol Syrup
Paracetamol Tablets
Hard Paraffin
Liquid Paraffin
Light Liquid Paraffin
Liquid Paraffin Emulsion
White Soft Paraffin
Yellow Soft Paraffin
Paraffin Ointment
Paraldehyde
Penicillamine
Penicillamine Tablets
Diluted Pentaerythritol Tetranitrate
Pentaerythritol Tetranitrate Tablets
Pentamidine Isethionate
Pentamidine Injection
Pentazocine
Pentazocine Hydrochloride
Pentazocine Tablets
Pentazocine Lactate
Pentazocine Injection
Pentobarbitone Sodium
Pentobarbitone Tablets
Pepsin
Peritoneal Dialysis Solutions
Pethidine Hydrochloride
Pethidine Injection
Pethidine Tablets
Phenindamine Tartrate
Phenindamine Tablets
Phenindione
Phenindione Tablets
Pheniramine Maleate
Pheniramine Injection
Pheniramine Tablets
Phenobarbitone
Phenobarbitone Tablets
Phenobarbitone Sodium
Phenobarbitone Injection
Phenobarbitone Sodium Tablets
Phenol
Phenolphthalein
Phenoxymethylpenicillin Potassium
Phenoxymethylpenicillin Potassium Tablets
Phentolamine Mesylate
Phentolamine Injection
Phenylbutazone
Phenylbutazone Tablets
Phenylephrine Hydrochloride
Phenylephrine Injection
Phenylmercuric Acetate
Phenylmercuric Nitrate
Phenytoin Sodium
Phenytoin Injection
Phenytoin Tablets
Pholcodine
Pholcodine Linctus
Phosphoric Acid
<table>
<thead>
<tr>
<th>Monographs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physostigmine Salicylate</td>
</tr>
<tr>
<td>Physostigmine Injection</td>
</tr>
<tr>
<td>Pilocarpine Nitrate</td>
</tr>
<tr>
<td>Pindolol</td>
</tr>
<tr>
<td>Pindolol Tablets</td>
</tr>
<tr>
<td>Piperazine Adipate</td>
</tr>
<tr>
<td>Piperazine Adipate Tablets</td>
</tr>
<tr>
<td>Piperazine Citrate</td>
</tr>
<tr>
<td>Piperazine Citrate Syrup</td>
</tr>
<tr>
<td>Piperazine Hydrate</td>
</tr>
<tr>
<td>Piperazine Phosphate</td>
</tr>
<tr>
<td>Piperazine Phosphate Tablets</td>
</tr>
<tr>
<td>Piroxicam</td>
</tr>
<tr>
<td>Piroxicam Capsules</td>
</tr>
<tr>
<td>Plaster Of Paris</td>
</tr>
<tr>
<td>Polyethylene Glycol 1500</td>
</tr>
<tr>
<td>Polyethylene Glycol 4000</td>
</tr>
<tr>
<td>Polyethylene Glycol 6000</td>
</tr>
<tr>
<td>Polysorbate 20</td>
</tr>
<tr>
<td>Polysorbate 80</td>
</tr>
<tr>
<td>Potassium Chloride</td>
</tr>
<tr>
<td>Potassium Chloride And Dextrose Injection</td>
</tr>
<tr>
<td>Potassium Chloride, Sodium Chloride And Dextrose Injection</td>
</tr>
<tr>
<td>Potassium Citrate</td>
</tr>
<tr>
<td>Potassium Clavulanate</td>
</tr>
<tr>
<td>Potassium Clavulanate Diluted</td>
</tr>
<tr>
<td>Potassium Iodide</td>
</tr>
<tr>
<td>Potassium Permanganate</td>
</tr>
<tr>
<td>Povidone</td>
</tr>
<tr>
<td>Povidone-Iodine</td>
</tr>
<tr>
<td>Povidone-Iodine Solution</td>
</tr>
<tr>
<td>Pralidoxime Chloride</td>
</tr>
</tbody>
</table>

893
<table>
<thead>
<tr>
<th>Drug Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Pralidoxime Chloride Injection</td>
<td></td>
</tr>
<tr>
<td>Prazosin Hydrochloride</td>
<td></td>
</tr>
<tr>
<td>Prazosin Tablets</td>
<td></td>
</tr>
<tr>
<td>Prednisolone</td>
<td></td>
</tr>
<tr>
<td>Prednisolone Tablets</td>
<td></td>
</tr>
<tr>
<td>Prednisone</td>
<td></td>
</tr>
<tr>
<td>Prednisone Tablets</td>
<td></td>
</tr>
<tr>
<td>Prednisolone Sodium Phosphate</td>
<td></td>
</tr>
<tr>
<td>Prednisolone Sodium Phosphate Injection</td>
<td></td>
</tr>
<tr>
<td>Primaquine Phosphate</td>
<td></td>
</tr>
<tr>
<td>Primaquine Tablets</td>
<td></td>
</tr>
<tr>
<td>Probenecid</td>
<td></td>
</tr>
<tr>
<td>Probenecid Tablets</td>
<td></td>
</tr>
<tr>
<td>Procainamide Hydrochloride</td>
<td></td>
</tr>
<tr>
<td>Procainamide Injection</td>
<td></td>
</tr>
<tr>
<td>Procainamide Tablets</td>
<td></td>
</tr>
<tr>
<td>Procaine Hydrochloride</td>
<td></td>
</tr>
<tr>
<td>Procaine And Adrenaline Injection</td>
<td></td>
</tr>
<tr>
<td>Procaine Penicillin</td>
<td></td>
</tr>
<tr>
<td>Fortified Procaine Penicillin Injection</td>
<td></td>
</tr>
<tr>
<td>Prochlorperazine Maleate</td>
<td></td>
</tr>
<tr>
<td>Prochlorperazine Tablets</td>
<td></td>
</tr>
<tr>
<td>Prochlorperazine Mesylate</td>
<td></td>
</tr>
<tr>
<td>Prochlorperazine Injection</td>
<td></td>
</tr>
<tr>
<td>Procyclidine Hydrochloride</td>
<td></td>
</tr>
<tr>
<td>Procyclidine Tablets</td>
<td></td>
</tr>
<tr>
<td>Proguanil Hydrochloride</td>
<td></td>
</tr>
<tr>
<td>Proguanil Tablets</td>
<td></td>
</tr>
<tr>
<td>Promethazine Hydrochlorid</td>
<td></td>
</tr>
<tr>
<td>Promethazine Injection</td>
<td></td>
</tr>
<tr>
<td>Promethazine Syrup</td>
<td></td>
</tr>
<tr>
<td>Promethazine Tablets</td>
<td></td>
</tr>
<tr>
<td>Promethazine Theoclolate</td>
<td></td>
</tr>
</tbody>
</table>
Promethazine Theoclate Tablets
Propanetheline Bromide
Propanetheline Tablets
Propranolol Hydrochloride
Propranolol Injection
Propranolol Tablets
Propyl Gallate
Propylene Glycol
Propylparaben
Propylthiouracil
Propylthiouracil Tablets
Propyphenazone
Protamine Sulphate
Protamine Sulphate Injection
Prothionamide
Prothionamide Tablets
Pseudoephedrine Hydrochloride
Pseudoephedrine Syrup
Pseudoephedrine Tablets
Psoralen
Pyrazinamide
Pyrazinamide Tablets
Pyridoxine Hydrochloride
Pyridoxine Tablets
Pyrimethamine
Pyrimethamine And Sulphadoxine Tablets
**Paclitaxel**

**Taxol**

A taxane derivative first isolated from the bark of the Pacific yew tree, *Taxus brevifolia*.

Paclitaxel contains not less than 97.0 per cent and not more than 102.0 per cent of $C_{47}H_{51}NO_{14}$, calculated on the anhydrous basis.

**Description.** A white or almost white powder.

*CAUTION — Paclitaxel is potentially cytotoxic. Great care should be taken in handling the powder and preparing solutions.*

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with paclitaxel RS.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Specific optical rotation** (2.4.22). – 49.0° to – 55.0°, determined in 1.0 per cent w/v solution in methanol.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 10 mg of substance under examination in 10 ml of acetonitrile.

**Reference solution (a).** A 0.001 per cent w/v solution of paclitaxel RS in acetonitrile.

**Reference solution (b).** A sloution containing 0.008 per cent w/v of 10 deacetyl-7-epipoelitoral and 0.1 per cent w/v of paclitaxel RS in acetonitrile.

**Chromatographic system**

- a stainless steel column 15 cm x 4.6 mm, packed with octadeccylsilane bonded to porous silica (3µm).
- column temperature 35°C.

**Assay**

Determine by liquid chromatography (2.4.14).

**Solvent mixture.** Dissolve 200 µl of glacial acetic acid in 1000 ml of methanol.

**Test solution.** Dissolve 0.1 g of the substance under examination in 100.0 ml in solvent mixture.

**Reference solution.** A 0.1 per cent w/v solution of paclitaxel RS in solvent mixture.

**Chromatographic system**

- mobile phase: A. a mixture of 60 volumes of water and 40 volumes of acetonitrile,
  B. acetonitrile
- flow rate. 1.2 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 227nm,
- a 10 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>20</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>60</td>
<td>10</td>
<td>90</td>
</tr>
<tr>
<td>62</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>70</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Inject reference solution (b). The test is not valid unless the resolution between the peak due to paclitaxel and 10-dactyl-7-epipactitaxyl is not less than 1.2 relative retention time for particles and 10-dactyl-7-epipactitaxyl is about 0.94.

Inject the test solution and reference solution (a). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 0.5 times the area of the peak in the chromatogram obtained with the reference solution (a) (0.5 per cent) and the sum of areas of all the secondary peaks is not more than twice the area of the peak in the chromatogram obtained with the reference solution (a) (2.0 per cent).

**Heavy metals.** (2.3.13). 1 g complies with the limit test for heavy metals, Method A (20 ppm).

**Loss on ignition** (2.4.20). Not more than 0.2 per cent.

**Water** (2.3.43). Not more than 4.0 per cent, determined on 0.1 g by coloumetry method.

**Bacterial endotoxins** (2.2.3). Not more than 0.4 Endotoxin Unit per mg of paclitaxel.

**Microbial contamination** (2.2.9). The total viable aerobic count does not exceed 100 cfu per g. It meets the requirements of the tests for the absence of *Staphylococcus aureus*, *Pseudomonas aeruginosa*, *Salmonella species*, and *Escherichia coli*.

**Assay.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** Dissolve 200 µl of glacial acetic acid in 1000 ml of methanol.

**Test solution.** Dissolve 0.1 g of the substance under examination in 100.0 ml in solvent mixture.

**Reference solution.** A 0.1 per cent w/v solution of paclitaxel RS in solvent mixture.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm packed with pentafluoro phenyl groups chemically bonded to porous silica (5 µm).
column temperature 35°,
mobile phase: a mixture of 11 volumes of water and 9 volumes of acetonitrile, filter.
flow rate. 1.5 ml per minute,
spectrophotometer set at 227nm,
a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 1.5. The relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.
Calculate the content of C₄₇H₅₁NO₁₄.

Storage. Store protected from light, at a temperature not exceeding 25º.

**Paclitaxel Injection**

Paclitaxel Injection is a sterile solution of Paclitaxel suitable for dilution, for intravenous use.

Paclitaxel Injection contains not less than 90.0 per cent and not more than 105.0 per cent of the related amount of paclitaxel, C₄₇H₅₁NO₁₄.

**Description.** A clear colourless to slight yellow viscous solution.

**Identification**

A. In the Related substances, the major peak in the chromatogram obtained with test solution corresponds to the peak in the chromatogram obtained with reference solution.

B. In the Assay, the principal peak in the chromatogram obtained with test solution corresponds to the peak in the chromatogram obtained with reference solution.

**Tests**

**pH** (2.4.24). 3.0 to 7.0, determined in a solution 10 per cent v/v solution in water.

**Light absorption.** Absorbance of the injection at about 425 nm, not more than 0.01.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Accurately measure the volume of injection containing 12 mg of Paclitaxel, dilute to 10 ml with acetonitrile.

**Reference solution (a).** A 0.12 per cent w/v solution of paclitaxel RS in acetonitrile.

**Reference solution (b).** Dilute 1 ml of reference solution (a) to 100 ml with acetonitrile.

**System suitability solution- A** sloution containing 0.006 per cent w/v of 10 deacetyl -7-epipoelitoral and 0.12 per cent w/v of paclitaxel in acetonitrile.

**Chromatographic system**

- a stainless steel column 15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (3 µm).
- column temperature 35°,
- mobile phase: A. a mixture of 60 volumes of water and 40 volumes of acetonitrile,
  B. acetonitrile
- flow rate. 1.2 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 227nm,
- a 10 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>26</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>66</td>
<td>17</td>
<td>83</td>
</tr>
<tr>
<td>67</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Inject reference solution (b). The test is not valid unless the column efficiency is not less than 2000 theoretical plates and the tailing factor is not more than 2.0.

Inject the test solution and reference solution (a). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 0.8 times the area of the peak in the chromatogram obtained with the reference solution (a) (0.8 per cent) and the sum of areas of all the secondary peaks is not more than twice the area of the peak in the chromatogram obtained with the reference solution (a) (2.0 per cent).

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Bacterial endotoxins** (2.2.3). Not more than 0.67 Endotoxin Unit per mg of paclitaxel.

**Sterility** (2.2.11). Complies with the test for sterility.

**Assay.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** Dissolve 200 µl of glacial acetic acid in 1000 ml of methanol.

**Test solution.** Accurately measure the volume of injection containing 6 mg of Paclitaxel and dissolve in 10 ml of solvent mixture.

**Reference solution.** A 0.06 per cent w/v solution of paclitaxel RS in solvent mixture.

**Chromatographic system**

- a stainless steel column 30 cm x 3.9 mm, packed with penta fluro phenyl group chemically bonded to porous silica (5 µm),

**Solvent mixture.** Dissolve 200 µl of glacial acetic acid in 1000 ml of methanol.

**Test solution.** Accurately measure the volume of injection containing 6 mg of Paclitaxel and dissolve in 10 ml of solvent mixture.

**Reference solution.** A 0.06 per cent w/v solution of paclitaxel RS in solvent mixture.

**Chromatographic system**

- a stainless steel column 30 cm x 3.9 mm, packed with penta fluro phenyl group chemically bonded to porous silica (5 µm),
Pancreatin

Pancreatin is a preparation of mammalian pancreas containing protease, lipase and amylase activity. It may contain Sodium Chloride.

Pancreatin contains not less than the minimum protease activity, amylase activity and lipase activity determined under the conditions of the Assay.

Description. A white or buff-coloured, amorphous powder; odour, meaty and not unpleasant.

Identification

A. Triturate 0.5 g with 10 ml of water and adjust to pH 8.0 by the addition of 1 M sodium hydroxide using cresol red solution as indicator. Divide the resulting solution into two equal portions. Boil one portion [solution (1)] and leave the other untreated [solution (2)]. To each add a few shreds of congo red fibrin, warm to 39° ± 1° and maintain at this temperature for 1 hour. Solution (2) is stained red and solution (1) is colourless or not more than slightly pink.

B. Triturate 0.25 g with 10 ml of water and adjust to pH 8.0 by the addition of 1 M sodium hydroxide using cresol red solution as indicator. Divide the resulting solution into two equal portions. Boil one portion [solution (1)] and leave the other untreated [solution (2)]. Dissolve 0.1 g of soluble starch in 100 ml of boiling water, boil for 2 minutes, cool and dilute to 150 ml with water. Add solution (1) to half the starch mucilage and solution (2) to the remainder and maintain the mixtures at 39° ± 1° for 5 minutes. To 1 ml of each mixture add 10 ml of iodinated potassium iodide solution. The liquid containing solution (2) retains the colour of the solution of iodine and the liquid containing solution (1) acquires an intense blue colour.

Tests

Fat. Not more than 5.0 per cent, determined by the following method. Extract 1 g with light petroleum (40° to 60°) for 3 hours in an apparatus for the continuous extraction of drugs (2.1.8), evaporate the extract and dry the residue at 105° for 2 hours.

Microbial contamination (2.2.9). 1 g is free from Escherichia coli; 10 g is free from salmonellae.

Loss on drying (2.4.19). Not more than 5.0 per cent, determined on 0.5 g by drying in an oven at 60° at a pressure not exceeding 0.7 kPa for 4 hours.

Assay. For protease activity — Weigh accurately 4.0 g of purified casein and dissolve in about 90 ml of water containing 3 ml of 1 M sodium hydroxide, adjust the pH of the solution to 8.7 and add sufficient water to produce 100.0 ml. Weigh accurately about 0.5 g of the substance under examination, triturate with water and add sufficient water to produce 300.0 ml to give the test solution. Dilute 15.0 ml of the casein solution with 30 ml of water, warm to 55° and add 10.0 ml of the unfiltered test solution. Heat rapidly to 55° and keep at this temperature for 20 minutes. Cool rapidly to room temperature. Dilute a further portion of 15.0 ml of the casein solution with 30 ml of water, add 10.0 ml of the unfiltered test solution, previously boiled and cooled, heat rapidly to 55° and keep at this temperature for 20 minutes. Cool to room temperature. To each solution add 0.75 ml of phenolphthalein solution and 10 ml of formaldehyde solution. Titrate each solution with 0.1 M sodium hydroxide until the colour of the solution matches that produced by mixing 10 ml of buffer solution pH 8.7 and 0.15 ml of phenolphthalein solution. The difference between the two titrations is not less than 4.5 ml.

For lipase activity — To 95 ml of water add 6.5 ml of triacetin and 0.2 ml of a 0.1 per cent w/v solution of bromocresol purple, neutralise with 0.5 M sodium hydroxide and add sufficient water to produce 110 ml. Place 50 ml of this solution in each of two large tubes 3 cm × 20 cm A and B contained in a thermostat at 30°. Insert in each tube a rubber stopper having two holes, one for the tip of a burette and the other for a short glass tube through which passes a thread operating a glass stirring coil. Stir the contents of the tube until they attain the temperature of the thermostat. Prepare a solution of 0.1 g of the substance under examination in 10.0 ml of water. To tube A add 1.0 ml of the solution, to tube B add 1.0 ml of the solution previously boiled. Adjust and maintain the pH of the solutions in the two tubes to 6.2 to 6.4 by the addition of 0.05 M sodium hydroxide dropwise, stirring frequently. After 30 minutes, the difference between the volumes of 0.05 M sodium hydroxide added to the two tubes is not less than 1.0 ml.

For amylase activity — Not less than 100 Units per g. Dissolve 0.1 g or a quantity containing 10 Units, accurately weighed, in.
sufficient buffer solution pH 6.8 to produce 1000.0 ml. Filter if necessary (1 ml of the test solution should be capable of digesting about 10 mg of dry soluble maize or corn starch). Into each of six stoppered test-tubes add 5.0 ml of starch substrate without touching the sides of the test-tube. Place the test-tubes in a water-bath maintained at 40° ± 0.1°. When the temperature of the solution in the tubes has reached 40°, add 0.35 ml, 0.4 ml, 0.45 ml, 0.5 ml, 0.55 ml and 0.6 ml of the test solution to each of the test-tubes marked 1 to 6 respectively and record the time of addition. Mix thoroughly and replace the tubes in the water-bath. After exactly 60 minutes remove the tubes and cool rapidly in cold water. Add to each tube 0.05 ml of 0.02 M iodine and mix well. Note the tube containing the lowest volume of test solution, which does not show a bluish or violet tinge (if there is doubt, warm the solution slightly, when the colour distinction is prominent). From this volume calculate the number of grams of dry soluble maize or corn starch digested by 1.0 g of the substance under examination. This represents the number of Units of amylase activity per g.

Storage. Store protected from moisture.

Labelling. The label states the name of any added substance.

D-Panthenol

Pantothenol; Dextro-pantothenyl Alcohol

\[
\text{C}_{17}\text{H}_{24}\text{NO}_{4}
\]

D-Panthenol is (R)-2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutanamide.

D-Panthenol contains not less than 6.60 per cent and not more than 6.95 per cent of nitrogen, N.

Description. White crystals or a white, crystalline powder.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with paracetamol RS or with the reference spectrum of paracetamol.

B. Dissolve 50 mg in sufficient methanol to produce 100 ml. To 1 ml of this solution add 0.5 ml of 0.1 M hydrochloric acid and dilute to 100 ml with methanol. Protect the resulting solution from bright light and immediately measure the absorbance at the maximum at about 249 nm; absorbance at 249 nm, about 0.44 (2.4.7).

C. Boil 0.1 g in 1 ml of hydrochloric acid for 3 minutes, add 10 ml of water and cool; no precipitate is produced. Add 0.05 ml of 0.0167 M potassium dichromate; a violet colour develops which does not turn red.

D. Gives the reaction of acetyl groups (2.3.1).

Tests

4-Aminophenol. Dissolve 0.5 g in sufficient methanol (50 per cent) to produce 10 ml. Add 0.2 ml of freshly prepared alkaline

\[
\text{C}_{8}\text{H}_{9}\text{NO}_{2}
\]

Mol. Wt. 151.2

Paracetamol is 4-hydroxyacetanilide.

Paracetamol contains not less than 99.0 per cent and not more than 101.0 per cent of C\(_8\)H\(_9\)NO\(_2\), calculated on the dried basis.

Description. White crystals or a white, crystalline powder.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with paracetamol RS or with the reference spectrum of paracetamol.

B. Dissolve 50 mg in sufficient methanol to produce 100 ml. To 1 ml of this solution add 0.5 ml of 0.1 M hydrochloric acid and dilute to 100 ml with methanol. Protect the resulting solution from bright light and immediately measure the absorbance at the maximum at about 249 nm; absorbance at 249 nm, about 0.44 (2.4.7).

C. Boil 0.1 g in 1 ml of hydrochloric acid for 3 minutes, add 10 ml of water and cool; no precipitate is produced. Add 0.05 ml of 0.0167 M potassium dichromate; a violet colour develops which does not turn red.

D. Gives the reaction of acetyl groups (2.3.1).

Tests

4-Aminophenol. Dissolve 0.5 g in sufficient methanol (50 per cent) to produce 10 ml. Add 0.2 ml of freshly prepared alkaline
sodium nitroprusside solution, mix and allow to stand for 30 minutes. Any blue colour in the solution is not more intense than that in 10 ml of a solution prepared at the same time and in the same manner containing 0.5 g of 4-aminoacetanilide-free paracetamol and 0.5 ml of a 0.005 per cent w/v solution of 4-aminoacetanilide in methanol (50 per cent) (50 ppm).

Related substances. Determine by thin layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 65 volumes of chloroform, 25 volumes of acetone and 10 volumes of toluene.

Test solution (a). Transfer 1 g of the substance under examination, finely powdered, to a ground-glass stoppered 15-ml centrifuge tube, add 5 ml of peroxide-free ether, shake mechanically for 30 minutes and centrifuge at 1000 rpm for 15 minutes or until a clear supernatant liquid is obtained.

Test solution (b). Dilute 1 ml of the test solution to 10 ml with ethanol (95 per cent).

Reference solution (a). A 0.005 per cent w/v solution of 4-chloroacetanilide in ethanol (95 per cent).

Reference solution (b). Dissolve 0.25 g of 4-chloroacetanilide and 0.1 g of the substance under examination in sufficient ethanol (95 per cent) to produce 100 ml.

Apply to the plate 200 µl of test solution (a) and 40 µl of each of test solution (b) and reference solutions (a) and (b). After development, dry the plate in a current of warm air and examine in ultraviolet light at 254 nm. Any spot corresponding to 4-chloroacetanilide in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a). Any other secondary spot in the chromatogram obtained with test solution (b) is not more intense than the spot in the chromatogram obtained with reference solution (a). The chromatogram obtained with reference solution (b) shows two clearly separated spots, the spot corresponding to paracetamol having the lower Rf value.

Heavy metals (2.3.13). 2.0 g complies with the limit test for heavy metals, Method B (10 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

Assay. Weigh accurately about 0.5 g, dissolve in a mixture of 10 ml of water and 50 ml of 1 M sulphuric acid. Boil under a reflux condenser for 1 hour, cool and dilute to 100.0 ml with water. To 20.0 ml of the solution add 40 ml of water, 40 g of water in the form of ice, 15 ml of 2 M hydrochloric acid and 0.1 ml of ferroin solution and titrate with 0.1 M ceric ammonium sulphate until a yellow colour is produced. Carry out a blank titration.

1 ml of 0.1 M ceric ammonium sulphate is equivalent to 0.00756 g of C₈H₉NO₂.

Storage. Store protected from light and moisture.

Paracetamol Syrup

Paracetamol Oral Solution; Acetaminophen Syrup

Paracetamol Syrup is a solution of Paracetamol in a suitable flavoured vehicle. Paracetamol Syrup contains not less than 95.0 per cent and not more than 105.0 per cent w/v solution of the stated amount of paracetamol, C₈H₉NO₂.

Identification

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 65 volumes of chloroform, 25 volumes of acetone, 10 volumes of toluene and 0.5 volumes of glacial acetic acid.

Test solution. Dilute a volume containing 25 mg of Paracetamol to 10 ml with methanol and filter if necessary.

Reference solution. A 0.25 per cent w/v solution of paracetamol RS in methanol

Apply to the plate 10 µl of each solution. After development, dry the plate in a current of warm air, examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

Tests

4-Aminophenol. Determine by liquid chromatography (2.4.14).

Test solution. Shake 5 ml of the preparation under examination with 15 ml of the mobile phase, dilute to 25 ml with the mobile phase and filter if necessary.

Reference solution. A 0.0025 per cent w/v solution of 4-aminoacetanilide in the mobile phase.

Chromatographic system

- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (10 µm),
- mobile phase: 0.01 M sodium butanesulphonate in a mixture of 85 volumes of water, 15 volumes of methanol and 0.4 volume of formic acid,
- flow rate: 2 ml per minute,
- spectrophotometer set at 272 nm,
- a 20 µl loop injector.

In the chromatogram obtained with the test solution, the area of any peak corresponding to 4-aminoacetanilide is not greater...
than the area of the peak in the chromatogram obtained with the reference solution. In the chromatogram obtained with the test solution peaks with a long retention time may occur due to preservatives in the preparations.

Other tests. Complies with the tests stated under Oral Liquids.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Mix an accurately weighed quantity of the preparation under examination containing 25 mg of Paracetamol in 100 ml of the mobile phase, dilute to 200.0 ml with the mobile phase and filter if necessary.

Reference Solution. A 0.0125 per cent w/v solution of paracetamol RS in the mobile phase.

Chromatographic system
- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (10 µm),
- mobile phase: 0.01 M sodium butanesulphonate in a mixture of 85 volumes of water, 15 volumes of methanol and 0.4 volume of formic acid,
- flow rate, 2 ml per minute,
- spectrophotometer set at 243 nm,
- a 20 µl loop injector.

Determine the weight per ml of the syrup (2.4.29), and calculate the percentage content of C₈H₉NO₂, weight in volume.

Storage. Store protected from light and moisture.

Paracetamol Tablets

Acetaminophen Tablets
Paracetamol Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of paracetamol, C₈H₉NO₂.

Identification
Extract a quantity of the powdered tablets containing 0.5 g of Paracetamol with 20 ml of acetone, filter, evaporate the filtrate to dryness and dry at 105⁰. The residue complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with paracetamol RS or with the reference spectrum of paracetamol.

B. Boil 0.1 g in 1 ml of hydrochloric acid for 3 minutes, add 10 ml of water and cool; no precipitate is produced. Add 0.05 ml of 0.0167 M potassium dichromate; a violet colour develops which does not turn red.

Tests

4-Aminophenol. Determine by liquid chromatography (2.4.14).

Test solution. Shake a quantity of the powdered tablets containing 1 g of Paracetamol with 15 ml of methanol, dilute to 100 ml with water and filter.

Reference solution. A 0.001 per cent w/v solution of 4-aminophenol in methanol (15 per cent).

Chromatographic system
- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (10 µm),
- mobile phase: 0.01 M sodium butanesulphonate in a mixture of 85 volumes of water, 15 volumes of methanol and 0.4 volume of formic acid,
- flow rate, 2 ml per minute,
- spectrophotometer set at 272 nm,
- a 20 µl loop injector.

In the chromatogram obtained with the test solution the area of any peak corresponding to 4-aminophenol is not greater than the area of the peak in the chromatogram obtained with the reference solution. In the chromatogram obtained with the test solution peaks with a long retention times may occur due to excipients.

Related substances. Determine by thin layer chromatography (2.4.17), coating the plate with silica gel F254.

Mobile phase. A mixture of 65 volumes of chloroform, 25 volumes of acetone and 10 volumes of toluene.

Test solution (a). Transfer a quantity of the powdered tablets containing 1 g of Paracetamol to a ground-glass stoppered 15-ml centrifuge tube, add 5 ml of peroxide-free ether, shake mechanically for 30 minutes, centrifuge at 1000 rpm for 15 minutes or until a clear supernatant liquid is obtained and use the supernatant liquid.

Test solution (b). Dilute 1 ml of the test solution to 10 ml with ethanol (95 per cent).

Reference solution (a). A 0.005 per cent w/v solution of 4-chloroacetanilide in ethanol (95 per cent).

Reference solution (b). Dissolve 0.25 g of 4-chloroacetanilide and 0.1 g of the substance under examination in sufficient ethanol (95 per cent) to produce 100 ml.

Apply to the plate 200 µl of test solution (a) and 40 µl of each of test solution (b) and reference solutions (a) and (b). After development, dry the plate in a current of warm air and examine in ultraviolet light at 254 nm. Any spot corresponding to 4-chloroacetanilide in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a). Any other secondary spot in the chromatogram obtained with test solution (b) is not more intense than the spot in the chromatogram obtained with reference solution (a). The chromatogram obtained with reference solution (b) shows two

902
clearly separated spots, the spot corresponding to paracetamol having the lower Rf value.

**Dissolution (2.5.2).**

Apparatus. No 1
Medium. 900 ml of phosphate buffer pH 5.8
Speed and time. 50 rpm and 30 minutes.
Withdraw a suitable volume of the medium and filter and dilute a suitable volume of the filtrate with the same solvent. Measure the absorbance of the resulting solution at the maximum at about 243 nm (2.4.7). Similarly measure the absorbance of a solution of known concentration of paracetamol RS. Calculate the content of C₈H₉NO₂.

D. Not less than 80 per cent of the stated amount of C₈H₉NO₂.

**Other tests.** Complies with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.15 g of Paracetamol, add 50 ml of 0.1 M sodium hydroxide, dilute with 100 ml of water; shake for 15 minutes and add sufficient water to produce 200.0 ml. Mix, filter and dilute 10.0 ml of the filtrate to 100.0 ml with water. To 10.0 ml of the resulting solution add 10 ml of 0.1 M sodium hydroxide, dilute to 100.0 ml with water and mix. Measure the absorbance of the resulting solution at the maximum at about 257 nm (2.4.7). Calculate the content of C₈H₉NO₂ taking 715 as the specific absorbance at 257 nm.

**Storage.** Store protected from light and moisture.

**Hard Paraffin**

Hard Paraffin is a purified mixture of solid hydrocarbons obtained from petroleum or from shale oil.

**Description.** A white or colourless, translucent mass, frequently showing a crystalline structure; odourless even when freshly cut; slightly greasy to the touch. Burns with a luminous flame. When melted, the liquid is free from fluorescence by daylight.

**Tests**

**Acidity or alkalinity.** To 10.0 g add 20 ml of boiling water, heat in a water-bath for 5 minutes, shake vigorously for 1 minute, cool, allow to separate and filter the aqueous layer. To 10 ml of the filtrate add 0.1 ml of phenolphthalein solution. The solution is colourless and not more than 0.1 ml of 0.1 M sodium hydroxide is required to change the colour of the solution to pink.

**Congealing range** (2.4.10). 50º to 65º.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Liquid Paraffin**

White Mineral Oil; Liquid Petrolatum

Liquid Paraffin is a purified mixture of liquid hydrocarbons obtained from petroleum to which not more than 10 ppm of tocopherol or of butylated hydroxytoluene may be added.

**Description.** A transparent, colourless, oily liquid, free from fluorescence by daylight; odourless or almost odourless.

**Tests**

**Weight per ml** (2.4.29). 0.860 g to 0.904 g.

**Dynamic viscosity** (2.4.28). 110 mPas to 230 mPas, determined at 20º ± 1º by Method B.

**Acidity or alkalinity.** To 10.0 g add 20 ml of boiling water, heat in a water-bath for 5 minutes, shake vigorously for 1 minute, cool, allow to separate and filter the aqueous layer. To 10 ml of the filtrate add 0.1 ml of phenolphthalein solution. The solution is colourless and not more than 0.1 ml of 0.1 M sodium hydroxide is required to change the colour of the solution to pink.

**Light absorption.** When examined in the range 240 nm to 280 nm (2.4.7), a 2.0 per cent w/v solution in 2,2,4-trimethylpentane shows an absorption of not more than 0.1.

**Readily carbonisable substances.** Place 5 ml in a dry, heat-resistant glass-stoppered test-tube (125 mm x 18 mm) previously rinsed with chromic acid solution, then with water and dried. Add 5 ml of nitrogen-free sulphuric acid (containing 94.5 per cent to 95.5 per cent w/w of H₂SO₄), insert the stopper and shake as vigorously as possible in the longitudinal direction of the tube for 5 seconds. Loosen the stopper, immediately place the tube in a bath of boiling water, supporting it so as to prevent contact of the tube with the bottom or side of the bath and heat for 10 minutes. At the end of the second, fourth, sixth, and eighth minutes, remove the tube from the bath and shake as vigorously as possible in the longitudinal direction of the tube for 5 seconds. At the end of 10 minutes from the time the tube was placed in the bath remove the tube and allow to stand for 10 minutes. The lower acid layer is not more intensely coloured than a mixture of 3 ml of FCS, 1.5 ml of CCS and 0.5 ml of CSS (2.4.1), overlaid with an acid layer is not more intensely coloured than a mixture of 3 ml of FCS, 1.5 ml of CCS and 0.5 ml of CSS (2.4.1), overlaid with 5 ml of liquid paraffin. If the sulphuric acid remains dispersed in the molten paraffin, the colour of the emulsion is not darker than that of the standard mixture when shaken vigorously.

**Solid paraffins.** Place a suitable quantity, previously dried by heating at 100º for 2 hours and cooled in a desiccator over sulphuric acid, in a glass cylindrical vessel having an internal diameter of approximately 25 mm. Close the vessel and immerse in a mixture of ice and water; after 4 hours the liquid is sufficiently clear that a black line, 0.5 mm in width, held vertically behind the vessel is easily seen.
**Sulphur compounds.** Mix 4 ml with 2 ml of *ethanol (95 per cent)*, and 2 drops of a clear, saturated solution of *lead monoxide in sodium hydroxide solution* and heat at 70º for 10 minutes with frequent shaking; the mixture remains colourless.

**Storage.** Store protected from light.

---

**Light Liquid Paraffin**

Light Mineral Oil; Light Liquid Petrolatum

Light Liquid Paraffin is a purified mixture of liquid saturated hydrocarbons obtained from petroleum. It may contain a suitable stabiliser.

**Description.** A transparent, colourless, oily liquid, free from fluorescence by daylight; almost odourless when cold.

**Tests**

**Weight per ml** (2.4.29). 0.820 g to 0.880 g.

**Dynamic viscosity** (2.4.28). 25 mPa s to 80 mPa s, determined at 20º ± 1º by Method B.

**Acidity or alkalinity.** To 10.0 g add 20 ml of boiling water, heat in a water-bath for 5 minutes, shake vigorously for 1 minute, cool, allow to separate and filter the aqueous layer. To 10 ml of the filtrate add 0.1 ml of *phenolphthalein solution*. The solution is colourless and not more than 0.1 ml of 0.1 M sodium hydroxide is required to change the colour of the solution to pink.

**Light absorption.** When examined in the range 240 nm to 280 nm (2.4.7), a 2.0 per cent w/v solution in 2,2,4-trimethylpentane shows an absorption of not more than 0.1.

**Readily carbonisable substances.** Place 5 ml in a dry, heat-resistant glass-stoppered test-tube (125 mm x 18 mm) previously rinsed with chromic acid solution, then with water and dried. Add 5 ml of *nitrogen-free sulphuric acid* (containing 94.5 per cent to 95.5 per cent w/w of H2SO4), insert the stopper and shake as vigorously as possible in the longitudinal direction of the tube for 5 seconds. Loosen the stopper, immediately place the tube in a bath of boiling water, supporting it so as to prevent contact of the tube with the bottom or side of the bath and heat for 10 minutes. At the end of the second, fourth, sixth, and eighth minutes, remove the tube from the bath and shake as vigorously as possible in the longitudinal direction of the tube for 5 seconds. At the end of 10 minutes from the time the tube was placed in the bath remove the tube and allow to stand for 10 minutes. The lower acid layer is not more intensely coloured than a mixture of 3 ml of FCS, 1.5 ml of CCS and 0.5 ml of CSS (2.4.1), overlaid with 5 ml of liquid paraffin. If the sulphuric acid remains dispersed in the molten paraffin, the colour of the emulsion is not darker than that of the standard mixture when shaken vigorously.

**Solid paraffins.** Place a suitable quantity, previously dried by heating at 100º for 2 hours and cooled in a desiccator over sulphuric acid, in a glass cylindrical vessel having an internal diameter of approximately 25 mm. Close the vessel and immerse in a mixture of ice and water; after 4 hours the liquid is sufficiently clear that a black line, 0.5 mm in width, held vertically behind the vessel is easily seen.

**Sulphur compounds.** Mix 4 ml with 2 ml of *ethanol (95 per cent)*, and 2 drops of a clear, saturated solution of *lead monoxide in sodium hydroxide solution* and heat at 70º for 10 minutes with frequent shaking; the mixture remains colourless.

**Storage.** Store protected from light.

---

**Liquid Paraffin Emulsion**

Liquid Paraffin Oral Emulsion

Liquid Paraffin Emulsion is an oral emulsion of Liquid Paraffin in Purified Water.

Liquid Paraffin Emulsion contains not less than 44.0 per cent and not more than 49.0 per cent w/w of liquid paraffin.

**Tests**

**Other tests.** Complies with the tests stated under Oral Liquids.

**Assay.** Weigh accurately about 5.0 g, add 10 ml of water, extract with two quantities, each of 40 ml, of a mixture of 2 volumes of *ethanol (95 per cent)*, 3 volumes of *light petroleum (40º to 60º)* and 3 volumes of *ether* and then with 30 ml of a mixture of equal volumes of *light petroleum (40º to 60º)* and *ether*. Wash the combined extracts with 15 ml of 0.5 M sodium hydroxide and then with 15 ml of water, evaporate the solvent, add 5 ml of acetone and evaporate again. Repeat the addition and evaporation of acetone until the residue is free from water, dry at 105º for 15 minutes and weigh.

**Storage.** Store protected from moisture.

---

**White Soft Paraffin**

White Petroleum Jelly

White Soft Paraffin is a purified, semi-solid mixture of hydrocarbons obtained from petroleum and bleached.

**Description.** A white, translucent, soft unctuous mass, retaining these characteristics on storage and when melted.
and allowed to cool without stirring; not more than slightly fluorescent by daylight, even melted; odourless when rubbed on the skin.

**Tests**

**Melting range** (2.4.21). 38° to 56°, determined by Method IV.

**Acidity or alkalinity.** To 10.0 g add 20 ml of boiling water, heat in a water-bath for 5 minutes, shake vigorously for 1 minute, cool, allow to separate and filter the aqueous layer. To 10 ml of the filtrate add 0.1 ml of phenolphthalein solution. The solution is colourless and not more than 0.1 ml of 0.1 M sodium hydroxide is required to change the colour of the solution to pink.

**Light absorption** (2.4.7). Absorbance of a 0.05 per cent w/v solution in 2,2,4-trimethylpentane at about 290 nm, not more than 0.5.

**Fixed oils, fats and resin.** Digest 10 g with 50 ml of sodium hydroxide solution at 100° for 30 minutes and allow the aqueous layer to separate. On acidifying the aqueous layer with dilute sulphuric acid, no precipitate or oily matter is produced.

**Foreign organic matter.** Volatilises when heated, without emitting an acrid odour.

**Consistency.** 100 to 300, determined by the following method.

**Apparatus.** The apparatus is essentially in agreement with IS 4887:1968 and comprises a penetrometer fitted with a polished cone-shaped metal plunger weighing 150 g having a detachable steel tip of the following dimensions. The tip of the cone has an angle of 30°, the point being truncated to a diameter of 0.38 ± 0.08 mm, the base of the tip is 8.38 ± 0.13 mm in diameter and the length of the tip is 15 ± 0.25 mm. The remaining portion of the cone has an angle of 90°, is 28 to 29 mm in height, and has a maximum diameter of 65.1 mm at the base. The containers of the test are flat-bottomed metal or glass cylinders that are 102 ± 6 mm in diameter and not less than 60 mm in height.

**Procedure.** Melt a sufficient quantity at a temperature below 85° and pour into one or more of the containers filling to within 6 mm of the rim. Cool to 25° ± 2.5° over a period of not less than 16 hours, protected from drafts. Two hours before the test, place the containers in a water-bath at 25° ± 0.5°. If the room temperature is below 23.5° or above 26.5°, adjust the temperature of the cone to 25° ± 0.5° by placing it in a water-bath.

Without disturbing the surface of the substance under examination, place the container on the penetrometer table, and lower the cone until the tip just touches the top surface of the test substance at a spot 25 mm to 38 mm from the edge of the container. Adjust the zero setting and quickly release the plunger, then hold it free for 5 seconds. Secure the plunger and read the total penetration from the scale. Make three or more trials, each so spaced that there is no overlapping of the areas of penetration. Where the penetration exceeds 20 mm, use a separate container of the test substance for each trial. Read the penetration to the nearest 0.1 mm. Calculate the average of the three or more readings and conduct further trials to a total of 10 if the individual results differ from the average by more than ± 3 per cent. The final average of the trials is not less than 10.0 mm and not more than 30.0 mm indicating a consistency value between 100 and 300.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Storage.** Store protected from light and moisture.

---

**Yellow Soft Paraffin**

**Yellow Petroleum Jelly**

Yellow Soft Paraffin is a purified, semi-solid mixture of hydrocarbons obtained from petroleum.

**Description.** A pale yellow to yellow, translucent, soft unctuous mass, retaining these characteristics on storage and when melted and allowed to cool without stirring; not more than slightly fluorescent by daylight, even melted; odourless when rubbed on the skin.

**Tests**

**Melting range** (2.4.21). 38° to 56°, determined by Method IV.

**Light absorption** (2.4.7). Absorbance of a 0.05 per cent w/v solution in 2,2,4-trimethylpentane at about 290 nm, not more than 0.75.

**Acidity or alkalinity.** To 10.0 g add 20 ml of boiling water, heat in a water-bath for 5 minutes, shake vigorously for 1 minute, cool, allow to separate and filter the aqueous layer. To 10 ml of the filtrate add 0.1 ml of phenolphthalein solution. The solution is colourless and not more than 0.1 ml of 0.1 M sodium hydroxide is required to change the colour of the solution to pink.

**Fixed oils, fats and resin.** Digest 10 g with 50 ml of sodium hydroxide solution at 100° for 30 minutes and allow the aqueous layer to separate. On acidifying the aqueous layer with dilute sulphuric acid, no precipitate or oily matter is produced.

**Foreign organic matter.** Volatilises when heated, without emitting an acrid odour.

**Consistency.** 100 to 300, determined by the following method.

**Apparatus.** The apparatus is essentially in agreement with IS 4887:1968 and comprises a penetrometer fitted with a polished cone-shaped metal plunger weighing 150 g having a detachable
steel tip of the following dimensions. The tip of the cone has an angle of 30°, the point being truncated to a diameter of 0.38 ± 0.08 mm, the base of the tip is 8.38 ± 0.13 mm in diameter and the length of the tip is 15 ± 0.25 mm. The remaining portion of the cone has an angle of 90°, is 28 to 29 mm in height, and has a maximum diameter of 65.1 mm at the base. The containers of the test are flat-bottomed metal or glass cylinders that are 102 ± 6 mm in diameter and not less than 60 mm in height.

Procedure. Melt a sufficient quantity at a temperature below 85° and pour into one or more of the containers filling to within 6 mm of the rim. Cool to 25°± 2.5° over a period of not less than 16 hours, protected from drafts. Two hours before the test, place the containers in a water-bath at 25° ± 0.5°. If the room temperature is below 23.5° or above 26.5°, adjust the temperature of the cone to 25° ± 0.5° by placing it in a water-bath.

Without disturbing the surface of the substance under examination, place the container on the penetrometer table, and lower the cone until the tip just touches the top surface of the test substance at a spot 25 mm to 38 mm from the edge of the container. Adjust the zero setting and quickly release the plunger, then hold it free for 5 seconds. Secure the plunger and read the total penetration from the scale. Make three or more trials, each so spaced that there is no overlapping of the areas of penetration. Where the penetration exceeds 20 mm, use a separate container of the test substance for each trial. Read the penetration to the nearest 0.1 mm. Calculate the average of the three or more readings and conduct further trials to a total of 10 if the individual results differ from the average by more than ± 3 per cent. The final average of the trials is not less than 10.0 mm and not more than 30.0 mm indicating a consistency value between 100 and 300.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Storage. Store protected from light and moisture.

Paraffin Ointment

White Beeswax 20 g
Hard Paraffin 30 g
Cetostearyl Alcohol 50 g
White Soft Paraffin* 900 g

*May be replaced by Yellow Soft Paraffin if other medicaments to be incorporated are coloured.

Mix the ingredients, heat gently with stirring until homogeneous and stir until cold.

Tests

Paraffin Ointment complies with the tests stated under Ointments.

Paraldehyde

\[
\text{C}_\text{H}_\text{O}_3 \quad \text{Mol. Wt. 132.7}
\]

Paraldehyde is 2,4,6-trimethyl-1,3,5-trioxane, the cyclic trimer of acetaldehyde. It may contain a suitable amount of antioxidant.

Description. A colourless or slightly yellow, transparent liquid; odour, strong and characteristic. Solidifies at low temperature to form a crystalline mass.

Identification

A. Heat 5 ml with 0.1 ml of 1 M sulphuric acid; acetaldehyde, recognisable by its odour, is evolved.

B. To 5 ml of a 10 per cent v/v solution add 5 ml of ammoniacal silver nitrate solution in a test-tube and heat on a water-bath; metallic silver is deposited as a mirror on the sides of the tube.

C. A 10 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), but becomes turbid on warming.

Tests

Congealing range (2.4.10). 10° to 13°.

Distillation range (2.4.8). Not more than 10 per cent distils below 123° and not less than 95 per cent distils below 126°.

Refractive index (2.4.27). 1.403 to 1.406.

Relative density (2.4.29). 0.991 to 0.996.

Acetaldehyde. Shake 5 ml with a mixture of 5 ml of ethanol (60 per cent), 5 ml of hydroxylamine hydrochloride reagent in ethanol (60 per cent) and 2 drops of methyl orange solution and titrate with 0.5 M sodium hydroxide to full yellow colour; not more than 0.8 ml of 0.5 M sodium hydroxide is required.

Acidity. Mix 5 ml with 45 ml of carbon dioxide-free water and titrate with 0.1 M sodium hydroxide using phenolphthalein solution as indicator; not more than 1.5 ml is required.

Chlorides. To 5 ml of a 1 per cent v/v solution add one drop of nitric acid and three drops of silver nitrate solution; no opalescence is produced immediately.

Sulphates. To 5 ml of a 1 per cent v/v solution add one drop of hydrochloric acid and three drops of barium chloride solution; no turbidity is produced.

Peroxides. In a stoppered vessel, dissolve 5 ml in sufficient of recently boiled and cooled water to produce 50 ml, add 5 ml of dilute sulphuric acid and 10 ml of potassium iodide solution.
Close the flask and set aside in the dark for 15 minutes. Titrate with 0.1 M sodium thiosulphate using starch solution as indicator; set aside for 5 minutes and, if necessary, complete the titration. Not more than 2.0 ml of 0.1 M sodium thiosulphate is required.

Non-volatile matter. Heat 5 ml in a small dish on a water-bath and dry at 105º for 1 hour; the residue weighs not more than 3 mg (0.06 per cent w/v).

Storage. Store protected from moisture, in complete darkness and at a temperature of 8º to 15º. If solidified, the whole of the contents of the container should be liquified by warming before use.

NOTE — Do not use Paraldehyde if it has a brownish colour or an odour of acetic acid. Avoid contact with rubber and plastics.

Labelling. The label states (1) the nature and the proportion of any antioxidant added; (2) that it may decompose on standing to form potentially harmful substances.

Penicillamine

D-Penicillamine

\[
\begin{align*}
\text{C}_6\text{H}_{11}\text{NO}_2\text{S} & \quad \text{Mol. Wt. 149.2} \\
\end{align*}
\]

Penicillamine is 3-mercapto-D-valine.

Penicillamine contains not less than 98.0 per cent and not more than 101.0 per cent of C₆H₁₁NO₂S, calculated on the dried basis.

Description. A white or almost white, crystalline powder.

Identification. A white or almost white, crystalline powder.

Test A may be omitted if test B, C and D carried out. Test D may be omitted if test A, B and C are carried out.

A. Determine by thin layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 40 volumes of 1-butanol, 10 volumes of glacial acetic acid and 10 volumes of water.

Test solution. Dissolve 0.25 g of the substance under examination in 100 ml of water.

Reference solution. A 0.25 per cent w/v solution of penicillamine RS in water.

Apply to the plate 2 µl of each solution. Allow the mobile phase to rise 10 cm. Dry the plate at 105º for 5 to 10 minutes and expose to iodine vapour for 5 to 10 minutes. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

B. Dissolve 0.5 g in a mixture of 0.5 ml of hydrochloric acid and 4 ml of warm acetone, cool in ice and scratch the inside of the tube with a glass rod to initiate crystallisation; a white precipitate is produced. Filter under vacuum, wash the precipitate with acetone and dry with suction. A 1 per cent w/v solution of the dried material is dextrorotatory.

C. To 4 ml of a 1 per cent w/v solution add 2 ml of phosphotungstic acid solution and heat nearly to boiling; a blue colour is produced.

D. In the test for Penicillamine disulphide, the principal peak in the chromatogram obtained with test solution (b) corresponds to the peak due to penicillamine in the chromatogram obtained with reference solution (a).

Tests

Appearance of solution. A 10.0 per cent w/v solution in carbon dioxide-free water (solution A) is clear (2.4.1), and not more intensely coloured than degree 6 of the appropriate range of reference solutions (2.4.1).

pH (2.4.24). 4.5 to 5.5, determined in a 1.0 per cent w/v solution.

Specific optical rotation (2.4.22). -61.0º to -65.0º, determined in a 5.0 per cent w/v solution in 1 M sodium hydroxide.

Heavy metals (2.3.13). 10 ml of solution A, complies with the limit test for heavy metals, Method D (20 ppm). Use lead standard solution (2 ppm Pb) to prepare the standard.

Mercuric salts. Determine by atomic absorption spectrophotometry (2.4.2), using a solution prepared in the following manner. To 1.0 g of the substance under examination add 10 ml of water and 0.15 ml of perchloric acid and swirl until dissolution is complete. Add 1 ml of ammonium pyrrolidinedithiocarbamate solution that has been washed three times immediately before use, each time with an equal volume of 4-methyl-2-pentanone. Mix, add 2 ml of 4-methyl-2-pentanone, shake for 1 minute, dilute to 25 ml with water, allow the layers to separate and use the 4-methyl-2-pentanone layer. Measure the absorbance at 254 nm using a mercury hollow-cathode lamp and an air-acetylene flame and setting the zero using a 4-methyl-2-pentanone layer obtained by repeating the procedure described above but omitting the substance under examination. For the standard solution dissolve 0.108 g of yellow mercuric oxide in the minimum volume of 2 M hydrochloric acid, add sufficient water to produce 1000.0 ml and treat suitable volumes in the same manner as the solution of the substance under examination (10 ppm).

Penicillamine disulphide. Determine by liquid chromatography (2.4.14).
Test solution (a). Dissolve 40 mg of the substance under examination in 5 ml of the mobile phase, add 1 ml of a 0.0025 per cent w/v solution of sulphanilamide (internal standard) in the mobile phase and dilute to 10 ml with the mobile phase.

Test solution (b). Dissolve 40 mg of the substance under examination in the mobile phase and dilute to 10 ml with the same solvent.

Reference solution (a). A 0.4 per cent w/v solution of penicillamine RS in the mobile phase.

Reference solution (b). Add 1 ml of test solution (a) to 1 ml of a 0.04 per cent w/v solution of penicillamine disulphide RS in the mobile phase and dilute to 10 ml with the mobile phase.

Chromatographic system
- a stainless steel column 25 cm x 5 mm, packed with octylsilane bonded to porous silica (5 to 10 µm),
- mobile phase: an equal volume of 0.2 per cent w/v solution of methanesulphonic acid and 0.01 per cent w/v solution of disodium edetate,
- flow rate. 2 ml per minute,
- spectrophotometer set at 220 nm,
- a 20 µl loop injector.

In the chromatogram obtained with test solution (a) the ratio of the area of any peak corresponding to penicillamine disulphide to the area of the peak due to the internal standard is not greater than the corresponding ratio in the chromatogram obtained with reference solution (b).

Penicillin. Carry out the following procedure in a penicillin-free atmosphere and with equipment reserved for the test. Sterilise the equipment at 180º for 3 hours and the buffer solutions at 121º for 20 minutes before use.

Liquefy a suitable nutrient medium such as that described below and inoculate at a suitable temperature with a culture of Micrococcus flavus (ATCC 9341) to give 5 x 10⁴ microorganisms per ml or a quantity necessary to obtain the required sensitivity and formation of clearly defined inhibition zones of suitable diameter. Immediately pour the inoculated medium into five Petri dishes (10 cm in diameter) to give uniform layers 2 to 5 mm in depth. Alternatively, the medium may consist of two layers, only the upper layer being inoculated. Store the dishes so that no appreciable growth or death of microorganisms occurs before use and so that the surface of the medium is dry at the time of use. In each dish, place five stainless steel hollow cylinders (6 mm in diameter) on the surface of the medium evenly spaced on a circle with a radius of about 25 mm and concentric with the dish. For each dish, place in separate cylinders 0.15 ml of each of the following five solutions.

For solution (1) dissolve 1.0 g of the substance under examination in 8 ml of phosphate buffer pH 2.5, add 8 ml of ether and shake vigorously for 1 minute. Repeat the extraction and combine the ether layers. Add 8 ml of phosphate buffer pH 2.5, shake for 1 minute, allow to settle and separate the ether layer quantitatively, taking care to eliminate the aqueous phase completely. (Penicillin is unstable at pH 2.5; carry out the operations at this pH within 6 to 7 minutes). Add 8 ml of phosphate buffer pH 6.0, shake for 5 minutes, allow to settle, separate the aqueous layer and check that the pH is 6.0. For solution (2) add 20 µl of penicillinase solution to 2 ml of solution (1) and incubate at 37º for 1 hour. For solution (3) dissolve 5 mg of benzylpenicillin sodium in 500 ml of phosphate buffer pH 6.0 and dilute 0.25 ml of this solution to 200 ml with phosphate buffer pH 2.5. Carry out the extraction procedure described under solution (1) using 8 ml of this solution and beginning at the words “add 8 ml of ether...”. For solution (4) add 20 ml of penicillinase solution to 2 ml of solution (3) and incubate at 37º for 1 hour. Prepare solution (5) in the same manner as solution (1) but omitting the substance under examination.

Maintain the dishes at 30º for at least 24 hours. Measure the diameters of the zones of inhibition to within 0.1 mm. The test is not valid unless solution (3) gives a clear zone of inhibition and solutions (4) and (5) give no zones of inhibition. If solution (1) gives a zone of inhibition it is caused by penicillin provided solution (2) gives no zone of inhibition. If this is the case, the average diameter of the zones of inhibition given by solution (1) for the five Petri dishes is less than that given by solution (3) (0.1 ppm).

Nutrient medium

<table>
<thead>
<tr>
<th>Component</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peptone</td>
<td>5 g</td>
</tr>
<tr>
<td>Yeast extract</td>
<td>1.5 g</td>
</tr>
<tr>
<td>Meat extract</td>
<td>1.5 g</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>3.5 g</td>
</tr>
<tr>
<td>Agar</td>
<td>15 g</td>
</tr>
<tr>
<td>Distilled water</td>
<td>1000 ml</td>
</tr>
<tr>
<td>Adjust the pH to</td>
<td>6.0</td>
</tr>
</tbody>
</table>

Penicillic acid. Absorbance of a 0.2 per cent w/v solution at about 268 nm, not more than 0.07 (2.4.7) (about 0.5 per cent).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 60º over phosphorus pentoxide at a pressure not exceeding 0.7 kPa.

Assay. Dissolve 0.1 g in 30 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01492 g of C₃H₅NO₂S.

Storage. Store protected from moisture.
Penicillamine Tablets

D-Penicillamine Tablets

Penicillamine Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of penicillamine, C₅H₁₁NO₂S. The tablets are coated.

Identification

A. Shake a quantity of the powdered tablets containing 20 mg of Penicillamine with 4 ml of water and filter. Add to the filtrate 2 ml of phosphotungstic acid solution and allow to stand for 5 minutes; a blue colour is produced.

B. Dissolve a quantity of the powdered tablets containing 10 mg of Penicillamine in 5 ml of water and add 0.3 ml of 5 M sodium hydroxide and 20 mg of ninhydrin; an intense blue or violet-blue colour is produced immediately.

Tests

Mercuric salts. Disperse a quantity of the powdered tablets containing 1 g of Penicillamine in 10 ml of water in a stoppered flask, add 0.2 ml of 9 M perchloric acid, mix, add 2 ml of 4-methyl-2-pentanone, shake for 1 minute and add sufficient water to produce 25 ml. Determine by atomic absorption spectrophotometry (2.4.2), using a mercury hollow-cathode lamp and an air-acetylene flame and setting the zero using a 4-methyl-2-pentanone layer obtained by repeating the procedure described above but omitting the substance under examination, measuring at 254 nm. Use mercury solution AAS, suitably diluted with water, for the standard solutions, adjusted to contain the same concentrations of 9 M perchloric acid, ammonium pyrrolidinedithiocarbamate solution and 4-methyl-2-pentanone as the solution under examination (40 ppm).

Penicillamine disulphide. Determine by liquid chromatography (2.4.14).

Test solution. Shake quantity of the powdered tablets containing 40 mg of Penicillamine with 10 ml of the mobile phase, filter and use the filtrate.

Reference solution. A 0.004 per cent w/v solution of penicillamine disulphide RS in the mobile phase.

In the chromatogram obtained with the test solution the area of any peak corresponding to penicillamine disulphide is not greater than the area of the principal peak in the chromatogram obtained with the reference solution (1.0 per cent).

Other tests. Complies with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 0.1 g of Penicillamine, dissolve as completely as possible in 50 ml of water and filter. Add to the filtrate 5 ml of 1 M sodium hydroxide and 0.2 ml of a 0.1 per cent w/v solution of dithizone in ethanol (95 per cent) and titrate with 0.02 M mercuric nitrate.

1 ml of 0.02 M mercuric nitrate is equivalent to 0.005968 g of C₅H₁₁NO₂S.

Storage. Store protected from moisture.

Diluted Pentaerythritol Tetranitrate

Diluted Pentaerythritol Tetranitrate is a dry mixture of 2,2-bis(hydroxymethyl)- propane1,3-diol tetranitrate with Lactose or Mannitol or a mixture of Lactose and Starch or any other suitable inert excipients which permit safe handling.

Diluted Pentaerythritol Tetranitrate contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of pentaerythritol tetranitrate, C₅H₈N₄O₁₂.

Description. A white or almost white, powder; odour, faint and mild.

Identification

A. Transfer a quantity containing 10 mg of pentaerythritol tetranitrate to a medium porosity sintered-glass filter, add 5 ml of dry acetone and collect the filtrate. Repeat with two further quantities, each of 5 ml, of dry acetone and evaporate the combined filtrate at a temperature not exceeding 60°, with the aid of a gentle current of air, and dry the residue at 60° for 4 hours; the residue melts at 138° to 142° (2.4.21).

B. Suspend 10 mg of the residue obtained in test A in a mixture of 2 ml of sulphuric acid and 1 ml of water; cool and carefully overlay with 3 ml of ferrous sulphate solution; a reddish brown colour is produced at the interface of the two liquids.
Sufficient heat for 5 minutes. Transfer 1.0 ml of the supernatant solution to a stoppered centrifuge tube and centrifuge at 1500 rpm for 5 minutes. Cool, dilute to volume with acetone and mix. Transfer a portion of the mixture to a glass-stoppered centrifuge tube and centrifuge at 1500 rpm for 5 minutes. Transfer 1.0 ml of the supernatant solution to a 100-ml volumetric flask and evaporate at 35º with the aid of a current of air to dryness. To the residue add 1.0 ml of glacial acetic acid and swirl to dissolve. Add 2 ml of phenoldisulphonic acid solution, mix and allow to stand for 5 minutes. Add 25 ml of water and 10 ml of strong ammonia solution, cool, dilute to volume with water and mix. Measure the absorbance of the resulting solution at the maximum at about 409 nm (2.4.7), using water as the blank. Weigh accurately 0.13 g of potassium nitrate, previously dried at 105º for 4 hours, dissolve in 3 ml of water, dilute with sufficient glacial acetic acid to produce 200.0 ml and mix well. Using 1.0 ml of this solution repeat the procedure beginning at the words “Add 2 ml of phenoldisulphonic acid solution,......”. Calculate the content of C₅H₈N₄O₁₂ from the values of the absorbances so obtained. 1 ml of the potassium nitrate solution is equivalent to 0.000503 g of C₅H₈N₄O₁₂. Storage. Store protected from light and moisture. NOTE — Undiluted pentaerythritol tetranitrate is a powerful explosive. It can be exploded with percussion or excessive heat. Great care and appropriate precautions should be taken in handling and only exceedingly small amounts should be isolated. Labelling. The label states the percentage content of pentaerythritol tetranitrate.

Pentaerythritol Tetranitrate Tablets

Pentaerythritol Tetranitrate Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of pentaerythritol tetranitrate, C₅H₈N₄O₁₂.

Identification

A. Transfer a quantity containing 10 mg of pentaerythritol tetranitrate to a medium porosity sintered-glass filter, add 5 ml of dry acetone and collect the filtrate. Repeat with two further quantities, each of 5 ml, of dry acetone and evaporate the combined filtrate at a temperature not exceeding 60º, with the aid of a gentle current of air, and dry the residue at 60º for 4 hours; the residue melts at 138º to 142º (2.4.21). Tests

Uniformity of content. (For tablets containing 10 mg or less) — Comply with the test stated under Tablets. Crush one tablet and transfer to a 50-ml volumetric flask with the aid of 15 ml of acetone. Add sufficient acetone to produce 25 ml, heat the mixture on a water-bath at a temperature not exceeding 60º and boil gently, with occasional swirling, for 5 minutes. Cool, dilute to volume with acetone and mix. Transfer a portion of the mixture to a glass-stoppered centrifuge tube and centrifuge at 1500 rpm for 5 minutes. Transfer 2.5 ml of the supernatant solution to a 100-ml volumetric flask and evaporate at 35º with the aid of a current of air to dryness. To the residue add 1.0 ml of glacial acetic acid and swirl to dissolve. Add 2 ml of phenoldisulphonic acid solution, mix and allow to stand for 5 minutes. Add 25 ml of water and 10 ml of strong ammonia solution, cool, dilute to volume with water and mix. Measure the absorbance of the resulting solution at the maximum at about 409 nm (2.4.7), using water as the blank. Weigh accurately 0.130 g of potassium nitrate, previously dried at 105º for 4 hours, dissolve in 3 ml of water, dilute with sufficient glacial acetic acid to produce 200.0 ml and mix well. Using 1.0 ml of this solution repeat the procedure beginning at the words “Add 2 ml of phenoldisulphonic acid solution,......”. Calculate the content of C₅H₈N₄O₁₂ in the tablet. 1 ml of the potassium nitrate solution is equivalent to 0.000503 g of C₅H₈N₄O₁₂. Other tests. Complies with the tests stated under Tablets. Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 50 mg of pentaerythritol tetranitrate and transfer to a 100-ml volumetric flask with the aid of about 30 ml of acetone. Add sufficient acetone to produce 50 ml and warm on a water-bath at a temperature not exceeding 60º and boil gently, with occasional swirling, for 5 minutes. Cool, dilute to volume with acetone and mix. Transfer a portion of the mixture to a glass-stoppered centrifuge tube and centrifuge at 1500 rpm for 5 minutes. Transfer 1.0 ml of the supernatant solution to a 100-ml volumetric flask and evaporate at 35º with the aid of a current of air to dryness. To the residue add 1.0 ml of glacial acetic acid and swirl to dissolve. Add 2 ml of phenoldisulphonic acid solution, mix and allow to stand for 5 minutes. Add 25 ml of water and 10 ml of strong ammonia solution, cool, dilute to volume with water and mix. Measure the absorbance of the
resulting solution at the maximum at about 409 nm (2.4.7), using water as the blank.

Weigh accurately 0.13 g of potassium nitrate, previously dried at 105º for 4 hours, dissolve in 3 ml of water, dilute with sufficient glacial acetic acid to produce 200.0 ml and mix well. Using 1.0 ml of this solution repeat the procedure beginning at the words “Add 2 ml of phenoldisulphonic acid solution,.......

Calculate the content of C₅H₈N₄O₁₂ from the values of the absorbances so obtained.

1 ml of the potassium nitrate solution is equivalent to 0.000503 g of C₅H₈N₄O₁₂.

Storage. Store protected from light and moisture.

Labelling. The label states the strength in terms of the equivalent amount of pentaerythritol tetranitrate.

Pentamidine Isethionate

H₂N
\[\text{O} - \text{O} - \text{O} - \text{O} - \text{NH}}_{2}\]
\[\text{HO} - \text{SO}_3\text{H}_2\]  

C₁₀H₂₃N₄O₂ · 2C₂H₆O₄S  

Mol. Wt. 592.7

Pentamidine Isethionate is 4,4′-[pentane-1,5-diylbis(oxy)]dibenzamidine di(2-hydroxyethanesulphonate).

Pentamidine Isethionate contains not less than 98.5 per cent and not more than 101.0 per cent of C₁₀H₂₃N₄O₂ · 2C₂H₆O₄S, calculated on the dried basis.

Description. A white or almost white powder or crystals; odourless or almost odourless; hygroscopic.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pentamidine isethionate RS or with the reference spectrum of pentamidine isethionate.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.01 M hydrochloric acid shows an absorption maximum only at about 262 nm; absorbance at about 262 nm, about 0.46.

C. To 10 ml of a 0.05 per cent w/v solution add 1 ml of a 0.1 per cent w/v solution of glyoxal sodium bisulphite and 1 ml of a solution prepared by dissolving 4 g of boric acid in a mixture of 27 ml of 1 M sodium hydroxide and sufficient water to produce 100 ml. Heat on a water-bath for 10 minutes; a magenta colour is produced.

Tests

pH (2.4.24). 4.5 to 6.5, determined in a 5.0 per cent w/v solution.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. The upper layer obtained by shaking together 50 volumes of water, 40 volumes of 1-butanol and 10 volumes of glacial acetic acid.

Test solution. Dissolve 0.5 g of the substance under examination in 10 ml of methanol.

Reference solution. A 0.025 per cent w/v solution of the substance under examination in 100 ml of methanol.

Activate the plate by heating at 105º for 1 hour, apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Ammonium isethionate. To 1.0 g in a test-tube (about 4 cm in diameter) add 10 ml of water and 20 ml of 1 M sodium hydroxide. Immediately attach a bung carrying a splash head and an aspirator tube (about 5 mm in diameter). Connect the splash head to two test-tubes in series, each containing 20 ml of 0.01 M sulphuric acid. Heat the tube containing the substance under examination in a water-bath at 45º to 50º and, maintaining this temperature, draw a current of air, previously passed through 1 M sulphuric acid, through the liquids in a series of tubes for 3 hours at such a rate that the bubbles are just too rapid to count. Titrate the combined solutions from the two absorption tubes with 0.02 M sodium hydroxide using methyl red-methylene blue solution as indicator; not less than 36.5 ml of 0.02 M sodium hydroxide is required.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 4.0 per cent, determined on 1.0 g by drying in an oven at 105º.

Assay. Dissolve 0.25 g in 50 ml of dimethylformamide. Titrate with 0.1 M tetrabutylammonium hydroxide, determining the end-point potentiometrically (2.4.25). Carry out a blank titration. 1 ml of 0.1 M tetrabutylammonium hydroxide is equivalent to 0.02963 g of C₁₀H₂₃N₄O₂ · 2C₂H₆O₄S.

Storage. Store protected from moisture.

Pentamidine Injection

Pentamidine Isethionate Injection

Pentamidine Injection is a sterile material consisting of Pentamidine Isethionate with or without buffering agents and other excipients. It is filled in a sealed container.
The injection is constituted by dissolving the contents of the sealed container in the requisite amount of sterile Water for Injections, immediately before use.

The constituted solution complies with the requirements for Clarity of solution and Particulate matter stated under Parenteral Preparations (Injections).

**Storage.** The constituted solution should be used immediately after preparation but, in any case, within the period recommended by the manufacturer.

Pentamidine Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of pentamidine isethionate, C₁₉H₂₄N₄O₂, ₂C₂H₆O₄S.

The contents of the sealed container comply with the requirements stated under Parenteral Preparations (Powders for Injection) and with the following requirements.

### Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pentamidine isethionate RS or with the reference spectrum of pentamidine isethionate.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.01 M hydrochloric acid shows an absorption maximum only at about 262 nm; absorbance at about 262 nm, about 0.46.

C. To 10 ml of a 0.05 per cent w/v solution add 1 ml of a 0.1 per cent w/v solution of glyoxal sodium bisulphite and 1 ml of a solution prepared by dissolving 4 g of boric acid in a mixture of 27 ml of 1 M sodium hydroxide and sufficient water to produce 100 ml. Heat on a water-bath for 10 minutes; a magenta colour is produced.

### Tests

**pH** (2.4.24). 4.5 to 6.5, determined in a 5.0 per cent w/v solution.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** The upper layer obtained by shaking together 50 volumes of water, 40 volumes of 1-butanol and 10 volumes of glacial acetic acid.

**Test solution.** Dissolve 0.5 g of the substance under examination in 10 ml of methanol.

**Reference solution.** A 0.025 per cent w/v solution of the substance under examination in 100 ml of methanol.

Activate the plate by heating at 105º for 1 hour, apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

### Assay

Dissolve 0.25 g of the mixed contents of 10 containers in 50 ml of dimethylformamide. Titrate with 0.1 M tetrahydroammonium hydroxide, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M tetrahydroammonium hydroxide is equivalent to 0.02963 g of C₁₉H₂₇NO₂, ₂C₂H₆O₄S.

**Storage.** Store in single dose containers.

### Pentazocine

*C₁₉H₂₇NO*  
Mol. Wt. 285.4

Pentazocine is (2RS,6RS,11RS)-6,11-dimethyl-3-(3-methylbut-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol.

Pentazocine contains not less than 98.0 per cent and not more than 101.0 per cent of C₁₉H₂₇NO, calculated on the dried basis.

**Description.** A white or pale cream powder.

### Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pentazocine RS or with the reference spectrum of pentazocine.

B. To 1 mg in a porcelain crucible add 0.5 ml of a solution of sulphuric acid containing 1 per cent w/v solution of
ammonium molybdate; an intense blue colour is produced which changes to bluish green, green and finally, on standing, yellow.

C. Dissolve 5 mg in 5 ml of sulphuric acid, add 0.05 ml of ferric chloride solution and mix; a yellow colour is produced which deepens slightly in intensity on warming. On the addition of 0.05 ml of nitric acid the yellow colour is unchanged.

Tests

Light absorption (2.4.7). To 0.1 g add 20 ml of water and 10 ml of 1 M hydrochloric acid, shake to dissolve and add sufficient water to produce 100 ml. Dilute 10 ml to 100 ml with water. The absorbance of the resulting solution at the maximum at about 278 nm, 0.67 to 0.71.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 94 volumes of chloroform, 3 volumes of 2-propylamine and 3 volumes of methanol.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of chloroform.

Reference solution (a). A 0.02 per cent w/v solution of the substance under examination in chloroform.

Reference solution (b). A 0.01 per cent w/v solution of the substance under examination in chloroform.

Reference solution (c). A 0.005 per cent w/v solution of the substance under examination in chloroform.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Heat the plate at 105º for 15 minutes, allow to cool, expose to iodine vapour and re-examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a); not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b) and not more than four such spots are more intense than the spot in the chromatogram obtained with reference solution (c).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 60º at a pressure not exceeding 0.7 kPa for 4 hours.

Assay. Weigh accurately about 0.6 g, dissolve in 50 ml of anhydrous glacial acetic acid and titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02854 g of C19H27NO.

Storage. Store protected from light and moisture.

Pentazocine Hydrochloride

C19H27NO.HCl Mol. Wt. 321.9

Pentazocine Hydrochloride is (2RS,6RS,11RS)-6,11-dimethyl-3-(3-methylbut-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol hydrochloride.

Pentazocine Hydrochloride contains not less than 98.0 per cent and not more than 101.0 per cent of C19H27NO.HCl, calculated on the dried basis.

Description. A white or pale cream-coloured, crystalline powder; odourless. The material exhibits polymorphism.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pentazocine hydrochloride RS or with the reference spectrum of pentazocine hydrochloride.

B. To 1 mg in a porcelain crucible add 0.5 ml of a solution of sulphuric acid containing 1 per cent w/v solution of ammonium molybdate; an intense blue colour is produced which changes to bluish green, green and finally, on standing, yellow.

C. Gives reaction A of chlorides (2.3.1).

Tests

pH (2.4.24). 4.0 to 6.0, determined in a 1.0 per cent w/v solution.

Light absorption (2.4.7). Dissolve 0.1 g in 10 ml of 1 M hydrochloric acid and add sufficient water to produce 100 ml; dilute 10 ml to 100 ml with water. Absorbance of the resulting solution at the maximum at about 278 nm, 0.59 to 0.63.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 94 volumes of chloroform, 3 volumes of 2-propylamine and 3 volumes of methanol.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of chloroform.

Reference solution (a). A 0.02 per cent w/v solution of the substance under examination in chloroform.
Reference solution (b). A 0.01 per cent w/v solution of the substance under examination in chloroform.

Reference solution (c). A 0.005 per cent w/v solution of the substance under examination in chloroform.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Heat the plate at 105º for 15 minutes, allow to cool, expose to iodine vapour and re-examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a); not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b) and not more than four such spots are more intense than the spot in the chromatogram obtained with reference solution (c).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 100º at a pressure not exceeding 0.7 kPa.

Assay. Weigh accurately about 0.5 g, dissolve in 50 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.03219 g of C₁₉H₂₇NO,HCl.

Storage. Store protected from light and moisture.

Pentazocine Tablets

Pentazocine Hydrochloride Tablets

Pentazocine Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of pentazocine hydrochloride, C₁₉H₂₇NO,HCl.

Identification

A. Shake a quantity of the powdered tablets containing 0.1 g of Pentazocine Hydrochloride with 10 ml of water, filter, add 1 ml of 1 M sodium hydroxide and shake the resulting solution with 20 ml of chloroform. Wash the chloroform extract with 5 ml of water, dry over anhydrous sodium sulphate and filter. Evaporate the chloroform using a rotary evaporator and dry the oily residue at a temperature not exceeding 25º at a pressure of 2 kPa for 1 hour.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pentazocine RS or with the reference spectrum of pentazocine.

B. To a quantity of the powdered tablets containing 50 mg of Pentazocine Hydrochloride add 70 ml of water, shake for 15 minutes, add sufficient water to produce 100 ml and filter. To 10 ml of the filtrate add 10 ml of 1 M sodium hydroxide and sufficient water to produce 100 ml. When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows absorption maxima at about 238 nm and 298 nm.

C. Shake a quantity of the powdered tablets containing 25 mg of Pentazocine Hydrochloride with 5 ml of water and 0.5 ml of 2 M nitric acid for 1 minute and filter. The filtrate gives reaction A of chlorides (2.3.1).

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 94 volumes of chloroform, 3 volumes of 2-propylamine and 3 volumes of methanol.

Test solution. Shake a quantity of the powdered tablets containing 0.2 g of Pentazocine Hydrochloride with 10 ml of 0.1 M methanolic ammonia for 10 minutes, centrifuge and use the supernatant liquid.

Reference solution (a). Dilute 1 volume of test solution to 100 volumes with the same solvent.

Reference solution (b). Dilute 1 volume of test solution to 200 volumes with the same solvent.

Reference solution (c). Dilute 1 volume of test solution to 400 volumes with the same solvent.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Heat the plate at 105º for 15 minutes, allow to cool, expose to iodine vapour and re-examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a); not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b) and not more than four such spots are more intense than the spot in the chromatogram obtained with reference solution (c).

Other tests. Complies with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 25 mg of Pentazocine Hydrochloride, shake with 100 ml of water for 15 minutes, add 2.5 ml of 1 M hydrochloric acid and sufficient water to produce 250.0 ml and filter. Measure the absorbance of the filtrate at the maximum at about 278 nm (2.4.7). Calculate the content of C₁₉H₂₇NO,HCl taking 61.2 as the specific absorbance at 278 nm.

Storage. Store protected from light and moisture.
Pentazocine Lactate

C_{19}H_{27}NO\cdot C_3H_6O_3  
Mol. Wt. 375.4

Pentazocine Lactate is (2RS,6RS,11RS)-6,11-dimethyl-3-(3-methylbut-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol lactate.

Pentazocine Lactate contains not less than 98.5 per cent and not more than 101.0 per cent of C_{19}H_{27}NO\cdot C_3H_6O_3, calculated on the dried basis.

Description. A white or pale cream-coloured, crystalline powder; odourless.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pentazocine lactate RS or with the reference spectrum of pentazocine lactate.

B. To 1 mg in a porcelain crucible add 0.5 ml of a solution of sulphuric acid containing 1 per cent w/v solution of ammonium molybdate; an intense blue colour is produced which changes to bluish green, green and finally, on standing, yellow.

C. Gives reaction A of lactates (2.3.1).

Tests

pH (2.4.24). 5.5 to 6.5, determined in a 1.0 per cent w/v solution.

Light absorption (2.4.7). Dissolve 0.1 g in 10 ml of 1 M hydrochloric acid and add sufficient water to produce 100 ml; dilute 10 ml to 100 ml with water. Absorbance of the resulting solution at the maximum at about 278 nm, 0.50 to 0.54.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 94 volumes of chloroform, 3 volumes of 2-propylamine and 3 volumes of methanol.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of chloroform.

Reference solution (a). A 0.02 per cent w/v solution of the substance under examination in chloroform.

Reference solution (b). A 0.01 per cent w/v solution of the substance under examination in chloroform.

Reference solution (c). A 0.005 per cent w/v solution of the substance under examination in chloroform.

Apply to the plate 25 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Heat the plate at 105º for 15 minutes, allow to cool, expose to iodine vapour and re-examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a); not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b) and not more than four such spots are more intense than the spot in the chromatogram obtained with reference solution (c).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 60º at a pressure not exceeding 0.7 kPa for 16 hours.

Assay. Weigh accurately about 0.75 g of the substance under examination, dissolve in 50 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.03754 g of C_{19}H_{27}NO\cdot C_3H_6O_3.

Storage. Store protected from light and moisture.

Pentazocine Injection

Pentazocine Lactate Injection

Pentazocine Injection is a sterile solution in Water for Injections of either Pentazocine Lactate or pentazocine lactate prepared by the interaction of Pentazocine and Lactic Acid.

Pentazocine Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of pentazocine, C_{19}H_{27}NO.

Description. A clear, colourless or almost colourless liquid.

Identification

A. To a volume containing 90 mg of pentazocine add 5 ml of 0.1 M sodium hydroxide and shake the resulting solution with 5 ml of chloroform. Wash the chloroform extract with 2 ml of water, dry over anhydrous sodium sulphate and filter. Evaporate the chloroform without applying heat and dry the oily residue at a temperature not exceeding 25º and at a pressure of 2 kPa for 1 hour.
On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pentazocine RS or with the reference spectrum of pentazocine (form B).

B. Dilute a volume containing 30 mg of pentazocine to 100 ml with water. To 10 ml add 10 ml of 1 M sodium hydroxide and sufficient water to produce 100 ml. When examined in the range 230 nm to 360 nm (2.4.7), the solution shows absorption maxima, at about 238 nm and 298 nm.

C. To a volume containing 30 mg of pentazocine add 2 ml of 0.1 M sodium hydroxide, extract with 2 ml of chloroform and evaporate 0.1 ml of the chloroform extract to dryness in a porcelain crucible. Add to the residue 0.5 ml of a 1 per cent w/v solution of ammonium molybdate in sulphuric acid; an intense blue colour is produced which changes to bluish green, green and finally, on standing, yellow.

Tests

pH (2.4.24). 4.0 to 5.0.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 94 volumes of chloroform, 3 volumes of 2-propylamine and 3 volumes of methanol.

Test solution. Dilute a volume of the injection with sufficient ethanol (95 per cent) to produce a solution containing 2.0 per cent w/v solution of pentazocine.

Reference solution (a). Dilute 1 volume of the test solution to 100 volumes with ethanol (95 per cent).

Reference solution (b). Dilute 1 volume of the test solution to 200 volumes with ethanol (95 per cent).

Reference solution (c). Dilute 1 volume of the test solution to 400 volumes with ethanol (95 per cent).

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Heat the plate at 105° for 15 minutes, allow to cool, expose to iodine vapour and re-examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a), not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b) and not more than four such spots are more intense than the spot in the chromatogram obtained with reference solution (c).

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. To an accurately measured volume containing about 0.15 g of pentazocine add sufficient water to produce 100.0 ml. To 5.0 ml add 1 ml of 1 M hydrochloric acid and sufficient water to produce 100.0 ml. Measure the absorbance of the resulting solution at the maximum at about 278 nm (2.4.7). Calculate the content of C19H27NO, taking 69 as the specific absorbance at 278 nm.

Storage. Store protected from light.

Labelling. The label states the strength in terms of the equivalent amount of pentazocine in a suitable dose-volume.

Pentobarbitone Sodium

Soluble Pentobarbitone; Pentobarbital Sodium

\[
\text{C}_{11}\text{H}_{17}\text{N}_{2}\text{NaO}_{3} \quad \text{Mol. Wt. 248.3}
\]

Pentobarbitone Sodium is sodium 5-ethyl-5-\{(1RS)-1-methylbutyl\}barbiturate.

Pentobarbitone Sodium contains not less than 99.0 per cent and not more than 101.5 per cent of C11H17N2NaO3, calculated on the dried basis.

Description. A white, crystalline powder or granules; hygroscopic.

Identification

A. To 10 ml of a 10 per cent w/v solution add 5 ml of 2 M acetic acid; a white, crystalline precipitate is produced. Filter, wash the precipitate with water and dry at 105°. Determine the melting point of the dried precipitate (2.4.21). Mix equal parts of the dried precipitate and phenobarbitone RS and determine the melting point (2.4.21). The difference between the melting points (which are about 131°) is not greater than 2°.

B. Complies with the test for identification of barbiturates (2.3.1), using the dried precipitate obtained in test A for preparing the test solution.

C. To 10 mg add 10 mg of vanillin and 2 ml of sulphuric acid, mix and heat on a water-bath for 2 minutes; a reddish-brown colour is produced. Cool and add 5 ml of ethanol; the colour changes to violet and then blue.

D. Ignite 1 g; the residue gives reaction A of sodium salts (2.3.1).
Tests

**Appearance of solution.** Prepare freshly a 10.0 per cent w/v solution in carbon dioxide-free water (solution A). Solution A is clear (2.4.1).

**pH** (2.4.24). 9.6 to 11.0, determined in solution A.

**Related substances.** Complies with the test for related substances in barbiturates (2.3.4), but applying 10 µl of each of the following solutions.

**Test solution.** A 2.0 per cent w/v solution of the substance under examination.

**Reference solution.** A 0.01 per cent w/v solution of the substance under examination. Not more than 3.5 per cent, determined by the following method. Weigh accurately about 0.4 g, dissolve in 5 ml of a 5 per cent w/v solution of 4-nitrobenzyl bromide dissolved in 10 ml of ethanol (95 per cent). Heat under a reflux condenser for 30 minutes, cool to 25º and scratch the side of the vessel with a glass rod if necessary to induce crystallisation and filter. Add 0.3 g of pentobarbitone sodium, C₁₁H₁₇N₂NaO₃.

**Isomer.** Dissolve 0.3 g in 5 ml of a 5 per cent w/v solution of anhydrous sodium carbonate and add 0.3 g of 4-nitrobenzyl bromide dissolved in 10 ml of ethanol (95 per cent). Heat under a reflux condenser for 30 minutes, cool to 25º and scratch the side of the vessel with a glass rod if necessary to induce crystallisation and filter. Wash the residue with five quantities, each of 5 ml, of water. Transfer the residue as completely as possible to a small flask, add 25 ml of ethanol (95 per cent) and heat under a reflux condenser for 10 minutes; the solid dissolves completely. Cool to 25º and scratch the side of the flask with a glass rod to induce crystallisation. Filter, wash the residue with two quantities, each of 5 ml, of water and dry at 105º for 30 minutes. The dried residue melts at 136º to 148º (2.4.21).

**Heavy metals** (2.3.13). 0.67 g complies with the limit test for heavy metals, Method B (30 ppm).

**Loss on drying** (2.4.19). Not more than 3.0 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.4 g, dissolve in 25 ml of a 12.75 per cent w/v solution of silver nitrate in pyridine and titrate with 0.1 M ethanolic sodium hydroxide using 0.5 ml of thymolphthalein solution as indicator, until a pure blue colour is obtained. Carry out a blank titration.

1 ml of 0.1 M ethanolic sodium hydroxide is equivalent to 0.02263 g of pentobarbitone.

**Storage.** Store protected from moisture.

Pentobarbitone Tablets

Pentobarbitone Sodium Tablets; Pentobarbital Sodium Tablets

Pentobarbitone Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of pentobarbitone sodium, C₁₁H₁₇N₂NaO₃.

**Identification**

A. Shake a quantity of the powdered tablets containing 0.1 g of Pentobarbitone Sodium with 10 ml of a 10 per cent w/v solution of pyridine and filter. Add to the filtrate 1 ml of cupric sulphate with pyridine solution and set aside for 10 minutes; a reddish violet precipitate is produced.

B. Shake a quantity of the powdered tablets containing 0.1 g of Pentobarbitone Sodium with 10 ml of water and filter. To the filtrate add 2 ml of hydrochloric acid; a white precipitate is produced (distinction from pentobarbitone).

C. The residue obtained in the Assay melts at 127º to 130º (2.4.21).

D. The powdered tablets, when moistened with hydrochloric acid and introduced on a platinum wire into a flame, impart a yellow colour to the flame.

**Tests**

**Isomer.** Dissolve a quantity of the powdered tablets containing 0.3 g of Pentobarbitone Sodium in 5 ml of a 5 per cent w/v solution of anhydrous sodium carbonate and add 0.3 g of 4-nitrobenzyl bromide dissolved in 10 ml of ethanol (95 per cent). Heat under a reflux condenser for 30 minutes, cool to 25º and scratch the side of the vessel with a glass rod if necessary to induce crystallisation and filter. Wash the residue with five quantities, each of 5 ml, of water. Transfer the residue as completely as possible to a small flask, add 25 ml of ethanol (95 per cent) and heat under a reflux condenser for 10 minutes; the solid dissolves completely. Cool to 25º and scratch the side of the flask with a glass rod to induce crystallisation. Filter, wash the residue with two quantities, each of 5 ml, of water and dry at 105º for 30 minutes. The dried residue melts at 136º to 148º (2.4.21).

**Other tests.** Complies with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.3 g of Pentobarbital Sodium, dissolve as completely as possible in 10 ml of a 2 per cent w/v solution of sodium hydroxide, saturate with sodium chloride, acidify with hydrochloric acid and extract with successive quantities, each of 15 ml, of ether until complete extraction is effected. Wash the combined extracts with two quantities, each of 2 ml, of water and extract the combined washings with 10 ml of ether. Add the ether to
the main ether layer, filter and wash the filter with ether. Evaporate the solvent and dry the residue to constant weight at 105º.

1 g of residue is equivalent to 1.097 g of C₁₁H₁₇N₂NaO₃.

Storage. Store protected from moisture.

**Pepsin**

Pepsin is obtained from the gastric mucosa of pigs, cattle or sheep. It contains gastric proteinases that are active in an acid medium, pH 1 to 5. It may contain a suitable diluent such as Lactose.

Pepsin has an activity equivalent to its ability to digest not less than 3000 times its weight of coagulated egg albumin when determined by the method given under Assay.

**Description.** A white or light buff-coloured, crystalline or amorphous powder or translucent scales; odour, faint and meaty but not rancid; hygroscopic.

**Identification**

A. Place 1 ml of *congo red fibrin* on a filter paper and wash until a colourless filtrate is obtained with a solution prepared by diluting 30 ml of *1 M hydrochloric acid* to 1000 ml with water and adjusting the pH 1.5 to 1.7. Perforate the filter paper and wash the congo red fibrin through it with 20 ml of the same hydrochloric acid solution. Shake this suspension before use. Dissolve about 10 mg of the substance under examination in 2 ml of the hydrochloric acid solution and adjust the pH 1.5 to 1.7. Place 4 ml of the congo red fibrin suspension in each of two tubes. To one of the tubes add 1 ml of the solution of the substance under examination and to the other tube add 1 ml of water (control solution). Mix the contents of each tube and place in a water-bath at 25º with gentle shaking for 15 minutes; the control solution is colourless and the solution of the substance under examination is violet blue.

B. The proteolytic activity of a solution in water is destroyed at once by boiling. It is destroyed by warming for 10 minutes at 40º at a pH of 8.0.

**Tests**

**Microbial contamination** (2.2.9). 1 g is free from *Escherichia coli* and 10 g is free from *salmonellae*.

**Sulphated ash** (2.3.18). Not more than 5.0 per cent.

**Loss on drying** (2.4.19). Not more than 5.0 per cent, determined on 1.0 g by drying in an oven at 60º at a pressure not exceeding 0.7 kPa for 4 hours.

**Assay.** Weigh accurately 0.25 g, triturate with 1.0 g of sodium chloride, add slowly acidified water prepared by diluting 65 ml of *1 M hydrochloric acid* to 1000 ml with water, continue the trituration, dilute to 1000.0 ml with the acidified water and shake for 15 minutes. Prepare coagulated egg albumin by boiling fresh hen-eggs in water for 15 minutes, cooling rapidly to room temperature by immersion in cold water, separating the whites and rubbing through a no. 44 sieve. Reject the first portion that passes through the sieve and triturate 15.0 g of freshly prepared coagulated egg albumin with 50 ml of the acidified water ensuring that the particles of egg albumin are thoroughly disintegrated, add a further 50 ml of the acidified water and keep in a water-bath at 51º ± 1º for 15 minutes. Add 20.0 ml of the prepared solution of the substance under examination and digest at 51º ± 1º for 4 hours, shaking at intervals of 15 minutes. Centrifuge and decant off most of the clear supernatant liquid, wash the remainder into a 10-ml graduated cylinder and allow to stand for 30 minutes. The volume of the undissolved albumin is not more than 2 ml.

**Storage.** Store protected from moisture.

**Peritoneal Dialysis Solutions**

**Intraperitoneal Dialysis Fluids**

Peritoneal Dialysis Solutions are sterile preparations for intraperitoneal use containing electrolytes with a concentration close to the electrolytic composition of plasma. They contain dextrose in varying concentrations and/or other suitable osmotic agents. They do not contain antioxidants such as metabisulphite salts.

Peritoneal Dialysis Solutions contain not less than 97.5 per cent and not more than 102.5 per cent of the stated amount of sodium, Na, not less than 95.0 per cent and not more than 105.0 per cent of the stated amounts of potassium, K, calcium, Ca, magnesium, Mg, chloride, Cl, acetate, C₂H₃O₂, lactate, C₃H₅O₃, sodium bicarbonate, NaHCO₃, bicarbonate, HCO₃ and dextrose, C₆H₁₂O₆.

**Description.** Clear, colourless or faintly straw-coloured solutions.

**Identification**

A. To 5 ml of the solution under examination, add 2 ml of dilute sodium hydroxide solution and 0.05 ml of potassium cupri-tartrate solution; the solution remains blue and clear. Heat to boiling; a copious red precipitate is formed.

Peritoneal Dialysis Solutions contain not less than 97.5 per cent and not more than 102.5 per cent of the stated amount of sodium, Na, not less than 95.0 per cent and not more than 105.0 per cent of the stated amounts of potassium, K, calcium, Ca, magnesium, Mg, chloride, Cl, acetate, C₂H₃O₂, lactate, C₃H₅O₃, sodium bicarbonate, NaHCO₃, bicarbonate, HCO₃ and dextrose, C₆H₁₂O₆.

**Description.** Clear, colourless or faintly straw-coloured solutions.

**Identification**

A. To 5 ml of the solution under examination, add 2 ml of dilute sodium hydroxide solution and 0.05 ml of potassium cupri-tartrate solution; the solution remains blue and clear. Heat to boiling; a copious red precipitate is formed.

B. 20 ml gives reactions of chlorides, sodium salts, potassium salts and calcium salts (2.3.1).

C. To 5 ml add 1 ml of *hydrochloric acid* in a test-tube fitted with a stopper and a bent tube, heat and collect a few ml of the distillate. The distillate gives reaction C of acetates (2.3.1).
D. To 0.1 ml of *titan yellow solution* add 10 ml of *water*, 2 ml of the solution under examination and 1 ml of 1 M sodium hydroxide; a pink colour is produced if magnesium salts are present.

E. Lactates and bicarbonates are identified together with the Assay for lactate and bicarbonate.

**Tests**

**Appearance of solution.** The solution under examination is clear (2.4.1), and not more intensely coloured than reference solution YS4 (2.4.1).

**pH** (2.4.24). 4.5 to 6.5. If the solution contains bicarbonate, 6.5 to 8.0.

**5-Hydroxymethylfurfural and Related substances.** Dilute a volume containing 1.0 g of Dextrose to 250.0 ml with *water* and measure the absorbance of the resulting solution (2.4.7) at the maximum at about 284 nm; absorbance at about 284 nm, not more than 0.25.

**Aluminium.** Adjust the pH of 400 ml of the solution under examination to pH 6.0 and add 10 ml of acetate buffer pH 6.0. Extract the resulting solution with successive quantities of 20, 20 and 10 ml of a 0.5 per cent w/v solution of 8-hydroxyquinoline in *chloroform* and dilute the combined extracts to 50.0 ml with *chloroform*. Use as the blank a mixture of 10 ml of acetate buffer pH 6.0 and 100 ml of water treated in the same manner and as the standard solution a mixture of 2.0 ml of aluminium standard solution (2 ppm Al), 10 ml of acetate buffer pH 6.0 and 90 ml of water treated in the same manner. Measure the fluorescence of the test solution (I₁) of the standard solution (I₂) and of the blank (I₃), (2.4.5), using an excitation wavelength of 392 nm and a secondary filter with a transmission band centred at 518 nm, or a monochromator set to transmit at this wavelength. The fluorescence of the test solution (I₁ − I₃) is not greater than that of the standard solution (I₂ − I₃).

**Particulate contamination** (2.5.9). Carry out the test using 50 ml of the solution under examination.

The preparation meets the requirements of the test if it contains particles within the maximum limits shown below.

<table>
<thead>
<tr>
<th>Particle size in µm (Equal to or larger than)</th>
<th>Maximum number of particles per ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>25</td>
<td>3</td>
</tr>
</tbody>
</table>

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Bacterial endotoxins** (2.2.3). Not more than 0.25 Endotoxin Unit per ml.

**Pyrogens** (2.2.8). Solutions for which a validated test for bacterial endotoxins cannot be carried out, comply with the test for pyrogens, injecting 10 ml of the solution per kg of the rabbit’s body weight.

**Sterility** (2.2.11). Complies with the test for sterility.

**Assay.** For sodium — Dilute suitably with *water* and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 589 nm and using sodium solution FP, or sodium solution AAS respectively, suitably diluted with *water* for the standard solutions.

For potassium — Dilute suitably with *water* and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 767 nm and using potassium solution FP or potassium solution AAS respectively, suitably diluted with *water* for the standard solutions.

For calcium — Dilute suitably with *water* and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 422.7 nm and using calcium solution FP or calcium solution AAS respectively, suitably diluted with *water* for the standard solutions.

For magnesium — To 50.0 ml add 50 ml of *water* and 5 ml of strong ammonia-ammonium chloride solution and titrate with 0.005 M disodium edetate using 50 mg of eriochrome black T mixture as indicator.

1 ml of 0.005 M disodium edetate is equivalent to 0.1215 mg of Mg.

For total chloride — Dilute an accurately measured volume containing about 60 mg of chloride to 50.0 ml with *water*. Add 25.0 ml of 0.1 M silver nitrate and 2 ml of nitric acid. Filter, wash the precipitate with *water* slightly acidified with nitric acid and titrate the excess of silver nitrate with 0.1 M ammonium thiocyanate using ferric ammonium sulphate solution as indicator until a reddish yellow colour is produced. Carry out a blank titration.

1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of total chloride, calculated as Cl.

For acetate (if present) — Determine by liquid chromatography (2.4.14).

**Test solution.** Dilute an accurately measured volume of the preparation under examination quantitatively with *water* to obtain a solution containing about 1.0 mg of acetate per ml.

**Reference solution.** Dissolve an accurately weighed quantity of sodium acetate in *water* to obtain a solution having a known concentration of about 0.12 per cent w/v of Sodium Acetate.

**Chromatographic system** — a stainless steel column 30 cm x 7.8 mm, packed with a strong cation-exchange resin consisting of sulphonated

919
cross-linked styrene-divinylbenzene copolymer in the hydrogen form (7 µm),
- mobile phase: filtered and degassed 0.1 M sulphuric acid,
- flow rate. 0.8 ml per minute,
- column temperature. 60º,
- spectrophotometer set at 210 nm,
- a 20 µl loop injector.

Inject the reference solution and record the chromatograms. The test is not valid unless the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject separately the test and standard solutions and record the chromatograms. Measure the responses for the major peak and calculate the content of acetate in the preparation under examination.

For lactate (if present) — Determine by liquid chromatography (2.4.14).

Test solution. Use the preparation under examination.

Reference solution (a). Dissolve an accurately weighed quantity of sodium lactate RS in water to obtain a solution having a known concentration of about 2 mg per ml.

Reference solution (b). Prepare a solution in water containing about 3 mg of anhydrous sodium acetate and 3 mg of sodium lactate RS per ml.

Chromatographic system
- a stainless steel column 10 cm x 4.6 mm, packed with octadecylsilane chemically bonded to porous silica or ceramic microparticles 3 to 10 µm,
- mobile phase: a filtered and degassed solution in water containing about 1 ml of formic acid and 1 ml of dicyclohexylamine per litre,
- flow rate. 1 ml per minute,
- spectrophotometer set at 210 nm,
- a 20 µl loop injector.

Inject separately reference solutions (a) and (b), and record the chromatograms. The test is not valid unless the resolution between the peaks due to acetate and lactate is not less than 2.0, the tailing factor for the analyte peak is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject separately the test solution and reference solution (a), and record the chromatograms. Measure the responses for the major peak and calculate the content of lactate in the preparation under examination.

For sodium bicarbonate — Titrate with 0.1 M hydrochloric acid a volume of the preparation under examination containing about 0.1 g of sodium bicarbonate, determining the end-point potentiometrically (2.4.25).

1 ml of 0.1 M hydrochloric acid is equivalent to 8.40 mg of NaHCO₃.

For lactate and bicarbonate — Determine by liquid chromatography (2.4.14).

Test solution. Use the preparation under examination.

Reference solutions. Dissolve accurately weighed quantities of lactates and bicarbonates in order to obtain solutions having concentrations of about 90 per cent, 100 per cent and 110 per cent of the claim in 100 ml of water.

Chromatographic system
- a stainless steel column 30 cm x 7.8 mm, packed with a cation-exchange resin (9 µm),
- column. temperature 85º,
- mobile phase: filtered and degassed 0.005 M sulphuric acid,
- flow rate. 0.6 ml per minute,
- differential refractometer detector,
- a 20 µl loop injector.

Inject separately the test solution and the reference solutions in duplicate, and record the chromatograms in the prescribed conditions. The peaks elute in the following order, lactates, then bicarbonates. Determine the concentration of lactates and bicarbonates in the test solution by interpolating the peak area for lactate and the peak height for bicarbonate from the linear regression curve obtained with the solutions prepared as reference solutions.

For dextrose — Transfer a volume of the preparation under examination containing about 25 mg of Dextrose to a 250-ml conical flask with a ground-glass neck and add 25.0 ml of cupri-citric solution. Add a few grains of pumice, fit a reflux condenser, heat so that boiling occurs within 2 minutes and boil for exactly 10 minutes. Cool and add 3 g of potassium iodide dissolved in 3 ml of water. Carefully add, in small amounts, 25 ml of a 25 per cent w/w solution of sulphuric acid. Titrate with 0.1 M sodium thiosulphate using starch solution as indicator. Carry out a blank titration using 25 ml of water.

Calculate the content of anhydrous dextrose, C₆H₁₂O₆, from the following Table.

<table>
<thead>
<tr>
<th>Volume of 0.1 M sodium thiosulphate consumed (ml)</th>
<th>Anhydrous dextrose (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>19.8</td>
</tr>
<tr>
<td>9</td>
<td>22.4</td>
</tr>
<tr>
<td>10</td>
<td>25.0</td>
</tr>
<tr>
<td>11</td>
<td>27.6</td>
</tr>
<tr>
<td>12</td>
<td>30.3</td>
</tr>
<tr>
<td>13</td>
<td>33.0</td>
</tr>
<tr>
<td>14</td>
<td>35.7</td>
</tr>
<tr>
<td>15</td>
<td>38.5</td>
</tr>
<tr>
<td>16</td>
<td>41.3</td>
</tr>
</tbody>
</table>
Storage. Peritoneal Dialysis Solutions are supplied in rigid or semi-rigid plastic containers, in flexible plastic containers fitted with a special connecting device (these are generally filled to a volume below their nominal capacity and presented in closed protective envelopes) or in glass containers. Store at a temperature not exceeding 30º.

CAUTION — Exposure to temperatures below 4 º may cause crystallisation and separation of solid particles rendering the preparation unsuitable for use.

Labelling. The label states (1) the formula of the solution for peritoneal dialysis, expressed in grams per litre and in millimoles per litre; (2) the total osmolar concentration in mOsmol per litre; (3) the nominal volume of the solution in the container; (4) that the solution is free from bacterial endotoxins, or where applicable, that it is apyrogenic; (5) that the solution is not to be used for intravenous infusion; (6) that any unused portion of the solution is to be discarded; (7) that the solution containing visible particles should not be used; (8) the storage conditions.

Pethidine Hydrochloride

Meperidine Hydrochloride

\[
\text{CH}_3\text{O} - \text{C} - \text{N} - \text{CH}_3, \text{HCl}
\]

\[
\text{C}_{15}\text{H}_{21}\text{NO}_2\text{HCl} \quad \text{Mol. Wt. 283.8}
\]

Pethidine Hydrochloride is ethyl 1-methyl-4-phenylpiperidine-4-carboxylate hydrochloride.

Pethidine Hydrochloride contains not less than 99.0 per cent and not more than 101.0 per cent of \(\text{C}_{15}\text{H}_{21}\text{NO}_2\text{HCl}\), calculated on the dried basis.

Description. Colourless crystals or a white, crystalline powder.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pethidine hydrochloride RS or with the reference spectrum of pethidine hydrochloride.

B. To 5 ml of a 1 per cent w/v solution add a few drops of potassium mercuri-iodide solution; a cream-coloured precipitate is produced.

C. Dissolve 5 mg in 0.5 ml of water and add 0.1 ml of formaldehyde solution and 2 ml of sulphuric acid; an orange-red colour is produced.

D. Gives reaction A of chlorides (2.3.1).

Tests

Appearance of solution. A 2.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and colourless (2.4.1).

Acidity or alkalinity. To 10 ml of a 2.0 per cent w/v solution in carbon dioxide-free water add 0.2 ml of methyl red solution and 0.2 ml of 0.01 M sodium hydroxide; the solution is yellow. Add 0.3 ml of 0.01 M hydrochloric acid; the solution is red.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with kieselguhr G.

Mobile phase. The upper layer obtained by shaking together 100 volumes of light petroleum (50º to 70º), 8 volumes of 2-phenoxyethanol and 1 volume of diethylamine.

Test solution. Dissolve 0.1 g in 5 ml of water, add 0.5 ml of 10 M sodium hydroxide and 2 ml of ether and shake; allow the layers to separate and use the upper layer.

Reference solution. Dilute 0.5 ml of the test solution to 50 ml with ether.

Impregnate the dry plate by placing it in a closed tank containing a mixture of 90 volumes of acetone and 10 volumes of 2-phenoxyethanol so that the plate dips about 5 mm beneath the surface of the liquid, allowing the impregnating solvent to ascend at least 15 cm, removing the plate from the tank and drying in a current of air. Use immediately, with the flow of the mobile phase in the same direction as the impregnation.

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in air for 10 minutes, return the plate to the tank and repeat the development. Remove the plate, allow it to dry in air for 10 minutes and spray with a 0.2 per cent w/v solution of 2,7-dichlorofluorescein in methanol. Allow to stand for 5 minutes and spray with water until the background is white to pale yellow. Examine in daylight. The chromatograms show red or orange spots. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution. Examine without delay in ultraviolet light at 365 nm. The chromatograms show spots with intense yellow fluorescence. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.
Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

Assay. Weigh accurately about 0.5 g, dissolve in 30 ml of anhydrous glacial acetic acid, add 12 ml of mercuric acetate solution. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02838 g of C15H21NO2.HCl.

Storage. Store protected from light and moisture.

Pethidine Injection
Pethidine Hydrochloride Injection; Meperidine Hydrochloride Injection

Pethidine Injection is a sterile solution of Pethidine Hydrochloride in Water for Injections.

Pethidine Injection contains not less than 95.0 per cent and not more than 105.0 per cent of pethidine hydrochloride, C15H21NO2.HCl.

Identification
A. To a volume containing 50 mg of Pethidine Hydrochloride add sufficient 1 M sodium hydroxide to make strongly alkaline to litmus paper and extract with two quantities, each of 10 ml, of chloroform. Wash the combined extracts with 5 ml of water, dry over anhydrous sodium sulphate, filter and evaporate the filtrate to dryness. Remove the last traces of chloroform by drying the residual oil at 60º at a pressure not exceeding 0.7 kPa.

On the oily residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pethidine hydrochloride RS or with the reference spectrum of pethidine.

B. To 0.5 ml add 0.1 ml of formaldehyde solution and 2 ml of sulphuric acid; an orange-red colour is produced.

C. Gives the reactions of chlorides (2.3.1).

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with kieselguhr G.

Mobile phase. The upper layer obtained by shaking together 100 volumes of light petroleum (50º to 70º), 8 volumes of 2-phenoxyethanol and 1 volume of diethylamine.

Test solution. The upper layer obtained by shaking a volume containing 0.1 g of Pethidine Hydrochloride, diluted if necessary to 5 ml with water, with 0.5 ml of 5 M sodium hydroxide and 2 ml of ether.

Reference solution. Dilute 0.5 ml of the test solution to 50 ml with ether.

Impregnate the dry plate by placing it in a closed tank containing a mixture of 90 volumes of acetone and 10 volumes of 2-phenoxyethanol so that the plate dips about 5 mm beneath the surface of the liquid, allowing the impregnating solvent to ascend at least 15 cm, removing the plate from the tank and drying in a current of air. Use immediately, with the flow of the mobile phase in the same direction as the impregnation.

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in air for 10 minutes, return the plate to the tank and repeat the development. Remove the plate, allow to dry in air for 10 minutes and spray with a 0.2 per cent w/v solution of 2,7-dichlorofluorescein in methanol. Allow to stand for 5 minutes and spray with water until the background is white to pale yellow. Examine in daylight. The chromatograms show red or orange spots. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution. Examine without delay in ultraviolet light at 365 nm. The chromatograms show spots with intense yellow fluorescence. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. Dilute an accurately measured volume containing about 0.1 g of Pethidine Hydrochloride with 40 ml of water, add 1 ml of 5 M sodium hydroxide and extract immediately with successive quantities of 25, 10 and 10 ml of chloroform. Wash each extract with the same 15 ml of water, filter into a dry flask and combine the extracts (which should be clear and free from droplets of water). Titrate with 0.02 M perchloric acid, using 0.15 ml of 1-naphthalbenzen solution as indicator. Carry out a blank titration.

1 ml of 0.02 M perchloric acid is equivalent to 0.005676 g of C15H21NO2.HCl.

Storage. Store protected from light.

Pethidine Tablets
Pethidine Hydrochloride Tablets; Meperidine Hydrochloride Tablets

Pethidine Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of pethidine hydrochloride, C15H21NO2.HCl.
**Identification**

A. Shake a quantity of the powdered tablets containing 50 mg of Pethidine Hydrochloride with 20 ml of chloroform, filter, evaporate the filtrate to dryness and dry the residue at a pressure of 2 kPa.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pethidine hydrochloride RS or with the reference spectrum of pethidine hydrochloride.

B. Shake a quantity of the powdered tablets containing 0.2 g of Pethidine Hydrochloride with 20 ml of water and filter. To 5 ml of the filtrate add 10 ml of picric acid solution. The crystals so obtained, after washing with water and drying, melt at about 190º (2.4.21).

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with kieselguhr G.

**Mobile phase.** The upper layer obtained by shaking together 100 volumes of light petroleum (50º to 70º), 8 volumes of 2-phenoxyethanol and 1 volume of diethylamine.

**Test solution.** The upper layer obtained by shaking a quantity of the powdered tablets containing 0.1 g of Pethidine Hydrochloride with 5 ml of water, filtering, shaking the filtrate with 0.5 ml of 5 M sodium hydroxide and 2 ml of ether and allowing the layers to separate.

**Reference solution.** Dilute 0.5 ml of the test solution to 50 ml with ether.

Impregnate the dry plate by placing it in a closed tank containing a mixture of 90 volumes of methanol, 10 volumes of 2-phenoxyethanol and 1 volume of diethylamine. Allow to stand for 5 minutes and spray with a 0.2 per cent w/v solution of 2,7-dichlorofluorescein in methanol. Allow to stand for 5 minutes and spray with water until the background is white to pale yellow. Examine in daylight. The chromatograms show red or orange spots. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.3 g of Pethidine Hydrochloride in 40 ml of water, add 2 ml of 5 M sodium hydroxide and extract immediately with successive quantities of 25, 10 and 10 ml of chloroform. Wash each extract with the same 15 ml of water and filter into a dry flask. Combine the extracts (which should be clear and free from droplets of water). Titrate with 0.05 M perchloric acid, using 0.15 ml of 1-naphtholbenzein solution as indicator. Carry out a blank titration. 1 ml of 0.05 M perchloric acid is equivalent to 0.01419 g of C19H21N2O6HCl.

**Storage.** Store protected from light and moisture.

---

**Phenindamine Tartrate**

\[
\begin{align*}
\text{C}_{19}\text{H}_{19}\text{N},\text{C}_{4}\text{H}_{6}\text{O}_{6} & \quad \text{Mol. Wt. 411.5} \\
\text{Phenindamine Tartrate is (RS)-2,3,4,9-tetrahydro-2-methyl-9-phenyl-1H-inden-2,1-c]pyridine (2R,3R)-tartrate.} \\
\text{Phenindamine Tartrate contains not less than 98.5 per cent and not more than 101.0 per cent of C}_{19}\text{H}_{19}\text{N},\text{C}_{4}\text{H}_{6}\text{O}_{6}, \text{calculated on the dried basis.} \\
\text{Description.} & \quad \text{A white or almost white voluminous powder; odourless or almost odourless.}
\end{align*}
\]

**Identification**

A. When examined in the range 230 nm to 360 nm (2.4.7), a 0.004 per cent w/v solution shows an absorption maximum only at about 259 nm; absorbance at about 259 nm, about 0.88.

B. Dissolve 25 mg in 5 ml of sulphuric acid; an orange-brown colour is produced which is discharged when the solution is carefully diluted with 20 ml of water.

C. Dissolve 0.5 g in 15 ml of hot water, add a slight excess of 5 M sodium hydroxide, filter and neutralise the filtrate to litmus paper with 2 M hydrochloric acid. The solution gives reaction B of tartrates (2.3.1).
D. Melting range (2.4.21). 160° to 162°, when heated to 163° it re-solidifies and melts again at about 168°, with decomposition.

Tests
pH (2.4.24). 3.4 to 3.9, determined in a 1.0 per cent w/v solution.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105°.

Assay. Weigh accurately about 0.4 g, dissolve in 40 ml of warm water, cool, add 10 ml of dilute sodium carbonate solution and extract with successive quantities of 25, 10 and 10 ml of chloroform, washing each extract with the same 15 ml of water and filtering into a dry flask. Combine the extracts (which should be clear and free from droplets of water). Titrate with 0.05 M perchloric acid, using oracet blue B solution as indicator. Carry out a blank titration.

1 ml of 0.05 M perchloric acid is equivalent to 0.02057 g of C₁₉H₁₉N, C₄H₆O₆.

Storage. Store protected from light and moisture.

Phenindamine Tablets
Phenindamine Tartrate Tablets
Phenindamine Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of phenindamine tartrate, C₁₉H₁₉N, C₄H₆O₆. The tablets are coated.

Identification
A. Shake a quantity of the powdered tablets containing 20 mg of Phenindamine Tartrate with 100 ml of water, dilute 10 ml to 100 ml with water and filter; absorbance of the filtrate at the maximum at about 259 nm, about 0.44 (2.4.7).

B. To a portion of the finely powdered tablets containing about 50 mg of Phenindamine Tartrate, add 5 ml of water and 3 ml of dilute ammonia solution and extract the liberated base with two successive quantities, each of 10 ml, of ether. Wash the combined ether extracts with 2 ml of water and evaporate to dryness. Dissolve 25 mg of the residue in 5 ml of sulphuric acid; an orange-brown colour is produced which is discharged when the solution is carefully diluted with 20 ml of water.

Tests
Other tests. Complies with the tests stated under Tablets.

Assay. Weigh and digest 20 tablets with 70 ml of water and 5 ml of dilute hydrochloric acid until completely disintegrated, filter and wash the residue with 20 ml of water. Dilute the combined filtrate and washings to 100.0 ml with water. To an accurately measured quantity of the filtrate containing about 0.2 g of Phenindamine Tartrate add 10 ml of 5 M sodium hydroxide, and extract with 25 ml and then with three quantities, each of 10 ml, of chloroform, washing each extract with the same 15 ml of water and filtering in a dry flask. Combine the extracts (which should be clear and free from droplets of water). Titrate with 0.02 M perchloric acid, using oracet blue B solution as indicator. Carry out a blank titration.

1 ml of 0.02 M perchloric acid is equivalent to 0.008229 g of C₁₀H₁₉N, C₄H₆O₆.

Storage. Store protected from light and moisture.

Phenindione

C₁₅H₁₀O₂ Mol. Wt. 222.2
Phenindione is 2-phenylindane-1,3-dione.
Phenindione contains not less than 98.0 per cent and not more than 100.5 per cent of C₁₅H₁₀O₂, calculated on the dried basis.

Description. Soft, white or creamy-white crystals; almost odourless.

Identification
A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with phenindione RS.

B. Dissolve 0.1 g in 30 ml of ethanol (95 per cent) with the aid of heat, cool and add sufficient ethanol (95 per cent) to produce 50 ml. Dilute 10 ml of this solution to 250 ml with 0.1 M sodium hydroxide and further dilute 5 ml to 100 ml with 0.1 M sodium hydroxide. When examined in the range 230 nm and 360 nm (2.4.7), the solution shows absorption maxima at about 278 nm and at about 330 nm; absorbance at about 278 nm, about 0.55 and at about 330 nm, about 0.16.

C. To 1 g add 50 ml of ethanol (95 per cent) and 0.5 ml of aniline; heat gently under a reflux condenser for 3 hours, cool in ice and filter. The residue, after washing with 2 ml of ethanol (95 per cent) and recrystallisation from chloroform, melts at about 225° (2.4.21).

Tests
Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.
Mobile phase. A 0.02 per cent w/v solution of butylated hydroxytoluene in a mixture of 80 volumes of toluene, 20 volumes of ethyl acetate and 4 volumes of glacial acetic acid.

Test solution. Dissolve 0.1 g of the substance under examination in 10 ml of dichloromethane.

Reference solution (a). A 0.02 per cent w/v solution of the substance under examination in dichloromethane.

Reference solution (b). A 0.005 per cent w/v solution of the substance under examination in dichloromethane.

Apply to the plate 10 µl of each solution. Allow the mobile phase to rise 4 cm. Dry the plate in warm air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in oven at 105º for 2 hours.

Assay. Weigh accurately about 0.3 g, add 50 ml of ethanol (95 per cent) and warm until solution is effected. Cool to room temperature, add 10 ml of a 10 per cent v/v solution of bromine in ethanol (95 per cent) and allow to stand for 10 minutes, shaking occasionally. Add 1 g of 2-naphthol and shake until the colour of the bromine is discharged. Remove any vapour of bromine in the flask with a current of air, add 50 ml of water and 10 ml of dilute potassium iodide solution and titrate the liberated iodine with 0.1 M sodium thiosulphate using starch solution as indicator.

1 ml of 0.1 M sodium thiosulphate is equivalent to 0.01111 g of C₁₅H₁₀O₂.

Storage. Store protected from moisture.

Phenindione Tablets

Phenindione Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of phenindione, C₁₅H₁₀O₂.

Identification

Shake a quantity of the powdered tablets containing 0.2 g of Phenindione with 50 ml of chloroform, filter and evaporate the filtrate to dryness. Recrystallise the residue from ethanol (95 per cent). The crystals complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with phenindione RS.

B. Dissolve 0.1 g in 30 ml of ethanol (95 per cent) with the aid of heat, cool and add sufficient ethanol (95 per cent) to produce 50 ml. Dilute 10 ml of this solution to 250 ml with 0.1 M sodium hydroxide and further dilute 5 ml to 100 ml with 0.1 M sodium hydroxide. When examined in the range 230 nm to 360 nm (2.4.7), the solution shows absorption maxima at about 278 nm and 330 nm; absorbance at about 278. about 0.55 and at about 330 nm, about 0.16.

C. To 50 mg add 1 ml of sulphuric acid; a deep blue to violet solution is produced. On dilution with water the solution becomes colourless and a white precipitate is produced.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A 0.02 per cent w/v solution of butylated hydroxytoluene in a mixture of 80 volumes of toluene, 20 volumes of ethyl acetate and 4 volumes of glacial acetic acid.

Test solution. Shake a quantity of the powdered tablets containing 50 mg of Phenindione with 15 ml of dichloromethane, filter, evaporate the filtrate to dryness and dissolve the residue in 5 ml of dichloromethane.

Reference solution (a). Dilute 1 volume of the test solution to 50 volumes with dichloromethane.

Reference solution (b). Dilute 1 volume of the test solution to 200 volumes with dichloromethane.

Apply to the plate 10 µl of each solution. Allow the mobile phase to rise 4 cm. Dry the plate in warm air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

Uniformity of content. (For tablets containing 50 mg or less) — Comply with the test stated under Tablets.

Place one tablet in 50 ml of 0.1 M sodium hydroxide, dissolve completely by shaking gently, add a further 100 ml of 0.1 M sodium hydroxide and shake for 1 hour. Dilute to 250.0 ml with 0.1 M sodium hydroxide, filter and dilute a portion of the filtrate with sufficient 0.1 M sodium hydroxide to produce a solution containing 4 µg of Phenindione per ml. Measure the absorbance of the resulting solution at the maximum at about 278 nm (2.4.7). Calculate the content of C₁₅H₁₀O₂ taking 1310 as the specific absorbance at 278 nm.
Other tests. Complies with the tests stated under Tablets.

Assay. Weigh and powder 20 Tablets. Weigh accurately a quantity of the powder containing about 50 mg of Phenindione and shake with 150 ml of 0.1 M sodium hydroxide for 1 hour, add sufficient 0.1 M sodium hydroxide to produce 250.0 ml, filter and dilute 5.0 ml of the filtrate to 250.0 ml with 0.1 M sodium hydroxide. Measure the absorbance of the resulting solution at the maximum at about 278 nm (2.4.7). Calculate the content of C₁₅H₁₀O₂ taking 1310 as the specific absorbance at 278 nm.

Storage. Store protected from moisture.

Pheniramine Maleate

\[
\text{Pheniramine Maleate is (3RS)-N,N-dimethyl-3-phenyl-3-(pyridin-2-yl)propan-1-amine hydrogen maleate.}
\]

Pheniramine Maleate contains not less than 99.0 per cent and not more than 101.0 per cent of C₁₆H₂₀N₂₄C₄H₄O₄, calculated on the dried basis.

Description. A white or almost white, crystalline powder; odourless or almost odourless.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pheniramine maleate RS or with the reference spectrum of pheniramine maleate.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in 0.1 M hydrochloric acid shows an inflection at about 262 nm; absorbance at about 265 nm, about 0.42.

C. Dissolve 0.25 g in 5 ml of water, add 2 ml of strong ammonia solution and extract with three quantities, each of 5 ml, of chloroform. Evaporate the aqueous extract to dryness, add 0.2 ml of 1 M sulphuric acid and 5 ml of water, extract with four quantities, each of 25 ml, of ether and evaporate the combined ether extracts to dryness in a current of warm air. To the residue add 50 mg of resorcinol and 1 ml of sulphuric acid, heat in a water-bath for 2 minutes, shake well, heat in a water-bath for a further 30 minutes and cool in ice. Carefully add 5 ml of water; a yellow colour is produced. To 2 ml of the solution add 3 ml of a 50 per cent w/v solution of ammonium acetate, previously cooled in ice; a pink colour is produced which persists for at least 10 minutes in the cooled solution.

Tests

\text{pH (2.4.24). 4.5 to 5.5, determined in a 1.0 per cent w/v solution.}

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of methanol.

Reference solution (a). A 0.02 per cent w/v solution of the substance under examination in methanol.

Reference solution (b). A 0.004 per cent w/v solution of the substance under examination in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air, spray with dilute potassium iodobismuthate solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

Heavy metals (2.3.13). Dissolve 1.0 g in 10 ml of water and add 2 ml of acetic acid and sufficient water to produce 25 ml. The resulting solution complies with the limit test for heavy metals, Method A (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 60º at a pressure not exceeding 0.7 kPa.

Assay. Weigh accurately about 0.4 g, dissolve in 20 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, using 1- naphtholbenzein solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01782 g of C₁₆H₂₀N₂₄C₄H₄O₄.

Storage. Store protected from light and moisture.

Pheniramine Injection

Pheniramine Maleate Injection

Pheniramine Injection is a sterile solution of Pheniramine Maleate in Water for Injections.
Pheniramine Injection contains not less than 90.0 per cent and
not more than 110.0 per cent of the stated amount of
pheniramine maleate, C_{16}H_{20}N_{2}, C_{4}H_{4}O_{4}.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the
plate with silica gel GF254.

*Mobile phase.* A mixture of 50 volumes of cyclohexane,
40 volumes of chloroform and 10 volumes of diethylamine.

*Test solution.* Evaporate an appropriate volume of the injection
to dryness in a current of nitrogen using the minimum amount
of heat, dissolve the residue in sufficient chloroform to
produce a solution containing 2.0 per cent w/v solution of
Pheniramine Maleate and centrifuge.

*Reference solution.* A 2.0 per cent w/v solution of pheniramine
maleate RS in chloroform.

Apply to the plate 10 µl of each solution. After development,
dry the plate in air and examine in ultraviolet light at 254 nm.
The two principal spots in the chromatogram obtained with
the test solution correspond to those in the chromatogram
obtained with the reference solution. Spray the plate with
dilute potassium iodobismuthate solution. The principal spot
in the chromatogram obtained with the test solution
corresponds to that in the chromatogram obtained with the
reference solution.

**Tests**

*pH* (2.4.24). 4.5 to 5.5.

*Related substances.* Determine by the method described under
the Identification test using as the reference solution a
solution prepared by diluting 1 volume of the test solution to
500 volumes with chloroform. Any secondary spot in the
chromatogram obtained with the test solution is not more intense
than the spot in the chromatogram obtained with the
reference solution.

*Other tests.* Complies with the tests stated under Parenteral
Preparations (Injections).

*Assay.* To an accurately measured volume containing about 0.11 g of Pheniramine Maleate add sufficient water to produce
50.0 ml and mix well. To 20.0 ml add sufficient 1 M sodium
hydroxide to make the solution just alkaline to litmus paper,
add 2 ml in excess and extract with two quantities, each of
50 ml of ether. Wash each ether extract in succession with 20,
20 and 5 ml of 0.1 M hydrochloric acid, dilute the combined
eextracts to 100.0 ml with 0.1 M hydrochloric acid and mix.
Dilute 5.0 ml to 100.0 ml with 0.1 M hydrochloric acid and
measure the absorbance of the resulting solution at the
maximum at about 265 nm (2.4.7), using 0.1 M hydrochloric
acid as the blank. Calculate the content of C_{16}H_{20}N_{2}, C_{4}H_{4}O_{4}
taking 210 as the specific absorbance at 265 nm.

*Storage.* Store protected from light.
chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

Other tests. Complies with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 45 mg of Pheniramine Maleate, shake with 20 ml of 0.1 M hydrochloric acid, centrifuge and transfer the supernatant liquid to a 100-ml volumetric flask. Repeat the extraction with three further quantities, each of 20 ml, of 0.1 M hydrochloric acid. Combine the extracts and add sufficient 0.1 M hydrochloric acid to produce 100.0 ml. Mix and dilute 5.0 ml to 100.0 ml with 0.1 M hydrochloric acid; measure the absorbance of the resulting solution at the maximum at about 265 nm (2.4.7), using 0.1 M hydrochloric acid as the blank. Calculate the content of C$_{16}$H$_{20}$N$_{2}$C$_{4}$H$_{4}$O$_{4}$ taking 210 as the specific absorbance at 265 nm.

Storage. Store protected from light and moisture.

Phenobarbitone

Phenobarbital

\[
\text{C}_{12}\text{H}_{12}\text{N}_{2}\text{O}_{3} \quad \text{Mol. Wt. 232.2}
\]

Phenobarbitone is 5-ethyl-5-phenylbarbituric acid.

Phenobarbitone contains not less than 99.0 per cent and not more than 101.0 per cent of C$_{12}$H$_{12}$N$_{2}$O$_{3}$, calculated on the dried basis.

Description. Colourless crystals or a white, crystalline powder; odourless.

Identification

Test A may be omitted if tests B, C, D and E are carried out. Tests C, D and E may be omitted if tests A and B are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with phenobarbitone RS or with the reference spectrum of phenobarbitone.

B. Determine the melting point (2.4.21) of the substance under examination and of a mixture of equal quantities of the substance under examination and phenobarbitone RS. The difference between the melting points, which are about 175º, is not greater than 2º.

C. Complies with the test for identification of barbiturates (2.3.2).

D. Dissolve about 20 mg in 5 ml of ethanol, add a drop of cobalt chloride solution and a drop of dilute ammonia solution; a violet colour is produced.

E. Gives the reaction of non-nitrogen substituted barbiturates (2.3.1).

Tests

Appearance of solution. A 10.0 per cent w/v solution in a mixture of 20 volumes of 2 M sodium hydroxide and 30 volumes of water is clear (2.4.1), and not more intensely coloured than reference solution YS6 (2.4.1).

Acidity. Mix 1.0 g with 50 ml of water, boil for 2 minutes, allow to cool, filter and adjust the volume to 50 ml. To 10 ml of the filtrate add 0.15 ml of methyl red solution; not more than 0.1 ml of 0.1 M sodium hydroxide is required to change the colour of the solution from orange-yellow to pure yellow.

Related substances. Complies with the test for related substances in barbiturates (2.3.4).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent w/w, determined on 1.0 g by drying in an oven at 105º for 2 hours.

Assay. Weigh accurately about 0.1 g, dissolve in 5 ml of pyridine, add 0.25 ml of thymolphthalein solution and 10 ml of silver nitrate-pyridine reagent and titrate with 0.1 M ethanolic sodium hydroxide until a pure blue colour is obtained. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of sodium hydroxide required.

1 ml of 0.1 M ethanolic sodium hydroxide is equivalent to 0.01161 g of C$_{12}$H$_{12}$N$_{2}$O$_{3}$.

Storage. Store protected from moisture.

Phenobarbitone Sodium

Phenobarbital Sodium; Soluble Phenobarbitone; Soluble Phenobarbital

\[
\text{C}_{12}\text{H}_{11}\text{N}_{2}\text{NaO}_{3} \quad \text{Mol. Wt. 254.2}
\]
Phenobarbital Sodium; Soluble Phenobarbitone; Soluble Phenobarbital.

Phenobarbital Sodium contains not less than 99.0 per cent and not more than 101.0 per cent of C₁₂H₁₁N₂NaO₃, calculated on the dried basis.

**Description.** A white powder or crystalline granules or flaky crystals; hygroscopic.

**Identification**

*Test A* may be omitted if tests *B, C, D, E* and *F* are carried out. Tests *C, D* and *E* may be omitted if tests *A, B* and *F* are carried out.

A. Dissolve 0.2 g in 20 ml of *ethanol (50 per cent)*, acidify with *dilute hydrochloric acid* and extract with 50 ml of *ether*. Wash the ether layer with 10 ml of *water*, dry over *anhydrous sodium sulphate* and filter. Evaporate the filtrate to dryness and dry the residue at 105º.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *phenobarbitone RS* or with the reference spectrum of phenobarbitone.

B. Determine the melting point (2.4.21), of the residue obtained in test *A* and of a mixture of equal quantities of the residue and *phenobarbitone RS*. The difference between the melting points, which are about 175º, is not greater than 2º.

C. Complies with the test for identification of barbiturates (2.3.2), but using the following solutions.

**Test solution.** A 0.1 per cent w/v solution of the substance under examination in *ethanol (50 per cent)*.

**Reference solution.** A 0.09 per cent w/v solution of *phenobarbitone RS* in *ethanol (50 per cent)*.

D. 1 g dissolves completely in 20 ml of *ethanol* (90 per cent) (distinction from barbitone sodium).

E. Gives the reaction of non-nitrogen substituted barbiturates (2.3.1).

F. Ignite about 0.1 g; the residue gives the reactions of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** A 10.0 per cent w/v solution in *ethanol (50 per cent)* is clear (2.4.1), and not more intensely coloured than reference solution YS7 (2.4.1).

**pH** (2.4.24). Not more than 10.2, determined in a 10.0 per cent w/v solution.

**Related substances.** Complies with the test for related substances in barbiturates (2.3.4), but using the following solutions.

---

**Phenobarbitone Injection**

Phenobarbital Sodium Injection; Phenobarbitone Sodium Injection; Soluble Phenobarbitone Injection

Phenobarbitone Injection is a sterile solution of Phenobarbitone Sodium in a mixture of nine volumes of Propylene Glycol and one volume of Water for Injections.

Phenobarbitone Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of phenobarbitone sodium, C₁₂H₁₁N₂NaO₃.

**Identification**

To a volume containing 1 g of Phenobarbitone Sodium add 15 ml of water if necessary, make slightly acidic with *1 M sulphuric acid* and filter. The residue, after washing with water and drying at 105º, complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *phenobarbitone RS* or with the reference spectrum of phenobarbitone.

B. Dissolve 50 mg in 2 ml of a 0.2 per cent w/v solution of *cobalt acetate* in *methanol*, warm, add 50 mg of powdered *borax* and heat to boiling; a bluish violet colour is produced.

**Tests**

**pH** (2.4.24). 10.0 to 11.0.
Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. Weigh accurately about 2.0 g, add 30 ml of water and 3 g of sodium carbonate, stir to dissolve and titrate with 0.1 M silver nitrate until a distinct turbidity is observed when viewed against a black background, the solution being stirred vigorously throughout the titration.

1 ml of 0.1 M silver nitrate is equivalent to 0.02542 g of C\textsubscript{12}H\textsubscript{11}N\textsubscript{2}NaO\textsubscript{3}.

Determine the weight per ml of the injection (2.4.29) and calculate the percentage weight in volume of C\textsubscript{12}H\textsubscript{11}N\textsubscript{2}NaO\textsubscript{3}.

Storage. Store in single dose containers.

Labelling. The label states that the injection should not be used if the solution is discoloured or if it contains a precipitate.

Phenobarbitone Sodium Tablets

Phenobarbital Sodium Tablets; Soluble Phenobarbitone Tablets; Soluble Phenobarbital Tablets

Phenobarbitone Sodium Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of phenobarbitone sodium, C\textsubscript{12}H\textsubscript{11}N\textsubscript{2}NaO\textsubscript{3}.

Identification

A. Heat 0.1 g of the residue obtained in Assay on a water-bath with 15 ml of ethanol (25 per cent) until dissolved, filter while hot and allow to cool. Filter through a sintered-glass crucible, wash with a small quantity of ethanol (25 per cent) and dry at 105º. Heat in a sealed tube at 105º for 1 hour.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with phenobarbitone RS or with the reference spectrum of phenobarbitone.

B. The residue obtained in test A melts at about 175º (2.4.21).

C. Dissolve 50 mg of the residue obtained in Assay in 2 ml of a 0.2 per cent w/v solution of cobaltous acetate in methanol, warm, add 50 mg of powdered borax and heat to boiling; a bluish violet colour is produced.

D. Triturate a quantity of the powdered tablets containing 0.2 g of Phenobarbitone Sodium with 5 ml of water and filter; the filtrate is alkaline to litmus solution and yields a white precipitate on the addition of dilute hydrochloric acid.

E. The powdered tablets, when moistened with hydrochloric acid and introduced on a platinum wire into a flame, impart a yellow colour to the flame.

Tests

Other tests. Complies with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.3 g of Phenobarbitone Sodium, dissolve as completely as possible in 10 ml of a 2 per cent w/v solution of sodium hydroxide, saturate with sodium chloride, acidify with hydrochloric acid and extract with successive quantities, each of 15 ml, of ether until complete extraction is effected. Wash the combined extracts with two quantities, each of 2 ml, of water and extract the combined washings with 10 ml of ether. Add the ether to the main ether layer and dry the residue to constant weight at 105º.

1 g of the residue is equivalent to 1.095 g of C\textsubscript{12}H\textsubscript{11}N\textsubscript{2}NaO\textsubscript{3}.

Storage. Store protected from moisture.
Phenol

Carbolic acid

\[ \text{C}_6\text{H}_5\text{O} \quad \text{Mol. Wt. 94.1} \]

Phenol contains not less than 99.0 per cent and not more than 100.5 per cent of C\(_6\)H\(_5\)O.

**Description.** Colourless or faintly pink or faintly yellowish crystals or crystalline masses; odour, characteristic; deliquescent.

**Identification**

A. 0.5 g dissolves completely in 2 ml of *strong ammonia solution*. Dilute this solution to about 100 ml with *water* and to 2 ml of the resulting solution add 0.05 ml of *sodium hypochlorite solution* (3 per cent Cl); a blue colour develops which becomes progressively more intense.

B. Dissolve 1.0 g in sufficient *water* to produce 15 ml (solution A) and to 1 ml add 10 ml of *water* and 0.1 ml of *ferric chloride solution*; a violet colour is produced which disappears on the addition of 5 ml of 2-propanol.

C. To 1 ml of solution A add 10 ml of *water* and 1 ml of *bromine solution*; a pale yellow precipitate is produced.

**Tests**

**Appearance of solution.** Solution A is clear (2.4.1), and not more intensely coloured than reference solution BS6 (2.4.1).

**Acidity.** To 2 ml of solution A add 0.05 ml of *methyl orange solution*; the solution is yellow.

**Freezing point** (2.4.11). Not less than 39.5\(^\circ\).

**Non-volatile matter.** Not more than 0.05 per cent, when 5.0 g is volatilised on a water-bath and dried to constant weight at 105\(^\circ\).

**Assay.** Weigh accurately about 0.5 g and dissolve in sufficient *water* to produce 250.0 ml. Transfer 25.0 ml to a ground-glass-stoppered flask, add 50.0 ml of 0.05 \(M\) bromine and 5 ml of *hydrochloric acid*, stopper, allow to stand for 30 minutes, swirling occasionally, and allow to stand for a further 15 minutes. Add 5 ml of a 20 per cent w/v solution of potassium iodide, shake and titrate with 0.1 \(M\) sodium thiosulphate until a faint yellow colour remains. Add 0.5 ml of *starch solution* and 10 ml of *chloroform* and continue the titration with vigorous shaking. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of bromine required.

1 ml of 0.05 \(M\) bromine is equivalent to 0.001569 g of C\(_6\)H\(_5\)O.

**Storage.** Store protected from light and moisture.

---

Phenolphthalein

\[ \text{C}_{20}\text{H}_{14}\text{O}_4} \quad \text{Mol. Wt. 318.3} \]

Phenolphthalein is 3,3-bis(4-hydroxyphenyl)phthalide.

Phenolphthalein contains not less than 98.0 per cent and not more than 102.0 per cent of C\(_{20}\)H\(_{14}\)O\(_4\), calculated on the dried basis.

**Description.** A white or yellowish white, crystalline or amorphous powder; odourless or almost odourless.

**Identification**

A. Dissolves in dilute solutions of alkali hydroxides and in hot solutions of alkali carbonates forming a red solution which is decolorised by dilute acids.

B. Melting range (2.4.21). 258\(^\circ\) to 263\(^\circ\).

**Tests**

**Heavy metals** (2.3.13). Heat 5 g with 50 ml of *dilute hydrochloric acid* on a water-bath for 5 min and filter. Evaporate the filtrate almost to dryness and dissolve the residue in 50 ml of *water*. 12 ml of this solution complies with the limit test for heavy metals, Method D (20 ppm). Use 10 ml of lead standard solution (2 ppm Pb) to prepare the standard.

**Fluoran.** 0.5 g dissolves completely in a mixture of 4 ml of 1 \(M\) sodium hydroxide and 50 ml of *water*.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105\(^\circ\).

**Assay.** Weigh accurately about 0.1 g, dissolve in 100.0 ml of *ethanol* (95 per cent), dilute 5.0 ml of this solution to 50.0 ml with *ethanol* (95 per cent) and evaporate 5.0 ml of the resulting
solution to dryness on a water-bath. Dissolve the residue in sufficient glycine buffer pH 11.3 to produce 100.0 mL, mix and immediately measure the absorbance of the resulting solution at the maximum at about 555 nm (2.4.7). Calculate the content of C₂₀H₁₄O₄ taking 1055 as the specific absorbance at 555 nm.

Storage. Store protected from moisture.

**Phenoxymethylpenicillin Potassium**

Penicillin V Potassium

![Chemical Structure](image)

Phenoxymethylpenicillin Potassium is potassium (6R)-6-(2-phenoxyacetamido)penicillinate, produced by the growth of certain strains of *Penicillium notatum* or related organisms on a culture medium containing an appropriate precursor, or obtained by any other means.

Phenoxymethylpenicillin Potassium contains not less than 86.0 per cent of total penicillins C₁₆H₁₇N₂O₅S, calculated on the anhydrous basis.

**Description.** A white, crystalline powder.

**Identification**

*Test A* may be omitted if *tests B and C* are carried out. *Test B* may be omitted if *tests A and C* are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *phenoxymethylpenicillin potassium RS*.

B. Gives reaction B of penicillins and cephalosporins (2.3.1).

C. Gives reaction A of potassium salts (2.3.1).

**Tests**

**pH** (2.4.24). 5.5 to 7.5, determined in a 0.5 per cent w/v solution.

**Specific optical rotation** (2.4.22). +215.0° to +230.0°, determined in a 1.0 per cent w/v solution in carbon dioxide-free water.

**Light absorption** (2.4.7). Absorbance of a 0.1 per cent w/v solution in 0.1 M sodium hydroxide at the maximum at about 306 nm, not more than 0.33. Absorbance of a 0.02 per cent w/v solution in 0.1 M sodium hydroxide at the maximum at about 274 nm, not less than 0.50.

**Phenoxyacetic acid.** (Not more than 0.5 per cent).

Determine by liquid chromatography (2.4.14).

**Diluent. pH 6.6. Phosphate buffer.**

*Test solution.* Weigh accurately a suitable quantity of the substance under examination, dissolve in the diluent and dilute to obtain a solution having a known concentration of about 20.0 mg per ml. (Use this solution on the day prepared).

*Reference solution.* Weigh accurately a suitable quantity of phenoxyacetic acid, dissolve in the diluent and dilute to obtain a solution having a known concentration of about 0.1 mg per ml.

**Limit of p-hydroxyphenoxymethylpenicillin.** Not more than 5.0 per cent.

Using the chromatograms obtained with the test solution in the Assay, calculate the content of *p-hydroxyphenoxymethylpenicillin* from the peak response of *p-hydroxyphenoxymethylpenicillin* and the sum of the peak responses of *p-hydroxyphenoxymethylpenicillin* and phenoxymethylpenicillin.

**Water** (2.3.43). Not more than 1.0 per cent, determined on 1.0 g.

**Assay.** Determine by liquid chromatography (2.4.14).

*Test solution.* Dissolve about 125 mg of the substance under examination in the mobile phase and dilute to 50.0 ml with the mobile phase.

*Reference solution (a).* Dissolve an accurately weighed quantity of *phenoxymethylpenicillin potassium RS* in the mobile phase and dilute to obtain a solution having a known concentration of about 2.5 mg per ml.

*Reference solution (b).* A solution in the mobile phase containing 0.25 per cent w/v each of benzylpenicillin potassium and phenoxymethylpenicillin potassium.
Chromatographic system
- a stainless steel column 30 cm x 4 mm, packed with octadecylsilane chemically bonded to porous silica (3 to 10 µm),
- mobile phase: a mixture of 650 volumes of water, 350 volumes of acetonitrile and 5.75 volumes of glacial acetic acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 254 nm,
- a 10 µl loop injector.

Inject reference solution (b). The relative retention times are about 0.8 for benzylpenicillin and 1.0 for phenoxymethylpenicillin. The column efficiency determined from the phenoxymethylpenicillin peak is not less than 1800 theoretical plates and the resolution between benzylpenicillin and phenoxymethylpenicillin is not less than 3.0.

Inject reference solution (a). The relative standard deviation for replicate injections is not more than 1.0 per cent.

Inject the test solution and reference solution (a). Record the chromatograms and measure the responses for the phenoxymethylpenicillin peak and any p-hydroxyphenoxymethylpenicillin peak with a retention time of about 0.4 relative to that of the main phenoxymethylpenicillin peak.

Calculate the content of C\textsubscript{16}H\textsubscript{17}N\textsubscript{2}O\textsubscript{5}S, from the sum of the peak responses of the p-hydroxyphenoxymethylpenicillin and phenoxymethylpenicillin peaks in the chromatograms obtained with the test solution and reference solution (a).

Storage. Store protected from moisture.

Phenoxympenillicillin Potassium Tablets

Phenoxympenillicillin Tablets; Penicillin V Potassium Tablets; Penicillin V Tablets

Phenoxympenillicillin Potassium Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of phenoxympenillicillin, C\textsubscript{16}H\textsubscript{18}N\textsubscript{2}O\textsubscript{5}S.

Identification

A. Shake a quantity of the powdered tablets containing 80 mg of phenoxympenillicillin with water, dilute to 250 ml with water and filter. When examined between 230 and 360 nm (2.4.7), the filtrate shows absorption maxima at about 268 nm and 274 nm and a minimum at about 272 nm.

B. Shake a quantity of the powdered tablets containing 10 mg of phenoxympenillicillin with 10 ml of water, filter and add 0.5 ml of neutral red solution. Add sufficient 0.01 M sodium hydroxide to produce a permanent orange colour and then add 1.0 ml of penicillinase solution; the solution changes rapidly to red.

C. Ignite 0.5 g of the powdered tablets, add 5 ml of 2 M hydrochloric acid, boil, cool and filter. The filtrate gives reaction B of potassium salts (2.3.1).

Tests

Dissolution (2.5.2).

Apparatus. No 1

Medium. 900 ml of water

Speed and time. 50 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate, suitably diluted if necessary, at the maximum at about 268 nm (2.4.7). At the same time measure the absorbance of a solution of known concentration of phenoxympenillicillin potassium RS at the maximum at about 268 nm. Calculate the content of C\textsubscript{16}H\textsubscript{18}N\textsubscript{2}O\textsubscript{5}S, in the medium.

D. Not less than 75 per cent of the stated amount of C\textsubscript{16}H\textsubscript{18}N\textsubscript{2}O\textsubscript{5}S.

Other tests. Complies with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh and finely powder 20 tablets. Dissolve an accurately weighed quantity of the powder containing about 0.25 g of phenoxympenillicillin in the mobile phase by shaking for 5 minutes and dilute to 100.0 ml with the mobile phase. Filter through a 0.5 µm or finer filter and use the filtrate.

Reference solution (a). Dissolve an accurately weighed quantity of phenoxympenillicillin potassium RS in the mobile phase and dilute to obtain a solution having a known concentration of about 2.5 mg per ml.

Reference solution (b). A solution in the mobile phase containing 0.25 per cent w/v each of benzylpenicillin potassium and phenoxympenillicillin potassium.

Chromatographic system
- a stainless steel column 30 cm x 4 mm, packed with octadecylsilane chemically bonded to porous silica,
- mobile phase: a mixture of 650 volumes of water, 350 volumes of acetonitrile and 5.75 volumes of glacial acetic acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 254 nm,
- a 10 µl loop injector.

Inject reference solution (b). The relative retention times are about 0.8 for benzylpenicillin and 1.0 for phenoxympenillicillin. The column efficiency determined from the phenoxympenillicillin peak is not less than 1800 theoretical plates and the resolution between the benzylpenicillin and phenoxympenillicillin peaks is not less than 3.0.
Inject reference solution (b). The relative standard deviation for replicate injections is not more than 1.0 per cent.

Inject the test solution and reference solution (a). Record the chromatograms and measure the responses for the phenoxy methylpenicillin peak and any p-hydroxyphenoxy methylpenicillin peak with a retention time of about 0.4 relative to that of the main phenoxy methylpenicillin peak.

Calculate the content of C_{16}H_{17}N_{2}O_{5}S, from the sum of the peak responses of the p-hydroxyphenoxymethylpenicillin and phenoxymethylpenicillin peaks in the chromatograms obtained with the test solution and reference solution (a).

Storage. Store protected from moisture.

Labelling. The label states the strength in terms of the equivalent amount of phenoxy methylpenicillin.

Phentolamine Mesylate

![Phentolamine Mesylate structure]

\[ \text{C}_{17}\text{H}_{19}\text{N}_{3}\text{O},\text{CH}_{4}\text{O}_{3}\text{S} \] \quad \text{Mol. Wt. 377.5}

Phentolamine Mesylate is 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)aminophenol methanesulphonate.

Phentolamine Mesylate contains not less than 99.0 per cent and not more than 100.5 per cent of C_{17}H_{19}N_{3}O, CH_{4}O_{3}S, calculated on the dried basis.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with phentolamine mesylate RS or with the reference spectrum of phentolamine mesylate.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution shows an absorption maximum only at about 278 nm; absorbance at about 278 nm, about 0.5.

C. Dissolve 0.5 g in 5 ml of ethanol (95 per cent) and 5 ml of 0.1 M hydrochloric acid and add 2 ml of a 0.5 per cent w/v solution of ammonium metavanadate; a light green precipitate is produced.

D. Mix 50 mg with 0.2 g of powdered sodium hydroxide, heat to fusion and continue the heating for a few seconds longer. Cool, add 0.5 ml of water and a slight excess of 2 M hydrochloric acid and warm; sulphur dioxide is evolved, which turns moistened starch iodate paper blue.

Tests

Acidity or alkalinity. Dissolve 0.1 g in 10 ml of carbon dioxide-free water and add 0.1 ml of methyl red solution. The solution is not red and not more than 0.05 ml of 0.1 M sodium hydroxide is required to change the colour of the solution.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 85 volumes of 2-butanone, 15 volumes of acetone and 5 volumes of strong ammonia solution.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of ethanol (95 per cent).

Reference solution. A 0.01 per cent w/v solution of the substance under examination in ethanol (95 per cent).

Apply to the plate 10 µl of each solution. After development, dry the plate in air, spray with dilute potassium iodobismuthate solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

Assay. Weigh accurately about 0.3 g and dissolve in 100 ml of anhydrous 2-propanol with the aid of ultrasound if necessary. Titrate with 0.1 M tetrabutylammonium hydroxide in 2-propanol. Determine the end-point potentiometrically (2.4.25), using a glass electrode and a calomel electrode containing a saturated solution of tetrabutylammonium chloride in 2-propanol. Carry out a blank titration.

1 ml of 0.1 M tetrabutylammonium hydroxide is equivalent to 0.03775 g of C_{17}H_{19}N_{3}O, CH_{4}O_{3}S.

Storage. Store protected from light and moisture.

Phentolamine Injection

Phentolamine Mesylate Injection

Phentolamine Injection is a sterile solution of Phentolamine Mesylate in Water for Injections containing Dextrose.
Phentolamine Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of phentolamine mesylate, \(\text{C}_{17}\text{H}_{19}\text{N}_3\text{O}, \text{CH}_4\text{O}_3\text{S}\).

**Identification**

The residue obtained in the Assay melts at about 138º (2.4.21).

**Tests**

**pH** (2.4.24). 3.5 to 5.0.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Dilute an accurately measured volume containing about 0.1 g of Phentolamine Mesylate to 40 ml with water, add 20 ml of a 20 per cent w/v solution of trichloroacetic acid, allow to stand for 3 hours, filter, wash the residue with two quantities, each of 5 ml, of water and dry to constant weight at 105º.

1 g of the residue is equivalent to 0.8487 g of \(\text{C}_{17}\text{H}_{19}\text{N}_3\text{O}, \text{CH}_4\text{O}_3\text{S}\).

**Storage.** Store protected from light.

---

**Phenylbutazone**

\[\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}_2\] \hspace{1cm} \text{Mol. Wt. 308.4}

Phenylbutazone is 4-butyl-1,2-diphenylpyrazolidine-3,5-dione.

Phenylbutazone contains not less than 98.0 per cent and not more than 100.5 per cent of \(\text{C}_{19}\text{H}_{20}\text{N}_2\text{O}_2\), calculated on the dried basis.

**Description.** A white or almost white, crystalline powder; odourless.

**Identification**

*Test A* may be omitted if *tests B and C* are carried out. *Tests B and C* may be omitted if *test A* is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with phenylbutazone \text{RS} or with the reference spectrum of phenylbutazone.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.01 \text{M sodium hydroxide} shows an absorption maximum at about 264 nm; absorbance at about 264 nm, about 0.66.

C. To 0.1 g add 1 ml of glacial acetic acid and 2 ml of hydrochloric acid and heat under a reflux condenser for 30 minutes. Cool, add 10 ml of water and filter. Add to the filtrate 3 ml of 0.1 \text{M sodium nitrite}; a yellow colour is produced. To 1 ml of this solution add a solution containing 10 mg of 2-naphthol in 5 ml of sodium carbonate solution; a reddish brown to reddish violet precipitate is produced.

**Tests**

**Appearance of solution** (2.4.1). Dissolve 1.0 g in 20 ml of 2 \text{M sodium hydroxide} and keep the solution at 25º for 3 hours. The solution is clear.

**Acidity or alkalinity.** Heat to boiling 1.0 g with 50 ml of water, cool with shaking in a stoppered vessel and filter. To 25 ml of the filtrate add 0.5 ml of phenolphthalein solution; the solution is colourless and not more than 0.5 ml of 0.01 \text{M sodium hydroxide} is required to change the colour of the solution. Add 0.6 ml of 0.01 \text{M hydrochloric acid} and 0.1 ml of methyl red solution; the solution is red or orange.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 50 volumes of chloroform, 40 volumes of cyclohexane and 10 volumes of glacial acetic acid.

Prepare the following solutions immediately before use.

**Test solution.** Dissolve 0.2 g of the substance under examination in a solution containing 0.02 per cent w/v of butylated hydroxytoluene in a mixture of equal volumes of chloroform and ethanol and dilute to 5 ml with the same solvent mixture.

**Reference solution.** Dilute 1 ml of the test solution to 200 ml with the same solvent mixture.

Before use, spray the plate evenly with a 2 per cent w/v solution of sodium metabisulphite until thoroughly wet, dry the plate in air for 15 minutes, heat at 120º for 30 minutes and allow to cool. Apply separately to the plate 5 µl of each solution. After development, dry the plate in a current of warm air for 10 minutes and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.
Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 80° over phosphorous pentoxide at a pressure of 1.5 to 2.5 kPa for 4 hours.

Assay. Weigh accurately about 0.5 g, dissolve in 25 ml of acetone and titrate with 0.1 M sodium hydroxide, using 0.5 ml of bromothymol blue solution as indicator and continuing the titration until the blue colour persists for at least 15 seconds. Carry out a blank titration.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.03084 g of C₁₉H₂₀N₂O₂.

Storage. Store protected from moisture.

Phenylbutazone Tablets

Phenylbutazone Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of phenylbutazone, C₁₉H₂₀N₂O₂. The tablets are coated.

Identification

Extract a quantity of the powdered tablets containing 0.2 g of Phenylbutazone with 40 ml of warm acetone and evaporate the filtrate to dryness. The residue complies with the following tests.

A. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.01 M sodium hydroxide shows an absorption maximum at about 264 nm; absorbance at about 264 nm, about 0.66.

B. To 0.1 g add 1 ml of glacial acetic acid and 2 ml of hydrochloric acid and heat under a reflux condenser for 30 minutes. Cool, add 10 ml of water and filter. Add to the filtrate 3 ml of 0.1 M sodium nitrite; a yellow colour is produced. To 1 ml of this solution add a solution containing 10 mg of 2-naphthol in 5 ml of sodium carbonate solution; a reddish brown to reddish violet precipitate is produced.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 50 volumes of chloroform, 40 volumes of cyclohexane and 10 volumes of glacial acetic acid.

Prepare the following solutions immediately before use.

Test solution. Shake a quantity of the powdered tablets containing 0.4 g of Phenylbutazone with 10 ml of a solution containing 0.02 per cent w/v of butylated hydroxytoluene in a mixture of equal volumes of chloroform and ethanol for 15 minutes and centrifuge. Use the supernatant liquid.

Reference solution. Dilute 1 ml of the test solution to 200 ml with the same solvent mixture.

Before use, spray the plate evenly with a 2 per cent w/v solution of sodium metabisulphite until thoroughly wet, dry the plate in air for 15 minutes, heat at 120° for 30 minutes and allow to cool. Apply to the plate 5 µl of each solution. After development, dry the plate in a current of warm air for 10 minutes and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Other tests. Complies with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.5 g of Phenylbutazone and shake vigorously with 150 ml of 0.1 M sodium hydroxide for 45 minutes. Add sufficient 0.1 M sodium hydroxide to produce 250.0 ml, mix and filter, rejecting the first 20 ml of the filtrate. To 5.0 ml of the filtrate add 50 ml of water and 4 ml of hydrochloric acid and extract with three quantities, each of 30 ml, of ether. Combine the ether extracts and extract with three quantities, each of 30 ml, of 0.1 M sodium hydroxide. Combine the aqueous extracts, pass nitrogen through the solution to remove the residual ether and add sufficient 0.1 M sodium hydroxide to produce 100.0 ml and mix well. To 10.0 ml of this solution add sufficient 0.1 M sodium hydroxide to produce 100.0 ml and measure the absorbance of the resulting solution at the maximum at about 264 nm (2.4.7), using 0.1 M sodium hydroxide as the blank.

Calculate the content of C₁₉H₂₀N₂O₂ from the absorbance obtained with the reference solution by carrying out the Assay simultaneously on 0.5 g of phenylbutazone RS in place of the substance under examination.

Storage. Store protected from moisture.

Phenylephrine Hydrochloride

\[ \text{HO} \quad \text{H} \quad \text{OH} \quad \text{H} \quad \text{N} \quad \text{CH}_3 \quad \text{HCl} \]

\[ \text{C}_9\text{H}_{13}\text{NO}_2 \text{HCl} \quad \text{Mol. Wt. 203.7} \]

Phenylephrine Hydrochloride is (R)-1-(3-hydroxyphenyl)-2-methylaminoethanol hydrochloride.

Phenylephrine Hydrochloride contains not less than 98.5 per cent and not more than 101.0 per cent of C₉H₁₃NO₂·HCl, calculated on the dried basis.

Description. A white or almost white, crystalline powder.
Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with phenylephrine hydrochloride RS or with the reference spectrum of phenylephrine hydrochloride.

B. Dissolve about 10 mg in 1 ml of water and add 0.05 ml of cupric sulphate solution and 1 ml of 5 M sodium hydroxide; a violet colour is produced. Add 1 ml of ether and shake; the ether layer remains colourless.

C. Dissolve 0.3 g in 3 ml of ether layer remains colourless.

D. Gives reaction A of chlorides (2.3.1).

Tests

Appearance of solution. Dissolve 2.0 g in 100 ml of carbon dioxide-free water prepared from distilled water (solution A). Solution A is clear (2.4.1), and colourless (2.4.1).

Acidity or alkalinity. To 10 ml of solution A add 0.1 ml of methyl red solution and 0.2 ml of 0.01 M sodium hydroxide. The solution is yellow and not more than 0.4 ml of 0.01 M hydrochloric acid is required to change the colour of the solution to red.

Specific optical rotation (2.4.22). –43.0° to –47.0°, determined in solution A.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H.

Mobile phase. A mixture of 80 volumes of 2-propanol, 15 volumes of 10 M ammonia and 5 volumes of chloroform.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of methanol.

Reference solution (a). A 0.01 per cent w/v solution of the substance under examination in methanol.

Reference solution (b). A 0.004 per cent w/v solution of the substance under examination in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in cold air, spray with ninhydrin solution, heat at 105º for 10 minutes and examine in daylight. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than two such spots are more intense than the spot in the chromatogram obtained with reference solution (b).

Phenylephrine Injection

Phenylephrine Hydrochloride Injection

Phenylephrine Injection is a sterile solution of Phenylephrine Hydrochloride in Water for Injections.

Phenylephrine Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of phenylephrine hydrochloride, C₉H₁₃NO₂.HCl.

Identification

A. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).

B. To a volume containing 10 mg of Phenylephrine Hydrochloride add, if necessary, sufficient water to produce 1 ml and then add 0.05 ml of cupric sulphate solution and 1 ml of 5 M sodium hydroxide; a violet colour is produced. Add 1 ml of ether and shake; the ether layer remains colourless.

C. Gives reaction A of chlorides (2.3.1).

Tests

pH (2.4.24). 4.5 to 6.5.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H.

Mobile phase. A mixture of 80 volumes of 2-propanol, 15 volumes of 10 M ammonia and 5 volumes of chloroform.

Test solution (a) Evaporate a volume of the injection containing 20 mg of Phenylephrine Hydrochloride to dryness and dissolve the residue in 1 ml of methanol.
Test solution (b). Dilute 1 volume of test solution (a) to 200 volumes with methanol.

Reference solution (a). Dilute 1 volume of test solution (b) to 2.5 volumes with methanol.

Reference solution (b). A 0.01 per cent w/v solution of phenylephrine hydrochloride RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in cold air, spray with ninhydrin solution, heat at 105º for 10 minutes and examine in daylight. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with test solution (b) and not more than two such spots are more intense than the spot in the chromatogram obtained with reference solution (a).

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. To an accurately measured volume containing about 50 mg of Phenylephrine Hydrochloride add sufficient 0.5 M sulphuric acid to produce 100.0 ml. Dilute 10.0 ml of this solution to 100.0 ml with 0.5 M sulphuric acid and measure the absorbance of the resulting solution at the maximum at about 273 nm (2.4.7). Calculate the content of C₉H₁₃NO₂.HCl taking 90 as the specific absorbance at 273 nm.

Storage. Store protected from light.

### Phenylmercuric Acetate

![Chemical structure of Phenylmercuric Acetate](image)

C₆H₅HgO₂  
Mol. Wt. 336.7

Phenylmercuric Acetate is (acetato)phenylmercury.

Phenylmercuric Acetate contains not less than 98.0 per cent and not more than 100.5 per cent of C₆H₅HgO₂.

Description. A white to creamy white, crystalline powder, or small white prisms or leaflets.

Identification

A. To 100 mg add 0.5 ml of nitric acid, warm gently until a dark brown colour is produced and dilute with water to 10 ml; the characteristic odour of nitrobenzene is produced.

B. To 100 mg add 0.5 ml of sulphuric acid and 1 ml of ethanol (95 per cent) and warm; the characteristic odour of ethyl acetate is produced.

C. To 5 ml of a saturated solution in water, add a few drops of a freshly prepared 10 per cent w/v solution of sodium sulphide; a white precipitate is formed which darkens slowly on boiling and allowing to stand.

Tests

Mercuric salts and heavy metals. Heat about 100 mg with 15 ml of water, cool and filter. To the filtrate add a few drops of a freshly prepared 10 per cent w/v solution of sodium sulphide; the precipitate formed shows no immediate colour.

Polymercurated benzene compounds. Shake 2.0 g with 100 ml of acetone. Filter, wash the residue with successive portions of acetone until a total of 50 ml is used, dry the residue at 105º for 1 hour and weigh. The weight of the residue does not exceed 30 mg (1.5 per cent).

Sulphated ash (2.3.18). Not more than 0.2 per cent.

Assay. Weigh accurately about 0.4 g, transfer to a 100-ml flask, add 15 ml of water, 5 ml of formic acid and 1 g of zinc dust and reflux for 30 minutes. Cool, filter and wash the filter paper and the amalgam with water until the washings are no longer acidic to litmus. Dissolve the amalgam in 40 ml of 8 M nitric acid. Heat on a water-bath for 3 minutes and add 0.5 g urea and sufficient 0.02 M potassium permanganate to produce a permanent pink colour. Cool and add hydrogen peroxide solution to decolorise the solution. Add 1 ml of ferric ammonium sulphate solution and titrate with 0.1 M ammonium thiocyanate. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of ammonium thiocyanate required.

1 ml of 0.1 M ammonium thiocyanate is equivalent to 0.01684 g of C₆H₅HgO₂.

Storage. Store protected from light and moisture.

### Phenylmercuric Nitrate

Phenylmercuric Nitrate is a mixture of phenylmercuric nitrate, C₆H₅HgNO₃ and phenylmercuric hydroxide, C₆H₅HgOH.

Phenylmercuric Nitrate contains not less than 62.5 per cent and not more than 63.5 per cent of mercury, Hg, calculated on the dried basis.

Description. A white or pale yellow powder.

Identification

A. To 0.1 g add 3 ml of sulphuric acid; the mixture becomes yellow and the characteristic odour of nitrobenzene is produced.

B. To 0.1 g add 45 ml of water and heat to boiling with shaking. Cool, filter and add sufficient water to produce 50 ml (solution A). To 1 ml of solution A add 1 ml of 2 M hydrochloric acid; a white, flocculent precipitate is produced.
C. To 5 ml of solution A add 8 ml of water and 0.1 ml of a freshly prepared 10 per cent w/v solution of sodium sulphide; a white precipitate is formed which darkens slowly on boiling and allowing to stand.

D. To 5 ml of solution A add 1 ml of 2 M hydrochloric acid, 2 ml of dichloromethane and 0.2 ml of dithizone solution and shake; the lower layer is orange-yellow.

E. Solution A gives reaction of nitrates (2.3.1).

Tests

Appearance of solution. Solution A is colourless (2.4.1).

Inorganic mercuric compounds. To a 10 ml of solution A add 2 ml of potassium iodide solution and 3 ml of 2 M hydrochloric acid and filter; the filtrate is colourless. Wash the precipitate with 2 ml of water, combine the filtrate and washings and add 2 ml of 2 M sodium hydroxide and sufficient water to produce 20 ml. 12 ml of the solution complies with the limit test for heavy metals, Method A (2.3.13). Use lead standard solution (1 ppm Pb) to prepare the standard (0.1 per cent).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying over phosphorus pentoxide at a pressure of 1.5 to 2.5 kPa for 24 hours.

Assay. Weigh accurately about 0.2 g and dissolve in a mixture of 90 ml of water and 10 ml of nitric acid. Add 2 ml of ferric ammonium sulphate solution and titrate with 0.1 M ammonium thiocyanate until a persistent reddish yellow colour is obtained. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of ammonium thiocyanate required.

1 ml of 0.1 M ammonium thiocyanate is equivalent to 0.02006 g of Hg.

Storage. Store protected from light and moisture.

Phenytoin Sodium

Diphenylhydantoin Sodium

\[
\begin{align*}
& \text{C}_6\text{H}_5\text{N}=\text{N} \quad \text{ONa} \\
& \text{C}_6\text{H}_5
\end{align*}
\]

C\text{\textsubscript{15}}H\text{\textsubscript{11}}N\text{\textsubscript{2}}NaO\text{\textsubscript{2}}

Phenytoin Sodium is 4-oxo-5,5-diphenyl-2-imidazolidin-2-olate

Phenytoin Sodium contains not less than 98.0 per cent and not more than 101.0 per cent of C\text{\textsubscript{15}}H\text{\textsubscript{11}}N\text{\textsubscript{2}}NaO\text{\textsubscript{2}}, calculated on the anhydrous basis.

Description. A white powder; odourless; somewhat hygroscopic.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6).

B. Dissolve 0.25 g in 5 ml of water and acidify with dilute hydrochloric acid; a white precipitate is produced.

C. Dissolve 0.1 g in 10 ml of a 10 per cent w/v solution of pyridine, add 1 ml of cupric sulphate with pyridine solution and allow to stand for 10 minutes; a blue precipitate is produced.

D. Incinerate 0.1 g; the residue after neutralisation with hydrochloric acid and addition of 2 ml of water gives the reactions of sodium salts (2.3.1).

Tests

Appearance of solution. Suspend 1.0 g in 5 ml of water and dilute to 20 ml with 0.1 M sodium hydroxide; the solution is clear (2.4.1), and not more intensely coloured than reference solution BYS6 (2.4.1).

Free phenytoin. Dissolve 0.3 g in 10 ml of a mixture of equal volumes of pyridine and water and add 0.5 ml of dilute phenolphthalein solution and 3 ml of silver nitrate-pyridine reagent. Not more than 1.0 ml of 0.1 M sodium hydroxide is required to change the colour of the solution to pink.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 45 volumes of chloroform, 45 volumes of 2-propanol and 10 volumes of strong ammonia solution.

Test solution. Dissolve 0.4 g of the substance under examination in 10 ml of methanol.

Reference solution (a). A 0.04 per cent w/v solution of the substance under examination in methanol.

Reference solution (b). A 0.02 per cent w/v solution of benzophenone in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate at 80º for 5 minutes and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and any spot corresponding to benzophenone is not more intense than the spot in the chromatogram obtained with reference solution (b).
**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Water** (2.3.43). Not more than 3.0 per cent, determined on 1.0 g.

**Assay.** Weigh accurately about 0.18 g, suspend in 2 ml of water, add 8 ml of 0.05 M sulphuric acid and heat gently for 1 minute. Add 30 ml of methanol, cool. Titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.4.25). After the first inflection, stop the addition of sodium hydroxide, add 5 ml of silver nitrate solution in pyridine, mix and continue the titration until a second inflection is reached. Record the volume of 0.1 M sodium hydroxide added between the two inflections.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.02743 g of C15H11N2NaO2.

**Storage.** Store protected from moisture.

---

**Phenytoin Injection**

Phenytoin Sodium Injection; Diphenylhydantoin Sodium injection

Phenytoin Injection is a sterile material consisting of Phenytoin Sodium with or without buffering agents and other excipients. It is filled in a sealed container.

The injection is constituted by dissolving the contents of the sealed container in the requisite amount of sterile Water for Injection or other suitable solvent, immediately before use.

The constituted solution complies with the requirements for Clarity of solution and Particulate matter stated under Parenteral Preparations (Injections).

**Storage.** The constituted solution should be used immediately after preparation but, in any case, within the period recommended by the manufacturer.

Phenytoin Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of phenytoin sodium, C15H11N2NaO2.

**Description.** A white powder; odourless; somewhat hygroscopic.

The contents of the sealed container comply with the requirements stated under Parenteral Preparations (Powders for Injection) and with the following requirements.

**Identification**

**Test A** may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with phenytoin sodium RS or with the reference spectrum of phenytoin sodium.

B. Dissolve 0.25 g in 5 ml of water and acidify with *dilute hydrochloric acid*; a white precipitate is produced.

C. Dissolve 0.1 g in 10 ml of a 10 per cent w/v solution of pyridine, add 1 ml of cupric sulphate with pyridine solution and allow to stand for 10 minutes; a blue precipitate is produced.

D. Incinerate 0.1 g; the residue after neutralisation with hydrochloric acid and addition of 2 ml of water gives the reactions of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** Suspend 1.0 g in 5 ml of water and dilute to 20 ml with 0.1 M sodium hydroxide; the solution is clear (2.4.1), and not more intensely coloured than reference solution BYS6 (2.4.1).

**Completeness of solution.** The contents dissolve in the quantity of the solvent recommended on the label and give a clear solution.

**pH** (2.4.24). 10.0 to 12.0, determined in a 5.0 per cent w/v solution in the stated solvent.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 45 volumes of chloroform, 45 volumes of 2-propanol and 10 volumes of *strong ammonia solution*.

**Test solution.** Dissolve 0.4 g of the substance under examination in 10 ml of methanol.

**Reference solution (a).** A 0.04 per cent w/v solution of the substance under examination in methanol.

**Reference solution (b).** A 0.02 per cent w/v solution of benzophenone in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate at 80º for 5 minutes and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and any spot corresponding to benzophenone is not more intense than the spot in the chromatogram obtained with reference solution (b).

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Water** (2.3.43). Not more than 3.0 per cent, determined on 1.0 g.

**Assay.** Weigh accurately about 0.18 g of the mixed contents of 10 containers, suspend in 2 ml of water, add 8 ml of 0.05 M sulphuric acid and heat gently for 1 minute. Add 30 ml of methanol, cool. Titrate with 0.1 M sodium hydroxide,
determining the end-point potentiometrically (2.4.25). After the first inflection, stop the addition of sodium hydroxide, add 5 ml of silver nitrate solution in pyridine, mix and continue the titration until a second inflection is reached. Record the volume of 0.1 M sodium hydroxide added between the two inflections.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.02743 g of C15H11N2NaO2.

Storage. Store protected from moisture at a temperature not exceeding 30º.

Labelling. The label states (1) the quantity of Phenytoin Sodium contained in it; (2) the directions for preparing the Injection.

Phenytoin Tablets

Phenytoin Sodium Tablets; Diphenylhydantoin Sodium Tablets

Phenytoin Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of phenytoin sodium, C15H11N2NaO2. The tablets are coated.

Identification

A. Shake a quantity of the powdered tablets containing 0.1 g of Phenytoin Sodium with 20 ml of water, filter, acidify with dilute hydrochloric acid and extract with 10 ml of chloroform. Wash the chloroform extract with water, dry with anhydrous sodium sulphate and evaporate to dryness and dry the residue at 105º. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with phenytoin sodium RS treated in the same manner or with the reference spectrum of phenytoin.

B. Triturate a quantity of the powdered tablets containing 0.5 g of Phenytoin Sodium with 10 ml of water and filter. Acidify with dilute hydrochloric acid; a white precipitate is produced.

C. The powdered tablets, when moistened with hydrochloric acid and introduced on a platinum wire into a flame, impart a yellow colour to the flame.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 75 volumes of hexane and 30 volumes of dioxan.

Test solution. Shake a quantity of the powdered tablets containing 0.1 g of Phenytoin Sodium with 5 ml of methanol, warm on a water-bath with shaking and filter.

Reference solution. A 0.01 per cent w/v solution of benzophenone in methanol.

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in air and examine in ultraviolet light at 254 nm. In the chromatogram obtained with the test solution any spot corresponding to benzophenone is not more intense than the spot in the chromatogram obtained with the reference solution.

Other tests. Complies with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.25 g of Phenytoin Sodium, shake with 40 ml of 0.01 M sodium hydroxide for 5 minutes and add sufficient 0.01 M sodium hydroxide to produce 50.0 ml. Centrifuge, acidify 25.0 ml of the clear liquid with 10 ml of 0.1 M hydrochloric acid and extract successively with 50, 40, 25 and 25 ml of ether. Wash the combined extracts with 10 ml of water, evaporate to dryness and dry the residue at 105º. Dissolve in 50 ml of anhydrous pyridine and titrate with 0.1 M tetrabutylammonium hydroxide, using 0.3 per cent w/v solution of thymol blue in pyridine as indicator and taking care to prevent absorption of carbon dioxide from the atmosphere. Carry out a blank titration.

1 ml of 0.1 M tetrabutylammonium hydroxide is equivalent to 0.02743 g of C15H11N2NaO2.

Storage. Store protected from moisture.

Pholcodine

\[
\text{C}_{23}\text{H}_{30}\text{N}_{2}\text{O}_{4}\text{H}_{2}\text{O} \quad \text{Mol. Wt. 416.5}
\]

Pholcodine is (5R,6S)-4,5-epoxy-N-methyl-3-(2-morpholinoethoxy)morphin-7-en-6-ol monohydrate.

Pholcodine contains not less than 98.0 per cent and not more than 101.0 per cent of C23H30N2O4, calculated on the dried basis.

Description. A white or almost white, crystalline powder.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pholcodine RS or with the reference spectrum of pholcodine.
B. To 10 ml of a 0.1 per cent w/v solution add 75 ml of water and 10 ml of 1 M sodium hydroxide and dilute to 100 ml with water. When examined in the range 230 nm and 360 nm (2.4.7), the resulting solution shows an absorption maximum at about 284 nm; absorbance at about 284 nm, 0.36 to 0.39.

C. Dissolve 50 mg in 1 ml of sulphuric acid and add 0.05 ml of a 10 per cent w/v solution of ammonium molybdate; a pale blue colour is produced. Warm gently; the colour changes to deep blue. Add 0.05 ml of 2 M nitric acid; the colour changes to brownish red.

Tests

**Specific optical rotation** (2.4.22). –94.0º to –98.0º, determined at 20º in a 2.0 per cent w/v solution in ethanol (95 per cent).

**Morphine.** Dissolve 0.1 g in sufficient of 0.1 M hydrochloric acid to produce 5 ml, add 2 ml of a 1 per cent w/v solution of sodium nitrite, allow to stand for 15 minutes and add 3 ml of 6 M ammonia. The solution is not more intensely coloured than reference solution BS4 (2.4.1).

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 70 volumes of ethanol (95 per cent), 70 volumes of toluene, 65 volumes of acetone and 5 volumes of strong ammonia solution.

**Test solution.** Dissolve 0.25 g of the substance under examination in 10 ml of chloroform.

**Reference solution (a).** A 0.025 per cent w/v solution of the substance under examination in chloroform.

**Reference solution (b).** A 0.0125 per cent w/v solution of the substance under examination in chloroform.

Apply to the plate 10 µl of each solution. After development, dry the plate in air, spray with dilute potassium iodobismuthate solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot of higher Rf value than the principal spot is more intense than the spot in the chromatogram obtained with reference solution (b).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). 3.9 to 4.5 per cent, determined on 0.5 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.18 g, dissolve in 50 ml of anhydrous glacial acetic acid, warming gently. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically at the second inflection (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01993 g of C_{23}H_{30}N_{2}O_{4}.5H_{2}O.

**Storage.** Store protected from moisture.

**Pholcodine Linctus**

Pholcodine Linctus is a solution containing 0.1 per cent w/v solution of Pholcodine and 1 per cent w/v solution of Citric Acid Monohydrate in a suitable flavoured vehicle.

Pholcodine Linctus contains not less than 0.090 per cent and not more than 0.110 per cent w/v of pholcodine, C_{23}H_{30}N_{2}O_{4}.

**Identification**

To 20 ml add 20 ml of water, make alkaline to litmus paper with 5 M ammonia, extract with two quantities, each of 20 ml, of chloroform, washing each extract with 5 ml of water, dry the combined extracts with anhydrous sodium sulphate, filter and evaporate to dryness. If necessary, add 0.1 ml of ether and scratch the sides of the vessel with a glass rod to induce crystallisation. The crystals, dried at a pressure not exceeding 2 kPa, comply with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pholcodine RS or with the reference spectrum of pholcodine.

B. When examined in the range 230 nm and 360 nm (2.4.7), a 0.01 per cent w/v solution in 0.01 M sodium hydroxide shows an absorption maximum only at about 284 nm.

C. To a portion of the crystals add 0.05 ml of nitric acid and mix; a yellow colour is produced.

D. Dissolve the remainder of the crystals in 1 ml of sulphuric acid and add 0.05 ml of ammonium molybdate-sulphuric acid solution; a pale blue colour is produced. Warm gently; the colour changes to deep blue. Add 0.05 ml of 2 M nitric acid; the colour changes to brownish red.

**Tests**

**Other tests.** Complies with the tests stated under Oral Liquids.

**Assay.** Weigh accurately about 50 g and add sufficient 5 M ammonia to make the solution alkaline to litmus paper, extract with four quantities, each of 25 ml, of chloroform, washing each extract with the same 5 ml of water. Combine the extracts and evaporate until the volume is reduced to 15 ml. Titrate with 0.02 M perchloric acid, using quinaldine red solution as indicator. Carry out a blank titration.

1 ml of 0.02 M perchloric acid is equivalent to 0.004165 g of C_{23}H_{30}N_{2}O_{4}.5H_{2}O.

Determine the weight per ml of the linctus (2.4.29), and calculate the content of C_{23}H_{30}N_{2}O_{4}.5H_{2}O, weight in volume.
Storage. Store protected from light.

Labelling. The label states the strength in terms of the equivalent amount of pholcodine.

Phosphoric Acid
Orthophosphoric Acid; Concentrated Phosphoric Acid
H₃PO₄  Mol. Wt. 98.0

Phosphoric acid contains not less than 84.0 per cent w/w and not more than 90.0 per cent w/w of H₃PO₄.

Description. A clear, colourless, syrupy liquid; corrosive. When kept at a low temperature it may solidify, producing a mass of colourless crystals which do not melt until the temperature reaches 28º.

Identification
A. Dilute with water; the solution is strongly acidic.
B. Dilute 10.0 g to 150 ml with water (solution A). Neutralise with 2 M sodium hydroxide; the resulting solution gives the reactions of phosphates (2.3.1).

Tests
Appearance of solution. Solution A is clear (2.4.1), and colourless (2.4.1).

Arsenic (2.3.10). Dissolve 5.0 g in 50 ml of water and add 10 ml of stannated hydrochloric acid; the resulting solution complies with the limit test for arsenic (2 ppm).

Heavy metals (2.3.13). Dilute 1.2 ml with 10 ml of water, neutralise with dilute ammonia solution, add sufficient dilute acetic acid to render the solution acidic and then dilute to 25 ml with water. The resulting solution complies with the limit test for heavy metals, Method A (10 ppm).

Iron (2.3.14). 10 ml of solution A complies with the limit test for iron (60 ppm).

Chlorides (2.3.12). 3 ml of solution A complies with the limit test for chlorides (50 ppm).

Sulphates (2.3.17). 20 ml of solution A complies with the limit test for sulphates (100 ppm).

Alkali phosphates. To 1.7 g in a graduated cylinder add 6 ml of ether and 2 ml of ethanol (95 per cent); no turbidity is produced.

Aluminium and calcium. To 1.7 g add 10 ml of water and 8 ml of dilute ammonia solution; the solution remains clear.

Hypophosphorus acid and phosphorous acid. To 5 ml of solution A add 2 ml of a 1.7 per cent w/v solution of silver nitrate and heat on a water-bath for 5 minutes; the appearance of the solution does not change.

Assay. Weigh accurately about 1.0 g, add a solution of 10 g of sodium chloride in 30 ml of water and titrate with 1 M sodium hydroxide using dilute phenolphthalein solution as indicator.

1 ml of 1 M sodium hydroxide is equivalent to 0.04900 g of H₃PO₄.

Storage. Store protected from moisture, in glass containers.

Physostigmine Salicylate
Eserine Salicylate

C₁₅H₂₁N₃O₂.C₇H₆O₃  Mol. Wt. 413.5

Physostigmine Salicylate is (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate salicylate.

Physostigmine Salicylate contains not less than 98.5 per cent and not more than 101.0 per cent of C₁₅H₂₁N₃O₂, C₇H₆O₃, calculated on the dried basis.

Description. A colourless or faintly yellow crystals, turning red gradually under the action of air and light and rapidly in presence of moisture; odourless.

Identification
Test A may be omitted if tests B, C and D are carried out. Test C may be omitted if tests A, B and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with physostigmine salicylate RS.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).

C. To a 1 per cent w/v solution add 1 M sodium hydroxide; a white precipitate which turns pink is produced. The precipitate dissolves in an excess of the reagent, producing a red solution.

D. A 0.9 per cent w/v solution in carbon dioxide-free water gives reaction A of salicylates (2.3.1).
Tests

Appearance of solution. Dissolve 0.9 g without heating in 95 ml of carbon dioxide-free water prepared from distilled water, and dilute to 100 ml with the same solvent (solution A). The solution, examined immediately after preparation, is clear (2.4.1), and colourless (2.4.1).

pH (2.4.24). 5.1 to 5.9, determined in solution A immediately after preparation.

Specific optical rotation (2.4.22). –90.0° to –94.0°, determined in solution A immediately after preparation.

Eseridin. To 5 ml of solution A, examined immediately after preparation, add a few crystals of potassium iodate and a drop of 2 M hydrochloric acid and 2 ml of chloroform and shake; the chloroform layer does not turn violet within 1 minute.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 100 volumes of cyclohexane, 23 volumes of 2-propanol and 2 volumes of strong ammonia solution.

Test solution (a). Dissolve 0.2 g of the substance under examination in 10 ml of ethanol (95 per cent).

Test solution (b). Dissolve 0.1 g of the substance under examination in 100 ml of ethanol (95 per cent).

Reference solution (a). A 0.1 per cent w/v solution of physostigmine salicylate RS in ethanol (95 per cent).

Reference solution (b). A 0.01 per cent w/v solution of physostigmine salicylate RS in ethanol (95 per cent).

Apply to the plate 20 µl of each solution. After development, dry the plate in cold air, carry out a second chromatographic development in the same direction, dry the plate in air and spray with freshly prepared acetic potassium iodobismuthate solution and then with hydroperoxide solution (10 vol). Examine the plate within 2 minutes. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (b).

 Sulphates (2.3.17). 15 ml of solution A complies with the limit test for sulphates (0.1 per cent).

Sulphated ash (2.3.18). Not more than 0.1 per cent, determined on the residue obtained in the test for Loss on drying.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105°C.

Assay. Weigh accurately about 0.35 g, dissolve in 50 ml of a mixture of equal volumes of chloroform and anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.04135 g of C15H21N3O2·C7H6O3.

Storage. Store protected from light and moisture.

Physostigmine Injection

Phystostigmine Salicylate Injection; Eserine Salicylate Injection

Phystostigmine Injection is a sterile solution of Physostigmine Salicylate in Water for Injections.

Physostigmine Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of phystostigmine salicylate, C15H21N3O2·C7H6O3.

Identification

A. Warm a volume containing 3 mg of Phystostigmine Salicylate with 0.3 ml of 5 M ammonia; a yellowish red solution is produced which on evaporation gives a bluish residue.

B. The residue obtained in test A dissolves in ethanol (95 per cent) producing a blue solution which, on the addition of 6 M acetic acid, appears blue by transmitted light and exhibits a red fluorescence which intensifies on dilution with water.

C. The residue obtained in test A dissolves in sulphuric acid producing a green solution which, on the gradual addition of ethanol (95 per cent), changes to red but reverts to green when the ethanol is evaporated.

Tests

pH (2.4.24). 4.0 to 6.0.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. Transfer an accurately measured volume containing 30 mg of Phystostigmine Salicylate to a separator, add about 0.25 g of sodium bicarbonate and extract with six quantities, each of 15 ml of chloroform. Filter the combined chloroform extracts through about 10 g of anhydrous sodium sulphate. Add 25 ml of anhydrous glacial acetic acid to the filtrate. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.01 M perchloric acid is equivalent to 0.004135 g of C15H21N3O2·C7H6O3.

Storage. Store protected from light, in single dose containers. The injection should not be used if it is more than slightly discoloured.
Pilocarpine Nitrate

\[
\text{C}_{11}\text{H}_{16}\text{N}_{2}\text{O}_{2}, \text{HNO}_{3}
\]
Mol. Wt. 271.3

Pilocarpine Nitrate is (3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one nitrate.

Pilocarpine Nitrate contains not less than 98.5 per cent and not more than 101.0 per cent of \(\text{C}_{11}\text{H}_{16}\text{N}_{2}\text{O}_{2}, \text{HNO}_{3}\), calculated on the dried basis.

**Description.** Colourless crystals or a white, crystalline powder; odourless; sensitive to light.

**Identification**

*Test A* may be omitted if tests *B, C and D* are carried out. Tests *B and C* may be omitted if tests *A and D* are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pilocarpine nitrate RS.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).

C. Dissolve about 10 mg in 2 ml of water, add 2 drops of a 5 per cent w/v solution of potassium dichromate, 1 ml of hydrogen peroxide solution (10 vol) and 2 ml of chloroform and shake; the chloroform layer turns violet.

D. Gives reaction A of nitrates (2.3.1).

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and not more intensely coloured than reference solution YS6 (2.4.1).

**pH** (2.4.24). 3.5 to 4.5, determined in a 5.0 per cent w/v solution prepared immediately before use in carbon dioxide-free water.

**Specific optical rotation** (2.4.22). +79.5° to +83.0°, determined in a 5.0 per cent w/v solution in carbon dioxide-free water, prepared immediately before use.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

*Mobile phase.* A mixture of 85 volumes of chloroform, 14 volumes of methanol and 1 volume of strong ammonia solution.

*Test solution (a).* Dissolve 0.3 g of the substance under examination in 10 ml of water.

**Pindolol**

\[
\text{C}_{14}\text{H}_{20}\text{N}_{2}\text{O}_{2}
\]
Mol. wt. 248.3

Pindolol is (RS)-1-indol-4-yloxy-3-isopropylaminopropan-2-ol.

Pindolol contains not less than 99.0 per cent and not more than 101.0 per cent of \(\text{C}_{14}\text{H}_{20}\text{N}_{2}\text{O}_{2}\), calculated on the dried basis.

**Description.** A white or almost white, crystalline powder.
Identification

Test A may be omitted if tests B and C are carried out. Test B and C may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pindolol RS.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in a 0.085 per cent v/v solution of hydrochloric acid in methanol shows absorption maxima at about 264 nm and at about 287 nm, and a shoulder at about 275 nm, absorbances at about 264 nm, 0.66 to 0.70 and at about 287 nm, 0.34 to 0.38.

C. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).

Tests

Appearance of solution. A 5.0 per cent w/v solution in dilute acetic acid is clear (2.4.1), and not more intensely coloured than reference solution BYS4 (2.4.1).

Related substances. Determine as rapidly as possible, protected from light.

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A freshly prepared mixture of 50 volumes of ethyl acetate, 50 volumes of methanol and 4 volumes of strong ammonia solution.

Prepare the following solutions immediately before use.

Test solution (a). Dissolve 0.2 g of the substance under examination in 10 ml of a mixture of 99 volumes of methanol and 1 volume of anhydrous glacial acetic acid.

Test solution (b). Dissolve 0.2 g of the substance under examination in 100 ml of a mixture of 99 volumes of methanol and 1 volume of anhydrous glacial acetic acid.

Reference solution (a). A 0.2 per cent w/v solution of pindolol RS in a mixture of 99 volumes of methanol and 1 volume of anhydrous glacial acetic acid.

Reference solution (b). A 0.006 per cent w/v solution of pindolol RS in a mixture of 99 volumes of methanol and 1 volume of anhydrous glacial acetic acid.

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 10 cm. Dry the plate immediately in a current of cold air and examine in ultraviolet at 254 nm without delay. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (b) (0.3 per cent).

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method C (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

Assay. Weigh accurately about 0.2 g, dissolve in 80 ml of methanol. Titrate with 0.1 M hydrochloric acid, determining the end point potentiometrically (2.4.25).

1 ml of 0.1 M hydrochloric acid is equivalent to 0.02483 g of C14H20N2O2.

Storage. Store protected from light and moisture.

Pindolol Tablets

Pindolol Tablets contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of pindolol, C14H20N2O2.

Identification

A. Shake a quantity of the powdered tablets containing 50 mg of Pindolol with 80 ml of ether for 30 minutes, filter and dry the extract with anhydrous sodium sulphate. Filter the extract, remove the ether using a rotary evaporator and dry the residue over phosphorus pentoxide at 110º at a pressure not exceeding 2 kPa for 1 hour. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pindolol RS.

B. When examined in the range 230 nm to 360 nm (2.4.7), the final solution obtained in the Assay shows absorption maxima at about 264 nm and 287 nm.

C. Shake a quantity of the powdered tablets containing 20 mg of Pindolol with 5 ml of a mixture of 99 volumes of methanol and 1 volume of glacial acetic acid for 45 minutes Centrifuge and dilute 1 ml of the supernatant liquid to 50 ml with the acetic acid-methanol mixture. To 2 ml of this solution add 1 ml of dimethylaminobenzaldehyde solution; a violet-blue colour is produced.

Tests

Related substances. Determine as rapidly as possible, protected from light.

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A freshly prepared mixture of 50 volumes of ethyl acetate, 50 volumes of methanol and 4 volumes of strong ammonia solution.
Test solution. Shake a quantity of the powdered tablets containing 20 mg of Pindolol with 5 ml of a mixture of 99 volumes of methanol and 1 volume of glacial acetic acid for 15 minutes, centrifuge and apply the supernatant liquid to the plate as the last solution.

Reference solution (a). Dilute 1 volume of the test solution to 10 volumes with the methanol-acetic acid mixture and further dilute 7 volumes of the solution to 100 volumes with the same solvent mixture.

Reference solution (b). Dilute 1 volume of the test solution to 10 volumes with the methanol-acetic acid mixture and further dilute 3 volumes of this solution to 100 volumes with the same solvent mixture.

Apply to the plate 10 µl of each solution. Allow the mobile phase to rise 10 cm. Dry the plate in air, spray immediately with dimethylaminobenzaldehyde solution and warm at 50º for 20 minutes. Any spot with Rf value of about 0.1 in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) (0.7 per cent). Any other secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (b) (0.3 per cent). Ignore any spot remaining on the line of application.

Other tests. Comply with the tests stated under tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powdered tablets containing about 90 mg of Pindolol and shake with 100.0 ml of methanol for 45 minutes. Centrifuge and dilute 15.0 ml of the supernatant liquid to 100 ml with methanol and measure the absorbance of the resulting solution at the maximum at about 264 nm (2.4.7). Calculate the content of C₁₄H₂₀N₂O₂ taking 338 as the specific absorbance at 264 nm.

Storage. Store protected from light.

Piperazine Adipate

\[
\text{C}_4\text{H}_{10}\text{N}_2, \text{C}_6\text{H}_{10}\text{O}_4 \quad \text{Mol. Wt. 232.3}
\]

Piperazine Adipate contains not less than 98.0 per cent and not more than 101.0 per cent of \(\text{C}_4\text{H}_{10}\text{N}_2, \text{C}_6\text{H}_{10}\text{O}_4\), calculated on the anhydrous basis.

Description. A white, crystalline powder.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with piperazine adipate RS or with the reference spectrum of piperazine adipate.

B. In the test for Related substances, examine the plate after spraying with both the ninhydrin and iodine solutions. The principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).

C. Dissolve 0.1 g in 5 ml of water, add 0.5 g of sodium bicarbonate, 0.5 ml of a freshly prepared 5.0 per cent w/v solution of potassium ferricyanide and 0.1 ml of mercury, shake vigorously for 1 minute and allow to stand for 20 minutes; a reddish colour slowly develops.

Tests

Appearance of solution. A 5.0 per cent w/v solution is clear (2.4.1), and not more intensely coloured than reference solution BS8 (2.4.1).

\[ \text{pH (2.4.24). 5.0 to 6.0, determined in a 5.0 per cent w/v solution.} \]

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A freshly prepared mixture of 80 volumes of acetone and 20 volumes of strong ammonia solution.

Test solution (a). Dissolve 1 g of the substance under examination in 10 ml of a mixture of 3 volumes of strong ammonia solution and 2 volumes of ethanol.

Test solution (b). Dissolve 1 g of the substance under examination in 100 ml of the same solvent mixture.

Reference solution (a). A 1 per cent w/v solution of piperazine adipate RS in the same solvent mixture.

Reference solution (b). A 0.025 per cent w/v solution of ethylenediamine in the same solvent mixture.

Reference solution (c). A 0.025 per cent w/v solution of triethylenediamine in the same solvent mixture.

Reference solution (d). A solution containing 0.025 per cent w/v of triethylenediamine and 1 per cent w/v of the substance under examination in the same solvent mixture.

Apply to the plate 5 µl of each solution. After development, dry the plate at 105º, spray with a 0.3 per cent w/v solution of ninhydrin in a mixture of 3 volumes of anhydrous acetic acid and 100 volumes of 1-butanol and then with a 0.15 per cent w/v solution of ninhydrin in ethanol and dry at 105º for 10
minutes. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (b). Spray the plate with 0.05 M iodine and allow to stand for about 10 minutes. Any spot corresponding to triethylenediamine in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (c). The test is not valid unless the chromatogram obtained with reference solution (d) shows two separated spots. Ignore any spot remaining on the line of application.

Heavy metals (2.3.13). Dissolve 1.0 g in 20 ml of water, 0.5 ml of 0.1 M hydrochloric acid and add sufficient water to produce 25 ml. The resulting solution complies with the limit test for heavy metals, Method A (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Water (2.3.43). Not more than 0.5 per cent, determined on 1.0 g.

Assay. Weigh accurately about 0.2 g, dissolve in 10 ml of anhydrous glacial acetic acid with gentle heating and dilute to 70 ml with the same solvent. Titrate with 0.1 M perchloric acid, using 0.25 ml of 1-naphtholbenzein solution as indicator and titrating until the colour of the solution changes from brownish yellow to green. Carry out a blank titration. 1 ml of 0.1 M perchloric acid is equivalent to 0.01161 g of C4H10N2, C6H10O4.

Storage. Store protected from moisture.

Piperazine Adipate Tablets

Piperazine Adipate Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of piperazine hydrate, C4H10N2, 6H2O.

Identification

A. Extract a quantity of the powdered tablets containing 1 g of Piperazine Hydrate with 20 ml of water and filter. Dilute 1 ml of the filtrate to 5 ml with water, add 0.5 g of sodium bicarbonate, 0.5 ml of a freshly prepared 5.0 per cent w/v solution of potassium ferricyanide and 0.1 ml of mercury, shake vigorously for 1 minute and allow to stand for 20 minutes; a reddish colour slowly develops.

B. To 10 ml of the filtrate obtained in test A add 5 ml of hydrochloric acid and extract with three quantities, each of 10 ml, of ether, evaporate the combined ether extracts to dryness; the residue, after washing with a small volume of water and drying at 105\(^{\circ}\), melts at about 152\(^{\circ}\) (2.4.21).

Tests

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.2 g of Piperazine Hydrate, shake with 10 ml of water for 1 hour, filter and wash the residue with two quantities, each of 10 ml, of water. To the combined extract and washings add 5 ml of 1 M sulphuric acid and 50 ml of picric acid solution, bring to boil, allow to stand for 1 hour and filter through a sintered-glass crucible (porosity No. 4) and wash the residue with successive quantities, each of 10 ml, of anhydrous glacial acetic acid until the washings are free from sulphate. Wash with five quantities, each of 10 ml, of ethanol and dry to constant weight at 105\(^{\circ}\). 1 g of the residue is equivalent to 0.3567 g of C10H10N2, 6H2O.

Storage. Store protected from moisture.

Labelling. The label states the strength in terms of the equivalent amount of piperazine hydrate.

Piperazine Citrate

\[
\begin{align*}
\text{Piperazine Citrate} & \quad \text{Mol. Wt. 642.7 (anhydrous)} \\
(C_4H_{10}N_2)_{3},2C_6H_8O_7 & \quad \text{(C4H10N2)3,2C6H8O7}\n\end{align*}
\]

Piperazine Citrate is a salt of piperazine with citric acid containing a variable amount of water of crystallisation.

Piperazine Citrate contains not less than 98.0 per cent and not more than 101.0 per cent of (C4H10N2)3, 2C6H8O7, calculated on the anhydrous basis.

Description. A white, granular powder; almost odourless.

Identification

Test A may be omitted if tests B and C are carried out. Test B may be omitted if tests A and C are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with piperazine citrate RS or with the reference spectrum of piperazine citrate.

B. In the test for Related substances, examine the plate after spraying with both the ninhydrin solutions. The principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).
C. A 10 per cent w/v solution gives the reactions of citrates (2.3.1).

Tests

Appearance of solution. A 5.0 per cent w/v solution is clear (2.4.1), and not more intensely coloured than reference solution BS8 (2.4.1).

pH (2.4.24). 5.0 to 6.0, determined in a 5.0 per cent w/v solution.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A freshly prepared mixture of 80 volumes of acetone and 20 volumes of strong ammonia solution.

Test solution (a). Dissolve 1 g of the substance under examination in 10 ml of a mixture of 3 volumes of strong ammonia solution and 2 volumes of ethanol.

Test solution (b). Dissolve 1 g of the substance under examination in 100 ml of the same solvent mixture.

Reference solution (a). A 1 per cent w/v solution of piperazine citrate RS in the same solvent mixture.

Reference solution (b). A 0.025 per cent w/v solution of ethylenediamine in the same solvent mixture.

Reference solution (c). A 0.025 per cent w/v solution of triethylenediamine in the same solvent mixture.

Reference solution (d). A solution containing 0.025 per cent w/v of triethylenediamine and 1 per cent w/v of the substance under examination in the same solvent mixture.

Apply to the plate 5 µl of each solution. After development, dry the plate at 105º, spray with a 0.3 per cent w/v solution of ninhydrin in a mixture of 3 volumes of anhydrous acetic acid and 100 volumes of l-butanol and then with a 0.15 per cent w/v solution of ninhydrin in ethanol and dry at 105º for 10 minutes. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (b). Spray the plate with 0.05 M iodine and allow to stand for about 10 minutes. Any spot corresponding to triethylenediamine in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (c). The test is not valid unless the chromatogram obtained with reference solution (d) shows two separated spots. Ignore any spot remaining on the line of application.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method A (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Water (2.4.19). 10.0 to 14.0 per cent, determined on 0.3 g.

Assay. Weigh accurately about 0.2 g, dissolve in 10 ml of anhydrous glacial acetic acid with gentle heating and dilute to 70 ml with the same solvent. Titrate with 0.1 M perchloric acid, using 0.25 ml of 1-naphthalbenzein solution as indicator and titrating until the colour of the solution changes from brownish yellow to green. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01071 g of \((\text{C}_{4}\text{H}_{10}\text{N}_{2})_3\text{C}_6\text{H}_8\text{O}_7\).

Storage. Store protected from light and moisture.

Piperazine Citrate Syrup

Piperazine Citrate Oral Solution; Piperazine Citrate Elixir

Piperazine Citrate Syrup is a solution of Piperazine Citrate in a suitable flavoured Vehicle.

Piperazine Citrate Syrup contains the equivalent of not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of piperazine hydrate, \(\text{C}_{4}\text{H}_{10}\text{N}_{2}, 6\text{H}_{2}\text{O}\).

Identification

A. To 1 ml add 5 ml of 2 M hydrochloric acid and, with stirring, 1 ml of a freshly prepared 50 per cent w/v solution of sodium nitrite, cool in ice for 15 minutes, induce crystallisation, wash the crystalline precipitate with water and dry at 105º. The crystals melt at about 159º (2.4.21).

B. Warm 10 ml with activated charcoal and filter. Boil a portion of the filtrate with an excess of mercuric sulphate solution, filter, boil the filtrate and add 0.25 ml of dilute potassium permanganate solution; the permanganate solution is decolourised and a white precipitate is produced.

C. Acidify a portion of the filtrate obtained in test B with 1 M sulphuric acid, add 0.25 ml of dilute potassium permanganate solution, warm until the colour is discharged and add an excess of bromine water; a white precipitate is produced either immediately or on cooling.

Tests

Other tests. Complies with the tests stated under Oral Liquids.

Assay. Weigh accurately a quantity containing about 0.2 g of Piperazine Hydrate, add 3.5 ml of 0.5 M sulphuric acid and 10 ml of water, add 100 ml of picric acid solution, heat on a water-bath for 15 minutes, allow to stand for 1 hour and filter through a sintered-glass crucible (porosity No. 4). Wash the residue with successive quantities, each of 10 ml, of a mixture of equal volumes of a saturated solution of picric acid and water until the washings are free from sulphate. Wash the residue with five quantities, each of 10 ml, of ethanol and dry to constant weight at 105º.

1 g of the residue is equivalent to 0.3567 g of \((\text{C}_{4}\text{H}_{10}\text{N}_{2})_3\text{C}_6\text{H}_8\text{O}_7\).
Determine the weight per ml of the syrup (2.4.29), and calculate the content of C₄H₁₀N₂, 6H₂O, weight in volume.

**Storage.** Store protected from light.

**Labelling.** The label states the strength in terms of the equivalent amount of piperazine hydrate.

### Piperazine Hydrate

![Piperazine Hydrate](image)

C₄H₁₀N₂, 6H₂O  
Mol. Wt. 194.2

Piperazine Hydrate contains not less than 98.0 per cent and not more than 101.0 per cent of C₄H₁₀N₂, 6H₂O.

**Description.** Colourless, glassy deliquescent crystals.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with piperazine hydrate RS.

B. In the test for Related substances, examine the plate after spraying with both the ninhydrin solutions. The principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).

C. Dissolve 0.2 g in 5 ml of dilute hydrochloric acid, add 0.5 g of sodium nitrite and heat to boiling. Cool in ice for 15 minutes, scratching the walls of the container with a glass rod and filter. The crystals, after washing with 10 ml of ice-cold water and drying at 105º, melt at about 159º (2.4.21).

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and not more intensely coloured than reference solution BS8 (2.4.1).

**pH** (2.4.24). 10.5 to 12.0, determined in a 5.0 per cent w/v solution in carbon dioxide-free water.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A freshly prepared mixture of 80 volumes of acetone and 20 volumes of strong ammonia solution.

Test solution (a). Dissolve 1 g of the substance under examination in 10 ml of a mixture of 3 volumes of strong ammonia solution and 2 volumes of ethanol.

Test solution (b). Dissolve 1 g of the substance under examination in 100 ml of the same solvent mixture.

Reference solution (a). A 1 per cent w/v solution of piperazine hydrate RS in the same solvent mixture.

Reference solution (b). A 0.025 per cent w/v solution of ethylenediamine in the same solvent mixture.

Reference solution (c). A 0.025 per cent w/v solution of triethylenediamine in the same solvent mixture.

Reference solution (d). A solution containing 0.025 per cent w/v of triethylenediamine and 1 per cent w/v of the substance under examination in the same solvent mixture.

Apply to the plate 5 µl of each solution. After development, dry the plate at 105º, spray with a 0.3 per cent w/v solution of ninhydrin in a mixture of 3 volumes of anhydrous acetic acid and 100 volumes of 1-butanol and then with a 0.15 per cent w/v solution of ninhydrin in ethanol and dry at 105º for 10 minutes. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (b). Spray the plate with 0.05 M iodine and allow to stand for about 10 minutes. Any spot corresponding to triethylenediamine in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (c). The test is not valid unless the chromatogram obtained with reference solution (d) shows two separated spots. Ignore any spot remaining on the line of application.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method A (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Assay.** Weigh accurately about 0.2 g, dissolve in 10 ml of anhydrous glacial acetic acid with gentle heating and dilute to 70 ml with the same solvent. Titrate with 0.1 M perchloric acid, using 0.25 ml of 1-naphtholbenzein solution as indicator and titrating until the colour of the solution changes from brownish yellow to green. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.009705 g of C₄H₁₀N₂, 6H₂O.

**Storage.** Store protected from light and moisture.

### Piperazine Phosphate

C₄H₁₀N₂, H₃PO₄, H₂O  
Mol. Wt. 202.2

Piperazine Phosphate contains not less than 98.5 per cent and not more than 100.5 per cent of C₄H₁₀N₂, H₃PO₄, calculated on the anhydrous basis.
**Description.** A white, crystalline powder; odourless or almost odourless.

**Identification**

A. Dissolve 0.2 g in 5 ml of *dilute hydrochloric acid*, add 0.5 g of *sodium nitrite* and heat to boiling. Cool in ice for 15 minutes, scratching the walls of the container with a glass rod and filter. The crystals, after washing with 10 ml of ice-cold *water* and drying at 105º, melt at about 159º (2.4.21).

B. Dissolve 0.1 g in 5 ml of *water*, add 0.5 g of *sodium bicarbonate*, 0.5 ml of a freshly prepared 5.0 per cent w/v solution of *potassium ferricyanide* and 0.1 ml of *mercury*, shake vigorously for 1 minute and allow to stand for 20 minutes; a reddish colour slowly develops.

C. Gives the reactions of phosphates (2.3.1).

**Tests**

**pH** (2.4.24). 6.0 to 6.5, determined in a 1.0 per cent w/v solution.

**Heavy metals** (2.3.13). Dissolve 1.0 g in 20 ml of 2 M *acetic acid* and add sufficient *water* to produce 25 ml. The solution complies with the limit test for heavy metals, Method A (20 ppm).

**Water** (2.3.43). 8.0 to 9.5 per cent, determined on 0.25 g.

**Assay.** Weigh accurately about 0.2 g, dissolve in a mixture of 3.5 ml of 0.5 M *sulphuric acid* and 10 ml of *water*. Add 100 ml of *picric acid solution*, heat on a water-bath for 15 minutes and allow to stand for 1 hour. Filter through a sintered-glass crucible (porosity No. 4) and wash the residue with successive quantities, each of 10 ml, of a mixture of equal volumes of a saturated solution of *picric acid* and *water* until the washings are free from sulphate. Wash the residue with five quantities, each of 10 ml, of *ethanol* and dry to constant weight at 105º.

1 g of the residue is equivalent to 0.3382 g of C₄H₁₀N₂, H₃PO₄.

**Storage.** Store protected from moisture.

**Piperazine Phosphate Tablets**

If the tablets are intended to be chewed before swallowing they may contain suitable flavouring agents.

Piperazine Phosphate Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of piperazine phosphate, C₄H₁₀N₂, H₃PO₄, H₂O.

**Identification**

Extract a quantity of the powder containing 1 g of Piperazine Phosphate with 20 ml of *water* and filter. The filtrate complies with the following tests.

**Tests**

**Disintegration.** The test does not apply to Piperazine Phosphate Tablets intended to be chewed before swallowing.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.15 g of Piperazine Phosphate, shake with 10 ml of *water* for 1 hour, filter and wash the residue with two quantities, each of 10 ml, of *water*. To the combined extract and washings add 5 ml of 1 M *sulphuric acid* and 50 ml of *picric acid solution*, boil, allow the mixture to stand for several hours and filter through a sintered glass crucible (porosity No. 4). Wash the residue with successive quantities, each of 10 ml, of *ethanol* and dry to constant weight at 105º.

1 g of the residue is equivalent to 0.3714 g of C₁₅H₁₃N₃O₄S, H₂O.

**Storage.** Store protected from moisture.

**Labelling.** The label states, where applicable, that the tablets are to be chewed before swallowing.

**Piroxicam**

![Piroxicam Structure]

C₁₅H₁₃N₃O₄S

Mol. Wt. 331.4

Piroxicam is 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide.
Piroxicam contains not less than 97.0 per cent and not more than 103.0 per cent of C\textsubscript{15}H\textsubscript{13}N\textsubscript{3}O\textsubscript{4}S, calculated on the anhydrous basis.

**Description.** An off-white to light tan or light yellow powder; odourless.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with piroxicam RS or with the reference spectrum of piroxicam.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.01 M methanolic hydrochloric acid shows absorption maxima at about 242 nm and 334 nm and a minimum at about 270 nm; absorbance at about 334 nm, about 0.87.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 95 volumes of toluene and 5 volumes of acetic acid.

**Test solution.** Dissolve 0.1 g of the substance under examination in 100 ml of a mixture of equal volumes of chloroform and methanol.

**Reference solution.** A 0.1 per cent w/v solution of piroxicam RS in a mixture of equal volumes of chloroform and methanol.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

**Tests**

**Heavy metals** (2.3.13). 0.4 g complies with the limit test for heavy metals, Method B (50 ppm).

**Sulphated ash** (2.3.18). Not more than 0.3 per cent.

**Water** (2.3.43). Not more than 0.5 per cent, determined on 2.0 g.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** A 0.005 per cent w/v solution of the substance under examination in 0.1 M methanolic hydrochloric acid.

**Reference solution.** A 0.005 per cent w/v solution of piroxicam RS in 0.1 M methanolic hydrochloric acid.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 45 volumes of methanol and 55 volumes of a buffer solution prepared by diluting a mixture of 7.72 g of anhydrous citric acid in 400 ml of water and 5.35 g of sodium phosphate in 100 ml of water to 1000 ml with water,
- flow rate. 1.2 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution. Calculate the content of C\textsubscript{15}H\textsubscript{13}N\textsubscript{3}O\textsubscript{4}S.

**Storage.** Store protected from light and moisture.

---

**Piroxicam Capsules**

Piroxicam Capsules contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of piroxicam, C\textsubscript{15}H\textsubscript{13}N\textsubscript{3}O\textsubscript{4}S.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 95 volumes of toluene and 5 volumes of acetic acid.

**Test solution.** Dissolve a portion of the contents of the capsules in sufficient of a mixture of equal volumes of chloroform and methanol to obtain a solution containing about 0.1 per cent w/v of Piroxicam. Shake for 10 minutes, filter and use the filtrate.

**Reference solution.** A 0.1 per cent w/v solution of piroxicam RS in a mixture of equal volumes of chloroform and methanol.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

**Tests**

**Dissolution** (2.5.2).

Apparatus No. 2

Medium. 900 ml of 0.1 M hydrochloric acid

Speed and time. 100 rpm and 45 minutes.

Withdraw 10 ml of the medium and filter. Measure the absorbance of the filtrate (2.4.7), suitably diluted if necessary, at the maximum at about 242 nm. Calculate the content of C\textsubscript{15}H\textsubscript{13}N\textsubscript{3}O\textsubscript{4}S, in the medium taking 352 as the specific absorbance at 242 nm.
D. Not less than 75 per cent of the stated amount of C_{15}H_{13}N_{3}O_{4}S.

**Uniformity of content.** *(For capsules containing 10 mg or less)* — Comply with the test stated under Capsules.

Test solution. Dissolve the contents of a capsule in 100.0 ml of 0.1 M methanolic hydrochloric acid and filter. Dilute further if necessary.

Determine by liquid chromatography (2.4.14) using the chromatographic system and the reference solution described under Assay.

Calculate the content of C_{15}H_{13}N_{3}O_{4}S in the capsule.

**Water** (2.3.43). Not more than 8.0 per cent, determined on 0.25 g.

**Other tests.** Comply with the tests stated under Capsules.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve an accurately weighed quantity of the mixed contents of the capsules containing about 50 mg of Piroxicam in 100.0 ml of 0.1 M methanolic hydrochloric acid.

Further dilute 1.0 ml of the solution to 10.0 ml with the same solvent.

**Reference solution.** A 0.005 per cent w/v solution of piroxicam RS in 0.1 M methanolic hydrochloric acid.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 45 volumes of methanol and 55 volumes of a buffer solution prepared by diluting a mixture of 7.72 g of anhydrous citric acid in 400 ml of water and 5.35 g of sodium phosphate in 100 ml of water to 1000 ml with water,
- flow rate. 1.2 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution.

Calculate the content of C_{15}H_{13}N_{3}O_{4}S in the capsules.

**Storage.** Store protected from light and moisture.

---

**Plaster Of Paris**

Dried Calcium Sulphate; Exsiccated Calcium Sulphate

CaSO_{4}.\frac{1}{2}H_{2}O  
Mol. Wt. 145.2

Plaster of Paris is prepared by heating powdered gypsum, CaSO_{4}.\frac{1}{2}H_{2}O, at about 150° in a controlled manner such that it is substantially converted into the hemihydrate, CaSO_{4}.\frac{1}{2}H_{2}O, with minimum production of the anhydrous phases of calcium sulphate. It may contain suitable accelerators or decelerators.

**Description.** A white or almost white powder; odourless or almost odourless; hygroscopic.

**Identification**

Gives the reactions of calcium salts and of sulphates (2.3.1).

**Tests**

**pH** (2.4.24). 6.5 to 9.0, determined in a 20.0 per cent w/v slurry in *water*.

**Acid insoluble matter.** Dissolve 0.5 g in 30 ml of a mixture of 1 volume of *hydrochloric acid* and 2 volumes of *water* and evaporate to dryness in a dish on a *water*-bath. Heat for 2 hours at 120° and again add 20 ml of the acid mixture. Warm for a few minutes and filter. Wash the residue with warm *water* until free from chlorides, dry, ignite and weigh. The residue weighs not more than 5 mg (1.0 per cent).

**Setting properties.** 20 g mixed with 10 ml of *water* at 15° to 20° in a cylindrical mould about 2.4 cm in diameter sets in not less than 4 minutes and not more than 6 minutes. The mass thus formed, after standing for 3 hours, possesses sufficient hardness to resist pressure of the fingers at the edges, which retain their sharpness of outline and do not crumble under pressure.

**Loss on ignition** (2.4.20). 4.5 to 8.0 per cent, determined by igniting to constant weight at red heat.

**Storage.** Store protected from moisture

---

**Polyethylene Glycol 1500**

Macrogol 1500

Polyethylene Glycol 1500 is a mixture of the polycondensation products of ethylene oxide and water obtained under controlled conditions. It is represented by the formula HOCH_{2}[CH_{2}OCH_{2}]_{n}CH_{2}OH, where *n* is between 28 and 36.

**Description.** A white or creamy white, soft, wax-like solid; odour, faint and characteristic.

**Tests**

**Appearance of solution** (2.4.1). A 25.0 per cent w/v solution is not more intensely coloured than reference solution BYS6.

**pH** (2.4.24). 4.0 to 7.0, determined in a 5.0 per cent w/v solution.

**Freezing point** (2.4.11). 42° to 46°.

**Hydroxyl value** (2.3.27). 70 to 86, determined on 5.0 g.

**Viscosity** (2.4.28). 25 mm²s⁻¹ to 32 mm²s⁻¹, determined at 100° by Method A using a U-tube viscometer (size D).
Arsenic (2.3.10). Mix 3.3 g with 3 g of anhydrous sodium carbonate, add 10 ml of bromine solution and mix thoroughly. Evaporate to dryness on a water-bath, gently ignite and dissolve the cooled residue in 16 ml of brominated hydrochloric acid and 45 ml of water. Remove the excess of bromine with 2 ml of stannous chloride solution AsT. The resulting solution complies with the limit test for arsenic (3 ppm).

Heavy metals (2.3.13). Dissolve 4.0 g in 5 ml of a 1.0 per cent w/v solution of hydrochloric acid and sufficient water to produce 25 ml. The solution complies with the limit test for heavy metals, Method A (5 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Storage. Store protected from moisture.

**Polyethylene Glycol 4000**

Macrogol 4000

Polyethylene Glycol 4000 is a mixture of the polycondensation products of ethylene oxide and water obtained under controlled conditions. It is represented by the formula HOCH₂[CH₂OCH₂]ₙCH₂OH, where \( n \) is between 69 and 84.

**Description.** A creamy white, hard, wax-like solid or flakes; odour, faint and characteristic.

**Tests**

**Appearance of solution** (2.4.1). A 20.0 per cent w/v solution is not more intensely coloured than reference solution BYS6.

**pH** (2.4.24). 4.5 to 7.5, determined in a 5.0 per cent w/v solution.

**Freezing point** (2.4.11). 53º to 56º.

**Hydroxyl value** (2.4.27). 30 to 36, determined on 20.0 g.

**Viscosity** (2.4.28). 76 mm²s⁻¹ to 110 mm²s⁻¹, determined at 100º by Method A using a U-tube viscometer (size E).

Arsenic (2.3.10). Mix 3.3 g with 3 g of anhydrous sodium carbonate, add 10 ml of bromine solution and mix thoroughly. Evaporate to dryness on a water-bath, gently ignite and dissolve the cooled residue in 16 ml of brominated hydrochloric acid and 45 ml of water. Remove the excess of bromine with 2 ml of stannous chloride solution AsT. The resulting solution complies with the limit test for arsenic (3 ppm).

**Heavy metals** (2.3.13). Dissolve 4.0 g in 5 ml of a 1.0 per cent w/v solution of hydrochloric acid and sufficient water to produce 25 ml. The solution complies with the limit test for heavy metals, Method A (5 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Storage.** Store protected from moisture.

**Polyethylene Glycol 6000**

Macrogol 6000

Polyethylene Glycol 6000 is a mixture of the polycondensation products of ethylene oxide and water obtained under controlled conditions. It is represented by the formula HOCH₂[CH₂OCH₂]ₙCH₂OH, where \( n \) is between 112 and 158.

**Description.** A white to creamy white, wax-like solid or flakes; odour, faint and characteristic.

**Tests**

**Appearance of solution** (2.4.1). A 15.0 per cent w/v solution is not more intensely coloured than reference solution BYS6.

**pH** (2.4.24). 4.5 to 7.5, determined in a 5.0 per cent w/v solution.

**Freezing point** (2.4.11). 56º to 60º.

**Viscosity** (2.4.28). 250 mm²s⁻¹ to 390 mm²s⁻¹, determined at 100º by Method A using a U-tube viscometer (size F).

Arsenic (2.3.10). Mix 3.3 g with 3 g of anhydrous sodium carbonate, add 10 ml of bromine solution and mix thoroughly. Evaporate to dryness on a water-bath, gently ignite and dissolve the cooled residue in 16 ml of brominated hydrochloric acid and 45 ml of water. Remove the excess of bromine with 2 ml of stannous chloride solution AsT. The resulting solution complies with the limit test for arsenic (3 ppm).

**Heavy metals** (2.3.13). Dissolve 4.0 g in 5 ml of a 1.0 per cent w/v solution of hydrochloric acid and sufficient water to produce 25 ml. The resulting solution complies with the limit test for heavy metals, Method A (5 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Storage.** Store protected from moisture.

**Polysorbate 20**

Polyoxyethylene 20 Sorbitan Monolaurate

\[
\text{HO(H}_2\text{CH}_2\text{CO)}_w \text{(OCH}_2\text{CH}_2)_x\text{OH} \\
\text{(OCH}_2\text{CH}_2)_y\text{OH} \text{C}_{11}\text{H}_{23}
\]

\[ w + x + y + z = 20 \]

Polyoxyethylene 20 Sorbitan Monolaurate

Polysorbate 20 is a mixture of partial lauric esters of D-glucitol and its anhydrides copolymerised with approximately 20 moles
of ethylene oxide for each mole of D-glucitol and its anhydrides. The lauric acid used for the esterification may contain other fatty acids.

**Description.** A clear or slightly opalescent, oily, yellowish or brownish yellow liquid; odour, faint and characteristic.

**Identification**

A. Dissolve 0.5 g in water at about 50º and dilute to 10 ml with the same solvent; the solution produces a copious foam on shaking. Add 0.5 g of sodium chloride and heat to boiling; the resulting cloudiness disappears during cooling to about 50º.

B. Dissolve 0.1 g in 5 ml of chloroform, add 0.1 g of potassium thiocyanate and 0.1 g of cobalt nitrate and stir with a glass rod; a blue colour is produced.

**Tests**

**pH** (2.4.24). 5.0 to 7.0, determined in a 5.0 per cent w/v solution in carbon dioxide-free water.

**Acid value** (2.3.23). Not more than 2.0, determined on 5.0 g.

**Hydroxyl value** (2.3.27). 96 to 108, determined on 2.0 g.

**Saponification value** (2.3.37). 40 to 50, using 15 ml of 0.5 M ethanolic potassium hydroxide and diluting with 50 ml of water before carrying out the titration.

**Iodine value** (2.3.28). Not more than 5.0, determined by the iodine bromide method.

**Heavy metals** (2.3.13). 2.0 g complies with the limit test for heavy metals, Method B (10 ppm).

**Reducing impurities.** Dissolve 2.0 g in 25 ml of hot water, add 25 ml of 1 M sulphuric acid and 0.1 ml of ferroin solution and titrate with 0.01 M ceric ammonium sulphate shaking continuously until the colour changes from red to greenish blue persists for 30 seconds. Carry out a blank titration. Not more than 2.0 ml of 0.01 M ceric ammonium sulphate is required.

**Sulphated ash.** Not more than 0.2 per cent, determined by the following method. Weigh accurately about 2.0 g in a silica or platinum crucible, add 0.5 ml of sulphuric acid and heat on a water-bath for 2 hours. Carefully ignite at a low temperature until thoroughly charred. Add to the carbonised mass 2 ml of nitric acid and 0.25 ml of sulphuric acid, cautiously heat until white fumes are evolved and then ignite at 600º until the carbon is completely burnt off. Allow to cool, weigh and repeat the operation for periods of 15 minutes until two successive weighings do not differ by more than 0.5 mg.

**Water** (2.3.43). Not more than 3.0 per cent, determined on 1.0 g.

**Storage.** Store protected from light and moisture.

---

**Polysorbate 80**

Polyoxyethylene 80 Sorbitan Monooleate

\[
\text{HO}((\text{H}_2\text{CH}_2\text{CO})_w (\text{OCH}_2\text{CH}_2)_x \text{OH}) (O\text{CH}_2\text{CH}_2)_y \text{OH} \quad \text{w}+x+y+z = 20
\]

Polysorbate 80 is a mixture of partial oleic esters of D-glucitol and its anhydrides copolymerised with approximately 20 moles of ethylene oxide for each mole of D-glucitol and its anhydrides.

**Description.** A clear or almost clear, oily, yellowish or brownish yellow liquid; odour, faint and characteristic.

**Identification**

A. Dissolve 0.5 g in water at about 50º and dilute to 10 ml with the same solvent; the solution produces a copious foam on shaking. Add 0.5 g of sodium chloride and heat to boiling; the resulting cloudiness disappears during cooling to about 50º.

B. Dissolve 0.1 g in 5 ml of chloroform, add 0.1 g of potassium thiocyanate and 0.1 g of cobalt nitrate and stir with a glass rod; a blue colour is produced.

C. To 2 ml of a 5 per cent w/v solution add 0.5 ml of bromine water; the bromine is decolourised.

**Tests**

**pH** (2.4.24). 6.0 to 8.0, determined in a 5.0 per cent w/v solution in carbon dioxide-free water.

**Acid value** (2.3.23). Not more than 2.0, determined on 5 g.

**Hydroxyl value** (2.3.27). 65 to 80, determined on 2.0 g.

**Saponification value** (2.3.37). 45 to 55, using 15 ml of 0.5 M ethanolic potassium hydroxide and diluting with 50 ml of water before carrying out the titration.

**Iodine value** (2.3.28). 18 to 24, determined by the iodine bromide method.

**Reducing impurities.** Dissolve 2.0 g in 25 ml of hot water, add 25 ml of 1 M sulphuric acid and 0.1 ml of ferroin solution and titrate with 0.01 M ceric ammonium sulphate shaking continuously until the colour changes from red to greenish blue persists for 30 seconds. Carry out a blank titration. Not more than 5.0 ml of 0.01 M ceric ammonium sulphate is required.

**Heavy metals** (2.3.13). 2.0 g complies with the limit test for heavy metals, Method B (10 ppm).
**Potassium Chloride**  

KCl  

Mol. Wt. 74.6  

Potassium Chloride contains not less than 99.0 per cent and not more than 100.5 per cent of KCl, calculated on the dried basis.  

**Description.** Colourless crystals or a white, crystalline powder; odourless.  

**Identification.**  
Dissolve 10 g in 100 ml of carbon dioxide-free water prepared from distilled water (solution A). The solution gives the reactions of potassium salts and of chlorides (2.3.1).  

**Tests**  

**Appearance of solution.** Solution A is clear (2.4.1), and colourless (2.4.1).  

**Acidity or alkalinity.** 5.0 g dissolved in 50 ml of carbon dioxide-free water requires not more than 0.5 ml of 0.01 M sodium hydroxide or 0.01 M hydrochloric acid for neutralisation to bromothymol blue solution.  

**Arsenic** (2.3.10). Dissolve 10.0 g in 50 ml of water and add 10 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (1 ppm).  

**Barium.** To 5 ml of solution A add 5 ml of water and 1 ml of 1 M sulphuric acid; the solution, after not less than 15 minutes, is not more opalescent than a mixture of 5 ml of solution A and 6 ml of water.  

**Heavy metals** (2.3.13). Dissolve 2.0 g in 10 ml of water to which are added 2 ml of dilute acetic acid and 13 ml of water. The solution complies with the limit test for heavy metals, Method A (10 ppm).  

**Calcium and magnesium.** Dissolve 1 g in 20 ml of water; add 1 ml of dilute ammonia solution and 1 ml of sodium phosphate solution; the solution remains clear.  

**Iron** (2.3.14). 20 ml of solution A complies with the limit test for iron (20 ppm).  

**Bromides.** Dilute 1.0 ml of solution A to 50.0 ml with water. To 5.0 ml of the solution add 2.0 ml of phenol red reagent and 1.0 ml of a 0.01 per cent solution of chloramine T and mix immediately. After exactly 2 minutes, add 0.15 ml of 0.1 M sodium thiosulphate, mix and dilute to 10.0 ml with water. The absorbance of the solution measured at about 590 nm (2.4.7), using water as the blank, is not more than that of a standard prepared at the same time and in the same manner, using 5.0 ml of a 0.0003 per cent w/v solution of potassium bromide (0.1 per cent).  

**Iodides.** Moisten 5 g by adding dropwise, a solution freshly prepared by mixing 25 ml of iodide-free starch solution, 2 ml of 0.5 M sulphuric acid, 0.15 ml of sodium nitrite solution and 25 ml of water and examine the mixture in daylight; the substance shows no blue colour after 5 minutes.  

**Sulphates** (2.3.17). 0.5 g complies with the limit test for sulphates (300 ppm).  

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105º.  

**Assay.** Weigh accurately about 0.15 g, dissolve in 50 ml of water and titrate with 0.1 M silver nitrate using potassium chromate solution as indicator.  

1 ml of 0.1 M silver nitrate is equivalent to 0.007455 g of KCl.  

**Potassium Chloride intended for use in the manufacture of dialysis solutions complies with the following additional requirement.**  

**Aluminium.** Dissolve 4.0 g in 100 ml of water and add 10 ml of acetate buffer pH 6.0. Extract with successive quantities of 20, 20 and 10 ml of a 0.5 per cent w/v solution of 8-hydroxyquinoline in chloroform and dilute the combined extracts to 50 ml with chloroform. Use as the standard solution a mixture of 2 ml of aluminium standard solution (2 ppm Al), 10 ml of acetate buffer pH 6.0 and 98 ml of water treated in the same manner and as the blank solution a mixture of 10 ml of acetate buffer pH 6.0 and 100 ml of water treated in the same manner. Measure the fluorescence of the test and standard solutions (2.4.5), using an excitation wavelength of about 392 nm and emission wavelength of about 518 nm and setting the instrument to zero with the blank solution in each case. The fluorescence of the test is not greater than that of the standard solution (1 ppm).  

Potassium chloride intended for use in the manufacture of Parenteral Preparations or for the preparation of haemodialysis solution complies with the following additional requirement.  

**Sodium.** Not more than 0.1 per cent, determined by atomic absorption spectrophotometry (2.4.2), using a 1.0 per cent
w/v solution and measuring at 589 nm. Use sodium solution AAS, suitably diluted with water, for the standard solutions.

**Storage.** Store protected from moisture.

**Labelling.** The label states whether or not the material is suitable for use in the manufacture of Parenteral Preparations or for the preparation of haemodialysis or dialysis solutions.

### Potassium Chloride And Dextrose Injection

Potassium Chloride in Dextrose Injection; Potassium Chloride and Dextrose Intravenous Infusion; Potassium Chloride and Glucose Intravenous Infusion

Potassium Chloride and Dextrose Injection is a sterile solution of Potassium Chloride and Dextrose in Water for Injections.

Potassium Chloride and Dextrose Injection contains not less than 95.0 per cent and not more than 110.0 per cent of the stated amount of potassium chloride, KCl, and not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of dextrose, C\textsubscript{6}H\textsubscript{12}O\textsubscript{6}. It contains no antimicrobial agent.

**Description.** A clear, colourless or faintly straw-coloured solution.

**Identification**

A. To 1 ml add 0.05 ml of potassium cupri-tartrate solution; the solution remains blue and clear. Heat to boiling, a copious red precipitate is formed.

B. Gives reaction B of potassium salts and reaction A of chlorides (2.3.1).

**Tests**

**pH** (2.4.24). 3.5 to 6.5.

**5-Hydroxymethylfurfural and Related substances.** Dilute a volume containing 1.0 g of Dextrose to 500.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 284 nm, absorbance at about 284 nm (2.4.7); not more than 0.25.

**Heavy metals** (2.3.13). Evaporate a volume containing 4.0 g of Dextrose to 10 ml and add 2 ml of dilute acetic acid and sufficient water to produce 25 ml. The solution complies with the limit test for heavy metals, Method A (5 ppm).

**Bacterial endotoxins** (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** For potassium chloride — Titrate an accurately measured volume containing 0.1 g of Potassium Chloride with 0.1 M silver nitrate using potassium chromate solution as indicator.

1 ml of 0.1 M silver nitrate is equivalent to 0.007455 g of KCl.

**For dextrose —** To an accurately measured volume containing 2 g to 5 g of Dextrose, add 0.2 ml of 05 M ammonia and sufficient water to produce 100.0 ml. Mix well, allow to stand for 30 minutes and measure the optical rotation in a 2-dm tube (2.4.22). The observed rotation in degrees multiplied by 0.9477 represents the weight, in g, of dextrose, C\textsubscript{6}H\textsubscript{12}O\textsubscript{6}, in the volume taken for assay.

**Storage.** Store in single dose containers.

**Labelling.** The label states (1) the strength as the percentages w/v of Potassium Chloride and Dextrose; (2) the total osmotic concentration in mOsmol per litre; (3) where the contents are less than 100 ml, or where the label states that the Injection is not for direct use but is to be diluted before use, the label alternatively may state the total osmolar concentration in mOsmol per ml; (4) the content of potassium in millimoles; (5) that the injection containing visible particles in the solution should not be used.

### Potassium Chloride, Sodium Chloride And Dextrose Injection

Potassium Chloride in Dextrose and Sodium Chloride Injection; Potassium Chloride, Sodium Chloride and Dextrose Intravenous Infusion; Potassium Chloride, Sodium Chloride and Glucose Intravenous Infusion

Potassium Chloride, Sodium Chloride and Dextrose Injection is a sterile solution of Potassium Chloride, Sodium Chloride and Dextrose in Water for Injections.

Potassium Chloride, Sodium Chloride and Dextrose Injection contains not less than 95.0 per cent and not more than 110.0 per cent of the stated amounts of sodium, Na, potassium, K, and chloride, Cl, and not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of dextrose, C\textsubscript{6}H\textsubscript{12}O\textsubscript{6}. It contains no antimicrobial agent.

**Identification**

A. To 1 ml add 0.05 ml of potassium cupri-tartrate solution; the solution remains blue and clear. Heat to boiling, a copious red precipitate is formed.

B. Gives reaction A of potassium salts, reaction B of sodium salts and reaction A of chlorides (2.3.1).

**Tests**

**pH** (2.4.24). 3.5 to 6.5, determined on a portion diluted with water, if necessary, to a concentration of not more than 5.0 per cent of dextrose.
5-Hydroxymethylfurfural and Related substances. Dilute a volume containing 1.0 g of Dextrose to 500.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 284 nm, absorbance at about 284 nm (2.4.7); not more than 0.25.

Heavy metals (2.3.13). Evaporate a volume containing 4.0 g of Dextrose to 10 ml and add 2 ml of dilute acetic acid and sufficient water to produce 25 ml. The solution complies with the limit test for heavy metals, Method A (5 ppm).

Bacterial endotoxins (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. For sodium — Dilute appropriately with water and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 589 nm and using sodium solution FP or sodium solution AAS respectively, suitably diluted with water for the standard solutions.

For potassium — Dilute appropriately with water and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 767 nm and using potassium solution FP or potassium solution AAS respectively, suitably diluted with water for the standard solutions.

For total chlorides — To 20.0 ml add 30 ml of water, 50.0 ml of 0.1 M silver nitrate and 2 ml of nitric acid. Filter, wash the precipitate with water slightly acidified with nitric acid and titrate the excess of silver nitrate with 0.1 M ammonium thiocyanate using ferric ammonium sulphate solution as indicator until a reddish yellow colour is produced. Carry out a blank titration.

1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of total chloride, calculated as Cl.

For dextrose — To an accurately measured volume containing 2 g to 5 g of Dextrose, add 0.2 ml of 5 M ammonia and sufficient water to produce 100.0 ml. Mix well, allow to stand for 30 minutes and measure the optical rotation in a 2-dm tube (2.4.22). The observed rotation in degrees multiplied by 0.9477 represents the weight, in g, of dextrose, C₆H₁₂O₆, in the volume taken for assay.

Storage. Store in single dose containers.

Labelling. The label states (1) the strength as the percentages w/v of Potassium Chloride, Sodium Chloride and Dextrose; (2) the total osmolar concentration in mOsmol per litre; (3) where the contents are less than 100 ml, or where the label states that the Injection is not for direct use but is to be diluted before use, the label alternatively may state the total osmolar concentration in mOsmol per ml; (4) the content of potassium, sodium and chloride in millimoles; (5) that the injection containing visible particles in the solution should not be used.

Potassium Citrate

\[
\text{C}_6\text{H}_5\text{K}_3\text{O}_7\cdot\text{H}_2\text{O} \\
\text{Mol. Wt. 324.4}
\]

Potassium citrate is tripotassium 2-hydroxypropane-1,2,3-tricarboxylate monohydrate.

Potassium Citrate contains not less than 99.0 per cent and not more than 101.0 per cent of C₆H₅K₃O₇, calculated on the anhydrous basis.

Description. White, granular crystals or a crystalline powder; odourless; hygroscopic.

Identification

A. Dissolve 10 g in 100 ml of carbon dioxide-free water prepared from distilled water (solution A). 0.5 ml of solution A gives the reactions of potassium salts (2.3.1).

B. To 1 ml of solution A add 4 ml of water; the solution gives the reactions of citrates (2.3.1).

Tests

Appearance of solution. Solution A is clear (2.4.1), and colourless (2.4.1).

Acidity or alkalinity. To 10 ml of solution A add 0.1 ml of dilute phenolphthalein solution; not more than 0.2 ml of 0.1 M hydrochloric acid or 0.1 M sodium hydroxide is required to change the colour of the solution.

Arsenic (2.3.10). Dissolve 5.0 g in 50 ml of water and add 15 ml of stannated hydrochloric acid. The resulting solution complies with the limit test for arsenic (2 ppm).

Heavy metals (2.3.13). 2.0 g complies with the limit test for heavy metals, Method A (10 ppm).

Sodium. Not more than 0.3 per cent, determined by atomic absorption spectrophotometry (2.4.2), Method II, measuring at 589 nm. Prepare the test solution by addition of 1 ml of 2 M hydrochloric acid to 10.0 ml of solution A and diluting to 100.0 ml with distilled water. Use sodium solution AAS, suitably diluted with distilled water, for the standard solutions.

Chlorides (2.3.12). Dilute 25.0 ml of solution A to 35 ml with water. The resulting solution complies with the limit test for chlorides (100 ppm).
**Oxalate.** Dissolve 0.5 g in 4 ml of water, add 3 ml of hydrochloric acid and 1 g of granulated zinc and heat on a water-bath for 1 minute. Allow to stand for 2 minutes, decant into 0.25 ml of a 1 per cent w/v solution of phenylhydrazine hydrochloride, heat to boiling, cool rapidly, add an equal volume of hydrochloric acid and 0.25 ml of potassium ferricyanide solution, shake and allow to stand for 30 minutes. Any pink colour produced is not more intense than that obtained by treating 4.0 ml of a 0.005 per cent w/v solution of oxalic acid at the same time and in the same manner (300 ppm, calculated as anhydrous oxalic acid).

**Sulphates (2.3.17).** To 10.0 ml of solution A add 2 ml of 7 M hydrochloric acid and dilute to 15 ml with distilled water; the solution complies with the limit test for sulphates (150 ppm).

**Readily carbonisable substances.** Heat 0.20 g, in powder, with 10 ml of sulphuric acid (96 per cent w/w) in a water-bath at 90º ± 1º for 60 minutes and cool rapidly. The solution is not more intensely coloured than reference solution YS2 or GYS2 (2.4.1).

**Water (2.3.43).** 4.0 to 7.0 per cent, determined on 0.5 g, titration being done after stirring for 15 minutes subsequent to addition of the substance under examination.

**Assay.** Weigh accurately about 0.2 g, dissolve in 20 ml of anhydrous glacial acetic acid, heat to about 50º, allow to cool. Titrate with 0.1 M perchloric acid, using 0.25 ml of 1-naphtholbenzein solution as indicator and titrating until a green colour is obtained. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01021 g of C₈H₈KNO₅.

**Storage.** Store protected from moisture.

---

**Potassium Clavulanate**

![Chemical Structure of Potassium Clavulanate](image)

C₈H₈KNO₅  Mol. Wt. 237.3

Potassium Clavulanate is potassium (Z)-(2R,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate.

Potassium Clavulanate contains not less than 96.5 per cent and not more than 102.0 per cent of potassium clavulanate, C₈H₈KNO₅, calculated on the anhydrous basis.

**Description.** A white to off white, crystalline hygroscopic powder.

---

**Identification**

A. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with reference solution (a).

B. Gives reaction A of potassium salts (2.3.1).

**Tests**

**pH (2.4.24).** 5.5 to 8.0, determined in 1.0 per cent w/v solution.

**Related substances.** Determine by liquid chromatography (2.4.14).

**NOTE – Prepare the solutions immediately before use.**

**Test solution** Dissolve 0.25 g of the substance under examination in mobile phase A and dilute to 25 ml with mobile phase A.

**Reference solution (a).** Dilute 1 ml of the test solution to 100 ml with mobile phase A.

**Reference solution (b).** A solution containing 0.01 per cent w/v each of lithium clavulanate RS and amoxycillin trihydrate RS in mobile phase A.

**Chromatographic system**

- a stainless steel column 10 cm x 4.6 mm, packed with octadecylsilyl silica gel (5 µm),
- column temperature 40º,
- mobile phase: A. a 0.78 per cent w/v solution of sodium dihydrogen phosphate adjusted to pH 4.0 with phosphoric acid and filtered through a 0.5 µm filter,
- mobile phase: B. a mixture of equal volumes of mobile phase A and methanol,
- a linear gradient programme using the conditions given below,
- flow rate. 1 ml per minute,
- spectrophotometer set at 230 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 – 4</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>4 – 15</td>
<td>100 → 50</td>
<td>0 50</td>
</tr>
<tr>
<td>15 – 18</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>18 – 24</td>
<td>50 →100</td>
<td>50 0</td>
</tr>
<tr>
<td>24 – 39</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Inject reference solution (b). The resolution between clavulanate (first peak) and amoxycillin (second peak) is not less than 13.

Inject the test solution and reference solution (b). The area of any individual impurity peak obtained is not more than the area of the principal peak in the chromatogram obtained with
reference solution (a) (1.0 per cent). The sum of all impurity peaks obtained is not more than twice the area of the principal peak in the chromatogram obtained with reference solution (a) (2.0 per cent). Ignore any peaks with an area 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.05 per cent).

**Water** (2.3.43). Not more than 1.5 per cent, determined on 0.5 g.

**Assay.** Determine by liquid chromatography (2.4.14).

NOTE – Prepare the solutions immediately before use.

**Test solution.** Dissolve 50.0 mg of the substance under examination in a 0.41 per cent w/v solution of sodium acetate previously adjusted to pH 6.0 with glacial acetic acid, and dilute to 50.0 ml with the same solution.

**Reference solution (a).** A 0.1 per cent w/v solution of lithium clavulanate RS in a 0.41 per cent w/v solution of sodium acetate previously adjusted to pH 6.0 with glacial acetic acid.

**Reference solution (b).** A solution containing 0.1 per cent w/v each of lithium clavulanate RS and amoxycillin trihydrate RS in a 0.41 per cent w/v solution of sodium acetate previously adjusted to pH 6.0 with glacial acetic acid.

**Chromatographic system**
- a stainless steel column 30 cm x 4.6 mm, packed with octadecylsilyl silica gel (5 µm),
- mobile phase: a mixture of 5 volumes of methanol and 95 volumes of a 1.5 per cent w/v solution of sodium dihydrogen phosphate previously adjusted to pH 4.0 with dilute phosphoric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 230 nm,
- a 10 µl loop injector.

Inject reference solution (b). The resolution between clavulanate (first peak) and amoxycillin (second peak) is not less than 3.5.

Inject alternately the test solution and reference solution (a).

Calculate the content of C₈H₈KNO₅.

1 mg of clavulanate (C₈H₉NO₅) is equivalent to 1.191 mg of C₈H₈KNO₅.

**Potassium Clavulanate Diluted**

C₈H₈KNO₅  Mol. Wt. 237.3

Potassium Clavulanate Diluted is a dry mixture of Potassium Clavulanate and Microcrystalline Cellulose, or Silica, colloidal anhydrous or Silica, colloidal hydrated.

Potassium Clavulanate Diluted contain not less than 91.2 per cent and not more than 107.1 per cent of the stated amount of potassium clavulanate, C₈H₈KNO₅.

**Description.** A white or almost white powder, hygroscopic.

**Identification**
A. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with reference solution (a).

B. Gives reaction A of potassium salts (2.3.1).

C. Depending on the diluent used, carry out one of the relevant identification tests given below.

(i) On a watch-glass place a quantity of the substance under examination corresponding to 20 mg of cellulose and disperse in 4 ml of iodinated zinc chloride solution. The powder becomes violet-blue in colour.

(ii) It gives the reaction of silicates (2.3.1).

**Tests**

**pH** (2.4.24) 4.8 to 8.0, determined on a quantity of the substance under examination containing 0.2 g of potassium clavulanate dissolved in 20 ml of carbon dioxide-free water.

**Light absorption.** When examined in the range 230 nm to 360 nm (2.4.7), a 0.1 per cent w/v solution in 0.1 M phosphate buffer solution pH 7.0 shows an absorption maximum only at about 278 nm; absorbance at about 278 nm, not more than 0.40.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve a quantity of the substance under examination containing 0.25 g of potassium clavulanate in 5 ml of mobile phase A, dilute to 25.0 ml with mobile phase A and filter.
**Reference solution (a).** Dilute 1.0 ml of the test solution to 100.0 ml with mobile phase A.

**Reference solution (b).** Dissolve 10 mg of amoxycillin trihydrate RS in 1 ml of the test solution and dilute to 100 ml with mobile phase A.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecysilyl silica gel (5 µm),
- mobile phase: A. a 0.78 per cent w/v solution of sodium dihydrogen phosphate with the pH adjusted to 4.0 with dilute phosphoric acid,
  
  B. a mixture of equal volumes of mobile phase A and methanol,
- flow rate. 1 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 230 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
<td>Isocratic</td>
</tr>
<tr>
<td>4</td>
<td>100</td>
<td>0</td>
<td>begin linear gradient</td>
</tr>
<tr>
<td>15</td>
<td>50</td>
<td>50</td>
<td>end chromatogram</td>
</tr>
<tr>
<td>18</td>
<td>50</td>
<td>50</td>
<td>return to 100A</td>
</tr>
<tr>
<td>24</td>
<td>100</td>
<td>0</td>
<td>end equilibration</td>
</tr>
</tbody>
</table>

Inject reference solution (b). The resolution between the clavulanate (first peak) and amoxycillin (second peak) is not less than 13.

Inject alternatively the test solution and reference solution (a). Any individual impurity is not more than 1.0 per cent and the sum of all impurities found is not more than 2.0 per cent.

**Water (2.3.43).** Not more than 2.5 per cent, determined on 1.0 g.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve a quantity of the substance under examination containing about 50.0 mg of potassium clavulanate in a 0.4 per cent w/v solution of sodium acetate with the pH previously adjusted to 6.0 with glacial acetic acid, dilute to 50.0 ml with the same solution and filter.

**Reference solution (a).** Dissolve 50.0 mg of lithium clavulanate RS in a 0.4 per cent w/v solution of sodium acetate with the pH previously adjusted to 6.0 with glacial acetic acid and dilute to 50.0 ml with the same solution.

**Reference solution (b).** Dissolve 10 mg of amoxycillin trihydrate RS in 10 ml of reference solution (a).

**Chromatographic system**
- a stainless steel column 03 cm x 4.6 mm, packed with octadecysilane bonded to porous silica (10 µm),
- mobile phase: a mixture of 5 volumes of methanol and 95 volumes of a 1.5 per cent w/v solution of sodium dihydrogen phosphate with the pH previously adjusted to 4.0 with dilute phosphoric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 230 nm,
- a 20 µl loop injector.

Inject reference solution (b). The resolution between the clavulanate peak and amoxycillin peak is not less than 3.5.

Inject alternately the test solution and reference solution (a).

Calculate the content of $C_8H_8KNO_5$.

1 mg of clavulanate ($C_8H_9NO_5$) is equivalent to 1.191 mg of $C_8H_8KNO_5$.

**Storage.** Store protected from moisture.

**Labelling.** The label states the percentage contents of potassium clavulanate and the diluent used to prepare the mixture.

**Potassium Iodide**

KI  
Mol. Wt. 166.0

Potassium iodide contains not less than 99.0 per cent and not more than 100.5 per cent of KI, calculated on the dried basis.

**Description.** Colourless crystals or a white powder; odourless.

**Identification**

Dissolve 10 g in 100 ml of carbon dioxide-free water (solution A). The solution gives the reactions of potassium salts, and of iodides (2.3.1).

**Tests**

**Appearance of solution.** Solution A is clear (2.4.1), and colourless (2.4.1).

**Alkalinity.** To 10 ml of solution A add 0.2 ml of 0.01 M sulphuric acid; no colour is produced on addition of a drop of phenolphthalein solution.

**Arsenic (2.3.10).** Dissolve 5.0 g in 50 ml of water and 12 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (2 ppm).
Heavy metals (2.3.13). 2.0 g complies with the limit test for heavy metals, Method A (10 ppm).

Iron (2.3.14). Solution A complies with the limit test for iron (20 ppm).

Barium. Dissolve 0.5 g in 10 ml of water and add 1 ml of dilute sulphuric acid; no turbidity develops within one minute.

Cyanide. Warm 5 ml of Solution A, add one drop of ferrous sulphate solution and 0.5 ml of sodium hydroxide solution and acidify with hydrochloric acid; no blue colour is produced.

Iodate. Dissolve 0.5 g in 10 ml of carbon dioxide-free water and add 0.15 ml of dilute sulphuric acid and a drop of iodide-free starch solution; no blue colour is produced within 2 minutes.

Sulphates (2.3.17). 1.0 g dissolved in 15 ml of water complies with the limit test for sulphates (150 ppm).

Thiosulphate. Dissolve 1 g in 10 ml of water, add 0.1 ml of starch solution and 0.1 ml of 0.005 M iodine; a blue colour is produced.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g of the powdered substance by drying in an oven at 105º for 3 hours.

Assay. Weigh accurately about 0.35 g, dissolve in about 10 ml of water, add 35 ml of hydrochloric acid and 5 ml of chloroform. Titrate with 0.05 M potassium iodate until the purple colour of iodine disappears from the chloroform. Add the last portion of the iodate solution dropwise and agitate vigorously and continuously. Allow to stand for 5 minutes. If any colour develops in the chloroform layer continue the titration until the chloroform is decolourised.

1 ml of 0.05 M potassium iodate is equivalent to 0.0166 g of KI.

Storage. Store protected from light and moisture.

Potassium Permanganate

KMnO₄

Mol. Wt. 158.0

Potassium Permanganate contains not less than 99.0 per cent and not more than 100.5 per cent of KMnO₄.

Description. A dark purple or brownish black, granular powder or dark purple or almost black slender, prismatic crystals, having a metallic lustre; odourless. It decomposes on contact with certain organic substances.

Identification

A. A solution in water acidified with sulphuric acid and heated to 70º is decolourised by hydrogen peroxide solution (20 vol).

B. Heated to redness, it decrepitates, evolves oxygen and leaves a black residue which with water forms potassium hydroxide solution; the resulting solution when neutralised with dilute hydrochloric acid gives the reactions of potassium salts (2.3.1).

Tests

Appearance of solution. Dissolve 1.5 g in 50 ml of distilled water, heat on a water-bath and add gradually 6 ml of ethanol (95 per cent), cool, dilute to 60 ml with distilled water and filter. The filtrate (solution A) is colourless (2.4.1).

Chlorides (2.3.12). 40 ml of solution A complies with the limit test for chlorides (250 ppm).

Sulphates (2.3.17). 10 ml of solution A complies with the limit test for sulphates (600 ppm).

Water-insoluble matter. Dissolve 0.5 g in 10 ml of water, heat to boiling, filter through a tared, sintered-glass filter (porosity No. 4) and wash with water until the filtrate is colourless. The weight of the residue, dried at 105º to constant weight, is not more than 5 mg (1.0 per cent).

Assay. Weigh accurately about 0.3 g, dissolve in sufficient water to produce 100.0 ml. To 20.0 ml add 20 ml of water, 1 g of potassium iodide and 10 ml of 2 M hydrochloric acid and titrate the liberated iodine with 0.1 M sodium thiosulphate using starch solution, added towards the end of the titration, as indicator.

1 ml of 0.1 M sodium thiosulphate is equivalent to 0.003160 g of KMnO₄.

Storage. Store protected from moisture.

CAUTION — Great care should be taken in handling potassium permanganate as dangerous explosions are liable to occur if it is brought into contact with organic or other readily oxidisable substances, either in solution or in the dry condition.

Povidone

Polyvinylpyrrolidone; Polyvidone

\[
\text{Povidone} \quad \left(\text{C}_4\text{H}_9\text{NO}\right)_n
\]

Mol. Wt. (111.2)ₙ
Povidone is poly(2-oxopyrrolidin-1-ylethylene) and consists of linear polymers of 1-vinylpyrrolidin-2-one. The different types of Povidone are characterised by their viscosity in solution, expressed as K-value, in the range 10 to 95.

Povidone with a nominal K-value of 15 or less has a K-value of not less than 85.0 per cent and not more than 115.0 per cent of the declared value. The K-value of povidone with a nominal K-value of more than 15, or a nominal K-value range with an average of more than 15, is not less than 90.0 per cent and not more than 107.0 per cent of the declared value or of the average of the declared range. It contains not less than 11.5 per cent and not more than 12.8 per cent of nitrogen, N, calculated on the anhydrous basis.

**Description.** A white or yellowish white powder or flakes; odourless or almost odourless; hygroscopic.

**Identification**

*Test A* may be omitted if tests *B, C* and *D* are carried out. Tests *B* and *C* may be omitted if tests *A* and *D* are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with povidone RS.

B. Add 2.5 g in small portions to a suitable volume of carbon dioxide-free water, stirring with a magnetic stirrer, and dilute to 25 ml with the same solvent (solution A). To 0.4 ml of solution A add 10 ml of water, 5 ml of 2 M hydrochloric acid and 2 ml of potassium dichromate solution; an orange-yellow precipitate is produced.

C. To 1 ml of solution A add 0.2 ml of dimethylamino-benzaldehyde reagent and 0.1 ml of sulphuric acid; a pink colour is produced.

D. To 0.1 ml of solution A add 5 ml of water and 0.2 ml of 0.05 M iodine; a red colour is produced.

**Tests**

**Appearance of solution.** Solution A is clear (2.4.1), and not more intensely coloured than reference solution BS6 or BYS6 (2.4.1).

**Heavy metals.** Mix 2.0 g with 0.5 g of magnesium oxide in a silica crucible. Ignite to dull red heat until a homogeneous white or greyish white mass is produced. Heat at 800º for about 1 hour, dissolve the residue using two quantities, each of 5 ml, of 5 M hydrochloric acid, add 0.1 ml of phenolphthalein solution and strong ammonia solution until a pink colour is produced. Cool, add glacial acetic acid until the solution is decolorised and add a further 0.5 ml. Filter if necessary and dilute the solution to 20 ml with water. To 12 ml of the resulting solution add 2 ml of acetate buffer pH 3.5, mix, add 1.2 ml of thioacetamide reagent, mix immediately and allow to stand for 2 minutes. Any brown colour produced is not more intense than that obtained by treating in the same manner a mixture of 2 ml of the test solution obtained above and 10 ml of the 20 ml of solution obtained by repeating the procedure using 2 ml of lead standard solution (10 ppm Pb) in place of the substance under examination, adding 0.5 g of magnesium oxide in a silica crucible and continuing as described above beginning at the words “Ignite to dull red heat....” (10 ppm).

**Aldehydes.** Boil 20.0 g in 180 ml of a 25 per cent w/v solution of sulphuric acid in a ground-glass-stoppered flask under a reflux condenser for 45 minutes and allow to cool. Fit a distillation head, distil and collect 60 ml of the distillate in 20 ml of a 7.0 per cent w/v solution of hydroxylamine hydrochloride, previously adjusted to pH 3.1 using 1 M sodium hydroxide, and cooled in ice. Titrate with 0.1 M sodium hydroxide to pH 3.1. Carry out a blank titration. Not more than 9.1 ml of 0.1 M sodium hydroxide is required (0.2 per cent, calculated as acetaldehyde, C₂H₄O).

**Vinylnpyrrolidone.** Dissolve 10.0 g in 80 ml of water and add 1 g of sodium acetate. Titrate with 0.05 M iodine until a persistent colour is obtained and add a further 3.0 ml of the iodine solution. Allow to stand for 10 minutes and titrate the excess of iodine with 0.1 M sodium thiosulphate using 3 ml of starch solution, added towards the end of the titration, as indicator. Repeat the operation without the substance under examination using the same total volume of 0.05M iodine. The difference between the titrations represents the amount of iodine consumed by the vinylnpyrrolidone monomer that may be present. Not more than 3.6 ml of 0.05 M iodine is required (0.2 per cent).

**Sulphated ash (2.3.18).** Not more than 0.1 per cent.

**Water (2.3.43).** Not more than 5.0 per cent determined on 0.5 g.

**K-value.** For Povidone with a stated K-value of 18 or less, prepare a 5.0 per cent w/v solution. For Povidone with a declared K-value of more than 18, prepare a 1.0 per cent w/v solution. Allow the solution to stand for 1 hour and carry out Method B for the determination of viscosity (2.4.28), at 25º ± 0.2º using a size no. 1 viscometer with a minimum flow time of 100 seconds. Calculate the K-value (K₀) from the expression

\[
K_0 = \frac{1.5 \log z - 1}{0.15 + 0.003c} + \frac{\sqrt{300c \log z + (c + 1.5c \log z)^2}}{0.15c + 0.003c^2}
\]

where \(c\) is the percentage concentration w/v of the substance under examination, calculated on the anhydrous basis, and \(z\) is the viscosity of the solution relative to that of water.

**Nitrogen (2.3.30).** Follow Method C, using 0.3 g, accurately weighed and 11 ml of nitrogen-free sulphuric acid. For complete destruction of organic matter repeat the addition of hydrogen peroxide (10 vol) (usually 3 to 6 times) until a clear, light-green solution is obtained, then heat for a further 4 hours.
Storage. Store protected from moisture.

Labelling. The label states the viscosity in terms of a K-value or K-range.

**Povidone-Iodine**

\[
\text{CH} - \text{CH}_2 \quad x \quad I_n
\]

Povidone-Iodine is a complex produced by interaction between iodine and poly(2-oxopyrrolidin-1-yethylene).

Povidone-Iodine contains not less than 9.0 per cent and not more than 12.0 per cent of available iodine, I, calculated on the dried basis.

**Description.** A yellowish brown amorphous powder; odour, slight and characteristic of iodine.

**Identification**

A. Add 0.05 ml of a 10 per cent w/v solution to a mixture of 1 ml of starch solution and 9 ml of water; a deep blue colour is produced.

B. Spread 1 ml of a 10 per cent w/v solution over an area of about 20 cm x 20 cm on a glass plate and allow it to dry in air at room temperature and in an atmosphere of low humidity overnight; a brown, dry, non-smearing film is formed which dissolves readily in water.

**Tests**

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Nitrogen** (2.3.30). 9.5 to 11.5 per cent, calculated on the dried basis, determined on about 0.3 g, by Method A.

**Iodide.** Not more than 6.6 per cent, calculated on the dried basis, determined by the following method. Weigh accurately about 0.5 g and dissolve in 100 ml of water. Add sufficient sodium bisulphite solution until the colour of iodine is discharged. Add 25.0 ml of 0.1 M silver nitrate and 10 ml of nitric acid and mix. Titrage with 0.1 M ammonium thiosulphate, using ferric ammonium sulphate solution as indicator. Repeat the procedure without the substance under examination. The difference between the titrations represents the amount of silver nitrate required. 1 ml of 0.1 M silver nitrate is equivalent to 0.01269 g of I. From the percentage of total iodine, calculated on the dried basis, subtract the percentage of available iodine determined in the Assay and obtain the percentage of iodide.

**Sulphated ash** (2.3.18). Not more than 0.2 per cent.

**Loss on drying** (2.4.19). Not more than 8.0 per cent, determined on 0.5 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 3 g, transfer to a beaker and add 200 ml of water. Cover the beaker and stir with a mechanical stirrer at room temperature for not more than 1 hour to dissolve as completely as possible. Titrate immediately thereafter with 0.1 M sodium thiosulphate using 3 ml of starch solution, added towards the end of the titration, as indicator.

1 ml of 0.1 M sodium thiosulphate is equivalent to 0.01269 g of I.

**Storage.** Store protected from light.

**Povidone-Iodine Solution**

Povidone-Iodine Solution is a solution of Povidone-Iodine in Purified Water. It may contain a small amount of Ethanol.

Povidone-Iodine Solution contains not less than 85.0 per cent and not more than 120.0 per cent of the stated amount of iodine, I.

**Description.** A deep brown liquid; odour, characteristic of iodine.

**Identification**

A. Dilute 1 ml to 20 ml with water and add 1 ml of the resulting solution to a mixture of 1 ml of starch solution and 9 ml of water; a deep blue colour is produced.

B. Transfer 10 ml to a small flask and cover the mouth of the flask with a filter paper soaked in starch solution; no blue colour is produced on the paper within 60 seconds.

C. Dilute 20 ml to 100 ml with water. To 10 ml add dropwise 0.1 M sodium thiosulphate until the colour is just discharged. To 5 ml of the resulting solution add 5 ml of 2 M hydrochloric acid and 2 ml of potassium dichromate solution; a red precipitate is produced.

**Tests**

**pH** (2.4.24). 3.0 to 6.5.

**Ethanol (if present)** (2.3.45). 90.0 to 110.0 per cent of the stated amount of C₂H₅OH, determined by Method A after decolorising the solution with just sufficient quantity of a 10 per cent w/v solution of sodium thiosulphate and treating with a few drops of dilute sodium hydroxide solution.

**Assay.** To an accurately measured volume containing about 50 mg of iodine add sufficient water to produce not less than
30 ml and titrate immediately with 0.02 M sodium thiosulphate, using 3 ml of starch solution, added towards the end of the titration, as indicator. Carry out a blank titration.

1 ml of 0.02 M sodium thiosulphate is equivalent to 0.002538 g of I.

**Storage.** Store protected from light.

**Labelling.** The label states the quantities of iodine and ethanol (if present) as percentages w/v.

### Pralidoxime Chloride

\[
\text{C}_7\text{H}_9\text{ClN}_2\text{O} \quad \text{Mol. Wt. 172.6}
\]

Pralidoxime Chloride is 2-hydroxyiminomethyl-1-methylpyridinium chloride.

Pralidoxime Chloride contains not less than 97.0 per cent and not more than 103.0 per cent of C7H9ClN2O, calculated on the dried basis.

**Description.** A white to pale yellow, crystalline powder; odourless.

**Identification.**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pralidoxime chloride RS or with the reference spectrum of pralidoxime chloride.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.0005 per cent w/v solution in 0.1 M hydrochloric acid shows absorption maxima at about 242 nm and 292 nm and in 0.1 M sodium hydroxide, a maximum at about 332 nm.

C. To 0.1 ml of a 20 per cent w/v solution add 1 ml of a 0.6 per cent w/v solution of ferric chloride; an amber-brown colour is produced.

D. Gives the reactions of chlorides (2.3.1).

**Tests.**

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method A (20 ppm).

**Chloride content.** 20.2 to 20.8 per cent, calculated on the dried basis, determined by the following method. Weigh accurately about 0.3 g, dissolve in about 150 ml of water, add 20 ml of glacial acetic acid and 10 drops of (4-tert-octylphenox) nonaethoxyethanol and titrate with 0.1 M silver nitrate, determining the end-point potentiometrically (2.4.25).

1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of Cl.

**Sulphated ash** (2.3.18). Not more than 0.5 per cent.

**Loss on drying** (2.4.19). Not more than 2.0 per cent, determined on 1.0 g by drying in an oven at 105º for 3 hours.

**Assay.** Weigh accurately about 0.5 g, dissolve in sufficient water to produce 250.0 ml and mix. Dilute 5.0 ml of this solution to 100.0 ml with water. Transfer 5.0 ml to a 50-ml volumetric flask, dilute to about 40 ml with water, add 5.0 ml of 1 M sodium hydroxide and dilute to volume with water. Within 10 minutes of the addition of the alkali, measure the absorbance of the solution at the maximum at about 332 nm (2.4.7), using a solution of 5.0 ml of 1 M sodium hydroxide diluted with water to 50.0 ml as the blank.

Calculate the content of C7H9ClN2O from the absorbance obtained by carrying out the assay simultaneously using about 0.5 g, accurately weighed, of pralidoxime chloride RS.

**Storage.** Store protected from moisture.

### Pralidoxime Chloride Injection

Pralidoxime Chloride Injection is a sterile material consisting of Pralidoxime Chloride with or without buffering agents and other excipients. It is filled in a sealed container.

The injection is constituted by dissolving the contents of the sealed container in the requisite amount of sterile Water for Injections, immediately before use.

The constituted solution complies with the requirements for Clarity of solution and Particulate matter stated under Parenteral Preparations (Injections).

**Storage.** The constituted solution should be used immediately after preparation but, in any case, within the period recommended by the manufacturer.

Pralidoxime Chloride Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of pralidoxime chloride, C7H9ClN2O.

**Description.** A white to pale yellow powder.

The contents of the sealed container comply with the requirements stated under Parenteral Preparations (Powders for Injection) and with the following requirements.

**Identification.**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pralidoxime chloride RS or with the reference spectrum of pralidoxime chloride.

965
B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.0005 per cent w/v solution in 0.1 M hydrochloric acid shows absorption maxima at about 242 nm and 292 nm and in 0.1 M sodium hydroxide, a maximum at about 332 nm.

C. To 0.1 ml of a 20 per cent w/v solution add 1 ml of a 0.6 per cent w/v solution of ferric chloride; an amber-brown colour is produced.

D. Gives the reactions of chlorides (2.3.1).

Tests

\textbf{pH} (2.4.24). 3.5 to 4.5, determined in a 5.0 per cent w/v solution.

\textbf{Heavy metals} (2.3.13). 1.0 g complies with the limit test for heavy metals, Method A (20 ppm).

\textbf{Bacterial endotoxins} (2.2.3). Not more than 0.1 Endotoxin Unit per mg of pralidoxime chloride.

\textbf{Assay}. Weigh accurately about 0.5 g, dissolve in sufficient water to produce 250.0 ml and mix. Dilute 5.0 ml of this solution to 100.0 ml with water, add 5.0 ml of 1 M sodium hydroxide and dilute to volume with water. Within 10 minutes of the addition of the alkali, measure the absorbance of the solution at the maximum at about 332 nm (2.4.7), using a solution of 5.0 ml of 1 M sodium hydroxide diluted with water to 50.0 ml as the blank.

Calculate the content of C\textsubscript{19}H\textsubscript{21}N\textsubscript{5}O\textsubscript{4}, HCl from the absorbance obtained by carrying out the assay simultaneously using about 0.5 g, accurately weighed, of pralidoxime chloride RS.

\textbf{Labelling}. The label states the period within which the constituted injection should be used.

\textbf{Prazosin Hydrochloride}

![Prazosin Hydrochloride structure](image)

\text{C}_{19}\text{H}_{21}\text{N}_{5}\text{O}_{4}, \text{HCl} \quad \text{Mol. Wt. 419.9}

Prazosin Hydrochloride is 2-[4-(2-furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-ylamine hydrochloride.

Prazosin Hydrochloride contains not less than 98.5 per cent and not more than 101.0 per cent of C\textsubscript{19}H\textsubscript{21}N\textsubscript{5}O\textsubscript{4}, HCl, calculated on the anhydrous basis.

\textbf{Description}. A white or almost white powder; odourless or almost odourless.

\textbf{Identification}

\textit{Test A} may be omitted if tests \textit{B}, \textit{C} and \textit{D} are carried out. Tests \textit{B} and \textit{C} may be omitted if tests \textit{A} and \textit{D} are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with prazosin hydrochloride RS.

B. Prepare a 0.05 per cent w/v solution of the substance under examination in a 0.1 per cent v/v solution of hydrochloric acid in methanol. Dilute separately 1 ml and 5 ml of this solution to 100 ml with the same acid solution (solutions A and B respectively). When examined in the range 220 nm to 280 nm (2.4.7), solution A shows an absorption maximum at about 247 nm; absorbance at the maximum, 0.66 to 0.70. When examined in the range 280 nm to 400 nm, solution B exhibits two maxima at about 330 nm and 343 nm; absorbances at the two maxima, 0.65 to 0.70 and 0.60 to 0.66 respectively.

C. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (a) corresponds to that in the chromatogram obtained with reference solution (b).

D. A 0.1 per cent w/v solution gives the reactions of chlorides (2.3.1).

\textbf{Tests}

\textbf{Iron}. To 1.0 g add dropwise about 1.5 ml of nitric acid, heat cautiously on a water-bath until fumes are no longer evolved. Ignite by slowly raising the temperature from 150° to 1000°, maintaining the final temperature for 1 hour. Cool, dissolve the residue in 20 ml of 2 M hydrochloric acid, evaporate to about 5 ml, dilute to 25 ml with 2 M hydrochloric acid and examine the resulting solution by atomic absorption spectrophotometry (2.4.2), measuring at 248 nm using an iron hollow-cathode light as a source of radiation, an air-acetylene flame and iron standard solution (8 ppm Fe), diluted as necessary with water to prepare the standard solutions (100 ppm).

Reserve about 10 ml of the solution for the Nickel test.

\textbf{Nickel}. Examine the final solution prepared in the test for Iron by atomic absorption spectrophotometry (2.4.2), measuring at 232 nm using an iron hollow-cathode light as a source of radiation, an air-acetylene flame and using nickel standard solution (10 ppm Ni), diluted as necessary with water to prepare the standard solutions (50 ppm).

\textbf{Related substances}. Determine by liquid chromatography (2.4.14).

\textit{Test solution}. Dissolve 50.0 mg of the substance under examination in the mobile phase and dilute to 50 ml with the mobile phase.
**Prazosin Tablets**

Prazosin Hydrochloride Tablets

Prazosin Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of prazosin, C_{19}H_{21}N_{5}O_{4}. The tablets may contain permitted colours.

**Identification**

Shake a quantity of the powdered tablets containing about 10 mg of prazosin with a mixture of 10 ml of dichloromethane and 10 ml of 0.05 M potassium hydroxide, filter the organic layer through cotton, evaporate to dryness and dry the residue at 60°C at a pressure not exceeding 2 kPa at 60°C for 2 hours.

On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with prazosin RS or with the reference spectrum of prazosin.

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

**Mobile phase.** A mixture of 95 volumes of ethyl acetate and 5 volumes of diethylamine.

**Test solution.** Shake a quantity of the powdered tablets containing 5 mg of prazosin with 2 ml of a mixture of 10 volumes of dichloromethane, 10 volumes of methanol and 1 volume of diethylamine, centrifuge and pass the supernatant liquid through a 0.5 µm PTFE (Polytetrafluoroethylene) filter.

**Reference solution (a).** Dilute 1 volume of test solution to 200 volumes with the same solvent mixture

**Reference solution (b).** Dilute 2 volumes of reference solution (a) to 5 volumes with the same solvent mixture.

Apply to the plate 20 µl of each solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than two such spots are more intense than the spot in the chromatogram obtained with reference solution (b).

**Uniformity of content.** Comply with the tests stated under Tablets.

Determine by liquid chromatography (2.4.14).

**Test solution.** Shake one tablet for 1 hour in a suitable volume of a mixture of 96 volumes of methanol, 2 volumes of glacial acetic acid and 2 volumes of water to produce a solution containing 0.002 per cent w/v solution of prazosin, centrifuge and use the supernatant liquid.

**Reference solution.** A 0.0022 per cent w/v solution of prazosin hydrochloride RS in the same solvent mixture.
Chromatographic system
- a stainless steel column 20 cm x 4 mm, packed with porous silica particles, (5 µm),
- mobile phase: 0.01 per cent w/v solution of diethylamine in a mixture of 96 volumes of methanol, 2 volumes of glacial acetic acid and 2 volumes of water,
- flow rate. 1 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Calculate the content of C_{19}H_{21}N_{5}O_{4} in the tablet.

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh and powder 20 tablets. Shake a quantity of the powdered tablets containing about 2 mg of prazosin with 100 ml in a mixture of 96 volumes of methanol, 2 volumes of glacial acetic acid and 2 volumes of water for 30 minutes, centrifuge and use the supernatant liquid.

Reference solution. A 0.0022 per cent w/v solution of prazosin hydrochloride RS in a mixture of 96 volumes of methanol, 2 volumes of glacial acetic acid and 2 volumes of water.

The chromatographic conditions as described under Uniformity of content may be used.

Calculate the content of C_{19}H_{21}N_{5}O_{4} in the tablets.

Storage. Store protected from light.

Labelling. The label states the strength in terms of the equivalent amount of prazosin.

**Prednisolone**

![Prednisolone structure](image)

C_{21}H_{28}O_{5}   Mol. Wt. 360.5

Prednisolone is 11β,17α,21-trihydroxypregna-1,4-diene-3,20-dione.

Prednisolone contains not less than 96.0 per cent and not more than 104.0 per cent of C_{21}H_{28}O_{5}, calculated on the dried basis.

**Description.** A white or almost white, crystalline powder; hygroscopic.

**Identification**

Test A may be omitted if tests B and C are carried out. Test C may be omitted if tests A and B are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with prednisolone RS or with the reference spectrum of prednisolone.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Solvent mixture.** A mixture of 90 volumes of acetone and 10 volumes of formamide.

**Mobile phase.** Chloroform.

Test solution. Dissolve 25 mg of the substance under examination in 10 ml of the solvent mixture.

**Reference solution (a).** Dissolve 25 mg of prednisolone RS in 10 ml of the solvent mixture.

**Reference solution (b).** Mix equal volumes of the test solution and reference solution (a).

Place the dry plate in a tank containing a shallow layer of the solvent mixture, allow the solvent mixture to ascend to the top, remove the plate from the tank and allow the solvent to evaporate. Use within 2 hours, with the flow of the mobile phase in the direction in which the aforementioned treatment was done.

Apply to the plate 2 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air, allow the solvent to evaporate, heat at 120º for 15 minutes and spray the hot plate with ethanolic sulphuric acid (20 per cent v/v). Heat at 120º for a further 10 minutes, allow to cool and examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot. A.

C. Dissolve 2 mg in 2 ml of sulphuric acid by shaking and allow to stand for 5 minutes; an intense red colour is produced with a reddish brown fluorescence when examined in ultraviolet light at 365 nm. Pour the solution into 10 ml of water and mix; the colour fades and there is a yellow fluorescence under ultra-violet light (365 nm).

**Tests**

**Specific optical rotation** (2.4.22). +96.0º to +102º, determined in a 1.0 per cent w/v solution in dioxan.

**Light absorption** (2.4.7). Absorbance of a 0.001 per cent w/v solution in ethanol (95 per cent) at the maximum at about 240 nm, 0.40 to 0.43.
Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 25 mg of the substance under examination in 2 ml of tetrahydrofuran and dilute to 10 ml with water.

Reference solution (a). Dissolve 2 mg of prednisolone RS and 2 mg of hydrocortisone RS in the mobile phase and dilute to 100 ml with the mobile phase.

Reference solution (b). Dilute 1 ml of the test solution to 100 ml with the mobile phase.

Chromatographic system
  - a stainless steel column 25 cm x 4.6 mm, packed with base deactivated end-capped octadecylsilyl silica gel (5 µm),
  - column temperature. 45º,
  - mobile phase: a mixture of 220 ml of tetrahydrofuran and 700 ml of water, allowed to equilibrate, diluted to 1000 ml with water and mixed again,
  - flow rate. 1 ml per minute,
  - spectrophotometer set at 254 nm,
  - a 20 µl loop injector.

Equilibrate the column with the mobile phase for about 30 minutes.

Adjust the sensitivity of the system so that the height of the principal peak in the chromatogram obtained with reference solution (b) is not less than 50 per cent of the full scale of the recorder.

Inject reference solution (a). The retention times are: prednisolone, about 14 minutes and hydrocortisone about 15.5 minutes. The test is not valid unless the resolution between the peaks corresponding to prednisolone and hydrocortisone is at least 2.2. If necessary, adjust the concentration of tetrahydrofuran in the mobile phase.

Inject separately the solvent mixture of the test solution as a blank, the test solution and reference solution (b). Continue the chromatography of the test solution for 4.5 times the retention time of the principal peak. In the chromatogram obtained with the test solution, the area of any peak other than the principal peak, is not greater than half the area of the principal peak in the chromatogram obtained with reference solution (b) (1 per cent) and not more than one such peak has an area greater than half the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent); the sum of the areas of all the peaks other than the principal peak is not greater than 2.0 times the area of the principal peak in the chromatogram obtained with reference solution (b) (2 per cent). Ignore any peak obtained with the blank run and any peak with an area less than 0.05 times that of the principal peak in the chromatogram obtained with reference solution (b).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105º for 3 hours.

Assay. Weigh accurately about 0.1 g and dissolve in sufficient ethanol to produce 100.0 ml. Dilute 2.0 ml of this solution to 100.0 ml with ethanol. Measure the absorbance of the resulting solution at the maximum at about 243.5 nm. Calculate the content of C₂₁H₂₈O₅ taking 415 as the specific absorbance at 243.5 nm.

Storage. Store protected from light and moisture.

Prednisolone Tablets

Prednisolone Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of prednisolone, C₂₁H₂₈O₅.

Identification

Extract a quantity of the powdered tablets containing 30 mg of Prednisolone with 10 ml of chloroform, filter and evaporate the filtrate to dryness. The residue complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with prednisolone RS or with the reference spectrum of prednisolone.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Solvent mixture. A mixture of 90 volumes of acetone and 10 volumes of formamide.

Mobile phase. Chloroform.

Test solution. Chloroform.

Reference solution (a). Dissolve 25 mg of prednisolone RS in 10 ml of the solvent mixture.

Reference solution (b). Mix equal volumes of the test solution and reference solution (a).

Place the dry plate in a tank containing a shallow layer of the solvent mixture, allow the solvent mixture to ascend to the top, remove the plate from the tank and allow the solvent to evaporate. Use within 2 hours, with the flow of the mobile phase in the direction in which the aforementioned treatment was done.

Apply to the plate 2 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air; allow the solvent to evaporate, heat at 120º for 15 minutes and spray the hot plate with ethanolic sulphuric acid (20 per cent v/v).
Heat at 120º for a further 10 minutes, allow to cool and examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

Tests

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Shake a quantity of the powdered tablets containing 10 mg of Prednisolone with 25 ml of methanol for 10 minutes and mix with the aid of ultrasound for 2 minutes; filter the extract (Whatman GF/F is suitable), wash the filter with two 10-ml quantities of methanol, combine the filtrate and washings and evaporate to dryness using a rotary evaporator and a warm water-bath, dissolve the residue in 10 ml of tetrahydrofuran and dilute to 20 ml with water.

Reference solution (a). Dissolve 2 mg of prednisolone RS and 2 mg of hydrocortisone RS in the mobile phase and dilute to 100 ml with the mobile phase.

Reference solution (b). Dilute 1 ml of the test solution to 100 ml with a 50 per cent v/v solution of tetrahydrofuran.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilyl silica gel (5 µm),
- column temperature. 45º,
- mobile phase: a mixture of 220 ml of tetrahydrofuran and 700 ml of water, allowed to equilibrate, diluted to 1000 ml with water and mixed again,
- flow rate. 1 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Equilibrate the column with the mobile phase for about 30 minutes.

Adjust the sensitivity of the system so that the height of the principal peak in the chromatogram obtained with reference solution (b) is not less than 50 per cent of the full scale of the recorder.

Inject reference solution (a). The retention times are: prednisolone, about 14 minutes and hydrocortisone about 15.5 minutes. The test is not valid unless the resolution between the peaks corresponding to prednisolone and hydrocortisone is at least 2.2. If necessary, adjust the concentration of tetrahydrofuran in the mobile phase.

Inject separately the solvent mixture of the test solution as a blank, the test solution and reference solution (b). Continue the chromatography of the test solution for 4.5 times the retention time of the principal peak. In the chromatogram obtained with the test solution, the area of any peak other than the principal peak, is not greater than half the area of the principal peak in the chromatogram obtained with reference solution (b) (1 per cent) and the sum of the areas of all the peaks other than the principal peak is not greater than three times the area of the principal peak in the chromatogram obtained with reference solution (b) (3 per cent). Ignore any peak obtained with the blank run and any peak with an area less than 0.05 times that of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent) and any peak with a retention time of 3 minutes or less.

Uniformity of content. (For tablets containing 10 mg or less)
— Comply with the test stated under Tablets.

Powder one tablet, add 50 ml of ethanol (95 per cent), shake for 30 minutes, add sufficient ethanol (95 per cent) to produce 100.0 ml. Centrifuge and pipette a suitable volume of the supernatant liquid containing 0.5 mg of Prednisolone and dilute to 50.0 ml with ethanol (95 per cent). Measure the absorbance of the resulting solution at the maximum at about 240 nm (2.4.7). Calculate the content of C₂₁H₂₈O₅ taking 415 specific absorbance at 240 nm.

Dissolution (2.5.2).

Apparatus. No 1
Medium. 900 ml of water
Speed and time. 50 rpm and 30 minutes.

Withdraw a suitable volume of the medium, filter and dilute a suitable volume of the filtrate with the same solvent. Measure the absorbance of the filtrate at the maximum at about 240 nm (2.4.7). Calculate the content of C₂₁H₂₈O₅ in the medium from the absorbance obtained from a solution of known concentration of prednisolone RS.

D. Not less than 70 per cent of the stated amount of C₂₁H₂₈O₅.

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 5 mg of Prednisolone, add 58 ml of methanol, shake for 10 minutes and add sufficient water to produce 100.0 ml. Mix well and filter.

Reference solution (a). A solution containing 0.005 per cent w/v of prednisolone RS and 0.0075 per cent w/v of dexamethasone (internal standard) in a mixture of 58 volumes of methanol and 42 volumes of water.

Reference solution (b). Prepare in the same manner as the test solution but adding 10 ml of a 0.075 per cent w/v solution of dexamethasone in methanol and 48 ml of methanol in place of 58 ml of methanol.
Chromatographic system
- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilica gel (5 µm),
- mobile phase: a mixture of 42 volumes of water and 58 volumes of methanol,
- flow rate. 1 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

The assay is not valid unless the resolution factor between the peaks due to prednisolone and dexamethasone is greater than 2.5 and the column efficiency, determined using the peak due to prednisolone in the chromatogram obtained with the test solution is greater than 15,000 theoretical plates per metre.

Calculate the content of C_{21}H_{28}O_{5} in the tablets.

Storage. Store protected from light.

**Prednisolone Sodium Phosphate**

C_{21}H_{27}Na_{2}O_{8}P  
Mol. Wt. 484.4

Prednisolone Sodium Phosphate is 11β,17α, 21-trihydroxyprog-1,4-diene-3,20-dione-21-(dihydrogenphosphate)disodium salt.

Prednisolone Sodium Phosphate contains not less than 96.0 per cent and not more than 102.0 per cent of C_{21}H_{27}Na_{2}O_{8}P, calculated on the dried basis.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with prednisolone sodium phosphate RS. If the spectra obtained in the solid state show differences, dissolve the substance under examination and the reference substance separately in the minimum volume of ethanol (95 per cent) evaporate to dryness on a water-bath and record the spectra again using the residues.

B. To about 40 mg add 2 ml of sulphuric acid and heat gently until white fumes are evolved. Add nitric acid dropwise, continue the heating until the solution is almost colourless and cool. Add 2 ml of water, heat until white fumes are again evolved, cool, add 10 ml of water and neutralise to red litmus paper with dilute ammonia solution. The solution complies with reaction A of sodium salts and reaction B of phosphates (2.3.1).

**Tests**

**pH** (2.4.24). 7.5 to 10.5 determined in 1.0 per cent w/v solution.

**Specific optical rotation** (2.4.22). +95.0º to +102.0º, determined in a 1.0 per cent w/v solution in a mixture of 9 volumes of phosphate buffer pH 7.0 and 1 volume of carbon dioxide-free water.

**Related substances.** Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 62.5 mg of the substance under examination in the mobile phase and dilute to 25.0 ml with the mobile phase.

Reference solution (a). Dissolve 25 mg of prednisolone sodium phosphate RS and 25 mg of prednisolone RS in the mobile phase and dilute to 25.0 ml with the same solvent. Dilute 1.0 ml of the solution to 25.0 ml with the mobile phase.

Reference solution (b). Dilute 1.0 ml of the test solution to 50.0 ml with the mobile phase.

Chromatographic system
- a stainless steel column 15 cm x 4.6 mm, packed with octadeccylsilane bonded to porous silica or ceramic microparticles (5 µm),
- mobile phase: weigh 1.360 g of potassium dihydrogen phosphate and 0.6 g of hexylamine, mix and allow to stand for 10 minutes and then dissolve in 185 ml of water, add 65 ml of acetonitrile, mix and filter through a 0.45 µm filter,
- flow rate. 1 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject reference solution (b). Adjust the sensitivity of the system so that the height of the principal peak in the chromatogram obtained with reference solution (b) is 70 per cent to 90 per cent of the full scale of the recorder.

Equilibrate the column with the mobile phase for about 30 minutes.

Inject reference solution (a). The retention times are: prednisolone sodium phosphate, about 6.5 minutes and prednisolone, about 8.5 minutes. The test is not valid unless the resolution between the peaks due to prednisolone sodium phosphate and prednisolone is at least 4.5; if this resolution is not achieved, increase the concentration of acetonitrile or increase the concentration of water in the mobile phase.

Inject separately the test solution and reference solution (b). Continue the chromatography for three times the retention
time of the principal peak. In the chromatogram obtained with the test solution, the area of any peak other than that from the principal peak is not greater than the area of the principal peak in the chromatogram obtained with reference solution (b) (2 per cent) and not more than one such peak has an area greater than half the area of the principal peak in the chromatogram obtained with reference solution (b) (1 per cent); the sum of the areas of all the peaks other than the principal peak is not greater than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (3 per cent). Ignore any peak due to the solvent and any peak with an area less than 0.025 times the area of the principal peak in the chromatogram obtained with reference solution (b).

Inorganic phosphate. Not more than 1.0 per cent of phosphate, PO₄.

Dissolve 50 mg in sufficient water to produce 100 ml. To 10 ml of the resulting solution add 5 ml of molybdenovanadic reagent, mix and allow to stand for 5 minutes. Any yellow colour in the solution is not more intense than that produced in a standard prepared at the same time in the same manner using 10 ml of phosphate standard solution (5 ppm PO₄).

Water (2.3.43). Not more than 6.5 per cent, determined on 1.0 g.

Assay. Weigh accurately about 0.1 g, dissolve in sufficient water to produce 100.0 ml and mix. Dilute 5.0 ml of the resulting solution to 250.0 ml with water. Measure the absorbance at the maximum at about 247 nm (2.4.7). Calculate the content of C₂₁H₂₉O₈P taking 312 as the specific absorbance at 247 nm.

Storage. Store protected from light.

**Prednisolone Sodium Phosphate Injection**

Prednisolone Sodium Phosphate Injection is a sterile solution of Prednisolone Sodium Phosphate in Water for Injections.

Prednisolone Sodium Phosphate Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of prednisolone phosphate, C₂₁H₂₉O₈P.

**Description.** A clear, colourless liquid.

**Identification**

A. In the Assay, the chromatogram obtained with the test solution corresponds to the peak due to prednisolone sodium phosphate in the chromatogram obtained with reference solution (a).

B. To a volume containing 0.2 mg of Prednisolone Sodium Phosphate slowly add 1 ml of sulphuric acid and allow to stand for 2 minutes. A deep red colour is produced.

**Tests**

pH (2.4.24). 7.0 to 8.0.

**Bacterial endotoxins** (2.2.3). Not more than 5.0 Endotoxin Units per mg of prednisolone phosphate.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dilute an accurately measured volume of the injection to obtain a solution containing 0.001 per cent w/v of prednisolone phosphate.

**Reference solution (a).** Weigh accurately about 10 mg of prednisolone sodium phosphate RS, dissolve in sufficient water to produce 100.0 ml (solution A) and dilute 10.0 ml of the solution to 100.0 ml with water.

**Reference solution (b).** Add 10 ml of a 0.01 per cent w/v solution of betamethasone sodium phosphate RS in water to 10 ml of solution A and dilute to 100 ml with water.

**Chromatographic system**

- a stainless steel column 20 cm x 4.6 mm, packed with octadecysilane bonded to porous silica or ceramic microparticles (10 µm) (such as Spherisorb ODS 1),
- mobile phase: a mixture of 45 volumes of methanol and 55 volumes of citro-phosphate buffer pH 5.0,
- flow rate. 2.0 ml per minute,
- spectrophotometer set at 247 nm,
- a 10 µl loop injector.

Inject reference solution (b). The test is not valid unless the resolution between the peaks due to betamethasone sodium phosphate and prednisolone sodium phosphate is at least 2.5.

Inject alternatively the test solution and reference solution (a). Calculate the content of C₂₁H₂₉O₈P in the injection.

**Storage.** Store protected from light, in a single-dose or in multidose containers.

**Prednisone**

\[
\text{C}_{21}\text{H}_{26}\text{O}_{5} \quad \text{Mol. Wt. 358.4}
\]

Prednisone is 17α,21-dihydroxyprogna-1,4-diene-3,11,20-trione.
Prednisone contains not less than 96.0 per cent and not more than 104.0 per cent of C$_{21}$H$_{26}$O$_{5}$, calculated on the dried basis.

**Description.** A white or almost white, crystalline powder; odourless.

**Identification.**

Tests A and B may be omitted if tests C and D are carried out. Tests C and D may be omitted if tests A and B are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with prednisone RS or with the reference spectrum of prednisone.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Solvent mixture.** A mixture of 90 volumes of acetone and 10 volumes of formamide.

**Mobile phase.** Chloroform.

**Test solution.** Dissolve 25 mg of the substance under examination in 10 ml of the solvent mixture.

**Reference solution (a).** Dissolve 25 mg of prednisone RS in 10 ml of the solvent mixture.

**Reference solution (b).** Mix equal volumes of the test solution and reference solution (a).

Place the dry plate in a tank containing a shallow layer of the solvent mixture, allow the solvent mixture to ascend to the top, remove the plate from the tank and allow the solvent to evaporate. Use within 2 hours, with the flow of the mobile phase in the direction in which the aforementioned treatment was done.

Apply to the plate 2 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air, allow the solvent to evaporate, heat at 120º for 15 minutes and spray the hot plate with ethanolic sulphuric acid (20 per cent v/v). Heat at 120º for a further 10 minutes, allow to cool and examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

C. Dissolve 2 mg in 2 ml of sulphuric acid and allow to stand for 5 minutes; an orange colour is produced within 5 minutes, which exhibits a blue fluorescence in ultraviolet light at 365 nm. Pour the solution into 10 ml of water; the colour changes first to yellow and then fades gradually but the blue fluorescence in ultraviolet light remains.

D. Dissolve 1 mg in 1 ml of ethanol (95 per cent), evaporate to dryness at a pressure not exceeding 0.7 kPa, add 5 ml of 1 M sodium hydroxide and heat at 70º for 30 minutes; not more than a slight yellow colour is produced (distinction from cortisone acetate).

**Tests.**

**Specific optical rotation** (2.4.22). +167º to +175º, determined in a 1.0 per cent w/v solution in dioxan.

**Light absorption** (2.4.7). Absorbance of a 0.001 per cent w/v solution in methanol at the maximum at about 240 nm, 0.40 to 0.43; the ratio of the absorbance at the maximum at about 240 nm to that at about 263 nm, 1.85 to 2.05.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 25 mg of the substance under examination in methanol and dilute to 10 ml with the same solvent.

**Reference solution (a).** Dissolve 2.0 mg of prednisolone RS and 2.0 mg of prednisone RS in methanol and dilute to 100 ml with the same solvent.

**Reference solution (b).** Dilute 1 ml of the test solution to 100 ml with methanol.

**Chromatographic system.**

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilyl silica gel (5 µm),
- column temperature. 45º,
- mobile phase: A. a mixture of 100 ml of acetonitrile, 200 ml of methanol and 650 ml of water, allowed to equilibrate, diluted to 1000 ml with water and mixed again,
- B. acetonitrile,
- flow rate. 2.5 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Mobile Phase A (per cent v/v)</th>
<th>Mobile Phase B (per cent v/v)</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
<td>Isocratic</td>
</tr>
<tr>
<td>25</td>
<td>100</td>
<td>0</td>
<td>begin linear gradient</td>
</tr>
<tr>
<td>40</td>
<td>40</td>
<td>60</td>
<td>end chromatogram, change to 100B</td>
</tr>
<tr>
<td>41</td>
<td>0</td>
<td>100</td>
<td>being treatment with B</td>
</tr>
<tr>
<td>46</td>
<td>0</td>
<td>100</td>
<td>end treatment, return to 100A</td>
</tr>
<tr>
<td>47</td>
<td>100</td>
<td>0</td>
<td>begin equilibration with A</td>
</tr>
<tr>
<td>52=0</td>
<td>100</td>
<td>0</td>
<td>end equilibration, begin next chromatogram</td>
</tr>
</tbody>
</table>
Equilibrate the column with the mobile phase B for at least 30 minutes and then with mobile phase A for 5 minutes. For subsequent chromatograms, use the conditions described from 40.0 to 52.0 minutes.

Adjust the sensitivity of the system so that the height of the principal peak in the chromatogram obtained with reference solution (b) is not less than 50 per cent of the full scale of the recorder.

Inject reference solution (a). The retention times are: prednisone, about 19 minutes and prednisolone about 23 minutes. The test is not valid unless the resolution between the peaks corresponding to prednisone and prednisolone is at least 2.7. If necessary, adjust the concentration of acetonitrile in mobile phase A.

Inject separately methanol as a blank, the test solution and reference solution (b). In the chromatogram obtained with the test solution: the area of any peak other than the principal peak is not greater than 0.25 times the area of the principal peak, is not greater than 0.75 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.75 per cent). Ignore any peak due to the blank run and any peak with an area less than 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (b).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105º for 3 hours.

Assay. Weigh accurately about 0.1 g and dissolve in sufficient ethanol to produce 100.0 ml. Dilute 2.0 ml of this solution to 100.0 ml with ethanol. Measure the absorbance of the resulting solution at the maximum at about 238 nm. Calculate the content of C_{21}H_{26}O_{5} taking 425 as the specific absorbance at 238 nm.

Storage. Store protected from light.

Prednisone Tablets

Prednisone Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of prednisone, C_{21}H_{26}O_{5}.

Identification

Shake a quantity of the powdered tablets containing 30 mg of Prednisone with 10 ml of chloroform, filter and evaporate the filtrate to dryness. The residue complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with prednisone RS or with the reference spectrum of prednisone.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Solvent mixture. A mixture of 90 volumes of acetone and 10 volumes of formamide.

Mobile phase. Chloroform.

Test solution. Dissolve 25 mg of the residue in 10 ml of the solvent mixture.

Reference solution (a). Dissolve 25 mg of prednisone RS in 10 ml of the solvent mixture.

Reference solution (b). Mix equal volumes of the test solution and reference solution (a).

Place the dry plate in a tank containing a shallow layer of the solvent mixture, allow the solvent mixture to ascend to the top, remove the plate from the tank and allow the solvent to evaporate. Use within 2 hours, with the flow of the mobile phase in the direction in which the aforementioned treatment was done.

Apply to the plate 2 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air, allow the solvent to evaporate, heat at 120º for 15 minutes and spray the hot plate with ethanolic sulphuric acid (20 per cent v/v). Heat at 120º for a further 10 minutes, allow to cool and examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

Tests

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Shake a quantity of the powdered tablets containing 25 mg of Prednisone with 10 ml of methanol for 10 minutes, mix with the aid of ultrasound for 2 minutes and filter the extract (Whatman GF/F is suitable).

Reference solution (a). Dissolve 2.0 mg of prednisolone RS and 2.0 mg of prednisone RS in methanol and dilute to 100 ml with the same solvent.

Reference solution (b). Dilute 1 ml of the test solution to 100 ml with methanol.

Chromatographic system

– a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilyl silica gel (5 µm),
column temperature. 45º,

mobile phase: A. a mixture of 100 ml of acetonitrile, 200 ml of methanol and 650 ml of water, allowed to equilibrate, diluted to 1000 ml with water and mixed again, B. acetonitrile,

flow rate. 2.5 ml per minute,

a linear gradient programme using the conditions given below,

spectrophotometer set at 254 nm,

a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Mobile Phase A (per cent v/v)</th>
<th>Mobile Phase B (per cent v/v)</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
<td>Isocratic</td>
</tr>
<tr>
<td>25</td>
<td>100</td>
<td>0</td>
<td>begin linear gradient</td>
</tr>
<tr>
<td>40</td>
<td>40</td>
<td>60</td>
<td>end chromatogram, change to 100B</td>
</tr>
<tr>
<td>41</td>
<td>0</td>
<td>100</td>
<td>being treatment with B</td>
</tr>
<tr>
<td>46</td>
<td>0</td>
<td>100</td>
<td>end treatment, return to 100A</td>
</tr>
<tr>
<td>47</td>
<td>100</td>
<td>0</td>
<td>begin equilibration with A</td>
</tr>
<tr>
<td>52=0</td>
<td>100</td>
<td>0</td>
<td>end equilibration, begin next chromatogram</td>
</tr>
</tbody>
</table>

Equilibrate the column with the mobile phase B for at least 30 minutes and then with mobile phase A for 5 minutes. For subsequent chromatograms use the conditions described from 40.0 to 52.0 minutes.

Adjust the sensitivity of the system so that the height of the principal peak in the chromatogram obtained with reference solution (b) is not less than 50 per cent of the full scale of the recorder.

Inject reference solution (a). The retention times are: prednisone, about 19 minutes and prednisolone about 23 minutes. The test is not valid unless the resolution between the peaks corresponding to prednisone and prednisolone is at least 2.7. If necessary, adjust the concentration of acetonitrile in mobile phase A.

Inject separately methanol as a blank, the test solution and reference solution (b). In the chromatogram obtained with the test solution: the area of any peak other than the principal peak is not greater than 0.25 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.25 per cent); the sum of the areas of all the peaks, apart from the principal peak, is not greater than 0.75 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.75 per cent). Ignore any peak due to the blank run and any peak with an area less than 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (b).

Uniformity of content. Comply with the test stated under Tablets.

Powder one tablet, add 50 ml of ethanol (95 per cent), shake for 30 minutes, add sufficient ethanol (95 per cent) to produce 100.0 ml. Centrifuge and pipette a suitable volume of the supernatant liquid equivalent to 0.5 mg of Prednisone and dilute to 50.0 ml with ethanol (95 per cent). Measure the absorbance of the resulting solution at the maximum at about 240 nm (2.4.7). Calculate the content of C₂₁H₂₆O₅ taking 415 as specific absorbance at 240 nm.

Dissolution (2.5.2).

Apparatus. No 1

Medium. 900 ml of water

Speed and time. 50 rpm and 30 minutes.

Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate at the maximum at about 240 nm (2.4.7). Calculate the content of C₂₁H₂₆O₅ in the medium from the absorbance obtained from a solution of known concentration of prednisone RS.

D. Not less than 70 per cent of the stated amount of C₂₁H₂₆O₅.

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).

Internal standard solution. Dissolve an accurately weighed quantity of acetanilide in a 50 per cent v/v solution of methanol to obtain a solution having a known concentration of 0.11 mg per ml.

Test solution. Weigh and powder 20 tablets. To an accurately weighed quantity of the powdered tablets containing about 20 mg of Prednisone add 5 ml of water, mix with the aid of ultrasound for 1 minute, add 50 ml of methanol and mix with the aid of ultrasound for 1 minute. Dilute with water to 100.0 ml and mix. To 5.0 ml of this solution add 5.0 ml of internal standard solution and dilute to 50.0 ml with a 50 per cent v/v solution of methanol and mix. Filter through a 5 µm filter and discard the first 20 ml of the filtrate.

Reference solution. Weigh accurately a suitable quantity of prednisone RS and dissolve in a 50 per cent v/v solution of methanol to obtain a solution having a concentration of about 0.2 mg per ml. To 5.0 ml of this solution add 5.0 ml of internal standard solution and dilute to 50.0 ml with a 50 per cent v/v solution of methanol.

Chromatographic system

- a stainless steel column 25 cm x 4 mm, packed with octadecylsilane chemically bonded to porous silica particles (3 to 10 µm),
mobile phase: a suitable filtered mixture of 688 volumes of water, 250 volumes of peroxide-free tetrahydrofuran and 62 volumes of methanol such that at a flow rate of 1 ml per minute the retention times of prednisone and acetanilide are about 8 and 6 minutes respectively, spectrophotometer set at 254 nm, a 10 µl loop injector.

Inject the reference solution. Adjust the operating parameters such that the peak obtained is about 50 per cent of the full scale. The relative standard deviation for replicate injections is not more than 2.0 per cent and the resolution between prednisone and the internal standard is not less than 3.0.

Inject alternately the test solution and the reference solution. Calculate the content of C₂₁H₂₆O₅ in the tablets.

Storage. Store protected from light.

Primaquine Phosphate

\[
\begin{align*}
\text{C}_{15}\text{H}_{21}\text{N}_3\text{O}, 2\text{H}_3\text{PO}_4, \text{ Mol. Wt. 455.3} \\
\text{Primaquine Phosphate is (RS)-8-(4-amino-1-methylbutylamino)-6-methoxyquinoline diphosphate.}
\end{align*}
\]

Primaquine Phosphate contains not less than 98.5 per cent and not more than 101.5 per cent of C₁₅H₂₁N₃O₂H₃PO₄, calculated on the dried basis.

Description. An orange, crystalline powder; odourless or almost odourless.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with primaquine phosphate RS or with the reference spectrum of primaquine phosphate.

B. When examined in the range 300 nm to 450 nm (2.4.7), a 0.015 per cent w/v solution in 0.01 M hydrochloric acid shows absorption maxima at about 332 nm and 415 nm; absorbance at about 332 nm, about 0.68 to 0.78 and at about 415 nm, 0.41 to 0.53. Dilute 5 ml of the solution to 50 ml with 0.01 M hydrochloric acid. When examined in the range 215 nm to 310 nm, the resulting solution shows absorption maxima at about 225 nm, 265 nm and 282 nm; absorbances at the maxima are 0.74 to 0.77, 0.50 to 0.53 and 0.50 to 0.52, respectively.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel F254.

Mobile phase. A mixture of 60 volumes of chloroform, 40 volumes of methanol and 1 volume of strong ammonia solution.

Test solution. Dissolve 0.2 g in 5 ml of water, dilute to 10 ml with methanol and dilute 1 volume of the resulting solution to 10 volumes with methanol (50 per cent).

Reference solution. Dissolve 20 mg of primaquine phosphate RS in 5 ml of water, dilute to 10 ml with methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

D. Dissolve 50 mg in 5 ml of water, add 2 ml of 2 M sodium hydroxide and shake with two quantities, each of 5 ml, of chloroform. The aqueous layer, acidified by the addition of nitric acid, gives reaction B of phosphates (2.3.1).

Tests

\[\text{pH (2.4.24). 2.5 to 3.5, determined in a 1.0 per cent w/v solution.}\]

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Add 0.2 ml of strong ammonia solution to 1 ml of a 1.0 per cent w/v solution of the substance under examination, shake with 10 ml of the mobile phase and use the clear, lower layer.

Reference solution (a). Dilute 3 ml of the test solution to 100 ml with the mobile phase.

Reference solution (b). Dilute 1 ml of the test solution to 10 ml with the mobile phase and further dilute 1 ml of the resulting solution to 50 ml with the same solvent.

Reference solution (c). Add 0.2 ml of strong ammonia solution to 1 ml of a 1.0 per cent w/v solution of the primaquine phosphate RS, shake with 10 ml of the mobile phase and use the clear, lower layer.

Chromatographic system

- a stainless steel column 20 cm x 4.6 mm, packed with porous silica particles (10 µm),
- mobile phase: a mixture of 45 volumes of chloroform, 45 volumes of hexane, 10 volumes of methanol and 0.1 volume of strong ammonia solution,
- flow rate, 3 ml per minute,
- spectrophotometer set at 261 nm,
- a 20 µl loop injector.

The test is not valid unless in the chromatogram obtained with reference solution (c) there is a peak just before the principal peak with an area of about 6 per cent of that of the principal peak and the resolution between these peaks is not less than 2.0.

Inject each solution and record the chromatograms for at least twice the retention time of primaquine. The sum of the areas of any secondary peaks in the chromatogram obtained with the test solution is not greater than the area of the principal peak in the chromatogram obtained with reference solution (a). Ignore any peak the area of which is less than that of the principal peak in the chromatogram obtained with reference solution (b).

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.2 g, dissolve in 40 ml of anhydrous glacial acetic acid with gentle heating. Titrate with 0.1 M perchloric acid, determining the end point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02277 g of C₁₅H₂₁N₃O₂H₃PO₄.

**Storage.** Store protected from light and moisture.

### Primaquine Tablets

**Primaquine Phosphate Tablets**

Primaquine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of primaquine, C₁₅H₂₁N₃O. The tablets are coated.

**Identification**

A. Dissolve a quantity of the powdered tablets containing 60 mg of primaquine in a mixture of 10 ml of water and 2 ml of 2 M sodium hydroxide and extract with two quantities, each of 20 ml, of chloroform. Wash the chloroform extracts with water, dry over anhydrous sodium sulphate, evaporate to dryness and dissolve the residue in 2 ml of chloroform. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with primaquine phosphate RS or with the reference spectrum of primaquine.

B. Extract a quantity of the powdered tablets containing 25 mg of primaquine with 10 ml of water and filter. To 2 ml of the filtrate add 3 ml of water and 1 ml of a 0.5 per cent w/v solution of ceric ammonium sulphate in 2 M nitric acid; a deep violet colour is produced immediately.

### Tests

**Uniformity of content.** Comply with the tests stated under Tablets.

Transfer one tablet into a suitable container, add 5 ml of hydrochloric acid, disperse the tablet in about 25 g of crushed ice and add sufficient water to produce 50.0 ml. Carry out the nitrite titration (2.3.31), using 0.01 M sodium nitrite as titrant. Carry out a blank titration.

1 ml of 0.01 M sodium nitrite is equivalent to 0.002594 g of C₁₅H₂₁N₃O.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.15 g of primaquine, dissolve in 20 ml of water, add 5 ml of 2 M sodium hydride and extract with four quantities, each of 25 ml, of chloroform. Combine the chloroform extracts and evaporate to a volume of about 10 ml. Add 40 ml of anhydrous glacial acetic acid, Titrate with 0.1 M perchloric acid, determining the end point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01297 g of C₁₅H₂₁N₃O.

**Storage.** Store protected from moisture.

**Labelling.** The label states the strength in terms of the equivalent amount of primaquine.

### Probenecid

**Tests**

**Uniformity of content.** If tests B and C are carried out, tests A may be omitted. Tests B and C may be omitted if test A is carried out.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.15 g of probenecid, dissolve in 20 ml of water, add 5 ml of 2 M sodium hydride and extract with four quantities, each of 25 ml, of chloroform. Combine the chloroform extracts and evaporate to a volume of about 10 ml. Add 40 ml of anhydrous glacial acetic acid, Titrate with 0.1 M perchloric acid, determining the end point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01297 g of C₁₅H₂₁N₃O.

**Storage.** Store protected from moisture.

**Labelling.** The label states the strength in terms of the equivalent amount of probenecid.
B. When examined in the range 210 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in a mixture of 9 volumes of ethanol (95 per cent) and 1 volume of 0.1 M hydrochloric acid shows absorption maxima at about 223 nm and 248 nm; absorbance at about 248 nm is about 0.33.

C. Dissolve 0.2 g in about 0.6 ml of 2 M ammonia and add 3 ml of 1.7 per cent w/v solution of silver nitrate; a white precipitate is produced which is soluble in an excess of dilute ammonia solution.

**Tests**

**Appearance of solution.** A 10.0 per cent w/v solution in 2 M sodium hydroxide is clear (2.4.1), and not more intensely coloured than reference solution YS6 (2.4.1).

**Acidity.** Add 2.0 g to 100 ml of water, heat on a water-bath for 30 minutes, cool, filter and dilute with water to 100.0 ml. Titrate 50.0 ml of the solution with 0.1 M sodium hydroxide using phenolphthalein solution as indicator. Not more than 0.5 ml of 0.1 M sodium hydroxide is required to change the colour of the solution.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 55 volumes of toluene, 20 volumes of di-isopropyl ether, 15 volumes of chloroform and 10 volumes of glacial acetic acid.

**Test solution.** Dissolve 0.1 g of the substance under examination in 10 ml of acetone.

**Reference solution.** A 0.005 per cent w/v solution of the substance under examination in acetone.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.5 g and dissolve in 100 ml of ethanol (95 per cent), shaking well and heating gently if necessary. Cool and titrate with 0.1 M sodium hydroxide, using bromothymol blue solution as indicator. Carry out a blank titration.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.02854 g of C₁₃H₁₉O₄S₃.

**Storage.** Store protected from moisture.

**Probenecid Tablets**

Probenecid Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of probenecid, C₁₃H₁₉O₄S₃.

**Identification**

A. Triturate a quantity of the powdered tablets containing 0.5 g of Probenecid with ethanol (95 per cent), filter and concentrate the filtrate by evaporation on a water-bath. Cool, filter and recrystallise the residue from ethanol (50 per cent). The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with probenecid RS or with the reference spectrum of probenecid.

B. When examined in the range 210 nm to 360 nm (2.4.7), the final solution obtained in the Assay shows absorption maxima at about 225 nm and 248 nm.

C. The residue obtained in test A melts at about 199º (2.4.21).

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 55 volumes of toluene, 20 volumes of di-isopropyl ether, 15 volumes of chloroform and 10 volumes of glacial acetic acid.

**Test solution.** Extract a quantity of the powdered tablets containing 0.2 g of Probenecid with 20 ml of acetone, filter and use the filtrate.

**Reference solution.** Dilute 1 ml of the test solution to 200 ml with acetone.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Dissolution** (2.5.2).

Apparatus. No 1 Medium. 900 ml of phosphate buffer pH 7.6

Speed and time. 50 rpm and 30 minutes.

Withdraw a suitable volume of the medium and filter, Dilute 4.0 ml of the filtrate to 100.0 ml with 0.1 M sodium hydroxide. Measure the absorbance of the resulting solution at the maximum at about 244 nm (2.4.7). Similarly measure the absorbance of a solution of a known concentration of probenecid RS. Calculate the content of C₁₃H₁₉O₄S₃.

D. Not less than 80 per cent of the stated amount of C₁₃H₁₉O₄S₃.
**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.2 g of Probencid, add 200 ml of ethanol (95 per cent) and 5 ml of 1 M hydrochloric acid, heat on a water-bath at 70° for 30 minutes, shaking occasionally. Cool, add sufficient ethanol (95 per cent) to produce 250.0 ml and filter. To 5.0 ml of the filtrate add 5 ml of 0.1 M hydrochloric acid, dilute to 250.0 ml with ethanol (95 per cent) and measure the absorbance of the resulting solution at the maximum at about 248 nm (2.4.7). Calculate the content of C₁₃H₁₉NO₄S taking 332 as specific absorbance at 248 nm.

**Storage.** Store protected from moisture.

---

**Procainamide Hydrochloride**

![Chemical Structure](https://example.com/structure.png)

C₁₃H₂₁N₃O.HCl  Mol. Wt. 271.8

Procainamide Hydrochloride is 4-amino-N-[2-(diethylamino)ethyl]benzamide hydrochloride.

Procainamide Hydrochloride contains not less than 98.0 per cent and not more than 101.0 per cent of C₁₃H₂₁N₃O.HCl, calculated on the dried basis.

**Description.** A white or very slightly yellow, crystalline powder; hygroscopic.

**Identification**

*Test A* may be omitted if tests *B, C and D* are carried out. Tests *B, C and D* may be omitted if test *A* is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *procainamide hydrochloride RS* or with the reference spectrum of procainamide hydrochloride.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.1 M sodium hydroxide shows an absorption maximum at about 273 nm; absorbance at about 273 nm, 0.58 to 0.61.

C. Dilute 1 ml of a solution, prepared by dissolving 2.5 g in sufficient carbon dioxide-free water to produce 25 ml, to 2 ml with water. 1 ml of this solution gives the reaction of primary aromatic amines (2.3.1).

D. A 2 per cent w/v solution gives reaction A of chlorides (2.3.1).

**Tests**

**Appearance of solution.** A 10.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and not more intensely coloured than reference solution BS6 (2.4.1).

**pH.** 5.6 to 6.3, determined in a 10.0 per cent w/v solution.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel GF254.*

**Mobile phase.** A mixture of 60 volumes of 1-butanol, 30 volumes of water and 15 volumes of glacial acetic acid.

**Test solution.** Dissolve 0.1 g of the substance under examination in 10 ml of ethanol (95 per cent).

**Reference solution.** A 0.005 per cent w/v solution of the substance under examination in ethanol (95 per cent).

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°.

**Assay.** Weigh accurately about 0.25 g, dissolve in 75 ml of water and 10 ml of hydrochloric acid and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02718 g of C₁₃H₂₁N₃O.HCl.

**Storage.** Store protected from moisture.

---

**Procainamide Injection**

Procainamide Hydrochloride Injection

Procainamide Injection is a sterile solution of Procainamide Hydrochloride in Water for Injections. It may contain Sodium Metabisulphite as a stabilising agent.

Procainamide Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of procainamide hydrochloride, C₁₃H₂₁N₃O.HCl.

**Identification**

A. Dilute a volume containing 0.25 g of Procainamide Hydrochloride to 25 ml with water, make alkaline with 5 M sodium hydroxide and extract with two quantities, each of 5 ml, of chloroform. Filter the combined extracts through anhydrous sodium sulphate, evaporate the filtrate to dryness...
using a rotatory evaporator and dissolve the residue in 5 ml of chloroform.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with procainamide hydrochloride RS or with the reference spectrum of procainamide.

B. Dilute a suitable volume of the injection with water to produce a solution containing 0.0005 per cent w/v of Procainamide Hydrochloride. Absorbance of the resulting solution at about 280 nm, about 0.30 (2.4.7).

C. Gives the reactions of chlorides (2.3.1).

**Tests**

**pH** (2.4.24). 4.0 to 5.5.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 60 volumes of 1-butanol, 30 volumes of water and 15 volumes of glacial acetic acid.

Test solution. Dilute a volume of the injection containing 0.1 g of Procainamide Hydrochloride to 5 ml with methanol.

Reference solution. Dilute 1 volume of the test solution to 100 volumes with methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** To a volume containing about 0.25 g of Procainamide Hydrochloride add 45 ml of 6 M hydrochloric acid and boil for 1 minute. Carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02718 g of C₁₃H₂₁N₃O, HCl.

**Storage.** Store protected from light.

**Procainamide Tablets**

Procainamide Hydrochloride Tablets

Procainamide Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of procainamide hydrochloride, C₁₃H₂₀N₂O₂.HCl.

**Identification**

A. Shake a quantity of the powdered tablets containing 0.25 g of Procainamide Hydrochloride with 25 ml of water, make alkaline with 5 M sodium hydroxide and extract with two quantities, each of 5 ml, of chloroform. Filter the combined extracts through anhydrous sodium sulphate, evaporate the filtrate to dryness using a rotatory evaporator and dissolve the residue in 5 ml of chloroform.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with procainamide hydrochloride RS or with the reference spectrum of procainamide.

B. Triturate a quantity of the powdered tablets containing 1 g of Procainamide Hydrochloride with 10 ml of water and filter. The filtrate gives the reactions of chlorides (2.3.1).

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 60 volumes of 1-butanol, 30 volumes of water and 15 volumes of glacial acetic acid.

Test solution. Shake a quantity of the powdered tablets containing 0.4 g of Procainamide Hydrochloride with 20 ml of methanol (90 per cent) for 15 minutes and filter.

Reference solution. Dilute 1 volume of the test solution to 100 volumes with methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.25 g of Procainamide Hydrochloride, add 100 ml of 6 M hydrochloric acid, shake for 15 minutes and boil for 1 minute. Carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02718 g of C₁₃H₂₁N₃O, HCl.

**Storage.** Store protected from light and moisture.

**Procaine Hydrochloride**

![Procaine Hydrochloride structure](image)

C₁₀H₁₅N₂O₂.HCl  Mol. Wt. 272.8

Procaine Hydrochloride is 2-(diethylamino)ethyl 4-aminobenzoate hydrochloride.
Procaine Hydrochloride contains not less than 99.0 per cent and not more than 101.0 per cent of C\textsubscript{13}H\textsubscript{20}N\textsubscript{2}O\textsubscript{2}, HCl, calculated on the dried basis.

**Description.** Colourless crystals or a white, crystalline powder; odourless.

**Identification**

*Test A may be omitted if tests B, C, D and E are carried out. Tests B, C and D may be omitted if tests A and E are carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with procaine hydrochloride RS or with the reference spectrum of procaine hydrochloride.

B. To 0.2 ml of a 5 per cent w/v solution add 2 ml of water and 0.5 ml of 1 M sulphuric acid, shake and add 1 ml of a 0.1 per cent w/v solution of potassium permanganate; the colour is immediately discharged.

C. To about 5 mg add 0.5 ml of fuming nitric acid, evaporate to dryness on a water-bath, cool, dissolve the residue in 5 ml of acetone and add 1 ml of 0.1 M ethanolic potassium hydroxide; only a brownish red colour develops.

D. Dilute 1 ml of a 5 per cent w/v solution to 100 ml with water; 2 ml of the solution gives the reaction of primary aromatic amines (2.3.1).

E. Gives reaction A of chlorides (2.3.1).

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and colourless (2.4.1).

**pH** (2.4.24). 5.0 to 6.5, determined in a 2.0 per cent w/v solution.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 80 volumes of dibutyl ether, 16 volumes of n-hexane and 4 volumes of glacial acetic acid.

**Test solution.** A 10 per cent w/v solution of the substance under examination in water.

**Reference solution.** A 0.005 per cent w/v solution of 4-aminobenzoic acid in water.

Apply to the plate 5 µl of each solution. After development, dry the plate at 105º for 10 minutes and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution. The principal spot remains on the line of application.

**Heavy metals** (2.3.13). 2.0 g complies with the limit test for heavy metals, Method A (10 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.3 g, dissolve in 50 ml of 2 M hydrochloric acid, add 3 g of potassium bromide, cool in ice and titrate slowly with 0.1 M sodium nitrite, stirring constantly. Determine the end point potentiometrically (2.4.25). 1 ml of 0.1 M sodium nitrite is equivalent to 0.02728 g of C\textsubscript{13}H\textsubscript{20}N\textsubscript{2}O\textsubscript{2}, HCl.

**Storage.** Store protected from light.

---

**Procaine and Adrenaline Injection**

Procaine Hydrochloride and Adrenaline Bitartrate Injection; Procaine Hydrochloride and Epinephrine Bitartrate Injection

Procaine and Adrenaline Injection is a sterile solution of Procaine Hydrochloride and Adrenaline Bitartrate in Water for Injections.

Procaine and Adrenaline Injection contains not less than 1.9 per cent and not more than 2.1 per cent w/v of procaine hydrochloride, C\textsubscript{13}H\textsubscript{20}N\textsubscript{2}O\textsubscript{2}, HCl and the equivalent of not less than 0.00175 per cent and not more than 0.00225 per cent w/v of adrenaline, C\textsubscript{9}H\textsubscript{13}NO\textsubscript{3}.

**Description.** A clear, colourless solution.

**Identification**

A. To 5 ml add 5 ml of water and 10 ml of picric acid solution, shake gently and set aside for 1 hour; the crystalline precipitate, after washing with water and drying at 100º, melts at about 134º (2.4.21).

B. To 5 ml add 1 ml of hydrochloric acid, cool to 0º, add 5 ml of sodium nitrite solution and pour the mixture into 2 ml of 2-naphthol solution containing 1 g of sodium acetate; an orange-red colour is produced.

C. To 10 ml add 4 ml of disodium hydrogen phosphate solution and sufficient 0.1 M iodine to produce a distinct brown colour. Add 0.1 M sodium thiosulphate to remove the excess of iodine; a pink colour is produced.

**Tests**

**pH** (2.4.24). 3.0 to 5.5.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** For procaine hydrochloride — To 10.0 ml of the injection add 0.5 g of sodium carbonate and extract with three
quantities, each of 20 ml, of a mixture of 1 volume of 2-propanol and 3 volumes of chloroform until complete extraction of procaine is effected. Shake the combined extracts with 5 ml of water, wash the water with the solvent mixture and add the washing to the combined extracts. Shake the combined extracts and washings with 10.0 ml of 0.1 M hydrochloric acid, separate the acid layer, wash the combined extracts and washings with 5 ml of water, add the aqueous extract to the separated acid layer and titrate with 0.1 M sodium hydroxide, using methyl red-methylene blue solution as indicator.

1 ml of 0.1 M hydrochloric acid is equivalent to 0.02728 g of C_{13}H_{20}N_{2}O_{2}.HCl.

For adrenaline — To 10.0 ml of the injection add 20 mg of sodium metabisulphite, 0.1 ml of ferrous sulphate-citrate solution, 1 ml of glycine buffer solution and mix. Allow to stand for 10 minutes, extract with 10 ml of ether, allow to separate, reject the ether and measure the absorbance of a 4-cm layer of the solution at about 540 nm (2.4.7). Calculate the content of adrenaline, C_{9}H_{13}NO_{3}, from a reference curve prepared by treating suitable aliquots of a solution of adrenaline bitartrate RS in the same manner.

1 mg of adrenaline bitartrate is equivalent to 0.0005497 g of C_{9}H_{13}NO_{3}.

Storage. Store protected from light.

Labelling. The label states the strength as “Procaine Hydrochloride, 2 per cent w/v; Adrenaline, 0.002 per cent w/v”.

**Procaine Penicillin**

![Chemical structure of Procaine Penicillin](image)

C_{13}H_{20}N_{2}O_{2}.C_{16}H_{18}N_{2}O_{4}S.H_{2}O  Mol. Wt. 588.7

Procaine Penicillin is 2-diethylaminoethyl 4-aminobenzoate (6R)-6-(2-phenylacetamido)penicillanate monohydrate.

Procaine Penicillin contains not less than 51 per cent and not more than 59.6 per cent of penicillin G, calculated as C_{16}H_{18}N_{2}O_{4}S, and not less than 37.5 per cent and not more than 43.0 per cent of procaine, C_{13}H_{20}N_{2}O_{2}, both calculated on the anhydrous basis.

**Description.** A white, crystalline powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *procaine penicillin RS* or with the reference spectrum of procaine penicillin.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution (a).

C. A turbid solution of 0.1 g in 2 ml of 2 M hydrochloric acid gives the reaction of primary aromatic amines (2.3.1).

**Tests**

**pH** (2.4.24). 5.0 to 7.5, determined in a solution prepared by shaking 50 mg in sufficient carbon dioxide-free water to produce 15 ml until dissolution is complete.

**Specific optical rotation** (2.4.22). +165º to +180º, determined in a solution prepared by dissolving 0.25 g in sufficient of a mixture of 3 volumes of acetone and 2 volumes of water to produce 25 ml.

**Water** (2.3.43). 2.8 to 4.2 per cent, determined on 0.5 g.

**Assay.** Determine the contents of benzyl penicillin and procaine by liquid chromatography, (2.4.14).

**Test solution.** Weigh accurately 70 mg of the substance under examination and dissolve in 30 ml of the mobile phase with the aid of ultrasound for about 2 minutes. Dilute to 50.0 ml with the mobile phase.

**Reference solution (a).** Weigh accurately about 56 mg of benzyl penicillin potassium RS and 40 mg of procaine hydrochloride RS and dissolve in 25 ml of the mobile phase with the aid of ultrasound for about 2 minutes. Dilute to 50.0 ml with the mobile phase.

**Reference solution (b).** Mix 1 volume of a 0.24 per cent w/v solution of phenoxymethylpenicillin potassium RS in the mobile phase with 3 volumes of reference solution (a).

**Chromatographic system**

- a stainless steel column 30 cm x 4 mm, packed with octadecylsilyl silica gel (10 µm),
- mobile phase: a mixture of 50 volumes of a solution prepared by mixing 14 g of potassium dihydrogen phosphate in 6.5 g of tetrabutylammonium hydroxide (40 per cent) and adjusting the pH to 7.0 with 1 M potassium hydroxide or dilute phosphoric acid, 25 volumes of acetonitrile and 25 volumes of water, flow rate. 1 ml per minute,
- spectrophotometer set at 235 nm,
- a 20 µl loop injector.

Inject reference solution (b). The resolution between benzyl penicillin potassium and phenoxymethylpenicillin potassium is not less than 2. The relative retention time of procaine with reference to benzyl penicillin is about 2.2.

Inject the test solution and reference solution (a). Record the peak responses of the main peaks of benzyl penicillin and
procaine. Calculate the content of benzyl penicillin, \(C_{16}H_{18}N_2O_4S\) and the content of procaine, \(C_{13}H_{20}N_2O_2\) using the factor of 0.866 for converting the content of procaine hydrochloride to that of procaine.

**Procaine Penicillin intended for use in the manufacture of Parenteral Preparations without a further procedure for the removal of bacterial endotoxins complies with the following additional requirement.**

**Bacterial endotoxins (2.2.3).** Not more than 0.10 Endotoxin Unit per mg.

**Procaine Penicillin intended for use in the manufacture of Parenteral Preparations without a further sterilisation procedure complies with the following additional requirement.**

**Sterility.** Complies with the test for sterility (2.2.11).

**Storage.** Store protected from moisture. If the material is intended for use in the manufacture of parenteral preparations, the container should be sterile and sealed so as to exclude micro-organisms.

**Labelling.** The label states (1) where applicable, that the contents are free from bacterial endotoxins; (2) where applicable, that the contents are sterile.

---

**Fortified Procaine Penicillin Injection**

**Procaine Penicillin with Benzylpenicillin Injection**

Fortified Procaine Penicillin Injection is a sterile mixture of five parts of Procaine Penicillin and one part of Benzylpenicillin Potassium or Benzylpenicillin Sodium, together with suitable dispersing and buffering agents. It is filled in a sealed container. The injection is constituted by suspending the contents of the sealed container in the requisite amount of sterile Water for Injections, immediately before use.

**Storage.** The constituted injection should be used within 24 hours (4 days if a buffering agent is present) of preparation when stored at a temperature not exceeding 20º or within 7 days (14 days if a buffering agent is present) when stored at a temperature between 2º and 8º.

Fortified Procaine Penicillin Injection contains a quantity of total penicillins calculated as \(C_{16}H_{18}N_2NaO_4S\) and equivalent to not less than 60.0 per cent and not more than 74.0 per cent of the stated amounts of procaine penicillin and benzylpenicillin potassium or benzylpenicillin sodium and a quantity of procaine, \(C_{13}H_{20}N_2O_2\), equivalent to not less than 36.0 per cent and not more than 44.0 per cent of the stated amount of procaine penicillin.

**Description.** A white or almost white powder.

The contents of the sealed container comply with the tests stated under Parenteral Preparations (Powders for Injection) and with the following requirements.

**Identification**

A. Dissolve 10 mg in 10 ml of water and add 0.5 ml of neutral red solution. Add sufficient 0.01 M sodium hydroxide to give a permanent orange colour and then add 1 ml of penicillinase solution; a red colour is produced rapidly.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

C. Give the reaction of primary aromatic amines (2.3.1), producing a bright, orange-red precipitate.

**Tests**

**Water (2.3.43).** Not more than 3.5 per cent, determined on 0.5 g.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh accurately a quantity of the mixed contents of 10 containers equivalent to about 70 mg of procaine penicillin and dissolve in 30 ml of the mobile phase with the aid of ultrasound for about 2 minutes. Dilute to 50.0 ml with the mobile phase.

**Reference solution (a).** Weigh accurately about 56 mg of benzylpenicillin potassium RS and 40 mg of procaine hydrochloride RS and dissolve in 25 ml of the mobile phase with the aid of ultrasound for about 2 minutes. Dilute to 50.0 ml with the mobile phase.

**Reference solution (b).** Mix 1 volume of a 0.24 per cent w/v solution of phenoxymethylpenicillin potassium RS in the mobile phase with 3 volumes of reference solution (a).

**Chromatographic system**

- a stainless steel column 30 cm x 4 mm, packed with octadecylsilyl silica gel (10 µm),
- mobile phase: a mixture of 50 volumes of a solution prepared by mixing 14 g of potassium dihydrogen phosphate in 6.5 g of tetrabutyl ammonium hydroxide (40 per cent) and adjusting the pH to 7.0 with 1 M potassium hydroxide or dilute phosphoric acid, 25 volumes of acetonitrile and 25 volumes of water,
- flow rate, 1 ml per minute,
- spectrophotometer set at 235 nm,
- a 20 µl loop injector.

Inject reference solution (b). The resolution between benzylpenicillin potassium and phenoxymethylpenicillin potassium is not less than 2. The relative retention time of procaine with reference to benzylpenicillin is about 2.2.
Inject the test solution and reference solution (a). Record the peak responses of the main peaks of benzyl penicillin and procaine. Calculate the total penicillin content as benzylpenicillin, C_{16}H_{18}N_{2}O_{4}S and the content of procaine, C_{13}H_{20}N_{2}O_{2} using the factor of 0.866 for converting the content of procaine hydrochloride to that of procaine.

**Labelling**. The label states (1) the quantities of Procaine Penicillin and Benzylpenicillin Potassium or Benzylpenicillin Sodium contained in it; (2) the names of any added dispersing and buffering agents; (3) “for intramuscular injection only”.

**Prochlorperazine Maleate**

![Chemical Structure of Prochlorperazine Maleate]

C_{20}H_{24}ClN_{3}S, 2C_{4}H_{4}O_{4}  
Mol. Wt. 606.1

Prochlorperazine Maleate is 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine di(hydrogen maleate).

Prochlorperazine Maleate contains not less than 98.0 per cent and not more than 101.0 per cent of C_{20}H_{24}ClN_{3}S, 2C_{4}H_{4}O_{4}, calculated on the dried basis.

**Description**. A white or pale yellow, crystalline powder; practically odourless.

**Identification**

*Test A* may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.

A. To 20 mg add 5 ml of water and 1 ml of 1 M sodium hydroxide, shake and extract with 10 ml of ether. Wash the ether extract with 5 ml of water, dry with anhydrous sodium sulphate, evaporate to dryness and dissolve the residue in 0.2 ml of chloroform.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *prochlorperazine maleate RS* or with the reference spectrum of prochlorperazine.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in ethanol (95 per cent) containing 0.01 per cent v/v of strong ammonia solution shows an absorption maximum at about 258 nm and a less well-defined maximum at about 313 nm; absorbance at about 258 nm, about 0.6.

C. Complies with the test for identification of phenothiazines (2.3.3).

*Test solution*. A solution containing 0.1 per cent w/v of the substance under examination in a mixture of equal volumes of methanol and chloroform.

*Reference solution*. A 0.1 per cent w/v solution of prochlorperazine maleate RS in the same solvent mixture

Apply 4 µl of each solution.

D. Triturate 0.2 g with a mixture of 3 ml of water and 1 ml of 10 M sodium hydroxide and shake with three quantities, each of 5 ml, of ether. To 0.1 ml of the aqueous layer add a solution of 10 mg of resorcinol in 3 ml of sulphuric acid and heat in a water-bath for 15 minutes; no colour develops. To the remainder of the aqueous layer add 2 ml of bromine solution, heat in a water-bath for 15 minutes, then heat to boiling and cool. To 0.1 ml of the solution add a solution of 10 mg of resorcinol in 3 ml of sulphuric acid and heat in a water-bath for 15 minutes; a blue colour develops.

**Tests**

*Ph* (2.4.24). 3.0 to 4.0, determined in a freshly prepared saturated solution.

**Related substances**. Complies with the test for related substances in phenothiazines (2.3.5), using mobile phase A. Prepare the test solution immediately before use.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay**. Weigh accurately about 0.2 g, in powder, dissolve in 50 ml of anhydrous glacial acetic acid, heating gently on a water-bath, allow to cool. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.03031 g of C_{20}H_{24}ClN_{3}S, 2C_{4}H_{4}O_{4}.

**Storage**. Store protected from light and moisture.

**Prochlorperazine Tablets**

Prochlorperazine Maleate Tablets

Prochlorperazine Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of prochlorperazine maleate, C_{20}H_{24}ClN_{3}S, 2C_{4}H_{4}O_{4}.

**Identification**

A. To a quantity of the powdered tablets containing 40 mg of Prochlorperazine Maleate add 10 ml of water and 2 ml of 1 M
sodium hydroxide, shake and extract with 15 ml of ether. Wash the ether with 5 ml of water, dry with anhydrous sodium sulphate, evaporate to dryness and dissolve the residue in 0.4 ml of chloroform.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with prochlorperazine maleate RS or with the reference spectrum of prochlorperazine.

B. To a quantity of the powdered tablets containing 5 mg of Prochlorperazine Maleate add 5 ml of sulphuric acid and allow to stand for 5 minutes; a red colour is produced.

C. Shake a quantity of the powdered tablets containing 0.2 g of Prochlorperazine Maleate with 2 ml of water and 1 ml of 5 M sodium hydroxide, mix and extract with three quantities, each of 10 ml, of ether. Dry the combined extracts with anhydrous sodium sulphate, filter, evaporate the filtrate to dryness and dissolve the residue in 10 ml of methanol and add a solution of 0.15 g of picric acid in 10 ml of methanol. The precipitate, after washing with a small quantity of methanol, melts at about 255º, with decomposition (2.4.21).

Tests

Related substances. Comply with the test for related substances in phenothiazines (2.3.5), using mobile phase A. Prepare the following solutions freshly.

Test solution. Extract a quantity of the powdered tablets containing 0.1 g of Prochlorperazine Maleate with 10 ml of methanol containing 0.5 per cent v/v of strong ammonia solution and filter.

Reference solution. Dilute 1 volume of the test solution to 200 volumes with the same solvent.

Apply to the plate 20 µl of each solution.

Uniformity of content. (For tablets containing 10 mg or less) — Comply with the test stated under Tablets.

Protect the solutions from light throughout the Assay.

Crush one tablet and extract with three quantities, each of 10 ml, of ethanol containing 1 per cent v/v of strong ammonia solution. Filter the extracts and to the combined filtrates add sufficient ethanol to produce 50.0 ml. Dilute 10.0 ml of this solution to 100.0 ml with ethanol. Dilute further with ethanol, if necessary, to give a final solution containing 10 µg of Prochlorperazine Maleate per ml and measure the absorbance of the resulting solution at the maximum at about 258 nm (2.4.7). Calculate the content of C_{20}H_{24}ClN_{3}S, 2C_{4}H_{4}O_{4} taking 620 as the specific absorbance at 258 nm.

Other tests. Comply with the tests stated under Tablets.

Assay. Protect the solutions from light throughout the Assay.

Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 25 mg of Prochlorperazine Maleate and extract with three quantities, each of 10 ml, of ethanol containing 1 per cent v/v of strong ammonia solution. Filter the extracts and to the combined filtrates add sufficient ethanol to produce 100.0 ml. Dilute 10.0 ml to 50.0 ml with ethanol, dilute 10.0 ml of this solution to 50.0 ml with ethanol and measure the absorbance of the resulting solution at the maximum at about 258 nm (2.4.7). Calculate the content of C_{20}H_{24}ClN_{3}S, 2C_{4}H_{4}O_{4} taking 620 as the specific absorbance at 258 nm.

Storage. Store protected from light and moisture.

Prochlorperazine Mesylate

![Chemical Structure of Prochlorperazine Mesylate](image_url)

C_{20}H_{24}ClN_{3}S, 2CH_{4}SO_{3}  
Mol. Wt. 566.2

Prochlorperazine Mesylate is 2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]phenothiazine di(methanesulphonate).

Prochlorperazine Mesylate contains not less than 98.0 per cent and not more than 101.0 per cent of C_{20}H_{24}ClN_{3}S, 2CH_{4}SO_{3}, calculated on the dried basis.

Description. A white or almost white powder; odourless.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with prochlorperazine mesylate RS or with the reference spectrum of prochlorperazine mesylate.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in ethanol containing 0.01 per cent v/v of strong ammonia solution shows an absorption maximum at about 258 nm and a less well-defined maximum at about 313 nm; absorbance at about 258 nm, about 0.6.

C. Dissolve 5 mg in 2 ml of sulphuric acid and allow to stand for 5 minutes; a red colour is produced.

D. Mix 50 mg with 0.2 g of powdered sodium hydroxide, heat to fusion and continue the heating for a few seconds longer. Cool, add 0.5 ml of water and a slight excess of 2 M hydrochloric acid and warm; sulphur dioxide is evolved which turns moistened starch iodate paper blue.
Tests

pH (2.4.24). 2.0 to 3.0, determined in a 2.0 per cent w/v solution.

Related substances. Complies with the test for related substances in phenothiazines (2.3.5), using mobile phase A.

Test solution. Dissolve the substance under examination in methanol containing 0.5 per cent v/v of strong ammonia solution.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 100º at a pressure not exceeding 0.7 kPa.

Assay. Weigh accurately about 0.5 g, dissolve in 10 ml of water, add 5 ml of 1 M sodium hydroxide and extract with successive quantities of 50, 25, 25 and 25 ml of ether. Wash the combined ether extracts with 5 ml of ether, add the ether to the combined ether extracts and evaporate to dryness. Add 2 ml of ethanol, evaporate to dryness. Titrate with 0.1 M perchloric acid, using 1-naphtholbenzein solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02831 g of C$_{20}$H$_{24}$ClN$_{3}$S, 2CH$_{4}$SO$_{3}$.

Storage. Store protected from light and moisture.

Prochlorperazine Injection

Prochlorperazine Mesylate Injection

Prochlorperazine Injection is a sterile solution of Prochlorperazine Mesylate in Water for Injections free from dissolved air.

Prochlorperazine Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of prochlorperazine mesylate, C$_{20}$H$_{24}$ClN$_{3}$S, 2CH$_{4}$SO$_{3}$.

Identification

A. To a volume containing 0.1 g of Prochlorperazine Mesylate add carefully 2 ml of sulphuric acid and allow to stand for 5 minutes; a red colour is produced.

Tests

pH (2.4.24). 5.5 to 6.5.

Related substances. Carry out the test for related substances in phenothiazines (2.3.5), using mobile phase A.

Test solution. Use the injection under examination.

Reference solution (a). Dilute 1 volume of the test solution to 40 volumes with methanol containing 0.5 per cent v/v of strong ammonia solution immediately before use.

Reference solution (b). Dilute 1 volume of the test solution to 200 volumes with the methanol-ammonia mixture immediately before use.

Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. Protect the solutions from light throughout the Assay.

To an accurately measured volume containing about 25 mg of Prochlorperazine Mesylate add sufficient ethanol containing 0.01 per cent v/v of strong ammonia solution to produce 200.0 ml. Dilute 5.0 ml of this solution to 100.0 ml with the ammoniacal ethanol and measure the absorbance of the resulting solution at the maximum at about 258 nm (2.4.7). Calculate the content of C$_{20}$H$_{24}$ClN$_{3}$S, 2CH$_{4}$SO$_{3}$ taking 635 as the specific absorbance at 258 nm.

Storage. Store protected from light.

Procyclidine Hydrochloride

![Procyclidine Hydrochloride](image_url)

C$_{19}$H$_{29}$NO.HCI  Mol. wt. 323.9

Procyclidine Hydrochloride is (RS)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol hydrochloride.
Procyclidine Hydrochloride contains not less than 99.0 per cent and not more than 101.0 per cent of C\textsubscript{19}H\textsubscript{29}NO.HCl, calculated on the dried basis.

**Description.** A white, crystalline powder, odourless or almost odourless.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with procyclidine hydrochloride RS.

B. Dissolve 0.25 g in 10 ml of water, make alkaline with 5 M ammonia and extract with three quantities, each of 10 ml, of ether. Dry the combined ethereal extracts over anhydrous sodium sulphate, filter, remove the ether and scratch the residue with a glass rod to induce solidification. The residue melts at about 85º (2.4.21).

C. Gives the reactions of chlorides (2.3.1).

**Tests**

**pH** (2.4.24). 4.5 to 6.5, determined in a 1.0 per cent w/v solution.

**Related substances.** A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 100 volumes of ether and 1 volume of strong ammonia solution.

**Test solution.** Dissolve 0.2 g of the substance under examination in 10 ml of chloroform.

**Reference solution (a).** A 0.004 per cent w/v solution of 1-phenyl-3-pyrrolidinopropan-1-one hydrochloride RS in chloroform.

**Reference solution (b).** A 0.01 per cent w/v solution of the substance under examination in chloroform.

Apply to the plate 5 µl of each solution. After development, dry the plate at 105º for 15 minutes and examine in ultraviolet light at 254 nm. Any spot corresponding to 1-phenyl-3-pyrrolidinopropan-1-hydrochloride-1-one in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a). Spray the plate with dilute potassium iodobismuthate solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (b).

B. Determine by gas chromatography (2.4.13).

**Test solution.** Add 5 ml of 1.25 M sodium hydroxide to 20 ml of a 0.015 per cent w/v solution of the substance under examination and mix. Extract with two quantities, each of 20 ml, of ether, add to the combined extracts 5 ml of a 0.06 per cent w/v solution of triphenylethylene (internal standard) in ether, shake with anhydrous sodium sulphate and filter. Evaporate the filtrate and dissolve the residue in 1 ml of ether.

**Reference solution (a).** Prepare in the same manner as the test solution but using 20 ml of a 0.5 per cent w/v solution of the substance under examination and omitting the addition of the internal standard solution.

**Reference solution (b).** Prepare in the same manner as the test solution but using 20 ml of a 0.5 per cent w/v solution of the substance under examination.

**Chromatographic system**

- a glass column 1.5 m x 4 mm, packed with acid-washed, silanised diatomaceous support (such as HP chromosorb W) coated with 10 per cent w/w of modified polyethylene glycol 20M (such as SP-1000) and 2 per cent w/w of potassium hydroxide,
- temperature: column. 240º, inlet port and detector at 240º,
- flow rate. 30 ml per minute of the carrier gas.

The ratio of the sum of the areas of any secondary peaks to the area of the peak due to the internal standard in the chromatogram obtained with reference solution (b) is not more than the ratio of the area of the principal peak to the area of the internal standard peak in the chromatogram obtained with the test solution.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.7 g, dissolve in 75 ml of anhydrous glacial acetic acid, warm if necessary to effect solution and cool. Add 10 ml of mercuric acetate solution. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.03239 g of C\textsubscript{19}H\textsubscript{29}NO.HCl.

**Storage.** Store protected from moisture.

**Procyclidine Tablets**

Procyclidine Hydrochloride Tablets

Procyclidine Tablets contain not than 90.0 per cent and not more than 110.0 per cent of the stated amount of procyclidine hydrochloride, C\textsubscript{19}H\textsubscript{29}NO.HCl.

**Identification**

A. Dissolve a quantity of the powdered tablets containing about 25 mg of Procyclidine Hydrochloride in 10 ml of water,
shake with 20 ml of ether and discard the ether layer. Make the aqueous layer alkaline with 2 M sodium hydroxide and extract with two quantities, each of 20 ml, of ether. Wash the combined ether extracts with two quantities, each of 10 ml, of water, dry by shaking with anhydrous sodium sulphate, filter and evaporate the filtrate to dryness. It necessary, induce crystallization by scratching with a glass rod.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with procyclidine hydrochloride RS.

B. The powdered tablets give the reactions of chlorides (2.3.1).

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 100 volumes of ether and 1 volume of strong ammonia solution.

Test solution. Shake a quantity of the powdered tablets containing 25 mg of Procyclidine Hydrochloride with 5 ml of chloroform and filter.

Reference solution (a). A 0.001 per cent w/v solution of 1-phenyl-3-pyrrolidinopropan-1-one hydrochloride RS in chloroform.

Reference solution (b). Dilute 1 volume of test solution to 200 volumes with chloroform.

Apply to the plate 20 µl of each solution. After development, dry the plate at 105º for 15 minutes and examine in ultraviolet light at 254 nm. Any spot corresponding to 1-phenyl-3-pyrrolidinopropan-1-one in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) (0.2 per cent). Spray the plate with dilute potassium iodobismuthate solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (b) (0.5 per cent). Ignore any spot due to excipients on the line of application.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 2.5 mg of Procyclidine Hydrochloride, transfer to a 100-ml volumetric flask, add 10.0 ml of water and mix, and dilute to volume with a 0.025 per cent w/v solution of bromocresol purple in 2 per cent v/v solution of glacial acetic acid. Allow the undissolved particles to settle. Transfer 5.0 ml of the supernatant solution to a separating funnel, extract with 20.0 ml of chloroform and filter the extract, discarding the first 5 ml of the filtrate. Measure the absorbance of the filtrate at the maximum at about 405 nm (2.4.7), using as the blank a solution prepared by treating 0.5 ml of water and 4.5 ml of a 0.025 per cent w/v solution of bromocresol purple in the same manner beginning at the words “extract with 20 ml of chloroform …….”.

Calculate the content of C₁₉H₂₉NO₄Cl from the absorbance obtained by repeating the operation using procyclidine hydrochloride RS in place of the powdered tablets.

Storage. Store protected from moisture.

Proguanil Hydrochloride

Chloroguanide Hydrochloride

\[
\text{C}_{11}\text{H}_{16}\text{ClN}_{5}\text{HCl} \quad \text{Mol. Wt. 290.2}
\]

Proguanil Hydrochloride is 1-(4-chlorophenyl)-5-isopropylbiguanide hydrochloride.

Proguanil Hydrochloride contains not less than 99.0 per cent and not more than 101.0 per cent of C₁₁H₁₆ClN₅, HCl, calculated on the dried basis.

Description. A white, crystalline powder; odourless.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with proguanil hydrochloride RS or with the reference spectrum of proguanil hydrochloride.

B. To 10 ml of a saturated solution add 0.25 ml of potassium ferrocyanide solution; a white precipitate is produced which dissolves on addition of a few drops of dilute nitric acid.

C. Dissolve 5 mg in 5 ml of a warm 1.0 per cent w/v solution of cetrimide and add 1 ml of 5 M sodium hydroxide and 1 ml of bromine solution; a deep red colour is produced.

D. Gives the reactions of chlorides (2.3.1).

Tests

Acidity or alkalinity. To 35 ml of water maintained at 60º to 65º add 0.2 ml of methyl red solution, neutralise with 0.01 M sodium hydroxide or 0.01 M hydrochloric acid, add 0.4 g of the substance under examination and stir until dissolved. The resulting solution is not acidic and requires for neutralisation not more than 0.2 ml of 0.01 M hydrochloric acid.

988
**4-Chloroaniline.** Dissolve 0.1 g in 1 ml of 2 M hydrochloric acid, add sufficient water to produce 20 ml, cool to 5°C, add 1 ml of 0.05 M sodium nitrite, allow to stand at 5°C for 5 minutes, add 2 ml of a 5 per cent w/v solution of ammonium sulphamate and allow to stand for 10 minutes. Add 2 ml of a 0.1 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride, dilute to 50 ml with water and allow to stand for 30 minutes. Any magenta colour produced is not more intense than that obtained by treating in the same manner and at the same time 20 ml of a solution containing 1.25 µg of 4-chloroaniline.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°C.

**Assay.** Weigh accurately about 0.15 g, dissolve in 25 ml of anhydrous glacial acetic acid and 10 ml of mercuric acetate solution. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01451 g of C11H16ClN5, HCl.

**Storage.** Store protected from light and moisture.

### Proguanil Tablets

**Proguanil Hydrochloride Tablets; Chloroguanide Hydrochloride Tablets**

Proguanil Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of proguanil hydrochloride, C11H16ClN5, HCl.

**Identification**

A. Boil a quantity of the powdered tablets containing 0.5 g of Proguanil Hydrochloride with 5 ml of dilute hydrochloric acid, cool and filter. To the filtrate add a slight excess of sodium hydroxide solution, extract with 30 ml of ether and evaporate the ethereal extract; the residue, after drying at 105°C, melts at about 131°C(2.4.21).

Dissolve the residue obtained in test A in the minimum quantity of dilute hydrochloric acid; the solution diluted with water to about 40 ml and neutralised if necessary, with cautious addition of dilute ammonia solution, complies with tests the following tests.

B. To 10 ml add 0.25 ml of potassium ferrocyanide solution; a white precipitate is produced which dissolves on addition of a few drops of dilute nitric acid.

C. To 0.5 ml add 5 ml of a warm 1.0 per cent w/v solution of cetrimide and add 1 ml of 5 M sodium hydroxide and 1 ml of bromine solution; a deep red colour is produced.

**Tests**

4-Chloroaniline. To a quantity of the powdered tablets containing about 0.1 g of Proguanil Hydrochloride add 5 ml of ethanol (95 per cent) and shake for 10 minutes. Add 2.5 ml of 2 M hydrochloric acid and 15 ml of water, mix and filter through a wetted filter paper, washing the filter with 5 ml of water. Cool to 5°C, add 1 ml of 0.05 M sodium nitrite, allow to stand at 5°C for 5 minutes, add 2 ml of a 5 per cent w/v solution of ammonium sulphamate and allow to stand for 10 minutes. Add 2 ml of a 0.1 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride, dilute to 50 ml with water and allow to stand for 30 minutes. Any magenta colour produced is not more intense than that obtained by treating in the same manner and at the same time 20 ml of a solution containing 1.25 µg of 4-chloroaniline.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.1 g of Proguanil Hydrochloride, add 5 ml of water and warm on a water-bath with stirring until a smooth paste is obtained. Add 50 ml of water, continue warming for 10 minutes, cool, add sufficient water to produce 100.0 ml and filter. Dilute 10.0 ml of the filtrate to 100.0 ml with water and to 10.0 ml of the resulting solution add 70 ml of water, 5 ml of 5 per cent w/v solution of cetrimide and 1 ml of 2-propanol. Adjust the temperature of the solution to 20°C and add 2 ml of alkaline sodium hypobromite solution and sufficient water to produce 100.0 ml. Allow to stand at 20°C for 25 minutes and measure the absorbance of the resulting solution at the maximum at about 480 nm (2.4.7).

Calculate the content of C11H16ClN5, HCl from the absorbance obtained by repeating the operation using 10 ml of a 0.01 per cent w/v solution of proguanil hydrochloride RS beginning at the words “add 70 ml of water, ...”.

**Storage.** Store protected from light and moisture.

### Promethazine Hydrochloride

**Promethazine Hydrochloride is (RS)-dimethyl(2-phenothiazin-10-ylpropyl)amine hydrochloride.**
Promethazine Hydrochloride contains not less than 98.5 per cent and not more than 101.0 per cent of \(\text{C}_{17}\text{H}_{20}\text{N}_{2}\text{S}, \text{HCl}\), calculated on the dried basis.

**Description.** A white or faintly yellowish, crystalline powder.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with promethazine hydrochloride RS or with the reference spectrum of promethazine hydrochloride.

B. Complies with the test for identification of phenothiazines (2.3.3).

C. Dissolve 0.1 g in 3 ml of water and add 1 ml of nitric acid dropwise; a precipitate is produced which dissolves rapidly to give a red solution which becomes orange and then yellow. Heat the solution to boiling; it becomes orange and an orange-red precipitate is produced.

D. Gives reaction B of chlorides (2.3.1).

**Tests**

**pH** (2.4.24). 4.0 to 5.0, determined in a 10.0 per cent w/v solution prepared immediately before use.

**Related substances.** Carry out the test for related substances in phenothiazines (2.3.5), protected from bright light using mobile phase B.

*Prepare the following solutions immediately before use.*

**Test solution.** Dissolve 0.2 g of the substance under examination in 10 ml of a mixture of 95 volumes of methanol and 5 volumes of diethylamine.

**Reference solution (a).** A 0.01 per cent w/v solution of the substance under examination in the same solvent mixture.

**Reference solution (b).** A 0.02 per cent w/v solution of isopromethazine hydrochloride RS in the same solvent mixture.

Apply to the plate 10 µl of each solution.

Any spot corresponding to isopromethazine in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (b) and any other secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.25 g, dissolve in a mixture of 5 ml of 0.01 M hydrochloric acid and 50 ml of ethanol (95 per cent) and titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.4.25). Record the volume added between the two inflections.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.03209 g of \(\text{C}_{17}\text{H}_{20}\text{N}_{2}\text{S}, \text{HCl}\).

**Storage.** Store protected from light and moisture.

---

**Promethazine Injection**

Promethazine Hydrochloride Injection

Promethazine Injection is a sterile solution of Promethazine Hydrochloride in Water for Injections free from dissolved air. It may contain suitable stabilising agents.

Promethazine Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of promethazine hydrochloride, \(\text{C}_{17}\text{H}_{20}\text{N}_{2}\text{S}, \text{HCl}\).

**Identification**

A. To a volume containing 0.1 g of Promethazine Hydrochloride add 20 ml of water and 2 ml of 10 M sodium hydroxide. Shake and extract the mixture with 25 ml of ether. Wash the ether layer with two quantities, each of 5 ml, of water, dry with anhydrous sodium sulphate and evaporate to dryness. Dissolve the residue in 1 ml of chloroform.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with promethazine hydrochloride RS treated in the same manner or with the reference spectrum of promethazine.

B. To a volume containing 0.2 g of Promethazine Hydrochloride add sufficient potassium carbonate to saturate the solution, extract with two quantities, each of 10 ml, of ether and evaporate the combined extracts to dryness. Dissolve the residue in 2 ml of methanol and pour into a solution of 0.4 g of picric acid in 10 ml of methanol, previously warmed to about 50º. Cool, scratch the sides of the tube to induce crystallisation, allow to stand for 3 to 4 hours and filter. The residue, after washing with methanol and drying, melts at about 160º (2.4.21).

C. To a volume containing 5 mg of Promethazine Hydrochloride add carefully 2 ml of sulphuric acid and allow to stand for 5 minutes; a red colour is produced.

**Tests**

**pH** (2.4.24). 5.0 to 6.0.

**Related substances.** Carry out the test for related substances in phenothiazines (2.3.5), using mobile phase B.
**Test solution.** Dilute a volume of the injection with a mixture of 95 volumes of methanol and 5 volumes of diethylamine to contain 1 per cent w/v of Promethazine Hydrochloride.

**Reference solution (a).** Dilute 1 volume of the test solution to 40 volumes with the same solvent mixture.

**Reference solution (b).** Dilute 1 volume of the test solution to 200 volumes with the same solvent mixture.

**Reference solution (c).** A 0.01 per cent w/v solution of isopromethazine hydrochloride RS in the same solvent mixture.

Apply separately to the plate 10 µl of each solution.

Any spot corresponding to isopromethazine in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (c). Any other secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Carry out the following procedure protected from light.

To an accurately measured volume containing about 25 mg of Promethazine Hydrochloride add sufficient 0.01 M hydrochloric acid to produce 100.0 ml. Dilute 10.0 ml to 100.0 ml with 0.01 M hydrochloric acid, dilute 10.0 ml of this solution to 50.0 ml with 0.01 M hydrochloric acid and measure the absorbance of the resulting solution at the maximum at about 249 nm (2.4.7). Calculate the content of C₁₇H₂₀N₂S, HCl taking 910 as the specific absorbance at 249 nm.

**Storage.** Store protected from light.

**Promethazine Tablets**

Promethazine Hydrochloride Tablets

Promethazine Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of promethazine hydrochloride, C₁₇H₂₀N₂S, HCl. The tablets are coated.

**Identification**

A. To a quantity of the powdered tablets containing 40 mg of Promethazine Hydrochloride add 10 ml of water and 2 ml of 1 M sodium hydroxide, shake and extract with 15 ml of ether. Wash the ether extract with 5 ml of water, dry with anhydrous sodium sulphate, evaporate to dryness and dissolve the residue in 0.4 ml of chloroform.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with promethazine.
hydrochloride RS treated in the same manner or with the reference spectrum of promethazine.

B. Dissolve a quantity of the powdered tablets containing 0.2 g of Promethazine Hydrochloride in 2 ml of water, filter, add sufficient potassium carbonate to saturate the solution, extract with two quantities, each of 10 ml, of ether and evaporate the combined extracts to dryness. Dissolve the residue in 2 ml of methanol and pour into a solution of 0.4 g of picric acid in 10 ml of methanol, previously warmed to about 50°C. Cool, scratch the sides of the tube to induce crystallisation, allow to stand for 3 to 4 hours and filter. The residue, after washing with methanol and drying, melts at about 160°C (2.4.21).

C. To a quantity of the powdered tablets containing 5 mg of Promethazine Hydrochloride add 5 ml of sulphuric acid and allow to stand for 5 minutes; a red colour is produced.

Tests

Related substances. Carry out the test for related substances in phenothiazines (2.3.5), using mobile phase B.

Test solution. A solution freshly prepared by extracting a quantity of the powdered tablets containing 0.1 g of Promethazine Hydrochloride with 10 ml of a mixture of 95 volumes of methanol and 5 volumes of diethylamine and filtering.

Reference solution (a). Dilute 1 volume of the test solution to 40 volumes with the same solvent.

Reference solution (b). Dilute 1 volume of the test solution to 200 volumes with the same solvent.

Reference solution (c). A 0.01 per cent w/v solution of isopromethazine hydrochloride RS in the same solvent.

Applying to the plate 10 µl of each solution. Any spot corresponding to isopromethazine in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (c). Any other secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

Uniformity of content. (For tablets containing 10 mg or less) — Comply with the test stated under Tablets.

Crush one tablet, add 1 ml of diethyl hydrochloric acid and 30 ml of water and shake for 15 minutes. Add sufficient water to produce 50.0 ml and centrifuge. Complete the procedure described in the Assay beginning at the words “To 5.0 ml of the clear supernatant liquid...”.

Other tests. Comply with the tests stated under Tablets.

Assay. Carry out the following procedure protected from light.

Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 50 mg of Promethazine Hydrochloride with 10 ml of 2 M hydrochloric acid and add 200 ml of water. Shake for 15 minutes, add sufficient water to produce 500.0 ml and centrifuge about 50 ml of the mixture. To 5.0 ml of the clear supernatant liquid add 10 ml of 0.1 M hydrochloric acid and sufficient water to produce 100.0 ml. Measure the absorbance of the resulting solution at the maximum at about 249 nm (2.4.7). Calculate the content of C₁₇H₂₀N₂S, HCl taking 910 as the specific absorbance at 249 nm.

Storage. Store protected from light and moisture.

Promethazine Theoclate

![Promethazine Theoclate](image)

C₁₇H₂₀N₂S,C₇H₇ClN₄O₂  Mol. Wt. 499.0

Promethazine Theoclate is the (RS)-dimethyl(2-phenothiazin-10-ylpropyl)amine salt of 8-chlorotheophylline.

Promethazine Theoclate contains not less than 98.0 per cent and not more than 101.0 per cent of C₁₇H₂₀N₂S,C₇H₇ClN₄O₂, calculated on the dried basis.

Description. A white or almost white powder; odourless or almost odourless.

Identification

Test A may be omitted if tests B, C, D and E are carried out. Tests B, C and D may be omitted if tests A and E are carried out.

A. Shake 0.15 g with 2.5 ml of water, add 1 ml of 5 M ammonia and extract with 30 ml of ether. Wash the ether extract with 10 ml of water, dry with anhydrous sodium sulphate and evaporate to dryness. Dissolve the residue in 1 ml of chloroform.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with promethazine RS or with the reference spectrum of promethazine.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.0007 per cent w/v solution in ethanol containing 0.01 per cent v/v of strong ammonia solution shows an absorption maximum at about 255 nm; absorbance at about 0.53.
C. Dissolve 5 mg in 2 ml of sulphuric acid and allow to stand for 5 minutes; a red colour is produced.

D. Shake 0.4 g with 10 ml of water, add 4 ml of 5 M ammonia, shake with two quantities, each of 30 ml, of ether and add 4 ml of hydrochloric acid to the aqueous solution; a white precipitate is produced. Filter, wash with water and dry at 105°C. Dissolve 10 mg of the residue in 1 ml of hydrochloric acid, add 0.1 g of potassium chlorate and evaporate to dryness; a reddish residue remains which becomes purple on exposure to the vapour of ammonia.

E. Fuse 50 mg of the residue obtained in test D with 0.5 g of anhydrous sodium carbonate, boil the residue with 5 ml of water, acidify to litmus paper with nitric acid and filter. The filtrate gives reaction A of chlorides (2.3.1).

Tests

Chlorides (2.3.12). Shake 1.5 g with 50 ml of water for 2 minutes and filter. 25 ml of the filtrate complies with the limit test for chlorides (330 ppm).

Related substances. Carry out the test for related substances in phenothiazines (2.3.5), protected from bright light, using mobile phase B.

Prepare the following solutions immediately before use.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of a mixture of 95 volumes of methanol and 5 volumes of diethylamine.

Reference solution (a). A 0.01 per cent w/v solution of the substance under examination in the same solvent mixture.

Reference solution (b). A 0.02 per cent w/v solution of isopromethazine hydrochloride RS in the same solvent mixture.

Apply to the plate 10 µl of each solution. Any spot corresponding to isopromethazine in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (b) and any other secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (a).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°C.

Assay. Weigh accurately about 1.0 g and dissolve in 200 ml of acetone. Titrate with 0.1 M perchloric acid, using 3 ml of a saturated solution of methyl orange in acetone as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.04990 g of C_{17}H_{20}N_2S.C7H7ClN4O2.

Storage. Store protected from light and moisture.

Promethazine Theoclolate Tablets

Promethazine Theoclolate Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of promethazine theoclolate, C_{17}H_{20}N_2S.C7H7ClN4O2.

Identification

A. To a quantity of the powdered tablets containing 40 mg of Promethazine Theoclolate add 10 ml of water and 2 ml of 1 M sodium hydroxide, shake and extract with 15 ml of ether. Wash the ether extract with 5 ml of water, dry with anhydrous sodium sulphate, evaporate to dryness and dissolve the residue in 0.4 ml of chloroform.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with promethazine theoclolate RS treated in the same manner or with the reference spectrum of promethazine.

B. Dissolve a quantity of the powdered tablets containing 0.2 g of Promethazine Theoclolate in 2 ml of water, filter, add sufficient potassium carbonate to saturate the solution, extract with two quantities, each of 10 ml, of ether and evaporate the combined extracts to dryness. Dissolve the residue in 2 ml of methanol and pour into a solution of 0.4 g of picric acid in 10 ml of methanol, previously warmed to about 50°C. Cool, scratch the sides of the tube to induce crystallisation, allow to stand for 3 to 4 hours and filter. The residue, after washing with methanol and drying, melts at about 160°C (2.4.21).

C. To a quantity of the powdered tablets containing 5 mg of Promethazine Theoclolate add 5 ml of sulphuric acid and allow to stand for 5 minutes; a red colour is produced.

D. Extract a quantity of the powdered tablets containing 0.2 g of Promethazine Theoclolate with chloroform, filter and evaporate the filtrate to dryness. Shake the residue with 10 ml of water, add 4 ml of 5 M ammonia and extract with two quantities, each of 30 ml, of ether. Wash the combined extracts with 10 ml of water. Combine the aqueous layer and washings, add 4 ml of hydrochloric acid; a white precipitate is produced. Filter, wash the residue with water and dry at 105°C. Dissolve 10 mg of the residue in 1 ml of hydrochloric acid, add 0.1 g of potassium chlorate and evaporate to dryness; a reddish residue remains which becomes purple on exposure to the vapour of ammonia.

Tests

Related substances. Carry out the test for related substances in phenothiazines (2.3.5), using mobile phase B.

Test solution. A solution freshly prepared by extracting a quantity of the powdered tablets containing 0.1 g of Promethazine Theoclolate with 10 ml of a mixture of 95 volumes of methanol and 5 volumes of diethylamine and filtering.
Reference solution (a). Dilute 1 volume of the test solution to 40 volumes with the same solvent mixture.

Reference solution (b). Dilute 1 volume of the test solution to 200 volumes with the same solvent mixture.

Reference solution (c). A 0.01 per cent w/v solution of isopromethazine hydrochloride RS in the same solvent mixture.

Apply to the plate 10 µl of each solution. Any spot corresponding to isopromethazine in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (c). Any other secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

Other tests. Comply with the tests stated under Tablets.

Assay. Carry out the following procedure protected from light.

Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 50 mg of Promethazine Theoclate, add 5 ml of water and 1 ml of strong ammonia solution and allow to stand for 5 minutes. Add 50 ml of ethanol, shake for 5 minutes and filter, washing the residue with five quantities, each of 5 ml, of ethanol. Add sufficient ethanol to the filtrate to produce 100.0 ml. Dilute 10.0 ml to 100.0 ml with ethanol and dilute 10.0 ml of this solution to 100.0 ml with ethanol. Measure the absorbance of the resulting solution at the maximum at about 255 nm (2.4.7). Calculate the content of C₁₇H₂₀N₂S, C₇H₇ClN₄O₂ taking 755 as the specific absorbance at 255 nm.

Storage. Store protected from light and moisture.

Propantheline Bromide

\[
\text{C}_{23}\text{H}_{30}\text{BrNO}_3 \quad \text{Mol. Wt. 448.4}
\]

Propantheline Bromide is N-methyl-N,N-bis(1-methylethyl)-2-[(9H-xanthen-9-ylcarbonyl)oxy]ethanaminium bromide.

Propantheline Bromide contains not less than 98.0 per cent and not more than 102.0 per cent of C₂₃H₃₀BrNO₃, calculated on the dried basis.

Description. White or yellowish white crystals or powder; odourless; slightly hygroscopic.

Identification

Test A may be omitted if tests B, C, D and E are carried out. Tests B and C may be omitted if tests A, D and E are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with propantheline bromide RS or with the reference spectrum of propantheline bromide.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.006 per cent w/v solution in methanol shows absorption maxima at about 246 nm and 282 nm; absorbance at about 246 nm, about 0.7 and at about 282 nm, about 0.37.

C. Dissolve 0.2 g in 15 ml of water, add 1 ml of 10 M sodium hydroxide, boil for 2 minutes, cool slightly, add 7.5 ml of 2 M hydrochloric acid, cool and filter. Wash the residue with water, recrystallise from ethanol (50 per cent) and dry at 105º for 1 hour. Dissolve about 10 mg of the crystals so obtained in 5 ml of sulphuric acid (96 per cent w/w); an intense yellow colour is produced which fluoresces strongly in ultraviolet light at 365 nm.

D. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).

E. Gives the reactions of bromides (2.3.1).

Tests

Appearance of solution. A 3.0 per cent w/v solution is clear (2.4.1).

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 140 volumes of 1,2-dichloroethane, 60 volumes of methanol, 2.5 volumes of anhydrous formic acid and 2.5 volumes of water.

Test solution (a). Dissolve 0.1 g of the substance under examination in 10 ml of chloroform.

Test solution (b). Dissolve 25 mg of the substance under examination in 100 ml of chloroform.

Reference solution (a). A 0.005 per cent w/v solution of the substance under examination in chloroform.

Reference solution (b). A 0.025 per cent w/v solution of propantheline bromide RS in chloroform.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm.
Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.4 g, dissolve in a mixture of 50 ml of acetic anhydride and 7 ml of mercuric acetate solution. Titrate with 0.1 M perchloric acid, using crystal violet solution as the indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.04484 g of C\textsubscript{23}H\textsubscript{30}BrNO\textsubscript{3}.

**Storage.** Store protected from moisture.

---

**Propantheline Tablets**

Propantheline Bromide Tablets

Propantheline Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of propantheline bromide, C\textsubscript{23}H\textsubscript{30}BrNO\textsubscript{3}. The tablets are coated.

**Identification**

Triturate a quantity of the powdered tablets containing 75 mg of Propantheline Bromide with 10 ml of chloroform, filter, evaporate the chloroform and stir the residue with 5 ml of ether until it solidifies. The solid complies with the following tests.

A. Dissolve 60 mg in 2 ml of water, add 2 ml of 5 M sodium hydroxide, boil for 2 minutes, cool slightly, acidify with 2 M hydrochloric acid, heat to boiling, add ethanol (95 per cent) dropwise until the precipitate just dissolves, cool and filter. The residue, after washing with water, recrystallising from ethanol (50 per cent) and drying at 105º for 1 hour, melts at about 215º (2.4.21).

B. To 10 mg of the crystals obtained in test A add 5 ml of sulphuric acid (96 per cent w/w); an intense yellow colour is produced which fluoresces strongly in ultraviolet light at 365 nm.

C. Gives the reactions of bromides (2.3.1).

**Tests**

**Xanthanoic acid.** Shake the combined ether extracts reserved in the Assay with two quantities, each of 30 ml, of 0.1 M sodium hydroxide containing 1.5 per cent w/v solution of sodium chloride. Remove the ether from the combined aqueous extracts by heating on a water-bath, add sufficient 0.1 M sodium hydroxide to produce 100.0 ml and dilute 25.0 ml to 100.0 ml with 0.1M sodium hydroxide. The absorbance of the resulting solution at the maximum at about 248 nm is not more than 0.31 (2.4.7).

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets or more if necessary. Weigh accurately a quantity of the powder containing about 0.5 g of Propantheline Bromide, place it on a sintered-glass filter, add 10 ml of peroxide-free ether, dried over sodium and distilled before use, stir and filter. Repeat the extraction with four quantities, each of 10 ml, of ether and reserve the combined ether extracts for the test for Xanthanoic acid. Extract the residue on the filter with four quantities, each of 10 ml, of chloroform, evaporate the combined chloroform extracts to about 10 ml, add 10 ml of mercuric acetate solution. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.04484 g of C\textsubscript{23}H\textsubscript{30}BrNO\textsubscript{3}.

**Storage.** Store protected from moisture.

---

**Propranolol Hydrochloride**

\[
\text{C}_{16}\text{H}_{21}\text{NO}_2\cdot\text{HCl} \\
\text{Mol. Wt. 295.8}
\]

Propranolol Hydrochloride is (2RS)-1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol hydrochloride.

Propranolol Hydrochloride contains not less than 99.0 per cent and not more than 101.0 per cent of C\textsubscript{16}H\textsubscript{21}NO\textsubscript{2}, HCl, calculated on the dried basis.

**Description.** A white or almost white powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with propranolol hydrochloride RS or with the reference spectrum of propranolol hydrochloride.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in methanol shows absorption maxima at about 290 nm, 306 nm and 319 nm.

C. Gives reaction A of chlorides (2.3.1).
Tests

Appearance of solution. A 10.0 per cent w/v solution in methanol is clear (2.4.1), and not more intensely coloured than degree 6 of the appropriate range of reference solutions (2.4.1).

pH (2.4.24). 5.0 to 6.0, determined in a 1.0 per cent w/v solution.

Specific optical rotation (2.4.22). –1.0º to +1.0º, determined in a 4.0 per cent w/v solution.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 90 volumes of toluene and 10 volumes of methanol.

Test solution. Dissolve 1.0 g of the substance under examination in 10 ml of methanol.

Reference solution. Dissolve 20.0 mg of the substance under examination in 100 ml of methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air, spray with anisaldehyde solution and heat at 105º for 15 minutes. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

Assay. Weigh accurately about 0.25 g, dissolve in 25 ml of ethanol (95 per cent) and titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.4.25).

1 ml of 0.1 M sodium hydroxide is equivalent to 0.02958 g of C16H21NO2, HCl.

Storage. Store protected from moisture.

Propranolol Injection

Propranolol Hydrochloride Injection

Propranolol Injection is a sterile solution of Propranolol Hydrochloride in Water for Injections containing Citric Acid.

Propranolol Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of propranolol hydrochloride, C16H21NO2, HCl.

Identification

A. Make alkaline with 1 M sodium hydroxide a volume containing 10 mg of Propranolol Hydrochloride and extract with three quantities, each of 5 ml, of ether. Wash the combined extracts with water until the washings are free from alkali, dry with anhydrous sodium sulphate, filter, evaporate the filtrate to dryness and dry the residue at 50º at a pressure of 2 kPa for 1 hour.

On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with propranolol hydrochloride RS treated in the same manner or with the reference spectrum of propranolol.

B. When examined in the range 230 nm to 360 nm (2.4.7), the solution obtained in the Assay shows absorption maxima at about 290 nm, 306 nm and 319 nm.

Tests

pH (2.4.24). 3.0 to 3.5.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. To an accurately measured volume containing about 2 mg of Propranolol Hydrochloride add sufficient methanol to produce 100.0 ml and measure the absorbance of the resulting solution at the maximum at about 290 nm (2.4.7). Calculate the content of C16H21NO2, HCl taking 206 as the specific absorbance at 290 nm.

Storage. Store protected from light, in a single dose containers.

Propranolol Tablets

Propranolol Hydrochloride Tablets

Propranolol Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of propranolol hydrochloride, C16H21NO2, HCl.

Identification

A. Suspend a quantity of the powdered tablets containing 0.1 g of Propranolol Hydrochloride in 20 ml of water, filter, make the filtrate alkaline with 1 M sodium hydroxide and extract with three quantities, each of 10 ml, of ether. Wash the combined extracts with water until the washings are free from alkali, dry with anhydrous sodium sulphate, filter, evaporate the filtrate to dryness and dry the residue at 50º at a pressure of 2 kPa for 1 hour.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with propranolol hydrochloride RS treated in the same manner or with the reference spectrum of propranolol.

B. When examined in the range 230 nm to 360 nm (2.4.7), the final solution obtained in the Assay shows absorption maxima at about 290 nm, 306 nm and 319 nm.
Tests

Uniformity of content. (For tablets containing 10 mg or less) — Comply with the test stated under Tablets.

Transfer one tablet to a 100-ml volumetric flask, add 5 ml of dilute hydrochloric acid and allow to stand, swirling occasionally, until it is disintegrated. Add about 70 ml of methanol and shake well for about 1 minute. Dilute to volume with methanol, mix and centrifuge an aliquot of the solution. Dilute a suitable volume of the clear solution with methanol to produce a solution containing 20 μg of Propranolol Hydrochloride per ml. Measure the absorbance of the resulting solution at the maximum at about 290 nm (2.4.7), using methanol as the blank. Calculate the content of C₁₆H₂₁NO₂, HCl taking 206 as the specific absorbance at 290 nm.

Dissolution (2.5.2).

Apparatus. No 1
Medium. 900 ml of 0.1 M hydrochloric acid
Speed and time. 100 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter. Dilute a suitable volume of the filtrate with the same solvent. Measure the absorbance of the resulting solution at the maximum at about 290 nm (2.4.7). Calculate the content of C₁₀H₁₂O₅, HCl taking 206 as the specific absorbance at 290 nm.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 20 mg of Propranolol Hydrochloride and shake with 20 ml of water for 10 minutes. Add 50 ml of methanol, shake for a further 10 minutes, add sufficient methanol to produce 100.0 ml and filter. Dilute 10.0 ml of the filtrate to 50.0 ml with methanol and measure the absorbance of the resulting solution at the maximum at about 290 nm (2.4.7). Calculate the content of C₁₀H₁₂O₅, HCl taking 206 as the specific absorbance at 290 nm.

Storage. Store protected from light and moisture.

Propylene Glycol

1, 2-Propanediol

\[
\text{C}_3\text{H}_8\text{O}_2 \quad \text{Mol. Wt. 75.1}
\]

Propylene Glycol is (RS)-propane-1,2-diol.

Description. A clear, colourless, viscous liquid; practically odourless; hygroscopic.

Identification

A. To 0.5 ml of a 0.01 per cent w/v solution, cooled in ice, add 5 ml of a cooled mixture of 10 ml of water and 90 ml of sulphuric acid. Heat for 10 minutes on a water-bath at 70°, cool and add 0.2 ml of a 3 per cent w/v solution of ninhydrin in a 2.5 per cent w/v solution of sodium metabisulphite; a violet colour slowly appears.
B. Heat 0.15 ml with 0.1 g of boric acid; a pleasant odour develops.

C. Add 1 ml to 0.5 g of potassium bisulphate and heat gently; a fruity odour develops and when the solution is heated to dryness, no sharp, acrid smell of acrolein is perceptible.

**Tests**

**Appearance of solution.** The substance under examination is clear (2.4.1), and colourless (2.4.1).

**Acidity.** Mix 10 ml with 40 ml of water and add 0.1 ml of bromothymol blue solution. The solution is greenish yellow and not more than 0.05 ml of 0.1 M sodium hydroxide is required to change the colour to blue.

**Boiling range** (2.4.8). 184º to 189º.

**Relative density** (2.4.29). 1.035 to 1.040.

**Refractive index** (2.4.27). 1.431 to 1.433.

**Heavy metals** (2.3.13). Dilute 3 ml to 12 ml with water. The resulting solution complies with the limit test for heavy metals, Method D (5 ppm). Use lead standard solution (1 ppm Pb) to prepare the standard.

**Oxidising substances.** To 10 ml add 5 ml of water, 2 ml of potassium iodide solution and 2 ml of 1 M sulphuric acid and allow to stand in a ground-glass-stoppered flask protected from light for 15 minutes. Titrate the liberated iodine with 0.05 M sodium thiosulphate using 1 ml of starch solution, added towards the end of the titration, as indicator. Not more than 0.2 ml of 0.05 M sodium thiosulphate is required.

**Reducing substances.** Mix 1 ml with 1 ml of 6 M ammonia and heat in a water-bath at 60º for 5 minutes; the solution is not yellow. Immediately add 0.15 ml of 0.1 M silver nitrate; the solution does not change its appearance within 5 minutes.

**Ethylene glycol and diethylene glycol.** Determine by gas chromatography (2.4.13).

**Test solution.** Dissolve 2 g of the substance under examination in sufficient ethanol (95 per cent) to produce 100 ml.

**Reference solution.** Dissolve 2 g of the substance under examination, 0.02 g of ethylene glycol and 0.02 g of diethylene glycol in ethanol (95 per cent) and dilute to 100 ml with the same solvent.

Chromatographic system
- a glass column 1.5 m x 3 mm, packed with 12 per cent Sorbitol on untreated siliceous earth (such as Chromosorb W-NAW (SINS),
- temperature:
  - column: 165º,
  - inlet port and detector at 260º,
- flow rate. 30 ml per minute of the carrier gas.

Inject 3 µl or other suitable volume of the test solution. Record the chromatograms adjusting the sensitivity so that the height of the peak due to propylene glycol is more than 50 per cent of the full-scale deflection in the chromatograms. Inject the same volume of reference solution and record the chromatograms. The order of elution is propylene glycol, ethylene glycol and diethylene glycol. The test is not valid unless in the chromatogram obtained with the reference solution, the resolution between the peaks due to propylene glycol (first peak) and ethylene glycol (second peak) is not less than 1.0.

No peaks corresponding to ethylene glycol and diethylene glycol are obtained in the chromatogram obtained with the test solution.

**Sulphated ash** (2.3.18). Not more than 0.01 per cent w/w, determined by the following method. Heat 50 g until it burns, and ignite. Allow to cool, moisten the residue with sulphuric acid and ignite; repeat the operations.

**Water** (2.3.43). Not more than 0.2 per cent, determined on 5.0 g.

**Storage.** Store protected from moisture.

---

**Propylparaben**

**Propyl Hydroxybenzoate**

\[
\begin{align*}
\text{C}_{10}\text{H}_{12}\text{O}_{3} & \quad \text{Mol. Wt. 180.2} \\
\end{align*}
\]

Propylparaben is propyl 4-hydroxybenzoate.

Propylparaben contains not less than 99.0 per cent and not more than 101.0 per cent of C_{10}H_{12}O_{3}, calculated on the dried basis.

**Description.** A white, crystalline powder; odourless.

**Identification**

A. When examined in the range 230 nm to 360 nm (2.4.7), a 0.0005 per cent w/v solution in ethanol (95 per cent) shows an absorption maximum at about 258 nm; absorption at 258 nm, 0.44 to 0.47.

B. To about 10 mg in a test-tube add 1 ml of sodium carbonate solution, heat to boiling for 30 seconds and cool (solution A). To a further 10 mg in a test-tube add 1 ml of sodium carbonate solution; the substance partly dissolves (solution B). Add at
the same time to each of the solutions A and B 5 ml of aminophenazone solution and 1 ml of potassium ferricyanide solution and mix. Solution B is yellow to orange-brown. Solution A is orange to red and the colour is clearly more intense than any similar colour that may be obtained with solution B.

Tests

Appearance of solution. A 10.0 per cent w/v solution in ethanol (95 per cent) is clear (2.4.1), and not more intensely coloured than reference solution BYS6 (2.4.1).

Acidity. Dissolve 1.0 g in sufficient ethanol (95 per cent) to produce 10 ml. To 2 ml of the solution add 3 ml of ethanol (95 per cent), 5 ml of carbon dioxide-free water and 0.1 ml of bromocresol green solution. Not more than 0.1 ml of 0.1 M sodium hydroxide is required to change the colour of the solution.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 88 volumes of dichloromethane, 10 volumes of ethyl acetate and 2 volumes of anhydrous formic acid.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of methanol.

Reference solution. A 0.02 per cent w/v solution of the substance under examination in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in a current of hot air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Chlorides (2.3.12). Heat 2.0 g with 100 ml of water, cool, add sufficient water to restore the original volume, and filter. 25 ml of the filtrate complies with the limit test for chlorides (500 ppm).

Sulphates. To 10 ml of the filtrate obtained in the test for Chlorides add 0.15 ml of dilute hydrochloric acid and 0.1 ml of barium chloride solution; no turbidity is produced within 10 minutes.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying over silica gel for 5 hours.

Assay. Weigh accurately about 80 mg, transfer to a glass-stoppered flask, add 25 ml of 2 M sodium hydroxide and boil gently under a reflux condenser for 30 minutes. Cool and add 25.0 ml of 0.0333 M potassium bromate, 5 ml of a 12.5 per cent w/v solution of potassium bromide and 40 ml of glacial acetic acid, cool in ice, add 10 ml of hydrochloric acid, immediately stopper the flask and allow to stand for 15 minutes. Add 15 ml of potassium iodide solution, mix and titrate the liberated iodine with 0.1 M sodium thiosulphate using 2 ml of starch solution, added towards the end of the titration, as indicator. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of potassium bromate required. The volume of 0.0333 M potassium bromate is equivalent to half of the volume of 0.1 M sodium thiosulphate required for the titration.

1 ml of 0.0333 M potassium bromate is equivalent to 0.006007 g of C_{10}H_{12}O_{3}.

Storage. Store protected from moisture.

Propylthiouracil

\[
\text{C}_{9}\text{H}_{16}\text{N}_{2}\text{O}_{3} \quad \text{Mol. Wt. 170.2}
\]

Propylthiouracil is 2,3-dihydro-6-propyl-2-thioxopyrimidin-4(1H)-one.

Propylthiouracil contains not less than 98.0 per cent and not more than 100.5 per cent of C_{9}H_{16}N_{2}O_{3}, calculated on the dried basis.

Description. A white or pale cream-coloured crystals or crystalline powder; odourless.

Identification

Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with propylthiouracil RS or with the reference spectrum of propylthiouracil.

B. Examine the chromatograms obtained in the test for Related substances in ultraviolet light at 254 nm before exposure of the plate to iodine vapour. The principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).

C. To about 20 mg add 8 ml of bromine water and shake for a few minutes. Boil until the mixture is decolourised, allow to cool and filter. Add 2 ml of barium chloride solution; a white
precipitate is produced. Add 5 ml of 2 M sodium hydroxide; the precipitate does not become violet.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 100 volumes of chloroform, 12 volumes of 2-propanol and 0.2 volume of glacial acetic acid.

Test solution (a). Dissolve 0.1 g of the substance under examination in 10 ml of methanol.

Test solution (b). Dissolve 0.1 g of the substance under examination in 100 ml of methanol.

Reference solution (a). A 0.01 per cent w/v solution of the substance under examination in methanol.

Reference solution (b). A 0.1 per cent w/v solution of propylthiouracil RS in methanol.

Reference solution (c). A 0.0005 per cent w/v solution of thiourea in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Expose the plate to iodine vapour for 10 minutes. By both methods of visualisation, any spot corresponding to thiourea in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (c) and any other secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (a).

Arsenic (2.3.10). Dissolve 2.0 g in 50 ml of water and add 10 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (5 ppm).

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method C (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in oven at 105°C.

Assay. Weigh accurately about 0.3 g, add 30 ml of water and 30.0 ml (n1, ml) of 0.1 M sodium hydroxide, boil and shake until solution is complete. Add 50 ml of 0.1 M silver nitrate with stirring, boil gently for 5 minutes, cool and titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.4.25) (n2, ml). Record the total volume (n1 + n2, ml) of 0.1 M sodium hydroxide added.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.008511 g of C7H10N2OS.

Storage. Store protected from light and moisture.

Propylthiouracil Tablets

Propylthiouracil Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of propylthiouracil, C7H10N2OS.

Identification

A. Shake a quantity of the powdered tablets containing 50 mg of Propylthiouracil with 20 ml of methanol for 10 minutes, filter and evaporate to dryness.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with propylthiouracil RS or with the reference spectrum of propylthiouracil.

B. Shake a quantity of the powdered tablets containing 50 mg of Propylthiouracil with 60 ml of methanol for 20 minutes, dilute to 100 ml with methanol and filter. Dilute 5 ml of the filtrate to 250 ml with methanol. When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum only at about 274 nm.

C. Extract a quantity of the powdered tablets in a continuous extraction apparatus (2.1.8) with ether and evaporate the solution to dryness. The residue, after drying at 105°C, melts at about 219°C (2.4.21).

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 100 volumes of chloroform, 12 volumes of 2-propanol and 0.2 volume of glacial acetic acid.

Test solution. Shake a quantity of the powdered tablets containing 50 mg of Propylthiouracil with 5 ml of methanol for 15 minutes, filter and use the filtrate.

Reference solution (a). Dilute 1 volume of the test solution to 100 volumes with methanol.

Reference solution (b). A 0.001 per cent w/v solution of thiourea in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Expose the plate to iodine vapour for 10 minutes. By both methods of visualisation, any spot corresponding to thiourea in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (b) and any other secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (a).
Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.15 g of Propylthiouracil, dissolve in a mixture of 20 ml of 0.1 M sodium hydroxide and 75 ml of water with the aid of gentle heat. Cool, add 4 g of sodium acetate, just acidify the solution to litmus paper with 6 M acetic acid, add 0.5 ml of a freshly prepared 0.5 per cent w/v solution of 1,5-diphenylcarbazone in ethanol (95 per cent) and titrate with 0.02 M mercuric nitrate until a pinkish violet colour persists for 2 to 3 minutes.

1 ml of 0.02 M mercuric nitrate is equivalent to 0.006808 g of C7H10N2OS.

Storage. Store protected from light and moisture.

Propyphenazone

![Propyphenazone structure](image)

C14H18N2O  Mol. Wt. 230.3

Propyphenazone is 4-isopropyl-2,3-dimethyl-1-phenyl-3-pyrazolin-5-one.

Propyphenazone contains not less than 99.0 per cent and not more than 101.0 per cent of C14H18N2O, calculated on the dried basis.

Description. A white or slightly yellowish, crystalline powder; odourless.

Identification

Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with propyphenazone RS or with the reference spectrum of propyphenazone.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).

C. Dissolve 2 g in sufficient of a mixture of equal volumes of ethanol (95 per cent) and carbon dioxide-free water to produce 50 ml (solution A). To 1 ml of solution A add 0.1 ml of ferric chloride solution; a brownish red colour is produced which becomes yellow on addition of 1 ml of 2 M hydrochloric acid.

Tests

Appearance of solution. Solution A is clear (2.4.1), and colourless (2.4.1).

Acidity or alkalinity. To 10 ml of solution A add 0.1 ml of phenolphthalein solution; the solution is colourless. Add 0.2 ml of 0.01 M sodium hydroxide; the solution is pink. Add 0.4 ml of 0.01 M hydrochloric acid; the solution becomes colourless. Add 0.2 ml of methyl red solution; the solution is orange or red.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 45 volumes of cyclohexane, 45 volumes of ethyl acetate and 10 volumes of I-butanol.

Test solution (a). An 8 per cent w/v solution of the substance under examination in methanol.

Test solution (b). A 1.6 per cent w/v solution of the substance under examination in methanol.

Reference solution (a). A 0.016 per cent w/v solution of the substance under examination in methanol.

Reference solution (b). A 1.6 per cent w/v solution of propyphenazone RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in a current of hot air for 15 minutes and examine in ultraviolet light at 254 nm. Spray the plate with a mixture of equal volumes of potassium ferricyanide solution and ferric chloride solution. By both methods of visualisation, any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a).

Arsenic (2.3.10). Mix 1.0 g with 10 ml of a 2 per cent w/v solution of magnesium nitrate in ethanol in a silica or platinum dish, evaporate on a water-bath and heat gradually in order to incinerate. If the material remains incompletely carbonised, moisten with a small quantity of nitric acid and ignite again. Cool, add 3 ml of hydrochloric acid and heat on a water-bath to dissolve the residue. The resulting solution complies with the limit test for arsenic (10 ppm).

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (10 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 60° over phosphorus pentoxide at a pressure of 1.5 to 2.5 kPa for 4 hours.
**Assay.** Weigh accurately about 0.2 g of the dried material, dissolve in 30 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02303 g of \( \text{C}_{12}\text{H}_{18}\text{N}_{2}\text{O} \).

**Storage.** Store protected from moisture.

---

**Protamine Sulphate**

Protamine Sulphate is a purified mixture of the sulphates of basic peptides prepared from the sperm or mature testes of suitable species of fish. It binds with heparin in solution, inhibiting its anticoagulant activity. It is prepared in conditions designed to minimise the degree of Microbial contamination.

Each mg of Protamine Sulphate precipitates not less than 100 Units of heparin sodium RS, calculated on the dried basis.

**Description.** A white or almost white powder; hygroscopic.

**Identification**

A. Produces a precipitate under the conditions of the Assay.

B. Dissolve 0.2 g in 5 ml of water and dilute to 10 ml with the same solvent (solution A). To 0.5 ml of solution A add 4.5 ml of water, 1 ml of a 10 per cent w/v solution of sodium hydroxide and 1 ml of a 0.02 per cent w/v solution of 1-naphthol and mix. Cool to 5º and add 0.5 ml of alkaline sodium hypobromite solution; an intense red colour is produced.

C. Heat 2 ml of solution A in a water-bath at 60º, add 0.1 ml of mercuric sulphate solution and mix; no precipitate is produced. Cool the mixture in ice; a white precipitate is produced.

D. Gives reaction A of sulphates (2.3.1).

**Tests**

**Appearance of solution.** To 2.5 ml of solution A add 7.5 ml of water. The resulting solution is not more opalescent than reference solution OS2 (2.4.1), and not more intensely coloured than reference solution BYS6 (2.4.1).

**Specific optical rotation** (2.4.22). –65.0º to –85.0º, determined at 20º in a 1.0 per cent w/v solution in 0.1 M hydrochloric acid.

**Light absorption** (2.4.7). Dilute 2.5 ml of solution A to 5.0 ml with water. Absorbance of the resulting solution at 260 to 280 nm is not more than 0.1.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Iron** (2.3.14). Dissolve 2.0 g in water with the aid of heat and dilute to 20 ml with water. The resulting solution complies with the limit test for iron (20 ppm).

**Mercury.** Add 20 ml of a mixture of equal volumes of nitric acid and sulphuric acid to 2.0 g in a 250-ml flask fitted with a ground-glass stopper, boil under a reflux condenser for 1 hour, cool and carefully dilute with water. Boil until nitrous fumes are no longer evolved. Cool, carefully dilute the solution to 200 ml with water, mix and filter. Transfer 50 ml of the filtrate to a separating funnel. Shake with successive small quantities of chloroform until the chloroform layer remains colourless. To the aqueous layer add 25 ml of 1 M sulphuric acid, 115 ml of water and 10 ml of a 20 per cent w/v solution of hydroxylamine hydrochloride. Titrate with dithizone solution; after each addition, shake the mixture 20 times and towards the end-point of the titration allow to separate and discard the chloroform layer. Titrate until a greenish blue colour is produced. Calculate the content of mercury using the equivalent of mercury in µg per ml of titrant determined in the standardisation of the dithizone solution (10 ppm).

**Nitrogen** (2.3.30). 21.0 to 26.0 per cent, calculated on the dried basis, determined by Method C.

**Sulphates.** 16 to 24 per cent, determined by the following method. Dissolve 0.15 g in 15 ml of water in a beaker, add 5 ml of 2 M hydrochloric acid and heat to boiling. Slowly add to the boiling solution 10 ml of barium chloride solution. Cover and heat on a water-bath for 1 hour. Filter and wash the precipitate several times with small quantities of hot water. Dry and ignite the residue to constant weight at 600º.

1 g of the residue is equivalent to 0.4117 g of SO₄₂⁻.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity, using 0.5 mg dissolved in 0.5 ml of water for injections.

**Loss on drying** (2.4.19). Not more than 5.0 per cent, determined on 1.0 g by drying in an oven at 105º for 3 hours.

**Assay.** Prepare solutions of the substance under examination in water containing (1) 0.015 per cent w/v (2) 0.01 per cent w/v and (3) 0.005 per cent w/v. Titrate each of the solutions in duplicate with a 174 IU per ml or a suitable dilution of heparin sodium RS using the following procedure. Introduce an accurately measured volume of the solution to be titrated, for example 1.5 ml, into the cell of a suitable spectrophotometer, set the instrument at a suitable wavelength (none is critical) in the visible range and add the titrant in small volumes until there is a sharp increase in the absorbance. Note the volume of titrant added.

Carry out three independent assays. For each individual titration, calculate the number of Units of heparin titrated per mg of the substance under examination. Calculate the result of the assay as the average of the 18 values. Test the linearity of the response by standard statistical methods. The assay is...
not valid unless the standard deviations calculated for the results obtained with each test solution are less than 5 per cent of the average result.

**Protamine Sulphate intended for use in the manufacture of Parenteral Preparations without a further appropriate procedure for the removal of bacterial endotoxins complies with the following additional requirement.**

**Bacterial endotoxins (2.2.3).** Not more than 7.0 Endotoxin Units per mg of protamine sulphate.

**Protamine Sulphate intended for use in the manufacture of Parenteral Preparations without a further appropriate sterilisation procedure complies with the following additional requirement.**

**Sterility.** Complies with the test for sterility (2.2.11).

**Storage.** Store protected from moisture. If it is intended for use in the manufacture of Parenteral Preparations, the container should be sterile and sealed so as to exclude micro-organisms.

**Labelling.** The label states whether or not the contents are intended for use in the manufacture of Parenteral Preparations.

---

**Protamine Sulphate Injection**

Protamine Sulphate Injection is a sterile solution of Protamine Sulphate in Water for Injections.

Protamine Sulphate Injection contains not less than 80.0 per cent of the stated amount of protamine sulphate.

**Identification**

A. Produces a precipitate under the conditions of the Assay.

B. Dilute a suitable volume with water to give a solution containing 0.2 per cent w/v solution of Protamine Sulphate. To 5 ml of this solution add 1 ml of a 10 per cent w/v solution of sodium hydroxide and 1 ml of a 0.02 per cent w/v solution of l-naphthol and mix. Cool to 5° and add 0.5 ml of alkaline sodium hypobromite solution; an intense red colour is produced.

C. Heat 2 ml in a water-bath at 60°, add 0.1 ml of mercuric sulphate solution and mix; no precipitate is produced. Cool the mixture in ice; a white precipitate is produced.

D. Gives reaction A of sulphates (2.3.1).

**Tests**

**pH** (2.4.24). 2.5 to 3.5.

**Optical rotation** (2.4.22). –0.52° to –0.68°, determined in a solution prepared by diluting the injection with 0.5 M hydrochloric acid so as to contain 0.8 per cent w/v of Protamine Sulphate.

**Light absorption.** Dilute the injection, if necessary, with water to produce a solution containing 1 per cent w/v solution of Protamine Sulphate. Absorbance of the resulting solution at 260 to 280 nm, not more than 0.1 (2.4.7).

**Bacterial endotoxins** (2.2.3). Not more than 7.0 Endotoxin Units per mg of protamine sulphate.

**Abnormal toxicity.** Complies with the test for abnormal toxicity (2.2.1), using a volume containing 0.5 mg of Protamine Sulphate.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Prepare solutions of the substance under examination in water containing (1) 0.015 per cent w/v (2) 0.01 per cent w/v and (3) 0.005 per cent w/v. Titrate each of the solutions in duplicate with a 174 IU per ml or a suitable dilution of heparin sodium RS using the following procedure. Introduce an accurately measured volume of the solution to be titrated, for example 1.5 ml, into the cell of a suitable spectrophotometer, set the instrument at a suitable wavelength (none is critical) in the visible range and add the titrant in small volumes until there is a sharp increase in the absorbance. Note the volume of titrant added.

Carry out three independent assays. For each individual titration, calculate the number of Units of heparin titrated per mg of the substance under examination. Calculate the result of the assay as the average of the 18 values. Test the linearity of the response by standard statistical methods. The assay is not valid unless the standard deviations calculated for the results obtained with each test solution are less than 5 per cent of the average result.

**Storage.** Store protected from light, in single dose containers.

**Labelling.** The label states (1) that the dose is calculated from the results of determinations of the amount required to produce an acceptable blood-clotting time in the patient; (2) the approximate number of Units of heparin activity 1 ml is capable of neutralising.

**Prothionamide**

![Prothionamide structure](image)

**C₉H₁₂N₂S**

Mol. wt. 180.3

Prothionamide is 2-propyl-4-pyridinecarbothioamide.
Prothionamide contains not less than 99.0 per cent and not more than 101.0 per cent of C₈H₁₀N₂S, calculated on the dried basis.

**Description.** A yellow, crystalline powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with prothionamide RS.

B. When examined in the range 230 nm to 350 nm (2.4.7), a 0.002 per cent w/v solution in ethanol (95 per cent) shows an absorption maximum only at about 291 nm. The absorbance at 291 nm is about 0.78.

**Tests**

**Acidity.** Dissolve 2.0 g in 20 ml of methanol, heating to about 50º, and add 20 ml of water. Cool slightly, shake until crystallisation occurs, if any and allow to cool to room temperature. Add 60 ml of water and titrate with 0.1 M sodium hydroxide using 0.2 ml of cresol red solution as indicator. Not more than 0.2 ml of 0.1 M sodium hydroxide is required to change the colour of the indicator to red.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 50 mg of the substance under examination in the mobile phase and dilute to 100 ml with the mobile phase.

**Reference solution.** A 0.025 per cent w/v solution of prothionamide RS in the mobile phase. Dilute 1 ml of the solution to 100 ml with the mobile phase.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 60 volumes of a buffer solution prepared by mixing 2.0 ml of triethylamine with 1000 ml of water, adjusting the pH to 6.0 with dilute orthophosphoric acid and 40 volumes of acetonitrile,
- flow rate, 1 ml per minute,
- spectrophotometer set at 290 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternatively the test solution and the reference solution. Calculate the content of C₉H₁₂N₂S.

**Storage.** Store protected from light and moisture.

**Prothionamide Tablets**

Prothionamide Tablets contain not less than 90.0 per cent not more than 110.0 per cent of the stated amount of prothionamide, C₉H₁₂N₂S. The tablets may be coated.

**Identification**

A. Extract a quantity of the powdered tablets containing 25 mg of Prothionamide with 5 ml of methanol, filter and evaporate the filtrate to dryness. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with prothionamide RS.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Dissolution** (2.5.2).

Apparatus. No 2

Medium. 900 ml 0.1 M hydrochloric acid.
Withdraw a suitable volume of the medium and filter. Measure
the absorbance of the filtered solution, suitably diluted with
the dissolution medium if necessary, at the maximum at about
290 nm (2.4.7). Calculate the content of C₉H₁₂N₂S in the medium
from the absorbance obtained from a solution of known
concentration of prothionamide RS in the same medium.

D. Not less than 75 per cent of the stated amount of C₉H₁₂N₂S.

Related substances. Determine by liquid chromatography
(2.4.14) as described under Assay using the following
solutions.

Test solution. Weigh accurately a quantity of the powdered
tables containing 50 mg of Prothionamide disperse in the
mobile phase, shake, dilute to 100 ml with the mobile phase
and filter.

Reference solution. A solution containing 0.025 per cent w/v
of prothionamide RS in the mobile phase. Dilute 1 ml of the
solution to 100 ml with the mobile phase.

Inject the reference solution. The test is not valid unless the
relative standard deviation for replicate injections is not more
than 2.0 per cent.

Inject alternatively the test solution and the reference solution.
In the chromatogram obtained with the test solution the area
of any individual impurity peak is not more than the area of
the peak in the chromatogram obtained with the reference
solution (0.5 per cent) and the sum of the areas of all such
impurities is not more than twice the area of the peak in the
chromatogram obtained with the reference solution (1.0 per
cent).

Other tests. Comply with the test stated under the Tablets.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh and powder 20 tablets. Weigh accurately
a quantity of the powder containing about 50 mg of Prothionamide, disperse in the mobile phase, shake and dilute
to 100.0 ml with the mobile phase. Dilute 5.0 ml of the resulting
solution to 50.0 ml with the mobile phase.

Reference solution. A 0.05 per cent w/v solution of
prothionamide RS in the mobile phase. Dilute 5.0 ml of the
solution to 50.0 ml with the mobile phase.

Chromatographic system
– a stainless steel column 25 cm x 4.6 mm, packed with
octadecylsilane bonded to porous silica (5 µm),
– mobile phase: a mixture of 60 volumes of a buffer solution
prepared by mixing 2.0 ml of triethylamine with 1000 ml
of water and adjusting the pH to 6.0 with dilute
orthophosphoric acid, and 40 volumes of acetonitrile,
– flow rate. 1 ml per minute,
– spectrophotometer set at 290 nm,
– a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the
tailing factor is not more than 2.0 the column efficiency is not
less than 5000 theoretical plates and the relative standard
deviation for replicate injections is not more than 2.0 per cent.

Inject alternatively the test solution and the reference solution.
Calculate the content of C₉H₁₂N₂S in the tablets.

Storage. Store protected from light and moisture.
**Pseudoephedrine Syrup**

**Pseudoephedrine Hydrochloride Syrup**

Pseudoephedrine Syrup is a solution of Pseudoephedrine Hydrochloride in a suitable flavoured vehicle.

Pseudoephedrine Syrup contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of pseudoephedrine hydrochloride, C₁₀H₁₅NO, HCl.

**Identification**

A. Shake a quantity of the syrup containing 120 mg of Pseudoephedrine Hydrochloride with two quantities, each of 30 ml, of *ether*, and discard the ether layer. Add 4 ml of 1 M sodium hydroxide to the aqueous layer and extract with two quantities, each of 10 ml, of *ether*. Dry the combined ether extracts with anhydrous sodium sulphate, filter and evaporate the filtrate to dryness.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *pseudoephedrine hydrochloride RS* treated in the same manner or with the reference spectrum of pseudoephedrine.

B. The residue obtained in test A melts at about 118° (2.4.21).

C. Dissolve 50 mg of the residue obtained in test A in 10 ml of 0.1 M hydrochloric acid; it is dextro-rotatory.

**Tests**

**Other tests.** Complies with the tests stated under Oral Liquids.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** To an accurately measured volume of the syrup containing about 0.12 g of Pseudoephedrine Hydrochloride, add 50 ml of 0.1 M hydrochloric acid mix, add sufficient 0.1 M hydrochloric acid to produce 100.0 ml, filter and use the filtrate.

**Reference solution.** A 0.12 per cent w/v solution of pseudoephedrine hydrochloride RS in 0.1 M hydrochloric acid.

**Chromatographic system**
- a stainless steel column 25 cm x 4.2 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 85 volumes of ethanol and 15 volumes of a 0.4 per cent w/v solution of ammonium acetate,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject the reference solution and record the chromatogram. The test is not valid unless the relative standard deviation is not more than 2.0 per cent and the tailing factor is not more than 1.5.

Inject alternately the test solution and the reference solution. Determine the weight per ml of the syrup (2.4.29), and calculate the content of C₁₀H₁₅NO, HCl weight in volume.

**Storage.** Store protected from light and moisture.

---

**Pseudoephedrine Tablets**

**Pseudoephedrine Hydrochloride Tablets**

Pseudoephedrine Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of pseudoephedrine hydrochloride, C₁₀H₁₅NO, HCl. The tablets may be coated.

**Identification**

A. Shake a quantity of the powdered tablets containing 60 mg of Pseudoephedrine Hydrochloride with 10 ml of water and
filter. Shake the filtrate with 10 ml of ether, discard the ether layer. Add 1 ml of 1M sodium hydroxide to the aqueous layer and extract with two quantities, each of 10 ml, of ether. Dry the combined ether extracts with anhydrous sodium sulphate, filter and evaporate the filtrate to dryness.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pseudoephedrine hydrochloride RS treated in the same manner or with the reference spectrum of pseudoephedrine.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 40 volumes of butyl acetate, 20 volumes of acetone, 20 volumes of 1-butanol, 10 volumes of 5 M ammonia and 10 volumes of methanol.

Test solution (a). Add 25 ml of methanol to a quantity of the powdered tablets containing 0.5 g of Pseudoephedrine Hydrochloride, shake for 5 minutes, filter, wash the filter with methanol and evaporate the combined filtrate and washings to dryness. Dissolve the residue as completely as possible in 5 ml of methanol, centrifuge and use the supernatant liquid.

Test solution (b). Dilute 1 volume of the test solution to 10 volumes with methanol.

Reference solution (a). Dilute 1 volume of the test solution to 100 volumes with methanol.

Reference solution (b). A 1.0 per cent w/v solution of pseudoephedrine hydrochloride RS in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in a current of warm air, spray with a solution containing 0.3 g of ninhydrin in a mixture of 100 ml 1-butanol and 3 ml of glacial acetic acid and heat at 120º for 20 minutes. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a). Ignore any yellow spot near the line of application.

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh and powder 20 tablets. To a quantity of the powdered tablets containing about 0.12 g of Pseudoephedrine Hydrochloride, add 50 ml of 0.1 M hydrochloric acid mix with the aid of ultrasound for 15 minutes, add sufficient methanol to produce 100.0 ml, filter and use the filtrate.

Reference solution. A 0.12 per cent w/v solution of pseudoephedrine hydrochloride RS in methanol (50 per cent).

Chromatographic system

– a stainless steel column 20 cm x 4.6 mm, packed with octadecysilane bonded to porous silica (10 µm),
– mobile phase: 0.005 M dioctyl sodium sulphonate in a mixture of 65 volumes of methanol, 35 volumes of water and 1 volume of glacial acetic acid,
– flow rate 1.5 ml per minute,
– spectrophotometer set at 258 nm,
– a 20 µl loop injector.

Inject alternately the test solution and the reference solution. Calculate the content of C₁₀H₁₅NO,HCl in the tablets.

Storage. Store protected from light and moisture.

Psoralen

C₁₀H₁₅NO,HCl
Mol. Wt. 186.1

Psoralen is 7H-furo[3,2-g][1]benzopyran-7-one, obtained from the fruits of Psoralea caryifolia Linn. (Fam. Leguminosae) and from the leaves of Ficus carica (Fam. Urticaceae) or prepared by synthesis.

Psoralen contains not less than 95.0 per cent and not more than 101.0 per cent of C₁₀H₁₅NO₃, calculated on the dried basis.

Description. Colourless needles; odourless.

Identification

A. Dissolve 1 mg in 5 ml of ethanol (95 per cent) and add 15 ml of a mixture containing 43 volumes of water, 5 volumes of acetic acid and 3 volumes of propylene glycol; a blue fluorescence is visible in ultraviolet light at 365 nm.

B. Dissolve 1 mg in 2 ml of ethanol (95 per cent) and add 0.1 ml of 0.1 M sodium hydroxide; a yellow fluorescence is visible in ultraviolet light at 365 nm.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 90 volumes of benzene and 10 volumes of ethyl acetate.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of chloroform.
Reference solution. Dilute 1 volume of the test solution to 100 volumes with chloroform.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 365 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105º.

Assay. Weigh accurately about 0.1 g and dissolve in sufficient methanol to produce 100.0 ml. Dilute 2.0 ml of this solution to 100.0 ml with methanol and measure the absorbance of the resulting solution at the maximum at about 247 nm (2.4.7).

Calculate the content of C₅H₅N₃O from the absorbance obtained by repeating the operation using a final solution of 20 µg of psoralen RS per ml in methanol in place of the substance under examination.

Storage. Store protected from light and moisture.

Pyrazinamide

Pyrazinamide is pyrazine-2-carboxamide.

Pyrazinamide contains not less than 99.0 per cent and not more than 100.5 per cent of C₅H₅N₃O, calculated on the anhydrous basis.

Description. A white or almost white, crystalline powder; odourless or almost odourless.

Identification

Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pyrazinamide RS or with the reference spectrum of pyrazinamide.

B. Dissolve 50 mg in water and dilute to 100 ml with the same solvent (solution A). Dilute 1 ml of solution A to 10 ml. When examined in the range 290 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum at about 310 nm. Dilute 2 ml of solution A to 100 ml with water. When examined in the range 230 nm to 290 nm, the solution shows an absorption maximum at about 268 nm; absorbance at about 268 nm, between 0.64 and 0.68.

C. Boil 20 mg with 5 ml of sodium hydroxide solution; ammonia, recognisable by its odour, is evolved.

Tests

Appearance of solution. A 1.0 per cent w/v solution in carbon dioxide-free water (solution B) is clear (2.4.1), and colourless (2.4.1).

Acidity or alkalinity. To 25 ml of solution B add 0.05 ml of phenolphthalein solution and 0.2 ml of 0.01 M sodium hydroxide; the solution is red. Add 1 ml of 0.01 M hydrochloric acid; the solution is colourless. Add 0.15 ml of methyl red solution; the solution is red.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 60 volumes of 1-butanol, 20 volumes of glacial acetic acid and 20 volumes of water.

Test solution. Dissolve 0.1 g of the substance under examination in 10 ml of a mixture of 90 volumes of chloroform and 10 volumes of methanol.

Reference solution. A 0.002 per cent w/v solution of the substance under examination in a mixture of 90 volumes of chloroform and 10 volumes of methanol.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Heavy metals (2.3.13). 2.0 g complies with the limit test for heavy metals, Method B (10 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Water (2.4.19). Not more than 0.5 per cent, determined on 5.0 g.

Assay. Weigh accurately about 0.3 g and transfer to the flask of an ammonia distillation apparatus. Add 200 ml of water and 75 ml of sodium hydroxide solution. Boil gently for 20 minutes, collecting the distillate in 50.0 ml of 0.05 M sulphuric acid. Boil vigorously to complete the distillation of the ammonia and titrate the excess of acid with 0.1 M sodium hydroxide, using methyl red solution as indicator. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of acid required to neutralise the ammonia formed.

1 ml of 0.05 M sulphuric acid is equivalent to 0.01231 g of C₅H₅N₃O.

Storage. Store protected from moisture.
Pyrazinamide Tablets

Pyrazinamide Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of pyrazinamide, C₅H₅N₃O.

Identification

A. Shake a quantity of the powdered tablets containing 0.25 g of Pyrazinamide with 20 ml of ethanol, filter, evaporate the filtrate to dryness and dry the residue at 105º for 30 minutes. On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pyrazinamide RS or with the reference spectrum of pyrazinamide.

B. Shake a quantity of the powdered tablets containing 50 mg of Pyrazinamide with 50 ml of water, dilute to 100 ml with water and filter (solution A). Dilute 1 ml of solution A to 10 ml with water. When examined in the range 290 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum at about 310 nm. Dilute 2 ml of solution A to 100 ml with water. When examined in the range 230 nm to 290 nm, the resulting solution shows an absorption maximum at about 268 nm; absorbance at 268 nm, between 0.64 and 0.68.

C. Boil a quantity of the powdered tablets containing 20 mg of Pyrazinamide with 5 ml of sodium hydroxide solution; ammonia, recognisable by its odour, is evolved.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 60 volumes of 1-butanol, 20 volumes of glacial acetic acid and 20 volumes of water.

Test solution. Shake a quantity of the powdered tablets containing 0.1 g of Pyrazinamide with 50 ml of a mixture of 90 volumes of chloroform and 10 volumes of methanol, filter, evaporate to dryness and dissolve the residue in sufficient of the same solvent mixture to produce 10 ml.

Reference solution. Dilute 1 volume of the test solution to 500 volumes with a mixture of 90 volumes of chloroform and 10 volumes of methanol.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.1 g of Pyrazinamide, add 200 ml of water, allow to stand for 10 minutes, swirling occasionally, mix with the aid of ultrasound for 10 minutes and dilute to 500.0 ml with water. Filter and discard the first 20 ml of the filtrate. Dilute 5.0 ml of the filtrate to 100.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 268 nm (2.4.7). Calculate the content of C₅H₅N₃O taking 650 as the specific absorbance at 268 nm.

Storage. Store protected from moisture.

Pyridoxine Hydrochloride

Vitamin B₆

![Pyridoxine Hydrochloride](attachment:image)

C₈H₁₃NO₃HCl   Mol. Wt. 205.6

Pyridoxine Hydrochloride is 5-hydroxy-6-methylpyridine-3,4-dimethanol hydrochloride.

Pyridoxine Hydrochloride contains not less than 99.0 per cent and not more than 101.0 per cent of C₈H₁₃NO₃HCl, calculated on the dried basis.

Description. A white or almost white, crystalline powder; odourless.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B may be omitted if tests A, C and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pyridoxine hydrochloride RS or with the reference spectrum of pyridoxine hydrochloride.

B. When examined in the range 250 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.1 M hydrochloric acid shows an absorption maximum at 288 nm to 296 nm; absorbance at the maximum, 0.420 to 0.445. A solution prepared by diluting 1 ml of a 0.1 per cent w/v solution in 0.1 M hydrochloric acid to 100 ml with 0.025 M standard phosphate buffer shows absorption maxima at 248 nm to 256 nm and at 320 nm to 327 nm; absorbances at the maxima, 0.175 to 0.195 and 0.345 to 0.365, respectively.

C. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).
D. A 5 per cent w/v solution gives reaction A of chlorides (2.3.1).

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution is clear (2.4.1), and not more intensely coloured than reference solution YS7 (2.4.1).

**pH** (2.4.24). 2.4 to 3.0, determined in a 5.0 per cent w/v solution.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

*Mobile phase.* A mixture of 65 volumes of acetone, 13 volumes of dichloromethane, 13 volumes of tetrahydrofuran and 9 volumes of strong ammonia solution.

*Test solution (a).* A 10 per cent w/v solution of the substance under examination in water.

*Test solution (b).* A 1 per cent w/v solution of the substance under examination in water.

*Reference solution (a).* A 0.025 per cent w/v solution of the substance under examination in water.

*Reference solution (b).* A 1 per cent w/v solution of pyridoxine hydrochloride RS in water.

Apply to the plate 2 µl of each solution. After development, dry the plate in air and spray with a 5 per cent w/v solution of sodium carbonate in a mixture of 70 volumes of water and 30 volumes of ethanol (95 per cent). Dry in a current of air, spray with a 0.1 per cent w/v solution of 2,6-dichloroquinone-4-chloroimide in ethanol (95 per cent) and examine immediately. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a). Ignore any spots remaining on the line of application.

**Heavy metals** (2.3.13). 12 ml of a 5.0 per cent w/v solution complies with the limit test for heavy metals, Method D (20 ppm). Use lead standard solution (1 ppm Pb) to prepare the standard.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°.

**Assay.** Weigh accurately about 0.15 g, dissolve in a mixture of 5 ml of anhydrous glacial acetic acid and 6 ml of mercuric acetate solution. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator, until a green colour is produced. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02056 g of C8H11NO3·HCl.

**Storage.** Store protected from moisture.

---

**Pyridoxine Tablets**

Pyridoxine Hydrochloride Tablets

Pyridoxine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of pyridoxine hydrochloride, C8H11NO3·HCl.

**Identification**

A. Shake a quantity of the powdered tablets containing 20 mg of Pyridoxine Hydrochloride with 50 ml of 0.025 M standard phosphate buffer for 15 minutes and dilute to 100 ml with the same solvent. Mix, filter and dilute 5 ml of the filtrate to 100 ml with the same solvent. When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution exhibits two maxima, at about 254 nm and 324 nm.

B. Triturate a quantity of the powdered tablets containing 20 mg of Pyridoxine Hydrochloride with 50 ml of water and allow to stand for 20 minutes. To 1 ml of the supernatant liquid add 10 ml of a 5 per cent w/v solution of sodium acetate, 1 ml of water and 1 ml of a 0.5 per cent w/v solution of 2,6-dichloroquinone-4-chloroimide in ethanol (95 per cent) and shake; a blue colour is produced which fades rapidly and becomes brown. Repeat the operation but adding 1 ml of a 0.3 per cent w/v solution of boric acid in place of 1 ml of water; no blue colour is produced.

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

*Mobile phase.* A mixture of 65 volumes of acetone, 13 volumes of dichloromethane, 13 volumes of tetrahydrofuran and 9 volumes of strong ammonia solution.

*Test solution.* Shake a quantity of the powdered tablets containing 40 mg of Pyridoxine Hydrochloride with 10 ml of water for 15 minutes, filter and use the filtrate.

*Reference solution.* Dilute 1 ml of test solution to 200 ml with water.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and spray with a 5 per cent w/v solution of sodium carbonate in a mixture of 70 volumes of water and 30 volumes of ethanol (95 per cent). Dry it in a current of air, spray with a 0.1 per cent w/v solution of 2,6-dichloroquinone-4-chloroimide in ethanol (95 per cent) and examine immediately. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution. Use boric acid solution in place of 1 ml of water.

**Uniformity of content.** Comply with the test stated under Tablets.

Powder one tablet, add 50 ml of 0.1 M hydrochloric acid and heat on a water-bath for 15 minutes, swirling occasionally.
Cool, dilute to 100.0 ml with \textit{0.1 M hydrochloric acid}, filter, discarding the first 20 ml of the filtrate. If necessary, dilute quantitatively and stepwise with \textit{0.1 M hydrochloric acid} to produce a solution containing 10 µg of the pyridoxine hydrochloride per ml and measure the absorbance of the resulting solution at the maximum at about 290 nm \textit{(2.4.7)}. Calculate the content of \(\text{C}_8\text{H}_{11}\text{NO}_3\), HCl taking 430 as the specific absorbance at 290 nm.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 20 mg of Pyridoxine Hydrochloride, add 50 ml of \textit{0.1 M hydrochloric acid} and heat on a water-bath for 15 minutes, swirling occasionally. Cool, dilute to 100.0 ml with \textit{0.1 M hydrochloric acid} and filter, discarding the first 20 ml of the filtrate. Dilute 5.0 ml of the filtrate to 100.0 ml with \textit{0.1 M hydrochloric acid} and measure the absorbance of the resulting solution at the maximum at about 290 nm \textit{(2.4.7)}. Calculate the content of \(\text{C}_8\text{H}_{11}\text{NO}_3\), HCl taking 430 as the specific absorbance at 290 nm.

**Storage.** Store protected from light and moisture.

### Pyrimethamine

\[
\begin{align*}
\text{C}_{12}\text{H}_{13}\text{ClN}_4 & \quad \text{Mol. Wt. 248.7} \\
\text{Pyrimethamine is 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine.} \\
\text{Pyrimethamine contains not less than 99.0 per cent and not more than 101.0 per cent of } \text{C}_{12}\text{H}_{13}\text{ClN}_4, \text{calculated on the dried basis.} \\
\text{Description.} & \quad \text{Colourless crystals or an almost white, crystalline powder; odourless.} \\
\text{Identification} & \quad \text{Test } A \text{ may be omitted if tests } B \text{ and } C \text{ are carried out. Tests } B \text{ and } C \text{ may be omitted if test } A \text{ is carried out.} \\
& \quad \text{A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pyrimethamine } RS \text{ or with the reference spectrum of pyrimethamine.} \\
& \quad \text{B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).} \\
& \quad \text{C. Dissolve 0.14 g in sufficient } \text{ethanol} \text{ to produce 100 ml, dilute 10 ml of this solution to 100 ml with } \text{0.1 M hydrochloric acid} \text{ and dilute 10 ml of the solution to 100 ml with the same solvent. When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum at about 272 nm; absorbance at about 272 nm, 0.43 to 0.46.} \\
\end{align*}
\]

**Tests**

**Appearance of solution.** Dissolve 0.25 g in sufficient of a mixture of 3 volumes of \textit{dichloromethane} and 1 volume of \textit{methanol} to produce 10 ml. The resulting solution is clear \textit{(2.4.1)}, and not more intensely coloured than reference solution BYS6 \textit{(2.4.1)}.

**Acidity or alkalinity.** Shake 1.0 g with 50 ml of \textit{water} for 2 minutes and filter (solution A). To 10 ml of solution A add 0.05 ml of \textit{phenolphthalein solution}; the solution is colourless and not more than 0.2 ml of \textit{0.01 M sodium hydroxide} is required to change the colour to pink. Add 0.4 ml of \textit{0.01 M hydrochloric acid} and 0.05 ml of \textit{methyl red solution}; the solution is red or orange.

**Related substances.** Determine by thin-layer chromatography \textit{(2.4.17)}, coating the plate with silica gel \textit{GF254}.

**Mobile phase.** A mixture of 76 volumes of \textit{toluene}, 12 volumes of \textit{glacial acetic acid}, 8 volumes of \textit{l-propanol} and 4 volumes of \textit{chloroform}.

**Prepare the following solutions immediately before use.**

**Test solution (a).** Dissolve 0.1 g of the substance under examination in 10 ml of a mixture of 90 volumes of \textit{chloroform} and 10 volumes of \textit{methanol}.

**Test solution (b).** Dissolve 0.1 g of the substance under examination in 100 ml of the same solvent mixture.

**Reference solution (a).** A 0.0025 per cent w/v solution of the substance under examination in the same solvent mixture.

**Reference solution (b).** A 0.1 per cent w/v solution of \textit{pyrimethamine RS} in the same solvent mixture.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Sulphates** \textit{(2.3.17)}. 25 ml of Solution A complies with the limit test for sulphates. Use a mixture of 5.0 ml of \textit{sulphate standard solution (10 ppm SO}_4^{2-}\text{)} and 10 ml of \textit{distilled water} to prepare the standard (100 ppm).

**Sulphated ash** \textit{(2.3.18)}. Not more than 0.1 per cent.

**Loss on drying** \textit{(2.4.19)}. Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º for 4 hours.
Assay. Weigh accurately about 0.2 g, dissolve in 25 ml of anhydrous glacial acetic acid, heating gently, cool. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration. 1 ml of 0.1 M perchloric acid is equivalent to 0.02487 g of C_{12}H_{13}ClN_{4}.

Storage. Store protected from light and moisture.

Pyrimethamine and Sulphadoxine Tablets

Pyrimethamine and Sulphadoxine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of pyrimethamine, C_{12}H_{13}ClN_{4}, and of sulphadoxine, C_{12}H_{14}N_{4}O_{4}S.

Identification

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 4 volumes of chloroform, 4 volumes of n-heptane, 1 volume of glacial acetic acid and 4 volumes of a mixture of 1 volume of methanol and 19 volumes of ethanol.

Test solution. Shake a quantity of the powdered tablets containing 25 mg of Pyrimethamine with 50 ml of a 2 per cent w/v solution of strong ammonia solution in methanol.

Reference solution (a). A 0.05 per cent w/v solution of pyrimethamine RS in methanol.

Reference solution (b). A 1.0 per cent w/v solution of sulphadoxine RS in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. One of the principal spots in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with reference solution (a) and the other corresponds to that in the chromatogram obtained with reference solution (b).

Tests

Other tests. Complies with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh accurately a quantity of the powdered tablets containing about 25 mg of Pyrimethamine and 500 mg of Sulphadoxine and shake with 35 ml of acetonitrile for 30 minutes in a 100-ml volumetric flask. Dilute to volume with the mobile phase, mix and filter. To 25.0 ml of the filtrate add 2.0 ml of solution A prepared by dissolving 0.1 g of phenacetin (internal standard) in 100 ml of acetonitrile and sufficient of the mobile phase to produce 50.0 ml.

Reference solution. Weigh accurately about 25 mg of pyrimethamine RS and 500 mg of sulphadoxine RS, add 35 ml of acetonitrile and sufficient of the mobile phase to produce 100.0 ml and mix. To 25.0 ml add 2.0 ml of solution A and add sufficient of the mobile phase to produce 50.0 ml and mix well.

Chromatographic system

– a stainless steel column 30 cm x 4 mm, packed with octadecylsilane bonded to porous silica (5 µm),
– mobile phase: a mixture of 4 volumes of a 1 per cent v/v solution of glacial acetic acid and 1 volume of acetonitrile,
– flow rate. 2 ml per minute,
– spectrophotometer set at 254 nm,
– a 20 µl loop injector.

Inject the reference solution. The relative standard deviation for replicate injections is not more than 2.0 percent.

Inject alternately the test solution and the reference solution. The relative retention times should be about 1.3 for pyrimethamine, 1.0 for phenacetin and 0.7 for sulphadoxine.

Calculate the content of C_{12}H_{13}ClN_{4} and the content of C_{12}H_{14}N_{4}O_{4}S in the tablets.

Storage. Store protected from light and moisture.
Q

Quinalbarbitone Sodium
Quinalbarbitone Tablets
Quinidine Sulphate
Quinidine Tablets
Quinine Bisulphate
Quinine Bisulphate Tablets
Quinine Dihydrochloride
Quinine Dihydrochloride Injection
Quinine Sulphate
Quinine Tablets
Quiniodochlor
Quiniodochlor Tablets
Quinalbarbitone Sodium
Quinalbarbital Sodium; Secobarbital Sodium; Secobarbitone Sodium; Soluble Quinalbarbitone

\[
\begin{align*}
\text{H}_2\text{C} & \quad \text{O} \\
\text{H}_3\text{C} & \quad \text{N} \\
\text{H}_3\text{C} & \quad \text{O} \\
\text{C}_12\text{H}_{17}\text{N}_2\text{NaO}_3 & \quad \text{Mol.Wt.260.3}
\end{align*}
\]

Quinalbarbitone Sodium is sodium (RS)-5-allyl-5-(1-methylbutyl)barbiturate.

Quinalbarbitone Sodium contains not less than 98.5 per cent and not more than 102.0 per cent of \( \text{C}_{12}\text{H}_{17}\text{N}_2\text{NaO}_3 \), calculated on the dried basis.

**Description.** A white powder; odourless; hygroscopic.

**Identification**

*Test A may be omitted if tests B, C, D and E are carried out. Tests B, C and D may be omitted if tests A and E are carried out.*

A. To 10 ml of a 10.0 per cent w/v solution in ethanol (95 per cent) add 120 ml of water and 5 ml of 2 M acetic acid, stir vigorously, add 200 ml of water and boil until the precipitate dissolves and no oily particles remain on the surface of the liquid. Allow to cool until a haziness begins to appear in the solution, induce crystallisation, if necessary and allow the solution to stand for 12 hours. Wash the crystals with three quantities, each of 10 ml, of water and dry the residue at 80º.

On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with quinalbarbitone RS treated in the same manner.

B. To 0.5 g add 5 ml of sodium carbonate solution and 10 ml of nitrobenzyl chloride solution. Heat for 30 minutes on a water-bath under reflux and allow to stand for 1 hour. Filter, wash the precipitate successively with 10 ml of dilute sodium hydroxide solution and 50 ml of water; recrystallise from a mixture of equal volumes of chloroform and ethanol (95 per cent) and dry at 105º. The crystals melt at about 156º (2.4.21)

C. Complies with the test for identification of barbiturates (2.3.2).

D. Gives the reaction of non-nitrogen substituted barbiturates (2.3.1).

E. Ignite 1 g; the residue gives the reactions of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** A freshly prepared 10.0 per cent w/v solution in ethanol (95 per cent) is clear (2.4.1), and not more intensely coloured than reference solution YS7 (2.4.1).

**pH** (2.4.24). Not more than 11.0, determined on a 10.0 per cent w/v solution.

**Heavy metals** (2.3.13). 0.67 g dissolved in a mixture of 5 ml of 1 M sodium hydroxide and 20 ml of water complies with the limit test for heavy metals, Method C (30 ppm).

**Related substances.** Complies with the test for related substances in barbiturates (2.3.4).

**Loss on drying** (2.4.19). Not more than 3.0 per cent, determined on 0.5 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.5 g, dissolve in 10 ml of ethanol, add 10 ml of silver nitrate-pyridine reagent and titrate with 0.1 M ethanolic sodium hydroxide using 0.5 ml of thymolphthalein solution as indicator, until a pure blue colour is obtained. Carry out a blank titration.

1 ml of 0.1 M ethanolic sodium hydroxide is equivalent to 0.02603 g of \( \text{C}_{12}\text{H}_{17}\text{N}_2\text{NaO}_3 \).

**Storage.** Store protected from moisture.

Quinalbarbitone Tablets
Quinalbarbital Sodium Tablets; Quinalbarbitone Sodium Tablets; Secobarbital Sodium Tablets; Secobarbitone Sodium Tablets

Quinalbarbitone Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of quinalbarbitone sodium, \( \text{C}_{12}\text{H}_{17}\text{N}_2\text{NaO}_3 \). The tablets are coated.

**Identification**

A. Shake a quantity of the powdered tablets containing about 0.5 g of Quinalbarbitone Sodium with 10 ml of water and filter. To 10 ml of the filtrate add 5 ml of silver nitrate-pyridine reagent and titrate with 10 ml of dilute sodium hydroxide solution and 50 ml of water; recrystallise from a mixture of equal volumes of chloroform and ethanol (95 per cent) and dry at 105º. The crystals melt at about 156º (2.4.21)

B. Triturate a quantity of the powdered tablets containing 0.5 g of Quinalbarbitone Sodium with 10 ml of water, filter, acidify the filtrate with acetic acid; oily drops are formed which may eventually crystallise.
C. The powdered tablets give the reactions of sodium salts (2.3.1).

**Tests**

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and digest 20 tablets with 50 ml of water until completely disintegrated and not more than a small residue remains. Add 5 ml of 1 M sodium hydroxide, filter and wash the residue with sufficient water to produce 100.0 ml. Extract a volume of the solution containing 0.5 g of Quinalbarbitone Sodium with two quantities, each of 10 ml, of ether, washing each ether extract with the same 3 ml of water. Add the water to the aqueous liquid, acidify with hydrochloric acid and extract with successive quantities, each of 15 ml, of ether until complete extraction is effected. Wash the combined extracts with 10 ml of water. Add the ether to the main ether layer, filter and wash the filter with ether. Evaporate the solvent and dry the residue to constant weight at 50º. 1 g of residue is equivalent to 1.092 g of C₁₂H₁₇N₂NaO₃.

**Storage.** Store protected from moisture.

---

**Quinidine Sulphate**

**Quinidine Bisulphate**

\[
\text{OC}_3\text{H}_3\text{N}_2\text{O}_2\text{H}_2\text{SO}_4\text{2H}_2\text{O}
\]

Mol. Wt. 783.0

Quinidine Sulphate is (8R,9S)-6'-methoxycinchonan-9-ol sulphate dihydrate. The alkaloid is obtained from the bark of various species of Cinchona and from Remijia pedunculata Fluckiger (Fam. Rubiaceae) or prepared from quinine.

Quinidine Sulphate contains not less than 99.0 per cent and not more than 101.5 per cent of alkaloid monosulphates, calculated as (C₁₉H₂₄N₂O₂)₂H₂SO₄ on the dried basis.

**Description.** A white or almost white, crystalline powder or needle-like crystals; odourless.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 60 volumes of toluene, 36 volumes of ether and 15 volumes of diethylamine.

**Test solution.** Dissolve 1 g of the substance under examination in 100 ml of methanol.

**Reference solution (a).** A 1 per cent w/v solution of quinidine sulphate RS in methanol.

**Reference solution (b).** A 1 per cent w/v solution of each of quinidine sulphate RS and quinine sulphate RS in methanol.

Apply to the plate 4 µl of each solution. After development, dry the plate in air for 15 minutes and repeat the development. Dry the plate at 105º for 30 minutes, allow to cool and spray with potassium iodoplatinate solution. The principal spot in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows two clearly separated spots.

B. To 5 ml of a 0.1 per cent w/v solution add 0.2 ml of bromine solution and 1 ml of dilute ammonia solution; an emerald-green colour is produced.

C. To a 0.5 per cent w/v solution add an equal volume of dilute sulphuric acid; a strong blue fluorescence is produced.

D. To 5 ml of a 1 per cent w/v solution add 1 ml of silver nitrate solution and stir with a glass rod; after a short interval, a white precipitate soluble in nitric acid is produced (distinction from many other alkaloids).

E. A 1 per cent w/v solution gives the reactions of sulphates (2.3.1).

**Tests**

**Appearance of solution.** A 2.0 per cent w/v solution in 0.1 M hydrochloric acid is clear (2.4.1), and not more intensely coloured than reference solution GYS4 (2.4.1).

**pH** (2.4.24). 6.0 to 6.8, determined in a 1.0 per cent w/v solution.

**Specific optical rotation** (2.4.22). +275º to +290º, determined in a 2.0 per cent w/v solution in 0.1 M hydrochloric acid.

**Dihydroquinidine sulphate.** Not more than 15.0 per cent, calculated on the dried basis and determined by the following method. Dissolve 0.2 g in 20 ml of water, add 0.5 g of potassium bromide and 15 ml of 2 M hydrochloric acid. Titrate slowly with 0.0167 M potassium bromate using methyl red solution as indicator until a yellow colour is obtained. Add a solution of 0.5 g of potassium iodide in 200 ml of water and stopper the flask immediately. Allow to stand in the dark for 5 minutes and titrate with 0.1 M sodium thiosulphate using starch solution, added towards the end of the titration, as indicator. Repeat the operation without the substance under examination.
1 ml of 0.0167 M potassium bromate is equivalent to 0.01867 g of (C\textsubscript{20}H\textsubscript{24}N\textsubscript{2}O\textsubscript{2})\textsubscript{2}, H\textsubscript{2}SO\textsubscript{4}.

Calculate the content of dihydroquinidine sulphate by subtracting the result from the assay result.

Other cinchona alkaloids. Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 20 mg of the substance under examination in 5 ml of the mobile phase. Heat gently, if necessary to dissolve the powder as completely as possible, cool, dilute to 10 ml with the mobile phase and mix.

Reference solution (a). Dissolve 20 mg of quinine sulphate RS, with gentle heating if necessary, in 5 ml of the mobile phase and dilute to 10 ml with the mobile phase.

Reference solution (b). Prepare in the same manner as reference solution (a) but using quinidine sulphate RS in place of quinine sulphate RS.

Reference solution (c). Mix equal volumes of reference solutions (a) and (b).

Reference solution (d). Dilute 1 volume of reference solution (a) to 10 volumes with the mobile phase and dilute 1 volume of the resulting solution to 50 volumes with the mobile phase.

Reference solution (e). A solution containing 0.1 per cent w/v of thiourea in the mobile phase.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm) (such as Hypersil ODS 5 µm),
- mobile phase: a solution prepared by dissolving 6.8 g of potassium dihydrogen orthophosphate and 3.0 g of hexylamine in 700 ml of water, adjusting the pH to 2.8 with 1 M orthophosphoric acid, adding 60 ml of acetonitrile and diluting to 1000 ml with water,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 250 nm for reference solution (e) and 316 nm for the other solutions,
- a 10 µl loop injector.

Inject separately reference solutions (b) and (e). If necessary, adjust the concentration of acetonitrile in the mobile phase so that in the chromatogram obtained with reference solution (b) the capacity factor of the peak due to quinidine is 3.5 to 4.5, \( V_0 \) (the distance along the baseline between the point of injection and the perpendicular dropped from the maximum of the peak of an unretained component) being calculated from the peak due to thiourea in the chromatogram obtained with reference solution (e).

Inject reference solutions (a), (b), (c) and (d). The chromatogram obtained with reference solution (a) shows a principal peak due to quinine and a peak due to dihydroquinidine with a retention time relative to quinine of about 1.4. The chromatogram obtained with reference solution (b) shows a principal peak due to quinidine and a peak due to dihydroquinidine, with a retention time relative to quinidine of about 1.2. The chromatogram obtained with reference solution (c) shows four peaks due to quinine, dihydroquinine, quinidine and dihydroquinidine which are identified by comparison of their retention times with those of the corresponding peaks in the chromatograms obtained with reference solutions (a) and (b).

The test is not valid unless (a) in the chromatogram obtained with reference solution (c) the resolution between the peaks due to quinine and quinidine is at least 1.5 and the resolution between the peaks due to dihydroquinidine and quinine is at least 1.0 and (b) the signal-to-noise ratio of the principal peak in the chromatogram obtained with reference solution (d) is at least 5.

Inject the test solution and allow the chromatography to proceed for 2.5 times the retention time of the principal peak. Calculate the percentage content of related substances by normalisation, ignoring any peaks the areas of which are less than that of the peak in the chromatogram obtained with reference solution (d) (0.2 per cent). The content of dihydroquinidine is not greater than 15 per cent, the content of any related substance eluting before quinidine is not greater than 5 per cent and the content of any other related substance is not greater than 2.5 per cent.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). 3.0 per cent to 5.0 per cent, determined on 1.0 g by drying in an oven at 130º.

Assay. Weigh accurately about 0.2 g, dissolve in a mixture of 10 ml of chloroform and 20 ml of acetic anhydride. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02490 g of (C\textsubscript{20}H\textsubscript{24}N\textsubscript{2}O\textsubscript{2})\textsubscript{2}, H\textsubscript{2}SO\textsubscript{4}.

Storage. Store protected from light.

**Quinidine Tablets**

Quinidine Sulphate Tablets

Quinidine Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of quinidine sulphate, (C\textsubscript{20}H\textsubscript{24}N\textsubscript{2}O\textsubscript{2})\textsubscript{2}, H\textsubscript{2}SO\textsubscript{4},2H\textsubscript{2}O.

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.
Mobile phase. A mixture of 80 volumes of toluene, 20 volumes of acetone and 10 volumes of diethylamine.

Test solution. Extract a quantity of the powdered tablets containing 0.1 g of Quinidine Sulphate with 10 ml of a mixture of 2 volumes of chloroform and 1 volume of ethanol (95 per cent) and filter.

Reference solution. 1.0 per cent w/v solution of quinidine sulphate RS in a mixture of 2 volumes of chloroform and 1 volume of ethanol (95 per cent).

Apply to the plate 2 µl of each solution. After development, dry the plate in air and spray with 0.05 M ethanolic sulphuric acid and then with dilute potassium iodobismuthate solution. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

B. Extract a quantity of the powdered tablets containing 0.1 g of Quinidine Sulphate with 20 ml of water and filter. The filtrate (solution A) is dextro-rotatory.

C. To 1 ml of solution A add 4 ml of water, 2 or 3 drops of bromine solution and 1 ml of dilute ammonia solution; an emerald green colour is produced.

D. Solution A gives the reactions of sulphates (2.3.1).

Tests

Dissolution (2.5.2).

Apparatus. No 2

Medium. 900 ml of 0.1 M hydrochloric acid

Speed and time. 100 rpm and 30 minutes.

Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate, suitably diluted if necessary, at the maximum at about 248 nm (2.4.7). Calculate the content of \( (C_{20}H_{24}N_2O_2)_2H_2SO_4 \cdot 2H_2O \) in the medium from the absorbance obtained from a solution of known concentration of quinidine sulphate RS.

D. Not less than 70 per cent of the stated amount of \( (C_{20}H_{24}N_2O_2)_2H_2SO_4 \cdot 2H_2O \).

Other cinchona alkaloids. Determine by liquid chromatography (2.4.14).

Test solution. Mix a quantity of the powdered tablets containing 50 mg of Quinidine Sulphate with 20 ml of the mobile phase. Heat gently to dissolve the powder as completely as possible, cool, dilute to 25 ml with the mobile phase and filter, discarding the first few ml of filtrate.

Reference solution (a). Dissolve 20 mg of quinidine sulphate RS, with gentle heating if necessary, in 5 ml of the mobile phase and dilute to 10 ml with the mobile phase.

Reference solution (b). Prepare in the same manner as reference solution (a) but using quinidine sulphate RS in place of quinine sulphate RS.

Reference solution (c). Mix equal volumes of reference solutions (a) and (b).

Reference solution (d). Dilute 1 volume of reference solution (a) to 10 volumes with the mobile phase and dilute 1 volume of the resulting solution to 50 volumes with the mobile phase.

Reference solution (e). A solution containing 0.1 per cent w/v of thiourea in the mobile phase.

Chromatographic system

– a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm) (such as Hypersil ODS 5 µm),
– mobile phase: a solution prepared by dissolving 6.8 g of potassium dihydrogen orthophosphate and 3.0 g of hexylamine in 700 ml of water; adjusting the pH to 2.8 with 1 M orthophosphoric acid, adding 60 ml of acetonitrile and diluting to 1000 ml with water,
– flow rate. 1.5 ml per minute,
– spectrophotometer set at 250 nm for reference solution (e) and 316 nm for the other solutions,
– a 10 µl loop injector.

Inject separately reference solutions (b) and (e). If necessary, adjust the concentration of acetonitrile in the mobile phase so that in the chromatogram obtained with reference solution (b) the capacity factor of the peak due to quinidine is 3.5 to 4.5, \( V_o \) (the distance along the baseline between the point of injection and the perpendicular dropped from the maximum of the peak of an unretained component) being calculated from the peak due to thiourea in the chromatogram obtained with reference solution (e).

Inject reference solutions (a), (b), (c) and (d). The chromatogram obtained with reference solution (b) shows a principal peak due to quinidine and a peak due to dihydroquinine with a retention time relative to quinine of about 1.4. The chromatogram obtained with reference solution (b) shows a principal peak due to quinine and a peak due to dihydroquinine, with a retention time relative to quinidine of about 1.2. The chromatogram obtained with reference solution (c) shows four peaks due to quinine, dihydroquinine, quinidine and dihydroquinidine which are identified by comparison of their retention times with those of the corresponding peaks in the chromatograms obtained with reference solutions (a) and (b).

The test is not valid unless (a) in the chromatogram obtained with reference solution (c) the resolution between the peaks due to quinine and quinidine is at least 1.5 and the resolution between the peaks due to dihydroquinidine and quinine is at least 1.0 and (b) the signal-to-noise ratio of the principal peak...
in the chromatogram obtained with reference solution (d) is at least 5.

Inject the test solution and allow the chromatography to proceed for 2.5 times the retention time of the principal peak. Calculate the percentage content of related substances by normalisation, ignoring any peaks the areas of which are less than that of the peak in the chromatogram obtained with reference solution (d) (0.2 per cent). The content of dihydroquinidine is not greater than 15 per cent, the content of any related substance eluting before quinidine is not greater than 5 per cent and the content of any other related substance is not greater than 2.5 per cent.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.4 g of Quinidine Sulphate, dissolve as completely as possible in 40 ml of acetic anhydride with the aid of heat and cool. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02610 g of (C₂₀H₂₄N₂O₂)₂,H₂SO₄,2H₂O.

**Storage.** Store protected from light.

---

**Quinine Bisulphate**

Quinine Acid Sulphate

![Quinine Bisulphate structure](image)

C₂₀H₂₄N₂O₄,H₂SO₄,7H₂O  Mol. Wt. 548.6

Quinine Bisulphate is (8S,9R)-6'-methoxycinchonan-9-ol hydrogen sulphate heptahydrate. The alkaloid is obtained from the bark of various species of *Cinchona*.

Quinine Bisulphate contains not less than 98.5 per cent and not more than 101.5 per cent of alkaloid hydrogen sulphates, calculated as C₂₀H₂₄N₂O₄,H₂SO₄ on the anhydrous basis.

**Description.** Colourless or faintly yellow crystals or a white or faintly yellow, crystalline powder; efflorescent in dry air.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel G*.
Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecysilane bonded to porous silica (5 µm) (such as Hypersil ODS 5 µm),
- mobile phase: a solution prepared by dissolving 6.8 g of potassium dihydrogen orthophosphate and 3.0 g of hexylamine in 700 ml of water, adjusting the pH to 2.8 with 1 M orthophosphoric acid, adding 60 ml of acetonitrile and diluting to 1000 ml with water,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 250 nm for reference solution (e) and 316 nm for the other solutions,
- a 10 µl loop injector.

Inject separately reference solutions (b) and (e). If necessary, adjust the concentration of acetonitrile in the mobile phase so that in the chromatogram obtained with reference solution (b) the capacity factor of the peak due to quinidine is 3.5 to 4.5, \( V_0 \) (the distance along the baseline between the point of injection and the perpendicular dropped from the maximum of the peak of an unretained component) being calculated from the peak due to thiourea in the chromatogram obtained with reference solution (e).

Inject reference solutions (a), (b), (c) and (d). The chromatogram obtained with reference solution (a) shows a principal peak due to quinine and a peak due dihydroquinine with a retention time relative to quinine of about 1.4. The chromatogram obtained with reference solution (b) shows a principal peak due to quinidine and a peak due to dihydroquinidine, with a retention time relative to quinidine of about 1.2. The chromatogram obtained with reference solution (c) shows four peaks due to quinine, dihydroquinine, quinidine and dihydroquinidine which are identified by comparison of their retention times with those of the corresponding peaks in the chromatograms obtained with reference solutions (a) and (b).

The test is not valid unless (a) in the chromatogram obtained with reference solution (c) the resolution between the peaks due to quinine and quinidine is at least 1.5 and the resolution between the peaks due to dihydroquinidine and quinine is at least 1.0 and (b) the signal-to-noise ratio of the principal peak in the chromatogram obtained with reference solution (d) is at least 5.

Inject the test solution and allow the chromatography to proceed for 2.5 times the retention time of the principal peak. Calculate the percentage content of related substances by normalisation, ignoring any peaks the areas of which are less than that of the peak in the chromatogram obtained with reference solution (d) (0.2 per cent). The content of dihydroquinine is not greater than 10 per cent, the content of any related substance eluting before quinine is not greater than 5 per cent and the content of any other related substance is not greater than 2.5 per cent.

**Quinine Bisulphate Tablets**

Quinine Acid Sulphate Tablets
Quinine Bisulphate Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of quinine bisulphate, \( \text{C}_20\text{H}_{24}\text{N}_2\text{O}_2\cdot\text{H}_2\text{SO}_4 \). The tablets are coated.

**Identification**
A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel \( G \).

**Mobile phase.** A mixture of 80 volumes of toluene, 20 volumes of acetone and 10 volumes of diethylyamine.

**Test solution.** Extract a quantity of the powdered tablets containing 0.1 g of Quinine Bisulphate with 10 ml of a mixture of 2 volumes of chloroform and 1 volume of ethanol (95 per cent) and filter.

**Reference solution.** A 1.0 per cent w/v solution of quinine sulphate in the same solvent mixture.

Apply to the plate 2 µl of each solution. After development, dry the plate in air and spray with 0.05 M ethanolic sulphuric acid and then with dilute potassium iodobismuthate solution. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.
B. Extract a quantity of the powdered tablets containing 0.1 g of Quinine Bisulphate with 20 ml of water and filter (solution A). To 5 ml of solution A add 0.2 ml of bromine solution and 1 ml of dilute ammonia solution; an emerald-green colour is produced.

C. Solution A is laevo-rotatory.

D. Solution A gives the reactions of sulphates (2.3.1).

**Tests**

**Dissolution (2.5.2).**

Apparatus. No 2

Medium. 900 ml of 0.1 M hydrochloric acid

Speed and time. 100 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate, suitably diluted if necessary, at the maximum at about 348 nm (2.4.7). Calculate the content of C₂₀H₂₄N₂O₂.H₂SO₄.7H₂O in the medium taking 99 as the specific absorbance at 348 nm.

D. Not less than 70 per cent of the stated amount of C₂₀H₂₄N₂O₂.H₂SO₄.7H₂O.

**Other cinchona alkaloids.** Determine by liquid chromatography (2.4.14).

**Test solution.** Remove any coating from the tablets and mix a quantity of the powdered tablet cores containing 50 mg of Quinine Bisulphate with 20 ml of the mobile phase. Heat gently to dissolve the powder as completely as possible, cool, dilute to 25 ml with the mobile phase and filter, discarding the first few ml of the filtrate.

**Reference solution (a).** Dissolve 20 mg of quinine sulphate RS, with gentle heating if necessary, in 5 ml of the mobile phase and dilute to 10 ml with the mobile phase.

**Reference solution (b).** Prepare in the same manner as reference solution (a) but using quinidine sulphate RS in place of quinine sulphate RS.

**Reference solution (c).** Mix equal volumes of reference solutions (a) and (b).

**Reference solution (d).** Dilute 1 volume of reference solution (a) to 10 volumes with the mobile phase and dilute 1 volume of the resulting solution to 50 volumes with the mobile phase.

**Reference solution (e).** A solution containing 0.1 per cent w/v of thiourea in the mobile phase.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm) (such as Hypersil ODS 5 µm),
- mobile phase: a solution prepared by dissolving 6.8 g of potassium dihydrogen orthophosphate and 3.0 g of hexylamine in 700 ml of water, adjusting the pH to 2.8 with 1 M orthophosphoric acid, adding 60 ml of acetonitrile and diluting to 1000 ml with water,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 250 nm for reference solution (e) and 316 nm for the other solutions,
- a 10 µl loop injector.

Inject separately reference solutions (b) and (e). If necessary, adjust the concentration of acetonitrile in the mobile phase so that in the chromatogram obtained with reference solution (b) the capacity factor of the peak due to quinidine is 3.5 to 4.5, \( V_0 \) (the distance along the baseline between the point of injection and the perpendicular dropped from the maximum of the peak of an unretained component) being calculated from the peak due to thiourea in the chromatogram obtained with reference solution (e).

Inject reference solutions (a), (b), (c) and (d). The chromatogram obtained with reference solution (a) shows a principal peak due to quinine and a peak due to dihydroquinine with a retention time relative to quinine of about 1.4. The chromatogram obtained with reference solution (b) shows a principal peak due to quinidine and a peak due to dihydroquinidine, with a retention time relative to quinidine of about 1.2. The chromatogram obtained with reference solution (c) shows four peaks due to quinine, dihydroquinine, quinidine and dihydroquinidine which are identified by comparison of their retention times with those of the corresponding peaks in the chromatograms obtained with reference solutions (a) and (b).

The test is not valid unless (a) in the chromatogram obtained with reference solution (c) the resolution \( R \) between the peaks due to quinine and quinidine is at least 1.5 and the resolution between the peaks due to dihydroquinidine and quinine is at least 1.0 and (b) the signal-to-noise ratio of the principal peak in the chromatogram obtained with reference solution (d) is at least 5.

Inject the test solution and allow the chromatography to proceed for 2.5 times the retention time of the principal peak. Calculate the percentage content of related substances by normalisation, ignoring any peaks the areas of which are less than that of the peak in the chromatogram obtained with reference solution (d) (0.2 per cent). The content of dihydroquinine is not greater than 10 per cent, the content of any related substance eluting before quinine is not greater than 5 per cent and the content of any other related substance is not greater than 2.5 per cent.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.6 g of Quinine Bisulphate, dissolve as completely as possible in 40 ml of
acetic anhydride with the aid of heat and cool. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.05486 g of C_{20}H_{24}N_{2}O_{2}\cdot\text{H}_{2}\text{SO}_{4}\cdot7\text{H}_{2}\text{O}.

Storage. Store protected from light.

Quinine Dihydrochloride
Quinine Acid Hydrochloride

\[
\text{C}_{20}\text{H}_{24}\text{N}_{2}\text{O}_{2}\cdot2\text{HCl} \quad \text{Mol. Wt. 397.3}
\]

Quinine Dihydrochloride is the \((8S,9R)-6′-\text{methoxycinchonan-9-ol dihydrochloride. The alkaloid is obtained from the bark of various species of Cinchona.}

Quinine Dihydrochloride contains not less than 99.0 per cent and not more than 101.5 per cent of alkaloid dihydrochlorides, calculated as C_{20}H_{24}N_{2}O_{2}\cdot2\text{HCl} on the dried basis.

Description. A white or almost white powder; odourless.

Identification
A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 60 volumes of toluene, 36 volumes of ether and 15 volumes of diethylamine.

Test solution. Dissolve 1 g of the substance under examination in 100 ml of methanol.

Reference solution (a). A 1 per cent w/v solution of quinidine sulphate RS in methanol.

Reference solution (b). A 1 per cent w/v solution of each of quinidine sulphate RS and quinine sulphate RS in methanol.

Apply to the plate 4 \(\mu\)l of each solution. After development, dry the plate in air for 15 minutes and repeat the development. Dry the plate at 105\(^\circ\) for 30 minutes, allow to cool and spray with potassium iodoplatinate solution. The principal spot in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows two clearly separated spots.

B. To a 0.5 per cent w/v solution add an equal volume of dilute sulphuric acid; a strong blue fluorescence is produced.

C. A 1 per cent w/v solution gives the reactions of chlorides (2.3.1).

Tests
pH (2.4.24). 2.0 to 3.0, determined in a 3.0 per cent w/v solution.

Specific optical rotation (2.4.22). \(-223^\circ\) to \(-229^\circ\), determined in a 3.0 per cent w/v solution in 0.1 M hydrochloric acid.

Barium. To 15 ml of a 2 per cent w/v solution add 1 ml of dilute sulphuric acid; the solution remains clear for at least 15 minutes.

Dihydroquinine dihydrochloride. Not more than 10.0 per cent, calculated on the dried basis and determined by the following method. Dissolve 0.2 g in 20 ml of water, add 0.5 g of potassium bromide and 15 ml of 2 M hydrochloric acid. Titrate slowly with 0.0167 M potassium bromate using methyl red solution as indicator until a yellow colour is obtained. Add a solution of 0.5 g of potassium iodide in 200 ml of water and stop the flask immediately. Allow to stand in the dark for 5 minutes and titrate with 0.1 M sodium thiosulphate using starch solution, added towards the end of the titration, as indicator. Repeat the operation without the substance under examination.

1 ml of 0.0167 M potassium bromate is equivalent to 0.01987 g of C_{20}H_{24}N_{2}O_{2}\cdot2\text{HCl}. Calculate the content of dihydroquinine dihydrochloride by subtracting the result from the assay result.

Other cinchona alkaloids. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 20 mg of the substance under examination in 5 ml of the mobile phase. Heat gently, if necessary to dissolve the powder as completely as possible, cool, dilute to 10 ml with the mobile phase and mix.

Reference solution (a). Dissolve 20 mg of quinine sulphate RS, with gentle heating if necessary, in 5 ml of the mobile phase and dilute to 10 ml with the mobile phase.

Reference solution (b). Prepare in the same manner as reference solution (a) but using quinidine sulphate RS in place of quinine sulphate RS.

Reference solution (c). Mix equal volumes of reference solutions (a) and (b).

Reference solution (d). Dilute 1 volume of reference solution (a) to 10 volumes with the mobile phase and dilute 1 volume of the resulting solution to 50 volumes with the mobile phase.

Reference solution (e). A solution containing 0.1 per cent w/v of thiourea in the mobile phase.
Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm) (such as Hypersil ODS 5 µm),
- mobile phase: a solution prepared by dissolving 6.8 g of potassium dihydrogen orthophosphate and 3.0 g of hexylamine in 700 ml of water, adjusting the pH to 2.8 with 1 M orthophosphoric acid, adding 60 ml of acetonitrile and diluting to 1000 ml with water
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 250 nm for reference solution (e) and 316 nm for the other solutions,
- a 10 µl loop injector.

Inject separately reference solutions (b) and (e). If necessary, adjust the concentration of acetonitrile in the mobile phase so that in the chromatogram obtained with reference solution (b) the capacity factor of the peak due to quinidine is 3.5 to 4.5, $V_0$ (the distance along the baseline between the point of injection and the perpendicular dropped from the maximum of the peak of an unretained component) being calculated from the peak due to thiourea in the chromatogram obtained with reference solution (e).

Inject reference solutions (a), (b), (c) and (d). The chromatogram obtained with reference solution (a) shows a principal peak due to quinine and a peak due to dihydroquinine with a retention time relative to quinine of about 1.4. The chromatogram obtained with reference solution (b) shows a principal peak due to quinidine and a peak due to dihydroquinidine, with a retention time relative to quinidine of about 1.2. The chromatogram obtained with reference solution (c) shows four peaks due to quinine, dihydroquinine, quinidine and dihydroquinidine which are identified by comparison of their retention times with those of the corresponding peaks in the chromatograms obtained with reference solutions (a) and (b).

The test is not valid unless (a) in the chromatogram obtained with reference solution (c) the resolution between the peaks due to quinidine and quinidine is at least 1.5 and the resolution between the peaks due to dihydroquinidine and quinine is at least 1.0 and (b) the signal-to-noise ratio of the principal peak in the chromatogram obtained with reference solution (d) is at least 5.

Inject the test solution and allow the chromatography to proceed for 2.5 times the retention time of the principal peak. Calculate the percentage content of related substances by normalisation, ignoring any peaks the areas of which are less than that of the peak in the chromatogram obtained with reference solution (d) (0.2 per cent). The content of dihydroquinine is not greater than 10 per cent, the content of any related substance eluting before quinine is not greater than 5 per cent and the content of any other related substance is not greater than 2.5 per cent.

**Quinine Dihydrochloride Injection**

**Quinine Acid Hydrochloride Injection**

Quinine Dihydrochloride Injection is a sterile solution of Quinine Dihydrochloride in Water for Injections. Quinine Dihydrochloride Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of quinine dihydrochloride, C$_{20}$H$_{24}$N$_{2}$O$_{2}$·2HCl.

**Description.** A clear, almost colourless to light yellow solution.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 80 volumes of toluene, 20 volumes of acetone and 10 volumes of diethylamine.

**Test solution.** Extract a volume of the injection containing 0.1 g of Quinine Dihydrochloride Bisulphate with 10 ml of a mixture of 2 volumes of chloroform and 1 volume of ethanol (95 per cent) and filter.

**Reference solution (a).** A 1 per cent w/v solution of quinine sulphate in the same solvent mixture.

**Reference solution (b).** A solution of 1 per cent w/v of each of quinidine sulphate RS and quinine sulphate RS in the same solvent mixture.

Apply to the plate 2 µl of each solution. After development, dry the plate in air and spray with 0.03 M ethanolic sulphuric acid.
adjust the concentration of acetonitrile in the mobile phase so that in the chromatogram obtained with reference solution (b) the capacity factor of the peak due to quinine is 3.5 to 4.5, \( V_o \) (the distance along the baseline between the point of injection and the perpendicular dropped from the maximum of the peak of an unretained component) being calculated from the peak due to thiourea in the chromatogram obtained with reference solution (e).

Inject reference solutions (a), (b), (c) and (d). The chromatogram obtained with reference solution (a) shows a principal peak due to quinine and a peak due to dihydroquinidine, with a retention time relative to quinine of about 1.4. The chromatogram obtained with reference solution (b) shows a principal peak due to quinidine and a peak due to dihydroquinidine, with a retention time relative to quinidine of about 1.2. The chromatogram obtained with reference solution (c) shows four peaks due to quinine, dihydroquinine, quinidine and dihydroquinidine which are identified by comparison of their retention times with those of the corresponding peaks in the chromatograms obtained with reference solutions (a) and (b).

The test is not valid unless (a) in the chromatogram obtained with reference solution (c) the resolution between the peaks due to quinine and quinidine is at least 1.5 and the resolution factor between the peaks due to dihydroquinidine and quinine is at least 1.0 and (b) the signal-to-noise ratio of the principal peak in the chromatogram obtained with reference solution (d) is at least 5.

Inject the test solution and allow the chromatography to proceed for 2.5 times the retention time of the principal peak. Calculate the percentage content of related substances by normalisation, ignoring any peaks the areas of which are less than that of the peak in the chromatogram obtained with reference solution (d) (0.2 per cent). The content of dihydroquinine is not greater than 10 per cent, the content of any related substance eluting before quinine is not greater than 5 per cent and the content of any other related substance is not greater than 2.5 per cent.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** To an accurately measured volume containing about 0.5 g of Quinine Dihydrochloride add 20 ml of water and 5 ml of sodium hydroxide solution. Extract with successive quantities, each of 10 ml, of chloroform until complete extraction of the alkaloid is effected, washing each extract with the same two quantities, each of 5 ml, of water. Remove the chloroform from the combined extracts, dissolve the residue in 50 ml of anhydrous glacial acetic acid and add 20 ml of acetic anhydride. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01987 g of C_{20}H_{24}N_{2}O_{2}.2HCl.
Storage. Store protected from light.

Labelling. The label states that the solution must be diluted to a strength not exceeding 30 mg per ml before administration and that care should be taken to ensure slow intravenous injection.

Quinine Sulphate

\[
\text{OCH}_3
\]

\[
\begin{array}{c}
\text{HO}
\end{array}
\]

\[
\text{N}
\]

\[
\text{H}
\]

\[
\text{H}
\]

\[
\text{H}
\]

\[
\text{HO}
\]

\[
\text{OCH}_3
\]

\[
,\text{H}_2\text{SO}_4, 2\text{H}_2\text{O}
\]

(C\text{20H24N2O2})\text{2},\text{H}_2\text{SO}_4,\text{2H}_2\text{O}

Mol. Wt.783.0

Quinine Sulphate is (8S,9R)-6'-methoxycinchonan-9-ol sulphate dihydrate. The alkaloid is obtained from the bark of various species of Cinchona.

Quinine Sulphate contains not less than 99.0 per cent and not more than 101.0 per cent of alkaloid monosulphates, calculated as (C\text{20H24N2O2})\text{2},\text{H}_2\text{SO}_4 on the dried basis.

Description. White or almost white, needle-like crystals or a crystalline powder.

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 40 volumes of toluene, 24 volumes of ether and 10 volumes of diethylamine.

Test solution. Dissolve 1 g of the substance under examination in 100 ml of methanol.

Reference solution. A 1 per cent w/v solution of quinine sulphate RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air for 15 minutes and repeat the development. Dry the plate at 105° for 30 minutes, allow to cool and spray with potassium iodoplatinate solution. The principal spot in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with the reference solution.

B. To 5 ml of a 0.1 per cent w/v solution add 0.2 ml of bromine solution and 1 ml of dilute ammonia solution; an emerald-green colour is produced.

C. To a 0.5 per cent w/v solution add an equal volume of dilute sulphuric acid; a strong blue fluorescence is produced.

D. To 5 ml of a 1 per cent w/v solution add 1 ml of silver nitrate solution and stir with a glass rod; after a short interval, a white precipitate soluble in nitric acid is produced (distinction from many other alkaloids).

E. A 1 per cent w/v solution gives the reactions of sulphates (2.3.1).

Tests

Appearance of solution. A 2.0 per cent w/v solution in 0.1 M hydrochloric acid is clear (2.4.1), and not more intensely coloured than reference solution GYS4 (2.4.1).

pH (2.4.24). 5.7 to 6.6, determined in a 1.0 per cent w/v suspension in water.

Specific optical rotation (2.4.22). –237° to –245°, determined in a 2.0 per cent w/v solution in 0.1 M hydrochloric acid.

Other cinchona alkaloids. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 20 mg of the substance under examination in 5 ml of the mobile phase. Heat gently, if necessary to dissolve the powder as completely as possible, cool, dilute to 10 ml with the mobile phase and mix.

Reference solution (a). Dissolve 20 mg of quinine sulphate RS, with gentle heating if necessary, in 5 ml of the mobile phase and dilute to 10 ml with the mobile phase.

Reference solution (b). Prepare in the same manner as reference solution (a) but using quinidine sulphate RS in place of quinine sulphate RS.

Reference solution (c). Mix equal volumes of reference solutions (a) and (b).

Reference solution (d). Dilute 1 volume of reference solution (a) to 10 volumes with the mobile phase and dilute 1 volume of the resulting solution to 50 volumes with the mobile phase.

Reference solution (e). A solution containing 0.1 per cent w/v of thiourea in the mobile phase.

Chromatographic system

– a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm) (such as Hypersil ODS 5 µm),
– mobile phase: a solution prepared by dissolving 6.8 g of potassium dihydrogen orthophosphate and 3.0 g of hexylamine in 700 ml of water; adjusting the pH to 2.8 with 1 M orthophosphoric acid, adding 60 ml of acetonitrile and diluting to 1000 ml with water,
– flow rate. 1.5 ml per minute,
– spectrophotometer set at 250 nm for reference solution (e) and 316 nm for the other solutions,
– a 10 µl loop injector.
Inject separately reference solutions (b) and (e). If necessary, adjust the concentration of acetonitrile in the mobile phase so that in the chromatogram obtained with reference solution (b) the capacity factor of the peak due to quinidine is 3.5 to 4.5, $V_0$ (the distance along the baseline between the point of injection and the perpendicular dropped from the maximum of the peak of an unretained component) being calculated from the peak due to thiourea in the chromatogram obtained with reference solution (e).

Inject reference solutions (a), (b), (c) and (d). The chromatogram obtained with reference solution (a) shows a principal peak due to quinine and a peak due to dihydroquinidine with a retention time relative to quinine of about 1.4. The chromatogram obtained with reference solution (b) shows a principal peak due to quinidine and a peak due to dihydroquinidine, with a retention time relative to quinidine of about 1.2. The chromatogram obtained with reference solution (c) shows four peaks due to quinine, dihydroquinine, quinidine and dihydroquinidine which are identified by comparison of their retention times with those of the corresponding peaks in the chromatograms obtained with solutions (a) and (b).

The test is not valid unless (a) in the chromatogram obtained with reference solution (c) the resolution between the peaks due to quinine and quinidine is at least 1.5 and the resolution between the peaks due to dihydroquinidine and quinine is at least 1.0 and (b) the signal-to-noise ratio of the principal peak in the chromatogram obtained with reference solution (d) is at least 5.

Inject the test solution and allow the chromatography to proceed for 2.5 times the retention time of the principal peak. Calculate the percentage content of related substances by normalisation, ignoring any peaks the areas of which are less than that of the peak in the chromatogram obtained with reference solution (d) (0.2 per cent). The content of dihydroquinine is not greater than 10 per cent, the content of any related substance eluting before quinine is not greater than 5 per cent and the content of any other related substance is not greater than 2.5 per cent.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). 3.0 to 5.0 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.2 g, dissolve in a mixture of 10 ml of chloroform and add 20 ml of acetic anhydride. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02490 g of (C$_{20}$H$_{24}$N$_2$O$_2$)$_2$H$_2$SO$_4$.2H$_2$O.

**Storage.** Store protected from light.

---

**Quinine Tablets**

**Quinine Sulphate Tablets**

Quinine Sulphate Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of quinine sulphate, (C$_{20}$H$_{24}$N$_2$O$_2$)$_2$H$_2$SO$_4$.2H$_2$O. The tablets are coated.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel* G.

*Mobile phase.* A mixture of 80 volumes of toluene, 20 volumes of acetone and 10 volumes of diethylamine.

*Test solution.* Extract a quantity of the powdered tablets containing 0.1 g of Quinine Sulphate with 10 ml of a mixture of 2 volumes of chloroform and 1 volume of ethanol (95 per cent) and filter.

*Reference solution.* A 1 per cent w/v solution of quinine sulphate in the same solvent mixture.

Apply to the plate 2 µl of each solution. After development, dry the plate in air and spray with 0.05 M ethanolic sulphuric acid and then with dilute potassium iodobismuthate solution. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

B. Extract a quantity of the powdered tablets containing 0.1 g of Quinine Sulphate with 20 ml of water and filter (solution A). To 5 ml of solution A add 0.2 ml of bromine solution and 1 ml of dilute ammonia solution; an emerald-green colour is produced.

C. Solution A is *laevo-rotatory*.

D. Solution A gives the reactions of sulphates (2.3.1).

**Tests**

**Dissolution** (2.5.2).

Apparatus. No 2

Medium. 900 ml of 0.1 M hydrochloric acid

Speed and time. 100 rpm and 30 minutes.

Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate, suitably diluted if necessary, at the maximum at about 348 nm (2.4.7). Calculate the content of C$_{20}$H$_{24}$N$_2$O$_2$. H$_2$SO$_4$. 2H$_2$O in the medium from a solution of known concentration of quinine sulphate RS.

D. Not less than 70 per cent of the stated amount of C$_{20}$H$_{24}$N$_2$O$_2$. H$_2$SO$_4$. 2H$_2$O.

**Other cinchona alkaloids.** Determine by liquid chromatography (2.4.14).
**Test solution.** Remove any coating from the tablets and mix a quantity of the powdered tablet cores containing 50 mg of Quinine Sulphate with 20 ml of the mobile phase. Heat gently to dissolve the powder as completely as possible, cool, dilute to 25 ml with the mobile phase and filter, discarding the first few ml of the filtrate.

**Reference solution (a).** Dissolve 20 mg of quinine sulphate RS, with gentle heating if necessary, in 5 ml of the mobile phase and dilute to 10 ml with the mobile phase.

**Reference solution (b).** Prepare in the same manner as reference solution (a) but using quinidine sulphate RS in place of quinine sulphate RS.

**Reference solution (c).** Mix equal volumes of reference solutions (a) and (b).

**Reference solution (d).** Dilute 1 volume of reference solution (a) to 10 volumes with the mobile phase and dilute 1 volume of the resulting solution to 50 volumes with the mobile phase.

**Reference solution (e).** A solution containing 0.1 per cent w/v of thiourea in the mobile phase.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm) (such as Hypersil ODS 5 µm),
- mobile phase: a solution prepared by dissolving 6.8 g of potassium dihydrogen orthophosphate and 3.0 g of hexylamine in 700 ml of water, adjusting the pH to 2.8 with 1 M orthophosphoric acid, adding 60 ml of acetonitrile and diluting to 1000 ml with water,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 250 nm for reference solution (e) and 316 nm for the other solutions,
- a 10 µl loop injector.

Inject separately reference solutions (b) and (e). If necessary, adjust the concentration of acetonitrile in the mobile phase so that in the chromatogram obtained with reference solution (b) the capacity factor of the peak due to quinidine is 3.5 to 4.5, $V_o$ (the distance along the baseline between the point of injection and the perpendicular dropped from the maximum of the peak of an unretained component) being calculated from the peak due to thiourea in the chromatogram obtained with reference solution (e).

Inject reference solutions (a), (b), (c) and (d). The chromatogram obtained with reference solution (a) shows a principal peak due to quinine and a peak due to dihydroquinine with a retention time relative to quinine of about 1.4. The chromatogram obtained with reference solution (b) shows a principal peak due to quinidine and a peak due to dihydroquinidine, with a retention time relative to quinidine of about 1.2. The chromatogram obtained with reference solution (c) shows four peaks due to quinine, dihydroquinine, quinidine and dihydroquinidine which are identified by comparison of their retention times with those of the corresponding peaks in the chromatograms obtained with reference solutions (a) and (b).

The test is not valid unless (a) in the chromatogram obtained with reference solution (c) the resolution between the peaks due to quinine and quinidine is at least 1.5 and the resolution between the peaks due to dihydroquinidine and quinine is at least 1.0 and (b) the signal-to-noise ratio of the principal peak in the chromatogram obtained with reference solution (d) is at least 5.

Inject the test solution and allow the chromatography to proceed for 2.5 times the retention time of the principal peak. Calculate the percentage content of related substances by normalisation, ignoring any peaks the areas of which are less than that of the peak in the chromatogram obtained with reference solution (d) (0.2 per cent). The content of dihydroquinine is not greater than 10 per cent, the content of any related substance eluting before quinine is not greater than 5 per cent and the content of any other related substance is not greater than 2.5 per cent.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.4 g of Quinine Sulphate, dissolve as completely as possible in 40 ml of acetic anhydride with the aid of heat and cool. Filter, if necessary through Whatman No.1 filter paper and rinse with an additional 40 ml of acetic anhydride in small volumes. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02610 g of (C$_{20}$H$_24$N$_2$O$_2$)$_2$H$_2$SO$_4$2H$_2$O.

**Storage.** Store protected from light.

**Quiniodochlor**

Clioquinol; Iodochlorhydroxyquinoline; Iodochlorhydroxyquin

Quiniodochlor is 5-chloro-7-iodoquinolin-8-ol.
Quiniodochlor contains not less than 97.0 per cent and not more than 103.0 per cent of C₉H₅ClINO, calculated on the dried basis.

**Description.** A yellowish white to brownish yellow powder; odour, faint and characteristic.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with quiniodochlor RS or with the reference spectrum of quiniodochlor.

B. When examined in the range 230 nm to 360 nm (2.4.7), a Ross shows an absorption maximum at about 267 nm.

C. Burn 20 mg by the oxygen-flask method (2.3.34), using 5 ml of 2 M sodium hydroxide as the absorbing liquid and dilute to 25 ml with water. To 5 ml add 1 ml of silver nitrate solution; a yellow precipitate is produced. Add 5 ml of 5 M ammonia, shake, filter and acidify the filtrate with nitric acid; a white precipitate is produced.

**Tests**

**Acidity or alkalinity.** Shake 0.5 g with 10 ml of water previously neutralised to phenolphthalein solution. The solution is colourless and not more than 0.05 ml of 0.1 M sodium hydroxide is required to change the colour of the solution to pink.

**Free iodine.** Shake 1.0 g with a solution of 1 g of potassium iodide in 20 ml of water for 30 seconds, allow to stand for 5 minutes and filter. To 10 ml of the filtrate add 1 ml of 1 M sulphuric acid and 2 ml of chloroform and shake. Any colour in the chloroform layer is discharged on the addition of 0.1 ml of 0.005 M sodium thiosulphate.

**Halide ions.** Shake 0.5 g with 25 ml of water for 1 minute and filter. To the filtrate add 0.5 ml of 2 M nitric acid and 0.5 ml of 0.1 M silver nitrate and allow to stand for 5 minutes. Any opalescence produced is not more intense than that obtained by adding 0.5 ml of 0.1 M silver nitrate to 25 ml of water containing 0.5 ml of 2 M nitric acid and 0.2 ml of 0.01 M hydrochloric acid and allowing to stand for 5 minutes.

**Related substances.** Determine by gas chromatography (2.4.13).

**Test solution.** Add 0.5 ml of N₂O-bis (trimethylsilyl)acetamide to 0.5 ml of a solution in pyridine containing 0.4 per cent w/v of each of 5-chloro-8-hydroxyquinoline, 5,7-dichloro-8-hydroxy-quinoline and 5-chloro-7-iodo-8-hydroxyquinoline and 0.04 per cent w/v of the substance under examination, mix, allow to stand for 15 minutes and add 5 ml of a 0.05 per cent w/v solution of dibutylphthalate (internal standard) in hexane.

Reference solution (a). Add 0.5 ml of N₂O-bis (trimethylsilyl)acetamide to a mixture of 0.1 g of the substance under examination and 0.5 ml of pyridine, mix, allow to stand for 15 minutes and add 5 ml of hexane.

Reference solution (b). Treat a mixture of 0.1 g of the substance under examination and 0.5 ml of pyridine as described for the test solution.

Chromatographic system

- a glass column 1.5 m x 4 mm, packed with silanised diatomaceous support (100 to 120 mesh) coated with 3 per cent w/w of methyl silicone gum,
- temperature: column, 190º, inlet port and detector, 240º,
- flame ionisation detector,
- nitrogen as carrier gas.

In the chromatogram obtained with the test solution the peaks following the solvent peak, in order of emergence, are due to (a) 5-chloro-8-hydroxyquinoline, (b) 5,7-dichloro-8-hydroxy-quinoline, (c) the internal standard, (d) quiniodochlor and (e) 5,7-diiodo-8-hydroxyquinoline.

In the chromatogram obtained with reference solution (b) calculate the content of 5-chloro-8-hydroxy-quinoline, 5,7-dichloro-8-hydroxyquinoline and 5,7-diiodo-8-hydroxyquinoline by reference to the corresponding peaks in the chromatogram obtained with the test solution.

The total content of the named impurities does not exceed 3.0 per cent w/w, the content of any other impurity does not exceed 0.2 per cent w/w and the sum of the contents is not more than 4.0 per cent w/w.

**Sulphated ash** (2.3.18). Not more than 0.2 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 24 hours.

**Assay.** Weigh accurately about 0.3 g and dissolve in 25 ml of anhydrous pyridine. Titrate with 0.1 M tetrabutylammonium hydroxide, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M tetrabutylammonium hydroxide is equivalent to 0.03055 g of C₉H₅ClINO.

**Storage.** Store protected from light.

**Quiniodochlor Tablets**

Clioquinol Tablets; Iodochlorhydroxyquinoline Tablets; Iodochlorhydroxyquin Tablets

Quiniodochlor Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of quiniodochlor, C₉H₅ClINO.
Identification

Triturate a quantity of the powdered tablets containing about 250 mg of Quiniodochlor with 20 ml of acetone, filter and add 20 ml of water to the filtrate. Collect the precipitate formed on a filter and dry at 105°C. The residue complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with quiniodochlor RS or with the reference spectrum of quiniodochlor.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.0005 per cent w/v solution in 3 M hydrochloric acid shows an absorption maximum at about 267 nm.

Tests

Disintegration (2.5.1). Maximum time, 30 minutes.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and finely powder 20 tablets. Weigh accurately a quantity of the powder containing 0.125 g of Quiniodochlor, shake with 20 ml of hot 2-methoxyethanol, decant the hot supernatant liquid through a fine filter. Repeat the extraction with two further quantities, of 20 ml and 10 ml, of 2-methoxyethanol, combine the filtered extracts and dilute to 50.0 ml with 2-methoxyethanol. To 5.0 ml of this solution add 1 ml of water and sufficient of a mixture of 24 volumes of 2-methoxyethanol and 6 volumes of water to produce 50.0 ml. To 10.0 ml of the solution add 10 ml of 2-methoxyethanol and 2 ml of a solution prepared by dissolving 0.5 g of ferric chloride hexahydrate in 80 ml of 2-methoxyethanol and adding 0.1 ml of hydrochloric acid and sufficient 2-methoxyethanol to produce 100 ml. Dilute the solution to 25.0 ml with 2-methoxyethanol and measure the absorbance of the resulting solution at the maximum at about 650 nm (2.4.7), using as blank a solution prepared by treating 10 ml of the aqueous 2-methoxyethanol in the same manner beginning at the words “add 10 ml of 2-methoxyethanol...”.

Calculate the content of C₉H₅ClINO from the absorbance obtained using 10.0 ml of a solution prepared in the following manner. Dissolve 0.125 g of quiniodochlor RS in sufficient 2-methoxyethanol to produce 50.0 ml, warming to effect solution; add 1 ml of water to 5.0 ml of the solution and add sufficient of the mixture of 24 volumes of 2-methoxyethanol and 6 volumes of water to produce 50.0 ml. Using 10.0 ml of this solution repeat the operation beginning at the words “add 10 ml of 2-methoxyethanol....”

Storage. Store protected from light.
R

Rabeprazole Sodium
Rabeprazole Tablets
Ramipril
Ramipril Capsules
Ramipril Tablets
Ranitidine Hydrochloride
Ranitidine Injection
Ranitidine Tablets
Purifid Rayon
Reserpine
Reserpine Injection
Reserpine Tablets
Riboflavine
Riboflavine Sodium Phosphate
Riboflavine Tablets
Rifampicin
Rifampicin Capsules
Rifampicin Oral Suspension
Rifampicin Tablets
Rifampicin and Isoniazid Tablets
Rifampicin, Isoniazid And Ethambutol Tablets
Rifampicin, Isoniazid and Pyrazinamide Tablets
Rifampicin, Isoniazid, Pyrazinamide And Ethambutol Tablets
Ritonavir
Ritonavir Capsules
Ritonavir Tablets
Rosiglitazone Maleate
Rosiglitazone Tablets
Rosuvastatin Calcium
Rosuvastatin Tablets
Roxithromycin
Roxithromycin Tablets
Rabeprazole Sodium

\[ \text{C}_{18}\text{H}_{20}\text{N}_3\text{O}_3\text{S.Na} \quad \text{Mol. Wt. 381.4} \]

Rabeprazole sodium is \( 2-(\text{[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl}) \text{sulphenyl})-1\text{H}-\text{benzimidazole sodium.} \)

Rabeprazole sodium contains not less than 98.0 per cent and not more than 102.0 per cent of \( \text{C}_{18}\text{H}_{20}\text{N}_3\text{O}_3\text{S.Na} \), calculated on the anhydrous basis.

**Description.** A white to light yellow, crystalline powder, hygroscopic.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with rabeprazole sodium RS.

B. A 10 per cent w/v solution in carbon dioxide-free water gives reaction of sodium (2.3.1).

**Tests**

**Related substances.** Determine by liquid chromatography (2.4.14).

*Test solution.* Dissolve 50 mg of the substance under examination in 100 ml with the mobile phase.

*Reference solution (a).* A 0.05 per cent w/v solution of rabeprazole sodium RS in the mobile phase.

*Reference solution (b).* Dilute 1 ml of reference solution (a) to 100 ml with mobile phase.

Chromatographic system as described under Assay.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution. Calculate the percentage content of \( \text{C}_{18}\text{H}_{20}\text{N}_3\text{O}_3\text{S.Na} \).

**Storage.** Store protected from light and moisture.

**Rabeprazole Tablets**

Rabeprazole Sodium Tablets

Rabeprazole Tablets contain Rabeprazole Sodium.

Rabeprazole Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of rabeprazole sodium, \( \text{C}_{18}\text{H}_{20}\text{N}_3\text{O}_3\text{SNa} \).

**Identification**

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Dissolution** (2.5.2).

Apparatus. No 1

Medium. 900 ml of 0.1 M hydrochloric acid.

Speed and time. 50 rpm for 120 minutes.

Replace the 0.1 M hydrochloric acid with phosphate buffer pH 7.4. Run the apparatus at 75 rpm for 45 minutes. Withdraw

**Water** (2.3.43). Not more than 7.0 per cent, determined on 0.3 g.

**Assay.** Determine by liquid chromatography (2.4.14).

*Test solution.* Dissolve 0.1 g of the substance under examination in 100.0 ml of mobile phase. Dilute 5.0 ml of the solution to 100.0 ml with the same solvent.

*Reference solution.* A 0.005 per cent w/v solution of rabeprazole sodium RS in the mobile phase.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm packed with octysilsane bonded to porous silica (5 µm) (such as Hypersil keystone betabasic C8),
- column temperature 40°,
- mobile phase: a mixture of 72 volumes of 0.1 M phosphate buffer pH 7.0 and 28 volumes of acetonitrile,
- flow rate. 1.4 ml per minute,
- spectrophotometer set at 282 nm,
- a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution. Calculate the percentage content of \( \text{C}_{18}\text{H}_{20}\text{N}_3\text{O}_3\text{S.Na} \).

**Storage.** Store protected from light and moisture.
a suitable volume of the medium and filter. Measure the absorbance of the filtered solution immediately, suitably diluted with phosphate buffer pH 10.4 if necessary, at the maximum at about 291 nm (2.4.7). Calculate the content of \( \text{C}_{18} \text{H}_{20} \text{N}_3 \text{O}_3 \text{SNa} \) in the medium from the absorbance obtained from a solution of known concentration of rabeprazole sodium RS, prepared by dissolving in minimum quantity of a mixture of 75 volumes of acetonitrile and 25 volumes of methanol and suitably diluted with phosphate buffer pH 10.4.

D. Not less than 70 per cent of the stated amount of \( \text{C}_{18} \text{H}_{20} \text{N}_3 \text{O}_3 \text{SNa} \).

**Related substances.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** 80 volumes of methanol, 20 volumes of water and 0.1 volume of diethylamine.

**Test solution.** Weigh accurately a quantity of the powdered tablet containing 50 mg of Rabeprazole Sodium, disperse in 20 ml of 0.1 M sodium hydroxide and dilute to 100.0 ml with solvent mixture, filter.

**Reference solution (a).** A 0.05 per cent w/v solution of rabeprazole sodium RS in the solvent mixture.

**Reference solution (b).** Dilute 1 ml of reference solution (a) to 100 ml with solvent mixture.

Chromatographic system as described under Assay.

Inject reference solution (a). The test is not valid unless the tailing factor is not more than 2.0 and the column efficiency in not less than 2000 theoretical plates.

Inject the test solution and reference solution. The test is not valid unless the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

**Uniformity of content.**

*For tablets containing 10 mg or less.*

Comply with the tests stated under Tablets.

Disperse 1 tablet in sufficient 0.1 M sodium hydroxide to produce 0.0015 per cent w/v solution. Measure the absorbance of the resulting solution at the maximum about 292 nm (2.4.7). Calculate the content of \( \text{C}_{18} \text{H}_{20} \text{N}_3 \text{O}_3 \text{SNa} \) from the absorbance obtained from same concentration of rabeprazole sodium RS in the same medium.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** 80 volumes of methanol, 20 volumes of water and 0.1 volume of diethylamine.

**Test solution.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powdered tablet containing 50 mg of Rabeprazole Sodium, disperse in 20 ml of 0.1 M sodium hydroxide and dilute to 100.0 ml with solvent mixture, filter.

**Reference solution.** Weigh accurately about 25 mg of rabeprazole sodium RS, dissolve in 10 ml of 0.1 M sodium hydroxide and dilute to 50.0 ml with solvent mixture.

**Chromatographic system.**

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 65 volumes of 0.15 per cent w/v solution of potassium dihydrogen phosphate previously adjusted pH to 6.0 with orthophosphoric acid and 35 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 280 nm,
- a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of \( \text{C}_{18} \text{H}_{20} \text{N}_3 \text{O}_3 \text{SNa} \).

**Storage.** Store protected from light and moisture.

---

**Ramipril**

\( \text{C}_{23} \text{H}_{32} \text{N}_2 \text{O}_5 \)  
Mol. Wt. 416.5

Ramipril is \( (2\overline{S},3\overline{a},6\overline{a})-1-\{\overline{S}\}-2-\{[(\overline{S})-1-(ethoxycarbonyl)-3-phenylpropyl]amino\}propanoyl\}\) octahydrocyclopenta[b]pyrrole-2-carboxylic acid.

Ramipril contains not less than 98.0 per cent and not more than 101.0 per cent of \( \text{C}_{23} \text{H}_{32} \text{N}_2 \text{O}_5 \), calculated on the dried basis.

**Description.** A white or almost white, crystalline powder.

**Identification.**

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ramipril RS.

**Tests.**

**Appearance of solution.** A 1.0 per cent w/v solution in methanol is clear (2.4.1) and colourless (2.4.1).

**Specific optical rotation** (2.4.22). + 32.0° to + 38.0°, determined in 1.0 per cent w/v solution in 0.1 M methanolic hydrochloric acid.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 25 mg of the substance under examination in 25 ml of mobile phase B.
Reference solution (a). A 0.1 per cent w/v solution of ramipril RS in the mobile phase B.

Reference solution (b). Dilute 1 ml of reference solution (a) to 100 ml with mobile phase B.

Chromatographic system
- a stainless steel column 25 cm x 4.0 mm packed with octadecylsilyl bonded to porous silica (5 µm),
- column temperature 65°C,
- mobile phase: A. dissolve 2.0 g of sodium perchlorate in a mixture of 0.5 ml of triethylamine and 800 ml of water; adjust pH to 3.6 with orthophosphoric acid and add 200 ml of acetonitrile,
- B. dissolve 2.0 g of sodium perchlorate in a mixture of 0.5 ml of triethylamine and 300 ml of water; adjust pH to 2.6 with orthophosphoric acid and add 700 ml of acetonitrile,
- a linear gradient programme using the conditions given below,
- flow rate. 1 ml per minute,
- spectrophotometer set at 210 nm,
- a 10 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>90</td>
<td>10</td>
</tr>
<tr>
<td>6</td>
<td>90</td>
<td>10</td>
</tr>
<tr>
<td>7</td>
<td>75</td>
<td>25</td>
</tr>
<tr>
<td>20</td>
<td>65</td>
<td>35</td>
</tr>
<tr>
<td>30</td>
<td>25</td>
<td>75</td>
</tr>
<tr>
<td>40</td>
<td>25</td>
<td>75</td>
</tr>
<tr>
<td>45</td>
<td>90</td>
<td>10</td>
</tr>
<tr>
<td>55</td>
<td>90</td>
<td>10</td>
</tr>
</tbody>
</table>

Inject reference solution (a). The test is not valid unless the tailing factor is not more than 2.0 and the column efficiency in not less than 2000 theoretical plates.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 0.5 times the area of the peak in the chromatogram obtained with reference solution (b) (0.5 per cent) and the sum of areas of all the secondary peaks is not more than the area of the peak in the chromatogram obtained with the reference solution (b) (1.0 per cent).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.2 per cent, determined on 1.0 g by drying in an oven at 60°C, under vaccumme, for 4 hours.

Assay. Weigh accurately about 0.3 gm, dissolve in 25 ml of methanol and add 25 ml of water. Titrate with 0.1 M sodium hydroxide. Determine the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.04165 gm of C₂₃H₃₂N₂O₅.

Storage. Store protected from light.

**Ramipril Capsules**

Ramipril Capsules contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of ramipril, C₂₃H₃₂N₂O₅.

**Identification**

Shake a quantity of the content of the capsules containing 25 mg of Ramipril with 50 ml of acetone, centrifuge for 10 minutes, filter. Evaporate the filtrate to dryness at 60°C for 3 hours. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ramipril RS.

**Tests**

**Dissolution (2.5.2).**

Apparatus. No 1
Medium. 500 ml of 0.1 M hydrochloric acid.
Speed and time. 75 rpm and 45 minutes.
Withdraw a suitable volume of the medium and filter.
Determine by liquid chromatography (2.4.14).

Test solution. Dilute the filtrate to get 0.00025 per cent w/v solution of Ramipril with 0.1 M hydrochloric acid.

Reference solution. A 0.00025 per cent w/v solution of ramipril RS in 0.1 M hydrochloric acid.

Chromatographic system as described under Assay.
Inject the test solution and the reference solution.
Calculate the content of C₂₃H₃₂N₂O₅.
D. Not less than 70 per cent of the stated amount of C₂₃H₃₂N₂O₅.

Uniformity of content (For capsules containing 10 mg or less). Comply with the test stated under Capsules.
Determine by liquid chromatography (2.4.14).

Test solution. Disperse one capsule in 100 ml of 0.1 M hydrochloric acid, sonicate for 15 minutes. Dilute if necessary to produce 0.025 per cent w/v solution of Ramipril in 0.1 M hydrochloric acid.

Reference solution. A 0.025 per cent w/v solution of ramipril RS in 0.1 M hydrochloric acid.
Chromatographic system as described under Assay.
Inject the test solution and the reference solution.

Calculate the content of C_{23}H_{32}N_{2}O_{5}.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh a quantity of the content of capsules containing 25 mg of Ramipril, disperse in 100.0 ml of 0.1 M hydrochloric acid, mix and centrifuge.

**Reference solution.** A 0.025 per cent w/v solution of ramipril RS in 0.1 M hydrochloric acid.

**Chromatographic system**

- a stainless steel column 12.5 cm x 4.6 mm packed with octadecylsilyl bonded to porous silica (5 µm),
- mobile phase: a mixture of 42 volumes of acetonitrile and 58 volumes of a solution containing 1.4 per cent w/v solution of sodium perchlorate and 0.58 per cent w/v solution of orthophosphoric acid adjusted to pH 2.5 with triethylamine, adjust the pH of the mixture to 2.1 with orthophosphoric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 210 nm,
- a 50 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C_{23}H_{32}N_{2}O_{5}.

**Ramipril Tablets**

Ramipril Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of ramipril, C_{23}H_{32}N_{2}O_{5}.

**Identification**

Shake a quantity of the powdered tablets containing 25 mg of Ramipril with 50 ml of acetone, centrifuge for 10 minutes, filter. Evaporate the filtrate to dryness at 60° for 3 hours. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ramipril RS.

**Tests**

**Dissolution (2.5.2).**

Apparatus. No 1

Medium. 500 ml of 0.1 M hydrochloric acid.

Speed and time. 75 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter.

Determine by liquid chromatography (2.4.14).

**Test solution.** Dilute the filtrate to get 0.00025 per cent w/v solution of Ramipril with 0.1 M hydrochloric acid.

**Reference solution.** A 0.00025 per cent w/v solution of ramipril RS in 0.1 M hydrochloric acid.

**Chromatographic system as described under Assay.**

Inject the test solution and the reference solution.

Calculate the content of C_{23}H_{32}N_{2}O_{5}.

D. Not less than 70 per cent of the stated amount of C_{23}H_{32}N_{2}O_{5}.

**Uniformity of content (For tablets containing 10 mg or less).** Comply with the test stated under Tablets.

Determine by liquid chromatography (2.4.14), as described under Assay.

**Test solution.** Take one tablet, add 5 ml of 0.1 M hydrochloric acid, sonicate for 10 minutes, dilute, if necessary, with sufficient 0.1 M hydrochloric acid to produce a solution containing 0.025 per cent w/v of Ramipril, centrifuge and use the supernatant liquid.

Calculate the content of C_{23}H_{32}N_{2}O_{5}.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh and powder 20 tablets. Weigh a quantity of powdered tablets containing 25 mg of Ramipril, disperse in 100.0 ml of 0.1 M hydrochloric acid and centrifuge.

**Reference solution.** A 0.025 per cent w/v solution of ramipril RS in 0.1 M hydrochloric acid.

**Chromatographic system**

- a stainless steel column 12.5 cm x 4.6 mm packed with octadecylsilyl bonded to porous silica (5 µm),
- mobile phase: a mixture of 42 volumes of acetonitrile and 58 volumes of a solution containing 1.4 per cent w/v solution of sodium perchlorate and 0.58 per cent w/v solution of orthophosphoric acid adjusted to pH 2.5 with triethylamine, adjust the pH of the mixture to 2.1 with orthophosphoric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 210 nm,
- a 50 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C_{23}H_{32}N_{2}O_{5}.

**Storage.** Store protected from moisture.
Ranitidine Hydrochloride

\[
\text{H}_3\text{C} - \text{N} - \text{C}_6\text{H}_4\text{O} - \text{S} - \text{N} - \text{CHNO}_2 - \text{HCl}
\]

C₁₃H₂₂N₄O₃S.HCl Mol. Wt. 350.9


Ranitidine Hydrochloride contains not less than 97.5 per cent and not more than 102.0 per cent of C₁₃H₂₂N₄O₃S.HCl, calculated on the dried basis.

**Description.** A white to pale yellow, crystalline powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ranitidine hydrochloride RS or with the reference spectrum of ranitidine hydrochloride.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).

C. A 5 per cent w/v solution gives the reactions of chlorides (2.3.1).

**Tests**

**Appearance of solution.** A 1.0 per cent w/v solution is clear (2.4.1), and not more intensely coloured than reference solution BYS5 (2.4.1).

**pH.** (2.4.24). 4.5 to 6.0, determined in a 1.0 per cent w/v solution in carbon dioxide-free water.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 25 volumes of ethyl acetate, 15 volumes of 2-propanol, 4 volumes of strong ammonia solution and 2 volumes of water.

**Test solution (a).** Dissolve 0.22 g of the substance under examination in 10 ml of methanol.

**Test solution (b).** Dilute 1 ml of test solution (a) to 100 ml with methanol.

**Reference solution (a).** Weigh accurately a quantity of ranitidine hydrochloride RS in methanol, and dilute with methanol to obtain a solution containing a known concentration of about 0.127 per cent w/v.

**Reference solution (b).** Weigh accurately a quantity of ranitidine hydrochloride related compound A RS in methanol, and dilute with methanol to obtain a solution containing a known concentration of about 0.5 per cent w/v.

**Reference solution (c).** Dilute 30.0 ml of reference solution (a) to 100 ml with methanol.

**Reference solution (d).** Dilute 5.0 ml of reference solution (a) to 100 ml with methanol.

**Reference solution (e).** Weigh accurately a quantity of ranitidine hydrochloride related compound A RS in methanol, and dilute with methanol to obtain a solution containing a known concentration of about 0.5 per cent w/v.

Apply to the plate 10 µl of each solution except reference solution (e). Apply separately an additional 10 µl of the test solution and on top of this application, apply 10 µl of reference solution (e). After development, dry the plate in air and expose it to iodine vapours in a closed chamber until the spots are revealed. Any spot in the chromatogram obtained with the test solution corresponding to the principal spot in the chromatogram obtained with reference solution (f) is not more intense than that of the principal spot in the chromatogram obtained with reference solution (b) (0.5 per cent) and no other spot in the chromatogram obtained with the test solution is more intense than the principal spot in the chromatogram obtained with reference solution (c) (0.3 per cent). The sum of the intensities of all the secondary spots in the chromatogram obtained with the test solution does not exceed 1.0 per cent. The test is not valid unless the chromatogram obtained with the combined test solution and reference solution (e) shows two clearly separated principal spots and the chromatogram obtained with reference solution (d) shows a clearly visible spot.

**Sulphated ash.** (2.3.18). Not more than 0.1 per cent.

**Loss on drying.** (2.4.19). Not more than 0.75 per cent, determined on 1.0 g by drying in an oven at 60º at a pressure not exceeding 2.75 kPa for 3 hours.

**Assay.** Determine by liquid chromatography (2.4.14)

**Test solution.** A 0.0112 per cent w/v of the substance under examination in the mobile phase.

**Reference solution.** 0.0112 per cent w/v of ranitidine hydrochloride RS in the mobile phase.

**Chromatographic system**

- a stainless steel column 25 cm x 4.0 mm, packed with octadecysilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 85 volumes of methanol and 15 volumes of 0.1 M ammonium acetate,
- flow rate. 2 ml per minute,
Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution. Calculate the content of C_{13}H_{22}N_{4}O_{3}S, HCl.

**Storage.** Store protected from light and moisture.

### Ranitidine Injection

**Ranitidine Hydrochloride Injection**

Ranitidine Injection is a sterile solution of Ranitidine Hydrochloride in Water for Injections and may be suitably buffered.

Ranitidine Hydrochloride Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of ranitidine, C_{13}H_{22}N_{4}O_{3}S.

**Identification**

A. To a volume of the injection containing 25 mg of ranitidine add 20 ml of methanol, mix and evaporate to dryness. Add 1 ml of light petroleum (60º to 80º) to the resulting residue, scratch the side of the vessel with a glass rod to induce crystallisation, evaporate to dryness and dry the residue at 60º for 10 minutes. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ranitidine hydrochloride RS or with the reference spectrum of ranitidine hydrochloride.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**pH** (2.4.24). 6.7 to 7.3, if the preparation is buffered; 4.5 to 7.0, if the preparation is unbuffered.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 25 volumes of ethyl acetate, 15 volumes of 2-propanol, 4 volumes of strong ammonia solution and 2 volumes of water.

Test solution. Dilute suitably a volume of the injection with water to produce a solution containing the equivalent of 2.5 per cent w/v of ranitidine in methanol.

Reference solution (a). Weigh accurately a quantity of ranitidine hydrochloride RS in water, and dilute with water to obtain a solution containing a known concentration of about 0.056 per cent w/v.

Reference solution (b). Dilute 10.0 ml of reference solution (a) to 20 ml with water.

Reference solution (c). Dilute 5.0 ml of reference solution (a) to 20 ml with water.

Reference solution (d). Dilute 6.0 ml of reference solution (c) to 10 ml with water.

Reference solution (e). Dilute 5.0 ml of reference solution (b) to 50 ml with water.

Reference solution (f). Dilute 5 ml of reference solution (e) to 10 ml with water.

Reference solution (g). A 0.127 per cent w/v of solution of ranitidine impurity A RS in methanol.

Apply to the plate 10 µl of each solution. Apply separately an additional 10 µl of the test solution and on top of this application, apply 10 µl of reference solution (g). After development, dry the plate in air and expose it to iodine vapours in a closed chamber until the spots are revealed. The major secondary spot in the chromatogram obtained with the test solution is not more intense than that of the principal spot in the chromatogram obtained with reference solution (a) (2.0 per cent) and no other secondary spot in the chromatogram obtained with the test solution is more intense than the principal spot in the chromatogram obtained with reference solution (b) (1.0 per cent). The sum of the intensities of all the secondary spots in the chromatogram obtained with the test solution does not exceed 5.0 per cent.

The test is not valid unless the chromatogram obtained with the combined test solution and reference solution (g) shows two clearly separated principal spots and the chromatogram obtained with reference solution (f) shows a clearly visible spot.

**Other tests.** Comply with the tests stated under Parenteral Preparations (Injections).

**Assay.** Determine by liquid chromatography (2.4.14)

Test solution. Dilute a volume of the injection containing 10.0 mg of ranitidine to 100.0 ml with the mobile phase.

Reference solution. A 0.0112 per cent w/v solution of ranitidine hydrochloride RS in the mobile phase.

Chromatographic system

- a stainless steel column 25 cm x 4.0 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 85 volumes of methanol and 15 volumes of 0.1 M ammonium acetate,
- flow rate. 2 ml per minute,
– spectrophotometer set at 322 nm,
– a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution.

Calculate the content of C₁₃H₂₂N₄O₃S in the injection.

Storage. Store protected from light.

Labelling. The label states (1) the strength in terms of the equivalent amount of ranitidine; (2) where appropriate, that the injection is buffered.

Ranitidine Tablets

Ranitidine Hydrochloride Tablets

Ranitidine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of the ranitidine, C₁₃H₂₂N₄O₃S. The tablets are coated.

Identification

A. Shake a quantity of the powdered tablets containing 25 mg of ranitidine with 5 ml of methanol for 5 minutes, filter and evaporate the filtrate to dryness. Add 1 ml of light petroleum (60°C to 80°C) to the resulting residue, scratch the side of the vessel with a glass rod to induce crystallisation, evaporate to dryness and dry the residue at 60°C for 10 minutes. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ranitidine hydrochloride RS or with the reference spectrum of ranitidine hydrochloride.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 25 volumes of ethyl acetate, 15 volumes of 2-propanol, 4 volumes of strong ammonia solution and 2 volumes of water.

Test solution. Shake a quantity of the powdered tablets containing 0.45 g of ranitidine with 20 ml of methanol and filter.

Reference solution (a). Weigh accurately a quantity of ranitidine hydrochloride RS in methanol, and dilute with methanol to obtain a solution containing a known concentration of about 0.022 per cent w/v.

Reference solution (b). Dilute 10 ml of reference solution (a) to 20 ml with methanol.

Reference solution (c). Dilute 30 ml of reference solution (a) to 100 ml with methanol.

Reference solution (d). Dilute 5 ml of reference solution (a) to 50 ml with methanol.

Reference solution (e). Dilute 5 ml of reference solution (a) to 100 ml with methanol.

Reference solution (f). Weigh accurately a quantity of ranitidine hydrochloride related compound A RS in methanol, and dilute with methanol to obtain a solution containing a known concentration of about 0.127 per cent w/v.

Apply to the plate 10 µl of each solution. Apply separately an additional 10 µl of the test solution and on top of this application, apply 10 µl of reference solution (f). After development, dry the plate in air and expose it to iodine vapours in a closed chamber until the spots are revealed. Any spot in the chromatogram obtained with the test solution corresponding to the principal spot in the chromatogram obtained with reference solution (f) is not more intense than that of the principal spot in the chromatogram obtained with reference solution (b) (0.5 per cent) and no other spot in the chromatogram obtained with the test solution is more intense than the principal spot in the chromatogram obtained with reference solution (c) (0.3 per cent). The sum of the intensities of all the secondary spots in the chromatogram obtained with the test solution does not exceed 2.0 per cent.

The test is not valid unless the chromatogram obtained with the combined test solution and reference solution (f) shows two clearly separated principal spots and the chromatogram obtained with reference solution (e) shows a clearly visible spot.

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14)

Test solution. Weigh and powder 20 tablets. Shake 1.5 g of the powder with 400 ml of the mobile phase, dilute to 500.0 ml with the mobile phase, filter and dilute the filtrate with the mobile phase to obtain a solution containing the equivalent of 0.01 per cent w/v of ranitidine.

Reference solution. A 0.0112 per cent w/v solution of ranitidine hydrochloride RS in the mobile phase.

Chromatographic system

– a stainless steel column 25 cm x 4.0 mm, packed with octadecylsilane bonded to porous silica (5 µm),
– mobile phase: a mixture of 85 volumes of methanol and 15 volumes of 0.1 M ammonium acetate,
PURIFIED RAYON

-- flow rate. 2 ml per minute,
-- spectrophotometer set at 322 nm,
-- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution.

Calculate the content of \(C_{13}H_{22}N_4O_3S\) in the tablets.

**Storage.** Store protected from light and moisture.

**Labelling.** The label states the strength in terms of the equivalent amount of ranitidine.

---

**Purified Rayon**

**Viscose Fibre; absorbent viscose**

**Description.** White or very slightly yellow, purified rayon is a fibrous form of bleached regenerated cellulose, which can be produced with a lustrous or matt appearance, and is soft to the touch. The fibres can be produced with average staple length between 32 mm to 80 mm, and are practically odourless.

**Identification**

A. When examined under a microscope in the dry state, or when mounted in ethanol (95 per cent) and water, the following characteristics are observed. They are usually of more or less uniform width. Many longitudinal parallel lines are distributed unequally over the width in the case of standard viscose fibres, but such lines are absent or very few in fibres produced through the zinc-free process. The ends are cut more or less straight. Matt fibres contain numerous granular particles of approximately 1 µ average diameter.

B. Treat with iodinated zinc chloride solution; the fibres become violet.

C. To 0.1 g add 10 ml of zinc chloride-formic acid solution, heat to 40° and allow to stand for 2 hours 30 minutes, shaking occasionally. The fibres dissolve completely except for the matt variety where titanium dioxide particles remain.

D. Dissolve the residue obtained in the test for Sulphated ash in 5 ml of sulphuric acid with slight warming, allow to cool, and carefully add 0.2 ml of hydrogen peroxide solution (10 volumes). The solution does not undergo colour change in case of lustrous variety of fibre, but for matt variety an orange-yellow colour is obtained, the intensity of which depends on the quantity of titanium dioxide present.

**Tests**

**Colour of extract.** Take 15 g of material under examination in a suitable vessel, add 150 ml of water, close the vessel and allow to macerate for 2 hours. Decant the solution, squeeze the residual liquid carefully from the sample with a glass rod mix and filter. The filtered extract is colourless. Compare the colour of the extract with water using identical tubes of colourless, transparent, neutral glass 12 mm in diameter measuring 2 ml. Compare the colours in diffused daylight, viewing horizontally against a white background.

**Acidity or alkalinity.** To 25 ml of filtered extract obtained in Colour of extract, add 0.1 ml of dilute phenolphthalein solution; to another 25 ml add 0.05 ml of methyl orange solution. Neither solution shows a pink colour.

**Foreign fibres.** When examined under a microscope, it is seen to consist exclusively of viscose fibres, except that occasionally a few isolated foreign fibres may be present.

**Fluorescence.** Examine a layer about 5 mm in thickness under ultraviolet light at 365 nm. It displays only a slight, brownish-violet fluorescence and a few yellow particles. Not more than a few isolated fibres show an intense blue fluorescence.

**Absorbency**

**A. Sinking time.** Not more than 10 seconds, determined by the following method.

**Apparatus**

A dry, cylindrical copper wire basket, 80 mm high and 50 mm in diameter, fabricated from wire of diameter 0.4 mm and having a mesh aperture of 15 to 20 mm; the basket weighs 2.4 to 3.0 g.

**Method**

Weigh the basket to the nearest 10 mg. Take five samples, each of approximately 1 g, from different places in the material under examination, place loosely in the basket and weigh the packed basket to the nearest 10 mg. Hold the basket with its long axis in the horizontal position and drop it from a height of about 10 mm into water at 25° contained in a beaker at least 12 cm in diameter and filled to a depth of 10 cm. Measure with a stopwatch the time taken by the basket to sink below the surface of the water. Repeat the procedure on two further samples and calculate the average value.

**B. Water-holding capacity.** Not less than 18.0 g per g, determined by the following method.

After the sinking time has been recorded in test A, remove the basket from the water; allow it to drain for 30 seconds with its long axis in the horizontal position over the beaker, transfer it to a tared beaker and weigh to the nearest 10 mg. Calculate the weight of water retained by the sample. Repeat the procedure on two further samples and calculate the average value.

**Colouring matter.** Slowly extract 10 g in a narrow percolator with ethanol (95 per cent) until 50 ml of extract is obtained. The extract is not more intensely coloured than reference
solution YS5 or GYS6, (2.4.1) or a solution prepared in the following manner. To 3.0 ml of CSS add 7.0 ml of a solution of hydrochloric acid containing 1 per cent w/v of hydrochloric acid and dilute 0.5 ml of the resulting solution to 10 ml with the same solution of hydrochloric acid.

Ether-soluble substances. Not more than 0.5 per cent, determined by the following method. Extract 5 g with ether in a continuous extraction apparatus such as a Soxhlet apparatus, for 4 hours in such a way that the rate is at least four extractions per hour. Evaporate the ether and dry the residue to constant weight at 105º.

Water-soluble substances. Not more than 0.7 per cent, determined by the following method. Boil 5 g with 500 ml of water for 30 minutes, stirring frequently and replacing the water lost by evaporation. Decant the liquid into a beaker, squeeze the residual liquid from the material carefully with a glass rod, mix the liquids and filter the extract whilst hot. Evaporate 400 ml of the filtrate and dry the residue to constant weight at 105º.

Hydrogen sulphide. To 10 ml of the filtered extract obtained in the Colour of extract, add 1.9 ml of water, 0.15 ml of dilute acetic acid and 1 ml of lead acetate solution. After 2 minutes, the solution is not more intensely coloured than a reference solution prepared at the same time using 0.15 ml of dilute acetic acid, 1.2 ml of thioacetamide reagent, 1.7 ml of lead standard solution (10 ppm Pb) and 10 ml of filtered extract.

Sulphated ash (2.3.18). Not more than 1.5 per cent.

Loss on drying (2.4.19). Not more than 13.0 per cent, determined on 5 g by drying in an oven at 105º.

Reserpine

\[
\text{C}_{34}\text{H}_{40}\text{N}_{2}\text{O}_{9}
\]

Mol. Wt. 608.7

Reserpine is methyl 11,17α-dimethoxy-18β-[3(3,4,5-trimethoxybenzoyl)oxy]-3β,20α-yohimbane-16β-carboxylate. Reserpine contains not less than 99.0 per cent and not more than 101.0 per cent of total alkaloids and not less than 98.0 per cent and not more than 102.0 per cent of reserpine, \(\text{C}_{34}\text{H}_{40}\text{N}_{2}\text{O}_{9}\), both calculated on the dried basis.

Description. White to slightly yellow small crystals or a crystalline powder which darkens slowly on exposure to light.

Identification

Test A may be omitted if tests B, C, D and E are carried out. Tests B, C, D and E may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with reserpine RS or with the reference spectrum of reserpine.

B. Dilute 1 ml of a 0.2 per cent w/v solution in chloroform to 100.0 ml with ethanol (95 per cent). When examined immediately after preparation, in the range 230 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum at about 268 nm; absorbance at about 268 nm, about 0.55. The range 288 nm to 295 nm, the spectrum exhibits a slight minimum and then a shoulder or a slight maximum; absorbance over this range, about 0.34.

C. To about 1 mg add 0.1 ml of a 0.1 per cent w/v solution of sodium molybdate in sulphuric acid; a yellow colour is produced which changes to blue within 2 minutes.

D. To 1 mg add 0.2 ml of a freshly prepared 1 per cent w/v solution of vanillin in hydrochloric acid; a pink colour develops within 2 minutes.

E. Mix about 0.5 mg with 5 mg of 4-dimethylaminobenzaldehyde and 0.2 ml of glacial acetic acid and add 0.2 ml of sulphuric acid; a green colour is produced. Add 1 ml of glacial acetic acid; the colour changes to red.

Tests

Specific optical rotation (2.4.22). –116º to –128º, determined in a solution prepared immediately before use by dissolving 0.25 g in sufficient chloroform to produce 25 ml.

Oxidation products. Absorbance of a 0.02 per cent w/v solution in glacial acetic acid at about 388 nm, measured immediately after preparation, not more than 0.10 (2.4.7).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 0.5 g by drying in an oven over phosphorus pentoxide — Weigh accurately about 0.5 g and dissolve in a mixture of 40 ml of anhydrous glacial acetic acid and 6 ml of acetic anhydride. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.06087 g of total alkaloids.

For reserpine, \(\text{C}_{34}\text{H}_{40}\text{N}_{2}\text{O}_{9}\) — Carry out the following procedure protected from light. Weigh accurately about
25.0 mg, moisten with 2 ml of ethanol (95 per cent), add 2 ml of 0.25 M sulphuric acid and 10 ml of ethanol (95 per cent) and warm gently to dissolve. Cool, dilute to 100.0 ml with ethanol (95 per cent) and dilute 5.0 ml to 50.0 ml with the same solvent (solution A). Transfer 10.0 ml to a boiling tube, add 2 ml of 0.25 M sulphuric acid and 2 ml of a freshly prepared 0.3 per cent w/v solution of sodium nitrite, mix and heat in a water-bath at 55º for 35 minutes. Cool, add 1 ml of a freshly prepared 5 per cent w/v solution of sulphamic acid and dilute to 25.0 ml with ethanol (95 per cent). Measure the absorbance of the resulting solution at the maximum at about 388 nm (2.4.7), using as the blank a solution prepared by treating a further 10.0 ml of solution A in the same manner and at the same time but omitting the sodium nitrite solution.

Calculate the content of C$_{33}$H$_{40}$N$_{2}$O$_{9}$ from the absorbance obtained by repeating the operation using reserpine RS in place of the substance under examination.

Storage. Store protected from light.

**Reserpine Injection**

Reserpine Injection is a sterile solution of Reserpine in Water for Injections prepared with the aid of a suitable acid. It may contain suitable antioxidants.

Reserpine Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of reserpine, C$_{33}$H$_{40}$N$_{2}$O$_{9}$.

**Identification**

Extract a suitable volume of the injection containing 10 mg of Reserpine with 10 ml of chloroform and evaporate the chloroform layer to dryness. The residue complies with the following tests.

*Test A may be omitted if tests B, C, D and E are carried out. Tests B, C, D and E may be omitted if test A is carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with reserpine RS or with the reference spectrum of reserpine.

B. Dilute 1 ml of a 0.2 per cent w/v solution in chloroform to 100 ml with ethanol (95 per cent). When examined immediately after preparation, in the range 230 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum at about 268 nm; absorbance at about 268 nm, about 0.55. Over the range 288 nm to 295 nm, the spectrum exhibits a slight minimum and then a shoulder or a slight maximum; absorbance over this range, about 0.34.

C. To about 1 mg add 0.1 ml of a 0.1 per cent w/v solution of sodium molybdate in sulphuric acid; a yellow colour is produced which changes to blue within 2 minutes.

D. To 1 mg add 0.2 ml of a freshly prepared 1 per cent w/v solution of vanillin in hydrochloric acid; a pink colour develops within 2 minutes.

E. Mix about 0.5 mg with 5 mg of 4-dimethylaminobenzaldehyde and 0.2 ml of glacial acetic acid and add 0.2 ml of sulphuric acid; a green colour is produced. Add 1 ml of glacial acetic acid; the colour changes to red.

**Tests**

**pH** (2.4.24). 3.0 to 4.0.

**Other tests.** Comply with the tests stated under Parenteral Preparations (Injections).

**Assay.** Protect the solutions from light throughout the assay.

Measure accurately a volume of the injection containing about 10 mg of Reserpine and dilute with a 2 per cent w/v solution of citric acid to 100.0 ml. Extract 10.0 ml of this solution for 2 minutes with three quantities, each of 15 ml, of chloroform. Wash the combined extracts with 10 ml of a 1 per cent w/v solution of sodium bicarbonate, add sufficient chloroform to produce 50.0 ml, mix and evaporate 10.0 ml to dryness on a water-bath. Dissolve the residue in 10 ml of ethanol (95 per cent), add 2 ml of 0.25 M sulphuric acid and 10 ml of ethanol (95 per cent) and warm gently to dissolve. Cool, dilute to 100.0 ml with ethanol (95 per cent) and dilute 5.0 ml to 50.0 ml with the same solvent (solution A). Transfer 10.0 ml to a boiling tube, add 2 ml of 0.25 M sulphuric acid and 2 ml of a freshly prepared 0.3 per cent w/v solution of sodium nitrite, mix and heat in a water-bath at 55º for 35 minutes. Cool, add 1 ml of a freshly prepared 5 per cent w/v solution of sulphamic acid and dilute to 25.0 ml with ethanol (95 per cent). Measure the absorbance of the resulting solution at the maximum at about 388 nm (2.4.7), using as the blank a solution prepared by treating a further 10.0 ml of solution A in the same manner and at the same time but omitting the sodium nitrite solution.

Calculate the content of C$_{33}$H$_{40}$N$_{2}$O$_{9}$ from the absorbance obtained by repeating the operation using reserpine RS in place of the substance under examination.

Storage. Store protected from light in single dose (or if stabilising agents are present, in multiple dose) containers.

**Reserpine Tablets**

Reserpine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of reserpine, C$_{33}$H$_{40}$N$_{2}$O$_{9}$.

**Identification**

A. Powder a few tablets and extract with chloroform. Evaporate the extract to dryness, add 0.1 ml of a 0.1 per cent w/v solution
of sodium molybdate in sulphuric acid; a yellow colour is produced which changes to blue within 2 minutes.

B. Powder a few tablets and extract with chloroform. Evaporate the extract to dryness, add 0.2 ml of a freshly prepared 1 per cent w/v solution of vanillin in hydrochloric acid; a pink colour develops within 2 minutes.

**Tests**

**Uniformity of content.** Protect the solutions from light throughout the test.

Comply with the test stated under Tablets.

Powder one tablet, disperse in 10 ml of a 2 per cent w/v solution of citric acid and extract for 2 minutes with three quantities, each of 5 ml, of chloroform, filter the extracts through a plug of cotton moistened with chloroform. Wash the chloroform extracts with 10 ml of a 1 per cent w/v solution of sodium bicarbonate and evaporate the chloroform extracts to dryness on a water-bath. For tablets containing up to 250 µg of Reserpine per tablet, dissolve the residue in 10.0 ml of ethanol (95 per cent). For tablets containing more than 250 µg of Reserpine per tablet, dissolve the residue in a suitable volume of ethanol (95 per cent) to give a concentration of 250 µg of Reserpine per 10.0 ml; add 2 ml of 0.25 M sulphuric acid and 2 ml of a freshly prepared 0.3 per cent w/v solution of sodium nitrite, mix and heat in a water-bath at 55º for 35 minutes. Cool, add 1 ml of a freshly prepared 5 per cent w/v solution of sulphamic acid and dilute to 25.0 ml with ethanol (95 per cent). Measure the absorbance of the resulting solution at the maximum at about 388 nm (2.4.7), using as the blank a solution prepared by treating a further 10.0 ml of solution A in the same manner and at the same time but omitting the sodium nitrite solution.

Calculate the content of C_{33}H_{40}N_{2}O_{9} from the absorbance obtained by repeating the operation using reserpine RS in place of the substance under examination.

**Storage.** Store protected from light.

**Riboflavine**

Lactoflavin; Vitamin B_{2}

\[
\begin{align*}
\text{C}_{17}\text{H}_{20}\text{N}_{4}\text{O}_{6} & \quad \text{Mol. Wt. 376.4} \\
\text{Riboflavine is 3,10-dihydro-7,8-dimethyl-10-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]benzopteridine-2,4-dione.} \\
\text{Riboflavine contains not less than 98.0 per cent and not more than 101.0 per cent of C}_{17}\text{H}_{20}\text{N}_{4}\text{O}_{6}, \text{calculated on the dried basis.} \\
\text{Description.} \text{ A yellow to orange-yellow, crystalline powder; odour, slight.}
\end{align*}
\]

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with riboflavine RS or with the reference spectrum of riboflavine.

B. Dissolve about 1 mg in 100 ml of water. The solution has a pale greenish yellow colour by transmitted light and an intense yellowish green fluorescence by reflected light, which disappears on addition of mineral acids or alkalis.

**Tests**

**pH** (2.4.24). 5.5 to 7.2, determined in a saturated solution.
Specific optical rotation (2.4.22). +115° to +135°, determined in a 0.5 per cent w/v solution in carbonate-free 0.05 M sodium hydroxide. Measure the angle of rotation within 30 minutes of preparing the solution.

Light absorption (2.4.7). Dilute a suitable volume of the final solution obtained in the Assay with an equal volume of water.

When examined in the range 210 nm to 460 nm, the resulting solution exhibits maxima at about 223 nm, 267 nm, 373 nm and 444 nm; the ratio of the absorbance at the maximum at about 373 nm to that at about 267 nm, 0.31 to 0.33 and the ratio of the absorbance at the maximum at about 444 nm to that at about 267 nm, 0.36 to 0.39.

Lumiflavine. Shake 25 mg with 10 ml of chloroform for 5 minutes and filter. The filtrate is not more intensely coloured than reference solution BYS6 (2.4.1).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.5 per cent, determined on 1.0 g by drying in an oven at 105º.

Assay. Carry out the procedure in subdued light.

Weigh accurately about 65 mg and transfer to an amber-glass 500-ml volumetric flask, suspend in 5 ml of water, ensuring that it is completely wetted. Dissolve in 5 ml of 2 M sodium hydroxide. As soon as dissolution is complete add 100 ml of water and 2.5 ml of glacial acetic acid and dilute to 500.0 ml with water. To 20.0 ml of this solution add 3.5 ml of a 1.4 per cent w/v solution of sodium acetate and dilute to 200.0 ml with water. Measure the absorbance of the resulting solution at the maximum at about 444 nm (2.4.7).

Calculate the content of C_{17}H_{20}N_{4}O_{6}, taking 328 as the specific absorbance at 444 nm.

Storage. Store protected from light.

Riboflavin Sodium Phosphate

Riboflavin-5-phosphate (Sodium Salt); Vitamin B\textsubscript{2} Sodium Phosphate

\[
\begin{align*}
\text{Riboflavin Sodium Phosphate is monosodium 3,10-dihydro-7,8-dimethyl-10-[(2S,3S,4R)-2,3,4-trihydroxypentyl] benzopteridine-2,4-dione 5-phosphate dihydrate.}
\end{align*}
\]

Riboflavin Sodium Phosphate contains the equivalent of not less than 73.0 per cent and not more than 79.0 per cent of C_{17}H_{20}N_{4}O_{6}, calculated on the dried basis.

Identification

A. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in phosphate buffer pH 7.0 shows an absorption maximum at about 267 nm; absorbance at about 267 nm, 0.58 to 0.64.

B. Dissolve about 10 mg in sufficient 2 M sodium hydroxide to produce 100 ml, expose 1 ml to ultraviolet light at 254 nm for 5 minutes, add sufficient 5 M acetic acid to make the solution acidic to litmus paper and shake the mixture with 2 ml of dichloromethane; the lower layer exhibits a yellow fluorescence.

C. To 0.5 g add 10 ml of nitric acid, evaporate the mixture to dryness on a water-bath, ignite the residue until the carbon is removed, dissolve the final residue in 5 ml of water and filter. The filtrate gives the reactions of sodium salts and reaction B of phosphates (2.4.1).

Tests

pH (2.4.24). 4.0 to 6.3, determined in a 2.0 per cent w/v solution.

Specific optical rotation (2.4.22). +38.0° to +42.0°, determined in a 1.5 per cent w/v solution in 5 M hydrochloric acid.

Heavy metals (2.3.13). To 2.0 g in a silica crucible add 2 ml of nitric acid dropwise followed by 0.25 ml of sulphuric acid. Heat cautiously until white fumes are evolved and ignite. Extract the cooled residue with two quantities, each of 2 ml, of hydrochloric acid and evaporate the extracts to dryness.

Dissolve the residue in 2 ml of 2 M acetic acid and dilute to 20 ml with water. 12 ml of the solution complies with the limit test for heavy metals, Method D (10 ppm). Use 1.0 ml of lead standard solution (10 ppm Pb) to prepare the standard.

Lumiflavine. Shake 35 mg with 10 ml of dichloromethane for 5 minutes and filter. The filtrate is not more intensely coloured than reference solution BYS6 (2.4.1).

Inorganic phosphate. Not more than 1.5 per cent, determined by the following method. Dissolve 0.1 g in sufficient water to produce 100 ml. Dilute 5 ml with 10 ml of water and add 5 ml of buffered cupric sulphate solution pH 4.0, 2 ml of a 3 per cent w/v solution of ammonium molybdate, 1 ml of a freshly prepared solution containing 2 per cent w/v of 4-methylaminophenol sulphate and 5 per cent w/v of sodium meta-
bisulphite and 1 ml of a 3 per cent v/v solution of perchloric acid. Add sufficient water to produce 25 ml, mix and measure the absorbance of the resulting solution at the maximum at about 800 nm (2.4.7), within 15 minutes of its preparation, using as the blank a solution prepared in the same manner but omitting the substance under examination. The absorbance is not greater than that produced by repeating the operation using a solution prepared in the same manner using 15 ml of phosphate standard solution (5 ppm PO₄) and beginning at the words “add 5 ml of buffered cupric sulphate solution pH 4.0.”

**Loss on drying** (2.4.19). Not more than 8.0 per cent, determined on 0.5 g by drying in an oven at 100º at a pressure not exceeding 0.7 kPa for 5 hours.

**Assay.** Carry out the procedure protected from light.

Weigh accurately about 0.1 g, dissolve in 150 ml of water, add 2 ml of glacial acetic acid and dilute to 1000.0 ml with water. To 10.0 ml add 3.5 ml of a 1.4 per cent w/v solution of sodium acetate, dilute to 50.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 444 nm (2.4.7). Calculate the percentage content of C₁₇H₂₀N₄O₆ taking 328 as the specific absorbance at 444 nm.

**Storage.** Store protected from light.

---

**Riboflavine Tablets**

Lactoflavin Tablets; Vitamin B₂ Tablets

Riboflavine Tablets contain not less than 90.0 per cent and not more than 115.0 per cent of the stated amount of riboflavine, C₁₇H₂₀N₄O₆.

**Identification**

Shake a quantity of the powdered tablets containing 1 mg of Riboflavine with 100 ml of water and filter; the filtrate has a pale greenish yellow colour by transmitted light and an intense yellowish green fluorescence by reflected light, which disappears on addition of mineral acids or alkalis.

**Tests**

**Uniformity of content.** Comply with the test stated under Tablets.

Powder one tablet, add a mixture of 2.5 ml of glacial acetic acid and 50 ml of water and heat on a water-bath for 1 hour with occasional stirring. Dilute with 50 ml of water, add 30 ml of 1 M sodium hydroxide with continuous stirring. Add sufficient water to produce 1000.0 ml, mix and filter, discarding the first few ml of the filtrate. Measure the absorbance of the filtrate at the maximum at about 444 nm (2.4.7).

Calculate the content of C₁₇H₂₀N₄O₆ taking 328 as the specific absorbance at 444 nm.

**Storage.** Store protected from light.

---

**Rifampicin**

**Rifampin**

[C₄₃H₅₈N₄O₁₂  Mol. Wt. 823.0]


Rifampicin contains not less than 97.0 per cent and not more than 102.0 per cent of C₄₃H₅₈N₄O₁₂, calculated on the dried basis.

**Description.** A brick-red to reddish brown, crystalline powder; practically odourless.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with rifampicin RS or with the reference spectrum of rifampicin.
B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**pH** (2.4.24). 4.5 to 6.5, determined in a 1.0 per cent w/v suspension.

**Related substances**. Determine by liquid chromatography (2.4.14).

**Solvent mixture**. A mixture of 10 volumes of a 21.01 per cent w/v solution of citric acid, 23 volumes of a 13.61 per cent w/v solution of potassium dihydrogen phosphate, 77 volumes of a 17.42 per cent w/v solution of dipotassium hydrogen phosphate, 640 volumes of water and 250 volumes of acetonitrile.

**Test solution**. Weigh accurately a quantity of powder containing 20 mg of Rifampicin, add 10 ml of acetonitrile, shake and filter. Dilute 5 ml of the filtrate to 50 ml with the solvent mixture.

**Reference solution**. A solution containing 0.02 per cent w/v of rifampicin quinone RS in acetonitrile. To 1 ml of the solution, add 1 ml of the test solution and dilute to 100 ml with the solvent mixture.

**Chromatographic system** – a stainless steel column 10 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),

– mobile phase: a mixture of 65 volumes of buffer solution pH 6.8 prepared by mixing 0.1 per cent w/v of phosphoric acid, 0.19 per cent w/v of sodium perchlorate, 0.59 per cent w/v of citric acid and 2.09 per cent w/v of potassium dihydrogen phosphate with water and adjusting the pH to 6.8 with dilute phosphoric acid, and 35 volumes of acetonitrile.

– flow rate. 1.5 ml per minute,

– spectrophotometer set at 254 nm,

– a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the resolution between the principal peaks is not less than 4.

In the chromatogram obtained with the test solution the area of any peak due to rifampicin quinone is not more than 1.5 times the area of the principal peak in the chromatogram obtained with the reference solution (1.5 per cent); the area of any peak, other than the principal peak and the peak corresponding to rifampicin quinone, is not more than the area of the peak due to rifampicin in the chromatogram obtained with the reference solution (1.0 per cent) and the sum of the areas of any such peaks is not more than 3.5 times the area of the peak due to rifampicin in the chromatogram obtained with the reference solution (3.5 per cent).

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 80º at a pressure not exceeding 0.7 kPa for 4 hours.

**Assay**. Determine by liquid chromatography (2.4.14).

**NOTE** — Prepare the solutions immediately before use.

**Solvent mixture**. A mixture of 10 volumes of a 21.01 per cent w/v solution of citric acid, 23 volumes of a 13.61 per cent w/v solution of potassium dihydrogen phosphate, 77 volumes of a 17.42 per cent w/v solution of dipotassium hydrogen phosphate, 640 volumes of water and 250 volumes of acetonitrile.

**Test solution**. Dissolve 20.0 mg of the substance under examination in 10.0 ml of acetonitrile and filter. Dilute 5.0 ml of the filtrate to 100.0 ml with the solvent mixture.

**Reference solution**. A solution containing 0.2 per cent w/v of rifampicin RS in acetonitrile. Dilute 5.0 ml of this solution to 100.0 ml with the solvent mixture.

Use the chromatographic system and the system suitability parameters described under the test for Related substances.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution. Calculate the content of C₄₃H₅₈N₄O₁₂.

**Storage**. Store protected from light, in an atmosphere of nitrogen.

---

**Rifampicin Capsules**

Rifampicin Capsules

Rifampicin Capsules contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of rifampicin, C₄₃H₅₈N₄O₁₂.

**Identification**

A. Shake a quantity of the contents of the capsules containing 0.15 g of Rifampicin with 5 ml of chloroform, filter and evaporate the filtrate to dryness. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with rifampicin RS or with the reference spectrum of rifampicin.
B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Related substances.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** A mixture of 10 volumes of a 21.01 per cent w/v solution of citric acid, 23 volumes of a 13.61 per cent w/v solution of potassium dihydrogen phosphate, 77 volumes of a 17.42 per cent w/v solution of dipotassium hydrogen phosphate, 640 volumes of water and 250 volumes of acetonitrile.

**Test solution.** Shake a quantity of the contents of the capsules containing 200 mg of Rifampicin, with 100 ml of acetonitrile and filter. Dilute 5 ml of the filtrate to 50 ml with the solvent mixture.

**Reference solution (a).** A solution containing 0.02 per cent w/v of rifampicin RS in acetonitrile. Dilute 1 ml of this solution to 100 ml with the solvent mixture.

**Reference solution (b).** A solution containing 0.01 per cent w/v each of rifampicin RS and rifampicin quinone RS in acetonitrile. Dilute 5 ml of this solution to 50 ml with the solvent mixture.

**Chromatographic system**

- a stainless steel column 10 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),
- column temperature 30°C,
- mobile phase: a mixture of 65 volumes of buffer solution pH 6.8 prepared by mixing 0.1 per cent w/v of phosphoric acid, 0.19 per cent w/v of sodium perchlorate, 0.59 per cent w/v of citric acid and 2.09 per cent w/v of potassium dihydrogen phosphate with water and adjusting then pH to 6.8 with dilute phosphoric acid, and 35 volumes of acetonitrile,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject reference solution (b). The test is not valid unless the resolution between rifampicin and rifampicin quinone is not less than 4, the tailing factor is not more than 2.0 and the column efficiency is not less than 2000 theoretical plates.

Inject the test solution and reference solution (a). The relative retention times are 1.0, 0.55, 1.25 and 2.61 for rifampicin, rifampicin quinone, rifampicin N-oxide and 3-formylrifamycin SV respectively. The response factors are 1.00, 1.19, 1.03 and 1.25 for rifampicin, rifampicin quinone, rifampicin N-oxide and 3-formylrifamycin SV respectively.

In the chromatogram obtained with the test solution the area of any peak due to rifampicin quinone should not be more than 4 times the area of the principal peak in the chromatogram obtained with the reference solution, the area of any peak due to rifampicin N-oxide should not be more than 1.5 times the area of the principal peak in the chromatogram obtained with the reference solution and the area of any peak due to 3-formylrifamycin SV should not be more than the area of the principal peak in the chromatogram obtained with the reference solution. In the chromatogram obtained with the test solution the area of any unknown peak should not be more than the area of the principal peak in the chromatogram obtained with the reference solution.

**Dissolution (2.5.2).**

Apparatus. No 2

Medium. 900 ml of 0.1 M hydrochloric acid

Speed and time. 100 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter promptly through a membrane filter disc having an average pore diameter not greater than 1.0 µm, rejecting the first 1 ml of the filtrate. Dilute the filtrate, if necessary, with the same solvent. Measure the absorbance (2.4.7) of the resulting solution at the maximum at about 475 nm. Calculate the content of C₄₃H₅₈N₄O₁₂ in the medium from the absorbance obtained from a solution of known concentration of rifampicin RS.

D. Not less than 75 per cent of the stated amount of C₃₀H₅₈N₄O₁₂.

**Other tests.** Comply with the tests stated under Capsules.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Shake a quantity of the contents of the capsules containing about 300.0 mg of Rifampicin, with 200.0 ml of acetonitrile, filter. Dilute 10.0 ml of the filtrate to 50.0 ml with acetonitrile. Dilute 5.0 ml of this solution to 50.0 ml with the solvent mixture.

**Reference solution (a).** A 0.15 per cent w/v solution of rifampicin RS in acetonitrile. Dilute 10.0 ml of this solution to 50.0 ml with acetonitrile. Dilute 5.0 ml of the resulting solution to 50.0 ml with the solvent mixture.

**Reference solution (b).** A solution containing 0.01 per cent w/v each of rifampicin RS and rifampicin quinone RS in acetonitrile. Dilute 5 ml of this solution to 50 ml with the solvent mixture.

Use the chromatographic system and system suitability parameters, as described under the test for Related substances.

Inject reference solution (a). The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and reference solution (a). Calculate the content of C₃₀H₅₈N₄O₁₂ in the capsules.

**Storage.** Store protected from light and moisture.
Rifampicin Oral Suspension

Rifampicin oral suspension contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of rifampicin, C₃₅H₅₈N₄O₁₂.

Identification

A. To a quantity containing 0.1 g of Rifampicin add 30 ml of water and shake with two quantities, each of 50 ml, of chloroform. Dry the combined extracts with anhydrous sodium sulphate, filter and evaporate the filtrate to dryness at a temperature not exceeding 70°. Wash the residue with 1 ml of ether and dry at 70°. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with rifampicin RS or with the reference spectrum of rifampicin.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

Tests

pH (2.4.24). 4.2 to 4.8.

Related substances. Determine by liquid chromatography (2.4.14).

Solvent mixture. A mixture of 10 volumes of a 21.01 per cent w/v solution of citric acid, 23 volumes of a 13.61 per cent w/v solution of potassium dihydrogen phosphate, 77 volumes of a 17.42 per cent w/v solution of dipotassium hydrogen phosphate, 640 volumes of water and 250 volumes of acetonitrile.

Test solution. Add 5 ml of water to a quantity of the oral suspension containing 20 mg of Rifampicin and extract with four quantities, each of 10 ml, of dichloromethane, filter the combined extracts and evaporate to dryness at a temperature not exceeding 40°. Dissolve the residue in 10 ml of acetonitrile. Dilute 5 ml of the resulting solution to 50 ml with the solvent mixture.

Reference solution (a). A solution containing 0.02 per cent w/v of rifampicin RS in acetonitrile. Dilute 1 ml of this solution to a 100 ml with the solvent mixture.

Reference solution (b). A solution containing 0.01 per cent w/v each of rifampicin RS and rifampicin quinone RS in acetonitrile. Dilute 5 ml of this solution to 50 ml with the solvent mixture.

Chromatographic system
  - a stainless steel column 10 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),
  - column temperature 30°,
  - mobile phase: a mixture of 65 volumes of buffer solution pH 6.8 prepared by mixing 0.1 per cent w/v of phosphoric acid, 0.19 per cent w/v of sodium perchlorate, 0.59 per cent w/v of citric acid and 2.09 per cent w/v of potassium dihydrogen phosphate with water and adjusting the pH to 6.8 with dilute phosphoric acid, and 35 volumes of acetonitrile,
  - flow rate. 1.5 ml per minute,
  - spectrophotometer set at 254 nm,
  - a 20 µl loop injector.

Inject reference solution (b). The test is not valid unless the resolution between rifampicin and rifampicin quinone is not less than 4; the tailing factor is not more than 2.0 and the column efficiency is not less than 2000 theoretical plates.

Inject the test solution and reference solution (a). The relative retention times are 1.0, 0.55, 1.25, 1.51 and 2.61 for rifampicin, rifampicin quinone, rifampicin N-oxide, 3-formylrifamycin SV Isonicotinyl hydrazone and 3-formylrifamycin SV respectively. Multiply the areas of each known impurity by their response factor. The response factors are 1.00, 1.19, 1.03, 1.22 and 1.25 for rifampicin, rifampicin quinone, rifampicin N-oxide, Isonicotinyl hydrazone and 3-formylrifamycin SV respectively.

In the chromatogram obtained with the test solution the area of any peak due to rifampicin quinone should not be more than 1.5 times the area of the principal peak in the chromatogram obtained with the reference solution, the area of any peak due to rifampicin N-oxide should not be more than the area of the principal peak in the chromatogram obtained with the reference solution and the area of any peak due to 3-formylrifamycin SV should not be more than 5.0 times the area of the principal peak in the chromatogram obtained with the reference solution. In the chromatogram obtained with the test solution the area of any unknown peak should not be more than the area of the principal peak in the chromatogram obtained with the reference solution.

Other tests. Comply with the tests stated under Oral Suspensions.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh accurately a quantity of the oral suspension containing about 150 mg of rifampicin and dilute to 100.0 ml with acetonitrile. Dilute 10.0 ml of this solution to 50.0 ml with acetonitrile. Dilute 10.0 ml of the resulting solution to 50.0 ml with the solvent mixture.

Reference solution (a). A 0.15 per cent w/v solution of rifampicin RS in acetonitrile. Dilute 10.0 ml of the solution to 50.0 ml with acetonitrile. Dilute 10.0 ml of the resulting solution to 50.0 ml with the solvent mixture.

Reference solution (b). A solution containing 0.01 per cent w/v of acetonitrile and the area of any peak due to rifampicin quinone should not be more than the area of the principal peak in the chromatogram obtained with the reference solution. In the chromatogram obtained with the test solution the area of any unknown peak should not be more than the area of the principal peak in the chromatogram obtained with the reference solution.

Reference solution (b). A solution containing 0.01 per cent w/v of rifampicin RS and rifampicin quinone RS in acetonitrile.
acetonitrile. Dilute 5 ml of this solution to 50 ml with the solvent mixture.

Use the chromatographic system and the system suitability parameters as described under the test for Related substances. Inject reference solution (a). The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and reference solution (a). Determine the weight per ml of the suspension (2.4.29) and calculate the content of C₄₃H₅₈N₄O₁₂ weight in volume.

Storage. Store protected from light and moisture.

Rifampicin Tablets

Rifampin Tablets

Rifampicin Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of rifampicin, C₄₃H₅₈N₄O₁₂.

Identification

A. Shake a quantity of the powdered tablets containing 0.15 g of Rifampicin with 5 ml of chloroform, filter and evaporate the filtrate to dryness. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with rifampicin RS or with the reference spectrum of rifampicin.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

Tests

Related substances. Determine by liquid chromatography (2.4.14).

Solvent mixture. A mixture of 10 volumes of a 21.01 per cent w/v solution of citric acid, 23 volumes of a 13.61 per cent solution w/v of potassium dihydrogen phosphate, 77 volumes of a 17.42 per cent w/v solution of dipotassium hydrogen phosphate, 640 volumes of water and 250 volumes of acetonitrile.

Test solution. Weigh accurately a quantity of the powdered tablets containing 200 mg of Rifampicin, dissolve in 100 ml of acetonitrile, filter. Dilute 5 ml of the filtrate to 50 ml with the solvent mixture.

Reference solution (a). A solution containing 0.02 per cent w/v of rifampicin RS in acetonitrile. Dilute 1 ml of this solution to a 100 ml with the solvent mixture.

Reference solution (b). A solution containing 0.01 per cent w/v of each of rifampicin RS and rifampicin quinone RS in acetonitrile. Dilute 5 ml of this solution to 50 ml with the solvent mixture.

Chromatographic system

- a stainless steel column 10 cm x 4.6 mm, packed with octysilane bonded to porous silica (5 µm),
- column. temperature 30º,
- mobile phase: a mixture of 65 volumes of buffer solution pH 6.8 prepared by mixing 0.1 per cent w/v of phosphoric acid, 0.19 per cent w/v of sodium perchlorate, 0.59 per cent w/v of citric acid and 2.09 per cent w/v of potassium dihydrogen phosphate with water and adjusting the pH to 6.8 with dilute phosphoric acid, and 35 volumes of acetonitrile,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject reference solution (b). The test is not valid unless the resolution between rifampicin and rifampicin quinone is not less than 4, the tailing factor is not more than 2.0 and the column efficiency is not less than 2000 theoretical plates.

Inject the test solution and reference solution (a). The relative retention times are 1.0, 0.55, 1.25 and 2.61 for rifampicin, rifampicin quinone, rifampicin N-oxide, and 3-formylrifamycin SV respectively. The response factors are 1.00, 1.19, 1.03 and 1.25 for rifampicin, rifampicin quinone, rifampicin N-oxide and 3-formylrifamycin SV respectively.

In the chromatogram obtained with the test solution the area of any peak due to rifampicin quinone should not be more than 1.5 times the area of the principal peak in the chromatogram obtained with the reference solution, the area of any peak due to rifampicin N-oxide should not be more than the area of the principal peak in the chromatogram obtained with the reference solution and the area of any peak due to 3-formylrifamycin SV should not be more than 5.0 times the area of the principal peak in the chromatogram obtained with the reference solution.

In the chromatogram obtained with the test solution the area of any unknown peak should not be more than the area of the principal peak in the chromatogram obtained with the reference solution.

Dissolution (2.5.2).

Apparatus. No 2

Medium. 900 ml of 0.1 M hydrochloric acid.

Speed and time. 100 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter promptly through a membrane filter disc having an average pore diameter not greater than 1.0 µm, rejecting the first 1 ml of the filtrate. Dilute the filtrate, if necessary, with the same solvent. Measure the absorbance (2.4.7) of the resulting solution at the maximum
RIFAMPICIN AND ISONIAZID TABLETS

at about 475 nm. Calculate the content of C₄₃H₅₈N₄O₁₂ in the medium from the absorbance obtained from a solution of known concentration of rifampicin RS.

D. Not less than 75 per cent of the stated amount of C₄₃H₅₈N₄O₁₂.

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh accurately a quantity of the powder containing about 300.0 mg of Rifampicin, dissolve in 200.0 ml of acetonitrile, filter. Dilute 10.0 ml of the filtrate to 50.0 ml with acetonitrile. Dilute 5.0 ml of this solution to 50.0 ml with the solvent mixture.

Reference solution (a). A 0.15 per cent w/v solution of rifampicin RS in acetonitrile. Dilute 10.0 ml of this solution to 50.0 ml with acetonitrile. Dilute 5.0 ml of the resulting solution to 50.0 ml with the solvent mixture.

Reference solution (b). A solution containing 0.01 per cent w/v each of rifampicin RS and rifampicin quinone RS in acetonitrile. Dilute 5.0 ml of this solution to 50.0 ml with the solvent mixture.

Use the chromatographic system and system suitability parameters described under the test for Related substances.

Inject reference solution (a). The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and reference solution (a).

Calculate the content of C₄₃H₅₈N₄O₁₂ in the tablets.

Storage. Store protected from light and moisture.

Rifampicin and Isoniazid Tablets

Rifampin and Isonicotinylhydrazid Tablets

Rifampicin and Isoniazid Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of rifampicin, C₄₃H₅₈N₄O₁₂ and isoniazid, C₃₈H₃₈N₁₀O₁₆.

Identification

A. In the Assay, the chromatogram obtained with the test solution shows peaks that correspond to the peaks due to rifampicin RS and isoniazid RS in the chromatogram obtained with the reference solution.

Tests

Related substances. Determine by liquid chromatography (2.4.14).

Solvent mixture. A mixture of 10 volumes of a 21.01 per cent w/v solution of citric acid, 23 volumes of a 13.61 per cent w/v solution of potassium dihydrogen phosphate, 77 volumes of a 17.42 per cent w/v solution of dipotassium hydrogen phosphate, 640 volumes of water and 250 volumes of acetonitrile.

Test solution. Weigh accurately a quantity of the powdered tablets containing 200 mg of Rifampicin in 100 ml of acetonitrile and filter. Dilute 5 ml of the filtrate to 50 ml with the solvent mixture.

Reference solution (a). Dissolve rifampicin RS in acetonitrile to obtain a solution containing 0.2 mg per ml. Dilute 1 ml of this solution to 100 ml with the solvent mixture.

Reference solution (b). A solution containing 0.01 per cent w/v each of rifampicin RS and rifampicin quinone RS in acetonitrile. Dilute 5 ml of this solution to 50 ml with the solvent mixture.

Chromatographic system

- a stainless steel column 10 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),
- column temperature 30º,
- mobile phase: a mixture of 65 volumes of buffer solution pH 6.8 prepared by mixing 0.1 per cent w/v of phosphoric acid, 0.19 per cent w/v of sodium perchlorate, 0.59 per cent w/v of citric acid and 2.09 per cent w/v of potassium dihydrogen phosphate with water and adjusting the pH to 6.8 with dilute phosphoric acid, and 35 volumes of acetonitrile,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject reference solution (b). The test is not valid unless the resolution between rifampicin and rifampicin quinone is not less than 4, the tailing factor is not more than 2.0 and the column efficiency is not less than 2000 theoretical plates.

Inject alternately the test solution and reference solution (a). The relative retention times are 1.0, 0.55, 1.25, 1.51 and 2.61 for rifampicin, rifampicin quinone, rifampicin N-oxide, 3-formylrifamycin SV respectively. Multiply the area of each known impurity by its response factor. The response factors are 1.00, 1.19, 1.03, 1.22 and 1.25 for rifampicin, rifampicin quinone, rifampicin N-oxide, isonicotinyl hydrazone and 3-formylrifamycin SV respectively.

In the chromatogram obtained with the test solution the area of any peak due to rifampicin quinone should not be more than 4 times the area of the principal peak in the chromatogram obtained with the reference solution (4 per cent), the area of any peak due to rifampicin N-oxide should not be more than 1.5 times the area of the principal peak in the chromatogram.
obtained with the reference solution (1.5 per cent), the area of
any peaks due to 3-formylrifamycin SV and isonicotinyl
hydrazone should not be more than 5 times the area of the
principal peak in the chromatogram obtained with the reference
solution (5 per cent) and the area of any peak due to
3-formylrifamycin SV should not be more than the area of the
principal peak in the chromatogram obtained with the reference
solution (1.0 per cent). In the chromatogram obtained with the
test solution the area of any unknown peak should not be
more than 1.5 times the area of the principal peak in the
chromatogram obtained with the reference solution (1.5 per
cent).

**Dissolution** (2.5.2).

Apparatus. No 2

Medium. 900 ml of 0.1 M hydrochloric acid.

Speed and time. 100 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter promptly
through a membrane filter disc with an average pore diameter
not greater than 0.8 µm. Reject the first few ml of the filtrate
and dilute a suitable volume of the filtrate with the medium.

**Reference stock solution.** A solution containing 0.0165 per
cent of rifampicin RS and 0.00825 per cent of isoniazid RS in
the dissolution medium.

**For rifampicin** — Measure the absorbance of the sample
solution and the reference stock solution suitably diluted with the
dissolution medium at 475 nm (2.4.7). Calculate the content
of \( \text{C}_{43}\text{H}_{58}\text{N}_{4}\text{O}_{12} \) in the medium from the absorbance obtained
from the reference stock solution.

**For isoniazid** — Determine by liquid chromatography
(2.4.14).

Use the reference stock solution and sample solution suitably
diluted with a solution of 0.05 M potassium dihydrogen
orthophosphate, adjust the pH to 6.2 with 0.1 M sodium
hydroxide to obtain the reference solution and the test
solution, respectively.

**Chromatographic system**
- a stainless steel column 30 cm x 3.9 mm, packed with
  octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 99 volumes of 0.05 M
  potassium dihydrogen phosphate and 1 volume of
  acetonitrile with the pH adjusted to 4.0 ± 0.05 with 2 per
  cent w/v solution of phosphoric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the
tailing factor is not more than 2.0, the column efficiency in not
less than 1500 theoretical plates and the relative standard
deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution.
Calculate the content of \( \text{C}_{43}\text{H}_{58}\text{N}_{4}\text{O}_{12} \) in the dissolution medium.

**D.** Not less than 75 per cent of the stated amounts of
\( \text{C}_{43}\text{H}_{58}\text{N}_{4}\text{O}_{12} \) and \( \text{C}_{6}\text{H}_{7}\text{N}_{3}\text{O} \).

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** Dissolve 1.4 g of disodium hydrogen
orthophosphate anhydrous in 1000 ml of water and adjust the
pH to 6.8 with dilute phosphoric acid.

**Test solution.** Weigh and powder 20 tablets. Weigh accurately
a quantity of the powder containing about 40 mg of Isoniazid,
dissolve in 100.0 ml of methanol and dilute to 500.0 ml with the
solvent mixture.

**Reference solution.** A solution containing 0.08 per cent w/v of
rifampicin RS and 0.04 per cent w/v of isoniazid RS in
methanol. Dilute 10.0 ml of this solution to 50.0 ml with the
solvent mixture.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with
  octadecylsilane bonded to porous silica (5 µm),
- column. temperature 30º,
- mobile phase: A. a mixture of 96 volumes of buffer
  solution pH 6.8 prepared by dissolving 1.4 g of disodium
  hydrogen orthophosphate anhydrous in 1000 ml of water and adjusting the pH to 6.8 ± 0.05 with dilute
  phosphoric acid, and 4 volumes of acetonitrile.
  B. a mixture of 45 volumes of the buffer
  solution and 55 volumes of acetonitrile,
- flow rate. 1.5 ml per minute,
- a linear gradient programme using the conditions given
  below,
- spectrophotometer set at 238 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>15</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>16</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>20</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

**NOTE** — Saturate the column with mobile phase B for about
1 hour before injection.

Inject the reference solution. The tailing factor is not more
than 2.0 for rifampicin and isoniazid; the column efficiency for
the isoniazid peak is not less than 3000 and for rifampicin not
less than 25000 theoretical plates and the relative standard
deviation for replicate injections is not more than 2.0 per cent.
Inject alternately the test solution and the reference solution. The retention times are about 1.0 for rifampicin and about 0.3 for isoniazid.

Calculate the contents of $\text{C}_{43}\text{H}_{58}\text{N}_{4}\text{O}_{12}$ and $\text{C}_{6}\text{H}_{7}\text{N}_{3}\text{O}$ in the tablets.

**Storage.** Store protected from moisture.

**Rifampicin, Isoniazid and Ethambutol Tablets**

Rifampin, Isonicotinylhydrazid and Ethambutol Hydrochloride Tablets

Rifampicin, Isoniazid and Ethambutol Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of rifampicin, $\text{C}_{43}\text{H}_{58}\text{N}_{4}\text{O}_{12}$, isoniazid, $\text{C}_{6}\text{H}_{7}\text{N}_{3}\text{O}$ and ethambutol hydrochloride $\text{C}_{10}\text{H}_{24}\text{N}_{2}\text{O}_{2}\cdot 2\text{HCl}$.

**Identification**

A. In the Assay for rifampicin and isoniazid, the principal peaks in the chromatogram obtained with the test solution correspond to the peaks in the chromatogram obtained with the reference solution.

B. In the Assay for ethambutol hydrochloride the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Related substances.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** A mixture of 10 volumes of a 21.01 per cent w/v solution of citric acid, 23 volumes of a 13.61 per cent w/v solution of potassium dihydrogen phosphate, 77 volumes of a 17.42 per cent w/v solution of dipotassium hydrogen phosphate, 640 volumes of water and 250 volumes of acetonitrile.

**Test solution.** Weigh accurately a quantity of the powdered tablets containing 200 mg of Rifampicin, dissolve in 100 ml of acetonitrile and filter. Dilute 5 ml of this solution to 50 ml with the solvent mixture.

**Reference solution (a).** A solution containing 0.02 per cent w/v of rifampicin RS in acetonitrile. Dilute 1 ml of this solution to 100 ml with the solvent mixture.

**Reference solution (b).** A solution containing 0.01 per cent w/v each of rifampicin RS and rifampicin quinone RS in acetonitrile. Dilute 5 ml of this solution to 50 ml with the solvent mixture.

**Chromatographic system**

- a stainless steel column 10 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),
- column. temperature 30º,
- mobile phase: a mixture of 65 volumes of buffer solution pH 6.8 prepared by mixing 0.1 per cent w/v of phosphoric acid, 0.19 per cent w/v of sodium perchlorate, 0.59 per cent w/v of citric acid and 2.09 per cent w/v of potassium dihydrogen phosphate with water and adjusting the pH to 6.8 with dilute phosphoric acid, and 35 volumes of acetonitrile,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject reference solution (b). The test is not valid unless the resolution between rifampicin and rifampicin quinone is not less than 4, the tailing factor is not more than 2.0 and the column efficiency is not less than 2000 theoretical plates.

Inject the test solution and reference solution (a). The relative retention times are 1.0, 0.55, 1.25, 1.51 and 2.61 for rifampicin, rifampicin quinone, rifampicin N-oxide, 3-formylrifamycin SV Isonicotinyl hydrazone and 3-formylrifamycin SV respectively.

Multiply the areas of each known impurity by its response factor. The response factors are 1.00, 1.19, 1.03, 1.22 and 1.25 for rifampicin, rifampicin quinone, rifampicin N-oxide, Isonicotinyl hydrazone and 3-formylrifamycin SV respectively.

In the chromatogram obtained with the test solution the area of any peak due to rifampicin quinone should not be more than 4 times the area of the principal peak in the chromatogram obtained with the reference solution (4 per cent), the area of any peak due to rifampicin N-oxide should not be more than 1.5 times the area of the principal peak in the chromatogram obtained with the reference solution (1.5 per cent), the area of any peak due to 3-formylrifamycin SV Isonicotinyl hydrazone should not be more than 5 times the area of the principal peak in the chromatogram obtained with the reference solution (5 per cent) and the area of any peak due to 3-formylrifamycin SV should not be more than the area of the principal peak in the chromatogram obtained with the reference solution (1 per cent). In the chromatogram obtained with the test solution the area of any unknown peak should not be more than 1.5 times the area of the principal peak in the chromatogram obtained with the reference solution (1.5 per cent).

**Dissolution (2.5.2).**

**Apparatus.** No 2

**Medium.** 900 ml of 0.1 M hydrochloric acid.

**Speed and time.** 100 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter promptly through a membrane filter disc with an average pore diameter not greater than 0.8 µm. Reject the first few ml of the filtrate.
Reference stock solution. A solution containing 0.0165 per cent w/v of rifampicin RS, 0.00825 per cent w/v of isoniazid RS and 0.031 per cent w/v of ethambutol hydrochloride RS in the dissolution medium. Keep this reference stock solution in the dissolution bath during the test run.

For rifampicin — Dilute the filtrate, if necessary, with the same solvent. Measure the absorbance (2.4.7) of the resulting solution at the maximum at about 475 nm. Calculate the content of C₄₃H₅₈N₄O₁² in the dissolution medium.

For isoniazid — Determine by liquid chromatography (2.4.14).

Test solution. Suitably dilute the filtered medium with 0.05 M potassium dihydrogen orthophosphate with the pH adjusted to 6.2 with 0.1 M sodium hydroxide.

Reference solution. Suitably dilute the reference stock solution with 0.05 M potassium dihydrogen orthophosphate with the pH adjusted to 6.2 with 0.1 M sodium hydroxide.

Chromatographic system

- a stainless steel column 30 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 99 volumes of 0.05 M potassium dihydrogen phosphate and 1 volume of acetonitrile previously adjusted to pH 4.0 with a 2 per cent w/v solution of phosphoric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency in not less than 1500 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution.

Calculate the content of C₆H₇N₃O in the dissolution medium.

For ethambutol hydrochloride — Determine by liquid chromatography (2.4.14).

Test solution. Suitably dilute the filtered medium with 0.05 M potassium dihydrogen orthophosphate adjusted to pH 6.2 with 0.1 M sodium hydroxide.

Reference solution. Suitably dilute the reference stock solution with 0.05 M potassium dihydrogen orthophosphate with the pH adjusted to 6.2 with 0.1 M sodium hydroxide.

Use the chromatographic system described under the Assay of ethambutol hydrochloride.

Calculate the content of C₁₀H₂₄N₂O₂·2HCl in the dissolution medium.

D. Not less than 75 per cent of the stated amounts of C₄₃H₅₈N₄O₁², C₆H₇N₃O and C₁₀H₂₄N₂O₂·2HCl.

Other tests. Comply with the tests stated under Tablets.

Assay. For rifampicin and isoniazid — Determine by liquid chromatography (2.4.14).

Test solution. Weigh and powder 20 tablets. Weigh accurately a quantity of the powdered tablets containing about 40 mg of Isoniazid dissolve in 100.0 ml of methanol, dilute to 500.0 ml with the diluent and mix.

Reference solution. A solution containing 0.08 per cent w/v of rifampicin RS and 0.04 per cent w/v of isoniazid RS in methanol. Dilute 10.0 ml of this solution to 50.0 ml with the diluent.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- column. temperature 30°,
- mobile phase: A. a mixture of 96 volumes of buffer solution pH 6.8 (diluent) prepared by dissolving 1.4 g of disodium hydrogen orthophosphate anhydrous in 1000 ml of water, and adjusting the pH to 6.8 ± 0.05 with dilute phosphoric acid, and 4 volumes of acetonitrile,
- B: a mixture of 45 volumes of the buffer solution and 55 volumes of acetonitrile,
- flow rate. 1.5 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 238 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>15</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>16</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>22</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

NOTE — Saturate the column with mobile phase B for about 1 hour.

Inject the reference solution. The test is not valid unless the tailing factor is not less than 2.0 for rifampicin and isoniazid, the column efficiency determined from isoniazid peak is not less than 3000 and that from rifampicin is not less than 25000 theoretical plates respectively, and the relative standard deviation for replicate injections is not more than 2.0 per cent. The relative retention times are about 1.0 for rifampicin and about 0.3 for isoniazid.

Calculate the contents of C₄₃H₅₈N₄O₁² and C₆H₇N₃O in the tablets.

For ethambutol hydrochloride — Determine by liquid chromatography (2.4.14).
Test solution. Weigh accurately a quantity of the powdered tablets containing about 60 mg of Ethambutol Hydrochloride and dissolve in 100.0 ml of the diluent.

Reference solution. A 0.06 per cent w/v solution of ethambutol hydrochloride RS in the diluent.

Chromatographic system

- A stainless steel column 15 cm x 4.6 mm, packed with nitrile groups chemically bonded to porous silica particles 5 (µm) (such as Zorbax SB CN),
- Mobile phase: a mixture of 50 volumes of acetonitrile, and 50 volumes of a buffer solution pH 7.0 prepared by dissolving 1 ml of triethylamine in 1000 ml of water and adjusting the pH to 7.0 with dilute phosphoric acid,
- Flow rate. 1 ml per minute,
- Spectrophotometer set at 254 nm,
- A 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent, the tailing factor is not more than 3.0 and the column efficiency determined from Ethambutol hydrochloride peak is not less than 1500 theoretical plates.

Inject alternately the test solution and the reference solution.

Calculate the content of C₁₀H₂₄N₂O₂·2HCl in the tablets.

Storage. Store protected from moisture.

Rifampicin, Isoniazid and Pyrazinamide Tablets

Rifampin, Isonicotinylhydrazid and Pyrazinamide Tablets

Rifampicin, Isoniazid and Pyrazinamide Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of rifampicin, C₉H₇N₃O, isoniazid, C₆H₇N₃O and pyrazinamide C₅H₅N₃O.

Identification

In the Assay of rifampicin, isoniazid and pyrazinamide, the principal peaks in the chromatogram obtained with the test solution correspond to the peaks in the chromatogram obtained with the reference solution.

Tests

Related substances. Determine by liquid chromatography (2.4.14).

Solvent mixture. A mixture of 10 volumes of a 21.01 per cent w/v solution of citric acid, 23 volumes of a 13.61 per cent w/v solution of potassium dihydrogen phosphate, 77 volumes of 17.42 per cent w/v solution of dipotassium hydrogen phosphate, 640 volumes of water and 250 volumes of acetonitrile.

Test solution. Weigh accurately a quantity of the powdered tablets containing about 200 mg of Rifampicin, dissolve in 100 ml of acetonitrile and filter. Dilute 5 ml of this solution to 50 ml with the solvent mixture.

Reference solution (a). A solution containing 0.02 per cent w/v of rifampicin RS in acetonitrile. Dilute 1 ml of this solution to a 100 ml with the solvent mixture.

Reference solution (b). A solution containing 0.01 per cent w/v each of rifampicin RS and rifampicin quinone RS in acetonitrile. Dilute 5 ml of this solution to 50 ml with the solvent mixture.

Chromatographic system

- A stainless steel column 10 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),
- Column. temperature 30º,
- Mobile phase: a mixture of 65 volumes of buffer solution pH 6.8 prepared by mixing 0.1 per cent w/v of phosphoric acid, 0.19 per cent w/v of sodium perchlorate, 0.59 per cent w/v of citric acid and 2.09 per cent w/v of potassium dihydrogen phosphate with water and adjusting the pH to 6.8 with dilute phosphoric acid, and 35 volumes of acetonitrile,
- Flow rate. 1.5 ml per minute,
- Spectrophotometer set at 254 nm,
- A 20 µl loop injector.

Inject reference solution (b). The test is not valid unless the resolution between rifampicin and rifampicin quinone is not less than 4, the tailing factor is not more than 2.0 and the column efficiency is not less than 2000 theoretical plates.

Inject the test solution and reference solution (a). The relative retention times are 1.0, 0.55, 1.25, 1.51 and 2.61 for rifampicin, rifampicin quinone, rifampicin N-oxide, 3-formylrifamycin SV Isonicotinyl hydrazone and 3-formylrifamycin SV respectively. Multiply the area of each known impurity by its response factor. The response factors are 1.00, 1.19, 1.03, 1.22 and 1.25 for rifampicin, rifampicin quinone, rifampicin N-oxide, Isonicotinyl hydrazone and 3-formylrifamycin SV respectively. In the chromatogram obtained with the test solution the area of any peak due to rifampicin quinone should not be more than 4 times the area of the principal peak in the chromatogram obtained with the reference solution (4 per cent), the area of any peak due to rifampicin N-oxide should not be more than 1.5 times the area of the principal peak in the chromatogram obtained with the reference solution (1.5 per cent), the area of any peak due to 3-formylrifamycin SV Isonicotinyl hydrazone should not be more than 5 times the area of the principal peak in the chromatogram obtained with the reference solution (5 per cent) and the area of any peak due to 3-formylrifamycin SV should not be more than the area of the principal peak in...
the chromatogram obtained with the reference solution (1 per cent). In the chromatogram obtained with the test solution the area of any unknown peak should not be more than 1.5 times the area of the principal peak in the chromatogram obtained with the reference solution (1.5 per cent).

**Dissolution** (2.5.2).

**Apparatus. No 2**

Medium. 900 ml of a solution containing 2 g of sodium chloride and 7.0 ml of hydrochloric acid in 1000 ml of water, with a pH of about 1.2.

Speed and time. 100 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter through a membrane filter disc with an average pore diameter not greater than 0.8 µm. Reject the first few ml of the filtrate.

**Reference stock solution.** A solution containing 0.0165 per cent w/v of rifampicin RS, 0.00825 per cent w/v of isoniazid RS and 0.04375 per cent w/v of pyrazinamide RS in the dissolution medium and filtered. Keep this reference stock solution in the dissolution bath during the test run.

**For rifampicin** — Dilute the filtrate, if necessary, with the same solvent. Measure the absorbance (2.4.7) of the resulting solution at the maximum at about 475 nm. Calculate the content of C43H58N4O12 in the medium from the absorbance obtained from suitably diluted reference stock solution.

**For isoniazid and pyrazinamide** — Determine by liquid chromatography (2.4.14).

**NOTE** — Use this solution within one hour from preparation.

**Test solution.** To 15.0 ml of the filtered medium, add 15 ml of 1 M dibasic potassium phosphate, dilute to 100.0 ml with the mobile phase and mix.

**Reference solution (a).** To 15.0 ml of the reference stock solution, add 15 ml of 1 M dibasic potassium phosphate, dilute to 100.0 ml with the mobile phase and mix.

**Reference solution (b).** To 10.0 ml of a 0.0125 per cent w/v solution of isonicotinic acid in the dissolution medium, add 4.0 ml of the reference stock solution and 15 ml of 1 M dibasic potassium phosphate, dilute to 100.0 ml with the mobile phase and mix.

**Chromatographic system**

- a stainless steel column 30 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 860 volumes of water, 100 volumes of 1 M monobasic potassium phosphate and 40 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 254 nm,
- a 50 µl loop injector.

Inject the test solution and reference solutions (a) and (b). The relative retention times are about 0.7 for isonicotinic acid, 1.0 for pyrazinamide and 1.8 for isoniazid.

The test is not valid unless in the chromatogram obtained with reference solution (b) the resolution between isonicotinic acid and pyrazinamide is not more than 2.5 and between pyrazinamide and isoniazid is not more than 4.0.

Calculate the contents of C43H58N4O12, C6H7N3O and C5H5N3O in the medium.

D. Not less than 75 per cent of the stated amounts of C6H7N3O and C5H5N3O.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** For rifampicin, isoniazid and pyrazinamide — Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powdered tablets containing about 40 mg of isoniazid, dissolve in 100.0 ml of methanol, dilute to 500 ml with the solvent mixture and mix.

**Reference solution.** A solution containing 0.08 per cent w/v of rifampicin RS, 0.04 per cent w/v of isoniazid RS and 0.2 per cent w/v of pyrazinamide RS in methanol. Dilute 10.0 ml of this solution to 50.0 ml with the solvent mixture.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- column. temperature 30º,
- mobile phase. A. a mixture of 96 volumes of buffer solution pH 6.8 (diluent) prepared by dissolving 1.4 g of disodium hydrogen orthophosphate anhydrous in 1000 ml of water, adjusted to pH 6.8 ± 0.05 with dilute phosphoric acid and 4 volumes of acetonitrile,
  - B. a mixture of 45 volumes of the buffer solution and 55 volumes of acetonitrile,
- flow rate. 1.5 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 238 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>15</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>16</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>22</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

**NOTE** — Saturate the column with mobile phase (B) for about 1 hour.

Inject the test solution and the reference solution. The test is not valid unless the tailing factor is not less than 2.0 for rifampicin, isoniazid and pyrazinamide, the column efficiencies determined from Isoniazid, pyrazinamide and that from rifampicin are not less than 3000, 5000 and 25000 theoretical
plates respectively, and the relative standard deviation for replicate injections is not more than 2.0 per cent. The relative retention times are about 1.8 for rifampicin, about 0.7 for isoniazid and about 1.0 for pyrazinamide.

Inject alternately the test solution and the reference solution. Calculate the contents of C43H58N4O12, C6H7N3O and C5H5N3O in the tablets.

Storage. Store protected from moisture.

**Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Tablets**

Rifampin, Isonicotinylhydrazid, Pyrazinamide and Ethambutol Hydrochloride Tablets

Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of rifampicin, C16H26N4O12, isoniazid, C8H7N3O, pyrazinamide, C5H5N3O and ethambutol hydrochloride, C10H24N2O2·2HCl.

**Identification**

A. In the Assay for rifampicin, isoniazid and pyrazinamide, the principal peaks in the chromatogram obtained with the test solution correspond to the peaks in the chromatogram obtained with the reference solution.

B. In the Assay for ethambutol hydrochloride, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Related substances.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** A mixture of 10 volumes of a 21.01 per cent w/v solution of citric acid, 23 volumes of a 13.61 per cent w/v solution of potassium dihydrogen phosphate, 77 volumes of a 17.42 per cent w/v solution of dipotassium hydrogen phosphate, 640 volumes of water and 250 volumes of acetonitrile.

**Test solution.** Weigh accurately a quantity of powdered tablets containing 200 mg of Rifampicin, dissolve in 100 ml of acetonitrile and filter. Dilute 5 ml of this solution to 50 ml with the solvent mixture.

**Reference solution (a).** Dissolve 20 mg of rifampicin RS in 100 ml of acetonitrile. Dilute 1 ml of this solution to a 100 ml with the solvent mixture.

**Reference solution (b).** A solution containing 0.01 per cent w/v each of rifampicin RS and rifampicin quinone RS in acetonitrile. Dilute 5 ml of this solution to 50 ml with the solvent mixture.

**Chromatographic system**

- a stainless steel column 10 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),
- column. temperature 30º,
- mobile phase: a mixture of 65 volumes of buffer solution pH 6.8 prepared by mixing 0.1 per cent w/v of phosphoric acid, 0.19 per cent w/v of sodium perchlorate, 0.59 per cent w/v of citric acid and 2.09 per cent w/v of potassium dihydrogen phosphate with water, adjusting the pH to 6.8 with dilute phosphoric acid, and 35 volumes of acetonitrile,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject reference solution (b). The test is not valid unless the resolution between rifampicin and rifampicin quinone is not less than 4, the tailing factor is not more than 2.0 and the column efficiency is not less than 2000 theoretical plates.

Inject the test solution and reference solution (a). The relative retention times are 1.0, 0.55, 1.25, 1.51 and 2.61 for rifampicin, rifampicin quinone, rifampicin N-oxide, 3-formylrifamycin SV Isonicotinyl hydrazone and 3-formylrifamycin SV respectively. Multiply the area of each known impurity by its response factor. The response factors are 1.00, 1.19, 1.03, 1.22 and 1.25 for rifampicin, rifampicin quinone, rifampicin N-oxide, Isonicotinyl hydrazone and 3-formylrifamycin SV respectively.

In the chromatogram obtained with the test solution the area of any peak due to rifampicin quinone should not be more than 4 times the area of the principal peak in the chromatogram obtained with the reference solution (4 per cent), the area of any peak due to rifampicin N-oxide should not be more than 1.5 times the area of the principal peak in the chromatogram obtained with the reference solution (1.5 per cent), the area of any peak due to 3-formylrifamycin SV Isonicotinyl hydrazone should not be more than 5 times the area of the principal peak in the chromatogram obtained with the reference solution (5 per cent) and the area of any peak due to 3-formylrifamycin SV should not be more than the area of the principal peak in the chromatogram obtained with the reference solution (1 per cent ). In the chromatogram obtained with the test solution the area of any unknown peak should not be more than 1.5 times the area of the principal peak in the chromatogram obtained with the reference solution (1.5 per cent).

**Dissolution (2.5.2).**

Apparatus. No 1

Medium. 900 ml of sodium phosphate buffer pH 6.8 prepared by dissolving 7 g of dibasic sodium phosphate anhydrous in 5000 ml of water and adjusting to pH 6.8 with phosphoric acid.
Speed and time. 100 rpm and 45 minutes.
Withdraw a suitable volume of the medium and filter through a membrane filter disc with an average pore diameter not greater than 0.8 µm. Reject the first few ml of the filtrate. Determine the amounts of rifampicin, C₄₃H₅₈N₄O₁₂, isoniazid, C₆H₇N₃O, pyrazinamide, C₅H₅N₃O and ethambutol hydrochloride, C₁₀H₂₄N₂O₂.2HCl by using the methods described in the Assay for rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride.
D. Not less than 75 per cent of the stated amounts of C₄₃H₅₈N₄O₁₂, C₆H₇N₃O, C₅H₅N₃O and C₁₀H₂₄N₂O₂.2HCl.
Other tests. Comply with the tests stated under Tablets.
Assay. For rifampicin, isoniazid and pyrazinamide — Determine by liquid chromatography (2.4.14).
Test solution. Weigh and powder 20 tablets. Weigh accurately a quantity of the powdered tablets containing about 40 mg of Isoniazid, dissolve in 100 ml of methanol, dilute to 500 ml with the solvent mixture, mix and filter.
Reference solution. A solution containing 0.08 per cent w/v of rifampicin RS, 0.04 per cent w/v of isoniazid RS and 0.2 per cent w/v of pyrazinamide RS in methanol. Dilute 10.0 ml of this solution to 50.0 ml with the solvent mixture.
Chromatographic system
– a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
– column temperature 30º,
– mobile phase: A. a mixture of 96 volumes of buffer solution pH 6.8 prepared by dissolving 1.4 g of disodium hydrogen orthophosphate anhydrous in 1000 ml of water, adjusting to pH 6.8 ± 0.05 with dilute phosphoric acid and 4 volumes of acetonitrile,
– B. a mixture of 45 volumes of the buffer solution and 55 volumes of acetonitrile,
– flow rate. 1.5 ml per minute,
– a linear gradient programme using the conditions given below,
– spectrophotometer set at 238 nm,
– a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>Solution A (per cent v/v)</th>
<th>Solution B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>15</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>16</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>22</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent, the tailing factor is not more than 2.0 for rifampicin, isoniazid and pyrazinamide and the column efficiencies for rifampicin, isoniazid and pyrazinamide are not less than 3000, 5000 and 25000 theoretical plates respectively. Inject alternately the test solution and the reference solution. The relative retention time for rifampicin is 1.8, for isoniazid, 0.7 and for pyrazinamide, 1.0.
Calculate the contents of C₄₃H₅₈N₄O₁₂, C₆H₇N₃O and C₅H₅N₃O in the tablets.
For ethambutol hydrochloride — Determine by liquid chromatography (2.4.14).
Test solution. Weigh accurately a quantity of the powdered tablets containing about 60 mg of Ethambutol Hydrochloride and dissolve in 100 ml of the solvent mixture.
Reference solution. A 0.06 per cent w/v solution of ethambutol hydrochloride RS in the solvent mixture.
Chromatographic system
– a stainless steel column 15 cm x 4.6 mm, packed with nitrile groups chemically bonded to porous silica particles (5 µm),
– mobile phase: a mixture of 50 volumes of acetonitrile, and 50 volumes of buffer solution pH 7.0 (diluent) prepared by dissolving 1 ml of triethylamine in 1000 ml of water and adjusting the pH to 7.0 with dilute phosphoric acid,
– flow rate. 1 ml per minute,
– spectrophotometer set at 200 nm,
– a 50 µl loop injector.
Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent, the tailing factor is not more than 3.0 and the column efficiency determined from ethambutol hydrochloride peak is not less than 1500 theoretical plates.
Calculate the content of C₁₀H₂₄N₂O₂.2HCl in the tablets.
Storage. Store protected from moisture.

Ritonavir

RITONA VIR

C₃₇H₄₈N₆O₅S₂ Mol. Wt. 721.0
Ritonavir is (5S,8S,10S,11S)-10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid 5-thiazolyl methyl ester.

Ritonavir contains not less than 98.0 per cent and not more than 102.0 per cent of C_{37}H_{48}N_{6}O_{5}S_{2}, calculated on the anhydrous basis.

**Description.** A white to off-white powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ritonavir RS or with the reference spectrum of ritonavir.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to ritonavir in the chromatogram obtained with the reference solution.

C. Melting point. 119º to 123º (2.4.21).

**Tests**

Specific optical rotation (2.4.22). +7.0º to +10.5º, determined in a 0.2 per cent w/v solution in methanol.

**Related substances.** Determine by liquid chromatography (2.4.14), as described in the Assay and calculate the percentage of each impurity peak in the chromatogram obtained with the test solution. Not more than 0.5 per cent of any individual impurity and not more than 1.0 per cent of total impurities is found.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent

**Water** (2.3.43). Not more than 0.5 per cent, determined on 2.0 g.

**Assay.** Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 25.0 mg of the substance under examination in sufficient of a mixture of 45 volumes of acetonitrile and 55 volumes of water to produce 100.0 ml.

Reference solution. A 0.025 per cent w/v solution of ritonavir RS in a mixture of 45 volumes of acetonitrile and 55 volumes of water.

Chromatographic system

- a stainless steel column 15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 45 volumes of acetonitrile and 55 volumes of a buffer solution prepared by dissolving 3.4 g of sodium acetate and 0.94 g of sodium hexanesulphonate in 1000 ml of water and adjusting the pH to 4.0 with hydrochloric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 239 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the column efficiency determined from the ritonavir peak is not less than 1000 theoretical plates, the tailing factor is not more than 2.0, and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution. Calculate the content of C_{37}H_{48}N_{6}O_{5}S_{2}.

**Storage.** Store protected from light.

**Ritonavir Capsules**

Ritonavir Capsules contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of ritonavir C_{37}H_{48}N_{6}O_{5}S_{2}.

**Identification**

A. In the test for Assay, the principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

B. When examined in the range 200 nm to 350 nm (2.4.7), a 0.001 per cent w/v solution in methanol shows absorption maxima at the same wavelengths as the reference solution.

**Tests**

**Dissolution** (2.5.2).

Apparatus. No 1

Medium. 900 ml of 0.1 M hydrochloric acid with 25 mM polyoxyethylene 10 lauryl ether prepared by dissolving 15.65 g of polyoxyethylene 10 lauryl ether in 950 ml of water. Add 8.5 ml of hydrochloric acid and dilute to 1000 ml with water.

Speed and time. 50 rpm and 90 minutes.

Withdraw a suitable volume of the medium and filter. Determine by liquid chromatography (2.4.14).

Test solution. Use the filtrate and if necessary, dilute with the dissolution medium.

Reference solution. A 0.1 per cent w/v solution of ritonavir RS in methanol. Dilute 5 ml of the solution to 50 ml with the dissolution medium.

Use the chromatographic system described under Assay. Inject the test solution and the reference solution. Calculate the content of C_{37}H_{48}N_{6}O_{5}S_{2}.

D. Not less than 70 per cent of the stated amount of C_{37}H_{48}N_{6}O_{5}S_{2}.
**Related substances.** Determine by liquid chromatography (2.4.14).

*Solvent mixture.* 40 volumes of 0.03M monobasic potassium phosphate buffer and 60 volumes of acetonitrile.

*Test solution.* Weigh accurately a quantity of the mixed contents of 20 capsules containing about 25 mg of Ritonavir, dissolve in 50 ml of the solvent mixture and filter.

*Reference solution (a).* A 0.05 per cent w/v solution of ritonavir RS in the solvent mixture.

*Reference solution (b).* Dilute 1 ml of the solution to 100 ml with the solvent mixture.

**Chromatographic system**
- a stainless steel column 15 cm x 4.6 mm, packed with butyl silane chemically bonded to porous silica (3 µm) (such as ACE C4),
- mobile phase: A. a mixture of 69 volumes of 0.03M monobasic potassium phosphate buffer prepared by dissolving 4.1 g of monobasic potassium phosphate in 1000 ml of water, 18 volumes of acetonitrile, 8 volumes of tetrahydrofuran and 5 volumes of n-butanol and filtering,
- B. a mixture of 40 volumes of 0.03M monobasic potassium phosphate buffer, 47 volumes of acetonitrile, 8 volumes of tetrahydrofuran and 5 volumes of n-butanol,
- flow rate. 1 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 240 nm,
- a 50 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>mobile phase A (per cent v/v)</th>
<th>mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>60</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>120</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>155</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Inject the reference solution (a). The test is not valid unless the tailing factor is not more than 2.0 and the column efficiency in not less than 5000 theoretical plates.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 2.5 times the area of the peak in the chromatogram obtained with the reference solution (b) (2.5 per cent) and the sum of areas of all the secondary peaks is not more than 5 times the area of the peak in the chromatogram obtained with the reference solution (b) (5.0 per cent).

**Other tests.** Comply with the tests stated under Capsules.

---

**Assay.** Determine by liquid chromatography (2.4.14).

*Test solution.* Weigh accurately a quantity of the mixed contents of 20 capsules containing about 25 mg of Ritonavir, disperse in 100.0 ml of methanol and filter.

*Reference solution. A 0.025 per cent w/v solution of ritonavir RS in methanol.*

**Chromatographic system**
- a stainless steel column 5 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (3.5 µm),
- column temperature 45º,
- mobile phase: a mixture of 55 volumes of a buffer solution prepared by dissolving 3.4 g of sodium acetate trihydrate and 0.94 g of sodium 1-hexanesulphonate in 1000 ml of water and adjusting the pH to 4.0 with hydrochloric acid, and 45 volumes of acetonitrile,
- flow rate. 2.5 ml per minute,
- spectrophotometer set at 240 nm,
- a 10 µl loop injector.

Inject the reference solution. Run the chromatogram 1.5 times the retention time (about 3 minutes)of the principal peak The test is not valid unless the tailing factor is not more than 2.0, the column efficiency in not less than 2000 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C_{37}H_{48}N_{6}O_{5}S_{2} in the capsules.

**Storage.** Store protected from light in a refrigerator (2º to 8º).

---

**Ritonavir Tablets**

Ritonavir Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of ritonavir, C_{37}H_{48}N_{6}O_{5}S_{2}.

**Identification**

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the principal peak in the chromatogram obtained with the reference solution.

**Tests**

**Dissolution** (2.5.2)

Apparatus. No 1 Medium. 900 ml of 0.1 M hydrochloric acid.

Speed and time. 100 rpm and 60 minutes.

Withdraw a suitable volume of the medium and filter.

Determine by liquid chromatography (2.4.14)
**Test solution.** The filtrate obtained as given above. Dilute the filtrate if necessary, with the dissolution medium.

**Reference solution.** A 0.1 per cent w/v solution of ritonavir RS in methanol. Dilute 5 ml of the solution to 50 ml with the dissolution medium.

Use the chromatographic system described under Assay.

Inject the reference solution. The test is not valid unless the tailing factor not more than 2.0 and the relative standard deviation of replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C\textsubscript{37}H\textsubscript{48}N\textsubscript{6}O\textsubscript{5}S\textsubscript{2}.

D. Not less than 75 per cent of the stated amount of C\textsubscript{37}H\textsubscript{48}N\textsubscript{6}O\textsubscript{5}S\textsubscript{2}

**Related substances.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** A mixture of 40 volumes of 0.03 M monobasic potassium phosphate and 60 volumes of acetonitrile.

**Test solution:** Shake a quantity of the powdered tablets containing 25 mg of Ritonavir with 50 ml of the solvent mixture.

**Reference solution (a).** A 0.05 per cent w/v solution of ritonavir RS in the solvent mixture.

**Reference solution (b).** Dilute 1 ml of reference solution (a) to 100 ml with the solvent mixture.

Chromatographic system

- a stainless steel column 15 cm x 4.6 mm, packed with silica gel consisting of porous spherical particles with chemically bonded with nitrile group (3µm) (such as YMCC4),
- mobile phase: A. a mixture of 69 volumes of 0.03 M monobasic potassium phosphate solution, 18 volumes of acetonitrile, 8 volumes of tetrahydrofuran and 5 volumes of n-butanol,
- B. a mixture of 40 volumes of 0.03 M monobasic potassium phosphate solution, 47 volumes of acetonitrile, 8 volumes of tetrahydrofuran and 5 volumes of n-butanol,
- flow rate. 1 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 240 nm,
- a 10 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>60</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>120</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>121</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>155</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Inject reference solution (a). The test is not valid unless the column efficiency is not less than 2000 theoretical plates and the tailing factor is not more than 2.0.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 2.5 times the area of the peak in the chromatogram obtained with the reference solution (b) (2.5 per cent) and the sum of areas of all the secondary peaks is not more than 5 times the area of the peak in the chromatogram obtained with the reference solution (b) (5.0 per cent).

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Determine by liquid chromatography (2.4.14)

**Test solution.** Weigh accurately a quantity of the powdered tablets containing 25 mg of Ritonavir and disperse in 100.0 ml of methanol.

**Reference solution.** A 0.025 per cent w/v solution of ritonavir RS in methanol.

Chromatographic system

- a stainless steel column 5 cm x 4.6 mm, packed with phenyl stationary phase bonded to porous silica (3µm),
- column temperature 45º,
- mobile phase: a mixture of 55 volumes of a buffer solution prepared by dissolving 3.4 g of sodium acetate trihydrate and 0.94 g of sodium 1-hexane sulphonate to 1000 ml with water and adjusting the pH to 4.0 with dilute hydrochloric acid, and 45 volumes of acetonitrile,
- flow rate. 2.5 ml per minute,
- spectrophotometer set at 239 nm,
- a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C\textsubscript{37}H\textsubscript{48}N\textsubscript{6}O\textsubscript{5}S\textsubscript{2} in the tablets.

**Storage.** Store protected from moisture, at a temperature not exceeding 30º.

Rosiglitazone Maleate

- [Chemical structure image]
- C\textsubscript{18}H\textsubscript{19}N\textsubscript{3}O\textsubscript{3}S, Mol. Wt. 473.5
- Rosiglitazone Maleate is (+)-5-{p-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedione maleate (1:1).
Rosiglitazone Maleate contains not less than 98.0 per cent and not more than 102.0 per cent of C_{18}H_{19}N_{3}O_{3}S, C_{4}H_{4}O_{4}, calculated on the anhydrous basis.

**Description.** A white to off-white crystalline powder.

**Identification**

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *rosiglitazone maleate RS*.

**Tests**

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 25 mg of the substance under examination in 50 ml of mobile phase.

**Reference solution (a).** A 0.05 per cent w/v solution of *rosiglitazone maleate RS* in the mobile phase.

**Reference solution (b).** Dilute 1 ml of reference solution (a) to 100 ml with mobile phase.

Chromatographic system as described under Assay.

Inject reference solution (a). The test is not valid unless the tailing factor is not more than 2.0 and the column efficiency in not less than 2000 theoretical plates.

Inject the test solution and reference solution (b). The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

**Heavy metals** (2.3.13). 1 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Water** (2.3.43). Not more than 0.5 per cent, determined on 1.0 g.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 20 mg of the substance under examination in 100.0 ml of mobile phase.

**Reference solution.** A 0.020 per cent w/v solution of *rosiglitazone maleate RS* in mobile phase.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 65 volumes of *buffer solution* prepared by dissolving 1.36 g of *potassium dihydrogen orthophosphat* e in 1000 ml of *water* and adjust the pH to 3.0 with *dilute phosphoric acid*, 25 volumes of *acetonitrile* and 10 volumes of *methanol*,
  - flow rate. 1 ml per minute,
  - spectrophotometer set at 235 nm,
  - a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution. Calculate the content of C_{18}H_{19}N_{3}O_{3}S, C_{4}H_{4}O_{4}.

**Storage.** Store protected from light.

**Rosiglitazone Tablets**

Rosiglitazone Maleate Tablets

Rosiglitazone Tablets contain Rosiglitazone Maleate. Rosiglitazone Tablets contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of rosiglitazone, C_{18}H_{19}N_{3}O_{3}S.

**Identification**

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Dissolution** (2.5.2).

Apparatus. No 1

Medium. 900 ml of *0.1 M hydrochloric acid*.

Speed and time. 75 rpm for 30 minutes.

Withdraw a suitable volume of the medium and filter promptly through a membrane filter disc having an average pore diameter not greater than 1.0 µm, rejecting the first 1 ml of the filtrate. Dilute the filtrate, if necessary, with the same solvent. Measure the absorbance of the resulting solution at the maximum at about 318 nm (2.4.7). Similarly measure the absorbance of a standard solution of known concentration of *rosiglitazone maleate RS* and calculate the content of C_{18}H_{19}N_{3}O_{3}S.

D. Not less than 70 per cent of the stated amount of C_{18}H_{19}N_{3}O_{3}S.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh accurately a quantity of powdered tablets containing 200 mg of Rosiglitazone, disperse in 100.0 ml of mobile phase. Centrifuge and use clear supernatant liquid.
Reference solution (a). A 0.2 per cent w/v solution of rosiglitazone maleate RS in the mobile phase.

Reference solution (b). Dilute 1 ml of reference solution (a) to 100 ml with mobile phase.

Chromatographic system as described under Assay.

Inject reference solution (a). The test is not valid unless the tailing factor is not more than 2.0 and the column efficiency in not less than 2000 theoretical plates.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than the area of the peak in the chromatogram obtained with reference solution (b) (1.0 per cent) and the sum of areas of all the secondary peaks is not more than twice the area of the peak in the chromatogram obtained with the reference solution (b) (2.0 per cent).

Uniformity of content. Comply with the tests stated under Tablets.

Disperse 1 tablet in 0.1 M hydrochloric acid to produce 0.004 per cent w/v solution. Measure the absorbance of the resulting solution at the maximum at about 318 nm (2.4.7). Calculate the content of C18H19N3O3S from the absorbance obtained from same concentration of rosiglitazone maleate RS in the same medium.

Other tests. Comply with the tests stated under Capsules.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh and powder 20 tablets. Weigh accurately a quantity of powdered tablets containing 20 mg of Rosiglitazone, disperse in 100.0 ml of mobile phase. Centrifuge and use clear supernatant liquid.

Reference solution. A 0.020 per cent w/v solution of rosiglitazone maleate RS in mobile phase.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecysilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 65 volumes of 0.01 M potassium hydrogen phosphate adjusted to pH 3.0 with orthophosphoric acid, 25 volumes of acetonitrile and 10 volumes of methanol,
- flow rate. 1 ml per minute,
- spectrophotometer set at 235 nm,
- a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency in not less than 4000 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C18H19N3O3S.

Storage. Store protected from light and moisture.
flow rate. 1 ml per minute,
spectrophotometer set at 248 nm,
a 20 µl loop injector.

Inject reference solution (a). The test is not valid unless the
tailing factor is not more than 2.0 and the column efficiency in
not less than 2000 theoretical plates.

Inject the test solution and reference solution (b). In the
chromatogram obtained with the test solution, the area of any
secondary peak is not more than 0.5 times the area of the peak
in the chromatogram obtained with reference solution (b) (0.5
per cent) and the sum of areas of all the secondary peaks is
not more than twice the area of the peak in the chromatogram
obtained with the reference solution (b) (2.0 per cent).

Water (2.3.43). Not more than 8.0 per cent, determined on
0.3 g.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 50 mg of the substance under
examination in 100.0 ml of mobile phase. Dilute 5.0 ml of the
solution to 25.0 ml with mobile phase, mix and filter.

Reference solution. A 0.05 per cent w/v of
rosuvastatin calcium RS in mobile phase. Dilute 5.0 ml of the
solution to 25.0 ml with mobile phase.

Chromatographic system
a stainless steel column 25 cm x 4.6 mm packed with
octadecylsilane bonded to porous silica (5 µm),
mobile phase: a mixture of 50 volumes of 0.2 per cent
acetic acid in water, 25 volumes of acetonitrile and
25 volumes of methanol, filter and degas.
flow rate. 1 ml per minute,
spectrophotometer set at 248 nm,
a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the
relative standard deviation for replicate injections is not more
than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C₂₂H₂₇FN₃O₆S.Ca.

Storage. Store protected from light and moisture.

Identification
In the Assay, the principal peak in the chromatogram obtained
with the test solution corresponds to the peak in the
chromatogram obtained with the reference solution.

Tests
Dissolution (2.5.2).
Apparatus. No 1
Medium. 900 ml of phosphate buffer pH 6.8,
Speed and time. 50 rpm for 30 minutes.
Withdraw a suitable volume of the medium and filter.
Determine by liquid chromatography (2.4.14).

Test solution. The filtrate obtained as given above.

Reference solution. A 0.05 per cent w/v solution of
rosuvastatin calcium RS in the mobile phase. Dilute 2 ml of
the solution to 100 ml with Dissolution medium.

Chromatographic system as described under Assay.

Calculate the content of C₂₂H₂₇FN₃O₆S.Ca.

D. Not less than 70 per cent of the stated amount of
C₂₂H₂₇FN₃O₆S.Ca.

Uniformity of content. Comply with the tests stated under
Tablets.

Determine by liquid chromatography (2.4.14), as described
under Assay.

Test solution. Disperse one tablet in 100 ml of the mobile phase.
Dilute 5 ml of the solution to 10 ml with mobile phase and
filter.

Related substances. Determine by liquid chromatography
(2.4.14).

Test solution. Weigh and powder 20 tablets. Weigh accurately
a quantity of powdered tablet containing 25 mg of
Rosuvastatin, disperse in 50 ml of mobile phase and filter.

Reference solution (a). A 0.05 per cent w/v solution of
rosuvastatin calcium RS in the mobile phase.

Reference solution (b). Dilute 1 ml of reference solution (a) to
100 ml with mobile phase.

Chromatographic system as described under Assay.

Inject reference solution (a). The test is not valid unless the
tailing factor is not more than 2.0 and the column efficiency in
not less than 2000 theoretical plates.

Inject the test solution and reference solution (b). In the
chromatogram obtained with the test solution, the area of any
secondary peak is not more than 1.5 times the area of the peak
in the chromatogram obtained with reference solution (b) (1.5
per cent) and the sum of areas of all the secondary peaks is

Rosuvastatin Tablets
Rosuvastatin Tablets contain Rosuvastatin Calcium.
Rosuvastatin Tablets contain not less than 90.0 per cent and
not more than 110.0 per cent of the stated amount of
rosuvastatin calcium, C₂₂H₂₇FN₃O₆S.Ca.
not more than 3.0 times the area of the peak in the chromatogram obtained with the reference solution (b) (3.0 per cent).

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh and powder 20 tablets. Weigh accurately a quantity of powdered tablet containing 25 mg of Rosuvastatin, disperse in 100.0 ml of mobile phase. Dilute 5.0 ml of the solution to 25.0 ml with mobile phase and filter.

**Reference solution.** A 0.025 per cent w/v solution of rosuvastatin calcium RS in mobile phase. Dilute 5.0 ml of the solution to 25.0 ml with mobile phase.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- column temperature 30°,
- mobile phase: a mixture of 585 volumes of a buffer solution prepared by dissolving 1.54 g of ammonium acetate in 900 ml of water, adjust pH to 4.0 with glacial acetic acid and dilute to 1000 ml with water, 360 volumes of acetonitrile and 50 volumes of tetrahydrofurane,
- flow rate, 1.5 ml per minute,
- spectrophotometer set at 248 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the column efficiency is not less than 2000 theoretical plates, the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution. Calculate the content of C_{22}H_{27}FN_{3}O_{6}S.Ca.

**Storage.** Store protected from light and moisture.

**Labelling.** The label states the strength in terms of the equivalent amount of Rosuvastatin.

---

**Roxithromycin**


Roxithromycin contains not less than 96.0 per cent and not more than 102.0 per cent of C_{41}H_{76}N_{2}O_{15}, calculated on the anhydrous basis.

**Description.** A white, crystalline powder.

**Identification**
A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with roxithromycin RS.
B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with reference solution (a).

**Tests**

**Appearance of solution.** A 1.0 per cent w/v solution in methanol is clear (2.4.1) and colourless (2.4.1).

**Specific optical rotation** (2.4.22). – 93.0º to – 96.0º, determined in a 1.0 per cent w/v solution in acetone.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** Mix 30 volumes of acetonitrile and 70 volumes of a 4.8 per cent w/v solution of ammonium dihydrogen phosphate and adjust the pH to 5.3 with dilute sodium hydroxide solution.

**Test solution.** Dissolve 50.0 mg of the substance under examination in 25.0 ml of the solvent mixture.

**Reference solution (a).** A 0.2 per cent w/v solution of roxithromycin RS in the solvent mixture.

**Reference solution (b).** Dilute 1 ml of reference solution (a) to 100 ml with the solvent mixture.

**Reference solution (c).** Dissolve 2 mg of erythromycin 9-(E)-[O-[2-(methoxyethoxy)methoxy]methyl]oxime] (impurity A) in 10 ml of reference solution (a). Further dilute 1 ml of this solution to 10 ml with reference solution (a).

**Reference solution (d).** Dilute 1.0 ml of toluene to 100 ml with acetonitrile. Dilute 0.2 ml of this solution to 200 ml with the solvent mixture.

**Chromatographic system**
- a stainless steel column 15 cm x 4.6 mm, packed with spherical end-capped octadecylsilyl silica gel for
chromatography (5 µm), with a 10 nm pore size and a carbon loading of about 19 per cent,

– column temperature 15º,
– mobile phase: A. a mixture of 26 volumes of acetonitrile and 74 volumes of a 5.97 per cent w/v solution of ammonium dihydrogen phosphate, adjusted to pH 4.3 with dilute sodium hydroxide solution,

B. a mixture of 30 volumes of water and 70 volumes of acetonitrile,
– flow rate. 1.1 ml per minute,
– a linear gradient programme using the conditions given below,
– spectrophotometer set at 205 nm,
– a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>50</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>80</td>
<td>90</td>
<td>10</td>
</tr>
<tr>
<td>100</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Inject reference solution (c). Relative retention time between roxithromycin and erythromycin 9-(E)-[O-[(2-methoxyethoxy)methoxy][methyl]oxime] (impurity A) is about 1.15. The test is not valid unless the peak-to-valley ratio \( H_p / H_v \) is not more than 2.0, where \( H_p \) = height above the baseline of the peak due to impurity A and \( H_v \) = height above the baseline of the lowest point of the curve separating this peak from the peak due to roxithromycin.

Inject the test solution and reference solutions (b) and (d). In the chromatogram obtained with the test solution the area of the impurity A peak obtained immediately after the peak obtained with roxithromycin is not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent). The area of any other individual impurity peak is not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent). The sum of the areas of all the peaks is not more than 3 times the area of the principal peak in the chromatogram obtained with reference solution (b) (3.0 per cent). Ignore any peak with an area 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent). Ignore any peak due to toluene identified using reference solution (d).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Water** (2.3.43). Not more than 3.0 per cent, determined on 0.2 g.

**Assay.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** Mix 30 volumes of acetonitrile and 70 volumes of a 4.8 per cent w/v solution of ammonium dihydrogen phosphate and adjust the pH to 5.3 with dilute sodium hydroxide solution.

**Test solution.** Dissolve 50.0 mg of the substance under examination in 25.0 ml of the solvent mixture.

**Reference solution (a).** A 0.2 per cent w/v solution of roxithromycin RS in the solvent mixture.

**Reference solution (b).** Dissolve 2 mg of erythromycin 9-(E)-[O-[(2-methoxyethoxy)methoxy][methyl]oxime] (impurity A) in 10.0 ml of reference solution (a). Further dilute 1.0 ml of this solution to 10.0 ml with reference solution (a). Calculate the content of C14H26N2O15.

**Chromatographic system**

– a stainless steel column 15 cm x 4.6 mm, packed with spherical end-capped octadecylsilyl silica gel for chromatography (5 µm), with a 10 nm pore size and a carbon loading of about 19 per cent,
– column temperature 15º,
– mobile phase: mix 307 volumes of acetonitrile and 693 volumes of a 4.91 per cent w/v solution of ammonium dihydrogen phosphate adjusted to pH 5.3 with dilute sodium hydroxide solution,
– flow rate. 1.5 ml per minute,
– a linear gradient programme using the conditions given below,
– spectrophotometer set at 205 nm,
– a 20 µl loop injector.

Inject the test solution and reference solution (a) alternately. The test is not valid unless the peak-to-valley ratio \( H_p / H_v \) is not less than 1.5.

**Storage.** Store protected from light and moisture.

### Roxithromycin Tablets

Roxithromycin Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of roxithromycin, C41H76N2O15.

**Identification**

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.
Tests

Dissolution (2.5.2).

Apparatus No. 1

Medium. 900 ml of phosphate buffer pH 6.0.

Speed and time. 50 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter.

Determine by liquid chromatography (2.4.14) as given under the Assay using the following test solution.

Test solution. The filtrate obtained as given above.

Calculate the content of C₄₁H₇₆N₂O₁₅ in the medium.

D. Not less than 70 per cent of the stated amount of C₄₁H₇₆N₂O₁₅.

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).

Solvent mixture. Mix 30 volumes of acetonitrile and 70 volumes of a 4.8 per cent w/v solution of ammonium dihydrogen phosphate and adjust the pH to 5.3 with dilute sodium hydroxide solution.

Test solution. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.2 g of Roxithromycin, add 80 ml of the solvent mixture and mix. Dilute to 100.0 ml with the solvent mixture and filter.

Reference solution (a). A 0.2 per cent w/v solution ofroxithromycin RS in the solvent mixture.

Reference solution (b). Dissolve 2 mg of erythromycin 9-(E)-[O-[[2-methoxyethoxy)methoxy[methyl]oxime] (impurity A) in 10 ml of reference solution (a). Further dilute 1 ml of this solution to 10 ml with reference solution (a).

Chromatographic system

– a stainless steel column 15 cm x 4.6 mm, packed with spherical end-capped octadecylsilyl silica gel (5 µm), with a 10 nm pore size and a carbon loading of about 19 per cent,

– column temperature. 15º,

– mobile phase: mix 307 volumes of acetonitrile and 693 volumes of a 4.91 per cent w/v solution of ammonium dihydrogen phosphate adjusted to pH 5.3 with dilute sodium hydroxide solution,

– flow rate. 1.5 ml per minute,

– spectrophotometer set at 205 nm,

– a 20 µl loop injector.

Inject reference solution (b). The relative retention time between roxithromycin and erythromycin -(E)-[O-[[2-methoxyethoxy)methoxy[methyl]oxime] (impurity A) is about 1.15. The test is not valid unless the peak-to-valley ratio Hₚ/ Hᵥ is not more than 1.5, where Hₚ = height above the baseline of the peak due to impurity A and Hᵥ = height above the baseline of the lowest point of the curve separating this peak from the peak due to Roxithromycin.

Inject reference solution (a). The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and reference solution (a).

Calculate the content of C₄₁H₇₆N₂O₁₅ in the tablets.

Storage. Store protected from light and moisture.

Labelling. If the tablets are dispersible, the label states that the tablets should be dispersed in water immediately before use.
Saccharin ...
Saccharin Sodium ...
Salbutamol ...
Salbutamol Inhalation ...
Salbutamol Sulphate ...
Salbutamol Injection ...
Salbutamol Syrup ...
Salbutamol Tablets ...
Salicylic Acid ...
Salmeterol Xinafoate ...
Salmetrol and Fluticasone Propionate Inhalation ...
Salmetrol and Fluticasone Propionate powder for Inhalation ...
Saquinavir ...
Saquinavir Mesylate ...
Saquinavir Mesylate Tablets ...
Sechidazole ...
Sechidazole Tablets ...
Colloidal Silicon Dioxide ...
Silver Nitrate ...
Sodium Acetate ...
Sodium Alginate ...
Sodium Aminosalicylate ...
Sodium Aminosalicylate Tablets ...
Sodium Ascorbate ...
Sodium Aurothiomalate ...
Sodium Aurothiomalate Injection ...
Sodium Benzoate ...
Sodium Bicarbonate ...
Sodium Bicarbonate Injection ...
Sodium Carbonate ...
<table>
<thead>
<tr>
<th>Compound</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium Chloride</td>
</tr>
<tr>
<td>Sodium Chloride And Dextrose Injection</td>
</tr>
<tr>
<td>Sodium Chloride And Fructose Injection</td>
</tr>
<tr>
<td>Compound Sodium Chloride And Dextrose Injection</td>
</tr>
<tr>
<td>Sodium Chloride Hypertonic Injection</td>
</tr>
<tr>
<td>Sodium Chloride Injection</td>
</tr>
<tr>
<td>Compound Sodium Chloride Injection</td>
</tr>
<tr>
<td>Compound Sodium Chloride Solution</td>
</tr>
<tr>
<td>Sodium Chloride Irrigation Solution</td>
</tr>
<tr>
<td>Sodium Citrate</td>
</tr>
<tr>
<td>Sodium Cromoglycate</td>
</tr>
<tr>
<td>Sodium Cromoglycate Powder for Inhalation</td>
</tr>
<tr>
<td>Sodium Diatrizoate</td>
</tr>
<tr>
<td>Sodium Diatrizoate Injection</td>
</tr>
<tr>
<td>Sodium Dihydrogen Phosphate Dihydrate</td>
</tr>
<tr>
<td>Sodium Fluoride</td>
</tr>
<tr>
<td>Sodium Formaldehyde Sulphoxylate</td>
</tr>
<tr>
<td>Sodium Fusidate</td>
</tr>
<tr>
<td>Sodium Fusidate Capsules</td>
</tr>
<tr>
<td>Sodium Hydroxide</td>
</tr>
<tr>
<td>Sodium Lactate Injection</td>
</tr>
<tr>
<td>Compound Sodium Lactate And Dextrose Injection</td>
</tr>
<tr>
<td>Half Strength Compound Sodium Lactate And Dextrose Injection</td>
</tr>
<tr>
<td>Modified Compound Sodium Lactate And Dextrose Injection</td>
</tr>
<tr>
<td>Compound Sodium Lactate Injection</td>
</tr>
<tr>
<td>Compound Sodium Lactate Solution For Irrigation</td>
</tr>
<tr>
<td>Sodium Lauryl Sulphate</td>
</tr>
<tr>
<td>Sodium Metabisulphite</td>
</tr>
<tr>
<td>Sodium Methylparaben</td>
</tr>
<tr>
<td>Sodium Phosphate</td>
</tr>
<tr>
<td>Sodium Phosphite</td>
</tr>
<tr>
<td>Sodium Propylparaben</td>
</tr>
<tr>
<td>Sodium Salicylate</td>
</tr>
<tr>
<td>Sodium Starch Glycollate</td>
</tr>
</tbody>
</table>
Sodium Stibogluconate
Sodium Stibogluconate Injection
Sodium Thiosulphate
Sodium Thiosulphate Injection
Sodium Valproate
Sodium Valproate Oral Solution
Sodium Valproate Tablets
Sorbic Acid
Sorbitol
Sorbitol Solution (70 Per Cent) (Crystallising)
Sorbitol Solution (70 Per Cent) (Non-Crystallising)
Spironolactone
Spironolactone Tablets
Stavudine
Stavudine Capsules
Stavudine Oral Solution
Stavudine And Lamivudine Tablets
Stearic Acid
Stearyl Alcohol
Stilboestrol
Stilboestrol Tablets
Prepared Storax
Streptokinase
Streptokinase Injection
Streptomycin Sulphate
Streptomycin Injection
Streptomycin Tablets
Succinylcholine Chloride
Succinylcholine Injection
Sucrose
Sulphacetamide Sodium
Sulphacetamide Eye Drops
Sulphadiazine
<table>
<thead>
<tr>
<th>Medicine</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sulphadiazine Tablets</td>
<td></td>
</tr>
<tr>
<td>Sulphadimethoxine</td>
<td></td>
</tr>
<tr>
<td>Sulphadimethoxine Tablets</td>
<td></td>
</tr>
<tr>
<td>Sulphadimidine</td>
<td></td>
</tr>
<tr>
<td>Sulphadimidine Sodium</td>
<td></td>
</tr>
<tr>
<td>Sulphadimidine Injection</td>
<td></td>
</tr>
<tr>
<td>Sulphadimidine Tablets</td>
<td></td>
</tr>
<tr>
<td>Sulphadoxine</td>
<td></td>
</tr>
<tr>
<td>Sulphafurazole</td>
<td></td>
</tr>
<tr>
<td>Sulphafurazole Tablets</td>
<td></td>
</tr>
<tr>
<td>Sulphalene</td>
<td></td>
</tr>
<tr>
<td>Sulphamethizole</td>
<td></td>
</tr>
<tr>
<td>Sulphamethoxazole</td>
<td></td>
</tr>
<tr>
<td>Sulphaphenazole</td>
<td></td>
</tr>
<tr>
<td>Sulphaphenazole Tablets</td>
<td></td>
</tr>
<tr>
<td>Sulphobromophthalein Sodium</td>
<td></td>
</tr>
<tr>
<td>Sulphobromophthalein Sodium Injection</td>
<td></td>
</tr>
</tbody>
</table>
Saccharin

\[
\text{C}_7\text{H}_5\text{NO}_3\text{S} \quad \text{Mol. Wt. 183.2}
\]

Saccharin is 1,2-benzisothiazol-3(2\(H\))-one 1,1-dioxide. Saccharin contains not less than 98.0 per cent and not more than 101.0 per cent of \(\text{C}_7\text{H}_5\text{NO}_3\text{S}\), calculated on the dried basis.

**Description.** White crystals or a white, crystalline powder; odourless or with a faint, aromatic odour.

**Identification**

*Test A* may be omitted if tests *B, C* and *D* are carried out. Tests *B, C* and *D* may be omitted if test *A* is carried out.

**A.** Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with saccharin RS.

**B.** Mix 20 mg with 20 mg of resorcinol, add 0.5 ml of sulphuric acid and heat over a small flame until a dark green colour is produced; allow to cool and add 10 ml of water and an excess of 2 M sodium hydroxide; a fluorescent green liquid is produced.

**C.** Dissolve 0.1 g in 5 ml of a 10 per cent w/v solution of sodium hydroxide, evaporate to dryness and gently fuse the residue over a small flame until ammonia is no longer evolved. Allow to cool, dissolve in 20 ml of water, make the solution just acidic to litmus paper, filter and add 0.05 ml of ferric chloride solution; a violet colour is produced.

**D.** A saturated solution is acidic to litmus paper.

**Tests**

**Appearance of solution.** Dissolve 5.0 g in 20 ml of a 20 per cent w/v solution of sodium acetate and dilute to 25 ml with the same solution; the solution is clear (2.4.1), and colourless (2.4.1).

**Related substances.** Determine by gas chromatography (2.4.13).

**Internal standard solution.** Dissolve 25 mg of caffeine in dichloromethane and dilute to 100 ml with the same solvent.

**Test solution.** Suspend 10.0 g of the substance under examination in 20 ml of water and dissolve using about 5 ml of strong sodium hydroxide solution. If necessary, adjust the pH of the solution to 7.8 with 1 M sodium hydroxide or 1 M hydrochloric acid and dilute to 50 ml with water. Shake the solution with 4 quantities, each of 50 ml, of dichloromethane.

Combine the lower layers, dry over anhydrous sodium sulphate and filter. Wash the filter and the sodium sulphate with 10 ml of dichloromethane. Combine the solution and the washings and evaporate almost to dryness in a water-bath at a temperature not exceeding 40°. With a small quantity of dichloromethane transfer quantitatively the residue into a suitable 10-ml tube, evaporate to dryness in a current of nitrogen and dissolve the residue in 1.0 ml of the internal standard solution.

**Blank solution.** Evaporate 200 ml of dichloromethane to dryness in a water-bath at a temperature not exceeding 40°. Dissolve the residue in 1 ml of dichloromethane.

**Reference solution.** Dissolve 20 mg of o-toluenesulphonamide and 20 mg of p-toluene sulphonamide in dichloromethane and dilute to 100 ml with the same solvent. Dilute 5 ml of the solution to 50 ml with dichloromethane. Evaporate 5 ml of the final solution to dryness in a current of nitrogen. Dissolve the residue in 1 ml of the internal standard solution.

**Chromatographic system**

- a fused silica column 10 m x 0.53 mm packed with polymethylphenylsiloxane (film thickness 2 µm),
- temperature: column.180°, inlet port and detector. 250°,
- flame ionization detector,
- flow rate. 10 ml per minute of nitrogen (carrier gas),
- split ratio. 1:2.

Inject 1 µl of each solution. The order of elution is o-toluenesulphonamide, p-toluene sulphonamide, caffeine. The test is not valid unless the resolution between the peaks due to o-toluenesulphonamide and p-toluene sulphonamide in the chromatogram obtained with the reference solution is not less than 1.5 and the chromatogram obtained with the blank solution does not show any peak with the same retention times as the internal standard, o-toluenesulphonamide and p-toluene sulphonamide.

In the chromatogram obtained with the test solution the ratio of the area of the peak due to o-toluenesulphonamide to that of the internal standard is not greater than the corresponding ratio in the chromatogram obtained with the reference solution (10 ppm).

In the chromatogram obtained with the test solution the ratio of the area of the peak due to p-toluene sulphonamide to that of the internal standard is not greater than the corresponding ratio in the chromatogram obtained with the reference solution (10 ppm).

**Arsenic** (2.3.10). Mix 5.0 g with 3.0 g of anhydrous sodium carbonate, add 10 ml of bromine solution and mix thoroughly. Evaporate to dryness on a water-bath, gently ignite and add to the cooled residue a mixture of 16 ml of brominated...
hydrochloric acid AsT and 5 ml of bromine solution. Add 40 ml of water and boil gently, adding sufficient bromine solution from time to time to maintain a slight excess. Filter and remove the excess of bromine with a sufficient quantity of stannous chloride solution AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

**Heavy metals** (2.3.13). 1.2 g complies with the limit test for heavy metals, Method D (20 ppm). Use lead standard solution (2 ppm Pb).

**Readily carbonisable substances.** Dissolve 0.2 g in 5 ml of sulphuric acid (96 per cent w/w) and maintain at about 50º for 10 minutes. The solution is not more intensely coloured than reference solution BYS6 (2.4.1).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105º for 4 hours.

**Assay.** Weigh accurately about 0.5 g, dissolve in 75 ml of hot water; cool quickly and titrate with 0.1 M sodium hydroxide using phenolphthalein solution as indicator.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.01832 g of C7H5NO3S.

**Storage.** Store protected from moisture.

### Saccharin Sodium

**Soluble Saccharin**

\[
\text{C}_7\text{H}_4\text{NNaO}_3\text{S} \quad \text{Mol. Wt. 205.2}
\]

Saccharin Sodium is the sodium salt of 1,2-benzisothiazol-3(2H)-3-one, 1,1-dioxide.

Saccharin Sodium contains not less than 99.0 per cent and not more than 101.0 per cent of C7H4NNaO3S, calculated on the anhydrous basis.

**Description.** A white, crystalline powder or colourless crystals; efflorescent in dry air.

**Identification**

Test A may be omitted if tests B, C, D and E are carried out. Tests B, C and D may be omitted if tests A and E are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with saccharin sodium RS.

B. Dissolve 0.1 g in 5 ml of a 10 per cent w/v solution of sodium hydroxide, evaporate to dryness and gently fuse the residue over a small flame until ammonia is no longer evolved. Allow to cool, dissolve in 20 ml of water, make the solution just acidic to litmus paper, filter and add 0.05 ml of ferric chloride solution; a violet colour is produced.

C. Mix 20 mg with 20 mg of resorcinol, add 0.5 ml of sulphuric acid and heat over a small flame until a dark green colour is produced; allow to cool and add 10 ml of water and an excess of 2 M sodium hydroxide; a fluorescent green liquid is produced.

D. To 5 ml of a 10 per cent w/v solution add 3 ml of 2 M hydrochloric acid; a white precipitate is produced. The precipitate, after washing with water and drying at 105º melts at 226º to 230º (2.4.21).

E. 0.5 ml of a 10 per cent w/v solution gives reaction B of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** Solution A is clear (2.4.1), and colourless (2.4.1).

**Acidity or alkalinity.** Dissolve 5.0 g in sufficient carbon dioxide-free water to produce 50 ml (solution A). To 10 ml of solution A add 10 ml of 0.005 M sulphuric acid, heat to boiling, cool and add 0.1 ml of phenolphthalein solution. Not less than 4.5 ml and not more than 5.5 ml of 0.01 M sodium hydroxide is required to change the colour of the solution to pink.

**Related substances.** Determine by gas chromatography (2.4.13).

**Internal standard solution.** Dissolve 25 mg of caffeine in dichloromethane and dilute to 100 ml with the same solvent.

**Test solution.** Suspend 10.0 g of the substance under examination in 50 ml of water. If necessary, adjust the pH of the solution to 7.8 with 1 M sodium hydroxide or 1 M hydrochloric acid and dilute to 50 ml with water. Shake the solution with 4 quantities, each of 50 ml, of dichloromethane. Combine the lower layers, dry over anhydrous sodium sulphate and filter. Wash the filter and the sodium sulphate with 10 ml of dichloromethane. Combine the solution and the washings and evaporate almost to dryness in a water-bath at a temperature not exceeding 40º. With a small quantity of dichloromethane transfer quantitatively the residue into a suitable 10-ml tube, evaporate to dryness in a current of nitrogen and dissolve the residue in 1.0 ml of the internal standard solution.
Blank solution. Evaporate 200 ml of dichloromethane to dryness in a water-bath at a temperature not exceeding 40º. Dissolve the residue in 1 ml of dichloromethane.

Reference solution. Dissolve 20 mg of o-toluenesulphonamide and 20 mg of p-toluene sulphonamide in dichloromethane and dilute to 100 ml with the same solvent. Dilute 5 ml of this solution to 50 ml with dichloromethane. Evaporate 5 ml of the final solution to dryness in a current of nitrogen. Dissolve the residue in 1 ml of the internal standard solution.

Chromatographic system
- a fused silica column 10 m x 0.53 mm packed with polymethylphenylsiloxane (film thickness 2 µm),
- temperature: column, 180°, inlet port and detector, 250°, flame ionization detector,
- flow rate, 10 ml per minute of nitrogen (carrier gas),
- split ratio: 1:2.

Inject 1 µl of each solution. The order of elution is o-toluenesulphonamide, p-toluene sulphonamide, caffeine.

The test is not valid unless the resolution between the peaks due to o-toluene sulphonamide and p-toluene sulphonamide in the chromatogram obtained with the reference solution is not less than 1.5 and the chromatogram obtained with the blank solution does not show any peak with the same retention times as the internal standard, o-toluene sulphonamide and p-toluene sulphonamide.

In the chromatogram obtained with the test solution the ratio of the area of the peak due to o-toluene sulphonamide to that of the internal standard is not greater than the corresponding ratio in the chromatogram obtained with the reference solution (10 ppm).

In the chromatogram obtained with the test solution the ratio of the area of the peak due to p-toluene sulphonamide to that of the internal standard is not greater than the corresponding ratio in the chromatogram obtained with the reference solution (10 ppm).

Arsenic (2.3.10). Mix 5.0 g with 3 g of anhydrous sodium carbonate, add 10 ml of bromine solution and mix thoroughly. Evaporate to dryness on a water-bath, gently ignite and add to the cooled residue a mixture of 16 ml of brominated hydrochloric acid AsT and 5 ml of bromine solution. Add 40 ml of water and boil gently, adding sufficient bromine solution from time to time to maintain a slight excess. Filter and remove the excess of bromine with a sufficient quantity of stannous chloride solution AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

Readily carbonisable substances. Dissolve 0.2 g in 5 ml of sulphuric acid (96 per cent w/w) and maintain at about 50º for 10 minutes. The solution is not more intensely coloured than reference solution BS6 (2.4.1).

Heavy metals (2.3.13). 12 ml of solution A complies with the limit test for heavy metals, Method D (20 ppm). Use lead standard solution (2 ppm Pb).

Water (2.3.43). Not more than 15.0 per cent, determined on 0.2 g.

Assay. Weigh accurately about 0.15 g, dissolve in 50 ml of anhydrous glacial acetic acid, with slight heating if necessary. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02052 g of C13H21NO3S.

Storage. Store protected from moisture.

Salbutamol
Albuterol

\[
\text{C}_{13}\text{H}_{21}\text{NO}_3
\]
Mol. Wt. 239.3

Salbutamol is (RS)-1-(4-hydroxy-3-hydroxymethylphenyl)-2-(tert-butylamino)ethanol.

Salbutamol contains not less than 98.0 per cent and not more than 101.0 per cent of C13H21NO3, calculated on the dried basis.

Description. A white or almost white, crystalline powder.

Identification
Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6), compare the spectrum with that obtained with salbutamol RS or with the reference spectrum of salbutamol.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.008 per cent w/v solution in 0.1 M hydrogenchloric acid shows an absorption maximum only at about 276 nm; absorbance at about 276 nm, about 0.53 to 0.60.

C. In the test for Related substances, the principal spot in the chromatogram obtained with reference solution (a) corresponds to that in the chromatogram obtained with reference solution (b).
D. Dissolve 10 mg in 50 ml of a 2 per cent w/v solution of 
*borax*, add 1 ml of a 3 per cent w/v solution of 
4-aminophenazone, 10 ml of a 2 per cent w/v solution of 
kaliun ferricyanide and 10 ml of chloroform, shake and 
allow to separate; an orange-red colour is produced in the 
chloroform layer.

Tests

**Appearance of solution.** A 2.0 per cent w/v solution in methanol 
is clear (2.4.1), and not more intensely coloured than reference 
solution BYS5 (2.4.1).

**Related substances.** Determine by thin-layer chromatography 
(2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 50 volumes of ethyl acetate, 
30 volumes of 2-propanol, 16 volumes of water and 4 volumes of 
strong ammonia solution.

**Test solution.** Dissolve 0.2 g of the substance under 
examination in 10 ml of methanol.

**Reference solution (a).** A 0.01 per cent w/v solution of the 
substance under examination in methanol.

**Reference solution (b).** A 0.01 per cent w/v solution of 
salbutamol RS in methanol.

Apply to the plate 5 µl of each solution. After development, 
dry the plate in air until the odour of the solvent is no longer 
detectable, place it for a few minutes in an atmosphere saturated 
with diethylamine and spray with diazotised sulphanilic acid 
solution. Any secondary spot in the chromatogram obtained 
with the test solution is not more intense than the spot in the 
chromatogram obtained with reference solution (a).

**Boron.** To 50 mg add 5 ml of a solution containing 1.3 per 
cent w/v of anhydrous sodium carbonate and 1.7 per cent w/v of 
kaliun carbonate, evaporate to dryness on a water-bath and 
dry at 120º. Ignite the residue rapidly until the organic 
matter has been destroyed, allow to cool, add 0.5 ml of water 
and 3.0 ml of a freshly prepared 0.125 per cent w/v solution of 
curcumin in glacial acetic acid. Evaporate to dryness and 
allow to cool. Add 3 ml of a mixture prepared by adding 5 ml of 
sulphuric acid, slowly and with stirring, to 5 ml of glacial 
acetic acid. Mix and allow to stand for 30 minutes. Add 
sufficient ethanol (95 per cent) to produce 100.0 ml, filter and 
measure the absorbance of the filtrate at 555 nm (2.4.7). Prepare 
a reference solution in the following manner. Dissolve 0.572 g 
of boric acid in 1000.0 ml of water. Dilute 1.0 ml to 100.0 ml with 
water. To 2.5 ml of this solution add 5 ml of a solution 
containing 1.3 per cent w/v of anhydrous sodium carbonate 
and 1.7 per cent w/v of potassium carbonate and treat this 
mixture in the same manner as described above beginning at 
the words “Evaporate to dryness…”. The absorbance of the 
solution prepared from the substance under examination is 
not more than that of the reference solution (50 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined 
on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.2 g, dissolve in 30 ml of 
anhydrous glacial acetic acid. Titrate with 0.1 M perchloric 
acid, determining the end-point potentiometrically (2.4.25). 
Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02393 g of 
C₁₃H₁₇NO₃.

**Storage.** Store protected from light.

Salbutamol Inhalation

Salbutamol Inhalation Aerosol; Albuterol Inhalation 
Aerosol

Salbutamol Inhalation is a suspension of microfine Salbutamol 
or Salbutamol Sulphate in a suitable liquid in a suitable 
pressurised container. It may contain suitable pharmaceutical 
 aids such as surfactants, stabilising agents etc.

Salbutamol Inhalation delivers not less than 80.0 per cent and 
not more than 120.0 per cent of the stated amount of 
salbutamol, C₁₃H₁₇NO₃, per inhalation, by actuation of the valve.

**Identification**

A. Discharge the container a sufficient number of times into a 
mortar to obtain about 2 mg of salbutamol, grind the residue 
thoroughly with 0.1 g of potassium bromide, add a further 0.2 
g of potassium bromide and mix thoroughly.

On the resultant dispersion determine by infrared absorption 
spectrophotometry (2.4.6). Compare the spectrum with that 
obtained with salbutamol RS or with the reference spectrum of 
salbutamol.

B. In the test for Related substances, the principal spot in the 
chromatogram obtained with reference solution (a) 
corresponds to that in the chromatogram obtained with 
reference solution (b).

**Tests**

**Related substances.** Determine by thin-layer chromatography 
(2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 50 volumes of ethyl acetate, 
30 volumes of 2-propanol, 16 volumes of water and 4 volumes of 
strong ammonia solution.

**Test solution.** Discharge the inhaler a sufficient number of 
times into a small, dry beaker to obtain 10 mg of Salbutamol 
dissolve the residue in 0.5 ml of methanol.
Calculate the amount of C\(_{13}\)H\(_{21}\)NO\(_3\) delivered per actuation of
RS suitable quantity of a 0.001 per cent w/v solution of
absorbance any spot with an R\(_f\) value higher than 0.85.
chromatogram obtained with reference solution (a). Ignore
with the test solution is not more intense than the spot in the
salbutamol RS
Use 30 ml of
(Pressurised metered-dose Preparations).
delivered per actuation stated under Inhalation Preparations
sulphate solution
and 30 ml of a mixture of equal volumes of
solution in a separating funnel add 180 ml of
solution containing 10 µg of salbutamol per ml. To 20 ml of the
a suitable volume of this solution with
the final solution and washings to 200.0 ml with
salbutamol sulphate and dilute the final solution and washings to 200.0 ml with
ethanol. Dilute a suitable volume of this solution with
ethanol to produce a solution containing 10 µg of salbutamol per ml. To 20 ml of the
in the following order, 4 ml of N,N-dimethyl-4-phenylenediamine
sulphate solution and 4 ml of a freshly prepared 8 per cent w/v solution of
potassium ferricyanide. Mix, allow to stand for
15 minutes in subdued light and extract with two quantities, each of 10 ml, of
chloroform. Filter the extracts through a plug
cotton wool, dilute to 25 ml with
chloroform and measure the absorbance of the resulting solution at 605 nm (2.4.7).
Calculate the content of C\(_{13}\)H\(_{21}\)NO\(_3\) in the solution from the
absorbance measured. When the active ingredient is Salbutamol Sulphate, the
quantity is stated in terms of the equivalent amount of salbutamol.

**Salbutamol Sulphate**

Albuterol Sulphate
(C\(_{13}\)H\(_{21}\)NO\(_3\))\(_2\), H\(_2\)SO\(_4\)  Mol. Wt. 576.7
Salbutamol Sulphate is (RS)-1-(4-hydroxy-3-hydroxy-methylphenyl)-2-(tert-butyramino)ethanol sulphate.
Salbutamol Sulphate contains not less than 98.0 per cent and
not more than 101.0 per cent of (C\(_{13}\)H\(_{21}\)NO\(_3\))\(_2\), H\(_2\)SO\(_4\), calculated
on the dried basis.

**Description.** A white or almost white, crystalline powder.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests
B and C may be omitted if tests A and D are carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6),
Compare the spectrum with that obtained with salbutamol sulphate RS or with the reference spectrum of salbutamol
sulphate.

B. When examined in the range 230 nm to 360 nm (2.4.7), a
0.008 per cent w/v solution in 0.1 M hydrochloric acid shows
an absorption maximum at about 276 nm; absorbance at about
276 nm, 0.44 to 0.51.

C. In this test for Related substances, the principal spot in the
chromatogram obtained with reference solution (a) corresponds to that in the chromatogram obtained with
reference solution (b).

D. Dissolve 10 mg in 50 ml of a 2 per cent w/v solution of
borax, add 1 ml of a 3 per cent w/v solution of
4-aminoazone, 10 ml of a 2 per cent w/v solution of
potassium ferricyanide and 10 ml of chloroform, shake and
allow to separate; an orange-red colour is produced in the
chloroform layer.

E. Gives reaction A of sulphates (2.3.1).

**Tests**

**Appearance of solution.** A 1.0 per cent w/v solution in carbon
dioxide-free water is clear (2.4.1), and not more intensely
coloured than reference solution BYS6 (2.4.1).

**Acidity or alkalinity.** To 10 ml of a 1.0 per cent w/v solution in
carbon dioxide-free water add 0.15 ml of methyl red solution
and 0.2 ml of 0.01 M sodium hydroxide. The solution is yellow
and not more than 0.4 ml of 0.01 M hydrochloric acid is
required to change the colour of the solution to red.
**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 50 volumes of ethyl acetate, 30 volumes of 2-propanol, 16 volumes of water and 4 volumes of strong ammonia solution.

**Test solution.** Dissolve 0.2 g of the substance under examination in 10 ml of water.

**Reference solution (a).** A 0.01 per cent w/v solution of the substance under examination in water.

**Reference solution (b).** A 0.01 per cent w/v of salbutamol sulphate RS in water.

Apply to the plate 5 µl of each solution. After development, dry the plate in air until the odour of the solvent is no longer detectable, place it for a few minutes in an atmosphere saturated with diethylamine and spray with diazotised sulphamic acid solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Boron.** To 50 mg add 5 ml of a solution containing 1.3 per cent w/v of anhydrous sodium carbonate and 1.7 per cent w/v of potassium carbonate, evaporate to dryness on a water-bath and dry at 120º. Ignite the residue rapidly until the organic matter has been destroyed, allow to cool, add 0.5 ml of water and 3.0 ml of a freshly prepared 0.125 per cent w/v solution of curcumin in glacial acetic acid. Evaporate to dryness and allow to cool. Add 3 ml of a mixture prepared by adding 5 ml of sulphuric acid, slowly and with stirring, to 5 ml of glacial acetic acid. Mix and allow to stand for 30 minutes. Add sufficient ethanol (95 per cent) to produce a solution containing 0.008 per cent w/v of salbutamol. When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum only at about 276 nm.

**Identification**

A. Dilute a volume with sufficient 0.1 M hydrochloric acid to produce a solution containing 0.008 per cent w/v of salbutamol. When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum only at about 276 nm.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G. A mixture of 50 volumes of ethyl acetate, 30 volumes of 2-propanol, 16 volumes of water and 4 volumes of strong ammonia solution.

**Test solution.** Evaporate a suitable volume of the injection to dryness using a rotary evaporator, wash the residue with four quantities, each of 5 ml of ethanol, filter, evaporate the filtrate to dryness and dissolve the residue in sufficient water to produce a solution containing the equivalent of 0.1 per cent w/v of salbutamol.

**Reference solution.** A 0.12 per cent w/v solution of salbutamol sulphate RS in water.

Apply to the plate 2 µl of each solution. After development, dry the plate in air until the odour of solvent is no longer detectable, place it for a few minutes in an atmosphere saturated with diethylamine and spray with diazotised nitroaniline solution. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

C. Dilute a volume containing 0.5 mg of salbutamol to 50 ml with water, add 1 ml of dilute ammonia solution, 1 ml of a 3 per cent w/v solution of 4-aminophenazone, 10 ml of a 2 per cent w/v solution of potassium ferricyanide and 10 ml of chloroform. Shake and allow to separate; an orange-red colour is produced in the chloroform layer.

D. A volume containing 1 mg of salbutamol gives the reactions of sulphates (2.3.1).

**Tests**

**pH** (2.4.24). 3.4 to 5.0.
Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. Dilute a volume, accurately measured, containing about 0.15 mg of salbutamol with sufficient water to produce 80 ml, add 4 ml of a 5 per cent w/v solution of sodium bicarbonate, 4 ml of N,N-dimethyl-4-phenylenediamine sulphate solution and 4 ml of a freshly prepared 8 per cent w/v solution of potassium ferricyanide. Mix, allow to stand for 15 minutes, protected from light. Extract with two quantities, each of 10 ml, of chloroform. Filter the extracts through a plug of cotton wool and dilute to 25.0 ml with chloroform. Measure the absorbance of the resulting solution at 605 nm (2.4.7).

Calculate the content of C_{13}H_{21}NO_{3} from the absorbance obtained by repeating the operation using 10.0 ml of a 0.0018 per cent w/v solution of salbutamol sulphate.

Storage. Store protected from light, in single dose containers in which the air has been displaced by nitrogen or other suitable inert gas.

Labelling. The label states the strength in terms of the equivalent amount of salbutamol in a suitable dose-volume.

Salbutamol Syrup

Albuterol Sulphate Syrup; Salbutamol Sulphate Syrup

Salbutamol Syrup contains Salbutamol Sulphate equivalent to not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of salbutamol, C_{13}H_{21}NO_{3}.

Identification

A. To 5 ml add 50 ml of a 2 per cent w/v solution of borax, 1 ml of a 3 per cent w/v solution of 4-aminophenazone, 10 ml of a 2 per cent w/v solution of potassium ferricyanide and 10 ml of chloroform. Shake and allow to separate; an orange-red colour is produced in the chloroform layer.

B. To 5 ml add sufficient 1 M sodium hydroxide to make the solution alkaline, add 1 ml of alkaline borate buffer pH 9.2 and 1 ml of a 0.04 per cent w/v solution of 2,6-dichloroquinone chlorimide in ethanol (95 per cent); a blue colour develops.

Tests

pH (2.4.24). 3.4 to 4.5.

Other tests. Complies with the tests stated under Oral Liquids.

Assay. To an accurately measured volume containing about 4 mg of salbutamol add 25 ml of 0.05 M sulphuric acid and extract with two quantities, each of 50 ml, of ether. Collect the aqueous layers into a 250-ml volumetric flask. Discard the ether extracts and dilute the aqueous solution with sufficient water to produce 250.0 ml. To 10.0 ml of this solution add sufficient water to produce 80 ml and add 4 ml of a 5 per cent w/v solution of sodium bicarbonate, 4 ml of N,N-dimethyl-4-phenylenediamine sulphate solution and 4 ml of a freshly prepared 8 per cent w/v solution of potassium ferricyanide. Mix, allow to stand for 15 minutes, protected from light. Extract with two quantities, each of 10 ml, of chloroform. Filter the extracts through a plug of cotton wool and dilute to 25.0 ml with chloroform. Measure the absorbance of the resulting solution at 605 nm (2.4.7).

Calculate the content of C_{13}H_{21}NO_{3} from the absorbance obtained by repeating the operation using 10.0 ml of a 0.0018 per cent w/v solution of salbutamol sulphate.

Storage. Store protected from light.

Labelling. The label states the strength in terms of the equivalent amount of salbutamol in a suitable dose-volume.

Salbutamol Tablets

Albuterol Sulphate Tablets; Salbutamol Sulphate Tablets

Salbutamol Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of salbutamol, C_{13}H_{21}NO_{3}.

Identification

A. Carry out the method described under Related substances applying separately to the plate 2 µl of each of the following solutions. For the test solution shake a quantity of the powdered tablets containing 10 mg of salbutamol with 10 ml of methanol (80 per cent) and filter. The reference solution contains 0.12 per cent w/v of salbutamol sulphate RS. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

B. Shake a quantity of the powdered tablets containing 8 mg of salbutamol with 50 ml of a 2 per cent w/v solution of borax, add 1 ml of a 3 per cent w/v solution of 4-aminophenazone, 10 ml of a 2 per cent w/v solution of potassium ferricyanide and 10 ml of chloroform. Shake and allow to separate; an orange-red colour is produced in the chloroform layer.

C. Shake a quantity of the powdered tablets containing 4 mg of salbutamol with 10 ml of water and filter; the filtrate gives the reactions of sulphates (2.3.1).

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.
Mobile phase. A mixture of 50 volumes of ethyl acetate, 30 volumes of 2-propanol, 16 volumes of water and 4 volumes of strong ammonia solution.

Test solution. Shake a quantity of the powdered tablets containing 10 mg of salbutamol with 1 ml of water for 15 minutes, centrifuge and use the supernatant liquid.

Reference solution. A 0.006 per cent w/v solution of salbutamol sulphate RS in water.

Apply to the plate 20 µl of each solution. After development, dry the plate in air until the odour of the solvent is no longer detectable, place it for a few minutes in an atmosphere saturated with diethylamine and spray with diazotised sulphanilic acid solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution. Ignore any pink spot near the line of application.

Uniformity of content. Comply with the test stated under Tablets.

Determine by liquid chromatography (2.4.14).

Test solution. Add 50 ml of water to one tablet, shake for 1 hour, add sufficient water to produce 100.0 ml, mix and centrifuge. Dilute further with water, if necessary, to produce a solution containing 0.002 per cent w/v of salbutamol.

Reference solution (a). A 0.0024 per cent w/v of salbutamol sulphate RS in water.

Reference solution (b). A solution containing 0.0024 per cent w/v of 2-tert-butylamino-1-(4-hydroxy-3-methylphenyl) ethanol sulphate RS and 0.0024 per cent w/v of salbutamol sulphate RS in methanol (10 per cent).

Follow the chromatographic procedure described under Uniformity of content. The test is not valid unless the resolution between the two principal peaks in the chromatogram obtained with reference solution (b) is at least 1.5.

Calculate the content of C₁₃H₂₁NO₃ in the tablets.

Storage. Store protected from light.

Labelling. The label states the strength in terms of the equivalent amount of salbutamol.

Salicylic Acid

\[
\text{C}_7\text{H}_6\text{O}_3 \quad \text{Mol. Wt. 138.1}
\]

Salicylic Acid is 2-hydroxybenzoic acid.

Salicylic Acid contains not less than 99.0 per cent and not more than 100.5 per cent of C₇H₆O₃, calculated on the dried basis.

Description. White or colourless, acicular crystals or a white, crystalline powder.

Identification

Test A may be omitted if tests B and C are carried out. Test B may be omitted if tests A and C are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with salicylic acid RS or with the reference spectrum of salicylic acid.

B. Dissolve about 30 mg in 5 ml of 0.05 M sodium hydroxide, neutralise if necessary and dilute to 20 ml with water. 1 ml of the solution gives reaction A of salicylates (2.3.1).

C. Melting point. 158º to 161º (2.4.21).
Tests

**Appearance of solution.** Dissolve 1.0 g in 10 ml of ethanol (95 per cent). The resulting solution is clear, and colourless (2.4.1).

**Heavy metals (2.3.13).** Dissolve 2.0 g in 15 ml of ethanol (95 per cent) and add 5 ml of water. 12 ml of the resulting solution complies with the limit test for heavy metals, Method D (20 ppm). Use lead standard solution (100 ppm Pb) diluted with a mixture of 3 volumes of ethanol (95 per cent) and 1 volume of water to contain 2 µg of Pb per ml to prepare the standard.

**Iron (2.3.14).** Boil 12.0 g with 14 ml of dilute ammonia solution and 35 ml of water. Cool and adjust the pH 5.0 to 6.0 by the dropwise addition of dilute ammonia solution or dilute sulphuric acid and dilute to 50 ml with water, if necessary. Any pink colour produced is not more intense than that obtained by boiling 2.0 g with 1 ml of iron standard solution (20 ppm Fe), 2 ml of dilute ammonia solution and 45 ml of water, adjusting the pH 5.0 to 6.0 and diluting to 50 ml with water (2 ppm).

**Chlorides (2.3.12).** Dissolve 5.0 g in 50 ml of boiling distilled water, cool and filter (solution A). 20 ml of solution A complies with the limit test for chlorides (125 ppm).

**Sulphates (2.3.17).** 7.5 ml of solution A complies with the limit test for sulphates (200 ppm).

**Sulphated ash (2.3.18).** Not more than 0.1 per cent, determined on 2.0 g.

**Loss on drying (2.4.19).** Not more than 0.5 per cent, determined on 1.0 g by drying over phosphorus pentoxide in a desiccator.

**Assay.** Weigh accurately about 0.3 g, dissolve in 50 ml of ethanol (95 per cent), add 20 ml of water and titrate with 0.1 M sodium hydroxide, using phenol red solution as indicator, until a reddish violet colour is obtained.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.01381 g of C\textsubscript{36}H\textsubscript{45}NO\textsubscript{7}.

**Storage.** Store protected from light.

Salmeterol Xinafoate

![Salmeterol Xinafoate structure](image)

C\textsubscript{36}H\textsubscript{45}NO\textsubscript{7}, C\textsubscript{11}H\textsubscript{8}O\textsubscript{3} Mol. Wt. 603.74

Salmeterol Xinafoate contains not less than 97.0 per cent and not more than 102.0 per cent of C\textsubscript{36}H\textsubscript{45}NO\textsubscript{7}, calculated on the anhydrous basis.

**Description.** A white to off-white powder.

**Identification.** Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with salmeterol xinafoate RS or with the reference spectrum of salmeterol xinafoate.

**Tests**

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 50 mg of the substance under examination in 50 ml of the mobile phase.

**Reference solution.** A 0.002 per cent w/v solution of salmeterol xinafoate RS in the mobile phase.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of a buffer solution prepared by dissolving 0.0816 g of potassium dihydrogen phosphate in 1000 ml of water and adjusting the pH to 7.0 with triethylamine and 40 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 220 nm,
- a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0 and the column efficiency in not less than 4500 theoretical plates.

Inject the test solution. Any individual impurity is not more than 0.5 per cent and the sum of all the impurities found is not more than 1.0 per cent.

**Heavy metals (2.3.13).** 1 g complies with limit test for heavy metals, Method B (20 ppm).

**Sulphated ash (2.3.18).** Not more than 0.1 per cent.

**Water (2.3.43).** Not more than 0.5 per cent, determined on 0.5 g.

**Assay.** Weigh accurately about 0.2 g and dissolve in 50 ml of glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.06038 g of C\textsubscript{36}H\textsubscript{45}NO\textsubscript{7}.

**Storage.** Store protected from light.
Salmeterol and Fluticasone Propionate Inhalation

Salmeterol and Fluticasone Propionate Inhalation is a suspension of microfine Salmeterol Xinafoate and Fluticasone Propionate in a suitable liquid filled in a suitable pressurised container. It may contain suitable pharmaceutical aids such as surfactants, stabilizing agents.

Salmeterol and Fluticasone Propionate Inhalation delivers not less than 80.0 per cent and not more than 120.0 per cent of the stated amounts of salmeterol, C_{25}H_{37}NO_{4} and fluticasone propionate, C_{25}H_{31}F_{3}O_{5}S, per inhalation by actuation of the valve.

Identification

In the Assay, the principal peaks in the chromatogram obtained with test solution correspond to the peaks in the chromatogram obtained with reference solution (c).

Tests

Other tests. Comply with the tests stated under Inhalation Preparations (Pressurised Metered-dose Preparations).

Follow the procedure described under Assay with suitable dilution of the reference solution wherever the amount of active substance is to be determined in any test.

Assay. Carry out the test for Content of active ingredient delivered per actuation stated under Inhalation Preparations (Pressurised Metered-dose Preparations).

Determine by liquid chromatography (2.4.14).

Test solution. Prepare using the mobile phase as described under the test for Content of active ingredient delivered per actuation stated under Inhalation Preparations (Pressurised Metered-dose Preparations).

Reference solution (a). A solution containing 0.5 mg of salmeterol per ml prepared by dissolving 10 mg of salmeterol xinafoate RS in 10 ml acetonitrile and adding sufficient of the mobile phase to produce 20 ml.

Reference solution (b) . A solution containing 0.5 mg of fluticasone propionate per ml prepared by dissolving 10 mg of fluticasone propionate RS in 10 ml acetonitrile and adding sufficient of the mobile phase to produce 20 ml.

Reference solution (c). Dilute suitable volumes of reference solution (a) and reference solution (b) with the mobile phase to obtain a solution containing 5 µg of salmeterol and 50 µg per ml of fluticasone propionate per ml.

Chromatographic system

- a stainless steel column 15 cm x 3.9 mm, packed with octylsilyl silica gel (5 µm),
- column temperature 40°C,
- mobile phase: a mixture of 45 volumes of a buffer solution prepared by dissolving 1.3 g of diammonium hydrogen orthophosphate to 1000 ml of water and adjusting the pH to 7.0 with orthophosphoric acid, 25 volumes of acetonitrile and 30 volumes of methanol,
- flow rate, 2 ml per minute,
- spectrophotometer set at 220 nm,
- inject 200 µl.

Inject reference solution(c). The test is not valid unless the column efficiency for salmeterol and fluticasone propionate peak is not less than 1000 and 2500 theoretical plates respectively and the tailing factor is not more than 2.0 for each peak and the relative standard deviation for replicate injections for each component is not more than 2.0 per cent.

Inject the test solution and reference solution (c).

Determine the contents of the active ingredients a second and third time by repeating the procedure on the middle ten and on the last ten successive combined actuations of the valve. For each of the three determinations the average contents of C_{25}H_{37}NO_{4} and C_{25}H_{31}F_{3}O_{5}S delivered per actuation of the valve meet the requirements.

Storage. Store protected from moisture at a temperature not exceeding 30°C.

Labelling. The label states the amounts of active ingredients delivered per inhalation.

Salmeterol and Fluticasone Propionate Powder for Inhalation

Salmeterol and Fluticasone Propionate Powder for Inhalation consists of Fluticasone Propionate and Salmeterol Xinafoate in microfine powder either alone or admixed with Lactose in a pre-metered unit for use in a suitable powder inhaler.

Salmeterol and Fluticasone Propionate Powder for Inhalation contains not less than 90.0 per cent and not more than 125.0 per cent of the stated amounts of salmeterol C_{25}H_{37}NO_{4} and fluticasone propionate, C_{25}H_{31}F_{3}O_{5}S per unit dose.

Identification

In the Assay, the principal peaks in the chromatogram obtained with the test solution correspond to the peaks in the chromatogram obtained with reference solution (c).

Tests

Other tests. Complies with the tests stated under the Inhalation Preparations (Powders for Inhalation).
Follow the procedure described under Assay with suitable dilution of the reference solution wherever the amount of active substance is to be determined in any test.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** To 10 intact capsules add 10 ml of water, and disperse with the aid of ultrasound till the shells get disintegrated. Add 60 ml of the mobile phase and mix further with the aid of ultrasound for 10 minutes with intermittent shaking. Add sufficient of the mobile phase to produce 100.0 ml. Dilute suitably with the mobile phase, if required, to get a final concentration of 5 µg per ml of Salmeterol in the mobile phase.

**Reference solution (a).** A solution containing 0.5 mg of salmeterol per ml prepared by dissolving 10 mg of salmeterol xinafoate RS in 10 ml acetonitrile and adding sufficient of the mobile phase to produce 20 ml.

**Reference solution (b).** A solution containing 0.5 mg of fluticasone propionate per ml prepared by dissolving 10 mg of fluticasone propionate RS in 10 ml acetonitrile and adding sufficient of the mobile phase to produce 20 ml.

**Reference solution (c).** Dilute suitable volumes of reference solution (a) and reference solution (b) with the mobile phase to obtain a solution containing 5 µg of salmeterol and 50 µg per ml of fluticasone propionate per ml.

**Chromatographic system**
- a stainless steel column 15 cm x 3.9 mm, packed with octylsilyl silica gel (5 mm),
- column temperature 40º,
- mobile phase: a mixture of 45 volumes of a buffer solution prepared by dissolving 1.3 g of diammonium hydrogen orthophosphate to 1000 ml of water and adjusting the pH to 7.0 with orthophosphoric acid, 25 volumes of acetonitrile and 30 volumes of methanol,
- flow rate. 2 ml per minute,
- spectrophotometer set at 220 nm,
- inject 200 µl.

Inject reference solution (c). The test is not valid unless the column efficiency determined from the salmeterol and fluticasone propionate peak is not less than 1000 and 2500 theoretical plates respectively, the tailing factor for each of salmeterol and fluticasone propionate peaks is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution (c).

Calculate the contents of C_{25}H_{37}NO_{4} and C_{25}H_{31}F_{3}O_{5}S per unit.

**Storage.** Store protected from moisture, at temperature not exceeding 30º.

**Labelling.** The label states the quantities of active ingredients per pre-metered unit.
Heavy metals (2.3.13). 2.0 g complies with the limit tests for heavy metals, Method B (10 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Water (2.3.43). Not more than 2.0 per cent, determined on 0.5 g.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 25.0 mg of the substance under examination in 100.0 ml of the mobile phase.

Reference solution (a). A 0.025 per cent w/v solution of saquinavir RS in the mobile phase.

Reference solution (b). Dissolve suitable quantities of saquinavir-related compound A RS and saquinavir RS in the mobile phase to obtain a solution containing 2 µg per ml of saquinavir-related compound A and 0.25 mg per ml of saquinavir.

Reference solution (c). A 0.000025 per cent w/v solution of saquinavir RS in the mobile phase.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 20 volumes of methanol, 50 volumes of acetonitrile and 30 volumes of a buffer prepared by dissolving 4 g of sodium dihydrogen phosphate in 1000.0 ml of water to which 1 ml of diethylamine and 1 g of sodium octane sulphonate has been added,
- flow rate. 1 ml per minute,
- spectrophotometer set at 210 nm,
- a 20 µl loop injector.

Inject reference solution (b). The relative retention times are about 0.89 for saquinavir-related compound A and about 1.0 for saquinavir. The test is not valid unless the resolution between the peaks due to saquinavir-related compound A and saquinavir is not less than 1.5, the column efficiency determined from the saquinavir peak is not less than 500 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Separately inject the test solution and reference solution (a). Record the chromatograms up to three times the retention time of the principal peak and measure the responses for the principal peak.

Calculate the content of C₃₈H₅₀N₆O₅.

Storage. Store protected from light.

Saquinavir Mesylate

\[
\text{C}_{38}\text{H}_{50}\text{N}_6\text{O}_5\cdot\text{CH}_3\text{O}_3\text{S}
\]

Mol. Wt. 767.0

Saquinavir mesylate is \((S)-N-([\alpha]S)-\alpha-\{[(1R)-2-[(3S,4aS,8aS)-3-(3-tert-butylcarbamoyl)octahydro-2(1H)-isoquinolyl]-1-hydroxyethyl]phenethyl]-2-quinaldamidosuccinamide methanesulphonate.

Saquinavir Mesylate contains not less than 98.5 per cent and not more than 101.0 per cent of C₃₈H₅₀N₆O₅, CH₄O₃S, calculated on the anhydrous basis.

Description. A white or almost white powder.

Identification
A. Determine by infrared absorption spectrophotometry (2.4.6), Compare the spectrum with that obtained with saquinavir mesylate RS or with the reference spectrum of saquinavir.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to saquinavir mesylate in the chromatogram obtained with reference solution (a).

Tests
Specific optical rotation (2.4.22). \(-66.8^\circ\) to \(-69.6^\circ\), determined in a 0.5 per cent w/v solution in methanol at 436 nm.

Related substances. Determine by liquid chromatography (2.4.14), as described in the Assay using the test solution and reference solution (c).

Inject reference solution (c). Calculate the amount of related substances by area normalisation method. In the chromatogram obtained with the test solution, the area of any peak other than the principal peak is not greater than the area of the principal peak in the chromatogram obtained with reference solution (c) (0.1 per cent) and the sum of the areas of all such peaks is not greater than 5 times the area of the principal peak in the chromatogram obtained with reference solution (c) (0.5 per cent).

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Methanesulphonic acid. 11.9 to 13.1 per cent w/w, calculated on the anhydrous basis, determined by the following method.
Weigh accurately about 0.1 g of the substance under examination, dissolve in 50 ml of methanol. Titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.00961 g of CH₃SO₃H.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Water** (2.3.43). Not more than 1.0 per cent, determined on 0.5 g.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 25.0 mg of the substance under examination in 100.0 ml of the mobile phase.

**Reference solution (a).** A 0.025 per cent w/v solution of saquinavir mesylate RS in the mobile phase.

**Reference solution (b).** Dissolve suitable quantities of saquinavir-related compound A RS and saquinavir mesylate RS in the mobile phase to obtain a solution containing 2 µg per ml of saquinavir-related compound A and 0.25 mg per ml of saquinavir mesylate.

**Reference solution (c).** A 0.000025 per cent w/v solution of saquinavir mesylate RS in the mobile phase.

**NOTE — Store the buffer solution protected from light. Make adjustments if necessary for system suitability.**

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 25 volumes of tetrahydrofuran, 5 volumes of acetonitrile and 17 volumes of a buffer prepared by mixing 10 ml of triethylamine with water to make 1000 ml and adjusting the pH of the solution to 2.5 with phosphoric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 210 nm,
- a 20 µl loop injector.

Inject reference solution (b). The relative retention times are about 0.89 for saquinavir-related compound A and about 1.0 for saquinavir mesylate. The test is not valid unless the resolution between the peaks due to saquinavir related compound A and saquinavir mesylate is not less than 1.5, the column efficiency determined from the saquinavir mesylate peak is not less than 500 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Separately inject the test solution and reference solution (a). Record the chromatograms upto three times the retention time of the principal peak and measure the responses for the principal peak.

Calculate the content of C₃₈H₅₀N₆O₅, CH₄O₃S.

**Storage.** Store protected from light.

---

**Saquinavir Mesylate Tablets**

Saquinavir Mesylate Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of saquinavir C₃₈H₅₀N₆O₅. The tablets may be coated.

**NOTE — Perform the tests and assay using low-actinic glassware.**

**Identification**

A. In the Assay, the principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution. B. When examined in the range 200 nm to 400 nm (2.4.7), 1 ml of a 0.1 per cent w/v solution in methanol diluted to 100 ml with citrate buffer pH 3.0 (see under Dissolution), shows absorption maxima at the same wavelengths as shown by the reference solution.

**Tests**

**Dissolution** (2.5.2).

Apparatus. No 1 Medium. 900 ml of citrate buffer pH 3.0 prepared by dissolving 5.82 mg of anhydrous dibasic sodium phosphate and 16.7 mg of citric acid monohydrate in 1000 ml of water and adjusting the pH to 3.0 with orthophosphoric acid.

Speed and time. 50 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter promptly. Dilute the filtrate, if necessary, with the medium. Measure the absorbance (2.4.7) of the resulting solution at the maximum at about 240 nm. Calculate the content of C₃₈H₅₀N₆O₅ in the medium from the absorbance obtained from a solution of known concentration of saquinavir mesylate RS.

D. Not less than 75 per cent of the stated amount of C₃₈H₅₀N₆O₅.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh and powder 20 tablets Weigh accurately a quantity of the powder containing 100 mg of saquinavir in 100 ml of the mobile phase and filter.

**Reference solution (a).** A 0.1 per cent w/v solution of saquinavir mesylate RS in the mobile phase.

**Reference solution (b).** Dilute 1 ml of reference solution (a) to 100 ml with the mobile phase.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 14 volumes of triethylamine phosphate solution prepared by diluting 10 ml of
triethylamine to 1000 ml with water and adjusting the pH to 2.5 with orthophosphoric acid, 5 volumes of tetrahydrofuran and 1 volume of acetonitrile,
– flow rate. 1 ml per minute,
– spectrophotometer set at 210 nm,
– a 20 µl loop injector.

Inject reference solution (a). The test is not valid unless the column efficiency is not less than 3000 theoretical plates and the tailing factor is not more than 2.0.

Inject the test solution and reference solution (b). Run the chromatogram for 5 times the retention time (about 12 minutes) of the principal peak. In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 0.2 times the area of the peak in the chromatogram obtained with the reference solution (b) (0.2 per cent) and the sum of areas of all the secondary peaks is not more than the area of the peak in the chromatogram obtained with the reference solution (b) (1.0 per cent).

Uniformity of content. Comply with the test stated under Tablets.

Determine by liquid chromatography (2.4.14), as described under Assay. Test solution. Disperse one tablet in 500 ml of the mobile phase and filter. Dilute 5 ml of the filtrate to 20 ml with the mobile phase.

Calculate the content of C_{38}H_{50}N_{6}O_{5} in the tablet.

Other tests. Comply with the tests stated under Tablets.

Water (2.3.43). Not more than 6.0 per cent, determined on 0.5 g.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 100 mg of saquinavir, dissolve in 100.0 ml of mobile phase and filter. Dilute 5.0 ml of the filtrate to 20.0 ml with the mobile phase.

Reference solution. A 0.1 per cent w/v solution of saquinavir mesylate RS in the mobile phase. Dilute 5.0 ml of the solution to 20.0 ml with the mobile phase.

Chromatographic system
– a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
– mobile phase: a mixture of 14 volumes of a solution prepared by diluting 10.0 ml of triethylamine to 1000 ml with water, adjusting the pH to 2.5 with orthophosphoric acid and filtering, 5 volumes of tetrahydrofuran and 1 volume of acetonitrile,
– flow rate. 1.5 ml per minute,
– spectrophotometer set at 210 nm,
– a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency in not less than 2000 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C_{38}H_{50}N_{6}O_{5} in the tablets.

Storage. Store protected from moisture.

Labelling. The label states the strength in terms of the equivalent amount of saquinavir.
Reference solution (a). Dilute 1.0 ml of the test solution to 100.0 ml with mobile phase. Dilute 1.0 ml of the solution to 10.0 ml with the same solvent.

Reference solution (b). A solution containing 0.005 per cent w/v each of 2-methyl-5-nitroimidazole RS and secnidazole RS in the mobile phase. Dilute 1.0 ml of the solution to 100.0 ml with the same solvent.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 35 volumes of methanol and 65 volumes of 0.14 per cent w/v solution of potassium dihydrogen phosphate,
- flow rate. 1 ml per minute,
- spectrophotometer set at 318 nm,
- a 10 µl loop injector.

Inject reference solution (b). The test is not valid unless the resolution between 2-methyl-4-nitroimidazole and secnidazole is not less than 1.5.

Inject the test solution and reference solution (a). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 0.2 times the area of the peak in the chromatogram obtained with the reference solution (a) (0.2 per cent) and the sum of areas of all the secondary peaks is not more than 0.5 times the area of the peak in the chromatogram obtained with the reference solution (b) (0.5 per cent). Disregard any peak which is 0.1 times the area of the principal peak in the chromatogram obtained with reference solution (a) (0.01 per cent).

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method A (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Water (2.3.43). 4.0 to 5.0 per cent, determined on 0.4 g.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 25 mg of the substance under examination in 25.0 ml of the mobile phase. Dilute 5.0 ml of the solution to 100.0 ml with the same solvent.

Reference solution. A 0.005 per cent w/v solution of secnidazole RS in mobile phase.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 35 volumes of methanol and 65 volumes of 0.14 per cent w/v solution of potassium dihydrogen phosphate,
- flow rate. 1 ml per minute,
- spectrophotometer set at 318 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution. Calculate the content of C7H11N3O3.

Storage. Store protected from light and moisture.

Secnidazole Tablets
Secnidazole Tablets contain not less than 95.0 per cent and not more than 110.0 per cent of the stated amount of secnidazole, C7H11N3O3.

Identification
In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

Tests
Dissolution (2.5.2).
Apparatus. No 1 Medium. 900 ml of 0.1 M hydrochloric acid.
Speed and time. 100 rpm and 30 minutes.
Withdraw a suitable volume of the medium and filter promptly through a membrane filter disc having an average pore diameter not greater than 1.0 µm, rejecting the first 1 ml of the filtrate. Dilute the filtrate, if necessary, with the same solvent. Measure the absorbance of the resulting solution at the maximum at about 277 nm (2.4.7). Calculate the content of C7H11N3O3 in the medium from the absorbance obtained from a solution of known concentration of secnidazole RS in the same medium.
D. Not less than 80 per cent of the stated amount of C7H11N3O3.

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Weigh accurately a quantity of powdered tablets containing 50 mg of Secnidazole, disperse in 100 ml of mobile phase and filter.

Reference solution (a). A 0.05 per cent w/v solution of secnidazole RS in the mobile phase.

Reference solution (b). Dilute 1 ml of reference solution (a) to 100 ml with mobile phase.

Chromatographic system as described under Assay.

Inject reference solution (a). The test is not valid unless the tailing factor is not more than 2.0 and the column efficiency in not less than 2000 theoretical plates.
Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than the area of the peak in the chromatogram obtained with reference solution (b) (1.0 per cent) and the sum of areas of all the secondary peaks is not more than 2.0 times the area of the peak in the chromatogram obtained with the reference solution (b) (2.0 per cent).

Water (2.3.43). Not more than 6.5 per cent, determined on 0.5 g.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh and powder 20 tablets. Weigh accurately a quantity of powdered tablet containing 50 mg of Secnidazole, disperse in 100.0 ml of mobile phase and filter. Dilute 5.0 ml of the filtrate to 50.0 ml with mobile phase.

Reference solution. A 0.005 per cent w/v solution of secnidazole RS in mobile phase.

Chromatographic system
– a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane chemically bonded to porous silica (5 µm),
– mobile phase: a mixture of 85 volumes of 0.01 M potassium dihydrogen orthophosphate and 15 volumes of acetonitrile,
– flow rate, 1 ml per minute,
– spectrophotometer set at 228 nm,
– a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the column efficiency is not less than 2000 theoretical plates, the tailing factor is not more than 2.0 and the relative standard deviation of replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C7H11N3O3.

Storage. Store protected from light and moisture.

Labelling. The label states the strength of secnidazole.

**Colloidal Silicon Dioxide**

Colloidal Anhydrous Silica

Colloidal Silicon Dioxide is a submicroscopic fumed silica prepared by the vapour-phase hydrolysis of a silicon compound.

Colloidal Silicon Dioxide contains not less than 99.0 per cent and not more than 100.5 per cent of SiO2, calculated on the ignite basis.

Description. A light, fine, white, amorphous powder. It has a particle size of about 15 nm.

Identification

About 20 mg gives the reaction of silicates (2.3.1).

Tests

pH (2.4.24). 3.5 to 5.5, determined in a suspension of 1.0 g in 30 ml of carbon dioxide-free water.

Arsenic (2.3.10). To 2.5 g contained in a round-bottomed flask add 50 ml of 3 M hydrochloric acid and heat under a reflux condenser for 30 minutes. Cool, filter with the aid of suction and transfer the filtrate to a 100-ml volumetric flask. Wash the filter with several portions of hot water and add the washings to the volumetric flask. Cool, dilute to volume with water and mix. To 50.0 ml of the solution add 3 ml of hydrochloric acid; the resulting solution complies with the limit test for arsenic (8 ppm).

Heavy metals (2.3.13). Suspend 2.5 g in sufficient water to produce a semi-fluid slurry and dry at 140°. When the dried substance is white, break up the mass using a glass rod, add 25 ml of 1 M hydrochloric acid, boil gently for 5 minutes, stirring frequently with the glass rod, centrifuge for 20 minutes and filter the supernatant liquid through a membrane filter. To the residue in the centrifuge tube add 3 ml of 2 M hydrochloric acid and 9 ml of water, boil, centrifuge for 20 minutes and filter the supernatant liquid through the same membrane filter. Wash the residue with small quantities of water, combine the filtrates and washings and dilute to 50.0 ml with water. To 20.0 ml of the solution add 50 mg of L-ascorbic acid and 1 ml of strong ammonia solution, neutralise with 2 M ammonia and dilute to 25 ml with water. 12 ml of the solution complies with the limit test for heavy metals, Method D (25 ppm). Use lead standard solution (1 ppm Pb) to prepare the standard.

Chlorides (2.3.12). To 1.0 g add a mixture of 20 ml of 2 M nitric acid and 30 ml of water, heat on a water-bath for 15 minutes, shaking frequently, dilute to 50 ml with water if necessary, filter and cool. The filtrate complies with the limit test for chlorides (250 ppm).

Loss on ignition (2.4.20). Not more than 5.0 per cent, determined on 0.2 g by igniting at 900° in a platinum crucible for 2 hours.

Assay. To the residue obtained in the test for Loss on ignition add 0.2 ml of sulphuric acid and sufficient ethanol (95 per cent) to moisten the residue completely, add 6 ml of hydrofluoric acid and evaporate to dryness on a hot plate at 95° to 105°, avoiding loss from sputtering. Wash the sides of the dish with 6 ml of hydrofluoric acid, evaporate to dryness in a well-ventilated hood, ignite at 1000°, allow to cool in a desiccator and weigh. The difference between the weight of the final residue and that of the residue obtained in the test for Loss on ignition represents the amount of SiO2 in the amount of the substance taken for the test for Loss on ignition.
Silver Nitrate

Silver Nitrate contains not less than 99.0 per cent and not more than 100.5 per cent of AgNO₃.

Description. Colourless crystals or a white, crystalline powder.

Identification

A. Gives the reactions of silver salts (2.3.1).
B. 10 mg gives reaction A of nitrates (2.3.1).

Tests

Appearance of solution. A 4.0 per cent w/v solution (solution A) is clear (2.4.1), and colourless (2.4.1).

Acidity or alkalinity. To 2 ml of solution A add 0.1 ml of bromocresol green solution; the solution is blue. To 2 ml of this solution add 0.1 ml of phenol red solution; the solution is yellow.

Aluminium, bismuth, copper and lead. Dissolve 1.0 g in a mixture of 4 ml of strong ammonia solution and 6 ml of water; the resulting solution is clear (2.4.1), and colourless (2.4.1).

Foreign salts. Not more than 0.3 per cent, determined by the following method. To 30 ml of solution A add 7.5 ml of 2 M hydrochloric acid, shake vigorously, heat for 5 minutes on a water-bath, filter and evaporate 20 ml of the filtrate to dryness on a water-bath. Dry the residue at 105º and weigh.

Assay. Weigh accurately about 0.25 g, dissolve in 50 ml of water, add 2 ml of 2 M nitric acid and 2 ml of ferric ammonium sulphate solution and titrate with 0.1 M ammonium thiocyanate until a reddish yellow colour is produced. 1 ml of 0.1 M ammonium thiocyanate is equivalent to 0.01699 g of AgNO₃.

Storage. Store protected from light and moisture, in non-metallic containers.

Sodium Acetate

CH₃COONa·3H₂O

C₂H₃NaO₂·3H₂O  Mol. Wt. 136.1

Sodium Acetate contains not less than 99.0 per cent and not more than 101.0 per cent of C₂H₃NaO₂, calculated on the dried basis.

Description. Colourless crystals or a white, crystalline powder.

Identification

Dissolve 10.0 g in sufficient carbon dioxide-free water to produce 100.0 ml (solution A). 1 ml of solution A gives reaction B of acetates and reaction A of sodium salts (2.3.1).

Tests

Appearance of solution. Solution A is clear (2.4.1), and colourless (2.4.1).

pH (2.4.24). 7.5 to 9.0, determined in a 5.0 per cent w/v solution.

Arsenic (2.3.10). Dissolve 5.0 g in 50 ml of water and add 15 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

Calcium and magnesium. Not more than 50 ppm, calculated as Ca, determined by the following method. Mix 200 ml of water with 10 ml of ammonia buffer pH 10.0, 0.1 g of mordant black 11 mixture and 2 ml of 0.05 M zinc chloride. Add dropwise 0.02 M disodium edetate until the colour changes from violet to blue. To this solution add 10 g of the substance under examination, shake to dissolve and titrate with 0.02 M disodium edetate until the blue colour is restored. Not more than 0.65 ml of 0.02 M disodium edetate is required.

Heavy metals (2.3.13). 12 ml of solution A complies with the limit test for heavy metals, Method D (10 ppm).

Iron (2.3.14). 20 ml of solution A complies with the limit test for iron (20 ppm).

Chlorides (2.3.12). 10 ml of solution A complies with the limit test for chlorides (250 ppm).

Sulphates (2.3.17). 15 ml of solution A complies with the limit test for sulphates (225 ppm).

Reducing substances. Dissolve 1.0 g in 100 ml of boiling water, add 5 ml of 1 M sulphuric acid and 0.5 ml of 0.002 M potassium permanganate, mix and boil gently for 5 minutes; the pink colour is not completely discharged.

Loss on drying (2.4.19). 39.0 to 40.5 per cent, determined on 0.2 g by drying in an oven at 130º. Place the substance under examination in the oven while the oven is still cold.

Assay. Weigh accurately about 0.25 g, dissolve in 50 ml of anhydrous glacial acetic acid, add 5 ml of acetic anhydride, mix and allow to stand for 30 minutes. Titrate with 0.1 M perchloric acid, using 0.3 ml of 1-naphtholbenzein solution as indicator, until a green colour is produced. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.00820 g of C₂H₃NaO₂. Sodium Acetate intended for use in the preparation of dialysis solutions complies with the following additional requirement.
Aluminium. Dissolve 20 g in 100 ml of water and adjust to pH 6.0 by the addition of about 10 ml of 1 M hydrochloric acid. Extract with successive quantities of 20, 20 and 10 ml of a 0.5 per cent w/v solution of 8-hydroxyquinoline in chloroform and dilute the combined extracts to 50 ml with chloroform. Use as the standard solution a mixture of 0.4 ml of aluminium standard solution (2 ppm Al), 10 ml of acetate buffer pH 6.0 and 100 ml of water treated in the same manner. Measure the fluorescence (2.4.5) of the test solution and the standard solution, using an excitation wavelength of about 392 nm and emission wavelength of about 518 nm, and setting the instrument to zero with the blank solution in each case. The fluorescence of the test solution is not greater than that of the standard solution (0.2 ppm).

Storage. Store protected from light.

Labelling. The label states whether or not the material is intended for use in the manufacture of dialysis solutions.

Sodium Alginate

Sodium Polymanuronate

Sodium Alginate consists mainly of the sodium salt of alginic acid which is a mixture of polyuronic acids [(C₆H₈O₆)ₙ] composed of residues of D-mannuronic acid and L-guluronic acids and is obtained mainly from algae belonging to the order Phaeophyceae.

Description. A cream-coloured to pale yellowish brown powder; almost odourless.

Identification

A. Dissolve 0.2 g with shaking in 20 ml of water and to 5 ml of the resulting solution add 1 ml of calcium chloride solution; a voluminous gelatinous precipitate is produced. B. To 10 ml of the solution obtained in test A add 1 ml of 1 M sulphuric acid; a gelatinous mass is produced. C. To 5 mg add 5 ml of water, 1 ml of a freshly prepared 1 per cent w/v solution of naphthalene-1,3-diol in ethanol (95 per cent) and 5 ml of hydrochloric acid. Boil for 3 minutes, cool, add 5 ml of water and shake with 15 ml of di-isopropyl ether. The upper layer exhibits a deeper bluish red colour than the upper layer obtained by repeating the procedure without the substance under examination. D. The residue obtained in the test for Sulphated ash gives reaction A of sodium salts (2.3.1).

Tests

Heavy metals (2.3.13). 0.5 g complies with the limit test for heavy metals, Method B (40 ppm), using nitric acid instead of sulphuric acid for wetting the sample.

Chloride. Not more than 1.0 per cent, determined by the following method. Shake 2.5 g with 50 ml of 2 M nitric acid for 1 hour, dilute to 100 ml with 2M nitric acid and filter. To 50 ml of the filtrate add 10.0 ml of 0.1 M silver nitrate and 5 ml of toluene. Titrate with 0.1 M ammonium thiocyanate using 2 ml of ferric ammonium sulphate solution as indicator and shaking vigorously towards the end-point.

1 ml of 0.1 M silver nitrate is equivalent to 0.00355 g of Cl.

Microbial contamination (2.2.9). 1 g is free from Escherichia coli; 10 g is free from salmonellae.

Sulphated ash (2.3.18). 30.0 to 36.0 per cent, determined on 0.1 g and calculated on the dried basis.

Loss on drying (2.4.19). Not more than 15.0 per cent, determined on 0.2 g by drying in an oven at 105°C for 4 hours.

Storage. Store protected from light.

Sodium Aminosalicylate

Sodium PAS

\[
\text{COONa} \quad \text{OH} \quad \text{2H}_2\text{O} \\
\text{NH}_2 \\
\text{C}_7\text{H}_6\text{NNaO}_3 \cdot 2\text{H}_2\text{O}.
\]

Mol. Wt. 211.2

Sodium Aminosalicylate is sodium 4-amino-2-hydroxybenzoate dihydrate.

Sodium Aminosalicylate contains not less than 99.0 per cent and not more than 101.0 per cent of \text{C}_7\text{H}_6\text{NNaO}_3, calculated on the anhydrous basis.

Description. A white to cream coloured crystalline powder.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sodium aminosalicylate RS or with the reference spectrum of sodium aminosalicylate.

B. A 5 per cent w/v solution complies with the tests for sodium salts (2.3.1).
Tests

**pH** (2.4.24). 6.5 to 8.5, determined in a 2.0 per cent w/v solution.

**3-aminophenol.** Determine by liquid chromatography (2.4.14).

*Test solution.* Dissolve 50.0 mg of the substance under examination in 100 ml of the mobile phase.

*Reference solution (a).* Dissolve 25.0 mg of 3-aminophenol RS in 100.0 ml of the mobile phase (solution A). Dilute 5.0 ml of the solution to 100.0 ml with the mobile phase. Dilute 5.0 ml of the resulting solution to 50.0 ml with the mobile phase.

*Reference solution (b).* Dissolve 25.0 mg of sodium aminosalicylate RS in 100.0 ml of the mobile phase. Dilute 5.0 ml of this solution and 5 ml of solution A to 100.0 ml with the mobile phase.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous base deactivated silica (5 µm) (such as Hypersil BDS),
- mobile phase: dissolve 6.0 g of disodium hydrogen orthophosphate and 6.6 g of sodium dihydrogen orthophosphate dihydrate in 1600 ml with water, add 19 ml of tetra n-butyl ammonium hydroxide (20 per cent solution) and make the volume to 1700 ml with water and add 300 ml of methanol,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 µl loop injector.

Inject reference solution (a). The relative standard deviation for replicate injections is not more than 5.0 per cent

Inject reference solution (b). The test is not valid unless the resolution between 3-aminophenol and sodium aminosalicylate is at least 5.0.

Inject the test solution and reference solution (a). In the chromatogram obtained with the test solution, the area of the peak corresponding to 3-aminophenol is not more than the area of the corresponding peak in the chromatogram obtained with reference solution (a) (0.25 per cent).

**Hydrogen Sulphide and Sulphur dioxide.** Dissolve 0.5 g in 5 ml of 1 M sodium hydroxide, add 6 ml of 3 M hydrochloric acid and stir vigorously. No odour of hydrogen sulphide or sulphur dioxide is perceptible, and not more than a faint odour of Amyl Alcohol is perceptible. A piece of moistened lead acetate paper held over the mixture does not become discoloured.

**Arsenic** (2.3.10). Mix 5.0 g with 10 ml of bromine solution and evaporate to dryness on a water-bath, ignite gently, dissolve the cooled residue, ignoring any carbon, in 50 ml of water and 14 ml of brominated hydrochloric acid AsT and remove the excess bromine with a few drops of stannous chloride solution AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

**Heavy metals** (2.3.13). 0.66 g complies with the limit test for heavy metals, Method B (30 ppm).

**Chlorides** (2.3.12). Dissolve 1.0 g in 10 ml of water, add 3 ml of acetic acid and filter, dilute the filtrate to 50 ml with water. 10 ml of the solution complies with the limit test for chlorides (0.25 per cent).

**Sulphates** (2.3.17). 0.1 g complies with the limit test for sulphates (0.15 per cent).

**Loss on drying** (2.4.19). 16.0 to 17.5 per cent, determined on 0.5 g by drying in an oven at 105º.

**Assay.** Determine by liquid chromatography (2.4.14).

*Test solution.* Dissolve 50.0 mg of the substance under examination in 100.0 ml of the mobile phase. Dilute 5.0 ml of this solution to 100.0 ml with the mobile phase.

*Reference solution (a).* Dissolve 50.0 mg of sodium aminosalicylate RS in 100.0 ml of the mobile phase (solution A). Dilute 5.0 ml of this solution to 100.0 ml with the mobile phase.

*Reference solution (b).* Dissolve 25.0 mg of 3-aminophenol RS in 100.0 ml of the mobile phase. Dilute 5.0 ml of this solution and 5 ml of solution A to 100.0 ml with the mobile phase.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: dissolve 6.0 g of disodium hydrogen orthophosphate and 6.6 g of sodium dihydrogen orthophosphate dihydrate in 1600 ml with water, add 19 ml of tetra n-butyl ammonium hydroxide (20 per cent solution) and make the volume to 1700 ml with water and add 300 ml of methanol,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject reference solution (a). The relative standard deviation for replicate injections is not more than 5.0 per cent

Inject reference solution (b). The test is not valid unless the resolution between m-aminophenol and sodium aminosalicylate is at least 5.0.

Inject the test solution and reference solution (a). In the chromatogram obtained with the test solution, the area of the peak corresponding to 3-aminophenol is not more than the area of the corresponding peak in the chromatogram obtained with reference solution (a) (0.25 per cent).

**Storage.** Store protected from light and moisture.
Sodium Aminosalicylate Tablets

Sodium PAS Tablets

Sodium aminosalicylate tablet contains not less than 95.0 per cent not more than 105.0 per cent of C₇H₆NNaO₃·2H₂O.

Identification

Digest a quantity of powdered tablets containing about 3.0 g of sodium aminosalicylate, with 40 ml of water, and filter. Add to the filtrate 15 ml of 1M acetic acid, and allow it to stand until precipitation has occurred. Collect the precipitate on a filter, wash well with water and dry at 105ºC for 30 min. The residue complies with the following tests.

A. Place about 1 g of the residue in a small, round-bottom flask, and add 10 ml of acetic anhydride. Heat the flask on a steam bath for 30 minutes, and add 40 ml of water, mix, filter, cool, and allow to stand until diacetyl derivative crystallizes, wash well with water, and dry at 105º for 1 hour. The diacetyl derivative so obtained melts at 191º to 197º.

B. Shake 0.1 g of the residue with 10 ml of water, and filter. To 5 ml of the filtrate add 1 drop of ferric chloride solution. A violet colour is produced.

C. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with reference solution (a) (1.0 per cent).

Tests

3-aminophenol. Determine by liquid chromatography (2.4.14).

Test solution. Weigh and powder 20 tablets. Weigh a quantity of the powder containing about 50 mg of Sodium Aminosalicylate and dissolve in 100 ml of the mobile phase.

Reference solution (a). A 0.024 per cent w/v solution of m-aminophenol RS in the mobile phase. Dilute 5 ml to 100 ml with the mobile phase. Dilute 5 ml of the resulting solution to 50 ml with the mobile phase.

Reference solution (b). A 0.024 per cent w/v solution of sodium aminosalicylate RS in the mobile phase.

Reference solution (c). Mix 5 ml each of reference solution (a) and reference solution (b) and dilute to 100 ml with the mobile phase.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous base deactivated silica (5 µm),
- mobile phase: dissolve 6.0 g of disodium hydrogen orthophosphate and 6.6 g of sodium dihydrogen orthophosphate dihydrate in 1600 ml with water, add 19 ml of tetra n-butyl ammonium hydroxide (20 per cent aqueous solution) and make the volume to 1700 ml with water, add 300 ml of methanol, mix well and degas,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject reference solution (a). The relative standard deviation for replicate injections is not more than 5.0 per cent.

Inject reference solution (c). The resolution between 3-aminophenol and sodium aminosalicylate is not less than 5.0.

Inject the test solution and reference solution (a). In the chromatogram obtained with the test solution, the area of the peak corresponding to 3-aminophenol is not more than the area of the peak in the chromatogram obtained with reference solution (a) (1.0 per cent).

Dissolution (2.5.2).

Apparatus. No 2

Medium. 900 ml water

Speed and time. 100 rpm for 45 minutes

Withdraw a suitable volume of the medium and filter.

Determine by liquid chromatography (2.4.14).

Test solution. The filtrate diluted with the mobile phase to produce a 0.055 per cent w/v solution.

Reference solution. A 0.055 per cent w/v solution of sodium aminosalicylate RS in the mobile phase.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: dissolve 6.0 g of disodium hydrogen orthophosphate and 6.6 g of sodium dihydrogen orthophosphate dihydrate in 1600 ml with water, add 19 ml of tetra n-butyl ammonium hydroxide (20 per cent aqueous solution) and make the volume to 1700 ml with water, add 300 ml of methanol, mix well and degas,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject the reference solution. The tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternatively the test solution and the reference solution.

Calculate the content of C₇H₆NNaO₃·2H₂O in the medium.

D. Not less than 75 per cent of the stated amount of C₇H₆NNaO₃·2H₂O.

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).
**Test solution.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.5 g of sodium aminosalicylate, add sufficient mobile phase to produce 100.0 ml and filter. Dilute 5.0 ml of this solution to 50.0 ml with the mobile phase.

**Reference solution.** A 0.05 per cent w/v solution of sodium aminosalicylate RS in the mobile phase.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: dissolve 6.0 g of disodium hydrogen orthophosphate and 6.6 g of sodium dihydrogen orthophosphate dihydrate in 1600 ml with water, add 19 ml of tetra n-butyl ammonium hydroxide (20 per cent aqueous solution) and make the volume to 1700 ml with water, add 300 ml of methanol, mix well and degas,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject the reference solution. The tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent

Inject alternately the test solution and the reference solution.

Calculate the content of C7H6NNaO3. 2H2O in the tablets.

**Storage.** Store protected from moisture.

### Sodium Ascorbate

![Sodium Ascorbate structure](image)

C6H7NaO6, Mol. Wt. 198.1

Sodium Ascorbate is L-ascorbic acid, monosodium salt.

Sodium Ascorbate contains not less than 99.0 per cent and not more than 101.0 per cent of C6H7NaO6, calculated on the dried basis.

**Description.** White or faintly yellow crystals or a crystalline powder; odourless or almost odourless. It darkens gradually on exposure to light.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Test B and C may be omitted if tests A and D are carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6), Compare the spectrum with that obtained with sodium ascorbate RS.

B. To 4 ml of a 2 per cent w/v solution add 1 ml of 0.1 M hydrochloric acid, add a few ml of 2,6-dichlorophenol-indophenol solution; the solution is decolorised.

C. To 4 ml of a 2 per cent w/v solution add 1 ml of 0.1 M hydrochloric acid, add 1 drop of a freshly prepared 5 per cent w/v solution of sodium nitroprusside and 2 ml of dilute sodium hydroxide solution. Add 0.6 ml of hydrochloric acid dropwise and stir; the yellow colour turns blue.

D. A 2 per cent w/v solution gives the reactions of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1) and not more intensely coloured than reference solution BYS7 (2.4.1).

**pH** (2.4.24). 7.0 to 8.0, determined in a 10.0 per cent w/v solution.

**Specific optical rotation** (2.4.22). +103° to +108°, determined in a 10.0 per cent w/v solution.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 0.25 per cent, determined on 1.0 g by drying over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 24 hours.

**Assay.** Weigh accurately about 0.2 g, dissolve in a mixture of 100 ml of carbon dioxide-free water and 25 ml of 1 M sulphuric acid. Titrate immediately with 0.05 M iodine, using 1 ml of starch solution as indicator, until a persistent violet-blue colour is obtained.

1 ml of 0.05 M iodine is equivalent to 0.009905 g of C6H7NaO6.

**Storage.** Store protected from light.

### Sodium Aurothiomalate

Sodium Aurothiomalate consists mainly of the disodium salt of (aurothio) succinic acid.

Sodium Aurothiomalate contains not less than 44.5 per cent and not more than 46.0 per cent of Au and not less than 10.8 per cent and not more than 11.5 per cent of Na, both calculated on the dried basis.

**Description.** A fine, pale yellow powder; odour, slight; hygroscopic.

**Identification**

A. Ignite 0.1 g and dissolve a portion of the residue by warming with 2 ml of a mixture of 3 volumes of hydrochloric acid and
1 volume of nitric acid and dilute to 20 ml with water (solution A). Reserve the remainder of the residue for use in test D. To 0.2 ml add 20 ml of water, boil, pour the boiling solution into 5 ml of stannous chloride solution and mix; a purple colour is produced.

B. To 2 ml of solution A add 2 ml of hydrogen peroxide solution (20 vol) and 1 ml of 5 M sodium hydroxide; a precipitate is produced which appears brownish black by reflected light and bluish green by transmitted light.

C. Solution A gives a black precipitate with hydrogen sulphide which is insoluble in 2 M hydrochloric acid but soluble in ammonium polysulphide solution.

D. Extract a portion of the residue obtained in test A with 10 ml of 2 M hydrochloric acid. The solution, after neutralisation if necessary, gives the reactions of sodium salts and the reaction of sulphates (2.3.1).

**Tests**

**pH** (2.4.24). 6.0 to 7.0, determined in a 10.0 per cent w/v solution.

**Stability.** Dissolve 1.0 g in 10 ml of water, filter, seal in an ampoule, heat at 100º for 1 hour, cool and add sufficient water to produce 100 ml. The solution remains bright and is not more intensely coloured than a 0.01 per cent w/v solution of potassium ferricyanide.

**Loss on drying** (2.4.19). Not more than 2.0 per cent, determined on 1.0 g by drying over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 24 hours.

**Assay.** For Au — Weigh accurately about 0.2 g, heat with 10 ml of sulphuric acid and continue to boil gently until a clear, pale yellow liquid is produced. Cool, add about 1 ml of nitric acid dropwise and boil again for 1 hour. Cool, dilute with 70 ml of water, boil for 5 minutes, filter, wash the residue of gold Au, with hot water, dry and ignite for 3 hours at a temperature not lower than 600º.

For Na — Evaporate to dryness the filtrate and washings obtained in the Assay for Au, moisten with sulphuric acid and ignite for 3 hours at 600º.

1 g of residue is equivalent to 0.3237 g of Na.

**Storage.** Store protected from light.

---

**Sodium Benzoate**

C₇H₅NaO₂  Mol. Wt. 144.1

Sodium Benzoate contains not less than 99.0 per cent and not more than 100.5 per cent of C₇H₅NaO₂, calculated on the dried basis.

**Description.** A white, crystalline or granular powder or flakes; odourless or with a faint odour; hygroscopic.

**Identification**

A. To a 10 per cent w/v solution add ferric chloride test solution; a buff coloured precipitate is formed. Add dilute hydrochloric acid; a white crystalline precipitate is produced.

---

**Sodium Aurothiomalate Injection**

Sodium Aurothiomalate Injection is a sterile solution of Sodium Aurothiomalate in Water for Injection.

Sodium Aurothiomalate Injection contains gold, Au, equivalent to not less than 42.3 per cent and not more than 48.3 per cent of the stated amount of sodium aurothiomalate.

**Identification**

A. To a volume equivalent to 20 mg of Sodium Aurothiomalate add 2 ml of hydrogen peroxide solution (100 vol) and 1 ml of 5 M sodium hydroxide and boil for 30 seconds; a colloidal precipitate is produced which appears bluish green by transmitted light.

B. To a volume equivalent to 10 mg of Sodium Aurothiomalate add 0.1 ml of potassium cyanide solution and 0.1 ml of a 1 per cent w/v solution of sodium nitroprusside; a deep magenta colour is produced.

**Tests**

**Appearance of solution.** Dilute, if necessary, with water to give a solution containing 1.0 per cent w/v of Sodium Aurothiomalate. The colour of the solution is not more intense than that of a 0.02 per cent w/v solution of potassium ferricyanide.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** To an accurately measured volume containing about 0.1 g of Sodium Aurothiomalate add 0.4 g of potassium bromide and 5 ml of nitric acid. Slowly evaporate the solution to dryness and continue heating until fumes cease to be evolved. Allow to cool, add 50 ml of water, warm, filter, wash the residue of gold, Au, with hot water, dry and ignite for 3 hours at a temperature not lower than 600º.

**Storage.** Store protected from light.
B. Gives the reactions of sodium salts and reactions B and C of benzoates (2.3.1).

**Tests**

**Appearance of solution.** A 10.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and not more intensely coloured than reference solution YS6 (2.4.1).

**Acidity or alkalinity.** To 20 ml of a 5.0 per cent w/v solution in carbon dioxide-free water add 0.2 ml of phenolphthalein solution. Not more than 0.2 ml of 0.1 M hydrochloric acid or 0.2 ml of 0.1 M sodium hydroxide is required to change the colour of the solution.

**Arsenic (2.3.10).** Mix 5.0 g with 10 ml of bromine solution and evaporate to dryness on a water-bath. Ignite gently, dissolve the cooled residue, ignoring any carbon, in 50 ml of water and 14 ml of brominated hydrochloric acid AsT, and remove the excess of bromine with 2 ml of stannous Chloride solution AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

**Heavy metals (2.3.13).** Dissolve 2.0 g in 45 ml of water and 5 ml of hydrochloric acid. 25 ml of the solution complies with the limit test for heavy metals, Method B (20 ppm).

**Chlorinated compounds.** Dissolve 0.33 g in 5 ml of 0.5 M sodium carbonate, evaporate to dryness and heat the residue until completely charred, keeping the temperature below 400º. Extract the residue with a mixture of 10 ml of water and 12 ml of dilute nitric acid and filter; the filtrate complies with the limit test for chlorides (2.3.12).

**Loss on drying (2.4.19).** Not more than 2.0 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.25 g, dissolve in 20 ml of anhydrous glacial acetic acid, warming to 50º if necessary, cool. Titrate with 0.1 M perchloric acid, using 0.05 ml of 1-naphtholbenzein solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01441 g of C₂H₂NaO₂.

**Storage.** Store protected from light.

---

**Sodium Bicarbonate**

Sodium Hydrogen Carbonate

NaHCO₃  Mol. Wt. 84.0

Sodium Bicarbonate contains not less than 99.0 per cent and not more than 101.0 per cent of NaHCO₃.

**Description.** A white, crystalline powder or small, opaque, monoclinic crystals. It gradually forms sodium carbonate on heating in the dry state or in solution.

**Identification**

**A.** To 5 ml of a 5.0 per cent w/v solution in carbon dioxide-free water (solution A) add 0.1 ml of phenolphthalein solution; a pale pink colour is produced. On heating, a gas is evolved and the solution becomes red.

B. Gives reaction A of bicarbonates (2.3.1).

C. Solution A gives the reactions of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** Solution A is clear (2.4.1), and colourless (2.4.1).

**Arsenic (2.3.10).** Dissolve 5.0 g in 50 ml of water, add 15 ml of brominated hydrochloric acid AsT and remove the excess of bromine with a few drops of stannous chloride solution AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

**Calcium.** A 2.0 per cent w/v solution, when boiled for 5 minutes, is clear.

**Heavy metals (2.3.13).** Mix 4.0 g with 5 ml of water and 18 ml of dilute hydrochloric acid, heat to boiling and maintain that temperature for 1 minute. Add 0.05 ml of phenolphthalein solution and sufficient 5 M ammonia dropwise to give the solution a faint pink colour, cool and dilute to 25 ml with water. The solution complies with the limit test for heavy metals, Method A (5 ppm).

**Iron (2.3.14).** Dissolve 2.0 g in 20 ml of water and 4 ml of hydrochloric acid and dilute to 40 ml with water; the resulting solution complies with the limit test for iron (20 ppm).

**Carbonate.** pH of solution A, when freshly prepared, not more than 8.6.

**Chlorides (2.3.12).** 1.25 g dissolved in 15 ml of water and 2 ml of nitric acid complies with the limit test for chlorides (200 ppm).

**Sulphates (2.3.17).** Suspend 1.0 g in 10 ml of distilled water, neutralise with hydrochloric acid and dilute to 15 ml with distilled water. The resulting solution complies with the limit test for sulphates (150 ppm).

**Assay.** Weigh accurately about 1.5 g, dissolve in 50 ml of carbon dioxide-free water and titrate with 1 M hydrochloric acid using 0.2 ml of methyl orange solution as indicator. 1 ml of 1 M hydrochloric acid is equivalent to 0.08401 g of NaHCO₃.

**Storage.** Store protected from moisture.
Sodium Bicarbonate Injection

Sodium Bicarbonate Intravenous Infusion

Sodium Bicarbonate Injection is a sterile solution of Sodium Bicarbonate in Water for Injections.

Sodium Bicarbonate Injection contains not less than 94.0 per cent and not more than 106.0 per cent of the stated amount of sodium bicarbonate, NaHCO₃.

Description. A clear, colourless solution.

Identification

A. The residue on evaporation, when moistened with hydrochloric acid and introduced on a platinum wire into a flame, imparts a yellow colour to the flame.

B. Gives reaction A of sodium salts and the reactions of bicarbonates (2.3.1).

Tests

pH (2.4.24). 7.0 to 8.5.

Bacterial endotoxins (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. Titrate a volume containing 1.5 g of Sodium Bicarbonate with 1 M hydrochloric acid using methyl orange solution as indicator.

1 ml of 1 M hydrochloric acid is equivalent to 0.08401 g of NaHCO₃.

Storage. Store in single dose containers.

Labelling. The label states (1) the strength as the percentage w/v of Sodium Bicarbonate; (2) the approximate concentrations, in millimoles per litre, of the sodium ions and the bicarbonate ions; (3) that an injection containing visible particles in the solution should not be used.

Sodium Carbonate

Na₂CO₃ Mol. Wt. 106.0 (anhydrous)
Na₂CO₃·H₂O Mol. Wt. 124.0 (monohydrate)

Sodium Carbonate is anhydrous or contains one molecule of water of hydration.

Sodium Carbonate contains not less than 99.5 per cent and not more than 100.5 per cent of Na₂CO₃, calculated on the dried basis.

Description. Anhydrous — A white or almost white, slightly granular powder, hygroscopic.

Monohydrate — A white, crystalline powder or colourless crystals.

Identification

A. Dissolve 1 g in water and dilute to 10 ml with water; the solution is strongly alkaline.

B. The solution prepared for test A gives reaction A of carbonates and reactions of sodium salts (2.3.1).

Tests

Appearance of solution. Dissolve 2.0 g in 10 ml of water. The resulting solution is clear and not more intensely coloured than reference solution YS6, (2.4.1).

Alkali hydroxides and bicarbonates. Dissolve 0.4 g in 20 ml of water, add 20 ml of barium chloride solution and filter. To 10 ml of the filtrate add 0.1 ml of phenolphthalein solution. The solution does not become red. Heat the remainder of the filtrate to boiling for 2 minutes. The solution remains clear.

Heavy metals (2.3.13). Dissolve 2.0 g in portions in a mixture of 5 ml of hydrochloric acid and 25 ml of water. Heat the solution to boiling and cool. Add dilute sodium hydroxide solution until the solution is neutral. Dilute to 50 ml with water (solution A). 12 ml of the resulting solution complies with the limit test for heavy metals, Method A (50 ppm). Use lead standard solution (2 ppm Pb) for the standard.

Iron (2.3.14). Dilute 5 ml of solution A to 10 ml with water. The solution complies with the limit test for iron (50 ppm).

Chlorides (2.3.12). Dissolve 0.4 g in water, add 4 ml of dilute nitric acid and dilute to 15 ml with water. The solution complies with the limit test for chlorides (125 ppm).

Sulphates (2.3.17). 15 ml of solution A complies with the limit test for sulphates, (250 ppm).

Loss on drying (2.4.19). Not more than 1.0 per cent (for anhydrous form) or between 12.0 per cent and 15.0 per cent (for monohydrate form), determined on 2.0 g by drying in an oven at 300º.

Assay. Weigh accurately about 1.0 g, dissolve in 25 ml of water and titrate with 1 M hydrochloric acid using methyl orange solution as indicator.

1 ml of 1 M hydrochloric acid is equivalent to 0.05299 g of Na₂CO₃.

Storage. Store in tightly-closed, non-metallic containers.

Labelling. The label states whether the material is anhydrous or monohydrate.
**Sodium Chloride**

**NaCl**  
Mol. Wt. 58.4

Sodium Chloride contains not less than 99.0 per cent and not more than 100.5 per cent of NaCl, calculated on the dried basis.

**Description.** White or colourless crystals or a white crystalline powder.

**Identification**

A. Gives the reactions of chlorides (2.3.1).

B. A 20 per cent w/v solution in carbon dioxide-free water prepared from distilled water (solution A) gives the reactions of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** Solution A is clear (2.4.1), and colourless (2.4.1).

**Acidity or alkalinity.** To 20 ml of solution A add 0.1 ml of bromothymol blue solution; not more than 0.5 ml of 0.01 M hydrochloric acid or of 0.01 M sodium hydroxide is required to change the colour of the solution.

**Arsenic** (2.3.10). Dissolve 10.0 g in 50 ml of water and 12 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (1 ppm).

**Barium.** Dissolve 2 g in 10 ml of water, and add 2 ml of dilute sulphuric acid; no turbidity is produced within 2 hours.

**Bromide.** To 0.5 ml of solution A add 4.0 ml of water, 2.0 ml of phenol red reagent and 1.0 ml of 0.01 per cent w/v solution of chloramine T and mix immediately. After exactly 2 minutes, add 0.15 ml of 0.1 M sodium thiosulphate, mix and dilute to 10.0 ml with water. The absorbance of the solution measured at about 590 nm (2.4.7), using water as the blank, is not more than that of the standard solution prepared at the same time and in the same manner, using 5.0 ml of a 0.0003 per cent w/v solution of potassium bromide (100 ppm).

**Calcium and magnesium.** Not more than 50 ppm, calculated as Ca, determined by the following method. Dissolve 20.0 g in 200 ml of water, and add 0.1 ml of hydrochloric acid, 5 ml of strong ammonia-ammonium chloride solution, 5 drops of eriochrome black T solution and titrate with 0.005 M disodium edetate to a blue end-point.

1 ml of 0.005 M disodium edetate is equivalent to 0.0002004 g of Ca.

**Ferro cyanide.** Dissolve 2.0 g in 6 ml of water and add 0.5 ml of a mixture of 5 ml of a 1 per cent w/v solution of ferric ammonium sulphate in a 0.25 per cent w/v solution of sulphuric acid, and 95 ml of a 1 per cent w/v solution of ferrous sulphate; no blue colour is produced within 10 minutes.

**Heavy metals** (2.3.13). 4.0 g in 2 ml of dilute acetic acid and sufficient water to produce 25 ml. The solution complies with the limit test for heavy metals, Method A (5 ppm).

**Iodide.** Moisten 5 g by adding dropwise, a solution freshly prepared by mixing 25 ml of iodide-free starch solution 2 ml of 0.5 M sulphuric acid, 0.15 ml of sodium nitrite solution and 25 ml of water and examine the mixture in daylight; the substance shows no blue colour after 5 minutes.

**Iron** (2.3.14). 2.0 g dissolved in 20 ml of water complies with the limit test for iron (20 ppm).

**Sulphates** (2.3.17). 2.5 ml of solution A diluted to 15 ml with water complies with the limit test for sulphates (300 ppm).

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105º for 3 hours.

**Assay.** Weigh accurately about 0.1 g and dissolve in 50 ml of water in a glass-stoppered flask. Add 50.0 ml of 0.1 M silver nitrate, 5 ml of 2 M nitric acid and 2 ml of dibutyl phthalate, shake well and titrate with 0.1 M ammonium thiocyanate using 2 ml of ferric ammonium sulphate solution as indicator, until the colour becomes reddish yellow.

1 ml of 0.1 M silver nitrate is equivalent to 0.005844 g of NaCl.

Sodium Chloride intended for use in the manufacture of parenteral preparations or in the manufacture of dialysis solutions complies with the following additional requirement.

**Potassium.** Not more than 0.1 per cent, determined by flame photometry (2.4.4), using a 1.0 per cent w/v solution and measuring at 768 nm. Use suitable dilutions in water of potassium solution FP for the standard solution.

Sodium Chloride intended for use in the preparation of dialysis solutions complies with the following additional requirement.

**Aluminium.** Not more than 0.2 ppm, determined by the following method. Dissolve 20 g in 100 ml of water and add 10 ml of acetate buffer pH 6.0. Extract the resulting solution with successive quantities of 20, 20 and 10 ml of a 0.5 per cent w/v solution of 8-hydroxyquinoline in chloroform and dilute the combined extracts to 50 ml with chloroform. Use as the blank solution a mixture of 10 ml of acetate buffer pH 6.0 and 100 ml of water treated in the same manner and as the standard solution a mixture of 2 ml of aluminium standard solution (2 ppm Al), 10 ml of acetate buffer pH 6.0 and 90 ml of water treated in the same manner. Measure the fluorescence of the test solution and of the standard solution (2.4.5), using an excitation wavelength of 392 nm and a secondary filter with a transmission band centered at 518 nm, or a monochromator set to transmit at this wavelength, and setting the instrument to zero with the blank solution in each case. The fluorescence of the test solution is not greater than that of the standard solution.

**Storage.** Store protected from light.
Labelling. The label states whether or not the material is suitable for use in the manufacture of parenteral preparations or for the preparation of dialysis solutions.

Sodium Chloride and Dextrose Injection

Sodium Chloride and Dextrose Intravenous Infusion; Sodium Chloride and Glucose Injection; Sodium Chloride and Glucose Intravenous Infusion

Sodium Chloride and Dextrose Injection is a sterile solution of Sodium Chloride and Dextrose in Water for Injections.

Sodium Chloride and Dextrose Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amounts of sodium chloride, NaCl, and dextrose, C₆H₁₂O₆.

Description. A clear, colourless or faintly straw-coloured solution.

Identification

A. To 1 ml add 0.05 ml of potassium cupri-tartrate solution; the solution remains blue and clear. Heat to boiling, a copious red precipitate is formed.

B. Gives reaction B of sodium salts and reaction A of chlorides (2.3.1).

Tests

pH (2.4.24). 3.5 to 6.5.

5-Hydroxymethylfurfural and related substances. Dilute a volume containing 1.0 g of dextrose, C₆H₁₂O₆, to 500 ml with water and measure the absorbance of the resulting solution at the maximum at about 284 nm (2.4.7); absorbance at about 284 nm, not more than 0.25.

Bacterial endotoxins (2.2.3). Not more than 10 Endotoxin Units per g of dextrose.

Other tests. Complies with the tests stated under Parenteral Preparations (Intravenous Infusions).

Assay. For sodium chloride — Titrate an accurately measured volume containing 0.1 g of Sodium Chloride with 0.1 M silver nitrate using potassium chromate solution as indicator.

1 ml of 0.1 M silver nitrate is equivalent to 0.005844 g of NaCl.

For dextrose — To an accurately measured volume containing 2 to 5 g of anhydrous dextrose, C₆H₁₂O₆, add 0.2 ml of 5 M ammonia and sufficient water to produce 100.0 ml. Mix well, allow to stand for 30 minutes and measure the optical rotation in a 2-dm tube (2.4.22). The observed rotation in degrees multiplied by 0.9477 represents the weight, in g, of dextrose, C₆H₁₂O₆, in the volume of the injection taken for assay.

Storage. Store in single dose containers. On keeping, small solid particles may separate from a glass container.

Labelling. The label states (1) the strength as the percentages w/v of Sodium Chloride and Dextrose; (2) that a solution containing visible particles must not be used.

When the preparation is intended for intravenous infusion, the label states the approximate concentrations, in millimoles per litre, of the sodium and chloride ions and the number of grams per litre of dextrose, C₆H₁₂O₆.

Sodium Chloride and Fructose Injection

Sodium Chloride and Fructose Intravenous Infusion; Sodium Chloride and Fructose Infusion; Fructose and Sodium Chloride Injection.

Sodium Chloride and Fructose Injection is a sterile solution of Sodium Chloride and Fructose in Water for Injections.

Sodium Chloride and Fructose Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amounts of sodium chloride, NaCl, and fructose, C₆H₁₂O₆. It contains no antimicrobial agent.

Description. A clear, colourless or faintly straw-coloured solution.

Identification

A. To 1 ml add 0.05 ml of potassium cupri-tartrate solution; the solution remains blue and clear. Heat to boiling, a copious red precipitate is formed.

B. The solution prepared in the Assay is laevo-rotatory.

C. Gives reaction B of sodium salts and reaction A of chlorides (2.3.1).

Tests

pH (2.4.24). 3.0 to 6.0.

5-Hydroxymethylfurfural and related substances. Dilute a volume containing 1.0 g of Fructose to 500.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 284 nm (2.4.7); absorbance at about 284 nm, not more than 0.50.

Heavy metals (2.3.13). Evaporate a volume containing 4.0 g of Fructose to 10 ml and add 2 ml of dilute acetic acid and sufficient water to produce 25 ml. The solution complies with the limit test for heavy metals, Method A (5 ppm).
Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Bacterial endotoxins (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

Assay. For sodium chloride — Titrate an accurately measured volume containing about 0.1 g of Sodium Chloride with 0.1 M silver nitrate using potassium chromate solution as indicator. 1 ml of 0.1 M silver nitrate is equivalent to 0.005844 g of NaCl.

For fructose — To an accurately measured volume containing about 5.0 g of Fructose, add 0.2 ml of 6 M ammonia and sufficient water to produce 100.0 ml. Mix well, allow to stand for 30 minutes and measure the optical rotation in a 2-dm tube (2.4.22). The observed rotation in degrees multiplied by 0.5427 represents the weight, in g, of fructose, C6H12O6, in the volume taken for assay.

Storage. Store in single dose containers. On keeping, small solid particles may separate from glass containers.

Labelling. The label states (1) the strength as the percentages w/v of Sodium Chloride and Fructose; (2) when the preparation is intended for intravenous infusion, the approximate concentrations, in millimoles per litre, of the sodium and chloride ions and the number of grams per litre of fructose; (3) that a solution containing visible particles should not be used.

### Compound Sodium Chloride and Dextrose Injection

Compound Sodium Chloride and Dextrose Injection is a sterile solution containing 0.86 per cent w/v of Sodium Chloride, 0.03 per cent w/v of Potassium Chloride, 0.033 per cent w/v of Calcium Chloride and 5 per cent w/v of Dextrose in Water for Injections.

Compound Sodium Chloride and Dextrose Injection contains not less than 0.82 per cent and not more than 0.90 per cent w/v of sodium chloride, NaCl, not less than 0.0285 per cent and not more than 0.0315 per cent w/v of potassium chloride, KCl, not less than 0.030 per cent and not more than 0.036 per cent w/v of calcium chloride, CaCl2,2H2O, and not less than 0.523 per cent and not more than 0.580 per cent w/v of chloride, Cl, and not less than 4.75 per cent and not more than 5.25 per cent w/v of dextrose, C6H12O6. It contains no antimicrobial agent.

Description. A clear, colourless or faintly straw-coloured solution.

Identification

A. To 1 ml add 0.05 ml of potassium cupri-tartrate solution; the solution remains blue and clear. Heat to boiling, a copious red precipitate is formed.

B. Gives reaction B of sodium salts and reaction A of chlorides (2.3.1).

C. After evaporation to one half of its original volume, the solution gives reaction A of potassium salts and reaction B of calcium salts (2.3.1).

Tests

pH (2.4.24). 3.5 to 6.5.

5-Hydroxymethylfurfural and related substances. Dilute a volume containing 1.0 g of Dextrose to 500.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 284 nm; absorbance at about 284 nm, not more than 0.25 (2.4.7).

Bacterial endotoxins (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. For sodium chloride — Dilute suitably with water and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 589 nm and using sodium solution FP or sodium solution AAS respectively, suitably diluted with water for the standard solutions. 1 g of Na is equivalent to 2.542 g of NaCl.

For potassium chloride — Dilute suitably with water and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 767 nm and using potassium solution FP or potassium solution AAS respectively, suitably diluted with water for the standard solutions. 1 g of K is equivalent to 1.907 g of KCl.

For calcium chloride — To 50.0 ml add 5.0 ml of 0.01 M magnesium sulphate and 5 ml of ammonia buffer pH 10.9 and titrate with 0.01 M disodium edetate using eriochrome black T mixture as indicator. From the volume of 0.01 M disodium edetate required subtract the volume of 0.01 M magnesium sulphate added. 1 ml of the remainder of 0.01 M disodium edetate is equivalent to 0.00147 g of CaCl2,2H2O.

For total chloride — To 20.0 ml add 30 ml of water, 50.0 ml of 0.1 M silver nitrate and 2 ml of nitric acid. Filter, wash the precipitate with water slightly acidified with nitric acid and titrate the excess of silver nitrate with 0.1 M ammonium

1085
thiocyanate using ferric ammonium sulphate solution as indicator until a reddish yellow colour is produced. Carry out a blank titration.

1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of total Chloride, calculated as Cl.

For dextrose — To an accurately measured volume containing 2 g to 5 g of Dextrose, add 0.2 ml of 5 M ammonia and sufficient water to produce 100.0 ml. Mix well, allow to stand for 30 minutes and measure the optical rotation in a 2-dm tube (2.4.22). The observed rotation in degrees multiplied by 0.9477 represents the weight, in g, of dextrose, \(C_6H_{12}O_6\), in the volume taken for assay.

Storage. Store in single dose containers of glass or plastic at a temperature not exceeding 30º. On keeping, small solid particles may separate from the solution in glass containers.

Labelling. The label states (1) the strength as the percentages w/v of Sodium Chloride, Potassium Chloride, Calcium Chloride and Dextrose; (2) that the injection contains, in millimoles per litre, the following approximate amounts of the ions: sodium, 147.5, potassium, 4, calcium, 4.5, and Chloride, 156; (3) the total osmolar concentration in mOsmol per litre; (4) that the injection should not be used if it contains visible particles.

**Sodium Chloride Hypertonic Injection**

Hypertonic Saline

Sodium Chloride Hypertonic Injection is a sterile 1.6 per cent w/v solution of Sodium Chloride in Water for Injections. It contains no antimicrobial agent.

Sodium Chloride Hypertonic Injection contains not less than 1.52 per cent w/v and not more than 1.68 per cent w/v of sodium chloride, NaCl.

Description. A clear, colourless solution.

Identification

Gives the reactions of sodium salts and reaction A of chlorides (2.3.1).

Tests

pH (2.4.24). 5.0 to 7.5.

Heavy metals (2.3.13). Evaporate 40 ml to about 20 ml, add 2 ml of dilute acetic acid and dilute to 25 ml with water. The solution complies with the limit test for heavy metals, Method A (0.5 ppm).

Bacterial endotoxins (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

Other tests. Complies with the tests stated under Parenteral Preparations (Intravenous Infusions).

Assay. To an accurately measured volume containing about 0.16 g of Sodium Chloride in a glass-stoppered flask add 50 ml of water and 50.0 ml of 0.1 M silver nitrate, 5 ml of 2 M nitric acid and 2 ml of dibutyl phthalate. Shake well and titrate with 0.1 M ammonium thiocyanate using 2 ml of ferric ammonium sulphate solution as indicator, until the colour becomes reddish yellow.

1 ml of 0.1 M silver nitrate is equivalent to 0.005844 g of NaCl.

Storage. Store in single dose containers of glass or plastic. On keeping, small solid particles may separate from a glass container.

Labelling. The label states (1) the strength as the percentage w/v of Sodium Chloride; (2) that a solution containing visible solid particles must not be used.

When the preparation is intended for intravenous infusion, the label states that the injection contains approximately 270 millimoles each of sodium and chloride ions per litre.

**Sodium Chloride Injection**

Sodium Chloride Intravenous Infusion

Sodium Chloride Injection is a sterile 0.9 per cent w/v solution of Sodium Chloride in Water for Injections. It contains no antimicrobial agent.

Sodium Chloride Injection contains not less than 0.85 per cent w/v and not more than 0.95 per cent w/v of sodium Chloride, NaCl.

Description. A clear, colourless solution.

Identification

Gives the reactions of sodium salts and reaction A of chlorides (2.3.1).

Tests

pH (2.4.24). 4.5 to 7.0.

Heavy metals (2.3.13). Evaporate 67 ml to about 20 ml, add 2 ml of dilute acetic acid and dilute to 25 ml with water. The solution complies with the limit test for heavy metals, Method A (0.3 ppm).

Bacterial endotoxins (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

Other tests. Complies with the tests stated under Parenteral Preparations (Intravenous Infusions).
Assay. To an accurately measured volume containing about 0.16 g of Sodium Chloride in a glass-stoppered flask add 50 ml of water and 50.0 ml of 0.1 M silver nitrate, 5 ml of 2 M nitric acid and 2 ml of dibutyl phthalate. Shake well and titrate with 0.1 M ammonium thiocyanate using 2 ml of ferric ammonium sulphate solution as indicator, until the colour becomes reddish yellow.

1 ml of 0.1 M silver nitrate is equivalent to 0.005844 g of NaCl.

Storage. Store in single dose containers of glass or plastic. On keeping, small solid particles may separate from a glass container.

Labelling. The label states (1) the strength as the percentage w/v of Sodium Chloride; (2) that a solution containing visible solid particles must not be used.

When the preparation is intended for intravenous infusion, the label states that the injection contains approximately 150 millimoles each of sodium and chloride ions per litre.

### Compound Sodium Chloride Injection

Ringer’s Injection

Compound Sodium Chloride Injection is a sterile solution containing 0.86 per cent w/v of Sodium Chloride, 0.03 per cent w/v of Potassium Chloride and 0.033 per cent w/v of Calcium Chloride in Water for Injections. It contains no antimicrobial agent.

Compound Sodium Chloride Injection contains not less than 0.82 per cent w/v and not more than 0.90 per cent w/v of sodium chloride, NaCl, not less than 0.0285 per cent w/v and not more than 0.0315 per cent w/v of potassium chloride, KCl, and not less than 0.030 per cent w/v and not more than 0.036 per cent w/v of calcium chloride, CaCl₂, 2H₂O.

Description. A clear, colourless solution.

Identification

Gives reaction B of sodium salts and reaction A of chlorides (2.3.1). When concentrated to one half of its original volume, it gives reaction A of potassium salts and reaction B of calcium salts (2.3.1).

**Tests**

**pH** (2.4.24). 5.0 to 7.5.

**Heavy metals** (2.3.13). Evaporate 67 ml to about 20 ml, add 2 ml of dilute acetic acid and dilute to 25 ml with water. The solution complies with the limit test for heavy metals, Method A (0.3 ppm).

**Bacterial endotoxins** (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

### Compound Sodium Chloride Solution

Ringer’s Solution

Compound Sodium Chloride Solution is a solution containing 0.86 per cent w/v of Sodium Chloride, 0.03 per cent w/v of Potassium Chloride and 0.033 per cent w/v of Calcium Chloride in Purified Water. The solution may be clarified by filtration.

Compound Sodium Chloride Solution contains not less than 0.82 per cent w/v and not more than 0.90 per cent of sodium chloride, NaCl, not less than 0.025 per cent and not more than 0.035 per cent w/v of potassium chloride, KCl, and not less than 0.030 per cent and not more than 0.036 per cent w/v of calcium chloride, CaCl₂, 2H₂O.
Description. A clear, colourless solution.

Identification

Gives reaction B of sodium salts and reaction A of chlorides (2.3.1). When concentrated to one half of its original volume, it gives reaction A of potassium salts and reaction B of calcium salts (2.3.1).

Tests

pH (2.4.24). 5.0 to 7.5.

Heavy metals (2.3.13). Evaporate 67 ml to about 20 ml, add 2 ml of *dilute acetic acid* and dilute to 25 ml with water. The solution complies with the limit test for heavy metals, Method A (0.3 ppm).

Assay. For sodium chloride — Dilute appropriately with water and determine by Method A for flame photometry (2.4.4), measuring at 589 nm or by Method A for atomic absorption spectrophotometry (2.4.2), using *sodium solution FP*, suitably diluted with water for the standard solutions.

1 g of Na is equivalent to 2.54 g of NaCl.

For potassium chloride — Dilute appropriately with water and determine by Method A for flame photometry (2.4.4), measuring at 767 nm or by Method A for atomic absorption spectrophotometry (2.4.2), using *potassium solution FP*, suitably diluted with water for the standard solutions.

1 g of K is equivalent to 1.007 g of KCl.

For calcium Chloride — To 50.0 ml add 5.0 ml of 0.01 M magnesium sulphate and 5 ml of ammonia buffer pH 10.9 and titrate with 0.01 M disodium edetate using *mordant black II mixture* as indicator. From the volume of 0.01 M disodium edetate required subtract the volume of 0.01M magnesium sulphate added.

1 ml of the remainder of 0.01 M disodium edetate is equivalent to 0.00147 g of CaCl₂, 2H₂O.

Sterility (2.2.11). Complies with the test for sterility.

Storage. Store protected from light.

Labelling. The label states the strength as the percentages w/v of Sodium Chloride, Potassium Chloride and Calcium Chloride. If the contents of the container are sterile, the label states (1) Sterile Compound Sodium Chloride Solution; (2) that the solution should not be used if it contains visible particles; (3) ‘For Irrigation only’ and ‘Not for Injection’; (4) that once the container is opened, the unused portion should be discarded.

Sodium Chloride Irrigation Solution

Sodium Chloride Irrigation Solution contains not less than 0.85 per cent w/v and not more than 0.95 per cent w/v of sodium chloride, NaCl. It contains no antimicrobial agent.

Description. A clear, colourless solution.

Identification

Gives the reactions of sodium salts and reaction A of chlorides (2.3.1).

Tests

pH (2.4.24). 4.5 to 7.0.

Heavy metals (2.3.13). Evaporate 67 ml to about 20 ml, add 2 ml of *dilute acetic acid* and dilute to 25 ml with water. The solution complies with limit test for heavy metals, Method A (0.3 ppm).

Bacterial endotoxins (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. Titrate an accurately measured volume containing about 0.135 g of Sodium Chloride with 0.1 M silver nitrate using *potassium chromate solution* as indicator.

1 ml of 0.1 M silver nitrate is equivalent to 0.005844 g of NaCl.

Storage. Store in single dose containers. The container may be designed to empty rapidly and may contain a volume of more than 1 litre.

Labelling. The label states (1) the strength as the percentage w/v of Sodium Chloride; (2) that the solution should not be used if it contains visible particles; (3) ‘For Irrigation only’ and ‘Not for Injection’; (4) that once the container is opened, the unused portion should be discarded.

Sodium Citrate

Trisodium Citrate

\[
\text{NaOOC-COONa}_3 \cdot 2\text{H}_2\text{O}
\]

C₆H₅Na₃O₇·2H₂O  Mol. Wt. 294.1

Sodium Citrate is trisodium 2-hydroxypropane-1,2,3-tricarboxylate dihydrate.

Sodium Citrate contains not less than 99.0 per cent and not more than 101.0 per cent of C₆H₅Na₃O₇, calculated on the anhydrous basis.

Description. White, granular crystals or a white, crystalline powder; odourless; slightly deliquescent in moist air.
Identification

A. 10.0 per cent w/v solution in carbon dioxide-free water (solution A) gives the reactions of sodium salts and reaction A of citrates (2.3.1).

Tests

Appearance of solution. Solution A is clear (2.4.1), and colourless (2.4.1).

Acidity or alkalinity. Titrate 20 ml of solution A with 0.05 M sulphuric acid or 0.1 M sodium hydroxide using thymol blue solution as indicator; not more than 0.5 ml of 0.05 M sulphuric acid or 0.1 M sodium hydroxide is required.

Arsenic (2.3.10). Dissolve 5.0 g in 50 ml of water and add 15 ml of stannated hydrochloric acid \textit{AsT}. The resulting solution complies with the limit test for arsenic (2 ppm).

Heavy metals (2.3.13). Dissolve 2.0 g in 10 ml of water, 5 ml of dilute hydrochloric acid and sufficient water to produce 25 ml. The solution complies with the limit test for heavy metals, Method A (10 ppm).

Chlorides (2.3.12). 25 ml of solution A complies with the limit test for chlorides (100 ppm).

Oxalate. Dissolve 0.5 g in 4 ml of water, add 3 ml of hydrochloric acid and 1 g of zinc, in granules, and heat on a water-bath for 1 minute. Allow to stand for 2 minutes, decant the liquid into a test-tube containing 0.25 ml of a 1 per cent w/v solution of phenylhydrazine hydrochloride and heat to boiling. Cool rapidly, transfer to a graduated cylinder and add an equal volume of hydrochloric acid and 0.25 ml of potassium ferrocyanide solution. Shake and allow to stand for 30 minutes. Any pink colour produced is not more intense than that produced. Weigh accurately about 0.15 g and dissolve in 20 ml of anhydrous glacial acetic acid, warming to about 50°. Allow to cool. Titrate with 0.1 M perchloric acid, using 0.25 ml of 1-naphtholbenzeno solution as indicator. Carry out a blank titration. 1 ml of 0.1 M perchloric acid is equivalent to 0.008602 g of \textit{C}_{23}\textit{H}_{14}\textit{Na}_{2}\textit{O}_{11}\textit{.}

Storage. Store protected from light.

Sodium Cromoglycate

Sodium Cromoglycate

\[
\text{NaOOC} \quad \text{O} \quad \text{OH} \quad \text{O} \quad \text{COONa}
\]

\[
\text{C}_{23}\text{H}_{14}\text{Na}_{2}\text{O}_{11}, \quad \text{Mol. Wt. 512.3}
\]

Sodium Cromoglycate is disodium 4,4′-dioxo-5,5′-(2-hydroxytrimethylenedioxy)dichromene-2-carboxylate.

Sodium Cromoglycate contains not less than 98.0 per cent and not more than 101.0 per cent of \textit{C}_{23}\textit{H}_{14}\textit{Na}_{2}\textit{O}_{11}, calculated on the dried basis.

Description. A white, crystalline powder; odourless; hygroscopic.

Identification

Test \textit{A} may be omitted if tests \textit{B}, \textit{C} and \textit{D} are carried out. Tests \textit{B} and \textit{C} may be omitted if tests \textit{A} and \textit{D} are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with \textit{sodium cromoglycate RS} or with the reference spectrum of sodium cromoglycate.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in phosphate buffer \textit{pH} 7.4 shows absorption maxima at about 239 nm and 327 nm. The ratio of the absorbance at 327 nm to that at about 239 nm, 0.25 to 0.30.

C. Dissolve about 5 mg in 0.5 ml of methanol, add 3 ml of a solution in methanol containing 0.5 per cent w/v of 4-aminophenazone and 1 per cent v/v of hydrochloric acid and allow to stand for 5 minutes; an intense yellow colour is produced.

D. Gives reaction \textit{A} of sodium salts (2.3.1).

Tests

Appearance of solution. A 2.0 per cent w/v solution in carbon dioxide-free water is not more opalescent than opalescence standard OS2 (2.4.1), and not more intensely coloured than reference solution BYS5 (2.4.1).
Acidity or alkalinity. To 10 ml of a 2.0 per cent w/v solution in carbon dioxide-free water add 0.1 ml of phenolphthalein solution; the solution is colourless. Add 0.2 ml of 0.01 M sodium hydroxide; the solution is pink. Add 0.4 ml of 0.01 M hydrochloric acid; the solution is colourless. Add 0.25 ml of methyl red solution; the solution is red.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 50 volumes of ethyl acetate, 50 volumes of toluene and 5 volumes of glacial acetic acid.

Test solution. A 2per cent w/v solution of the substance under examination in a mixture of 6 volumes of water, 4 volumes of tetrahydrofuran and 1 volume of acetone.

Reference solution. A 0.01 per cent w/v of 1,3-bis(2-acetyl-3-hydroxyphenoxy)-2-propanol RS in chloroform.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the reference solution is not more intense than the spot in the chromatogram obtained with the test solution. The principal spot does not move from the line of application.

Heavy metals (2.3.13). 2.0 g complies with the limit test for heavy metals, Method A (10 ppm).

Oxalate. Dissolve 0.1 g in 20 ml of water, add 5.0 ml of iron salicylate solution and sufficient water to produce 50 ml. Measure the absorbance of the resulting solution at the maximum at about 480 nm (2.4.7). The absorbance is not less than that obtained by repeating the operation using 0.35 mg of oxalic acid in place of the substance under examination.

Loss on drying (2.4.19). Not more than 10.0 per cent, determined on 0.5 g by drying over phosphorus pentoxide at 105º at a pressure of 0.3 kPa to 0.6 kPa.

Assay. Weigh accurately about 0.2 g, dissolve in a mixture of 25 ml of ethane-1,2-diol and 5 ml of 2-propanol with the aid of heat and cool, add 30 ml of dioxan. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02562 g of C23H14Na2O11.

Storage. Store protected from moisture.

Sodium Cromoglycate Powder for Inhalation

Sodium Cromoglicate Powder for Inhalation; Sodium Cromoglycate Insufflation

Sodium Cromoglycate Powder for Inhalation consist of hard gelatin capsules containing either Sodium Cromoglycate appropriately treated or Sodium Cromoglycate admixed with an approximately equal amount of Lactose. The contents of the capsules are in powder of a suitable fineness.

Sodium Cromoglycate Powder for Inhalation contain not less than 100.0 per cent and not more than 120.0 per cent of the stated amount of sodium cromoglycate, C23H14Na2O11.

Description. A white powder; hygroscopic.

Identification

A. Dissolve a suitable quantity in sufficient phosphate buffer pH 7.4 to produce a solution containing 0.001 per cent w/v of Sodium Cromoglycate.

When examined in the range 230 nm to 360 nm, (2.4.7), the resulting solution shows absorption maxima at about 239 nm and 327 nm.

B. To a quantity containing 0.1 g of Sodium Cromoglycate add 2 ml of water and 2 ml of 1.25 M sodium hydroxide and boil for 1 minute; a yellow colour is produced. Add 0.5 ml of diazobenzenesulphonic acid solution; a blood-red colour is produced.

C. Gives reaction A of sodium salts (2.3.1).

D. For capsules containing Lactose, the contents on heating with potassium cupri-tartrate solution give a copious red precipitate.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 50 volumes of ethyl acetate, 50 volumes of toluene and 5 volumes of glacial acetic acid.

Test solution. Dissolve a quantity containing 0.1 g of Sodium Cromoglycate in sufficient of a mixture of 6 volumes of water, 4 volumes of tetrahydrofuran that has been freed from stabiliser by passage through a column of suitable alumina and 1 volume of acetone to produce 5 ml and filter.

Reference solution. Dilute 1 volume of the test solution to 200 volumes with the same solvent.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution. The principal spot does not move from the line of application.

Uniformity of weight. Weigh one capsule. Open without loss of shell material, remove the contents and weigh all parts of the shell; the difference between the weights represents the weight of the contents. Repeat the operation with a further 19
capsules and calculate the average weight of the contents of the 20 capsules.

For preparations containing no Lactose the weight of the contents of each capsule does not deviate from the average weight by more than 25 per cent. For preparations containing Lactose, the weight of the contents of each capsule does not deviate from the average weight by more than 15 per cent except that, for two capsules, the weight of the contents may deviate by more than 25 per cent.

**Loss on drying** (2.4.19). 9.0 to 18.0 per cent for capsules containing no Lactose and 5.5 to 10.0 per cent for capsules containing Lactose, determined on 0.5 g by drying in an oven at 105º at a pressure not exceeding 0.7 kPa.

**Assay.** Weigh accurately a quantity of the mixed contents of 20 capsules containing about 0.1 g of Sodium Cromoglycate, dissolve in sufficient phosphate buffer pH 7.4 to produce 200.0 ml. Dilute 5.0 ml to 100.0 ml with phosphate buffer pH 7.4 and measure the absorbance of the resulting solution at 327 nm (2.4.7).

Calculate the content of C$_2$H$_{14}$Na$_2$O$_{11}$ in a capsule of average content weight taking 164 as the specific absorbance at 327 nm.

**Storage.** Store protected from light and moisture at a temperature not exceeding 30º.

**Labelling.** The label states (1) the strength in terms of the equivalent amount of Sodium Cromoglycate; (2) that the capsules are intended for use in an inhaler and are not to be swallowed; (3) where applicable, that the capsules contain Lactose.

**Sodium Diatrizoate**

Diatrizoate Sodium

\[
\text{C}_11\text{H}_8\text{I}_3\text{N}_2\text{NaO}_4 \quad \text{Mol. Wt. 635.9}
\]

Sodium Diatrizoate is sodium 3,5-diacetamido-2,4,6-triiodobenzoate.

Sodium Diatrizoate contains not less than 98.0 per cent and not more than 101.0 per cent of C$_{11}$H$_8$I$_3$N$_2$NaO$_4$, calculated on the anhydrous basis.

**Description.** A white powder; odourless or almost odourless.

**Identification**

Tests A and D may be omitted if tests B, C, E and F are carried out. Tests B, C and F may be omitted if tests A, D and E are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sodium diatrizoate RS or with the reference spectrum of sodium diatrizoate.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 20 volumes of chloroform, 10 volumes of methanol and 2 volumes of strong ammonia solution.

**Test solution.** Dissolve 0.1 g of the substance under examination in 100 ml of 0.08 per cent w/v solution of sodium hydroxide in methanol.

**Reference solution.** A 0.1 per cent w/v of sodium diatrizoate RS in 0.08 per cent w/v solution of sodium hydroxide in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

C. Heat 0.5 g in a crucible; violet vapours of iodine are evolved.

D. To 20 mg add 5 ml of 1 M sodium hydroxide and boil gently under a reflux condenser for 10 minutes. Cool, add 5 ml of 2 M hydrochloric acid and cool in ice for 5 minutes. Add 4 ml of a 1 per cent w/v solution of sodium nitrite, cool in ice for 5 minutes, add 0.3 g of sulphamic acid, shake gently until effervescence ceases and add 2 ml of a 0.4 per cent w/v solution of N-(1-naphthyl) ethylenediamine dihydrochloride; an orange-red colour is produced.

E. Heat 0.5 g with 1 ml of sulphuric acid on a water-bath until a pale violet solution is produced, add 2 ml of ethanol (95 per cent) and heat again; odour of ethyl acetate is produced.

F. Gives the reactions of sodium salts (2.3.1).

**Tests**

**pH** (2.4.24). 7.5 to 9.5, determined in a 50 per cent w/v solution.

**Free amine.** Place 1.0 g in a 50-ml glass-stoppered volumetric flask, add 5 ml of water, 10 ml of 0.1 M sodium hydroxide and 25 ml of dimethyl sulphoxide. Stopper the flask, mix the contents gently and cool in ice, protected from light. After 5 minutes, slowly add 2 ml of hydrochloric acid, mix and allow to stand for 5 minutes. Add 2 ml of a 2 per cent w/v solution of sodium nitrite, mix and allow to stand for 5 minutes. Add 1 ml...
of an 8 per cent w/v solution of **sulphamic acid**, mix and allow to stand for 5 minutes. Add 2 ml of a 0.1 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride in a 70 per cent w/v solution of 1,2-propanediol and mix. Remove the flask from the ice and allow to stand in water at 25º ± 2º for 10 minutes, with occasional shaking. Add sufficient **dimethyl sulfoxide** to produce 50 ml and mix. Within 5 minutes, measure the absorbance of the resulting solution at the maximum at about 470 nm (2.4.7), using as the blank a solution prepared by treating 5 ml of water in the same manner; absorbance, not more than 0.40, calculated on the anhydrous basis.

**Free iodine and iodide.** Dissolve 2.0 g in 24 ml of water taken in a 50-ml glass-stoppered centrifuge tube. Add 5 ml of toluene and 5 ml of 1 M sulphuric acid, shake well and centrifuge; no red colour appears in the toluene layer. To the mixture add 1 ml of a 2 per cent w/v solution of sodium nitrite, shake and centrifuge; any red colour in the toluene layer is not more intense than that produced in a solution prepared in the same manner using 2.0 ml of a 0.025 per cent w/v solution of potassium iodide and 22 ml of water (220 ppm).

**Heavy metals.** Dissolve 1.0 g in 20.0 ml of water and 5 ml of 1 M sodium hydroxide, transfer the solution to a 50-ml Nessler cylinder, dilute with water to 40 ml and mix. Add 10 ml of sodium sulphide solution, shake and allow to stand for 5 minutes (20 ppm), the colour of the solution when viewed downward over a white surface is not more intense than that produced by treating 2.0 ml of lead standard solution (10 ppm Pb) in the same manner in place of the substance under examination.

**Water** (2.3.43). 4.0 to 7.0 per cent, determined on 0.4 g.

**Assay.** Weigh accurately about 0.4 g in a glass-stoppered conical flask, add 12 ml of 5 M sodium hydroxide and 1 g of zinc powder and boil under a reflux condenser for 30 minutes. Cool, rinse the condenser with 30 ml of water, filter through cotton and wash the flask and filter with two quantities, each of 20 ml, of water. To the combined filtrate and washings add 80 ml of hydrochloric acid, cool and titrate with 0.05 M potassium iodate until the dark brown colour becomes pale brown. Add 5 ml of chloroform and continue the titration, shaking well after each addition, until the chloroform becomes colourless.

1 ml of 0.05 M potassium iodate is equivalent to 0.02120 g of C₇H₂N₃NaO₃.

**Storage.** Store protected from light.

**Sodium Diatrizoate**

Diatrizoate Sodium Injection

Sodium Diatrizoate Injection is a sterile solution of Sodium Diatrizoate in Water for Injections. It may contain small amounts of suitable buffers, stabilisers and antimicrobial agents but the preparation intended for intravenous administration contains no antimicrobial preservative.

Sodium Diatrizoate Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sodium diatrizoate, C₁₁H₇I₃N₂NaO₄.

**Identification**

Evaporate a volume of the injection containing 1 g of Sodium Diatrizoate to dryness. The residue complies with following tests.

A. Heat 0.5 g of residue in a crucible; violet vapours of iodine are evolved.

B. To 20 mg of the residue add 5 ml of 1 M sodium hydroxide and boil gently under a reflux condenser for 10 minutes. Cool, add 5 ml of 2 M hydrochloric acid and cool in ice for 5 minutes. Add 4 ml of a 1 per cent w/v solution of sodium nitrite, cool in ice for 5 minutes, add 0.3 g of sulphamic acid, shake gently until effervescence ceases and add 2 ml of a 0.4 per cent w/v solution of N-(1-naphthyl) ethylenediamine dihydrochloride; an orange-red colour is produced.

C. Heat 0.5 g of residue with 1 ml of sulphuric acid on a water-bath until a pale violet solution is produced, add 2 ml of ethanol (95 per cent) and heat again; odour of ethyl acetate is produced.

**Tests**

**pH** (2.4.24). 6.6 to 7.6.

**Free amine.** To a volume containing 1.0 g of Sodium Diatrizoate in a 50-ml glass-stoppered volumetric flask, add 5 ml of water, 10 ml of 0.1 M sodium hydroxide and 25 ml of dimethyl sulfoxide. Stopper the flask, mix the contents gently and cool in ice, protected from light. After 5 minutes, slowly add 2 ml of hydrochloric acid, mix and allow to stand for 5 minutes. Add 2 ml of a 2 per cent w/v solution of sodium nitrite, mix and allow to stand for 5 minutes. Add 1 ml of an 8 per cent w/v solution of sulphamic acid, mix and allow to stand for 5 minutes. Add 2 ml of a 0.1 per cent w/v solution of N-(1-naphthyl) ethylenediamine dihydrochloride in a 70 per cent w/v solution of 1,2-propanediol and mix. Remove the flask from the ice and allow to stand in water at 25º ± 2º for 10 minutes, with occasional shaking. Add sufficient dimethyl sulfoxide to produce 50 ml and mix. Within 5 minutes, measure the absorbance of the resulting solution at the maximum at about 470 nm (2.4.7), using as the blank a solution prepared by treating 5 ml of water in the same manner; absorbance, not more than 0.30, calculated on the anhydrous basis.

**Free iodine and iodide.** To a volume containing 2.0 g of Sodium Diatrizoate in 24 ml of water taken in a 50-ml glass-stoppered centrifuge tube add 5 ml of toluene and 5 ml of 1 M sulphuric acid and cool in ice for 5 minutes. Add 2 ml of a 2.0 per cent solution of ferric chloride and mix. Within 5 minutes, measure the absorbance of the resulting solution at the maximum at about 530 nm (2.4.7), using as the blank a solution prepared by treating 5 ml of water in the same manner; absorbance, not more than 0.30, calculated on the anhydrous basis.
acid, shake well and centrifuge; no red colour appears in the toluene layer. To the mixture add 1 ml of a 2 per cent w/v solution of sodium nitrite, shake and centrifuge; any red colour in the toluene layer is not more intense than that produced in a solution prepared in the same manner using 2.0 ml of a 0.025 per cent w/v solution of potassium iodide and 22 ml of water (220 ppm).

Pyrogens (2.2.8). Complies with test for pyrogens, using per kg of the rabbit’s weight a volume containing 2.5 g of Sodium Diatrizoate.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. Weigh accurately about 0.5 g in a glass-stoppered conical flask, add 12 ml of 5 M sodium hydroxide and 1 g of zinc powder and boil under a reflux condenser for 30 minutes. Cool, rinse the condenser with 30 ml of water, filter through cotton and wash the flask and filter with two quantities, each of 20 ml, of water. To the combined filtrate and washings add 80 ml of hydrochloric acid, cool and titrate with 0.05 M potassium iodate until the dark brown colour becomes pale brown. Add 5 ml of chloroform and continue the titration, shaking well after each addition, until the chloroform becomes colourless.

1 ml of 0.05 M potassium iodate is equivalent to 0.02120 g of C₁₁H₈I₃N₂NaO₄.

Storage. Store protected from light.

Labelling. The label states (1) the concentration of the active ingredient; (2) whether the contents are intended for intravenous injection and, if so, that the unused portion remaining in the container after use must be discarded.

Sodium Dihydrogen Phosphate Dihydrate

Sodium Acid Phosphate
NaH₂PO₄,2H₂O Mol. Wt. 156.0

Sodium Dihydrogen Phosphate Dihydrate contains not less than 98.0 per cent and not more than 100.5 per cent of NaH₂PO₄, calculated on the dried basis.

Description. Colourless crystals or a white powder; odourless.

Identification
A. Dissolve 10.0 g in sufficient carbon dioxide-free water to produce 100 ml (solution A). Solution A is faintly acid.
B. Solution A neutralised with a 10 per cent w/v solution of potassium hydroxide gives reaction A of sodium salts (2.3.1).
C. Solution A gives the reactions of phosphates (2.3.1).

Tests

Appearance of solution. Solution A is clear (2.4.1), and colourless (2.4.1).

pH (2.4.24). 4.2 to 4.5, determined in a mixture of 5 ml of solution A and 5 ml of carbon dioxide-free water.

Arsenic (2.3.10). Dissolve 0.5 g in 50 ml of water and add 10 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

Heavy metals (2.3.13). 12 ml of solution A complies with the limit test for heavy metals, Method D (10 ppm). Use lead standard solution (1 ppm Pb) to prepare the standard.

Iron (2.3.14). 20 ml of solution A complies with the limit test for iron (20 ppm).

Chlorides (2.3.12). 10 ml of solution A diluted to 20 ml with water complies with the limit test for chlorides (250 ppm).

Sulphates (2.3.17). To 5 ml of solution A add 0.5 ml of hydrochloric acid and dilute to 15 ml with distilled water; the solution complies with the limit test for sulphates (300 ppm).

Reducing substances. To 5 ml of solution A add 0.25 ml of 0.02 M potassium permanganate and 5 ml of 1 M sulphuric acid and heat in a water-bath for 5 minutes; the pink colour is not completely discharged.

Disodium phosphate. Dilute 10 ml of solution A to 50 ml with water and titrate with 0.05 M sulphuric acid using bromocresol green solution as indicator; not more than 1 ml of 0.05 M sulphuric acid is required.

Loss on drying (2.4.19). 21.5 to 24.0 per cent, determined on 0.25 g by drying in an oven at 130º.

Assay. Weigh accurately about 2.5 g, dissolve in 40 ml of water and titrate with carbonate-free 1 M sodium hydroxide, determining the end-point potentiometrically (2.4.25).

1 ml of 1 M sodium hydroxide is equivalent to 0.120 g of NaH₂PO₄.

Storage. Store protected from moisture.

Sodium Fluoride

NaF Mol. Wt. 41.9

Sodium Fluoride contains not less than 98.5 per cent and not more than 100.5 per cent of NaF, calculated on the dried basis.

Description. A white powder or colourless crystals.
Sodium Formaldehyde Sulphoxylate

**Identification**

A. Dissolve 2.5 g in sufficient *carbon dioxide-free water* without heating to produce 100 ml (solution A). To 2 ml of solution A add 0.5 ml of *calcium chloride solution*; a gelatinous white precipitate is produced which dissolves on adding 5 ml of *chloride solution*.

B. Add about 4 mg to a mixture of 0.1 ml of *alizarin red S solution* and 0.1 ml of *zirconyl nitrate solution* and mix; the colour changes to yellow.

C. Gives reaction A of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** Solution A is clear (2.4.1), and colourless (2.4.1).

**Acidity or alkalinity.** Dissolve 2.5 g of *potassium nitrate* in 40 ml of solution A, dilute to 50 ml with *carbon dioxide-free water*, cool to 0º and add 0.2 ml of *dilute phenolphthalein solution*. If the solution is colourless, not more than 1.0 ml of 0.1 M sodium hydroxide is required to produce a red colour that persists for not less than 15 seconds. If the solution is red, not more than 0.25 ml of 0.1 M hydrochloric acid is required to change the colour of the solution. Reserve the neutralised solution for the test for Fluorosilicate.

**Chlorides** (2.3.12). 40 ml of solution A complies with the limit test for chlorides (250 ppm).

**Fluorosilicate.** Heat to boiling the solution reserved in the test for Acidity or alkalinity and titrate while hot with 0.1 M sodium hydroxide until a red colour is produced. Not more than 1.5 ml of 0.1 M sodium hydroxide is required.

**Sulphates** (2.3.17). Dissolve 0.25 g in 10 ml of a saturated solution of *boric acid* in *distilled water* and add 5 ml of distilled water and 0.6 ml of 7 M hydrochloric acid. The solution complies with the limit test for sulphates (200 ppm). Prepare the standard by mixing together 0.6 ml of 7 M hydrochloric acid, 5 ml of sulphate standard solution (10 ppm SO₄) and 10 ml of a saturated solution of boric acid in distilled water.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 130º for 3 hours.

**Assay.** Weigh accurately about 80 mg, add a mixture of 5 ml of *acetic anhydride* and 20 ml of *anhydrous glacial acetic acid* and heat to dissolve. Cool, add 20 ml of *dioxan*. Titrate with 0.1 M perchloric acid, using *crystal violet solution* as indicator, until a green colour is produced. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.004199 g of NaF.

**Storage.** Store protected from moisture.

### Sodium Formaldehyde Sulphoxylate

![Sodium Formaldehyde Sulphoxylate](image)

CH₃NaO₃S₂H₂O

Mol Wt. 154.1

Sodium Formaldehyde Sulphoxylate is monosodium hydroxymethane sulphinate dihydrate. It may contain a suitable stabilising agent such as sodium carbonate.

Sodium Formaldehyde Sulphoxylate contains an amount of CH₃NaO₃S equivalent to not less than 45.0 per cent and not more than 55.0 per cent of SO₂, calculated on the dried basis.

**Description.** White crystals or hard white masses; odour, characteristic and garlic-like.

**Identification**

A. Dissolve about 4 g in 10 ml of water in a test-tube and add 1 ml of *ammoniacal silver nitrate solution*; metallic silver is produced either as a finely divided grey precipitate or as a bright metallic mirror on the inner surface of the tube.

B. Add about 50 mg to a solution of 40 mg of *salicylic acid* in 5 ml of *sulphuric acid* and warm very gently; a permanent deep red colour develops.

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution in *carbon dioxide-free water* is clear (2.4.1), and colourless (2.4.1).

**Alkalinity.** Dissolve 1.0 g in 50 ml of water and add 0.15 ml of *dilute phenolphthalein solution*; not more than 3.5 ml of 0.05 M sulphuric acid is required to change the colour of the solution.

**pH** (2.4.24). 9.5 to 10.5, determined in a 2.0 per cent w/v solution in carbon dioxide-free water.

**Iron** (2.3.14). Ignite 1.0 g, initially at a low temperature until thoroughly charred and finally at about 600º, preferably in a muffle furnace, until all the carbon has been burnt off. Cool, dissolve the residue in 2 ml of *hydrochloric acid* and dilute to 50 ml with water. Add about 50 mg of *ammonium persulphate* and 5 ml of *ammonium thiocyanate solution*, mix and transfer to a Nessler cylinder. The red colour of the solution is not more intense than that of 1.0 ml of *iron standard solution* (10 ppm) treated in the same manner.

**Sulphides.** Dissolve 6 g in 14 ml of water in a test-tube and wet a strip of *lead acetate paper* in the clear solution; no discolouration is evident within 5 minutes.

**Sodium sulphite.** Not more than 5.0 per cent, calculated as
Na₂SO₃, determined by the following method. Transfer 4.0 ml of the solution obtained in the Assay to a flask, add 2 ml of formaldehyde solution and titrate with 0.1 M iodine that is used for the Assay, adding starch solution towards the end of the titration as indicator.

Calculate the percentage of Na₂SO₃ from the expression $78.775(V₂ - V₁)/W$,

where $V₁$ and $V₂$ are the volumes, in ml, of 0.1 M iodine consumed in this test and in the Assay respectively and $W$ is the weight, in g, of the substance under examination taken for the Assay.

Loss on drying (2.4.19). Not more than 27.0 per cent, determined on 0.5 g by drying in an oven at 105º for 3 hours.

Assay. Weigh accurately about 1.0 g, dissolve in 25 ml of water, add sufficient water to produce 50.0 ml and mix. To 4.0 ml of this solution add 100 ml of water and titrate with 0.1 M iodine using 3 ml of starch solution, added towards the end of the titration, as indicator.

1 ml of 0.1 M iodine is equivalent to 0.001602 g of SO₂.

Storage. Store protected from light and moisture.

Sodium Fusidate

C₃₁H₄₇NaO₆  Mol. Wt. 538.7

Sodium Fusidate is sodium (17Z)-16β-acetoxy-3α,11α-dihydroxyfusida-17(20),24-dien-21-oate, produced by the growth of certain strains of *Fusidium coccineum* or by any other means.

Sodium Fusidate contains not less than 97.5 per cent and not more than 101.0 per cent of C₃₁H₄₇NaO₆, calculated on the anhydrous basis.

Description. A white or almost white, crystalline powder; slightly hygroscopic.

Identification

A. Dissolve 0.1 g in 5 ml of water, add 5 ml of chloroform and 0.1 ml of a 10 per cent w/w solution of phosphoric acid, shake vigorously for 1 minute, allow to separate and filter the lower layer through absorbent cotton covered with anhydrous sodium sulphate. Repeat the extraction with two quantities, each of 5 ml, of chloroform, evaporate the combined extracts at a pressure of 2 kPa, dry the residue over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 2 hours and dissolve in 1 ml of chloroform IR.

On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with fusidic acid RS or with the reference spectrum of fusidic acid.

B. In the test for Related substances, the principal spot in the chromatogram obtained with the test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).

C. Ignite 1 g. The residue gives the reactions of sodium salts (2.3.1).

Tests

Appearance of solution. A 15.0 per cent w/v solution in carbon dioxide-free water is not more intensely coloured than reference solution BS6 (2.4.1).

pH (2.4.24). 7.5 to 9.0, determined in a 1.25 per cent w/v solution.

Specific optical rotation (2.4.22). +5.0º to +8.0º, determined at 20º by dissolving 1.5 g in 25 ml of water, adding 0.1 ml of 5 M ammonia and diluting to 50 ml with water.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 80 volumes of chloroform, 10 volumes of glacial acetic acid, 10 volumes of cyclohexane and 2.5 volumes of methanol.

Test solution (a). Dissolve 0.2 g of the substance under examination in 10 ml of ethanol.

Test solution (b). Dissolve 0.2 g of the substance under examination in 100 ml of ethanol.

Reference solution (a). A 0.24 per cent w/v solution of diethanolamine fusidate RS in ethanol.

Reference solution (b). A 0.04 per cent w/v solution of diethanolamine fusidate RS in ethanol.

Reference solution (c). A 0.04 per cent w/v solution of 3-ketofusidic acid RS in ethanol.

Apply to the plate 5 µl of each solution. After development, dry the plate at 110º for 10 minutes, spray with anhydrous sulphuric acid (10 per cent), dry at 110º for 10 minutes and examine in ultraviolet light at 365 nm. Any red secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained
with reference solution (b). Any yellow secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (c).

**Water** (2.3.43). Not more than 2.0 per cent, determined on 0.5 g.

**Assay.** Weigh accurately about 0.2 g and dissolve in a mixture of 15 ml of water and 20 ml of ethanol (95 per cent). Titrate with 0.1 M hydrochloric acid to pH 4.1, stirring continuously, determining the end-point potentiometrically (2.4.25).

1 ml of 0.1 M hydrochloric acid is equivalent to 0.05387 g of C_{31}H_{47}NaO_{6}.

**Storage.** Store protected from light and moisture.

---

**Sodium Fusidate Capsules**

Sodium Fusidate Capsules contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of sodium fusidate, C_{31}H_{47}NaO_{6}.

**Identification**

A. Dissolve a quantity of the contents of the capsules containing 0.1 g of Sodium Fusidate in 5 ml of water, add 5 ml of chloroform and 0.1 ml of a 10 per cent w/w solution of phosphoric acid, shake vigorously for 1 minute, allow to separate and filter the lower layer through absorbent cotton covered with anhydrous sodium sulphate. Repeat the extraction with two quantities, each of 5 ml, of chloroform, evaporate the combined extracts at a pressure of 2 kPa, dry the residue over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 2 hours and dissolve in 1 ml of chloroform IR.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with fusidic acid RS or with the reference spectrum of fusidic acid.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).

C. Ignite a portion of the contents of the capsules. The residue gives the reactions of sodium salts (2.3.1).

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 80 volumes of chloroform, 10 volumes of glacial acetic acid, 10 volumes of cyclohexane and 2.5 volumes of methanol.

Test solution (a). Extract a quantity of the contents of the capsules containing 50 mg of Sodium Fusidate with 5 ml of ethanol (95 per cent), centrifuge and use the supernatant liquid.

Test solution (b). Dissolve 0.2 g of the substance under examination in 100 ml of ethanol.

Reference solution (a). A 0.24 per cent w/v solution of diethanolamine fusidate RS in ethanol.

Reference solution (b). A 0.04 per cent w/v solution of diethanolamine fusidate RS in ethanol.

Reference solution (c). A 0.04 per cent w/v solution of 3-ketofusidic acid RS in ethanol.

Apply to the plate 5 µl of each solution. After development, dry the plate at 110º for 10 minutes, spray with ethanolic sulphuric acid (10 per cent), dry at 110º for 10 minutes and examine in ultraviolet light (365 nm). Any red secondary spot in the chromatogram obtained with the test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (b). Any yellow secondary spot in the chromatogram obtained with the test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (c).

**Other tests.** Complies with the tests stated under Capsules.

**Assay.** Determine by liquid chromatography (2.4.14)

Test solution. Dissolve a quantity of the mixed contents of 20 capsules containing about 25 mg of Sodium Fusidate in 20.0 ml of the mobile phase.

Reference solution. A 0.15 per cent w/v solution of diethanolamine fusidate RS in the mobile phase.

Chromatographic system
- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm), (such as Lichrosorb RP 18),
- mobile phase: a mixture of 60 volumes of acetonitrile, 30 volumes of a 1 per cent v/v solution of glacial acetic acid and 10 volumes of methanol,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 235 nm,
- a 20 µl loop injector.

Inject alternately the test solution and the reference solution. The column efficiency, determined using the principal peak in the chromatogram obtained with the reference solution, should be not less than 14,000 theoretical plates per metre.

Calculate the content of C_{31}H_{47}NaO_{6} in the capsules.

**Storage.** Store protected from light and moisture.
Sodium Hydroxide

Caustic Soda

NaOH  Mol. Wt. 40.0

Sodium Hydroxide contains not less than 97.0 per cent and not more than 100.5 per cent of total alkali, calculated as NaOH.

Description. White, crystalline masses supplied as sticks, pellets or slabs; deliquescent. Readily absorbs carbon dioxide.

CAUTION — Great care should be exercised in handling Sodium Hydroxide as it rapidly destroys tissues.

Identification

A. Carefully dissolve 5.0 g in 12 ml of distilled water, add 17 ml of 7 M hydrochloric acid, adjust the pH to 7.0 with 1 M hydrochloric acid and add sufficient distilled water to produce 50 ml (solution A). 2 ml of solution A gives reaction A of sodium salts (2.3.1).

B. pH of a 0.01 per cent w/v solution, not less than 11.0 (2.4.24).

Tests

Appearance of solution. A 10.0 per cent w/v solution is clear (2.4.1), and colourless (2.4.1).

Arsenic (2.3.10). Dissolve 2.5 g in 50 ml of water, add 16 ml of brominated hydrochloric acid AsT, and remove the excess of bromine with a few drops of stannous chloride solution AsT. The resulting solution complies with the limit test for arsenic (4 ppm).

Heavy metals (2.3.13). Dissolve 1.0 g in 5 ml of water and 10 ml of 3 M hydrochloric acid, heat to boiling, cool and dilute to 25 ml with water. The solution complies with the limit test for heavy metals, Method A (20 ppm).

Iron (2.3.14). 20 ml of solution A complies with the limit test for iron (20 ppm).

Carbonates. Not more than 2.0 per cent, calculated as Na₂CO₃, determined in the Assay.

Chlorides (2.3.12). Dissolve 2.0 g in 5 ml of water, acidify with about 8 ml of nitric acid and dilute to 20 ml with water. The solution, without the addition of dilute nitric acid, complies with the limit test for chlorides (125 ppm).

Sulphates (2.3.17). Dissolve 2.0 g in 6 ml of distilled water, adjust the pH to 7 with hydrochloric acid and dilute to 20 ml with distilled water. The resulting solution complies with the limit test for sulphates (75 ppm).

Potassium. Acidify 2.5 ml of solution A with acetic acid and add 0.15 ml of sodium cobaltinitrite solution; no precipitate is formed.

Assay. Weigh accurately about 2.0 g, dissolve in about 80 ml of carbon dioxide-free water, add 0.3 ml of phenolphthalein solution and titrate with 1 M hydrochloric acid. Add 0.3 ml of methyl orange solution and continue the titration with 1 M hydrochloric acid.

1 ml of 1 M hydrochloric acid used in the second part of the titration is equivalent to 0.0530 g of Na₂CO₃.

1 ml of 1 M hydrochloric acid used in the combined titrations is equivalent to 0.0400 g of total alkali, calculated as NaOH.

Storage. Store protected from moisture, in non-metallic containers.

Sodium Lactate Injection

Sodium Lactate Injection is a sterile solution containing 1.85 per cent w/v of sodium lactate in Water for Injections. It is prepared from Lactic Acid with the aid of Sodium Hydroxide and sufficient Dilute Hydrochloric Acid to adjust the pH of the solution.

Sodium Lactate Injection contains not less than 1.75 per cent and not more than 1.95 per cent w/v of sodium lactate, C₃H₅NaO₃.

Description. A clear, colourless solution.

Identification

A. When warmed with potassium permanganate, gives acetaldehyde, recognisable by its odour.

B. The residue on evaporation, when moistened with hydrochloric acid and introduced on a platinum wire into a flame, imparts a yellow colour to the flame.

C. Carry out reaction C of calcium salts (2.3.1); no white precipitate is produced.

Tests

pH (2.4.24). 5.0 to 7.0.

Bacterial endotoxins (2.2.3). Not more than 2.0 Endotoxin Units per millimole.

Other tests. Complies with the tests stated under Parenteral Preparations (Intravenous Infusions).

Assay. Measure accurately 10 ml, evaporate to dryness in a platinum dish and ignite very gently until completely carbonised. Boil the residue with 25.0 ml of 0.05 M sulphuric acid, filter and wash thoroughly with hot water. Titrate the excess of acid in the combined filtrate and washings with 0.1 M sodium hydroxide using methyl orange solution as indicator.

1 ml of 0.05 M sulphuric acid is equivalent to 0.01121 g of C₃H₅NaO₃.
**Storage.** Store in single dose containers of glass or plastic. On keeping, small solid particles may separate from the solution in glass containers.

**Labelling.** The label states (1) that the Injection is one-sixth molar and contains, in one litre, approximately 167 millimoles each of sodium ions and of bicarbonate ions (as lactate); (2) that the injection should not be used if the solution contains visible solid particles.

### Compound Sodium Lactate and Dextrose Injection

Compound Sodium Lactate with Dextrose Intravenous Infusion; Ringer-Lactate Solution with Dextrose for Injection; Hartmann’s Solution with Dextrose for Injection.

Compound Sodium Lactate and Dextrose Injection is a sterile solution containing 0.24 per cent v/v of Lactic Acid (equivalent to 0.32 per cent w/v of sodium lactate) with 0.6 per cent w/v of Sodium Chloride, 0.04 per cent w/v of Potassium Chloride, 0.027 per cent w/v of Calcium Chloride and 5 per cent w/v of Dextrose in Water for Injections.

Compound Sodium Lactate and Dextrose Injection contains not less than 0.27 per cent and not more than 0.32 per cent w/v of sodium, Na, not less than 0.019 per cent and not more than 0.022 per cent w/v of potassium, K, not less than 0.37 per cent and not more than 0.42 per cent w/v of total chloride, Cl, not less than 0.025 per cent and not more than 0.029 per cent w/v of calcium chloride, CaCl₂,2H₂O, and not less than 0.23 per cent and not more than 0.28 per cent w/v of lactate, calculated as C₆H₁₂O₆, and not less than 4.50 per cent and not more than 5.25 per cent w/v of dextrose, C₆H₁₂O₆. It contains no antimicrobial agent.

**Description.** A clear, colourless or faintly straw-coloured solution.

**Identification.**

A. To 1 ml add 0.05 ml of *potassium cupri-tartrate solution*; the solution remains blue and clear. Heat to boiling, a copious red precipitate is formed.

B. When warmed with *potassium permanganate* gives acetaldehyde, recognisable by its odour.

C. The residue on evaporation, when moistened with *hydrochloric acid* and introduced on a platinum wire into a flame imparts a yellow colour to the flame. When viewed through a suitable blue glass, the flame is tinged reddish purple.

D. Gives reaction C of calcium salts and reaction A of chlorides (2.3.1).

**Tests**

**pH** (2.4.24). 4.0 to 6.5.

**5-Hydroxymethylfurfural and Related substances.** Dilute a volume containing 1.0 g of Dextrose to 500.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 284 nm; absorbance at about 284 nm, not more than 0.25 (2.4.7).

**Heavy metals** (2.3.13). Evaporate a volume containing 4 g of dextrose to 10 ml and add 2 ml of *dilute acetic acid* and sufficient water to produce 25 ml. The solution complies with the limit test for heavy metals, Method A (5 ppm).

**Bacterial endotoxins** (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** For *sodium* — Dilute suitably with water and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 589 nm and using sodium solution FP or sodium solution AAS respectively, suitably diluted with water for the standard solutions.

For *potassium* — Dilute suitably with water and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 767 nm and using potassium solution FP or potassium solution AAS respectively, suitably diluted with water for the standard solutions.

For *total chlorides* — To 20.0 ml add 30 ml of water, 50.0 ml of 0.1 M silver nitrate and 2 ml of *nitric acid*. Filter, wash the precipitate with water slightly acidified with *nitric acid* and titrate the excess of silver nitrate with 0.1 M ammonium thiocyanate using *ferric ammonium sulphate* solution as indicator until a reddish yellow colour is produced. Carry out a blank titration.

1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of total chloride, calculated as Cl.

For *calcium chloride* — To 50.0 ml add 5.0 ml of 0.01 M magnesium sulphate and 5 ml of ammonium buffer pH 10.9 and titrate with 0.01 M disodium edetate using eriochrome black T mixture as indicator. From the volume of 0.01 M disodium edetate required subtract the volume of 0.01 M magnesium sulphate added.

1 ml of the remainder of 0.01 M disodium edetate is equivalent to 0.00147 g of CaCl₂, 2H₂O.

For *lactate* — Determine by liquid chromatography (2.4.14).
**Test solution.** The preparation under examination.

**Reference solution.** A 0.28 per cent w/v solution of lithium lactate RS in the mobile phase.

**Chromatographic system**
- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 90 volumes of water and 10 volumes of a 2 per cent v/v solution of octylamine in acetonitrile, the pH of which is adjusted to 7.0 with a 10 per cent v/v solution of phosphoric acid,
- flow rate. 2 ml per minute,
- spectrophotometer set at 210 nm,
- a 10 µl loop injector.

Inject separately the test solution and the reference solution and measure the responses for the major peak.

Calculate the content of C\textsubscript{6}H\textsubscript{12}O\textsubscript{6}, in the injection.

**For dextrose** — To an accurately measured volume containing 2 g to 5 g of Dextrose, add 0.2 ml of 5 M ammonia and sufficient water to produce 100.0 ml. Mix well, allow to stand for 30 minutes and measure the optical rotation in a 2-dm tube (2.4.22). The observed rotation in degrees multiplied by 0.9477 represents the weight, in g, of dextrose, C\textsubscript{6}H\textsubscript{12}O\textsubscript{6}, in the volume taken for assay.

**Storage.** Store in single dose containers of glass or plastic at a temperature not exceeding 30º. On keeping, small particles may separate from the solution in glass containers.

**Labelling.** The label states (1) that the injection contains, in millimoles per litre, the following approximate amounts of the ions. sodium, 131, potassium, 5, calcium, 2; bicarbonate (as lactate), 29 and Chloride, 111; (2) the total osmolar concentration in mOsmol per litre; (3) that the injection should not be used if it contains visible particles.

**Half Strength Compound Sodium Lactate and Dextrose Injection**

Half Strength Compound Sodium Lactate with Dextrose Intravenous Infusion; Half Strength Ringer-Lactate Solution with Dextrose Injection

Half Strength Compound Sodium Lactate and Dextrose Injection is a sterile solution containing 0.12 per cent v/v of Lactic Acid (equivalent to 0.16 per cent w/v of sodium lactate) with 0.3 per cent w/v of Sodium Chloride, 0.02 per cent w/v of Potassium Chloride, 0.0135 per cent w/v of Calcium Chloride and 5 per cent w/v of Dextrose in Water for Injections.

Compound Sodium Lactate and Dextrose Injection contains not less than 0.135 per cent and not more than 0.16 per cent w/v of sodium, Na, not less than 0.0095 per cent and not more than 0.011 per cent w/v of potassium, K, not less than 0.185 per cent and not more than 0.210 per cent w/v of total chloride, Cl, not less than 0.0125 per cent and not more than 0.0145 per cent w/v of calcium chloride, CaCl\textsubscript{2}2H\textsubscript{2}O\textsubscript{6}, and not less than 0.115 per cent and not more than 0.140 per cent w/v of lactate, calculated as C\textsubscript{3}H\textsubscript{6}O\textsubscript{3}, and not less than 4.5 per cent and not more than 5.25 per cent w/v of dextrose, C\textsubscript{6}H\textsubscript{12}O\textsubscript{6}. It contains no antimicrobial agent.

**Description.** A clear, colourless or faintly straw-coloured solution.

**Identification**

A. To 1 ml add 0.05 ml of potassium cupri-tartrate solution; the solution remains blue and clear. Heat to boiling, a copious red precipitate is formed.

B. When warmed with potassium permanganate gives acetaldehyde, recognisable by its odour.

C. The residue on evaporation, when moistened with hydrochloric acid and introduced on a platinum wire into a flame imparts a yellow colour to the flame. When viewed through a suitable blue glass, the flame is tinged reddish purple.

D. Gives reaction C of calcium salts and reaction A of chlorides (2.3.1).

**Tests**

**pH** (2.4.24). 4.0 to 6.5.

**5-Hydroxymethylfurfural and Related substances.** Dilute a volume containing 1.0 g of Dextrose to 500.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 284 nm; absorbance at about 284 nm, not more than 0.25 (2.4.7).

**Bacterial endotoxins** (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** For sodium — Dilute suitably with water and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 589 nm and using sodium solution FP or sodium solution AAS respectively, suitably diluted with water for the standard solutions.

For potassium — Dilute suitably with water and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 767 nm and using potassium solution FP or potassium solution AAS respectively, suitably diluted with water for the standard solutions.
For total chlorides — To 20.0 ml add 30 ml of water, 50.0 ml of 0.1 M silver nitrate and 2 ml of nitric acid. Filter, wash the precipitate with water slightly acidified with nitric acid and titrate the excess of silver nitrate with 0.1 M ammonium thiocyanate using ferric ammonium sulphate solution as indicator until a reddish yellow colour is produced. Carry out a blank titration.

1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of total chloride, calculated as Cl.

For calcium chloride — To 50.0 ml add 5.0 ml of 0.01 M magnesium sulphate and 5 ml of ammonia buffer pH 10.9 and titrate with 0.01 M disodium edetate using eriochrome black T mixture as indicator. From the volume of 0.01 M disodium edetate required subtract the volume of 0.01 M magnesium sulphate added.

1 ml of the remainder of 0.01 M disodium edetate is equivalent to 0.00147 g of CaCl2, 2H2O.

For lactate — Determine by liquid chromatography (2.4.14).

Test solution. The preparation under examination.

Reference solution. A 0.28 per cent w/v solution of lithium lactate RS in the mobile phase.

Chromatographic system
- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 90 volumes of water and 10 volumes of a 2 per cent v/v solution of octylamine in acetonitrile, the pH of which is adjusted to 7.0 with a 10 per cent v/v solution of phosphoric acid,
- flow rate. 2 ml per minute,
- spectrophotometer set at 210 nm,
- a 10 µl loop injector.

Inject separately the test solution and the reference solution and measure the responses for the major peak.

Calculate the content of C3H6O3 in the injection.

For dextrose — To an accurately measured volume containing 2 g to 5 g of Dextrose, add 0.2 ml of 5 M ammonia and sufficient water to produce 100.0 ml. Mix well, allow to stand for 30 minutes and measure the optical rotation in a 2-dm tube (2.4.22). The observed rotation in degrees multiplied by 0.9477 represents the weight, in g, of dextrose, C6H12O6, in the volume taken for assay.

Storage. Store in single dose containers of glass or plastic at a temperature not exceeding 30º. On keeping, small particles may separate from the solution in glass containers.

Labelling. The label states (1) that the injection contains, in millimoles per litre, the following approximate amounts of the ions. sodium, 65.5, potassium, 2.5, calcium, 1, bicarbonate (as lactate), 14.5, and chloride, 55.5; (2) the total osmolar concentration in mOsmol per litre; (3) that the injection should not be used if it contains visible particles.

Modified Compound Sodium Lactate and Dextrose Injection

Modified Compound Sodium Lactate with Dextrose Intravenous Infusion; Modified Lactated Ringer’s and Dextrose Injection.

Modified Compound Sodium Lactate and Dextrose Injection is a sterile solution containing 0.048 per cent v/v of Lactic Acid (equivalent to 0.064 per cent w/v of sodium lactate) with 0.12 per cent w/v of Sodium Chloride, 0.008 per cent w/v of Potassium Chloride, 0.0054 per cent w/v of Calcium Chloride and 5 per cent w/v of Dextrose in Water for Injections.

Modified Compound Sodium Lactate and Dextrose Injection contains not less than 0.054 per cent and not more than 0.064 per cent w/v of sodium, Na, not less than 0.0038 per cent and not more than 0.0044 per cent w/v of potassium, K, not less than 0.074 per cent and not more than 0.084 per cent w/v of total chloride, Cl, not less than 0.005 per cent and not more than 0.0058 per cent w/v of calcium chloride, CaCl2,2H2O, and not less than 0.046 per cent and not more than 0.056 per cent w/v of lactate, calculated as C3H6O3, and not less than 4.5 per cent and not more than 5.25 per cent w/v of dextrose, C6H12O6. It contains no antimicrobial agent.

Description. A clear, colourless or faintly straw-coloured solution.

Identification
A. To 1 ml add 0.05 ml of potassium cupri-tartrate solution; the solution remains blue and clear. Heat to boiling, a copious red precipitate is formed.

B. When warmed with potassium permanganate gives acetaldehyde, recognisable by its odour.

C. The residue on evaporation, when moistened with hydrochloric acid and introduced on a platinum wire into a flame imparts a yellow colour to the flame. When viewed through a suitable blue glass, the flame is tinged reddish purple.

D. Gives reaction C of calcium salts and reaction A of chlorides (2.3.1).

Tests
pH (2.4.24). 4.0 to 6.5.

5-Hydroxymethylfurfural and Related substances. Dilute a volume containing 1.0 g of Dextrose to 500.0 ml with water
and measure the absorbance of the resulting solution at the maximum at about 284 nm; absorbance at about 284 nm (2.4.7), not more than 0.25.

**Bacterial endotoxins** (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** For sodium — Dilute suitably with water and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 589 nm and using sodium solution FP or sodium solution AAS respectively, suitably diluted with water for the standard solutions.

For potassium — Dilute suitably with water and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 767 nm and using potassium solution FP or potassium solution AAS respectively, suitably diluted with water for the standard solutions.

For total chlorides — To 20.0 ml add 30 ml of water, 10.0 ml of 0.1 M silver nitrate and 2 ml of nitric acid. Filter, wash the precipitate with water slightly acidified with nitric acid and titrate the excess of silver nitrate with 0.1 M ammonium thiocyanate using ferric ammonium sulphate solution as indicator until a reddish yellow colour is produced. Carry out a blank titration.

1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of total chloride, calculated as Cl.

For calcium chloride — Evaporate 100.0 ml on a water-bath to 50 ml, add to this solution 5.0 ml of 0.01 M magnesium sulphate and 5 ml of ammonia buffer pH 10.9 and titrate with 0.01 M disodium edetate using eriochrome black T mixture as indicator. From the volume of 0.01 M disodium edetate required subtract the volume of 0.01 M magnesium sulphate added.

1 ml of the remainder of 0.01 M disodium edetate is equivalent to 0.00147 g of CaCl₂,2H₂O.

For lactate — Determine by liquid chromatography (2.4.14).

**Test solution.** The preparation under examination.

**Reference solution.** A 0.28 per cent w/v solution of lithium lactate RS in the mobile phase.

Chromatographic system
- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 90 volumes of water and 10 volumes of a 2 per cent v/v solution of octylamine in acetonitrile, the pH of which is adjusted to 7.0 with a 10 per cent v/v solution of phosphoric acid,
- flow rate, 2 ml per minute,
- spectrophotometer set at 210 nm,
- a 10 µl loop injector.

Inject separately the test solution and the reference solution and measure the responses for the major peak.

Calculate the content of C₃H₆O₃ in the injection.

**For dextrose** — To an accurately measured volume containing 2 g to 5 g of Dextrose, add 0.2 ml of 5 M ammonia and sufficient water to produce 100.0 ml. Mix well, allow to stand for 30 minutes and determine the optical rotation in a 2-dm tube (2.4.22). The observed rotation in degrees multiplied by 0.9477 represents the weight, in g, of dextrose, C₆H₁₂O₆, in the volume taken for assay.

**Storage.** Store in single dose containers of glass or plastic at a temperature not exceeding 30°. On keeping, small particles may separate from the solution in glass containers.

**Labelling.** The label states (1) that the injection contains, in millimoles per litre, the following approximate amounts of the ions: sodium, 26.2, potassium, 1, calcium, 0.4, bicarbonate (as lactate), 5.8, and chloride, 22.2; (2) the total osmolar concentration in mOsmol per litre; (3) that the injection should not be used if it contains visible particles.

---

**Compound Sodium Lactate Injection**

**Compound Sodium Lactate Intravenous Infusion; Ringer-Lactate Solution for Injection; Hartmann’s Solution for Injection**

Compound Sodium Lactate Injection is a sterile solution containing 0.24 per cent v/v of Lactic Acid (equivalent to 0.32 per cent w/v of sodium lactate) with 0.6 per cent w/v of Sodium Chloride, 0.04 per cent w/v of Potassium Chloride and 0.027 per cent w/v of Calcium Chloride in Water for Injections.

Compound Sodium Lactate Injection contains not less than 0.27 per cent and not more than 0.32 per cent w/v of sodium, Na, not less than 0.019 per cent and not more than 0.022 per cent w/v of potassium, K, not less than 0.37 per cent and not more than 0.42 per cent w/v of total chloride, Cl, not less than 0.025 per cent and not more than 0.029 per cent w/v of calcium chloride, CaCl₂,2H₂O, and not less than 0.23 per cent and not more than 0.28 per cent w/v of lactate, calculated as C₃H₆O₃.

**Description.** A clear, colourless solution.

**Identification.**

A. When warmed with potassium permanganate gives acetaldehyde, recognizable by its odour.

B. The residue on evaporation, when moistened with hydrochloric acid and introduced on a platinum wire into a
flame, imparts a yellow colour to the flame. When viewed through a suitable blue glass, the flame is tinged with reddish purple.

C. Gives reaction C of calcium salts (2.3.1).

Tests

pH (2.4.24). 5.0 to 7.0.

Bacterial endotoxins (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

Other tests. Complies with the tests stated under Parenteral Preparations (Intravenous Infusions).

Assay. For sodium — Dilute suitably with water and determine by Method A for flame photometry (2.4.4), or by atomic absorption spectrophotometry (2.4.2), measuring at 589 nm and using sodium solution FP or sodium solution AAS, suitably diluted for the standard solutions.

For potassium — Dilute suitably with water and determine by Method A for flame photometry (2.4.4), or by atomic absorption spectrophotometry (2.4.2), measuring at 767 nm and using potassium solution FP or potassium solution AAS, suitably diluted for the standard solutions.

For total chlorides — To 20 ml add 30 ml of water, 50.0 ml of 0.1 M silver nitrate and 2 ml of nitric acid, filter, wash the precipitate with water slightly acidified with nitric acid and titrate the excess of silver nitrate with 0.1 M ammonium thiocyanate using ferric ammonium sulphate solution as indicator. Carry out a blank titration.

1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of total chloride, calculated as Cl.

For calcium chloride — To 50 ml add 5.0 ml of 0.01 M magnesium sulphate and 5 ml of ammonia buffer pH 10.9 and titrate with 0.01 M disodium edetate using mordant black 11 mixture as indicator. From the volume of 0.01 M disodium edetate required subtract the volume of 0.01 M magnesium sulphate added.

1 ml of the remainder of 0.01 M disodium edetate is equivalent to 0.00147 g of CaCl2, 2H2O.

For lactate, calculated as C3H6O3 — Evaporate 50 ml to dryness in a platinum dish and ignite very gently until completely carbonised. Boil the residue with 25.0 ml of 0.05 M sulphuric acid, filter, and wash thoroughly with hot water. Titrate the excess of acid in the combined filtrate and washings with 0.1 M sodium hydroxide using methyl orange solution as indicator.

1 ml of 0.05 M sulphuric acid is equivalent to 0.009008 g of C3H6O3.

Storage. Store in single dose containers of glass or plastic.

On keeping, small solid particles may separate from the solution in glass containers.

Labelling. The label states (1) that the injection contains, in millimoles per litre, the following approximate amounts of the ions. sodium, 131, potassium, 5, calcium, 2, bicarbonate (as lactate), 29 and chloride, 111; (2) that the injection should not be used if the solution contains visible solid particles.

Compound Sodium Lactate Solution
For Irrigation

Ringer-Lactate Solution for Irrigation; Hartmann’s Solution for Irrigation

Compound Sodium Lactate Solution for Irrigation is a sterile solution containing 0.24 per cent v/v of Lactic Acid (equivalent to 0.32 per cent w/v of sodium lactate) with 0.6 per cent w/v of Sodium Chloride, 0.04 per cent w/v of Potassium Chloride and 0.027 per cent w/v of Calcium Chloride in Water for Injections.

Compound Sodium Lactate Solution for Irrigation contains not less than 0.27 per cent and not more than 0.32 per cent w/v of sodium, Na, not less than 0.019 per cent and not more than 0.022 per cent w/v of potassium, K, not less than 0.37 per cent and not more than 0.42 per cent w/v of total chloride, Cl, not less than 0.025 per cent and not more than 0.029 per cent w/v of calcium chloride, CaCl2,2H2O, and not less than 0.23 per cent and not more than 0.28 per cent w/v of lactate, calculated as C3H6O3. It contains no antimicrobial agent.

Description. A clear, colourless solution.

Identification

A. When warmed with potassium permanganate gives acetaldehyde, recognisable by its odour.

B. The residue on evaporation, when moistened with hydrochloric acid and introduced on a platinum wire into a flame imparts a yellow colour to the flame. When viewed through a suitable blue glass, the flame is tinged reddish purple.

C. Gives reaction C of calcium salts and reaction A of chlorides (2.3.1).

Tests

pH (2.4.24). 5.0 to 7.0.

Bacterial endotoxins (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).
**Assay.** For sodium — Dilute suitably with water and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 589 nm and using sodium solution FP or sodium solution AAS respectively, suitably diluted with water for the standard solutions.

For potassium — Dilute suitably with water and determine by Method A for flame photometry (2.4.4), or by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 767 nm and using potassium solution FP or potassium solution AAS respectively, suitably diluted with water for the standard solutions.

For calcium chloride — To 50.0 ml add 5.0 ml of 0.01 M magnesium sulphate and 5 ml of ammonia buffer pH 10.9 and titrate with 0.01 M disodium edetate using eriochrome black T mixture as indicator. From the volume of 0.01 M disodium edetate required subtract the volume of 0.01 M magnesium sulphate added.

1 ml of the remainder of 0.01 M disodium edetate is equivalent to 0.00147 g of CaCl₂, 2H₂O.

For total chlorides — To 20.0 ml add 30 ml of water, 50.0 ml of 0.1 M silver nitrate and 2 ml of nitric acid. Filter, wash the precipitate with water slightly acidified with nitric acid and titrate the excess of silver nitrate with 0.1 M ammonium thiocyanate using ferric ammonium sulphate solution as indicator until a reddish yellow colour is produced. Carry out a blank titration.

1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of total chloride, calculated as Cl.

For lactate — Determine by liquid chromatography (2.4.14).

**Test solution.** The preparation under examination.

**Reference solution.** A 0.28 per cent w/v solution of lithium lactate RS in the mobile phase.

Chromatographic system
- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 μm),
- mobile phase: a mixture of 90 volumes of water and 10 volumes of a 2 per cent v/v solution of octylamine in acetonitrile, the pH of which is adjusted to 7.0 with a 10 per cent v/v solution of phosphoric acid,
- flow rate, 2 ml per minute,
- spectrophotometer set at 210 nm,
- a 10 μl loop injector.

Inject separately the test solution and the reference solution and measure the responses for the major peak.

Calculate the content of C₃H₆O₃ in the injection.

**Storage.** Store in single dose containers of glass or plastic. On keeping, small solid particles may separate from the solution in glass containers. The container may be designed to empty rapidly and may contain a volume of more than one litre.

**Labelling.** The label states (1) that the irrigation solution contains, in millimoles per litre, the following approximate amounts of the ions: sodium, 1311; potassium, 5; calcium, 2, bicarbonate (as lactate), 29, and chloride, 111; (2) that the solution should not be used if it contains visible particles; (3) ‘For irrigation only’ and ‘Not for injection’; (4) that once the container is opened, the unused portion should be discarded.

**Sodium Lauryl Sulphate**

Sodium Lauryl Sulphate is a mixture of sodium alkyl sulphates consisting mainly of sodium dodecyl sulphate, CH₃(CH₂)₁₀CH₂OSO₃Na.

Sodium Lauryl Sulphate contains not less than 85.0 per cent of sodium alkyl sulphates, calculated as C₁₂H₂₅NaO₄S.

**Description.** A white or pale yellow powder or crystals.

**Identification**

A. A 1 per cent w/v solution, when shaken, produces plenty of foam.

B. Mix 0.1 ml of a 1 per cent w/v solution with 0.1 ml of a 0.1 per cent w/v solution of methylene blue and 2 ml of 1 M sulphuric acid, add 2 ml of dichloromethane and shake; the dichloromethane layer is intensely blue.

C. Mix about 10 mg with 10 ml of ethanol and heat to boiling on a water-bath, shaking frequently. Filter immediately and evaporate the ethanol. Dissolve the residue in 8 ml of water, add 3 ml of 2 M hydrochloric acid, evaporate the solution to half its volume and cool. Filter and then the filtrate add 1 ml of barium chloride solution; a white, crystalline precipitate is produced.

D. Gives reaction B of sodium salts (2.3.1).

**Tests**

**Alkalinity.** Dissolve 1.0 g in 100 ml of carbon dioxide-free water and add 0.1 ml of phenol red solution. Not more than 0.5 ml of 0.1 M hydrochloric acid is required to change the colour of the solution.

**Non-esterified alcohols.** Not more than 4 per cent, determined by the following method. Dissolve 10.0 g in 100 ml of water, add 100 ml of ethanol (95 per cent) and extract the solution with three quantities, each of 50 ml, of n-pentane, adding sodium chloride, if necessary, to promote separation of the two layers. Wash the combined organic layers with three quantities, each of 50 ml, of water. Dry the organic solution over anhydrous sodium sulphate, filter and evaporate on a
water-bath until the odour of pentane is no longer detectable. Heat the residue at 105° for 15 minutes, cool and weigh.

**Sodium Chloride and Sodium Sulphate.** Not more than a total of 8.0 per cent, determined by the following methods.

*For sodium chloride* — Dissolve 5.0 g in 50 ml of water; add 2 M nitric acid dropwise until the solution is neutral to litmus paper, add 2 ml of potassium chromate solution and titrate with 0.1 M silver nitrate.

1 ml of 0.1 M silver nitrate is equivalent to 0.005844 g of NaCl.

*For sodium sulphate* — Dissolve 0.5 g in 20 ml of water; warming gently if necessary, and add 1 ml of a 0.05 per cent w/v solution of dithizone in acetone. If the solution is red, add 1 M nitric acid, dropwise, until it becomes bluish green. Add 2 ml of dichloroacetic acid solution and 80 ml of acetone and titrate with 0.01 M lead nitrate until a permanent orange-red colour is obtained.

1 ml of 0.01 M lead nitrate is equivalent to 0.001420 g of Na₂SO₄.

**Assay.** Weigh accurately about 1.15 g, dissolve in sufficient water to produce 1000.0 ml, warming if necessary. To 20.0 ml add 15 ml of chloroform, 10 ml of dilute sulphuric acid and 1 ml of dimethyl yellow-oracet blue B solution and titrate with 0.004 M benzethonium chloride, shaking vigorously and allowing the layers to separate after each addition, until the chloroform layer acquires a permanent clear green colour.

1 ml of 0.004 M benzethonium chloride is equivalent to 0.001154 g of sodium alkyl sulphates, calculated as C₁₂H₂₅NaO₄S.

**Storage.** Store protected from moisture.

**Sodium Metabisulphite**

Sodium Pyrosulphite; Sodium Disulphite

Na₂S₂O₅ Mol. Wt. 190.1

Sodium Metabisulphite may be prepared by saturating a solution of Sodium Hydroxide with sulphur dioxide and allowing crystallisation to occur.

Sodium Metabisulphite contains not less than 95.0 per cent and not more than 100.5 per cent of Na₂S₂O₅.

**Description.** Colourless, prismatic crystals or a white or creamy white powder; odour, sulphurous.

**Identification**

A. Gives the reactions of sodium salts (2.3.1).

B. A solution decolorises *iodinated potassium iodide* solution and the resulting solution gives the reactions of sulphates (2.3.1).

**Tests**

**Acidity.** A solution is acidic to *phenol red solution*.

**Arsenic** (2.3.10). Mix 2.5 g in a porcelain dish with 10 ml of water, 1.25 g of potassium chlorate and 16 ml of hydrochloric acid and heat to expel chlorine, remove the last traces of chlorine with a few drops of *stannous chloride solution AsT* and add 35 ml of water. The resulting solution complies with the limit test for arsenic (4 ppm).

**Heavy metals** (2.3.13). Dissolve 1.0 g in 10 ml of water; add 5 ml of hydrochloric acid and evaporate to dryness on a water-bath. Dissolve the residue in 25 ml of water containing 2 ml of *dilute acetic acid*. The solution complies with the limit test for heavy metals, Method A (20 ppm).

**Iron.** To 0.5 g add 2 ml of hydrochloric acid and evaporate on a water-bath to dryness. Dissolve the residue in 2 ml of hydrochloric acid and 20 ml of water and add a few drops of *bromine solution*, cool, dilute with water to 25 ml, then add 50 mg of *ammonium persulphate* and 5 ml of *ammonium thiocyanate solution*. Any colour produced is not more intense than that obtained by adding 5 ml of *ammonium thiocyanate solution* to a mixture of iron standard solution (20 ppm Fe), 2 ml of hydrochloric acid, 50 mg of ammonium persulphate and sufficient water to produce 25 ml (40 ppm).

**Thiosulphate.** Dissolve 1.0 g in 10 ml of 2 M hydrochloric acid and heat on a water-bath for 10 minutes; not more than a faint opalescence is produced.

**Assay.** Weigh accurately about 0.1 g and dissolve in 50.0 ml 0.05 M iodine, add 1 ml of hydrochloric acid and titrate the excess of iodine with 0.1 M sodium thiosulphate using starch solution, added towards the end of the titration, as indicator.

1 ml of 0.05 M iodine is equivalent to 0.004753 g of Na₂S₂O₅.

**Storage.** Store protected from light and moisture. On exposure to air and moisture it is slowly oxidised to sulphate with disintegration of the crystals.

**Sodium Methylparaben**

Sodium Methyl Hydroxybenzoate

C₈H₇NaO Mol. Wt. 174.1

Sodium Methylparaben is the sodium salt of methyl 4-hydroxybenzoate.
Sodium Methylparaben contains not less than 99.0 per cent and not more than 102.0 per cent of C₈H₇NaO₃, calculated on the anhydrous basis.

**Description.** A white, crystalline powder; odourless or almost odourless; hygroscopic.

**Identification**

A. Dissolve 0.5 g in 5 ml of water and acidify to litmus paper with hydrochloric acid; a white precipitate is produced. Wash the precipitate with water and dry.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with methylparaben RS.

B. The residue on ignition gives the reactions of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** A 10.0 per cent w/v solution in water is clear (2.4.1).

**pH** (2.4.24). 9.5 to 10.5, determined in a 0.1 per cent w/v solution.

**Chlorides** (2.3.10). Dissolve 1.0 g in 20 ml of water, add 0.2 ml of nitric acid and filter. 15 ml of the filtrate complies with the limit test for chlorides (330 ppm).

**Sulphates** (2.3.17). Dissolve 0.5 g in 40 ml of water, add 3.5 ml of 2 M hydrochloric acid, dilute to 60 ml with water and filter. 15 ml of the filtrate complies with the limit test for sulphates (0.12 per cent).

**Water** (2.3.43). Not more than 5.0 per cent, determined on 1.0 g.

**Assay.** Weigh accurately about 0.1 g, gently boil under a reflux condenser with 25 ml of 1.25 M sodium hydroxide for 30 minutes. Allow to cool, add 25.0 ml of 0.033 M potassium bromate, 5 ml of a 12.5 per cent w/v solution of potassium bromide and 10 ml of hydrochloric acid and immediately stopper the flask. Shake for 15 minutes and allow to stand for 15 minutes. Add 25 ml of dilute potassium iodide solution and shake vigorously. Titrate the liberated iodine with 0.1 M sodium thiosulphate using starch solution, added towards the end of the titration, as indicator. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of potassium bromate required. The volume of 0.033 M potassium bromate used is equivalent to half of the volume of 0.1 M sodium thiosulphate required for the titration.

1 ml of 0.033 M potassium bromate is equivalent to 0.005804 g of C₈H₇NaO₃.

**Storage.** Store protected from moisture.

---

**Sodium Phosphate**

Dissodium Hydrogen Phosphate; Disodium Hydrogen Phosphate Dodecahydrate

\[ \text{Na}_2\text{HPO}_4\cdot\text{12H}_2\text{O} \quad \text{Mol. Wt. 358.1} \]

Sodium Phosphate contains not less than 98.0 per cent and not more than 101.0 per cent of Na₂HPO₄, calculated on the anhydrous basis.

**Description.** Colourless, transparent crystals; very efflorescent.

**Identification**

A 10.0 per cent w/v solution in distilled water (solution A) gives the reactions of sodium salts and of phosphates (2.3.1).

**Tests**

**Appearance of solution.** Solution A is clear (2.4.1), and colourless (2.4.1).

**Arsenic** (2.3.10). Dissolve 5.0 g in 50 ml of water and add 10 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

**Heavy metals** (2.3.14). 20 ml of solution A complies with the limit test for iron (20 ppm).

**Chlorides** (2.3.10). To 10 ml of solution A add 10 ml of 2 M nitric acid and dilute to 20 ml with water. The resulting solution complies with the limit test for chlorides (250 ppm).

**Sulphates** (2.3.17). To 2.5 ml of solution A add 2 ml of 2 M hydrochloric acid and dilute to 15 ml with distilled water. The resulting solution complies with the limit test for sulphates (600 ppm).

**Reducing substances.** To 5 ml of solution A add 5 ml of 1 M sulphuric acid and 0.25 ml of 0.02 M potassium permanganate and heat on a water-bath for 5 minutes; the red colour is not completely discharged.

**Sodium dihydrogen phosphate.** The value of the expression \( n_2 - 25)/(25 - n_1) \), where \( n_1 \) and \( n_2 \) are the titres of 1 M sodium hydroxide obtained in the Assay, does not exceed 0.025.

**Water** (2.3.43). 57.0 to 61.0 per cent, determined on 0.1 g dissolved in a mixture of 10 volumes of methanol and 40 volumes of dimethylformamide.

**Assay.** Weigh accurately about 4.0 g (w), dissolve in 25 ml of water, add 25.0 ml of 1 M hydrochloric acid and titrate...
potentiometrically with 1 M sodium hydroxide to the first inflection of the pH curve \((n_1 \text{ ml})\). Continue the titration until the second inflection of the curve is reached; the total volume of sodium hydroxide required is \(n_2 \text{ ml}\).

Calculate the content of \(\text{Na}_2\text{HPO}_4\) from the expression 
\[
1420 \frac{(25 - n_1)/w}{(100 - d)},
\]
where \(d\) is the percentage water content.

**Storage.** Store protected from moisture.

**Sodium Propylparaben**
Sodium Propyl Hydroxybenzoate

\[
\begin{align*}
&\text{C}_{10}\text{H}_{11}\text{NaO}_3 & \text{Mol. Wt.} & 202.2 \\
\end{align*}
\]

Sodium Propylparaben is the sodium salt of propyl 4-hydroxybenzoate.

Sodium Propylparaben contains not less than 99.0 per cent and not more than 102.0 per cent of \(\text{C}_{10}\text{H}_{11}\text{NaO}_3\), calculated on the anhydrous basis.

**Description.** A white, crystalline powder; odourless or almost odourless; hygroscopic.

**Identification**

A. Dissolve 0.5 g in 5 ml of water and acidify to litmus paper with hydrochloric acid; a white precipitate is produced. Wash the precipitate with water and dry.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with propylparaben RS.

B. The residue on ignition gives the reactions of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** A 10.0 per cent w/v solution in water is clear (2.4.1).

**pH** (2.4.24). 9.5 to 10.5, determined in a 0.1 per cent w/v solution.

**Chlorides** (2.3.10). Dissolve 1.0 g in 20 ml of water, add 0.2 ml of nitric acid and filter. 15 ml of the filtrate complies with the limit test for chlorides (330 ppm).

**Sulphates** (2.3.17). Dissolve 0.5 g in 40 ml of water, add 3.5 ml of 2 M hydrochloric acid, dilute to 60 ml with water and filter. 15 ml of the filtrate complies with the limit test for sulphates (0.12 per cent).

**Water** (2.3.43). Not more than 5.0 per cent, determined on 1.0 g.

**Assay.** Weigh accurately about 0.1 g, gently boil under a reflux condenser with 25 ml of 1.25 M sodium hydroxide for 30 minutes. Allow to cool, add 25.0 ml of 0.0333 M potassium bromate, 5 ml of a 12.5 per cent w/v solution of potassium bromide and 10 ml of hydrochloric acid and immediately stopper the flask. Shake for 15 minutes and allow to stand for 15 minutes. Add 25 ml of dilute potassium iodide solution and shake vigorously. Titrate the liberated iodine with 0.1 M sodium thiosulphate using starch solution, added towards the end of the titration, as indicator. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of potassium bromate required. The volume of 0.0333 M potassium bromate used is equivalent to half of the volume of 0.1 M sodium thiosulphate required for the titration.

1 ml of 0.0333 M potassium bromate is equivalent to 0.00674 g of \(\text{C}_{10}\text{H}_{11}\text{NaO}_3\).

**Storage.** Store protected from moisture.

**Sodium Salicylate**

\[
\begin{align*}
&\text{C}_7\text{H}_5\text{NaO}_3 & \text{Mol. Wt.} & 160.1 \\
\end{align*}
\]

Sodium Salicylate is sodium 2-hydroxybenzoate.

Sodium Salicylate contains not less than 99.0 per cent and not more than 101.0 per cent of \(\text{C}_7\text{H}_5\text{NaO}_3\), calculated on the dried basis.

**Description.** Colourless, small crystals or shiny flakes or a white, crystalline powder.

**Identification**

Test A may be omitted if tests B and C are carried out. Test B may be omitted if tests A and C are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sodium salicylate RS or with the reference spectrum of sodium salicylate.

B. A 10.0 per cent w/v solution in carbon dioxide-free water prepared from distilled water (solution A) gives the reactions of salicylates (2.3.1).
C. Gives reaction B of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** Solution A is clear (2.4.1), and not more intensely coloured than reference solution BYS6 (2.4.1).

**Acidity.** To 20 ml of solution A add 0.1 ml of phenol red solution; the solution is yellow. Titrate with 0.01 M sodium hydroxide to a reddish violet colour; not more than 2.0 ml of 0.01 M sodium hydroxide is required.

**Arsenic** (2.3.10). Mix 5.0 g with 10 ml of bromine solution and evaporate to dryness on a water-bath. Ignite gently, cool, dissolve the residue, ignoring any carbon, in 50 ml of water and 14 ml of brominated hydrochloric acid AsT and remove the excess of bromine with 2 ml of stannous chloride solution AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

**Heavy metals** (2.3.13). Dissolve 2.0 g in 46 ml of water, add with constant stirring 4 ml of dilute hydrochloric acid, filtering and using 25 ml of the filtrate. The solution complies with the limit test for heavy metals, Method A (20 ppm).

**Chlorides** (2.3.12). To 25 ml of solution A add 15 ml of water and 10 ml of 2 M nitric acid and filter. 25 ml of the filtrate complies with the limit test for chlorides (200 ppm).

**Sulphates** (2.3.17). 2.5 ml of solution A diluted to 15 ml with distilled water complies with the limit test for sulphates (600 ppm).

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.15 g, dissolve in 30 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01601 g of C₇H₅NaO₃.

**Storage.** Store protected from light and moisture.

---

**Sodium Starch Glycollate**

Sodium Carboxymethyl Starch

Sodium Starch Glycollate is the sodium salt of a poly-α-glucopyranose in which some of the hydroxyl groups are in the form of carboxymethyl ether.

Sodium Starch Glycollate contains not less than 2.8 per cent and not more than 4.5 per cent of sodium, Na, calculated on the material washed with Ethanol (95 per cent) and dried as described under Assay.

**Description.** A very fine, white or off-white, free-flowing powder; odourless or almost odourless.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sodium starch glycollate RS or with the reference spectrum of sodium starch glycollate.

B. To 5 ml of a 2 per cent w/v dispersion in water add 0.05 ml of 0.005 M iodine; a dark blue colour is produced.

C. The solution obtained in the test for Heavy metals gives the reactions of sodium salts (2.3.1).

---

**Tests**

**pH** (2.4.24). 5.5 to 7.5, determined in a 2.0 per cent w/v dispersion in carbon dioxide-free water.

**Heavy metals** (2.3.13). To 4.0 g in a silica or platinum dish add 2 ml of a 50 per cent w/v solution of sulphuric acid, heat in a water-bath and then cautiously over a flame at about 600º. Continue heating until all black particles have disappeared, allow to cool, add 0.1 ml of 1 M sulphuric acid, heat to ignition once again and allow to cool. Add 0.1 ml of 2 M ammonium carbonate, evaporate to dryness and cautiously ignite. To the residue add 5 ml of hydrochloric acid, evaporate to dryness on a water-bath and dissolve the residue in 100 ml of water. 25 ml of a solution complies with the limit test for heavy metals, Method A (20 ppm).

**Iron** (2.3.14). 50 ml of the solution obtained in the test for Heavy metals complies with the limit test for iron (20 ppm).

**Sodium Chloride.** Not more than 10.0 per cent, determined by the following method. To 1.0 g add 20.0 ml of 0.1 M silver nitrate and 30 ml of nitric acid and boil carefully for 30 minutes. Cool and add a sufficient volume of a saturated solution of potassium permanganate to change the colour of the solution to red. Discharge the colour by the dropwise addition of hydrogen peroxide solution (10 vol), add 3 ml of dibutyl phthalate and titrate with 0.1 M ammonium thiocyanate using ferric ammonium sulphate solution as indicator, shaking vigorously after each addition of titrant. Carry out a blank titration.

1 ml of 0.1 M silver nitrate is equivalent to 0.005844 g of NaCl.

**Sodium glycollate.** To 0.2 g add 5 ml of glacial acetic acid, mix well and add 5 ml of water, stirring occasionally until solution is complete. Slowly add 50 ml of acetone with stirring and then add 1 g of sodium chloride. Filter, wash the residue with acetone and dilute the filtrate to 100 ml with acetone. Transfer 2 ml of this solution to an open flask, heat on a water-bath for exactly 20 minutes, cool, add 5 ml of naphthalenediol reagent and mix thoroughly. Add a further 15 ml of the same
reagent, mix, cover the flask with aluminium foil and heat on a water-bath for 20 minutes. Cool and dilute to 25 ml with sulphuric acid. The absorbance (2.4.7) of the resulting solution at the maximum at about 540 nm using water as the blank, is not more than that of a solution prepared in the following manner. To 5 ml of a 0.062 per cent w/v solution of glycollic acid, previously dried at a pressure not exceeding 2 kPa for 16 hours, add 5 ml of glacial acetic acid, dilute to 100 ml with acetone and complete the procedure described above beginning at the words “Transfer 2 ml...” (2.0 per cent).

**Microbial Contamination** (2.2.9). 1.0 g is free from *Escherichia coli* and *Salmonellae*.

**Loss on drying** (2.4.19). Not more than 10.0 per cent, determined on 0.5 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 4.0 g, add 350 ml of a mixture of 4 volumes of ethanol (95 per cent) and 1 volume of water, add 0.25 ml of phenolphthalein solution and mix. Add 1 M sodium hydroxide dropwise until the colour of the suspension becomes faintly pink, shake for 30 minutes and decant through a sintered glass crucible. Repeat the extraction three times, or until a test for chloride ions is negative. Transfer the bulk of the residue to the crucible, wash the residue with ethanol (95 per cent) and dry at 110º to constant weight. Weigh accurately 0.5 g of the residue, add 80 ml of anhydrous glacial acetic acid, heat under a reflux condenser for 2 hours, cool. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25).

1 ml of 0.1 M perchloric acid is equivalent to 0.0023 g of Na.

**Storage.** Store protected from light and moisture.

**Sodium Stibogluconate**

Sodium Antimony Gluconate

![Chemical Structure](image)

Sodium Stibogluconate is mainly the disodium salt of \(\mu\)-oxy-bis[gluconato(3-)O\(\delta\)O\(\beta\)O\(\gamma\)-hydroxo-antimony].

The method of manufacture is such as to ensure consistently controlled reaction stoichiometry in order to yield sodium stibogluconate that is satisfactory with regard to intrinsic toxicity.

Sodium Stibogluconate contains not less than 30.0 per cent and not more than 34.0 per cent of pentavalent antimony, calculated on the dried and methanol-free basis.

**Description.** A colourless, mostly amorphous powder; odourless or almost odourless.

**Identification**

A. An aqueous solution is dextro-rotatory.

B. Pass hydrogen sulphide into a 5 per cent w/v solution for several minutes; an orange precipitate is produced.

C. When heated, it chars without melting, emitting an odour of burnt sugar and leaving a residue which gives the reactions of antimony compounds and the reactions of sodium salts (2.3.1).

**Tests**

**pH** (2.4.24). 5.0 to 5.6, determined in the solution obtained in the test for Stability of solution.

**Stability of solution.** Heat a solution containing 10.0 per cent w/v of pentavalent antimony in an autoclave at 115.5º and at a pressure of 70 kPa for 30 minutes. The resulting solution is colourless or almost colourless.

**Trivalent antimony.** Dissolve 2.0 g in 30 ml of water, add 15 ml of hydrochloric acid and titrate with 0.00833 M potassium bromate using methyl orange solution as indicator. Not more than 1.3 ml of 0.00833 M potassium bromate is required.

**Chlorides.** Dissolve 2.5 g in 50 ml of water and add 2 ml of 2 M nitric acid and 75 ml of acetate buffer pH 5.0. Titrate with 0.1 M silver nitrate, determining the end-point potentiometrically (2.4.25). Not more than 3.0 ml of 0.1 M silver nitrate is required.

**Methanol.** Not more than 2.0 per cent w/w, determined by gas chromatography (2.4.13).

**Test solution.** Add 5 ml of water to 0.5 g of the substance under examination and mix with the aid of ultrasound until the solution is complete.

**Reference solution (a).** Add 5 ml of a 0.2 per cent v/v solution of ethanol (internal standard) to 0.5 g of the substance under examination and mix with the aid of ultrasound until the solution is complete.

**Reference solution (b).** Add 1 ml of a 1.0 per cent v/v solution of methanol to 5 ml of a 0.2 per cent v/v solution of the internal standard.

**Chromatographic system**

- a glass column 1.5 m x 4 mm, packed with porous polymer beads (80 to 100 mesh),
- temperature: column. 130º.
Calculate the percentage w/w of methanol taking 0.792 g as its weight per ml at 20º.

**Undue toxicity.** Dissolve a suitable quantity of the substance under examination in water for injections to give a solution containing 28 mg of pentavalent antimony per ml. Inject intravenously 0.3 ml of the solution into each of 10 mice that have been deprived of food for not less than 17 hours. After injections allow the mice access to food and water. None of the mice dies within 24 hours. If one of the mice dies within 24 hours, repeat the test. None of the second group of mice dies within 24 hours.

**Loss on drying** (2.4.19). Not more than 15.0 per cent, determined on 0.25 g by drying in an oven at 130º at a pressure not exceeding 0.7 kPa.

**Assay.** Weigh accurately about 0.16 g, dissolve in 30 ml of hydrochloric acid, add 70 ml of phosphoric acid and stir carefully until completely mixed. Titrate with 0.05 M ferric ammonium sulphate prepared using sulphuric acid (1 per cent), determining the end-point potentiometrically (2.4.25), using a platinum electrode and a silver-silver chloride reference electrode.

1 ml of 0.05 M ferric ammonium sulphate is equivalent to 0.003044 g of pentavalent antimony.

**Storage.** Store protected from moisture.

### Sodium Thiosulphate

**Sodium Thiosulphate**

Sodium Hyposulphite

\[ \text{Na}_2\text{S}_2\text{O}_3\cdot5\text{H}_2\text{O} \]  
Mol. Wt. 248.2

Sodium Thiosulphate contains not less than 99.0 per cent and not more than 101.0 per cent of \( \text{Na}_2\text{S}_2\text{O}_3\cdot5\text{H}_2\text{O} \).

**Description.** Colourless large crystals or a coarse, crystalline powder; odourless; deliquescent in moist air and effloresces in dry air at temperature above 33º. It dissolves in its water of crystallisation at about 49º.

**Identification**

A. To 0.5 ml of a 10.0 per cent w/v solution in carbon dioxide-free water (solution A) add 0.5 ml of water and 2 ml of 0.1 M silver nitrate; a white precipitate is produced which quickly becomes yellowish and finally black.

B. To a portion of solution A add a few drops of iodine solution; the colour is discharged.

C. Dilute 2.5 ml of solution A to 5 ml with water and add 1 ml of hydrochloric acid; a gas is evolved which turns starch-iodate paper blue and a precipitate of sulphur is produced.

D. 1 ml of solution A gives reaction A of sodium salts (2.3.1).
Tests

**Appearance of solution.** Solution A is clear (2.4.1), and colourless (2.4.1).

**pH** (2.4.24). 6.0 to 8.4, determined in solution A.

**Arsenic** (2.3.10). Dissolve 5.0 g in 50 ml of water and add 10 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

**Heavy metals** (2.3.13). Dissolve 1.0 g in 10 ml of water. Slowly add 5 ml of dilute hydrochloric acid and evaporate the mixture to dryness on a water-bath. Gently boil the residue with 15 ml of water for 2 minutes and filter. Heat the filtrate to boiling, add a slight excess of bromine solution to the hot filtrate to produce a clear solution and add a drop of phenolphthalein solution and sodium hydroxide solution until a slight pink colour is produced. Add 2 ml of dilute acetic acid and dilute with water to 25 ml. The solution complies with the limit test for heavy metals, Method A (20 ppm).

**Chlorides** (2.3.12). To 12.5 ml of solution A add 15 ml of 2 M nitric acid, boil gently for 3 to 4 minutes, cool and filter. The filtrate complies with the limit test for chlorides (200 ppm).

**Sulphides**. To 10 ml of solution A add 0.05 ml of a freshly prepared 5 per cent w/v solution of sodium nitroprusside; the solution does not become violet.

**Sulphates and sulphites** (2.3.17). Dilute 2.5 ml of solution A to 10 ml with distilled water. To 3 ml of this solution add 2 ml of iodine solution and gradually add more iodine solution and dilute to 15 ml with distilled water. The resulting solution complies with the limit test for sulphates (0.2 per cent).

**Assay.** Weigh accurately about 0.5 g, dissolve in 20 ml of water and titrate with 0.05 M iodine using starch solution, added towards the end of the titration, as indicator.

1 ml of 0.05 M iodine is equivalent to 0.02482 g of Na₂S₂O₃,5H₂O.

**Storage.** Store in single dose containers.

Identification

A. To 0.5 ml of a 10.0 per cent w/v solution in carbon dioxide-free water (solution A) add 0.5 ml of water and 2 ml of 0.1 M silver nitrate; a white precipitate is produced which quickly becomes yellowish and finally black.

B. To a portion of solution A add a few drops of iodine solution; the colour is discharged.

C. Dilute 2.5 ml of solution A to 5 ml with water and add 1 ml of hydrochloric acid; a gas is evolved which turns starch-iodate paper blue and a precipitate of sulphur is produced.

D. 1 ml of solution A gives reaction A of sodium salts (2.3.1).

Tests

**pH** (2.4.24). 7.0 to 9.0.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** To an accurately measured volume containing about 0.5 g of Sodium Thiosulphate add about 20 ml of water and titrate with 0.05 M iodine, using 3 ml of starch solution, added towards the end of the titration, as indicator.

1 ml of 0.05 M iodine is equivalent to 0.02482 g of Na₂S₂O₃,5H₂O.

**Storage.** Store in single dose containers.

Sodium Thiosulphate Injection

Sodium Hyposulphite Injection

Sodium Thiosulphate Injection is a sterile solution of Sodium Thiosulphate in Water for Injections.

Sodium Thiosulphate Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sodium thiosulphate, Na₂S₂O₃,5H₂O.

**Description.** A clear, colourless solution.

Sodium Valproate

C₃H₁₅NaO₂

Mol. Wt. 166.2

Sodium Valproate is sodium 2-propylpentanoate.

Sodium Valproate contains not less than 98.5 per cent and not more than 101.0 per cent of C₃H₁₅NaO₂, calculated on the dried basis.

**Description.** A white or almost white, crystalline powder; hygroscopic.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sodium valproate RS or with the reference spectrum of sodium valproate.

B. In the test for Related substances, the principal peak in the chromatogram obtained with test solution (b) corresponds to
C. Dissolve 1.25 g in 20 ml of distilled water in a separating funnel, add 5 ml of 2 M nitric acid, shake and allow the mixture to stand for 12 hours; the lower layer (solution A) gives reactions of sodium salts (2.3.1).

Tests

Appearance of solution. A 20.0 per cent w/v solution is not more opalescent than opalescence standard OS2 (2.4.1), and is not more intensely coloured than reference solution YS6 (2.4.1).

Acidity or alkalinity. To 10 ml of a 10.0 per cent w/v solution in carbon dioxide-free water add 0.1 ml of dilute phenolphthalein solution; not more than 0.75 ml of either 0.1 M sodium hydroxide or 0.1 M hydrochloric acid is required to change the colour of the solution.

Related substances. Determine by gas chromatography (2.3.13).

Test solution (a). Add 5 ml of 1 M sulphuric acid to 10 ml of a 0.04 per cent w/v solution of the substance under examination and shake with three quantities, each of 20 ml, of ether. Add 10 ml of a 0.02 per cent w/v solution of butyric acid (internal standard) in ether to the combined ether extracts, shake with anhydrous sodium sulphate, filter and evaporate the filtrate to a volume of about 10 ml at a temperature not exceeding 30º using a rotary evaporator.

Test solution (b). Add 0.5 ml of 1 M sulphuric acid to 10 ml of a 0.04 per cent w/v solution of the substance under examination and shake with three quantities, each of 5 ml, of ether. Shake the combined ether extracts with anhydrous sodium sulphate, filter and evaporate the filtrate to a volume of about 10 ml at a temperature not exceeding 30º using a rotary evaporator.

Test solution (c). Dissolve 0.5 g of the substance under examination in 10 ml of water, add 5 ml of 1 M sulphuric acid and treat as described for test solution (a) beginning at the words “shake with three...”.

Reference solution. Prepare in the same manner as test solution (b) but using sodium valproate RS in place of the substance under examination.

Chromatographic system

- a glass column 2.6 m x 2 mm, packed with silanised diatomaceous support (125 to 180 mesh) impregnated with 5 per cent w/w of polyethylene glycol 20,000 2-nitroterephthalate and 1 per cent w/w of phosphoric acid,
- temperature. column.150º to 170º to obtain a retention time of about 12 minutes for valproic acid [the principal peak in test solution (b)],
- inlet port at 200º and detector at 300º,
- flow rate. 20 ml per minute of the carrier gas.

Allow the chromatography to proceed for 2.5 times the retention time of valproic acid. Adjust the sensitivity so that the height of the peak due to the internal standard in the chromatogram obtained with test solution (a) is not less than 70 per cent of the full-scale deflection on the recorder. In the chromatogram obtained with test solution (c), the sum of the areas of any secondary peaks is not greater than the area of the peak due to the internal standard. Ignore any peaks the area of which is less than 1 per cent of the area of the peak due to the internal standard. The test is not valid unless the resolution between the peak due to the internal standard and the principal peak in the chromatogram obtained with test solution (a) is at least 12.

Chlorides (2.3.12). Dissolve 1.25 g in 10 ml of water. The resulting solution complies with the limit test for chlorides (200 ppm).

Sulphates (2.3.17). Solution A complies with the limit test for sulphates (200 ppm).

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B. Use 2 ml of lead standard solution (10 ppm) to prepare the standard (20 ppm).

Loss on drying (2.4.19). Not more than 2.0 per cent, determined on 1.0 g by drying in an oven at 105º.

Assay. Weigh accurately about 0.15 g and dissolve in 25 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration. 1 ml of 0.1 M perchloric acid is equivalent to 0.01662 g of C8H15NaO2.

Storage. Store protected from moisture.

Sodium Valproate Oral Solution

Sodium Valproate Elixir

Sodium Valproate Oral Solution is a solution of Sodium Valproate in a suitable flavoured vehicle.

Sodium Valproate Oral Solution contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sodium valproate, C8H15NaO2.

Identification

A. Shake a quantity containing about 0.25 g of Sodium Valproate with two quantities, each of 25 ml, of chloroform and discard the chloroform extracts. Add 10 ml of a saturated solution of sodium chloride and 10 ml of 2 M hydrochloric acid...
SODIUM VALPROATE TABLETS

**Acid, mix and shake with 25 ml of chloroform. Wash the chloroform layer with 5 ml of water, shake with anhydrous sodium sulphate, filter and evaporate to dryness.**

On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with valproic acid RS or with the reference spectrum of valproic acid.

B. Shake a quantity containing about 0.25 g of Sodium Valproate with a mixture of 10 ml of a saturated solution of sodium chloride, 10 ml of 2 M hydrochloric acid and 25 ml of chloroform. Evaporate the chloroform layer to dryness, dissolve the residue in 2 ml of water, make just alkaline with 2 M sodium hydroxide and add 0.5 ml of a 10 per cent w/v solution of cobalt nitrate; a purple precipitate is produced which is soluble in dichromomethane.

**Tests**

**Related substances.** Determine by gas chromatography (2.4.13).

**Test solution (a).** Mix a quantity of the oral solution containing 0.50 g of Sodium Valproate with 10 ml of water, acidify with 2 M sulphuric acid and shake with three quantities, each of 20 ml, of dichromomethane. Wash the combined dichromomethane extracts with 10 ml of water, shake with anhydrous sodium sulphate, filter and evaporate the filtrate to a volume of about 10 ml at a temperature not exceeding 30º using a rotary evaporator.

**Test solution (b).** Mix a quantity of the oral solution containing 0.5 g of Sodium Valproate with 10 ml of a 0.02 per cent w/v solution of octanoic acid (internal standard) in 0.1 M sodium hydroxide and continue as described for test solution (a) beginning at the words “acidity of 2 M sulphuric acid...”.

**Reference solution.** A 0.02 per cent w/v solution of the internal standard in dichromomethane.

**Chromatographic system**
- A glass column 1.5 m x 4 mm, packed with acid-washed, silanised diatomaceous support (80 to 180 mesh) coated with 15 per cent w/w of free fatty acid phase (such as Supelco FFAP 2-1063) and 1 per cent w/w of phosphoric acid,
- Temperature: column 170º.

In the chromatogram obtained with test solution (b) the sum of the areas of any secondary peaks is not greater than the area of the peak due to the internal standard.

**Other tests.** Complies with the tests stated under Oral Liquids.

**Assay.** Weigh accurately a quantity containing about 0.15 g of Sodium Valproate, add 50 ml of water, mix thoroughly and add 10 ml of saturated solution of sodium chloride, 10 ml of 2 M hydrochloric acid and 40 ml of a mixture of 2 volumes of ether and 1 volume of light petroleum (40º to 60º), shake, allow to separate and reserve the ether layer. Shake the aqueous layer with a further 40 ml of the ether-light petroleum mixture and discard the aqueous layer. Shake each of the ether extracts with the same three quantities, each of 10 ml, of a saturated solution of sodium chloride, combine the extracts and evaporate to a volume of about 1 ml at a temperature not exceeding 30º. Add 50 ml of ethanol (95 per cent), previously neutralised with 0.01 M sodium hydroxide using dilute phenolphthalein solution as indicator, and titrate with 0.1 M sodium hydroxide.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.01662 g of C8H15NaO2.

Determine the weight per ml of the preparation (2.4.29) and calculate the content of C8H15NaO2 weight in volume.

**Sodium Valproate Tablets**

Sodium Valproate Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sodium valproate, C8H15NaO2.

**Identification**

A. Shake a quantity of the powdered tablets containing about 0.5 g of Sodium Valproate with 10 ml of water and centrifuge. Acidify 5 ml of the supernatant liquid with 2 M sulphuric acid, shake with 25 ml of chloroform and wash the chloroform layer with 5 ml of water. Dry by shaking with anhydrous sodium sulphate, filter and evaporate the chloroform.

On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with valproic acid RS or with the reference spectrum of valproic acid.

B. Shake a quantity of the powdered tablets containing about 0.25 g of Sodium Valproate with 3 ml of water and centrifuge. To 2 ml of the supernatant liquid add 0.5 ml of a 10 per cent w/v solution of cobalt nitrate; a purple precipitate is produced which is soluble in dichromomethane.

**Tests**

**Related substances.** Determine by gas chromatography (2.4.13).

**Test solution (a).** Shake a quantity of the powdered tablets containing about 0.50 g of Sodium Valproate with 10 ml of water and centrifuge, acidify with 2 M sulphuric acid and shake with three quantities, each of 20 ml, of dichromomethane. Wash the combined dichromomethane extracts with 10 ml of water, shake with acid-washed anhydrous sodium sulphate, filter and evaporate the filtrate to a volume of about 10 ml at a temperature not exceeding 30º using a rotary evaporator.
Test solution (b). Shake a quantity of the powdered tablets containing 0.50 g of Sodium Valproate with 10 ml of a 0.020 per cent w/v solution of octanoic acid (internal standard) in 0.1 M sodium hydroxide and continue as described for test solution (a) beginning at the words “acidify with 2 M sulphuric acid...”.

Reference solution. A 0.02 per cent w/v of the internal standard in dichloromethane.

Chromatographic system
- a glass column 1.5 m x 4 mm, packed with acid-washed, silanised diatomaceous support (80 to 180 mesh) coated with 15 per cent w/w of free fatty acid phase (such as Supelco FFAP 2-1063) and 1 per cent w/w of phosphoric acid,
- temperature: column, 170°.

In the chromatogram obtained with test solution (b) the sum of the areas of any secondary peaks is not greater than the area of the peak due to the internal standard.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.3 g of Sodium Valproate, add 70 ml of water, shake for 10 minutes, dilute to 100.0 ml with water and filter. To 50.0 ml of the filtrate add 10 ml of a 30 per cent w/v solution of sodium chloride and 10 ml of 2 M hydrochloric acid. Extract with 40 ml of a mixture of 2 volumes of ether and 1 volume of light petroleum (boiling range 40° to 60°) and allow to separate. Shake the aqueous layer with a further 40 ml of the ether-light petroleum mixture. Shake each of the ether extracts with the same three quantities, each of 10 ml, of a saturated solution of sodium chloride, combine the ether extracts and evaporate to a volume of about 1 ml at a temperature not exceeding 30°. Add 50 ml of ethanol (95 per cent), previously neutralised with 0.01 M sodium hydroxide using dilute phenolphthalein solution as indicator, and titrate with 0.1 M sodium hydroxide.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.01662 g of C₆H₈O₂:NaO₂.

Sorbic Acid

\[
\text{C}_6\text{H}_8\text{O}_2 \quad \text{Mol. Wt. 112.1}
\]

Sorbic Acid is (2E,4E)-hexa-2,4-dienoic acid.

Sorbic Acid contains not less than 99.0 per cent and not more than 101.0 per cent of C₆H₈O₂, calculated on the anhydrous basis.

Description. A white or almost white, crystalline powder.

Identification

Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sorbic acid RS or with the reference spectrum of sorbic acid.

B. Dissolve 50 mg in sufficient water to produce 250 ml and dilute 2 ml of this solution to 200 ml with 0.1 M hydrochloric acid.

When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum at about 264 nm; absorbance at about 264 nm, 0.43 to 0.51.

C. Dissolve 0.2 g in 2 ml of ethanol (95 per cent) and add 0.2 ml of bromine water; the solution is decolorised.

Tests

Appearance of solution. A 5.0 per cent w/v solution in ethanol (95 per cent) is clear (2.4.1), and colourless (2.4.1).

Heavy metals (2.3.13). 2.0 g complies with the limit test for heavy metals, Method A (10 ppm).

Aldehydes. Not more than 0.15 per cent, determined by the following method. Dissolve 1.0 g in a mixture of 50 ml of 2-propanol and 30 ml of water, adjust the pH of the solution to 4.0 with 0.1 M hydrochloric acid or 0.1 M sodium hydroxide and dilute to 100 ml with water. To 10 ml of the resulting solution add 1 ml of decolorised fuchsin solution and allow to stand for 30 minutes. Any colour produced is not more intense than that obtained in a solution prepared simultaneously by adding 1 ml of decolorised fuchsin solution to a mixture of 1.5 ml of acetaldehyde standard solution (100 ppm C₂H₅O) and 4 ml of 2-propanol and 4.5 ml of water.

Sulphated ash (2.3.18). Not more than 0.2 per cent.

Water (2.3.43). Not more than 1.0 per cent, determined on 2.0 g.

Assay. Weigh accurately about 0.2 g, dissolve in 20 ml of ethanol (95 per cent) and titrate with 0.1 M sodium hydroxide, using 0.2 ml of phenolphthalein solution as indicator, until a pink colour is produced.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.01121 g of C₆H₈O₂.

Storage. Store protected from light and moisture.
Sorbitol

D-Glucitol

\[
\begin{align*}
\text{C}_{6}\text{H}_{14}\text{O}_{6} & \quad \text{Mol. Wt. 182.2} \\
\text{Sorbitol is D-glucitol, a hexahydric alcohol related to glucose.} \\
\text{Sorbitol contains not less than 98.0 per cent and not more than 101.0 per cent of C}_{6}\text{H}_{14}\text{O}_{6}, \text{calculated on the anhydrous basis.} \\
\text{Identification} & \quad \text{A white, crystalline powder; odourless.} \\
\text{Identification} & \quad \text{A. Determine by thin-layer chromatography (2.4.17), coating the plate with a uniform 0.75-mm thick layer of the following mixture. Mix 0.1 g of carboxer with 110 ml of water and allow to stand, with gentle stirring, for 1 hour. Adjust to pH 7.0 by the gradual addition, with continuous shaking, of 2 M sodium hydroxide and add 30 g of silica gel H. Heat the plate at 110º for 1 hour, allow to cool and use immediately.} \\
\text{Mobile phase} & \quad \text{A mixture of 85 volumes of 2-propanol and 15 volumes of a 0.2 per cent w/v solution of boric acid.} \\
\text{Test solution} & \quad \text{Dissolve 0.25 g of the substance under examination in 100 ml of ethanol (95 per cent).} \\
\text{Reference solution} & \quad \text{A 0.25 per cent w/v solution of sorbitol RS in ethanol (95 per cent).} \\
\text{Apply to the plate 2 µl of each solution. After development, dry the plate at 100º to 105º for 15 minutes, allow to cool, spray with a 0.5 per cent w/v solution of potassium permanganate in 1 M sodium hydroxide and heat at 100º for 2 minutes. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.} \\
\text{B. Dissolve 50 mg in 3 ml of water, add 3 ml of catechol solution and pour the mixture into 6 ml of sulphuric acid; a pink colour is produced.} \\
\text{C. Dissolve 5 g in 3 ml of water with the aid of gentle heat, cool, add 7 ml of methanol, 1 ml of benzaldehyde and 1 ml of hydrochloric acid, mix and shake continuously for 2 hours. Filter, dissolve the crystals in 20 ml of boiling sodium bicarbonate solution and allow to crystallise. The residue, after washing rapidly with 5 ml of a mixture of equal volumes of methanol and water and drying in a current of air, melts at about 175º (2.4.21).} \\
\text{Tests} \\
\text{Appearance of solution} & \quad \text{Solution A is clear (2.4.1), and colourless (2.4.1).} \\
\text{Acidity or alkalinity} & \quad \text{Dissolve 5.0 g in sufficient carbon dioxide-free water prepared from distilled water to produce 50 ml (solution A). To 10 ml of solution A add 10 ml of carbon dioxide-free water. To 10 ml of the resulting solution add 0.05 ml of phenolphthalein solution; not more than 0.2 ml of 0.01 M sodium hydroxide is required to change the colour of the solution to pink. To a further 10 ml of the solution add 0.05 ml of methyl red solution; Not more than 0.3 ml of 0.01 M hydrochloric acid is required to change the colour of the solution to red.} \\
\text{Specific optical rotation} & \quad +4.0º to +7.0º, determined in a solution prepared in the following manner. Dissolve a mixture of 5.0 g of the substance under examination and 6.4 g of borax in 40 ml of water, allow to stand for 1 hour, shaking occasionally, dilute to 50 ml with water and filter, if necessary.} \\
\text{Arsenic} & \quad (2.3.10). Dissolve 5.0 g in 50 ml of water and add 10 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (2 ppm).} \\
\text{Heavy metals} & \quad (2.3.13). 2.0 g complies with the limit test for heavy metals, Method A (10 ppm).} \\
\text{Chlorides} & \quad (2.3.12). 5.0 g complies with the limit test for chlorides (50 ppm).} \\
\text{Nickel} & \quad \text{Dissolve 10.0 g in sufficient water to produce 20 ml, add 3 ml of bromine water and 2 ml of a 20 per cent w/v solution of citric acid, mix and add 10 ml of 6 M ammonia and 1 ml of a 1 per cent w/v solution of dimethylglyoxime in ethanol (95 per cent). Mix, dilute to 50 ml with water and allow to stand for 5 minutes; any colour produced is not more intense than that produced by treating in the same manner and at the same time 1.0 ml of nickel standard solution (10 ppm Ni) diluted to 20 ml with water (1 ppm).} \\
\text{Sulphates} & \quad (2.3.17). 12 ml of solution A complies with the limit test for sulphates (125 ppm).} \\
\text{Reducing sugars} & \quad \text{Dissolve 5.0 g in 3 ml of water with the aid of gentle heat, cool, add 20 ml of cupri-citric solution and a few glass beads, heat in such a manner that the solution boils in 4 minutes and continue boiling for a further 3 minutes. Cool rapidly and add 100 ml of a 2.4 per cent v/v solution of glacial acetic acid followed by 20.0 ml of 0.025 M iodine. Add, shaking continuously, 25 ml of a 6 per cent v/v solution of hydrochloric acid and, when any precipitate has redissolved, titrate the excess iodine with 0.05 M sodium thiosulphate.}
using 1 ml of *starch solution*, added towards the end of the titration, as indicator. Not less than 12.8 ml of 0.05 M sodium thiosulphate is required.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Water** (2.3.43). Not more than 1.5 per cent, determined on 1.0 g.

**Assay.** Weigh accurately about 0.4 g and dissolve in sufficient water to produce 100.0 ml. To 10.0 ml of the solution add 20 ml of a 2.14 per cent w/v solution of sodium periodate and 2 ml of 1 M sulphuric acid and heat on a water-bath for exactly 15 minutes. Cool, add 3 g of sodium bicarbonate, in small quantities, and 25.0 ml of 0.1 M sodium arsenite, mix, add 5 ml of a 20 per cent w/v solution of potassium iodide and allow to stand for 15 minutes. Titrate with 0.05 M iodine until the first trace of yellow colour appears. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of iodine required.

1 ml of 0.05 M iodine is equivalent to 0.001822 g of C₆H₁₄O₆.

Sorbitol intended for use in the manufacture of parenteral preparations without a further appropriate procedure for removal of bacterial endotoxins complies with the following additional requirement.

**Bacterial endotoxins** (2.2.3). Not more than 4.0 Endotoxin Units per g for parenteral preparations having a concentration of less than 10 per cent w/v of sorbitol and not more than 2.5 Endotoxin Units per g for parenteral preparations containing 10 per cent w/v or more of sorbitol.

**Storage.** Store protected from moisture.

**Labelling.** The label states whether or not the contents are intended for use in the manufacture of parenteral preparations.

### Sorbitol Solution (70 Per Cent) (Crystallising)

**Sorbitol Solution (70 per cent) (Crystallising)**

Sorbitol Solution (70 per cent) (Crystallising) is an aqueous solution of hexitols.

Sorbitol Solution (70 per cent) (Crystallising) contains not less than 68.0 per cent w/w and not more than 72.0 per cent w/w of hexitols, calculated as D-glucitol (C₆H₁₄O₆).

**Description.** A clear, colourless, syrupy liquid.

**Identification**

A. Dilute 7.0 g with 40 ml of water, add 6.4 g of borax, allow to stand for 1 hour, shaking occasionally, and dilute to 50.0 ml with water. Filter if necessary. The optical rotation of the resulting solution is 0º to +1.5º (2.4.22).

B. Dry 1 g over phosphorus pentoxide at a pressure of 1.5 to 2.5 kPa. Heat 0.5 g of the residue with a mixture of 5 ml of acetic anhydride and 0.5 ml pyridine with the aid of heat and allow to stand for 10 minutes. Pour the mixture into 25 ml of water, allow to stand in ice for 2 hours and filter. The precipitate, after recrystallisation from a small volume of ethanol (95 per cent) and drying over phosphorus pentoxide at a pressure of 1.5 to 2.5 kPa, melts at about 100º (2.4.21).

C. Determine by thin-layer chromatography (2.4.17), coating the plate with a uniform 0.75-mm thick layer of the following mixture. Mix 0.1 g of carbomer with 110 ml of water and allow to stand, with gentle stirring, for 1 hour. Adjust to pH 7.0 by the gradual addition, with continuous shaking, of 2 M sodium hydroxide and add 30 g of silica gel H. Heat the plate at 110º for 1 hour, allow to cool and use immediately.

**Mobile phase.** A mixture of 85 volumes of 2-propanol and 15 volumes of a 0.2 per cent w/v solution of boric acid.

**Test solution.** Dissolve 0.35 g of the substance under examination in 100 ml of ethanol (95 per cent).

**Reference solution.** A 0.25 per cent w/v solution of sorbitol RS in ethanol (95 per cent).

Apply to the plate 2 µl of each solution. After development, dry the plate at 100º to 105º for 15 minutes, allow to cool and spray with a 0.5 per cent w/v solution of potassium permanganate in 1 M sodium hydroxide and heat at 100º for 2 minutes. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

**Tests**

**Appearance of solution.** A 14.0 per cent w/v solution in carbon dioxide–free water (solution A) is clear (2.4.1), and colourless (2.4.1).

**Acidity or alkalinity.** To 10 ml of solution A add 0.05 ml of phenolphthalein solution; not more than 0.2 ml of 0.01 M sodium hydroxide is required to change the colour of the solution to pink. To a further 10 ml of the solution add 0.05 ml of methyl red solution. Not more than 0.3 ml of 0.01 M hydrochloric acid is required to change the colour of the solution to red.

**Refractive index** (2.4.27). 1.457 to 1.462.

**Relative density** (2.4.29). Not less than 1.290.

**Arsenic** (2.3.10). Dissolve 5.0 g in 50 ml of water and add 10 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

**Heavy metals** (2.3.13). 2.0 g complies with the limit test for heavy metals, Method A (10 ppm).

**Chlorides** (2.3.12). 5.0 g complies with the limit test for chlorides (50 ppm).
Nickel. Dissolve 10.0 g in sufficient water to produce 20 ml, add 3 ml of bromine water and 2 ml of a 20 per cent w/v solution of citric acid, mix and add 10 ml of 6 M ammonia and 1 ml of a 1 per cent w/v solution of dimethylglyoxime in ethanol (95 per cent). Mix, dilute to 50 ml with water and allow to stand for 5 minutes; any colour produced is not more intense than that produced by treating in the same manner and at the same time 1.0 ml of nickel standard solution (10 ppm Ni) diluted to 20 ml with water (1 ppm).

Sulphates (2.3.17). 12 ml of solution A complies with the limit test for sulphates (125 ppm).

Reducing sugars. Dissolve 5.0 g in 3 ml of water with the aid of gentle heat, cool, add 20 ml of cupri-citric solution and a few glass beads, heat in such a manner that the solution boils in 4 minutes and continue boiling for a further 3 minutes. Cool rapidly and add 100 ml of a 2.4 per cent v/v solution of glacial acetic acid followed by 20.0 ml of 0.025 M iodine. Add, shaking continuously, 25 ml of a 6 per cent v/v solution of hydrochloric acid and, when any precipitate has redissolved, titrate the excess iodine with 0.05 M sodium thiosulphate using 1 ml of starch solution, added towards the end of the titration, as indicator. Not less than 12.8 ml of 0.05 M sodium thiosulphate is required.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Assay. Measure accurately a volume containing about 0.6 g of Sorbitol and dissolve in sufficient water to produce 100.0 ml. To 10.0 ml of the solution add 20 ml of a 2.14 per cent w/v solution of sodium periodate and 2 ml of 1 M sulphuric acid and heat on a water-bath for exactly 15 minutes. Cool, add 3 g of sodium bicarbonate, in small quantities, and 25.0 ml 0.1 M sodium arsenite, mix, add 5 ml of a 20 per cent w/v solution of potassium iodide and allow to stand for 15 minutes. Titrate with 0.05 M iodine until the first trace of yellow colour appears. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of iodine required.

1 ml of 0.05 M iodine is equivalent to 0.001822 g of C₆H₁₂O₆.

Storage. Store protected from moisture.

Sorbitol Solution (70 Per Cent) (Non-Crystallising)

Sorbitol (70 per cent) (Non-crystallising)

Sorbitol Solution (70 per cent) (Non-crystallising) is an aqueous solution of hydrogenated, partly hydrolysed starch.

Sorbitol Solution (70 per cent) (Non-crystallising) contains not less than 68.0 per cent w/w and not more than 72.0 per cent w/w of solid matter and not less than 62.0 per cent w/w of polyols expressed as D-glucitol (C₆H₁₂O₆).

Description. A clear, colourless or faintly yellow, syrupy liquid; odourless.

Identification

A. Dilute 7.0 g with sufficient carbon dioxide-free water to produce 50 ml (solution A). To 3 ml of a freshly prepared 10 per cent w/v solution of catechol add 6 ml of sulphuric acid while cooling in ice. To 3 ml of the mixture add 0.3 ml of solution A and heat gently over a naked flame for 30 seconds; a pink colour is produced which becomes deep brownish red.

B. Dry 1 g over phosphorus pentoxide at 80º at a pressure of 1.5 to 2.5 kPa. Dissolve 0.5 g of the residue in a mixture of 5 ml of acetic anhydride and 0.5 ml of pyridine with the aid of heat and allow to stand for 10 minutes. Pour the mixture into 25 ml of water, allow to stand in ice for 2 hours and filter. The residue, after recrystallisation from a small volume of ethanol (95 per cent) and drying over phosphorus pentoxide at a pressure of 1.5 to 2.5 kPa, melts at about 100º (2.4.21).

C. Determine by thin-layer chromatography (2.4.17), coating the plate with a uniform 0.75-mm thick layer of the following mixture. Mix 0.1 g of carboxer with 110 ml of water and allow to stand, with gentle stirring, for 1 hour. Adjust to pH 7.0 by the gradual addition, with continuous shaking, of 2 M sodium hydroxide and add 30 g of silica gel H. Heat the plate at 110º for 1 hour, allow to cool and use immediately.

Mobile phase. A mixture of 85 volumes of 2-propanol and 15 volumes of a 0.2 per cent w/v solution of boric acid.

Test solution. Dissolve 0.35 g of the substance under examination in 100 ml of ethanol (95 per cent).

Reference solution. A 0.25 per cent w/v solution of sorbitol RS in ethanol (95 per cent).

Apply to the plate 2 µl of each solution. After development, dry the plate at 100º to 105º for 15 minutes, allow to cool, spray with a 0.5 per cent w/v solution of potassium permanganate in 1 M sodium hydroxide and heat at 100º for 2 minutes. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

Tests

Appearance of solution. Solution A is clear (2.4.1), and colourless (2.4.1).

Acidity or alkalinity. To 10 ml of solution A add 10 ml of carbon dioxide-free water. To 10 ml of the resulting solution add 0.05 ml of phenolphthalein solution; not more than 0.2 ml of 0.01 M sodium hydroxide is required to change the colour of the solution to pink. To a further 10 ml of the solution add
0.05 ml of methyl red solution; Not more than 0.3 ml of 0.01 M hydrochloric acid is required to change the colour of the solution to red.

Optical rotation (2.4.22). +1.5° to +3.5°, determined in a solution prepared in the following manner. Dilute 7.0 g with 40 ml of water, add 6.4 g of borax, allow to stand for 1 hour, shaking occasionally, dilute to 50 ml with water and filter, if necessary.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

**Sulphates** (2.3.17). 12 ml of solution A complies with the limit test for sulphates (125 ppm).

Reducing sugars. Dissolve 5.0 g in 3 ml of water with the aid of gentle heat, cool, add 20 ml of cupri-citric solution and a few glass beads, heat in such a manner that the solution boils in 4 minutes and continue boiling for a further 3 minutes. Cool rapidly and add 100 ml of a 2.4 per cent v/v solution of glacial acetic acid followed by 20.0 ml of 0.025 M iodine. Add, shaking continuously, 25 ml of a 6 per cent v/v solution of hydrochloric acid and, when any precipitate has dissolved, titrate the excess iodine with 0.05 M sodium thiosulphate using 1 ml of starch solution, added towards the end of the titration, as indicator. Not less than 12.8 ml of 0.05 M sodium thiosulphate is required.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

**Assay.** For solid matter — Weigh accurately about 1.0 g and dry to constant weight over phosphorus pentoxide at 80° at a pressure of 1.5 to 2.5 kPa. Weigh the residue.

For polyols — Measure accurately a volume containing about 0.4 g of Sorbitol and dissolve in sufficient water to produce 100.0 ml. To 10.0 ml of the solution add 20 ml of a 2.14 per cent w/v solution of sodium periodate and 2 ml of 1 M sulphuric acid and heat on a water-bath for exactly 15 minutes. Cool, add 3 g of sodium bicarbonate, in small quantities, and 25.0 ml of 0.1 M sodium arsenite, mix, add 5 ml of a 20 per cent w/v solution of potassium iodide and allow to stand for 15 minutes. Titrate with 0.05 M iodine until the first trace of yellow colour appears. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of iodine required.

1 ml of 0.05 M iodine is equivalent to 0.001822 g of C₈H₁₄O₆.

**Storage.** Store protected from moisture.

### Spironolactone

**C₃₂H₃₂O₄S**

Spironolactone is 7α-acetylthio-3-oxo-17α-pregn-4-ene-21,17β-carbolactone.

Spironolactone contains not less than 97.0 per cent and not more than 102.0 per cent of C₃₂H₃₂O₄S, calculated on the dried basis.

**Description.** A yellowish white to buff coloured powder; odourless or with a slight odour of thioacetic acid. It exhibits polymorphism.

**Identification**

*Test A may be omitted if tests B and C are carried out. Test B may be omitted if tests A and C are carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with spironolactone RS or with the reference spectrum of spironolactone. Examine the substances as 5 per cent w/v solutions in chloroform.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Solvent mixture.** A mixture of 90 volumes of acetone and 10 volumes of 1,2-propanediol.

**Mobile phase.** A mixture of 40 volumes of cyclohexane and 10 volumes of toluene.
Test solution. Dissolve 25 mg of the substance under examination in 10 ml of the solvent mixture.

Reference solution (a). Dissolve 25 mg of spironolactone RS in 10 ml of the solvent mixture.

Reference solution (b). Mix equal volumes of the test solution and reference solution (a).

Apply to the plate 2 µl of each solution. Allow the mobile phase in the direction in which the aforementioned treatment was done.

Dry the plate in a current of warm air, allow to cool and examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

C. Shake about 10 mg with 2 ml of sulphuric acid (50 per cent); an orange solution with an intense yellowish fluorescence is produced. Heat the solution gently; the colour becomes deep red and hydrogen sulphide is evolved which turns lead acetate paper black. Add the solution to 10 ml of water; a greenish yellow solution is produced which shows opalescence or a precipitate.

Tests

Specific optical rotation (2.4.22). –33.0º to –37.8º, determined in a 1.0 per cent w/v solution in chloroform.

Chromium. Mix 0.2 g with 1 g of potassium carbonate and 0.3 g of potassium nitrate in a platinum crucible, heat gently until fused and ignite at 600º to 650º until the carbon is removed. Cool, dissolve the residue as completely as possible in 10 ml of water with the aid of gentle heat, filter and dilute to 20 ml with water. To 10 ml of the solution add 0.5 g of urea and just acidify with sulphuric acid (14 per cent). When effervescence ceases add a further 1 ml of sulphuric acid (14 per cent), dilute to 20 ml with water and add 0.5 ml of diphenylcarbazide solution. Any colour produced is not more intense than that obtained by adding 1 ml of sulphuric acid (14 per cent) to 0.5 ml of a freshly prepared 0.00283 per cent w/v solution of potassium dichromate, diluting to 20 ml with water and adding 0.5 ml of diphenylcarbazide solution (50 ppm).

Free mercapto compounds. Shake 2.0 g with 20 ml of water for 1 minute and filter. To 10 ml of the filtrate add 0.05 ml of 0.01 M iodine and 0.1 ml of starch solution and mix; a blue colour develops.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º for 3 hours.

Assay. Weigh accurately about 50 mg, dissolve in sufficient methanol to produce 250.0 ml, dilute 5.0 ml to 100.0 ml with methanol and measure the absorbance of the resulting solution at the maximum at about 238 nm (2.4.7).

Calculate the content of C24H32O4S taking 470 as the specific absorbance at 238 nm.

Storage. Store protected from light and moisture.

Spironolactone Tablets

Spironolactone Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of spironolactone, C24H32O4S. The tablets may contain added flavouring agents and may be coated.

Identification

A. Extract a quantity of the powdered tablets containing 0.125 g of Spironolactone with two quantities, each of 10 ml, of chloroform, filter, evaporate the combined filtrates to dryness and dissolve the residue in 2.5 ml of chloroform.

On the resulting solution determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with spironolactone RS or with the reference spectrum of spironolactone.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Solvent mixture. A mixture of 90 volumes of acetone and 10 volumes of 1,2-propanediol.

Mobile phase. A mixture of 40 volumes of cyclohexane and 10 volumes of toluene.

Test solution. Extract a quantity of the powdered tablets containing 50 mg of Spironolactone with 10 ml of chloroform, filter and evaporate the filtrate to dryness. Dissolve 25 mg the residue in 10 ml of the solvent mixture.

Reference solution (a). Dissolve 25 mg of spironolactone RS in 10 ml of the solvent mixture.

Reference solution (b). Mix equal volumes of the test solution and reference solution (a).

Place the dry plate in a tank containing a shallow layer of the solvent mixture, allow the solvent mixture to ascend to the
top, remove the plate from the tank and allow the solvent to evaporate. Use within 2 hours, with the flow of the mobile phase in the direction in which the aforementioned treatment was done.

Apply to the plate 2 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air, allow the solvent to evaporate, heat at 120º for 15 minutes and spray the hot plate with *ethanolic sulphuric acid* (20 per cent *v/v*). Heat at 120º for a further 10 minutes, allow to cool and examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

C. Shake about 10 mg of the residue obtained in test B with 2 ml of *sulphuric acid* (50 per cent); an orange solution with an intense yellowish fluorescence is produced. Heat the solution gently; the colour becomes deep red and hydrogen sulphide is evolved which turns *lead acetate paper* black. Add the solution to 10 ml of *water*; a greenish yellow solution is produced which shows opalescence or a precipitate.

**Tests**

**Dissolution (2.5.2).**

Apparatus. No 1

Medium. 1000 ml of 0.1 *M hydrochloric acid* containing 0.1 per cent *w/v* of *sodium dodecyl sulphate*.

Speed and time. 75 rpm and 60 minutes.

Withdraw a suitable volume of the medium, filter through a membrane filter disc with an average pore diameter not greater than 1.0 µm. Measure the absorbance of the filtrate, suitably diluted if necessary, at the maximum at about 242 nm (2.4.7). Calculate the content of C$_{10}$H$_{12}$N$_2$O$_4$ in the medium taking 445 as the specific absorbance at 242 nm.

D. Not less than 70.0 per cent of the stated amount of C$_{10}$H$_{12}$N$_2$O$_4$S.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 25 mg of Spironolactone, add 100 ml of methanol and heat just to boiling, with swirling. Cool, add sufficient methanol to produce 250.0 ml, dilute 10.0 ml to 100.0 ml with methanol and measure the absorbance of the resulting solution at the maximum at about 238 nm (2.4.7).

Calculate the content of C$_{10}$H$_{12}$N$_2$O$_4$S taking 470 as the specific absorbance at 238 nm.

**Storage.** Store protected from light and moisture.

---

**Stavudine**

C$_{10}$H$_{12}$N$_2$O$_4$  Mol. Wt. 224.2

Stavudine is 2',3',didehydro-3'-deoxythymidine.

Stavudine contains not less than 98.0 per cent and not more than 102.0 per cent of C$_{10}$H$_{12}$N$_2$O$_4$, calculated on the dried basis.

**Description.** A white or almost white powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *stavudine RS* or with the reference spectrum of stavudine.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to stavudine in the chromatogram obtained with reference solution (c).

C. Melts at about 164º (2.4.21).

**Tests**

**Specific optical rotation** (2.4.22). –39.0º to – 46.0º, determined in a 0.7 per cent *w/v* solution in *water*.

**Related substances.** Determine by liquid chromatography (2.4.14), as described in the Assay.

Separately inject the test solution, reference solutions (a) and (b) and record the chromatograms for at least three times the retention time of the principal peak. In the chromatogram obtained with the test solution, the area of any peak corresponding to thymine is not greater than the area of the peak in the chromatogram obtained with reference solution (b) (1 per cent); the area of any peak corresponding to α-thymidine is not greater than the area of the corresponding peak in the chromatogram obtained with reference solution (a) (1 per cent); the area of any individual impurity peak other than thymine and α-thymidine is not more than 0.5 per cent and the sum of the areas of all the impurity peaks other than thymine and α-thymidine is not more than 1.0 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.3 per cent.
Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying at 105° for 3 hours.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 50.0 mg of the substance under examination in 100.0 ml of the mobile phase.

Reference solution (a). A solution containing 0.05 per cent w/v of stavudine RS, 0.01 per cent w/v of thymine and 0.0005 per cent w/v of α-thymidine in the mobile phase.

Reference solution (b). A 0.0005 per cent w/v solution of thymine in the mobile phase.

Reference solution (c). A 0.05 per cent w/v solution of stavudine RS in the mobile phase.

Chromatographic system
– a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
– column temperature 50°,
– mobile phase: a mixture of 20 volumes of methanol and 80 volumes of water;
– flow rate. 1 ml per minute,
– spectrophotometer set at 265 nm,
– a 20 µl loop injector.

Inject separately reference solutions (a) and (c). The order of elution in the chromatogram obtained with reference solution (a) is thymine, α-thymidine and stavudine with relative retention times of about 0.5, 0.7 and 1.0 respectively. The test is not valid unless the column efficiency determined from the stavudine peak in the chromatogram obtained with reference solution (a) is not less than 3000 theoretical plates, the tailing factor is not more than 1.5 and the relative standard deviation for replicate injections of reference solution (c) is not more than 2.0 per cent.

Inject separately the test solution and reference solution (c) and measure the responses of the principal peak.

Calculate the content of C_{10}H_{12}N_{2}O_{4}.

Storage. Store protected from light and moisture.

Stavudine Capsules

Stavudine Capsules contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of stavudine, C_{10}H_{12}N_{2}O_{4}.

Identification

A. Shake a quantity of the mixed contents of the capsules containing about 50 mg of Stavudine with 80 ml of water for 10 minutes. Add sufficient water to produce 100 ml, mix and filter. Dilute 10 ml of the filtrate to 100 ml with water.

When examined in the range 200 nm to 300 nm (2.4.7), the resulting solution shows an absorption maximum at about 265 nm.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to stavudine in the chromatogram obtained with the reference solution.

Tests

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Mix well the contents of 20 capsules and transfer an accurately weighed quantity containing about 50 mg of Stavudine to a 100-ml volumetric flask. Add about 60 ml of water, mix with the aid of ultrasound for 10 minutes, dilute to volume with water, mix and filter.

Reference solution. Weigh 5 mg each of stavudine RS and thymine RS and transfer to a 25-ml volumetric flask. Add 5 ml of methanol, mix with the aid of ultrasound to dissolve and dilute to volume with water.

Chromatographic system
– a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),
– mobile phase: gradient mixtures of acetonitrile and 0.1 M ammonium acetate,
– flow rate. 1 ml per minute,
– a linear gradient programme using the conditions given below,
– spectrophotometer set at 270 nm,
– a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>0.1 M Ammonium acetate (per cent v/v)</th>
<th>Acetonitrile (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>25</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>30</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>31</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>35</td>
<td>95</td>
<td>5</td>
</tr>
</tbody>
</table>

Inject the reference solution. The test is not valid unless the column efficiency determined from the peaks of stavudine and thymine is not less than 7000 theoretical plates and the tailing factor is not more than 2.0.

Inject separately water and the test solution. Examine the water chromatogram for any extraneous peaks and ignore the corresponding peaks observed in the chromatogram obtained with the test solution.

Any secondary peak observed in the chromatogram obtained with the test solution corresponding to thymine is not more
than 3.0 per cent. Any other secondary peak observed in the chromatogram obtained with the test solution is not more than 0.5 per cent and the sum of the areas of all the secondary peaks is not more than 4.0 per cent when calculated by percentage area normalisation.

**Dissolution** (2.5.2).

**Apparatus.** No 1

**Medium.** 900 ml of 0.01 M hydrochloric acid

**Speed and time.** 75 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter.

**Determine by liquid chromatography** (2.4.14).

**Test solution.** The filtrate obtained as given above.

**Reference solution.** In the case of capsules containing 30 mg of Stavudine, weigh accurately about 30 mg of stavudine RS and transfer to a 100-ml volumetric flask. Dissolve and dilute to volume with 0.01 M hydrochloric acid; in the case of capsules containing 40 mg of stavudine RS and transfer to a 100-ml volumetric flask. Dissolve and dilute to volume with 0.01 M hydrochloric acid.

**Chromatographic system** – a stainless steel column 15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),

– mobile phase: a mixture of 85 volumes of water and 15 volumes of methanol,

– flow rate. 1.5 ml per minute,

– spectrophotometer set at 266 nm,

– a 20 µl loop injector.

Inject the reference solution and record the chromatograms for twice the retention time of stavudine. The test is not valid unless the column efficiency determined from the stavudine peak is not less than 3000 theoretical plates, the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject separately the test solution and the reference solution and measure the responses for the major peak.

**Calculate the content of C₁₀H₁₂N₂O₄ in the medium.**

**Storage.** Store protected from moisture.

### Stavudine Oral Solution

Stavudine Oral Solution is a mixture consisting of Stavudine with buffering agents and other excipients. It contains a suitable flavouring agent. It is filled in a sealed container.

The oral solution is constituted by dispersing the contents of the sealed container in the specified volume of water just before issue.

Stavudine Oral Solution contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of stavudine C₁₀H₁₂N₂O₄.

**Storage.** Store the constituted solution in a refrigerator (2º to 8º). Discard any unused portion after 30 days of reconstitution.

The contents of the sealed container comply with the requirements stated under Oral Liquids and with the following requirements.

### Identification

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with reference solution (a).
**Tests**

**pH** (2.4.24). 5.0 to 7.0, determined in the reconstituted solution.

**Related substances.** Determine by liquid chromatography (2.4.14).

*NOTE — Prepare the solutions immediately before use.*

**Test solution.** Weigh accurately a quantity of the reconstituted solution containing 10 mg of stavudine and dissolve in 20 ml of water.

**Reference solution (a).** A 0.05 per cent w/v solution of stavudine RS in water.

**Reference solution (b).** Dilute 1 ml of reference solution (a) to 100 ml with water.

**Reference solution (c).** A solution containing 0.0125 per cent w/v each of thymine and thymidine in water. Dilute 2 ml of the solution to 100 ml of water.

Use the chromatographic system described under Assay.

Inject reference solution (a). The test is not valid unless the tailing factor is not more than 2.0 and the column efficiency in not less than 2000 theoretical plates.

Inject reference solution (c). The test is not valid unless the resolution between thymine and thymidine peak is not less than 8.4.

Inject the test solution and reference solution (b). Run the chromatogram for 4 times the retention time (about 9 minutes) of the principal peak. In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 1.5 times the area of the peak in the chromatogram obtained with the reference solution (b) (1.5 per cent) and the sum of areas of all the secondary peaks is not more than 3 times the area of the peak in the chromatogram obtained with the reference solution (b) (3.0 per cent).

**Other tests.** Complies with the tests stated under Oral Liquids.

**Water** (2.3.43). Not more than 2.0 per cent, determined on 0.5 g.

**Assay.** Determine by liquid chromatography (2.4.14).

*NOTE — Prepare the solutions immediately before use.*

**Test solution.** Weigh accurately a quantity of the powdered tablets containing about 100 mg of lamivudine and transfer to sufficient water, disperse in sufficient water and dilute to 100.0 ml with water.

**Reference solution (a).** A 0.01 per cent w/v solution of stavudine RS in water.

**Reference solution (b).** A solution containing 0.0125 per cent w/v each of thymine and thymidine in water. Dilute 2 ml of the solution to 100 ml with water.

**Chromatographic system**

- a stainless steel column 3.3 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: A. 95 volumes of 25 mM ammonium acetate and 5 volumes of methanol,
- mobile phase: B. 50 volumes of 25 mM ammonium acetate and 50 volumes of methanol.
- flow rate. 1 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 268 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>mobile phase A (per cent v/v)</th>
<th>mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>60</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>120</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>155</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Inject reference solution (b). The test is not valid unless the resolution between thymine and thymidine is not less than 8.4.

Inject reference solution (a). The test is not valid unless the tailing factor is not more than 2.0, the column efficiency in not less than 2000 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution (a).

Calculate the content of C₁₀H₁₂N₂O₄ in the oral solution.

**Storage.** Store protected from moisture, at a temperature not exceeding 30°.

**Stavudine And Lamivudine Tablets**

Stavudine and Lamivudine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of stavudine, C₁₀H₁₂N₂O₄ and lamivudine, C₈H₁₁N₃O₃S. The tablets may be coated.

**Identification**

In the Assay, the two principal peaks in the chromatogram obtained with the test solution correspond to the peaks due to stavudine and lamivudine in the chromatogram obtained with the reference solution.

**Tests**

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh accurately a quantity of the powdered tablets containing about 100 mg of lamivudine and transfer to
a 200-ml volumetric flask. Add about 100 ml of water, mix with the aid of ultrasound for 10 minutes with occasional shaking to obtain a uniform dispersion, cool to room temperature, dilute to volume with water and mix. Filter through a membrane filter disc with an average pore diameter not greater than 1.0 µm, rejecting the first few ml of the filtrate.

Reference solution (a). Weigh accurately about 65 mg of stavudine RS and 6.5 mg of thymine RS, and transfer to a 25-ml volumetric flask. Add 5 ml of methanol, sonicate to dissolve, dilute to volume with water and mix.

Reference solution (b). Weigh accurately about 100 mg of lamivudine RS, transfer to a 200-ml volumetric flask. Add about 100 ml of water and mix with the aid of ultrasound to dissolve. Add 10 ml of reference solution (a) to this solution and dilute to volume with water and mix.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm),
- mobile phase: gradient mixtures of acetonitrile and 0.1 M ammonium acetate,
- flow rate. 1 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 270 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>0.1 M Ammonium acetate (per cent v/v)</th>
<th>Acetonitrile (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>25</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>30</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>31</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>35</td>
<td>95</td>
<td>5</td>
</tr>
</tbody>
</table>

Inject separately reference solutions (b) and (c). The test is not valid unless the column efficiency determined from the thymine, stavudine and lamivudine peaks is not less than 3000 theoretical plates and the tailing factor for the same peaks is not more than 2.0.

Inject separately water and the test solution. Examine the chromatogram obtained with water for any extraneous peaks and ignore the corresponding peaks observed in the chromatogram obtained with the test solution.

Any secondary peak observed in the chromatogram obtained with the test solution corresponding to thymine is not more than 3.0 per cent. Any other secondary peak observed in the chromatogram obtained with the test solution is not more than 0.5 per cent and the sum of the areas of all the secondary peaks is not more than 4.0 per cent when calculated by percentage area normalisation.

Dissolution (2.5.2).
Apparatus. No 1
Medium. 900 ml of 0.01 M hydrochloric acid
Speed and time. 50 rpm and 45 minutes.
Withdraw a suitable volume of the medium and filter.
Determine by liquid chromatography (2.4.14).

Test solution. The filtrate obtained as given above.

Reference solution. In the case of tablets containing 30 mg of stavudine, weigh accurately about 33 mg of stavudine RS and 167 mg of lamivudine RS and transfer to a 100-ml volumetric flask. Add about 20 ml of methanol, sonicate to dissolve and dilute to volume with a solvent mixture of equal volumes of methanol and water (diluent). Dilute 5.0 ml of this solution to 50.0 ml with 0.01 M hydrochloric acid; in the case of tablets containing 40 mg of stavudine, weigh accurately about 44 mg of stavudine RS and 167 mg of lamivudine RS and transfer to a 100-ml volumetric flask. Add about 20 ml of methanol, mix with the aid of ultrasound to dissolve and dilute to volume with the diluent. Dilute 5.0 ml of this solution to 50.0 ml with 0.01 M hydrochloric acid.

Chromatographic system
- a stainless steel column 15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 35 volumes of methanol and 65 volumes of a buffer prepared by dissolving 0.68 g of potassium dihydrogen phosphate and 1.0 g of sodium octanesulphonate in 1000.0 ml of water to which 1 ml of triethylamine is added and the pH of which is adjusted to 2.5 with phosphoric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 266 nm,
- a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the column efficiency determined from the lamivudine peak is not less than 2000 theoretical plates, the tailing factor for the individual stavudine and lamivudine peaks is not more than 1.5 and the relative standard deviation for replicate injections for each of the peaks corresponding to stavudine and lamivudine is not more than 1.0 per cent.

Inject separately the test solution and the reference solution to measure the responses for the major peaks due to stavudine and lamivudine.

Calculate the contents of C_{10}H_{12}N_{2}O_{4} and C_{8}H_{11}N_{3}O_{3}S in the medium.

D. Not less than 70 per cent of the stated amounts of C_{10}H_{12}N_{2}O_{4} and C_{8}H_{11}N_{3}O_{3}S.

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14).
**Test solution.** Weigh and powder 20 tablets. Transfer an accurately weighed quantity of the powder containing about 150 mg of Lamivudine to a 100-ml volumetric flask, add about 20 ml of methanol and 50 ml of a mixture of equal volumes of water and methanol, mix with the aid of ultrasound for 5 minutes with occasional shaking to obtain a uniform dispersion. Cool to room temperature and dilute to volume with the same solvent mixture. Filter the solution through a membrane filter disc with an average pore diameter not greater than 1.0 µm, rejecting the first few ml of the filtrate. Dilute suitably with the same solvent mixture to obtain a solution with a concentration of 0.15 mg per ml of lamivudine.

**Reference solution.** A similarly prepared solution containing 0.015 per cent w/v of lamivudine RS and a concentration of stavudine RS similar to that of the concentration of stavudine in test solution.

Use the chromatographic system described under Dissolution. Inject the reference solution. The test is not valid unless the column efficiency determined from the lamivudine peak is not less than 2000 theoretical plates, the tailing factor for the individual peaks due to lamivudine and stavudine is not more than 1.5 and the relative standard deviation for replicate injections for each of the peaks corresponding to stavudine and lamivudine is not more than 2.0 per cent.

Inject separately the test solution and the reference solution and measure the responses for the major peaks.

Calculate the contents of C\text{10}H\text{12}N\text{2}O\text{4} and C\text{8}H\text{11}N\text{3}O\text{3}S in the tablets.

**Storage.** Store protected from moisture.

---

**Stearic Acid**

H\text{3}C\text{16}H\text{15}O\text{2}\text{}—\text{}H\text{3}C\text{16}H\text{15}O\text{2}

Stearic Acid consists of a mixture of fatty acids, chiefly stearic acid (C\text{18}H\text{36}O\text{2}) and palmitic acid (C\text{16}H\text{32}O\text{2}). It may contain a suitable antioxidant.

Stearic Acid contains not less than 40.0 per cent of C\text{18}H\text{36}O\text{2} and the sum of the contents of C\text{18}H\text{36}O\text{2} and C\text{16}H\text{32}O\text{2} is not less than 90.0 per cent.

**Description.** A white powder or white, greasy, flaky crystals or hard masses showing signs of crystallisation.

**Identification**

In the Assay, the chromatogram obtained with the test solution shows two principal peaks which correspond to the two principal peaks in the chromatogram obtained with reference solution (c).

**Tests**

**Congealing temperature** (2.4.10). Not lower than 54º.

**Acid value** (2.3.23). 200 to 212, determined on 1.0 g.

**Iodine value** (2.3.28). Not more than 4.0 (iodine monochloride method).

**Mineral acid.** Shake 5 g of the melted substance with an equal volume of hot water for 2 minutes, cool and filter. To the filtrate add 0.05 ml of methyl orange solution; no red colour is produced.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent, determined on 2.0 g.

**Assay.** Determine by gas chromatography (2.4.13).

**Test solution.** Add 5 ml of boron trifluoride solution to 0.1 g of the substance under examination and heat under a reflux condenser for 15 minutes, cool and transfer to a separating funnel with the aid of 10 ml of hexane. Add 10 ml of a saturated solution of sodium chloride and 10 ml of water, shake, discard the lower aqueous layer and dry the upper layer over anhydrous sodium sulphate.

**Reference solution (a).** Add 5 ml of a 1 per cent w/v solution of nonadecanoic acid (internal standard) in toluene to a mixture of 50 mg of stearic acid RS and 50 mg of palmitic acid RS and evaporate to dryness. Add 5 ml of boron trifluoride solution and complete the procedure described for the test solution beginning at the words “heat under a reflux condenser....”.

**Reference solution (b).** Add 5 ml of the internal standard solution to 0.1 g of the substance under examination, evaporate to dryness, add 5 ml of boron trifluoride solution and complete the procedure described for the test solution beginning at the words “heat under a reflux condenser......”.

**Reference solution (c).** Prepare in the same manner as reference solution (a) but omitting the internal standard.

**Chromatographic system**

- a glass column 1.5 m x 4 mm, packed with acid-washed, silanised diatomaceous support (100 to 120 mesh) coated with 15 per cent w/w of diethylene glycol succinate polyester,
- temperature: column 170º, inlet port and detector at 240º,
- flow rate: 30 ml per minute of the carrier gas.

Calculate the content of C\text{18}H\text{36}O\text{2} and C\text{16}H\text{32}O\text{2}.

**Storage.** Store protected from moisture.
**Stearyl Alcohol**

Stearyl Alcohol is a mixture of solid alcohols consisting chiefly of 1-octadecanol, \((C_{18}H_{38}O)\).

**Description.** A white, unctuous mass or almost white flakes or granules; odour, faint and characteristic.

**Tests**

**Appearance of solution.** Dissolve 0.5 g in 20 ml of ethanol (95 per cent) by heating to boiling and allow to cool. The solution is clear (2.4.1), and not more intensely coloured than reference solution BS6 (2.4.1).

**Melting range (2.4.21).** 55º to 60º.

**Acid value** (2.3.23). Not more than 2.0.

**Hydroxyl value** (2.3.27). 195 to 220.

**Iodine value** (2.3.28). Not more than 2.0 (iodine bromide method), determined on 2.0 g dissolved in 25 ml of chloroform, warming if necessary to effect solution.

**Saponification value** (2.3.37). Not more than 2.0, determined on 10.0 g.

**Storage.** Store protected from moisture.

---

**Stilboestrol**

Diethylstilboestrol

![Stilboestrol molecule](image_url)

\[\text{C}_{18}\text{H}_{20}\text{O}_{2}\]  
Mol. Wt. 268.4

Stilboestrol is \((E)\)-\(\alpha,\beta\)-diethylstilbene-4,4'-diol.

Stilboestrol contains not less than 97.0 per cent and not more than 101.0 per cent of \(\text{C}_{18}\text{H}_{20}\text{O}_{2}\), calculated on the dried basis.

**Description.** A white or almost white, crystalline powder; odourless.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with stilboestrol RS or with the reference spectrum of stilboestrol.

B. When examined in the range 230 nm to 450 nm (2.4.7), the irradiated solution prepared as directed in the Assay shows absorption maxima at about 292 nm and 418 nm.

C. In the test for mono- and di-methyl ethers, the principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a).

D. Dissolve 0.5 mg in 0.2 ml of glacial acetic acid, add 1 ml of phosphoric acid and heat in a water-bath for 3 minutes; a deep yellow colour is produced which almost disappears on dilution with 3 ml of glacial acetic acid (distinction from dienoestrol).

**Tests**

**4,4'-Dihydroxystilben and related ethers.** Absorbance of a 1.0 per cent w/v solution in ethanol at about 325 nm, not more than 0.50 (2.4.7).

**Mono- and di-methyl ethers.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel.

**Mobile phase.** A mixture of 90 volumes of toluene and 10 volumes of diethylamine.

**Test solution.** Dissolve 0.5 g of the substance under examination in 100 ml of ethanol (95 per cent).

**Reference solution (a).** A 0.5 per cent w/v solution of stilboestrol RS in ethanol (95 per cent).

**Reference solution (b).** A 0.05 per cent w/v solution of stilboestrol monomethyl ether RS in ethanol (95 per cent).

**Reference solution (c).** A 0.05 per cent w/v solution of stilboestrol dimethyl ether RS in ethanol (95 per cent).

**Reference solution (d).** A solution containing 0.25 per cent w/v each of dienoestrol RS and stilboestrol RS

Apply to the plate 1 µl of each solution. After development, dry the plate in air, spray with ethanolic sulphuric acid (20 per cent) and heat at 120º for 10 minutes. Any secondary spots in the chromatogram obtained with the test solution corresponding to the mono-and di-methyl ethers of stilboestrol are not more intense than the spots in the chromatograms obtained with reference solutions (b) and (c) respectively. Stilboestrol sometimes produces two spots. The test is not valid unless the chromatogram obtained with reference solution (d) shows two clearly separated spots of approximately the same intensity.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 20 mg, dissolve in sufficient ethanol to produce 100.0 ml and dilute 10.0 ml of this solution...
to 100.0 ml with ethanol. To 25.0 ml of the resulting solution add 25.0 ml of a solution prepared by dissolving 1 g of dipotassium hydrogen phosphate in 55 ml of water, transfer a portion of the mixture to a 1-cm closed quartz cell, place the cell 10 cm from a 15-watt short-wave, ultraviolet light of mercury lamp and irradiate for 10 minutes. Measure the absorbance of the irradiated solution at the maximum at about 418 nm (2.4.7). Calculate the content of C18H20O2 from the absorbance obtained by repeating the operation using stilboestrol RS in place of the substance under examination.

Storage. Store protected from light and moisture.

Stilboestrol Tablets

Diethylstilboestrol Tablets

Stilboestrol Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of stilboestrol, C18H20O2. The tablets may be coated.

Identification

A. When examined in the range 230 nm to 450 nm (2.4.7), the irradiated solution prepared as directed in the Assay shows absorption maxima at about 292 nm and 418 nm.

B. Extract a quantity of the powdered tablets containing 3 mg of Stilboestrol with ether, filter and evaporate the filtrate to dryness. Dissolve 0.5 mg of the residue in 0.2 ml of glacial acetic acid, add 1 ml of phosphoric acid and heat in a water-bath for 3 minutes; a deep yellow colour is produced which almost disappears on dilution with 3 ml of glacial acetic acid (distinction from dienoestrol).

Tests

Uniformity of content. For tablets containing 10 mg or less — Comply with the test stated under Tablets.

Finely crush one tablet, add 10 ml of ethanol, shake for 30 minutes, add sufficient ethanol to produce 25.0 ml and centrifuge. Pipette an aliquot of the supernatant liquid containing 0.5 mg of Stilboestrol add 25.0 ml of a solution prepared by dissolving 1 g of dipotassium hydrogen phosphate in 55 ml of water, transfer a portion of the mixture to a 1-cm closed quartz cell, place the cell 10 cm from a 15-watt short-wave, ultraviolet light of mercury lamp and irradiate for 10 minutes. Measure the absorbance of the irradiated solution at the maximum at about 418 nm (2.4.7). Calculate the content of C18H20O2 in the tablet from the absorbance obtained by repeating the operation using stilboestrol RS in place of the substance under examination.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 5 mg of Stilboestrol, add 5 ml of ethanol, shake for 15 minutes, add sufficient ethanol to produce 100.0 ml and centrifuge. Dilute 20.0 ml of the clear, supernatant liquid to 50.0 ml with ethanol and mix. To 25.0 ml of the resulting solution, add 25.0 ml of a solution prepared by dissolving 1 g of dipotassium hydrogen phosphate in 55 ml of water, transfer a portion of the mixture to a 1-cm closed quartz cell, place the cell 10 cm from a 15-watt short-wave, ultraviolet light of mercury lamp and irradiate for 10 minutes. Measure the absorbance of the irradiated solution at 418 nm (2.4.7). Calculate the content of C18H20O2 in the tablet from the absorbance obtained by repeating the operation using stilboestrol RS in place of the substance under examination.

Storage. Store protected from light and moisture.

Prepared Storax

Storax

Prepared Storax is a balsam obtained from the wounded trunk of Liquidambar orientalis Miller (Fam. Hamameli-daceae) and subsequently purified by solution in Ethanol (95 per cent), filtration and evaporation of the solvent. Prepared Storax contains not less than 30.0 per cent of total balsamic acids calculated as cinnamic acid, C9H8O2, on the dried basis.

Description. A brown, viscous substance, transparent in thin layers; odour, agreeable and balsamic.

Identification

Shake 1 g with a 10 per cent w/v solution of potassium chromate and 1 ml of sulphuric acid; the odour of benzaldehyde is produced.

Tests

Acid value (2.3.23). 50 to 80, calculated on the dried basis.

Ester value (2.3.26). 100 to 133, calculated on the dried basis.

Saponification value (2.3.37). 170 to 200, calculated on the dried basis.

Ethanol-soluble matter. Not less than 70 per cent, determined by the following method. Weigh accurately about 10.0 g in a beaker and heat at 105º for 30 minutes. Dissolve the residue in 100 ml of hot ethanol (95 per cent), filter through a tared sintered glass crucible, wash the residue with small amounts of hot ethanol (95 per cent) until the last washing is nearly colourless. Reserve the residue for the Ethanol-insoluble matter.
test. Combine the filtrate and the washings and evaporate at a temperature not exceeding 60°. Dry the residue at 105° for 1 hour, cool and weigh.

**Ethanol-insoluble matter.** Not more than 5 per cent, determined by the following method. Dry the residue obtained in the test for Ethanol-soluble matter at 105° for 1 hour, cool and weigh.

**Loss on drying** (2.4.19). Not more than 5 per cent, determined on 1.0 g by drying in a thin layer over phosphorus pentoxide at 60° at a pressure not exceeding 2.7 kPa.

**Assay.** Weigh accurately about 1.25 g and boil with 25 ml of dilute ethanolic potassium hydroxide solution under a reflux condenser for 1 hour. Remove the ethanol and digest the residue with 50 ml of hot water until diffused. Cool the liquid, add 150 ml of water and 1.5 g of magnesium sulphate dissolved in 50 ml of water. Mix thoroughly and set aside for 10 minutes. Filter, wash the residue on the filter with 20 ml of water, acidify the combined filtrate and washings with hydrochloric acid and extract with successive quantities of 50, 40, 30, 30 and 30 ml of ether. Combine the ether extracts and discard the aqueous portion. Extract with successive quantities of 20, 20, 10, 10 and 10 ml of sodium bicarbonate solution, washing each aqueous extract with the same 20 ml of ether. Discard the ether layers, acidify the combined aqueous extracts with hydrochloric acid and extract with successive quantities of 30, 20, 20 and 10 ml of chloroform, filtering each chloroform extract through a plug of cotton wool on which a layer of anhydrous sodium sulphate is placed. Evaporate the chloroform on a water-bath until about 10 ml remains and remove the remainder in a current of air stopping immediately when the last trace of solvent is removed. Dissolve the residue by warming with 10 ml of ethanol (95 per cent), previously neutralised to phenol red solution, cool and titrate with 0.1 M sodium hydroxide using phenol red solution as indicator.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.01482 g of total balsamic acids, calculated as cinnamic acid, C₆H₅O₂.

**Storage.** Store protected from moisture.

**Streptokinase**

Streptokinase is a preparation of a protein obtained from culture filtrates of certain strains of Streptococcus haemolyticus group C. It has the property of combining with human plasminogen to form plasminogen activator and is purified to contain not less than 600 Units of Streptokinase activity per µg of nitrogen before addition of any stabiliser or carrier. It usually contains a buffer and may be stabilised by the addition of suitable substances such as Human Albumin.

**Description.** A white powder or a white, friable solid; hygroscopic.

**Identification**

A. Place 0.5 ml of citrated human, canine or rabbit plasma in a haemolysis tube maintained in a water-bath at 37°. Add 0.1 ml of a solution of the substance under examination containing 10,000 Units per ml in citro-phosphate buffer pH 7.2 and 0.1 ml of a solution of thrombin containing 20 Units per ml in citro-phosphate buffer pH 7.2 and shake immediately; a clot forms and lyses within 30 minutes. Repeat the procedure using citrated bovine plasma; lysis does not occur within 1 hour.

B. Dissolve 0.6 g of agar in 50.0 ml of mixed barbitone buffer pH 8.6, heating until a clear solution is obtained. Place glass plates (50 mm x 50 mm) that are free from traces of grease on a level surface. Apply to each plate 4 ml of the agar solution and allow to cool until set. Bore a hole 6 mm in diameter in the centre of the agar and an appropriate number of holes (not exceeding six) at distances of 11 mm from the central hole removing the residual agar by means of a cannula connected to a vacuum pump. Place a quantity of 80 µl of goat or rabbit antistreptokinase serum containing 10,000 Units of antistreptokinase activity per ml in the central hole and 80 µl of a solution of the substance under examination containing 125,000 Units of streptokinase activity per ml of each of the surrounding holes. Place the plates in a humidified tank for 24 hours.

Only one precipitation arc is produced which is well-defined and localised between the application point of the serum and each hole containing the solution of the substance under examination.

**Tests**

**pH** (2.4.24). 6.8 to 7.5, determined on a solution prepared in freshly boiled and cooled water containing 5000 Units per ml.

**Streptodornase.** Introduce 0.5 ml of a 0.1 per cent w/v solution of sodium deoxyribonucleate in imidazole buffer pH 6.5 into each of eight centrifuge tubes. To each of the first two tubes add 0.25 ml of imidazole buffer pH 6.5 and 0.25 ml of solution of the substance under examination in imidazole buffer pH 6.5 containing 150,000 Units per ml (solution A) followed immediately by 3.0 ml of 0.25 M perchloric acid. Mix the contents of each tube, centrifuge for 5 minutes at 3000 rpm and measure the absorbance of each of the supernatant liquids at about 260 nm (2.4.7), using as the blank a mixture of 1.0 ml of imidazole buffer pH 6.5 and 3.0 ml of 0.25 M perchloric acid. Calculate the sum of the two absorbances (A₁). To each of the remaining six tubes add, respectively, 0.25, 0.25, 0.125, 0.125, 0 and 0 ml of imidazole buffer pH 6.5 followed by 0.25 ml of solution A and finally 0, 0, 0.125, 0.125, 0.25 and 0.25 ml respectively of a solution of the Standard Preparation containing 20 Units of streptodornase activity per ml in imidazole buffer pH 6.5. [The Standard Preparation is the 1st International Standard Preparation for Streptodornase,
established in 1964, consisting of a freeze-dried mixture of streptodornase and streptokinase with lactose (supplied in ampoules containing 2400 Units of streptodornase activity), or another suitable preparation the activity of which has been determined in relation to the International Standard. Mix the contents of each tube, incubate at 37º for 15 minutes and add to each tube 3.0 ml of 0.25 M perchloric acid. Mix the contents of each tube, centrifuge and measure the absorbance of each of the supernatant liquids at about 260 nm (2.4.7), using as the blank the mixture specified above. If the sum of the absorbances of the liquids in the third and fourth tubes is \( A_2 \), that of the liquids in the fifth and sixth tubes is \( A_3 \), and that of the liquids in the seventh and eighth tubes is \( A_4 \), \((A_2 - A_3)\) is less than 0.5\((A_1 + A_3 - A_4)\).

**Streptolysin.** Dissolve a quantity of the substance under examination containing 500,000 Units in 0.5 ml of a mixture of 90 volumes of saline solution and 10 volumes of citro-phosphate buffer pH 7.2 in a haemolysis tube. Add 0.4 ml of a 2.3 per cent w/v solution of sodium thioglycollate and incubate in a water-bath at 37º for 10 minutes. Add 0.1 ml of a solution of a reference preparation of human antistreptolysin O containing 5 Units per ml and incubate at 37º for 5 minutes. Add 1 ml of rabbit erythrocyte suspension, continue the incubation for 30 minutes and centrifuge at about 1000 rpm. The absorbance of the supernatant liquid at about 550 nm (2.4.7), is not more than 1.5 times the absorbance obtained by repeating the above procedure using 0.5 ml of the mixture of saline solution and citro-phosphate buffer pH 7.2 in place of the solution containing the substance under examination.

**Loss on drying (2.4.19).** Not more than 4.0 per cent, determined on 1.0 g by drying over phosphorus pentoxide at a pressure not exceeding 2.7 kPa for 24 hours.

**Assay.** The potency of streptokinase is determined by comparing its ability to activate human plasminogen to form plasmin with that of the Standard Preparation. The plasmin generated is determined by measurement of the time taken to lyse a fibrin clot under the conditions of a suitable method of assay.

**Standard Preparation**

The Standard Preparation is the 2nd International Standard for Streptokinase, established in 1989, consisting of freeze-dried streptokinase (supplied in ampoules containing 700 Units of streptokinase activity), or another suitable preparation the activity of which has been determined in relation to the International reference preparation.

**Method**

Use citro-phosphate buffer pH 7.2 containing 3 per cent w/v of bovine serum albumin for the preparation of solutions and dilutions. Prepare a solution of the Standard Preparation to contain 1000 Units of streptokinase activity per ml and prepare a solution of the preparation under examination expected to have the same concentration; keep the solutions in ice and use within 6 hours. Prepare three 1.5-fold serial dilutions of the solution of the Standard Preparation so that the longest clot-lysis time is less than 20 minutes and prepare three similar dilutions of the solution of the preparation under examination. Keep the solutions in ice and use within 1 hour. Using 24 tubes, 8 mm in diameter, label the tubes \( S_i \), \( T_i \), \( T_2 \) for the dilutions of the Standard Preparation and \( T_1 \), \( T_2 \), \( T_3 \) for the dilutions of the preparation under examination, allocating four tubes to each dilution. Place the tubes in ice. Into each tube introduce 0.2 ml of the appropriate dilution, 0.2 ml of citro-phosphate buffer pH 7.2 containing 3 per cent w/v of bovine serum albumin and 0.1 ml of a solution containing 20 Units of thrombin per ml. Place the tubes in a water-bath at 37º and allow to stand for 2 minutes to attain temperature equilibrium. Using an automatic pipette, introduce into the bottom of the first tube 0.5 ml of a 1 per cent w/v solution to human euglobulins ensuring mixing. At 5-second intervals introduce successively into the remaining tubes 0.5 ml of a 1 per cent w/v solution of human euglobulins. Using a stop-watch, measure for each tube the time in seconds that elapses between the addition of the euglobulin and the lysis of the clot.

Using the logarithms of the lysis times, calculate the result of the assay by standard statistical methods.

The estimated potency is not less than 90 per cent and not more than 111 per cent of the stated potency. The fiducial limits of error are not less than 80 per cent and not more than 125 per cent of the stated potency.

Streptokinase intended for use in the manufacture of parenteral preparations complies with the following additional requirements.

**Abnormal toxicity (2.2.1).** Determine by Method A, using a solution containing 50,000 Units in 0.5 ml of water for injections administered in 15 to 20 seconds.

**Bacterial endotoxins (2.2.3).** Dissolve the contents of the sealed container in water BET to give a solution containing 10,000 Units of Streptokinase per ml. Carry out the test on the resulting solution; the maximum allowable endotoxin concentration of the solution is 23.33 Units of endotoxin per ml. Carry out the test using the maximum valid dilution of the prepared solution calculated from the declared sensitively of the lysate used in the test.

**Sterility (2.2.11).** Complies with the test for sterility.

**Storage.** Store in sealed containers, protected from light. The containers should be sterile, tamper-evident and sealed so as to exclude micro-organisms. Under these conditions the contents may be expected to retain their potency for 2 years.
**Labelling.** The label states (1) the number of Units of streptokinase activity in the container; (2) the number of Units of streptokinase activity per mg, calculated with reference to the dried preparation; (3) the name and quantity of any added substances; (4) the storage conditions; (5) whether or not it is intended for use in the manufacture of parenteral preparations.

**Streptokinase Injection**

Streptokinase Injection is a sterile material consisting of Streptokinase with or without auxiliary agents. It is filled in a sealed container.

The injection is constituted by dissolving the contents of the sealed container in the requisite amount of sterile Water for Injections, immediately before use.

*The constituted solution complies with the requirements for Clarity of solution and Particulate matter stated under Parenteral Preparations (Injections).*

**Storage.** The constituted solution should be used immediately after preparation but, in any case, within the period recommended by the manufacturer.

The contents of the sealed container comply with the requirements stated under Parenteral Preparations (Powders for Injection) and with the following requirements.

**Identification**

A. Place 0.5 ml of citrated human, canine or rabbit plasma in a haemolysis tube maintained in a water-bath at 37º. Add 0.1 ml of a solution of the contents of the container containing 10,000 Units per ml in citro-phosphate buffer pH 7.2 and 0.1 ml of a solution of thrombin containing 20 Units per ml in citro-phosphate buffer pH 7.2 and shake immediately; a clot forms and lyses within 30 minutes. Repeat the procedure using citrated bovine plasma; lysis does not occur within 1 hour.

B. Dissolve 0.6 g of agar in 50.0 ml of mixed barbitone buffer pH 8.6, heating until a clear solution is obtained. Place glass plates (50 mm x 50 mm) that are free from traces of grease on a level surface. Apply to each plate 4 ml of the agar solution and allow to cool until set. Bore a hole 6 mm in diameter in the centre of the agar and an appropriate number of holes (not exceeding six) at distances of 11 mm from the central hole removing the residual agar by means of a cannula connected to a vacuum pump. Place a quantity of 80 µl of goat or rabbit antistreptokinase serum containing 10,000 Units of antistreptokinase activity per ml in the central hole and 80 µl of a solution of the contents of the container containing 125,000 Units of streptokinase activity per ml of each of the surrounding holes. Place the plates in a humidified tank for 24 hours.

Only one precipitation arc is produced which is well-defined and localised between the application point of the serum and each hole containing the solution of the substance under examination.

**Tests**

**pH** (2.4.24). 6.8 to 7.5, determined on a freshly constituted injection containing 5000 Units per ml.

**Streptodornase.** Introduce 0.5 ml of a 0.1 per cent w/v solution of sodium deoxyribonucleate in imidazole buffer pH 6.5 into each of eight centrifuge tubes. To each of the first two tubes add 0.25 ml of imidazole buffer pH 6.5 and 0.25 ml of solution of the contents of the container with the substance under examination in imidazole buffer pH 6.5 containing 150,000 Units per ml. Add 0.25 ml of 0.25 M perchloric acid. Mix the contents of each tube, centrifuge for 5 minutes at 3000 rpm and measure the absorbance of each of the supernatant liquids at about 260 nm (2.4.7), using as the blank a mixture of 1.0 ml of imidazole buffer pH 6.5 and 3.0 ml of 0.25 M perchloric acid. Calculate the sum of the two absorbances (A₁). To each of the remaining six tubes add, respectively, 0.25, 0.25, 0.125, 0.125, 0 and 0 ml of imidazole buffer pH 6.5 followed by 0.25 ml of solution A and finally 0, 0, 0.125, 0.125, 0.25 and 0.25 ml respectively of a solution of the Standard Preparation containing 20 Units of streptodornase activity per ml in imidazole buffer pH 6.5. [The Standard Preparation is the 1st International Standard Preparation for Streptodornase, established in 1964, consisting of a freeze-dried mixture of streptodornase and streptokinase with lactose (supplied in ampoules containing 2400 Units of streptodornase activity), or another suitable preparation the activity of which has been determined in relation to the International Standard]. Mix the contents of each tube, incubate at 37º for 15 minutes and add to each tube 3.0 ml of 0.25 M perchloric acid. Mix the contents of each tube, centrifuge and measure the absorbance of each of the supernatant liquids at about 260 nm (2.4.7), using as the blank the mixture specified above. If the sum of the absorbances of the liquids in the third and fourth tubes is A₁, that of the liquids in the fifth and sixth tubes is A₂, and that of the liquids in the seventh and eighth tubes is (A₁–A₂), 0.5(A₁+A₂)–A₂ is less than 0.5(A₁+A₂)–A₂.

**Streptolysin.** Dissolve a quantity of the contents of the container containing 500,000 Units in 0.5 ml of a mixture of 90 volumes of saline solution and 10 volumes of citro-phosphate buffer pH 7.2 in a haemolysis tube. Add 0.4 ml of a 2.3 per cent w/v solution of sodium thioglycollate and incubate in a water-bath at 37º for 10 minutes. Add 0.1 ml of a solution of a reference preparation of human antistreptolysin O containing 5 Units per ml and incubate at 37º for 5 minutes. Add 1 ml of rabbit erythrocyte suspension, continue the incubation for 30 minutes and centrifuge at about 1000 rpm.
The absorbance of the supernatant liquid at about 550 nm (2.4.7), is not more than 1.5 times the absorbance obtained by repeating the above procedure using 0.5 ml of the mixture of saline solution and citro-phosphate buffer pH 7.2 in place of the solution containing the substance under examination.

**Bacterial endotoxins** (2.2.3). Dissolve the contents of the sealed container in *water BET* to give a solution containing 10,000 Units of Streptokinase per ml. Carry out the test on the resulting solution; the maximum allowable endotoxin concentration of the solution is 23.33 Units of endotoxin per ml. Carry out the test using the maximum valid dilution of the prepared solution calculated from the declared sensitively of the lysate used in the test.

**Assay.** Determine on the mixed contents of ten containers.

The potency of streptokinase is determined by comparing its ability to activate human plasminogen to form plasmin with that of the Standard Preparation. The plasmin generated is determined by measurement of the time taken to lyse a fibrin clot under the conditions of a suitable method of assay.

**Standard Preparation**

The Standard Preparation is the 2nd International Standard for Streptokinase, established in 1989, consisting of freeze-dried streptokinase (supplied in ampoules containing 700 Units of streptokinase activity), or another suitable preparation the activity of which has been determined in relation to the International reference preparation.

**Method**

Use citro-phosphate buffer pH 7.2 containing 3 per cent w/v of bovine serum albumin for the preparation of solutions and dilutions.

Prepare a solution of the Standard Preparation to contain 1000 Units of streptokinase activity per ml and prepare a solution of the contents of the container expected to have the same concentration; keep the solutions in ice and use within 6 hours. Prepare three 1.5-fold serial dilutions of the solution of the Standard Preparation so that the longest clot-lysis time is less than 20 minutes and prepare three similar dilutions of the solution of the preparation under examination. Keep the solutions in ice and use within 1 hour. Using 24 tubes, 8 mm in diameter, label the tubes S₁, S₂, S₃ for the dilutions of the Standard Preparation and T₁, T₂, T₃ for the dilutions of the preparation under examination, allocating four tubes to each dilution. Place the tubes in ice. Into each tube introduce 0.2 ml of the appropriate dilution, 0.2 ml of citro-phosphate buffer pH 7.2 containing 3 per cent w/v of bovine serum albumin and 0.1 ml of a solution containing 20 Units of thrombin per ml. Place the tubes in a water-bath at 37º and allow to stand for 2 minutes to attain temperature equilibrium. Using an automatic pipette, introduce into the bottom of the first tube 0.5 ml of a 1 per cent w/v solution to human euglobulins ensuring mixing. At 5-second intervals introduce successively into the remaining tubes 0.5 ml of a 1 per cent w/v solution of human euglobulins. Using a stop-watch, measure for each tube the time in seconds that elapses between the addition of the euglobulin and the lysis of the clot.

Using the logarithms of the lysis times, calculate the result of the assay by standard statistical methods.

The estimated potency is not less than 90 per cent and not more than 111 per cent of the stated potency. The fiducial limits of error are not less than 80 per cent and not more than 125 per cent of the stated potency.

**Storage.** Store in sealed containers, protected from light in a refrigerator (2º to 8º). The containers should be sterile and sealed so as to exclude micro-organisms. Under these conditions the contents may be expected to retain their potency for 2 years.

**Labelling.** The label states the total number of Units of streptokinase activity contained in it.

---

**Streptomycin Sulphate**

![Streptomycin Sulphate](image)

(C₂₁H₃₉N₁₇O₁₄)₂·₃H₂SO₄  
Mol. Wt. 1457.4

Streptomycin Sulphate is the sulphate of O-2-deoxy-2-methylamino-α-L-glucopyranosyl-(1→2)-O-5-deoxy-3-C-formyl-α-L-lyxofuranosyl(1→4)-N⁺,N⁶-diamidino-D-streptamine, a substance produced by the growth of certain strains of *Streptomyces griseus* or obtained by any other means.
Streptomycin Sulphate has a potency equivalent to not less than 700 µg and not more than 850 µg of streptomycin per mg. It contains not less than 90.0 per cent of the stated amount of streptomycin, C_{31}H_{39}N_{7}O_{12}, calculated on the dried basis.

**Description.** A white or almost white powder; odourless or with slight odour; hygroscopic.

**Identification**

A. Determine by thin-layer chromatography (2.4.17). Prepare the plate by mixing 0.3 g of carbonomer with 240 ml of water, allowing to stand with moderate stirring for 1 hour, adjusting the pH to 7.0 by the gradual addition with constant shaking of 2 M sodium hydroxide and adding 30 g of silica gel H. Spread a uniform layer of the resulting suspension 0.75 mm thick. Heat the plate at 110º for 1 hour, allow to cool and use immediately.

**Mobile phase.** A 7 per cent w/v solution of potassium dihydrogen phosphate.

**Test solution.** Dissolve 0.1 g of the substance under examination in 100 ml of water.

**Reference solution (a).** A 0.1 per cent w/v of streptomycin sulphate RS in water.

**Reference solution (b).** A solution containing 0.1 per cent w/v of streptomycin sulphate RS, 0.1 per cent w/v of neomycin sulphate RS and 0.1 per cent w/v of kanamycin monosulphate RS in water.

Apply to the plate 10 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in warm air, spray with a mixture of equal volumes of a 0.2 per cent w/v solution of naphthalene-1,3-diol in ethanol (95 per cent) and sulphuric acid (45 per cent) and heat at 150º for 5 to 10 minutes. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

B. Dissolve 5 to 10 mg in 4 ml of water and add 1 ml of 1 M sodium hydroxide. Heat in a water-bath for 4 minutes. Add a slight excess of 2 M hydrochloric acid and 0.1 ml of a 10 per cent w/v solution of ferric chloride; a violet colour is produced.

C. Dissolve 0.1 g in 2 ml of water and add 1 ml of dilute 1-naphthol solution and 2 ml of a mixture of equal volumes of dilute sodium hypochlorite solution and water; a red colour is produced.

D. Dissolve 10 mg in 5 ml of water and add 1 ml of 1 M hydrochloric acid. Heat in a water-bath for 2 minutes. Add 2 ml of a 0.5 per cent w/v solution of 1-naphthol in 1 M sodium hydroxide and heat in a water-bath for 1 minute; a faint yellow colour is produced.

E. Gives the reactions of sulphates (2.3.1).

**Tests**

**Appearance of solution.** A 25.0 per cent w/v solution in carbon dioxide-free water is not more intensely coloured than degree 3 of the appropriate range of reference solutions (2.4.1). The solution, after standing protected from light at a temperature of about 20º for 24 hours, is not more opalescent than opalescence standard OS2 (2.4.1).

**pH** (2.4.24). 4.5 to 7.0, determined in a 25.0 per cent w/v solution.

**Sulphates.** 18.0 to 21.5 per cent, calculated on the dried basis, when determined by the following method. Dissolve 0.25 g in 100 ml of water, adjust the pH to 11 with strong ammonia solution and add 10.0 ml of 0.1 M barium chloride and 0.5 mg of metaphthalic acid. Titrate the excess of barium chloride with 0.1 M disodium edetate, adding 50 ml of ethanol (95 per cent) when the colour of the solution begins to change and continuing the titration until the violet-blue colour disappears.

1 ml of 0.1 M barium chloride is equivalent to 0.009606 g of sulphate, SO₄.

**Colorimetric test.** Dissolve 0.1 g in sufficient water to produce 100 ml. To 5 ml, add 5 ml of 0.2 M sodium hydroxide and heat in a water-bath for exactly 10 minutes. Cool in ice for exactly 5 minutes, add 3 ml of a 1.5 per cent w/v solution of ferric ammonium sulphate in 0.25 M sulphuric acid and sufficient water to produce 25 ml and mix. Exactly 20 minutes after the addition of the ferric ammonium sulphate solution, measure the absorbance of a 2-cm layer of the solution at the maximum of 525 nm (2.4.7), using as the blank a solution prepared in the same manner but omitting the substance under examination. The absorbance is not less than 90.0 per cent of that obtained by carrying out the procedure at the same time and in the same manner using streptomycin sulphate RS in place of the substance under examination, each absorbance being calculated on the dried basis.

**Streptomycin B.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 50 volumes of toluene, 25 volumes of glacial acetic acid and 25 volumes of methanol.

**Test solution.** Dissolve 0.2 g of the substance under examination in 5 ml of a freshly prepared mixture of 97 volumes of methanol and 3 volumes of sulphuric acid, heat under a reflux condenser for 1 hour, cool, wash down the condenser with methanol and add sufficient methanol to produce 20 ml.

**Reference solution.** Dissolve 36 mg of D-mannose in 5 ml of a freshly prepared mixture of 97 volumes of methanol and 3 volumes of sulphuric acid, heat under a reflux condenser for 1 hour, cool, wash down the condenser with methanol and add sufficient methanol to produce 50 ml. Dilute 5 ml of the
resulting solution to 50 ml with methanol; this solution contains the equivalent of 0.03 per cent w/v of streptomycin B (1 mg of D-mannose is equivalent to 4.13 mg of streptomycin B).

Apply to the plate 10 µl of each solution. Allow the mobile phase to rise 13 to 15 cm. Dry the plate in air, and spray with a freshly prepared mixture of equal volumes of a 0.2 per cent w/v solution of naphthalene-1,3-diol in ethanol (95 per cent) and a 20 per cent v/v solution of sulphuric acid and heat at 110º for 5 minutes. Any spot in the chromatogram obtained with the test solution is not more intense than the corresponding spot in the chromatogram with the reference solution.

**Methanol.** Determine by gas chromatography (2.4.13).

**Test solution.** A 4 per cent w/v solution of the substance under examination in water.

**Reference solution.** A 0.012 per cent w/v solution of methanol in water.

Chromatographic system
- a glass column 1.5 to 2.0 m x 2 to 4 mm, packed with ethylvinylbenzene-divinylbenzene copolymer (150 to 180 µm) porous polymer beads (such as Porapak Q),
- temperature: column 120º to 140º,
- inlet port and detector at least 50º higher than that of the column,
- flow rate. 30 to 40 ml per minute of the carrier gas.

The area of any peak corresponding to methanol in the chromatogram obtained with the test solution is not greater than that of the peak in the chromatogram obtained with reference solution (0.3 per cent).

**Sulphated ash** (2.3.18). Not more than 1.0 per cent.

**Loss on drying** (2.4.19). Not more than 7.0 per cent, determined on 1.0 g by drying over phosphorus pentoxide at 60º at a pressure not exceeding 0.1 kPa for 24 hours.

**Assay.** Determine by the microbiological assay of antibiotics, Method A or B (2.2.10), and express the results in µg of streptomycin per mg.

Streptomycin Sulphate intended for use in the manufacture of parenteral preparations without a further appropriate procedure for removal of bacterial endotoxins complies with the following additional requirement.

**Bacterial endotoxins** (2.2.3). Not more than 0.25 Endotoxin Unit per mg of streptomycin.

Streptomycin Sulphate intended for use in the manufacture of parenteral preparations without a further appropriate sterilisation procedure complies with the following additional requirement.

**Sterility** (2.2.11). Complies with the test for sterility.

**Storage.** Store protected from light and moisture. If it is intended for use in the manufacture of parenteral preparations the container should be sterile and sealed so as to exclude micro-organisms.

**Labelling.** The label states (1) the equivalent weight of streptomycin contained in it; (2) whether or not the contents are intended for use in the manufacture of parenteral preparations; (3) the name and quantity of any added stabiliser.

### Streptomycin Injection

**Streptomycin Sulphate Injection**

Streptomycin Injection is a sterile material consisting of Streptomycin Sulphate with or without auxiliary agents. It is filled in a sealed container.

The injection is constituted by dissolving the contents of the sealed container in the requisite amount of sterile Water for Injections, immediately before use.

The constituted solution complies with the requirements for Clarity of solution and Particulate matter stated under Parenteral Preparations (Injections).

**Storage.** The constituted solution should be used immediately after preparation but, in any case, within the period recommended by the manufacturer.

Streptomycin Injection contains not less than 90.0 per cent and not more than 115.0 per cent of the stated amount of streptomycin, C_{21}H_{39}N_{7}O_{12}, calculated on the dried basis.

The contents of the sealed container comply with the requirements stated under Parenteral Preparations (Powders for Injection) and with the following requirements.

**Description.** A white or almost white powder which yields a clear, colourless or faintly yellow coloured solution when dissolved in water.

**Identification.** A. Determine by thin-layer chromatography (2.4.17). Prepare the plate by mixing 0.3 g of carbomer with 240 ml of water, allowing to stand with moderate stirring for 1 hour, adjusting the pH to 7.0 by the gradual addition with constant shaking of 2 M sodium hydroxide and adding 30 g of silica gel H. Spread a uniform layer of the resulting suspension 0.75 mm thick. Heat the plate at 110º for 1 hour, allow to cool and use immediately.

**Mobile phase.** A 7 per cent w/v solution of potassium dihydrogen phosphate.

**Test solution.** Dissolve 0.1 g of the substance under examination in 100 ml of water.

**Reference solution (a).** A 0.1 per cent w/v of streptomycin sulphate RS in water.
Reference solution (b). A solution containing 0.1 per cent w/v of streptomycin sulphate RS, 0.1 per cent w/v of neomycin sulphate RS and 0.1 per cent w/v of kanamycin monosulphate RS in water.

Apply to the plate 10 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in warm air, spray with a mixture of equal volumes of a 0.2 per cent w/v solution of naphthalene-1,3-diol in ethanol (95 per cent) and sulphuric acid (45 per cent) and heat at 150º for 5 to 10 minutes. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

B. Dissolve 5 to 10 mg in 4 ml of water and add 1 ml of 1 M sodium hydroxide. Heat in a water-bath for 4 minutes. Add a slight excess of 2 M hydrochloric acid and 0.1 ml of a 10 per cent w/v solution of ferric chloride; a violet colour is produced.

C. Dissolve 0.1 g in 2 ml of water and add 1 ml of dilute 1-naphthol solution and 2 ml of a mixture of equal volumes of dilute sodium hypochlorite solution and water; a red colour is produced.

D. Dissolve 10 mg in 5 ml of water and add 1 ml of 1 M hydrochloric acid. Heat in a water-bath for 2 minutes. Add 2 ml of a 0.5 per cent w/v solution of 1-naphthol in 1 M sodium hydroxide and heat in a water-bath for 1 minute; a faint yellow colour is produced.

Tests

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.3 g of streptomycin and, triturate with 20 ml of buffer solution pH 8.0. Dilute to 100.0 ml with water. Determine by the microbiological assay of antibiotics, Method A or B (2.2.10).

Storage. Store protected from moisture.

Labelling. The label states the strength in terms of the equivalent amount of streptomycin.

Streptomycin Tablets

Streptomycin Sulphate Tablets

Streptomycin Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of streptomycin, C21H39N7O12.

Identification

A. Triturate a quantity of the powdered tablets containing 0.2 g of streptomycin in a mixture of 2 ml of methanol and 0.1 ml of sulphuric acid, filter, if necessary, and allow to stand at about 25º; crystals of streptidine sulphate separate in the course of 2 to 3 days. Dissolve the crystals in a solution of 0.1 g of picric acid in 10 ml of hot water and cool; the precipitate, after recrystallisation from hot water, melts at about 283º (2.4.21).

B. Boil a small quantity of the powdered tablets containing 0.1 g of streptomycin with 5 ml of 1 M sodium hydroxide for a few minutes, add a slight excess of 2 M hydrochloric acid and 0.15 ml of a 10 per cent w/v solution of ferric chloride; a brilliant violet colour is produced.

Succinylcholine Chloride

Suxamethonium Chloride

Succinylcholine Chloride is 2,2'-succinyldioxybis(ethyltrimethylammonium) dichloride dihydrate.

Succinylcholine Chloride contains not less than 98.0 per cent and not more than 101.0 per cent of C14H30Cl2N2O4, calculated on the anhydrous basis.

Description. A white or almost white, crystalline powder; almost odourless; hygroscopic.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.
A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with succinylcholine chloride RS or with the reference spectrum of succinylcholine chloride.

B. Dissolve about 25 mg in 1 ml of water, add 0.1 ml of a 1 per cent w/v solution of cobalt chloride and 0.1 ml of potassium ferrocyanide solution; a green colour is produced. Carry out a blank, using perchloric acid and 10 ml of succinylcholine chloride RS Reference solution examination in 10 ml of Test solution.

C. Dissolve 1 g in sufficient carbon dioxide-free water to produce 20 ml. To 1 ml of this solution add 9 ml of water, 10 ml of 1 M sulphuric acid and 30 ml of ammonium reineckate solution; a pink precipitate is produced. Allow to stand for 30 minutes, filter and wash with water, then with ethanol (95 per cent) and finally with ether. The residue, after drying at 80º melts at 180º to 185º (2.4.21).

D. Gives the reactions of chlorides (2.3.1).

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution in carbon dioxide-free water (solution A) is clear (2.4.1). 4 ml of solution A diluted to 10 ml with water is colourless (2.4.1).

**pH** (2.4.24). 4.0 to 5.0, determined in a 0.5 per cent w/v solution.

**Choline chloride.** Determine by thin-layer chromatography (2.4.17), coating the plate with microcrystalline cellulose.

**Mobile phase.** A mixture of 50 volumes of 1-butanol, 40 volumes of water and 10 volumes of anhydrous formic acid, shake for 10 minutes, allow to separate. Use the upper layer as the mobile phase.

**Test solution.** Dissolve 0.4 g of the substance under examination in 10 ml of methanol.

**Reference solution.** A solution containing 4 per cent w/v of succinylcholine chloride RS and 0.02 per cent w/v of choline chloride in methanol.

Apply to the plate 5 μl of each solution. After development, dry the plate in air, spray with potassium iodobismuthate solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot due to choline chloride in the chromatogram obtained with the reference solution. The test is not valid unless the chromatogram obtained with the reference solution shows two clearly separated spots.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Water** (2.3.43). 8.0 to 10.0 per cent, determined on 0.3 g.

**Assay.** Weigh accurately about 0.3 g, dissolve in 30 ml of anhydrous glacial acetic acid, add 30 ml of acetic anhydride and 10 ml of mercuric acetate solution. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator, until a bluish green colour is produced. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01807 g of C₁₄H₂₂Cl₂N₂O₄.

**Storage.** Store protected from light and moisture.

**Succinylcholine Injection**

Suxamethonium Chloride Injection

Succinylcholine Injection is a sterile solution of Succinylcholine Chloride in Water for Injections.

Succinylcholine Injection contains not less than 90.0 per cent and not more than 107.5 per cent of the stated amount of succinylcholine chloride, C₁₄H₂₂Cl₂N₂O₄.2H₂O.

**Identification**

Dilute a volume containing 20 mg of Succinylcholine Chloride to 50 ml with water. To 0.5 ml add 2 ml of chloroform, 2 ml of a solution containing 0.16 per cent w/v of citric acid and 6.6 per cent w/v of disodium hydrogen phosphate and 0.1 ml of a solution containing 0.15 per cent w/v of each of bromothymol blue and anhydrous sodium carbonate. Shake for 2 minutes and allow to separate. The chloroform layer is yellow.

**Tests**

**pH** (2.4.28). 3.0 to 5.0.

**Hydrolysis products.** The volume of 0.1 M sodium hydroxide required for the preliminary neutralisation in the Assay is not more than one tenth of the total volume of 0.1 M sodium hydroxide required for the preliminary neutralisation and the hydrolysis.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** To an accurately measured volume containing about 0.25 g of Succinylcholine Chloride add 30 ml of carbon dioxide-free water and shake with five quantities, each of 25 ml, of ether. Wash the combined ether solutions with two quantities, each of 10 ml, of water and discard the ether. Shake the combined washings with two quantities, each of 10 ml, of ether; add the washings to the original aqueous solution and neutralise with 0.1 M sodium hydroxide using bromothymol blue solution as indicator. Add 25.0 ml of 0.1 M sodium hydroxide, heat under a reflux condenser for 40 minutes, allow to cool and titrate the excess of alkali with 0.1 M hydrochloric acid using bromothymol blue solution as indicator. Repeat the operation using 40 ml of carbon dioxide-free water beginning at the words “Add 25.0 ml of 0.1 M sodium hydroxide.....”. The difference between the titrations represents the amount of sodium hydroxide required.
1 ml of 0.1 M sodium hydroxide is equivalent to 0.01987 g of C₁₂H₁₉Cl₂N₂O₄·2H₂O.

Storage. Store protected from light. The injection should not be allowed to freeze.

Sucrose

Refined Sugar

\[
\text{C}_{12}\text{H}_{22}\text{O}_{11} \quad \text{Mol. Wt. 342.3}
\]

Sucrose is \(\beta\)-D-fructofuranosyl-\(\alpha\)-D-glucopyranoside.

Description. An almost white or colourless crystals, dry crystalline powder; odourless; taste, sweet.

Identification

Dissolve 150.0 g in sufficient carbon dioxide-free water prepared from distilled water to produce 300 ml (solution A). Dilute 1 ml of solution A to 100 ml with water. To 5 ml of the solution add 2 ml of freshly prepared 2 M sodium hydroxide and 0.15 ml of a freshly prepared copper sulphate solution; the solution is clear and blue and remains so on boiling. To the hot solution add 4 ml of 2 M hydrochloric acid, heat to boiling and add 4 ml of 2 M sodium hydroxide; an orange precipitate is produced immediately.

Tests

Acidity or alkalinity. To 10 ml of solution A add 0.3 ml of phenolphthalein solution. The solution is colourless and not more than 0.6 ml of 0.01 M sodium hydroxide is required to change the colour of the solution to pink.

Specific optical rotation (2.4.22). +65.9° to +67.0°, determined in a 10 per cent w/v solution.

Barium. To 10 ml of solution A add 1 ml of 1 M sulphuric acid. When examined immediately and after 1 hour any opalescence is not more intense than that of a mixture of 1 ml of distilled water and 10 ml of solution A.

Calcium. To 1 ml of solution A add 9 ml of water and 1 ml of ammonium oxalate solution; the solution remains clear for at least 1 minute.

Heavy metals (2.3.13). Add 0.1 ml of dilute hydrochloric acid to 4 ml of solution A and dilute with sufficient water to produce 25 ml. The solution complies with the limit test for heavy metals, Method A (10 ppm).

Sulphites. To 4 ml of solution A add sufficient water to produce 20 ml, add 0.05 ml of 0.1 M iodine and 0.05 ml of starch solution; a blue colour develops.

Dextrins. To 2 ml of solution A add 8 ml of water, 0.05 ml of 2 M hydrochloric acid and 0.05 ml of 0.05 M iodine; the solution remains yellow or becomes faint bluish green.

Glucose and invert sugar. Dissolve 20 g in sufficient water to make 100 ml and filter if necessary. Place 50 ml of the clear solution in a 250-ml beaker, add 50 ml of alkaline cupric tartarate solution, cover the beaker with a watch glass, heat the mixture at such a rate that it comes to a boil in approximately 4 minutes and continue boiling for exactly 2 minutes. Add immediately 100 ml of recently boiled and cooled water and collect the precipitated cuprous oxide on a tared sintered glass crucible. Wash the residue with the hot water, then with 10 ml of ethanol (95 per cent) and finally with 10 ml of ether. Dry at 105° for 1 hour; the weight of the cuprous oxide is not more than 112 mg.

Colouring matter. A. To 100 ml of solution A in a ground-glass-stoppered tube add 1 ml of dilute hypophosphorous acid and allow to stand for 1 hour; no unpleasant odour is detectable.

B. Examine solution A in ultraviolet light at 365 nm. Any fluorescence is not more intense than that of a solution containing 0.4 mg of quinine sulphate in 0.005 M sulphuric acid.

Sulphated ash (2.3.18). Not more than 0.1 per cent determined by dissolving 5.0 g in 5 ml of water, adding 2 ml of sulphuric acid, evaporating to dryness and igniting to constant weight.

Storage. Store protected from light and moisture.

Sulphacetamide Sodium

Sulphacetamide Sodium is the monohydrate of the sodium salt of \(N^1\)-acetylsulphanilamide.
Sulphacetamide Sodium contains not less than 99.0 per cent and not more than 101.0 per cent of \( \text{C}_8\text{H}_9\text{N}_2\text{NaO}_3\text{S} \), calculated on the anhydrous basis.

**Description.** A white or yellowish white, crystalline powder; odourless.

**Identification.**

**Test A** may be omitted if tests B, C, D, E and F are carried out. **Tests B, C, D and E** may be omitted if tests A and F are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *sulphacetamide sodium* RS or with the reference spectrum of sulphacetamide sodium.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in citro-phosphate buffer pH 7.0 shows an absorption maximum at about 255 nm; absorbance at about 255 nm, 0.66 to 0.72.

C. Dissolve 1 g in 10 ml of water, add 6 ml of 2 \( \text{M acetic acid} \) and filter. Wash the precipitate with a small volume of water and dry at 105º for 4 hours. The melting range of the precipitate is 181º to 185º (2.4.21).

D. Dissolve 0.1 g of the precipitate obtained in test C in 5 ml of ethanol (95 per cent), add 0.2 ml of sulphuric acid and heat; ethyl acetate, recognizable by its odour, is produced.

E. Dissolve 1 mg of the precipitate obtained in test C in 5 ml of water with the aid of heat. The solution gives the reaction of primary aromatic amines (2.3.1), producing an orange-red precipitate.

F. A 5 per cent w/v solution gives the reactions of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and not more intensely coloured than reference solution GYS4 (2.4.1).

**pH** (2.4.28). 8.0 to 9.5, determined in a 5.0 per cent w/v solution.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

**Mobile phase.** A mixture of 50 volumes of 1-butanol, 25 volumes of ethanol, 25 volumes of water and 10 volumes of strong ammonia solution.

**Test solution.** A 10 per cent w/v solution of the substance under examination in water.

**Reference solution (a).** A 0.05 per cent w/v solution of *sulphanilamide* in water.

**Reference solution (b).** A 0.025 per cent w/v solution of *sulphanilamide* in water.

**Reference solution (c).** A 0.05 per cent w/v solution of *sulphanilamide* in the test solution.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and spray with a freshly prepared 2 per cent w/v solution of dimethylaminobenzaldehyde in a mixture of 55 volumes of hydrochloric acid and 45 volumes of water. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b). The chromatogram obtained with reference solution (c) shows two clearly separated spots.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphates** (2.3.17). Dissolve 1.5 g in sufficient distilled water to produce 25 ml, add 25 ml of 2 \( \text{M acetic acid} \), shake for 30 minutes and filter. 25 ml of the filtrate complies with the limit test for sulphates (200 ppm).

**Water** (2.3.43). 6.0 to 8.0 per cent, determined on 0.2 g.

**Assay.** Weigh accurately about 0.25 g, dissolve in a mixture of 50 ml of water and 20 ml of 2 \( \text{M hydrochloric acid} \), add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02362 g of \( \text{C}_8\text{H}_9\text{N}_2\text{NaO}_3\text{S} \).

**Storage.** Store protected from light and moisture.

**Sulphacetamide Eye Drops**

Sulphacetamide Sodium Eye Drops are a sterile solution of Sulphacetamide Sodium in Purified Water. It may contain a suitable antimicrobial agent.

Sulphacetamide Eye Drops contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sulphacetamide sodium, \( \text{C}_8\text{H}_9\text{N}_2\text{NaO}_3\text{S} \).

**Identification.**

To a volume containing 0.5 g of Sulphacetamide Sodium add 6 ml of 5 \( \text{M acetic acid} \), stirring constantly. Filter the precipitate, wash with water and dry at 105º for 4 hours. The residue complies with the following tests.
A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphacetamide RS or with the reference spectrum of sulphacetamide.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in citro-phosphate buffer pH 7.0 shows an absorption maximum at about 255 nm; absorbance at about 255 nm, 0.66 to 0.72.

C. Dissolve 10 mg in 2 ml of 2 M hydrochloric acid. The solution gives the reaction of primary aromatic amines (2.3.1).

Tests

Appearance of solution. Dilute the eye drops, if necessary, to contain 10.0 per cent w/v of Sulphacetamide Sodium. The solution is not more intensely coloured than reference solution BYS4 (2.4.1).

pH (2.4.24). 6.6 to 8.6.

Related substances. Determine by thin-layer chromatography (2.4.14), coating the plate with silica gel HF254.

Mobile phase. A mixture of 50 volumes of 1-butanol, 25 volumes of ethanol, 25 volumes of water and 10 volumes of strong ammonia solution.

Test solution. Dilute a suitable volume with water to produce a solution containing 4 per cent w/v of Sulphacetamide Sodium.

Reference solution. A 0.2 per cent w/v solution of sulphanilamide in water.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and spray with a freshly prepared 2 per cent w/v solution of dimethylaminobenzaldehyde in a mixture of 55 volumes of hydrochloric acid and 45 volumes of water. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Other tests. Comply with the tests stated under Eye Drops.

Assay. To an accurately measured volume containing about 0.5 g of Sulphacetamide Sodium add 75 ml of water and 10 ml of hydrochloric acid. Add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02542 g of C10H10N4O2S, H2O.

Storage. Store protected from light and moisture. The Eye Drops should not be allowed to freeze.

Labelling. The label states (1) the name and concentration of any antimicrobial agent used; (2) that it is not meant for injection; (3) that the solution should be used within one month of opening the container; (4) that the solution should not be used if it is dark brown in colour; (5) that it should not be allowed to freeze.

Sulphadiazine

C10H10N4O2S Mol. Wt. 250.3

Sulphadiazine is N-(pyrimidin-2-yl)sulphanilamide.

Sulphadiazine contains not less than 99.0 per cent and not more than 101.0 per cent of C10H10N4O2S, calculated on the dried basis.

Description. White, yellowish white or pinkish white crystals or crystalline powder; almost odourless.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests C and D may be omitted if tests A and B are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphadiazine RS or with the reference spectrum of sulphadiazine.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with the reference solution.

C. Dissolve about 5 mg in 10 ml of 1 M hydrochloric acid and dilute 1 ml of this solution to 10 ml with water. The solution, without further acidification, gives the reaction of primary aromatic amines (2.3.1).

D. Heat 3 g in a test-tube inclined at an angle of 45º with the lower part immersed in a silicone oil-bath at about 270º. It decomposes and a white or yellowish white sublimate is produced. The sublimate, after recrystallisation from toluene and drying at 100º melts at 123º to 127º (2.4.21).

Tests

Appearance of solution. Dissolve 0.8 g in 10 ml of 1 M sodium hydroxide. The solution is not more intensely coloured than reference solution YS5, BYS5 or GYS5 (2.4.1).

Acidity. Heat 1.25 g of the finely powdered substance at about 70º with 25 ml of carbon dioxide-free water for 5 minutes. Cool for about 15 minutes in ice and filter. To 20 ml of the filtrate add 0.1 ml of bromothymol blue solution. Not more than 0.2 ml of 0.1 M sodium hydroxide is required to change the colour of the solution.

Related substances (2.3.7). Complies with test C.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).
**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.2 g, dissolve in a mixture of 20 ml of 2 M hydrochloric acid and 50 ml of water. Add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02503 g of C₁₀H₁₀N₄O₂S.

**Storage.** Store protected from light and moisture.

---

**Sulphadiazine Tablets**

Sulphadiazine Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sulphadiazine, C₁₀H₁₀N₄O₂S.

**Identification**

A. Triturate a quantity of the powdered tablets containing 0.5 g Sulphadiazine with two successive quantities, each of 5 ml, of chloroform and reject the chloroform. Triturate the residue with 10 ml of dilute ammonia solution for 5 minutes, add 10 ml of water and filter. Warm the filtrate until most of the ammonia has been expelled, cool and acidify with acetic acid. Collect the precipitate, wash with water and dry at about 100º; the residue melts at about 256º, with decomposition (2.4.21).

B. On the residue obtained in test A determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphadiazine RS or with the reference spectrum of sulphadiazine.

C. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with the reference solution.

**Tests**

**Related substances** (2.3.7). Complies with test C, but using the following solutions.

**Test solution (a).** Extract a quantity of the powdered tablets containing 0.5 g of Sulphadiazine with 25 ml of a mixture of 90 volumes of methanol and 10 volumes of strong ammonia solution by shaking for 10 minutes, filter and use the filtrate.

**Test solution (b).** Dilute 1 volume of test solution (a) to 5 volumes with a mixture of 24 volumes of methanol and 1 volume of strong ammonia solution.

**Test solution (c).** Dilute 1 volume of test solution (a) to 200 volumes with the same solvent mixture.

**Reference solution.** A 0.4 per cent w/v solution of sulphadiazine RS in the same solvent mixture.

---

**Dissolution** (2.5.2).

**Apparatus.** No 1

**Medium.** 900 ml of 0.1 M hydrochloric acid

**Speed and time.** 100 rpm and 60 minutes.

Withdraw a suitable volume of the sample and filter promptly through a membrane filter disc with an average pore diameter not greater than 1.0 mm. Reject the first few ml of the filtrate and dilute a suitable volume of the filtrate with the same solvent. Dilute suitably with 0.01 M sodium hydroxide. Measure the absorbances of the resulting solution and of a standard solution of sulphadiazine RS of similar concentration in the same medium at the maximum at about 254 nm (2.4.7).

Calculate the content of C₁₀H₁₀N₄O₂S in the medium.

D. Not less than 70.0 per cent of the stated amount of C₁₀H₁₀N₄O₂S.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.5 g of Sulphadiazine and dissolve as completely as possible in a mixture of 50 ml of water and 10 ml of hydrochloric acid. Carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02503 g of C₁₀H₁₀N₄O₂S.

**Storage.** Store protected from light and moisture.

---

**Sulphadimethoxine**

![Sulphadimethoxine](image)

C₁₂H₁₄N₄O₄S

Mol. Wt. 310.3

Sulphadimethoxine is N¹-(2,6-dimethoxypyrimidin-4-yl) sulphanilamide.

Sulphadimethoxine contains not less than 99.0 per cent and not more than 101.0 per cent of C₁₂H₁₄N₄O₄S, calculated on the dried basis.

**Description.** A white or creamy-white, crystalline powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphadimethoxine RS or with the reference spectrum of sulphadimethoxine.
B. Dissolve about 0.1 g in 3 ml of 5 M sodium hydroxide and 50 ml of water and dilute to 100 ml with water. To 5 ml of the solution add 100 mg of phenol, heat to boiling, cool and add 0.5 ml of sodium hypochlorite solution and 0.15 ml of 5 M sodium hydroxide; a yellow colour is produced.

C. Dissolve about 5 mg in 10 ml of 1 M hydrochloric acid and dilute 1 ml to 10 ml with water. The resulting solution, without further acidification, gives the reaction of primary aromatic amines (2.3.1).

D. Suspend about 20 mg in 5 ml of water and add 5 M sodium hydroxide until completely dissolved. Add 0.2 ml of cupric sulphate solution; the solution turns yellow and a yellow precipitate is formed.

E. Melting point (2.4.21). 197º to 204º.

**Tests**

**Related substances** (2.3.7). Complies with test B.

**Heavy metals** (2.3.1.3). Dissolve 1.0 g in 5 ml of 5 M sodium hydroxide and 20 ml of water. The solution complies with the limit test for heavy metals, Method A (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay**. Weigh accurately about 0.3 g, dissolve in a mixture of 20 ml of 2 M hydrochloric acid and 50 ml of water. Add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.03103 g of C₁₂H₁₄N₄O₄S.

**Storage**. Store protected from light and moisture.

**Sulphadimethoxine Tablets**

Sulphadimethoxine Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sulphadimethoxine, C₁₂H₁₄N₄O₄S.

**Identification**

Triturate a quantity of the powdered tablets containing 0.5 g of Sulphadimethoxine with 5 ml of 0.5 M hydrochloric acid, filter and neutralise the filtrate to litmus paper with 0.5 M sodium hydroxide. The precipitate, after washing with water and drying at 105º, complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphadimethoxine RS or with the reference spectrum of sulphadimethoxine.

**Sulphadimidine**

C₁₂H₁₄N₄O₂S  Mol. Wt. 278.3

Sulphadimidine is N¹-(4,6-dimethylpyrimidin-2-yl) sulphanilamide.
Sulphadimidine contains not less than 99.0 per cent and not more than 101.0 per cent of C₁₂H₁₄N₄O₂S, calculated on the dried basis.

**Description.** White or almost white crystals or powder.

**Identification**

*Test A* may be omitted if *tests B, C and D* are carried out. *Tests C and D* may be omitted if *tests A and B* are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *sulphadimidine RS* or with the reference spectrum of sulphadimidine.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with the reference solution.

C. Heat 3 g in a test-tube inclined at an angle of about 45° with the lower part immersed in a silicone oil-bath at about 270°. It decomposes and a white or yellowish white sublimate is produced. The sublimate, after recrystallisation from *toluene* and drying at 100° melts at 150° to 154° (2.4.31).

D. Dissolve about 5 mg in 10 ml of *1 M hydrochloric acid* and dilute 1 ml of this solution to 10 ml with *water*. The solution, without further acidification, gives the reaction of primary aromatic amines (2.3.1).

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution in *1 M sodium hydroxide* is not more intensely coloured than reference solution YS5, BYS5 or GYS5 (2.4.1).

**Acidity.** Heat 1.25 g of the finely powdered substance at about 70° with 25 ml of *carbon dioxide-free water* for 5 minutes. Cool for about 15 minutes in ice and filter. To 20 ml of the filtrate add 0.1 ml of *bromothymol blue solution*. Not more than 0.2 ml of *0.1 M sodium hydroxide* is required to change the colour of the solution.

**Related substances** (2.3.7). Complies with test C.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°.

**Assay.** Weigh accurately about 0.25 g, dissolve in 20 ml of *2 M hydrochloric acid* and 50 ml of *water*, add 3 g of *potassium bromide*, cool in ice and carry out the nitrite titration (2.3.31). 1 ml of *0.1 M sodium nitrite* is equivalent to 0.02783 g of C₁₂H₁₄N₄O₂S.

**Storage.** Store protected from light and moisture.

---

**Sulphadimidine Sodium**

C₁₂H₁₃N₄NaO₂S  Mol. Wt. 300.3

Sulphadimidine Sodium is the sodium salt of N₁-(4,6-dimethylpyrimidin-2-yl)sulphanilamide.

Sulphadimidine Sodium contains not less than 98.0 per cent and not more than 101.0 per cent of C₁₂H₁₃N₄NaO₂S, calculated on the dried basis.

**Description.** White or creamy white crystals or powder; odourless or almost odourless; hygroscopic.

**Identification**

A. Dissolve 0.1 g in 10 ml *water*, acidify with *1 M hydrochloric acid*, filter, wash the precipitate with *water* and dry the residue at 105°.

B. Acidify a solution of 0.1 g in 5 ml of *water* with *6 M acetic acid*. A precipitate is produced which, after washing with cold *water* and drying at 105°, gives the reaction of primary aromatic amines (2.3.1), producing a bright orange-red precipitate.

C. The washed and dried precipitate obtained in test B melts at about 198° (2.4.21).

D. Incinerate 0.5 g. The residue, when moistened with *hydrochloric acid* and introduced on a platinum wire into the flame of a Bunsen burner, imparts a yellow colour to the flame.

**Tests**

**Appearance of solution.** A 33.3 per cent w/v solution in *1 M sodium hydroxide* is not more intensely coloured than reference solution YS4 (2.4.1).

**pH** (2.4.24). 10.0 to 11.0, determined in a 10.0 per cent w/v solution.

**Related substances** (2.3.7). Complies with test A, but using as the test solution a solution prepared by dissolving the substance under examination in 1 volume of strong *ammonia solution* and then diluting with 9 volumes of *ethanol (95 per cent)* to produce a 1.0 per cent w/v solution.

**Loss on drying** (2.4.19). Not more than 2.0 per cent, determined on 1.0 g by drying in an oven at 105°.

**Assay.** Weigh accurately about 0.3 g, dissolve in a mixture of 75 ml of *water* and 10 ml of *hydrochloric acid*, add 3 g of *potassium bromide*, cool in ice and carry out the nitrite titration (2.3.31). 1 ml of *0.1 M sodium nitrite* is equivalent to 0.03003 g of C₁₂H₁₃N₄NaO₂S.
Storage. Store protected from light and moisture.

**Sulphadimidine Injection**

Sulphadimidine Sodium Injection

Sulphadimidine Injection is a sterile solution of Sulphadimidine Sodium in Water for Injections free from dissolved air. It is prepared either from Sulphadimidine Sodium or by the interaction of Sulphadimidine and Sodium Hydroxide.

Sulphadimidine Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sulphadimidine sodium, C₁₂H₁₃N₄NaO₂S.

Identification

A. Acidify a volume containing 0.1 g of Sulphadimidine Sodium with 6 M acetic acid, filter, reserving the filtrate, wash the precipitate with water and dry at 105º. On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphadimidine RS or with the reference spectrum of sulphadimidine.

B. The residue obtained in test A gives the reaction of primary aromatic amines (2.3.1).

C. Evaporate the filtrate obtained in test A and incinerate. The residue, when moistened with hydrochloric acid and introduced on a platinum wire into the flame of a Bunsen burner, imparts a yellow colour to the flame.

Tests

**Appearance of solution.** An injection containing 1.0 g of Sulphadimidine Sodium in 3 ml is not more intensely coloured than reference solution YS4 (2.4.1).

**pH** (2.4.24). 10.0 to 11.0.

**Related substances** (2.3.7). Complies with test A, using following solutions.

*Test solution.* The injection under examination diluted with water to contain 0.2 per cent w/v of sulphadimidine sodium

*Reference solution.* A 0.002 per cent w/v solution of sulphanilamide in a mixture of 1 volume of strong ammonia solution and 9 volumes of ethanol (95 per cent).

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Dilute an accurately measured volume containing about 0.5 g of Sulphadimidine Sodium to 75 ml with water, add 10 ml of hydrochloric acid and pass air slowly through the solution until the odour of sulphur dioxide is no longer detectable and the vapours do not turn moistened starch iodate paper blue.

Add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.03003 g of C₁₂H₁₃N₄NaO₂S.

Storage. Store protected from light, in single dose containers.

**Labelling.** When the injection is prepared from Sulphadimidine the strength is stated as the amount of sulphadimidine sodium in a suitable dose-volume.

**Sulphadimidine Tablets**

Sulphadimidine Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sulphadimidine, C₁₂H₁₄N₄O₂S.

Identification

A. Triturate a quantity of the powdered tablets containing 0.5 g of Sulphadimidine with two quantities, each of 5 ml, of chloroform and discard the chloroform. Triturate the residue with 10 ml of 5 M ammonia for 5 minutes, add 10 ml of water and filter. Warm the filtrate until most of the ammonia has been removed, cool, acidify with 6 M acetic acid, wash the precipitate with water and dry at 105º.

On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphadimidine RS or with the reference spectrum of sulphadimidine.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with the reference solution.

C. The residue obtained in test A gives the reaction of primary aromatic amines (2.3.1), producing a bright orange-red precipitate.

Tests

**Related substances** (2.3.7). Complies with test C, but using the following solutions.

*Test solution (a).* Extract a quantity of the powdered tablets containing 0.5 g of Sulphadimidine with 25 ml of a mixture of 9 volumes of methanol and 1 volume of strong ammonia solution by shaking for 10 minutes, filter and use the filtrate.

*Test solution (b).* Dilute 1 volume of test solution (a) to 5 volumes with a mixture of 24 volumes of methanol and 1 volume of strong ammonia solution.

*Test solution (c).* Dilute 1 volume of test solution (a) to 200 volumes with the same solvent mixture.

Reference solution. A 0.4 per cent w/v of sulphadimidine RS in the same solvent mixture.
**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.25 g of Sulphadimidine, dissolve as completely as possible in a mixture of 50 ml of water and 10 ml of hydrochloric acid, add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02783 g of C₁₂H₁₄N₄O₂S.

**Storage.** Store protected from light and moisture.

### Sulphadoxine

Sulphormethoxine; Sulphoethomidine

![Sulphadoxine structure](image)

C₁₂H₁₄N₄O₄S  \text{Mol. Wt. 310.3}

Sulphadoxine is \(N¹\)-(5,6-dimethoxypyrimidin-4-yl)sulphanilamide.

Sulphadoxine contains not less than 99.0 per cent and not more than 101.0 per cent of C₁₂H₁₄N₄O₄S, calculated on the dried basis.

**Description.** White or yellowish white crystals or crystalline powder.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests B and D may be omitted if tests A and C are carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphadoxine RS or with the reference spectrum of sulphadoxine.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with the reference solution.

C. Dissolve 0.5 g in 1 ml of sulphuric acid (40 per cent), heating gently to effect solution, and continue heating until a crystalline precipitate is produced. Allow to cool, add 10 ml of 2 M sodium hydroxide, cool again, add 25 ml of ether and shake for 5 minutes. Dry the upper layer over anhydrous sodium sulphate, filter and evaporate the solvent by heating on a water-bath. The residue melts either at 80° to 82° or at 90° to 92° (2.4.21).

D. Dissolve about 5 mg in 10 ml of 1 M hydrochloric acid and dilute 1 ml to 10 ml with water. The resulting solution, without further acidification, gives the reaction of primary aromatic amines (2.3.1).

**Tests**

**Appearance of solution.** Dissolve 0.8 g in 10 ml of 1 M sodium hydroxide. The solution is not more intensely coloured than reference solution YS5, BYS5 or GYS5 (2.4.1).

**Acidity.** Heat 1.25 g of the finely powdered substance at about 70° with 25 ml of carbon dioxide-free water for 5 minutes. Cool for about 15 minutes in ice and filter. To 20 ml of the filtrate add 0.1 ml of bromothymol blue solution. Not more than 0.2 ml of 0.1 M sodium hydroxide is required to change the colour of the solution.

**Related substances** (2.3.7). Complies with test C, but using the following solution.

*Test solution (a).* A 2 per cent w/v solution of the substance under examination in a mixture of 24 volumes of methanol and 1 volume of strong ammonia solution.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°.

**Assay.** Weigh accurately about 0.25 g, dissolve in 50 ml of 2 M hydrochloric acid, add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.03103 g of C₁₂H₁₄N₄O₄S.

**Storage.** Store protected from light and moisture.

### Sulphafurazole

Sulfisoxazole

![Sulphafurazole structure](image)

C₁₁H₁₃N₃O₃S  \text{Mol. Wt. 267.3}

Sulphafurazole is \(N¹\)-(3,4-dimethylisoxazol-5-yl)sulphanilamide.

Sulphafurazole contains not less than 99.0 per cent and not more than 101.0 per cent of C₁₁H₁₃N₃O₃S, calculated on the dried basis.
**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests B and D may be omitted if tests A and C are carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphafurazole RS or with the reference spectrum of sulphafurazole.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).

C. Dissolve 0.5 g in 1 ml of sulphuric acid (40 per cent), heating gently to effect solution, and continue heating until a crystalline precipitate is produced. Allow to cool, add 10 ml of 2 M sodium hydroxide, cool again, add 25 ml of ether and shake for 5 minutes. Dry the upper layer over anhydrous sodium sulphate, filter and evaporate the solvent by heating on a water-bath. The residue melts at 119º to 123º (2.4.21).

D. Dissolve about 5 mg in 10 ml of 1 M hydrochloric acid and dilute 1 ml to 10 ml with water. The resulting solution, without further acidification, gives the reaction of primary aromatic amines (2.3.1).

**Tests**

**Appearance of solution.** Dissolve 0.8 g in 10 ml of 1 M sodium hydroxide. The solution is not more intensely coloured than reference solution YS5, BYS5 or GYS5 (2.4.1).

**Acidity.** Heat 1.25 g of the finely powdered substance at about 70º with 25 ml of carbon dioxide-free water for 5 minutes. Cool for about 15 minutes in ice and filter. To 20 ml of the filtrate add 0.1 ml of bromothymol blue solution. Not more than 0.2 ml of 0.1 M sodium hydroxide is required to change the colour of the solution.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

*Mobile phase.* A mixture of 75 volumes of dichloromethane, 25 volumes of methanol and 1 volume of strong ammonia solution.

*Test solution (a).* Dissolve 0.2 g of the substance under examination in 10 ml of a mixture of 1 volume of strong ammonia solution and 24 volumes of methanol.

*Test solution (b).* Dissolve 0.4 g of the substance under examination in 100 ml of a mixture of 1 volume of strong ammonia solution and 24 volumes of methanol.

*Reference solution (a).* Dissolve 10 mg of the substance under examination in 100 ml of a mixture of 1 volume of strong ammonia solution and 24 volumes of methanol.

*Reference solution (b).* A 0.4 per cent w/v of sulphafurazole RS in a mixture of 1 volume of strong ammonia solution and 24 volumes of methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate at 105º and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.5 g, dissolve in 50 ml of dry acetone. Titrate with 0.1 M tetrabutylammonium hydroxide, using 0.4 per cent w/v solution of thymol blue in methanol as indicator. Carry out a blank titration.

1 ml of 0.1 M tetrabutylammonium hydroxide is equivalent to 0.02673 g of C₁₁H₁₃N₃O₃S.

**Storage.** Store protected from light and moisture.

---

**Sulphafurazole Tablets**

Sulphafurazole Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sulphafurazole, C₁₁H₁₃N₃O₃S.

**Identification**

A. Shake a quantity of the powdered tablets containing 0.6 g of Sulphafurazole with 30 ml of acetone, filter and evaporate the filtrate to dryness; Dry the residue for 2 hours at 105º. On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphafurazole RS or with the reference spectrum of sulphafurazole.

B. Dissolve 0.5 g of residue obtained in test A in 1 ml of sulphuric acid (40 per cent), heating gently to effect solution, and continue heating until a crystalline precipitate is produced. Allow to cool, add 10 ml of 2 M sodium hydroxide, cool again, add 25 ml of ether and shake for 5 minutes. Dry the upper layer over anhydrous sodium sulphate, filter and evaporate the solvent by heating on a water-bath. The residue melts at 119º to 123º (2.4.21).

C. Extract a quantity of the powdered tablets containing 50 mg of Sulphafurazole with 2 ml of warm dilute hydrochloric acid and filter. The filtrate gives the reaction of primary aromatic amines (2.3.1).
Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 75 volumes of dichloromethane, 25 volumes of methanol and 1 volume of strong ammonia solution.

Test solution (a). Extract a quantity of the powdered tablets containing 0.5 g of Sulphafurazole with 25 ml of a mixture of 90 volumes of methanol and 10 volumes of strong ammonia solution by shaking for 10 minutes, filter and use the filtrate.

Test solution (b). Dissolve 0.4 g of the substance under examination in 100 ml of a mixture of 1 volume of strong ammonia solution and 24 volumes of methanol.

Reference solution (a). Dissolve 10 mg of the substance under examination in 100 ml of a mixture of 1 volume of strong ammonia solution and 24 volumes of methanol.

Reference solution (b). A 0.4 per cent w/v solution of sulphafurazole RS in a mixture of 1 volume of strong ammonia solution and 24 volumes of methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate at 105º and examine in ultraviolet light at 254 nm.

Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a).

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.5 g of Sulphafurazole, dissolve as completely as possible in 50 ml of dry acetone. Titrate with 0.1 M tetrabutylammonium hydroxide, using 0.4 per cent w/v solution of thymol blue in methanol as indicator. Carry out a blank titration.

1 ml of 0.1 M tetrabutylammonium hydroxide is equivalent to 0.02673 g of C_{11}H_{13}N_{3}O_{3}S.

Storage. Store protected from light and moisture.

Sulphalene

Sulphamethopyrazine; Sulphamethoxypyrazine

Sulphalene contains not less than 99.0 per cent and not more than 101.0 per cent of C_{11}H_{12}N_{4}O_{3}S, calculated on the dried basis.

Description. A white or yellowish white powder; odourless or almost odourless.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphalene RS or with the reference spectrum of sulphalene.

B. Dissolve about 5 mg in 10 ml of 1 M hydrochloric acid and dilute 1 ml of this solution to 10 ml with water. The solution, without further acidification, gives the reaction of primary aromatic amines (2.3.1).

C. Melting range (2.4.21). 175º to 178º.

Tests

Acidity. Heat 1.25 g of the finely powdered substance at about 70º for 5 minutes with 25 ml of carbon dioxide-free water. Cool in ice for about 15 minutes and filter. To 20 ml of the filtrate add 0.1 ml of bromothymol blue solution. Not more than 0.2 ml of 0.1 M sodium hydroxide is required to change the colour of the solution.

Related substances (2.3.7). Complies with test B.

Heavy metals (2.3.13). Dissolve 1.0 g in 5 ml of 5 M sodium hydroxide and 20 ml of water. The solution complies with the limit test for heavy metals, Method A (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

Assay. Weigh accurately about 0.3 g, dissolve in a mixture of 20 ml of 2 M hydrochloric acid and 50 ml of water. Add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02803 g of C_{11}H_{12}N_{4}O_{3}S.

Storage. Store protected from light and moisture.

Sulphamethizole

Sulphamethizole is N\textsubscript{1}-(5-methyl-1,3,4-thiadiazol-2-yl)sulphanilamide.

C_{9}H_{10}N_{4}O_{2}S_{2} Mol. Wt. 270.3

Sulphamethizole is N\textsubscript{1}-(5-methyl-1,3,4-thiadiazol-2-yl)sulphanilamide.
Sulphamethizole contains not less than 99.0 per cent and not more than 101.0 per cent of C₉H₁₀N₄O₂S₂, calculated on the dried basis.

**Description.** White or yellowish white crystals or crystalline powder; odourless.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests C and D may be omitted if tests A and B are carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphamethizole RS or with the reference spectrum of sulphamethizole.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).

C. Dissolve 50 mg in 4 ml of methanol and add 0.2 ml of a 4.0 per cent w/v solution of cupric acetate; a flocculent, yellowish green precipitate is produced which becomes dark green.

D. Dissolve about 5 mg in 10 ml of 1 M hydrochloric acid and dilute 1 ml of this solution to 10 ml with water. The solution, without further acidification, gives the reaction of primary aromatic amines (2.3.1).

**Tests**

**Appearance of solution.** Dissolve 0.8 g in 10 ml of 1 M sodium hydroxide. The solution is not more intensely coloured than reference solution Y55, BY55 or GY55 (2.4.1).

**Acidity.** Heat 1.25 g of the finely powdered substance at about 70° with 25 ml of carbon dioxide-free water for 5 minutes. Cool for about 15 minutes in ice and filter. To 20 ml of the filtrate add 0.1 ml of bromothymol blue solution. Not more than 0.2 ml of 0.1 M sodium hydroxide is required to change the colour of the solution.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

- **Mobile phase.** A mixture of 80 volumes of chloroform and 15 volumes of methanol.
- **Test solution (a).** Dissolve 0.3 g of the substance under examination in 10 ml of acetone.
- **Test solution (b).** Dissolve 0.3 g of the substance under examination in 100 ml of acetone.
- **Reference solution (a).** Dissolve 15 mg of the substance under examination in 100 ml of acetone.
- **Reference solution (b).** A 0.3 per cent w/v solution of sulphamethizole RS in acetone.

Apply to the plate 2 µl of each solution. After development, dry the plate at 105° and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°.

**Assay.** Weigh accurately about 0.25 g, dissolve in 50 ml of 2 M hydrochloric acid, add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02703 g of C₉H₁₀N₄O₂S₂.

**Storage.** Store protected from light and moisture.

---

Sulphamethoxazole

![Sulphamethoxazole molecule](image)

C₁₀H₁₁N₃O₃S  
Mol. Wt. 253.3

Sulphamethoxazole is N₁-(5-methylisoxazol-3-yl)sulphanilamide.

Sulphamethoxazole contains not less than 99.0 per cent and not more than 101.0 per cent of C₁₀H₁₁N₃O₃S, calculated on the dried basis.

**Description.** A white or almost white, crystalline powder; almost odourless.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphamethoxazole RS or with the reference spectrum of sulphamethoxazole.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with the reference solution.

C. Dissolve about 5 mg in 10 ml of 1 M hydrochloric acid and dilute 1 ml to 10 ml with water. The resulting solution, without
further acidification, gives the reaction of primary aromatic amines (2.3.1).

D. Melting range (2.4.21). 169° to 172°.

Tests

Appearance of solution. Dissolve 0.8 g in 10 ml of 1 M sodium hydroxide. The solution is not more intensely coloured than reference solution YS5, BYS5 or GYS5 (2.4.1).

Acidity. Heat 1.25 g of the finely powdered substance with 25 ml of carbon dioxide-free water at 70° for 5 minutes. Cool for about 15 minutes in ice and filter. To 20 ml of the filtrate add 0.1 ml of bromothymol blue solution. Not more than 0.3 ml of 0.1 M sodium hydroxide is required to change the colour of the solution.

Related substances (2.3.7). Complies with test C, but using the following solution.

Test solution (a). Dissolve 0.1 g of the substance under examination in sufficient of a mixture of 1 volume of strong ammonia solution and 24 volumes of methanol to produce 5 ml.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°.

Assay. Weigh accurately about 0.2 g, dissolve in 50 ml of 2 M hydrochloric acid, add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02533 g of C_{15}H_{14}N_{4}O_{2}S.

Storage. Store protected from light and moisture.

Sulphaphenazole

\[
\text{C}_{15}\text{H}_{14}\text{N}_{4}\text{O}_{2}\text{S} \quad \text{Mol. Wt. 314.4}
\]

Sulphaphenazole is \(N^1\)-(1-phenyl-1H pyrazol-5-yl)sulphanilamide.

Sulphaphenazole contains not less than 99.0 per cent and not more than 101.0 per cent of \(\text{C}_{15}\text{H}_{14}\text{N}_{4}\text{O}_{2}\text{S}\), calculated on the dried basis.

Description. A white or almost white, crystalline powder.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphaphenazole RS.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with the reference solution.

C. Dissolve about 5 mg in 10 ml of 1 M hydrochloric acid and dilute 1 ml of this solution to 10 ml with water. The solution, without further acidification, gives the reaction of primary aromatic amines (2.3.1).

D. Melting range (2.4.21). 178° to 183°.

Tests

Appearance of solution. Dissolve 0.8 g in 10 ml of 1 M sodium hydroxide. The solution is not more intensely coloured than reference solution YS5, BYS5 or GYS5 (2.4.1).

Acidity. Heat 1.25 g of the finely powdered substance at about 70° with 25 ml of carbon dioxide-free water for 5 minutes. Cool for about 15 minutes in ice and filter. To 20 ml of the filtrate add 0.1 ml of bromothymol blue solution. Not more than 0.2 ml of 0.1 M sodium hydroxide is required to change the colour of the solution.

Related substances (2.3.7). Complies with test C.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Iron (2.3.14). Ignite 2.0 g with 1 g of anhydrous sodium carbonate, cool, dissolve the residue in 5 ml of hydrochloric acid and dilute to 35 ml with water. The resulting solution complies with the limit test for iron (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°.

Assay. Weigh accurately about 0.2 g, dissolve in a mixture of 20 ml of 2 M hydrochloric acid and 50 ml of water. Add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.03144 g of \(\text{C}_{15}\text{H}_{14}\text{N}_{4}\text{O}_{2}\text{S}\).

Storage. Store protected from light and moisture.
Sulphaphenazole Tablets

Sulphaphenazole Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sulphaphenazole, C₁₅H₁₄N₄O₂S.

Identification

Mix a quantity of the powdered tablets containing about 1.5 g of Sulphaphenazole with 30 ml of acetone and heat under a reflux condenser for 5 minutes. Filter, evaporate the filtrate on a water-bath to a volume of about 10 ml, add 40 ml of water, heat for a further 15 minutes and cool in ice; a precipitate is formed which, after washing with water and drying at 105º, complies with the following tests.

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphaphenazole RS or with the reference spectrum of sulphaphenazole.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with the reference solution.

C. Dissolve about 5 mg in 10 ml of 1 M hydrochloric acid and dilute 1 ml of this solution to 10 ml with water. The solution, without further acidification, gives the reaction of primary aromatic amines (2.3.1).

D. Melting range (2.4.21). 178º to 183º.

Tests

Related substances (2.3.7). Comply with test C, but using the following solutions.

Test solution (a). Extract a quantity of the powdered tablets containing 0.5 g of Sulphaphenazole with 25 ml of a mixture of 90 volumes of methanol and 10 volumes of strong ammonia solution by shaking for 10 minutes, filter and use the filtrate.

Test solution (b). Dilute 1 volume of test solution (a) to 5 volumes with a mixture of 24 volumes of methanol and 1 volume of strong ammonia solution.

Test solution (c). Dilute 1 volume of test solution (a) to 200 volumes with the same solvent mixture.

Reference solution. A 0.4 per cent w/v of sulphaphenazole RS in the same solvent mixture.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.25 g of Sulphaphenazole, dissolve as completely as possible in a mixture of 50 ml of water and 10 ml of hydrochloric acid, cool in ice and carry out the nitrite titration (2.3.31). 1 ml of 0.1 M sodium nitrite is equivalent to 0.03144 g of C₁₅H₁₄N₄O₂S. Storage. Store protected from light and moisture.

Sulphobromophthalein Sodium

C₂₀H₈Br₄Na₂O₁₀S₂   Mol. Wt. 837.9

Sulphobromophthalein Sodium is disodium 5,5’-(4,5,6,7-tetrabromo-1,3-dihydro-3-oxo-isobenzofuran-1,1-diyl)bis(2-hydroxybenzenesulphonate).

Sulphobromophthalein Sodium contains not less than 7.4 per cent and not more than 8.2 per cent of sulphur, S, and not less than 36.0 per cent and not more than 39.0 per cent of bromine, Br, both calculated on the dried basis.

Description. A white, crystalline powder; hygroscopic. Identification. A. Absorbance of a 0.0005 per cent w/v solution in 0.05 M sodium hydroxide at the maximum at about 580 nm, about 0.4 (2.4.7). B. Mix 0.1 g with 0.5 g of sodium carbonate and ignite until thoroughly charred. Cool, add 5 ml of hot water, heat for 5 minutes on a water-bath and filter; the filtrate gives the reactions of bromides (2.3.1). C. Gives reaction A of sodium salts (2.3.1).

Tests

Appearance of solution. A 2.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and colourless (2.4.1).

Halide ions. To 5 ml of a 1.0 per cent w/v solution add 1 ml of dilute nitric acid and 1 ml of silver nitrate solution; not more than a slight opalescence is produced.

Calcium. Ignite 5.0 g in a platinum dish until free from carbon, cool, add 1 ml of hydrochloric acid and 10 ml of water, heat
on a water-bath for 5 minutes, add 1 g of ammonium sulphate and 4 ml of dilute ammonia solution and heat for a further 5 minutes. Transfer the contents of the dish to a flask with the aid of 50 ml of water, add 20 ml of strong ammonia solution, dilute to 100 ml with water, add 0.3 ml of sodium sulphide solution, 1 ml of potassium cyanide solution and 75 ml of ethanol (95 per cent) and titrate with 0.01 M disodium edetate using 0.1 g of a mixture of 99 parts of potassium nitrate and 1 part of methyl thymol blue as indicator until a faint grey colour is produced. Not more than 6.25 ml of 0.01 M disodium edetate is required.

**Sulphates.** To 10 ml of a 0.2 per cent w/v solution add 0.25 ml of dilute hydrochloric acid, boil and add 1 ml of barium chloride solution; the hot solution remains clear for 2 minutes.

**Loss on drying** (2.4.19). Not more than 5.0 per cent determined on 1.0 g by drying in an oven at 105º.

**Assay.** For sulphur — Determine by the oxygen-flask method (2.3.34), burning 0.2 g in a 1000-ml glass-stoppered flask and a mixture of 30 ml of water and 0.5 ml of hydrogen peroxide solution (100 vol) as the absorbing liquid. When the process is complete, add 2 ml of hydrochloric acid, dilute to 250 ml with water, heat to boiling and slowly add 10 ml of barium chloride solution. Heat on a water-bath for 1 hour, filter, wash the precipitate with water, dry and ignite at a temperature of about 600º until, after further ignition, two successive weighings do not differ by more than 0.2 per cent.

1 g of residue is equivalent to 0.1374 g of sulphur, S.

For bromine — Determine by the oxygen-flask method (2.3.34), burning 0.2 g in a 1000-ml glass-stoppered flask and a mixture of 10 ml of 0.1 M sodium hydroxide, 0.5 ml of hydrogen peroxide solution (100 vol) and 10 ml of water as the absorbing liquid. When the process is complete, boil the solution for 5 minutes, cool, acidify with 2 M nitric acid, add 20.0 ml of 0.1 M silver nitrate, shake, and titrate the excess of silver nitrate with 0.1 M ammonium thiocyanate using ferric ammonium sulphate solution as indicator.

1 ml of 0.1 M silver nitrate is equivalent to 0.007991 g of bromine, Br.

**Storage.** Store protected from moisture.

---

**Sulphobromophthalein Sodium Injection**

Sulphobromophthalein Sodium Injection is a sterile solution of Sulphobromophthalein Sodium in Water for Injections.

Sulphobromophthalein Sodium Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sulphobromophthalein sodium, C_{20}H_{8}Br_{4}Na_{2}O_{10}S_{2}.

**Identification**

A. To 5 ml add 0.15 ml of 1 M sodium hydroxide; an intense purple colour is produced which disappears on the addition of an acid.

B. To a volume containing 50 mg of Sulphobromophthalein Sodium add 0.25 g of sodium carbonate, evaporate to dryness and ignite. Cool the residue, add 2.5 ml of hot water, heat for 5 minutes on a water-bath and filter; the filtrate gives the reactions of bromides (2.3.1).

**Tests**

**pH** (2.4.24). 5.0 to 6.5, determined by using a suitable agar-potassium nitrate salt bridge.

**Bacterial endotoxins** (2.2.3). Not more than 1.0 Endotoxin Unit per mg of Sulphobromophthalein Sodium.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** To an accurately measured volume containing 0.1 g of Sulphobromophthalein Sodium add sufficient water to produce 500.0 ml and mix. To 5.0 ml of this solution add sufficient of a 1.0 per cent w/v solution of sodium carbonate to produce 200.0 ml and mix. Measure the absorbance of the resulting solution at the maximum at about 580 nm (2.4.7), using as the blank the sodium carbonate solution.

Calculate the content of C_{20}H_{8}Br_{4}Na_{2}O_{10}S_{2} from the absorbance obtained by carrying out the determination simultaneously on 0.1 g, accurately weighed, of sulphobromophthalein sodium RS.
Talc
Tamoxifen Citrate
Tamoxifen Tablets
Tartaric Acid
Tenofovir Disoproxil Fumarate
Tenofovir Disoproxil Fumarate Tablets
Tenofovir and Emtricitabine Tablets
Terbutaline Sulphate
Terbutaline Inhalation
Terbutaline Injection
Terbutaline Tablets
Testosterone Propionate
Testosterone Propionate Injection
Tetracycline
Tetracycline Hydrochloride
Tetracycline Capsules
Tetracycline Ointment
Theophylline
Theophylline Injection
Thiabendazole
Thiabendazole Tablets
Thiacetazone
Thiacetazone And Isoniazid Tablets
Thiamine Hydrochloride
Thiamine Injection
Thiamine Tablets
Thiamine Mononitrate
Thiomersal
Thiopentone Sodium
Thiopentone Injection
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thiotepa</td>
<td>....</td>
</tr>
<tr>
<td>Thiotepa Injection</td>
<td>....</td>
</tr>
<tr>
<td>Thymol</td>
<td>....</td>
</tr>
<tr>
<td>Thyroxine Sodium</td>
<td>....</td>
</tr>
<tr>
<td>Thyroxine Tablets</td>
<td>....</td>
</tr>
<tr>
<td>Timolol Maleate</td>
<td>....</td>
</tr>
<tr>
<td>Timolol Eye Drops</td>
<td>....</td>
</tr>
<tr>
<td>Timolol Tablets</td>
<td>....</td>
</tr>
<tr>
<td>Tinidazole</td>
<td>....</td>
</tr>
<tr>
<td>Tinidazole Tablets</td>
<td>....</td>
</tr>
<tr>
<td>Tiotropium Bromide Monohydrate</td>
<td>....</td>
</tr>
<tr>
<td>Tiotropium powder for Inhalation</td>
<td>....</td>
</tr>
<tr>
<td>Titanium Dioxide</td>
<td>....</td>
</tr>
<tr>
<td>Tizanidine Hydrochloride</td>
<td>....</td>
</tr>
<tr>
<td>Tizanidine Tablets</td>
<td>....</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>....</td>
</tr>
<tr>
<td>Tobramycin Injection</td>
<td>....</td>
</tr>
<tr>
<td>Tocopheryl Acetate</td>
<td>....</td>
</tr>
<tr>
<td>Tolbutamide</td>
<td>....</td>
</tr>
<tr>
<td>Tolbutamide Tablets</td>
<td>....</td>
</tr>
<tr>
<td>Topotecan Hydrochloride</td>
<td>....</td>
</tr>
<tr>
<td>Topotecan Injection</td>
<td>....</td>
</tr>
<tr>
<td>Triamcinolone</td>
<td>....</td>
</tr>
<tr>
<td>Triamcinolone Tablets</td>
<td>....</td>
</tr>
<tr>
<td>Triamcinolone Acetonide</td>
<td>....</td>
</tr>
<tr>
<td>Triamcinolone Acetonide Injection</td>
<td>....</td>
</tr>
<tr>
<td>Triamterene</td>
<td>....</td>
</tr>
<tr>
<td>Triamterene Capsules</td>
<td>....</td>
</tr>
<tr>
<td>Trifluoperazine Hydrochloride</td>
<td>....</td>
</tr>
<tr>
<td>Trifluoperazine Injection</td>
<td>....</td>
</tr>
<tr>
<td>Trifluoperazine Tablets</td>
<td>....</td>
</tr>
<tr>
<td>Triflupromazine Hydrochloride</td>
<td>....</td>
</tr>
<tr>
<td>Triflupromazine Injection</td>
<td>....</td>
</tr>
<tr>
<td>Monograph</td>
<td>Page</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Triflupromazine Tablets</td>
<td>.....</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>.....</td>
</tr>
<tr>
<td>Trimethoprim and Sulphamethoxazole Oral Suspension</td>
<td>.....</td>
</tr>
<tr>
<td>Trimethoprim And Sulphamethoxazole Tablets</td>
<td>.....</td>
</tr>
<tr>
<td>Trimethoprim Tablets</td>
<td>.....</td>
</tr>
<tr>
<td>Triprolidine Hydrochloride</td>
<td>.....</td>
</tr>
<tr>
<td>Triprolidine Tablets</td>
<td>.....</td>
</tr>
<tr>
<td>Trisodium Edetate Concentrate for Injection</td>
<td>.....</td>
</tr>
<tr>
<td>Tropicamide</td>
<td>.....</td>
</tr>
<tr>
<td>Tropicamide Eye Drops</td>
<td>.....</td>
</tr>
<tr>
<td>Troxidone</td>
<td>.....</td>
</tr>
<tr>
<td>Troxidone Capsules</td>
<td>.....</td>
</tr>
<tr>
<td>Tubocurarine Chloride</td>
<td>.....</td>
</tr>
<tr>
<td>Tubocurarine Injection</td>
<td>.....</td>
</tr>
</tbody>
</table>
Talc
Purified Talc; Talcum

Talc is a powdered, selected natural hydrated magnesium silicate. It may contain varying amounts of aluminium and iron in forms insoluble in 1M sulphuric acid.

Description. A white or almost white powder, free from grittiness; readily adheres to the skin; unctuous to the touch; odourless.

Identification

A. When examined microscopically, shows irregular plates, the majority less than 50 µm in length. The particles are not notably stained by a 0.1 per cent w/v solution of methylene blue in ethanol (95 per cent).

B. Melt 0.5 g in a metal crucible with 1 g of potassium nitrate and 3 g of anhydrous sodium carbonate, add 20 ml of boiling water, mix and filter. Wash the residue with 50 ml of water. Mix the residue with a mixture of 0.5 ml of hydrochloric acid and 5 ml of water and filter. To the filtrate add 1 ml of 9 M ammonia and 1 ml of ammonium chloride solution and filter. To the filtrate add 1 ml of disodium hydrogen phosphate solution; a white, crystalline precipitate is produced.

C. Gives the reaction of silicates (2.3.1).

Tests

Acidity or alkalinity. Shake 5.0 g with 25 ml of carbon dioxide-free water for 1 minute, filter and add to the filtrate 0.5 ml of bromothymol blue solution; the solution is not acid and requires not more than 0.3 ml of 0.1 M hydrochloric acid to make it acid.

Iron (2.3.14). Boil 4.0 g with 25 ml of water for 30 minutes, replacing the water lost by evaporation, and filter. The filtrate, after the addition of 5 ml of nitric acid, complies with the limit test for iron (10 ppm).

Acid-soluble substances. Not more than 2.0 per cent, determined by the following method. Digest 2.0 g with 40 ml of dilute hydrochloric acid for 15 minutes, filter, evaporate the filtrate; to the residue add 0.1 ml of sulphuric acid and ignite to constant weight.

Water-soluble substances. Shake 5.0 g with 25 ml of water for 1 minute, filter, evaporate the filtrate and dry to constant weight; the residue weighs not more than 10 mg.

Carbonates. To 1 g add 20 ml of dilute hydrochloric acid; no effervescence is produced.

Chlorides (2.3.12). Suspend 2.0 g in 10 ml of water, add 10 ml of 2 M nitric acid, shake for 15 minutes and filter. 10 ml of the filtrate complies with the limit test for chlorides (250 ppm).

Organic compounds. The residue obtained in the test for Loss on drying is not more than slightly yellow or grey.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 180º for 1 hour.

Storage. Store protected from moisture.

Tamoxifen Citrate

C_{26}H_{29}NO.C_{6}H_{8}O_{7}     Mol. Wt. 563.7
Tamoxifen Citrate is (Z)-2-[4-(1,2-diphenylbut-1-enyl)-1-phenoxy]ethyl dimethylamine citrate.

Tamoxifen Citrate contains not less than 99.0 per cent and not more than 101.0 per cent of C_{26}H_{29}NO, C_{6}H_{8}O_{7}, calculated on the dried basis.

Description. A white or almost white, crystalline powder.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests C and D may be omitted if tests A and B are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tamoxifen citrate RS or with the reference spectrum of tamoxifen citrate.

B. When examined in the range 220 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in methanol shows absorption maxima at about 237 nm and 275 nm.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 90 volumes of toluene and 10 volumes of triethylamine.

Test solution. Dissolve 0.1 g of the substance under examination in 10 ml of methanol.

Reference solution. A 1 per cent w/v solution of tamoxifen citrate RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.
D. To 10 mg add 4 ml of pyridine and 2 ml of acetic anhydride and shake; a yellow colour is produced. Heat in a water-bath for 2 minutes; a pink to red colour is produced.

Tests

E-Isomer and related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 0.25 g of the substance under examination in 100 ml of a mixture of 60 volumes of acetonitrile, 25 volumes of water and 15 volumes of tetrahydrofuran.

Reference solution (a). A 0.0025 per cent w/v solution of the substance under examination in a mixture of 60 volumes of acetonitrile, 25 volumes of water and 15 volumes of tetrahydrofuran.

Reference solution (b). A 0.25 per cent w/v solution of tamoxifen citrate impurity standard RS in the same solvent mixture.

Chromatographic system
- a stainless steel column 20 cm x 5 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 60 volumes of acetonitrile, 25 volumes of water, 15 volumes of tetrahydrofuran and 0.4 volume of strong ammonia solution,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 240 nm,
- a 20 µl loop injector.

In the chromatogram obtained with reference solution (b) a peak due to E-isomer appears immediately following the peak due to Z-tamoxifen. Adjust the sensitivity of the instrument so that the height of the peak due to E-isomer is about 15 per cent of the full-scale deflection on the recorder. Measure the height of the peak due to E-isomer by dropping a perpendicular from the top of the peak to a line drawn tangentially between the troughs on each side of the E-isomer peak or the trough between the E- and Z-isomer peaks and the baseline, whichever is appropriate.

The test is not valid unless the height of the trough separating the peaks due to E- and Z-tamoxifen in the chromatogram obtained with reference solution (b) is less than 7 per cent of full-scale deflection on the recorder and the retention time of the principal peak is less than 30 minutes. (The retention time decreases with increasing concentration of ammonia in the mobile phase).

The content of E-isomer in the substance under examination is not more than 1 per cent calculated from the declared content of E-isomer in tamoxifen citrate impurity standard RS. The area of any secondary peak in the chromatogram obtained with the test solution, other than a peak due to E-isomer, is not greater than half that of the peak due to tamoxifen citrate in the chromatogram obtained with reference solution (a) and the sum of the areas of all such peaks is not greater than the area of the peak due to tamoxifen in the chromatogram obtained with reference solution (a). Ignore any peak with a retention time less than 2.5 minutes and any peak with an area less than 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (a).

Heavy metals (2.3.13). 2.0 g complies with limit the test for heavy metals, Method B (10 ppm).

Sulphated ash (2.3.18). Not more than 0.2 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

Assay. Weigh accurately about 1.0 g, dissolve in 150 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, using 1-naphtholbenzein solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.05636 g of C26H29NO, C6H8O7.

Storage. Store protected from light and moisture.

Tamoxifen Tablets

Tamoxifen Citrate Tablets

Tamoxifen Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of tamoxifen, C26H29NO.

Identification

A. To a quantity of the powdered tablets containing 0.1 g of tamoxifen add 20 ml of water, warm, add 2 ml of 5 M sodium hydroxide and cool. Extract with two quantities, each of 10 ml, of ether, filtering after each extraction. Combine the ether extracts and evaporate to dryness in a stream of nitrogen at room temperature. Dry the residue at a pressure not exceeding 0.7 kPa for 30 minutes.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tamoxifen citrate RS or with the reference spectrum of tamoxifen citrate.

B. When examined in the range 220 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in methanol of the residue obtained in test A shows absorption maxima at about 237 nm and 275 nm.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.
Mobile phase. A mixture of 100 volumes of ethyl acetate, 10 volumes of methanol and 1 volume of strong ammonia solution.

Test solution. Shake a quantity of the powdered tablets containing 0.1 g tamoxifen with 10 ml of methanol, filter, evaporate the filtrate to dryness on a water-bath, dry the residue at 100° for 30 minutes and dissolve 10 mg of the residue in 10 ml of methanol.

Reference solution. A 0.1 per cent w/v solution of tamoxifen citrate RS in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

D. Dissolve 10 mg of the residue obtained in the preparation of the test solution in test C in 4 ml of pyridine, add 2 ml of acetic anhydride and heat on a water-bath for 2 minutes; a pink to red colour is produced.

Tests

E-Isomer and Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Mix a quantity of the powdered tablets containing 60 mg of tamoxifen with 60 ml of a mixture of 60 volumes of acetonitrile, 25 volumes of water and 15 volumes of tetrahydrofuran with the aid of ultrasound for 5 minutes, dilute to 100 ml with the same solvent mixture and filter through Whatman No. 1 filter paper.

Reference solution (a). Dilute 1.0 ml of the test solution to 100 ml with the same solvent mixture.

Reference solution (b). A 0.1 per cent w/v solution of tamoxifen citrate impurity standard RS in the same solvent mixture.

Chromatographic system

– a stainless steel column 20 cm x 5 mm, packed with octadecylsilane bonded to porous silica (5 μm),
– mobile phase: a mixture of 60 volumes of acetonitrile, 25 volumes of water, 15 volumes of tetrahydrofuran and 0.4 volume of strong ammonia solution,
– flow rate. 1.5 ml per minute,
– spectrophotometer set at 240 nm,
– a 20 μl loop injector.

In the chromatogram obtained with reference solution (b) a peak due to E-isomer appears immediately following the peak due to Z-tamoxifen. Adjust the sensitivity of the instrument so that the height of the peak due to E-isomer is about 15 per cent of full-scale deflection on the recorder. Measure the height of the peak due to E-isomer by dropping a perpendicular from the top of the peak to a line drawn tangentially between the troughs on each side of the E-isomer peak or the trough between the E- and Z-isomer peaks and the baseline, whichever is appropriate.

The test is not valid unless the height of the trough separating the peaks due to E- and Z-tamoxifen in the chromatogram obtained with reference solution (b) is less than 7 per cent of the full-scale deflection on the recorder and the retention time of the principal peak is less than 30 minutes. (The retention time decreases with increasing concentration of ammonia in the mobile phase).

The content of E-isomer in the substance under examination is not more than 1 per cent calculated from the declared content of E-isomer in tamoxifen citrate impurity standard RS. The area of any secondary peak in the chromatogram obtained with the test solution, other than a peak due to E-isomer, is not greater than half that of the peak due to tamoxifen citrate in the chromatogram obtained with reference solution (a) and the sum of the areas of all such peaks is not greater than the area of the peak due to tamoxifen in the chromatogram obtained with reference solution (a). Ignore any peak with a retention time less than 2.5 minutes and any peak with an area less than 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (a).

Uniformity of content. (For tablets containing equivalent of 10 mg or less) — Comply with the test stated under Tablets.

Crush one tablet and transfer to a 100-ml volumetric flask with the aid of 75 ml of methanol. Shake well for 5 minutes, add sufficient methanol to produce 100.0 ml and filter. Dilute 10.0 ml of the filtrate to 100.0 ml with methanol. Measure the absorbance of the resulting solution at the maximum at about 275 nm (2.4.7). Calculate the content of C₂₆H₂₉NO in the tablet taking 325 as the specific absorbance at 275 nm.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 25 mg of tamoxifen, shake with 100 ml of methanol for 15 minutes, add sufficient methanol to produce 250.0 ml and filter. Dilute 10.0 ml of the filtrate to 100.0 ml with methanol and measure the absorbance of the resulting solution at the maximum at about 275 nm (2.4.7). Calculate the content of C₂₆H₂₉NO taking 325 as the specific absorbance at 275 nm.

Storage. Store protected from light and moisture.

Labelling. The label states the strength in terms of the equivalent amount of tamoxifen.
Tartaric Acid

L-Tartaric Acid

\[
\text{C}_4\text{H}_6\text{O}_6 \quad \text{Mol. Wt. 150.1}
\]

Tartaric Acid is (2R,3R)-2,3-dihydroxybutanedioic acid.

Tartaric Acid contains not less than 99.5 per cent and not more than 101.0 per cent of C₄H₆O₆, calculated on the dried basis.

**Description.** Colourless crystals or a white or almost white crystalline powder.

**Identification**

A. Ignite a few mg; it gradually decomposes giving off an odour resembling that of burnt sugar (distinction from citric acid).

B. A 10 per cent w/v solution in distilled water (solution A) is strongly acidic.

C. Gives reactions A and B of tartrates (2.3.1).

**Tests**

**Appearance of solution.** Solution A is clear (2.4.1), and not more intensely coloured than reference solution YS6 (2.4.1).

**Specific optical rotation** (2.4.22). +12.0° to +12.8°, determined in a 20.0 per cent w/v solution.

**Arsenic** (2.3.10). Dissolve 5.0 g in 50 ml of water and add 10 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

**Heavy metals** (2.3.13). 2.0 g complies with the limit test for heavy metals, Method A (10 ppm).

**Chlorides** (2.3.12). 20 ml of solution A complies with the limit test for chlorides (125 ppm).

**Sulphates** (2.3.17). 10 ml of solution A complies with the limit test for sulphates (150 ppm).

**Oxalate.** Neutralise 10 ml of solution A with dilute ammonia solution, add 0.1 ml of dilute acetic acid and 10 ml of calcium sulphate solution; no opalescence is produced within 20 minutes.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.2 per cent, determined on 1.0 g by drying in an oven at 105°.

**Assay.** Weigh accurately about 1.0 g, dissolve in 25 ml of water and titrate with 1 M sodium hydroxide using 0.5 ml of phenolphthalein solution as indicator.

1 ml of 1 M sodium hydroxide is equivalent to 0.07505 g of C₄H₆O₆.

**Storage.** Store protected from moisture.

---

Tenofovir Disoproxil Fumarate

\[
\text{C}_{19}\text{H}_{30}\text{N}_5\text{O}_{10}\text{P},\text{C}_4\text{H}_4\text{O}_4 \quad \text{Mol. Wt. 635.5}
\]

Tenofovir Disoproxil Fumarate salt of bis(isopropyloxycarbonyloxymethyl ester of (R)-9-(2-phosphonomethoxypropyl)adenine with fumaric acid.

Tenofovir Disoproxil Fumarate contain not less than 97.0 per cent and not more than 102.0 per cent of C₉H₃₀N₅O₁₀P,C₄H₄O₄, calculated on the anhydrous basis.

**Description.** A white to off-white crystalline powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tenofovir disoproxil fumarate RS or with the reference spectrum of tenofovir disoproxil fumarate.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Related substances.** Determine by liquid chromatography (2.4.14).

**NOTE — Prepare the solutions immediately before use.**

**Test solution.** Dissolve 100 mg of the substance under examination in 50 ml of methanol.

**Reference solution (a).** A 0.2 per cent w/v solution of tenofovir disoproxil fumarate RS in methanol.

**Reference solution (b).** Dilute 1.0 ml of reference solution (a) to 100.0 ml with methanol.

**Reference solution (c).** Dissolve 10 mg of the fumaric acid in 50 ml of methanol.
Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm) (such as ODS 3V),
- column temperature 30º,
- mobile phase: A. 0.1 M ammonium acetate solution with the pH adjusted to 3.8 with glacial acetic acid,
  B. a mixture of 70 volumes of methanol and 30 volumes of acetonitrile,
- flow rate. 1.5 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 260 nm,
- a 10 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>mobile phase A (per cent v/v)</th>
<th>mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>10</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>25</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>50</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>60</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>65</td>
<td>95</td>
<td>5</td>
</tr>
</tbody>
</table>

Inject reference solution (a). The test is not valid unless the tailing factor is not more than 2.0 and the column efficiency is not less than 2000 theoretical plates.

Inject the test solution, reference solution (b) and reference solution (c). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than the area of the peak in the chromatogram obtained with the reference solution (b) (1.0 per cent) and the sum of all the secondary peaks is not more than 2.5 times the area of the peak in the chromatogram obtained with the reference solution (b) (2.5 per cent). Ignore any peak corresponding to the peak obtained in the chromatogram in the reference solution (c) and any peak having area less than 0.02 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.02 per cent).

Fumaric Acid. 17.5 per cent to 19.0 per cent.

Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 25 mg of the substance under examination in 100 ml of the mobile phase.

Reference solution. Dissolve 25 mg of the fumaric acid in 50 ml of the mobile phase. Dilute 10 ml of the solution to 100 ml with the mobile phase.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 40 volumes of acetonitrile and 60 volumes of a buffer solution prepared by adding 1 ml triethylamine to 0.05M sodium dihydrogen phosphate with the pH adjusted to 2.3 with orthophosphoric acid and filtered,
- flow rate. 1 ml per minute,
- spectrophotometer set at 260 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency in not less than 2000 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of fumaric acid.

Water (2.3.43). Not more than 1.0 per cent, determined on 1.0 g.

Assay. Determine by liquid chromatography (2.4.14).

NOTE — Prepare the solutions immediately before use and carry out the test protected from light.

Test solution. Dissolve 50 mg of the substance under examination in 50.0 ml of the mobile phase. Dilute 5.0 ml of the solution to 50.0 ml with the mobile phase.

Reference solution. A 0.1 per cent w/v solution of tenofovir disoproxil fumarate RS in the mobile phase. Dilute 5.0 ml of the solution to 50.0 ml with the mobile phase.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 40 volumes of acetonitrile and 60 volumes of a buffer solution prepared by adding 1 ml triethylamine to 0.05M sodium dihydrogen phosphate with the pH adjusted to 2.3 with orthophosphoric acid and filtered,
- flow rate. 1 ml per minute,
- spectrophotometer set at 260 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency in not less than 2000 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C19H30N5O10P,C4H4O4.

Storage. Store protected from light in a refrigerator (2º to 8º).

Tenofovir Disoproxil Fumarate Tablets

Tenofovir Disoproxil Fumarate Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of tenofovir disoproxil fumarate, C19H30N5O10P,C4H4O4.
Identification

A. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

B. When examined in the range 200 nm to 400 nm (2.4.7), a 0.001 per cent w/v solution in methanol shows an absorption maximum at the same wavelength as the reference solution.

Tests

Dissolution (2.5.2).
Apparatus. No 1
Medium. 900 ml of 0.1 M hydrochloric acid.
Speed and time. 50 rpm and 45 minutes
Withdraw a suitable volume of the medium and filter promptly. Dilute the filtrate, if necessary, with the same solvent. Measure the absorbance (2.4.7) of the resulting solution at the maximum at about 260 nm. Calculate the content of C_{19}H_{30}N_{5}O_{10}P,C_{4}H_{4}O_{4} in the medium from the absorbance obtained from a solution of known concentration of tenofovir disoproxil fumarate RS.

D. Not less than 80 per cent of the stated amount of C_{19}H_{30}N_{5}O_{10}P.C_{4}H_{4}O_{4}.

Related substances. Determine by liquid chromatography (2.4.14).
NOTE — Prepare the solutions immediately before use.
Test solution. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 100 mg of Tenofovir Disoproxil Fumarate and disperse in 50 ml of methanol and filter.

Reference solution (a). A solution of tenofovir disoproxil fumarate RS containing 0.2 per cent of tenofovir disoproxil in methanol.

Reference solution (b). Dilute 1 ml of reference solution (a) to 100 ml with methanol.

Reference solution (c). Dissolve 10 mg of fumaric acid in 50 ml of methanol.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: A. dissolve 1.9 g of ammonium acetate in 1000 ml of water and adjust the pH to 3.8 with glacial acetic acid,
  - B. methanol,
- flow rate. 1.5 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 260 nm,
- a 10 µl loop injector.

Inject reference solution (a). The test is not valid unless the tailing factor is not more than 2.0 and the column efficiency in not less than 2000 theoretical plates.

Inject the test solution, reference solutions (b) and (c). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 3.5 times the area of the peak in the chromatogram obtained with the reference solution (b) (3.5 per cent) and the sum of areas of all the secondary peaks is not more than 6 times the area of the peak in the chromatogram obtained with the reference solution (b) (6.0 per cent). Ignore the peak corresponding to the peak in the chromatogram obtained in the reference solution (c).

Other tests. Comply with the tests stated under Tablets.
Water (2.3.43). Not more than 5.0 per cent, determined on 0.5 g.

Assay: Determine by liquid chromatography (2.4.14).
NOTE — Prepare the solutions immediately before use.
Solvent mixture. Equal volumes of water and methanol.
Test solution. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 300 mg of Tenofovir Disoproxil Fumarate, dissolve in 100 ml of solvent mixture and filter. Dilute 5.0 ml of the filtrate to 50.0 ml with the mobile phase.

Reference solution. A 0.120 per cent w/v solution of tenofovir disoproxil fumarate RS in the solvent mixture. Dilute 5.0 ml of the solution to 20.0 ml with the mobile phase.

Chromatographic system
- a stainless steel column 15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm) (such as Inertsil ODS 3V),
- mobile phase: a mixture of 60 volumes of a buffer solution prepared by dissolving 7.8 g of sodium dihydrogen orthophosphate in 1000 ml of water, adding 1 ml of triethylamine and adjusting the pH to 2.3 with orthophosphoric acid (10 per cent v/v), and 40 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 260 nm,
- a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency in not
less than 2000 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of $C_{19}H_{30}N_5O_{10}P$ in the tablets.

Storage. Store protected from moisture, at a temperature not exceeding 30º.

**Tenofovir and Emtricitabine Tablets**

Tenofovir and Emtricitabine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of tenofovir disoproxil fumarate, $C_{19}H_{30}N_5O_{10}P$ and emtricitabine, $C_{8}H_{10}FN_3O_3S$.

**Identification**

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Dissolution (2.5.2).**

- **Apparatus.** No 1
- **Medium.** 900 ml of 0.1 M hydrochloric acid,
- **Speed and time.** 50 rpm and 45 minutes.
- **Withdraw a suitable volume of the medium and filter.**
- **Determine by liquid chromatography (2.4.14)**

**Test solution.** The filtrate obtained as given above. Dilute the filtrate if necessary, with the dissolution medium.

**Reference solution.** A solution containing 0.32 per cent w/v of tenofovir disoproxil fumarate RS and 0.24 per cent w/v of emtricitabine RS in methanol. Dilute 5 ml of the solution to 50 ml with the dissolution medium.

Use the chromatographic system given under Assay.

Inject the test solution and the reference solution.

Calculate the contents of $C_{19}H_{30}N_5O_{10}P.C_4H_4O_4$ and $C_{8}H_{10}FN_3O_3S$.

D. Not less than 75 per cent of the stated amounts of $C_{19}H_{30}N_5O_{10}P.C_4H_4O_4$ and $C_{8}H_{10}FN_3O_3S$.

**Related substances.** Determine by liquid chromatography (2.4.14).

**For Emtricitabine**

**Test solution.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 50 mg of Emtricitabine, disperse in 5 ml of methanol, dilute to 50 ml with mobile phase A and filter.

**Reference solution (a).** A 0.1 per cent w/v solution of emtricitabine RS in mobile phase A.

**Reference solution (b).** Dilute 1 ml of reference solution (a) to 100 ml with mobile phase A.

Chromatographic system,

- a stainless steel column 25 cm x 4.6 mm, packed with octadecysilane bonded to porous silica (5µm),
- column temperature 35º,
- mobile phase: A. a mixture of 95 volumes of a buffer solution prepared by dissolving 1.9 g of ammonium acetate in 1000 ml of water, adjusted the pH to 3.8 with glacial acetic acid, and 5 volumes of methanol and filtered,
  - B. a filtered mixture of 30 volumes of the buffer solution and 70 volumes of methanol,
- flow rate. 1 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 277 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.01</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>30</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>35</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>55</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>60</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>75</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Inject reference solution (a). The test is not valid unless the column efficiency is not less than 500 theoretical plates and the tailing factor is not more than 2.0.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than the area of the peak in the chromatogram obtained with the reference solution (b) (1.0 per cent) and the sum of areas of all the secondary peaks is not more than 3 times the area of the peak in the chromatogram obtained with the reference solution (b) (3.0 per cent).

**For Tenofovir Disoproxil Fumarate**

**Test solution.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 50 mg of Tenofovir Disoproxil Fumarate and disperse in 50 ml of methanol.

**Reference solution (a).** A 0.1 per cent w/v solution of tenofovir disoproxil fumarate RS in methanol.

**Reference solution (b).** Dilute 1 ml of reference solution (a) to 100 ml with methanol.
Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5µm),
- mobile phase: A. a buffer solution prepared by dissolving 1.9 g of ammonium acetate in 1000 ml of water and adjusting the pH to 3.8 with glacial acetic acid,
- B. methanol,
- flow rate. 1.5 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 260 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in mins)</th>
<th>Mobile phase A (per cent)</th>
<th>Mobile phase B (per cent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>10</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>25</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>50</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>60</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>75</td>
<td>95</td>
<td>5</td>
</tr>
</tbody>
</table>

Inject reference solution (a). The test is not valid unless the column efficiency is not less than 2000 theoretical plates and the tailing factor is not more than 2.0.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 3.5 times the area of the peak in the chromatogram obtained with the reference solution (b) (3.5 per cent) and the sum of areas of all the secondary peaks is not more than 6 times the area of the peak in the chromatogram obtained with the reference solution (b) (6.0 per cent).

Other tests. Comply with the tests stated under the Tablets.

Assay. Determine by liquid chromatography (2.4.14).

Solvent mixture. 30 volumes of water and 70 volumes of methanol.

Test solution. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 100 mg of Tenofovir Disoproxil Fumarate, disperse in 10 ml of water and dilute to 250.0 ml with methanol. Dilute 5.0 ml of the solution to 25.0 ml with the solvent mixture.

Reference solution. A solution containing 0.025 per cent w/v of emtricitabine RS and 0.04 per cent w/v of tenofovir disoproxil fumarate RS in methanol. Dilute 5.0 ml of the solution to 25.0 ml with the solvent mixture.

Chromatographic system
- a stainless steel column 4.6 mm x 5 cm packed with octadecylsilane bonded to porous silica (3µm),
- column temperature 40º,
- mobile phase: A. a buffer solution prepared by dissolving 1.35 g of monobasic potassium phosphate in 1000 ml of water and adjusting the pH to 3.0 with orthophosphoric acid,
- B. a mixture of 20 volumes of the buffer solution and 80 volumes of acetonitrile,
- flow rate. 1.5 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 260 nm,
- a 10 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in mins)</th>
<th>Mobile phase A (per cent)</th>
<th>Mobile phase B (per cent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>94</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>94</td>
<td>6</td>
</tr>
<tr>
<td>5</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>8</td>
<td>35</td>
<td>65</td>
</tr>
<tr>
<td>9</td>
<td>94</td>
<td>6</td>
</tr>
<tr>
<td>12</td>
<td>94</td>
<td>6</td>
</tr>
</tbody>
</table>

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency is not less than 2000 theoretical plates for the peak due to tenofovir disoproxil, 500 theoretical plates for the peak due to emtricitabine and the relative standard deviation for replicate injections is not more than 2.0 per cent for each component.

Inject the test solution and the reference solution.

Calculate the contents of C₁₅H₂₇N₅O₁₀P₄C₄H₄O₄ and C₈H₁₀FN₃O₃S in the tablets.

Storage. Store protected from moisture, at a temperature not exceeding 30º.

Terbutaline Sulphate

\[
\begin{align*}
\text{Terbutaline Sulphate is} & \quad \text{RS)-2-} \quad \text{(RS)-2-(tert-butylamino)-1-(3,5-} \\
& \quad \text{diydroxyphenyl)ethanol sulphate.} \\
& \quad \text{Terbutaline Sulphate contains not less than 98.0 per cent and} \\
& \quad \text{not more than 101.0 per cent of} \quad \text{C₁₂H₁₉NO₃}_₂H₂SO₄, \text{calculated on} \\
& \quad \text{the dried basis.}
\end{align*}
\]
**Description.** A white or almost white, crystalline powder; odourless or almost odourless.

**Identification**

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with terbutaline sulphate RS or with the reference spectrum of terbutaline sulphate.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.007 per cent w/v solution in 0.1 M hydrochloric acid shows absorption maxima at about 276 nm and 280 nm, which may be fused; absorbance at both 276 nm and 280 nm, 0.46 to 0.49.

C. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).

D. A 2.0 per cent w/v solution in carbon dioxide-free water gives reaction A of sulphates (2.3.1).

**Tests**

**Appearance of solution.** A 2.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1); absorbance of a 2-cm layer at 400 nm, not more than 0.11 (2.4.7).

**Acidity.** Dissolve 0.2 g in 10 ml of carbon dioxide-free water and titrate with 0.01 M sodium hydroxide, using methyl red solution as indicator. Not more than 1.2 ml of 0.01 M sodium hydroxide is required to change the colour of the solution to yellow.

**tert-Butylamino-3,5-dihydroxyacetophenone.** Absorbance of a 2 per cent w/v solution in 0.01 M hydrochloric acid at about 330 nm, not more than 0.50 (2.4.7).

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 90 volumes of aldehyde-free methanol, 10 volumes of water and 1.5 volumes of strong ammonia solution.

**Test solution (a).** Dissolve 0.25 g of the substance under examination in 1 ml of water and add sufficient ethanol (95 per cent) to produce 10 ml.

**Test solution (b).** Dilute 1 ml of test solution (a) to 5 ml with ethanol (95 per cent).

**Reference solution (a).** Dilute 1 ml of test solution (a) to 200 ml with ethanol (95 per cent).

**Reference solution (b).** Dissolve 25 mg of terbutaline sulphate RS in 0.5 ml of water and add sufficient ethanol (95 per cent) to produce 5 ml.

Wash the plate with the mobile phase and apply to the plate 20 µl of each solution. After development, dry the plate in air, spray with dilute potassium permanganate solution. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Heavy metals** (2.3.13). Mix 1.6 g with 0.6 g of anhydrous sodium sulphate and ignite without melting the sodium sulphate. Cool, add 3 ml of 2 M hydrochloric acid, boil and dilute to 50 ml with water. Cool and filter, 25 ml of the filtrate complies with the limit test for heavy metals, Method A (25 ppm).

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º for 3 hours.

**Assay.** Weigh accurately about 0.5 g, dissolve in 60 ml of anhydrous glacial acetic acid with the aid of heat. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4,25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.05486 g of (C12H19NO3)2.H2SO4.

**Storage.** Store protected from light and moisture.

**Labelling.** The label states (1) the number of metered doses in the container; (2) the amount of active ingredient delivered per inhalation; (3) that the container should be shaken before use each time; (4) a warning that the container is pressurised and must be kept away from heat and direct sunlight and that it must not be punctured, broken or incinerated even when apparently empty; (5) the warning “Keep out of reach of children”.

**Terbutaline Inhalation**

Terbutaline Sulphate Inhalation; Terbutaline Inhalation Aerosol; Terbutaline Sulphate Inhalation Aerosol

Terbutaline Inhalation is a suspension of Terbutaline Sulphate, as a superfine powder, in a suitable liquid in a suitable pressurised container. It may contain suitable pharmaceutical aids such as surfactants, stabilising agents, etc.

Terbutaline Inhalation delivers not less than 75.0 per cent and not more than 125.0 per cent of the stated amount of terbutaline sulphate (C12H19NO3)2.H2SO4 per inhalation, by actuation of the valve.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 65 volumes of 2-propanol, 25 volumes of cyclohexane and 5 volumes of formic acid.
Test solution. Remove the actuator from the pressurised container, shake the container for about 30 seconds and place it in an inverted position in a small beaker containing 5 ml of water. Discharge a sufficient number of deliveries containing 5 mg of Terbutaline Sulphate, under the surface of the solvent.

Reference solution. A 0.1 per cent w/v solution of terbutaline sulphate RS in water.

Apply to the plate 2 µl of each solution. After development, dry the plate in air, spray with a 2 per cent w/v solution of 4-aminoantipyrine in methanol. Examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to the chromatogram obtained with reference solution.

Tests

Other tests. Complies with the tests stated under Inhalation Preparations (Pressurised metered-dose Preparations).

Follow the procedure described under Assay wherever the amount of active substance is to be determined in any test.

Assay. Carry out the test for Content of active ingredient delivered per actuation stated under Inhalation Preparations (Pressurised metered-dose Preparations).

Use 35 ml of water and finally dilute to 50.0 ml with water. Dilute a suitable volume of this solution with water to produce a solution containing 50 µg of Terbutaline Sulphate per ml. To 10.0 ml of this solution in a 50-ml volumetric flask add 35 ml of buffer solution pH 9.5 and 1.0 ml of 4-aminoantipyrine solution. Mix, add 1.0 ml of potassium ferricyanide solution with vigorous swirling of the flask, dilute to volume with water and mix. Exactly 75 seconds after the addition of the potassium ferricyanide solution measure the absorbance of the resulting solution at the maximum at about 550 nm (2.4.7), using as the blank a solution prepared in the same manner using 10.0 ml of water in place of the solution of the substance under examination.

Calculate the content of (C₁₂H₁₉NO₃)₂H₂SO₄ in the solution from the absorbance obtained by repeating the operation using a solution containing 100 µg of terbutaline sulphate RS in place of the solution of the substance under examination.

Calculate the amount of (C₁₂H₁₉NO₃)₂H₂SO₄ delivered per actuation of the valve.

Determine the content of active ingredient a second and third time by repeating the procedure on the middle ten and on the last ten successive combined actuations of the valve. For each of the three determinations the average content of (C₁₂H₁₉NO₃)₂H₂SO₄ delivered per actuation of the valve meets the requirements.

Storage. Store protected from moisture at a temperature not exceeding 30º.

Labelling. The label states the amount of active ingredient delivered per inhalation.

Terbutaline Injection

Terbutaline Sulphate Injection

Terbutaline Injection is a sterile solution of Terbutaline Sulphate in Water for Injections.

Terbutaline Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of terbutaline sulphate (C₁₂H₁₉NO₃)₂H₂SO₄.

Identification

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 65 volumes of 2-propanol, 25 volumes of cyclohexane and 5 volumes of formic acid.

Test solution. Use the injection.

Reference solution. A 0.1 per cent w/v solution of terbutaline sulphate RS in saline solution.

Apply to the plate 2 µl of each solution. After development, dry the plate in air, spray with a 2 per cent w/v solution of 4-aminoantipyrine in methanol. Dry the plate in air and spray with a freshly prepared 8.0 per cent w/v solution of potassium ferricyanide in a mixture of 4 volumes of strong ammonia solution and 1 volume of water. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

Tests

pH (2.4.24). 3.0 to 5.0.

Other tests. Complies with the tests stated under Parenteral preparations (Injections).

Assay. Measure accurately a volume containing about 5 mg of Terbutaline Sulphate and add sufficient water to produce 50.0 ml. To 5.0 ml add 35 ml of a buffer solution prepared by dissolving 36.3 g of tris (hydroxymethyl) aminomethane in 900 ml of water, adjusting the pH to between 9.4 and 9.6 and adding sufficient water to produce 1000 ml. Add 1.0 ml of a freshly prepared 2.0 per cent w/v solution of 4-aminoantipyrine, mix and add 1.0 ml of a freshly prepared 8.0 per cent w/v solution of potassium ferricyanide with vigorous swirling and sufficient of the buffer solution to produce 50.0 ml. Exactly 75 seconds after the addition of the potassium ferricyanide solution measure the absorbance of the resulting solution at the maximum at about 550 nm (2.4.7), using water as the blank.
Calculate the content of \((\text{C}_{12}\text{H}_{19}\text{NO}_3)_2\cdot\text{H}_2\text{SO}_4\) from the absorbance obtained by repeating the operation using a 0.01 per cent w/v solution of terbutaline sulphate RS and beginning at the words “To 5.0 ml add 35 ml...”.

**Storage.** Store protected from light, in single dose containers.

**Labelling.** The label states that the injection should not be used if the solution is discoloured.

**Terbutaline Tablets**

Terbutaline Tablets Tablets

Terbutaline Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of terbutaline sulphate \((\text{C}_{12}\text{H}_{19}\text{NO}_3)_2\cdot\text{H}_2\text{SO}_4\).

**Identification**

A. Shake a quantity of the powdered tablets containing 20 mg of Terbutaline Sulphate with 50 ml of 0.1 M sodium hydroxide for 10 minutes, dilute to 100 ml with 0.1 M sodium hydroxide and filter. Dilute 20 ml of the filtrate to 50 ml with 0.1 M sodium hydroxide.

When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum at about 296 nm.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 65 volumes of 2-propanol, 25 volumes of cyclohexane and 5 volumes of formic acid.

**Test solution.** Shake a quantity of the powdered tablets containing 10 mg of Terbutaline Sulphate with 4 ml of a mixture of equal volumes of ethanol (95 per cent) and water for 10 minutes, centrifuge and use the clear supernatant liquid.

**Reference solution (a).** A 0.25 per cent w/v solution of terbutaline sulphate RS in water.

**Reference solution (b).** A mixture of equal volumes of the test solution and reference solution (a).

Apply to the plate 2 \(\mu\)l of each solution. After development, dry the plate in air, allow to stand for a few minutes in an atmosphere saturated with diethylamine and spray with diazotised nitroaniline solution. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a) and the principal spot in the chromatogram obtained with reference solution (b) appears as a single compact spot.

**Tests**

**Uniformity of content.** Comply with the test stated under Tablets.

**Calculation of the content of Terbutaline Sulphate Tablets.**

To 5.0 ml add 35 ml of a buffer solution prepared by dissolving 36.3 g of tris (hydroxymethyl) aminomethane in 900 ml of water, adjusting the pH to between 9.4 and 9.6 and adding sufficient water to produce 1000 ml. Add 1.0 ml of a freshly prepared 2.0 per cent w/v solution of 4-aminoantipyrine, mix and add 1.0 ml of a freshly prepared 8.0 per cent w/v solution of potassium ferricyanide with vigorous swirling and sufficient of the buffer solution to produce 50.0 ml. Exactly 75 seconds after the addition of the potassium ferricyanide solution measure the absorbance of the resulting solution at the maximum at about 550 nm (2.4.7), using water as the blank.

Calculate the content of \((\text{C}_{12}\text{H}_{19}\text{NO}_3)_2\cdot\text{H}_2\text{SO}_4\) from the absorbance obtained by carrying out the Assay simultaneously using terbutaline sulphate RS.

**Storage.** Store protected from light and moisture.

**Testosterone Propionate**

[Chemical structure of Testosterone Propionate]

Testosterone Propionate is 3-oxoandrost-4-en-17β-yl propionate.
Testosterone Propionate contains not less than 97.0 per cent and not more than 103.0 per cent of C\textsubscript{22}H\textsubscript{32}O\textsubscript{3}, calculated on the dried basis.

**Description.** A white or almost white powder or colourless crystals; odourless.

**Identification**

Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with testosterone propionate RS or with the reference spectrum of testosterone propionate.

B. In the test for Related substances the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to testosterone propionate in the chromatogram obtained with reference solution (a).

C. Melting range. 119º to 123º (2.4.21).

**Tests**

**Specific optical rotation** (2.4.22). +83.0º to +90.0º, determined in a 1.0 per cent w/v solution in ethanol.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 50 mg of the substance under examination in methanol and dilute to 50 ml with the same solvent.

**Reference solution (a).** Dissolve 2 mg of the substance under examination and 2 mg of testosterone acetate RS in methanol and dilute to 50 ml with the same solvent.

**Reference solution (b).** Dilute 1 ml of the test solution to 100 ml with methanol.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 20 volumes of water and 80 volumes of methanol,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject the test solution and the reference solutions. Continue the chromatography for twice the retention time for testosterone propionate.

The relative retention time of about four impurities with reference to testosterone propionate (retention time, about 9 minutes) range from 0.5 to about 1.4.

The test is not valid unless in the chromatogram obtained with reference solution (a) the resolution between the peaks due to testosterone and testosterone acetate is not less than 4.0.

In the chromatogram obtained with the test solution the area of any peak other than the principal peak is not more than 0.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent); the sum of the areas of any secondary peaks is not greater than the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent). Ignore any peak with an area less than 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.05 per cent).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º for 2 hours.

**Assay.** Weigh accurately about 25 mg, dissolve in sufficient ethanol to produce 250.0 ml, mix, dilute 5.0 ml to 50.0 ml with the same solvent and measure the absorbance of the resulting solution at the maximum at about 241 nm (2.4.7).

Calculate the content of C\textsubscript{22}H\textsubscript{32}O\textsubscript{3} taking 490 as the specific absorbance at 241 nm.

**Storage.** Store protected from light and moisture.

**Testosterone Propionate Injection**

Testosterone Propionate Injection is a sterile solution of Testosterone Propionate in Ethyl Oleate or any other suitable ester, in a suitable fixed oil or in any mixture of these.

Testosterone Propionate Injection contains not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of testosterone propionate, C\textsubscript{22}H\textsubscript{32}O\textsubscript{3}.

**Identification**

Dissolve a volume containing 50 mg of Testosterone Propionate in 8 ml of light petroleum (40º to 60º) and extract with three quantities, each of 8 ml, of a mixture of 7 volumes of glacial acetic acid and 3 volumes of water. Wash the combined extracts with 10 ml of light petroleum (40º to 60º), dilute with water until the solution becomes turbid, allow to stand for 2 hours in ice and filter. The precipitate, after washing with water and drying at 105º, complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with testosterone propionate RS or with the reference spectrum of testosterone propionate.
B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Solvent mixture. A mixture of 90 volumes of light petroleum (40° to 60°) and 10 volumes of liquid paraffin.

Mobile phase. A mixture of 30 volumes of water and 20 volumes of glacial acetic acid.

Test solution. Dissolve 25 mg of the residue in 10 ml of the solvent mixture.

Reference solution (a). A 0.25 per cent w/v solution of testosterone propionate RS in the solvent mixture.

Reference solution (b). Mix equal volumes of the test solution and reference solution (a).

Place the dry plate in a tank containing a shallow layer of the solvent mixture, allow the solvent mixture to ascend to the top, remove the plate from the tank and allow the solvent to evaporate. Use within 2 hours, with the flow of the mobile phase in the direction in which the aforementioned treatment was done.

Apply to the plate 2 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air, allow the solvent to evaporate, heat at 120° for 15 minutes and spray the hot plate with ethanolic sulphuric acid (20 per cent v/v). Heat at 120° for a further 10 minutes, allow to cool and examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

Tests

Other tests. Complies with the tests stated under Parenteral preparations (Injections).

Assay. To an accurately measured volume containing about 0.1 g of Testosterone Propionate add sufficient chloroform to produce 100.0 ml and mix. Dilute 3.0 ml to 50.0 ml with chloroform and to 5.0 ml of the solution add 10 ml of isoniazid solution and sufficient methanol to produce 20.0 ml. Allow to stand for 45 minutes and measure the absorbance of the resulting solution at the maximum at about 380 nm (2.4.7), using as the blank a solution prepared by treating 5 ml of chloroform in the same manner.

Calculate the content of C_{22}H_{32}O_{8} from the absorbance obtained by repeating the operation using a 0.006 per cent w/v solution of testosterone propionate RS in chloroform and beginning at the words “to 5.0 ml of the solution......”.

Storage. Store protected from light.
Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 to 10 µm),
- mobile phase: a mixture of 680 ml of 0.1 M ammonium oxalate, 270 ml of dimethylformamide and 50 ml of 0.2 M dibasic ammonium phosphate, the pH of the mixture being adjusted, if necessary, to 7.6 to 7.7 with 3 M ammonia or 3 M phosphoric acid,
- flow rate. 2 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 µl loop injector.

The test is not valid unless the resolution between the two principal peaks in the chromatogram obtained with reference solution (b) is not less than 1.5. In the chromatogram obtained with the test solution, the area of any peak corresponding to 4-epitetracycline is not greater than the area of the principal peak in the chromatogram obtained with reference solution (a) and the total area of all the peaks other than the principal peak is not greater than 5.0 per cent.

Heavy metals (2.3.13). 0.5 g complies with the limit test for heavy metals, Method B (50 ppm). Use 2.5 ml of lead standard solution (10 ppm Pb) to prepare the standard.

Sulphated ash (2.3.18). Not more than 0.5 per cent.

Loss on drying (2.4.19). Not more than 13.0 per cent, determined on 0.5 g by drying in an oven at 105º.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh accurately about 50 mg of the substance under examination and dissolve in 100.0 ml of a mixture of 68 ml of 0.1 M ammonium oxalate and 27 ml of dimethylformamide (diluting solvent).

Reference solution (a). A 0.05 per cent w/v solution of tetracycline hydrochloride RS in the diluting solvent.

Reference solution (b). A solution containing 0.0025 per cent w/v of 4-epitetracycline hydrochloride RS and 0.01 per cent w/v of tetracycline hydrochloride RS in the diluting solvent.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 to 10 µm),
- mobile phase: a mixture of 680 ml of 0.1 M ammonium oxalate, 270 ml of dimethylformamide and 50 ml of 0.2 M dibasic ammonium phosphate, the pH of the mixture being adjusted, if necessary, to 7.6 to 7.7 with 3 M ammonia or 3 M phosphoric acid,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 µl loop injector.

The test is not valid unless the resolution between the two principal peaks in the chromatogram obtained with reference solution (b) is not less than 1.5.

Calculate the content of C_{22}H_{24}N_{2}O_{8}.
1 mg of C_{22}H_{24}N_{2}O_{8}, HCl is equivalent to 0.92 mg of C_{22}H_{24}N_{2}O_{8}.

Storage. Store protected from light and moisture.

Tetracycline Hydrochloride

C_{22}H_{24}N_{2}O_{8}HCl  
Mol. Wt. 480.9

Tetracycline Hydrochloride is (4S,4aS,5aS,6S,12aS)-4-dimethylamino-1,4,4a,5,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxonaphthacene-2-carboxamide hydrochloride.

Tetracycline Hydrochloride contains not less than 95.0 per cent and not more than 100.5 per cent of C_{22}H_{24}N_{2}O_{8}, HCl, calculated on the dried basis.

Description. A yellow, crystalline powder.

Identification
A. In the test for Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to tetracycline hydrochloride in the chromatogram obtained with reference solution (a).

B. To about 2 mg add 5 ml of sulphuric acid; a reddish violet colour develops. Add the solution to 2.5 ml of water; the colour changes to yellow.

C. Gives reaction A of chlorides (2.3.1).

Tests

pH (2.4.24). 1.8 to 3.0, determined in a 1.0 per cent w/v suspension in carbon dioxide-free water.

Specific optical rotation (2.4.22). –239º to –255º, determined at 20º in a 1.0 per cent w/v solution in 0.1 M hydrochloric acid.

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 0.1 g of the substance under examination in 100 ml of a mixture of 68 ml of 0.1 M ammonium oxalate and 27 ml of dimethylformamide (diluting solvent).

Reference solution (a). A 0.0025 per cent w/v solution of 4-epitetracycline hydrochloride RS in the diluting solvent.
Reference solution (b). A solution containing 0.0025 per cent w/v of 4-epitetracycline hydrochloride RS and 0.01 per cent w/v of tetracycline hydrochloride RS in the diluting solvent.

Chromatographic system

- A stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 to 10 µm),
- mobile phase: a mixture of 680 volumes of 0.1 M ammonium oxalate, 270 volumes of dimethylformamide and 50 volumes of 0.2 M dibasic ammonium phosphate, the pH of the mixture being adjusted, if necessary, to 7.6 to 7.7 with 3 M ammonium or 3 M phosphoric acid,
- flow rate, 1.5 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 µl loop injector.

The test is not valid unless the resolution between the two principal peaks in the chromatogram obtained with reference solution (b) is not less than 1.5. In the chromatogram obtained with the test solution the area of any peak corresponding to 4-epitetracycline is not greater than the area of the principal peak in the chromatogram obtained with reference solution (a) and the total area of all peaks other than the principal peak is not greater than 5.0 per cent.

Heavy metals (2.3.13). 0.5 g complies with the limit test for heavy metals, Method B (50 ppm). Use 2.5 ml of lead standard solution (10 ppm Pb) to prepare the standard.

Sulphated ash (2.3.18). Not more than 0.5 per cent.

Loss on drying (2.4.19). Not more than 2.0 per cent, determined on 1.0 g by drying in an oven at 60º over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 3 hours.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh accurately about 50 mg of the substance under examination and dissolve in about 50 ml of the diluting solvent described in the test for related substances and further add sufficient diluting solvent to produce 100.0 ml.

Reference solution (a). A 0.05 per cent w/v solution of tetracycline hydrochloride RS in the diluting solvent.

Reference solution (b). A solution containing 0.0025 per cent w/v of 4-epitetracycline hydrochloride RS and 0.01 per cent w/v of tetracycline hydrochloride RS in the diluting solvent.

Chromatographic system

- A stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 to 10 µm),
- mobile phase: a mixture of 680 volumes of 0.1 M ammonium oxalate, 270 volumes of dimethylformamide and 50 volumes of 0.2 M dibasic ammonium phosphate, the pH of the mixture being adjusted, if necessary, to 7.6 to 7.7 with 3 M ammonium or 3 M phosphoric acid,
- flow rate, 1.5 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 µl loop injector.

Test

Related substances. Determine by liquid chromatography (2.4.14).
**Test solution.** Shake a quantity of the mixed contents of 20 capsules containing about 25 mg of Tetracycline Hydrochloride with 80 ml of 0.01 M methanolic hydrochloric acid for 10 minutes, dilute to 100 ml with the same solvent, mix and filter if necessary.

*Reference solution (a).* A 0.002 per cent w/v solution of 4-epitetracycline hydrochloride RS in 0.01 M methanolic hydrochloric acid.

*Reference solution (b).* A solution containing 0.0015 per cent w/v each of 4-epitetracycline hydrochloride RS and tetracycline hydrochloride RS in 0.01 M methanolic hydrochloric acid.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (10 µm),
- column. temperature 40º,
- mobile phase: a mixture of 5 volumes of dimethylformamide and 95 volumes of 0.1 M oxalic acid, the pH of the mixture being adjusted to 3.9 with triethylamine,
- flow rate. 2 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 µl loop injector.

The test is not valid unless the resolution between the two principal peaks in the chromatogram obtained with reference solution (b) is not less than 2.0. In the chromatogram obtained with the test solution the area of any peak corresponding to 4-epitetracycline hydrochloride is not greater than the area of the principal peak in the chromatogram obtained with reference solution (a) and the total area of all the peaks other than the principal peak is not greater than 10.0 per cent.

**Dissolution (2.5.2).**

Apparatus. No 1

Medium. 900 ml of water freshly prepared by distillation.

Speed and time. 75 rpm and 60 minutes.

Withdraw a suitable volume of the medium and filter through a membrane filter disc having an average pore diameter not greater than 1.0 µm, rejecting the first few ml of the filtrate. Measure the absorbance of the resulting solution, suitably diluted if necessary, at the maximum at about 276 nm (2.4.7).

Calculate the content of C22H24N2O8, HCl in the capsules.

**Storage.** Store protected from light and moisture.

**Tetracycline Ointment**

Tetracycline Hydrochloride Eye Ointment

Tetracycline Ointment contains not less than 90.0 per cent and not more than 115.0 per cent of the stated amount of tetracycline hydrochloride, C22H24N2O8, HCl.

**Identification**

In the test for Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to tetracycline hydrochloride in the chromatogram obtained with the reference solution.

**Tests**

**Water (2.3.43).** Not more than 0.5 per cent, determined on 2.0 g dissolved in a mixture of 2 volumes of carbon
**Tetrachloride**

**2 volumes of chloroform and 1 volume of methanol.**

**Other tests.** Complies with the tests stated under Eye Ointments.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh accurately a quantity containing about 25 mg of Tetracycline Hydrochloride and transfer to a separating funnel with the aid of 15 ml of cyclohexane. Add 15 ml of a mixture of 68 volumes of 0.1 M ammonium oxalate and 27 volumes of dimethylformamide (diluting solvent) and shake well. Collect the lower layer in a 50-ml volumetric flask. Repeat the extraction with two further quantities, each of 15 ml, of the diluting solvent, combining the extracts in the same 50-ml volumetric flask. Add sufficient diluting solvent to produce 50.0 ml, mix and filter.

**Reference solution.** A 0.05 per cent w/v solution of tetracycline hydrochloride RS in the diluting solvent.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 to 10 µm),
- mobile phase: a mixture of 68 volumes of 0.1 M ammonium oxalate and 27 volumes of dimethylformamide and 5 volumes of 0.2 M dibasic ammonium phosphate, the pH of the mixture being adjusted, if necessary, to 7.6 to 7.7 with 3 M ammonia or 3 M phosphoric acid,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 µl loop injector.

Calculate the content of C_{22}H_{24}N_{2}O_{8}, HCl in the eye ointment.

**Storage.** Store protected from moisture.

---

**Theophylline**

Theophylline is 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione. It contains one molecule of water or is anhydrous.

Theophylline contains not less than 98.0 per cent and not more than 101.0 per cent of C_{7}H_{8}N_{4}O_{2}, calculated on the dried basis.

**Description.** A white, crystalline powder; odourless.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests B and D may be omitted if tests A and C are carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with theophylline RS or with the reference spectrum of theophylline.

B. Dissolve about 10 mg in 10 ml of water; add 0.5 ml of a 5 per cent w/v solution of mercuric acetate and allow to stand; a white, crystalline precipitate is produced.

C. The melting range, after drying at 105º, 270º to 274º (2.4.21).

D. Gives the reaction of xanthines (2.3.1).

**Tests**

**Appearance of solution.** Dissolve 0.5 g in 75 ml of carbon dioxide-free water with heating; the resulting solution (solution A), is clear (2.4.1), and colourless (2.4.1).

**Acidity.** To 50 ml of solution A add 0.1 ml of methyl red solution. The solution is red and not more than 1.0 ml of 0.01 M sodium hydroxide is required to change the colour of the solution to yellow.

**Light absorption** (2.4.7). Absorbance of a 0.001 per cent w/v solution in 0.1 M hydrochloric acid at the maximum at about 270 nm, not less than 0.53.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Test solution.** Dissolve 0.2 g of the substance under examination in 10 ml of a mixture of 60 volumes of chloroform and 40 volumes of methanol.

**Reference solution.** Dissolve 10 mg of the substance under examination in 100 ml of a mixture of 60 volumes of chloroform and 40 volumes of methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent (for the anhydrous form) and 8.0 per cent to 9.5 per cent (for the hydrated form).
hydrated form), determined on 1.0 g by drying in an oven at 105°.

**Assay.** Weigh accurately about 0.25 g, add 50 ml of water and gently warm the mixture on a water-bath until complete solution is effected. Cool, add 20.0 ml of 0.1 M silver nitrate and 1.0 ml of bromothymol solution and titrate with 0.1 M sodium hydroxide until a blue colour is obtained.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.01802 g of C7H8N4O2.

**Storage.** Store protected from moisture.

### Theophylline Injection

**Theophylline in Dextrose Injection**

Theophylline Injection is a sterile solution of Theophylline and Dextrose in Water for Injections.

Theophylline Injection contains not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of anhydrous theophylline, C7H8N4O2, and not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of dextrose, C6H12O6,H2O.

**Identification**

A. When examined in the range 230 nm to 360 nm (2.4.7), the solution obtained in the Assay for theophylline shows an absorption maximum at about 274 nm.

B. Add 0.2 ml of the injection to 5 ml of potassium cupri-tartrate solution and heat to boiling; a red to orange precipitate is formed.

**Tests**

**pH** (2.4.24). 3.5 to 6.5.

**5-Hydroxymethylfurfural and Related substances.** Use a glass chromatographic column (66 cm × 11 mm) with a sealed-in, coarse-porosity sintered disc or a glass wool plug and fitted with a stopcock. Mix 8 g of a 20- to 50-mesh styrenedivinylbenzene anion-exchange resin in the hydroxide form with 25 ml of water, allow to settle and decant the supernatant liquid until a slurry of resin remains. Pour the slurry into the column and allow to settle as a homogeneous bed having a bed volume of about 15 ml. Wash the resin bed at a flow rate of about 3 ml per minute with 100 ml of a 5.7 per cent w/v solution of ammonium carbonate followed by washing with water until the eluate has a pH of 7.

Dilute an accurately measured volume of the injection containing 1.0 g of Dextrose, C6H12O6,H2O, to 250.0 ml with water. Pass this solution through the resin bed in the column at a flow rate of about 3.5 ml per minute, discarding the first 50 ml of the eluate. Measure the absorbance of the eluate at 284 nm, using water as the blank; the absorbance is not more than 0.25 (2.4.7).

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** For theophylline — Dilute a suitable volume of the injection with sufficient 0.1 M sodium hydroxide to produce a solution containing 0.008 per cent w/v of anhydrous theophylline. Measure the absorbance of the resulting solution at the maximum about 274 nm (2.4.7), using as the blank a solution prepared in the same manner omitting the substance under examination.

Calculate the content of C7H8N4O2 from the absorbance obtained by repeating the operation using theophylline RS in place of the substance under examination.

For dextrose — Transfer an accurately measured volume of the injection containing about 5 mg of Dextrose to a 100-ml volumetric flask, add 0.2 ml of 6 M ammonia, dilute to volume with water and mix. Determine the optical rotation of the resulting solution in a suitable polarimeter tube at 25° (2.4.22). The observed rotation, in degrees multiplied by 1.0425, represents the weight, in g, of C6H12O6,H2O in the volume of the injection taken for the assay, where A is the ratio 200 divided by the length, in mm, of the polarimeter tube employed.

**Storage.** Store protected from light, in single dose containers.

**Labelling.** The label states the strength in terms of the amounts of anhydrous theophylline and Dextrose.

### Thiabendazole

**Thiabendazole**

- **Thiabendazole**

  C10H7N3S

  Mol. Wt. 201.3

  Thiabendazole is 2-(1,3-thiazol-4-yl)-1H-benzimidazole.

  Thiabendazole contains not less than 98.0 per cent and not more than 101.0 per cent of C10H7N3S, calculated on the anhydrous basis.

**Description.** A white or almost white, crystalline powder.

**Identification**

Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.
A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with thiabendazole RS or with the reference spectrum of thiabendazole.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.0005 per cent w/v solution in 0.1 M hydrochloric acid shows absorption maxima at about 243 nm and 302 nm; ratio of the absorbance at the maximum at about 302 nm to that at about 243 nm, 1.8 to 2.1.

C. In the test for Related substances, the principal spot in the chromatogram obtained with the test solution (b) corresponds to that in the chromatogram obtained with reference solution (c).

D. Dissolve 5 mg in 5 ml of 0.1 M hydrochloric acid, add 3 mg of 4-phenylenediamine dihydrochloride and shake until dissolved. Add 0.1 g of zinc powder, mix, allow to stand for 2 minutes and add 10 ml of ferric ammonium sulphate solution; a deep blue or bluish violet colour is produced.

Tests

Appearance of solution. Add 5 ml of methanol to 0.5 g in a flask fitted with a ground-glass stopper, stir for 5 minutes, with a magnetic stirrer and filter through a sintered-glass filter (1.6 µm to 4 µm). The solution is not more intensely coloured than reference solution BS6 (2.4.1).

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 62.5 volumes of toluene, 25 volumes of glacial acetic acid, 10 volumes of acetone and 2.5 volumes of water.

Test solution (a). Dissolve 0.1 g of the substance under examination in 10 ml of methanol.

Test solution (b). Dilute 2 ml of test solution (a) to 20 ml with methanol.

Reference solution (a). Dilute 1 ml of test solution (b) to 10 ml with methanol.

Reference solution (b). Dilute 1 ml of test solution (b) to 25 ml with methanol.

Reference solution (c). Dissolve 20 mg of thiabendazole RS in 20 ml of methanol.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b)

Heavy metals (2.3.13). 2.0 g complies with the limit test for heavy metals, Method B (10 ppm).

Sulphated ash (2.3.18). Not more than 0.2 per cent.

Water (2.3.43). Not more than 0.5 per cent, determined on 1.0 g.

Assay. Weigh accurately about 0.15 g, dissolve in 30 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02013 g of C_{10}H_{7}N_{3}S.

Storage. Store protected from light and moisture.

Thiabendazole Tablets

Thiabendazole Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of thiabendazole, C_{10}H_{7}N_{3}S. The tablets may contain permitted colours.

Identification

A. When examined in the range 230 nm to 360 nm (2.4.7), the final solution obtained in the Assay shows an absorption maximum at about 302 nm.

B. Dissolve a quantity of the powdered tablets containing 30 mg of Thiabendazole in 5 ml of 0.1 M hydrochloric acid, add 3 mg of 4-phenylenediamine dihydrochloride and shake until dissolved. Add 0.1 g of zinc powder, mix, allow to stand for 2 minutes and add 10 ml of ferric ammonium sulphate solution; a deep bluish violet colour is produced.

Tests

Disintegration. The test does not apply.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.1 g of Thiabendazole, add 75 ml of 0.1 M hydrochloric acid, warm on a water-bath for 15 minutes, shaking occasionally, cool, dilute to 100.0 ml with 0.1 M hydrochloric acid and filter. Dilute 5.0 ml of the filtrate to 1000.0 ml with 0.1 M hydrochloric acid and measure the absorbance of the resulting solution at the maximum at about 302 nm (2.4.7).

Calculate the content of C_{10}H_{7}N_{3}S taking 1230 as the specific absorbance at 302 nm.

Storage. Store protected from light and moisture.

Labelling. The label states that the tablets should be chewed before swallowing.
Thiacetazone

\[ \text{C}_{10}\text{H}_{12}\text{N}_{4}\text{OS} \quad \text{Mol. Wt. 236.3} \]

Thiacetazone is 4-acetamidobenzaldehyde thiosemicarbazone.

Thiacetazone contains not less than 98.0 per cent and not more than 102.0 per cent of \( \text{C}_{10}\text{H}_{12}\text{N}_{4}\text{OS} \), calculated on the dried basis.

**Description.** Pale yellow crystals or a crystalline powder; almost odourless.

**Identification**

*Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with thiacetazone RS or with the reference spectrum of thiacetazone.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.0003 per cent w/v solution in ethanol (95 per cent) shows an absorption maximum at about 328 nm absorbance at about 328 nm, about 0.55.

C. Boil 10 mg with 5 ml of 1 M hydrochloric acid for 3 minutes, cool and add sufficient water to produce 200 ml. Mix 5 ml of this solution with 0.25 ml of sodium nitrite solution and add the mixture to 0.5 ml of 2-naphthol solution; a red colour is produced.

**Tests**

**Thiosemicarbazide.** To 2.0 g, finely powdered, add sufficient water to produce 50 ml, shake, allow to stand for 1 hour with occasional shaking and filter, discarding the first few ml of the filtrate. Acidify 25 ml of the clear filtrate with dilute sulphuric acid, add 0.1 ml of o-phenanthroline-ferrous complex solution and titrate with 0.1 M ceric ammonium sulphate to a blue end-point which persists for 1 minute; not more than 0.8 ml is required.

**4-acetamidobenzalazine.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** Ethyl acetate.

**Test solution.** Dissolve 0.4 g of the substance under examination in 100 ml of methanol.

Reference solution. Dissolve with the aid of heat 0.016 g of 4-acetamidobenzalazine RS in 150 ml of methanol, cool and dilute to 200 ml with methanol and further dilute 5 ml of this solution to 50 ml with methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air, spray with 2 M nitric acid and within 2 minutes examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Heavy metals** (2.3.13). 2.0 g complies with the limit test for heavy metals, Method B (10 ppm).

**Sulphated ash** (2.3.18). Not more than 0.2 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.1 g, dissolve in 60 ml of methanol by heating at 60º in a water-bath, add slowly 20 ml of hot methanolic silver nitrate solution, maintain the solution at 60º until the precipitate coagulates and leaves a clear supernatant liquid. Cool, filter through a sintered-glass crucible (porosity No. 4), wash the residue with methanol until the washings are free from silver nitrate and dry to constant weight at 105º.

1 g of residue is equivalent to 0.4606 g of \( \text{C}_{10}\text{H}_{12}\text{N}_{4}\text{OS} \).

**Storage.** Store protected from light and moisture.

Thiacetazone And Isoniazid Tablets

Thiacetazone and Isoniazid Tablets contain one part by weight of Thiacetazone and two parts by weight of Isoniazid.

Thiacetazone and Isoniazid Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amounts of thiacetazone, \( \text{C}_{10}\text{H}_{12}\text{N}_{4}\text{OS} \), and isoniazid, \( \text{C}_{6}\text{H}_{7}\text{N}_{3}\text{O}_{2} \).

**Identification**

A. Extract a quantity of the powdered tablets containing about 30 mg of Thiacetazone with 70 ml of ethanol (95 per cent) with the aid of heat for 15 minutes with occasional shaking. Cool, dilute to 100 ml with ethanol (95 per cent) and filter. Dilute 1 ml to 100 ml with ethanol (95 per cent). The solution complies with the following test.

When examined in the range 230 nm to 360 nm (2.4.7), a 0.0005 per cent w/v solution in 0.1 M hydrochloric acid shows absorption maxima at about 243 nm and 302 nm; ratio of the absorbance at the maximum at about 302 nm to that at about 243 nm, 1.8 to 2.1.

B. Shake a quantity of the powdered tablets containing 1 mg of Isoniazid with 50 ml of ethanol (95 per cent) and filter. To
5 ml of the filtrate add 0.1 g of borax and 5 ml of a 5 per cent w/v solution of 1-chloro-2,4-dinitrobenzene in ethanol (95 per cent), evaporate to dryness on a water-bath and continue heating for a further 10 minutes. To the residue add 10 ml of methanol and mix; a reddish purple colour is produced.

**Tests**

**Disintegration** (2.5.1). 30 minutes.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** For thiacetazone — Weigh and finely powder 20 tablets. Weigh accurately a quantity of the powder containing about 30 mg of Thiacetazone, add 70 ml of ethanol (95 per cent) to produce 100.0 ml and filter. To 1.0 ml of the filtrate add sufficient ethanol (95 per cent) to produce 100.0 ml and measure the absorbance of the resulting solution at the maximum at about 328 nm (2.4.7), using ethanol (95 per cent) as the blank. Calculate the content of C_{10}H_{12}N_{4}OS from the absorbance obtained by repeating the operation using thiacetazone RS in place of the tablets under examination.

For isoniazid — Weigh accurately a quantity of the powdered tablets containing about 0.2 g of Isoniazid, dissolve as completely as possible in 100 ml of water and filter. Wash the residue with water, combine the filtrate and washings and dilute to 250.0 ml with water. To 50.0 ml of the resulting solution add 0.9 ml of 1 M sodium hydroxide and 0.2 g of sodium sulphite in place of the 1.6 ml of 1 M sodium hydroxide; practically no fluorescence is produced.

C_{12}H_{17}ClN_{4}OS, HCl contains not less than 98.5 per cent and not more than 101.5 per cent of C_{12}H_{17}ClN_{4}OS, HCl, calculated on the dried basis.

**Description.** A white or almost white, crystalline powder or small colourless crystals; odour, slight and characteristic.

**Identification**

Test A may be omitted if tests B and C are carried out. Test B may be omitted if tests A and C are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with thiamine hydrochloride RS or with the reference spectrum of thiamine hydrochloride.

B. Dissolve about 20 mg in 10 ml of water, add 1 ml of 2 M acetic acid and 1.6 ml of 1 M sodium hydroxide, heat on a water-bath for 30 minutes and allow to cool. Add 5 ml of 2 M sodium hydroxide, 10 ml of potassium ferricyanide solution and 10 ml of 1-butanol and shake vigorously for 2 minutes. The upper layer exhibits an intense light blue fluorescence, particularly in ultraviolet light at 365 nm. Repeat the test but adding 0.9 ml of 1 M sodium hydroxide and 0.2 g of sodium sulphite in place of the 1.6 ml of 1 M sodium hydroxide; practically no fluorescence is produced.

C. Gives reaction A of chlorides (2.3.1).

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution is clear (2.4.1), and not more intensely coloured than reference solution YS7 or GYS6 (2.4.1).

**pH** (2.4.24). 2.7 to 3.3, determined in a 2.5 per cent w/v solution.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method A (20 ppm).

**Nitrates.** To 2 ml of a 2.0 per cent w/v solution add 2 ml of sulphuric acid, cool and superimpose 2 ml of ferrous sulphate solution; no brown ring is produced at the junction of the two layers.

**Sulphates** (2.3.17). 0.5 g complies with the limit test for sulphates (300 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 5.0 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.15 g, dissolve in 5 ml of anhydrous formic acid, add 65 ml of anhydrous glacial acetic acid and 10 ml of mercuric acetate solution, with stirring. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration. 1 ml of 0.1 M perchloric acid is equivalent to 0.01686 g of C_{12}H_{17}ClN_{4}OS, HCl.

**Storage.** Store protected from light and moisture.

**Thiamine Hydrochloride**

Aneurine Hydrochloride; Vitamin B_{1}

Thiamine Hydrochloride is 3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methylthiazolium chloride hydrochloride hydrate.

C_{12}H_{17}ClN_{4}OS, HCl

Mol. Wt. 337.3

Thiamine Hydrochloride contains not less than 98.5 per cent and not more than 101.5 per cent of C_{12}H_{17}ClN_{4}OS, HCl, calculated on the dried basis.
Storage. Store protected from light and moisture, non-metallic containers.

**Thiamine Injection**

Thiamine Hydrochloride Injection; Aneurine Hydrochloride Injection; Vitamin B₁ Injection

Thiamine Injection is a sterile solution of Thiamine Hydrochloride in Water for Injection.

Thiamine Injection contains not less than 95.0 per cent and not more than 110.0 per cent of the stated amount of thiamine hydrochloride, C₁₂H₁₇ClN₄OS, HCl.

**Identification**

A. To a volume containing 20 mg of Thiamine Hydrochloride in 10 ml of water, add 1 ml of 2 M acetic acid and 1.6 ml of 1 M sodium hydroxide, heat on a water-bath for 30 minutes and allow to cool. Add 5 ml of 2 M sodium hydroxide, 10 ml of potassium ferricyanide solution and 10 ml of 1-butanol and shake vigorously for 2 minutes. The upper layer exhibits an intense light blue fluorescence, particularly in ultraviolet light at 365 nm. Repeat the test but adding 0.9 ml of 1 M sodium hydroxide and 0.2 g of sodium sulphite in place of the 1.6 ml of 1 M sodium hydroxide; practically no fluorescence is produced.

B. To a mixture of 0.1 ml of nitrobenzene and 0.2 ml of sulphuric acid add a volume containing 5 mg of Thiamine Hydrochloride. Allow to stand for 10 minutes, cool in ice and add slowly with stirring 5 ml of water followed by 5 ml of 10 M sodium hydroxide. Add 5 ml of acetone and allow to stand; no violet colour is produced in the upper layer.

**Tests**

**pH** (2.4.24). 2.5 to 4.5.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Determine by liquid chromatography (2.4.14).

- **Test solution.** Dilute a volume of the injection containing about 0.1 g of Thiamine Hydrochloride to 100.0 ml with 0.1 M hydrochloric acid and further dilute 5.0 ml to 100.0 ml with water.

- **Reference solution.** A 0.005 per cent w/v solution of thiamine mononitrate RS in 0.005 M hydrochloric acid.

- **Chromatographic system.**
  - a stainless steel column 10 cm x 4.6 mm, packed with octadecysilane bonded to porous silica (5 µm),
  - mobile phase: a solution prepared by dissolving 1 g of sodium heptanesulphonate in a mixture of 180 ml of methanol and 10 ml of triethylamine, diluting to 1000 ml with water and adjusting the pH to 3.2 with phosphoric acid,
  - flow rate. 2 ml per minute,
  - spectrophotometer set at 244 nm,
  - a 20 µl loop injector.

Calculate the content of C₁₂H₁₇ClN₄OS.

1 mg of C₁₂H₁₇N₄O₅S is equivalent to 1.030 mg of C₁₂H₁₇ClN₄OS, HCl.

**Storage.** Store protected from light.

**Thiamine Tablets**

Thiamine Hydrochloride Tablets; Aneurine Hydrochloride Tablets; Vitamin B₁ Tablets

Thiamine Tablets contain not less than 92.5 per cent and not more than 110.0 per cent of the stated amount of thiamine hydrochloride, C₁₂H₁₇ClN₄OS, HCl.

**Identification**

A. Dissolve a quantity of the powdered tablets containing 20 mg of Thiamine Hydrochloride as completely as possible in 10 ml of water and 2 ml of 1 M acetic acid and filter. Add 5 ml of 2 M sodium hydroxide, 10 ml of potassium ferricyanide solution and 10 ml of 1-butanol and shake vigorously for 2 minutes. The upper layer exhibits an intense light blue fluorescence, particularly in ultraviolet light at 365 nm. Repeat the test but adding 0.9 ml of 1 M sodium hydroxide and 0.2 g of sodium sulphite in place of the 1.6 ml of 1 M sodium hydroxide; practically no fluorescence is produced.

B. To a mixture of 0.1 ml of nitrobenzene and 0.2 ml of sulphuric acid add the powdered tablets containing 5 mg of Thiamine Hydrochloride. Allow to stand for 10 minutes, cool in ice and add slowly with stirring 5 ml of water followed by 5 ml of 10 M sodium hydroxide. Add 5 ml of acetone and allow to stand; no violet colour is produced in the upper layer.

C. The powdered tablets give the reactions of chlorides (2.3.1).

**Tests**

**Uniformity of content.** (For tablets containing 10 mg or less)

- Comply with the test stated under Tablets.

Finely crush one tablet, add 20 ml of ethanol (95 per cent), stir the mixture for 30 minutes and centrifuge. Repeat the extraction with three further quantities, each of 15 ml, of ethanol (95 per cent). Combine the extracts, add sufficient ethanol (95 per cent) to produce 100.0 ml and mix. Dilute a
suitable volume of the resulting solution containing 1 mg of Thiamine Hydrochloride with sufficient ethanol (95 per cent) to produce 100.0 ml. Measure the absorbance of the resulting solution at the maximum at about 233 nm (2.4.7).

Calculate the content of C₁₂H₁₇ClN₄OS, HCl in the tablet taking 380 as the specific absorbance at 233 nm.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** For tablets containing less than 10 mg of Thiamine Hydrochloride, add 5 ml of 0.1 M hydrochloric acid and 50 ml of water to a quantity of the powdered tablets containing 6 mg of Thiamine Hydrochloride, shake for 20 minutes, dilute to 100.0 ml with water and filter. For tablets containing 10 mg or more of Thiamine Hydrochloride, add 50 ml of 0.1 M hydrochloric acid and 500 ml of water to a quantity of the powdered tablets containing 60 mg of Thiamine Hydrochloride, shake for 20 minutes, dilute to 1000.0 ml with water and filter.

**Reference solution.** A 0.006 per cent w/v solution of thiamine mononitrate RS in 0.005 M hydrochloric acid.

**Chromatographic system**
- a stainless steel column 10 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a solution prepared by dissolving 1 g of sodium heptanesulphonate in a mixture of 180 ml of methanol and 10 ml of triethylamine, diluting to 1000 ml with water and adjusting the pH to 3.2 with phosphoric acid,
- flow rate. 2 ml per minute,
- spectrophotometer set at 244 nm,
- a 20 µl loop injector.

Calculate the content of C₁₂H₁₇N₄O₄S in the tablets.

1 mg of C₁₂H₁₇N₄O₄S is equivalent to 1.030 mg of C₁₂H₁₇ClN₄OS, HCl.

**Storage.** Store protected from light and moisture, non-metallic containers.

### Thiamine Mononitrate

Thiamine Nitrate

![Thiamine Mononitrate Structure](image)

C₁₂H₁₇N₄O₄S  
Mol. Wt. 327.4

Thiamine Mononitrate is 3-[(4-amino-2-methyl|pyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methylthiazolium nitrate.

Thiamine Mononitrate contains not less than 98.0 per cent and not more than 102.0 per cent of C₁₂H₁₇N₄O₄S, calculated on the dried basis.

**Description.** A white or almost white, crystalline powder or small, colourless crystals.

**Identification**

**Test A may be omitted if tests B and C are carried out. Test B may be omitted if tests A and C are carried out.**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with thiamine mononitrate RS or with the reference spectrum of thiamine mononitrate.

B. Dissolve about 20 mg in 10 ml of water, add 1 ml of 2 M acetic acid and 1.6 ml of 1 M sodium hydroxide, heat on a water-bath for 30 minutes and allow to cool. Add 5 ml of 2 M sodium hydroxide, 10 ml of potassium ferricyanide solution and 10 ml of 1-butanol and shake vigorously for 2 minutes. The upper layer exhibits an intense light blue fluorescence, particularly in ultraviolet light at 365 nm. Repeat the test but adding 0.9 ml of 1 M sodium hydroxide and 0.2 g of sodium sulphite in place of the 1.6 ml of 1 M sodium hydroxide; practically no fluorescence is produced.

C. Gives reaction A of nitrates (2.3.1).

**Tests**

**Appearance of solution.** A 2.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and not more intensely coloured than reference solution YS7 (2.4.1).

**pH** (2.4.24). 6.8 to 7.6, determined in a 2.0 per cent w/v solution.

**Heavy metals** (2.3.13). 1.0 g complies with limit test for heavy metals, Method A (20 ppm).

**Chlorides** (2.3.12). 1.0 g complies with the limit test for chlorides (250 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.15 g, dissolve in 5 ml of anhydrous formic acid, add 70 ml of acetic anhydride. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01637 g of C₁₂H₁₇N₄O₄S.

**Storage.** Store protected from light and moisture, non-metallic containers.
**Thiomersal**

Thimerosal

\[
\text{C}_9\text{H}_9\text{HgNaO}_2\text{S} \quad \text{Mol. Wt. 404.8}
\]

Thiomersal is the sodium salt of [(2-carboxyphenyl)thio] ethylmercury.

Thiomersal contains not less than 97.0 per cent and not more than 101.0 per cent of \(\text{C}_9\text{H}_9\text{HgNaO}_2\text{S}\), calculated on the dried basis.

**Description.** A light cream, crystalline powder; odour, slight and characteristic.

**Identification**

A. Dissolve 0.1 g in 10 ml of water and add 2 ml of silver nitrate solution; a pale yellow precipitate is produced.

B. Dissolve 0.5 g in 10 ml of water and add 2 ml of 2 M hydrochloric acid; a white precipitate is produced which, after washing with water and drying over phosphorus pentoxide at a pressure not exceeding 0.7 kPa, melts at about 110º (2.4.21).

**Tests**

**pH** (2.4.24). 6.0 to 8.0, determined in a 1.0 per cent w/v solution.

**Ether-soluble matter.** Shake 0.5 g with 20 ml of ether for 10 minutes, filter and evaporate to dryness. The residue, after drying over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 24 hours, weighs not more than 3 mg.

**Inorganic mercury compounds.** Not more than 0.7 per cent, determined by the following method.

Protect the solutions from light throughout the procedure.

Label five 10-ml volumetric flasks A, B, C, D and E. Place 5 ml of a 0.1 per cent w/v solution of the substance under examination in each of flasks A, B, C and D. To each of flasks C and D add 0.5 ml of a 0.0095 per cent w/v solution of mercuric chloride. Add sufficient water to flasks A and C to produce 10.0 ml and add sufficient of a freshly prepared 33.2 per cent w/v solution of potassium iodide to flasks B and D to produce 10.0 ml. Place 5 ml of the potassium iodide solution in flask E and add sufficient water to produce 10.0 ml. Measure the absorbances of each of the solutions (Ab, Aa, Ac, Ad, Ae) at about 323 nm (2.4.7), using water as the blank.

Calculate the content of inorganic mercury compounds, expressed as Hg, in the substance under examination from the expression 0.7019 \((\text{Ab} - \text{Aa} - \text{Ae})/(\text{Aa} + \text{Ad} - \text{Ab} - \text{Ac})\), where the figure 0.7019 is a constant obtained from the formula

\[
\frac{\text{atomic weight of mercury}}{\text{molecular weight of HgCl}_2} \times \text{concentration of HgCl}_2
\]

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 24 hours.

**Assay.** Weigh accurately about 0.5 g, transfer to a 100-ml long-necked flask, add 5 ml of sulphuric acid and heat gently until charring occurs; continue to heat and add hydrogen peroxide solution (100 vol) dropwise, until the mixture is colourless. Dilute with water, evaporate until slight fuming occurs, dilute to 10 ml with water, cool and titrate with 0.1 M ammonium thiocyanate using ferric ammonium sulphate solution as indicator.

1 ml of 0.1 M ammonium thiocyanate is equivalent to 0.02024 g of \(\text{C}_9\text{H}_9\text{HgNaO}_2\text{S}\).

**Storage.** Store protected from light and moisture.

---

**Thiopentone Sodium**

Thiopental Sodium

\[
\text{C}_{11}\text{H}_{17}\text{N}_2\text{O}_2\text{S} \quad \text{Mol. Wt. 264.3}
\]

Thiopentone Sodium is a mixture of sodium (RS)-5-ethyl-5-(1-methylbutyl)-2-thiobarbiturate and anhydrous sodium carbonate.

Thiopentone Sodium contains not less than 84.0 per cent and not more than 87.0 per cent of \(\text{C}_{11}\text{H}_{18}\text{N}_2\text{O}_2\text{S}\) and not less than 10.2 per cent and not more than 11.2 per cent of Na, both calculated on the dried basis.

**Description.** A yellowish white powder; odour, faintly resembling garlic; hygroscopic.

**Identification**

Test A may be omitted if tests B, C, D and E are carried out. Tests B and D may be omitted if tests A, C and E are carried out.

A. Acidify 10 ml of a 10 per cent w/v solution in carbon dioxide-free water with 2 M hydrochloric acid; the solution
effervesces. Shake the solution with 20 ml of ether, separate the ether layer, wash with 10 ml of water and dry over anhydrous sodium sulphate. Filter, evaporate the filtrate to dryness and dry the residue at 105º.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with thiopentone RS or with the reference spectrum of thiopentone.

B. Complies with the test for identification of barbiturates (2.3.2), but using the following solutions.

**Test solution.** A 0.1 per cent w/v solution of the substance under examination in water.

**Reference solution.** Dissolve 85 mg of thiopentone RS in 10 ml of 2 M sodium hydroxide and dilute to 100 ml with water.

C. Acidify 5 ml of a 5 per cent w/v solution with dilute acetic acid and filter. Wash the precipitate with water, recrystallise from water and dry at 70º; the crystals melt at about 160º (2.4.21).

D. Dissolve 1 mg of the crystals obtained in test A in 1 ml of 0.1 M sodium hydroxide. Add about 1 mg of sodium nitroprusside and, after 15 minutes, 1 ml of dilute hydrochloric acid, a reddish violet colour is produced.

E. Gives the reactions of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** A 10.0 per cent w/v solution in carbon dioxide-free water (solution A) is clear (2.4.1), and not more intensely coloured than reference solution GYS3 (2.4.1).

**Related substances** (2.3.4). Complies with the test, but using water as the solvent for the test solution and the reference solution. After development, examine the plate in ultraviolet light at 254 nm but do not spray it with the diphenylcarbazone-mercury reagent.

**Chlorides** (2.3.12). To 10 ml of solution A add 30 ml of water and 10 ml of 2 M nitric acid. Shake successively with three quantities, each of 25 ml, of ether, discard the ether layers and heat the aqueous solution on water-bath to remove any residual ether. 30 ml of the aqueous layer complies with the limit test for chlorides (330 ppm).

**Loss on drying** (2.4.19). Not more than 2.5 per cent, determined on 0.5 g by drying in an oven at 100º at a pressure of 1.5 to 2.5 kPa for 4 hours.

**Assay. For thiopentone —** Weigh accurately about 0.15 g, dissolve in 5 ml of water, add 2 ml of 1 M sulphuric acid and extract with four quantities, each of 10 ml, of chloroform. Filter the combined chloroform extracts, evaporate the filtrate to dryness on a water-bath and dissolve the residue in 30 ml of dimethylformamide, previously neutralised with 0.1 M lithium methoxide. Titrate immediately with 0.1 M lithium methoxide, using 1 drop of a 0.2 per cent w/v solution of thymol blue in methanol as indicator, until a blue colour is obtained. Protect the solution from absorption of carbon dioxide during the titration.

1 ml of 0.1 M lithium methoxide is equivalent to 0.02423 g of C₃H₁₃N₂O₅S.

For sodium — Weigh accurately about 0.4 g, dissolve in 30 ml of water, add 1 drop of methyl red solution and titrate with 0.05 M sulphuric acid until the yellow colour changes to red. Boil gently for 2 minutes, cool and, if necessary, continue the titration with 0.05 M sulphuric acid until the red colour is restored.

1 ml of 0.05 M sulphuric acid is equivalent to 0.002299 g of Na.

**Storage.** Store protected from light and moisture.

**Thiopentone Injection**

Thiopentone Sodium Injection; Thiopental Injection

Thiopentone Injection is a sterile material consisting of Thiopentone Sodium with or without auxiliary agents. It is filled in a sealed container.

The injection is constituted by dissolving the contents of the sealed container in the requisite amount of sterile Water for Injections, immediately before use.

The constituted solution complies with the requirements for Clarity of solution and Particulate matter stated under Parenteral Preparations (Injections).

**Storage.** The constituted solution should be used immediately after preparation but, in any case, within the period recommended by the manufacturer.

Thiopentone Injection contains thiopentone, C₃H₁₃N₂O₅S that is not less than 77.0 per cent and not more than 92.0 per cent and sodium, Na that is not less than 9.4 per cent and not more than 11.8 per cent of the stated amount of thiopentone sodium.

The contents of the sealed container comply with the requirements stated under Parenteral Preparations (Powders for Injection) and with the following requirements.

**Description.** A yellowish white powder, hygroscopic.

**Identification**

Test A may be omitted if tests B, C, D and E are carried out. Tests B and D may be omitted if tests A, C and E are carried out.

A. Acidify 10 ml of a 10 per cent w/v solution in carbon dioxide-free water with 2 M hydrochloric acid; the solution
Dissolve 85 mg of thiopentone RS in 10 ml of 2 M sodium hydroxide and dilute to 100 ml with water. Acidify 5 ml of a 5 per cent w/v solution with dilute acetic acid and filter. Wash the precipitate with water, recrystallise from water and dry at 70º; the crystals melt at about 160º (2.4.21).

D. Dissolve 1 mg of the crystals obtained in test A in 1 ml of 0.1 M sodium hydroxide. Add about 1 mg of sodium nitroprusside and, after 15 minutes, 1 ml of dilute hydrochloric acid; a reddish violet colour is produced.

E. Gives the reactions of sodium salts (2.3.1).

Tests

Appearance of solution. A 10.0 per cent w/v solution in carbon dioxide-free water (solution A) is clear (2.4.1), and not more intensely coloured than reference solution GYS3 (2.4.1).

Related substances (2.3.4). Complies with the test, but using water as the solvent for the test solution and the reference solution. After development, examine the plate in ultraviolet light at 254 nm but do not spray it with the diphenylcarbazone-mercury reagent.

Loss on drying (2.4.19). Not more than 2.5 per cent, determined on 0.5 g by drying in an oven at 100º at a pressure of 1.5 to 2.5 kPa for 4 hours.

Assay. For thiopentone — Mixed the contents of 10 containers and weigh accurately about 0.15 g, of the contents, dissolve in 5 ml of water, add 2 ml of 1 M sulphuric acid and extract with four quantities, each of 10 ml, of chloroform. Filter the combined chloroform extracts, evaporate the filtrate to dryness on a water-bath and dissolve the residue in 30 ml of dimethylformamide, previously neutralised with 0.1 M lithium methoxide. Titrate immediately with 0.1 M lithium methoxide, using 1 drop of a 0.2 per cent w/v solution of thymol blue in methanol as indicator, until a blue colour is obtained. Protect the solution from absorption of carbon dioxide during the titration.

1 ml of 0.1 M lithium methoxide is equivalent to 0.02423 g of C₁₁H₁₈N₂O₂S.

For sodium — Mixed the contents of 10 containers and weigh accurately about 0.4 g of the contents, dissolve in 30 ml of water, add 1 drop of methyl red solution and titrate with 0.05 M sulphuric acid until the yellow colour changes to red. Boil gently for 2 minutes, cool and, if necessary, continue the titration with 0.05 M sulphuric acid until the red colour is restored.

1 ml of 0.05 M sulphuric acid is equivalent to 0.002299 g of Na.

Storage. Store in single dose containers.

Labelling. The label states the amount of active ingredient in terms of Thiopentone Sodium.
**Water** (2.3.43). Not more than 2.0 per cent, determined on 1.2 g.

**Assay.** Weigh accurately about 0.2 g into a stoppered flask, add 50 ml of a 20 per cent w/v solution of *sodium thiosulphate* and titrate immediately with 0.1 M *hydrochloric acid*, using *methyl orange solution* as indicator, until a faint red colour persists for 10 seconds. Stopper the flask, allow to stand for 30 minutes and titrate with 0.1 M *sodium hydroxide* using *phenolphthalein solution* as indicator. Subtract the volume of 0.1 M *sodium hydroxide* used from the volume of 0.1 M *hydrochloric acid* used. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of hydrochloric acid required.

1 ml of 0.1 M *hydrochloric acid* is equivalent to 0.006307 g of C₆H₁₂N₃PS.

**Storage.** Store protected from light and moisture. At higher temperatures it tends to polymerise with loss of activity.

---

**Thiotepa Injection**

Thiotepa Injection is a sterile material consisting of Thiotepa with or without auxiliary agents. It is filled in a sealed container.

The injection is constituted by dissolving the contents of the sealed container in the requisite amount of sterile Water for Injections, immediately before use.

*The constituted solution complies with the requirements for Clarity of solution and Particulate matter stated under Parenteral Preparations (Injections).*

**Storage.** The constituted solution should be used immediately after preparation but, in any case, within the period recommended by the manufacturer.

Thiotepa Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of thiotepa, C₆H₁₂N₃PS.

*The contents of the sealed container comply with the requirements stated under Parenteral Preparations (Powders for Injection) and with the following requirements.*

**Description.** A white powder.

**Identification**

A. Determine on 20 mg by the oxygen-flask method (2.3.34), using 5 ml of 1.25 M *sodium hydroxide* as the absorbing liquid. When the process is complete, dilute to 25 ml with *water* (solution A). To 5 ml of solution A add 0.1 ml of *hydrogen peroxide solution* (100 vol) and 1 ml of 1 M *hydrochloric acid*, mix and add 0.05 ml of *barium chloride solution*; a turbidity is produced.

B. To 2 ml of solution A add 40 ml of *water* and 4 ml of *ammonium molybdate-sulphuric acid solution*, mix, add 0.1 g of *L-ascorbic acid* and boil for 1 minute; a blue colour is produced.

**Tests**

**Appearance of solution.** Dissolve a quantity containing 15 mg of Thiotepa in 4 ml of *water*; the solution is clear (2.4.1).

**pH.** 5.5 to 7.5, determined in a 1.0 per cent w/v solution in carbon dioxide-free water.

**Bacterial endotoxins** (2.2.3). Not more than 6.25 Endotoxin Units per mg of Thiotepa.

**Assay.** Determine by liquid chromatography (2.4.14).

*Test solution.* Dilute a suitable quantity of the injection containing 0.15 g of Thiotepa in 100 ml of *water*.

*Reference solution.* A 0.15 per cent w/v solution of thiotepa RS in water.

*Chromatographic system* – a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm), – mobile phase: a mixture of 70 volumes of *water* and 30 volumes of *acetonitrile*, – flow rate. 1 ml per minute, – spectrophotometer set at 215 nm, – a 20 µl loop injector.

Calculate the content of C₆H₁₂N₃PS in the injection.

**Storage.** Store protected from light. If solid matter separates from the constituted injection, the solution should not be used.

---

**Thymol**

![Thymol Structure](image)

C₁₀H₁₄O  
Mol. Wt. 150.2

Thymol is 2-isopropyl-5-methylphenol.

Thymol contains not less than 99.0 per cent and not more than 101.0 per cent of C₁₀H₁₄O.

**Description.** Colourless crystals; odour, characteristic.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.*
A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with thymol RS or with the reference spectrum of thymol.

B. Dissolve 0.2 g with heating in 2 ml of 2 M sodium hydroxide, add 0.2 ml of chloroform and heat on a water-bath; a violet colour develops.

C. Dissolve about 2 mg in 1 ml of anhydrous acetic acid, add 0.15 ml of sulphuric acid and 0.05 ml of nitric acid; a bluish green colour develops.

D. Melting range (2.4.21). 48º to 52º.

Tests

Appearance of solution. Dissolve 1.0 g in 10 ml of 2 M sodium hydroxide. The solution is not more opalescent than opalescence standard OS4 (2.4.1), and not more intensely coloured than reference solution RS6 (2.4.1).

Acidity. To 1.0 g in a glass-stoppered flask add 20 ml of water, boil until dissolution is complete, cool, stopper the flask and shake vigorously for 1 minute. Add a few crystals of the substance under examination to induce crystallisation, shake vigorously for 1 minute and filter. To 5 ml of the filtrate add 0.05 ml of methyl red solution and 0.05 ml of 0.01 M sodium hydroxide; the solution is yellow.

Related substances. Determine by gas chromatography (2.4.13).

Test solution. Dissolve 0.1 g in sufficient ethanol (95 per cent) to produce 10 ml.

Reference solution (a). Dilute 1 ml of the test solution to 100 ml with ethanol (95 per cent).

Reference solution (b). Dilute 1 ml of reference solution (a) to 10 ml with ethanol (95 per cent).

Reference solution (c). Dilute 5 ml of reference solution (b) to 10 ml with ethanol (95 per cent).

Chromatographic system

- a glass column 4 m x 2 mm, packed with diatomaceous support (125 to 180 mesh) impregnated with a mixture suitable for the separation of free fatty acids (such as FFAP),
- temperature: column 80º, inlet port at 250º and detector at 300º,
- flow rate. 30 ml per minute of the carrier gas.

Inject separately 1 µl of each solution and, after 2 minutes, increase the temperature of the column to 240º at a rate of 8º per minute and maintain at this temperature for 15 minutes.

In the chromatogram obtained with the test solution the sum of the areas of any secondary peaks is not greater than the area of the principal peak in the chromatogram obtained with reference solution (a). Ignore any peak with an area less than that of the principal peak in the chromatogram obtained with reference solution (c).

Residue on evaporation. Evaporate 2.0 g on a water-bath and heat at 105º for 1 hour. The residue weighs not more than 1.0 mg (0.05 per cent).

Assay. Weigh accurately about 0.1 g, transfer to an iodine flask and dissolve in 25 ml of 1 M sodium hydroxide. Add 20 ml of hot dilute hydrochloric acid and immediately titrate with 0.05 M bromine to within 1 to 2 ml of the calculated end-point. Warm the solution to about 75º, add 0.1 ml of methyl orange solution and shake vigorously. If the solution is red, continue the titration, dropwise and with shaking until the red colour is discharged. Repeat the alternate addition of 0.05 M bromine and methyl orange solution until the red colour is discharged after the addition of the methyl orange solution. 1 ml of 0.05 M bromine is equivalent to 0.003755 g of C10H14O.

Storage. Store protected from light and moisture.

Thyroxine Sodium

Levothyroxine Sodium; L-Thyroxine Sodium

\[
O
\begin{array}{c}
\text{COONa} \\
\text{NH}_2 \\
, x\text{H}_2\text{O}
\end{array}
\]

\[
\text{H}
\begin{array}{c}
\text{I} \\
\text{I} \\
\text{OH}
\end{array}
\]

\[
\text{C}_{15}\text{H}_{10}\text{I}_4\text{NNaO}_4, x\text{H}_2\text{O}
\]

Mol. Wt. 798.9 (anhydrous)

Thyroxine Sodium is sodium $\text{O}^\text{4-}$-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosinate and contains a variable quantity of water of crystallisation.

Thyroxine Sodium contains not less than 97.0 per cent and not more than 101.0 per cent of $\text{C}_{15}\text{H}_{10}\text{I}_4\text{NNaO}_4$, calculated on the dried basis.

Description. A white or slightly brownish yellow powder, slightly coloured, crystalline powder.

Identification

A. When examined in the range 230 nm to 360 nm (2.4.7), a 0.01 per cent w/v solution in 0.1 M sodium hydroxide shows
an absorption maximum at about 325 nm; absorbance at about 325 nm, 0.73 to 0.79.

B. In the test for Liothyronine, the principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (b).

C. To about 50 mg in a porcelain dish add a few drops of sulphuric acid (96 per cent w/w); violet vapors are evolved.

D. To 20 mg add 2 ml of 1 M sulphuric acid. Heat on a water-bath followed by heating carefully over a naked flame, increasing the temperature to about 600º. Continue ignition until most of the black particles have disappeared. Dissolve the residue in 2 ml of water; the solution gives reaction A of sodium salts (2.3.1).

Tests

Appearance of solution. Dissolve 0.5 g in 23 ml of a gently boiling mixture of 4 volumes of ethanol (95 per cent) and 1 volume of 1 M hydrochloric acid. Cool and dilute to 25 ml with the same mixture of solvents (solution A). The freshly prepared solution is not more intensely coloured than reference solution BYS3 (2.4.1).

Specific optical rotation (2.4.22). +16.0º to +20.0º, determined in solution A.

Liothyronine. Determine by thin-layer chromatography (2.4.17), coating the plate with a slurry of 30 g of silica gel H in 60 ml of a 0.75 per cent w/v solution of soluble starch.

Solvent mixture. 70 volumes of methanol and 5 volumes of strong ammonia solution.

Mobile phase. A mixture of 55 volumes of ethyl acetate, 35 volumes of 2-propanol and 20 volumes of strong ammonia solution.

Test solution. Dissolve 0.1 g of the substance under examination in 10 ml of the solvent mixture.

Reference solution (a). A solution containing 1.0 per cent w/v of the substance under examination and 0.01 per cent w/v of the liothyronine RS in the solvent mixture.

Reference solution (b). A 1 per cent w/v solution of levothyroxine sodium RS in the solvent mixture.

Reference solution (c). A 0.01 per cent w/v solution of liothyronine RS in the solvent mixture.

Apply to the plate 5 µl of each solution. After development, dry the plate in air, spray lightly with ferric chloride-ferriyanide-arsenite solution. Any spot corresponding to liothyronine in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (c). The test is not valid unless the chromatogram obtained with reference solution (a) shows two clearly separated spots.

Loss on drying (2.4.19). 6.0 to 12.0 per cent, determined on 0.5 g by drying in an oven at 105º.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. A 0.001 per cent w/v solution of the substance under examination in 0.1 M methanolic sodium hydroxide.

Reference solution. A 0.001 per cent w/v solution of levothyroxine sodium RS in 0.1 M methanolic sodium hydroxide.

Chromatographic system

– a stainless steel column 25 cm x 4.6 mm, packed with silicagel consisting of porous spherical particles with chemically bonded nitrile groups (5 µm),
– mobile phase: a mixture of 65 volumes of water, 0.2 volume of orthophosphoric acid and 35 volumes of acetonitrile,
– flow rate. 1 ml per minute,
– spectrophotometer set at 225 nm,
– a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution. Calculate the content of C₁₅H₁₀I₄N₄NaO₄.

Storage. Store protected from light and moisture.

Thyroxine Tablets

Thyroxine Sodium Tablets; Levothyroxine Tablets; Levothyroxine Sodium Tablets; L-Thyroxine Sodium Tablets

Thyroxine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of anhydrous thyroxine sodium, C₁₅H₁₀I₄N₄NaO₄.

Identification

A. To a quantity of the powdered tablets containing 500 µg of anhydrous thyroxine sodium add a mixture of 3 ml of ethanol (50 per cent) and 0.2 ml of hydrochloric acid, boil gently for 30 seconds, cool, filter, add 0.1 ml of a 10 per cent w/v solution of sodium nitrite and boil; a yellow colour is produced. Cool and make alkaline with 5 M ammonia; the solution becomes orange.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due
to thyroxine sodium in the chromatogram obtained with the reference solution.

**Tests**

**Uniformity of content.** Comply with the test stated under Tablets. using the following solutions.

*Test solution.* Place one tablet in a 25-ml volumetric flask, add 10 ml of 0.1 M methanolic sodium hydroxide and shake for about 30 minutes. Dilute to volume with 0.1 M methanolic sodium hydroxide. Dilute further, if necessary, with 0.1 M methanolic sodium hydroxide to produce a solution containing 0.0002 per cent w/v solution of Thyroxine Sodium.

*Reference solution.* A 0.0002 per cent w/v solution of levothyroxine sodium RS in 0.1 M methanolic sodium hydroxide.

Follow the procedure described under Assay.

Calculate the content of C₁₅H₁₀I₄NNaO₄ in the tablet.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Determine by liquid chromatography (2.4.14).

*Test solution.* Weigh accurately a quantity of the powdered tablets containing about 1000 µg of Thyroxine Sodium, transfer to a 100-ml volumetric flask and add 40 ml of 0.1 M methanolic sodium hydroxide. Shake for about 30 minutes, mix well and dilute to volume with the same solvent, mix well and filter.

*Reference solution.* A 0.001 per cent w/v solution of levothyroxine sodium RS in 0.1 M methanolic sodium hydroxide.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with a stationary phase consisting of porous silica particles (5 to 10 µm) to which nitrile groups are chemically bonded,
- mobile phase: a mixture of 65 volumes of water, 0.2 volume of orthophosphoric acid and 35 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 225 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution.

Calculate the content of C₁₅H₁₀I₄NNaO₄ in the tablets.

**Storage.** Store protected from light and moisture.

**Labelling.** The label states the strength in terms of the equivalent amount of anhydrous thyroxine sodium.

---

**Timolol Maleate**

C₁₃H₂₄N₄O₃S,C₄H₄O₄ Mol. Wt. 432.5

Timolol Maleate is (S)-1-tert-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-ol hydrogen maleate.

Timolol Maleate contains not less than 98.5 per cent and not more than 101.0 per cent of C₁₃H₂₄N₄O₃S,C₄H₄O₄, calculated on the dried basis.

**Description.** A white or almost white, crystalline powder or colourless crystals.

**Identification**

*Test A* may be omitted if tests *B* and *C* are carried out. Tests *B* and *C* may be omitted if test *A* is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with timolol maleate RS or with the reference spectrum of timolol maleate.

B. In the test for Related substances, after exposure to iodine vapour, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).

C. Triturate 0.1 g with a mixture of 1 ml of 2 M sodium hydroxide and 3 ml of water and shake with three quantities, each of 5 ml, of either. To 0.1 ml of the aqueous layer add a solution of 10 µg of resorcinol in 3 ml of sulphuric acid and heat on a water-bath for 15 minutes; no violet-red colour is produced. Neutralise the remainder of the aqueous layer with 1 M sulphuric acid, add 1 ml of bromine water, heat on a water-bath for 15 minutes, then heat to boiling and cool. To 0.2 ml of this solution add a solution of 10 µg of resorcinol in 3 ml of sulphuric acid and heat on a water-bath for 15 minutes; a violet-red colour is produced. Add 0.2 ml of a 10 per cent w/v solution of potassium bromide and heat on a water-bath for 5 minutes; the colour changes to violet-blue.

**Tests**

**Appearance of solution.** A 2.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and not more intensely coloured than reference solution BS8 (2.4.1).

**pH** (2.4.24). 3.8 to 4.3, determined in a 2.0 per cent w/v solution.

**Specific optical rotation** (2.4.22). −5.7º to −6.2º, determined in a 10.0 per cent w/v solution in M hydrochloric acid.
**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 80 volumes of dichloromethane, 20 volumes of methanol and 1 volume of strong ammonia solution.

**Test solution (a).** Dissolve 0.5 g of the substance under examination in 10 ml of methanol.

**Test solution (b).** Dissolve 0.1 g of the substance under examination in 100 ml of methanol.

**Reference solution (a).** A 0.02 per cent w/v solution of the substance under examination in methanol.

**Reference solution (b).** A 0.1 per cent w/v solution of timolol maleate RS in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm and then expose to iodine vapour for 2 hours and examine in daylight. By both methods of visualisation, any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.35 g, dissolve in 60 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.04325 g of C_{13}H_{24}N_{4}O_{3}S, C_{4}H_{4}O_{4}.

**Storage.** Store protected from light and moisture.

---

**Timolol Eye Drops**

Timolol Maleate Eye Drops

Timolol Eye Drops are a sterile solution of Timolol Maleate in Purified Water. They may contain suitable antimicrobial preservatives, buffering agents, stabilisers and suitable substances to increase the viscosity of the solution.

Timolol Eye Drops contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of timolol, C_{13}H_{24}N_{4}O_{3}S.

**Identification**

A. Add a volume containing 50 mg of timolol to an equal volume of carbonate buffer pH 9.7 and extract with two quantities, each of 40 ml, of dichloromethane. Reserve the aqueous layer for test B. Dry the combined dichloromethane extracts with anhydrous sodium sulphate and evaporate to dryness. Dry the residue at 60º at a pressure of 2 kPa for 15 minutes.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with timolol RS or with the reference spectrum of timolol.

B. Filter the aqueous layer reserved in test A and evaporate to about 1 ml. Add 1 ml of bromine solution, heat in a water-bath for 10 minutes, boil, cool and add 0.1 ml of the solution to a solution of 10 mg resorcinol in 3 ml of sulphuric acid; a bluish black colour is produced on heating in a water-bath for 15 minutes.

**Tests**

**pH** (2.4.24). 6.5 to 7.5.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Use the undiluted eye drops.

**Reference solution (a).** Dilute 1 volume of the eye drops to 250 volumes with the mobile phase.

**Reference solution (b).** Dilute 1 volume of the eye drops to 500 volumes with the mobile phase.

**Reference solution (c).** A 0.3 per cent w/v solution of maleic acid in the mobile phase.

**Chromatographic system**

- a stainless steel column 20 cm x 4 mm, packed with octadecylsilane bonded to porous silica (10 µm),
- mobile phase: a mixture of 57.5 volumes of methanol and 42.5 volumes of 0.02 M sodium octanesulphonate, adjusted to pH 3.0 with glacial acetic acid,
- flow rate. 2 ml per minute,
- spectrophotometer set at 295 nm,
- a 20 µl loop injector.

Record the chromatogram of the test solution for 4 times the retention time of the principal peak. In the chromatogram obtained with the test solution the area of any secondary peak, other than the peak corresponding to maleic acid, is not greater than the area of the peak in the chromatogram obtained with reference solution (a) and not more than two such peaks have an area greater than that of the peak obtained with reference solution (b).

**Other tests.** Comply with the tests stated under Eye Drops.

**Assay.** To a volume containing about 25 mg of timolol add water to produce 50.0 ml and mix. To 5.0 ml add 15 ml of...
carbonate buffer pH 9.7 and extract with three quantities, each of 20 ml, and one quantity of 10 ml of toluene. Wash each extract successively with the same 10-ml volume of carbonate buffer pH 9.7. Combine the toluene extracts and extract with four quantities, each of 20 ml, of 0.05 M sulphuric acid. Combine the extracts, dilute to 100.0 ml, filter and measure the absorbance of the filtrate at the maximum at about 295 nm (2.4.7), using as the blank a solution prepared by treating 5.0 ml of water in the same manner beginning at the words “add 15 ml of carbonate buffer pH 9.7...”.

Calculate the content of $C_{13}H_{24}N_4O_3S$ taking 279 as the specific absorbance at 295 nm.

Storage. Store protected from light and moisture.

Labelling. The label states (1) the strength in terms of the equivalent amount of timolol; (2) the names and concentration of any added antimicrobial preservatives.

Timolol Tablets

Timolol Maleate Tablets

Timolol Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of timolol maleate, $C_{13}H_{24}N_4O_3S$. $C_4H_4O_4$.

Identification

A. To a quantity of the powdered tablets containing 70 mg of Timolol Maleate add 20 ml of carbonate buffer pH 9.7 and extract with two quantities, each of 40 ml, of dichloromethane. Reserve the aqueous layer for test B. Dry the extracts with anhydrous sodium sulphate, evaporate to dryness using a rotary evaporator, dry the residue at 60º at a pressure of 2 kPa for 15 minutes.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with timolol RS or with the reference spectrum of timolol.

B. Filter the aqueous layer reserved in test A and evaporate to about 1 ml. Add 1 ml of bromine water, heat on a water-bath for 15 minutes, then heat to boiling and cool. Add 0.1 ml of this solution to a solution of 10 mg of resorcinol in 3 ml of sulphuric acid and heat on a water-bath for 15 minutes; a bluish black colour is produced.

Tests

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Shake a quantity of the powdered tablets containing 0.1 g of Timolol Maleate with 10 ml of the mobile phase for 10 minutes and filter.

Reference solution (a). Dilute 1 volume of the test solution to 250 volumes with the mobile phase.

Reference solution (b). Dilute 1 volume of the test solution to 500 volumes with the mobile phase.

Chromatographic system

- a stainless steel column 20 cm x 4 mm, packed with octadecylsilane bonded to porous silica (10 µm),
- mobile phase: a mixture of 57.5 volumes of methanol and 42.5 volumes of 0.02 M sodium octanesulphonate, adjusted to pH 3.0 with glacial acetic acid,
- flow rate. 2 ml per minute,
- spectrophotometer set at 295 nm,
- a 20 µl loop injector.

Record the chromatogram of the test solution for 4 times the retention time of the principal peak. In the chromatogram obtained with the test solution the area of any secondary peak, other than the peak corresponding to maleic acid, is not greater than the area of the peak in the chromatogram obtained with reference solution (a) and not more than two such peaks have an area greater than that of the peak obtained with reference solution (b).

Uniformity of content. Comply with the test stated under Tablets.

To one tablet add 25.0 ml of 0.05 M sulphuric acid, shake for 20 minutes and complete the Assay beginning at the words “and centrifuge...”.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 15 mg of Timolol Maleate, add 25.0 ml of 0.05 M sulphuric acid, shake for 20 minutes and centrifuge until clear. Add 5.0 ml of the resulting supernatant liquid to 15 ml of carbonate buffer pH 9.7 and extract with three quantities, each of 20 ml, and one quantity of 10 ml of toluene. Wash each extract successively with the same 10-ml volume of carbonate buffer pH 9.7, combine the toluene extracts and extract with four quantities, each of 20 ml, of 0.05 M sulphuric acid. Combine the acid extracts, dilute to 100.0 ml, filter and measure the absorbance of the filtrate at the maximum at about 295 nm (2.4.7), using as the blank a solution prepared by treating a mixture of 5 ml of water and 15 ml of carbonate buffer pH 9.7 in the same manner beginning at the words “and extract with three quantities....”

Calculate the content of $C_{13}H_{24}N_4O_3S$. $C_4H_4O_4$ taking 204 as the specific absorbance at 295 nm.

Storage. Store protected from moisture.
Tinidazole

\[
\begin{align*}
\text{NO}_2 & \quad \text{O} \quad \text{S} \\
\text{CH}_3 & \quad \text{CH}_3 \\
\text{N} & \quad \text{N} \\
\text{C}_8\text{H}_{13}\text{N}_3\text{O}_4\text{S} & \quad \text{Mol. Wt. 247.3}
\end{align*}
\]

Tinidazole is 1-[2-(ethylsulphonyl)ethyl]-2-methyl-5-nitroimidazole.

Tinidazole contains not less than 98.0 per cent and not more than 100.5 per cent of C\textsubscript{8}H\textsubscript{13}N\textsubscript{3}O\textsubscript{4}S, calculated on the dried basis.

**Description.** Pale yellow crystals or a crystalline powder; odour, slight and characteristic.

**Identification**

*Test A* may be omitted if tests *B* and *C* are carried out. Tests *B* and *C* may be omitted if test *A* is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with *tinidazole RS* or with the reference spectrum of *tinidazole*.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in *methanol* shows an absorption maximum at about 310 nm; absorbance at about 310 nm, about 0.35.

C. To about 5 mg add 5 ml of *0.1 M hydrochloric acid*, 50 mg of *zinc powder*, 4 ml of *hydrochloric acid* and allow to stand for 30 minutes. Add 4 ml of a 1 per cent w/v solution of *vanillin*, heat on a boiling water-bath for 20 minutes, allow to cool to room temperature and dilute to 20 ml with *water*; a greenish yellow colour is produced.

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel GF254*.

*Mobile phase.* A mixture of 95 volumes of *ethyl acetate*, 5 volumes of *methanol* and 5 volumes of *diethylamine*.

*Test solution.* Dissolve 0.2 g of the substance under examination in 10 ml of a mixture of equal volumes of *chloroform* and *methanol*.

*Reference solution.* A 0.02 per cent w/v solution of the substance under examination in a mixture of equal volumes of *chloroform* and *methanol*.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Sulphated ash** (2.3.18). Not more than 0.2 per cent.

**Loss on drying** (2.4.19). Not more than 2.0 per cent, determined on 1.0 g by drying in an oven at 105º for 4 hours.

**Assay.** Weigh accurately about 0.5 g, dissolve in 30 ml of *anhydrous glacial acetic acid*. Titrate with 0.1 M *perchloric acid*, using 0.15 ml of *nile blue A solution* as indicator. Carry out a blank titration.

1 ml of 0.1 M *perchloric acid* is equivalent to 0.02473 g of C\textsubscript{8}H\textsubscript{13}N\textsubscript{3}O\textsubscript{4}S.

**Storage.** Store protected from light and moisture.

**Tinidazole Tablets**

Tinidazole Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of tinidazole, C\textsubscript{8}H\textsubscript{13}N\textsubscript{3}O\textsubscript{4}S. The tablets may be coated.

**Identification**

A. When examined in the range 230 nm to 360 nm (2.4.7), the final solution obtained in the Assay shows an absorption maximum at about 310 nm.

Extract a quantity of the powdered tablets containing 0.1 g of Tinidazole with 10 ml of *methanol*, filter and evaporate the filtrate to dryness. The residue complies with the following tests.

B. To about 5 mg add 5 ml of *0.1 M hydrochloric acid*, 50 mg of *zinc powder*, 4 ml of *hydrochloric acid* and allow to stand for 30 minutes. Add 4 ml of a 1 per cent w/v solution of *vanillin*, heat on a boiling water-bath for 20 minutes, allow to cool to room temperature and dilute to 20 ml with *water*; a greenish yellow colour is produced.

C. Melting range (2.4.21). 125º to 128º.

**Tests**

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.15 g of Tinidazole, add 20 ml of *methanol*, shake well and add sufficient *methanol* to produce 100.0 ml. Mix well and filter. Dilute 10.0 ml of the solution to 100.0 ml with *methanol* and further dilute 10.0 ml of this solution to 100.0 ml with *methanol*. Measure the absorbance of the resulting solution at the maximum at about 310 nm (2.4.7).

Calculate the content of C\textsubscript{8}H\textsubscript{13}N\textsubscript{3}O\textsubscript{4}S taking 356 as the specific absorbance at 310 nm.
Storage. Store protected from light and moisture.

Titanium Dioxide

\[ \text{TiO}_2 \quad \text{Mol. Wt. 79.9} \]

Titanium Dioxide contains not less than 98.0 per cent and not more than 100.5 per cent of TiO₂.

Description. A white or almost white, infusible powder; odourless.

Identification

A. When strongly heated it becomes pale yellow; the colour is discharged on cooling.

B. To 0.5 g add 5 g of anhydrous sodium sulphate and 10 ml of water and mix. Add 10 ml of sulphuric acid and boil gently until clear; cool, add slowly 30 ml of a 25 per cent v/v solution of sulphuric acid and dilute with water to 100 ml (solution A). To 5 ml of solution A add 0.1 ml of strong hydrogen peroxide solution; an orange-red colour is produced.

C. To 5 ml of solution A add 0.5 g of zinc, in granules; after 45 minutes a violet-blue colour is produced.

Tests

Appearance of solution. Solution A is not more opalescent than opalescence standard OS2 (2.4.1), and colourless (2.4.1).

Acidity or alkalinity. Shake 5.0 g with 50 ml of carbon dioxide-free water for 5 minutes and centrifuge until a clear solution is obtained. To 10 ml of the solution add 0.1 ml of bromothymol blue solution. Not more than 1.0 ml of either 0.01 M hydrochloric acid or 0.01 M sodium hydroxide is required to change the colour of the solution.

Water-soluble substances. Not more than 0.5 per cent, determined by the following method. Boil 10.0 g for 5 minutes with 150 ml of water containing 0.5 g of ammonium sulphate. Cool, dilute to 200 ml with water and filter until a clear solution is obtained. Evaporate 100 ml of the filtrate to dryness ignite and weigh.

Arsenic (2.3.10). To 0.2 g in a 100-ml Kjeldahl flask add 2 g of anhydrous sodium sulphate, 7 ml of sulphuric acid and 5 ml of nitric acid. Heat gently until a clear solution is obtained, cool, add 10 ml of water, cool again and add 5 g of hydrazine reducing mixture and 10 ml of hydrochloric acid. Immediately attach an air condenser and distill into 15 ml of cooled water until a total volume of 30 ml is obtained. Rinse the condenser with 5 ml of water and dilute the combined distillate and rinsings to 40 ml with water. 20 ml of the resulting solution complies with the limit test for arsenic. Use a mixture of 0.5 ml of arsenic standard solution (1 ppm As) and 24.5 ml of water to prepare the standard (5 ppm).

Barium. Shake 20.0 g with 30 ml of hydrochloric acid, add 100 ml of distilled water and boil. Filter while hot through a hardened filter paper until a clear filtrate is obtained. Wash the filter with 60 ml of distilled water and dilute the combined filtrate and washings to 200 ml with distilled water. To 10 ml of this solution add 1 ml of 1 M sulphuric acid. After 30 minutes any opalescence is not more intense than that of a mixture of 10 ml of the test solution and 1 ml of distilled water.

Heavy metals (2.3.13). Dilute 10 ml of the solution prepared in the test for Barium to 20 ml with water. 12 ml of the solution complies with the limit test for heavy metals, Method D (20 ppm).

Iron. To 8 ml of solution A add 4 ml of water, mix and add 0.05 ml of bromine water, allow to stand for 5 minutes, remove the excess of bromine with a current of air and add 3 ml of potassium thiocyanate solution. Any colour in the solution is not more intense than that in a standard prepared at the same time and in the same manner using a mixture of 4 ml of iron standard solution (2 ppm Fe) and 8 ml of a 20 per cent w/v solution of sulphuric acid (200 ppm).

Assay. Weigh accurately about 0.5 g, transfer to a 300-ml Kjeldahl flask, add 5 g of anhydrous sodium sulphate and 10 ml of water, mix and add 10 ml of sulphuric acid. Boil gently until clear, cool, add slowly 40 ml of cooled sulphuric acid (25 per cent), cool again and dilute with water to 100.0 ml (solution B). To 300 g of zinc, in granules, add 300 ml of a 2 per cent w/v solution of mercuric nitrate and 2 ml of nitric acid, shake for 10 minutes and wash with water. Pack the zinc amalgam into a glass tube (400 mm x 20 mm) fitted with a tap and a filter plate. Pass through the column, at a rate of about 3 ml per minute, 100 ml of 1 M sulphuric acid followed by 100 ml of water, ensuring that the amalgam is covered with liquid throughout. Pass slowly through the column, at a rate of about 3 ml per minute, 200 ml of 0.5 M sulphuric acid followed by 100 ml of water. Collect the combined eluates in a 500-ml conical flask containing 50 ml of a 15 per cent w/v solution of ferric ammonium sulphate in sulphuric acid (25 per cent) and titrate immediately with 0.1 M ceric ammonium nitrate using ferroin solution as indicator until a greenish colour is obtained (n₁ ml). Pass slowly through the column 100 ml of 0.5 M sulphuric acid followed by 20.0 ml of solution B, wash with 100 ml of 0.5 M sulphuric acid followed by 100 ml of water. Collect the combined eluates in a 500-ml conical flask containing 50 ml of a 15 per cent w/v solution of ferric ammonium sulphate in sulphuric acid (25 per cent), rinse the lower end of the column with water and titrate immediately with 0.1 M ceric ammonium nitrate using ferroin solution as indicator until a greenish colour is obtained (n₂ ml). Calculate the percentage content of TiO₂ from the expression 3.99(n₂ - n₁)/w

Where, w is the weight, in g, of the substance under examination used in the preparation of solution A.
Storage. Store protected from moisture. Avoid contact with aluminium.

Tiotropium Bromide Monohydrate

\[
\text{C}_{19}\text{H}_{22}\text{BrNO}_{4}\text{S}_{2}, \text{HCl}
\]

Mol. Wt. 508.9

Tiotropium Bromide Monohydrochloride is \(6\beta,7\beta\)-epoxy-8-hydroxy-3\(\beta\)-methyl-1\(\alpha\)H-5\(\alpha\)H-tropanium bromide hydrochloride.

Tiotropium Bromide Monohydrate contains not less than 98.0 per cent and not more than 102.0 per cent of tiotropium bromide, \(\text{C}_{19}\text{H}_{22}\text{NO}_{4}\text{S}_{2}\text{Br}\), calculated on the anhydrous basis.

Description. A white to off-white powder.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tiotropium bromide monohydrate \(RS\) or with the reference spectrum of tiotropium bromide monohydrate.

B. In the Assay, the principal peak in the chromatogram obtained with test solution corresponds to the principal peak in the chromatogram obtained with the reference solution.

Tests

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 10 mg of the substance under examination in 100 ml of the mobile phase.

Reference solution. A 0.002 per cent w/v solution of tiotropium bromide monohydrate \(RS\) in the mobile phase.

Chromatographic system

- a stainless steel column 25 cm \(\times\) 4.6 mm, packed with octadecylsilane bonded to porous silica (5 \(\mu\)m),
- mobile phase: a mixture of 45 volumes of methanol and 55 volumes of a buffer solution prepared by dissolving 3.85 g of ammonium acetate in 1000 ml of water and adjusting the pH to 5.5 with dilute acetic acid (10 per cent v/v),
- flow rate, 1 ml per minute,
- spectrophotometer set at 235 nm,
- a 20 \(\mu\)l loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency is not less than 3000 theoretical plates.

Inject the test solution. Any individual impurity is not more than 0.5 per cent and the sum of all the impurities is not more than 1.0 per cent.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Sulphated ash (2.3.18). Not more than 0.3 per cent.

Water (2.3.43). 3.5 to 4.5 per cent, determined on 0.5 g.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 20 mg of the substance under examination in 100.0 ml of the mobile phase. Dilute 5.0 ml of the resulting solution to 50.0 ml with the mobile phase.

Reference solution. A 0.002 per cent w/v solution of tiotropium bromide monohydrate \(RS\) in the mobile phase.

Chromatographic system

- a stainless steel column 25 cm \(\times\) 4.6 mm, packed with octadecylsilane bonded to porous silica (5 \(\mu\)m),
- mobile phase: a mixture of 45 volumes of methanol and 55 volumes of a buffer solution prepared by dissolving 3.85 g of ammonium acetate in 1000 ml of water and adjusting the pH to 5.5 with dilute acetic acid (10 per cent v/v),
- flow rate, 1 ml per minute,
- spectrophotometer set at 235 nm,
- a 20 \(\mu\)l loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0, the column efficiency is not less than 3000 theoretical plates and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution. Calculate the content of \(\text{C}_{19}\text{H}_{22}\text{NO}_{4}\text{S}_{2}\text{Br}\).

Storage. Store protected from light and moisture.

Tiotropium Powder for Inhalation

Tiotropium Powder for Inhalation consists of Tiotropium Bromide in microfine powder either alone or admixed with Lactose in a pre-metered unit for use in a suitable powder inhaler.
Tiotropium Powder for Inhalation contains not less than 90.0 per cent and not more than 125.0 per cent of the stated amount of tiotropium, \( \text{C}_{19}\text{H}_{22}\text{NO}_{4}\text{S}_{2} \) per unit dose.

**Identification**

In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Other tests.** Complies with the tests stated under Inhalation Preparations (Powders for Inhalation).

Follow the procedure described under Assay with suitable dilution of the reference solution wherever the amount of active substance is to be determined in any test.

**Assay.**

Determine by liquid chromatography (2.4.14).

*Solvent mixture.* 90 volumes of 0.05 per cent \( \text{v/v} \) orthophosphoric acid and 10 volumes of acetonitrile.

*Test solution.* To 10 intact capsules add about 70 ml of the solvent mixture and disperse with the aid of ultrasound for about 5 minutes with intermittent shaking. Add sufficient of the solvent mixture to produce 100.0 ml and dilute suitably, if required, to get a solution containing 1.8 \( \mu \text{g} \) per ml of Tiotropium per ml.

*Reference solution.* A solution containing 1.8 \( \mu \text{g} \) per ml of tiotropium bromide RS per ml in the solvent mixture.

Chromatographic system
- a stainless steel column 15 cm x 4.6 mm, packed with octadecylsililica gel (5 mm),
- mobile phase: a mixture of 80 volumes of a buffer solution prepared by dissolving 2 ml triethylamine in 1000 ml of water and adjusting the pH to 2.5 with orthophosphoric acid, and 20 volumes of acetonitrile,
- flow rate, 2 ml per minute,
- spectrophotometer set at 237 nm,
- inject 200 \( \mu \text{l} \).

Inject the reference solution. The test is not valid unless the column efficiency is not less than 4500 theoretical plates, the tailing factor is not more than 1.7 and the relative standard deviation for replicate injections is not more than 2.0 per cent. Inject the test solution and the reference solution.

Calculate the content of \( \text{C}_{19}\text{H}_{22}\text{NO}_{4}\text{S}_{2} \) per unit.

**Storage.** Store protected from moisture, at temperature not exceeding 30º.

**Labelling.** The label states the quantity of active ingredient per pre-metered unit.

---

Tizanidine Hydrochloride

\[
\text{C}_9\text{H}_8\text{ClN}_5\text{S.HCl} \quad \text{Mol. Wt. 290.2}
\]

Tizanidine Hydrochloride is 5-chloro-\( \text{N}-(2\text{-imidazolin-2-yl})-2,1,3\text{-benzothiadiazol-4-yl-amine} \).

Tizanidine Hydrochloride contains not less than 98.0 per cent and not more than 102.0 per cent of \( \text{C}_9\text{H}_8\text{ClN}_5\text{S.HCl} \), calculated on the dried basis.

**Description.** A white to yellowish white, crystalline powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tizanidine hydrochloride RS.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

C. Gives reaction A for chlorides (2.3.1).

**Tests**

**pH** (2.4.24). 3.5 to 5.3, determined on 5.0 per cent w/v solution in water.

**Related substances.** Determine by liquid chromatography (2.4.14).

*Test solution.* Dissolve 50 mg of the substance under examination in 50.0 ml of the mobile phase.

*Reference solution (a).* A 0.1 per cent w/v solution of tizanidine hydrochloride RS in the mobile phase.

*Reference solution (b).* Dilute 1 ml of reference solution (a) to 100 ml with mobile phase.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadeclisilane bonded to porous silica (5 \( \mu \text{m} \)),
- column temperature 50º,
- mobile phase: a mixture of 80 volumes of a buffer solution prepared by dissolving 3.5 g of sodium-1-pentane sulphonate in 1000 ml of water, adjust the pH to 3.0 with 12 per cent orthophosphoric acid solution or \( 1 \text{ M sodium hydroxide} \) and 20 volumes of acetonitrile,
flow rate. 1 ml per minute,
spectrophotometer set at 230 nm,
a 10 µl loop injector.

Inject reference solution (a). The test is not valid unless the tailing factor is not more than 2.0 and the column efficiency in not less than 5000 theoretical plates.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 0.5 times the area of the peak in the chromatogram obtained with reference solution (b) (0.5 per cent) and the sum of areas of all the secondary peaks is not more than the area of the peak in the chromatogram obtained with the reference solution (b) (1.0 per cent).

Heavy metals (2.3.13). Dissolve 1.0 g in 20 ml of water. 12 ml of this solution complies with limit test for heavy metals, Method D (20 ppm).

Total Chloride. 11.9 per cent to 12.5 per cent.
Weigh accurately about 0.5 g and dissolve in 50 ml of water. Titrate with 0.1 M silver nitrate. Determine the end point potentiometrically (2.4.25). Carry out a blank titration.
1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of chloride.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1 g by drying in an oven at 105° for 3 hours.

Assay. Determine by liquid chromatography (2.4.14).
Test solution. Dissolve 25 mg of the substance under examination in 50.0 ml of the mobile phase. Dilute 10.0 ml of the solution to 50.0 ml with the same solvent.

Reference solution. A 0.01 per cent w/v solution of tizanidine hydrochloride RS in the mobile phase.

Chromatographic system
- a stainless steel column 15 cm x 4.6 mm packed with octylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 50 volumes of a buffer solution prepared by dissolving 6.8 g of monobasic potassium phosphate in 1000 ml of water adjusting the pH to 7.5 with 5.3 M potassium hydroxide, and 50 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 230 nm,
- a 10 µl loop injector.

Inject the reference solution. The test is not valid unless the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.
Calculate the content of C₉H₈ClN₅S.HCl.

Storage. Store protected from light.

Tizanidine Tablets
Tizanidine Hydrochloride Tablets
Tizanidine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of tizanidine, C₉H₈ClN₅S.

Identification
In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

Tests
Dissolution (2.5.2).
Apparatus. No 1
Medium: 900 ml of 0.1 M hydrochloric acid.
Speed and time. 50 rpm for 45 minutes.
Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate, suitably diluted with dissolution medium if necessary, at the maximum at about 320 nm (2.4.7). Calculate the content of C₉H₈ClN₅S in the medium from the absorbance obtained from a solution of known concentration of tizanidine Hydrochloride RS in the same medium.

D. Not less than 70 per cent of the stated amount of C₉H₈ClN₅S.

Uniformity of content. Comply with the tests stated under Tablets.

Determine by liquid chromatography (2.4.14), as described under Assay.
Test solution. Crush one tablet and disperse in 50 ml phosphate buffer pH 6.6, dilute to 100.0 ml with acetonitrile and filter.

Calculate the content of C₉H₈ClN₅S.

Other tests. Comply with the tests stated under Tablets.
Assay. Determine by liquid chromatography (2.4.14).
Test solution. Weigh and powder 20 tablets. Weigh accurately a quantity of the powdered tablet containing about 20 mg of Tizanidine, disperse in 50 ml phosphate buffer pH 6.6 and dilute to 100.0 ml with acetonitrile and filter.

Reference solution. Weigh accurately 10 mg of tizanidine hydrochloride RS, dissolve in 25 ml phosphate buffer pH 6.6 and dilute to 50.0 ml with acetonitrile.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
mobile phase: a mixture of 80 volumes of phosphate buffer pH 6.6 and 20 volumes of acetonitrile,
flow rate. 1 ml per minute,
spectrophotometer set at 320 nm,
a 20 µl loop Injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C₉H₈ClN₅S.

Storage. Store protected from light and moisture.

Labelling. The label states the strength in terms of the equivalent amount of Tizanidine.

Tobramycin

Tobramycin is 6-O-(3-amino-3-deoxy-α-D-glucopyranosyl)-2-deoxy-4-O-(2,6-diamino-2,3,6-trideoxy-α-D-ribo-hexopyranosyl)-D-streptamine, an antimicrobial substance produced by Streptomyces tenebrarius or by any other means.

Tobramycin has potency not less than 930 Units per mg, calculated on the anhydrous and 2-methyl-1-propanol-free basis.

Description. A white or almost white powder.

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H.

Mobile phase. A mixture of 60 volumes of methanol, 40 volumes of strong ammonia solution and 20 volumes of chloroform.

Test solution. Dissolve 0.4 g of the substance under examination in 100 ml of water.

Reference solution (a). A 0.4 per cent w/v solution of tobramycin RS in water.

Reference solution (b). A solution containing 0.4 per cent w/v each of kanamycin sulphate RS, neomycin sulphate RS and tobramycin RS in water.

Apply to the plate 5 µl of each solution. After development, dry the plate in warm air, spray with a mixture of equal volumes of a 46 per cent w/v solution of sulphuric acid and a 0.2 per cent w/v solution of 1,3-naphthalenediol in ethanol (95 per cent) and heat at 105º for 10 minutes. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated principal spots.

B. Dissolve about 5 mg in 5 ml of water, add 5 ml of a 0.1 per cent w/v solution of ninhydrin in ethanol (95 per cent) and heat in a water-bath for 3 minutes; a violet-blue colour develops.

Tests

pH (2.4.24). 9.0 to 11.0, determined in a 10.0 per cent w/v solution.

Specific optical rotation (2.4.22). +138º to +148º, determined in a 4.0 per cent w/v solution.

2-Methyl-1-propanol. Not more than 1.0 per cent w/w, determined by gas chromatography (2.4.13).

Test solution (a). A 10 per cent w/v solution of the substance under examination in water.

Test solution (b). A solution containing 10 per cent w/v of the substance under examination and 0.2 per cent v/v of 2-propanol (internal standard).

Reference solution. A solution containing 0.1 per cent w/v of 2-methyl-1-propanol and 0.2 per cent v/v of the internal standard.

Chromatographic system

- a glass column 1.5 m x 4 mm, packed with porous polymer beads (80 to 100 mesh) (such as Porapak Q),
- temperature. column 165º,

Calculate the percentage w/w of 2-methyl-1-propanol.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H.

Mobile phase. A mixture of equal volumes of strong ammonia solution, 2-butanone and ethanol (95 per cent).
Test solution. Dissolve 0.8 g of the substance under examination in 100 ml of 0.02 M ammonia.

Reference solution. A 0.008 per cent w/v solution of the substance under examination in 0.02 M ammonia.

Apply to the plate 5 µl of each solution. After development, dry the plate in warm air, heat at 110º for 10 minutes and spray the hot plate with a solution prepared immediately before use by diluting sodium hypochlorite solution (3 per cent Cl) with water to contain 0.5 per cent w/v of available chlorine.

Dry in a current of cold air until a sprayed area of the plate below the line of application gives at most a very faint blue colour with a drop of potassium iodide and starch solution; avoid prolonged exposure to cold air. Spray the plate with potassium iodide and starch solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Sulphated ash (2.3.18). Not more than 0.3 per cent.

Water (2.3.43). Not more than 8.0 per cent, determined on 0.3 g.

Assay. Determine by the microbiological assay of antibiotics, Method B (2.2.10).

Tobramycin intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins complies with the following additional requirement.

Bacterial endotoxins (2.2.3). Not more than 2.0 Endotoxin Units per mg of tobramycin.

Tobramycin intended for use in the manufacture of parenteral preparations or eye drops without a further appropriate sterilisation procedure complies with the following additional requirements.

Sterility (2.2.11). Complies with the test for sterility.

Storage. Store protected from moisture. If the material is sterile, the container should be sterile, tamper-evident and sealed so as to exclude micro-organisms.

Labelling. The label states (1) the number of Units per mg; (2) where applicable, that it is sterile; (3) where applicable, that it is free from bacterial endotoxins and depressor substances.

Tobramycin Injection contains not less than 90.0 per cent and not more than 120.0 per cent of the stated amount of tobramycin, C18H37N5O9.

Description. A colourless solution.

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H.

Mobile phase. A mixture of 60 volumes of methanol, 40 volumes of strong ammonia solution and 20 volumes of chloroform.

Test solution. Dilute a suitable volume of the injection with water to produce a solution containing 0.4 per cent w/v solution of tobramycin.

Reference solution (a). A 0.4 per cent w/v solution of tobramycin RS in water.

Reference solution (b). A solution containing 0.4 per cent w/v each of kanamycin sulphate RS, neomycin sulphate RS and tobramycin RS in water.

Apply to the plate 5 µl of each solution. After development, dry the plate in warm air, spray with a mixture of equal volumes of a 46 per cent w/v solution of sulphuric acid and a 0.2 per cent w/v solution of 1,3-naphthalenediol in ethanol (95 per cent) and heat at 105º for 10 minutes. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated principal spots.

B. Gives the reactions of sulphates (2.3.1).

Tests

pH (2.4.24). 3.5 to 6.0.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H.

Mobile phase. A mixture of equal volumes of strong ammonia solution, 2-butanol and ethanol (95 per cent).

Test solution. Dilute a suitable volume of the injection with 0.01 M ammonia to obtain a solution containing 40 mg of Tobramycin in 4 ml. Shake with 10 ml of ether and use the aqueous layer.

Reference solution. A 0.008 per cent w/v solution of the substance under examination in 0.02 M ammonia.

Apply to the plate 5 µl of each solution. After development, dry the plate in warm air, heat at 110º for 10 minutes and spray the hot plate with a solution prepared immediately before use by diluting sodium hypochlorite solution (3 per cent Cl)
with water to contain 0.5 per cent w/v of available chlorine. Dry in a current of cold air until a sprayed area of the plate below the line of application gives at most a very faint blue colour with a drop of potassium iodide and starch solution; avoid prolonged exposure to cold air. Spray the plate with potassium iodide and starch solution. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Bacterial endotoxins** (2.2.3). Not more than 2.0 Endotoxin Units per mg of tobramycin.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Determine by the microbiological assay of antibiotics, Method B (2.2.10).

Calculate the content of tobramycin in the injection, taking each 1000 Units found to be equivalent to 1 mg of tobramycin.

The upper fiducial limits of error is not less than 97.0 per cent and not more than 110.0 per cent of the stated potency.

**Tocopheryl Acetate**

α-Tocopheryl Acetate; α-Tocopherol Acetate; Vitamin E Acetate

![Tocopheryl Acetate structure](image)

C_{31}H_{52}O_{3}  \quad \text{Mol. Wt. 472.8}

Tocopheryl Acetate is (2RS,4'SS,8'RS)-6-acetoxy-2,5,7,8-tetramethyl-2-(4',8',12'-trimethyltridecyl)chroman (all-rac-α-tocopherol acetate).

Tocopheryl Acetate contains not less than 96.0 per cent and not more than 102.0 per cent of C_{31}H_{52}O_{3}.

**Description.** A clear, slightly greenish yellow, viscous, oily liquid.

**Identification**

*Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with a-tocopheryl acetate RS.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.01 per cent w/v solution in ethanol exhibits a maximum at about 284 nm, a shoulder at about 278 nm and a minimum at about 254 nm.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

**Mobile phase.** A mixture of 80 volumes of cyclohexane and 20 volumes of ether.

**Test solution (a).** Dissolve 0.5 g of the substance under examination in 100 ml of cyclohexane.

**Test solution (b).** Dissolve 10 mg of the substance under examination in 2 ml of 5 M ethanolic sulphuric acid, heat on a water-bath for 5 minutes, cool, add 2 ml of water and 2 ml of cyclohexane and shake for 1 minute; use the upper layer.

**Reference solution (a).** A 0.5 per cent w/v solution of a-tocopheryl acetate RS in cyclohexane.

**Reference solution (b).** Prepare in the same manner as test solution (b) but using 10 mg of a-tocopheryl acetate RS in place of the substance under examination.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with test solution (a) corresponds to that in the chromatogram obtained with reference solution (a). There are two spots in each of the chromatograms obtained with test solution (b) and reference solution (b). The spots of higher Rf value are due to a-tocopheryl acetate and correspond to that in the chromatogram obtained with reference solution (a). The spots of lower Rf value are due to a-tocopheryl. Spray the plate with a mixture of 1 volume of hydrochloric acid, 4 volumes of a 0.25 per cent w/v solution of ferric chloride in ethanol (95 per cent) and 4 volumes of a 1.0 per cent w/v solution of 1,10-phenanthroline hydrochloride in ethanol (95 per cent). In the chromatograms obtained with test solution (b) and reference solution (b) the spot of lower Rf value a-tocopheryl is orange.

**Tests**

**Refractive index** (2.4.27). 1.494 to 1.498, determined at 20º.

**Acid value** (2.3.23). Not more than 2.0, determined on 2.0 g.

**Free tocopherol.** Not more than 2.0 per cent, determined by the following method. Weigh accurately about 0.5 g, dissolve in 100 ml of 0.25 M ethanolic sulphuric acid, add 20 ml of water and 0.1 ml of a 0.25 per cent w/v solution of diphenylamine in sulphuric acid and titrate with 0.01 M ceric ammonium nitrate until a blue colour is produced that persists for at least 5 seconds. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of ceric ammonium nitrate required.
1 ml of 0.01 M ceric ammonium nitrate is equivalent to 0.002154 g of tocopherol.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Assay. Weigh accurately about 0.3 g, dissolve in 25 ml of ethanol (95 per cent), add 20 ml of 2.5 M ethanolic sulphuric acid and heat on a water-bath under a reflux condenser for 3 hours. Cool, transfer the solution quantitatively to a 200-ml volumetric flask, rinse the apparatus with ethanol (95 per cent) and add the rinsings to the flask. Make up to volume with ethanol (95 per cent) and mix. To 25.0 ml of the resulting solution in a flask add 25 ml of 0.25 M ethanolic sulphuric acid, 10 ml of water and titrate with 0.01 M ceric ammonium nitrate using 0.1 ml of diphenylamine as indicator, until a blue colour persisting for at least 5 seconds is obtained. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of ceric ammonium nitrate required.

1 ml of 0.01 M ceric ammonium nitrate is equivalent to 0.002364 g of C_{12}H_{18}N_{2}O_{3}S.

Storage. Store protected from light and moisture.

Tolbutamide

C_{12}H_{18}N_{2}O_{3}S  Mol. Wt. 270.4

Tolbutamide is 3-butyl-1-[(4-methylphenyl)sulphonyl]urea.

Tolbutamide contains not less than 99.0 per cent and not more than 101.0 per cent of C_{12}H_{18}N_{2}O_{3}S, calculated on the dried basis.

Description. A white, crystalline powder; almost odourless.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tolbutamide RS or with the reference spectrum of tolbutamide.

B. Dissolve 25 mg in sufficient methanol to produce 100.0 ml. When examined in the range 245 nm to 360 nm (2.4.7), the resulting solution shows absorption maxima at about 258 nm, 263 nm and 275 nm and a shoulder at about 268 nm. Dilute the solution with methanol to produce a 0.001 per cent w/v solution. When examined in the range 220 nm to 235 nm, the resulting solution shows an absorption maximum at about 228 nm; absorbance at about 228 nm, about 0.50.

C. Boil 0.1 g with 8 ml of a 50 per cent v/v solution of sulphuric acid under a reflux condenser for 30 minutes. Make the solution strongly alkaline with sodium hydroxide solution and steam distil for 30 minutes, receiving the distillate in 20 ml of 0.1 M hydrochloric acid. To 1 ml of the solution containing the distillate add 0.1 g of sodium acetate and 10 ml of buffer solution pH 9.4. Cool in an ice-bath for 10 minutes, add 1 ml of diazotised nitroaniline solution, set aside for 20 minutes and add dropwise 1 ml of sodium hydroxide solution; an orange-red colour is produced.

D. Boil 0.1 g with 8 ml of a 50 per cent v/v solution of sulphuric acid under a reflux condenser for 30 minutes. Cool in an ice-bath; a crystalline precipitate of 4-toluenesulphonylamide is formed, which after recrystallisation from hot water and drying at 105º melts at 135º to 140º (2.4.21).

Tests

Appearance of solution. A 2.0 per cent w/v solution in 1 M sodium hydroxide is clear (2.4.1), and colourless (2.4.1).

pH (2.4.24). 4.5 to 5.5, determined in a solution prepared by dissolving 2.0 g in 50 ml of carbon dioxide-free water by heating at 70º for 5 minutes, cooling rapidly and filtering.

Non-sulphonyl urea. Dissolve 0.5 g in 1 ml of dilute ammonia solution and 9 ml of water; not more than a faint opalescence is produced.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 90 volumes of chloroform, 8 volumes of methanol and 2 volumes of anhydrous formic acid.

Test solution. Dissolve 0.5 g of the substance under examination in 10 ml of acetone.

Reference solution (a). A 0.015 per cent w/v solution of 4-toluenesulphonylamide in acetone.

Reference solution (b). A mixture of equal volumes of the test solution and reference solution (a).

Apply to the plate 5 µl of each of test solution and reference solution (a) and 10 µl of reference solution (b). After development, dry the plate in a current of warm air and heat at 110º for 10 minutes. While still hot, place the plate in a chromatographic tank with an evaporating dish containing a 5 per cent w/v solution of potassium permanganate, add an equal volume of hydrochloric acid and close the tank. Leave the plate in the tank for 2 minutes, then place it in a current of
cold air until the excess of chlorine is removed and an area of coating below the line of application gives only a very faint blue colour with potassium iodide and starch solution; avoid prolonged exposure to cold air. Spray the plate with potassium iodide and starch solution and allow to stand for 5 minutes. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a). The chromatogram obtained with reference solution (b) shows two clearly separated spots.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º for 3 hours.

**Assay.** Weigh accurately about 0.5 g and dissolve in a mixture of 40 ml of ethanol (95 per cent) and 20 ml of water. Titrate with 0.1 M sodium hydroxide using phenolphthalein solution as indicator.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.02704 g of C12H18N2O3S.

**Storage.** Store protected from moisture.

## Tolbutamide Tablets

Tolbutamide Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of tolbutamide, C12H18N2O3S.

### Identification

Extract a quantity of the powdered tablets containing 1 g of Tolbutamide with 10 ml of chloroform, filter, evaporate the filtrate to dryness, scratching the sides of the vessel, if necessary, to induce crystallisation, and dry the residue at 105º for 30 minutes. The residue complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tolbutamide RS or with the reference spectrum of tolbutamide.

B. Boil 0.1 g of residue with 8 ml of a 50 per cent v/v solution of sulphuric acid under a reflux condenser for 30 minutes. Cool in an ice-bath; a crystalline precipitate of 4-toluenesulphonylamide is formed, which after recrystallisation from hot water and drying at 105º melts at 135º to 140º.

### Tests

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 90 volumes of chloroform, 8 volumes of methanol and 2 volumes of anhydrous formic acid.

**Test solution.** Shake a quantity of the powdered tablets containing 0.5 g of Tolbutamide with 10 ml of acetone and filter.

**Reference solution (a).** A 0.015 per cent w/v solution of 4-tolu enesulphonamide in acetone.

**Reference solution (b).** A mixture of equal volumes of the test solution and reference solution (a).

Apply to the plate 5 µl of each of test solution and reference solution (a) and 10 µl of reference solution (b). After development, dry the plate in a current of warm air and heat at 110º for 10 minutes. While still hot, place the plate in a chromatographic tank with an evaporating dish containing a 5 per cent w/v solution of potassium permanganate, add an equal volume of hydrochloric acid and close the tank. Leave the plate in the tank for 2 minutes, then place it in a current of cold air until the excess of chlorine is removed and an area of coating below the line of application gives only a very faint blue colour with potassium iodide and starch solution; avoid prolonged exposure to cold air. Spray the plate with potassium iodide and starch solution and allow to stand for 5 minutes. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a). The chromatogram obtained with reference solution (b) shows two clearly separated spots.

### Dissolution (2.5.2).

**Apparatus.** No 1

Medium. 900 ml of a solution containing 2.04 per cent w/v of disodium hydrogen phosphate and 0.135 per cent w/v of potassium dihydrogen phosphate.

Speed and time. 50 rpm and 30 minutes.

Withdraw a suitable volume of the medium and filter. Measure the absorbance of the filtrate suitably diluted if necessary, at the maximum at about 228 nm (2.4.7). Calculate the content of C12H18N2O3S in the medium taking 417 as the specific absorbance at 228 nm.

D. Not less than 70 per cent of the stated amount of C12H18N2O3S.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.5 g of Tolbutamide, add 50 ml of ethanol (95 per cent), previously neutralised to phenolphthalein solution, warm to dissolve, add 25 ml of water and titrate with 0.1 M sodium hydroxide using phenolphthalein solution as indicator.
1 ml of 0.1 M sodium hydroxide is equivalent to 0.02704 g of C₁₂H₁₈N₂O₃S.

Storage. Store protected from moisture.

**Topotecan Hydrochloride**

![Chemical structure of Topotecan Hydrochloride](image)

C₂₃H₂₃N₃O₅.HCl  Mol. Wt. 457.9

Topotecan Hydrochloride is (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)dione hydrochloride.

Topotecan Hydrochloride contains not less than 98.0 per cent and not more than 102.0 per cent of C₂₃H₂₃N₃O₅.HCl, calculated on the anhydrous basis.

**Description.** A light yellow to greenish yellow powder.

**CAUTION –** Topotecan Hydrochloride is cytotoxic; extra care required to prevent inhaling particles and exposing the skin to it.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with topotecan hydrochloride RS.

B. In the Assay, the principal peak in the chromatogram of the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Appearance of solution.** A 1.0 per cent w/v solution is clear (2.4.1) and not more intensely coloured than the reference solution GYS3 (2.4.1).

**pH** (2.4.24). 3.5 to 4.5, determined in a 1.0 per cent w/v solution.

**Specific optical rotation** (2.4.22). + 30° to 38°, determined on 1.0 per cent w/v solution in methanol.

**Total Chloride.** 7.6 per cent to 8.1 per cent.

Weigh accurately about 0.5 g, dissolve in 10 ml of methanol, add 20 ml of water and 20 ml of glacial acetic acid. Titrate with 0.1 M silver nitrate solution using eosin yellow solution as indicator. Colour changes from orange to dark pink.

1 ml of 0.1 M silver nitrate is equivalent to 0.003545 g of Cl.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Solvent mixture.** A mixture of 30 volumes of acetonitrile and 70 volumes of buffer solution prepared by diluting 1 ml of trifluoroacetic acid in 1000 ml of water.

**Test solution.** Dissolve 40 mg of the substance under examination in 100 ml of solvent mixture.

**Reference solution (a).** A 0.04 per cent w/v solution of topotecan hydrochloride RS in solvent mixture.

**Reference solution (b).** Dilute 1 ml of the reference solution (a) to 100 ml with solvent mixture.

Chromatographic system as described under Assay.

Inject reference solution (a). The test is not valid unless the column efficiency is not less than 2000 theoretical plates and the tailing factor is not more than 2.0.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 0.15 times the area of the peak in the chromatogram obtained with the reference solution (b) (0.15 per cent) and the sum of areas of all the secondary peaks is not more than the area of the peak in the chromatogram obtained with the reference solution (b) (1.0 per cent).

**Heavy metals** (2.3.13). 1.0 g complies with limit test for heavy metals, Method B (20 ppm).

**Test solution.** Weigh accurately about 0.5 g of the substance under examination in 5 ml of dimethylsulphoxide. Pipette a 2 ml of this solution to a 10 ml head space vial, capped the vial.

**Reference solution (a).** To 30 ml of dimethylsulphoxide, add 300 mg of methanol, 500 mg ethyl acetate, 500 mg isopropyl alcohol, 200 mg of acetone, 500 mg of ethanol and 200 mg of N,N′ dimethyl formamide, diluted to 100 ml with dimethylsulphoxide.

**Reference solution (b).** Dilute 10 ml of each of the reference solutions (a) and (b) to 100 ml with dimethylsulphoxide. Pipette 2 ml of this solution to a head space vial.

Chromatographic system

- a capillary column 30 m x 0.53 mm, packed with megabore coated with a mixture of 6 per cent cyanopropyl-phenyl and 94 per cent dimethylpolysiloxane (3 µm),
temperature:
column. 35º for 5 minutes increase @ 5º per minute to
150º @ 20º per minute to 220º hold for 2 minutes,
inlet port 180º and detector. 260º,
Head space conditions
Vial equilibrium temperature 90º, loop temperature 100º, Transfer
line 115º, vial equilibrium 15 minutes, vial pressurisation 0.02
minute, sample loop fill 0.02 minute, loop equilibrium 0.05 minute
sample injection 1 minute, vial pressure 10 psi.
- a flame ionisation detector,
- nitrogen as carrier gas.

Inject 1 ml of the reference solution (c). The test is not valid
unless the resolution between two adjacent peaks is not less
than 1.0.

Inject 1 ml of the test solution and reference solution (c). In
the chromatogram obtained with test solution, the area of
peaks due to methanol, ethyl acetate, isopropyl alcohol,
acetone, ethanol, chloroform and N,N'-dimethyl formamide is
not more than the area of peaks obtained in the chromatogram
due to the reference solution (c).

Loss on ignition (2.4.20). Not more than 0.1 per cent.

Water (2.3.43). Not more than 5.0 per cent, determined on 0.5 g.

Bacterial endotoxins (2.2.3). Not more than 16 Endotoxin Unit
per mg of topotecan hydrochloride.

Microbial contamination (2.2.9). Total viable aerobic count,
not more than 100 cfu per g. It also meets the requirements of
the tests for the absence of Staphylococcus aureus,
Pseudomonas aeruginosa, Salmonella species, and
Escherichia coli.

Assay. Determine by liquid chromatography (2.4.14).

Solvent mixture. A mixture of 30 volumes of acetonitrile and
70 volumes of buffer solution, prepared by diluting 1 ml of
trifluoroacetic acid in 1000 ml of water.

Test solution. Dissolve 10 mg of the substance under
examination in 25.0 ml of solvent mixture.

Reference solution. A 0.04 per cent w/v solution of topotecan
hydrochloride RS in solvent mixture.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with
  octadecyslylane bonded to porous silica (5 µm),
- mobile phase: A. dissolve 1 ml of trifluoroacetic acid
  in 1000 ml of water,
  B. acetonitrile,
- flow rate. 1.2 ml per minute,
- a linear gradient programme using the conditions given
  below,
- spectrophotometer set at 260 nm,
- a 10 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>85</td>
<td>15</td>
</tr>
<tr>
<td>28</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>38</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>43</td>
<td>85</td>
<td>15</td>
</tr>
<tr>
<td>48</td>
<td>85</td>
<td>15</td>
</tr>
</tbody>
</table>

Inject the reference solution. The test is not valid unless the
relative standard deviation for replicate injections is not more
than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of C23H23N3O5.HCl.

Storage. Store protected from light, at a temperature between
2° to 8°.

Topotecan Injection

Topotecan Hydrochloride Injection

Topotecan Injection is a sterile, stabilised solution of
Topotecan Hydrochloride in Water for Injection.

Topotecan Injection contains not less than 90.0 per cent and
not more than 110.0 per cent of the stated amount of the
topotecan, C23H23N3O5.

Description. A clear, light yellow solution.

Identification

A. In the Assay, the principal peak in the chromatogram
obtained with the test solution corresponds to the peak in the
chromatogram obtained with the reference solution.

B. It gives the reaction of chlorides (2.3.1).

Tests

pH (2.4.24). 2.5 to 3.5.

Other tests. Complies with the tests stated under Parenteral
Preparations (Injections).

Bacterial endotoxins (2.2.3). Not more than 64.9 Endotoxin
Unit per mg of topotecan.

Sterility (2.2.11). Complies with the test for sterility.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Accurately measure the volume of injection
containing 2 mg of Topotecan, diluted to 50.0 ml with mobile
phase.

Reference solution. Dissolve 10 mg of topotecan RS in 5 ml of
water and dilute to 25.0 ml with mobile phase. Dilute 5.0 ml of
the solution to 50.0 ml with mobile phase.
Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 78 volumes of water, 22 volumes of acetonitrile and 1 volume of 1 M hydrochloric acid,
- flow rate. 0.7 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation is not more than 2.0 per cent.

Inject the test solution and the reference solution. Calculate the content of C23H23N3O5.

Storage. Store protected from light, at a temperature not exceeding 2º to 8º.

Triamcinolone

\[
\text{C}_{21}\text{H}_{27}\text{FO}_{6} \quad \text{Mol. Wt. 394.4}
\]

Triamcinolone is \(9\alpha\)-fluoro-\(11\beta,16\alpha,17\alpha,21\)-tetrahydroxypregna-1,4-diene-3,20-dione.

Triamcinolone contains not less than 97.0 per cent and not more than 103.0 per cent of \(\text{C}_{21}\text{H}_{27}\text{FO}_{6}\), calculated on the dried basis.

Description. A white or almost white, crystalline powder; slightly hygroscopic.

Identification
A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with triamcinolone RS or with the reference spectrum of triamcinolone.
B. When examined in the range 220 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in methanol shows an absorption maximum at about 238 nm; absorbance at about 238 nm, about 0.76.
C. Dissolve 1 mg in 6 ml of ethanol (95 per cent), add 5 ml of a 1 per cent w/v solution of butylated hydroxytoluene in ethanol (95 per cent) and 5 ml of 1 M sodium hydroxide and heat on a water-bath under a reflux condenser for 20 minutes; a pinkish lavender colour is produced.

Tests
Specific optical rotation (2.4.22). +65.0º to +72.0º, determined in a 1.0 per cent w/v solution in dimethylformamide.

Related substances. Determine by liquid chromatography (2.4.14).

Prepare the following solutions immediately before use and protect from light.

Test solution. Dissolve 25 mg of the substance under examination in a mixture of equal volumes of methanol and water and dilute to 10 ml with the same solvent mixture.

Reference solution. Dilute 1 ml of the test solution to 100 ml with a mixture of equal volumes of methanol and water.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with base-deactivated end-capped octadecylsilyl silica gel (5 µm),
- mobile phase: a mixture prepared by mixing 525 ml of methanol with 400 ml of water, allowing to equilibrate, adjusting the volume to 1000.0 ml with water and mixing again,
- flow rate. 1 ml per minute,
- spectrophotometer set at 238 nm,
- a 20 µl loop injector.

Inject the test solution and the reference solution. Continue the chromatography for 4.5 times the retention time of triamcinolone (about 11 minutes).

In the chromatogram obtained with the test solution the area of any peak other than the principal peak is not more than the area of the principal peak in the chromatogram obtained with the reference solution (1 per cent); not more than two such peaks have an area greater than half the area of the principal peak in the chromatogram obtained with the reference solution (0.5 per cent); the sum of the areas of all the peaks other than the principal peak is not more than twice the area of the principal peak in the chromatogram obtained with the reference solution (2 per cent). Ignore any peak with an area less than 0.05 times the area of the principal peak in the chromatogram obtained with the reference solution (0.05 per cent).

Heavy metals (2.3.13). 0.8 g complies with the limit test for heavy metals, Method B (25 ppm).

Sulphated ash (2.3.18). Not more than 0.2 per cent.

Loss on drying (2.4.19). Not more than 2.0 per cent, determined on 1.0 g by drying in an oven at 60º at a pressure not exceeding 0.7 kPa for 3 hours.

Assay. Weigh accurately about 25 mg, dissolve in sufficient ethanol (95 per cent) to produce 100.0 ml and mix. Dilute
2.0 ml to 50.0 ml with ethanol (95 per cent) and measure the absorbance of the resulting solution at the maximum at about 238 nm (2.4.7).

Calculate the content of C₂₁H₂₇FO₆ taking 380 as the specific absorbance at 238 nm.

**Storage.** Store protected from light and moisture.

---

**Triamcinolone Tablets**

Triamcinolone Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of triamcinolone, C₂₁H₂₇FO₆.

**Identification**

A. Dissolve 1 mg of the residue obtained in the test for Related substances in 6 ml of ethanol (95 per cent), add 5 ml of a 1 per cent w/v solution of butylated hydroxytoluene in ethanol (95 per cent) and 5 ml of 1 M sodium hydroxide and heat on a water-bath under a reflux condenser for 20 minutes; a pinkish lavender colour is produced.

B. In the Assay, the chromatogram obtained with the principal peak obtained with the test solution corresponds to the peak due to triamcinolone in the chromatogram obtained with reference solution (a).

**Tests**

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Shake a quantity of the powdered tablets containing 15 mg of Triamcinolone with 15 ml of ethanol for 15 minutes, filter under reduced pressure through a fine filter paper (such as Whatman No 42) and evaporate the filtrate to dryness using a rotary evaporator. Reserve 1 mg of the residue for Identification test A. Dissolve the remainder of the residue in 15 ml of methanol.

**Reference solution (a).** Dilute 4 ml of the test solution to 100 ml with methanol.

**Reference solution (b).** Dilute 5 ml of the test solution to 50 ml with methanol. Dilute 5 ml of the resulting solution to 50 ml with the same solvent.

**Chromatographic system**

- a stainless steel column 20 cm x 4.6 mm, packed with octadecysilysilica gel (5 µm),
- mobile phase: a mixture of methanol and water, adjusted so that the retention time of triamcinolone is about 5 minutes (approximately equal volumes of methanol and water),
- flow rate. 2 ml per minute,
- spectrophotometer set at 238 nm,
- a 20 µl loop injector.

Inject reference solution (b) and record the chromatogram for 4 times the retention time of the triamcinolone peak.

The test is not valid unless the column efficiency determined from the principal peak in the chromatogram obtained with reference solution (a) is at least 10,000 theoretical plates per metre.

In the chromatogram obtained with the test solution the area of any secondary peak is not greater than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (2 per cent) and not more than one such peak has an area greater than that of the principal peak in the chromatogram obtained with reference solution (b) (1 per cent). The sum of the areas of any such peaks is not greater than the area of the principal peak in the chromatogram obtained with reference solution (a) (4 per cent).

**Uniformity of content.** Comply with the test stated under Tablets.

Crush one tablet to a fine powder, add 100 ml of ethanol (95 per cent) and shake for 10 minutes. Filter, dilute 2.0 ml of the filtrate with sufficient ethanol (95 per cent) to produce a solution containing 0.002 per cent w/v of Triamcinolone and measure the absorbance of the resulting solution at the maximum at about 238 nm (2.4.7).

Calculate the content of C₂₁H₂₇FO₆ in the tablet taking 380 as the specific absorbance at 238 nm.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 2.5 mg of Triamcinolone, shake with 5 ml of methanol and 20 ml of a mixture of 5 volumes of methanol and 3 volumes of water. Shake for 15 minutes, mix with the aid of ultrasound for 10 minutes, centrifuge and use the supernatant liquid.

**Reference solution (a).** Prepare in the same manner as the test solution but add 5 ml of a 0.06 per cent w/v solution of testosterone (internal standard) in methanol (solution A) in place of the 5 ml of methanol.

**Reference solution (b).** Add 5 ml of solution A to 5 ml of a 0.08 per cent w/v solution of triamcinolone RS in methanol and add 15 ml of methanol (50 per cent).

**Chromatographic system**

- a stainless steel column 20 cm x 4 mm, packed with octadecysilane bonded to porous silica (10 µm),
- mobile phase: a mixture of 70 volumes of methanol, 30 volumes of water and 0.1 volume of glacial acetic acid,
Calculate the content of C_{21}H_{27}FO_6 in the tablets.

Storage. Store protected from moisture.

**Triamcinolone Acetonide**

![Chemical Structure](image)

C_{24}H_{31}FO_6  
Mol. Wt. 434.5

Triamcinolone Acetonide is 9α-fluoro-11β,21-dihydroxy-16α,17α-isopropylidenedioxy-1,4-pregnadiene-3,20-dione.

Triamcinolone Acetonide contains not less than 96.0 per cent and not more than 104.0 per cent of C_{24}H_{31}FO_6, calculated on the anhydrous basis.

**Description.** A white or almost white, crystalline powder; odourless or almost odourless.

**Identification**

Test A may be omitted if tests B and C are carried out. Test C may be omitted if tests A and B are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with triamcinolone acetonide RS.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Solvent mixture.** A mixture of 90 volumes of acetone and 10 volumes of formamide.

**Mobile phase.** A mixture of 115 volumes of cyclohexane, 56 volumes of chloroform and 29 volumes of toluene.

**Test solution.** Dissolve 25 mg of the substance under examination in 10 ml of the solvent mixture.

**Reference solution (a).** Dissolve 25 mg of triamcinolone acetonide RS in 10 ml of the solvent mixture.

**Reference solution (b).** Mix equal volumes of the test solution and reference solution (a).

Place the dry plate in a tank containing a shallow layer of the solvent mixture, allow the solvent mixture to ascend to the top, remove the plate from the tank and allow the solvent to evaporate. Use within 2 hours, with the flow of the mobile phase in the direction in which the aforementioned treatment was done.

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air, allow the solvent to evaporate, heat at 120° for 15 minutes and spray the hot plate with ethanolic sulphuric acid (20 per cent v/v). Heat at 120° for a further 10 minutes, allow to cool and examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

C. Heat 0.5 ml of chromic-sulphuric acid in a test-tube (5 cm x about 6 mm) in a naked flame until white fumes are evolved; the solution wets the sides of the tube readily and there is no greasiness. Add about 2 mg of the substance under examination and again heat in a naked flame until white fumes appear; the solution does not wet the sides of the tube and does not pour easily from the tube.

**Tests**

**Light absorption** (2.4.7). When examined in the range 230 nm to 360 nm, a 0.001 per cent w/v solution in ethanol (95 per cent) shows an absorption maximum at about 239 nm; absorbance at about 239 nm, 0.34 to 0.37.

**Specific optical rotation** (2.4.22). +100° to +107°, determined in a 1.0 per cent w/v solution in dioxan.

**Related substances.** Determine by liquid chromatography (2.4.14).

Carry out the test protected from light.

**Test solution.** Dissolve 25 mg of the substance under examination in 7 ml of methanol and dilute to 10 ml with water.

**Reference solution (a).** Dissolve 2 mg of triamcinolone acetonide RS and 2 mg of triamcinolone in the mobile phase and dilute to 100 ml with the mobile phase.

**Reference solution (b).** Dilute 1 ml of the test solution to 100 ml with the mobile phase.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilyl silica gel (5 µm),
- mobile phase: a mixture prepared by mixing 525 ml of methanol with 400 ml of water, allowing to equilibrate, adjusting the volume to 1000.0 ml with water and mixing again,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.
Equilibrate the column with the mobile phase for about 10 minutes.

Inject reference solution (b). Adjust the sensitivity of the system so that the height of the principal peak is at least 50 per cent of the full scale of the recorder.

Inject reference solution (a). The retention times are: triamcinolone, about 5 minutes and triamcinolone acetonide about 17 minutes. The test is not valid unless the resolution between the peaks corresponding to triamcinolone and triamcinolone acetonide is at least 15; if necessary, adjust the concentration of methanol in the mobile phase.

Inject the test solution and reference solution (b). Continue the chromatography for 3.5 times the retention time of the principal peak in the chromatogram obtained with the test solution. In the chromatogram obtained with the test solution the area of any peak other than the principal peak is not more than 0.25 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.25 per cent); the sum of the areas of all the peaks other than the principal peak is not greater than half the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent). Ignore any peak due to the solvent and any peak with an area less than 0.05 times the area of the principal peak in the chromatogram obtained with reference solution (b).

Sulphated ash (2.3.18). Not more than 0.2 per cent.

Water (2.3.43). Not more than 2.0 per cent, determined on 0.2 g.

Assay. Weigh accurately about 25 mg and dissolve in sufficient ethanol to produce 100.0 ml and mix. Dilute 5.0 ml to 100.0 ml with ethanol (95 per cent) and measure the absorbance of the resulting solution at the maximum at about 239 nm (2.4.7). Calculate the content of C24H31FO6 taking 354 as the specific absorbance at 239 nm.

Storage. Store protected from light and moisture.

**Triamcinolone Acetonide Injection**

Triamcinolone Acetonide Injection is a sterile suspension of Triamcinolone Acetonide in very fine particles in Water for Injections containing suitable dispersing agents.

Triamcinolone Acetonide Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of triamcinolone acetonide, C24H31FO6.

Identification

Extract a volume containing about 50 mg of Triamcinolone Acetonide with two quantities, each of 10 ml, of peroxide-free ether and discard the ether extracts. Filter the aqueous layer through a sintered-glass filter, wash the residue with four quantities, each of 5 ml of water and dry at 105º for 1 hour. The residue complies with the following tests.

*Test A may be omitted if tests B and C are carried out. Test C may be omitted if tests A and B are carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with triamcinolone acetonide RS or with the reference spectrum of triamcinolone acetonide.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Solvent mixture.** A mixture of 90 volumes of acetone and 10 volumes of formamide.

**Mobile phase.** A mixture of 115 volumes of cyclohexane, 56 volumes of chloroform and 29 volumes of toluene.

**Test solution.** Dissolve 25 mg of the substance under examination in 10 ml of the solvent mixture.

**Reference solution (a).** Dissolve 25 mg of triamcinolone acetonide RS in 10 ml of the solvent mixture.

**Reference solution (b).** Mix equal volumes of the test solution and reference solution (a).

Place the dry plate in a tank containing a shallow layer of the solvent mixture, allow the solvent mixture to ascend to the top, remove the plate from the tank and allow the solvent to evaporate. Use within 2 hours, with the flow of the mobile phase in the direction in which the aforementioned treatment was done.

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air, allow the solvent to evaporate, heat at 120º for 15 minutes and spray the hot plate with ethanolic sulphuric acid (20 per cent v/v). Heat at 120º for a further 10 minutes, allow to cool and examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

C. Heat 0.5 ml of chromic-sulphuric acid in a test-tube (5 cm x about 6 mm) in a naked flame until white fumes are evolved; the solution wets the sides of the tube readily and there is no greasiness. Add about 2 mg of the substance under examination and again heat in a naked flame until white fumes appear; the solution does not wet the sides of the tube and does not pour easily from the tube.

**Tests**

**pH** (2.4.24). 5.0 to 7.5.
**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Mix an accurately measured volume of the injection, diluted with methanol, with sufficient of a solution of prednisolone RS (internal standard) with methanol to obtain a final concentration of 0.02 per cent w/v of triamcinolone acetonide and 0.01 per cent w/v of prednisolone, centrifuge and use the clear supernatant liquid.

**Reference solution (a).** A solution containing 0.02 per cent w/v of triamcinolone acetonide RS and 0.01 per cent w/v of prednisolone RS in methanol.

**Reference solution (b).** Prepare in the same manner as test solution but omitting the internal standard.

**Chromatographic system**
- a stainless steel column 25 cm x 4 mm, packed with octadecylsilane bonded to porous silica (10 µm),
- mobile phase: a mixture of 56 volumes of methanol and 44 volumes of water,
- flow rate. 1.4 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Adjust the flow rate of the mobile phase such that the separation of the triamcinolone acetonide and internal standard is optimised with a retention time of about 15 minutes for triamcinolone acetonide.

Calculate the content of C$_{24}$H$_{31}$FO$_{6}$ in the injection.

**Storage.** Store protected from light.

---

**Triamterene**

![Triamterene Structure](image)

C$_{12}$H$_{11}$N$_{7}$ Mol. Wt. 253.3

Triamterene is 2,4,7-triamino-6-phenylpteridine.

Triamterene contains not less than 99.0 per cent and not more than 101.0 per cent of C$_{12}$H$_{11}$N$_{7}$, calculated on the dried basis.

**Description.** A yellow, crystalline powder; odourless.

**Identification**

A. When examined in the range 250 nm to 380 nm (2.4.6), a 0.001 per cent w/v solution in a mixture of 9 volumes of ethanol (95 per cent) and 1 volume of 1 M hydrochloric acid shows absorption maxima at about 262 nm and 360 nm, and a shoulder at about 285 nm.

B. A 0.1 per cent w/v solution in anhydrous formic acid, when examined in ultraviolet light at 365 nm shows an intense blue fluorescence. Solutions in other acids also exhibit a blue fluorescence.

**Tests**

**Acidity.** Boil 1.0 g with 20 ml of water for 5 minutes, cool, filter and wash the filter with three quantities, each of 10 ml, of water. Combine the filtrate and washings and add 0.3 ml of phenolphthalein solution. Not more than 1.5 ml of 0.01 M sodium hydroxide is required to change the colour of the solution.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 90 volumes of ethyl acetate, 10 volumes of 18 M ammonia and 10 volumes of methanol.

**Test solution.** Dissolve 0.1 g of the substance under examination in 20 ml of dimethyl sulphoxide and dilute 2 ml of the resulting solution to 50 ml with methanol.

**Reference solution.** Dilute 1 volume of the test solution to 200 volumes with methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air until the odour of solvent is no longer detectable and examine in ultraviolet light at 365 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Sulphated ash (2.3.18).** Not more than 0.1 per cent.

**Loss on drying (2.4.19).** Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105º.

**Assay.** Weigh accurately about 0.15 g, dissolve in 5 ml of anhydrous formic acid, add 100 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02533 g of C$_{12}$H$_{11}$N$_{7}$.

**Storage.** Store protected from light and moisture.

---

**Triamterene Capsules**

Triamterene Capsules contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of triamterene, C$_{12}$H$_{11}$N$_{7}$.
Identification

The final solution obtained in the Assay has a bluish fluorescence and when examined in the range 250 nm to 380 nm (2.4.7), shows an absorption maximum at about 360 nm.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G. Mobile phase. A mixture of 90 volumes of ethyl acetate, 10 volumes of 18 M ammonia and 10 volumes of methanol. Test solution. Dissolve a quantity of the contents of the capsules containing 0.1 g of Triamterene in sufficient dimethyl sulfoxide to produce 20 ml and dilute 2 ml to 50 ml with methanol. Reference solution. Dilute 1 volume of the test solution to 200 volumes with methanol. Apply to the plate 5 µl of each solution. After development, dry the plate in air until the odour of solvent is no longer detectable and examine in ultraviolet light at 365 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Other tests. Comply with the tests stated under Capsules.

Assay. Weigh accurately a quantity of the contents of 20 capsules containing about 0.1 g of Triamterene, dissolve in 50 ml of a mixture of equal volumes of glacial acetic acid and water with the aid of gentle heat, cool and add sufficient water to produce 500.0 ml. Dilute 5.0 ml of this solution to 100.0 ml with 1 M acetic acid and measure the absorbance of the resulting solution at the maximum at about 360 nm (2.4.7). Calculate the content of C₁₂H₁₁N₇ from the absorbance obtained by repeating the operation using triamterene RS in place of the contents of the capsules.

Storage. Store protected from moisture.

Trifluoperazine Hydrochloride

Trifluoperazine Hydrochloride contains not less than 99.0 per cent and not more than 101.0 per cent of C₂₁H₂₄F₃N₃S, 2HCl, calculated on the dried basis.

Description. A white to pale yellow, crystalline powder; odourless or almost odourless; slightly hygroscopic.

NOTE — In the following procedures, the test and standard specimens and the solutions containing them should be protected by carrying out the tests without delay and in subdued light.

Identification

A. Dissolve 20 mg in 10 ml of water, make the solution alkaline to litmus paper with 5 M sodium hydroxide and extract with two quantities, each of 20 ml, of light petroleum (60° to 80°). Combine the extracts, wash with 10 ml of water, shake with 5 g of anhydrous sodium sulphate, filter and evaporate the filtrate carefully to dryness. On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with trifluoperazine hydrochloride RS or with the reference spectrum of trifluoperazine hydrochloride.

B. Complies with the test for identification of phenothiazines (2.3.3), using as reference solution a 0.2 per cent w/v solution of trifluoperazine hydrochloride RS in chloroform.

C. When examined in the range 280 nm to 360 nm (2.4.7), a 0.01 per cent w/v solution in 0.1 M hydrochloric acid measured immediately after preparation shows an absorption maximum at about 305 nm. Dilute 10 ml of the solution to 100 ml with 0.1 M hydrochloric acid. When examined in the range 230 nm to 280 nm, the resulting solution shows an absorption maximum at about 256 nm; absorbance at about 256 nm, about 0.65.

D. Dissolve 5 mg in 2 ml of sulphuric acid and allow to stand for 5 minutes; an orange colour is produced.

E. A 10 per cent w/v solution gives the reactions of chlorides (2.3.1).

Tests

pH (2.4.24). 1.7 to 2.6, determined in a 10.0 per cent w/v solution.

Related substances. Complies with the test for related substances in phenothiazines (2.3.5), using mobile phase A.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105° at a pressure not exceeding 0.7 kPa.

Assay. Weigh accurately about 0.4 g, dissolve in 50 ml of anhydrous glacial acetic acid add 10 ml of mercuric acetate
solution. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02402 g of C₂₁H₂₄F₃N₃S·2HCl.

Storage. Store protected from light and moisture.

Trifluoperazine Tablets

Trifluoperazine Hydrochloride Tablets

Trifluoperazine Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of trifluoperazine, C₂₁H₂₄F₃N₃S. The tablets are coated.

NOTE — In the following procedures, the test and standard specimens and the solutions containing them should be protected by carrying out the tests without delay and in subdued light.

Identification

A. Shake a quantity of the powdered tablets containing 20 mg of trifluoperazine with 30 ml of 1 M hydrochloric acid for 10 minutes, filter, make the filtrate alkaline to litmus paper with 5 M sodium hydroxide and extract with two quantities, each of 20 ml, of light petroleum (60º to 80º). Combine the extracts, wash with 10 ml of water, shake with 5 g of anhydrous sodium sulphate, filter and evaporate the filtrate carefully to dryness. On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with trifluoperazine hydrochloride RS or with the reference spectrum of trifluoperazine hydrochloride.

B. Extract a quantity of the powdered tablets containing 5 mg of trifluoperazine with 5 ml of acetone, filter and evaporate the filtrate to dryness. Add 2 ml of sulphuric acid to the residue and allow to stand for 5 minutes; an orange colour is produced.

Tests

Uniformity of content. Comply with the test stated under Tablets.

Place one tablet in a 100-ml volumetric flask, add 50 ml of a mixture of 19 volumes of water and 1 volume of hydrochloric acid, shake until the tablet has completely disintegrated, dilute to volume with the same mixture, mix and filter, rejecting the first few ml of the filtrate. Dilute suitably, if necessary with the same solvent mixture and measure the absorbance of the resulting solution at the maximum at about 256 nm (2.4.7). Calculate the content of C₂₁H₂₄F₃N₃S·2HCl taking 743 as the specific absorbance at 256 nm.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 5 mg of trifluoperazine, shake for 15 minutes with 400 ml of a mixture of 19 volumes of water and 1 volume of hydrochloric acid, dilute to 500.0 ml with the same solvent mixture, mix and filter. Measure the absorbance of the filtrate at the maximum at about 256 nm (2.4.7). Calculate the content of C₂₁H₂₄F₃N₃S·2HCl taking 743 as the specific absorbance at 256 nm.
Storage. Store protected from light and moisture.

Labelling. The label states the strength in terms of the equivalent amount of trifluoperazine.

Triflupromazine Hydrochloride

Flupromazine Hydrochloride

\[
\begin{align*}
\text{S} & \quad \text{CH}_3 \\
\text{N} & \quad \text{CH}_3 \\
\text{CF}_3 & \quad , \text{ HCl}
\end{align*}
\]

C\textsubscript{18}H\textsubscript{19}F\textsubscript{3}N\textsubscript{2}S, HCl Mol. Wt. 388.9

Triflupromazine Hydrochloride is 10-[(3-(dimethylamino)propyl)]-2-trifluoromethylphenothiazine hydrochloride.

Triflupromazine Hydrochloride contains not less than 97.0 per cent and not more than 103.0 per cent of C\textsubscript{18}H\textsubscript{19}F\textsubscript{3}N\textsubscript{2}S, HCl, calculated on the dried basis.

Description. A white to pale yellowish brown, crystalline powder; odour slight and characteristic.

NOTE — In the following procedures, the test and standard specimens and the solutions containing them should be protected by carrying out the tests without delay and in subdued light.

Identification

A. Dissolve 20 mg in 10 ml of water, make the solution alkaline to litmus paper with 5 M sodium hydroxide and extract with two quantities, each of 20 ml, of light petroleum (60° to 80°). Combine the extracts, wash with 10 ml of water, shake with 5 g of anhydrous sodium sulphate, filter and evaporate the filtrate carefully to dryness.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with triflupromazine hydrochloride RS or with the reference spectrum of triflupromazine hydrochloride.

B. Complies with the test for identification of phenothiazines (2.3.3), using as reference solution a 0.2 per cent w/v solution of triflupromazine hydrochloride RS in chloroform.

C. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.1 M hydrochloric acid shows an absorption maximum at about 256 nm and a less well-defined maximum at about 305 nm.

D. A 10 per cent w/v solution gives the reactions of chlorides (2.3.1).

Tests

Related substances. Complies with the test for related substances in phenothiazines (2.3.5), using mobile phase A.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105° for 2 hours.

Assay. Weigh accurately about 0.8 g, dissolve in 50 ml of anhydrous glacial acetic acid add 10 ml of mercuric acetate solution. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.03889 g of C\textsubscript{18}H\textsubscript{19}F\textsubscript{3}N\textsubscript{2}S, HCl.

Storage. Store protected from light and moisture.

Triflupromazine Injection

Triflupromazine Hydrochloride Injection; Flupromazine Hydrochloride Injection; Flupromazine Injection

Triflupromazine Injection is a sterile solution of Triflupromazine Hydrochloride in Water for Injections.

Triflupromazine Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of triflupromazine hydrochloride, C\textsubscript{18}H\textsubscript{19}F\textsubscript{3}N\textsubscript{2}S, HCl.

Description. A clear, almost colourless solution.

NOTE — In the following procedures, the test and standard specimens and the solutions containing them should be protected by carrying out the tests without delay and in subdued light.

Identification

A. To an appropriate quantity of the injection add sufficient 0.1 M hydrochloric acid to produce a solution containing 0.001 per cent w/v solution of Triflupromazine Hydrochloride.

When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum at about 256 nm.

B. To a volume containing about 100 mg of Triflupromazine Hydrochloride add 5 ml of 8 M nitric acid and mix; a pink to amber colour develops which quickly turns dark brown and then changes to a clear solution having a yellow tint.

Tests

pH (2.4.24). 3.5 to 5.2.
Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. To an accurately measured volume of the injection containing about 20 mg of Triflupromazine Hydrochloride add sufficient of a mixture of 19 volumes of water and 1 volume of hydrochloric acid to produce 100.0 ml and mix. Dilute 5.0 ml of the solution to 100.0 ml with the same mixture and mix. Measure the absorbance of the resulting solution at the maximum at about 256 nm (2.4.7).

Calculate the content of C_{18}H_{19}F_{3}N_{2}S, HCl taking 700 as the specific absorbance at 256 nm.

Storage. Store protected from light.

Triflupromazine Tablets

Triflupromazine Hydrochloride Tablets; Flupromazine Hydrochloride Tablets; Flupromazine Tablets

Triflupromazine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of triflupromazine hydrochloride, C_{18}H_{19}F_{3}N_{2}S, HCl.

NOTE — In the following procedures, the test and standard specimens and the solutions containing them should be protected by carrying out the tests without delay and in subdued light.

Identification

A. Shake a quantity of the powdered tablets containing 20 mg of Triflupromazine Hydrochloride with 30 ml of 1 M hydrochloric acid for 10 minutes, filter, make the filtrate alkaline to litmus paper with 5 M sodium hydroxide and extract with two quantities, each of 20 ml, of light petroleum (boiling range 60º to 80º). Combine the extracts, wash with 10 ml of water, shake with 5 g of anhydrous sodium sulphate, filter and evaporate the filtrate carefully to dryness.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with triflupromazine hydrochloride RS or with the reference spectrum of triflupromazine hydrochloride.

B. Extract a quantity of the powdered tablets containing 5 mg of Triflupromazine Hydrochloride with 5 ml of acetone, filter and evaporate the filtrate to dryness.

When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.1 M hydrochloric acid shows an absorption maximum at about 256 nm.

Tests

Uniformity of content. For tablets containing 10 mg or less. Comply with the test stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 50 mg of Triflupromazine Hydrochloride and shake for 15 minutes with 200 ml of a mixture of 19 volumes of water and 1 volume of hydrochloric acid. Dilute to 500.0 ml with the same solvent mixture, mix and filter, rejecting the first few ml of the filtrate. Dilute 10.0 ml to 100.0 ml with the same solvent mixture. Measure the absorbance of the filtrate at the maximum at about 256 nm (2.4.7).

Calculate the content of C_{18}H_{19}F_{3}N_{2}S, HCl taking 700 as the specific absorbance at 256 nm.

Storage. Store protected from light and moisture.

Trimethoprim

\[
\begin{align*}
\text{C}_{14}\text{H}_{18}\text{N}_{4}\text{O}_{3} & \quad \text{Mol. Wt. 290.3} \\
\text{Trimeoprim is 5-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine.} \\
\text{Trimeoprim contains not less than 98.5 per cent and not more than 101.0 per cent of C}_{14}\text{H}_{18}\text{N}_{4}\text{O}_{3}, \text{calculated on the dried basis.} \\
\text{Description. A white or yellowish white powder; odourless or almost odourless.} \\
\text{Identification} \\
\text{Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.} \\
\text{A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with trimethoprim RS or with the reference spectrum of trimethoprim.} \\
\text{B. Dissolve 25 mg in 25 ml of ethanol (95 per cent) and dilute 2.0 ml to 100 ml with 0.1 M sodium hydroxide.}
\end{align*}
\]
When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum at about 287 nm; absorbance at about 287 nm, about 0.49.

C. Dissolve about 25 mg in 5 ml of 0.005 M sulphuric acid, with heating if necessary, add 2 ml of a 1.6 per cent w/v solution of potassium permanganate in 0.1 M sodium hydroxide. Heat to boiling and to the hot solution add 0.4 ml of formaldehyde solution. Mix, add 1 ml of 0.5 M sulphuric acid, mix and heat to boiling. Cool and filter. Add 2 ml of chloroform to the filtrate and shake vigorously. The chloroform layer exhibits a green fluorescence when examined in ultraviolet light at 365 nm.

Tests

Appearance of solution. A 5.0 per cent w/v solution in a mixture of 10 volumes of chloroform, 9 volumes of methanol and 2 volumes of water is not more intensely coloured than reference solution BYS7 (2.4.1).

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 85 volumes of ethyl acetate, 10 volumes of methanol, 5 volumes of water and 2 volumes of anhydrous formic acid.

Test solution. Dissolve 0.4 g of the substance under examination in 10 ml of a mixture of 10 volumes of chloroform, 9 volumes of methanol and 2 volumes of water.

Reference solution. A 0.008 per cent w/v solution of the substance under examination in a mixture of 10 volumes of chloroform, 9 volumes of methanol and 2 volumes of water.

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 17 cm. Dry the plate in a current of cold air for 5 minutes and examine in ultraviolet light at 254 nm. Place an evaporating dish containing a mixture of 2 volumes of a 1.5 per cent w/v solution of potassium permanganate, 1 volume of 7 M hydrochloric acid and 1 volume of water at the bottom of a closed tank and allow to stand for 15 minutes. Place the dried plate in the closed tank and expose to the chlorine vapour for 5 minutes. Remove the plate from the tank and remove the chlorine in a current of cold air until an area below the line of application does not give a blue colour on the addition of 0.05 ml of potassium iodide and starch solution. Spray the plate with potassium iodide and starch solution and examine in daylight. By both methods of visualisation any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105°.

Assay. Weigh accurately about 0.25 g, dissolve in 50 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02903 g of C₃.H₁₈.N₄.O₃.

Storage. Store protected from light.

Trimethoprim and Sulphamethoxazole Oral Suspension

Sulphamethoxazole and Trimethoprim Oral Suspension; Co-trimoxazole Oral Suspension; Co-trimoxazole Mixture

Trimethoprim and Sulphamethoxazole Oral Suspension is a suspension of Trimethoprim and Sulphamethoxazole in a suitable flavoured vehicle. It contains 5 parts of Sulphamethoxazole for 1 part, by weight, of Trimethoprim.

Trimethoprim and Sulphamethoxazole Oral Suspension contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of trimethoprim, C₃.H₁₈.N₄.O₃, and sulphamethoxazole, C₃₀.H₁₁.N₅.O₃.S.

Identification

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF.

Mobile phase. A mixture of 20 volumes of chloroform, 2 volumes of methanol and 1 volume of dimethylformamide.

Test solution. Add 20 ml of methanol (or a suitable volume of methanol to yield 0.4 per cent w/v solution of Trimethoprim) to 5 ml of the suspension, mix, shake with 10 g of anhydrous sodium sulphate, centrifuge and use the supernatant liquid.

Reference solution (a). A 2.0 per cent w/v solution of sulphamethoxazole RS in methanol.

Reference solution (b). A 0.4 per cent w/v solution of trimethoprim RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air, spray with dilute potassium iodobismuthate solution. One of the principal spots in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a) and the other corresponds to that in the chromatogram obtained with reference solution (b).

Tests

pH (2.4.24). 5.0 to 6.5.

Other tests. Complies with the tests stated under Oral liquids.
**Assay.** *For trimethoprim —* Weigh accurately about 4 g, add 30 ml of 0.1 M sodium hydroxide, shake and extract with four quantities, each of 50 ml, of chloroform, washing each extract with the same two quantities, each of 10 ml, of 0.1 M sodium hydroxide. Reserve the combined aqueous solution and washings for the Assay for sulphamethoxazole. Extract the combined chloroform extracts with four quantities, each of 50 ml, of 1 M acetic acid. Wash the combined extracts with 5 ml of chloroform and dilute the aqueous extracts to 250.0 ml with 1 M acetic acid. To 10.0 ml of this solution add 10 ml of 1 M acetic acid and sufficient water to produce 100.0 ml, mix and measure the absorbance of the resulting solution at the maximum at about 271 nm (2.4.7).

Calculate the content of C$_{14}$H$_{18}$N$_{4}$O$_{3}$ taking 204 as the specific absorbance at 271 nm. Determine the weight per ml of the suspension (2.4.29), and calculate the content of C$_{14}$H$_{18}$N$_{4}$O$_{3}$, weight in volume.

*For sulphamethoxazole —* Carry out the following procedure protected from light.

Dilute the combined aqueous solution reserved in the Assay for trimethoprim to 250.0 ml with water, filter and dilute 5.0 ml of the filtrate to 200.0 ml with water (solution A). To 2.0 ml of solution A add 0.5 ml of 4 M hydrochloric acid and 1 ml of a 0.1 per cent w/v solution of sodium nitrite and allow to stand for 2 minutes. Add 1 ml of a 0.5 per cent w/v solution of ammonium sulphamate and allow to stand for 3 minutes. Add 1 ml of a 0.1 per cent w/v solution of N- (1-naphthyl) ethylenediamine dihydrochloride and allow to stand for 10 minutes. Dilute the solution to 25.0 ml with water and measure the absorbance of the resulting solution at about 538 nm (2.4.7), using as the blank a solution prepared in the same manner but using 2 ml of water in place of solution A. Weigh accurately about 0.25 g of sulphamethoxazole RS, dissolve in 50 ml of 0.1 M sodium hydroxide and dilute to 250.0 ml with water. Dilute 5.0 ml of the resulting solution to 200.0 ml with water (solution B). Repeat the procedure using 2.0 ml of solution B and beginning at the words “add 0.5 ml of 4 M hydrochloric acid......”.

Calculate the content of C$_{10}$H$_{11}$N$_{3}$O$_{3}$S from the values of the absorbances obtained. Calculate the content of C$_{10}$H$_{11}$N$_{3}$O$_{3}$S, weight in volume from the weight per ml determined in the Assay for trimethoprim.

**Storage.** Store protected from light and moisture. The suspension should not be allowed to freeze.

**Labelling.** The label states (1) the content of Trimethoprim and of Sulphamethoxazole in each 5 ml of the suspension; (2) that the contents should be shaken before use; (3) that a suspension containing 40 mg of Trimethoprim and 200 mg of Sulphamethoxazole in 5 ml is meant for paediatric use.

**Trimethoprim And Sulphamethoxazole Tablet**

Sulphamethoxazole and Trimethoprim Tablets; Cotrimoxazole Tablets

Trimethoprim and Sulphamethoxazole Tablets contain 5 parts of Sulphamethoxazole for 1 part, by weight, of Trimethoprim. Trimethoprim and Sulphamethoxazole Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amounts of trimethoprim, C$_{14}$H$_{18}$N$_{4}$O$_{3}$, and sulphamethoxazole, C$_{10}$H$_{11}$N$_{3}$O$_{3}$S.

**Identification**

A. To a quantity of the powdered tablets containing 50 mg of Trimethoprim add 30 ml of 0.1 M sodium hydroxide and extract with two quantities, each of 50 ml, of chloroform. Wash the combined chloroform extracts with two quantities, each of 10 ml, of 0.1 M sodium hydroxide and then with 10 ml of water. Combine the aqueous extract and washings (solution A) and reserve for test B. Shake with 5 g of anhydrous sodium sulphate, filter and evaporate to dryness using a rotary evaporator.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with trimethoprim RS or with the reference spectrum of trimethoprim.

B. Filter solution A, add, dropwise, sufficient 2 M hydrochloric acid to the filtrate to make it just acid and extract with 50 ml of ether. Wash the ether layer with 10 ml of water, shake with 5 g of anhydrous sodium sulphate, filter and evaporate the filtrate to dryness using a rotary evaporator. Dissolve the residue in the minimum volume of 5 per cent w/v solution of sodium carbonate, add 1 M hydrochloric acid dropwise until precipitation is complete and filter. Wash the residue sparingly with water and dry at 105º.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphamethoxazole RS or with the reference spectrum of sulphamethoxazole.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 20 volumes of chloroform, 2 volumes of methanol and 1 volume of dimethylformamide.

**Test solution.** Shake a quantity of the powdered tablets containing 0.4 g of Sulphamethoxazole with 20 ml of methanol and filter.

**Reference solution (a).** A 2.0 per cent w/v solution of sulphamethoxazole RS in methanol.
Reference solution (b). A 0.4 per cent w/v solution of trimethoprim RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air, spray with dilute potassium iodosobismuthate solution. One of the principal spots in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a) and the other corresponds to that in the chromatogram obtained with reference solution (b).

Tests

Other tests. Comply with the tests stated under Tablets.

Assay. For trimethoprim — Weigh accurately a quantity of the powdered tablets containing about 50 mg of Trimethoprim, add 30 ml of 0.1 M sodium hydroxide and extract with four quantities, each of 50 ml, of chloroform, washing each extract with the same two quantities, each of 10 ml, of 0.1 M sodium hydroxide. Combine the chloroform extracts and extract with four quantities, each of 50 ml, of 1 M acetic acid. Wash the combined extracts with 5 ml of chloroform and dilute the aqueous extracts to 250.0 ml with 1 M acetic acid. To 10.0 ml of the solution add 10 ml of 1 M acetic acid and sufficient water to produce 100.0 ml, mix and measure the absorbance of the resulting solution at the maximum at about 271 nm (2.4.7).

Calculate the content of C₁₄H₁₈N₄O₃ taking 204 as the specific absorbance at 271 nm.

For sulphamethoxazole — Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.2 g of Sulphamethoxazole, dissolve as completely as possible in 60 ml of water and 10 ml of hydrochloric acid. Add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02533 g of C₁₀H₁₁N₃O₃S.

Storage. Store protected from light and moisture.

Labelling. The label states the quantities of Trimethoprim and of Sulphamethoxazole in each tablet.

Trimethoprim Tablets

Trimethoprim Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of trimethoprim, C₁₄H₁₈N₄O₃.

Identification

A. Shake a quantity of the powdered tablets containing 0.1 g of Trimethoprim with 10 ml of chloroform, filter and evaporate the filtrate to dryness.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with trimethoprim RS or with the reference spectrum of trimethoprim.

B. Shake a quantity of the powdered tablets containing 0.1 g of Trimethoprim with 60 ml of 0.1 M hydrochloric acid for 20 minutes, add sufficient 0.1 M hydrochloric acid to produce 100 ml, filter and dilute 5 ml of the filtrate to 250 ml with 0.1 M sodium hydroxide.

When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum at about 287 nm.

Tests

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Shake a quantity of the powdered tablets containing 0.2 g of Trimethoprim with 50 ml of the mobile phase, filter and use the filtrate.

Reference solution. Dilute 1 volume of the test solution to 100 volumes with the mobile phase.

Chromatographic system

- a stainless steel column 20 cm x 5 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 0.14 per cent w/v solution of sodium perchlorate in methanol (60 per cent) adjusted to pH 3.1 with 0.1 M hydrochloric acid,
- flow rate. 1.3 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 µl loop injector.

The column efficiency, determined using the peak due to trimethoprim in the chromatogram obtained with reference solution, should be at least 8,000 theoretical plates per metre.

In the chromatogram obtained with the test solution the sum of the areas of any secondary peaks is not greater than the area of the principal peak in the chromatogram obtained with reference solution.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 0.1 g of Trimethoprim, add 100 ml of glacial acetic acid, shake for 20 minutes, dilute to 200.0 ml with glacial acetic acid and filter. To 5.0 ml of the filtrate add 15 ml of glacial acetic acid and dilute to 100.0 ml with water. Measure the absorbance of the resulting solution at the maximum at about 271 nm (2.4.7).

Calculate the content of C₁₄H₁₈N₄O₃ taking 204 as the specific absorbance at 271 nm.

Storage. Store protected from moisture.
Triprolidine Hydrochloride

\[
\text{C}_{19}\text{H}_{22}\text{N}_{2}\cdot\text{HCl}\cdot\text{H}_{2}\text{O} \quad \text{Mol. Wt. 332.9}
\]

Triprolidine Hydrochloride is (E)-2-(3-pyrrolidin-1-yl-1-(4-tolyl)prop-1-enyl)pyridine hydrochloride monohydrate.

Triprolidine Hydrochloride contains not less than 98.0 per cent and not more than 101.0 per cent of C\textsubscript{19}H\textsubscript{22}N\textsubscript{2}, HCl, calculated on the anhydrous basis.

**Description.** A white, crystalline powder; almost odourless.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with triprolidine hydrochloride RS or with the reference spectrum of triprolidine hydrochloride.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution shows absorption maxima at about 230 nm and 276 nm; absorbance at about 230 nm, about 0.50 and at about 276 nm, about 0.25.

C. When examined in the range 230 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in 0.05 M sulphuric acid shows an absorption maximum at about 290 nm; absorbance at about 290 nm, about 0.6.

D. Dissolve 0.1 g in 2 ml of 2 M hydrochloric acid and add 0.5 ml of potassium mercuri-iodide solution; a pale yellow precipitate is produced.

E. A 5 per cent w/v solution gives the reactions of chlorides (2.3.1).

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

**Mobile phase.** A mixture of equal volumes of 2-butanone and dimethylformamide.

**Test solution.** Dissolve 0.1 g of the substance under examination in 10 ml of methanol.

**Reference solution (a).** Dissolve 10 mg of the substance under examination in 100 ml of methanol.

**Reference solution (b).** A 0.02 per cent w/v solution of Z-triprolidine RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. In the chromatogram obtained with the test solution any spot corresponding to Z-triprolidine is not more intense than the spot in the chromatogram obtained with reference solution (b) and any other secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Water** (2.3.43). 4.0 to 6.0 per cent, determined on 0.4 g.

**Assay.** Weigh accurately about 0.25 g and dissolve in a mixture of 50 ml of anhydrous glacial acetic acid and 0.5 ml of acetic anhydride. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01574 g of C\textsubscript{19}H\textsubscript{22}N\textsubscript{2}, HCl.

**Storage.** Store protected from light and moisture.

**Triprolidine Tablets**

Triprolidine Hydrochloride Tablets

Triprolidine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of triprolidine hydrochloride, C\textsubscript{19}H\textsubscript{22}N\textsubscript{2}, HCl, H\textsubscript{2}O.

**Identification**

A. Extract a quantity of the powdered tablets containing 10 mg of Triprolidine Hydrochloride with ether, filter, discard the ether extract and dry the residue. Extract the residue with chloroform, filter and evaporate the filtrate to dryness. Add 0.1 ml of ether, stir and allow to evaporate.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with triprolidine hydrochloride RS or with the reference spectrum of triprolidine hydrochloride.

B. In the test for Related substances, the principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (b).

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

**Mobile phase.** A mixture of equal volumes of 2-butanone and dimethylformamide.

**Test solution.** Extract a quantity of powdered tablets containing 10 mg of Triprolidine Hydrochloride with methanol, filter, evaporate to dryness and dissolve the residue in 1 ml of methanol.
Reference solution (a). A 0.02 per cent w/v solution of Z-triprolidine RS in methanol.

Reference solution (b). A 1 per cent w/v solution of triprolidine hydrochloride RS in methanol.

Reference solution (c). A 0.01 per cent w/v solution of triprolidine hydrochloride RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. In the chromatogram obtained with the test solution any spot corresponding to Z-triprolidine is not more intense than the spot in the chromatogram obtained with reference solution (a) and any other secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (c).

Uniformity of content. For tablets containing 10 mg or less.

Comply with the test stated under Tablets.

Powder one tablet, weigh accurately a quantity of the powder containing about 7.5 mg of Triprolidine Hydrochloride and carry out the Assay beginning at the words “add 15 ml of water....”.

Calculate the content of C19H22N2, HCl, H2O in the tablet.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 7.5 mg of Triprolidine Hydrochloride, add 15 ml of water and 1 g of sodium chloride, shake for 2 to 3 minutes and add sufficient 5 M sodium hydroxide to make it alkaline. Extract with four quantities, each of 20 ml, of ether and wash the combined extracts with two quantities, each of 5 ml, of a mixture of equal volumes of a saturated solution of sodium chloride and water. Extract the ether solution with 20 ml of 0.1 M hydrochloric acid, wash the ether with two quantities, each of 5 ml, of water and add the washings to the acid extract. Heat on a water-bath for 30 minutes, cool and add sufficient water to produce 50.0 ml. Dilute 10.0 ml to 100.0 ml with 0.1 M hydrochloric acid. Measure the absorbance of the resulting solution at the maximum at about 290 nm (2.4.7).

Calculate the content of C19H22N2, HCl, H2O taking 290 as the specific absorbance at 290 nm.

Storage. Store protected from light and moisture.

Trisodium Edetate Concentrate for Injection

Trisodium Edetate Concentrate for Injection is a sterile solution in Water for Injections containing 20 per cent w/v solution of trisodium edetate prepared by the interaction of Disodium Edetate and Sodium Hydroxide. It should be diluted with a suitable diluent in accordance with the manufacturer’s instructions.

Trisodium Edetate Concentrate for Injection contains not less than 19.0 per cent w/v and not more than 21.0 per cent w/v solution of trisodium edetate, C10H13N2Na3O8.

Description. A colourless solution.

Identification

A. Dissolve 2 g in 25 ml of water; add 6 ml of lead nitrate solution, shake and add 3 ml of potassium iodide solution; no yellow precipitate is produced. Make alkaline to red litmus paper with 2 M ammonia and add 5 ml of ammonium oxalate solution; no precipitate is produced.

B. Dissolve 0.5 g in 10 ml of water, add 0.5 ml of a 10 per cent w/v solution of calcium chloride, make alkaline to red litmus paper with 2 M ammonia and add 3 ml of ammonium oxalate solution; no precipitate is produced.

C. Evaporate to dryness and ignite. The residue gives the reactions of sodium salts (2.3.1).

Tests

pH (2.4.24). 7.0 to 8.0.

Pyrogens (2.2.8). Complies with the test, using per kg of the rabbit’s weight 5 ml of a solution prepared in the following manner. To 1 volume of the injection add 2.5 volumes of calcium gluconate solution. Dilute the resulting solution with sufficient water for injections to give a final concentration of 5.0 per cent w/v solution of trisodium edetate.

Other tests. Complies with the tests stated under Parenteral Preparations (Concentrated Solutions for Injection).

Assay. Dilute 10.0 ml to 100.0 ml with water and use this solution to titrate a mixture of 25.0 ml of 0.05 M magnesium sulphate and 10 ml of ammonia buffer pH 10.9 using mordant black II mixed triturate as indicator.

1 ml of 0.05 M magnesium sulphate is equivalent to 0.01791 g of C10H13N2Na3O8.

Storage. Store in hermetically-sealed, lead-free glass containers.

Labelling. The label states (1) the strength in terms of anhydrous trisodium edetate contained in a suitable dose-volume; (2) ‘Trisodium Edetate Concentrate for Injection’; (3) that the solution must be diluted with either Sodium Chloride Intravenous Infusion or Dextrose Intravenous Infusion before administration.
**Tropicamide**

![Chemical Structure of Tropicamide](image)

C₁₇H₂₀N₂O₂  Mol. Wt. 284.4

Tropicamide is (RS)-N-ethyl-3-hydroxy-2-phenyl-N-(pyrid-4-ylmethyl)propionamide

Tropicamide contains not less than 99.0 per cent and not more than 101.0 per cent of C₁₇H₂₀N₂O₂, calculated on the dried basis.

**Description.** A white or almost white, crystalline powder; odourless or almost odourless.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tropicamide RS or with the reference spectrum of tropicamide.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.003 per cent w/v solution in 0.1 M hydrochloric acid shows an absorption maximum only at about 254 nm; absorbance at about 254 nm, about 0.54.

C. Dissolve 5 mg in 3 ml of a mixture of 9 ml of acetic anhydride, 1 ml of 6 M acetic acid and 0.1 g of citric acid and heat on a water-bath for 5 to 10 minutes; a reddish yellow colour is produced.

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 95 volumes of chloroform, 5 volumes of methanol and 0.5 volume of strong ammonia solution.

**Test solution.** Dissolve 0.1 g of the substance under examination in 10 ml of chloroform.

**Reference solution (a).** A 0.005 per cent w/v solution of the substance under examination in chloroform.

**Reference solution (b).** A 0.002 per cent w/v solution of the substance under examination in chloroform.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 80º at a pressure not exceeding 0.7 kPa for 4 hours.

**Assay.** Weigh accurately about 0.5 g, dissolve in 80 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, using 1-naphtholbenzein solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02844 g of C₁₇H₂₀N₂O₂.

**Storage.** Store protected from light and moisture.

---

**Tropicamide Eye Drops**

Tropicamide Eye Drops are a sterile solution of Tropicamide in Purified Water. They may contain stabilisers, suitable antimicrobial agents and suitable substances to increase the viscosity of the solution.

Tropicamide Eye Drops contain not less than 95.0 per cent and not more than 110.0 per cent of the stated amount of tropicamide, C₁₇H₂₀N₂O₂.

**Identification**

A. Shake a volume containing 20 mg of Tropicamide with 10 ml of chloroform, dry the chloroform layer over anhydrous sodium sulphate, filter and evaporate the filtrate to dryness. Dissolve the residue in minimum quantity of chloroform, add dropwise to finely powdered potassium bromide IR, mix and dry at 60º.

On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tropicamide RS or with the reference spectrum of tropicamide.

B. When examined in the range 230 nm to 360 nm (2.4.7), the final solution obtained in the Assay shows an absorption maximum at about 254 nm.

**Tests**

**pH** (2.4.24). 4.0 to 5.8.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 95 volumes of chloroform, 5 volumes of methanol and 0.5 volume of strong ammonia solution.
Test solution. A volume of the eye drops containing 0.2 mg of Tropicamide.

Reference solution (a). Dilute 1 volume of the eye drops to 200 volumes with chloroform.

Reference solution (b). Dilute 1 volume of the eye drops to 500 volumes with chloroform.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm.

Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

Other tests. Comply with the tests stated under Eye Drops.

Assay. To a volume containing about 30 mg of Tropicamide add sufficient water to produce 100.0 ml. To 10.0 ml of the resulting solution add 2 ml of a 10 per cent w/v solution of anhydrous sodium carbonate and extract with four quantities, each of 20 ml, of chloroform. Wash the combined chloroform extracts with 25 ml of phosphate buffer pH 6.5. Wash the aqueous layer with 10 ml of chloroform, combine the chloroform extracts and shake with four quantities, each of 20 ml, of 0.5 M sulphuric acid. Combine the acid extracts, dilute to 100.0 ml with 0.5 M sulphuric acid and measure the absorbance of the resulting solution at the maximum at about 254 nm (2.4.7). Calculate the content of C17H20N2O2 taking 172 as the specific absorbance at 254 nm.

Storage. Store in a refrigerator (8º to 15º). It should not be allowed to freeze.

Troixidone

Trimethadione

Troxidone is 3,5,5-trimethylazolidine-2,4-dione.

Troxidone contains not less than 98.0 per cent and not more than 102.0 per cent of C₆H₉NO₃, calculated on the dried basis.

Description. Colourless or almost colourless crystals; odour, slightly camphoraceous.

Identification

Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with troxidone RS.

B. To 2 ml of a 5.0 per cent w/v solution in carbon dioxide-free water (solution A) add 1 ml of barium hydroxide solution; a white precipitate is produced which dissolves on the addition of 1 ml of 2 M hydrochloric acid.

C. Dissolve 0.3 g in a mixture of 5 ml of ethanolic potassium hydroxide solution and 5 ml of ethanol (95 per cent) and allow to stand for 10 minutes. Add 0.05 ml of phenolphthalein solution and carefully add hydrochloric acid until the solution is neutral. Evaporate to dryness on a water-bath, shake the residue with four quantities, each of 5 ml, of ether, filter the combined ether extracts and evaporate the filtrate to dryness. The residue, after recrystallisation from 5 ml of toluene and drying, melts at about 80º (2.4.21).

Tests

Appearance of solution. Solution A is clear (2.4.1), and colourless (2.4.1).

Acidity or alkalinity. To 10 ml of solution A add 0.1 ml of methyl red solution. Not more than 0.1 ml of 0.01 M hydrochloric acid or 0.01 M sodium hydroxide is required to change the colour of the solution.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying over anhydrous silica gel for 6 hours.

Assay. Determine by gas chromatography (2.4.13).

Test solution. Weigh accurately 0.1 g of the substance under examination and dissolve in sufficient solutions prepared by dissolving 0.125 g of 1-decanol (internal standard) in sufficient ethanol to produce 25.0 ml (solution B).

Reference solution. Dissolve 0.1 g of troxidone RS in sufficient solution B to produce 10.0 ml.

Chromatographic system

- a stainless steel column 0.75 m x 3 mm, packed with porous polymer beads (120 to 150 µm),
- temperature: column 210º;
  - inlet port at 240º and detector at 270º,
- flow rate. 30 ml per minute of the carrier gas.

Inject 1 µl of the test solution and the reference solution.
Calculate the content of C₆H₈NO₃.

Storage. Store protected from light and moisture.

**Troxidone Capsules**

Trimethadione Capsules

Troxidone Capsules contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of troxidone, C₆H₈NO₃.

**Identification**

To a quantity of the contents of the capsules containing 1 g of Troxidone add 25 ml of ether, set aside in a stopped flask for 20 minutes, decant the ether through a filter, and if an insoluble residue remains, digest it with another 10-ml portion of ether as before, and filter into the first ether filtrate. Evaporate the ether extracts to dryness with the aid of air and dry the residue at a pressure of 2 kPa for 2 hours. The residue complies with the following tests.

Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with troxidone RS or with the reference spectrum of troxidone.

B. To 2 ml of a 5.0 per cent w/v solution in carbon dioxide-free water (solution A) add 1 ml of barium hydroxide solution; a white precipitate is produced which dissolves on the addition of 1 ml of 2 M hydrochloric acid.

C. Dissolve 0.3 g in a mixture of 5 ml of ethanolic potassium hydroxide solution and 5 ml of ethanol (95 per cent) and allow to stand for 10 minutes. Add 0.05 ml of phenolphthalein solution and carefully add hydrochloric acid until the solution is neutral. Evaporate to dryness on a water-bath, shake the residue with four quantities, each of 5 ml, of ether, filter the filtrate to dryness. The residue, after recrystallisation from 5 ml of toluene and drying, melts at about 80° (2.4.21).

**Tests**

**Other tests.** Comply with the tests stated under Capsules.

**Assay.** Determine by gas chromatography (2.4.13).

**Test solution.** To a quantity of the contents of the capsules containing about 1.0 g of Troxidone add 25 ml of a 0.5 per cent w/v solution of 1-decanol (internal standard) in ethanol, shake for 30 minutes, add sufficient of internal standard solution to produce 100.0 ml, mix and centrifuge. Use the supernatant liquid.

Reference solution. Dissolve 0.1 g of troxidone RS in sufficient solution B to produce 10.0 ml.

Chromatographic system

- a stainless steel column 0.75 m x 3 mm, packed with porous polymer beads (120 to 150 µm),
- temperature:
  - column 210°,
  - inlet port at 240° and detector at 270°,
- flow rate. 30 ml per minute of the carrier gas.

Inject 1 µl of the test solution and the reference solution. Calculate the content of C₆H₈NO₃ in the capsules.

**Storage.** Store protected from moisture.

**Tubocurarine Chloride**

**C₃₇H₄₁ClN₂O₆.HCl,5H₂O**

Mol. Wt. 771.7

Tubocurarine Chloride is 7′,12′-dihydroxy-6,6′-dimethoxy-2,2′,2′-trimethyltubocuraranium chloride hydrochloride pentahydrate.

Tubocurarine Chloride contains not less than 98.0 per cent and not more than 102.0 per cent of C₃₇H₄₁ClN₂O₆.HCl, calculated on the anhydrous basis.

**Description.** A white or yellowish white, crystalline powder.

**Identification**

Test A may be omitted if tests B, C, D and E are carried out. Tests B, C and D may be omitted if tests A and E are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tubocurarine chloride RS or with the reference spectrum of tubocurarine chloride.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.005 per cent w/v solution shows an absorption maximum at
about 280 nm and a minimum at about 255 nm, 0.56 to 0.62, calculated on the anhydrous basis.

C. To 1 ml of a 2.5 per cent w/v solution add 0.2 ml of ferric chloride solution and heat in a water-bath for 1 minute; a green colour is produced; 1 ml of water treated in the same manner gives a brown colour.

D. To 20 ml of a 0.05 per cent w/v solution add 0.2 ml of sulphuric acid and 2 ml of a 1 per cent w/v solution of potassium iodate, mix and warm on a water-bath for 30 minutes; a yellow colour is produced.

E. Gives reaction A of chlorides and the reactions of alkaloids (2.3.1).

Tests

Appearance of solution. Dissolve 0.5 g in sufficient carbon dioxide-free water to produce 50.0 ml (solution A). Solution A is clear (2.4.1), and not more intensely coloured than reference solution YS6 (2.4.1).

pH (2.4.24). 4.0 to 6.0, determined in Solution A.

Specific optical rotation (2.4.22). +210º to +222º, determined in solution A 3 hours after preparation.

Chloroform-soluble substances. Not more than 2 per cent, determined by the following method. Dissolve 0.25 g in 150 ml of water contained in a separating funnel with a grease-free stopcock. Add 5 ml of a saturated solution of sodium bicarbonate and extract with three quantities, each of 20 ml, of chloroform. Wash the combined chloroform extracts with 10 ml of water, filter the chloroform solution into a tared beaker and wash the filter with two successive quantities, each of 5 ml, of chloroform. Add the washings to the filtrate. Remove the chloroform on a water-bath, dry the residue at 105º for 1 hour, cool and weigh. The residue does not dissolve in 10 ml of water but dissolves on the addition of 1 ml of 2 M hydrochloric acid.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. The lower layer of a mixture of equal volumes of chloroform, methanol and a 12.5 per cent w/v solution of trichloroacetic acid.

Test solution. Dissolve 0.25 g of the substance under examination in 10 ml of water.

Reference solution (a). A 0.0375 per cent w/v solution of the substance under examination in water.

Reference solution (b). A 0.01875 per cent w/v solution of the substance under examination in water.

Apply to the plate 5 µl of each solution. After development, dry the plate in a current of cold air and spray with a mixture of 1 volume of potassium ferricyanide solution, 1 volume of water and 2 volumes of ferric chloride solution, prepared immediately before use. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

Sulphated ash (2.3.18). Not more than 0.25 per cent, determined on 0.2 g.

Water (2.3.43). 9.0 to 12.0 per cent, determined on 0.3 g.

Assay. Weigh accurately about 25 mg, dissolve in sufficient water to produce 500.0 ml and measure the absorbance of the resulting solution at the maximum at about 280 nm (2.4.7).

Calculate the content of C37H41ClN2O6.HCl from the absorbance obtained by repeating the operation using 25 mg, accurately weighed, of tubocurarine chloride RS in place of the substance under examination.

Storage. Store protected from moisture.

Tubocurarine Injection

Tubocurarine Chloride Injection

Tubocurarine Injection is a sterile solution of Tubocurarine Chloride in Water for Injections. It may contain suitable buffering agents.

Tubocurarine Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of tubocurarine chloride, C37H41ClN2O6.HCl.5H2O.

Description. A colourless or faintly coloured solution.

Identification

A. Mix a volume containing 15 mg of Tubocurarine Chloride with 5 ml of acetone, evaporate the liquid at a pressure of 2 kPa and add successive quantities of 2 ml of acetone, evaporating each quantity at a pressure of 2 kPa until a dry residue is obtained.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tubocurarine chloride RS or with the reference spectrum of tubocurarine chloride.

B. Dilute 1 ml to 30 ml with water. To 1 ml of the resulting solution add 0.5 ml of mercuric nitrate solution; a cherry-red colour slowly develops.

Tests

pH (2.4.24). 4.0 to 6.0.
Optical rotation (2.4.22). +0.172° to +0.206° for each mg of tubocurarine chloride, C_{37}H_{41}ClN_2O_6.HCl.5H_2O per ml stated on the label.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. The lower layer of a mixture of equal volumes of chloroform, methanol and a 12.5 per cent w/v solution of trichloroacetic acid.

Test solution. A volume of the injection containing 10 mg of Tubocurarine Chloride diluted to 1 ml.

Reference solution (a). Dilute 3 volumes of test solution to 200 volumes with water.

Reference solution (b). Dilute 1 volume of reference solution (a) to 2 volumes with water.

Apply to the plate 10 µl of each solution. After development, dry the plate in a current of cold air and spray with a mixture of 1 volume of potassium ferricyanide solution, 1 volume of water and 2 volumes of ferric chloride solution, prepared immediately before use. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. Dilute a volume containing about 50 mg of Tubocurarine Chloride to 1000.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 280 nm (2.4.7). Calculate the content of C_{37}H_{41}ClN_2O_6.HCl.5H_2O taking 105 as the specific absorbance at 280 nm.

Storage. Store protected from moisture.
U

Undecenoic Acid
Urea
Urea Cream
Urokinase
Undecenoic Acid

Undecylenic Acid

\[
\text{H}_2\text{C} \quad \text{COOH}
\]

\[\text{C}_{11}\text{H}_{20}\text{O}_2\quad \text{Mol. Wt. 184.3}\]

Undecenoic Acid is 10-undecenoic acid.

Undecenoic Acid contains not less than 97.0 per cent and not more than 102.0 per cent of \(\text{C}_{11}\text{H}_{20}\text{O}_2\).

**Description.** A white or very pale yellow, crystalline mass or colourless or pale yellow liquid; odour, characteristic.

**Identification**

A. Dissolve 0.1 g in a mixture of 2 ml of \(1 \text{ M sulphuric acid}\) and 5 ml of \(\text{glacial acetic acid}\) and add dropwise 0.25 ml of \(\text{potassium permanganate solution}\); the colour of the permanganate solution is discharged.

B. Boil 2 g under a reflux condenser with 2 ml of freshly distilled \(\text{aniline}\) for 10 minutes, allow to cool, add 30 ml of \(\text{ether}\) and extract with three quantities, each of 20 ml, of \(2 \text{ M hydrochloric acid}\) and then with 20 ml of \(\text{water}\). Evaporate the organic layer to dryness on a water-bath. The residue, after recrystallising twice from \(\text{ethanol (70 per cent)}\) and drying over \(\text{phosphorus pentoxide}\) at a pressure of 1.5 to 2.5 kPa for 3 hours melts at 66º to 68º.

**Tests**

**Congealing range** (2.4.10). 21º to 24º.

**Refractive index** (2.4.27). 1.447 to 1.450.

**Peroxide value** (2.3.35). Not more than 10.

**Iodine value** (2.3.28). 131 to 140.

**Fixed and mineral oils.** Boil 1.0 g with 25 ml of \(\text{water}\) and 5 ml of \(\text{sodium carbonate solution}\) for 3 minutes. The hot solution is not more opalescent than opalescence standard OS2 (2.4.1).

**Water-soluble acids.** Shake 2.0 g with 20 ml of warm \(\text{water}\), allow to separate and filter the aqueous layer through a moistened filter paper. To 5 ml of the filtrate add 0.01 ml of \(\text{dilute phenolphthalein solution}\). Not more than 0.1 ml of \(0.1 \text{ M sodium hydroxide}\) is required to change the colour of the solution.

**Heavy metals** (2.3.13). 2.0 g complies with the limit test for heavy metals, Method B (10 ppm).

**Sulphated ash** (2.3.18). Not more than 0.15 per cent.

**Assay.** Weigh accurately about 0.75 g, dissolve in 10 ml of \(\text{ethanol (95 per cent)}\) and titrate with \(0.5 \text{ M sodium hydroxide}\) using 0.1 ml of \(\text{dilute phenolphthalein solution}\) as indicator.

1 ml of \(0.5 \text{ M sodium hydroxide}\) is equivalent to 0.09214 g of \(\text{C}_{11}\text{H}_{20}\text{O}_2\).

**Storage.** Store protected from light and moisture.

Urea

\[
\text{H}_2\text{N} \quad \text{NH}_2
\]

\[\text{CH}_2\text{N}_2\text{O}\quad \text{Mol. Wt. 60.1}\]

Urea is the diamide of carbonic acid.

Urea contains not less than 99.0 per cent and not more than 101.0 per cent of \(\text{CH}_2\text{N}_2\text{O}\); calculated on the dried basis.

**Description.** A white, crystalline powder or transparent crystals; odourless or almost odourless, but may gradually develop a slight odour of ammonia upon long standing; slightly hygroscopic.

**Identification**

Test A may be omitted if tests B and C are carried out. Tests B and C may be omitted if test A is carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with urea RS or with the reference spectrum of urea.

B. Heat 0.5 g in a test-tube; it liquefies, and ammonia is evolved which is recognised by its characteristic odour. Heat further until the liquid is turbid, cool and dissolve in 10 ml of \(\text{water}\). Add 1 ml of a 10 per cent w/v solution of \(\text{sodium hydroxide}\) and 0.05 ml of \(\text{copper sulphate solution}\); a reddish violet colour is produced.

C. Dissolve 0.1 g in 1 ml of \(\text{water}\) and add 1 ml of \(\text{nitric acid}\); a white, crystalline precipitate is produced.

**Tests**

**Appearance of solution.** Solution A is clear (2.4.1), and colourless (2.4.1).

**Alkalinity.** To 10 ml of a 5.0 per cent w/v solution (solution A) add 0.1 ml of \(\text{methyl red solution}\) and 0.4 ml of 0.01 M \(\text{hydrochloric acid}\); the resulting solution is red to orange.

**Biuret.** Not more than 0.1 per cent, determined by the following method. To 10 ml of a 20 per cent w/v solution add 5 ml of \(\text{water}\), 0.5 ml of a 0.5 per cent w/v solution of \(\text{copper sulphate}\) and 0.5 ml of \(10 \text{ M sodium hydroxide}\) and allow to stand for 5 minutes. Any reddish violet colour obtained is not more intense than that in a standard prepared at the same time and in the same manner using 10 ml of a 0.02 per cent w/v solution of \(\text{biuret}\) in place of the substance under examination.
Ethanol-insoluble matter. Not more than 0.04 per cent, determined by the following method. Dissolve 5.0 g in 50 ml of warm ethanol (95 per cent), filter through a tared filter, wash the filter with 20 ml of warm ethanol (95 per cent) and dry at 105º for 1 hour.

Heavy metals (2.3.13). Dissolve 1.0 g in 20 ml of water and 5 ml of 0.1 M hydrochloric acid. The solution complies with the limit test for heavy metals, Method A (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105º for 1 hour.

Assay. Weigh accurately about 0.5 g, dissolve in sufficient of a 10 per cent v/v solution of sulphuric acid to produce 100.0 ml and mix. Place 5.0 ml of the resulting solution in a long-necked flask, add 10 ml of sulphuric acid and heat gently until evolution of gas ceases. Boil gently for 10 minutes, cool, cautiously add 40 ml of water, cool again and place in a steam-distillation apparatus. Add 50 ml of 10 M sodium hydroxide and distil immediately by passing steam through the mixture. Continue the distillation for 1 hour, collecting the distillate in 40 ml of a 4 per cent w/v solution of boric acid. Titrate with 0.1 M hydrochloric acid, using 0.25 ml of methyl red-methylene blue solution as indicator. Carry out a blank titration.

1 ml of 0.1 M hydrochloric acid is equivalent to 0.003003 g of CH₄N₂O.

Storage. Store protected from moisture.

Urea Cream

Urea Cream contains Urea in a suitable basis.

Urea Cream contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of urea, CH₄N₂O.

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. For the first development use 2,2,4-trimethylpentane. Dry the plate in air. For the second development use a mixture of 99 volumes of ethanol and 1 volume of strong ammonia solution.

Test solution. Disperse with heating a quantity of the cream containing 50 mg of Urea in 1 ml of water, cool, add 4 ml of acetone, mix and filter.

Reference solution (a). Dissolve 50 mg of urea RS in 1 ml of water and add 4 ml of acetone.

Reference solution (b). A mixture of equal volumes of the test solution and reference solution (a).

Apply to the plate 10 µl of each solution. After development, dry the plate in air, spray with a solution containing 0.5 per cent w/v solution of 4-dimethylaminobenzaldehyde and 0.5 per cent v/v of sulphuric acid in ethanol. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The chromatogram obtained with reference solution (b) shows a single, compact spot.

B. To a quantity containing 0.1 g of Urea add 50 ml of water and heat until dispersed, cool in ice and filter through glass wool. Adjust the pH to 6.0 to 7.0 using 0.1 M hydrochloric acid or 0.1 M sodium hydroxide as necessary. To 5 ml add 5 ml of a 0.1 per cent w/v suspension of urease-active meal and allow to stand for 30 minutes in a stopped flask at 37º. When the resulting solution is heated in a water-bath a vapour is produced that turns moist red litmus paper blue.

Tests

Other tests. Comply with the tests stated under Creams.

Assay. Weigh accurately a quantity containing about 42 mg of Urea, shake with 150 ml of hot water for 20 minutes, allow to cool and dilute to 500.0 ml with water. Filter through a fine glass microfibre filter paper or by any other means, transfer 1.0 ml of the filtrate to a 100-ml volumetric flask, add 2 ml of a 0.1 per cent w/v suspension of urease-active meal, stopper the flask and allow to stand for 15 minutes at 37º. Immediately add 25 ml of a solution containing 12 g of sodium salicylate and 0.24 g of sodium nitroprusside in 200 ml and 25 ml of a solution prepared by diluting a volume of sodium hypochlorite solution containing 0.66 g of available chlorine with 0.2 M sodium hydroxide to 1000 ml. Mix well, allow to stand at 37º for 5 minutes and dilute to 100.0 ml with water. Measure the absorbance of the resulting solution at the maximum at about 665 nm (2.4.17), using as the blank a solution prepared in the same manner but using 1.0 ml of water in place of 1.0 ml of the filtrate.

Calculate the content of CH₄N₂O from the absorbance obtained by using 42 mg of urea RS in place of the substance under examination.

Storage. Store in accordance with the instructions of the manufacturer.

Urokinase

Urokinase is an enzyme, obtained from human urine that activates plasminogen. It consists of a mixture of low molecular weight and high molecular weight forms, the high molecular weight form being predominant. The molecular weights of the low and high molecular weight forms are 33,000 and 54,000 respectively.
It is prepared in conditions designed to minimise microbial and viral contamination. In particular, adequate measures, such as heating the substance in solution at 60°C for 10 hours, are taken to inactivate viruses.

Urokinase contains not less than 70,000 Units of urokinase activity per mg of protein.

**Description.** A white or almost white, amorphous powder.

**Identification**

A. Place 0.5 ml of citrated human plasma and 0.5 ml of citrated bovine plasma in two separate haemolysis tubes maintained in a water-bath at 37°C. To each tube add 0.1 ml of a solution of the substance under examination containing 1000 Units per ml in phosphate buffer pH 7.4 and 0.1 ml of a solution of thrombin containing 20 Units per ml in phosphate buffer pH 7.4 and shake immediately; in both tubes, a clot forms and lyses within 30 minutes.

B. Carry out a suitable immunodiffusion test.

**Tests**

**Appearance of solution.** A 0.1 per cent w/v solution in water is clear (2.4.1), and colourless (2.4.1).

**Molecular fractions.** Determine by size-exclusion chromatography (2.4.16)

**Test solution.** Dissolve 0.1 g of the substance under examination in 100 ml of 0.02 M phosphate buffer pH 8.0.

Chromatographic system

- a column 90 cm x 16 mm, packed with a cross-linked dextran suitable for fractionation of proteins in the range of molecular weight from 4000 to 150,000 (such as Sephadex G-100), at 5°C,
- mobile phase: 1.75 per cent w/v solution of sodium chloride in 0.02 M phosphate buffer pH 8.0,
- flow rate: 6 ml per hour,
- spectrophotometer set at 280 nm.

Apply 1 ml of the test solution to the column, rinse twice with 0.5-ml portions of the buffer and then carry out the elution. The eluate may be collected in 1-ml fractions. Plot the individual absorbances on a graph. Draw perpendicular lines towards the axis of the abscissae from the minima before the high molecular weight peak, between the high and the low molecular weight peaks, and after the low molecular weight peak. Combine separately the high and low molecular weight fractions and for each combined fraction determine the activity by the method described under Assay. The ratio of the activity in the combined high molecular weight fraction to that in the combined low molecular weight fraction is not less than 2.0.

**Total protein.** Determine by Method C for the determination of nitrogen (2.3.30), using 10 mg of the substance under examination and multiplying the result by 6.25 to obtain the content of protein.

**Hepatitis-B surface antigen.** Examine by a suitably sensitive method such as radio-immunoassay; hepatitis-B surface antigen is not detected.

**Abnormal toxicity** (2.2.1). Complies with the test, using a solution containing 2,500 Units in 0.5 ml of saline solution.

**Thromboplastic contaminants.** Dissolve suitable quantities of the substance under examination in barbitone buffer pH 7.4 to obtain solutions containing 5000, 2500, 1250, 625 and 312 Units per ml. Into each of six haemolysis tubes, 1 cm in internal diameter, place 0.1 ml of citrated rabbit plasma. Add 0.1 ml of one of each of the solutions of the substance under examination to each of five of the tubes and 0.1 ml of barbitone buffer pH 7.4 to the sixth (control). Incubate the six tubes at 25°C ± 0.5°C for 5 minutes and then add 0.1 ml of a 0.3675 per cent w/v solution of calcium chloride. Using a stop-watch, measure the clotting time for each solution and the control. Plot the shortening of the recalcification time (control clotting time minus clotting time for each solution) against log concentration. Extrapolate the best-fitting straight line through the five points until it reaches the log concentration axis. The urokinase activity at the intersection point represents the limit concentration for clotting activity (zero clotting activity). The zero clotting activity is not less than 150 Units per ml.

**Vasoactive substances.** Anesthetise a rabbit by intraperitoneal injection of 0.15 g of phenobarbitone sodium per kg of body weight. Dissolve in normal saline solution a sufficient quantity of the substance under examination to give a solution containing 40,000 Units per ml. Administer by intravenous infusion at a rate of 1 ml per minute a sufficient volume of the solution of the substance under examination such that the dose is 20,000 Units per kg of body weight. Measure the arterial pressure and heart rate at intervals of 15 minutes for 5 hours after the infusion. No significant and lasting alterations in arterial pressure or heart rate are produced, except those arising from the effects of the anaesthetic.

**Assay.** The potency of urokinase is determined by comparing its ability to activate human plasminogen to form plasmin with that of the Standard Preparation. The plasmin generated is determined by measurement of the time taken to lyse a fibrin clot under the conditions of a suitable method of Assay.

**Standard Preparation**

The Standard Preparation is the 1st International Reference Preparation for Urokinase, human, established in 1968, consisting of partially purified freeze-dried urokinase from human urine with lactose (supplied in ampoules containing 4800 Units of urokinase activity) or another suitable preparation the activity of which has been determined in relation to the International Reference Preparation.
Method

Unless otherwise prescribed, use phosphate buffer pH 7.4 containing 3 per cent w/v solution of bovine albumin for the preparation of solutions and dilutions.

Prepare a solution of the Standard Preparation containing 1000 Units of urokinase activity per ml and prepare a solution of the preparation under examination expected to have the same concentration; keep the solutions in ice and use within 6 hours. Prepare three 1.5-fold serial dilutions of the solution of the Standard Preparation so that the longest clot-lysis time is less than 20 minutes and the shortest clot-lysis time is greater than 3 minutes. Prepare three similar dilutions of the solution of the preparation under examination. Keep the solutions in ice and use within 1 hour. Using 24 tubes 8 mm in diameter, label the tubes S₁, S₂, S₃ for the dilutions of the Standard Preparation and T₁, T₂, T₃ for the dilutions of the preparation under examination, allocating four tubes to each dilution. Place the tubes in ice. Into each tube introduce 0.2 ml of the appropriate dilution, 0.2 ml of phosphate buffer pH 7.4 containing 3 per cent w/v solution of bovine albumin and 0.1 ml of a solution containing 20 Units of thrombin per ml. Place the tubes in a water-bath at 37º and allow to stand for 2 minutes to attain temperature equilibrium. Using an automatic pipette, introduce into the bottom of the first tube 0.5 ml of a 1.0 per cent w/v solution of bovine euglobulin fraction ensuring mixing. At 5-second intervals introduce successively into the remaining tubes 0.5 ml of a 1.0 per cent w/v solution of bovine euglobulin fraction. Using a stop-watch, measure for each tube the time in seconds that elapses between the addition of the euglobulin and the lysis of the clot.

Using the logarithms of the lysis times, calculate the result of the assay by standard statistical methods.

The estimated potency is not less than 90.0 per cent and not more than 111.0 per cent of the stated potency.

The fiducial limits of error are not less than 80 per cent and not more than 125 per cent of the stated potency.

Urokinase intended for use in the manufacture of parenteral preparations or ophthalmic preparations complies with the following additional requirements.

Bacterial endotoxins (2.2.3). Not more than 0.002 Endotoxin Unit per Unit of urokinase activity.

Sterility (2.2.11). Complies with the test for sterility.

Storage. Store protected from light in a refrigerator (2º to 8º). The containers should be sterile, tamper-evident and sealed so as to exclude micro-organisms.

Labelling. The label states (1) the number of Units of urokinase activity in the container; (2) the number of Units of urokinase activity per mg of protein; (3) the storage conditions; (4) whether or not it is intended for use in the manufacture of parenteral preparations or ophthalmic preparations.
Vanillin
Vasopressin Injection
Verapamil Hydrochloride
Verapamil Injection
Verapamil Tablets
Vinblastine Sulphate
Vinblastine Injection
Vincristine Sulphate
Vincristine Injection
Vinorelbine Tartrate
Vinorelbine Tartrate Injection
Vitamin A Concentrate Oil
Vitamin A Concentrate Powder
Water-Miscible Vitamin A Concentrate
Vitamins A And D Capsules
Concentrated Vitamin D Solution
Concentrated Vitamins A And D Solution
Vanillin

\[
\text{C}_8\text{H}_8\text{O}_3 \quad \text{Mol. Wt. 152.2}
\]

Vanillin is 4-hydroxy-3-methoxybenzaldehyde.

Vanillin contains not less than 99.0 per cent and not more than 101.0 per cent of \( \text{C}_8\text{H}_8\text{O}_3 \), calculated on the dried basis.

**Description.** A white or slightly yellow powder or crystalline needles; odour, characteristic of vanilla.

**Identification**

*Test A may be omitted if tests B, C and D are carried out. Tests B, C and D may be omitted if test A is carried out.*

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with vanillin RS.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b). Examine the chromatograms in daylight after spraying.

C. To 5 ml of a saturated solution add 0.2 ml of ferric chloride solution; a blue colour is produced. Heat to 80º; the solution becomes brown and a white precipitate is produced on cooling.

D. Melting range (2.4.21). 81º to 84º.

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution in ethanol (95 per cent) is clear (2.4.1), and not more intensely coloured than reference solution BS6 (2.4.1).

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

*Mobile phase.* A mixture of 98.5 volumes of dichloromethane, 1 volume of methanol and 0.5 volume of anhydrous acetic acid.

*Test solution (a).* Dissolve 0.2 g of the substance under examination in 10 ml of methanol.

*Test solution (b).* Dissolve 0.2 g of the substance under examination in 100 ml of methanol.

*Reference solution (a).* Dissolve 10 mg of the substance under examination in 100 ml of methanol.

*Reference solution (b).* A 0.2 per cent w/v solution of vanillin RS in methanol.

Use an unsaturated tank and allow the mobile phase to rise 10 cm. Apply to the plate 5 µl of each solution. After development, dry the plate in cold air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a). Spray with dinitrophenylhydrazine-aceto-hydrochloric solution and examine in daylight. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Sulphated ash (2.3.18).** Not more than 0.1 per cent.

**Loss on drying (2.4.19).** Not more than 1.0 per cent, determined on 1.0 g by drying over phosphorus pentoxide for 4 hours.

**Assay.** Weigh accurately about 0.12 g, dissolve in 20 ml of ethanol (95 per cent), add 60 ml of carbon dioxide-free water. Titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.4.25).

1 ml of 0.1 M sodium hydroxide is equivalent to 0.01521 g of \( \text{C}_8\text{H}_8\text{O}_3 \).

**Storage.** Store protected from light and moisture.

Vasopressin Injection

Vasopressin Injection is a sterile aqueous solution containing the water-soluble pressor principle obtained from the posterior lobe of the pituitary of healthy oxen or other mammals or by synthesis.

Vasopressin Injection contains a pressor activity equivalent to not less than 90.0 per cent and not more than 110.0 per cent of the stated number of Units.

**Description.** A clear, colourless or practically colourless liquid; odour, faint and characteristic.

**Identification**

A. Inject into the vein of a mammal, anaesthetised by a general anaesthetic or by destruction of the brain; it causes a rise of blood pressure.

B. Inject under the skin of a mammal and at the same time administer a volume of water by mouth; it causes a delay in the excretion of the water.

**Tests**

**pH (2.4.24).** 2.5 to 4.5.

**Oxytocin activity.** Not more than 1.2 Units per 20 Units of vasopressor activity, determined by the biological assay of oxytocin.
Vasopressor activity. Not more than 0.5 Unit per 20 Units of oxytocic activity, when assayed by the following method.

The vasopressor activity is estimated by comparing the activity of the preparation under examination with that of the Standard Preparation of arginine vasopressin under the conditions of a suitable method of assay.

Standard Preparation

The Standard Preparation is the 1st International Standard for Arginine vasopressin, established in 1978, consisting of freeze-dried synthetic arginine vasopressin peptide acetate with human albumin and citric acid (supplied in ampoules containing 8.20 Units), or another suitable preparation the potency of which has been determined in relation to that of the International Standard.

Suggested Method

Inject slowly into the tail vein of a male albino rat weighing about 300 g a solution of a suitable a-adrenoceptor blocking agent, for example 10 ml per kg of body weight of a solution prepared by dissolving 5 mg of phenoxybenzamine hydrochloride in 0.1 ml of ethanol (95 per cent), adding 0.05 ml of 1 M hydrochloric acid and diluting to 5 ml with saline solution. After 18 hours, anaesthetise the rat with an anaesthetic that will maintain a prolonged and uniform blood pressure. After 45 to 60 minutes, tie the rat on its back to the operating table by its hind legs. Cannulate the trachea with a short polyethylene tube of external diameter about 2.5 mm and dissect a carotid artery ready for cannulation. Then cannulate the femoral vein close to the inguinal ligament. Retract the abdominal muscles to expose the inguinal ligament. Retract the superficial pudendal vein to one side and dissect the femoral vein towards the inguinal ligament from the corresponding artery. When dissecting, a deep branch reaching the femoral vein must be found and tied off to prevent bleeding during cannulation. Tie a short polyethylene cannula of external diameter about 1 mm into the femoral vein by two ligatures and join by a short piece of flexible tubing to a 1-ml burette with an attached thistle funnel containing saline solution at about 37°C. Firmly fix a wet absorbent cotton swab to the thigh so as to cover the incision and cannula. At this stage inject through the venous cannula 200 Units of heparin, dissolved in saline solution, per 100 g of body weight. Then tie in a carotid cannula of external diameter about 1 mm and connect by a column of saline solution containing heparin with a suitable pressure measuring device such as a mercury manometer of internal diameter about 2 to 3 mm.

The central and peripheral nervous system including both vagus and associated sympathetic nerves is left intact. No artificial respiration is necessary. Taking care that no air is injected, inject all solutions through the venous cannula by means of a 1-ml syringe graduated in 0.01 ml and wash in with 0.2 ml of saline solution from the burette.

Dilute the extract of the Standard Preparation and the preparation under examination with saline solution so that the volume to be injected is 0.1 ml to 0.5 ml.

Choose two doses of the Standard Preparation such that the elevation of the blood pressure is about 4 kPa for the lower dose and about 7 kPa but always submaximal for the higher dose, the ratio of low to high dose being determined by the response and usually being 3 to 5. As an initial approximation doses of 3 and 5 milliUnits may be tried. Choose two doses of the preparation under examination with the same inter-dose ratio, matching the effects of the dose of the Standard Preparation as closely as possible. Inject doses at intervals of 10 to 15 minutes.

The two doses of the Standard Preparation and the two doses of the preparation under examination should be given in a randomised block or a Latin square design and four to five responses to each should be recorded.

Measure all the responses and calculate the result of the assay by standard statistical methods.

Storage. Store in a refrigerator (2° to 8°).

Labelling. The label states (1) the number of Units of the vasopressor activity per ml; (2) either the animal source of the vasopressin or that it is synthetic.

Verapamil Hydrochloride

Verapamil Chloride; Iproveratril Hydrochloride

C_{27}H_{38}N_{2}O_{4}, HCl, 

Verapamil Hydrochloride is (2RS)-2-(3,4-dimethoxyphenyl)-5-[[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino]-2-(1-methylethyl)pentanenitrile hydrochloride.

Verapamil Hydrochloride contains not less than 99.0 per cent and not more than 101.0 per cent of C_{27}H_{38}N_{2}O_{4}, HCl, calculated on the dried basis.

Description. A white, crystalline powder.

Identification

Test A may be omitted if tests B, C and D are carried out. Tests B and C may be omitted if tests A and D are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with verapamil.
hydrochloride RS or with the reference spectrum of verapamil hydrochloride.

B. When examined in the range 220 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in 0.01 M hydrochloric acid shows absorption maxima at about 229 nm and 278 nm and there may be a shoulder at about 282 nm. The ratio of the absorbance at the maximum at about 278 nm to that at the maximum at about 229 nm is 0.35 to 0.39.

C. In test A for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).

D. Gives reaction B of chlorides (2.3.1).

Tests

Appearance of solution. A 5.0 per cent w/v solution in carbon dioxide-free water prepared with the aid of gentle heat is clear (2.4.1), and colourless (2.4.1).

pH (2.4.24). 4.5 to 6.0, determined in a 5.0 per cent w/v solution prepared with the aid of gentle heat.

Related substances. A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 70 volumes of toluene, 20 volumes of methanol, 5 volumes of glacial acetic acid and 5 volumes of acetone.

Test solution (a). Dissolve 0.5 g of the substance under examination in 10 ml of chloroform.

Test solution (b). Dilute 1 ml of test solution (a) to 100 ml with chloroform.

Reference solution (a). A 0.05 per cent w/v solution of verapamil hydrochloride RS in chloroform.

Reference solution (b). Dilute 5 ml of reference solution (a) to 100 ml with chloroform.

Reference solution (c). A 0.001 per cent w/v solution of verapamil hydrochloride RS in chloroform.

Apply to the plate 10 μl of each solution. After development, dry the plate at 110º for 30 minutes and allow to stand until the odour of solvent is no longer detectable. Spray with a solution prepared by dissolving 5 g of ferric chloride hexahydrate and 2 g of iodine in sufficient of a mixture of equal volumes of acetone and a 20 per cent w/v solution of (+)-tartaric acid to produce 100 ml, applying a total of 15 to 20 ml of the reagent for a plate (20 cm x 20 cm), and examine immediately. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the principal spot in the chromatogram obtained with reference solution (b) and not more than three such spots are more intense than the spot in the chromatogram obtained with reference solution (c). The test is not valid unless the spot in the chromatogram obtained with reference solution (c) is clearly visible. Ignore any spot remaining on the line of application.

B. Carry out test A but using a mixture of 85 volumes of cyclohexane and 15 volumes of diethylamine as the mobile phase and applying separately to the plate 10 μl of each of test solution (a), reference solutions (b) and (c) and heat at 110º for 90 minutes after the second development.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105º.

Assay. Weigh accurately about 0.4 g, dissolve in 40 ml of anhydrous glacial acetic acid, add 6 ml of mercuric acetate solution. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration. 1 ml of 0.1 M perchloric acid is equivalent to 0.04911 g of C27H38N2O4, HCl.

Storage. Store protected from light and moisture.

Verapamil Injection

Verapamil Hydrochloride Injection; Verapamil Chloride Injection; Iproveratril Hydrochloride Injection

Verapamil Injection is a sterile solution of Verapamil Hydrochloride in Water for Injections.

Verapamil Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of verapamil hydrochloride, C27H38N2O4, HCl.

Identification

A. Dilute a volume containing 10 mg of Verapamil Hydrochloride to 5 ml with 0.1 M hydrochloric acid, extract with 5 ml of ether, discard the ether extract and make the aqueous layer just alkaline with 2 M potassium carbonate. Extract with 5 ml of ether, filter the ether layer through anhydrous sodium sulphate and evaporate to dryness. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with verapamil hydrochloride RS treated in the same manner or with the reference spectrum of verapamil.

B. To a volume containing 5 mg of Verapamil Hydrochloride add 0.2 ml of a 5 per cent w/v solution of mercuric chloride; a white precipitate is produced.

C. To a volume containing 5 mg of Verapamil Hydrochloride add 0.5 ml of 3 M sulphuric acid and 0.2 ml of dilute potassium permanganate solution; a violet precipitate is produced which quickly dissolves to produce a very pale yellow solution.
Tests

pH (2.4.24). 4.5 to 6.0.

Related substances. A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 70 volumes of toluene, 20 volumes of methanol, 5 volumes of glacial acetic acid and 5 volumes of acetone.

Test solution. Evaporate a volume containing 5 mg of Verapamil Hydrochloride carefully to dryness on a water-bath in a current of nitrogen and dissolve the residue as completely as possible in 0.25 ml of chloroform.

Reference solution. Dilute 1 volume of the test solution to 100 volumes with chloroform and dilute 1 volume of the resulting solution to 10 volumes with chloroform.

Apply to the plate 30 µl of each solution. After development, dry the plate in air for 10 minutes and repeat the development. Dry the plate at 110º for 30 minutes and allow to stand until the odour of solvent is no longer detectable. Spray with a solution prepared by dissolving 5 g of ferric chloride hexahydrate and 2 g of iodine in sufficient of a mixture of equal volumes of acetone and a 20 per cent w/v solution of (+)-tartaric acid to produce 100 ml, applying a total of 15 to 20 ml of the reagent for a plate (20 cm x 20 cm), and examine immediately. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the principal spot in the chromatogram obtained with the reference solution. Ignore any spot remaining on the line of application.

B. Carry out test A but using a mixture of 85 volumes of cyclohexane and 15 volumes of diethylamine as the mobile phase and applying separately to the plate 30 µl of each of the test solution and the reference solution.

Other tests. Comply with the tests stated under Parenteral Preparations (Injections).

Assay. Dilute an accurately measured volume containing 5 mg of Verapamil Hydrochloride to 100.0 ml with 0.01 M hydrochloric acid and measure the absorbance at the maximum at about 278 nm (2.4.7). Calculate the content of C_{27}H_{38}N_{2}O_{4}, HCl taking 118 as the specific absorbance at 278 nm.

Storage. Store protected from light.

Verapamil Tablets

Verapamil Hydrochloride Tablets; Verapamil Chloride Tablets; Iproveratril Hydrochloride Tablets

Verapamil Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of verapamil hydrochloride, C_{27}H_{38}N_{2}O_{4}, HCl. The tablets may be coated.
solution is not more intense than the spot in the chromatogram
obtained with the reference solution. Ignore any spot remaining
on the line of application.

B. Carry out test A but using a mixture of 85 volumes of
cyclohexane and 15 volumes of diethylamine as the mobile
phase and applying separately to the plate 10 µl of each of the
test solution and the reference solution and heat at 110º for
90 minutes after the second development.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a
quantity of the powder containing 0.1 g of Verapamil
Hydrochloride, shake with 150 ml of 0.1 M hydrochloric acid
for 10 minutes, add sufficient 0.1 M hydrochloric acid
to produce 200.0 ml and filter. Dilute 10.0 ml of the filtrate to
100.0 ml with water and measure the absorbance
of the resulting solution at the maximum at about 278 nm (2.4.7).
Calculate the content of C27H38N2O4, HCl taking 118 as the
specific absorbance at 278 nm.

Vinblastine Sulphate

![](Vinblastine_Sulphate.png)

Vinblastine Sulphate is methyl (3aR,4R,5S,5aR,10bR,13aR)-4-acetoxy-3a-ethyl-9-[(5S,7R,9S)-5-ethyl-5-hydroxy-9-
methoxy carbonyl-1,4,5,6,7,8,9,10-octahydro-2H-3,7-
methanoazacycloundecino[5,4-b]indol-9-yl]-6-formyl-5-
hydroxy-8-methoxy-3a,4,5,5a,6,11,12,13a-octahydro-1H-

Vinblastine Sulphate contains not less than 95.0 per cent and
not more than 104.0 per cent of C_{27}H_{38}N_{2}O_{4}, H_{2}SO_{4}, calculated
on the dried basis.

Description. A white or yellowish, amorphous or crystalline
powder; very hygroscopic.

CAUTION—Handle Vinblastine Sulphate with great care
since it is a potent cytotoxic agent. Avoid contact with eyes;
irritant to tissues.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6).
Compare the spectrum with that obtained with vinblastine
sulphate RS.

B. In the Assay, the principal peak in the chromatogram
obtained with the test solution corresponds to the peak due
to vinblastine sulphate in the chromatogram obtained with
reference solution (b).

C. A 10 per cent w/v solution gives the reaction of sulphates
(2.3.1).

Tests

Appearance of solution. A 0.5 per cent w/v solution in carbon
dioxide-free water is clear (2.4.1), and not more intensely
coloured than reference solution YS7 (2.4.1).

pH (2.4.24). 3.5 to 5.0, determined in a 0.15 per cent w/v solution.

Related substances. In the Assay, the area of any secondary
peak in the chromatogram obtained with the test solution is
not greater than that of the principal peak in the chromatogram
obtained with reference solution (c) and the sum of the areas
of any such peaks is not greater than 2.5 times the area of the
principal peak in the chromatogram obtained with reference
solution (c). Ignore any peak with an area less than that of the
peak in the chromatogram obtained with reference solution (d).

Loss on drying (2.4.19). Not more than 15.0 per cent,
determined by Method B, on an appropriately calibrated
instrument using about 3.0 mg, accurately weighed. Heat the
substance under examination at the rate of 5º per minute
between ambient temperature and 200º in a current of nitrogen
for chromatography with a flow rate of 40 ml per minute. From
the thermogram, determine the accumulated loss in weight
between ambient temperature and a point on the plateau before
decomposition is indicated (at about 160º).

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 0.1 g of the substance under
examination in 100 ml of water.

Reference solution (a). A solution containing 0.1 per cent
w/v each of vinblastine sulphate RS and vincristine sulphate
RS in water.

Reference solution (b). A 0.1 per cent w/v solution of
vinblastine sulphate RS in water.

Reference solution (c). A 0.002 per cent w/v solution of
vinblastine sulphate RS in water.

Reference solution (d). A 0.0001 per cent w/v solution of
vinblastine sulphate RS in water.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with
  octylsilane bonded to porous silica (5 µm), (b) a guard
column packed with a suitable silica gel placed between the pump and the injection device,

- mobile phase: a mixture of 50 volumes of methanol, 38 volumes of a 1.5 per cent v/v solution of diethylamine adjusted to pH 7.5 with phosphoric acid and 12 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 262 nm,
- a 10 µl loop injector.

NOTE — Store all solutions in ice before use.

Inject each solution and record the chromatograms for 3 times the retention time of the peak due to vinblastine.

The assay is not valid unless the resolution between the peaks due to vincristine and vinblastine in the chromatogram obtained with reference solution (a) is at least 4 and the signal-to-noise ratio of the peak in the chromatogram obtained with reference solution (d) is at least 5.

Calculate the percentage content of C₄₆H₅₈N₄O₉.H₂SO₄.

Vinblastine Sulphate intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins complies with the following additional requirement.

Bacterial endotoxins (2.2.3). Not more than 10.0 Endotoxin Units per mg.

Vinblastine Sulphate intended for use in the manufacture of parenteral preparations without a further appropriate sterilisation procedure complies with the following additional requirement.

Identification

CAUTION — Handle Vinblastine Injection with great care since it is a potent cytotoxic agent. Avoid contact with eyes; irritant to tissues.

A. When examined in the range 230 nm to 360 nm (2.4.7), the solution obtained in the Assay shows an absorption maximum at about 267 nm.

B. In the test for Related substances, the principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a).

C. To 1 ml add 0.2 ml of a freshly prepared 1 per cent w/v solution of vanillin in hydrochloric acid; a pink colour is produced in about 1 minute (distinction from Vincristine Sulphate).

Tests

pH (2.4.24). 3.5 to 5.0, determined in a 0.15 per cent w/v solution of the dried contents.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 80 volumes of toluene, 40 volumes of chloroform and 6 volumes of diethylamine.

Test solution. Dissolve a quantity of the contents of a container in sufficient methanol to produce a solution containing the equivalent of 1 per cent w/v of dried vinblastine sulphate.

Reference solution (a). A 1 per cent w/v solution of vinblastine sulphate RS in methanol.

Reference solution (b). A 0.02 per cent w/v solution of vincristine sulphate RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (b).
**Bacterial endotoxins** (2.2.3). Not more than 10.0 Endotoxin Units per mg of the dried contents.

**Assay.** Weigh the contents of 20 sealed containers. Weigh accurately a quantity of the mixed contents containing about 20 mg of dried vinblastine sulphate and dissolve it in 100.0 ml of methanol. Dilute 10.0 ml to 100.0 ml with methanol and measure the absorbance of the resulting solution at the maximum at about 267 nm (2.4.7). Calculate the content of C_{46}H_{58}N_{4}O_{9},H_{2}SO_{4} taking 185 as the specific absorbance at 267 nm.

**Storage.** Store in sealed containers in a deep freezer (Below -18º).

**Labelling.** The label states (1) the strength in terms of the weight of dried vinblastine sulphate contained in it; (2) the names of auxiliary substances, if any; (3) that the contents are to be used by intravenous injection only; (4) the storage conditions.

**Vincristine Sulphate**

![Chemical structure of vincristine sulphate]

C_{46}H_{58}N_{4}O_{9},H_{2}SO_{4}  \quad \text{Mol. Wt. 923.1}

Vinblastine Sulphate is methyl (3aR,4R,5S,5aR,10bR,13aR)-4-acetoxy-3a-ethyl-9-[(5S,7R,9S)-5-ethyl-5-hydroxy-9-methoxy carbonyl-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-5-hydroxy-8-methoxy-6-methyl-3a,4,5,5a,6,11,12,13a-octahydro-JH-indolizin[8,1-c,d]carbazole-5-carboxylate sulphate.

Vincristine Sulphate contains not less than 95.0 per cent and not more than 104.0 per cent of C_{46}H_{58}N_{4}O_{9},H_{2}SO_{4}, calculated on the dried basis.

**Description.** A white to slightly yellowish, amorphous or crystalline powder; very hygroscopic.

CAUTION—Handle Vincristine Sulphate with great care since it is a potent cytotoxic agent. Avoid contact with eyes: irritant to tissues.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with vincristine sulphate RS.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to vincristine sulphate in the chromatogram obtained with reference solution (b).

C. A 10 per cent w/v solution gives the reaction for sulphates (2.3.1).

**Tests**

**Appearance of solution.** A 0.5 per cent w/v in carbon dioxide-free water is clear (2.4.1), and not more intensely coloured than reference solution YS7 (2.4.1).

**pH** (2.4.24). 3.5 to 4.5. Determined in a 0.1 per cent w/v solution.

**Related substances.** In the Assay, the area of any secondary peak in the chromatogram obtained with the test solution is not greater than that of the principal peak in the chromatogram obtained with reference solution (c) and the sum of the areas of any such peaks is not greater than 2.5 times the area of the principal peak in the chromatogram obtained with reference solution (c). Ignore any peak with an area less than that of the peak in the chromatogram obtained with reference solution (d).

**Loss on drying** (2.4.19). Not more than 12.0 per cent, determined by Method B, on an appropriately calibrated instrument using about 3.0 mg, accurately weighed. Heat the substance under examination at the rate of 5º per minute between ambient temperature and 200º in current of nitrogen for chromatography with a flow rate of 40 ml per minute.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 0.1 g of the substance under examination in 100 ml of water.

**Reference solution (a).** A solution containing 0.1 per cent w/v each of vinblastine sulphate RS and vincristine sulphate RS in water.

**Reference solution (b).** A 0.1 per cent w/v solution of vincristine sulphate RS in water.

**Reference solution (c).** A 0.002 per cent w/v solution of vincristine sulphate RS in water.

**Reference solution (d).** A 0.0001 per cent w/v solution of vincristine sulphate RS in water.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm), (b) a guard column packed with a suitable silica gel placed between the pump and the injection device,
- mobile phase: a mixture of 70 volumes of methanol and 30 volumes of a 1.5 per cent v/v solution of diethylamine adjusted to pH 7.5 with phosphoric acid,
- flow rate. 1 ml per minute,
Vincristine Injection

Vincristine Sulphate Injection

Vincristine Injection is a sterile material consisting of Vincristine Sulphate with or without auxiliary substances. It is filled in a sealed container.

The injection is constituted by dissolving the contents of the sealed container in the requisite amount of sterile 0.9 per cent w/v solution of Sodium Chloride, immediately before use.

The constituted solution complies with the requirements for Clarity of solution and Particulate matter stated under Parenteral Preparations (Injections).

Storage. The constituted solution should be used immediately after preparation but, in any case, within the period recommended by the manufacturer.

Vincristine Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of vincristine sulphate, C_{46}H_{56}N_{4}O_{10}.H_{2}SO_{4}.

The contents of the sealed container comply with the requirements stated under Parenteral Preparations (Powders for Injection) and with the following requirements.

Identification

CAUTION — Handle Vincristine Injection with great care since it is a potent cytotoxic agent. Avoid contact with eyes; irritant to tissues.

A. When examined in the range 230 nm to 360 nm (2.4.7), the solution obtained in the Assay shows an absorption maximum at about 297 nm.

B. In the test for Related substances, the principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (b).

C. Shake a quantity containing 1 mg of dried vincristine sulphate with 3 ml of chloroform, filter and wash the filter with 2 ml of chloroform. Reserve the residue for test D. Evaporate the combined chloroform solutions to dryness at 40º. Add 0.2 ml of a freshly prepared 1 per cent w/v solution of vanillin in hydrochloric acid to the residue; an orange colour is produced in about 1 minute (distinction from vinblastine sulphate).

D. Dissolve the residue reserved in test C in 1 ml of water. The solution complies with the following tests.

Heat 0.5 ml with 1 ml of potassium cupri-tartrate solution; a copious precipitate of copper oxide is produced.

Heat 0.5 ml with 0.3 ml of a 6.5 per cent w/v solution of cupric acetate in a 1 per cent v/v solution of glacial acetic acid; no precipitate is produced (distinction from fructose, glucose and galactose).

Tests

Appearance of solution. A solution prepared by dissolving the contents of a sealed container in 10 ml of carbon dioxide-free water is clear (2.4.1).

pH (2.4.24). 3.5 to 5.0, determined in a solution containing 0.15 per cent w/v solution of the dried contents.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 80 volumes of toluene, 40 volumes of chloroform and 6 volumes of diethylamine.

Test solution. Dissolve a quantity of the contents of a container in sufficient methanol (75 per cent) to produce a solution containing the equivalent of 1 per cent w/v of dried vincristine sulphate.
Reference solution (a). A 0.02 per cent w/v solution of vinblastine sulphate RS in methanol.

Reference solution (b). A 1 per cent w/v solution of vincristine sulphate RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (a).

Bacterial endotoxins (2.2.3). Not more than 62.5 Endotoxin Units per mg of dried vincristine sulphate.

Assay. Weigh the contents of 20 sealed containers. Weigh accurately a quantity of the mixed contents of the containers containing about 20 mg of dried vincristine sulphate and dissolve it in 100.0 ml of methanol. Dilute 10.0 ml to 100.0 ml with methanol and measure the absorbance of the resulting solution at the maximum at about 297 nm (2.4.7). Calculate the content of C_{46}H_{56}N_{4}O_{10},H_{2}SO_{4} taking 177 as the specific absorbance at 297 nm.

Storage. Store in sealed containers in a deep freezer (Below -18º).

Labelling. The label states (1) the strength in terms of the weight of dried vincristine sulphate contained in it; (2) the names of auxiliary substances, if any; (3) that the contents are to be used by intravenous injection only; (4) the storage conditions.

Vinorelbine Tartrate

![Chemical structure of Vinorelbine Tartrate]

C_{45}H_{54}N_{4}O_{8}, 2C_{4}H_{6}O_{6} Mol. Wt. 1079.11

Vinorelbine Tartrate is the ditartrate salt of vinorelbine, a semisynthetic Vinca alkaloid; structurally relate to vinblastine.

Vinorelbine Tartrate contains not less than 98.0 per cent and not more than 102.0 per cent of C_{45}H_{54}N_{4}O_{8}, 2C_{4}H_{6}O_{6} calculated on the anhydrous basis.

Description. A white to yellow or light brown amorphous powder.

CAUTION – Vinorelbine Tartrate is cytotoxic: extra care required to prevent inhaling particles and exposing the skin to it.

Identification

A. Dissolve 10 mg in 5 ml of water, add 0.5 ml of 5 M sodium hydroxide, and extract with 5 ml of methylene chloride. Filter the organic layer through anhydrous sodium sulphate, and evaporate to dryness.

Determine by Infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with vinorelbine tartrate RS treated in the same manner.

B. In the test for Related substances, the principal peak in the chromatogram of the test solution corresponds to that due to vinorelbine tartrate in the chromatogram obtained with the reference solution.

C. It gives the reactions for tartrate (2.3.1).

Tests

Appearance of solution. A 1.0 per cent w/v solution is clear (2.4.1).

Light absorption (2.4.7). The absorbance of 1.0 per cent w/v solution, at about 420 nm is not more than 0.03.

pH (2.4.24). 3.3 to 3.8, determined on a 1.0 per cent w/v solution.

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 35 mg of the substance under examination in 25 ml of mobile phase.

Reference solution (a). A 0.14 per cent w/v solution of vinorelbine tartrate RS in mobile phase.

Reference solution (b). Dilute 1 ml of the reference solution (a) to 100 ml with mobile phase.

Chromatographic system as described under Assay. Inject reference solution (a). The test is not valid unless the column efficiency is not less than 2000 theoretical plates and the tailing factor is not more than 2.0.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 0.3 times the area of the peak in the chromatogram obtained with the reference solution (b) (0.3 per cent) and the sum of areas of all the secondary peaks is not more than the area of the peak in the chromatogram obtained with the reference solution (b) (1.0 per cent). Ignore any secondary peak having area less than 0.1 per cent.

Test solution. Weigh accurately about 0.2 g of the substance under examination, add 0.5 ml of water and 0.5 ml of N,N'-dimethyl formamide in to a 10 ml head space vial and seal it.
Reference solution (a). To 50 ml of \(N,N'\)-dimethyl formamide, add 600 mg of methanol and 1000 mg of acetone, diluted to 100 ml with \(N,N'\)-dimethyl formamide.

Reference solution (b). To 50 ml of \(N,N'\)-dimethyl formamide, add 2400 mg of dichloromethane, 2880 mg of tetrahydrofuran and 240 mg of chloroform, diluted to 100 ml with \(N,N'\)-dimethyl formamide. Dilute 5 ml of the solution to 100 ml with \(N,N'\)-dimethyl formamide.

Reference solution (c). Dilute 10 ml each of reference solutions (a) and (b) to 50 ml with \(N,N'\)-dimethyl formamide. Mix 0.5 ml of this solution with 0.5 ml of water in a 10 ml head space vial and seal it.

Chromatographic system
- a capillary column 30 m x 0.32 mm, coated with 1 per cent vinyl and 5 per cent phenylmethylpolysiloxane (0.5 µm),
- temperature: column, 40º for 12 minutes increase @ 30º per minute to 220º hold for 5 minutes, inlet port 120º and detector, 250º,
- nitrogen as carrier gas with a flow rate 0.5 ml per min.

Headspace conditions
Sample oven temperature 75º, Sample valve temperature 95º, Transfer line 100º, vial equilibrium 30 minutes, vial Pressurisation 0.2 minute, sample loop fill 0.2 minute, loop equilibrium 0.05 minute sample injection 1 minute.
- a flame ionisation detector,
Inject 1 ml of the reference solution (c). The test is not valid unless the resolution between two adjacent peaks is not less than 1.5.

Inject 1 ml of the test solution and reference solution (c). In the chromatogram obtained with test solution, the area of peaks due to methanol, acetone, dichloromethane, chloroform and tetrahydrofuran is not more than the area of peaks obtained in the chromatogram due to reference solution (c).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Water (2.3.43). Not more than 4.0 per cent, determined on 0.1 g.

Bacterial endotoxins (2.2.3). Not more than 1.5 Endotoxin Unit per mg of vinorelbine base.

Microbial contamination (2.2.9). Total viable aerobic count, not more than 100 cfu per g, total combined molds and yeast does not exceed 50 cfu per g. It also meets the requirement of the tests for the absence of Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella species, Escherichia coli, Enterobacteria and Closteridia.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 35 mg of the substance under examination in 25.0 ml of mobile phase.

Reference solution. A 0.14 per cent w/v solution of vinorelbine tartrate RS in mobile phase.

Chromatographic system
- a stainless steel column 15 cm x 3.9 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- column temperature 40º,
- mobile phase: 62 volumes of methanol containing 1.22 g of sodium 1-decane sulphonate and 38 volumes of phosphate buffer solution, prepared by dissolving 6.9 g of monobasic sodium phosphate in 900 ml of water, adjust the pH to 4.2 with orthophosphoric acid and dilute to 1000 ml with water,
- flow rate. 1 ml per minute,
- spectrophotometer set at 267 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution. Calculate the content of C\(_{45}\)H\(_{54}\)N\(_4\)O\(_8\).2C\(_4\)H\(_6\)O\(_6\).

Storage. Store protected from light, at a temperature not exceeding 25º.

**Vinorelbine Injection**

Vinorelbine Tartrate Injection

Vinorelbine Injection is a sterile solution of vinorelbine tartrate in Water for Injection.

Vinorelbine Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of vinorelbine, C\(_{45}\)H\(_{54}\)N\(_4\)O\(_8\).2C\(_4\)H\(_6\)O\(_6\).

**Description.** A clear, colourless to pale yellow solution.

**Identification**

A. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with the reference solution.

B. When examined in the range 220 nm to 380 nm (2.4.7), a solution containing 0.01 per cent w/v of Vinorelbine Tartrate, exhibits the maxima at about 267 nm.

**Tests**

**pH** (2.4.24). 3.0 to 3.8.

**Light absorption.** The absorbance of the injection at about 420 nm (2.4.7), is not more than 0.06.

**Related substances.** Determine by liquid chromatography (2.4.14).

Test solution. Accurately measured volume of injection containing 10 mg of Vinorelbine Tartrate, dilute to 10 ml with mobile phase.
Reference solution (a). A 0.1 per cent w/v solution of vinorelbine tartrate RS in mobile phase.

Reference solution (b). Dilute 1 ml of the reference solution (a) to 100 ml with mobile phase.

Chromatographic system as described under Assay.

Inject reference solution (a). The test is not valid unless the column efficiency is not less than 2000 theoretical plates and the tailing factor is not more than 2.0.

Inject the test solution and reference solution (b). Run the chromatograms three times the retention time of the peak due to vinorelbine. In the chromatogram obtained with the test solution, the area of any secondary peak is not more than 0.2 times the area of the peak in the chromatogram obtained with the reference solution (b) (0.2 per cent) and the sum of areas of all the secondary peaks is not more than twice the area of the peak in the chromatogram obtained with the reference solution (b) (2.0 per cent).

Other tests. Complies with the tests stated under Parenteral Preparation (Injections).

Bacterial endotoxins (2.2.3). Not more than 3.0 Endotoxin Unit per mg of vinorelbine tartrate

Sterility (2.2.11). Complies with the test for sterility.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Accurately measured volume of injection containing 10 mg of Vinorelbine Tartrate, diluted to 100.0 ml with water.

Reference solution. A 0.1 per cent w/v solution of vinorelbine tartrate RS in water.

Chromatographic system

- a stainless steel column 15 cm x 3.9 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- column temperature 40°C,
- mobile phase: a mixture of 62 volumes of methanol containing 1.22 g of sodium1-decane sulphonate and 38 volumes of phosphate buffer solution prepared by dissolving 6.9 g of monobasic sodium phosphate in 900 ml of water adjusted the pH to 4.2 with orthophosphoric acid and dilute to 1000 ml with water,
- flow rate. 1 ml per minute,
- spectrophotometer set at 267 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation is not more than 2.0 per cent.

Inject the test solution and the reference solution.

Calculate the content of C45H54N4O8.

Storage. Store protected from light, in single-dose container.

Vitamin A Concentrate Oil

Synthetic Vitamin A Concentrate (Oily Form); Synthetic Retinol Concentrate (Oily Form)

Vitamin A Concentrate Oil consists of an ester or a mixture of esters of retinol (as acetate, propionate or palmitate) prepared by synthesis. It may be diluted with a suitable vegetable oil. It may contain suitable stabilising agents such as antioxidants.

Vitamin A Concentrate Oil contains not less than 500,000 Units of Vitamin A per g, and not less than 95.0 per cent and not more than 110.0 per cent of the stated number of Units of Vitamin A per g.

Description. A yellow to brownish yellow, oily liquid; odour, faint and characteristic.

Identification

A. When examined in the range 230 nm to 360 nm (2.4.7), a solution in 2-propanol containing 10 to 15 Units per ml shows an absorption maximum at about 325 nm to 327 nm.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 80 volumes of cyclohexane and 20 volumes of ether.

Test solution. Prepare a solution containing 5 Units per µl of the substance under examination in cyclohexane.

Reference solution (a). Prepare a solution containing 5 Units per µl of retinyl acetate RS in cyclohexane.

Reference solution (b). Prepare a solution containing 5 Units per µl of retinyl propionate RS in cyclohexane.

Reference solution (c). Prepare a solution containing 5 Units per µl of retinyl palmitate RS in cyclohexane.

C. Dissolve a quantity containing 10 to 15 Units in 1 ml of chloroform and add 5 ml of antimony trichloride solution; a transient bright blue colour is produced immediately.

Tests

Acid value (2.3.23). Not more than 2.0, determined on 2.0 g.

Peroxides. Add 0.3 g to 25.0 ml of a mixture of 6 volumes of toluene and 4 volumes of methanol (solution A). Add in a test-tube, in the following order, mixing after each addition, 0.3 ml of a 1.8 per cent w/v solution of ammonium thiocyanate,
10.0 ml of methanol, 0.3 ml of ferrous sulphate solution and 15.0 ml of toluene and add 1.0 ml of solution A. The colour produced after 5 minutes is not more intense than that obtained in a solution prepared at the same time and in the same manner but using a solution prepared in the following manner in place of solution A. Add 1.0 ml of a 27.0 per cent w/v solution of ferric chloride hexahydrate to 99 ml of a mixture of 6 volumes of toluene and 4 volumes of methanol and dilute 2.0 ml to 100.0 ml with the same solvent mixture.

**Assay.** Carry out the assay of vitamin A, Method A (2.3.41).

**Storage.** Store protected from light, in well-filled containers. Once the container has been opened, its contents should be used as soon as possible; any part of the contents not used at once should be protected by an atmosphere of an inert gas.

**Labelling.** The label states (1) the number of Units of Vitamin A per g; (2) the name of the ester or esters; (3) the name(s) of any added stabilising agent(s); (4) the method of restoring the solution if partial crystallisation has occurred.

---

**Vitamin A Concentrate Powder**

Synthetic Vitamin A Concentrate (Powder Form); Synthetic Retinol Concentrate (Powder Form)

Vitamin A Concentrate Powder consists of an ester or a mixture of esters of retinol (as acetate, propionate or palmitate) prepared by synthesis and dispersed in a matrix of Gelatin, Acacia or any other suitable material. It may contain suitable stabilising agents such as antioxidants.

Vitamin A Concentrate Powder contains not less than 250,000 Units of Vitamin A per g, and not less than 95.0 per cent and not more than 115.0 per cent of the stated number of Units of Vitamin A per g.

**Description.** A yellowish powder usually in the form of pellets or particles of almost uniform size.

**Identification**

To a quantity containing 50,000 Units of Vitamin A add 1.5 ml of 2 M ammonia previously heated to 60°, and heat in a water-bath at 60°, shaking occasionally. After 10 minutes add 40 ml of ethanol, dilute to 200 ml with ether and shake. Allow to stand for a few minutes and use the supernatant liquid (solution A) for the following tests.

Certain samples may not react sufficiently during the course of the above treatment. In such cases the volume of solution A used in the following tests should be increased which may be as much as 10-fold.

---

**A. When examined in the range 230 nm to 360 nm (2.4.7), a solution in 2-propanol containing 10 to 15 Units per ml shows an absorption maximum at about 325 nm to 327 nm.**

**B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.**

**Mobile phase.** A mixture of 80 volumes of cyclohexane and 20 volumes of ether.

**Test solution.** Evaporate 10 ml of solution A to dryness in a current of nitrogen and dissolve the residue in 0.5 ml of cyclohexane.

**Reference solution (a).** Prepare a solution containing 5 Units per µl of retinyl acetate RS in cyclohexane.

**Reference solution (b).** Prepare 5 Units per µl of retinyl propionate RS in cyclohexane.

**Reference solution (c).** Prepare a solution containing 5 Units per µl of retinyl palmitate RS in cyclohexane.

Apply to the plate 2 µl of each solution. After development, dry the plate in air, spray with antimony trichloride solution. The principal spot or spots in the chromatogram obtained with the test solution correspond to one or more of the spots in the chromatograms obtained with reference solutions (a), (b) and (c).

**C. Dilute 2 ml of solution A to 50 ml with n-pentane and evaporate 1 ml of the solution to dryness in a current of nitrogen. Dissolve the residue in 1 ml of chloroform and add 5 ml of antimony trichloride solution; a transient bright blue colour is produced immediately.**

**Tests**

**Related substances and degradation products.** Using the relative absorbances obtained in the Assay, the ratio A300/A325 is not more than 0.612 and the sum of the ratios A300/A325 and A325/A325 is not more than 1.054, where A300, A325 and A350 are the absorbances measured at about 300 nm, 325 nm and 350 nm respectively.

**Assay.** Carry out the assay of vitamin A, Method B (2.3.41), adding 5 ml of water to the mixture for saponification, using 2-propanol as the blank and taking 0.612 as the maximum value of the ratio A300/A325.

**Storage.** Store protected from light. Once the container has been opened, its contents should be used as soon as possible; any part of the contents not used at once should be protected by an atmosphere of an inert gas.

**Labelling.** The label states (1) the number of Units of Vitamin A per g; (2) the name of the ester or esters; (3) the name of the principal excipient or excipients used; (4) the name of any added stabilising agents.
Water-Miscible Vitamin A Concentrate

Synthetic Vitamin A Concentrate (Water-dispersible Form); Synthetic Retinol Concentrate (Water-dispersible Form)

Water-miscible Vitamin A Concentrate consists of an ester or a mixture of esters of retinol (as acetate, propionate or palmitate) prepared by synthesis to which suitable solubilisers have been added. It may contain suitable stabilising agents such as antimicrobial preservatives and antioxidants.

Water-miscible Vitamin A Concentrate contains not less than 100,000 Units of Vitamin A per g, and not less than 95.0 per cent and not more than 115.0 per cent of the stated number of Units of Vitamin A per g.

Description. A yellow or yellowish liquid of variable opalescence and viscosity; odour, characteristic. Highly concentrated solutions may become cloudy at low temperatures or gel at room temperature.

Identification

To a quantity containing about 10,000 Units of Vitamin A add 5 ml of water and homogenise. Add 5 ml of ethanol (95 per cent) and 20 ml of n-pentane and shake vigorously for 30 seconds. Allow to stand for a few minutes and use the supernatant liquid (solution A) for the following tests.

A. Dilute solution A with sufficient 2-propanol so that the absorbance at the wavelength of maximum absorption is 0.3 to 0.7 (2.4.7).

When examined in the range 230 nm to 360 nm (2.4.7), the solution shows an absorption maximum at 325 to 327 nm.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G. Mobile phase. A mixture of 80 volumes of cyclohexane and 20 volumes of ether. Test solution. Evaporate 10 ml of solution A to dryness in a current of nitrogen and dissolve the residue in 0.5 ml of cyclohexane.

Reference solution (a). Prepare a solution containing 5 Units per µl of retinyl acetate RS in cyclohexane.

Reference solution (b). Prepare a solution containing 5 Units per µl of retinyl propionate RS in cyclohexane.

Reference solution (c). Prepare a solution containing 5 Units per µl of retinyl palmitate RS in cyclohexane.

Apply to the plate 2 µl of each solution. After development, dry the plate in air, spray with antimony trichloride solution. The principal spot or spots in the chromatogram obtained with the test solution correspond to one or more of the spots in the chromatograms obtained with reference solutions (a), (b) and (c).

C. Evaporate 0.1 ml of solution A to dryness in a current of nitrogen, dissolve the residue in 1 ml of chloroform and add 5 ml of antimony trichloride solution; a transient bright blue colour is produced immediately.

Tests

Water miscibility. Mix about 1 g with 10 ml of water previously heated to 50° and cool to 20°. Immediately after cooling, a uniform, slightly opalescent and slightly yellow dispersion is obtained.

Related substances and degradation products. Using the relative absorbances obtained in the Assay, the ratio A_{300}/A_{325} is not more than 0.618 and the sum of the ratios A_{300}/A_{325} and A_{350}/A_{325} is not more than 1.060, where A_{300}, A_{325} and A_{350} are the absorbances measured at about 300 nm, 325 nm and 350 nm respectively.

Assay. Carry out the assay of vitamin A, Method B (2.3.41), using 2-propanol as the blank and taking 0.618 as the maximum value of the ratio A_{300}/A_{325}.

Storage. Store protected from light at the temperature stated on the label. Once the container has been opened, its contents should be used as soon as possible; any part of the contents not used at once should be protected by an atmosphere of an inert gas.

Labelling. The label states (1) the number of Units of Vitamin A per g; (2) the name of the ester or esters; (3) the name of the principal excipient or excipients used; (4) the temperature at which it should be stored.

Vitamins A And D Capsules

Vitamins A and D Capsules contain Vitamin A Oil and a source of vitamin D such as Cholecalciferol or Ergocalciferol in an edible vegetable oil.

Vitamins A and D Capsules contain not less than 90.0 per cent of the stated number of Units of vitamin A and vitamin D.

Tests

Other tests. Comply with the tests stated under Capsules.

Assay. For vitamin A — Weigh accurately a portion of the mixed contents of 20 capsules containing about 500 Units of Vitamin A and carry out the assay of vitamin A, Method A (2.3.41).

For vitamin D — Weigh accurately a portion of the mixed contents of 20 capsules containing about 5000 Units of vitamin D and carry out the assay of vitamin D (2.3.42).
Storage. Store protected from light and moisture.

Labelling. The label states the number of Units of vitamin A and vitamin D per capsule.

**Concentrated Vitamin D Solution**

Concentrated Vitamin D Solution is a solution of Cholecalciferol or Ergocalciferol in an edible vegetable oil. It may contain suitable stabilising agents such as antioxidants.

Concentrated Vitamin D Solution contains not less than 10,000 Units of vitamin D and not less than 90.0 per cent of the stated number of Units of vitamin D.

**Description.** A pale yellow to yellow, oily liquid; odour, faint but not rancid.

**Identification**

Dissolve a quantity containing about 1000 Units of vitamin D in 1 ml of chloroform and add 10 ml of antimony trichloride solution; a pinkish red colour appears at once.

**Tests**

**Acid value** (2.3.23). Not more than 2.5, determined on 2.0 g.

**Assay.** Carry out the assay of vitamin D (2.3.42).

**Storage.** Store protected from light, in well-filled containers at a temperature of 6º to 15º. The contents of an opened container should be used as soon as possible.

Labelling. The label states (1) the number of Units of vitamin D per g; (2) the storage conditions; (3) the nature and concentration of any stabilising agent added.

**Concentrated Vitamins A And D Solution**

Concentrated Vitamins A and D Solution is a solution of Vitamin A Oil and a source of vitamin D such as Cholecalciferol or Ergocalciferol in an edible vegetable oil. It may contain suitable stabilising agents such as antioxidants.

Concentrated Vitamins A and D Solution contains not less than 50,000 Units of vitamin A and 5000 Units of vitamin D per g, and not less than 90.0 per cent and not more than 110.0 per cent of the stated number of Units of Vitamin A and vitamin D per g.

**Tests**

**Acid value** (2.3.23). Not more than 2.5, determined on 2.0 g.

**Assay.** For vitamin A — Carry out the assay of vitamin A, Method A (2.3.41).

For vitamin D — Carry out the assay of vitamin D (2.3.42).

**Storage.** Store protected from light and moisture.

Labelling. The label states (1) the number of Units of vitamin A and vitamin D per gram; (2) the storage conditions.
W

Warfarin Sodium
Warfarin Sodium Clathrate
Warfarin Tablets
Purified Water
Water For Injections
Water For Injections in Bulk
Sterile Water For Injections
Wool Fat
Hydrous Wool Fat
Warfarin Sodium

\[
\text{C}_{19}\text{H}_{15}\text{NaO}_4 \quad \text{Mol. Wt. 330.3}
\]

Warfarin Sodium is sodium 2-oxo-3-[(1\text{RS})-3-oxo-1-phenylbutyl]-2H-1-benzopyran-4-olate.

Warfarin Sodium contains not less than 98.0 per cent and not more than 102.0 per cent of C\text{19}H\text{15}NaO\text{4}, calculated on the anhydrous basis.

**Description.** A white powder; hygroscopic.

**Identification**

Test A may be omitted if tests B, C, D and E are carried out. Tests B and D may be omitted if tests A, C and E are carried out.

A. Dissolve 1 g in 25 ml of water, add 2 ml of 2 M hydrochloric acid and filter. Wash the residue with water and dry over phosphorus pentoxide.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with warfarin sodium RS or with the reference spectrum of warfarin sodium.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).

C. Dissolve 1 g in 10 ml of water, add 5 ml of nitric acid and filter. To the filtrate add 2 ml of potassium dichromate solution, shake for 5 minutes and allow to stand for 20 minutes; the solution is not greenish blue when compared with a blank.

D. The residue obtained in test A, after washing with water and drying at 105°, melts at 159° to 163° (2.4.21).

E. The filtrate obtained in test A gives the reactions of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution is clear (2.4.1), and colourless (2.4.1).

**pH** (2.4.24). 7.6 to 8.6, determined in a 1.0 per cent w/v solution.

**Phenolic ketones.** Absorbance of a 12.5 per cent w/v solution in a 5.0 per cent w/v solution of sodium hydroxide at the maximum at about 385 nm, measured within 15 minutes of preparation, is not more than 0.20 (2.4.7).

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 50 volumes of chloroform, 50 volumes of cyclohexane and 20 volumes of glacial acetic acid.

**Test solution (a).** Dissolve 0.2 g of the substance under examination in 10 ml of acetone.

**Test solution (b).** Dissolve 0.4 g of the substance under examination in 100 ml of acetone.

**Reference solution (a).** A 0.002 per cent w/v solution of the substance under examination in acetone.

**Reference solution (b).** A 0.4 per cent w/v solution of warfarin sodium RS in acetone.

**Reference solution (c).** A solution containing 0.1 per cent w/v of acenocoumarol RS and 0.2 per cent w/v of the substance under examination in acetone.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (c) shows two clearly separated spots and the chromatogram obtained with reference solution (a) shows a clearly visible spot.

**Water** (2.3.43). Not more than 4.0 per cent, determined on 0.75 g.

**Assay.** Weigh accurately about 0.1 g and dissolve in sufficient 0.01 M sodium hydroxide to produce 100.0 ml. Dilute 10.0 ml to 100.0 ml with 0.01 M sodium hydroxide and dilute 5.0 ml to 50.0 ml with 0.01 M sodium hydroxide. Measure the absorbance of the resulting solution at the maximum at about 308 nm (2.4.7). Calculate the content of C\text{19}H\text{15}NaO\text{4} taking 431 as the specific absorbance at 308 nm.

**Storage.** Store protected from light and moisture.

Warfarin Sodium Clathrate

Warfarin Sodium Clathrate is a clathrate form of Warfarin Sodium consisting principally of Warfarin Sodium and Isopropyl Alcohol in a 2.1 molecular ratio.

Warfarin Sodium Clathrate contains not less than 97.0 per cent and more than 102.0 per cent of C\text{19}H\text{15}NaO\text{4} calculated on the anhydrous, isopropyl alcohol-free basis and not less than 8.0 per cent and not more than 8.5 per cent of isopropyl alcohol.
**Description.** A white crystalline powder; hygroscopic.

**Identification**

Test A may be omitted if test B, C, D and E are carried out. Tests B and D may be omitted if tests A, C and E are carried out.

A. Dissolve about 1 g in 25 ml of water, add 2 ml of 2 M hydrochloric acid and filter. Wash the precipitate 5 to 6 times with water. Dry the residue over phosphorus pentoxide.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with warfarin sodium RS or with the reference spectrum of warfarin sodium.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (b).

C. Dissolve 1 g in 10 ml of water, add 5 ml of nitric acid and filter. To the filtrate add 2 ml of potassium dichromate solution, shake for 5 minutes and allow to stand for 20 minutes; the solution is not greenish-blue when compared with a blank.

D. The residue obtained in test A, after washing with water and drying at 105° melts at 159° to 163°.

E. The filtrate obtained in test A gives the reactions of sodium salts (2.3.1).

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution is clear (2.4.1), and colourless (2.4.1).

**pH** (2.4.24). 7.2 to 8.3, determined in a 1.0 per cent w/v solution.

**Phenolic ketones.** Absorbance of a 12.5 per cent w/v solution in a 5.0 per cent w/v solution of sodium hydroxide at the maximum at about 385 nm, measured within 15 minutes of preparation, is not more than 0.20 (2.4.7).

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 50 volumes of chloroform, 50 volumes of cyclohexane and 20 volumes of glacial acetic acid.

**Test solution (a).** Dissolve 0.2 g of the substance under examination in 10 ml of acetone.

**Test solution (b).** Dissolve 0.4 g of the substance under examination in 100 ml of acetone.

**Reference solution (a).** A 0.002 per cent w/v solution of the substance under examination in acetone.

**Reference solution (b).** A 0.4 per cent w/v solution of warfarin sodium RS in acetone.

**Reference solution (c).** A solution containing 0.1 per cent w/v of acenocumarol RS and 0.2 per cent w/v of the substance under examination in acetone.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (c) show two clearly separated spots and the chromatogram obtained with reference solution (a) shows a clearly visible spot.

**Water** (2.3.43). Not more than 4.0 per cent, determined on 0.75 g.

**Isopropyl alcohol.** Determine by gas chromatography (2.4.13).

**Test solution.** Dissolve 0.5 g of the substance under examination in sufficient water to produce 10 ml.

**Reference solution (a).** A solution containing 5.0 per cent w/v of the substance under examination and 0.5 per cent v/v of propan-1-ol (internal standard).

**Reference solution (b).** A solution containing 0.5 per cent v/v of propan-2-ol and the internal standard.

**Chromatographic system**

- a glass column 1.5 m x 4 mm, packed with porous polymer beads (125 to 150 mm) (such as Porapak Q),
- temperature: column 150°, inlet port at 180° and detector at 200°,
- flow rate. 40 ml per minute of the carrier gas.

The column temperature may be varied so that the resolution, R, between propan-1-ol and propanol-2 ol is not less than 2.0, the tailing factor, T, for the propan-2-ol is not less than 2.0 the tailing factor, T, for the propan-2-ol peak is not more than 1.5 and the relative standard deviation of the ratio of the area due to the peak of propanol-2-ol to that due to propan-1-ol for five replicate injections of reference solution (b) is not more than 2.0 per cent.

Calculate the content of isopropyl alcohol.

**Assay.** Weigh accurately about 0.1 g and dissolve in sufficient 0.01 M sodium hydroxide to produce 100.0 ml. Dilute 10.0 ml to 100.0 ml with 0.01 M sodium hydroxide and dilute 5.0 ml to 50.0 ml with 0.01 M sodium hydroxide. Measure the absorbance of the resulting solution at the maximum at about 308 nm (2.4.7). Calculate the content of C₁₉H₁₅NaO₄ taking 431 as the specific absorbance at 308 nm.

**Storage.** Store protected from light and moisture.
**Warfarin Tablets**

**Warfarin Sodium Tablets**

Warfarin Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of warfarin sodium, C₁₉H₁₅NaO₄.

**Identification**

A. Extract a quantity of the powdered tablets containing 0.1 g of Warfarin Sodium with 30 ml of water, add 0.1 ml of 2 M hydrochloric acid, filter, wash the precipitate with water and dry. Warm the residue gently with 3 ml of ethanol (95 per cent), filter and add the filtrate to 25 ml of water containing 0.1 ml of 2 M hydrochloric acid. Filter, wash the precipitate with water and dry it at 105°.

On the residue, determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with warfarin sodium RS or with the reference spectrum of warfarin sodium.

B. The final residue obtained in test A melts at about 159° (2.4.21).

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 50 volumes of chloroform, 50 volumes of cyclohexane and 20 volumes of glacial acetic acid.

**Test solution.** Shake a quantity of the powdered tablets containing 40 mg of Warfarin Sodium with 30 ml of water for 15 minutes, add 0.1 ml of hydrochloric acid and extract with three quantities, each of 10 ml, of chloroform, drying each extract with anhydrous sodium sulphate. Evaporate the combined extracts at a temperature not exceeding 40° and dissolve the residue in 2 ml of acetone.

**Reference solution (a).** Dilute 1 volume of the test solution to 200 volumes with acetone.

**Reference solution (b).** A 0.002 per cent w/v solution of (E)-4-phenylbut-3-en-2-one in acetone.

**Reference solution (c).** A 0.02 per cent w/v solution of 4-hydroxycoumarin in acetone.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine immediately in visible light noting the position of any coloured spots and then examine in ultraviolet light at 254 nm, ignoring any spot that was noted in visible light. Any spots corresponding to (E)-4-phenylbut-3-en-2-one and 4-hydroxycoumarin in the chromatogram obtained with the test solution are not more intense than the spots in the chromatograms obtained with reference solutions (b) and (c) respectively and any other secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Uniformity of content.** Comply with the test stated under Tablets.

Determine by liquid chromatography (2.4.14).

**Test solution.** Shake one tablet with 10 ml of 0.01 M sodium hydroxide for 15 minutes, add 10 ml of a 2 per cent v/v solution of glacial acetic acid in acetonitrile, centrifuge for 10 minutes and use the clear supernatant liquid.

**Chromatographic system**

- a stainless steel column 10 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 55 volumes of formic acid, 45 volumes of water and 1 volume of glacial acetic acid,
- flow rate. 2 ml per minute,
- spectrophotometer set at 283 nm,
- a 20 µl loop injector.

Determine the content of C₁₉H₁₅NaO₄ in the tablet.

**Dissolution** (2.5.2).

**Apparatus.** No 1

**Medium.** 900 ml of a 0.68 per cent w/v solution of potassium dihydrogen phosphate with the pH adjusted to 6.8 by the addition of 1 M sodium hydroxide

**Speed and time.** 100 rpm and 45 minutes.

For tablets containing 2 mg or less of warfarin sodium, use three tablets for each test; for tablets containing more than 2 mg of warfarin sodium, use a single tablet for each test.

Withdraw a suitable volume of the medium and filter. Measure the absorbance of a layer of suitable thickness of the filtrate, suitably diluted if necessary, at the maxima at about 307 nm and 360 nm (2.4.7), and calculate the difference between the two absorbances (DA). Use this value to calculate the content of the tablet by the method described in 2.4.7 (Quantitative determination of Warfarin).

D. Not less than 70 per cent of the stated amount of C₁₉H₁₅NaO₄.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 20 mg of Warfarin Sodium and shake with 250.0 ml of 0.01 M sodium hydroxide for 15 minutes and filter. To 20.0 ml of the filtrate add 0.15 ml of hydrochloric acid and extract with three quantities, each of 15 ml, of chloroform. Extract the combined chloroform layers with three quantities, each of 20 ml, of 0.01 M sodium hydroxide.

Dilute the combined aqueous layers to 100.0 ml with 0.01 M sodium hydroxide.
sodium hydroxide, filter and measure the absorbance of the resulting solution at the maximum at about 307 nm (2.4.7). Calculate the content of C₁₉H₁₅NaO₄ taking 431 as the specific absorbance at 307 nm.

**Storage.** Store protected from light.

### Purified Water

**H₂O**  
Mol. Wt. 18.0

Purified Water is prepared by distillation, by means of ion exchange or by any other appropriate means from suitable potable water that complies with all relevant statutory regulations.

During production and subsequent storage, it is recommended that adequate measures are taken to ensure that the microbial quality is controlled and monitored. Appropriate alert and action limits are set so as to detect adverse trends. Under controlled conditions, an appropriate action limit is a total viable count (2.2.9) of 100 micro-organisms per ml, determined by membrane filtration. In addition, the test for oxidisable substances (given below) is carried out. The adequacy of these measures may be determined by carrying out the test for conductivity (2.4.9) off-line or in-line.

**Description.** A clear, colourless liquid; odourless and tasteless.

**Tests**

- **Acidity or alkalinity.** To 10 ml, freshly boiled and cooled in a borosilicate glass flask, add 0.05 ml of *methyl red solution*; the resulting solution is not red. To 10 ml add 0.1 ml of *bromothymol blue solution*; the resulting solution is not blue.

- **Ammonium.** To 20 ml add 1 ml of *alkaline potassium mercuri-iodide solution*, and allow to stand for 5 minutes. When viewed vertically the solution is not more intensely coloured than a solution prepared at the same time by adding 1 ml of *alkaline potassium mercuri-iodide solution* to a mixture of 4.0 ml of *ammonium standard solution (1 ppm NH₄)* and 16.0 ml of *ammonia-free water (0.2 ppm)*.

- **Calcium and magnesium.** To 100 ml add 2 ml of *ammonia buffer pH 10.0, 50 mg of mordant black II mixture* and 0.5 ml of 0.01 M *disodium edetate*; a pure blue colour is produced.

- **Heavy metals** (2.3.13). Evaporate 150 ml to 15 ml on a water-bath; 12 ml of the solution complies with the limit test for heavy metals, Method D (0.1 ppm). Use *lead standard solution (1 ppm Pb)* to prepare the standard.

- **Chlorides** (2.3.12). To 10 ml add 1 ml of 2 M *nitric acid* and 0.2 ml of 0.1 M *silver nitrate*; the appearance of the solution does not change for at least 15 minutes.

- **Nitrates.** To 5 ml in a test-tube immersed in ice add 0.4 ml of a 10 per cent w/v solution of *potassium chloride*, 0.1 ml of *diphenylamine solution* and, dropwise with shaking, 5 ml of *sulphuric acid*. Transfer the tube to a water-bath at 50° and allow to stand for 15 minutes. Any blue colour in the solution is not more intense than that in a solution prepared at the same time and in the same manner using a mixture of 4.5 ml of *nitrate-free water* and 0.5 ml of *nitrate standard solution (2 ppm NO₃)* (0.2 ppm).

- **Sulphates** (2.3.17). To 10 ml add 0.1 ml of 2 M *hydrochloric acid* and 0.1 ml of *barium chloride solution*. The appearance of the solution does not change for at least 1 hour.

- **Oxidisable substances.** To 100 ml add 10 ml of 1 M *sulphuric acid* and 0.1 ml of 0.02 M *potassium permanganate* and boil for 5 minutes; the solution remains faintly pink.

- **Residue on evaporation.** Evaporate 100 ml to dryness on a water-bath and dry to constant weight at 105°. The residue weighs not more than 1 mg (0.001 per cent).

- **Purified Water intended for use in the manufacture of dialysis solutions and also without a further procedure for the removal of bacterial endotoxins complies with the following additional requirements.**

- **Aluminium** (2.3.8). Not more than 10 ppb, determined using the following solutions.

  **Test solution.** To 400 ml of the water under examination add 10 ml of *acetate buffer solution pH 6.0* and 100 ml of *distilled water*.

  **Reference solution.** Mix 2 ml of *aluminium standard solution (2 ppm Al)*, 10 ml of *acetate buffer solution pH 6.0* and 98 ml of *distilled water*.

  **Blank solution.** Mix 10 ml of *acetate buffer solution pH 6.0* and 100 ml of *distilled water*.

  **Bacterial endotoxins** (2.2.3). Not more than 0.25 Endotoxin Unit per ml.

**Storage.** Store protected from light.

### Water For Injections

**H₂O**  
Mol. Wt. 18.0

Water for Injections is water intended for use in the preparations of medicines for parenteral administration when water is used as a vehicle (Water for Injections in bulk) and for dissolving or diluting substances or preparations for injectable preparations (Sterile Water for Injections).
Water For Injections in Bulk

Production

Water for Injections in bulk is obtained by distilling potable water or Purified Water from a neutral glass, quartz or suitable metal still fitted with an effective device for preventing the entrainment of droplets; the still must be suitably maintained to ensure the production of a pyrogenic water. The first portion of the distillate is discarded and the remainder is collected and stored in conditions designed to prevent the growth of micro-organisms and to avoid any other contamination.

During production and subsequent storage, it is recommended that adequate measures are taken to ensure that the microbial quality is controlled and monitored. Appropriate alert and action limits are set so as to detect adverse trends. The adequacy of these measures is determined by the following tests that may be done off-line or in-line.

Total organic carbon (2.4.30). Not more than 0.5 mg per litre.
Conductivity (2.4.9). Meets the requirements of the test.
Description. A clear and colourless liquid; odourless and tasteless.

Tests

Acidity or alkalinity. To 10 ml, freshly boiled and cooled in a borosilicate glass flask, add 0.05 ml of methyl red solution; the resulting solution is not red. To 10 ml add 0.1 ml of bromothymol blue solution; the resulting solution is not blue.

Ammonium. To 20 ml add 1 ml of alkaline potassium mercuri-iodide solution and allow to stand for 5 minutes. When viewed vertically the solution is not more intensely coloured than a solution prepared at the same time by adding 1 ml of alkaline potassium mercuri-iodide solution to a solution containing 2.5 ml of dilute ammonium chloride solution and 7.5 ml of the liquid under examination.

Calcium and magnesium. To 100 ml add 2 ml of ammonia buffer pH 10.0, 50 mg of mordant black II mixture and 0.5 ml of 0.01 M disodium edetate; a pure blue colour is produced.

Heavy metals (2.3.13). Evaporate 150 ml to 15 ml on a water-bath. 12 ml of the solution complies with the limit test for heavy metals, Method D (0.1 ppm). Use lead standard solution (1 ppm Pb) to prepare the standard.

Chlorides (2.3.12). To 10 ml add 1 ml of 2 M nitric acid and 0.2 ml of 0.1 M silver nitrate; the appearance of the solution does not change for at least 15 minutes.

Nitrates. To 5 ml in a test-tube immersed in ice add 0.4 ml of a 10 per cent w/v solution of potassium chloride, 0.1 ml of diphenylamine solution and, dropwise with shaking, 5 ml of sulphuric acid. Transfer the tube to a water-bath at 50° and allow to stand for 15 minutes. Any blue colour in the solution is not more intense than that in a solution prepared at the same time and in the same manner using a mixture of 4.5 ml of nitrate-free water and 0.5 ml of nitrate standard solution (2 ppm NO₃) (0.2 ppm).

Sulphates (2.3.17). To 10 ml add 0.1 ml of 2 M hydrochloric acid and 0.1 ml of barium chloride solution. The appearance of the solution does not change for at least 1 hour.

Aluminium (2.3.8) For water for injections intended for use in the manufacture of dialysis solutions.

Not more than 10 ppb, determined using the following solutions.

Test solution. To 400 ml of the water under examination add 10 ml of acetate buffer solution pH 6.0 and 100 ml of distilled water.

Reference solution. Mix 2 ml of aluminium standard solution (2 ppm Al), 10 ml of acetate buffer solution pH 6.0 and 98 ml of distilled water.

Blank solution. Mix 10 ml of acetate buffer solution pH 6.0 and 100 ml of distilled water.

Bacterial endotoxins (2.2.3). Not more than 0.25 Endotoxin Unit per ml.

Storage. Store protected from moisture in containers designed to prevent the growth of micro-organisms.

Labelling. The label on the container in which the bulk has been distributed states that the contents have not been sterilised.

Sterile Water For Injections

Sterile Water for Injections is Water for Injections in bulk that has been distributed in suitable containers of glass or any other material, sealed and sterilised by heat under conditions that ensure that the water complies with the test for bacterial endotoxins. It is free from any added substances. Each container contains a sufficient quantity of Water for Injections to permit the withdrawal of the nominal volume.

Description. A clear, colourless liquid; odourless.

Tests

Appearance of solution. When examined in suitable conditions of visibility, it is clear (2.4.1) colourless (2.4.1) and practically free from suspended particles.

Acidity or alkalinity. To 20 ml add 0.05 ml of phenol red solution. If the solution is yellow, it becomes red on the addition of 0.1 ml of 0.01 M sodium hydroxide; if red, it becomes yellow on the addition of 0.15 ml of 0.01 M hydrochloric acid.
Ammonium. To 20 ml add 1 ml of alkaline potassium mercuri-iodide solution and allow to stand for 5 minutes. When viewed vertically the solution is not more intensely coloured than a solution prepared at the same time by adding 1 ml of alkaline potassium mercuri-iodide solution to a solution containing 2.5 ml of dilute ammonium chloride solution and 7.5 ml of the liquid under examination.

Calcium and magnesium. To 100 ml add 2 ml of ammonia buffer pH 10.0, 50 mg of mordant black II mixture and 0.5 ml of 0.01 M disodium edetate; a pure blue colour is produced.

Heavy metals (2.3.12). Evaporate 150 ml to 15 ml on a water-bath. 12 ml of the solution complies with the limit test for heavy metals, Method D (0.1 ppm). Use lead standard solution (1 ppm Pb) to prepare the standard.

Chlorides. To 10 ml add 1 ml of 2 M nitric acid and 0.2 ml of 0.1 M silver nitrate; the appearance of the solution does not change for at least 15 minutes.

For containers with a nominal volume of 100 ml or less, 15 ml complies with the limit test for chlorides (2.3.12) (0.5 ppm), using a standard solution prepared by mixing 1.5 ml of chloride standard solution (5 ppm Cl) and 13.5 ml of water.

Nitrates. To 5 ml in a test-tube immersed in ice add 0.4 ml of a 10 per cent w/v solution of potassium chloride, 0.1 ml of diphenylamine solution and, dropwise with shaking, 5 ml of sulphuric acid. Transfer the tube to a water-bath at 50° and allow to stand for 15 minutes. Any blue colour in the solution is not more intense than that in a solution prepared at the same time and in the same manner using a mixture of 4.5 ml of nitrate-free water and 0.5 ml of nitrate standard solution (2 ppm NO₃) (0.2 ppm).

Sulphates. To 10 ml add 0.1 ml of 2 M hydrochloric acid and 0.1 ml of barium chloride solution. The appearance of the solution does not change for at least 1 hour.

Oxidisable substances. Boil 100 ml with 10 ml of 1 M sulphuric acid, add 0.4 ml of 0.02 M potassium permanganate (for Sterile Water for Injection in containers with fill volume of less than 50 ml) or 0.2 ml of 0.02 M potassium permanganate (for Sterile Water for Injection in containers with fill volume of 50 ml or more) and boil for 5 minutes. If a precipitate forms, cool in an ice-bath to room temperature and filter through a sintered glass filter (porosity No.3). The pink colour of the solution does not disappear completely.

Residue on evaporation. Evaporate 100 ml to dryness on a water-bath and dry the residue to constant weight at 105°. For containers with a nominal volume of 10 ml or less, the residue weighs not more than 4 mg (0.004 per cent) and for containers with a nominal volume greater than 10 ml, the residue weighs not more than 3 mg (0.003 per cent).

Particulate contamination (2.5.9). Complies with the requirements of Method 1 or Method 2.

Bacterial endotoxins (2.2.3). Not more than 0.25 Endotoxin Unit per ml.

Sterility (2.2.11). Complies with the test for sterility.

Storage. Store in single dose containers of not larger than one litre size.

Wool Fat

Anhydrous Lanolin

Wool Fat is purified, anhydrous, waxy material obtained from the wool of sheep. It may contain Butylated Hydroxytoluene as an antioxidant.

Description. A pale yellow, unctuous substance; odour, characteristic.

Identification

A. To a solution of 0.5 g in 5 ml of chloroform add 1 ml of acetic anhydride and 0.1 ml of sulphuric acid; a green colour develops.

B. To a solution of 50 mg in 5 ml of chloroform add 5 ml of sulphuric acid and shake; a red colour is produced and a strong fluorescence appears in the lower layer.

Tests

Melting range (2.4.21). 34° to 44°, determined by Method IV. To fill the metal cup, melt the substance under examination on a water-bath, cool to about 50°, pour into the cup and allow to stand at 15° to 20° for 24 hours.

Acid value (2.3.23). Not more than 1.0, determined on 5.0 g dissolved in 25 ml of the prescribed mixture of solvents.

Peroxide value (2.3.35). Not more than 20.

Saponification value (2.3.37). 90 to 105. Heat for 4 hours.

Water-absorption capacity. Weigh 10.0 g into a mortar. Add water in quantities of 0.2 to 0.5 ml from a burette and stir vigorously, incorporating all the water before proceeding to the next addition. The end-point is reached when visible droplets remain that cannot be incorporated; not less than 20 ml of water is absorbed.

Water-soluble acidic or alkaline substances. Shake vigorously 5.0 g, previously melted on a water-bath, for 2 minutes with 75 ml of water previously heated to 90° to 95°. Allow to cool and filter through filter paper previously washed with water. To 60 ml of the filtrate, which may not be clear, add 0.25 ml of bromothymol blue solution. Not more than 0.2 ml of 0.02 M hydrochloric acid or 0.15 ml of 0.02 M sodium hydroxide is required to change the colour of the solution.
Water-soluble oxidisable substances. To 10 ml of the filtrate obtained in the test for Water-soluble acidic or alkaline substances add 1 ml of 1 M sulphuric acid and 0.1 ml of 0.02 M potassium permanganate; the solution is not completely decolourised within 10 minutes.

Ammonia. To 10 ml of the filtrate obtained in the test for Water-soluble acidic or alkaline substances add 1 ml of 1 M sodium hydroxide and boil; the vapours do not turn red litmus paper blue.

Chlorides. Boil 1.0 g with 20 ml of ethanol (90 per cent) under a reflux condenser for 5 minutes, cool, add 40 ml of water and 0.5 ml of nitric acid and filter. To the filtrate add 0.15 ml of a 1 per cent w/v solution of silver nitrate in ethanol (90 per cent). After 5 minutes, protected from light; any opalescence produced is not more intense than that obtained by adding 0.15 ml of a 1 per cent w/v solution of silver nitrate in ethanol (90 per cent) to a mixture of 0.2 ml of 0.02 M hydrochloric acid, 20 ml of ethanol (90 per cent), 40 ml of water and 0.5 ml of nitric acid (150 ppm).

Paraffins. Prepare an alumina column 23 cm x 2 cm by adding a slurry of anhydrous aluminium oxide and light petroleum (40° to 60°) to a glass tube fitted with a tap and containing the light petroleum; the tap and absorbent cotton plugs should be free from grease. Allow to settle and reduce the depth of the solvent above the column to about 4 cm. Dissolve 3.0 g of the substance under examination in 50 ml of warm light petroleum; the tap and absorbent cotton plugs should stand at 15° to 20° for 24 hours.

Identification
A. To a solution of 0.5 g in 5 ml of chloroform add 1 ml of acetic anhydride and 0.1 ml of sulphuric acid; a green colour develops.

Tests
Melting range (2.4.21). 34° to 44°, determined by Method IV.

Acid value (2.3.23). Not more than 1.0, determined on 5.0 g dissolved in 25 ml of the prescribed mixture of solvents.

Paraffins. Prepare an alumina column 23 cm x 2 cm by adding a slurry of anhydrous aluminium oxide and light petroleum (40° to 60°) to a glass tube fitted with a tap and containing the light petroleum; the tap and absorbent cotton plugs should be free from grease. Allow to settle and reduce the depth of the solvent above the column to about 4 cm. Dissolve 3 g of the substance under examination in 50 ml of warm light petroleum (40° to 60°), cool, pass the solution through the column at a rate of 3 ml per minute and wash with 250 ml of the carrier gas.

Calculation of the content of butylated hydroxytoluene in the substance under examination from the heights or areas of the peaks due to butylated hydroxytoluene and the internal standard in the chromatograms obtained with test solution (b) and the reference solution.
light petroleum. Distil the combined eluate and washings to low bulk, evaporate to dryness on a water-bath and heat the residue at 105° for periods of 10 minutes until the difference between two successive weighings is not greater than 1 mg; the residue weighs not more than 30 mg.

**Peroxide value** (2.3.35). Not more than 15.

**Saponification value** (2.3.37). 67 to 79. Heat for 4 hours.

**Water-absorption capacity.** Weigh 10.0 g of the residue obtained in the test for Wool fat content into a mortar. Add water in quantities of 0.2 to 0.5 ml from a burette and stir vigorously, incorporating all the water before proceeding to the next addition. The end-point is reached when visible droplets remain that cannot be incorporated; not less than 20 ml of water is absorbed.

**Water-soluble acidic or alkaline substances.** Shake vigorously 6.7 g, previously melted on a water-bath, for 2 minutes with 75 ml of water previously heated to 90° to 95°. Allow to cool and filter through filter paper previously washed with water. To 60 ml of the filtrate, which may not be clear, add 0.25 ml of bromothymol blue solution. Not more than 0.2 ml of 0.02 M hydrochloric acid or 0.15 ml of 0.02 M sodium hydroxide is required to change the colour of the solution.

**Water-soluble oxidisable substances.** 10 ml of the filtrate obtained in the test for Water-soluble acidic or alkaline substances add 1 ml of 1 M sulphuric acid and 0.1 ml of 0.02 M potassium permanganate; the solution is not completely decolorised within 10 minutes.

**Ammonia.** To 10 ml of the filtrate obtained in the test for Water-soluble acidic or alkaline substances add 1 ml of 1 M sodium hydroxide and boil; the vapours do not turn red litmus paper blue.

**Chlorides.** Boil 1.0 g with 20 ml of ethanol (90 per cent) under a reflux condenser for 5 minutes, cool, add 40 ml of water and 0.5 ml of nitric acid and filter. To the filtrate add 0.15 ml of a 1 per cent w/v solution of silver nitrate in ethanol (90 per cent). After 5 minutes, protected from light, any opalescence produced is not more intense than that obtained by adding 0.15 ml of a 1 per cent w/v solution of silver nitrate in ethanol (90 per cent) to a mixture of 0.2 ml of 0.02 M hydrochloric acid, 20 ml of ethanol (90 per cent), 40 ml of water and 0.5 ml of nitric acid (150 ppm).

**Wool fat content.** 72.5 to 77.5 per cent, determined by the following method. Weigh accurately about 30 g in a tared porcelain dish containing a glass rod, heat on a water-bath with continuous stirring to constant weight and weigh the residue. Titrate with 0.1 M perchloric acid, using 1-naphtholbenzein solution as indicator. Carry out a blank titration. 1 ml of 0.1 M perchloric acid is equivalent to 0.02808 g of C_{16}H_{24}N_{2}, HCl.

**Storage.** Store protected from light and moisture.
X

Xylometazoline Hydrochloride
Xylometazoline Nasal Drops
Xylose
Xylometazoline Hydrochloride

\[
\text{CH}_3 \quad \text{CH}_3 \quad \text{N}, \text{ HCl} \\
\text{CH}_3 \quad \text{H}_3\text{C} \\
\text{CH}_3 \quad \text{H}_3\text{C} \quad \text{N}, \text{ HCl} \\
\text{CH}_3
\]

C₁₆H₂₄N₂.HCl Mol. Wt. 280.8

Xylometazoline Hydrochloride is 2-(4-tert-butyl-2,6-dimethylbenzyl)-2-imidazoline hydrochloride.

Xylometazoline Hydrochloride contains not less than 99.0 per cent and not more than 101.0 per cent of C₁₆H₂₄N₂, HCl, calculated on the dried basis.

**Description.** A white or almost white, crystalline powder; odourless or almost odourless.

**Identification.**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with xylometazoline hydrochloride RS or with the reference spectrum of xylometazoline.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.05 per cent w/v solution in 0.1 M hydrochloric acid shows an absorption maximum at about 265 nm and a minimum at about 257 nm with two inflections at about 270 nm and 275 nm; absorbance at about 265 nm, about 0.5.

C. To 1 ml of a 0.05 per cent w/v solution, add 0.2 ml of a 5 per cent w/v solution of sodium nitroprusside and 0.1 ml of 5 M sodium hydroxide, allow to stand for 10 minutes and add 2 ml of sodium bicarbonate solution; a violet colour is produced.

D. Gives the reactions of chlorides (2.3.1).

**Tests.**

**pH** (2.4.24). 5.0 to 6.6, determined in a 5.0 per cent w/v solution.

**N-(2-Aminoethyl)-4-tert-butyl-2,6-xylylacetamide.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

**Mobile phase.** A mixture of 200 volumes of methanol and 3 volumes of strong ammonia solution.

**Test solution.** Dissolve 0.2 g of the substance under examination in 10 ml of methanol.

**Reference solution.** A 0.01 per cent w/v solution of N-(2-aminoethyl)-4-tert-butyl-2,6-xylyl-acetamide RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air, spray with a solution containing 0.3 g of ninhydrin in a mixture of 100 ml of 1-butanol and 3 ml of glacial acetic acid. Heat at 100° for 10 minutes, allow to cool, and spray with dilute potassium iodobismuthate solution. Any spot corresponding to N-(2-aminoethyl)-4-tert-butyl-2,6-xylyl-acetamide in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

**Iron** (2.4.14). Moisten the residue obtained in the test for Sulphated ash with 5 ml of hydrochloric acid, evaporate to dryness and dissolve in sufficient water to produce 50 ml. 10 ml of the resulting solution complies with the limit test for iron (50 ppm).

**Sulphates** (2.3.17). 0. 75 g complies with the limit test for sulphates (200 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°.

**Assay.** Weigh accurately about 0.5 g, dissolve in 50 ml of anhydrous glacial acetic acid, add 10 ml of mercuric acetate solution. Titrate with 0.1 M perchloric acid, using 1-naphtholbenzein solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02808 g of C₁₆H₂₄N₂, HCl.

**Storage.** Store protected from light and moisture.

Xylometazoline Nasal Drops

Xylometazoline Hydrochloride Nasal Drops

Xylometazoline Nasal Drops are a solution of Xylometazoline Hydrochloride in Purified Water.

Xylometazoline Nasal Drops contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of xylometazoline hydrochloride, C₁₆H₂₄N₂, HCl.

**Identification.**

A. To a volume containing 50 mg of Xylometazoline Hydrochloride add 5 ml of 0.1 M sodium hydroxide, extract with 10 ml of dichloromethane, evaporate to dryness and dissolve the residue in 0.5 ml of dichloromethane.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with xylometazoline hydrochloride RS treated in the same manner or with the reference spectrum of xylometazoline.

B. To a volume containing 0.5 mg of Xylometazoline Hydrochloride add 0.2 ml of a 5 per cent w/v solution of sodium
nitroprusside and 0.1 ml of 5 M sodium hydroxide, allow to stand for 10 minutes and add 1 ml of sodium bicarbonate solution; a violet colour is produced.

**Tests**

**pH** (2.4.24), 5.6 to 6.6.

**N-(2-Aminoethyl)-4-tert-butyl-2,6-xylylacetamide.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

*Mobile phase.* A mixture of 200 volumes of methanol and 3 volumes of strong ammonia solution.

*Test solution.* Add a volume containing 10 mg of Xylometazoline Hydrochloride to 30 ml of water; add 5 ml of 5 M sodium hydroxide, mix, extract with three quantities, each of 20 ml, of dichloromethane, evaporate the combined extracts to dryness and dissolve the residue in 1 ml of dichloromethane.

*Reference solution.* A 0.03 per cent w/v solution of N-(2-aminoethyl)-4-tert-butyl-2,6-xylylacetamide RS in dichloromethane.

Apply to the plate 5 µl of each solution. After development, dry the plate in air, spray with a solution containing 0.3 g of ninhydrin in a mixture of 100 ml of 1-butanol and 3 ml of glacial acetic acid. Heat at 100° for 10 minutes, allow to cool, and spray with dilute potassium iodobismuthate solution. Any spot corresponding to N-(2-aminoethyl)-4-tert-butyl-2,6-xylylacetamide in the chromatogram obtained with test solution is not more intense than the spot in the chromatogram obtained with reference solution.

**Other tests.** Comply with the tests stated under Nasal Preparations.

**Assay.** To a volume containing 10 mg of Xylometazoline Hydrochloride add 5 ml of water, 10 ml of 2 M hydrochloric acid and 10 ml of dichloromethane and shake for 1 minute. Discard the dichloromethane layer and repeat the extraction with two further quantities, each of 10 ml, of dichloromethane. Add to the aqueous extract 10 ml of 5 M sodium hydroxide and 10 ml of dichloromethane, shake for 1 minute and allow to separate. Filter the dichloromethane extract through glass wool and repeat the extraction with four further quantities, each of 10 ml, of dichloromethane. Evaporate the combined dichloromethane extracts almost to dryness on a water-bath, remove the final traces of solvent in a current of air and dissolve the residue in 10.0 ml of 0.01 M hydrochloric acid. To 2.0 ml of this solution add 3 ml of water, 2.5 ml of 1 M sodium hydroxide and 2.5 ml of a 5 per cent w/v solution of sodium nitroprusside, mix and allow to stand protected from light for 10 minutes. Add 10 ml of a freshly prepared 8.3 per cent w/v solution of sodium bicarbonate, dilute to 100.0 ml with water, allow to stand protected from light for 10 minutes and measure the absorbance of the resulting solution at the maximum at about 560 nm (2.4.7), using as blank a solution prepared by treating 5 ml of water and 2.5 ml of 1 M sodium hydroxide in the same manner beginning at the words “and 2.5 ml of a 5 per cent w/v solution of sodium nitroprusside,......”.

Calculate the content of C$_{16}$H$_{24}$N$_2$.HCl from the absorbance obtained by repeating the operation using a 0.1 per cent w/v solution of xylometazine hydrochloride RS in place of the nasal drops.

**Storage.** Store protected from light and moisture.

**Xylose**

D-Xylo; D-Xylopyranose

C$_{12}$H$_{22}$O$_7$ Mol. Wt. 150.1

Xylose contains not less than 98.0 per cent and not more than 102.0 per cent of C$_{12}$H$_{22}$O$_7$, calculated on the dried basis.

**Description.** Colourless needles or a white, crystalline powder.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), coating the plate with a suspension of silica gel G in a 0.3 per cent w/v solution of sodium acetate to form a uniform layer 0.5 mm thick.

*Mobile phase.* A mixture of 70 volumes of glacial acetic acid, 60 volumes of chloroform and 10 volumes of water.

*Test solution.* Dissolve 0.5 g of the substance under examination in 10 ml of water.

*Reference solution (a).* A 5.0 per cent w/v solution of xylose RS in water.

*Reference solution (b).* A mixture of equal volumes of the test solution and reference solution (a).

Apply to the plate 2 µl of each solution. Develop the plate in a continuous elution tank for about 4 hours. Dry the plate in warm air, spray with a solution in acetone containing 1 per cent w/v solution of diphenylamine, 1 per cent v/v of aniline and 1 per cent v/v of phosphoric acid and heat for 10 minutes at 130°. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.
B. When heated with potassium cupri-tartrate solution it produces a copious precipitate of cuprous oxide.

Tests

Appearance of solution. A 10.0 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and colourless (2.4.1).

Acidity. Dissolve 5.0 g in 50 ml of carbon dioxide-free water. Not more than 0.2 ml of 0.1 M sodium hydroxide is required to neutralise the solution using dilute phenolphthalein solution as indicator.

Specific optical rotation (2.4.22). +18.5° to +19.5°, determined at 20° in a 10.0 per cent w/v solution containing 0.4 per cent v/v of 5 M ammonia.

Arsenic (2.3.10). Dissolve 10.0 g in 50 ml of water and add 10 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (1 ppm).

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method A (20 ppm).

Iron (2.3.14). A solution of 4.0 g in 25 ml of water complies with the limit test for iron (10 ppm).

Chlorides (2.3.12). Dissolve 3.0 g in 20 ml of water. 5 ml of the resulting solution complies with the limit test for chlorides (330 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 100° at a pressure not exceeding 0.7 kPa.

Assay. Carry out the following procedure keeping strict control of time between steps.

Weigh accurately about 1.0 g of the substance under examination, dissolve in a saturated solution of benzoic acid in a 100-ml volumetric flask and dilute to volume with the same solvent. Dilute 1.0 ml of this solution to 100.0 ml with the same solvent. To 1.0 ml of the resulting solution, in two different test-tubes, add 5 ml of 4-bromoaniline solution into each tube and mix. Loosely stopper one tube, place in a water-bath maintained at 70° for 10 minutes, remove, cool rapidly to room temperature and mix. Keep the tube in the dark for 70 minutes and measure the absorbance at the maximum at about 520 nm (2.4.7), using the untreated solution in the second test tube as the blank. Simultaneously, carry out the operation using 1.0 ml of a 0.01 per cent w/v solution of xylose RS in a saturated solution of benzoic acid beginning at the words “add 5 ml of 4-bromoaniline solution.....”.

Calculate the content of C₅H₁₀O₅.

Storage. Store protected from moisture.
Z

Zidovudine
Zidovudine Capsules
Zidovudine Injection
Zidovudine Oral Solution
Zidovudine Tablets
Zidovudine, Lamivudine And Nevirapine Tablets
Zinc Chloride
Zinc Oxide
Zinc Oxide Cream
Zinc Stearate
Zinc Stearate
Zinc Sulphate
Zinc Sulphate Eye Drops
Zinc Undecenoate
Zinc Undecenoate Ointment
Zidovudine

\[ \text{C}_{10}\text{H}_{13}\text{N}_{5}\text{O}_{4} \]  \hspace{1cm} \text{Mol. Wt. 267.2} \\
Zidovudine is \( 1-(3\text{-azido}-2,3\text{-dideoxy-\(\beta\)-d-ribofuranosyl})\text{-5-methylpyrimidine-2,4(1H,3H)} \)-dione. \\
Zidovudine contains not less than 97.0 per cent and not more than 102.0 per cent of \( \text{C}_{10}\text{H}_{13}\text{N}_{5}\text{O}_{4} \), calculated on the anhydrous basis.

**Description.** A white or almost white powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with zidovudine RS or with the reference spectrum of zidovudine.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to zidovudine in the chromatogram obtained with reference solution (a).

C. Melting range (2.4.21). 122° to 125°.

**Tests**

**Specific optical rotation** (2.4.22). +60.5° to +63.0°, determined in a 1.0 per cent w/v solution in ethanol (95 per cent).

**Related substances.** A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

- **Mobile phase.** A mixture of 90 volumes of dichloromethane and 10 volumes of methanol.
- **Test solution.** Dissolve 0.2 g of the substance under examination in 10 ml of methanol.
- **Reference solution.** A solution containing 0.01 per cent w/v each of zidovudine RS and triphenylmethanol in methanol.

Apply to the plate 10 µl of each solution. Allow the mobile phase to rise to about three-fourths of the height of the plate. Dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spots observed in the chromatogram obtained with the test solution correspond to those of the principal spots in the chromatogram obtained with the reference solution. No secondary spot in the chromatogram obtained with the test solution is more intense than the principal spot in the chromatogram obtained with the reference solution (0.5 per cent).

Spray the plate with a mixture of 0.5 g of carbazole in 95 ml of ethanol (95 per cent) and 5 ml of sulphuric acid, heat for 10 minutes at 120° and compare the intensities of any secondary spots observed in the chromatogram obtained with the test solution with those of the principal spots in the chromatogram obtained with the reference solution. No spot corresponding to triphenylmethanol (Rf value about 2.3 relative to the Rf of zidovudine) is more intense than the corresponding spot in the chromatogram obtained with the reference solution (0.5 per cent). No secondary spot in the chromatogram obtained with the test solution is more intense than the principal spot in the chromatogram obtained with the reference solution.

B. Determine by liquid chromatography (2.4.14).

- **Test solution.** Dissolve 0.1 g of the substance under examination in 100 ml of methanol.
- **Reference solution (a).** A 0.001 per cent w/v solution of zidovudine RS in methanol.
- **Reference solution (b).** A solution containing 0.1 per cent w/v of zidovudine RS and 0.001 per cent w/v each of zidovudine-related compound B RS and zidovudine-related compound C RS in methanol.

**Chromatographic system**

- a stainless steel column 15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: A water
  B. methanol,
- flow rate. 1 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 265 nm,
- a 10 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>Water (per cent v/v)</th>
<th>Methanol (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>90</td>
<td>10</td>
</tr>
<tr>
<td>15</td>
<td>35</td>
<td>65</td>
</tr>
<tr>
<td>30</td>
<td>35</td>
<td>65</td>
</tr>
<tr>
<td>35</td>
<td>5</td>
<td>95</td>
</tr>
<tr>
<td>40</td>
<td>5</td>
<td>95</td>
</tr>
<tr>
<td>45</td>
<td>90</td>
<td>10</td>
</tr>
</tbody>
</table>

Inject reference solution (b). The test is not valid unless the resolution between the peaks due to zidovudine and
zidovudine-related compound B is not less than 1.5 and the tailing factor for zidovudine is not more than 1.5.

Separately inject the test solution and reference solution (a). The area of the peak corresponding to zidovudine-related compound B is not greater than 1.0 per cent and of that to zidovudine-related compound C is not greater than 2.0 per cent.

The sum of the percentages of related substances by tests A and B is not greater than 3.0 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with limit test for heavy metals, Method B (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.25 per cent.

**Water** (2.3.43). Not more than 1.0 per cent, determined on 0.5 g.

**Assay.** Determine by liquid chromatography (2.4,14).

*Test solution.* Weigh accurately about 100 mg of the substance under examination, dissolve in a suitable quantity of methanol in a 50-ml volumetric flask and make up to volume with the mobile phase. Dilute 5.0 ml of this solution to 50.0 ml with the mobile phase.

*Reference solution (a).* Weigh accurately about 100 mg of zidovudine RS, dissolve in a suitable quantity of methanol in a 50-ml volumetric flask and make up to volume with the mobile phase (solution A). Dilute 5.0 ml of solution A to 50.0 ml with the mobile phase.

*Reference solution (b).* Transfer 2.0 ml of a 0.005 per cent w/v solution of zidovudine-related compound B RS in the mobile phase to a 50-ml volumetric flask, add 5.0 ml of solution A and make up to volume with the mobile phase.

**Chromatographic system**
- a stainless steel column 15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 70 volumes of water and 30 volumes of methanol,
- flow rate. 1 ml per minute,
- spectrophotometer set at 265 nm,
- a 20 µl loop injector.

Inject reference solution (b). The test is not valid unless the resolution between the peaks due to zidovudine and zidovudine-related compound B is not less than 2.0.

Inject reference solution (a). The relative standard deviation for replicate injections is not more than 2.0 per cent.

Separately inject the test solution and reference solution (a) and measure the responses for the principal peak.

Calculate the content of C₁₀H₁₃N₅O₄.

**Storage.** Store protected from light.

---

**Zidovudine Capsules**

Zidovudine Capsules contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of zidovudine, C₁₀H₁₃N₅O₄.

**Identification**

A. Transfer a quantity of the mixed contents of the capsules containing about 15 mg of Zidovudine to a 100-ml volumetric flask. Add about 80 ml of a mixture of 75 volumes of methanol and 25 volumes of water, shake for 10 minutes and dilute to volume with the same solvent mixture, mix and filter. Dilute 10 ml of the filtrate to 100 ml with the same solvent mixture.

When examined in the range 200 nm to 300 nm (2.4,7), the resulting solution shows an absorption maximum at about 265 nm.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to zidovudine in the chromatogram obtained with reference solution (c).

**Tests**

**Related substances.** Determine by liquid chromatography (2.4,14).

*Test solution.* Weigh accurately a quantity of the mixed contents of 20 capsules containing about 100 mg of Zidovudine and transfer to a 100-ml volumetric flask. Add about 60 ml of the mobile phase, mix with the aid of ultrasound for 10 minutes, dilute to volume with the mobile phase, mix and filter. Dilute 5.0 ml of the filtrate to 50.0 ml with the mobile phase.

*Reference solution (a).* Weigh accurately about 100 mg of zidovudine RS and transfer to a 100-ml volumetric flask. Dissolve in about 60 ml of the mobile phase and dilute to volume with the mobile phase.

*Reference solution (b).* Weigh accurately about 20 mg of thymine and transfer to a 200-ml volumetric flask, dissolve and make up to volume with methanol.

*Reference solution (c).* Transfer 10.0 ml of the reference solution (a) and 2.0 ml of reference solution (b) to a 100-ml volumetric flask and make up to the volume with the mobile phase.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 20 volumes of methanol and 80 volumes of water,
- flow rate. 1 ml per minute,
- spectrophotometer set at 265 nm,
- a 10 µl loop injector.
Inject reference solution (c). The test is not valid unless the relative retention times are about 0.2 for thymine and 1.0 for zidovudine, the resolution between zidovudine and thymine is not less than 5.0, the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject separately the test solution and reference solution (c) and measure the responses for the thymine peak. The content of thymine in the capsules should not be more than 3.0 per cent.

**Dissolution (2.5.2).**

Apparatus. No 1

Medium. 900 ml of water

Speed and time. 50 rpm and 45 minutes.

Withdraw a suitable volume of the medium and filter promptly through a membrane filter disc having an average pore diameter not greater than 1.0 µm, rejecting the first few ml of the filtrate and dilute a suitable volume of the filtrate, if necessary with water.

Determine by liquid chromatography (2.4.14).

*Test solution.* The filtrate obtained as given above.

*Reference solution.* A known quantity of zidovudine RS is dissolved in 1 ml of methanol and suitably diluted with water to obtain a solution having a similar concentration as that of the test solution.

**Chromatographic system**

– a stainless steel column 25 cm × 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
– mobile phase: a mixture of 20 volumes of methanol and 80 volumes of water,
– flow rate. 1 ml per minute,
– spectrophotometer set at 265 nm,
– a 10 µl loop injector.

Inject the reference solution. The tailing factor is not more than 2.0 for zidovudine peak and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution and measure the peak responses of the major peak.

Calculate the content of \( \text{C}_{10}\text{H}_{13}\text{N}_{5}\text{O}_{4} \) in the medium.

D. Not less than 75 per cent of the stated amount of \( \text{C}_{10}\text{H}_{13}\text{N}_{5}\text{O}_{4} \)

**Other tests.** Comply with the tests stated under Capsules.

**Assay.** Determine by liquid chromatography (2.4.14), as described under Related substances. Inject separately the test solution and reference solution (c) and measure the responses for the principal peak.

Calculate the content of \( \text{C}_{10}\text{H}_{13}\text{N}_{5}\text{O}_{4} \) in the capsules.

**Storage.** Store protected from moisture.

**Zidovudine Injection**

Zidovudine Injection is a sterile solution of Zidovudine in Water for Injections.

Zidovudine Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of \( \text{C}_{10}\text{H}_{13}\text{N}_{5}\text{O}_{4} \).

**Description.** A clear, colourless solution.

**Identification**

A. When examined in the range 220 nm to 360 nm (2.4.7), a 0.0015 per cent w/v solution in a mixture of 75 volumes of methanol and 25 volumes of water shows absorption maxima similar to those obtained with a solution of zidovudine RS of the same concentration.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

**Tests**

**pH (2.4.24).** 3.5 to 7.0, in a mixture containing a volume of injection containing 150 mg of zidovudine and 5 ml of 0.12 M potassium chloride.

**Related substances.** Determine by liquid chromatography (2.4.14).

*Test solution. Dilute an accurately measured volume of the injection containing 25 mg of Zidovudine, to 25 ml with methanol.*

*Reference solution (a). A 0.1 per cent w/v solution of zidovudine RS in methanol.*

*Reference solution (b). A solution containing 0.1 per cent w/v of zidovudine RS and 0.001 per cent w/v of zidovudine related compound C (thymine).*

**Chromatographic system**

– a stainless steel column 25 cm × 4.0 mm, packed with octadecylsilane bonded to porous silica (5 µm),
– mobile phase: a mixture of 80 volumes of water and 20 volumes of methanol,
– flow rate. 1 ml per minute,
– spectrophotometer set at 265 nm,
– a 10 µl loop injector.

Inject reference solution (b). The test is not valid unless the resolution between zidovudine and thymine is not less than 4.0, the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.
Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution the area of any peak corresponding to thymine is not greater than twice the area of the corresponding peak in the chromatogram obtained with reference solution (b) (2.0 per cent).

Other tests. Complies with the tests stated under Parenteral preparations (Injections).

Bacterial endotoxins (2.2.3). Not more than 1.0 Endotoxin Unit per mg of zidovudine.

Assay. Determine by liquid chromatography (2.4.14), as given under the test for Related substances.

Inject alternately the test solution and reference solution (a). Calculate the content of $C_{10}H_{13}N_5O_4$ in the injection.

Storage. Store protected from light and moisture.

Zidovudine Oral Solution

Zidovudine Oral Solution is a solution of Zidovudine in a suitable flavoured vehicle.

Zidovudine Oral Solution contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of zidovudine, $C_{10}H_{13}N_5O_4$.

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 40 volumes of 1-butanol, 30 volumes of heptane, 30 volumes of acetone and 10 volumes of strong ammonia solution.

Test solution. Dilute the preparation under examination with methanol to obtain a solution containing 5 mg of zidovudine per ml.

Reference solution. A 0.5 per cent w/v solution of zidovudine RS in a mixture of 75 volumes of methanol and 25 volumes of water.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to zidovudine in the chromatogram obtained with reference solution (c).

Tests

pH (2.4.24). 3.0 to 4.0, determined in a mixture containing a volume of the preparation under examination containing 150 mg of zidovudine and 5 ml of 0.12 M potassium chloride.

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Transfer an accurately measured volume of the preparation under examination containing about 100 mg of zidovudine to a 100-ml volumetric flask, dissolve and dilute to volume with the mobile phase and mix. Dilute 5.0 ml of this solution to 50.0 ml with the mobile phase.

Reference solution (a). Weigh accurately about 100 mg of zidovudine RS and transfer to a 100-ml volumetric flask, add about 50 ml of the mobile phase, mix with the aid of ultrasound to dissolve, dilute to volume with the mobile phase and mix.

Reference solution (b). Weigh accurately about 20 mg of thymine RS and transfer to a 200-ml volumetric flask, add about 150 ml of the mobile phase, mix with the aid of ultrasound to dissolve, dilute to volume with the mobile phase and mix.

Reference solution (c). Transfer 10.0 ml of the reference solution (a) and 2.0 ml of reference solution (b) to a 100-ml volumetric flask and make up to the volume with the mobile phase.

Chromatographic system

- a stainless steel column 12.5 cm x 4.0 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 90 volumes of 0.04 M sodium acetate, 9 volumes of methanol, 1 volume of acetonitrile and 0.2 volume of glacial acetic acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 240 nm,
- a 10 µl loop injector.

Inject reference solution (c). The test is not valid unless the relative retention times are about 0.12 for thymine and 1.0 for zidovudine, the resolution between zidovudine and thymine is not less than 4.0, the tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject separately the test solution and reference solution (c) and measure the responses for the thymine peak. The content of thymine in the capsules should not be more than 3.0 per cent.

Other tests. Comply with the tests stated under Oral Liquids.

Assay. Determine by liquid chromatography (2.4.14), as described under Related substances. Inject separately the test solution and reference solution (c) and measure the responses for the major peak.
Calculate the content of C\textsubscript{10}H\textsubscript{13}N\textsubscript{5}O\textsubscript{4} in the preparation under examination.

**Storage.** Store protected from light and moisture.

**Zidovudine Tablets**

Zidovudine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of zidovudine, C\textsubscript{10}H\textsubscript{13}N\textsubscript{5}O\textsubscript{4}. The tablets may be coated.

**Identification**

A. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak due to Zidovudine in the chromatogram obtained with reference solution (a).

B. Remove the coating from a few tablets and crush them in a mortar so that no large pieces remain.

On the powder determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with zidovudine RS or with the reference spectrum of zidovudine.

**Tests**

**Related substances.** Determine by liquid chromatography (2.4.14)

**Test solution.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 100 mg of Zidovudine and transfer to a 100-ml volumetric flask. Add about 60 ml of the mobile phase and mix with the aid of ultrasound for 10 minutes. Make up to volume with the mobile phase, mix and filter through a membrane filter disc with an average pore diameter not greater than 1.0 \(\mu\)m, rejecting the first few ml of the filtrate. Further dilute 5.0 ml of the filtrate to 50.0 ml with the mobile phase.

**Reference solution (a).** Weigh accurately about 100 mg of the zidovudine RS and transfer to a 100-ml volumetric flask. Dissolve in about 50 ml of the mobile phase and make up to volume with the mobile phase.

**Reference solution (b).** Weigh accurately about 20 mg of thymine and transfer to a 200-ml volumetric flask, dissolve and make up to volume with methanol.

**Reference solution (c).** Transfer 10.0 ml of reference solution (a) and 2.0 ml of reference solution (b) to a 100-ml volumetric flask and make up to volume with the mobile phase.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 \(\mu\)m),
- mobile phase: a mixture of 90 ml of methanol and 40 ml of acetonitrile and a buffer solution prepared by dissolving 3.0 g of sodium acetate and 3.0 g of sodium octanesulphonate in 900 ml of water and adjusting the pH to 5.3 with glacial acetic acid,
- flow rate. 1.3 ml per minute,
- spectrophotometer set at 265 nm,
- a 20 \(\mu\)l loop injector.

Inject reference solution (c). The test is not valid unless the resolution between zidovudine and the peak having relative retention time of 1.2 is not less than 2.5, the tailing factor for the zidovudine peak is not more than 2.0 and relative standard deviation for replicate injections is not more than 2.0 per cent. Separately inject the test solution and record the chromatograms for 3 times the retention time of zidovudine. The content of the impurity at a relative retention time of 0.17 compared to that of the zidovudine peak is not greater than 1.5 per cent and that of any other impurity is not greater than 0.2 per cent. The sum of all the impurities is not greater than 2.0 per cent.

**Dissolution (2.5.2).**

**Apparatus.** No 1

Medium. 900 ml of water

Speed and time. 50 rpm and 30 minutes.

Withdraw a suitable volume of the medium and filter promptly through a membrane filter disc having an average pore diameter not greater than 1.0 \(\mu\)m, rejecting the first few ml of the filtrate and dilute a suitable volume of the filtrate, if necessary with water.

Determine by liquid chromatography (2.4.14).

**Test solution.** The filtrate obtained as given above.

**Reference solution.** A known quantity of zidovudine RS is dissolved in 1 ml of methanol and suitably diluted with water to obtain a solution having a similar concentration as that of the test solution.

**Chromatographic system**

- a stainless steel column 15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 \(\mu\)m),
- mobile phase: a mixture of 90 ml of methanol and 40 ml of acetonitrile and a buffer prepared by dissolving 3.0 g of sodium acetate and 3.0 g of sodium 1-octanesulphonate in 900 ml of water and adjusting the pH to 5.3 with glacial acetic acid,
- flow rate. 1.3 ml per minute,
- spectrophotometer set at 265 nm,
- a 10 \(\mu\)l loop injector.

Inject the reference solution. The tailing factor is not more than 2.0 for zidovudine peak and the relative standard deviation for replicate injections is not more than 2.0 per cent.
Inject separately the test solution and the reference solution and measure the peak responses of the major peak.

Calculate the content of \( C_{10}H_{13}N_{5}O_{4} \) in the medium.

D. Not less than 80 per cent of the stated amount of \( C_{10}H_{13}N_{5}O_{4} \).

Other tests. Comply with the tests stated under Tablets.

Assay. Determine by liquid chromatography (2.4.14), as described under Related substances. Separately inject the test solution and reference solution (c) and measure the peak responses for the major peak.

Calculate the content of \( C_{10}H_{13}N_{5}O_{4} \) in the tablets.

Storage. Store protected from light and moisture.

**Zidovudine, Lamivudine and Nevirapine Tablets**

Zidovudine, Lamivudine and Nevirapine Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of zidovudine, \( C_{10}H_{13}N_{5}O_{4} \), lamivudine, \( C_{8}H_{11}N_{3}O_{3}S \) and nevirapine, \( C_{15}H_{14}N_{4}O \). The tablets may be coated.

**Identification**

A. In the Assay, the three principal peaks in the chromatogram obtained with the test solution correspond to the peaks due to zidovudine, lamivudine and nevirapine in the chromatogram obtained with the reference solution.

**Tests**

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh accurately a quantity of the powdered tablets containing about 100 mg of Zidovudine and transfer to a 200-ml volumetric flask. Add about 150 ml of water, mix with the aid of ultrasound for 10 minutes, dilute to volume with water, mix and filter.

**Reference solution.** Weigh accurately about 100 mg of zidovudine RS, 50 mg of lamivudine RS and 65 mg of nevirapine RS and transfer to a 200-ml volumetric flask. Add about 20 ml of methanol, mix with the aid of ultrasound to dissolve, dilute to volume with water and mix.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm) (such as Hypersil C8),
- mobile phase: A. 0.1 M ammonium acetate, B. acetonitrile,
- flow rate. 1 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 270 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>0.1 M ammonium acetate</th>
<th>acetonitrile</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(per cent v/v)</td>
<td>(per cent v/v)</td>
</tr>
<tr>
<td>0</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>25</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>30</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>31</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>35</td>
<td>95</td>
<td>5</td>
</tr>
</tbody>
</table>

Inject the reference solution. The test is not valid unless the column efficiency determined from the zidovudine, lamivudine and nevirapine peaks is not less than 3000 theoretical plates and the tailing factor for the same peaks is not more than 2.0.

Inject separately water and the test solution. Examine the chromatogram obtained with water for any extraneous peaks and ignore the corresponding peaks observed in the chromatogram obtained with the test solution.

Any secondary peak observed in the chromatogram obtained with the test solution corresponding to a relative retention time of 0.35 should not be more than 1.0 per cent. Any other secondary peak observed in the chromatogram obtained with the test solution should not be more than 0.5 per cent and the sum of the areas of all the secondary peaks should not be more than 2.5 per cent when calculated by percentage area normalisation.

**Dissolution (2.5.2).**

Apparatus. No 1

Medium. 900 ml of 0.1 M hydrochloric acid

Speed and time. 50 rpm and 30 minutes.

Withdraw a suitable volume of the medium and filter promptly through a membrane filter disc having an average pore diameter not greater than 1.0 µm, rejecting the first few ml of the filtrate and dilute a suitable volume of the filtrate, if necessary with water.

Determine by liquid chromatography (2.4.14).

**Test solution.** The filtrate obtained as given above.

**Reference solution.** Weigh accurately about 300 mg of zidovudine RS, 150 mg of lamivudine RS and 200 mg of nevirapine RS and transfer to a 100-ml volumetric flask. Add about 20 ml of methanol, mix with the aid of ultrasound to dissolve and dilute to volume with a solvent mixture of equal volumes of methanol and water. Dilute 5.0 ml of this solution to 50.0 ml with 0.1 M hydrochloric acid.
Chromatographic system
- a stainless steel column 15 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 35 volumes of methanol and 65 volumes of a buffer solution prepared by dissolving 0.68 g of potassium dihydrogen phosphate and 1.0 g of sodium octanesulphonate in 1000.0 ml of water to which 1 ml of triethylamine is added and the pH of which is adjusted to 2.5 with phosphoric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 266 nm,
- a 10 µl loop injector.

Inject the reference solution. The tailing factor for the individual zidovudine, lamivudine and nevirapine peaks is not more than 2.0 and the relative standard deviation for replicate injections of all the analyte peaks is not more than 2.0 per cent.

Inject the test solution and the reference solution and measure the peak responses of the major peaks due to zidovudine, lamivudine and nevirapine.

Inject separately the test solution and the reference solution and measure the responses for the major peaks.

Calculate the contents of C\textsubscript{10}H\textsubscript{13}N\textsubscript{5}O\textsubscript{4}, C\textsubscript{8}H\textsubscript{11}N\textsubscript{3}O\textsubscript{3}S and C\textsubscript{15}H\textsubscript{14}N\textsubscript{4}O in the tablets.

Storage. Store protected from moisture.

Zinc Chloride
ZnCl\textsubscript{2}  
Mol. Wt. 136.3

Zinc Chloride contains not less than 95.0 per cent and not more than 100.5 per cent of ZnCl\textsubscript{2}.

Description. A white or practically white, crystalline powder; odourless; very deliquescent.

Identification
A. To 2 g add 38 ml of carbon dioxide-free water prepared from distilled water and add 2 M hydrochloric acid dropwise until solution is complete and dilute to 40 ml with carbon dioxide-free water prepared from distilled water (solution A). Solution A gives the reaction of zinc salts (2.3.1).
B. A 5 per cent w/v solution in 2 M nitric acid gives the reactions of chlorides (2.3.1).

Tests
pH (2.4.24). 4.6 to 6.0, determined in a solution prepared by dissolving 1.0 g in 9 ml of freshly boiled and cooled water, ignoring any slight turbidity.

Aluminium, calcium, heavy metals, iron and magnesium. To 8 ml of solution A add 2 ml of strong ammonia solution and shake; the solution is clear (2.4.1), and colourless (2.4.1). Add 1 ml of a 9 per cent w/v solution of disodium hydrogen phosphate; the resulting solution remains clear for at least 5 minutes. Add 0.2 ml of sodium sulphide solution; a white precipitate is produced and the supernatant liquid remains colourless.

Ammonium salts. To 5 ml of a 10 per cent w/v solution add 1 M sodium hydroxide until the precipitate first formed is redissolved and then warm the solution; no odour of ammonia is perceptible.

Oxychlorides. Dissolve 1.5 g in 1.5 ml of carbon dioxide-free water; the solution is not more opalescent than opalescence standard OS2 (2.4.1). Add 7.5 ml of ethanol (95 per cent); the solution may become cloudy within 10 minutes but becomes clear on the addition of 0.2 ml of 2 M hydrochloric acid.

Sulphates (2.3.17). 15 ml of solution A complies with the limit test for sulphates (225 ppm).

Assay. Weigh accurately about 3.0 g, dissolve in 125 ml of water, add 3 g of ammonium chloride and add sufficient water to produce 250.0 ml. To 25.0 ml of the resulting solution add 100 ml of water and 10 ml of strong ammonia-ammonium chloride solution. Titrate with 0.1 M disodium edetate, using
1 ml of 0.1 M disodium edetate is equivalent to 0.01363 g of ZnCl₂.

Storage. Store protected from moisture, in non-metallic containers.

**Zinc Oxide**

ZnO  Mol. Wt. 81.4

Zinc Oxide contains not less than 99.0 per cent and not more than 100.5 per cent of ZnO, calculated on the ignited basis.

Description. A soft, white or faintly yellowish white amorphous powder, free from grittiness. It gradually absorbs carbon dioxide from air.

Identification

A. It becomes yellow when strongly heated; the yellow colour disappears on cooling.

B. Dissolve 0.1 g in 1.5 ml of 2 M hydrochloric acid and dilute to 5 ml with water. The solution gives the reaction of zinc salts (2.3.1).

Tests

Alkalinity. Shake 1.0 g with 10 ml of boiling water, add 0.1 ml of phenolphthalein solution and filter. If the filtrate is red, not more than 0.3 ml of 0.1 M hydrochloric acid is required to discharge the colour.

Carbonate and substances insoluble in acids. Dissolve 1.0 g in 15 ml of 2 M hydrochloric acid; no effervescence is produced and the solution is not more opalescent than opalescence standard OS2 (2.4.1), and colourless (2.4.1).

Arsenic (2.3.10). Dissolve 2.0 g in 15 ml of brominated hydrochloric acid AsT and 45 ml of water and remove the excess of bromine with a few drops of stannous chloride solution AsT. The resulting solution complies with the limit test for arsenic (5 ppm).

Iron (2.3.14). Dissolve 0.1 g in a mixture of 5 ml of water and 1 ml of hydrochloric acid and dilute to 40 ml with water. The resulting solution complies with the limit test for iron (400 ppm). Use 0.5 ml of thioglycollic acid in the test.

Lead. Dissolve 2 g in a mixture of 20 ml water and 5 ml of glacial acetic acid and add 0.25 ml of potassium chromate solution; the solution remains clear.

Loss on ignition (2.4.20). Not more than 1.0 per cent, determined on 2.0 g by igniting at 500°C.

**Assay.** Dissolve 0.15 g in 10 ml of 2 M acetic acid and dilute to 50 ml with water. To the resulting solution add about 50 mg of xylenol orange triturate and sufficient hexamine to produce violet-pink colour. Add a further 2 g of hexamine and titrate with 0.1 M disodium edetate until the solution becomes yellow.

1 ml of 0.1 M disodium edetate is equivalent to 0.008138 g of ZnO.

Storage. Store protected from moisture.

**Zinc Oxide Cream**

Zinc Cream

Zinc Oxide Cream contains 32 per cent w/v of Zinc Oxide in a suitable water-in-oil emulsified base.

Zinc Oxide Cream contains not less than 30.0 per cent and not more than 34.0 per cent w/w of zinc oxide, ZnO.

Identification

The residue obtained in the Assay is yellow when hot and white when cool.

Assay. Weigh accurately about 0.5 g in a porcelain dish, heat gently over a small flame until the base is completely volatilised or charred. Increase the heat until all the carbon is removed. Dissolve the residue in 10 ml of 2 M acetic acid and add sufficient water to produce 50 ml. To the resulting solution add about 50 mg of xylenol orange triturate and sufficient hexamine to produce violet-pink colour. Add a further 2 g of hexamine and titrate with 0.1 M disodium edetate until the solution becomes yellow.

1 ml of 0.1 M disodium edetate is equivalent to 0.008138 g of ZnO.

**Zinc Stearate**

(C₁₇H₃₅COO)₂Zn  Mol. Wt. 632.3

Zinc Stearate consists mainly of zinc stearate but many contain variable proportions of zinc palmitate (C₁₅H₃₁COO)₂Zn, and zinc oleate (C₁₇H₃₃COO)₂Zn.

Zinc Stearate contains not less than 10.0 per cent and not more than 12.0 per cent of zinc, Zn.

Description. A fine, white, bulky, amorphous powder, free from grittiness; odour, faint and characteristic.
Identification

A. To 5.0 g add 50 ml of ether and 40 ml of a 7.5 per cent v/v solution of nitric acid in distilled water and heat under a reflux condenser until dissolution is complete. Allow to cool, separate the aqueous layer and shake the ether layer with two quantities, each of 4 ml, of distilled water. Combine the washings with the aqueous layer, wash with 15 ml of ether and heat on a water-bath until ether is completely eliminated. Allow to cool and dilute to 50.0 ml with distilled water (solution A). Evaporate the ether layer to dryness and dry the residue at 105º. The freezing point of the residue is not lower than 53º (2.4.11).

B. Neutralise 5 ml of solution A to red litmus paper with 10 M sodium hydroxide. The solution gives the reactions of zinc salts (2.3.1).

Tests

Appearance of solution. Solution A is not more intensely coloured than reference solution YS6 (2.4.1).

Acidity or alkalinity. Shake 1.0 g with 5 ml of ethanol (95 per cent) and add 20 ml of carbon dioxide-free water and 0.1 ml of phenol red solution. Not more than 0.3 ml of 0.1 M hydrochloric acid or 0.1 ml of 0.1 M sodium hydroxide is required to change the colour of the solution.

Alkalis and alkaline earths. Add 1.0 g to a mixture of 25 ml of water and 5 ml of hydrochloric acid, boil, filter immediately and wash with 25 ml of hot water. Add dilute ammonia solution to make the filtrate just alkaline and then add ammonium sulphide solution in excess to precipitate the zinc as zinc sulphide completely. Filter, add 0.5 ml of sulphuric acid to the filtrate, evaporate to dryness and ignite to constant weight; the residue weighs not more than 20 mg.

Arsenic (2.3.10). Mix 5.0 g with 10 ml of bromine solution and evaporate to dryness on a water-bath. Ignite gently, dissolve the cooled residue, ignoring any carbon, in 50 ml of water and 14 ml of brominated hydrochloric acid AsT and remove the excess of bromine with 2 ml of stannous chloride solution AsT. The resulting solution complies with the limit test for arsenic (2 ppm).

Heavy metals (2.3.13). Heat 5.0 g with 40 ml of 2 M acetic acid and allow to cool. Filter, wash the residue with two successive quantities, each of 5 ml, of warm water and dilute the combined filtrate and washings to 100.0 ml with water. 12 ml of the solution complies with the limit test for heavy metals, Method D (20 ppm). Use 1.0 ml of lead standard solution (10 ppm Pb) to prepare the standard.

Chlorides (2.3.12). 10 ml of solution A complies with the limit test for chlorides (250 ppm).

Sulphates (2.3.17). 2.5 ml of solution A complies with the limit test for sulphates (0.6 per cent).

Assay. Weigh accurately about 1.0 g and boil with 50 ml of 2 M acetic acid until the fatty acid layer which separates is clear, adding more water if necessary to maintain the original volume. Cool, filter and wash the filter and the flask thoroughly with water until the last washing is not acidic to blue litmus paper. To the combined filtrate and washings add about 50 mg of xylene orange triturate and sufficient hexamine to produce violet-pink colour. Add a further 2 g of hexamine and titrate with 0.1 M disodium edetate until the colour changes to yellow. 1 ml of 0.1 M disodium edetate is equivalent to 0.00654 g of Zn.

Zinc Sulphate

ZnSO₄, 7H₂O

Mol. Wt. 287.5

Zinc Sulphate contains not less than 99.0 per cent and not more than 104.0 per cent of ZnSO₄, 7H₂O.

Description. Colourless, transparent crystals or a white, crystalline powder; odourless; efflorescent.

Identification

Dissolve 2.5 g in sufficient carbon dioxide-free water to produce 50 ml (solution A). Solution A gives the reactions of zinc salts and sulphates (2.3.1).

Tests

Appearance of solution. Solution A is clear (2.4.1), and colourless (2.4.2).

pH (2.4.24). 4.4 to 5.6, determined in solution A.

Arsenic (2.3.10). Dissolve 1.0 g in 50 ml of water and add 10 ml of stannated hydrochloric acid AsT. The resulting solution complies with the limit test for arsenic (10 ppm).

Iron (2.3.14). Dissolve 0.4 g in 20 ml of water. The resulting solution complies with the limit test for iron (100 ppm).

Chlorides (2.3.12). 20 ml of solution A complies with the limit test for chlorides (250 ppm).

Assay. Weigh accurately about 0.5 g and dissolve in 5 ml of 2 M acetic acid and dilute to 50 ml with water. To the resulting solution add about 50 mg of xylene orange triturate and sufficient hexamine to produce violet-pink colour. Add a further 2 g of hexamine and titrate with 0.1 M disodium edetate until the colour changes to yellow.

1 ml of 0.1 M disodium edetate is equivalent to 0.02875 g of ZnSO₄, 7H₂O.

Storage. Store protected from moisture, in non-metallic containers.
Zinc Sulphate Eye Drops

Zinc Sulphate Eye Drops are a sterile solution containing 0.25 per cent w/v of Zinc Sulphate in Purified Water.

Zinc Sulphate Eye Drops contain not less than 0.22 per cent and not more than 0.28 per cent w/v of zinc sulphate, ZnSO₄, 7H₂O.

Description. A clear, colourless solution.

Identification

Give the reactions of zinc salts and of sulphates (2.3.1).

Tests

Other tests. Comply with the tests stated under Eye Drops.

Assay. To 5.0 ml add 50 ml of water and 5 ml of ammonia buffer pH 10.9 and titrate with 0.01 M disodium edetate using mordant black II solution as indicator.

1 ml of 0.01 M disodium edetate is equivalent to 0.002875 g of ZnSO₄, 7H₂O.

Storage. Store in containers of glass or any other non-metallic material and sealed so as to exclude micro-organisms.

Zinc Undecenoate

\[
\text{C}_{22}\text{H}_{38}\text{O}_4\text{Zn} \quad \text{Mol. Wt. 431.9}
\]

Zinc Undecenoate is zinc di(undec-10-enolate).

Zinc Undecenoate contains not less than 98.0 per cent and not more than 102.0 per cent of C₂₂H₃₈O₄Zn, calculated on the dried basis.

Description. A white or almost white, fine powder.

Identification

A. To 2.5 g add 10 ml of water and 10 ml of 1 M sulphuric acid and extract with two quantities, each of 10 ml, of ether. Reserve the aqueous layer for test C. Wash the combined ether extracts with water and evaporate to dryness. To the residue add 2 ml of freshly distilled aniline and boil under a reflux condenser for 10 minutes, cool and add 30 ml of ether. Extract with three quantities, each of 20 ml, of 2 M hydrochloric acid and then with 20 ml of water. Evaporate the ether extract to dryness on a water-bath. The residue, after recrystallising twice from ethanol (70 per cent) and drying at a pressure not exceeding 2 kPa for 3 hours, melts at about 67º (2.4.21).

B. Dissolve 0.1 g in a mixture of 2 ml of 1 M sulphuric acid and 5 ml of glacial acetic acid and add, dropwise, 0.25 ml of potassium permanganate solution; the pink colour of permanganate is discharged.

C. A mixture of 1 ml of the aqueous layer reserved in test A and 4 ml of water gives the reaction of zinc salts (2.3.1).

D. Melting range (2.4.21). 115º to 121º.

Tests

Alkalinity. Mix 1.0 g with 5 ml of ethanol (95 per cent) and 0.5 ml of phenol red solution, add 50 ml of carbon dioxide-free water and examine immediately; no reddish colour is produced.

Alkalis and alkaline earths. Add 1.0 g to a mixture of 25 ml of water and 5 ml of hydrochloric acid, boil, filter immediately and wash with 25 ml of hot water. Add dilute ammonia solution to make the filtrate just alkaline and then add ammonium sulphate solution in excess to precipitate the zinc as zinc sulphide completely. Filter, add 0.5 ml of sulphuric acid to the filtrate, evaporate to dryness and ignite to constant weight; the residue weighs not more than 20 mg.

Sulphates (2.3.17). To 0.25 g add a mixture of 10 ml of distilled water and 5 ml of 2 M hydrochloric acid. Cool, filter and dilute to 20 ml with distilled water. The resulting solution complies with the limit test for sulphates (600 ppm).

Degree of unsaturation. Dissolve 0.1 g in a mixture of 5 ml of 2 M hydrochloric acid and 30 ml of glacial acetic acid and titrate with 0.05 M bromine using 0.05 ml of ethoxychrysoidine hydrochloride solution, added towards the end of the titration, as indicator. Not less than 9.1 ml and not more than 9.4 ml of 0.05 M bromine is required to discharge the red colour.

Loss on drying (2.4.19). Not more than 1.5 per cent, determined on 0.5 g by drying in an oven at 105º.

Assay. Weigh accurately about 0.35 g, add 25 ml of 2 M acetic acid, heat to boiling, cool and dilute to 50 ml with water. Add about 50 mg of xylene orange tritrate and sufficient hexamine to produce a violet-pink colour. Add a further 2 g of hexamine and titrate with 0.1 M disodium edetate until the colour changes to yellow.

1 ml of 0.1 M disodium edetate is equivalent to 0.04319 g of C₂₂H₃₈O₄Zn.

Storage. Store protected from light and moisture.

Zinc Undecenoate Ointment

Zinc Undecylenate Ointment

Zinc Undecenoate Ointment contains 20 per cent w/v of Zinc Undecenoate in a suitable ointment basis.
Zinc Undecenoate Ointment contains not less than 18.0 per cent and not more than 22.0 per cent of zinc undecenoate, C_{22}H_{38}O_4Zn, and not less than 4.5 per cent and not more than 5.5 per cent of free undecenoic acid, C_{11}H_{20}O_2.

**Tests**

**Other tests.** Complies with the tests stated under Ointments.

**Assay.** For zinc undecenoate — Weigh accurately about 2.0 g, add 20 ml of dilute hydrochloric acid and boil under a reflux condenser for at least 20 minutes or until the fatty layer is clear. Filter while hot and wash the residue with hot water. Cool the combined filtrate and washings, neutralise to litmus paper with dilute ammonia solution, add 3 ml of dilute hydrochloric acid and 5 g of hexamine and titrate with 0.05 M disodium edetate using xylene orange solution as indicator, until the colour changes to yellow.

1 ml of 0.05 M disodium edetate is equivalent to 0.02160 g of C_{22}H_{38}O_4Zn.

For free undecenoic acid — Weigh accurately about 5.0 g, add 100 ml of dilute hydrochloric acid and heat to 70º with constant stirring. Cool and transfer to a separator with the aid of four quantities, each of 25 ml, of ether and add the rinsings to the mixture in the separator. Dilute the aqueous phase to 300 ml, saturate it with sodium chloride and shake the mixture. Transfer the aqueous layer to a second separator and extract with another 100 ml of ether. Wash the combined ether extracts with successive quantities, each of 10 ml, of water until the washings are free from chloride. Transfer the ether solution to a beaker and evaporate on a water-bath to about 5 ml. Add 20 ml of carbon tetrachloride, mix, transfer the mixture to a small separator and drain the carbon tetrachloride layer into a 100-ml volumetric flask. Rinse the beaker with three quantities, each of 5 ml, of carbon tetrachloride and transfer the rinsings to the volumetric flask, dilute to volume with carbon tetrachloride and mix. Evaporate 50.0 ml of the resulting solution to about 5 ml, add 100 ml of ethanol (95 per cent), previously neutralised, and 0.15 ml of phenolphthalein solution and titrate the total undecenoic acid with 0.1 M sodium hydroxide.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.01843 g of C_{11}H_{20}O_2.

Calculate the content of free undecenoic acid from the difference between the total undecenoic acid and the undecenoic acid equivalent to the determined zinc undecenoate (the content of zinc undecenoate multiplied by 0.8533 gives the equivalent of undecenoic acid).

**Storage.** Store protected from light and moisture.
VACCINES AND IMMUNOSERA FOR HUMAN USE

General Requirements

Monographs

Adsorbed Diphtheria, Tetanus and Hepatitis B (rDNA) Vaccine

Adsorbed Diphtheria, Tetanus and Pertussis (Acellular Component) and Haemophilus Type b Conjugate Vaccine

Adsorbed Diphtheria, Tetanus and Pertussis (Acellular Component) and Hepatitis B (rDNA) Vaccine

Adsorbed Diphtheria, Tetanus and Pertussis (Acellular Component), Inactivated Poliomyelitis Vaccine and Haemophilus Type b Conjugate Vaccine

Adsorbed Diphtheria, Tetanus, Pertussis (Acellular Component) and Inactivated Poliomyelitis Vaccine

Adsorbed Diphtheria, Tetanus, Pertussis and Poliomyelitis (Inactivated) Vaccine

Adsorbed Diphtheria, Tetanus, Pertussis (Acellular Component) and Haemophilus Type b Conjugate Vaccine

Adsorbed Pertussis Vaccine (Acellular Component)

Adsorbed Pertussis Vaccine (Acellular, Co-purified)

Bacillus Calmette-Guerin Vaccine (Freeze-Dried)

Diphtheria and Tetanus Vaccine (Adsorbed)

Diphtheria and Tetanus Vaccine (Adsorbed) for Adults and Adolescents

Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed)

Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (Adsorbed)

Diphtheria, Tetanus, Pertussis (Whole Cell) Hepatitis B (rDNA) Vaccine (Adsorbed)

Diphtheria, Tetanus, Pertussis (Whole Cell) and Haemophilus Type b Conjugate Vaccine (Adsorbed)

Diphtheria Vaccine (Adsorbed)

Haemophilus Type b Conjugate Vaccine

Hepatitis A (Inactivated) and Hepatitis B (rDNA) Vaccine (Adsorbed)

Hepatitis B Vaccine (rDNA)

Inactivated Hepatitis A Vaccine (Adsorbed)

Inactivated Hepatitis B Vaccine
<table>
<thead>
<tr>
<th>Vaccine Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inactivated Influenza Vaccine (Split Virion)</td>
<td></td>
</tr>
<tr>
<td>Inactivated Influenza Vaccine (Surface Antigen)</td>
<td></td>
</tr>
<tr>
<td>Inactivated Influenza Vaccine (Whole Virion)</td>
<td></td>
</tr>
<tr>
<td>Japanese Encephalitis Vaccine (Human)</td>
<td></td>
</tr>
<tr>
<td>Measles and Rubella Vaccine (Live)</td>
<td></td>
</tr>
<tr>
<td>Measles Vaccine (Live)</td>
<td></td>
</tr>
<tr>
<td>Measles, Mumps and Rubella Vaccine (Live)</td>
<td></td>
</tr>
<tr>
<td>Meningococcal Polysaccharide Vaccine</td>
<td></td>
</tr>
<tr>
<td>Mumps Vaccine (Live)</td>
<td></td>
</tr>
<tr>
<td>Pertussis Vaccine</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal Polysaccharide Vaccine</td>
<td></td>
</tr>
<tr>
<td>Poliomyelitis Vaccine (Inactivated)</td>
<td></td>
</tr>
<tr>
<td>Poliomyelitis Vaccine, Live (Oral)</td>
<td></td>
</tr>
<tr>
<td>Rabies Vaccine, Human</td>
<td></td>
</tr>
<tr>
<td>Rubella Vaccine (Live)</td>
<td></td>
</tr>
<tr>
<td>Tetanus Vaccine (Adsorbed)</td>
<td></td>
</tr>
<tr>
<td>Tick-borne Encephalitis Vaccine (Inactivated)</td>
<td></td>
</tr>
<tr>
<td>Tuberculin Purified Protein Derivative</td>
<td></td>
</tr>
<tr>
<td>Typhoid (Strain Ty 21a) Vaccine, Live (Oral)</td>
<td></td>
</tr>
<tr>
<td>Typhoid Polysaccharide Vaccine</td>
<td></td>
</tr>
<tr>
<td>Typhoid Vaccine</td>
<td></td>
</tr>
<tr>
<td>Typhoid Vaccine (Freeze Dried)</td>
<td></td>
</tr>
<tr>
<td>Varicella Vaccine (Live)</td>
<td></td>
</tr>
<tr>
<td>Viper Venom</td>
<td></td>
</tr>
<tr>
<td>Yellow Fever Vaccine (Live)</td>
<td></td>
</tr>
</tbody>
</table>
Vaccines : General Requirements

Vaccines are preparations of antigenic substances that are administered for the purpose of inducing in the recipient a specific and active immunity against the infective agent or toxin produced by it.

Vaccines may contain living micro-organisms suitably treated to attenuate their virulence but retain their antigenic potency or they may consist of pathogenic organisms which have been killed or inactivated. Some vaccines consist of antigenic fractions or substances produced by the same pathogenic organisms but rendered harmless whilst retaining their antigenic efficiency. Vaccines may be prepared from one species only or from a mixture of two or more species.

Vaccines may be prepared by the method described in the individual monographs or by the general methods given below or in any other manner provided the identity of the antigens is maintained and the vaccines are free from microbial contamination and extraneous agents. Suitable adjuvants may be added during the preparation but streptomycin, penicillin or other β-lactam antibiotics may not be added at any stage of manufacture or in the final vaccine. A suitable bactericide may be added to sterile and inactivated vaccines. The final products are distributed aseptically into sterile containers which are then sealed to exclude extraneous micro-organisms. Unless otherwise indicated in the monograph, the final vaccine may be filled into single dose or multiple dose containers but vaccines in multiple dose containers must invariably contain a bactericide.

Bacterial Vaccines. Bacterial vaccines are either sterile suspensions of live or killed bacteria or sterile extracts of derivatives of bacteria. They may be simple vaccines prepared from one species or may be mixed vaccines prepared by blending two or more simple vaccines from different species or strains.

Bacterial vaccines may be prepared from cultures grown on suitable solid or liquid media. The whole culture or parts of it may be used in preparing the vaccine. The identity, antigenic potency and purity of each bacterial culture must be carefully controlled.

Vaccines containing killed organisms may be prepared by killing the organisms by chemical or physical means provided the antigenic potency of the vaccine is preserved. Vaccines containing living bacteria may be prepared from strains which are avirulent for humans but which stimulate the production of antibodies active against pathogenic strains of the same species. The final vaccines must be free from any substance known to cause toxic, allergic or other undesirable immunological reactions in humans.

Bacterial vaccines are suspensions of varying degrees of opacity in colourless or slightly coloured liquids or they may be freeze-dried so that the water content is not more than 3.0 per cent w/w unless otherwise stated in the individual monograph. They may be standardized in terms of interopacity units or, where appropriate, by numbers of living or killed bacteria determined by direct cell count or by viable count.

Bacterial toxoids. Bacterial toxoids are toxins or material derived therefrom, the toxicity of which has been reduced to a very low level or completely eliminated by chemical or physical means without destroying their immunizing potency. The toxins are obtained from selected strains of specific micro-organisms, grown in media free from ingredients known to cause toxic, allergic or other undesirable immunological reactions in humans. Toxoids produced by the action of formaldehyde are known as formol toxoids.

Bacterial toxoids may be liquid or may be prepared by adsorbing on mineral carriers such as aluminium phosphate, aluminium hydroxide or any other suitable adsorbent; the adsorbed product may be separated, washed and suspended in a saline or other appropriate solution isotonic with blood.

Bacterial toxoids are clear or slightly opalescent liquids, colourless or slightly yellow. Adsorbed toxoids may be white or greyish white suspensions or pale-yellow liquids with a sediment at the bottom of the container. Freeze-dried preparations are greyish white or yellowish white powders or pellets.

Viral and rickettsial vaccines. Viral and rickettsial vaccines are suspensions of viruses or rickettsiae and are prepared from infected tissues or blood obtained from artificially infected animals, from cultures in fertile eggs, or from cell or tissue culture. Viral vaccines may be live or killed and they may be freeze-dried. Live vaccines are usually prepared using attenuated strains of the specific organisms. Killed vaccines may be inactivated by suitable chemical or physical means.

Mixed Vaccines. Mixed vaccines are mixtures of two or more vaccines. A suitable antibacterial substance may be added to inactivated or live viral and rickettsial vaccines provided that it has no action against the specific organisms.

Production

General provisions. Requirements for production including in-process testing are included in individual monographs. Where justified and authorized, certain tests may be omitted where it can be demonstrated, for example by validation studies, that the production process consistently ensures compliance with the test.

Unless otherwise justified and authorized, vaccines are produced using a seed-lot system. The methods of preparation are designed to maintain adequate immunogenic properties, to render the preparation harmless and to prevent contamination with extraneous agents.
Unless otherwise justified and authorized, in the production of a final lot of vaccine, the number of passages of a virus, or the number of subcultures of a bacterium, from the master seed lot shall not exceed that used for production of the vaccine shown in clinical studies to be satisfactory with respect to safety and efficacy.

Vaccines are as far as possible free from ingredients known to cause toxic, allergic or other undesirable reactions in man. Suitable additives, including stabilizers and adjuvants may be incorporated. Penicillin and streptomycin are neither used at any stage of production nor added to the final product; however, master seed lots prepared with media containing penicillin or streptomycin may, where justified and authorized, be used for production.

Substrates for propagation. Substrates for propagation comply with the relevant requirements of the Pharmacopoeia or in the absence of such requirements with those of the competent authority. Processing of cell banks and subsequent cell cultures is done under aseptic conditions in an area where no other cells are being handled. Serum and trypsin used in the preparation of cell suspensions shall be shown to be free from extraneous agents.

Seed lot. The strain of bacterium or virus used in a master seed lot is identified by historical records that include information on the origin of the strain and its subsequent manipulation. No micro-organism other than the seed strain shall be present in a seed lot.

Culture media. Culture media are as far as possible free from ingredients known to cause toxic, allergic or other undesirable reactions in man; if inclusion of such ingredients is necessary, it shall be demonstrated that the amount present in the final lot is reduced to such a level as to render the product safe. Approved animal (but not human) serum may be used in the growth medium for cell cultures but the medium used for maintaining cell growth during virus multiplication shall not contain serum, unless otherwise stated. Cell culture media may contain a pH indicator such as phenol red and approved antibiotics at the lowest effective concentration although it is preferable to have a medium free from antibiotics during production.

Propagation and harvest. The seed cultures are propagated and harvested under defined conditions. The purity of the harvest is verified by suitable tests as defined in the monograph.

Control cells. For vaccines produced in cell cultures, control cells are maintained and tested as prescribed. In order to provide a valid control, these cells must be maintained in conditions that are rigorously identical with those used for the production cell cultures, including use of the same batches of media and media changes.

Control eggs. For live vaccines produced in eggs, control eggs are incubated and tested as prescribed in the monograph.

Purification. Where applicable, validated purification procedures may be applied.

Inactivation. Inactivated vaccines are produced using a validated inactivation process whose effectiveness and consistency have been demonstrated. Where there are recognised potential contaminants of a harvest, for example in vaccines produced in eggs from healthy, non-SPF flocks, the inactivation process is also validated with respect to the potential contaminants. A test for inactivation is carried out as soon as possible after the inactivation process, unless otherwise justified and authorised.

Intermediates. Where applicable, the stability of intermediates in given storage conditions shall be evaluated and a period of validity established.

Final bulk. The final bulk is prepared by aseptically blending the ingredients of the vaccine.

Adsorbents. Vaccines may be adsorbed on aluminium hydroxide, aluminium phosphate, calcium phosphate or other suitable adsorbent; the adsorbents are prepared in special conditions which confer the appropriate physical form and adsorptive properties.

Antimicrobial preservative. A suitable antimicrobial preservative may be included in sterile and inactivated vaccines and is invariably added if these preparations are issued in multidose containers, unless otherwise stated. If an antimicrobial preservative is used, it shall be shown that it does not impair the safety or efficacy of the vaccine and its effectiveness throughout the period of validity shall be demonstrated.

Final lot. For vaccines for parenteral administration, the final lot is prepared by aseptically distributing the final bulk into sterile tamper-proof containers which, after freeze-drying where applicable, are closed so as to exclude contamination. For vaccines for administration by a non-parenteral route, the final lot is prepared by distributing the final bulk under suitable conditions into sterile, tamper-proof containers.

Stability. Maintenance of potency of the final lot throughout the period of validity shall be demonstrated by validation studies; the loss of potency in the recommended storage conditions is assessed and excessive loss even within the limits of acceptable potency may indicate that the vaccine is unacceptable.

Degree of adsorption. During development of an adsorbed vaccine, the degree of adsorption is evaluated as part of the consistency testing. A release specification for the degree of adsorption is established in the light of results found for batches used in clinical testing. From the stability data
generated for the vaccine it must be shown that at the end of
the period of validity the degree of adsorption will not be less
than for batches used in clinical testing.

Tests

Vaccines, reconstituted where necessary, comply with the
following requirements unless otherwise stated in the
individual monograph.

Phenol (If present) (2.3.36). Not more than 0.25 per cent w/v.
Thiomersal (If present) (2.3.48). Between 0.005 per cent w/v
and 0.02 per cent w/v.
Free formaldehyde (If present) (2.3.20). Maximum 0.02 g/l.
Aluminium (If present) (2.3.9). Not more than 1.25 mg per
dose.
Sterility (2.2.11). Unless otherwise stated all vaccines comply
with tests for sterility, except that for living bacterial vaccines,
growth of the organism from which the vaccine was prepared
is permitted (sterility means absence of bacterial and fungal
contaminants except where specified in the individual
monograph).

Abnormal toxicity (2.2.1). Unless otherwise stated, all vaccines
comply with the test for abnormal toxicity, Method B. In
vaccines containing phenol as preservative, the test in mice
may be inappropriate.

NOTE — The statements given in this general chapter is
intended to be read in conjunction with the monographs on
the individual vaccine in this Pharmacopoeia which refer to
preparations for human use: they do not necessarily apply
to vaccines for use in veterinary practice.

Storage. Liquid vaccines must be stored at a temperature
between 2° and 8° and should not be allowed to freeze unless
otherwise specified in the individual monograph. Freeze-dried
preparations must be stored at temperatures below –20° or as
specified in the individual monograph. At higher temperatures
vaccines deteriorate rapidly.

Labelling. The label states (1) for liquid vaccines, the total
number of ml in the container and, for dried vaccines, the
number of doses in the container; (2) unless otherwise
indicated the minimum number of Units per dose or per ml or,
for viral vaccines, the minimum viral titre; (3) the dose and
route of administration; (4) the name and proportion of any
antibacterial preservative or other auxiliary substances added
to the vaccine; (5) the date after which the vaccine is not
intended to be used; (6) the conditions under which it should
be stored; (7) for dried vaccines, the liquid to be used for
reconstitution and its volume; (8) that the vaccine should be
used immediately after reconstitution; (9) unless otherwise
directed, that the vaccine should be shaken well before use;
(10) any contraindication to the use of the vaccine.

Adsorbed Diphtheria, Tetanus and Hepatitis B (rDNA) Vaccine

Diphtheria, Tetanus and Hepatitis B (rDNA) Vaccine
(Adsorbed) is a combined vaccine composed of: diphtheria
formol toxoid; tetanus formol toxoid; hepatitis B surface
antigen (HBsAg); a mineral adsorbent such as aluminium
hydroxide or hydrated aluminium phosphate.

The formol toxoids are prepared from the toxins produced by
the growth of Corynebacterium diphtheriae and Clostridium
tetani, respectively.

HBsAg is a component protein of hepatitis B virus; the antigen
is obtained by recombinant DNA technology.

Production

General provisions

The production method shall have been shown to yield
consistently vaccines comparable with the vaccine of proven
clinical efficacy and safety in man.

The production method is validated to demonstrate that the
product, if tested, would comply with the test for abnormal
toxicity for antisera and vaccines, and with the following test
for specific toxicity of the diphtheria and tetanus components:
inject subcutaneously 5 times the single human dose stated
on the label into each of 5 healthy guinea-pigs, each weighing
between 250 and 350 g, that have not previously been treated
with any material that will interfere with the test. If within 42
days of the injection any of the animals shows signs of or dies
from diphtheria toxaemia or tetanus, the vaccine does not
comply with the test. If more than 1 animal dies from non-
specific causes, repeat the test once; if more than 1 animal
dies in the second test, the vaccine does not comply with the
test.

The content of bacterial endotoxins in the bulk purified
diphtheria toxoid and tetanus toxoid is determined to monitor
the purification procedure and to limit the amount in the final
vaccine. For each component, the content of bacterial
endotoxin is less than the limit approved for the particular
vaccine and in any case the contents are such that the final
vaccine contains less than 100 IU per single human dose.

Reference vaccine(s)

Provided valid assays can be performed, monocomponent
reference vaccines may be used for the assays on the combined
vaccine. If this is not possible because of interaction between
the components of the combined vaccine or because of the
difference in composition between monocomponent reference
vaccine and the test vaccine, a batch of combined vaccine
shown to be effective in clinical trials or a batch representative
thereof is used as a reference vaccine. For the preparation of
a representative batch, strict adherence to the production process used for the batch tested in clinical trials is necessary. The reference vaccine may be stabilised by a method that has been shown to have no effect on the assay procedure.

Production of the components

The production of the components complies with the requirements of the monographs on Diphtheria Vaccine (Adsorbed), Tetanus Vaccine (Adsorbed) and Hepatitis B Vaccine (rDNA).

FINAL BULK VACCINE

The final bulk vaccine is prepared by adsorption, separately or together, of suitable quantities of bulk purified diphtheria toxoid, tetanus toxoid and HBsAg onto a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate. Suitable antimicrobial preservatives may be added.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

FINAL LOT

Only a final lot that is satisfactory with respect to the test for osmolality and with respect to each of the requirements given below under Identification, Tests and Assay may be released for use.

Provided the test for antimicrobial preservative and the assays for the diphtheria and tetanus components have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

Provided the content of free formaldehyde has been determined on the bulk purified antigens or on the final bulk and it has been shown that the content in the final lot will not exceed 0.2 g/l, the test for free formaldehyde may be omitted on the final lot.

If an in vivo assay is used for the hepatitis B component, provided it has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

Osmolality (2.4.23). The osmolality of the vaccine is within the limits approved for the particular preparation.

Identification

A. Diphtheria toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. Dissolve in the vaccine under examination sufficient sodium citrate to give a 10 per cent w/v solution. Maintain at 37° for about 16 hours and centrifuge until a clear supernatant is obtained. The clear supernatant liquid reacts with a suitable diphtheria antitoxin, giving a precipitate.

B. Tetanus toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. The clear supernatant liquid obtained during identification test A reacts with a suitable tetanus antitoxin, giving a precipitate.

C. The assay or, where applicable, the electrophoretic profile, serves also to identify the hepatitis B component of the vaccine.

Tests

Aluminium (2.3.9). Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

Free formaldehyde (2.3.20). Maximum 0.2 g/l.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Complies with the test for sterility.

Pyrogens (2.2.8). Complies with the test for pyrogens. Inject the equivalent of 1 human dose into each rabbit.

Assay

Diphtheria component

Carry out one of the prescribed methods for the assay as stated under Diphtheria Vaccine (Adsorbed).

The lower confidence limit (P = 0.95) of the estimated potency is not less than 30 IU per single human dose.

Tetanus component

Carry out one of the prescribed methods for the assay as stated under Tetanus Vaccine (Adsorbed).

The lower confidence limit (P = 0.95) of the estimated potency is not less than 40 IU per single human dose.

Hepatitis B component

It complies with the assay of Hepatitis B Vaccine.

Labelling. The label states (1) the minimum number of International Units of diphtheria and tetanus toxoid per single human dose; (2) the amount of HBsAg per single human dose; (3) the type of cells used for production of the HBsAg component; (4) where applicable, that the vaccine is intended for primary vaccination of children and is not necessarily
Adsorbed Diphtheria, Tetanus, Pertussis (Acellular Component) and Haemophilus Type B Conjugate Vaccine

Diphtheria, Tetanus, Pertussis (Acellular Component) and Haemophilus Type b Conjugate Vaccine (Adsorbed) is a combined vaccine composed of: diphtheria formol toxoid; tetanus formol toxoid; individually purified antigenic components of \textit{Bordetella pertussis}; polyribosylribitol phosphate (PRP) covalently bound to a carrier protein; a mineral absorbent such as aluminium hydroxide or hydrated aluminium phosphate. The product may be presented with the haemophilus type b component in a separate container, the contents of which are mixed with the other components immediately before use.

The formol toxoids are prepared from the toxins produced by the growth of \textit{Corynebacterium diphtheriae} and \textit{Clostridium tetani} respectively. The vaccine contains either pertussis toxoid or a pertussis-toxin-like protein free from toxic properties produced by expression of a genetically modified form of the corresponding gene. Pertussis toxoid is prepared from pertussis toxin by a method that renders the toxin harmless while maintaining adequate immunogenic properties and avoiding reversion to toxin. The acellular pertussis component may also contain filamentous haemagglutinin, pertactin (a 69 kDa outer-membrane protein) and other defined components of \textit{B. pertussis} such as fimbrial-2 and fimbrial-3 antigens. The latter two antigens may be copurified. The antigenic composition and characteristics are based on evidence of protection and freedom from unexpected reactions in the target group for which the vaccine is intended.

PRP is a linear copolymer composed of repeated units of \(3\,\beta\,D\text{-ribofuranosyl-(1}\rightarrow{}1\text{-)}\,\text{ribofuranosyl-5-phosphate} ([C_{10}H_{19}O_{12}P]), with a defined molecular size and derived from a suitable strain of \textit{Haemophilus influenzae} type b. The carrier protein, when conjugated to PRP, is capable of inducing a T-cell-dependent B-cell immune response to the polysaccharide.

Production

General provisions

The production method shall have been shown to yield consistently the vaccines comparable with the vaccine of proven clinical efficacy and safety in man.

If the vaccine is presented with the haemophilus component in a separate vial, as part of consistency studies the assays of the diphtheria, tetanus and pertussis components are carried out on a suitable number of batches of vaccine reconstituted for use. For subsequent routine control, the assays of these components may be carried out without mixing with the haemophilus component.

The content of bacterial endotoxins in bulk purified diphtheria toxoid, tetanus toxoid, pertussis components and PRP conjugate is determined to monitor the purification procedure and to limit the amount in the final vaccine. For each component, the content of bacterial endotoxins is less than the limit approved for the particular vaccine; if the vaccine is presented with the haemophilus component in a separate container, the contents of the diphtheria, tetanus and pertussis antigens are in any case such that the final vial for these components contains less than 100 IU per single human dose.

The production method is validated to demonstrate that the product, if tested, would comply with the test for abnormal toxicity for antisera and vaccines.

During development studies and wherever revalidation is necessary, it shall be demonstrated by tests in animals that the vaccine induces a T-cell dependent B-cell immune response to PRP.

Reference vaccine

Provided valid assays can be performed, monocomponent reference vaccines may be used for the assays on the combined vaccine. If this is not possible because of interaction between the components of the combined vaccine or because of the difference in composition between monocomponent reference vaccine and the test vaccine, a batch of combined vaccine shown to be effective in clinical trials or a batch representative thereof is used as a reference vaccine. For the preparation of a representative batch, strict adherence to the production process used for the batch tested in clinical trials is necessary. The reference vaccine may be stabilised by a method that has been shown to have no effect on the assay procedure.

Production of the components

The production of the components complies with the tests of the monographs on Diphtheria Vaccine (Adsorbed), Tetanus Vaccine (Adsorbed), Pertussis Vaccine (Acellular Component, Adsorbed) and Haemophilus Type b Conjugate Vaccine.
toxoid, acellular pertussis components and PRP conjugate onto a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate; or 2 final bulks may be prepared and filled separately, one containing the diphtheria, tetanus and pertussis components, the other the haemophilus component, which may be freeze-dried. Suitable antimicrobial preservatives may be added.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

Only a final lot that is satisfactory with respect to the test for osmolality shown below and with respect to each of the requirements given below under Identification, Tests and Assay may be released for use.

Provided the tests for absence of residual pertussis toxin, irreversibility of pertussis toxoid and antimicrobial preservative and the assays have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

Provided the free formaldehyde content has been determined on the bulk purified antigens or the final bulk and it has been shown that the content in the final lot will not exceed 0.2 g/l, the test for free formaldehyde may be omitted on the final lot.

**Osmolality** (2.4.23). The osmolality of the vaccine, reconstituted where applicable, is within the limits approved for the particular preparation.

**pH** (2.4.24). The pH of the vaccine, reconstituted if necessary, is within the range approved for the particular product.

**Free PRP.** Unbound PRP is determined after removal of the conjugate, for example by anion-exchange, size-exclusion or hydrophobic chromatography (2.4.16), ultrafiltration or other validated methods. The amount of free PRP is not greater than that approved for the particular product.

**Identification**

If the vaccine is presented with the haemophilus component in a separate vial: identification tests A, B and C are carried out using the vial containing the diphtheria, tetanus and pertussis components; identification test D is carried out on the vial containing the haemophilus components.

A. Diphtheria toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. Dissolve in the vaccine under examination sufficient sodium citrate to give a 10 per cent w/v solution. Maintain at 37° for about 16 h and centrifuge until a clear supernatant is obtained. The clear supernatant reacts with a suitable diphtheria antitoxin, giving a precipitate.

B. Tetanus toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. The clear supernatant obtained as described in Identification test A reacts with a suitable tetanus antitoxin, giving a precipitate.

C. The pertussis components are identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. The clear supernatant obtained as described in Identification test A reacts with a specific antiserum to the pertussis components of the vaccine.

D. The haemophilus component is identified by a suitable immunochemical method (2.2.14) for PRP.

**Tests**

If the product is presented with the haemophilus component in a separate container: the tests for absence of residual pertussis toxin, irreversibility of pertussis toxoid, aluminium, free formaldehyde, antimicrobial preservative and sterility are carried out on the container with the diphtheria, tetanus and pertussis components; the tests for PRP content, water (where applicable), sterility and pyrogens are carried out on the container with the haemophilus component.

If the haemophilus component is freeze-dried, some tests may be carried out on the freeze-dried product rather than on the bulk conjugate where the freeze-drying process may affect the component under test.

**Absence of residual pertussis toxin and irreversibility of pertussis toxoid**

*This test is not necessary for the product obtained by genetic modification.* Use 3 groups each of not less than 5 histamine-sensitive mice. Inject intraperitoneally into each mouse of the first group twice the single human dose of the vaccine stored at 2° to 8°. Inject intraperitoneally into each mouse of the second group twice the single human dose of the vaccine incubated at 37° for 4 weeks. Inject diluent into the third group of mice. After 5 days, inject into each mouse 2 mg of histamine base intraperitoneally in a volume not exceeding 0.5 ml and observe for 24 h. The test is invalid if 1 or more control mice die following histamine challenge. The vaccine complies with the test if no animal in the first or second group dies following histamine challenge. If 1 mouse dies in either or both of the first and second groups, the test may be repeated with the same number of mice or with a greater number and the results of valid tests combined; the vaccine complies with the test if, in both of the groups given the vaccine, not more than 5.0 per cent of the total number of mice die following histamine challenge.
The histamine sensitivity of the strain of mice used is verified at suitable intervals as follows: inject intravenously threefold dilutions of a reference pertussis toxin preparation in phosphate-buffered saline solution containing 0.2 per cent w/v of gelatin and challenge with histamine as above; the strain is suitable if more than 50 per cent of the animals are sensitised by 50 ng of pertussis toxin and none of the control animals injected with only diluent and challenged similarly with histamine shows symptoms of sensitisation.

**PRP.** Minimum 80.0 per cent of the amount of PRP stated on the label. PRP is determined either by assay of ribose (2.7.1) or phosphorus (2.7.1), by an immunochemical method (2.2.14) or by anion-exchange liquid chromatography with pulsed-amperometric detection.

**Aluminium** (2.3.9). Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

**Free formaldehyde** (2.3.20). Maximum 0.2 g/l.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Water** (2.3.43). Maximum 3.0 per cent for the freeze-dried haemophilus component.

**Sterility** (2.2.11). Complies with the test for sterility.

**Pyrogens** (2.2.8). Complies with the test for pyrogens. Inject per kg of the rabbit’s mass a quantity of the vaccine equivalent to: 1 mg of PRP for a vaccine with diphtheria toxoid or CRM 197 diphtheria protein as carrier; 0.1 mg of PRP for a vaccine with tetanus toxoid as carrier; 0.025 mg of PRP for a vaccine with OMP as carrier.

**Assay**

**Diphtheria component**

Carry out one of the prescribed methods for the assay as stated under Diphtheria Vaccine (Adsorbed).

The lower confidence limit (P = 0.95) of the estimated potency is not less than the minimum potency stated on the label. Unless otherwise justified and authorised, the minimum potency stated on the label is 30 IU per single human dose.

**Tetanus component**

Carry out one of the prescribed methods for the assay as stated under Tetanus Vaccine (Adsorbed).

The lower confidence limit (P = 0.95) of the estimated potency is not less than 40 IU per single human dose.

**Pertussis component**

The vaccine complies with the assay as the stated Adsorbed Pertussis Vaccine (Acellular Component).

**Labelling.** The label states (1) the minimum number of International Units of diphtheria and tetanus toxoid per single human dose; (2) the names and amounts of the pertussis components per single human dose; (3) the number of micrograms of PRP per single human dose; (4) the type and nominal amount of carrier protein per single human dose; (5) where applicable, that the vaccine is intended for primary vaccination of children and is not necessarily suitable for reinforcing doses or for administration to adults; (6) the name and the amount of the adsorbent; (7) that the vaccine must be shaken before use; (8) that the vaccine is not to be frozen (9) where applicable, that the vaccine contains a pertussis toxin-like protein produced by genetic modification.

**Adsorbed Diphtheria, Tetanus and Pertussis (Acellular Component) and Hepatitis B (rDNA) Vaccine**

Diphtheria, Tetanus, Pertussis (Acellular Component) and Hepatitis B (rDNA) Vaccine (Adsorbed) is a combined vaccine composed of: diphtheria formol toxoid; tetanus formol toxoid; individually purified antigenic components of *Bordetella pertussis*; hepatitis B surface antigen; a mineral adsorbent such as aluminium hydroxide or hydrated aluminium phosphate.

The formol toxoids are prepared from the toxins produced by the growth of *Corynebacterium diphtheriae* and *Clostridium tetani*, respectively.

The vaccine contains either pertussis toxoid or a pertussis-toxin-like protein free from toxic properties, produced by expression of a genetically modified form of the corresponding gene. Pertussis toxoid is prepared from pertussis toxin by a method that renders the latter harmless while maintaining adequate immunogenic properties and avoiding reversion to toxin. The vaccine may also contain filamentous haemagglutinin, pertactin (a 69 kDa outer-membrane protein) and other defined components of *B. pertussis* such as fimbrial-2 and fimbrial-3 antigens. The latter 2 antigens may be copurified. The antigenic composition and characteristics are based on evidence of protection and freedom from unexpected reactions in the target group for which the vaccine is intended.

Hepatitis B surface antigen is a component protein of hepatitis B virus; the antigen is obtained by recombinant DNA technology.

**Production**

**General provisions**

The production method shall have been shown to yield consistently vaccines comparable with the vaccine of proven
clinical efficacy and safety in man.

The content of bacterial endotoxins in the bulk purified diphtheria toxoid, tetanus toxoid and pertussis components is determined to monitor the purification procedure and to limit the amount in the final vaccine. For each component, the content of bacterial endotoxins is less than the limit approved for the particular vaccine.

Reference vaccine(s)

Provided valid assays can be performed, monocomponent reference vaccines may be used for the assays on the combined vaccine. If this is not possible because of interaction between the components of the combined vaccine or because of the difference in composition between monocomponent reference vaccine and the test vaccine, a batch of combined vaccine shown to be effective in clinical trials or a batch representative thereof is used as a reference vaccine. For the preparation of a representative batch, strict adherence to the production process used for the batch tested in clinical trials is necessary. The reference vaccine may be stabilised by a method that has been shown to have no effect on the assay procedure.

Production of the components

The production of the components complies with the requirements of the monographs on Diphtheria Vaccine (Adsorbed), Tetanus Vaccine (Adsorbed), Pertussis Vaccine (Acellular Component, Adsorbed) and Hepatitis B Vaccine (rDNA).

FINAL BULK VACCINE

The final bulk vaccine is prepared by adsorption, separately or together, of suitable quantities of bulk purified diphtheria toxoid, tetanus toxoid, acellular pertussis components and hepatitis B surface antigen onto a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate. Suitable antimicrobial preservatives may be added.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

FINAL LOT

Only a final lot that is satisfactory with respect to the test for osmolality and with respect to each of the requirements given below under Identification, Tests and Assay may be released for use.

Provided the tests for absence of residual pertussis toxin, irreversibility of pertussis toxoid and antimicrobial preservative and the assays for the diphtheria, tetanus and pertussis components have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

Provided the content of free formaldehyde has been determined on the bulk purified antigens or on the final bulk and it has been shown that the content in the final lot will not exceed 0.2 g/l, the test for free formaldehyde may be omitted on the final lot.

If an in vivo assay is used for the hepatitis B component, provided it has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

Osmolality (2.2.23). The osmolality of the vaccine is within the limits approved for the particular preparation.

Identification

A. Diphtheria toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. Dissolve in the vaccine under examination sufficient sodium citrate to give a 10 per cent w/v solution. Maintain at 37° for about 16 h and centrifuge until a clear supernatant is obtained. The clear supernatant reacts with a suitable diphtheria antitoxin, giving a precipitate.

B. Tetanus toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. The clear supernatant obtained as described in identification test A reacts with a suitable tetanus antitoxin, giving a precipitate.

C. The pertussis components are identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. The clear supernatant obtained as described in identification test A reacts with a specific antiserum to the pertussis components of the vaccine.

D. The assay or, where applicable, the electrophoretic profile, serves also to identify the hepatitis B component of the vaccine.

Tests

Absence of residual pertussis toxin and irreversibility of pertussis toxoid

This test is not necessary for the product obtained by genetic modification. Use 3 groups each of not less than 5 histamine-sensitive mice. Inject intraperitoneally into each mouse of the first group twice the single human dose of the vaccine stored at 2° to 8°. Inject intraperitoneally into each mouse of the second group twice the single human dose of the vaccine incubated at 37° for 4 weeks. Inject diluent into the third group of mice. After 5 days, inject into each mouse 2 mg of histamine
base intraperitoneally in a volume not exceeding 0.5 ml and observe for 24 h. The test is invalid if 1 or more control mice die following histamine challenge. The vaccine complies with the test if no animal in the first or second group dies following histamine challenge. If 1 mouse dies in either or both of the first and second groups, the test may be repeated with the same number of mice or with a greater number and the results of valid tests combined; the vaccine complies with the test if, in both of the groups given the vaccine, not more than 5 per cent of the total number of mice die following histamine challenge.

The histamine sensitivity of the strain of mice used is verified at suitable intervals as follows: inject intravenously threefold dilutions of a reference pertussis toxin preparation in phosphate-buffered saline solution containing 0.2 per cent w/v of gelatin and challenge with histamine as above; the strain is suitable if more than 50.0 per cent of the animals are sensitised by 50 ng of pertussis toxin and none of the control animals injected with only diluent and challenged similarly with histamine shows symptoms of sensitisation.

Aluminium (2.3.9). Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

Free formaldehyde (2.3.20). Maximum 0.2 g/l.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Complies with the test for sterility.

Pyrogens (2.2.8). Complies with the test for pyrogens. Inject the equivalent of 1 human dose into each rabbit.

Assay

Diphtheria component

Carry out one of the prescribed methods for the assay as stated under Diphtheria Vaccine (Adsorbed).

The lower confidence limit (P = 0.95) of the estimated potency is not less than the minimum potency stated on the label.

Unless otherwise justified and authorised, the minimum potency stated on the label is 30 IU per single human dose.

Tetanus component

Carry out one of the prescribed methods for the assay as stated under Tetanus Vaccine (Adsorbed).

The lower confidence limit (P = 0.95) of the estimated potency is not less than 40 IU per single human dose.

Pertussis component

The vaccine complies with the assay as stated under Adsorbed Pertussis Vaccine (Acellular Component).

Hepatitis B component

The vaccine complies with the assay as stated under Hepatitis B Vaccine (rDNA).

Labelling. The label states (1) the minimum number of International Units of diphtheria and tetanus toxoid per single human dose; (2) the names and amounts of the pertussis components per single human dose; (3) the amount of HBsAg per single human dose; (4) the type of cells used for production of the hepatitis B component; (5) where applicable, that the vaccine is intended for primary vaccination of children and is not necessarily suitable for reinforcing doses or for administration to adults; (6) the name and the amount of the adsorbent; (7) that the vaccine must be shaken before use; (8) that the vaccine is not to be frozen (9) where applicable, that the vaccine contains a pertussis toxin-like protein produced by genetic modification.

Adsorbed Diphtheria, Tetanus, Pertussis (Acellular Component), Inactivated Poliomyelitis Vaccine and Haemophilus Type b Conjugate Vaccine

Diphtheria, Tetanus, Pertussis (Acellular Component) and Haemophilus Type b Conjugate Vaccine (Adsorbed) is a combined vaccine composed of: diphtheria formol toxoid; tetanus formol toxoid; individually purified antigenic components of Bordetella pertussis; polyribosylribitol phosphate (PRP) covalently bound to a carrier protein; a mineral absorbent such as aluminium hydroxide or hydrated aluminium phosphate. The product may be presented with the haemophilus type b component in a separate container, the contents of which are mixed with the other components immediately before use.

The formol toxoids are prepared from the toxins produced by the growth of Corynebacterium diphtheriae and Clostridium tetani respectively.

The vaccine contains either pertussis toxoid or a pertussis-toxin-like protein free from toxic properties produced by expression of a genetically modified form of the corresponding gene. Pertussis toxoid is prepared from pertussis toxin by a method that renders the toxin harmless while maintaining adequate immunogenic properties and avoiding reversion to toxin. The acellular pertussis component may also contain filamentous haemagglutinin, pertactin (a 69 kDa outer-
membrane protein) and other defined components of *B. pertussis* such as fimbrial-2 and fimbrial-3 antigens. The latter 2 antigens may be co-purified. The antigenic composition and characteristics are based on evidence of protection and freedom from unexpected reactions in the target group for which the vaccine is intended.

PRP is a linear copolymer composed of repeated units of $3-\beta-D$-ribofuranosyl-(1→1)-ribitol-5-phosphate \([\text{C}_{10}\text{H}_{19}\text{O}_{12}\text{P}]\), with a defined molecular size and derived from a suitable strain of *Haemophilus influenzae* type b. The carrier protein, when conjugated to PRP, is capable of inducing a T-cell-dependent B-cell immune response to the polysaccharide.

**Production**

**General provisions**

The production method shall have been shown to yield consistently vaccines comparable with the vaccine of proven clinical efficacy and safety in man.

The content of bacterial endotoxins in bulk purified diphtheria toxoid, tetanus toxoid, pertussis components, purified, inactivated monovalent poliovirus harvests and bulk PRP conjugate is determined to monitor the purification procedure and to limit the amount in the final vaccine. For each component, the content of bacterial endotoxins is less than the limit approved for the particular vaccine and, in any case, the contents are such that the final vaccine contains less than 100 IU per single human dose.

The production method is validated to demonstrate that the product, if tested, would comply with the following test. Inject subcutaneously 5 times the single human dose stated on the label into each of 5 healthy guinea-pigs, each weighing between 250 and 350 g, that have not previously been treated with any material that will interfere with the test. If within 42 days of the injection any of the animals shows signs of or dies from diphtheria, toxaemia or tetanus, the vaccine does not comply with the test. If more than 1 animal dies from non-specific causes, repeat the test once; if more than 1 animal dies in the second test, the vaccine does not comply with the test.

During development studies and wherever revalidation is necessary, it shall be demonstrated by tests in animals that the vaccine induces a T-cell dependent B-cell immune response to PRP.

As part of consistency studies the assays of the diphtheria, tetanus, pertussis and poliomyelitis components are carried out on a suitable number of batches of vaccine reconstituted for use. For subsequent routine control, the assays of these components may be carried out without mixing with the haemophilus component.

**Reference vaccine(s)**

Provided valid assays can be performed, monocomponent reference vaccines may be used for the assays on the combined vaccine. If this is not possible because of interaction between the components of the combined vaccine or because of the difference in composition between monocomponent reference vaccine and the test vaccine, a batch of combined vaccine shown to be effective in clinical trials or a batch representative thereof is used as a reference vaccine. For the preparation of a representative batch, strict adherence to the production process used for the batch tested in clinical trials is necessary. The reference vaccine may be stabilised by a method that has been shown to have no effect on the assay procedure.

**Production of the components**

The production of the components complies with the requirements of the monographs on Diphtheria Vaccine (Adsorbed), Tetanus Vaccine (Adsorbed), Pertussis Vaccine (Acellular Component, Adsorbed), Poliomyelitis Vaccine (Inactivated) and Haemophilus Type b Conjugate Vaccine.

**FINAL BULK VACCINE**

The final bulk of the diphtheria, tetanus, pertussis and poliomyelitis components is prepared by adsorption, separately or together, of suitable quantities of bulk purified diphtheria toxoid, bulk purified tetanus toxoid and bulk purified acellular pertussis components onto a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate and admixture of suitable quantities of purified, monovalent harvests of human polioviruses 1, 2 and 3 or a suitable quantity of a trivalent pool of such monovalent harvests. Suitable antimicrobial preservatives may be added.

The final bulk of the haemophilus component is prepared by dilution of the bulk conjugate to the final concentration with a suitable diluent. A stabiliser may be added.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Bovine serum albumin.** Determine on the poliomyelitis components by a suitable immunochemical method (2.2.14) during preparation of the final bulk vaccine, before addition of the adsorbent, the amount of bovine serum albumin is such that the content in the final vaccine will not be more than 50 ng per single human dose.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility (2.2.11).** Carry out test for sterility using 10 ml of bulk for each sterility medium.
**FINAL LOT**

The final bulk of the haemophilus component is freeze-dried.

Only a final lot that is satisfactory with respect to the test for osmolality shown below and with respect to each of the requirements given below under Identification, Tests and Assay may be released for use.

Provided that the test for absence of residual pertussis toxin and irreversibility of pertussis toxoid, the test for antimicrobial preservative and the assay have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

Provided that the free formaldehyde content has been determined on the bulk purified antigens and the purified monovalent harvests or the trivalent pool of polioviruses or the final bulk and it has been shown that the content in the final lot will not exceed 0.2 g/l, the test for free formaldehyde may be omitted on the final lot.

Provided that the *in vivo* assay for the poliomyelitis component has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

**Osmolality** (2.4.23). The osmolality of the vaccine, reconstituted where applicable, is within the limits approved for the particular preparation.

**Free PRP**

Unbound PRP is determined on the haemophilus component after removal of the conjugate, for example by anion-exchange, size-exclusion or hydrophobic chromatography (2.4.16), ultrafiltration or other validated methods. The amount of free PRP is not greater than that approved for the particular product.

**Identification**

Identification tests A, B, C and D are carried out using the vial containing the diphtheria, tetanus, pertussis and poliomyelitis components; identification test E is carried out on the vial containing the haemophilus component.

A. Diphtheria toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. The clear supernatant obtained during identification test A reacts with a suitable diphtheria antitoxin, giving a precipitate.

B. Tetanus toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. The clear supernatant obtained during identification test A reacts with a suitable tetanus antitoxin, giving a precipitate.

C. The pertussis components are identified by suitable immunochemical methods (2.2.14). The following method, applicable to certain vaccines, is given as an example. The clear supernatant obtained during identification test A reacts with specific antisera to the pertussis components of the vaccine.

D. The vaccine is shown to contain human polioviruses 1, 2 and 3 by a suitable immunochemical method (2.2.14), such as determination of D-antigen by enzyme-linked immunosorbent assay (ELISA).

E. The haemophilus component is identified by a suitable immunochemical method (2.2.14) for PRP.

**Tests**

The tests for absence of residual pertussis toxin, irreversibility of pertussis toxoid, aluminium, free formaldehyde, antimicrobial preservative and sterility are carried out on the container with the diphtheria, tetanus, pertussis and poliomyelitis components; the tests for PRP content, water, sterility and pyrogens are carried out on the container with the haemophilus component.

Some tests for the haemophilus component may be carried out on the freeze-dried product rather than on the bulk conjugate where the freeze-drying process may affect the component under test.

**Absence of residual pertussis toxin and irreversibility of pertussis toxoid**

*This test is not necessary for the product obtained by genetic modification.* Use 3 groups each of not fewer than 5 histamine-sensitive mice. Inject intraperitoneally into each mouse of the first group twice the single human dose of the vaccine stored at 2° to 8°. Inject intraperitoneally into each mouse of the second group twice the single human dose of the vaccine incubated at 37° for 4 weeks. Inject diluent into the third group of mice. After 5 days, inject into each mouse 2 mg of histamine base intraperitoneally in a volume not exceeding 0.5 ml and observe for 24 hours. The test is invalid if 1 or more control mice die following histamine challenge. The vaccine complies with the test if no animal in the first or second group dies following histamine challenge. If 1 mouse dies in either or both of the first and second groups, the test may be repeated with the same number of mice or with a greater number and the results of valid tests combined; the vaccine complies with the test if, in both of the groups given the vaccine, not more than 5 per cent of the total number of mice die following histamine challenge.

The histamine sensitivity of the strain of mice used is verified at suitable intervals as follows: inject intravenously threefold dilutions of a *reference pertussis toxin preparation* in phosphate-buffered saline solution containing 0.2 per cent w/v of gelatin and challenge with *histamine* as above; the
strain is suitable if more than 50.0 per cent of the animals are sensitised by 50 ng of pertussis toxin and none of the control animals injected with only diluent and challenged similarly with histamine show symptoms of sensitisation.

**PRP.** Minimum 80.0 per cent of the amount of PRP stated on the label. PRP is determined either by assay of ribose (2.7.1) or phosphorus (2.7.1), by an immunochemical method (2.2.14) or by anion-exchange liquid chromatography with pulsed-amperometric detection.

**Aluminium (2.3.9).** Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

**Free formaldehyde (2.3.20).** Maximum 0.2 g/l.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Water (2.3.43).** Maximum 3.0 per cent for the haemophilus component.

**Sterility (2.2.11).** Complies with the test for sterility.

**Pyrogens (2.2.8).** Complies with the test for pyrogens. Inject per kg of the rabbit’s mass a quantity of the vaccine equivalent to: 1 mg of PRP for a vaccine with diphtheria toxoid or CRM 197 diphtheria protein as carrier; 0.1 mg of PRP for a vaccine with tetanus toxoid as carrier; 0.025 mg of PRP for a vaccine with OMP as a carrier.

**Assay**

**Diphtheria component**

Carry out one of the prescribed methods for the assay as stated under Diphtheria Vaccine (Adsorbed).

Unless otherwise justified and authorised, the lower confidence limit (P = 0.95) of the estimated potency is not less than 30 IU per single human dose.

**Tetanus component**

Carry out one of the prescribed methods for the assay as stated under Tetanus Vaccine (Adsorbed).

The lower confidence limit (P = 0.95) of the estimated potency is not less than 40 IU per single human dose.

**Pertussis component**

It complies with the assay as stated under Adsorbed Pertussis Vaccine (Acellular Component).

**Poliomyelitis component**

**D-antigen content**

As a measure of consistency of production, determine the D-antigen content for human polioviruses 1, 2 and 3 by a suitable immunochemical method (2.2.14) using a reference preparation calibrated in units of D-antigen. For each type, the content, expressed with reference to the amount of D-antigen stated on the label, is within the limits approved for the particular product. **Poliomyelitis vaccine (inactivated) reference preparation** is calibrated in Units and intended for use in the assay of D-antigen. The Unit and the International Unit are equivalent.

**In vivo test**

The vaccine complies with the in vivo assay as stated under Inactivated Poliomyelitis Vaccine.

**Labelling.** The label states (1) the minimum number of International Units of diphtheria and tetanus toxoid per single human dose (2) the names and amounts of the pertussis components per single human dose; (3) the nominal amount of poliovirus of each type (1, 2 and 3), expressed in units of D-antigen per single human dose; (4) the type of cells used for production of the poliomyelitis component; (5) the number of micrograms of PRP per single human dose; (6) the type and nominal amount of carrier protein per single human dose; (7) where applicable, that the vaccine is intended for primary vaccination of children and is not necessarily suitable for reinforcing doses or for administration to adults; (8) the name and the amount of the adsorbent; (9) that the vaccine must be shaken before use; (10) that the vaccine is not to be frozen; (11) where applicable, that the vaccine contains a pertussis toxin-like protein produced by genetic modification.

**Adsorbed Diphtheria, Tetanus, Pertussis (Acellular Component) and Inactivated Poliomyelitis Vaccine**

Diphtheria, Tetanus, Pertussis (Acellular Component) and Poliomyelitis (Inactivated) Vaccine is a combined vaccine containing: diphtheria formol toxoid; tetanus formol toxoid; individually purified antigenic components of *Bordetella pertussis*; suitable strains of human polioviruses 1, 2 and 3 grown in suitable cell cultures and inactivated by a validated method; a mineral adsorbent such as aluminium hydroxide or hydrated aluminium phosphate.

The formol toxoids are prepared from the toxins produced by the growth of *Corynebacterium diphtheriae* and *Clostridium tetani* respectively.

The vaccine contains either pertussis toxoid or a pertussis-toxin-like protein free from toxic properties produced by expression of a genetically modified form of the corresponding gene. Pertussis toxoid is prepared from pertussis toxin by a method that renders the toxin harmless while maintaining
adequate immunogenic properties and avoiding reversion to
toxin. The vaccine may also contain filamentous
haemagglutinin, pertactin (a 69 kDa outer-membrane protein)
and other defined components of B. pertussis such as fimbrial-
2 and fimbrial-3 antigens. The latter 2 antigens may be
copurified. The antigenic composition and characteristics are
based on evidence of protection and freedom from unexpected
reactions in the target group for which the vaccine is intended.

Production
General provisions
The production method shall have been shown to yield
consistently vaccines comparable with the vaccine of proven
clinical efficacy and safety in man.

The production method is validated to demonstrate that the
product, if tested, would comply with the test for abnormal
toxicity for antisera and vaccines.

The content of bacterial endotoxins in bulk purified diphtheria
toxoid, tetanus toxoid, pertussis components and purified,
inactivated monovalent poliovirus harvests is determined to
monitor the purification procedure and to limit the amount in
the final vaccine. For each component, the content of bacterial
endotoxins is less than the limit approved for the particular
vaccine and, in any case, the contents are such that the final
vaccine contains less than 100 IU per single human dose.

Reference vaccine(s)
Provided valid assays can be performed, monocomponent
reference vaccines may be used for the assays on the combined
vaccine. If this is not possible because of interaction between
the components of the combined vaccine or because of the
difference in composition between monocomponent reference
vaccine and the test vaccine, a batch of combined vaccine
shown to be effective in clinical trials or a batch representative
thereof is used as a reference vaccine. For the preparation of
a representative batch, strict adherence to the production
process used for the batch tested in clinical trials is necessary.
The reference vaccine may be stabilised by a method that has
been shown to have no effect on the assay procedure.

Production of the components
The production of the components complies with the
requirements of the monographs on Diphtheria Vaccine
(Adsorbed), Tetanus Vaccine (Adsorbed), Pertussis Vaccine
(Acellular Component, Adsorbed) and Poliomyelitis Vaccine
(Inactivated).

FINAL BULK VACCINE
The final bulk vaccine is prepared by adsorption onto a mineral
carrier such as aluminium hydroxide or hydrated aluminium
phosphate, separately or together, of suitable quantities of
bulk purified diphtheria toxoid, tetanus toxoid, acellular
pertussis components and admixture of suitable quantities of
purified monovalent harvests of human polioviruses 1, 2 and
3 or a suitable quantity of a trivalent pool of such purified
monovalent harvests. Suitable antimicrobial preservatives may
be added.

Only a final bulk vaccine that complies with the following
requirements may be used in the preparation of the final lot.

Bovine serum albumin. Determine on the poliomyelitis
components by a suitable immunochemical method (2.2.14)
after virus harvest and before addition of the adsorbent in the
preparation of the final bulk vaccine, the amount of bovine
serum albumin is such that the content in the final vaccine will
be not more than 50 ng per single human dose.

Antimicrobial preservative. Where applicable, determine the
amount of antimicrobial preservative by a suitable chemical
method. The content is not less than 85.0 per cent and not
greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Carry out test for sterility using 10 ml of bulk
for each sterility medium.

FINAL LOT
Only a final lot that is satisfactory with respect to the test for
osmolality and with respect to each of the requirements given
below under Identification, Tests and Assay may be released
for use.

Provided the tests for absence of residual pertussis toxin,
irreversibility of pertussis toxoid and antimicrobial preservative
and the assays for the diphtheria, tetanus and pertussis
components have been carried out with satisfactory results
on the final bulk vaccine, they may be omitted on the final lot.

Provided the free formaldehyde content has been determined
on the bulk purified antigens or on the final bulk and it has
been shown that the content in the final lot will not exceed
0.2 g/l, the test for free formaldehyde may be omitted on the
final lot.

Provided that the determination of D-antigen content has been
carried out with satisfactory results during preparation of the
final bulk before addition of the adsorbent, it may be omitted
on the final lot.

Provided that the in vivo assay for the poliomyelitis component
has been carried out with satisfactory results on the final bulk
vaccine, it may be omitted on the final lot.

Osmolality (2.4.23). The osmolality of the vaccine is within
the limits approved for the particular preparation.

Identification
A. Diphtheria toxoid is identified by a suitable immunochemical
method (2.2.14). The following method, applicable to certain vaccines, is given as an example. Dissolve in the vaccine under examination sufficient sodium citrate to give a 10 per cent w/v solution. Maintain at 37° for about 16 h and centrifuge until a clear supernatant is obtained. The clear supernatant reacts with a suitable diphtheria antitoxin, giving a precipitate.

B. Tetanus toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. The clear supernatant obtained as described in Identification test A reacts with a suitable tetanus antitoxin, giving a precipitate.

C. The pertussis components are identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. The clear supernatant obtained as described in Identification test A reacts with a specific antisera to the pertussis components of the vaccine.

D. The vaccine is shown to contain human polioviruses 1, 2 and 3 by a suitable immunochemical method (2.2.14) such as the determination of D-antigen by enzyme-linked immuno-sorbent assay (ELISA).

Tests

Absence of residual pertussis toxin and irreversibility of pertussis toxoid

This test is not necessary for the product obtained by genetic modification. Use 3 groups each of not less than 5 histamine-sensitive mice. Inject intraperitoneally into each mouse of the first group twice the single human dose of the vaccine stored at 2° to 8°. Inject intraperitoneally into each mouse of the second group twice the single human dose of the vaccine incubated at 37° for 4 weeks. Inject diluent into the third group of mice. After 5 days, inject into each mouse 2 mg of histamine base intraperitoneally in a volume not exceeding 0.5 ml and observe for 24 hours. The test is invalid if 1 or more control mice die following histamine challenge. The vaccine complies with the test if no animal in the first or second group dies following histamine challenge. The vaccine complies with the test if no animal in the first or second group dies following histamine challenge. If 1 mouse dies in either or both of the first and second groups, the test may be repeated with the same number of mice or with a greater number and the results of valid tests combined; the vaccine complies with the test if, in both of the groups given the vaccine, not more than 5.0 per cent of the total number of mice die following histamine challenge.

The histamine sensitivity of the strain of mice used is verified at suitable intervals as follows: inject intravenously three-fold dilutions of a reference pertussis toxin preparation in phosphate-buffered saline solution containing 0.2 per cent w/v of gelatin and challenge with histamine as above; the strain is suitable if more than 50.0 per cent of the animals are sensitised by 50 ng of pertussis toxin and none of the control animals injected with only diluent and challenged similarly with histamine shows symptoms of sensitisation.

Aluminium (2.3.9). Maximum 1.25 mg per single human dose if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

Free formaldehyde (2.3.20). Maximum 0.2 g/l.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Complies with the test for sterility.

Assay

Diphtheria component

Carry out one of the prescribed methods for the assay as stated under Diphtheria Vaccine (Adsorbed). The lower confidence limit (P = 0.95) of the estimated potency is not less than the minimum potency stated on the label. Unless otherwise justified and authorised, the minimum potency stated on the label is 30 IU per single human dose.

Tetanus component

Carry out one of the prescribed methods for the assay as stated under Tetanus Vaccine (Adsorbed). The lower confidence limit (P = 0.95) of the estimated potency is not less than 40 IU per single human dose.

Pertussis component

The vaccine complies with the assay as stated under Adsorbed Pertussis Vaccine (Acellular Component).

Poliomyelitis component

D-antigen content

As a measure of consistency of production, determine the D-antigen content for human polioviruses 1, 2 and 3 by a suitable immunochemical method (2.2.14) following desorption using a reference preparation calibrated in units of D-antigen. For each type, the content, expressed with reference to the amount of D-antigen stated on the label, is within the limits approved for the particular product. Poliomyelitis vaccine (inactivated) reference preparation is calibrated in Units and intended for use in the assay of D-antigen. The Unit and the International Unit are equivalent.

In vivo test

The vaccine complies with the in vivo assay as stated under Inactivated Poliomyelitis Vaccine.
Labelling. The label complies with the requirements stated under Vaccine and also states (1) the minimum number of International Units of diphtheria and tetanus toxoid per single human dose (2) the names and amounts of the pertussis components per single human dose; (3) the nominal amount of poliovirus of each type (1, 2 and 3), expressed in units of D-antigen per single human dose; (4) the type of cells used for production of the poliomyelitis component; (5) the number of micrograms of PRP per single human dose; (6) the type and nominal amount of carrier protein per single human dose; (7) where applicable, that the vaccine is intended for primary vaccination of children and is not necessarily suitable for reinforcing doses or for administration to adults; (8) the name and the amount of the adsorbent; (9) that the vaccine must be shaken before use; (10) that the vaccine is not to be frozen; (11) where applicable, that the vaccine contains a pertussis toxin-like protein produced by genetic modification.

Adsorbed Diphtheria, Tetanus, Pertussis and Poliomyelitis (Inactivated) Vaccine

Diphtheria, Tetanus, Pertussis and Poliomyelitis (Inactivated) Vaccine (Adsorbed) is a combined vaccine containing: diphtheria formol toxoid; tetanus formol toxoid; an inactivated suspension of *Bordetella pertussis*; suitable strains of human polioviruses 1, 2 and 3 grown in suitable cell cultures and inactivated by a validated method; a mineral adsorbent such as aluminium hydroxide or hydrated aluminium phosphate.

The formol toxoids are prepared from the toxins produced by the growth of *Corynebacterium diphtheriae* and *Clostridium tetani* respectively.

Production

General provisions

The production method shall have been shown to yield consistently the vaccines comparable with the vaccine of proven clinical efficacy and safety in man.

The production method is validated to demonstrate that the product, if tested, would comply with the test for abnormal toxicity for antisera and vaccines, and with the following test for specific toxicity of the diphtheria and tetanus components: inject subcutaneously 5 times the single human dose stated on the label into each of 5 healthy guinea-pigs, each weighing between 250 and 350 g, that have not previously been treated with any material that will interfere with the test. If within 42 days of the injection any of the animals shows signs of or dies from diphtheria toxæmia or tetanus, the vaccine does not comply with the test. If more than 1 animal dies from non-specific causes, repeat the test once; if more than 1 animal dies in the second test, the vaccine does not comply with the test.

Reference vaccine(s)

Provided valid assays can be performed, monocomponent reference vaccines may be used for the assays on the combined vaccine. If this is not possible because of interaction between the components of the combined vaccine or because of the difference in composition between monocomponent reference vaccine and the test vaccine, a batch of combined vaccine shown to be effective in clinical trials or a batch representative thereof is used as a reference vaccine. For the preparation of a representative batch, strict adherence to the production process used for the batch tested in clinical trials is necessary. The reference vaccine may be stabilised by a method that has been shown to have no effect on the assay procedure.

Production of the components

The production of the components complies with the requirements of the monographs on Diphtheria Vaccine (Adsorbed), Tetanus Vaccine (Adsorbed), Pertussis Vaccine (Adsorbed) and Poliomyelitis Vaccine (Inactivated).

FINAL BULK VACCINE

The final bulk vaccine is prepared by adsorption onto a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate, separately or together, of suitable quantities of bulk purified diphtheria toxoid and bulk purified tetanus toxoid and admixture of suitable quantities of an inactivated suspension of *B. pertussis* and purified monovalent harvests of human polioviruses 1, 2 and 3 or a suitable quantity of a trivalent pool of such purified monovalent harvests. Suitable antimicrobial preservatives may be added.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Specific toxicity

Use not less than 5 healthy mice each weighing between 14 and 16 g for the vaccine group and for the saline control. Use mice of the same sex or distribute males and females equally between the groups. Allow the animals access to food and water for at least 2 hours before injection and during the test. Inject each mouse of the vaccine group intraperitoneally with 0.5 ml, containing a quantity of the vaccine equivalent to not less than half the single human dose. Inject each mouse of the control group with 0.5 ml of a 0.9 per cent sterile solution of sodium chloride, preferably containing the same amount of antimicrobial preservative as that injected with the vaccine. Weigh the groups of mice immediately before the injection and 72 hours and 7 days after the injection. The vaccine
complies with the test if: (a) at the end of 72 hours the total mass of the group of vaccinated mice is not less than that preceding the injection; (b) at the end of 7 days the average increase in mass per vaccinated mouse is not less than 60 per cent of that per control mouse; and (c) not more than 5 per cent of the vaccinated mice die during the test. The test may be repeated and the results of the tests combined.

**Bovine serum albumin.** Determine on the poliomyelitis components by a suitable immunochemical method (2.2.14) during preparation of the final bulk vaccine; before addition of the adsorbent, the amount of bovine serum albumin is such that the content in the final vaccine will be not more than 50 ng per single human dose.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

Only a final lot that is satisfactory with respect to the test for osmolality and with respect to each of the requirements given below under Identification, Tests and Assay may be released for use.

Provided that the tests for specific toxicity and antimicrobial preservative, and the assays for the diphtheria, tetanus and pertussis components have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

Provided that the free formaldehyde content has been determined on the bulk purified antigens, the inactivated *B. pertussis* suspension and the purified monovalent harvests or the trivalent pool of polioviruses or on the final bulk and it has been shown that the content in the final lot will not exceed 0.2 g/l, the test for free formaldehyde may be omitted on the final lot.

Provided that the in vivo assay for the poliomyelitis component has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

**Osmolality** (2.4.23). The osmolality of the vaccine is within the limits approved for the particular preparation.

**Identification**

A. Diphtheria toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. Dissolve in the vaccine under examination sufficient sodium citrate to give a 10 per cent solution. Maintain at 37° for about 16 hours and centrifuge until a clear supernatant is obtained. The clear supernatant reacts with a suitable diphtheria antitoxin, giving a precipitate.

B. Tetanus toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. The clear supernatant obtained during identification test A reacts with a suitable tetanus antitoxin, giving a precipitate.

C. The centrifugation residue obtained in identification A may be used. Other suitable methods for separating the bacteria from the adsorbent may also be used. Identify pertussis vaccine by agglutination of the bacteria from the resuspended precipitate by antisera specific to *B. pertussis* or by the assay of the pertussis component prescribed under Assay.

D. The vaccine is shown to contain human polioviruses 1, 2 and 3 by a suitable immunochemical method (2.2.14) such as the determination of D-antigen by enzyme-linked immunoabsorbent assay (ELISA).

**Tests**

**Aluminium** (2.3.9). Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

**Free formaldehyde** (2.3.20). Maximum 0.2 g/l.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Complies with the test for sterility.

**Assay**

**Diphtheria component**

Carry out one of the prescribed methods for the assay as stated under Diphtheria Vaccine (Adsorbed).

The lower confidence limit (P = 0.95) of the estimated potency is not less than 30 IU per single human dose.

**Tetanus component**

Carry out one of the prescribed methods for the assay as stated under Tetanus Vaccine (Adsorbed).

If the test is carried out in guinea pigs, the lower confidence limit (P = 0.95) of the estimated potency is not less than 40 IU per single human dose; if the test is carried out in mice, the lower confidence limit (P = 0.95) of the estimated potency is not less than 60 IU per single human dose.

**Pertussis component**

Carry out the assay as stated under Pertussis Vaccine.

The estimated potency is not less than 4 IU per single human
The vaccine complies with the in vivo assay as stated under Poliomyelitis Vaccine (Inactivated).

**Labelling.** The label states (1) the minimum number of International Units of diphtheria and tetanus toxoid per single human dose; (2) the minimum number of International Units of pertussis vaccine per single human dose; (3) the nominal amount of poliovirus of each type (1, 2 and 3), expressed in units of D-antigen per single human dose; (4) the type of cells used for production of the poliomyelitis component; (5) where applicable, that the vaccine is intended for primary vaccination of children and is not necessarily suitable for reinforcing doses or for administration to adults; (6) the name and the amount of the adsorbent; (7) that the vaccine must be shaken before use; (8) that the vaccine is not to be frozen.

**Adsorbed Diphtheria, Tetanus, Pertussis, Poliomyelitis (Inactivated) and Haemophilus Type b Conjugate Vaccine**

Diphtheria, Tetanus, Pertussis, Poliomyelitis (Inactivated) and Haemophilus Type b Conjugate Vaccine (Adsorbed) is a combined vaccine composed of: diphtheria formol toxoid; tetanus formol toxoid; an inactivated suspension of *Bordetella pertussis*; suitable strains of human polioviruses 1, 2 and 3 grown in suitable cell cultures and inactivated by a suitable method; polyriboylribitol phosphate (PRP) covalently bound to a carrier protein; a mineral adsorbent such as aluminium hydroxide or hydrated aluminium phosphate. The product is presented with the haemophilus component in a separate container, the contents of which are mixed with the other components immediately before use.

The formol toxoids are prepared from the toxins produced by the growth of *Corynebacterium diphtheriae* and *Clostridium tetani* respectively.

PRP is a linear copolymer composed of repeated units of 3-β-D-ribofuranosyl-(1→1)-ribofuranosyl-5-phosphate \([C_{15}H_{29}O_{12}P_n]_{1-3}\), with a defined molecular size and derived from a suitable strain of *Haemophilus influenzae* type b. The carrier protein, when conjugated to PRP, is capable of inducing a T-cell-dependent B-cell immune response to the polysaccharide.

**Production**

**General provisions**

The production method shall have been shown to yield consistently vaccines comparable with the vaccine of proven clinical efficacy and safety in man.

The production method is validated to demonstrate that the product, if tested, would comply with the test for abnormal toxicity for antisera and vaccines, and with the following test for specific toxicity of the diphtheria and tetanus components: inject subcutaneously 5 times the single human dose stated on the label into each of 5 healthy guinea-pigs, each weighing between 250 and 350 g, that have not previously been treated with any material that will interfere with the test. If within 42 days of the injection any of the animals shows signs of or dies from diphtheria toxæmia or tetanus, the vaccine does not comply with the test. If more than 1 animal dies from non-specific causes, repeat the test once; if more than 1 animal dies in the second test, the vaccine does not comply with the test.

During development studies and wherever revalidation is necessary, it shall be demonstrated by tests in animals that the vaccine induces a T-cell dependent B-cell immune response to PRP.

As part of consistency studies the assays of the diphtheria, tetanus, pertussis and poliomyelitis components are carried out on a suitable number of batches of vaccine reconstituted for use. For subsequent routine control, the assays of these components may be carried out without mixing with the haemophilus component.

**Reference vaccine(s)**

Provided valid assays can be performed, monocomponent reference vaccines may be used for the assays on the combined vaccine. If this is not possible because of interaction between the components of the combined vaccine or because of the difference in composition between monocomponent reference vaccine and the test vaccine, a batch of combined vaccine shown to be effective in clinical trials or a batch representative thereof is used as a reference vaccine. For the preparation of a representative batch, strict adherence to the production process used for the batch tested in clinical trials is necessary.
The reference vaccine may be stabilised by a method that has been shown to have no effect on the assay procedure.

**Production of components**

The production of the components complies with the requirements of the monographs on Diphtheria Vaccine (Adsorbed), Tetanus Vaccine (Adsorbed), Pertussis Vaccine (Adsorbed), Poliomyelitis Vaccine (Inactivated) and Haemophilus Type b Conjugate Vaccine.

**FINAL BULK VACCINE**

The final bulk of the diphtheria, tetanus, pertussis and poliomyelitis components is prepared by adsorption, separately or together, of suitable quantities of bulk purified diphtheria toxoid, and bulk purified tetanus toxoid onto a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate and admixture of suitable quantities of an inactivated suspension of *B. pertussis* and of purified, monovalent harvests of human polioviruses 1, 2 and 3 or a suitable quantity of a trivalent pool of such monovalent harvests. Suitable antimicrobial preservatives may be added.

The final bulk of the haemophilus component is prepared by dilution of the bulk conjugate to the final concentration with a suitable diluent. A stabiliser may be added.

Only final bulk that complies with the following requirements may be used in the preparation of the final lot.

**Specific toxicity**

Use not less than 5 healthy mice each weighing between 14 and 16 g, for the vaccine group and for the saline control. Use mice of the same sex or distribute males and females equally between the groups. Allow the animals access to food and water for at least 2 hours before injection and during the test. Inject each mouse of the vaccine group intraperitoneally with 0.5 ml, containing a quantity of the vaccine equivalent to not less than half the single human dose. Inject each mouse of the control group with 0.5 ml of a 0.9 per cent sterile solution of sodium chloride, preferably containing the same amount of antimicrobial preservative as that injected with the vaccine.

Weigh the groups of mice immediately before the injection and 72 hours and 7 days after the injection. The vaccine complies with the test if (a) at the end of 72 hours the total mass of the group of vaccinated mice is not less than that preceding the injection; (b) at the end of 7 days the average increase in mass per vaccinated mouse is not less than 60 per cent of that per control mouse; and (c) not more than 5 per cent of the vaccinated mice die during the test. The test may be repeated and the results of the tests combined.

**Bovine serum albumin**. Determine on the poliomyelitis components by a suitable immunochemical method (2.2.14) during preparation of the final bulk vaccine, before addition of the adsorbent, the amount of bovine serum albumin is such that the content in the final vaccine will not be more than 50 ng per single human dose.

**Antimicrobial preservative**. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

The final bulk of the haemophilus component is freeze-dried.

Only a final lot that is satisfactory with respect to the test for osmolality shown below and with respect to each of the requirements given below under Identification, Tests and Assay may be released for use.

Provided that the tests for specific toxicity and antimicrobial preservative, and the assays for the diphtheria, tetanus and pertussis components have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

Provided that the free formaldehyde content has been determined on the bulk purified antigens, the inactivated *B. pertussis* suspension and the purified monovalent harvests or the trivalent pool of polioviruses or on the final bulk and it has been shown that the content in the final lot will not exceed 0.2 g/l, the test for free formaldehyde may be omitted on the final lot.

Provided that the in vivo assay for the poliomyelitis component has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

**Osmolality** (2.4.23). The osmolality of the vaccine, reconstituted where applicable, is within the limits approved for the particular preparation.

**Free PRP**

Unbound PRP is determined on the haemophilus component after removal of the conjugate, for example by anion-exchange, size-exclusion or hydrophobic chromatography (2.4.16), ultrafiltration or other validated methods. The amount of free PRP is not greater than that approved for the particular product.

**Identification**

Identification tests A, B, C and D are carried out using the vial containing the diphtheria, tetanus, pertussis and poliomyelitis components; identification test E is carried out on the vial containing the haemophilus component.

A. Diphtheria toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain
vaccines, is given as an example. Dissolve in the vaccine under examination sufficient sodium citrate to give a 10 per cent w/v solution. Maintain at 37° for about 16 hours and centrifuge until a clear supernatant is obtained. The clear supernatant reacts with a suitable diphtheria antitoxin, giving a precipitate.

B. Tetanus toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. The clear supernatant obtained during identification test A reacts with a suitable tetanus antitoxin, giving a precipitate.

C. The centrifugation residue obtained in identification A may be used. Other suitable methods for separating the bacteria from the adsorbent may also be used. Identify pertussis vaccine by agglutination of the bacteria from the resuspended precipitate by antisera specific to B. pertussis or by the assay of the pertussis component prescribed under Assay.

D. The vaccine is shown to contain human polioviruses 1, 2 and 3 by a suitable immunochemical method (2.2.14), such as determination of D-antigen by enzymelinked immunosorbent assay (ELISA).

E. The haemophilus component is identified by a suitable immunochemical method (2.2.14) for PRP.

Tests
The tests for specific toxicity, aluminium, free formaldehyde, antimicrobial preservative and sterility are carried out on the container with diphtheria, tetanus, pertussis and poliomyelitis components; the tests for PRP content, water, sterility and pyrogens are carried out on the container with the haemophilus component.

Some tests for the haemophilus component may be carried out on the freeze-dried product rather than on the bulk conjugate where the freeze-drying process may affect the component under test.

PRP. Minimum 80.0 per cent of the amount of PRP stated on the label. PRP is determined either by assay of ribose (2.7.1) or phosphorus (2.7.1), by an immunochemical method (2.2.14) or by anion-exchange liquid chromatography with pulsed-amperometric detection.

Aluminium (2.3.9). Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

Free formaldehyde (2.3.20). Maximum 0.2 g/l.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Water (2.3.43). Maximum 3.0 per cent for the haemophilus component.

Sterility (2.2.11). Complies with the test for sterility.

Pyrogens (2.2.8). Complies with the test for pyrogens. Inject per kg of the rabbit’s mass a quantity of the vaccine equivalent to 1 mg of PRP for a vaccine with diphtheria toxoid or CRM 197 diphtheria protein as carrier; 0.1 mg of PRP for a vaccine with tetanus toxoid as carrier; 0.025 mg of PRP for a vaccine with OMP as carrier.

Assay
Diphtheria component
Carry out one of the prescribed methods for the assay as stated under Diphtheria Vaccine (Adsorbed).

The lower confidence limit (P = 0.95) of the estimated potency is not less than 30 IU per single human dose.

Tetanus component
Carry out one of the prescribed methods for the assay as stated under Tetanus Vaccine (Adsorbed).

If the test is carried out in guinea-pigs, the lower confidence limit (P = 0.95) of the estimated potency is not less than 40 IU per single human dose; if the test is carried out in mice, the lower confidence limit (P = 0.95) of the estimated potency is not less than 60 IU per single human dose.

Pertussis component
Carry out the assay as stated under Pertussis Vaccine.

The estimated potency is not less than 4 IU per single human dose and the lower confidence limit (P = 0.95) of the estimated potency is not less than 2 IU per single human dose.

Poliomyelitis component
D-antigen content
As a measure of consistency of production, determine the D-antigen content for human polioviruses 1, 2 and 3 by a suitable immunochemical method (2.2.14) using a reference preparation calibrated in Units of D-antigen. For each type, the content, expressed with reference to the amount of D-antigen stated on the label, is within the limits approved for the particular product. Poliomyelitis vaccine (inactivated) reference preparation is calibrated in Units and intended for use in the assay of D-antigen. The Unit and the IU are equivalent.

In vivo test
The vaccine complies with the in vivo assay as stated under Poliomyelitis Vaccine (Inactivated).

Labelling. The label states (1) the minimum number of International Units of diphtheria and tetanus toxoid per single human dose; (2) the minimum number of International Units of pertussis vaccine per single human dose; (3) the nominal amount of poliovirus of each type (1, 2 and 3), expressed in
Units of D-antigen per single human dose; (4) the type of cells used for production of the poliomyelitis component; (5) the number of micrograms of PRP per single human dose; (6) the type and nominal amount of carrier protein per single human dose; (7) where applicable, that the vaccine is intended for primary vaccination of children and is not necessarily suitable for reinforcing doses or for administration to adults; (8) the name and the amount of the adsorbent; (9) that the vaccine must be shaken before use; (9) that the vaccine is not to be frozen.

Adsorbed Pertussis Vaccine (Acellular Component)

Pertussis Vaccine (Acellular Component, Adsorbed) is a preparation of individually prepared and purified antigenic components of *Bordetella pertussis* adsorbed on a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate.

The vaccine contains either pertussis toxoid or a pertussis toxin, like protein free from toxic properties, produced by expression of a genetically modified form of the corresponding gene. Pertussis toxoid is prepared from pertussis toxin by a method that renders the latter harmless while maintaining adequate immunogenic properties and avoiding reversion to toxin. The vaccine may also contain filamentous haemagglutinin, pertactin (a 69 kDa outer-membrane protein) and other defined components of *B. pertussis* such as fimbrial-2 and fimbrial-3 antigens. The latter 2 antigens may be copurified. The antigenic composition and characteristics are based on evidence of protection and freedom from unexpected reactions in the target group for which the vaccine is intended.

**Production**

**General provisions**

The production method shall have been shown to yield consistently the vaccines comparable with the vaccine of proven clinical efficacy and safety in man.

**Reference vaccine**

A batch of vaccine shown to be effective in clinical trials or a batch representative thereof is used as a reference vaccine. For the preparation of a representative batch, strict adherence to the production process used for the batch tested in clinical trials is necessary. The reference vaccine is preferably stabilised by a method that has been shown to have no significant effect on the assay procedure when the stabilised and non-stabilised batches are compared.

**CHARACTERISATION OF COMPONENTS**

During development of the vaccine, the production process shall be validated to demonstrate that it yields consistently individual components that comply with the following requirements; after demonstration of consistency, the tests need not be applied routinely to each batch.

**Adenylate cyclase.** Not more than 500 ng in the equivalent of 1 dose of the final vaccine, determined by immunoblot analysis or another suitable method.

**Tracheal cytotoxin.** Not more than 2 pmol in the equivalent of 1 dose of the final vaccine, determined by a suitable method such as a biological assay or liquid chromatography (2.4.14).

**Absence of residual dermonecrotic toxin.** Inject intradermally into each of 3 unweaned mice, in a volume of 0.1 ml, the amount of component or antigenic fraction equivalent to 1 dose of the final vaccine. Observe for 48 hours. No dermonecrotic reaction is demonstrable.

**Specific properties.** The components of the vaccine are analysed by one or more of the methods shown below in order to determine their identity and specific properties (activity per unit amount of protein) in comparison with reference preparations.

**Pertussis toxin**

Chinese hamster ovary (CHO) cell-clustering effect and haemagglutulation as *in vitro* methods; lymphocytosis-promoting activity, histamine-sensitising activity and insulin secretory activity as *in vivo* methods. The toxin shows ADP-ribosyl transferase activity using transducin as the acceptor.

**Filamentous haemagglutinin**

Haemagglutination and inhibition by specific antibody.

**Pertactin, fimbrial-2 and fimbrial-3 antigens.** Reactivity with specific antibody.

**Pertussis toxoid**

The toxoid induces in animals production of antibodies capable of inhibiting all the properties of pertussis toxin.

**PURIFIED COMPONENTS**

Production of each component is based on a seed-lot system. The seed cultures from which toxin is prepared are managed to conserve or where necessary restore toxinogenicity by deliberate selection.

None of the media used at any stage contains blood or blood products of human origin. Media used for the preparation of seed lots and inocula may contain blood or blood products of animal origin.

Pertussis toxin and, where applicable, filamentous haemagglutinin and pertactin are purified and, after appropriate characterisation, detoxified using suitable chemical reagents, by a method that avoids reversion of the toxoid to toxin, particularly on storage or exposure to heat. Other components such as fimbrial-2 and fimbrial-3 antigens are purified either
separately or together, characterised and shown to be free from toxic substances. The purification procedure is validated to demonstrate appropriate clearance of substances used during culture or purification.

The content of bacterial endotoxins is determined to monitor the purification procedure and to limit the amount in the final vaccine. The limits applied for the individual components are such that the final vaccine contains less than 100 IU per single human dose.

Before detoxification, the purity of the components is determined by a suitable method such as polyacrylamide gel electrophoresis (PAGE) or liquid chromatography. SDS-PAGE or immunoblot analysis with specific monoclonal or polyclonal antibodies may be used to characterise subunits. Requirements are established for each individual product.

Only purified components that comply with the following requirements may be used in the preparation of the final bulk vaccine.

**Sterility** (2.2.11). Carry out the test for sterility using for each medium a quantity of purified component equivalent to not less than 100 doses.

**Absence of residual pertussis toxin**

This test is not necessary for the product obtained by genetic modification. Use a group of not fewer than 5 histamine-sensitive mice each weighing between 18 and 26 g. Inject into each mouse the equivalent of 1 human dose intravenously or twice the human dose intraperitoneally, diluted to not more than 0.5 ml with phosphate-buffered saline solution containing 0.2 per cent w/v of gelatin. Inject diluent into a second group of control mice. After 5 days, inject 2 mg of histamine base intraperitoneally in a volume not exceeding 0.5 ml and observe for 24 hours. If no animal dies, the preparation complies with the test.

The histamine sensitivity of the strain of mice used is verified at suitable intervals as follows: inject three-fold dilutions of a reference pertussis toxin preparation in phosphate-buffered saline solution containing 0.2 per cent w/v of gelatin and challenge with histamine as above; the strain is suitable if more than 50 per cent of the animals are sensitised by 50 ng of pertussis toxin and none of the control animals injected with only diluent and challenged similarly with histamine show symptoms of sensitisation.

A validated test based on the clustering effect of the toxin for Chinese hamster ovary (CHO) cells may be used instead of the test on mice.

**Residual detoxifying agents and other reagents**

The content of residual detoxifying agents and other reagents is determined and shown to be below approved limits unless validation of the process has demonstrated acceptable clearance.

**Antigen content**

Determine the antigen content by a suitable immunochemical method (2.2.14) and protein nitrogen by sulphuric acid digestion (2.2.30) or another suitable method. The ratio of antigen content to protein nitrogen is within the limits established for the product.

**FINAL BULK VACCINE**

The vaccine is prepared by adsorption of suitable quantities of purified components, separately or together, onto aluminium hydroxide or hydrated aluminium phosphate. A suitable antimicrobial preservative may be added.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Antimicrobial preservative**. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

Only a final lot that is satisfactory with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided that the tests for absence of residual pertussis toxin and irreversibility of pertussis toxoid, antimicrobial preservative, free formaldehyde and the assay have been carried out with satisfactory results on the final bulk vaccine, these tests may be omitted on the final lot.

**Identification**

Subject the vaccine to a suitable desorption procedure such as the following: dissolve in the vaccine under examination sufficient sodium citrate to give a 10 per cent w/v solution; maintain at 37° for about 16 h and centrifuge until a clear supernatant liquid is obtained. Examined by a suitable immunochemical method (2.2.14), the clear supernatant liquid reacts with specific antisera to the components stated on the label.

**Tests**

**Absence of residual pertussis toxin and irreversibility of pertussis toxoid**

This test is not necessary for the product obtained by genetic modification. Use 3 groups each of not fewer than 5 histamine-sensitive mice. Inject intraperitoneally into the first group twice
the single human dose of the vaccine stored at 2° to 8°. Inject intraperitoneally into the second group twice the single human dose of the vaccine incubated at 37° for 4 weeks. Inject diluent into the third group of mice. After 5 days, inject into each mouse 2 mg of histamine base intraperitoneally in a volume not exceeding 0.5 ml and observe for 24 hours. The test is invalid if 1 or more control mice die following histamine challenge. The vaccine complies with the test if no animal in the first or second group dies following histamine challenge. If 1 mouse dies in either or both of the first and second groups, the test may be repeated with the same number of mice or with a greater number and the results of valid tests combined; the vaccine complies with the test if, in both of the groups given the vaccine, not more than 5.0 per cent of the total number of mice die following histamine challenge.

The histamine sensitivity of the strain of mice used is verified at suitable intervals as follows: inject intravenously threefold dilutions of a reference pertussis toxin preparation in phosphate-buffered saline solution containing 0.2 per cent w/v of gelatin and challenge with histamine as above; the strain is suitable if more than 50.0 per cent of the animals are sensitised by 50 ng of pertussis toxin and none of the control animals injected with only diluent and challenged similarly with histamine show symptoms of sensitisation.

**Aluminium** (2.3.9). Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

**Free formaldehyde** (2.3.20). Maximum 0.2 g/l.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Complies with the test for sterility.

**Assay**

The capacity of the vaccine to induce the formation of specific antibodies is compared with the same capacity of a reference preparation examined in parallel; antibodies are determined using suitable immunochemical methods (2.2.14) such as enzyme-linked immunosorbent assay (ELISA). The test on mice shown below uses a three-point model but, after validation, for routine testing a single-dilution method may be used.

**Requirement**

The capacity to induce antibodies is not significantly (P = 0.95) less than that of the reference vaccine.

The following test model is given as an example of a method that has been found to be satisfactory.

**Selection and distribution of test animals**

Use in the test healthy mice (for example, CD1 strain) of the same stock 4 to 8 weeks old. Distribute the animals in 6 groups of a number appropriate to the requirements of the assay. Use 3 dilutions of the vaccine under examination and 3 dilutions of a reference preparation and attribute each dilution to a group of mice. Inject intraperitoneally or subcutaneously into each mouse 0.5 ml of the dilution attributed to its group.

**Collection of serum samples**

4 to 5 weeks after vaccination, bleed the mice individually under anaesthesia. Store the sera at -20° until tested for antibody content.

**Antibody determination**

Assay the individual sera for content of specific antibodies to each component using a validated method such as the ELISA test shown below.

**ELISA**

Microtitre plates (poly(vinyl chloride) or polystyrene as appropriate for the specific antigen) are coated with the purified antigen at a concentration of 100 ng per well. After washing, unreacted sites are blocked by incubating with a solution of bovine serum albumin and then washed. Two-fold dilutions of sera from mice immunised with test or reference vaccines are made on the plates. After incubation at 22° to 25° for 1 h, the plates are washed. A suitable solution of anti-mouse IgG enzyme conjugate is added to each well and incubated at 22° to 25° for 1 h. After washing, a substrate is added from which the bound enzyme conjugate liberates a chromophore which can be quantified by measurement of absorbance. The test conditions are designed to obtain a linear response for absorbance with respect to antibody content over the range of measurement used and absorbance values within the range 0.1 to 2.0.

A reference antiserum of assigned potency is used in the test and serves as the basis for calculation of the antibody levels in test sera. A standardised control serum is also included in the test.

The test is not valid if (a) the value found for the control serum differs by more than 2 standard deviations from the assigned value; (b) the confidence interval of the potency estimate is greater than 50.0 per cent to 200.0 per cent.

**Calculation**

The antibody titres in the sera of mice immunised with reference and test vaccines are calculated and from the values obtained the potency of the test vaccine in relation to the reference vaccine is calculated by the usual statistical methods.

**Labelling.** The label states (1) the names and amounts of the components present in the vaccine; (2) where applicable, that
the vaccine contains a pertussis toxin-like protein produced by genetic modification; (3) the name and amount of the adsorbent; (4) that the vaccine must be shaken before use; (5) that the vaccine is not to be frozen.

Adsorbed Pertussis Vaccine (Acellular, Co-Purified)

Pertussis Vaccine (Acellular, Co-Purified, Adsorbed) is a preparation of antigenic components of *Bordetella pertussis* adsorbed on a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate.

The vaccine contains an antigenic fraction purified without separation of the individual components. The antigenic fraction is treated by a method that transforms pertussis toxin to toxoid, rendering it harmless while maintaining adequate immunogenic properties of all the components and avoiding reversion to toxin. The antigenic fraction is composed of pertussis toxoid, filamentous haemagglutinin, pertactin (a 69 kDa outer-membrane protein) and other defined components of *B. pertussis* such as fimbrial-2 and fimbrial-3 antigens. It may contain residual pertussis toxin up to a maximum level approved by the competent authority. The antigenic composition and characteristics are based on evidence of protection and freedom from unexpected reactions in the target group for which the vaccine is intended.

Production

**General provisions.** The production method shall have been shown to yield consistently vaccines comparable with the vaccine of proven clinical efficacy and safety in man.

**Reference vaccine.** A batch of vaccine shown to be effective in clinical trials or a batch representative thereof is used as a reference vaccine. For the preparation of a representative batch, strict adherence to the production process used for the batch tested in clinical trials is necessary. The reference vaccine is preferably stabilised, by a method that has been shown to have no significant effect on the assay procedure when the stabilised and non-stabilised batches are compared.

**CHARACTERISATION OF COMPONENTS**

During development of the vaccine, the production process shall be validated to demonstrate that it yields consistently an antigenic fraction that complies with the following requirements; after demonstration of consistency, the tests need not be applied routinely to each batch.

**Adenylate cyclase.** Not more than 500 ng in the equivalent of 1 dose of the final vaccine, determined by immunoblot analysis or another suitable method.

**Tracheal cytotoxin.** Not more than 2 pmol in the equivalent of 1 dose of the final vaccine, determined by a suitable method such as a biological assay or liquid chromatography (2.4.14).

**Absence of residual dermonecrotic toxin.** Inject intradermally into each of 3 unweaned mice, in a volume of 0.1 ml, the amount of antigenic fraction equivalent to 1 dose of the final vaccine. Observe for 48 hours. No dermonecrotic reaction is demonstrable.

**Specific properties.** The antigenic fraction is analyzed by one or more of the methods shown below in order to determine the identity and specific properties (activity per unit amount of protein) of its components in comparison with reference preparations.

**Pertussis toxin**

Chinese hamster ovary (CHO) cell-clustering effect and haemagglutination as *in vitro* methods; lymphocytosis-promoting activity, histamine-sensitising activity and insulin secretory activity as *in vivo* methods. The toxin shows ADP-ribosyl transferase activity using transducin as the acceptor.

**Filamentous haemagglutinin**

Haemagglutination and inhibition by specific antibody.

**Pertactin, fimbrial-2 and fimbrial-3 antigens.** Reactivity with specific antibody.

**Pertussis toxoid**

The toxoid induces in animals the production of antibodies capable of inhibiting all the properties of pertussis toxin.

**PURIFIED ANTIGENIC FRACTION**

Production of the antigenic fraction is based on a seed-lot system. The seed cultures are managed to conserve or, where necessary, restore toxinogenicity by deliberate selection.

None of the media used at any stage contains blood or blood products of human origin. Media used for the preparation of seed batches and inocula may contain blood or blood products of animal origin.

The antigenic fraction is purified and, after appropriate characterisation, detoxified using suitable reagents by a method that ensures minimal reversion of toxoid to toxin, particularly on or exposure to heat. The purification procedure is validated to demonstrate appropriate clearance of substances used during culture or purification.

The content of bacterial endotoxins is determined to monitor the purification procedure and to limit the amount in the final vaccine. The limits applied are such that the final vaccine contains not more than 100 IU per single human dose.

Before detoxification, the purity of the antigenic fraction is
determined by a suitable method such as polyacrylamide gel electrophoresis (PAGE) (2.4.12) or liquid chromatography (2.4.14). SDS-PAGE or immunoblot analysis with specific monoclonal or polyclonal antibodies may be used to characterise subunits. Requirements are established for each individual product.

Only a purified antigenic fraction that complies with the following requirements may be used in the preparation of the final bulk vaccine.

Sterility (2.2.11). Carry out the test for sterility using for each medium a quantity of purified antigenic fraction equivalent to not less than 100 doses of the final vaccine.

Test for residual pertussis toxin. Use 3 groups of not fewer than 5 histamine-sensitive mice each weighing between 18 and 26 g. Using phosphate-buffered saline containing 0.2 per cent of gelatin, prepare a series of dilutions of the purified antigenic fraction that have been shown to yield a graded response and attribute each dilution to a separate group of mice. Inject intraperitoneally into each mouse the dilution attributed to its group. Inject diluent into a fourth group of control mice. After 5 days, inject intraperitoneally into each mouse 1 mg of histamine base in a volume not exceeding 0.5 ml. Record the number of animals that die within 24 h of histamine challenge. Calculate the weight or volume of a preparation that sensitises 50.0 per cent of the mice injected using a suitable statistical method such as probit analysis. The residual activity of pertussis toxin does not exceed that of batches shown to be safe in clinical studies.

The histamine sensitivity of the strain of mice used is verified at suitable intervals as follows: inject threefold dilutions of a reference pertussis toxin preparation in phosphate-buffered saline solution containing 0.2 per cent w/v of gelatin and challenge with histamine as described above; the strain is suitable if more than 50 per cent of the animals are sensitised by 50 ng of pertussis toxin and none of the control animals injected with only diluent and challenged similarly with histamine show symptoms of sensitisation.

A validated test based on the clustering effect of the toxin for Chinese hamster ovary (CHO) cells may be used instead of the test on mice.

Residual detoxifying agents and other reagents. The content of residual detoxifying agents and other reagents is determined and shown to be below approved limits unless validation of the process has demonstrated acceptable clearance.

Antigen content. Determine the complete quantitative antigen composition of the antigenic fraction by suitable immunochemical methods (2.2.14) and protein nitrogen by sulphuric acid digestion or another suitable method. The ratio of total antigen content to protein nitrogen is within the limits established for the product.

Final Bulk Vaccine

The vaccine is prepared by adsorption of a suitable quantity of the antigenic fraction onto aluminium hydroxide or hydrated aluminium phosphate. A suitable antimicrobial preservative may be added.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

Final Lot

Only a final lot that is satisfactory with respect to each of the requirements given below under Identification, Tests and Assay may be released for use.

Provided that the tests for residual pertussis toxin, reversibility of toxoid, antimicrobial preservative, free formaldehyde and the assay have been carried out with satisfactory results on the final bulk vaccine, these tests may be omitted on the final lot.

Identification

Subject the vaccine to a suitable desorption procedure such as the following: dissolve in the vaccine under examination sufficient sodium citrate to give a 10 per cent w/v solution; maintain at 37°C for about 16 h and centrifuge until a clear supernatant is obtained. Examine by a suitable immunochemical method (2.2.14), the clear supernatant reacts with specific antisera to the components in the vaccine.

Tests

Test for residual pertussis toxin. Use 3 groups of not fewer than 5 histamine-sensitive mice (see under Production) each weighing between 18 and 26 g. Using phosphate-buffered saline containing 0.2 per cent w/v of gelatin, prepare a series of dilutions of the vaccine under examination that have been shown to yield a graded response and attribute each dilution to a separate group of mice. Inject intraperitoneally into each mouse the dilution attributed to its group. Inject diluent into a fourth group of control mice. After 5 days, inject intraperitoneally into each mouse 1 mg of histamine base in a volume not exceeding 0.5 ml. Note the number of animals that die within 24 h of histamine challenge. Calculate the weight or volume of a preparation that sensitises 50 per cent of the mice injected using a suitable statistical method such as probit analysis. The residual activity of pertussis toxin does not exceed that of batches shown to be safe in clinical studies.
Reversibility of toxoid. Carry out the test for residual pertussis toxin described above using the vaccine incubated at 37°C for 4 weeks in parallel with a sample stored at 2° to 8°. The degree of reversibility does not exceed that of batches shown to be safe in clinical studies.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Aluminium (2.3.9). Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

Free formaldehyde (2.3.20). Maximum 0.2 g/l.

Sterility (2.2.11). Complies with the test for sterility.

Assay
The vaccine complies with the assay as stated under Adsorbed Pertussis Vaccine (Acellular Component).

Labelling. The label states (1) the names and amounts of the antigenic components present in the vaccine; (2) the maximum amount of residual pertussis toxin present in the vaccine; (3) the maximum degree of reversion of toxoid to toxin during the period of validity; (4) the name and amount of the adsorbent; (5) that the vaccine must be shaken before use; (6) that the vaccine is not to be frozen.

Bacillus Calmette-Guerin Vaccine (Freeze-Dried)
Freeze-dried BCG Vaccine is a preparation of live bacteria derived from a culture of the bacillus of Calmette and Guérin (Mycobacterium bovis BCG) capacity of which to protect against tuberculosis has been established.

Vaccine complies with the requirements stated under Vaccines with the following modifications.

Production
General provisions
The production method is validated to demonstrate that the product, if tested, would comply with the tests for safety and efficacy.

BCG vaccine shall be produced by a staff consisting of healthy persons who do not work with other infectious agents; in particular they shall not work with virulent strains of Mycobacterium tuberculosis, during the course of production cycle nor shall they be exposed to a known risk of tuberculosis infection. BCG vaccine is susceptible to sunlight: the procedures for the preparation of the vaccine shall be so designed that all cultures and vaccines are protected from direct sunlight and from ultraviolet light at all stages of manufacture, testing and storage.

Production of the vaccine is based on a seed-lot system. The production method shall have been shown to yield consistently BCG vaccines that induce adequate sensitivity to tuberculin in man, that have acceptable protective potency in animals and are safe. The vaccine is prepared from cultures which are derived from the master seed lot by as few subcultures as possible and in any case not more than 12 subcultures e.g. If the secondary seed lot is 4 culture passages removed from the primary seed lot, the no. of passages from the secondary seed lot must not exceed 8.

The capacity of the working seed lot to induce sensitivity to tuberculin in guinea-pigs is demonstrated.

If a bioluminescence test or other biochemical method is used instead of viable count, the method is validated against the viable count for each stage of the process at which it is used.

SEED LOT
The strain used to establish the master seed lot is chosen for and maintained to preserve its stability, its capacity to sensitise man and guinea-pigs to tuberculin and to protect animals against tuberculosis, and its relative absence of pathogenicity for man and laboratory animals. The strain used shall be identified by historical records that include information on its origin and subsequent manipulation.

A suitable batch of vaccine is prepared from the first working seed lot and is reserved for use as the comparison/ in-house reference vaccine. When a new working seed lot is established, a suitable test for delayed hypersensitivity in guinea-pigs is carried out on a batch of vaccine prepared from the new working seed lot; the vaccine is shown to be not significantly different in activity from the comparison vaccine.

Only a working seed lot that complies with the following requirements may be used for propagation.

Identification
The bacteria in the working seed lot are identified as Mycobacterium bovis BCG using microbiological techniques, which may be supplemented by molecular biology techniques (for example, nucleic acid amplification and restriction-fragment-length polymorphism).

Sterility (2.2.11). Complies with the test for sterility, carried out using 10 ml for each medium. The working seed lot complies with the test for sterility except for the presence of mycobacteria.

Virulent mycobacteria
Examine the working seed lot as prescribed under Tests, using 10 guinea pigs.
PROPAGATION AND HARVEST

The bacteria are grown in a suitable medium for not more than 21 days by surface or submerged culture. The culture medium shall contain no substances known to cause toxic or allergic reactions in human beings or to cause the bacteria to become virulent for guinea-pigs. The culture is harvested and suspended in a sterile liquid medium that protects the viability of the vaccine as determined by a suitable method of viable count.

Test for purity. Purity is checked by acid fast staining.

FINAL BULK VACCINE

The final bulk vaccine is prepared from a single harvest or by pooling a number of single harvests. A stabiliser may be added; if the stabiliser interferes with the determination of bacterial concentration on the final bulk vaccine, the determination is carried out before addition of the stabiliser.

Only final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Virulent mycobacteria. Examine as prescribed under Tests.

Sterility (2.2.11). Complies with the test for sterility using 10 ml for each medium except for the presence of mycobacteria.

Count of viable units

Determine the number of viable units per ml by viable count on solid medium using a method suitable for the vaccine under examination or by determination of adenosine triphosphate by a bioluminescence reaction. Carry out the test in parallel on a reference preparation of the same strain.

Bacterial concentration

Determine the total bacterial concentration by a suitable method, either directly by determining the mass of the micro-organisms, or indirectly by an opacity method that has been calibrated in relation to the mass of the organisms; if the bacterial concentration is determined before addition of a stabiliser, the concentration in the final bulk vaccine is established by calculation. The total bacterial concentration is within the limits approved for the particular product by National Regulatory Authority.

The ratio of the count of viable units to the total bacterial concentration is not less than that approved for the particular product by National Regulatory Authority.

FINAL LOT

The final bulk vaccine is distributed into sterile containers and freeze-dried to a moisture content favourable to the stability of the vaccine; the containers are closed either under vacuum or under a gas that is not deleterious to the vaccine.

Except where the filled and closed containers are stored at a temperature of -20° or lower, the expiry date is not later than 4 years from the date of harvest.

Only a final lot that complies with the following requirement for count of viable units and with each of the requirements given below under Identification, Tests and Assay may be released for use. Provided the test for virulent mycobacteria has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot. Provided the test for excessive dermal reactivity has been carried out with satisfactory results on the working seed lot and on 5 consecutive final lots produced from it, the test may be omitted on the final lot.

Count of viable units

Determine the number of viable units per ml of the reconstituted vaccine by viable count on solid medium using a method suitable for the vaccine under examination or by determination of adenosine triphosphate by a bioluminescence reaction. The ratio of the count of viable units after freeze-drying to that before is not less than that approved for the particular product.

Identification

BCG vaccine is identified by microscopic examination of the bacilli in stained smears demonstrating their acid-fast property and by the characteristic appearance of colonies grown on solid medium. Alternatively, molecular biology techniques (like nucleic acid amplification) may be used.

Tests

Virulent mycobacteria

If this test is satisfactory at final bulk stage it can be omitted at the final lot.

Inject subcutaneously or intramuscularly into each of 6 guinea-pigs, each weighing between 250 and 400 g and having received no treatment likely to interfere with the test, a quantity of vaccine equivalent to at least 50 human doses. Observe the animals for at least 42 days. At the end of this period, kill the guinea-pigs and examine by autopsy for signs of infection with tuberculosis, ignoring any minor reactions at the site of injection. Animals that die during the observation period are also examined for signs of tuberculosis. The vaccine complies with the test if none of the guinea-pigs shows signs of tuberculosis and if not more than one animal dies during the observation period. If 2 animals die during this period and autopsy does not reveal signs of tuberculosis repeat the test on 6 other guinea-pigs. The vaccine complies with the test if not more than one animal dies during the 42 days following the injection and autopsy does not reveal any sign of tuberculosis.
Sterility (2.2.11). The reconstituted vaccine complies with the test for sterility except for the presence of mycobacteria.

Excessive dermal reactivity

Use 6 healthy white or pale-coloured guinea-pigs, each weighing not less than 250 g and having received no treatment likely to interfere with the test. Inject intradermally into each guinea-pig, according to a randomised plan, 0.1 ml of the reconstituted vaccine and of 2 tenfold serial dilutions of the vaccine and identical doses of the comparison vaccine. Observe the lesions formed at the site of the injection for 4 weeks. The vaccine complies with the test if the reaction it produces is not markedly different from that produced by the comparison vaccine.

Temperature stability

Maintain samples of the freeze-dried vaccine at 37° for 4 weeks. Determine the number of viable units in the heated vaccine and in unheated vaccine as described below. The number of viable units in the heated vaccine is not less than 20.0 per cent of that in unheated vaccine.

Water (2.3.43). Not more than 3.0 per cent, determined by the semi-micro determination of water.

Assay

Determine the number of viable units in the reconstituted vaccine by viable count on solid medium or using a suitable validated biochemical method for the vaccine under examination. The number is within the range stated on the label. Determine the number of viable units in the comparison vaccine in parallel.

Labelling. The label states (1) the minimum and maximum number of viable units per ml in the reconstituted vaccine; (2) that the vaccine must be protected from direct sunlight; (3) that the vaccine is to be used immediately after broaching the container; (4) the age group for which the vaccine is intended; (5) the dose for each age group; (6) follow instructions as mentioned in the product insert/leaflet.

Diphtheria and Tetanus Vaccine (Adsorbed)

Diphtheria and Tetanus Vaccine (Adsorbed) is a preparation of diphtheria formol toxoid and tetanus formol toxoid adsorbed on mineral carrier. The formol toxoids are prepared from the toxins produced by the growth of Corynebacterium diphtheriae and Clostridium tetani, respectively.

The specification for individual component used in formulation is referred in the text of individual monograph.

Production

General provisions

Bulk purified diphtheria and tetanus toxoids

The bulk purified diphtheria and tetanus toxoids are prepared as described in the monographs on Diphtheria vaccine (adsorbed) and Tetanus vaccine (adsorbed) and comply with the requirements prescribed therein.

Sterility (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

Absence of toxin and irreversibility of toxoid

Inject subcutaneously into each of 5 guinea-pigs at least 500 Lf of the non-incubated bulk purified toxoid in a volume of 1 ml, using the same buffer solution as for the final vaccine, without adsorbent. Animals that die shall be autopsied and examined for symptoms of diphtheria intoxication (red adrenals). The bulk purified toxoid shall pass the test if no guinea-pig shows symptoms of specific intoxication within six weeks of injection and if at least 80 per cent of the animals survive the test period. The guinea-pigs shall not have been used previously for experimental purposes.

Alternatively, a cell-culture test system may be used; in this case, the sensitivity of the test shall have been demonstrated to be not less than that of the guinea-pig test, and the test procedures shall be approved by the National Regulatory Authority.

Each bulk purified toxoid shall be tested to ensure that reversion to toxicity cannot take place on storage. The bulk purified toxoid shall be diluted in order to obtain the same concentration and chemical environment as that present in the final bulk vaccine, except for the presence of adjuvant.

To determine whether reversion has occurred, diluted toxoids that have been stored at 37° for six weeks shall be tested. The test employed shall be approved by the National Regulatory Authority and should be sufficiently sensitive to detect very small amounts of toxin. No toxicity shall be detected.

Intradermal tests in guinea-pigs and cell-culture tests both are considered to be suitable.

Antigenic purity

Not less than 1500 Lf per mg of protein nitrogen for diphtheria toxoid and not less than 1000 Lf/mg of protein nitrogen for tetanus toxoid.

FINAL BULK VACCINE

The final bulk vaccine is prepared by adsorption of suitable quantities of bulk purified diphtheria toxoid and tetanus toxoid onto mineral carrier such as hydrated aluminium phosphate,
aluminium hydroxide; the resulting mixture is approximately isotonic with blood. Suitable antimicrobial preservatives may be added. Antimicrobial preservatives of the phenolic type must not be used.

Only final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Identification

A. Dissolve sufficient sodium citrate in the vaccine under examination to give a 10 per cent w/v concentration. Maintain at 37° for about 16 hours and centrifuge. The clear supernatant reacts with a suitable diphtheria antitoxin and yields a precipitate.

B. The clear supernatant obtained in test A reacts with a suitable tetanus antitoxin and yields a precipitate.

pH (2.4.24). 6.0 to 7.0.

Specific toxicity. Use 5 normal, healthy guinea-pigs weighing between 250 and 350 g which have been maintained for at least 1 week on a uniform, unrestricted diet, and have not been previously treated with any material that will interfere with the test. Weigh the animals separately and record their weights. Inject subcutaneously into each animal 5 times the dose stated on the label. Weigh all the animals at weekly intervals for 6 weeks. None of the animals shows any symptoms of diphtheria or tetanus toxaemia or dies from diphtheria within 42 days or loses weight at the end of the test. If more than one animal dies from non-specific causes or loses weight, repeat the test. If an animal dies or loses weight in the second test, the vaccine fails the test.

Assay

Diphtheria toxoid

Complies with the test as stated under Diphtheria Vaccine (Adsorbed).

Tetanus toxoid

Complies with the test as stated under Tetanus Vaccine (Adsorbed).

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The amount is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Free formaldehyde (2.3.20). Maximum 0.2 g/l

Sterility (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

FINAL LOT

The final bulk vaccine is filled and stored aseptically into sterile containers. The containers are closed so as to prevent contamination.

Only a final lot that is satisfactory with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided the tests for specific toxicity, free formaldehyde and antimicrobial preservative and the assay have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

Identification

A. Diphtheria toxoid is identified by a suitable immuno-chemical method (2.2.14).

B. Tetanus toxoid is identified by a suitable immuno-chemical method (2.2.14).

The clear supernatant liquid obtained during test A reacts with a suitable tetanus antitoxin, giving a precipitate or visible floccules.

Tests

Sterility (2.2.11). Complies with the test for sterility.

Abnormal toxicity (2.2.1). Complies with the test for abnormal toxicity

Aluminium (2.3.9.). Not more than 1.25 mg per single human dose when hydrated aluminium phosphate or aluminium hydroxide is used as the adsorbent.

pH (2.4.24). The pH of the vaccine is within the range approved for the product (6.0 to 7.0).

Free formaldehyde (2.3.20). Maximum 0.2 g/l.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the quantity stated on the label.

Assay

Diphtheria component

Carry out one of the described methods for the assay of Diphtheria Vaccine (Adsorbed).

Viz a) Intradermal challenge method, b) Lethal challenge method, c) Antibody induction method, d) Validated serological assay in guinea pigs or mice as approved by National Regulatory Authority.

Tetanus component

Carry out one of the described methods for the assay of Tetanus Vaccine (Adsorbed) Viz a) Antibody induction
method; b) Challenge method in guinea pigs/mice; c) Validated serological assay in guinea pigs or mice as approved by National Regulatory Authority.

**Labelling.** The label states (1) the human dose; (2) the minimum Lf units per single human dose or the minimum International Units per single human dose if potency test done by challenge method; (3) the name and the amount of the adsorbent and preservative; (4) that the vaccine must be shaken before use; (5) that the vaccine is not to be frozen.

**Diphtheria and Tetanus Vaccine (Adsorbed) for Adults and Adolescents**

Diphtheria and Tetanus Vaccine (Adsorbed) for Adults and Adolescents is a preparation of diphtheria formol toxoid and tetanus formol toxoid adsorbed on a mineral carrier. The formol toxoids are prepared from the toxins produced by the growth of *Corynebacterium diphtheriae* and *Clostridium tetani*, respectively.

**Production**

**General provisions**

**Bulk purified diphtheria and tetanus toxoids**

The bulk purified diphtheria and tetanus toxoids are prepared as described in the monographs on *Diphtheria vaccine (adsorbed)* and *Tetanus vaccine (adsorbed)* and comply with the requirements prescribed therein.

**FINAL BULK VACCINE**

The vaccine is prepared by adsorption of suitable quantities of bulk purified diphtheria toxoid and tetanus toxoid onto a mineral carrier such as hydrated aluminium phosphate or aluminium hydroxide. Suitable antimicrobial preservatives may be added. Certain antimicrobial preservatives, particularly those of the phenolic type, adversely affect the antigenic activity and must not be used.

Only final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Identification**

A. Dissolve sufficient *sodium citrate* in the vaccine under examination to give a 10 per cent w/v concentration. Maintain at 37° for about 16 hours and centrifuge. The clear supernatant reacts with a suitable diphtheria antitoxin and yields a precipitate.

B. The clear supernatant obtained in test A reacts with a suitable tetanus antitoxin and yields a precipitate.

**pH** (2.4.24). 6.0 to 7.0.

**Specific toxicity**

Inject subcutaneously 5 times the single human dose stated on the label into each of 5 healthy guinea-pigs, each weighing between 250 and 350 g, that have not previously been treated with any material that will interfere with the test. If within 42 days of the injection any of the animals shows signs of or dies from diphtheria toxaemia or tetanus, the vaccine does not comply with the test. If more than 1 animal dies from non-specific causes, repeat the test once; if more than 1 animal dies in the second test, the vaccine does not comply with the test.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable physicochemical method. The amount is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Free formaldehyde** (2.3.20). Maximum 0.2 g/l.

**Sterility** (2.2.11). Carry out the test for sterility using 10 ml for each medium.

**FINAL LOT**

The final bulk vaccine is distributed aseptically into sterile, tamper-proof containers. The containers are closed so as to prevent contamination.

Only a final lot that is satisfactory with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided the tests for free formaldehyde and antimicrobial preservative and the assay have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

**Identification**

A. Diphtheria toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. Dissolve in the vaccine under examination sufficient *sodium citrate* to give a 10 per cent w/v solution. Maintain at 37° for about 16 hours and centrifuge until a clear supernatant is obtained. The clear supernatant reacts with a suitable diphtheria antitoxin, giving a precipitate.

B. Tetanus toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain
vaccines, is given as an example. The clear supernatant obtained during identification test A reacts with a suitable tetanus antitoxin, giving a precipitate.

**Tests**

**Aluminium** (2.3.9). Maximum 1.25 mg per single human dose.

**Free formaldehyde** (2.3.20). Maximum 0.2 g/l.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable physicochemical method. The amount is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Complies with the test for sterility.

**pH** (2.4.24). 6.0 to 7.0.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity.

**Assay**

**Diphtheria component**

Carry out the prescribed method for assay of Diphtheria Vaccine by lethal challenge method described in the assay of Diphtheria Vaccine (Adsorbed).

The lower confidence limit (P = 0.95) of the estimated potency is not less than 2 IU per single human dose.

**Tetanus component**

Carry out one of the prescribed methods for the assay as stated under Tetanus Vaccine (Adsorbed).

The lower confidence limit (P = 0.95) of the estimated potency is not less than 40 IU per single human dose.

**Labelling.** The label states (1) the human dose; (2) the minimum number of International Units of each component per single human dose, if potency determined by challenge method or the minimum Lf units per single human dose if test done by antibody induction method; (3) the name and the amount of the adsorbent; (4) that the vaccine must be shaken before use; (5) that the vaccine is not to be frozen.

**Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed)**

Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed) is a preparation of diphtheria formol toxoid, tetanus formol toxoid adsorbed on mineral carrier and a suspension of killed *Bordetella pertussis* organisms. The formal toxoids are prepared from the toxins produced by the growth of *Corynebacterium diphtheriae* and *Clostridium tetani*, respectively. The *Bordetella pertussis* suspension is prepared by growth of suitable strains in an appropriate medium, under controlled conditions.

The specification for individual component used in formulation is referred in the text of individual monograph.

**Production**

**General provisions**

The production method must be validated to demonstrate that the product if tested, would comply with the tests for safety as described under monographs of Diphtheria Vaccine, Tetanus Vaccine (Adsorbed) and Pertussis Vaccine.

Bulk purified diphtheria and tetanus toxoids, bulk inactivated *B. pertussis* suspension

The bulk purified diphtheria and tetanus toxoids and inactivated *B. pertussis* suspension are prepared as described in the monograph on Diphtheria Vaccine (Adsorbed), Tetanus Vaccine (Adsorbed) and Pertussis Vaccine respectively and comply with the respective requirements.

**FINAL BULK VACCINE**

The final bulk vaccine is prepared by adsorption of suitable quantities of bulk purified diphtheria toxoid and tetanus toxoid onto hydrated aluminium phosphate or aluminium hydroxide and admixture of an appropriate quantity of a suspension of inactivated *B. pertussis*. The *B. pertussis* concentration of the final bulk vaccine does not exceed that corresponding to an opacity of 20 I.U. per single human dose. If two or more strains of *B. pertussis* are used, the composition of consecutive lots of the final bulk vaccine shall be consistent with respect to the proportion of each strain as measured in opacity units. Suitable antimicrobial preservatives may be added to the bulk vaccine. Antimicrobial preservatives particularly those of phenolic type which affect the antigenic activity must not be used.

Only final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 percent and not more than 115.0 percent of the intended amount.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

The final bulk vaccine is filled and stored aseptically into sterile containers. The containers are closed so as to prevent contamination.
Only a final lot that is satisfactory with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided the tests for specific toxicity of diphtheria, tetanus and pertussis components, free formaldehyde, antimicrobial preservative and the Assay have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

**Identification**

A. Diphtheria toxoid is identified by a suitable immunochemical method (2.2.14).

Dissolve in the vaccine under examination by adding sufficient sodium citrate to give a 10 per cent w/v solution. Maintain at 37°C for about 16 hours and centrifuge until a clear supernatant is obtained; reserve the precipitate for identification test C. The clear supernatant reacts with a suitable diphtheria antitoxin, giving a precipitate.

B. Tetanus toxoid is identified by a suitable immuno-chemical method (2.2.14).

The clear supernatant obtained during identification test A reacts with a suitable tetanus antitoxin, giving a precipitate.

C. The pertussis component is identified by agglutination of the bacteria from the resuspended centrifugation residue (see identification test A; other suitable methods for separating the bacteria from the adsorbent may also be used) by antisera specific to *B. pertussis* or by the assay of the pertussis component.

**Tests**

**Sterility** (2.2.11). Complies with the test for sterility.

**Abnormal toxicity** (2.2.1). Each final lot shall be tested for abnormal toxicity by injecting intraperitoneally one human dose, but not more than 0.25 ml into each of the five mice weighing between 17 and 22 g and at least one human dose but not more than 1.0 ml into each of the two guinea pigs weighing between 250 and 350 g. The preparation passes the test if none of the animals dies or shows signs of ill health in 7 days following the injection. If one of the animal dies or shows the signs of ill health, repeat the test. The preparation passes the test if none of the animals in the second group dies or shows signs of ill health in the time interval specified.

**Specific toxicity**

*Diphtheria and tetanus components.* Inject subcutaneously five times the single human dose stated on the label into each of five healthy guinea-pigs, each weighing between 250 and 350 g, that have not previously been treated with any material that will interfere with the test. The animals should be weighted every week and observations be made. If within 42 days of the injection any of the animals shows signs of or dies from diphtheria toxemia or tetanus, the vaccine does not comply with the test. If more than one animal dies from non-specific causes, repeat the test once; if more than one animal dies in the second test, the vaccine does not comply with the test.

**Pertussis component.** Use not less than 10 healthy mice each weighing between 14 and 16 g for the vaccine group and for the saline control. Use mice of the same sex or distribute males and females equally between the groups. Allow the animals access to food and water for at least 2 hours before injection and during the test. Inject each mouse of the vaccine group intraperitoneally with 0.5 ml, containing a quantity of the vaccine equivalent to not less than half the single human dose. Inject each mouse of the control group with 0.5 ml of a 0.9 per cent sterile solution of sodium chloride, preferably containing the same amount of antimicrobial preservative as that injected with the vaccine. Weigh the mice immediately before the injection and 72 hours and 7 days after the injection. The vaccine complies with the test if: (a) at the end of 72 hours the total mass of the group of vaccinated mice is not less than that preceding the injection; (b) at the end of 7 days the average increase in mass per vaccinated mouse is not less than 60 per cent of that per control mouse; and (c) not more than 5 per cent of vaccinated mice should die during the test. The test may be repeated and the results of the tests combined.

**Aluminium** (2.3.9). Not more than 1.25 mg per single human dose, when hydrated aluminium phosphate or aluminium hydroxide is used as the adsorbent.

**pH** (2.4.24). 6.0 to 7.0.

**Free formaldehyde** (2.3.20). Maximum 0.2 g/l.

**Antimicrobial preservative** (2.2.2) Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not more than 115.0 per cent of the intended amount.

**Assay**

**Diphtheria component**

Carry out one of the methods for the assay as stated under Diphtheria Vaccine (Adsorbed).

**Tetanus component**

Carry out one of the methods for the assay as stated under Tetanus Vaccine (Adsorbed).

**Pertussis component**

Carry out the assay as stated under Pertussis Vaccine.

**Labelling.** The label states (1) in case done by challenge method the minimum number of International Units; if units (as applicable for each component) per single human dose;
Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (Adsorbed)

Diphtheria, Tetanus, Pertussis (Whole cell), Hepatitis B (rDNA) and Haemophilus Type b Conjugate Vaccine (Adsorbed) is a combined vaccine composed of diphtheria formol toxoid containing not less than 1,500 Lf, (2.2.16) per mg of protein nitrogen, purified tetanus formol toxoid containing not less than 1,000 Lf, (2.2.16), per mg of protein nitrogen, hepatitis B surface antigen and haemophilus type b conjugated to suitable protein with a mineral adsorbent to which a suspension of killed Bordetella pertussis has been added. Mineral adsorbent is a suspension of hydrated aluminium hydroxide, aluminium phosphate or calcium phosphate, in saline solution or other appropriate solution isotonic with blood.

The formol toxoids are prepared from the toxin produced by the growth of Corynebacterium diphtheriae and Clostridium tetani, respectively, in suitable media. The toxins are converted to toxoids by treatment with formaldehyde solution by methods which avoid reversibility of the toxoids.

Hepatitis B surface antigen is a component protein of hepatitis B virus; the antigen is obtained by recombinant DNA technology.

The polysaccharide, polyribosyl ribitol phosphate, PRP is a linear copolymer composed of repeated units of 3-β-D-ribofuranosyl-(1→1)-ribitol-5-phosphate \([\left(C_{10}H_{19}O_{12}P\right)_n]\) with a defined molecular size and derived from a suitable strain of Haemophilus influenzae type b. The carrier protein, when conjugated to PRP, is capable of inducing a T-cell dependent B-cell immune response to the polysaccharide.

The product may be presented with the haemophilus component in a separate container, the contents of which are mixed with the other components immediately before or during use.

The final product contains a suitable antimicrobial preservative. The antigenic properties of the vaccine are adversely affected by the presence of certain antimicrobial preservatives particularly those of the phenolic type and some of the quaternary ammonium type and must not be used.

Production

General provisions

The production method shall have been shown to yield consistently the vaccines comparable with the vaccine of proven clinical efficacy and safety in man.

If the vaccine is presented with the haemophilus component in a separate vial, as part of consistency studies the assays of the diphtheria, tetanus, pertussis and hepatitis B are carried out on a suitable number of batches of vaccine reconstituted as for use. For subsequent routine control, the assays of these components may be carried out without mixing with the haemophilus component.

The production method is validated to demonstrate that the product, if tested, would comply with the following test for specific toxicity of the diphtheria and tetanus component: inject subcutaneously 5 times the single human dose stated on the label into each of 5 healthy guinea pigs, each weighing between 250 and 350 g, that have not previously been treated with any material that will interfere with the test. If within 42 days of the injection any of the animals shows signs of or dies from diphtheria, toxemia or tetanus, the vaccine does not comply with the test. If more than 1 animal dies from non-specific causes, repeat the test once; if more than 1 animal shows signs of or dies in the second test, the vaccine does not comply with the test.

The stability of the final lot and the relevant intermediates is evaluated using one or more indicator tests. For the haemophilus component, such tests may include determination of molecular size, determination of free PRP in the conjugate and kinetics of depolymerisation. Taking account of the results of the stability testing, release requirements are set for these indicator tests to ensure that the vaccine will be satisfactory at the end of the period of validity.

Reference vaccine(s)

Provided valid assays can be performed, monocomponent reference vaccines may be used for the assays on the combined vaccine. If this is not possible because of interaction between the components of the combined vaccine or because of the difference in composition between monocomponent reference vaccine and the test vaccine, a batch of combined vaccine shown to be effective in clinical trials or a batch representative thereof is used as a reference vaccine. For the preparation of a representative batch, strict adherence to the production
process used for the batch tested in clinical trials is necessary. The reference vaccine may be stabilized by a method that has been shown to have no effect on the assay procedure.

**Production of the components**

The production of the components complies with the requirements of the monographs on Diphtheria Vaccine (Adsorbed), Tetanus Vaccine (Adsorbed), Pertussis Vaccine, Hepatitis B Vaccine (rDNA) and Haemophilus Type b Conjugate Vaccine.

**FINAL BULK VACCINE**

**Vaccine with all components in the same container**

The final bulk is prepared by adsorption, separately or together, of suitable quantities of bulk purified diphtheria toxoid, bulk purified tetanus toxoid, bulk purified hepatitis B surface antigen onto a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate, admixture of an appropriate quantity of a suspension of inactivated *B. pertussis* component and admixture of a suitable quantity of PRP conjugate; the resulting mixture is approximately isotonic with blood. The *B. pertussis* concentration of the final bulk vaccine does not exceed that corresponding to an opacity of 20 IU per single human dose. If 2 or more strains of *B. pertussis* are used, the composition of consecutive lots of the final bulk vaccine shall be consistent with respect to the proportion of each strain as measured in opacity units. Suitable antimicrobial preservatives may be added.

**Vaccine with the haemophilus component in a separate container**

The final bulk is prepared by adsorption, separately or together, of suitable quantities of bulk purified diphtheria toxoid, bulk purified tetanus toxoid, bulk purified hepatitis B surface antigen onto a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate, admixture of an appropriate quantity of a suspension of inactivated *B. pertussis* component and admixture of a suitable quantity of PRP conjugate; the resulting mixture is approximately isotonic with blood. The *B. pertussis* concentration of the final bulk vaccine does not exceed that corresponding to an opacity of 20 IU per single human dose. If 2 or more strains of *B. pertussis* are used, the composition of consecutive lots of the final bulk vaccine shall be consistent with respect to the proportion of each strain as measured in opacity units. The final bulk is filled separately. Suitable antimicrobial preservatives may be added. The final bulk of the haemophilus component is prepared by dilution of the bulk conjugate to the final concentration with a suitable diluent. A stabilizer may be added.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The amount is not less than 85.0 per cent and not greater than 115.0 per cent of the intended content.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

Only a final lot that is satisfactory with respect to the test for osmolality and with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided the tests for specific toxicity of diphtheria toxoid, tetanus toxoid and pertussis component and antimicrobial preservative and the assays for the diphtheria, tetanus and pertussis components have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot. Provided the content of free formaldehyde has been determined on the bulk purified antigens or on the final bulk and it has been shown that the content in the final lot will not exceed 0.2 g/l, the test for free formaldehyde may be omitted on the final lot. If an *in vivo* assay is used for the hepatitis B component, provided it has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

**Free PRP**

Unbound PRP is determined after removal of the conjugate, for example by anion exchange, size exclusion or hydrophobic chromatography (2.4.16), ultrafiltration or other validated methods. The amount of free PRP is not greater than that approved for the particular product.

**Osmolality** (2.4.23). The osmolality of the vaccine is within the limits approved for the particular preparation.

**pH** (2.4.24). 6.0 to 7.0.

**Description.** Whitish turbid liquid in which the mineral carrier tends to settle down slowly on keeping.

**Identification**

Tests A, B, C, D and E may be omitted if test F is carried out. Test F may be omitted if tests A, B, C, D and E are carried out.

A. **Diphtheria toxoid.** Dissolve sufficient sodium citrate in the vaccine under examination to give a 10 per cent w/v concentration. Maintain at 37°C for about 16 hours and centrifuge. Reserve the residue for test C. The clear supernatant reacts with a suitable diphtheria antitoxin and yields a precipitate.

B. **Tetanus toxoid.** The clear supernatant obtained in test A reacts with a suitable tetanus antitoxin and yields a precipitate.

C. **Pertussis component.** To a suspension of the residue
obtained in test A in saline solution add a suitable Bordetella pertussis antiserum; agglutination indicates presence of pertussis component.

D. *Hepatitis B surface antigen*. The suspension of the residue obtained in test A gives a positive reactions when tested by suitable *in-vitro* assay.

E. PRP. The suspension of the residue obtained in the test A gives a positive reaction when tested by a suitable immunochemical method for PRP.

F. The vaccine confers an active immunity in mice and guinea-pigs when administered as directed in the test for Assay.

**Tests**

*If the product is presented with the haemophilus component in a separate container; the tests for specific toxicity of diphtheria toxoid, tetanus toxoid and pertussis component, aluminium, free formaldehyde, antimicrobial preservative and sterility are carried out on the container with the diphtheria, tetanus, pertussis and hepatitis B components; the tests for PRP content, water (where applicable), sterility and pyrogens are carried out on the container with the haemophilus component.*

*If the haemophilus component is freeze-dried, some tests may be carried out on the freeze-dried product rather than on the bulk conjugate where the freeze-drying process may affect the component under test.*

**PRP.** Not less than 80.0 per cent of the amount of PRP stated on the label. PRP is determined either by assay of ribose (2.7.1), or phosphorus (2.7.1), by an immunochemical method (2.2.14) or by anion exchange liquid chromatography with pulsed amperometric detection.

**Aluminium** (2.3.9). Not more than 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

**Free formaldehyde** (2.3.20). Maximum 0.2 g/l.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Complies with the test for sterility.

**Abnormal toxicity** (2.2.1). Each final lot shall be tested for abnormal toxicity by injecting intraperitoneally one human dose, but not more than 0.25 ml into each of five mice weighing between 17 and 22 g and at least one human dose but not more than 1.0 ml into each of two guinea pigs weighing between 250 and 350 g. The preparation passes the test if none of the animals dies or shows signs of ill health in seven days following the injection. If one of the animals dies or shows signs of ill health, repeat the test. The preparation passes the test if none of the animals in the second group dies or shows signs of ill health in the time interval specified.

**Pyrogens** (2.2.8). This test is carried out for Haemophilus influenzae type b vaccine only if Haemophilus influenzae type b vaccine is presented as separate lyophilized vial. The vaccine complies with the test for pyrogens. Inject per kg of the rabbit’s mass a quantity of the vaccine equivalent to: 1 mg of PRP for a vaccine with diphtheria toxoid or CRM 197 diphtheria toxoid as carrier; 0.1 mg of PRP for a vaccine with tetanus toxoid as carrier protein; 0.025 mg of PRP for vaccine with OMP as carrier.

**Specific toxicity**

*Diphtheria and tetanus components*

Complies with the test as stated under Diphtheria and Tetanus Vaccine (Adsorbed).

*Pertussis component*

Complies with the test as stated under Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed).

**Assay**

*Diphtheria toxoid (adsorbed)*

Complies with the test as stated under Diphtheria and Tetanus Vaccine (Adsorbed).

*Tetanus toxoid (adsorbed)*

Complies with the test as stated under assay of Tetanus Vaccine (Adsorbed).

*Pertussis vaccine*

Complies with the test as stated under Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed).

*Hepatitis B surface antigen (adsorbed)*

Complies with the test as stated under Hepatitis B Vaccine (Adsorbed).

**Storage.** When stored under the prescribed conditions the vaccine may be expected to retain potency for not less than 2 years from the date on which the potency test for the pertussis component was started.

**Labelling.** The label states (1) the human dose; (2) Diphtheria and Tetanus components; (a) in case done by challenge method, the minimum number of International Units (as applicable for each component) per single human dose; (b) in case done by antibody induction, the minimum Lf units per single human dose; (3) pertussis component – IU or IOU per single human dose; (4) hepatitis B component - mg HBsAg per single human dose; (5) haemophilus conjugate component
- mg PRP per single human dose; (6) the type and nominal amount of carrier protein per single human dose; (7) the name and amount of adsorbent and added preservative; (8) that the vaccine must be shaken before use; (9) that the vaccine is not to be frozen.

Diphtheria, Tetanus, Pertussis (Whole Cell) and Hepatitis B (rDNA) Vaccine (Adsorbed)

Diphtheria, Tetanus, Pertussis and Hepatitis B (rDNA) Vaccine (Adsorbed) is a combined vaccine composed of diphtheria formol toxoid containing not less than 1,500 Limes flocculationis (Lf) (2.2.16), per mg of protein nitrogen, purified tetanus formol toxoid containing not less than 1,000 Lf (2.2.16), per mg of protein nitrogen and hepatitis B surface antigen with a mineral adsorbent to which a suspension of killed Bordetella pertussis has been added. Mineral adsorbent is a suspension of hydrated aluminium hydroxide, aluminium phosphate or calcium phosphate in saline solution or other appropriate solution isotonic with blood.

The formol toxoids are prepared from the toxin produced by the growth of Corynebacterium diphtheriae and Clostridium tetani, respectively, in suitable media. The toxins are converted to toxoids by treatment with formaldehyde solution by methods, which avoid reversibility of the toxoids.

Hepatitis B surface antigen is a component protein of hepatitis B virus; the antigen is obtained by recombinant DNA technology.

The final product contains a suitable antimicrobial preservative. The antigenic properties of the vaccine are adversely affected by the presence of certain antimicrobial preservatives particularly those of the phenolic type and some of the quaternary ammonium type and must not be used.

Production

General provisions

The production method shall have been shown to yield consistently the vaccines comparable with the vaccine of proven clinical efficacy and safety in man.

The production method is validated to demonstrate that the product, if tested, would comply with the following test for specific toxicity of the diphtheria and tetanus component: inject subcutaneously 5 times the single human dose stated on the label into each of 5 healthy guinea pigs, each weighing between 250 and 350 g, that have not previously been treated with any material that will interfere with the test. If within 42 days of the injection any of the animals shows signs of or dies from diphtheria, toxaemia or tetanus, the vaccine does not comply with the test. If more than 1 animal dies from non-specific causes, repeat the test once; if more than 1 animal shows signs of or dies in the second test, the vaccine does not comply with the test.

The stability of the final lot and the relevant intermediates is evaluated using one or more indicator tests. Taking account of the results of the stability testing, release requirements are set for these indicator tests to ensure that the vaccine will be satisfactory at the end of the period of validity.

Reference vaccine(s)

Provided valid assays can be performed, monocomponent reference vaccines may be used for the assays on the combined vaccine. If this is not possible because of interaction between the components of the combined vaccine or because of the difference in composition between monocomponent reference vaccine and the test vaccine, a batch of combined vaccine shown to be effective in clinical trials or a batch representative thereof is used as a reference vaccine.

Production of the components

The production of the components complies with the requirements of the monographs on Diphtheria Vaccine (Adsorbed), Tetanus Vaccine (Adsorbed), Pertussis Vaccine and Hepatitis B Vaccine (rDNA).

FINAL BULK VACCINE

The final bulk vaccine is prepared by adsorption, separately or together, of suitable quantities of bulk purified diphtheria toxoid, tetanus toxoid, pertussis components and hepatitis B surface antigen onto a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate. Suitable antimicrobial preservatives may be added. Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The amount is not less than 85.0 per cent and not greater than 115.0 per cent of the intended content.

pH (2.4.24). 6.0 to 7.0.

Sterility (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

FINAL LOT

Only a final lot that is satisfactory with respect to the test for osmolality and with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided the tests for specific toxicity of diphtheria toxoid, tetanus toxoid and pertussis component and antimicrobial preservative and the assays for the diphtheria,
tetanus and pertussis components have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot. Provided the content of free formaldehyde has been determined on the bulk purified antigens or on the final bulk and it has been shown that the content in the final lot will not exceed 0.2 g/l, the test for free formaldehyde may be omitted on the final lot. If an in vivo assay is used for the hepatitis B component, provided it has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

Osmolality (2.4.23). The osmolality of the vaccine is within the limits approved for the particular preparation.

Description. Whitish turbid liquid in which the mineral carrier tends to settle down slowly on keeping.

Identification

Tests A, B, C and D may be omitted if test E is carried out. Test E may be omitted if tests A, B C and D are carried out.

A. Diphtheria toxoid. Dissolve sufficient sodium citrate in the vaccine under examination to give a 10 per cent w/v concentration. Maintain at 37° for about 16 hours and centrifuge. Reserve the residue for test C. The clear supernatant reacts with a suitable diphtheria antitoxin and yields a precipitate.

B. Tetanus toxoid. The clear supernatant obtained in test A reacts with a suitable tetanus antitoxin and yields a precipitate.

C. Pertussis component. To a suspension of the residue obtained in test A in saline solution add a suitable B. pertussis antiserum; agglutination indicates presence of pertussis component.

D. Hepatitis B surface antigen. The suspension of the residue obtained in test A gives a positive reactions when tested by suitable in-vitro assay.

E. The vaccine confers an active immunity in mice and guinea-pigs when administered as directed under Assay.

Tests

pH (2.4.24). 6.0 to 7.0.

Aluminium (2.3.9). Not more than 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

Free formaldehyde (2.3.20). Maximum 0.2 g/l.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Complies with the test for sterility.

Abnormal toxicity (2.2.1). Each final lot shall be tested for abnormal toxicity by injecting intraperitoneally one human dose, but not more than 0.25 ml into each of five mice weighing between 17 and 22 g and at least one human dose but not more than 1.0 ml into each of two guinea pigs weighing between 250 and 350 g. The preparation passes the test if none of the animals dies or shows signs of ill health in seven days following the injection. If one of the animals dies or shows signs of ill health, repeat the test. The preparation passes the test if none of the animals in the second group dies or shows signs of ill health in the time interval specified.

Specific toxicity

Diphtheria and tetanus components

Complies with the test as stated under Diphtheria and Tetanus Vaccine (Adsorbed).

Pertussis component

Complies with the test as stated under Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed).

Assay

Diphtheria toxoid (adsorbed)

Complies with the test as stated under Diphtheria and Tetanus Vaccine (Adsorbed).

Tetanus toxoid (adsorbed)

Complies with the test as stated under assay for Tetanus Vaccine (Adsorbed).

Pertussis vaccine

Complies with the test as stated under Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed).

Hepatitis B surface antigen (adsorbed)

Complies with the test as stated under Hepatitis B Vaccine (Adsorbed).

Storage. When stored under the prescribed conditions the vaccine may be expected to retain potency for not less than 2 years from the date on which the potency test for the pertussis component was started.

Labelling. The label states (1) the human dose (ml); (2) diphtheria and tetanus components, (a) in case done by challenge method, the minimum number of International Units (as applicable for each component) per single human dose and (b) in case done by antibody induction, the minimumLf units per single human dose; (3) pertussis component - IU or IOU per single human dose; (4) hepatitis B component - mg HBsAg per single human dose; (5) the name and amount of adsorbent and added preservative; (6) that the vaccine must be shaken before use; (7) that the vaccine is not to be frozen.
Conjugate Vaccine (Adsorbed)

Diphtheria, Tetanus, Pertussis and Haemophilus type b Conjugate Vaccine (Adsorbed) is a combined vaccine composed of diphtheria formol toxoid containing not less than 1,500 Limes flocculationis; (Lf), (2.2.16) per mg of protein nitrogen, purified tetanus formol toxoid containing not less than 1,000 Lf, (2.2.16), per mg of protein nitrogen, and Haemophilus type b conjugated to suitable protein with a mineral adsorbent to which a suspension of killed Bordetella pertussis has been added. The mineral adsorbent is a suspension of hydrated aluminium hydroxide, aluminium phosphate or calcium phosphate, in saline solution or other appropriate solution isotonic with blood.

The formol toxoids are prepared from the toxin produced by the growth of Corynebacterium diphtheriae and Clostridium tetani, respectively in suitable media. The toxins are converted to toxoids by treatment with formaldehyde solution by methods which avoid reversibility of the toxoids.

The polysaccharide, polyribosyl ribitol phosphate, PRP is a linear copolymer composed of repeated units of 3-β-D-ribofuranosyl-(1→1)-ribitol-5-phosphate [(C<sub>10</sub>H<sub>20</sub>O<sub>12</sub>P)<sub>n</sub>], with a defined molecular size and derived from a suitable strain of Haemophilus influenzae type b. The carrier protein, when conjugated to PRP, is capable of inducing a T-cell dependent B-cell immune response to the polysaccharide.

The product may be presented with the haemophilus component in a separate container, the contents of which are mixed with the other components immediately before or during use.

The final product contains a suitable antimicrobial preservative. The antigenic properties of the vaccine are adversely affected by the presence of certain antimicrobial preservatives particularly those of the phenolic type and some of the quaternary ammonium type must not be used.

Production

General provisions

The production method shall have been shown to yield consistently the vaccines comparable with the vaccine of proven clinical efficacy and safety in man.

If the vaccine is presented with the haemophilus component in a separate vial, as part of consistency studies, the assays of the diphtheria, tetanus and pertussis are carried out on a suitable number of batches of vaccine reconstituted for use. For subsequent routine control, the assays of these components may be carried out without mixing with the haemophilus component.

The production method is validated to demonstrate that the product, if tested, would comply with the following test for specific toxicity of the diphtheria and tetanus component: inject subcutaneously 5 times the single human dose stated on the label into each of 5 healthy guinea pigs, each weighing between 250 and 350 g, that have not previously been treated with any material that will interfere with the test. If within 42 days of the injection any of the animals shows signs of or dies from diphtheria, toxemia or tetanus, the vaccine does not comply with the test. If more than 1 animal dies from non-specific causes, repeat the test once; if more than 1 animal shows signs of or dies in the second test, the vaccine does not comply with the test.

The stability of the final lot and the relevant intermediates is evaluated using one or more indicator tests. For the haemophilus component, such tests may include determination of molecular size, determination of free PRP in the conjugate and kinetics of depolymerisation. Taking account of the results of the stability testing, release requirements are set for these indicator tests to ensure that the vaccine will be satisfactory at the end of the period of validity.

Reference vaccine(s)

Provided valid assays can be performed, monocomponent reference vaccines may be used for the assays on the combined vaccine. If this is not possible because of interaction between the components of the combined vaccine or because of the difference in composition between monocomponent reference vaccine and the test vaccine, a batch of combined vaccine shown to be effective in clinical trials or a batch representative thereof is used as a reference vaccine. For the preparation of a representative batch, strict adherence to the production process used for the batch tested in clinical trials is necessary. The reference vaccine may be stabilized by a method that has been shown to have no effect on the assay procedure.

Production of the components

The production of the components complies with the requirements of the monographs on Diphtheria Vaccine (Adsorbed), Tetanus Vaccine (Adsorbed), Pertussis Vaccine (Whole Cell) and Haemophilus influenzae Type b Conjugate Vaccine.

FINAL BULK VACCINE

Vaccine with all components in the same container

The final bulk is prepared by adsorption, separately or together, of suitable quantities of bulk purified diphtheria toxoid, bulk purified tetanus toxoid, onto a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate, admixture of an appropriate quantity of a suspension of inactivated B. pertussis component and admixture of a suitable
quantity of PRP conjugate; the resulting mixture is approximately isotonic with blood. The \textit{B. pertussis} concentration of the final bulk vaccine does not exceed that corresponding to an opacity of 20 IU per single human dose. If 2 or more strains of \textit{B. pertussis} are used, the composition of consecutive lots of the final bulk vaccine shall be consistent with respect to the proportion of each strain as measured in opacity units. Suitable antimicrobial preservatives may be added.

**Vaccine with the haemophilus component in a separate container**

The final bulk is prepared by adsorption, separately or together, of suitable quantities of bulk purified diphtheria toxoid, bulk purified tetanus toxoid onto a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate, admixture of an appropriate quantity of a suspension of inactivated \textit{B. pertussis} component and admixture of a suitable quantity of PRP conjugate; the resulting mixture is approximately isotonic with blood. The \textit{B. pertussis} concentration of the final bulk vaccine does not exceed that corresponding to opacity of 20 IU per single human dose. If 2 or more strains of \textit{B. pertussis} are used, the composition of consecutive lots of the final bulk vaccine shall be consistent with respect to the proportion of each strain as measured in opacity units. The final bulk is filled separately. Suitable antimicrobial preservatives may be added. The final bulk of the haemophilus component is prepared by dilution of the bulk conjugate to the final concentration with a suitable diluent. A stabilizer may be added.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The amount is not less than 85.0 per cent and not greater than 115.0 per cent of the intended content.

**Sterility (2.2.11).** Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

Where the haemophilus component is in a separate container, the final bulk of the haemophilus component is freeze-dried.

Only a final lot that is satisfactory with respect to the test for osmolality and with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided the tests specific toxicity of diphtheria toxoid, tetanus toxoid and pertussis component and antimicrobial preservative and the assays for the diphtheria, tetanus and pertussis components have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot. Provided the content of free formaldehyde has been determined on the bulk purified antigens or on the final bulk and it has been shown that the content in the final lot will not exceed 0.2 g/l, the test for free formaldehyde may be omitted on the final lot.

**Free PRP.** Unbound PRP is determined after removal of the conjugate, for example by anion exchange, size exclusion or hydrophobic chromatography (2.4.16), ultrafiltration or other validated methods. The amount of free PRP is not greater than approved for the particular product.

**Osmolality (2.4.23).** The osmolality of the vaccine is within the limits approved for the particular preparation.

**pH (2.4.24).** 6.0 to 7.0.

**Description.** Whitishe turbid liquid in which the mineral carrier tends to settle down slowly on keeping.

**Production**

**Identification**

Tests \(A, B, C\) and \(D\) may be omitted if test \(E\) is carried out. Test \(E\) may be omitted if tests \(A, B, C\) and \(D\) are carried out.

\(A.\) \textit{Diphtheria toxoid.} Dissolve sufficient sodium citrate in the vaccine under examination to give a 10 per cent w/v concentration. Maintain at 37° for about 16 hours and centrifuge. Reserve the residue for test \(C\). The clear supernatant reacts with a suitable diphtheria antitoxin and yields a precipitate.

\(B.\) \textit{Tetanus toxoid.} The clear supernatant obtained in test \(A\) reacts with a suitable tetanus antitoxin and yields a precipitate.

\(C.\) \textit{Pertussis component.} To a suspension of the residue obtained in test \(A\) in saline solution add a suitable \textit{Bordetella pertussis} antiserum; agglutination indicates presence of pertussis component.

\(D.\) \textit{PRP.} The suspension of the residue obtained in test \(A\) gives a positive reaction when tested by a suitable immunochemical method for PRP.

\(E.\) The vaccine confers an active immunity in mice and guinea pigs when administered as directed in the test for Potency.

**Tests**

If the product is presented with the haemophilus component in a separate container; the tests for specific toxicity of diphtheria toxoid, tetanus toxoid and pertussis component, aluminium, free formaldehyde, antimicrobial preservative and sterility are carried out on the container with the diphtheria, tetanus and pertussis components; the tests for PRP content, water (where applicable), sterility and pyrogens are carried out on the container with the haemophilus component.
If the haemophilus component is freeze-dried, some tests may be carried out on the freeze-dried product rather than on the bulk conjugate where the freeze-drying process may affect the component under test.

PRP. Not less than 80.0 per cent of the amount of PRP stated on the label. PRP is determined either by assay of ribose (2.7.1) or phosphorus (2.7.1), by an immunochemical method (2.2.14) or by anion exchange liquid chromatography with pulsed amperometric detection.

Aluminium (2.3.9). Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

Free formaldehyde (2.3.20). Maximum 0.2 g/l.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Complies with the test for sterility.

Abnormal toxicity (2.2.1). Each final lot shall be tested for abnormal toxicity by injecting intraperitoneally one human dose, but not more than 0.25 ml into each of the five mice weighing between 17 to 22 g and at least one human dose but not more than 1.0 ml into each of the two guinea pigs weighing between 250 and 350 g. The preparation passes the test if none of the animals dies or shows signs of ill health in 7 days following the injection. If one of the animals dies or shows the signs of ill health, repeat the test. The preparation passes the test if none of the animals in the second group dies or shows signs of ill health in the time interval specified.

Pyrogens (2.2.8). This test is carried out for Haemophilus influenzae type b vaccine only if Haemophilus influenzae type b vaccine is presented as separate lyophilized vial. The vaccine complies with the test for pyrogens. Inject per kg of the rabbit’s mass a quantity of the vaccine equivalent to: 1 mg of PRP for a vaccine with diphtheria toxoid or CRM 197 diphtheria toxoid as carrier; 0.1 mg of PRP for a vaccine with tetanus toxoid as carrier protein; 0.025 mg of PRP for vaccine with OMP as carrier.

Specific toxicity

Diphtheria and tetanus components

Complies with the test as stated under Diphtheria and Tetanus Vaccine (Adsorbed).

Pertussis component

Complies with the test as stated under Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed).

Assay

Diphtheria toxoid (adsorbed)

Complies with the test as stated under Diphtheria and Tetanus Vaccine (Adsorbed).

Tetanus toxoid (adsorbed)

Complies with the test as stated under assay of Tetanus Vaccine (Adsorbed).

Pertussis vaccine

Complies with the test as stated under Diphtheria, Tetanus and Pertussis Vaccine (Adsorbed).

Storage. When stored under the prescribed conditions the vaccine may be expected to retain potency for not less than 2 years from the date on which the potency test for the pertussis component was started.

Labelling. The label states (1) the human dose (ml); (2) Diphtheria and Tetanus components (a) in case done by challenge method the minimum number of international units (as applicable for each component) per single human dose; (b) in case done by antibody induction method, the minimum Lf units per single human dose; (3) pertussis component – IU or IOU per single human dose; (4) haemophilus conjugate component - g PRP per single human dose; (5) the type and nominal amount of carrier protein per single human dose; (6) the name and amount of adsorbent and added preservative; (7) that the vaccine must be shaken before use; (9) that the vaccine is not to be frozen.

Diphtheria Vaccine (Adsorbed)

Diphtheria Vaccine (Adsorbed) is a preparation of diphtheria formol toxoid with a mineral adsorbent. The formol toxoid is prepared from the toxin produced by the growth of Corynebacterium diphtheriae.

Production

General provisions

The maximum number of Lf units per single human dose of diphtheria vaccine (adsorbed) is 30.

Bulk purified toxoid

For the production of diphtheria toxin, from which toxoid is prepared, seed cultures are managed in a defined seed-lot system in which toxigenicity is conserved and, where necessary, restored by deliberate reselection. A highly toxigenic strain of Corynebacterium diphtheriae with known origin and history is grown in a suitable liquid medium. At the end of cultivation, the purity of each culture is tested and contaminated cultures are discarded. Toxin-containing culture medium is separated aseptically from the bacterial mass.
as soon as possible. The toxin content (Lf per ml) is checked to monitor consistency of production. Single harvests may be pooled to prepare the bulk purified toxoid. The toxin is purified to remove components likely to cause adverse reactions in humans. The purified toxin is detoxified with formaldehyde by a method that avoids destruction of the immunogenic potency of the toxoid and reversion of the toxoid to toxin, particularly on exposure to heat. Alternatively, purification may be carried out after detoxification.

Only bulk purified toxoid that complies with the following requirements may be used in the preparation of the final bulk vaccine.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**Absence of toxin and irreversibility of toxoid**

Inject subcutaneously into each of 5 guinea-pigs at least 500 Lf of the *non-incubated bulk purified toxoid* in a volume of 1 ml, using the same buffer solution as for the final vaccine, without adsorbent. Animals that die shall be autopsied and examined for symptoms of diphtheria intoxication (red adrenals). The bulk purified toxoid shall pass the test if no guinea-pig shows symptoms of specific intoxication within six weeks of injection and if at least 80 percent of the animals survive the test period. The guinea-pigs shall not have been used previously for experimental purposes.

Alternatively, a cell-culture test system may be used; in this case, the sensitivity of the test shall have been demonstrated to be not less than that of the guinea-pig test, and the test procedures shall be approved by the National Regulatory Authority.

Each bulk purified toxoid shall be tested to ensure that reversion to toxicity cannot take place on storage. The bulk purified toxoid shall be diluted in order to obtain the same concentration and chemical environment as those present in the final bulk vaccine, except for the presence of adjuvant.

To determine whether reversion has occurred, diluted toxoids that have been stored at 37° for six weeks shall be tested. The test employed shall be approved by the National Regulatory Authority and should be sufficiently sensitive to detect very small amounts of toxin. No toxicity shall be detected.

Intradermal tests in guinea-pigs and cell-culture tests both are considered to be suitable.

**Cell culture method**

Using the same buffer solution as for the final vaccine, without adsorbent, prepare a solution of bulk purified toxoid at 100 Lf per ml. Divide the solution into 2 equal parts. Maintain 1 part at 5° ± 3° and the other at 37° for 6 weeks. Carry out a test in Vero cells for active diphtheria toxin using 50 μl per well of both samples. The sample should not contain antimicrobial preservatives and detoxifying agents should be determined to be below the concentration toxic to Vero cells. Non-specific toxicity may be eliminated by dialysis.

Use freshly trypsinised Vero cells at a suitable concentration, for example 2.5 × 10⁸ per ml and a reference diphtheria toxoid diluted in 100 Lf per ml *diphtheria toxoid*. A suitable reference *diphtheria toxoid* will contain either not less than 100 LD₅₀/ml or 67 to 133 hr/100 in 1 Lf and 25,000 to 50,000 minimal reacting doses for guinea-pig skin in 1 Lf (*diphtheria toxoid* *RP* is suitable for use as the reference toxin). Dilute the toxin in 100 Lf/ml *diphtheria toxoid* to a suitable concentration, for example 2 × 10⁵ Lf per ml. Prepare serial twofold dilutions of the diluted diphtheria toxin and use undiluted test samples (50 μl per well). Distribute them in the wells of a sterile tissue culture plate containing a medium suitable for Vero cells. To ascertain that any cytotoxic effect noted is specific to diphtheria toxin, prepare in parallel dilutions where the toxin is neutralised by a suitable concentration of *diphtheria antitoxin*, for example 100 IU/ml. Include control wells without toxoid or toxoid and with non-toxic toxoid at 100 Lf per ml on each plate to verify normal cell growth. Add cell suspension to each well, seal the plates and incubate at 37° for 5 to 6 days. Cytotoxic effect is judged to be present where there is complete metabolic inhibition of the Vero cells, indicated by the pH indicator of the medium. Confirm cytopathic effect by microscopic examination or suitable staining such as *MTT dye*. The test is invalid if 5 × 10⁴ Lf per ml of reference diphtheria toxoid in 100 Lf per ml toxoid has no cytotoxic effect on Vero cells or if the cytotoxic effect of this amount of toxin is not neutralised in the wells containing *diphtheria antitoxin*. The bulk purified toxoid complies with the test if no toxicity neutralisable by antitoxin is found in either sample.

**Antigenic purity.** Not less than 1,500 Lf per mg of protein nitrogen.

**FINAL BULK VACCINE**

The final bulk vaccine is prepared by adsorption of a suitable quantity of bulk purified toxoid onto a mineral carrier such as hydrated aluminium phosphate or aluminium hydroxide; the resulting mixture is approximately isotonic with blood. Suitable antimicrobial preservatives may be added. Certain antimicrobial preservatives, particularly those of the phenolic type, adversely affect the antigenic activity and must not be used.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Identification**

Dissolve sufficient *sodium citrate* in the vaccine under examination to give a 10 per cent w/v concentration. Maintain at 37° for about 16 hours and centrifuge. The clear supernatant
reacts with a suitable diphtheria antitoxin and yields a precipitate.

**pH** (2.4.24). 6.0 to 7.0.

**Specific toxicity.** Use 5 normal, healthy guinea-pigs weighing between 250 and 350 g, which have been maintained for at least 1 week on a uniform, unrestricted diet, and have not been previously treated with any material that will interfere with the test. Weigh the animals separately and record their weights. Inject subcutaneously into each animal 5 times the dose stated on the label. Weigh all the animals at weekly intervals for 6 weeks. None of the animals shows any symptoms of diphtheria or tetanus toxemia or dies from diphtheria within 42 days or loses weight at the end of the test. If more than one animal dies from non-specific causes of loses weight, repeat the test. If an animal dies or loses weight in the second test, the vaccine fails the test.

**Potency.** Determine by any of the methods of biological assay of Adsorbed Diphtheria Vaccine described.

**Biological assay of adsorbed diphtheria vaccine**

**(a) Intradermal challenge method**

The potency of adsorbed diphtheria vaccine is determined by comparing the dose necessary to protect guinea-pigs against the erythrogenic effects of a range of intradermal injections of diphtheria toxin with the dose of the Standard preparation of adsorbed diphtheria toxoid necessary to give the same protection. For this comparison, the Standard preparation of adsorbed diphtheria toxoid and a suitable preparation of diphtheria toxin, for use as a challenge toxin, are required.

**Standard preparation**

The Standard preparation is International standard of Diphtheria toxoid, adsorbed, or another suitable preparation the potency of which has been determined in relation to the International Standard.

**Suggested method**

**Test animals.** Use white guinea-pigs, weighing between 250 and 350 g, from the same stock. Distribute the guinea-pigs into no fewer than six equal groups; use groups containing a number of animals sufficient to obtain results that fulfill the requirements for a valid Assay prescribed below. The guinea-pigs are all of the same sex or the males and females are distributed equally among the groups. If the challenge toxin to be used has not been shown to be stable or has not been adequately standardized, include five guinea-pigs as unvaccinated controls.

**Selection of the challenge toxin.** Select a preparation of diphtheria toxin containing 67 to 133 Limes reactionis/100 (Lt/100) in Limes flocculationis (Lf) and 25,000 to 50,000 minimal reacting doses for guinea-pig skin in 1 Lf. If the challenge toxin preparation has been shown to be stable, it is not necessary to verify the activity for every assay.

**Preparation of the challenge toxin solutions.** Immediately prior to use, dilute the challenge toxin with a suitable diluent to obtain a challenge toxin solution containing about 512x10^{-4} Lf in 0.2 ml. Dilute a portion of this challenge toxin solution to give a series of five 4-fold dilutions.

**Determination of potency of the vaccine.** Prepare in saline solution dilutions of the vaccine under examination and of the Standard preparation such that, for each, the dilutions form a series differing by not more than 2.5 fold steps and in which the dilutions of intermediate concentration, when injected subcutaneously in 1.0 ml volumes into guinea-pigs, result in an intradermal score of approximately three when the animals are challenged. Allocate the dilutions, one to each of the groups of guinea-pigs, and inject subcutaneously 1.0 ml of each dilution into each guinea-pig in the group to which that dilution is allocated. After 28 days shave both flanks of each guinea-pig and inject each animal intradermally with 0.2 ml of the challenge toxin solution and with 0.2 ml of each of the five dilutions thereof in such a way as to minimize interference between adjacent sites. If necessary, inject the unvaccinated control guinea-pigs with dilutions containing 8x10^{-4}, 4x10^{-4}, 2x10^{-4}, 1x10^{-4} and 5x10^{-6} Lf of the challenge toxin.

Examine all the injection sites 48 hours after injection of the challenge toxin and record the incidence of specific diphtheria erythema. Record also the number of sites free from such reactions as the intradermal challenge score. Tabulate the intradermal challenge scores for all the animals receiving the same dilution of vaccine and use those data with a suitable transformation, such as (score)^2 or arcsin [(score/6)^2], to obtain an estimate of the relative potency for each of the test preparations by parallel-line quantitative analysis.

The test is not valid unless (a) for both the preparation under examination and the Standard preparation, the mean score obtained at the lowest dose level is more than three; (b) if applicable, the toxin dilution that contains 4x10^{-5} Lf gives a positive erythema in at least 80.0 per cent of the control guinea-pigs and the dilution that contains 2x10^{-4} Lf gives no reaction in at least 80 per cent of the guinea-pigs (if these criteria are not met a different toxin has to be selected); (c) the fiducial limits of the assay fall between 50.0 and 200.0 per cent of the estimated potency; (d) the statistical analysis shows no deviation from linearity and parallelism. The test may be repeated but when more than one test is performed the results of all valid tests must be combined in the estimate of potency.

The lower fiducial limit of error of the estimated potency is not less than 30 Units per dose.

**(b) Lethal challenge method**

**Test animals.** Use healthy, white or light-coloured guinea-
pigs from the same stock, weighing between 250 and 350 g. Distribute them into six groups of sixteen; and four groups of four. The guinea-pigs should all be of the same sex or the males and females should be distributed equally between the six groups of sixteen.

**Challenge toxin.** Select a preparation of diphtheria toxin containing not less than 100 LD₅₀ in 1.0 ml.

**Preparation of the challenge toxin solutions.** Immediately prior to use, prepare from the challenge toxin by dilution in phosphate buffered saline pH 7.4, or normal saline a challenge toxin containing approximately 100 LD₅₀ in 1.0 ml. Dilute portions of this challenge toxin solution to 2LD₅₀, 1 LD₅₀ and ½ LD₅₀ in the same solution.

**Determination of potency of the vaccine.** Prepare in saline solution three dilutions of the vaccine under examination and three dilutions of the Standard preparation such that for each, the dilutions form a series differing by not more than 2.5 fold steps and in which the dilutions of intermediate concentration, when injected subcutaneously in 1.0 ml volumes into guinea-pigs, protect approximately 50 per cent of the animals from the lethal effects of the subcutaneous injection of the quantity of diphtheria toxin prescribed for this test. Allocate the six dilutions, one to each of the six groups of six guinea-pigs, and inject subcutaneously 1.0 ml of each dilution into each guinea-pig in the groups to which that dilution is allocated. After 28 days inject subcutaneously into each animal in the six groups of sixteen, 1.0 ml of the challenge toxin solution. Allocate the challenge toxin solution and the three dilutions made from it, one to each of the four groups of four guinea-pigs and inject subcutaneously 1.0 ml of each toxin solution into each guinea-pig in the group to which that solution is allocated. Examine the guinea-pigs twice in a day, remove dead animals and kill the animals showing definite signs of diphtheria. Count the number of surviving animals 5 days later and calculate the potency of the vaccine under examination relative to the potency of the Standard preparation on the basis of the number of animals that survive in each of the six groups of sixteen, using appropriate statistical methods.

The test is not valid unless (a) for the vaccine under examination and the Standard preparation the 50.0 per cent protective doses lie between the largest and smallest doses of the preparations given to the guinea-pigs; (b) the survivors among the four groups of guinea-pigs injected with the challenge toxin and its dilutions indicate that the challenge was approximately 100 LD₅₀ and; (c) statistical analysis shows parallelism, linearity and a significant slope of the dose-response lines. The test may be repeated any number of times but when more than one test is performed the results of all valid tests must be combined in the estimate of potency.

If the lower limit of 95.0 per cent confidence interval of estimated potency is less than 30 IU per single human dose then the limits of the 95.0 per cent confidence interval should be within 50 to 200 of the estimated potency.

**(c) Antibody induction method.**

Inject subcutaneously on each of two occasions separated by an interval of not more than 4 weeks, one-fiftieth of the stated human dose diluted to 1 ml with saline solution, into each of 10 normal, healthy guinea-pigs weighing between 250 and 350 g. Not earlier than 2 weeks and not later than 3 weeks after the second injection, collect the serum from each animal and determine the antitoxin content of the serum of each animal, as described under Diphtheria Antitoxin or any other method approved by National Regulatory Authority. The geometric mean of the antitoxin contents shall be not less than 2.0 Units per ml with reference to the Diphtheria antitoxin standard.

**(d) Any other validated serological assay in guinea pigs or mice as approved by National Regulatory Authority.**

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The amount is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

The final bulk vaccine is distributed aseptically into sterile, tamper-proof containers. The containers are closed so as to prevent contamination.

Only a final lot that is satisfactory with respect to each of the requirements given below under, Identification, Tests and Assay may be released for use. Provided the tests for specific toxicity, free formaldehyde and antimicrobial preservative and the assay have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

**Identification**

Diphtheria toxoid is identified by a suitable immunochemical method. The following method, applicable to certain vaccines, is given as an example. Dissolve in the vaccine under examination sufficient sodium citrate to give a 10 per cent w/v solution. Maintain at 37°C for about 16 hours and centrifuge until a clear supernatant liquid is obtained. The clear supernatant liquid reacts with a suitable diphtheria antitoxin, giving a precipitate.

**Tests**

**Aluminium (2.3.9).** Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the absorbent.
Free formaldehyde (2.3.20). Maximum 0.2 g/l.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Complies with the test for sterility.

Abnormal toxicity (2.2.1). Complies with the test for abnormal toxicity.

pH (2.4.24). 6.0 to 7.0.

Assay

Carry out one of the prescribed methods for the assay of Diphtheria Vaccine (Adsorbed).

The lower confidence limit (P = 0.95) of the estimated potency is not less than 30 IU per single human dose.

Labelling. The label states (1) the human dose; (2) the minimumLf units per single human dose or the minimum International Units per single human dose if potency test done by challenge method; (3) the name and the amount of the adsorbent and preservative; (4) that the vaccine must be shaken before use; (5) that the vaccine is not to be frozen.

Haemophilus Type b Conjugate Vaccine

Haemophilus Type b Conjugate Vaccine is a liquid or freeze-dried preparation of a polysaccharide, derived from a suitable strain of Haemophilus influenzae type b, covalently bound to a carrier protein. The polysaccharide, polyribosylribitol phosphate, referred to as PRP, is a linear copolymer composed of repeated units of 3-β-D-ribofuranosyl-(11)-ribitol-5-phosphate [(C\textsubscript{10}H\textsubscript{19}O\textsubscript{12}P)\textsubscript{n}], with a defined molecular size. The carrier protein, when conjugated to PRP, is capable of inducing a T-cell-dependent B-cell immune response to the polysaccharide.

Production

General provisions

The production method shall have been shown to yield consistently H. influenzae type b conjugate vaccines of adequate safety and immunogenicity in humans. The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy of Vaccines. The stability of the final lot and relevant intermediates is evaluated using one or more indicator tests. Such tests may include determination of molecular size, determination of free PRP in the conjugate and the immunogenicity test on mice. Taking account of the results of the stability testing, release requirements are set for these indicator tests to ensure that the vaccine will be satisfactory at the end of the period of validity.

SEED LOT

The strain of H. influenzae type b used in preparing Haemophilus type b conjugate vaccine shall be identified by a record of its history, including the source from which it was obtained and the tests made to determine the characteristics of the strain. The strain shall have been shown to be capable of producing Type b polysaccharide.

The production of PRP and of the carrier protein is based on defined seed lot systems. Master seed lot and working seed lot shall be properly characterized and defined. Cultures derived from the working seed shall have the same characteristics as of the master seed lot. The sample of culture of single harvests taken before killing shall be tested for contamination by examination of Gram-stained smears and by inoculation on suitable media.

H. influenzae Type b Polysaccharide (PRP)

H. influenzae Type b is grown in a liquid medium that does not contain high-molecular-weight polysaccharides; if any ingredient of the medium contains blood-group substances, the process shall be validated to demonstrate that after the purification step they are no longer detectable. The culture may be inactivated. PRP is separated from the culture liquid and purified by a suitable method. Volatile matter, including water, in the purified polysaccharide is determined by methods such as thermogravimetry, Karl Fischer or any other suitable method. All chemical analysis shall be based on the dry weight of the polysaccharide, in its salt form.

Only those pools of PRP that comply with the following requirements may be used in the preparation of the conjugate. The partially purified PRP shall be stored frozen at or below -20°C.

Identification

The PRP is identified by an immunochemical method (2.2.14) or other suitable method (e.g. 1H or 13C NMR spectroscopy).

Molecular size. The percentage of PRP eluted before a given \( K_v \) value or within a range of \( K_v \) values, is determined by gel filtration or high performance size-exclusion chromatography (HPSEC) (2.4.16), either alone or in combination with light scattering and refractive index detectors (e.g. multiple angle laser light scattering i.e. MALLS) or any other suitable method.

An acceptable value is established for the particular product and each batch of PRP must be shown to comply with this limit. Limits for currently approved products, using the indicated stationary phases, are shown for information in
### Table 1 - Specifications for different components of Haemophilus Type b Conjugate Vaccine.

<table>
<thead>
<tr>
<th>Polysaccharide</th>
<th>Carrier Protein</th>
<th>Conjugation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of PRP</td>
<td>Nominal amount per dose</td>
<td>Type</td>
</tr>
<tr>
<td>Polysaccharide (size reduced)</td>
<td>25 µg</td>
<td>Diphtheria toxoid</td>
</tr>
<tr>
<td>K0 60.0 per cent:</td>
<td>0.6-0.7</td>
<td>Tetanus toxoid</td>
</tr>
<tr>
<td>PRP ≥ 50.0 per cent ≤ K0:</td>
<td>0.30</td>
<td>CRM 197 diphtheria protein</td>
</tr>
<tr>
<td>Polysaccharide (size reduced)</td>
<td>10 µg</td>
<td>Meningococcal outer membrane protein (OMP)</td>
</tr>
<tr>
<td>K0 0.3–0.6</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:**

- ADH = adipic acid dihydrazide
- BrAc = bromoacetyl chloride
- BuA2 = butane-1, 4-diamide
- CDI = carbonyldi-imidazole
- DM = degree of polymerization
- EDAC = l-ethyl-3-(3-dimethylaminopropyl) carbodiimide
- IM = imidazolium
- Mw = weight-average molecular weight.

### Table 2 - Requirements on bulk conjugate

<table>
<thead>
<tr>
<th>Test Specifications</th>
<th>Diptheria toxoid</th>
<th>Tetanus toxoid</th>
<th>CRM 197</th>
<th>OMP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Free Polysaccharide (PRP)</td>
<td>&lt;37.0 per cent</td>
<td>&lt;20.0 per cent</td>
<td>&lt;25.0 per cent</td>
<td>&lt;15.0 per cent</td>
</tr>
<tr>
<td>Unbound protein</td>
<td>&lt;5.0 per cent, where applicable</td>
<td>&lt;1.0 per cent, where applicable</td>
<td>&lt;1.0 per cent or &lt;2.0 per cent, depending on the coupling method</td>
<td>Not applicable</td>
</tr>
<tr>
<td>PRP to protein ratio</td>
<td>1.25-1.75</td>
<td>0.30-0.55</td>
<td>0.3-0.7</td>
<td>0.05-0.1</td>
</tr>
<tr>
<td>Molecular size (K0): Cross-linked agarose for chromatography R</td>
<td>95.0 per cent &lt;0.75</td>
<td>60.0 per cent &lt;0.2</td>
<td>50.0 per cent</td>
<td>0.05-0.1</td>
</tr>
<tr>
<td>Cross-linked agarose for chromatography R1</td>
<td>0.6-0.7</td>
<td>85.0 per cent &lt;0.5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

44
Tables 1 and 2. Where applicable, the molecular-size distribution is also determined after chemical modification of the polysaccharide.

A validated determination of the degree of polymerization or of the weight-average molecular weight and the dispersion of molecular masses may be used instead of the determination of molecular size distribution.

Ribose (2.7.1). Not less than 32.0 per cent, calculated with reference to the dried substance, as estimated by Bial reaction for pentose, using D-ribose as a standard or any other suitable assay.

Phosphorus (2.7.1). 6.8 per cent to 9.0 per cent, calculated with reference to the dried substance.

Protein (2.3.49). Not more than 1.0 per cent, calculated with reference to the dried substance. Use sufficient PRP to allow detection of 1 per cent of protein (e.g. a minimum of 1 mg of PRP).

Nucleic acid (2.7.1). Not more than 1.0 per cent, calculated with reference to the dried substance by spectroscopy or any other suitable method.

Bacterial endotoxins (2.2.3). Not more than 25 IU of endotoxin per microgram of PRP.

Residual reagents. Where applicable, tests are carried out to determine residues of reagents used during inactivation and purification. An acceptable value for each reagent is established for the particular product and each batch of PRP must be shown to comply with this limit. Where validation studies have demonstrated removal of a residual reagent, the test on PRP may be omitted.

Carrier protein

The carrier protein is chosen in a way so that when the PRP is conjugated it is able to induce a T-cell-dependent immune response. Currently approved carrier proteins and coupling methods are listed for information in Table 1. The carrier proteins are produced by culture of suitable microorganisms; the bacterial purity of the culture is verified; the culture may be inactivated; the carrier protein is purified by a suitable method.

Only a carrier protein that complies with the following requirements may be used in preparation of the conjugate.

Identification

The carrier protein is identified by a suitable immunochemical method (2.2.14).

Sterility (2.2.11). Carry out the test for sterility using for each medium 10 ml or the equivalent of one hundred doses, whichever is less.

Diphtheria toxoid. Diphtheria toxoid is produced as stated under Diphtheria Vaccine (Adsorbed) and complies with the requirements prescribed there for bulk purified toxoid.

Tetanus toxoid. Tetanus toxoid is produced as stated under Tetanus Vaccine (Adsorbed) and complies with the requirements prescribed there for bulk purified toxoid except that the antigenic purity is not less than 1500 Lf per mg of protein nitrogen.

Diphtheria protein CRM 197. Suitable tests are carried out, for validation or routinely, to demonstrate that the product is non-toxic. The protein obtained contains not less than 90.0 per cent of diphtheria CRM 197 protein, when prepared by liquid chromatography (2.4.14) or any other suitable method. The carrier protein shall be characterized by a suitable chemical or physicochemical method like SDS-PAGE, HPLC, isoelectric focusing, amino acid sequencing, circular dichroism, fluorescence spectroscopy, peptide mapping or mass spectroscopy, as appropriate.

OMP (Meningococcal group B outer membrane protein complex)

OMP complex of Neisseria meningitidis complies with the following requirements for lipopolysaccharide and pyrogens. Lipopolysaccharide. Not more than 8.0 per cent of lipopolysaccharide, determined by a suitable method.

Pyrogens (2.2.8). Inject into each rabbit 0.25 µg of OMP per kg body weight, for determining the pyrogenic effect.

Bulk conjugate

PRP is chemically modified to enable conjugation; it is usually partly depolymerised either before or during this procedure. Reactive functional groups or spacers may be introduced into the carrier protein or PRP prior to conjugation. The conjugate is obtained by the covalent binding of PRP and carrier protein. Where applicable, unreacted but potentially reactogenic functional groups are made unreactive by means of capping agents; the conjugate is purified to remove reagents. Where validation studies have demonstrated removal of a residual reagent (eg. CN, Br etc.), the test on bulk conjugate may be omitted.

Only a bulk conjugate that complies with the following requirements may be used in preparation of the final bulk vaccine. For each test and for each particular product, limits of acceptance are established and each batch of conjugate must be shown to comply with these limits. Limits applied to currently approved products for some of these tests are listed for information in Table 2.

PRP. The PRP content is determined by assay of phosphorus (2.7.1) or by assay of ribose (2.7.1) or by an immunochemical method (2.2.14) or by any suitable method.
Protein (2.7.1). The protein content is determined by a suitable chemical method.

PRP to protein ratio. Determine the ratio by calculation.

Molecular size. Molecular-size distribution is determined by gel filtration or size-exclusion chromatography (2.4.16), using a gel matrix, appropriate to the expected size of the conjugate.

Free PRP. Unbound PRP is determined after removal of the conjugate, for example by size-exclusion or hydrophobic chromatography (2.4.16), ultra-filtration or other validated methods.

Free carrier protein. Free carrier protein is determined by a suitable method (which may include deriving the content by calculation from the results of other tests). The amount is within the limits approved for the particular product.

Unreacted functional groups. No unreacted functional groups are detectable in the bulk conjugate unless process validation has shown that unreacted functional groups detectable at this stage are removed during the subsequent manufacturing process (for example, owing to short half-life).

Residual reagents. Removal of residual reagents such as cyanide, EDAC (ethyldimethylaminopropylcarbodiimide) and phenol is confirmed by suitable tests or by validation of the purification process.

Sterility (2.2.11). Carry out the tests for sterility using for each medium 10 ml or the equivalent of one hundred doses, whichever is less.

FINAL BULK VACCINE

An adjuvant, an antimicrobial preservative and a stabilizer may be added to the bulk conjugate before dilution to the final concentration with a suitable diluent.

Only a final bulk vaccine that complies with the following requirements may be used in preparation of the final lot.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

FINAL LOT

The final lots are filled in suitable containers, under stringent aseptic conditions.

Only a final lot that is satisfactory with respect to each of the requirements given under Identification, Tests and Assay may be released for use. Provided the test for antimicrobial preservative has been carried out on the final bulk vaccine, it may be omitted on the final lot.

Identification

The vaccine is identified by a suitable immunochemical method (2.2.14) for PRP or the assay serves also to identify the vaccine.

Tests

Sterility (2.2.11). Complies with the test for sterility.

Abnormal toxicity (2.2.1). Complies with the test for abnormal toxicity.

Pyrogens (2.2.8). Complies with the test for pyrogens. Inject per kg of the rabbit's mass a quantity of the vaccine equivalent to 1 µg of PRP for a vaccine with diphtheria toxoid or CRM 197 diphtheria protein as carrier; 0.1 µg of PRP for a vaccine with tetanus toxoid as carrier; 0.025 µg of PRP for a vaccine with OMP as carrier.

pH (2.4.24). The pH of the vaccine, reconstituted if necessary, is within the range approved for the product (6.5 to 7.5).

Aluminium (2.3.9). When aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent, the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Water (2.3.43). Not more than 3.0 per cent.

PRP. Not less than 80.0 per cent of the amount of PRP stated on the label as determined by ribose assay (2.7.1) or by phosphorus assay (2.7.1) or by an immunochemical method (2.2.14) or by any other suitable method like colorimetry or by anion exchange liquid chromatography (2.4.14) with pulsed amperometric detection.

Free PRP. Unbound PRP is determined after removal of the conjugate for example by size-exclusion or hydrophobic chromatography (2.4.16), ultra filtration or other validated methods.

Labelling. The label states (1) the number of micrograms of PRP per human dose; (2) the type and nominal amount of carrier protein per single human dose; (3) for vaccine contained in single-dose containers where the space is too small to accommodate the full name of the vaccine the abbreviation ‘Hib’ may be used in the label on the container provided that the same code is also stated in the label on the package.

Hepatitis A (Inactivated) and Hepatitis B (rDNA) Vaccine (Adsorbed)

Hepatitis A (Inactivated) and Hepatitis B (rDNA) Vaccine (Adsorbed) is a suspension consisting of a suitable strain of hepatitis A virus, grown in cell cultures and inactivated by a
validated method, and of hepatitis B surface antigen (HBsAg), a component protein of hepatitis B virus obtained by recombinant DNA technology; the antigens are adsorbed on a mineral carrier such as aluminium hydroxide or hydrated aluminium phosphate.

**Production**

**General provisions**

The two components are prepared as described in the monographs on Hepatitis A Vaccine (Inactivated, Adsorbed) and Hepatitis B Vaccine (rDNA) and comply with the requirements prescribed therein. The production method is validated to demonstrate that the product, if tested, would comply with the test for abnormal toxicity for antisera and vaccines.

**Reference preparation**

The reference preparation is part of a representative batch shown to be at least as immunogenic in animals as a batch that, in clinical studies in young, healthy adults, produces not less than 95.0 per cent seroconversion, corresponding to a level of neutralizing antibody recognized to be protective, after a full-course primary immunization. For hepatitis A, an antibody level not less than 20 mIU/ml determined by enzyme-linked immunosorbent assay is recognized as being protective. For hepatitis B, antibody level not less than 10 mIU/ml against HBsAg is recognized as being protective.

**FINAL BULK VACCINE**

The final bulk vaccine is prepared from one or more inactivated harvests of hepatitis A virus and one or more batches of purified antigen of Hepatitis B (rDNA).

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

Only a final lot that complies with each of the requirements given below under Identification, Tests and Assay may be released for use. Provided that the tests for free formaldehyde (where applicable) and antimicrobial preservative content (where applicable) have been carried out on the final bulk vaccine with satisfactory results, they may be omitted on the final lot. If the assay of the hepatitis A and/or the hepatitis B component is carried out *in vivo*, then provided it has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

**Identification**

The vaccine is shown to contain hepatitis A virus antigen and hepatitis B surface antigen by suitable immunochemical methods (2.2.14), using specific antibodies or by the mouse immunogenicity tests described under assay.

**Tests**

- **Aluminium** (2.3.9). Maximum 1.25 mg per single human dose if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.
- **Free formaldehyde** (2.3.20). Maximum 0.2 g/l.
- **Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.
- **Sterility** (2.2.11). Complies with the test for sterility.
- **Bacterial endotoxins** (2.2.3). Less than 2 IU per human dose.
- **Assay**
  - **Hepatitis A component**
    Complies with the assay as stated under Inactivated Hepatitis A Vaccine (Adsorbed).
  - **Hepatitis B component**
    Complies with the assay as stated under Hepatitis B Vaccine (rDNA).

**Labelling**. The label states (1) the amount of hepatitis A virus antigen and hepatitis B surface antigen per container; (2) the type of cells used for production of the vaccine; (3) the name and amount of the adsorbent used; (4) that the vaccine must be shaken before use; (5) that the vaccine must not be frozen.

**Hepatitis B Vaccine (rDNA)**

Hepatitis B Vaccine (rDNA) is a non-infectious preparation containing the purified major surface antigen of Hepatitis B virus (HBsAg). This preparation is white or almost white translucent liquid in which the mineral carrier tends to settle down slowly on keeping but is free from foreign particles/floccules.

**Production**

**General provisions**

The antigen is manufactured by recombinant DNA technology by culturing genetically engineered yeast cells or other suitable
cell lines which carry the gene that codes for major surface antigen of the Hepatitis-B virus as approved by the competent authority. Several physico-chemical steps are employed to purify the Hepatitis-B surface antigen (HBsAg). The vaccine may contain the product of the S gene (major protein), a combination of the S gene and pre-S2 gene products (middle protein) or a combination of S gene, the pre-S2 gene, and pre-S1 gene products (large protein). The purity of the antigen is determined by comparison with a reference preparation using liquid chromatography or other suitable methods such as SDS-PAGE with any suitable staining method. The purified antigen is finally adsorbed on aluminium hydroxide or aluminium phosphate.

The method used for production of the vaccine must have been shown to yield a product consistently complying with the requirements for immunogenicity and safety. It must also have been shown to induce specific, protective antibodies in human beings.

The production method must be validated to demonstrate that the product if tested, would comply with the tests for safety and efficacy.

Reference preparation. A part of a batch shown to be at least as immunogenic as a batch that was used in clinical studies and approved by National Regulatory Authority and determined by any suitable method. For hepatitis B, antibody level not less than 10 mIU/ml against HBsAg is recognized as being protective.

Characterisation of the substance

Development studies are carried out to characterize the antigen. The complete protein, lipid and carbohydrate structure of the antigen is established. The morphological characteristics of the antigen particles are established by electron microscopy. The buoyant density of the antigen particles is determined by a physico-chemical method, for example gradient centrifugation. The antigenic epitopes are characterized. The protein fraction of the antigen is characterized in terms of the primary structure (for example, by determination of the amino-acid composition, by partial amino-acid sequence analysis and by peptide mapping).

PROPAGATION AND HARVEST

Identity, microbial purity, plasmid retention and consistency of yield are determined at suitable production stages. If mammalian cells are used, tests for extraneous agents and mycoplasmas are performed in accordance with tests for extraneous agents in viral vaccines for human use.

Purified antigen

Only a purified antigen that complies with the following requirements may be used in the preparation of the final bulk.

Total protein (2.3.49). The total protein is determined by a validated method. The content is within the limits approved for the specific product.

Antigen content and identification. The quantity and specificity of HBsAg is determined in comparison with the International standard for HBsAg subtype ad or an in-house reference, by a suitable immunochemical method such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), immunoblot (preferably using a monoclonal antibody directed against a protective epitope) or single radial diffusion. The antigen/protein ratio is within the limits approved for the specific product.

The molecular weight of the major band in a sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) under reduced conditions corresponds to the value expected from the gene sequence and possible glycosylation.

Antigenic purity. The purity of the antigen is determined by comparison with a reference preparation using liquid chromatography or other suitable methods such as SDS-PAGE with staining. A suitable method is sensitive enough to detect a potential contaminant at a concentration of 1.0 per cent of total protein. Not less than 95.0 per cent of the total protein consists of hepatitis B surface antigen.

Composition. The content of proteins, lipids, nucleic acids and carbohydrates is determined.

Host-cell and vector-derived DNA (2.2.15). If mammalian cells are used for production, not more than 10 pg of DNA in the quantity of purified antigen equivalent to a single human dose of vaccine.

Caesium. If a caesium salt is used during production, a test for residual caesium is carried out on the purified antigen. The content is within the limits approved for the specific product.

Sterility (2.2.11). The purified antigen complies with the test for sterility, carried out using 10 ml for each medium. Additional tests on the purified antigen may be required depending on the production method used: for example, a test for residual animal serum where mammalian cells are used for production or tests for residual chemicals used during extraction and purification.

Final bulk vaccine

An antimicrobial preservative and an adjuvant may be included in the vaccine. Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.
Sterility (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

FINAL LOT

Only a final lot that complies with each of the requirements given below under Identification, Tests and Assay may be released for use. Provided that the tests for free formaldehyde, antimicrobial preservative content and the assay in animals, where applicable, have been carried out on the final bulk vaccine with satisfactory results, they may be omitted on the final lot.

Identification

The assay or, where applicable, the electrophoretic profile, also serves to identify the vaccine.

Tests

Aluminium (2.3.9). Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbant.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Complies with the test for sterility.

Pyrogens (2.2.8). Complies with the test for pyrogens. Inject the equivalent of one human dose into each rabbit.

A validated test for bacterial endotoxins may be used instead of the test for pyrogens.

Assay. The vaccine complies with the assay of Hepatitis-B Vaccine (rDNA) described below.

Potency. The upper fiducial limit (P = 0.95) of the estimated relative potency is not less than 1.0.

Determine the potency either in animals (Method A) or by a validated in vitro procedure (Method B) described below:

Method A (Biological)

The potency of the vaccine under examination is determined in animals by comparing in given conditions its capacity to induce specific anti-HBsAg antibodies in mice or guinea-pigs with the same capacity as with the reference standard.

Inject intraperitoneally not less than three doses of suitable dilutions of the vaccine under examination diluted with adjuvant used in the vaccine into groups of a suitable strain of mice, weighing between 15 and 20 g (about 5 weeks old), of either sex distributed randomly into several groups of mice. Healthy guinea pigs weighing between 300 and 350 g (about 7 weeks old) that have not been previously treated with any material that will interfere with the test will also be suitable for the test. Use animals of the same sex in the test. Inject similar groups of animals with the reference preparation of Hepatitis-B vaccine (r DNA). One group of control animals remains unvaccinated but is injected intraperitoneally with the same volume of the diluent alone. Anaesthetize and bleed the animals 28 to 42 days later, keeping the individual sera separate. Assay the individual sera for specific HBsAg antibody concentration by a suitable immunochemical method such as ELISA or RIA.

Calculate the result of the assay by standard statistical methods (5.7). From the distribution of reaction levels measured on all the sera in the unvaccinated (control group), the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion. The percentage of animals showing seroconversion in each group is transformed along with the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay is determined. Any response in the vaccinated animals that exceeds this level is by definition seroconversion.

Method B (In vitro)

The potency of the vaccine under examination is determined by an in vitro method that has been validated against the biological test.

Enzyme Linked Immunosorbent Assay (ELISA) using monoclonal antibodies specific for protection inducing epitopes of HBsAg have been shown to be suitable. Adequate number of dilutions and replicates of the vaccine under examination and the reference standard are employed in the assay. The data obtained is analyzed by a parallel-line model and may be suitably transformed for statistical evaluation. Commercially available kits for measuring HBsAg in vitro may be used provided they are validated to produce equally precise and accurate results.

The test is not valid unless (a) the statistical analysis shows no deviation from linearity or parallelism; (b) the fiducial limits of the estimated relative potency fall between 33.0 and 300.0 per cent of the estimated potency.

Labelling. The label states (a) the amount of HBsAg per dose; (b) the type of cells used for production of the vaccine; (c) the
name and amount of the adjuvant; (d) that the vaccine must be shaken before use; (e) that the vaccine must not be frozen.

**Inactivated Hepatitis A Vaccine (Adsorbed)**

Hepatitis A Vaccine (Inactivated, Adsorbed) is a liquid preparation of a suitable strain of hepatitis A virus grown in cell cultures, inactivated by a validated method and adsorbed on a mineral carrier. The vaccine is an opalescent suspension.

The vaccine complies with the monograph on Vaccines.

**Production**

Production of the vaccine is based on a virus seed-lot system and a cell-bank system. The production method shall have been shown to yield consistently vaccines that comply with the requirements for immunogenicity, safety and stability.

The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy.

Unless otherwise justified and authorised, the virus in the final vaccine shall not have undergone more passages from the master seed lot than were used to prepare the vaccine shown in clinical studies to be satisfactory with respect to safety and efficacy.

**Reference preparation.** A part of a batch shown to be at least as immunogenic as a batch that, in clinical studies in young healthy adults, produced not less than 95.0 per cent seroconversion, corresponding to a level of neutralising antibody accepted to be protective, after a full-course of primary immunisation is used as a reference preparation. An antibody level of 20 mIU /ml determined by enzyme-linked immunosorbent assay is recognised as being protective.

**Substrate for virus propagation**

The virus is propagated in a human diploid cell line or in a continuous cell line approved by the competent authority.

**SEED LOT**

The strain of hepatitis A virus used to prepare the master seed lot shall be identified by historical records that include information on the origin of the strain and its subsequent manipulation.

Only a seed lot that complies with the following requirements may be used for virus propagation.

**Description.** A clear, colourless or light coloured liquid.

**Identification**

Each master and working seed lot is identified as hepatitis A virus using specific antibodies.

**Virus concentration.** The virus concentration of each master and working seed lot is determined to monitor consistency of production.

**Extraneous agents (2.7.3).** The master and working seed lots comply with the requirements for seed lots for virus vaccines. In addition, if primary monkey cells have been used for isolation of the strain, measures are taken to ensure that the strain is not contaminated with simian viruses such as simian immunodeficiency virus and filoviruses.

**PROPAGATION AND HARVEST**

All processing of the cell bank and subsequent cell cultures is done under aseptic conditions in an area where no other cells are being handled. Animal serum (but not human serum) may be used in the cell culture media. Serum and trypsin used in the preparation of cell suspensions and media are shown to be free from extraneous agents. The cell culture media may contain a pH indicator, such as phenol red and approved antibiotics at the lowest effective concentration. Not less than 500 ml of the cell cultures employed for vaccine production is set aside as uninfected cell cultures (control cells). Multiple harvests from the same production cell culture may be pooled and considered as a single harvest.

Only a single harvest that complies with the following requirements may be used in the preparation of the vaccine. When the determination of the ratio of virus concentration to antigen content has been carried out on a suitable number of single harvests to demonstrate consistency, it may subsequently be omitted as a routine test.

**Identification**

The test for antigen content also serves to identify the single harvest.

**Sterility (2.2.11).** The single harvest complies with the test for sterility, carried out using 10 ml for each medium.

**Mycoplasmas (2.7.4).** The single harvest complies with the test for mycoplasmas carried out using 1ml for each medium.

**Control cells.** The control cells of the production cell culture comply with a test for identity and the requirements for extraneous agents.

**Antigen content.** Determine the hepatitis A antigen content by a suitable immunochemical method (2.2.14) to monitor production consistency; the content is within the limits approved for the particular product.

**Ratio of virus concentration to antigen content.** The consistency of the ratio of the concentration of infectious virus, as determined by a suitable cell culture method, to antigen content is established by validation on a suitable number of single harvests.
PURIFICATION AND PURIFIED HARVEST

The harvest, which may be a pool of several single harvests, is purified by validated methods. If continuous cell lines are used for production, the purification process shall have been shown to reduce consistently the level of host-cell DNA. Only a purified harvest that complies with the following requirements may be used in the preparation of the inactivated harvest.

**Virus concentration.** The concentration of infective virus in the purified harvest is determined by a suitable cell culture method to monitor production consistency and as a starting point for monitoring the inactivation curve.

**Antigen:total protein ratio.** Determine the hepatitis A virus antigen content by a suitable immunochemical method (2.2.14). Determine the total protein by a validated method. The ratio of hepatitis A virus antigen content to total protein content is within the limits approved for the particular product.

**Bovine serum albumin.** Not more than 50 ng in the equivalent of a single human dose, determined by a suitable immunochemical method (2.2.14). Where appropriate in view of the manufacturing process, other suitable protein markers may be used to demonstrate effective purification.

**Residual host-cell DNA (2.2.15).** If a continuous cell line is used for virus propagation, the content of residual host-cell DNA, determined using a suitable method, is not greater than 100 pg in the equivalent of a single human dose.

**Residual chemicals.** If chemical substances are used during the purification process, tests for these substances are carried out on the purified harvest (or on the inactivated harvest), unless validation of the process has demonstrated total clearance. The concentration must not exceed the limits approved for the particular product.

INACTIVATION AND INACTIVATED HARVEST

Several purified harvests may be pooled before inactivation. In order to avoid interference with the inactivation process, virus aggregation must be prevented or aggregates must be removed immediately before and/or during the inactivation process. The virus suspension is inactivated by a validated method; the method shall have been shown to be consistently capable of inactivating hepatitis A virus without destroying the antigenic and immunogenic activity; as part of the validation studies, an inactivation curve is plotted representing residual live virus concentration measured on at least three occasions (for example, on days 0, 1 and 2 of the inactivation process). If formaldehyde is used for inactivation, the presence of excess free formaldehyde is verified at the end of the inactivation process.

Only an inactivated harvest that complies with the following requirements may be used in the preparation of the final bulk vaccine.

**Inactivation.** Carry out an amplification test for residual infectious hepatitis A virus by inoculating a quantity of the inactivated harvest equivalent to 5 per cent of the batch or if the harvest contains the equivalent of 30,000 doses or more, not less than 1,500 doses of vaccine into cell cultures of the same type as those used for production of the vaccine and incubating the cells for at least 28 days. Make two passages and at the end of incubation carry out a test of suitable sensitivity for residual infectious virus. No evidence of hepatitis A virus multiplication is found in the samples taken at the end of the inactivation process. Use infective virus inocula concurrently as positive controls to demonstrate cellular susceptibility and absence of interference.

**Sterility (2.2.11).** The inactivated viral harvest complies with the test for sterility, carried out using 10 ml for each medium.

**Bacterial endotoxins (2.2.3).** Not more than 2 IU of endotoxin in the equivalent of a single human dose.

**Antigen content.** Determine the hepatitis A virus antigen content by a suitable immunochemical method (2.2.14).

**Residual chemicals.** As stated under Purification and Purified Harvest.

FINAL BULK VACCINE

The final bulk vaccine is prepared from one or more inactivated harvests. Approved adjuvants, stabilisers and antimicrobial preservatives may be added.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility (2.2.11).** Carry out test for sterility using 10 ml of bulk for each sterility medium.

FINAL LOT

The final bulk vaccine is distributed aseptically into sterile containers. The containers are then closed so as to avoid contamination.

Only a final lot that complies with each of the requirements given below under Identification, Tests and Assay may be released for use. Provided that the tests for free formaldehyde (where applicable) and antimicrobial preservative content (where applicable) and the assay have been carried out on the final bulk vaccine with satisfactory results, these tests may be omitted on the final lot. If the assay is carried out using mice or other animals, then provided it has been carried with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.
Identification
The vaccine is shown to contain hepatitis A virus antigen by a suitable immunochemical method using specific antibodies or by the mouse immunogenicity test described under Assay.

Tests
Aluminium (2.3.9). Maximum 1.25 mg per single human dose, if hydrated aluminium phosphate or aluminium hydroxide is used as the adsorbent.

Free formaldehyde (2.3.20). When formaldehyde has been used for inactivation, the vaccine complies with the test prescribed in Vaccines.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Complies with the test for sterility.

Abnormal toxicity (2.2.1). Complies with the test for abnormal toxicity.

Assay
The vaccine complies with the assay of Hepatitis A vaccine.

The assay is carried out either in vivo, by comparing in given condition the capacity to induce specific antibodies in mice with the same capacity of a reference preparation or in vitro by an immunochemical determination of antigen content (2.2.14).

In vivo assay
The test on mice shown below is given as an example of a method that has been found suitable for a given vaccine; other validated methods may also be used.

Selection and distribution of the test animals. Healthy mice from the same stock, about 5 weeks old and from a strain shown to be suitable should be used in the test. Use animals of the same sex. Distribute the animals in at least seven equal groups of a number suitable for the requirements of the assay.

Determination of potency of the vaccine under examination. Using a 0.9 per cent w/v solution of sodium chloride containing the aluminium adjuvant used for the vaccine, prepare at least three dilutions of the vaccine under examination and matching dilutions of the reference preparation. Allocate the dilutions one to each of the groups of animals and inject subcutaneously not more than 0.5 ml of each dilution into each animal in the group to which that dilution is allocated. Maintain a group of unvaccinated controls, injected subcutaneously with the same volume of diluent. After 28 to 32 days, anaesthetise and bleed all animals, keeping the individual sera separate. Assay the individual sera for specific antibodies against hepatitis A virus by a suitable immunochemical method (2.2.14).

Calculations. Carry out the calculations by the usual statistical methods (5.7) for an assay with a quantal response.

From the distribution of reaction levels measured on all the sera in the unvaccinated group, determine the maximum reaction level that can be expected to occur in an unvaccinated animal for that particular assay. Any response in vaccinated animals that exceeds this level is by definition a seroconversion.

Make a suitable transformation of the percentage of animals showing seroconversion in each group (for example, a probit transformation) and analyse the data according to a parallel-line log dose-response model. Determine the potency of the test preparation relative to the reference preparation.

Validity conditions. The test is not valid unless (a) for both the test and the reference vaccine, the \( ED_{50} \) lies between the smallest and the largest doses given to the animals; (b) the statistical analysis shows no significant deviation from linearity or parallelism; (c) the fiducial limits of the estimated relative potency fall between 33.0 and 300.0 per cent of the estimated potency.

Potency. The upper fiducial limit (\( P = 0.95 \)) of the estimated relative potency is not less than 1.0.

In vitro assay
Carry out an immunochemical determination of antigen content (2.2.14) with acceptance criteria validated against the in vivo test. The acceptance criteria are approved for a given reference preparation by the National Regulatory Authority in the light of the validation data.

Labelling. The label states (1) the biological origin of the cells and; (2) the adjuvant used for the preparation of the vaccine.

Inactivated Hepatitis B Vaccine
Inactivated Hepatitis B Vaccine is a non-infectious inactivated liquid preparation derived from the surface antigen of Hepatitis B virus (HbsAg). This preparation is white or almost white translucent liquid in which the mineral carrier tends to settle down slowly on keeping but is free from foreign particles / floccules.

Production
The antigen is harvested and purified from the plasma of human carriers of Hepatitis B virus. The surface antigen contains all the three antigen species (S, Pre-S1, Pre-S2). The individual donor plasma is shown by sensitive tests to be seronegative for HIV-1 and HIV-2 and for HCV. The plasma pool is tested for freedom from adventitious viruses and blood borne
transmissible pathogens by appropriate methods. The purified antigen is further inactivated by a validated method, usually with formalin or any other inactivating agent, to render the hepatitis B virus harmless. The preparation is also tested for the residual HBV DNA using a sensitive test approved by the competent authority and the level is shown to be less than 1 pg HBV DNA per 50 doses.

The method used for production of the vaccine must have been shown to yield a product consistently complying with the requirements of immunogenicity, safety and stability. The production method must also be validated to demonstrate that the product, if tested, would comply with the tests for safety and efficacy.

**Reference preparation.** A part of a batch shown to be at least as immunogenic as a batch that produced in clinical studies in young healthy adults not less than 95.0 per cent seroconversion, corresponding to a level of neutralizing antibody accepted to be protective (HbsAg antibody titre not less than 10 mIU/ml after a full course of primary immunization determined by enzyme-linked immunosorbent assay (ELISA) is used as a reference preparation.

**Characterisation of the substance**

Development studies are carried out to characterize the antigen. The complete protein, lipid and carbohydrate structure of the antigen is established. The morphological characteristics of the antigen particles are established by electron microscopy. The buoyant density of the antigen particles is determined by a physico-chemical method (2.4.29), for example gradient centrifugation. The antigenic epitopes are characterized. The protein fraction of the antigen is characterized in terms of the primary structure (for example, by determination of the amino-acid composition, by partial amino-acid sequence analysis and by peptide mapping).

**PROPAGATION AND HARVEST**

Identity, microbial purity, plasmid retention and consistency of yield are determined at suitable production stages.

**PURIFIED ANTIGEN**

Only a purified antigen that complies with the following requirements may be used in the preparation of the final bulk.

**Total protein (2.3.49).** The total protein is determined by a validated method. The content is within the limits approved for the specific product.

**Antigen content and identification.** The quantity and specificity of HBsAg is determined in comparison with the International standard for HBsAg subtype ad or an in-house reference, by a suitable immunochemical method such as radio immunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), immunoblot (preferably using a monoclonal antibody directed against a protective epitope) or single radial diffusion. The antigen/protein ratio is within the limits approved for the specific product.

The molecular weight of the major band in a sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) under reduced conditions corresponds to the value expected from the gene sequence and possible glycosylation.

**Antigenic purity.** The purity of the antigen is determined by comparison with a reference preparation using liquid chromatography or other suitable methods such as SDS-PAGE with staining. A suitable method is sensitive enough to detect a potential contaminant at a concentration of 1.0 per cent of total protein. Not less than 95.0 per cent of the total protein consists of hepatitis B surface antigen.

**Composition.** The content of proteins, lipids, nucleic acids and carbohydrates is determined.

**Sterility (2.2.11).** The purified antigen complies with the test for sterility carried out using 10 ml for each medium.

Additional tests on the purified antigen may be required depending on the production method used.

**FINAL BULK VACCINE**

An antimicrobial preservative and an adjuvant may be included in the vaccine.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical or physico-chemical method. The amount is not less than the 85.0 per cent and not greater than 115.0 per cent of that stated on the label.

**Sterility (2.2.11).** Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

Only a final lot that complies with each of the requirements given below under Identification, Tests and Assay may be released for use. Provided that the tests for free formaldehyde, antimicrobial preservative content and the assay in animals, where applicable, have been carried out on the final bulk vaccine with satisfactory results, they may be omitted on the final lot.

**Identification**

The assay or, where applicable, the electrophoretic profile, also serves to identify the vaccine.

**Tests**

**Aluminium (2.3.9).** When hydrated aluminium phosphate or aluminium hydroxide is used as the adsorbent, the vaccine
complies with the test prescribed in the monograph on Vaccines.

**Test for inactivating agent.** The concentration of any inactivating agent remaining in the final vaccine shall be determined by methods approved by the competent authority. The concentration shall not exceed a specified upper limit.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Complies with the test for sterility.

**Pyrogens** (2.2.8). Complies with the test for pyrogens. Inject the equivalent of one human dose into each rabbit. A validated test for bacterial endotoxins (2.2.3) may be used instead of the test for pyrogens.

**Assay**

The upper fiducial limit ($P = 0.95$) of the estimated relative potency is not less than 1.0.

Determine the potency by method A (Biological) as described under Hepatitis-B vaccine (rDNA).

**Labelling.** The label states (1) the amount of HBsAg per dose; (2) the name and amount of inactivating agent; (3) the name and amount of the adjuvant; (4) that the vaccine must be shaken before use; (5) that the vaccine must not be frozen.

**Inactivated Influenza Vaccine (Split Virion)**

Influenza Vaccine (Split Virion, Inactivated) is a sterile, aqueous suspension of a strain or strains of influenza virus, type A or B, or a mixture of strains of the two types grown individually in eggs derived from specific pathogen free flock or cell cultures, inactivated and treated so that the integrity of the virus particles has been disrupted without diminishing the antigenic properties of the haemagglutinin and neuraminidase antigens. The stated amount of haemagglutinin antigen for each strain present in the vaccine is 15 µg per dose, unless clinical evidence supports the use of a different amount.

**Production**

The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy.

**Choice of vaccine strain**

The World Health Organisation reviews the world epidemiological situation annually and if necessary recommends new strains corresponding to prevailing epidemiological evidence.

The origin and passage history of virus strains shall be approved by the National Regulatory Authority.

**Substrate for virus propagation**

Influenza virus seed to be used in the production of vaccine is propagated in fertilised eggs from chicken flocks free from specified pathogens or in suitable cell cultures, such as chick-embryo fibroblasts or chick kidney cells obtained from chicken flocks free from specified pathogens. For production, the virus of each strain is grown in the allantoic cavity of eggs derived from specific pathogen free flocks.

**SEED LOT**

The production of vaccine is based on a seed-lot system. Working seed lots represent not more than fifteen passages from the approved reassorted virus or the approved virus isolate. The final vaccine represents one passage from the working seed lot. The haemagglutinin and neuraminidase antigens of each seed lot are identified as originating from the correct strain of influenza virus by suitable methods.

Only a working virus seed lot that complies with the following requirements may be used in the preparation of the monovalent pooled harvest.

**Sterility** (2.2.11). Carry out the test for sterility using 10 ml for each medium.

**Mycoplasmas** (2.7.4). Carry out the test for mycoplasmas using 10 ml.

**PROPAGATION AND HARVEST**

An antimicrobial agent may be added to the inoculum. After incubation at a controlled temperature, the allantoic fluids are harvested and combined to form a monovalent pooled harvest. An antimicrobial agent may be added at the time of harvest. At no stage in the production, penicillin or streptomycin is used.

**MONOVALENT POOLED HARVEST**

To limit the possibility of contamination, inactivation is initiated as soon as possible after preparation. The virus is inactivated by a method that has been demonstrated on three consecutive batches to be consistently effective for the manufacturer. The inactivation process shall have been shown to be capable of inactivating the influenza virus without destroying its antigenicity; the process should cause minimum alteration of the haemagglutinin and neuraminidase antigens. The inactivation process shall also have been shown to be capable of inactivating avian leucosis viruses and mycoplasmas. If the monovalent pooled harvest is stored after inactivation, it
is held at a temperature of 5±3°C. If formaldehyde solution is used, the concentration does not exceed 0.2 g/l of formaldehyde at any time during inactivation; if betapropiolactone is used, the concentration does not exceed 0.1 per cent v/v at any time during inactivation.

Before or after the inactivation procedure, the monovalent pooled harvest is concentrated and purified by high-speed centrifugation or other suitable method and the virus particles are disrupted into component subunits by the use of approved procedures. For each new strain, a validation test is carried out to show that the monovalent bulk consists predominantly of disrupted virus particles.

Only a monovalent pooled harvest that complies with the following requirements may be used in the preparation of the final bulk vaccine.

Haemagglutinin antigen. Determine the content of haemagglutinin antigen by an immunodiffusion test (2.2.14), by comparison with a haemagglutinin antigen reference preparation or with an antigen preparation calibrated against it. Carry out the test at 20° to 25°.

For some vaccines, the physical form of the haemagglutinin particles prevents quantitative determination by immunodiffusion after inactivation of the virus. For these vaccines, a determination of haemagglutinin antigen is made on the monovalent pooled harvest before inactivation. The production process is validated to demonstrate suitable conservation of haemagglutinin antigen and a suitable tracer is used for formulation, for example, protein content.

Neuraminidase antigen. The presence and type of neuraminidase antigen are confirmed by suitable enzymatic or immunological methods (2.2.14) on the first three monovalent pooled harvests from each working seed lot.

Sterility (2.2.11). Carry out the test for sterility using 10 ml for each sterility medium.

FINAL LOT

The final bulk vaccine is distributed aseptically into sterile, tamper-proof containers. The containers are closed so as to prevent contamination.

Only a final lot that is satisfactory with respect to each of the requirements given below under Tests and Assay may be released for use. Provided that the test for viral inactivation has been performed with satisfactory results on each monovalent pooled harvest and that the tests for free formaldehyde, ovalbumin and total protein have been performed with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

Description. The vaccine is a slightly opalescent liquid.

Identification

The assay serves to confirm the antigenic specificity of the vaccine.

Tests

Viral inactivation. Inoculate 0.2 ml of the vaccine into the allantoic cavity of each of ten fertilised eggs and incubate at 33° to 37° for 3 days. The test is not valid unless at least eight of the ten embryos survive. Harvest 0.5 ml of the allantoic fluid from each surviving embryo and pool the fluids. Inoculate 0.2 ml of the pooled fluid into a further ten fertilised eggs and incubate at 33° to 37° for 3 days. The test is not valid unless at least eight of the ten embryos survive. Harvest about 0.1 ml of the allantoic fluid from each surviving embryo and examine each individual harvest for live virus by a haemagglutination test. If haemagglutination is found for any of the fluids, carry out for that fluid a further passage in eggs and test for haemagglutination; no haemagglutination occurs.

Total protein (2.3.49). Not more than six times the total haemagglutinin content of the vaccine as determined in the assay, but in any case, not more than 100 µg of protein per virus strain per human dose and not more than a total of 300 µg of protein per human dose.

Ovalbumin. Not more than 1 µg of ovalbumin per human dose, determined by a suitable technique using a suitable reference preparation of ovalbumin.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Complies with the test for sterility.

Abnormal toxicity (2.2.1). Complies with the test for abnormal toxicity.
**Bacterial endotoxins** (2.2.3). Not more than 100 IU of endotoxin per human dose.

**Assay**

Determine the content of haemagglutinin antigen by an immunodiffusion test (2.2.14), by comparison with an appropriate haemagglutinin antigen reference preparation. Carry out the test at 20 to 25°C. The confidence interval (P = 0.95) of the assay is not greater than 80.0 per cent to 125.0 per cent of the estimated content. The lower confidence limit (P = 0.95) of the estimate of haemagglutinin antigen content is not less than 80.0 per cent of the amount stated on the label for each strain.

For some vaccines, quantitative determination of haemagglutinin antigen with respect to available reference preparations is not possible. An immunological identification of the haemagglutinin antigen and a semi-quantitative determination are carried out instead by suitable methods.

**Labelling.** The label complies with the requirements stated under Vaccines and also states (a) that the vaccine has been prepared on eggs; (b) the strain or strains of influenza virus used to prepare the vaccine; (c) the method of inactivation; (d) the haemagglutinin content in µg per virus strain per dose; (e) the season during which the vaccine is intended to protect.

### Inactivated Influenza Vaccine (Surface Antigen)

Influenza Vaccine (Surface Antigen, Inactivated) is a sterile, aqueous suspension of a strain or strains of influenza virus, type A or B, or a mixture of strains of the two types grown individually in eggs derived from specific pathogen free flocks or cell cultures, inactivated and treated so that the preparation consists predominantly of haemagglutinin and neuraminidase antigens, without diminishing the antigenic properties of these antigens. The stated amount of haemagglutinin antigen for each strain present in the vaccine is 15 µg per dose, unless clinical evidence supports the use of a different amount.

**Production**

The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy.

**Choice of vaccine strain**

The World Health Organisation reviews the world epidemiological situation annually and if necessary recommends new strains corresponding to prevailing epidemiological evidence.

The origin and passage history of virus strains shall be approved by the competent authority.

### Substrate for virus propagation

Influenza virus seed to be used in the production of vaccine is propagated in fertilised eggs from chicken flocks free from specified pathogens or in suitable cell cultures, such as chick-embryo fibroblasts or chick kidney cells obtained from chicken flocks free from specified pathogens. For production, the virus of each strain is grown in the allantoic cavity of eggs derived from SPF flocks.

### SEED LOT

The production of vaccine is based on a seed-lot system. Working seed lots represent not more than fifteen passages from the approved reassorted virus or the approved virus isolate. The final vaccine represents one passage from the working seed lot. The haemagglutinin and neuraminidase antigens of each seed lot are identified as originating from the correct strain of influenza virus by suitable methods.

Only a working virus seed lot that complies with the following requirements may be used in the preparation of the monovalent pooled harvest.

**Sterility** (2.2.11). Carry out the test for sterility using 10 ml for each medium.

**Mycoplasmas** (2.7.4). Carry out the test for mycoplasmas using 10 ml.

### PROPAGATION AND HARVEST

An antimicrobial agent may be added to the inoculum. After incubation at a controlled temperature, the allantoic fluids are harvested and combined to form a monovalent pooled harvest. An antimicrobial agent may be added at the time of harvest. At no stage in the production penicillin or streptomycin is used.

### MONOVALENT POOLED HARVEST

To limit the possibility of contamination, inactivation is initiated as soon as possible after preparation. The virus is inactivated by a method that has been demonstrated on three consecutive batches to be consistently effective for the manufacturer. The inactivation process shall have been shown to be capable of inactivating the influenza virus without destroying its antigenicity; the process should cause minimum alteration of the haemagglutinin and neuraminidase antigens. The inactivation process shall also have been shown to be capable of inactivating avian leucosis viruses and mycoplasmas. If the monovalent pooled harvest is stored after inactivation, it is held at a temperature of 5±3°C. If formaldehyde solution is used, the concentration does not exceed 0.2 g/l of formaldehyde at any time during inactivation; if betapropiolactone is used, the concentration does not exceed
0.1 per cent v/v at any time during inactivation. Before or after the inactivation process, the monovalent pooled harvest is concentrated and purified by high-speed centrifugation or other suitable method. Virus particles are disrupted into component subunits by approved procedures and further purified so that the monovalent bulk consists mainly of haemagglutinin and neuraminidase antigens.

Only a monovalent pooled harvest that complies with the following requirements may be used in the preparation of the final bulk vaccine.

**Haemagglutinin antigen.** Determine the content of haemagglutinin antigen by an immunodiffusion test (2.2.14), by comparison with a haemagglutinin antigen reference preparation or with an antigen preparation calibrated against it. Carry out the test at 20° to 25°.

**Neuraminidase antigen.** The presence and type of neuraminidase antigen are confirmed by suitable enzymatic or immunological methods (2.2.14) on the first three monovalent pooled harvests from each working seed lot.

**Sterility** (2.2.11). Carry out the test for sterility, using 10 ml for each medium.

**Viral inactivation.** Carry out the test described below under Tests.

**Purity.** The purity of the monovalent pooled harvest is examined by polyacrylamide gel electrophoresis or by other approved techniques. Mainly haemagglutinin and neuraminidase antigens shall be present.

**Chemicals used for disruption and purification.** Tests are carried out on the monovalent pooled harvest for the chemicals used for disruption and purification, the limits being approved by the competent authority.

**FINAL BULK VACCINE**

Appropriate quantities of the monovalent pooled harvests are blended to make the final bulk vaccine. Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Carry out the test for sterility using 10 ml for each medium.

**FINAL LOT**

The final bulk vaccine is distributed aseptically into sterile, tamper-proof containers. The containers are closed so as to prevent contamination. Only a final lot that is satisfactory with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided that the test for viral inactivation has been performed with satisfactory results on each monovalent pooled harvest and that the tests for free formaldehyde, ovalbumin and total protein have been performed with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

**Description.** The vaccine is a clear liquid.

**Identification**

The assay serves to confirm the antigenic specificity of the vaccine.

**Tests**

**Viral inactivation.** Inoculate 0.2 ml of the vaccine into the allantoic cavity of each of ten fertilised eggs and incubate at 33° to 37° for 3 days. The test is not valid unless at least eight of the ten embryos survive. Harvest 0.5 ml of the allantoic fluid from each surviving embryo and pool the fluids. Inoculate 0.2 ml of the pooled fluid into a further ten fertilised eggs and incubate at 33° to 37° for 3 days. The test is not valid unless at least eight of the ten embryos survive. Harvest about 0.1 ml of the allantoic fluid from each surviving embryo and examine each individual harvest for live virus by a haemagglutination test. If haemagglutination is found for any of the fluids, carry out for that fluid a further passage in eggs and test for haemagglutination; no haemagglutination occurs.

**Total protein** (2.3.49). Not more than 40 µg of protein other than haemagglutinin per virus strain per human dose and not more than a total of 120 µg of protein other than haemagglutinin per human dose.

**Ovalbumin.** Not more than 1 µg of ovalbumin per human dose, determined by a suitable technique using a suitable reference preparation of ovalbumin.

**Free formaldehyde** (2.3.20). Complies with the test for free formaldehyde as stated under General Requirements for Vaccines for Human Use.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity.

**Sterility** (2.2.11). Complies with the test for sterility.

**Bacterial endotoxins** (2.2.3). Not more than 100 IU of endotoxin per human dose.

**Assay**

Determine the content haemagglutinin antigen by an
immunodiffusion test (2.2.14), by comparison with an appropriate haemagglutinin antigen reference preparation. Carry out the test at 20° to 25°. The confidence interval (P = 0.95) of the assay is not greater than 80.0 per cent to 125.0 per cent of the estimated content. The lower confidence limit (P = 0.95) of the estimate of haemagglutinin antigen content is not less than 80.0 per cent of the amount stated on the label for each strain.

Labelling. The label states (1) that the vaccine has been prepared on eggs; (2) the strain or strains of influenza virus used to prepare the vaccine; (3) the method of inactivation; (4) the haemagglutinin content in micrograms per virus strain per dose; (5) the season during which the vaccine is intended to protect.

Inactivated Influenza Vaccine (Whole Virion)

Influenza Vaccine (Whole Virion, Inactivated) is a sterile, aqueous suspension of a strain or strains of influenza virus, type A or B, or a mixture of strains of the two types grown individually in eggs derived from specific pathogen free flocks or cell culture and inactivated in such a manner that their antigenic properties are retained. The stated amount of haemagglutinin antigen for each strain present in the vaccine is 15 µg per dose, unless clinical evidence supports the use of a different amount.

Production

The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy.

Choice of vaccine strain

The World Health Organisation reviews the world epidemiological situation annually and, if necessary, recommends new strains corresponding to prevailing epidemiological evidence.

The origin and passage history of virus strains shall be approved by the competent authority.

Substrate for virus propagation

Influenza virus seed to be used in the production of vaccine is propagated in fertilised eggs from chicken flocks free from specified pathogens or in suitable cell cultures, such as chick-embryo fibroblasts or chick kidney cells obtained from chicken flocks free from specified pathogens. For production, the virus of each strain is grown in the allantoic cavity of eggs derived from specific pathogen free flocks.

SEED LOT

The production of vaccine is based on a seed-lot system. Working seed lots represent not more than fifteen passages from the approved reassorted virus or the approved virus isolate. The final vaccine represents one passage from the working seed lot. The haemagglutinin and neuraminidase antigens of each seed lot are identified as originating from the correct strain of influenza virus by suitable methods.

Only a working virus seed lot that complies with the following requirements may be used in the preparation of the monovalent pooled harvest.

Sterility (2.2.11). Carry out the test for sterility using 10 ml for each medium.

Mycoplasmas (2.7.4). Carry out the test for mycoplasmas using 10 ml.

PROPAGATION AND HARVEST

An antimicrobial agent may be added to the inoculum. After incubation at a controlled temperature, the allantoic fluids are harvested and combined to form a monovalent pooled harvest. An antimicrobial agent may be added at the time of harvest. At no stage in the production is penicillin or streptomycin used.

MONOVALENT POOLED HARVEST

To limit the possibility of contamination, inactivation is initiated as soon as possible after preparation. The virus is inactivated by a method that has been demonstrated on three consecutive batches to be consistently effective for the manufacturer. The inactivation process shall have been shown to be capable of inactivating the influenza virus without destroying its antigenicity; the process should cause minimum alteration of the haemagglutinin and neuraminidase antigens. The inactivation process shall also have been shown to be capable of inactivating avian leucosis viruses and mycoplasmas. If the monovalent pooled harvest is stored after inactivation, it is held at a temperature of 5±3°. If formaldehyde solution is used, the concentration does not exceed 0.2 g/l of formaldehyde at any time during inactivation; if betapropiolactone is used, the concentration does not exceed 0.1 per cent v/v at any time during inactivation.

Before or after the inactivation process, the monovalent pooled harvest is concentrated and purified by high-speed centrifugation or other suitable method.

Only a monovalent pooled harvest that complies with the following requirements may be used in the preparation of the final bulk vaccine.

Haemagglutinin antigen. Determine the content of haemagglutinin antigen by an immunodiffusion test (2.2.14), by comparison with a haemagglutinin antigen reference
preparation or with an antigen preparation calibrated against it. Carry out the test at 20° to 25°.

**Neuraminidase antigen.** The presence and type of neuraminidase antigen are confirmed by suitable enzymatic or immunological methods (2.2.14) on the first three monovalent pooled harvests from each working seed lot.

**Sterility** (2.2.11). Carry out the test for sterility using 10 ml for each medium.

**Viral inactivation.** Carry out the test described below under Tests.

**FINAL BULK VACCINE**

Appropriate quantities of the monovalent pooled harvests are blended to make the final bulk vaccine.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

The final bulk vaccine is distributed aseptically into sterile, tamper-proof containers. The containers are closed so as to prevent contamination.

Only a final lot that is satisfactory with respect to each of the requirements given below under Tests and Assay may be released for use. Provided that the test for viral inactivation has been performed with satisfactory results on each monovalent pooled harvest and that the tests for free formaldehyde, ovalbumin and total protein have been performed with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

**Description.** The vaccine is a slightly opalescent liquid.

**Identification**

The assay serves to confirm the antigenic specificity of the vaccine.

**Tests**

**Viral inactivation.** Inoculate 0.2 ml of the vaccine into the allantoic cavity of each of ten fertilised eggs and incubate at 33° to 37° for 3 days. The test is not valid unless at least eight of the ten embryos survive. Harvest 0.5 ml of the allantoic fluid from each surviving embryo and examine each individual harvest for live virus by a haemagglutination test. If haemagglutination is found for any of the fluids, carry out for that fluid a further passage in eggs and test for haemagglutination; no haemagglutination occurs.

**Total protein** (2.3.49). Not more than six times the total haemagglutinin content of the vaccine as determined in the assay, but in any case, not more than 100 µg of protein per virus strain per human dose and not more than a total of 300 µg of protein per human dose.

**Ovalbumin.** Not more than 1 µg of ovalbumin per human dose, determined by a suitable technique using a suitable reference preparation of ovalbumin.

**Free formaldehyde** (2.3.20). Maximum 0.2 g/l.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than the minimum amount shown to be effective and is not greater than 115.0 per cent of the quantity stated on the label.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity.

**Sterility** (2.2.11). Complies with the test for sterility.

**Bacterial endotoxins** (2.2.3). Not more than 100 IU of endotoxin per human dose.

**Assay**

Determine the content of haemagglutinin antigen by an immunodiffusion test (2.2.14), by comparison with an appropriate haemagglutinin antigen reference preparation. Carry out the test at 20° to 25°. The confidence interval (P = 0.95) of the assay is not greater than 80.0 per cent to 125.0 per cent of the estimated content. The lower confidence limit (P = 0.95) of the estimate of haemagglutinin antigen content is not less than 80.0 per cent of the amount stated on the label for each strain.

**Labelling.** The label states (1) that the vaccine has been prepared on eggs; (2) the strain or strains of influenza virus used to prepare the vaccine; (3) the method of inactivation; (4) the haemagglutinin content in micrograms per virus strain per dose; (5) the season during which the vaccine is intended to protect.

**Japanese Encephalitis Vaccine** (Human)

Japanese Encephalitis Vaccine for human use is a liquid or freeze dried preparation of Japanese encephalitis virus grown in approved substrate and inactivated by a validated method.
Production

General provisions

The vaccine is produced on the basis of virus seed lot system. The production method shall have been shown to yield consistently the vaccines that comply with the tests for immunogenicity, safety and stability. The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy.

Substrate for virus propagation

The virus is propagated in an approved cell substrate like a Vero cell line.

SEED LOT

The strain of Japanese encephalitis virus used shall be identified by historical records that include information on the origin of the strain and its subsequent manipulation.

The National Regulatory Authority shall determine the acceptable number of passages from the master virus seed lot to produce working virus seed lots.

Only a working seed lot that complies with the following tests may be used for virus propagation.

Identification

Each working seed lot is identified as Japanese encephalitis virus using specific antibodies by an approved method.

Virus concentration. The virus concentration of each working seed lot is determined by a cell culture method using immunofluorescence or any other approved method.

Extraneous agents (2.7.3). The working seed lot complies with the tests for the virus seed lots.

PROPAGATION AND HARVEST

a) Mouse brain vaccine

The vaccine is prepared by using a seed-lot system. An approved strain of virus is grown by inoculating intracerebrally into healthy mice. Virus harvests are pooled, concentrated and inactivated by addition of formalin or any other suitable inactivating agent. It may contain a suitable preservative. The vaccine may be issued in single or multidose containers.

b) Cell culture vaccine

All processing of the cell bank and subsequent cell cultures are done under aseptic conditions in an area where no other cells are handled. Approved animal (but not human) serum may be used in the media, but the final medium for maintaining cell growth during virus multiplication does not contain animal serum; the media may contain human albumin. Serum proteins, if present are reduced to an acceptable level by suitable method of purification. Serum and trypsin used in the preparation of cell suspension and media are shown to be free from infectious extraneous agents. The cell culture media may contain a pH indicator such as phenol red. Not less than 500 ml of the cell cultures employed for vaccine production are set aside as uninfected cell cultures (control cells). The virus suspension is harvested on one or more occasions during incubation. Multiple harvests from the same production cell culture may be pooled and considered as a single harvest.

Virus harvests that comply with the tests given under Identification and Virus concentration are pooled in the preparation of the inactivated viral harvest.

Control cells. The control cells of the production cell culture from which the single harvest is derived should comply with the test for identification and with the tests for extraneous agents (2.7.3).

Purification and inactivation

The virus harvest may be concentrated and/or purified by suitable methods; the virus harvest is inactivated by a validated method at a fixed, well defined stage of the process which may be before, during or after any concentration or purification. The method shall have been shown to be capable of inactivating Japanese encephalitis virus without destruction of the immunogenic activity. If formalin is used, the concentration shall at no time exceed 1:2000.

Only an inactivated viral suspension that complies with the following tests may be used in the preparation of the final bulk vaccine.

Inactivation. Inactivation is confirmed by carrying out an amplification test for residual infectious Japanese encephalitis virus. Inoculate a quantity of inactivated viral suspension equivalent to not less than 25 doses into cell cultures of the same type as those used for production of the vaccine. Make a passage after 7 days. Maintain the cultures for a further period of 14 days and then examine the cell cultures for Japanese encephalitis virus using an immunofluorescence test. No Japanese encephalitis virus is detected. Alternatively, 5 ml of each culture fluid is pooled on day 14 and 21 and 0.03 ml is inoculated intracerebrally into each of the 10 mice weighing between 12 and 15 g. The mice are observed for 14 days for symptoms caused by Japanese encephalitis virus, and mice showing symptoms of Japanese encephalitis virus are sacrificed and virus presence is confirmed by immunofluorescence test. No Japanese encephalitis virus shall be detected.

Residual host-cell DNA (2.2.15). The content of residual host-cell DNA, determined using a suitable method, should not be greater than 10 ng per single human dose if cells are used in the production.
FINAL BULK VACCINE

The final bulk vaccine is prepared from one or more inactivated viral suspensions. An approved stabilizer may be added to maintain the activity of the product. Thiomersal can be used as preservative.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Formaldehyde** (2.3.20). Not more than 0.01 per cent w/v.

**Antimicrobial preservative**. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

FINAL LOT

The final bulk vaccine is distributed aseptically into sterile containers. The containers are then sealed so as to prevent contamination.

Only a final lot that complies with each of the tests given under Identification, Tests and Assay may be released for use. Provided that the test for inactivation has been carried out with satisfactory results on the inactivated virus suspension and the test for bovine serum albumin has been carried out with satisfactory results on the final bulk vaccine, these tests may be omitted on the final lot.

Identification

The vaccine is shown to contain Japanese encephalitis virus antigen by a suitable immunochemical method using specific antibodies, alternatively, the Assay also serves to identify the vaccine.

Tests

Complies with the test for Inactivation under final Purification and Inactivation.

Sterility (2.2.11). Complies with the test for sterility.

**Bacterial endotoxins** (2.2.3). Less than 25 IU per single human dose.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity.

**Bovine serum albumin (for cell culture vaccine)**. Not more than 50 ng per single human dose, determined by a suitable immunochemical method (2.2.14).

**Residual host-cell DNA (for continuous cell line vaccines)** (2.2.15). Not more than 10 ng per single human dose.

**Free formaldehyde** (2.3.20). Not more than 0.01 per cent w/v.

**Antimicrobial preservative**. Determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than the minimum amount shown to be effective and is not greater than 115.0 per cent of that stated on the label.

Biological assay

Potency of Japanese encephalitis virus vaccine is determined by titrating the neutralizing antibodies produced in the immunized mice by plaque reduction method or serum neutralization test (SNT) using appropriate cell culture.

Standard preparation

The Standard preparation is a freeze-dried Japanese encephalitis virus vaccine the potency of which has been determined in relation to the Japanese encephalitis reference vaccine obtained from the National Institute of Health, Tokyo, Japan.

Suggested method

Preparation of challenge virus suspension

The approved challenge virus strain is stored in freeze-dried form or in liquid form stored below -70°. Prepare a working pool of the challenge virus strain by inoculating intracerebrally 0.03 ml of 100 fold dilution of the standard strain in Hanks’ balanced salt solution containing 5 per cent calf serum into a suitable number of 2-day old suckling mice. Sacrifice the animals after they show characteristic symptoms of encephalitis and become moribund. Harvest their brains aseptically, wash them in chilled sterile saline solution to remove blood clots. Homogenize the brains with Hanks’ balanced salt solution containing 5 per cent calf serum to make a 10 per cent emulsion. Centrifuge the emulsion at 2000 g for 30 minutes. Dilute the supernatant with Hanks’ balanced salt solution containing 5 per cent calf serum so as to contain about 200 Plaque-Forming Units (PFU) of the virus per 0.4 ml.

Determination of potency

Prepare appropriate dilutions of the vaccine under examination and of the Standard Preparation in a suitable medium. Inject intraperitoneally in two doses of 0.5 ml each at 7-day interval into at least 20 mice of 4 weeks of age. Bleed each mouse 7 days after the second injection, pool the separated serum from each group and inactivate the sera by heating at 56° for 30 minutes. The inactivated sera may be stored at -20°, if necessary.

Dilute the sera appropriately, e.g. 1:40, 1:160, 1:640 etc., mix with an equal volume of the challenge virus suspension and incubate at 37° for 90 minutes for neutralization. Inoculate the mixture into cell cultures and overlay the infected cells with 1 per cent agar. After incubation for an appropriate time (about
48 hours), stain the cells and count the number of plaques formed on the cultures to obtain the plaque reduction rates for the vaccine under examination and the Standard preparation. Calculate the neutralizing antibody titres for each group using standard statistical methods (5.7). The test is not valid unless (a) the mean number of plaques obtained with the Standard preparation is between 100 and 150 per dish and (b) the potency of the vaccine under examination is not less than that of the Standard preparation.

**Labelling.** The label states (1) the biological origin of the cells used for the preparation of the vaccine; (2) the strain of virus used.

### Measles and Rubella Vaccine (Live)

Measles and Rubella Vaccine (Live) is a freeze-dried preparation of suitable attenuated strains of measles virus and rubella virus grown in suitable cell cultures.

The vaccine is reconstituted immediately before use to give a clear liquid that may be coloured owing to the presence of a pH indicator.

### Production

**General provisions**

The two components are prepared as described in the monographs on Measles vaccine (live) and Rubella vaccine (live) and comply with the tests prescribed therein.

The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy.

**FINAL BULK VACCINE**

Virus harvests for each component are pooled and clarified to remove cells. A suitable stabilizer may be added and the pooled harvests diluted as appropriate. Suitable quantities of the pooled harvest for each component are mixed.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Sterility (2.2.11).** Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

For each component, a minimum virus concentration for release of the product is established such as to ensure, in the light of stability data, that the minimum concentration stated on the label will be present at the end of the period of validity.

Only a final lot that complies with the tests for minimum virus concentration of each component for release, with the following test for thermal stability and with each of the tests given below under Identification and Tests and Assay may be released for use. Provided that the test for bovine serum albumin has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

**Thermal stability.** Maintain samples of the final lot of freeze-dried vaccine in the dry state at 37° for 7 days. Determine the virus concentration as described under Assay in parallel for the vaccine held at 37° for 7 days and for vaccine stored at 2° to 8°. For each component, the virus concentration of the heated vaccine is not more than 1.0 log_{10} lower than that of the unheated vaccine.

### Identification

When the vaccine reconstituted as stated on the label is mixed with antibodies specific for measles virus and rubella virus, it is no longer able to infect cell cultures susceptible to these viruses. When the vaccine reconstituted as stated on the label is mixed with quantities of specific antibodies sufficient to neutralize any one viral components, the second viral component infects susceptible cell cultures.

### Tests

**Water (2.3.43).** Not more than 3.0 per cent, determined by Karl Fischer, semi-micro determination of water or by any suitable validated method.

**Sterility (2.2.11).** The reconstituted vaccine complies with the test for sterility.

**Abnormal toxicity (2.2.1).** Complies with the test for abnormal toxicity.

**Bovine serum albumin.** Not more than 50 ng per single human dose, determined by a suitable immunochemical method (2.2.14).

### Assay

**A.** Mix the vaccine with a sufficient quantity of antibodies specific for rubella virus. Titrate the vaccine for infective measles virus at least in triplicate, using at least eight cell cultures for each dilution 0.5 log_{10} step or by a method of equal precision. Use an appropriate virus reference preparation to validate each assay. The estimated measles virus concentration is not less than that stated on the label; the minimum measles virus concentration stated on the label is not less than 1x10^3 CCID_{50} per single human dose. The assay is not valid if the confidence limits (P = 0.95) of the logarithm of the virus concentration are greater than ± 0.3.

*Measles vaccine (Live) RS is suitable for use as a reference preparation.*

**B.** Titrate the vaccine for infective rubella virus at least in triplicate, using at least eight cell cultures for each 0.5 log_{10}
dilution step or by a method of equal precision. Use an appropriate virus reference preparation to validate each assay. The estimated rubella virus concentration is not less than that stated on the label; the minimum rubella virus concentration stated on the label are not less than \(1 \times 10^3\) CCID\(_{50}\) per single human dose. The assay is not valid if the confidence limits \((P = 0.95)\) of the logarithm of the virus concentration are greater than \(\pm 0.3\).

Rubella vaccine (Live) RS is suitable for use as a reference preparation.

Labelling. The label states (1) the strains of virus used in the preparation of the vaccine; (2) the type and origin of the cells used for the preparation of the vaccine; (3) the minimum virus concentration for each component of the vaccine; (4) the time within which the vaccine must be used after reconstitution; (5) that the vaccine must not be given to a pregnant woman and that a woman should not become pregnant within two months after having the vaccine.

Measles Vaccine (Live)

Measles Vaccine (Live) is a freeze-dried preparation of a suitable attenuated strain of measles virus. The vaccine is reconstituted immediately before use, as stated on the label, to give a clear liquid that may be coloured owing to the presence of a pH indicator.

Production

General provisions

The production of vaccine is based on a virus seed-lot system and, if the virus is propagated in human diploid cells, a cell-bank system. Unless otherwise justified and authorized, the virus in the final vaccine shall have undergone no more passages from the master seed lot than were used to prepare the vaccine shown in clinical studies to be satisfactory with respect to abnormal toxicity and efficacy; even with authorized exceptions, the number of passages beyond the level used for clinical studies shall not exceed five.

The production method is validated to demonstrate that the product, if tested, would comply with the tests for abnormal toxicity and efficacy.

Substrate for virus propagation

The virus is propagated in human diploid cells or in cultures of chick embryo cells derived from a chicken flock free from specified pathogens.

SEED LOT

The strain of measles virus used in the production of measles vaccine shall be identified by historical records that include information on the origin of the strain and its subsequent manipulation. Virus seed lots are prepared in large quantities and stored at temperatures below -20° if freeze-dried, or below -60° if not freeze-dried.

Only a seed lot that complies with the following tests may be used for virus propagation.

Identification

The master and working seed lots are identified as measles virus by serum neutralization in cell culture, using specific antibodies.

Virus concentration. The virus concentration of the master and working seed lots is determined to monitor consistency of production.

Extraneous agents (2.7.3). The working seed lot complies with the tests for seed lots.

Neurovirulence (2.7.5). The master/working seed lot complies with the test for neurovirulence of live virus vaccines. Macaca and Cercopithecus monkeys susceptible to measles virus are suitable for the test.

PROPAGATION AND HARVEST

All processing of the cell bank and subsequent cell cultures is done under aseptic conditions in an area where no other cells are handled. Suitable animal (but not human) serum may be used in the growth medium, but the final medium for maintaining cell growth during virus multiplication does not contain animal serum. Serum and trypsin used in the preparation of cell suspensions and culture media are shown to be free from extraneous agents. The cell culture medium may contain a pH indicator such as phenol red and suitable antibiotics at the lowest effective concentration. It is preferable to have a substrate free from antibiotics during production. Not less than 500 ml of the production cell culture is set aside as uninfected cell cultures (control cells). The viral suspensions are harvested at a time appropriate to the strain of virus being used.

Only a single harvest that complies with the following tests may be used in the preparation of the final bulk vaccine.

Identification

The single harvest contains virus that is identified as measles virus by serum neutralisation in cell culture, using specific antibody.

Virus concentration. The virus concentration in the single harvest is determined as prescribed under Assay to monitor consistency of production and to determine the dilution to be used for the final bulk vaccine.

Extraneous agents (2.7.3). Complies with the test for extraneous agents.
Control cells. If human diploid cells are used for production, the control cells comply with the test for identification and extraneous agents.

FINAL BULK VACCINE

Virus harvests that comply with the above tests are pooled and clarified to remove cells. A suitable stabilizer may be added and the pooled harvests diluted as appropriate.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Sterility (2.2.11). The final bulk vaccine complies with the test for sterility carried out using 10 ml for each medium.

FINAL LOT

A minimum virus concentration for release of the product is established so as to ensure, in the light of stability data, that the minimum concentration stated on the label will be present at the end of the period of validity.

Only a final lot that complies with the tests for minimum virus concentration for release, with the following requirement for thermal stability and with each of the requirements given below under Identification, Tests and Assay may be released for use. Provided that the test for bovine serum albumin has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

Thermal stability. Maintain samples of the final lot of freeze-dried vaccine in the dry state at 37° for 7 days. Determine the virus concentration as described under Assay in parallel for the vaccine held at 37° for 7 days and for vaccine stored at 2° to 8°. The virus concentration of the heated vaccine is not more than 1.0 log₁₀ lower than that of the unheated vaccine.

Identification

When the vaccine reconstituted as stated on the label is mixed with specific measles antibodies, it is no longer able to infect susceptible cell cultures.

Tests

Water (2.3.43). Not more than 3.0 per cent, determined by Karl Fischer, semi-micro determination of water or by any suitable validated method.

Sterility (2.2.11). The reconstituted vaccine complies with the test for sterility.

Abnormal toxicity (2.2.1). Complies with the test for abnormal toxicity.

Bovine serum albumin. Not more than 50 ng per single human dose, determined by a suitable immunochemical method (2.2.14).

Assay

Titrate the vaccine for infective virus at least in triplicate, using at least five cell cultures for each 0.5 log₁₀ dilution step or by a method of equal precision. Use an appropriate virus reference preparation to validate each assay. The estimated virus concentration is not less than that stated on the label; the minimum virus concentration stated on the label is not less than 1 × 10³ CCID₅₀ per human dose. The assay is not valid if the confidence limits (P = 0.95) of the logarithm of the virus concentration is greater than ± 0.3.

Measles vaccine (Live) RS is suitable for use as a reference preparation.

Labelling. The label states (1) the strain of virus used for the preparation of the vaccine; (2) the type and origin of the cells used for the preparation of the vaccine; (3) the minimum virus concentration; (4) the time within which the vaccine must be used after reconstitution.

Measles, Mumps and Rubella Vaccine (Live)

Measles, Mumps and Rubella Vaccine (Live) is a freeze-dried preparation of suitable attenuated strains of measles virus, mumps virus and rubella virus grown in suitable cell cultures.

The vaccine is reconstituted immediately before use to give a clear liquid that may be coloured owing to the presence of a pH indicator.

Production

General provisions

The three components are prepared as described in the monographs on Measles Vaccine (Live), Mumps Vaccine (Live) and Rubella Vaccine (Live) and comply with the tests prescribed therein.

The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy.

FINAL BULK VACCINE

Virus harvests for each component are pooled and clarified to remove cells. A suitable stabilizer may be added and the pooled harvests diluted as appropriate. Suitable quantities of the pooled harvest for each component are mixed.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Sterility (2.2.11). Carry out the test for sterility using 10 ml for each medium.
FINAL LOT

For each component, a minimum virus concentration for release of the product is established such as to ensure, in the light of stability data, that the minimum concentration stated on the label will be present at the end of the period of validity.

Only a final lot that complies with the tests for minimum virus concentration of each component for release, with the following requirement for thermal stability and with each of the requirements given below under Identification and Tests may be released for use. Provided that the test for bovine serum albumin has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

Thermal stability. Maintain samples of the final lot of freeze-dried vaccine in the dry state at 37°C for 7 days. Determine the virus concentration as described under Assay in parallel for the vaccine held at 37°C for 7 days and for vaccine stored at 2 to 8°C. The virus concentration of the heated vaccine is not more than 1.0 log10 lower than that of the unheated vaccine.

Identification

When the vaccine reconstituted as stated on the label is mixed with antibodies specific for measles virus, mumps virus and rubella virus, it is no longer able to infect cell cultures susceptible to these viruses. When the vaccine reconstituted as stated on the label is mixed with quantities of specific antibodies sufficient to neutralize any two viral components, the third viral component infects susceptible cell cultures.

Tests

Water (2.3.43). Not more than 3.0 per cent, determined by Karl Fischer, semi-micro determination of water or by any suitable validated method.

Sterility (2.2.11). The reconstituted vaccine complies with the test for sterility.

Abnormal toxicity (2.2.1). Complies with the test for abnormal toxicity.

Bovine serum albumin. Not more than 50 ng per single human dose, determined by a suitable immunochemical method (2.2.14).

Assay

A. Mix the vaccine with a sufficient quantity of antibodies specific for mumps virus and rubella virus. Titrate the vaccine for infective measles virus at least in triplicate, using at least eight cell cultures for each dilution 0.5 log10 step or by a method of equal precision. Use an appropriate virus reference preparation to validate each assay. The estimated measles virus concentration is not less than that stated on the label; the minimum measles virus concentration stated on the label is not less than 1x10^3 CCID₅₀ per single human dose. The assay is not valid if the confidence limits (P = 0.95) of the logarithm of the virus concentration are greater than ± 0.3.

Measles vaccine (Live) RS is suitable for use as a reference preparation.

B. Mix the vaccine with a sufficient quantity of antibodies specific for measles virus and rubella virus. Titrate the vaccine for infective mumps virus at least in triplicate, using at least eight cell cultures for each dilution 0.5 log₁₀ step or by a method of equal precision. Use an appropriate virus reference preparation to validate each assay. The estimated mumps virus concentration is not less than that stated on the label; the minimum mumps virus concentration stated on the label is not less than 5 x 10^3 CCID₅₀ per single human dose. The assay is not valid if the confidence limits (P = 0.95) of the logarithm of the virus concentration are greater than ± 0.3.

Mumps vaccine (Live) RS is suitable for use as a reference preparation.

C. Mix the vaccine with a sufficient quantity of antibodies specific for mumps virus. Titrate the vaccine for infective rubella virus at least in triplicate, using at least eight cell cultures for each dilution 0.5 log₁₀ step or by a method of equal precision. Use an appropriate virus reference preparation to validate each assay. The estimated rubella virus concentration is not less than that stated on the label; the minimum rubella virus concentration stated on the label is not less than 1x10^3 CCID₅₀ per single human dose. The assay is not valid if the confidence limits (P = 0.95) of the logarithm of the virus concentration are greater than ± 0.3.

Rubella vaccine (Live) RS is suitable for use as a reference preparation.

Labelling. The label states (1) the strains of virus used in the preparation of the vaccine; (2) the type and origin of the cells used for the preparation of the vaccine; (3) the minimum virus concentration for each component of the vaccine; (4) the time within which the vaccine must be used after reconstitution; (5) that the vaccine must not be given to a pregnant woman and that a woman should not become pregnant within two months after having the vaccine.

Meningococcal Polysaccharide Vaccine

Meningococcal Polysaccharide Vaccine is a freeze-dried preparation of one or more purified capsular polysaccharides obtained from one or more suitable strains of Neisseria meningitidis group A, group C, group Y and group W135 that are capable of consistently producing polysaccharides known to be safe and effective in man.
**N. meningitidis** group A polysaccharide consists of partly O-acetylated repeating units of N-acetylmannosamine, linked with \( 1\alpha\rightarrow6 \) phosphodiester bonds.

**N. meningitidis** group C polysaccharide consists of partly O-acetylated repeating units of sialic acid, linked with \( 2\alpha\rightarrow9 \) glycosidic bonds.

**N. meningitidis** group Y polysaccharide consists of partly O-acetylated alternating units of sialic acid and D-glucose, linked with \( 2\alpha\rightarrow6 \) and \( 1\alpha\rightarrow4 \) glycosidic bonds.

**N. meningitidis** group W135 polysaccharide consists of partly O-acetylated alternating units of sialic acid and D-galactose, linked with \( 2\alpha\rightarrow6 \) and \( 1\alpha\rightarrow4 \) glycosidic bonds.

**Production**

**General provisions**

Production of the meningococcal polysaccharides is based on a well defined seed-lot system. The method of production shall have been shown to yield consistently meningococcal polysaccharide vaccines of satisfactory immunogenicity and safety for man.

The production method is validated to demonstrate that the product, if tested, would comply with the test of abnormal toxicity for antisera and vaccines.

**SEED LOT**

The strains of **N. meningitidis** used for the master seed lots shall be identified by historical records that include information on their origin and by their biochemical, serological, physicochemical or molecular characteristics. Cultures from the working seed lot shall have the same characteristics as the strain that was used to prepare the master seed lot. The strains have the following characteristics:

a) Colonies obtained from a culture are round, uniform in shape and smooth with a mucous, opalescent, greyish appearance.

b) Gram staining reveals characteristic Gram-negative diplococci in ‘coffee-bean’ arrangement.

c) The oxidase test is positive.

d) The culture utilizes glucose and maltose.

e) Suspensions of the culture agglutinate with specific antisera of known titre.

**PROPAGATION AND HARVEST**

The working seed lots are cultured on solid media that do not contain blood-group substances or ingredients of mammalian origin. The inoculum may undergo one or more subcultures in liquid medium before being used for inoculating the final medium. The liquid media used and the final medium are semisynthetic and free from substances precipitated by cetrimonium bromide (hexadecyltrimethylammonium bromide) and do not contain blood-group substances or high-molecular-mass polysaccharides. The bacterial purity of the culture is verified by microscopic examination of Gram-stained smears and by inoculation into appropriate media. The cultures are centrifuged and the polysaccharides precipitated from the supernatant by addition of cetrimonium bromide. The precipitate obtained is harvested and may be stored at or below -20° awaiting further purification.

**PURIFIED POLYSACCHARIDES**

The polysaccharides are purified, after dissociation of the complex of polysaccharide and cetrimonium bromide, using suitable procedures to remove successively nucleic acids, proteins and lipopolysaccharides. The purification step consists of ethanol precipitation of the polysaccharides or purification with chloroform and n-butanol or by cold phenol treatment, which are then dried and stored at or below -20°.

The loss on drying is determined by thermogravimetry, Karl Fischer or any other suitable method and the value is used to calculate the results of the other chemical tests with reference to the dried substance.

Only purified polysaccharides that tested comply with the following requirements may be used in the preparation of the final bulk vaccine.

**Protein** (2.7.1). Not more than 10 mg of protein per gram of purified polysaccharide for group A and C organisms and less than 50 mg of protein per gram of polysaccharide for group Y and W135 calculated using bovine plasma albumin as a reference or other methods approved by National Regulatory Authority.

**Nucleic acids** (2.7.1). Not more than 10 mg of nucleic acids per gram of purified polysaccharide, calculated with reference to the dried substance.

**O-Acetyl groups** (2.7.1). Not less than 2 mmol of O-acetyl groups per gram of purified polysaccharide for group A, not less than 1.5 mmol per gram of polysaccharide for group C, not less than 0.3 mmol per gram of polysaccharide for groups Y and W135, all calculated with reference to the dried substance.

**Phosphorus** (2.7.1). Not less than 80 mg of phosphorus per gram of group A purified polysaccharide, calculated with reference to the dried substance.

**Sialic acid** (2.7.1). Not less than 800 mg of sialic acid per gram of group C polysaccharide and not less than 560 mg of sialic acid per gram of purified polysaccharide for groups Y and W135, all calculated with reference to the dried substance.

Use the following reference solutions:
**Group C polysaccharide.** A 150 mg/l solution of N-acetylneuraminic acid.

**Group Y polysaccharide.** A solution containing 95 mg/l of N-acetylneuraminic acid and 55 mg/l of glucose.

**Group W135 polysaccharide.** A solution containing 95 mg/l of N-acetylneuraminic acid and 55 mg/l of galactose.

**Calcium.** If a calcium salt is used during purification, determination of calcium is carried out on the purified polysaccharide by a suitable method; the content is within the limits approved for the product.

**Molecular size.** Examine by gel filtration or high performance size-exclusion chromatography (HPSEC) (2.4.16), using agarose for chromatography or cross-linked agarose for chromatography either alone or in combination with light scattering and refractive index detector (e.g. multiple angle LASER light scattering, MALLS) or any other suitable method. Use a column 0.9 m x 15 mm equilibrated with a solvent having an ionic strength of 0.2 mol/kg and a pH of 7.0 to 7.5. Apply to the column about 2.5 mg of polysaccharide in a volume of about 1.5 ml and elute at about 20 ml/h. Collect fractions of about 2.5 ml and determine the content of polysaccharide by a suitable method.

At least 65.0 per cent of group A polysaccharide, 75.0 per cent of group C polysaccharide, 80.0 per cent of group Y polysaccharide and 80.0 per cent of group W135 polysaccharide is eluted before a distribution coefficient (K₀) of 0.50 is reached. In addition, the percentages eluted before this distribution coefficient are within the limits approved for the particular product.

**Identification and serological specificity**

The identity and serological specificity are determined by a suitable immunochemical method (2.2.14). Identity and purity of each polysaccharide shall be confirmed; it shall be shown that there is not more than 1.0 per cent m/m of group-heterologous *N. meningitidis* polysaccharide.

**Pyrogens** (2.2.8). Complies with the test for pyrogens. Inject each of the rabbit with 1ml per kg body weight of solution containing

a) 0.025 µg of polysaccharide for a monovalent vaccine,
b) 0.050 µg of polysaccharide for a bivalent vaccine,
c) 0.075 µg of polysaccharide for a trivalent vaccine,
d) 0.100 µg of polysaccharide for a tetravalent vaccine.

**Water** (2.3.43). Not more than 3.0 per cent, of moisture content by thermogravimetry, Karl Fischer or any other suitable method.

**Final bulk vaccine.**

One or more purified polysaccharides of one or more *N. meningitidis* groups are dissolved in a suitable solvent that may contain a stabilizer. Only a final bulk vaccine that complies with the following requirement may be used in the preparation of the final lot.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**Final lot**

The final bulk vaccine is distributed aseptically into sterile containers. The containers are then closed so as to avoid contamination. Only a final lot that is satisfactory with respect to each of the requirements prescribed below under Identification, Tests and Assay may be released for use.

**Identification**

Carry out an identification test for each polysaccharide present in the vaccine by a suitable immunochemical method (2.2.14).

**Tests**

**Sterility** (2.2.11). Complies with the test for sterility.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity.

**Pyrogens** (2.2.8). Complies with the test for pyrogens. Inject each of the rabbit with 1ml per kg body weight of solution containing

a) 0.025 µg of polysaccharide for a monovalent vaccine,
b) 0.050 µg of polysaccharide for a bivalent vaccine,
c) 0.075 µg of polysaccharide for a trivalent vaccine,
d) 0.100 µg of polysaccharide for a tetravalent vaccine.

**Water** (2.3.43). Not more than 3.0 per cent, of moisture content by thermogravimetry, Karl Fischer or any other suitable method.

**Molecular size.** Examine by gel filtration or size-exclusion chromatography (2.4.16). Use a column about 0.9 m long and 16 mm in internal diameter equilibrated with a solvent having an ionic strength of 0.2 mol/kg and a pH of 7.0 to 7.5. Apply to the column about 2.5 mg of each polysaccharide in a volume of about 1.5 ml and elute at about 20 ml/h. Collect fractions of about 2.5 ml and determine the content of polysaccharide by a suitable method.

Use cross-linked agarose for chromatography and apply a suitable immunochemical method (2.2.14) to establish the elution pattern of the different polysaccharide(s). The vaccine complies with the test if:

a) 65.0 per cent of Group A polysaccharide is eluted before K₀ of 0.50,
b) 75.0 per cent of Group C polysaccharide is eluted before K₀ of 0.50,
c) 80.0 per cent of Group Y & W135 polysaccharide is eluted before K₀ of 0.50.
For a tetravalent vaccine (group A + group C + group Y and group W135), use cross linked agarose for chromatography and apply a suitable immunochemical method (2.2.14) to establish the elution pattern of the different polysaccharides. The vaccine complies with the test if $K_0$ for the principal peak is

a) not greater than 0.70 for group A and group C polysaccharide,
b) not greater than 0.57 for group Y polysaccharide,
c) not greater than 0.68 for group W135 polysaccharide.

Assay

Carry out an assay as stated under each polysaccharide present in the vaccine.

For a divalent vaccine (group A + group C), use measurement of phosphorus (2.7.1) to determine the content of polysaccharide A and measurement of sialic acid (2.7.1) to determine the content of polysaccharide C. To determine sialic acid, use as reference solution a 150 mg/l solution of N-acetylneuraminic acid.

For a tetravalent vaccine (group A + group C + group Y + group W135) a suitable immunochemical method (2.2.14) is used with a reference preparation of purified polysaccharide for each group.

The vaccine contains not less than 70.0 per cent and not more than 130.0 per cent of the quantity of each polysaccharide stated on the label.

Labelling. The label states (1) the group or groups of polysaccharides (A, C, Y or W135) present in the vaccine; (2) the number of µg of polysaccharide per human dose.

Mumps Vaccine (Live)

Mumps Vaccine (Live) is a freeze-dried preparation of a suitable attenuated strain of mumps virus. The vaccine is reconstituted immediately before use to give a clear liquid that may be coloured owing to the presence of a pH indicator.

Production

General provisions

The production of vaccine is based on a virus seed-lot system and, if the virus is propagated in human diploid cells, a cell-bank system. The production method shall have been shown to yield consistently live mumps vaccines of adequate immunogenicity and safety in man.

Unless otherwise justified and authorised, the virus in the final vaccine shall have undergone no more passages from the master seed lot than were used to prepare the vaccine shown in clinical studies to be satisfactory with respect to safety and efficacy even with authorized exceptions, the number of passages beyond the level used for clinical studies shall not exceed five.

The production method is validated to demonstrate that the product, if tested, would comply with the tests for safety and efficacy.

Substrate for virus propagation

The virus is propagated in human diploid cells or in primary cultures of chick embryo cells derived from a chicken flock free from specified pathogens.

SEED LOT

The strain of mumps virus used shall be identified by historical records that include information on the origin of the strain and its subsequent manipulation. To avoid unnecessary use of monkeys in the test for neurovirulence, Virus seed lots are prepared in large quantities and stored at temperatures below -20° if freeze-dried, or below -60° if not freeze-dried.

Only a seed lot that complies with the following tests may be used for virus propagation.

Identification

The master and working seed lots are identified as mumps virus by serum neutralisation in cell culture, using specific antibodies.

Virus concentration. The virus concentration of the master and working seed lots is determined to ensure consistency of production.

Extraneous agents (2.7.3). The working seed lot complies with the tests for seed lots.

Neurovirulence (2.7.5). The master/working seed lot complies with the test for neurovirulence of live virus vaccines. Macaca and Cercopithecus monkeys are suitable for the test.

PROPAGATION AND HARVEST

All processing of the cell bank and subsequent cell cultures is done under aseptic conditions in an area where no other cells are handled. Suitable animal (but not human) serum may be used in the growth media. Serum and trypsin used in the preparation of cell suspensions and culture media are shown to be free from extraneous agents. The cell culture medium may contain a pH indicator such as phenol red and suitable antibiotics at the lowest effective concentration. It is preferable to have a substrate free from antibiotics during production. Not less than 500 ml of the production cell culture is set aside as uninfected cell culture (control cells). The viral suspensions are harvested at a time appropriate to the strain of virus being used.
Only a single harvest that complies with the following requirements may be used in the preparation of the final bulk vaccine.

Identification

The single harvest contains virus that is identified as mumps virus by serum neutralization in cell culture, using specific antibodies.

Virus concentration. The virus concentration in the single harvest is determined as prescribed under Assay to monitor consistency of production and to determine the dilution to be used for the final bulk vaccine.

Sterility (2.2.11). Single harvest complies with sterility test should be processed further.

Control cells. The control cells comply with a test for extraneous agents (2.7.3).

FINAL BULK VACCINE

Single harvests that comply with the above tests are pooled and clarified to remove cells. A suitable stabiliser may be added and the pooled harvests diluted as appropriate.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Sterility (2.2.11). The final bulk vaccine complies with the test for sterility, carried out using 10 ml for each medium.

FINAL LOT

A minimum virus concentration for release of the product is established such as to ensure, in the light of stability data, that the minimum concentration stated on the label will be present at the end of the period of validity.

Only a final lot that complies with the tests for minimum virus concentration for release, with the following requirement for thermal stability and with each of the requirements given below under Identification and Tests and Assay may be released for use. Provided that the test for bovine serum albumin has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

Thermal stability. Maintain samples of the final lot of freeze-dried vaccine in the dry state at 37° for 7 days. Determine the virus concentration as described under Assay in parallel for the vaccine held at 37° for 7 days and for vaccine stored at 2° to 8°. The virus concentration of the vaccine exposed to 37° for 7 days is not more than 1.0 log₁₀ lower than that of the unheated vaccine.

Identification

When the vaccine is reconstituted as stated on the label is mixed with specific mumps antibodies, it is no longer able to infect susceptible cell cultures.

Tests

Water (2.3.43). Not more than 3.0 per cent, determined by Karl Fischer, semi-micro determination of water or by any suitable validated method.

Sterility (2.2.11). Complies with the test for sterility.

Abnormal toxicity (2.2.1). Complies with the test for abnormal toxicity.

Bovine serum albumin. Not more than 50 ng per single human dose, determined by a suitable immunochemical method (2.2.14).

Assay

Titrate the vaccine for infective virus at least in triplicate, using at least five cell cultures for each 0.5 log₁₀ dilution step or by a method of equal precision. Use an appropriate virus reference preparation to validate each assay. The estimated virus concentration is not less than that stated on the label; the minimum virus concentration stated on the label is not less than 5 x 10³ CCID₅₀ per human dose. The assay is not valid if the confidence limits (P = 0.95) of the logarithm of the virus concentration is greater than 0.3.

Mumps vaccine (Live) RS is suitable for use as a reference preparation.

Labelling. The label states (1) the strain of virus used for the preparation of the vaccine; (2) the type and origin of the cells used for the preparation of the vaccine; (3) the minimum virus concentration and; (4) the time within which the vaccine must be used after reconstitution.

Pertussis Vaccine

Pertussis Vaccine is a sterile saline suspension of inactivated whole cells of one or more strains of Bordetella pertussis.

Production

General provisions

Inactivated B. pertussis suspension

Production is based on a seed-lot system. One or more strains of B. pertussis with known origin and history are used. Strains, culture medium and cultivation method are chosen in such a way that agglutinogens 1, 2 and 3 are present in the final vaccine. Each strain is grown for 24 to 72 hours in a liquid medium or on a solid medium; the liquid medium used in the final cultivation stage does not contain blood or blood products. Human blood or blood products are not used in any culture media. The bacteria are harvested, washed to remove substances derived from the medium and suspended in a 0.9 per cent w/v solution of sodium chloride or other suitable
**PERTUSSIS VACCINE**

**isotonic solution.** The opacity of the suspension is determined not later than 2 weeks after harvest by comparison with the reference preparation of Opacity and used as the basis of calculation for subsequent stages in vaccine preparation. Single harvests are not used for the final bulk vaccine unless they have been shown to contain *B. pertussis* cells with the same characteristics with regard to growth and agglutinogens, as the parent strain and to be free from contaminating bacteria and fungi. The bacteria are killed and detoxified in controlled conditions by means of a suitable chemical agent or by heating or by a combination of these methods. Freedom from live *B. pertussis* is tested using a suitable culture medium. The suspension is maintained at $5 \pm 3^\circ$ for a suitable period to diminish its toxicity.

**FINAL BULK VACCINE**

Suitable quantities of the inactivated single harvests are pooled to prepare the final bulk vaccine. Suitable antimicrobial preservatives may be added. The bacterial concentration of the final bulk vaccine does not exceed that corresponding to an opacity of 20 IU per single human dose. If 2 or more strains of *B. pertussis* are used, the composition of consecutive lots of the final bulk vaccine shall be consistent with respect to the proportion of each strain as measured in opacity units.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The amount is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility (2.2.11).** Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

The final bulk vaccine is distributed aseptically into sterile, tamper-proof containers. The containers are closed so as to prevent contamination.

Only a final lot that is satisfactory with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided the tests for specific toxicity, free formaldehyde and antimicrobial preservative and the assay have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

**Identification**

Identify pertussis vaccine by agglutination of the bacteria in the vaccine by antisera specific to *B. pertussis*.

**Tests**

**Specific toxicity**

Use not less than 10 healthy mice each weighing between 14 to 16 g for the vaccine group and for the saline control. Use mice of the same sex or distribute males and females equally between the groups. Allow the animals access to food and water for at least 2 hours before injection and during the test. Inject each mouse of the vaccine group intraperitoneally with 0.5 ml, containing a quantity of the vaccine equivalent to not less than half the single human dose. Inject each mouse of the control group with 0.5 ml of a 0.9 per cent w/v sterile solution of sodium chloride, preferably containing the same amount of antimicrobial preservative as that injected with the vaccine. Weigh the groups of mice immediately before the injection, 72 hours and 7 days after the injection. The vaccine complies with the test if (a) at the end of 72 h the total mass of the group of vaccinated mice is not less than that preceding the injection; (b) at the end of 7 days the average increase in mass per vaccinated mouse is not less than 60.0 per cent of that per control mouse; and (c) not more than 5.0 per cent of the vaccinated mice die during the test. The test may be repeated and the results of the tests combined.

**Free formaldehyde (2.3.20).** Maximum 0.2 g/l.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not more than 115.0 per cent of the intended amount.

**Sterility (2.2.11).** Complies with the test for sterility.

**Assay**

Carry out the assay of Pertussis Vaccine as described below:

**Biological assay of pertussis vaccine**

The potency of Pertussis Vaccine is determined by comparison of the dose necessary to protect mice against the effects of a lethal dose of *Bordetella pertussis* challenge culture, administered intracerebrally, with the dose of a reference preparation, calibrated in International Units, required to give the same level of protection. For this comparison, the Standard preparation of Pertussis vaccine & a suitable strain of *B. pertussis* (e.g.18323, to be used as challenge strain), are required.

**Reference preparation**

The reference preparation is an International standard of Pertussis vaccine, consisting of a freeze dried vaccine or another suitable preparation, calibrated in comparison to International standard, from time to time. The International Unit is the activity contained in a stated amount of the International standard, which consists of a quantity of dried pertussis vaccine. The equivalence in International Units of the International Standard is stated by the World Health Organization.

Use healthy mice of a suitable strain, weighing between 13 and 16 g from the same stock. Distribute the mice randomly, in
six to eight groups of not less than 16 and not more than 24 and four groups of 10. The mice should all be of the same sex or the males and females should be distributed equally between the groups. Half of the groups of 16 to 24 should receive the reference preparation and the other half should receive the vaccine under examination. The four groups of 10 each should be used for the \( \text{LD}_{50} \) titration of challenge suspension.

Use at least three dilutions of the reference vaccine and similar dilutions of the vaccine under examination. In each case the dilutions are so selected that the dilution protecting 50 per cent of the mice (\( \text{ED}_{50} \)) is as near as possible to middle of the dilution range. For example, suggested dilutions are (1/8, 1/40 and 1/200 of the human dose of the vaccine under examination) and (0.5 IU, 0.1 IU and 0.02 IU or any other suitable standardized dilutions, of the reference preparation), each dose being contained in a volume, not exceeding 0.5 ml. For each dilution use 16 to 24 mice and inject intraperitoneally, into each mouse one dose of the dilution.

Select a suitable strain of \( B. \) pertussis (e.g. 18323), capable of causing the death of mice within 14 days of intracerebral injection. Make two subcultures after reviving the strain on a suitable medium (e.g. B.G. medium) and suspend the harvested growth in a solution containing 1 per cent w/v of casein hydrolysate (e.g. casamino acid) and 0.85 per cent w/v of sodium chloride and having a pH of 7.0 to 7.2 or in another suitable solution. Determine the opacity of the suspension by using 5th International reference preparation for opacity (10 OU) and/or spectrophotometrically. Alternatively, aliquots of challenge suspension frozen in liquid nitrogen with a suitable preservative like 10 per cent DMSO may be used, to avoid heterogeneity. After 14 to 17 days of immunization, inject intracerebrally, a dose of 0.02 to 0.03 ml of the challenge dilution randomly, into each immunized mouse. The challenge should contain, approximately 1,00,000 organisms and 100 to 1000 \( \text{LD}_{50} \) per dose, in a volume of not more than 0.03 ml. In the same way, inject 4 groups of 10 control mice each, for \( \text{LD}_{50} \) titration of challenge preparation, prepared by a series of dilutions, from the dilution selected for challenge. The challenge should be completed within 2 to 2.5 hours of preparation. Exclude any mouse from consideration, that dies within 3 days of challenge. Count the number of mice surviving in each of the groups, after 14 days. On the basis of the numbers of animals surviving in each of the groups of 16 to 24 mice, calculate the potency of vaccine under examination, against the potency of reference preparation. Seed a suitable highest dilution of the challenge suspension, into each of two B.G medium plates, before and after challenge. Incubate the plates at 37°C for 48 to 72 hours and calculate the number of colony forming units (CFUs).

Calculate the potency of the vaccine by Probit analysis and \( \text{LD}_{50} \) of the challenge suspension by Reed and Munch Method.
and the culture is inactivated with phenol. Impurities are removed by such techniques as fractional precipitation, enzymatic digestion and ultrafiltration. The polysaccharide is obtained by fractional precipitation, washed, and dried in a vacuum to a residual moisture content shown to be favourable to the stability of the polysaccharide. The residual moisture content is determined by drying under reduced pressure over diphosphorus pentoxide or by thermogravimetric analysis and the value obtained is used to calculate the results of the tests shown below with reference to the dried substance. The monovalent bulk polysaccharide is stored at a suitable temperature in conditions that avoid the uptake of moisture. Only a monovalent bulk polysaccharide that complies with the following requirements may be used in the preparation of the final bulk vaccine. Percentage contents of components, determined by the methods prescribed below, are shown in the Table 1.

The purified polysaccharides comply with the following tests as applicable:

**Protein (2.7.1).** Comply with the test for protein.

**Nucleic acids (2.7.1).** Comply with the test for nucleic acids.

**Total nitrogen (2.3.30).** Comply with the test for total nitrogen.

**Phosphorus (2.7.1).** Comply with the test for phosphorus.

**Uronic acids (2.7.1).** Comply with the test for uronic acids.

**Hexosamine (2.7.1).** Comply with the test for hexosamine.

**Methylpentoses (2.7.1).** Comply with the test for methylpentoses.

### Table 1- Specifications on monovalent bulk polysaccharides (per cent contents):

<table>
<thead>
<tr>
<th>Molecular Type*</th>
<th>Proteins ≤ 2</th>
<th>Nucleic acids ≤ 2</th>
<th>Total Molecular size K&lt;sub&gt;e&lt;/sub&gt; CL-4B**</th>
<th>Phosphorus ≤ 0.15</th>
<th>CL-2B*** ≤ 0.60</th>
<th>Uronic acids CL-2B ≥ 12</th>
<th>Hexosamines ≥ 20</th>
<th>Methylpentoses ≥ 13</th>
<th>O-acetyl Groups ≥ 9</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>≤ 2</td>
<td>≤ 2</td>
<td>3.5-6</td>
<td>0-1.5</td>
<td>≤ 0.15</td>
<td>≥ 45</td>
<td>≥ 1.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>≤ 2</td>
<td>≤ 2</td>
<td>0-1</td>
<td>0-1.0</td>
<td>≤ 0.15</td>
<td>≥ 15</td>
<td>≥ 38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>≤ 5</td>
<td>≤ 2</td>
<td>0-1</td>
<td>0-1.0</td>
<td>≤ 0.15</td>
<td>≥ 40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>≤ 3</td>
<td>≤ 2</td>
<td>4-6</td>
<td>0-1.5</td>
<td>≤ 0.15</td>
<td>≥ 40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>≤ 7.5</td>
<td>≤ 2</td>
<td>2.5-6.0</td>
<td>≤ 0.60</td>
<td>≥ 12</td>
<td>≥ 20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6B</td>
<td>≤ 2</td>
<td>≤ 2</td>
<td>0-2</td>
<td>2.5-5.0</td>
<td>≤ 0.50</td>
<td>≥ 15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7F</td>
<td>≤ 5</td>
<td>≤ 2</td>
<td>1.5-4.0</td>
<td>0-1.0</td>
<td>≤ 0.20</td>
<td>≥ 13</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>≤ 2</td>
<td>≤ 2</td>
<td>0-1</td>
<td>0-1.0</td>
<td>≤ 0.15</td>
<td>≥ 25</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9N</td>
<td>≤ 2</td>
<td>≤ 1</td>
<td>2.2-4</td>
<td>0-1.0</td>
<td>≤ 0.20</td>
<td>³ 20</td>
<td>≥ 28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9W</td>
<td>≤ 2</td>
<td>≤ 2</td>
<td>0.5-3</td>
<td>0-1.0</td>
<td>≤ 0.45</td>
<td>³ 15</td>
<td>≥ 13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10A</td>
<td>≤ 7</td>
<td>≤ 2</td>
<td>0.5-3.5</td>
<td>1.5-3.5</td>
<td>≤ 0.65</td>
<td>≥ 12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11A</td>
<td>≤ 3</td>
<td>≤ 2</td>
<td>0-2.5</td>
<td>2.0-5.0</td>
<td>≤ 0.40</td>
<td>≥ 9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12F</td>
<td>≤ 3</td>
<td>≤ 2</td>
<td>3-5</td>
<td>0-1.0</td>
<td>≤ 0.25</td>
<td>≥ 25</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>≤ 5</td>
<td>≤ 2</td>
<td>1.5-4</td>
<td>0-1.0</td>
<td>≤ 0.30</td>
<td>≥ 20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15B</td>
<td>≤ 3</td>
<td>≤ 2</td>
<td>1-3</td>
<td>2.0-4.5</td>
<td>≤ 0.55</td>
<td>≥ 15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17A or 17F</td>
<td>≤ 2</td>
<td>≤ 2</td>
<td>0-1.5</td>
<td>0-3.5</td>
<td>≤ 0.45</td>
<td>≥ 20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18C</td>
<td>≤ 3</td>
<td>≤ 2</td>
<td>0-1</td>
<td>2-4.4-9</td>
<td>≤ 0.15</td>
<td>≥ 14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19A</td>
<td>≤ 2</td>
<td>≤ 2</td>
<td>0.6-3.5</td>
<td>3.0-7.0</td>
<td>≤ 0.45</td>
<td>≥ 12</td>
<td>≥ 20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19F</td>
<td>≤ 3</td>
<td>≤ 2</td>
<td>1.4-3.5</td>
<td>3.0-5.5</td>
<td>≤ 0.20</td>
<td>≥ 12.5</td>
<td>≥ 20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>≤ 2</td>
<td>≤ 2</td>
<td>0.5-2.5</td>
<td>1.5-4.0</td>
<td>≤ 0.60</td>
<td>≥ 12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22F</td>
<td>≤ 2</td>
<td>≤ 2</td>
<td>0-2</td>
<td>0-1.0</td>
<td>≤ 0.55</td>
<td>≥ 15</td>
<td>≥ 25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23F</td>
<td>≤ 2</td>
<td>≤ 2</td>
<td>0-1</td>
<td>3.0-4.5</td>
<td>≤ 0.15</td>
<td>≥ 37</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>33F</td>
<td>≤ 2.5</td>
<td>≤ 2</td>
<td>0-2</td>
<td>0-1.0</td>
<td>≤ 0.50</td>
<td>≥ 15</td>
<td>≥ 20</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The different types are indicated using the Danish nomenclature

** Cross linked agarose for chromatography R

*** Cross linked agarose for chromatography R1
O-Acetyl groups (2.7.1). Comply with the test for O-acetyl groups.

Sterility (2.2.11). Comply with the test for sterility.

Molecular size. Molecular size is determined by gel filtration or high performance size-exclusion chromatography (HPSEC) (2.4.16) using cross linked Agarose for chromatography R or chromatography Agarose for chromatograph R1, either alone or Multiple angle light laser scattering (MALLS) or any other suitable method.

Identification

Confirm the identity of the monovalent bulk polysaccharide by immunochemical method (2.2.14)(except for polysaccharides 7F, 14 and 33F).

Specificity

For establishing the specificity, no reaction should occur, when the antigens are tested against all the antisera specific for the other polysaccharides of the vaccine, including factor sera for distinguishing types within groups. The polysaccharides are tested at a concentration of 50 µg/ml using a method capable of detecting 0.5 µg/ml.

FINAL BULK VACCINE

The final bulk vaccine is obtained by aseptically mixing the different polysaccharide powders. The uniform mixture is aseptically dissolved in a suitable isotonic solution so that one human dose of 0.5 ml contains 25 µg of each polysaccharide. An antimicrobial preservative may be added. The solution is sterilized by filtration through a bacteria-retentive filter.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

FINAL LOT

The final bulk vaccine is distributed and filled aseptically into sterile containers (vials or ampoules). Only a final lot that is satisfactory with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided that the tests for phenol and for antimicrobial preservative have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot. When consistency of production has been established on a suitable number of consecutive batches, the assay may be replaced by a qualitative test that identifies each polysaccharide, provided that an assay has been performed on each monovalent bulk polysaccharide used in the preparation of the final lot.

Identification

The assay also serves to identify the vaccine.

Tests

Sterility (2.2.11). Complies with the test for sterility.

Abnormal Toxicity (2.2.1). Complies with the test for abnormal toxicity with the following modifications.

Inject 10 human doses each in two guinea pigs weighing between 250 and 350 g by intraperitoneal route and observe for 12 days,

Pyrogens (2.2.8). Complies with the test for pyrogens. Inject each of the rabbit with 1 ml of a dilution of the vaccine containing 2.5 µg/ml of each polysaccharide.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Phenol (2.3.36). Not more than 2.5 g/l.

pH (2.4.24). 4.5 to 7.4.

Assay

Determine the content of each polysaccharide by a suitable biochemical, physicochemical or immunochemical method (2.2.14), using antisera specific for each polysaccharide contained in the vaccine, including factor sera for types within groups, and purified polysaccharides of each type as standards.

The vaccine contains not less than 70.0 per cent and not more than 130.0 per cent of the quantity stated on the label for each polysaccharide. The confidence interval (P = 0.95) of the assay is not less than 80.0 and not more than 120.0 per cent of the estimated content.

Labelling. The label states (1) the number of µg of each polysaccharide per human dose; (2) the total amount of polysaccharide in the container.

Poliomyelitis Vaccine (Inactivated)

Poliomyelitis Vaccine (Inactivated) is a liquid preparation of suitable strains of human polioviruses 1, 2 and 3 grown in suitable cell cultures and inactivated by a validated method.

Production

General provisions

The production method should consistently yield vaccines of acceptable safety and immunogenicity in man.
Production of the vaccine is based on a virus seed-lot system. Cell lines are used according to a cell-bank system. If primary, secondary or tertiary monkey kidney cells are used, production complies with the requirements indicated below.

Unless otherwise justified and authorised, the virus in the final vaccine shall not have undergone more passages from the master seed lot than was used to prepare the vaccine shown in clinical studies to be satisfactory with respect to safety and efficacy.

The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy.

**Substrate for virus propagation**

The virus is propagated in a human diploid cell line (2.7.2), in a continuous cell line (2.7.2) or in primary, secondary or tertiary monkey kidney cells.

**Primary, secondary or tertiary monkey kidney cells.** The following special requirements for the substrate for virus propagation apply to primary, secondary or tertiary monkey kidney cells.

Monkeys used in the preparation of kidney cell cultures for production and control of the vaccine. The animals used are of a species approved by the competent authority, in good health and, unless otherwise justified and authorised, have not been previously employed for experimental purposes. Kidney cells used for vaccine production and control are derived from monitored, closed colonies of monkeys bred in captivity, not from animals caught in the wild; a previously approved seed lot prepared using virus passaged in cells from wild monkeys may, subject to approval by the competent authority, be used for vaccine production if historical data on safety justify this.

Monitored, closed colonies of monkeys. The monkeys are kept in groups in cages. Freedom from extraneous agents is achieved by the use of animals maintained in closed colonies that are subject to continuous and systematic veterinary and laboratory monitoring for the presence of infectious agents. The supplier of animals is certified by the competent authority. Each monkey is tested serologically at regular intervals during a quarantine period of not less than 6 weeks imposed before entering the colony and then during its stay in the colony.

The monkeys used are shown to be tuberculin-negative and free from antibodies to simian virus 40 (SV40) and simian immunodeficiency virus. If Macaca spp. monkeys are used for production, the monkeys are also shown to be free from antibodies to herpesvirus B (Cercopithecine herpesvirus 1) infection. Human herpesvirus 1 has been used as an indicator for freedom from herpesvirus B antibodies on account of the danger of handling herpesvirus B (Cercopithecine herpesvirus 1).

Monkeys from which kidneys are to be removed are thoroughly examined, particularly for evidence of tuberculosis and herpesvirus B (Cercopithecine herpesvirus 1) infection. If a monkey shows any pathological lesion relevant to the use of its kidneys in the preparation of a seed lot or vaccine, it is not to be used nor are any of the remaining monkeys of the group concerned unless it is evident that their use will not impair the safety of the product.

All the operations described in this section are conducted outside the area where the vaccine is produced.

**Monkey cell cultures for vaccine production.** Kidneys that show no pathological signs are used for preparing cell cultures. Each group of cell cultures derived from a single monkey forms a separate production cell culture giving rise to a separate single harvest.

The primary monkey kidney cell suspension complies with the test for mycobacteria; disrupt the cells before carrying out the test.

If secondary or tertiary cells are used, it shall be demonstrated by suitable validation tests that cell cultures beyond the passage level used for production are free from tumorigenicity.

**SEED LOT**

Each of the three strains of poliovirus used shall be identified by historical records that include information on the origin of the strain and its subsequent manipulation.

Only a working seed lot that complies with the following requirements may be used for virus propagation.

**Identification**

Each working seed lot is identified as human poliovirus 1, 2 or 3 by virus neutralisation in cell culture using specific antibodies.

**Virus concentration.** The virus concentration of each working seed lot is determined to define the quantity of virus to be used for inoculation of production cell cultures.

**Extraneous agents (2.7.3).** The working seed lot complies with the requirements for seed lots for virus vaccines. In addition, if primary, secondary or tertiary monkey kidney cells have been used for isolation of the strain, measures are taken to ensure that the strain is not contaminated with simian viruses such as simian immunodeficiency virus, simian virus 40, filoviruses and herpesvirus B (Cercopithecine herpesvirus 1). A working seed lot produced in primary, secondary or tertiary monkey kidney cells complies with the requirements given below under Virus Propagation and Harvest for single harvests produced in such cells.
PROPAGATION AND HARVEST

All processing of the cell bank and subsequent cell cultures is done under aseptic conditions in an area where no other cells or viruses are being handled. Approved animal serum (but not human serum) may be used in the cell culture media. Serum and trypsin used in the preparation of cell suspensions and media are shown to be free from extraneous agents. The cell culture media may contain a pH indicator such as phenol red and approved antibiotics at the lowest effective concentration. Not less than 500 ml of the cell cultures employed for vaccine production is set aside as uninfected cell cultures (control cells); where continuous cell lines in a fermenter are used for production, 200 x 10⁶ cells are set aside to prepare control cells; where primary, secondary or tertiary monkey kidney cells are used for production, a cell sample equivalent to at least 500 ml of the cell suspension, at the concentration employed for vaccine production, is taken to prepare control cell cultures.

Only a single harvest that complies with the following requirements may be used in the preparation of the vaccine. The tests for Identification and Sterility may be carried out instead on the purified, pooled monovalent harvest. After demonstration of consistency of production at the stage of the single harvest, the test for virus concentration may be carried out instead on the purified, pooled monovalent harvest.

**Control cells.** The control cells of the production cell culture comply with a test for Identification (if a cell-bank system is used for production) and with the requirements for extraneous agents, where primary, secondary or tertiary monkey kidney cells are used, the tests in cell cultures are carried out as shown below under Test in Rabbit Kidney Cell Cultures and Test in Cercopithecus Kidney Cell Cultures).

**Test in rabbit kidney cell cultures.** Test a sample of at least 10 ml of the pooled supernatant fluid from the control cultures for the absence of herpesvirus B (Cercopithecine herpesvirus 1) and other viruses in rabbit kidney cell cultures. The dilution of supernatant in the nutrient medium is at least 1:4 and the area of the cell layer is at least 3 cm² per ml of inoculum. Set aside one or more containers of each batch of cells with the same medium as non-inoculated control cells. Incubate the cultures at 37° and observe for at least 2 weeks. The test is not valid if more than 20 per cent of the control cells are discarded for non-specific, accidental reasons.

**Test in Cercopithecus kidney cell cultures.** Test a sample of at least 10 ml of the pooled supernatant fluid from the control cultures for the absence of SV40 virus and other extraneous agents by inoculation onto cell cultures prepared from the kidneys of cercopithecus monkeys, or other cells shown to be at least as sensitive for SV40, by the method described under Test in Rabbit Kidney Cell Cultures. The test is not valid if more than 20 per cent of the control cell cultures are discarded for non-specific, accidental reasons.

**Identification**

The single harvest is identified as containing human poliovirus 1, 2 or 3 by virus neutralisation in cell cultures using specific antibodies.

**Virus concentration.** The virus concentration of each single harvest is determined by titration of infectious virus in cell cultures.

**Sterility (2.2.11).** The single harvest complies with the test for sterility, carried out using 10 ml for each medium.

**Mycoplasmas (2.7.4).** The single harvest complies with the test for mycoplasmas, carried out using 10 ml.

**Test in rabbit kidney cell cultures.** Where primary, secondary or tertiary monkey kidney cells are used for production, test a sample of at least 10 ml of the single harvest for the absence of herpesvirus B (Cercopithecine herpesvirus 1) and other viruses in rabbit kidney cell cultures as described for the control cells.

**Test in Cercopithecus kidney cell cultures.** Where primary, secondary or tertiary monkey kidney cells are used for production, test a sample of at least 10 ml of the single harvest for the absence of SV40 virus and other extraneous agents. Neutralise the sample by a high-titre antiserum against the specific type of poliovirus. Test the sample in primary cercopithecus kidney cell cultures or cells that have been demonstrated to be at least as susceptible for SV40. Incubate the cultures at 37° and observe for 14 days. At the end of this period, make at least one subculture of fluid in the same cell culture system and observe both primary cultures and subcultures for an additional 14 days.

**PURIFICATION AND PURIFIED MONOVALENT HARVEST**

Several single harvests of the same type may be pooled and may be concentrated. The monovalent harvest or pooled monovalent harvest is purified by validated methods. If continuous cell lines are used for production, the purification process shall have been shown to reduce consistently the content of substrate-cell DNA to not more than 500 pg per single human dose.

Only a purified monovalent harvest that complies with the following requirements may be used for the preparation of the inactivated monovalent harvest.

**Identification**

The virus is identified by virus neutralisation in cell cultures using specific antibodies or by determination of D-antigen.

**Virus concentration.** The virus concentration is determined by titration of infectious virus.
Specific activity. The ratio of the virus concentration or the D-antigen content, determined by a suitable immunochemical method (2.2.14), to the total protein content (specific activity) of the purified monovalent harvest is within the limits approved for the particular preparation.

INACTIVATION AND INACTIVATED MONOVALENT HARVEST

Several purified monovalent harvests of the same type may be mixed before inactivation. To avoid failures in inactivation caused by the presence of virus aggregates, filtration is carried out before and during inactivation; inactivation is started within a suitable period, preferably not more than 24 h and in any case not more than 72 h, of the prior filtration. The virus suspension is inactivated by a validated method that has been shown to inactivate poliovirus without destruction of immunogenicity; during validation studies, an inactivation curve with at least four points (for example, time 0, 24, 48, and 96 h) is established showing the decrease in concentration of live virus with time. If formaldehyde is used for inactivation, the presence of an excess of formaldehyde at the end of the inactivation period is verified.

Only an inactivated monovalent harvest that complies with the following requirements may be used in the preparation of a trivalent pool of inactivated monovalent harvests or a final bulk vaccine.

Test for effective inactivation. After neutralisation of the formaldehyde with sodium bisulphite (where applicable), verify the absence of residual live poliovirus by inoculation on suitable cell cultures of two samples of each inactivated monovalent harvest, corresponding to at least 1500 human doses. Take one sample not later than three-quarters of the way through the inactivation period and the other at the end. Inoculate the samples in cell cultures such that the dilution of vaccine in the nutrient medium is not greater than 1/4 and the area of the cell layer is at least 3 cm² per ml of inoculum. Set one or more controls with the same medium as non-inoculated control cells. Observe the cell cultures for at least 3 weeks. Make not fewer than two passages from each container, one at the end of the observation period and the other 1 week before; for the passages, use cell culture supernatant and inoculate as for the initial sample. Observe the subcultures for at least 2 weeks. No sign of poliovirus multiplication is present in the cell cultures. At the end of the observation period, test the susceptibility of the cell culture used by inoculation of live poliovirus of the same type as that present in the inactivated monovalent harvest.

Sterility (2.2.11). The inactivated monovalent harvest complies with the test for sterility, carried out using 10 ml for each medium.

D-antigen content. The content of D-antigen determined by a suitable immunochemical method (2.2.14) is within the limits approved for the particular preparation.

FINAL BULK VACCINE

The final bulk vaccine is prepared directly from the inactivated monovalent harvests of human polioviruses 1, 2 and 3 or from a trivalent pool of inactivated monovalent harvests. If a trivalent pool of inactivated monovalent harvests is used, a test for effective inactivation is carried out on this pool instead of on the final bulk vaccine. A stabiliser and an antimicrobial preservative may be added.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Sterility (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

Inactivation. Before addition of any antimicrobial preservative, a sample of at least 1500 ml or, for a purified and concentrated vaccine, the equivalent of 1500 doses is tested for residual live poliovirus in cell cultures, as described for the inactivated monovalent harvest. If the final bulk vaccine is prepared from a trivalent pool of inactivated monovalent harvests, the test for inactivation is carried out on that pool rather than on the final bulk vaccine.

FINAL LOT

Only a final lot that complies with each of the requirements given below under Identification, Tests and Assay may be released for use. Provided that the tests for free formaldehyde and antimicrobial preservative and the in vivo assay have been performed with satisfactory results on the final bulk vaccine, they may be omitted on the final lot. Provided that the test for bovine serum albumin has been performed with satisfactory results on the trivalent pool of inactivated monovalent harvests or on the final bulk vaccine, it may be omitted on the final lot.

Identification

The vaccine is shown to contain human polioviruses 1, 2 and 3 by a suitable immunochemical method such as the determination of D-antigen by enzyme-linked immunosorbent assay (ELISA).

Tests

Free formaldehyde (2.3.20). Maximum 0.2 g/l.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical
**Protein content (2.3.49).** Not more than 10 μg of protein nitrogen per human dose.

**Bovine serum albumin.** Not more than 50 ng per single human dose, determined by a suitable immunochemical method (2.2.14).

**Sterility (2.2.11).** Complies with the test for sterility.

**Bacterial endotoxins (2.2.3).** Not more than 5 IU per human dose.

**Assay**

**D-antigen content.** As a measure of consistency of production, determine the D-antigen content for human polioviruses 1, 2 and 3 by a suitable immunochemical method (2.2.14) using an appropriate reference preparation calibrated in D-antigen units. For each type, the content, expressed with reference to the amount of D-antigen stated on the label, is within the limits approved for the particular product.

**In vivo test.** The capacity of the vaccine to induce the formation of neutralizing antibodies is determined **in-vivo** by one of the following methods:

**Test in chicks or guinea-pigs.** Prepare a suitable series of at least three dilutions of the vaccine under examination using a suitable buffered saline solution. Inject 0.5 ml of the dilutions intramuscularly into groups of ten 3-week-old chickens or groups of ten guinea-pigs, each weighing between 250 and 350 g, using a separate group for each dilution of vaccine. Bleed the animals on the fifth or sixth day after the injection and separate the sera. Examine the sera for the presence of neutralizing antibody, at a dilution of 1 in 4, to each of the human polioviruses 1, 2 and 3. Mix 100 CCID₅₀ of virus with the dilution of serum and incubate at 37° for 4 h 30 min to 6 h. Keep at 5 ± 3° for 12 to 18 h. Inoculate the mixtures into cell cultures for the detection of unneutralised virus and read the results up to 7 days after inoculation. For each group of animals, note the number of sera which have neutralising antibody and calculate the dilution of the vaccine giving an antibody response in 50.0 per cent of the animals. Carry out in parallel a control test using a suitable reference preparation.

The vaccine complies with the test if a dilution of 1 in 100 or more produces an antibody response for each of the three types of virus in 50.0 per cent of the animals.

**Test on rats.** A suitable **in vivo** assay method consists of intramuscular injection into the hind limb(s) of not fewer than 3 dilutions of the vaccine under examination and a reference vaccine, using for each dilution a group of 10 specific pathogen-free rats of the suitable strain. Use of 4 dilutions is often necessary to obtain valid results for all 3 serotypes. The number of animals per group must be sufficient to obtain results that meet the validity criteria; groups of 10 rats are usually sufficient although valid results may be obtained with fewer animals per group. The weight of individual animal must not vary by more than 10.0 per cent from the group mean. An inoculum of 0.5 ml per rat is used. The dose range is chosen such that a dose response to all 3 poliovirus types is obtained. Bleed the animals after 20 to 22 days. Neutralising titres against all 3 poliovirus types are measured separately using 100 CCID₅₀ of the Sabin strains as challenge viruses. Vero or Hep2 as indicator cells, and neutralization conditions of 3 h at 35° to 37° followed by 18 h at 2° to 8°. Results are read following fixation and staining after 7 days of incubation at 35°. For a valid antibody assay, the titre of each challenge virus must be shown to be within the range of 10 to 1000 CCID₅₀, and the neutralizing antibody titre of a control serum must be within 2 twofold dilutions of the geometric mean titre of the serum.

The potency is calculated by comparison of the preparation of responders for the vaccine under examination and the reference vaccine by the probit method or, after validation, using a parallel-line model. For the probit method it is necessary to establish a cut-off neutralising antibody titre for each poliovirus type to define a responder. Due to interlaboratory variation, it is not possible to define cut-off values that could be applied by all laboratories. Rather, the cut-off values are determined for each laboratory based on a minimum series of 3 tests with the reference vaccine. The mid-point on a log 2 scale of the minimum and maximum geometric mean titres of the series of 3 or more tests is used as the cut-off value. For each of the 3 poliovirus types, the potency of the vaccine is not significantly less than that of the reference preparation. The test is not valid unless (1) for both the test and reference vaccines the ED₅₀ lies between the smallest and the largest doses given to the animals; (2) the statistical analysis shows no significant deviation from linearity or parallelism; (3) the fiducial limits of the estimated relative potency fall between 25.0 per cent and 400.0 per cent of the estimated potency.

**Labelling.** The label states (1) the types of poliovirus contained in the vaccine; (2) the nominal amount of virus of each type (1, 2 and 3), expressed in units of D-antigen per single human dose; (3) the cell substrate used to prepare the vaccine.

**Poliomyelitis Vaccine, Live (Oral)**

Oral Poliomyelitis Vaccine is a preparation of approved strains of live attenuated poliovirus type 1, 2 or 3 grown **in vitro** cultures of approved cells, containing any one type or any combination of the three types of Sabin strains, prepared in a form suitable for oral administration.
Production

General provisions

The vaccine strains and the production method should consistently yield vaccines that are both immunogenic and safe in man.

The production of vaccine is based on a virus seed-lot system. Cell lines are used according to a cell-bank system. If primary monkey kidney cells are used, production complies with the requirements indicated below. Unless otherwise justified and authorised, the virus in the final vaccine shall not have undergone more than two passages from the master seed lot.

Substrate for virus propagation

The virus is propagated in human diploid cells (2.7.2) or in continuous cell lines (2.7.2) or in primary monkey kidney cells (including serially passaged cells from primary monkey kidney cells). Continuous cell lines are approved by the competent authority.

Primary monkey cells. The following special requirements for the substrate for virus propagation apply to primary monkey cells.

Monkeys used for preparation of kidney cell cultures and for testing of virus. If the vaccine is prepared in monkey kidney cell cultures, animals of a species approved by the competent authority, in good health, and not previously employed for experimental purposes shall be used.

The monkeys shall be kept in well-constructed and adequately ventilated animal rooms in cages spaced as far apart as possible. Adequate precautions shall be taken to prevent cross-infection between cages. Not more than two monkeys shall be housed per cage and cage-mates shall not be interchanged. The monkeys shall be kept in the country of manufacture of the vaccine in quarantine groups for a period of not less than 6 weeks before use. A quarantine group is a colony of selected, healthy monkeys kept in one room, with separate feeding and cleaning facilities, and having no contact with other monkeys during the quarantine period. If at any time during the quarantine period the overall death rate of a shipment consisting of one or more groups reaches 5 per cent (excluding deaths from accidents or where the cause was specifically determined not to be an infectious disease), monkeys from that entire shipment shall continue in quarantine from that time for a minimum of 6 weeks. The groups shall be kept continuously in isolation, as in quarantine, even after completion of the quarantine period, until the monkeys are used. After the last monkey of a group has been taken, the room that housed the group shall be thoroughly cleaned and decontaminated before being used for a fresh group. If kidneys from near-term monkeys are used, the mother is quarantined for the term of pregnancy.

Monkeys from which kidneys are to be removed shall be anaesthetised and thoroughly examined, particularly for evidence of tuberculosis and cercopithecid herpesvirus 1 (B virus) infection.

If a monkey shows any pathological lesion relevant to the use of its kidneys in the preparation of a seed lot or vaccine, it shall not be used, nor shall any of the remaining monkeys of the quarantine group concerned be used unless it is evident that their use will not impair the safety of the product.

All the operations described in this section shall be conducted outside the areas where the vaccine is produced.

The monkeys used shall be shown to be free from antibodies to simian virus 40 (SV40) and simian immunodeficiency virus. If Macaca spp. are used for production, the monkeys shall also be shown to be free from antibodies to cercopithecid herpesvirus 1 (B virus). Human herpesvirus has been used as an indicator for freedom from B virus antibodies on account of the danger of handling cercopithecid herpesvirus 1 (B virus).

Monkey kidney cell cultures for vaccine production. Kidneys that show no pathological signs are used for preparing cell cultures. If the monkeys are from a colony maintained for vaccine production, serially passaged monkey kidney cell cultures from primary monkey kidney cells may be used for virus propagation, otherwise the monkey kidney cells are not propagated in series. Virus for the preparation of vaccine is grown by aseptic methods in such cultures. If animal serum is used in the propagation of the cells, the maintenance medium after virus inoculation shall contain no added serum.

Each group of cell cultures derived from a single monkey or from fetuses from no more than ten near-term monkeys is prepared and tested as an individual group.

SEED LOT

The strains of poliovirus used shall be identified by historical records that include information on the origin and subsequent manipulation of the strains.

Working seed lots are prepared by a single passage from a master seed lot and at an approved passage level from the original Sabin virus. Virus seed lots are prepared in large quantities and stored at a temperature below -60°C.

Only a virus seed lot that complies with the following requirements may be used for virus propagation.

Identification

Each working seed lot is identified as poliovirus of the given type, using specific antibodies.

Virus concentration. Determined by the method described below, the virus concentration is the basis for the quantity of virus used in the neurovirulence test.
Extraneous agents (2.7.3). If the working seed lot is produced in human diploid cells (2.7.2) or in continuous cell lines (2.7.2) it complies with the requirements for seed lots for virus vaccines. If the working seed lot is produced in primary monkey cells, it complies with the requirements given below under Propagation and Harvest and Monovalent Pooled Harvest and with the tests in adult mice, suckling mice and guinea-pigs given under Tests for extraneous agents in viral vaccines for human use.

Working seed lot shall be free from detectable DNA sequences from simian virus 40 (SV40)

Neurovirulence (2.7.6). Each master and working seed lot complies with the test for neurovirulence of poliomyelitis vaccine (oral) in monkeys. Furthermore, the seed lot shall cease to be used in vaccine production if the frequency of failure of the monovalent pooled harvests produced from it is greater than predicted statistically. This statistical prediction is calculated after each test on the basis of all the monovalent pooled harvests tested; it is equal to the probability of false rejection on the occasion of a first test (i.e. 1 per cent), the probability of false rejection on retest being negligible. If the test is carried out only by the manufacturer, the test slides are provided to the control authority for assessment.

Genetic markers. Each working seed lot is tested for its replicating properties at temperatures ranging from 36° to 40° as described under Monovalent Pooled Harvest.

PROPAGATION AND HARVEST

All processing of the cell-banks and subsequent cell-cultures is done under aseptic conditions in an area where no other cells are handled. Approved animal (but not human) serum may be used in the media, but the final medium for maintaining cell growth during virus multiplication does not contain animal serum. Serum and trypsin used in the preparation of cell suspensions and media are shown to be free from live extraneous agents. The cell-culture medium may contain a pH indicator such as phenol red and approved antibiotics at the lowest effective concentration. It is preferable to have a substrate free from antibiotics during production. Not less than 5 per cent and not more than 1000 ml of the cell cultures employed for vaccine production are set aside as uninfected cell cultures (control cells); special requirements, given below, apply to control cells when the vaccine is produced in primary monkey cells. The virus suspension is harvested not later than 4 days after virus inoculation. After inoculation of the production cell culture with the virus working seed lot, inoculated cells are maintained at a fixed temperature, shown to be suitable, within the range 33° to 35°; the temperature is maintained constant to ±0.5°; control cell cultures are maintained at 33° to 35° for the relevant incubation periods. Only a single virus harvest that complies with the following requirements may be used in the preparation of the monovalent pooled harvest.

Virus concentration. The virus concentration of virus harvests is determined as prescribed under Assay to monitor consistency of production and to determine the dilution to be used for the final bulk vaccine.

Extraneous agents (2.7.3). Complies with tests for extraneous agents.

Control cells. The control cells of the production cell culture from which the virus harvest is derived comply with a test for identity and with the requirements for extraneous agents or, where primary monkey cells are used, as shown below.

Primary monkey cells. The following special requirements apply to virus propagation and harvest in primary monkey cells.

Cell cultures. On the day of inoculation with virus seed, each cell culture is examined for degeneration caused by an infective agent. If, in this examination, evidence is found of the presence in a cell culture of any extraneous agent, the entire group of cultures concerned shall be rejected.

On the day of inoculation with the virus working seed lot, a sample of at least 30 ml of the pooled fluid removed from the cell cultures of the kidneys of each single monkey or from fetuses from not more than ten near-term monkeys is divided into two equal portions. One portion of the pooled fluid is tested in monkey kidney cell cultures prepared from the same species, but not the same animal, as that used for vaccine production. The other portion of the pooled fluid is, where necessary, tested in monkey kidney cell cultures from another species so that tests on the pooled fluids are done in cell cultures from at least one species known to be sensitive to SV40. The pooled fluid is inoculated into bottles of these cell cultures in such a way that the dilution of the pooled fluid in the nutrient medium does not exceed 1 in 4. The area of the cell sheet is at least 3 cm² per ml of pooled fluid. At least one bottle of each kind of cell culture remains uninoculated to serve as a control. If the monkey species used for vaccine production is known to be sensitive to SV40, a test in a second species is not required. Animal serum may be used in the propagation of the cells, provided that it does not contain SV40 antibody, but the maintenance medium after inoculation of test material contains no added serum except as described below.

The cultures are incubated at a temperature of 35° to 37° and are observed for a total period of at least 4 weeks. During this observation period and after not less than 2 weeks’ incubation, at least one subculture of fluid is made from each of these cultures in the same cell culture system. The subcultures are also observed for at least 2 weeks.

Serum may be added to the original culture at the time of subculturing, provided that the serum does not contain SV40 antibody.
Fluorescent-antibody techniques may be useful for detecting SV40 virus and other viruses in the cells.

A further sample of at least 10 ml of the pooled fluid is tested for cercopithecid herpesvirus 1 (B virus) and other viruses in rabbit kidney cell cultures. Serum used in the nutrient medium of these cultures shall have been shown to be free from inhibitors of B virus. Human herpesvirus has been used as an indicator for freedom from B virus inhibitors on account of the danger of handling cercopithecid herpesvirus 1 (B virus). The sample is inoculated into bottles of these cell cultures in such a way that the dilution of the pooled fluid in the nutrient medium does not exceed 1 in 4. The area of the cell sheet is at least 3 cm² per ml of pooled fluid. At least one bottle of the cell cultures remains uninoculated to serve as a control.

The cultures are incubated at a temperature of 35° to 37° and observed for at least 2 weeks.

A further sample of 10 ml of the pooled fluid removed from the cell cultures on the day of inoculation with the seed lot virus is tested for the presence of extraneous agents by inoculation into human cell cultures sensitive to measles virus.

The tests are not valid if more than 20 per cent of the culture vessels have been discarded for non-specific accidental reasons by the end of the respective test periods.

If, in these tests, evidence is found of the presence of an extraneous agent, the single harvest from the whole group of cell cultures concerned is rejected.

If the presence of cercopithecid herpesvirus 1 (B virus) is demonstrated, the manufacture of oral poliomyelitis vaccine shall be discontinued and the competent authority shall be informed. Manufacturing shall not be resumed until a thorough investigation has been completed and precautions have been taken against any reappearance of the infection, and then only with the approval of the competent authority.

If these tests are not done immediately, the samples of pooled cell-culture fluid shall be kept at a temperature of -60° or below, with the exception of the sample for the test for B virus, which may be held at 4°, provided that the test is done not more than 7 days after it has been taken.

Control cell cultures. On the day of inoculation with the virus working seed lot 25 per cent (but not more than 2500 ml) of the cell suspension obtained from the kidneys of each single monkey or from not more than ten near-term monkeys is taken to prepare uninoculated control cell cultures. These control cell cultures are incubated in the same conditions as the inoculated cultures for at least 2 weeks and are examined during this period for evidence of cytopathic changes. The tests are not valid if more than 20 per cent of the control cell cultures have been discarded for non-specific, accidental reasons. At the end of the observation period, the control cell cultures are examined for degeneration caused by an infectious agent. If this examination or any of the tests required in this section shows evidence of the presence in a control culture of any extraneous agent, the poliovirus grown in the corresponding inoculated cultures from the same group shall be rejected.

Tests for haemadsorbing viruses. At the time of harvest or within 4 days of inoculation of the production cultures with the virus working seed lot, a sample of 4 per cent of the control cell cultures is taken and tested for haemadsorbing viruses. At the end of the observation period, the remaining control cell cultures are similarly tested. The tests are made as described in (2.7.3), Tests for extraneous agents in viral vaccines for human use.

Tests for other extraneous agents. At the time of harvest, or within 7 days of the day of inoculation of the production cultures with the working seed lot, a sample of at least 20 ml of the pooled fluid from each group of control cultures is taken and tested in two kinds of monkey kidney cell culture, as described above.

At the end of the observation period for the original control cell cultures, similar samples of the pooled fluid are taken and the tests referred to in this section in the two kinds of monkey kidney cell culture and in the rabbit cell cultures are repeated, as described above under Cell cultures.

If the presence of Cercopithecid herpesvirus 1 (B virus) is demonstrated, the production cell cultures shall not be used and the measures concerning vaccine production described above must be undertaken.

The fluids collected from the control cell cultures at the time of virus harvest and at the end of the observation period may be pooled before testing for extraneous agents. A sample of 2 per cent of the pooled fluid is tested in each of the cell culture systems specified.

Single harvests

Tests for neutralised single harvests in monkey kidney cell cultures. A sample of at least 10 ml of each single harvest is neutralised by a type-specific poliomyelitis antiserum prepared in animals other than monkeys. In preparing antisera for this purpose, the immunising antigens used shall be prepared in non-simian cells.

Half of the neutralised suspension (corresponding to at least 5 ml of single harvest) is tested in monkey kidney cell cultures prepared from the same species, but not the same animal, as that used for vaccine production. The other half of the neutralised suspension is tested, if necessary, in monkey kidney cell cultures from another species so that the tests on the neutralised suspension are done in cell cultures from at least one species known to be sensitive to SV40.
The neutralised suspensions are inoculated into bottles of these cell cultures in such a way that the dilution of the suspension in the nutrient medium does not exceed 1 in 4. The area of the cell sheet is at least 3 cm² per ml of neutralised suspension. At least one bottle of each type of cell culture remains uninoculated to serve as a control and is maintained by nutrient medium containing the same concentration of the specific antiserum used for neutralisation.

Animal serum may be used in the propagation of the cells, provided that it does not contain SV40 antibody, but the maintenance medium, after the inoculation of the test material, contains no added serum other than the poliovirus neutralising antiserum, except as described below.

The cultures are incubated at a temperature of 35° to 37° and observed for a total period of at least 4 weeks. During this observation period and after not less than 2 weeks' incubation, at least one subculture of fluid is made from each of these cultures in the same cell-culture system. The subcultures are also observed for at least 2 weeks.

Serum may be added to the original cultures at the time of subculturing, provided that the serum does not contain SV40 antibody.

Additional tests are made for extraneous agents on a further sample of the neutralised single harvests by inoculation of 10 ml into human cell cultures sensitive to measles virus.

Fluorescent-antibody techniques may be useful for detecting SV40 virus and other viruses in the cells.

The tests are not valid if more than 20 per cent of the culture vessels have been discarded for non-specific accidental reasons by the end of the respective test periods.

If any cytopathic changes occur in any of the cultures, the causes of these change are investigated. If the cytopathic changes are shown to be due to unneutralised poliovirus, the test is repeated. If there is evidence of the presence of SV40 or other extraneous agents attributable to the single harvest, that single harvest is rejected.

**MONOVALENT POOLED HARVEST**

Monovalent pooled harvests are prepared by pooling a number of satisfactory single harvests of the same virus type. Monovalent pooled harvests from continuous cell lines may be purified. Each monovalent pooled harvest is filtered through a bacteria-retentive filter.

Only a monovalent pooled harvest that complies with the following requirements may be used in the preparation of the final bulk vaccine.

**Identification**

Each monovalent pooled harvest is identified as poliovirus of the given type, using specific antiserum.

**Virus concentration**

The virus concentration is determined by the method described below and serves as the basis for calculating the dilutions for preparation of the final bulk, for the quantity of virus used in the neurovirulence test and to establish and monitor production consistency.

**Genetic markers.** A ratio of the replication capacities of the virus in the monovalent pooled harvest is obtained over a temperature range between 36° and 40° in comparison with the seed lot or a reference preparation for the marker tests and with appropriate rct/40- and rct/40+ strains of poliovirus of the same type. The incubation temperatures used in this test are controlled to within ±0.1°. The monovalent pooled harvest passes the test if, for both the virus in the harvest and the appropriate reference material, the titre determined at 36° is at least 5.0 log greater than that determined at 40°. If growth at 40° is so low that a valid comparison cannot be established, a temperature in the region of 39.0° to 39.5° is used, at which temperature the reduction in titre of the reference material must be in the range 3.0 to 5.0 log of its value at 36°; the acceptable minimum reduction is determined for each virus strain at a given temperature. If the titres obtained for one or more of the reference viruses are not concordant with the expected values, the test must be repeated.

**Neurovirulence (2.7.6).** Each monovalent pooled harvest complies with the test for neurovirulence of poliomylitis vaccine (oral). If the test is carried out only by the manufacturer, the test slides are provided to the competent authority for assessment. The TgPVR21 transgenic mouse model provides a suitable alternative to the monkey neurovirulence test for neurovirulence testing of types 1, 2 or 3 vaccines once a laboratory qualifies as being competent to perform the test and the experience gained is to the satisfaction of the competent authority. The test is carried out using a standard operating procedure approved by the competent authority. A suitable procedure (Neurovirulence test of type 1, 2 or 3 live poliomyelitis vaccines (oral) in transgenic mice susceptible to poliovirus) is available from WHO, Quality and Safety of Biologicals, Geneva.

**Primary monkey cells.** The following special requirements apply to monovalent pooled harvests derived from primary monkey cells.

**Retroviruses.** The monovalent pooled harvest is examined using a reverse transcriptase assay. No indication of the presence of retrovirus is found.

**Test on rabbits.** A sample of the monovalent pooled harvest is tested for cercopithecid herpesvirus 1 (B virus) and other viruses by injection of not less than 100 ml into not fewer than 10 healthy rabbits each weighing between 1.5 and 2.5 kg. Each rabbit receives not less than 10 ml and not more than 20 ml, of
which 1 ml is given intradermally at multiple sites, and the remainder subcutaneously. The rabbits are observed for at least 3 weeks for death or signs of illness.

All rabbits that die after the first 24 h of the test and those showing signs of illness are examined by autopsy, and the brain and organs removed for detailed examination to establish the cause of death.

The test is not valid if more than 20.0 per cent of the inoculated rabbits show signs of intercurrent infection during the observation period. The monovalent pooled harvest passes the test if none of the rabbits shows evidence of infection with B virus or with other extraneous agents or lesions of any kind attributable to the bulk suspension.

If the presence of B virus is demonstrated, the measures concerning vaccine production described above under Cell cultures are taken.

**Test on guinea-pigs.** Administer to not less than five guinea-pigs, each weighing between 350 and 450 g, 0.1 ml of the monovalent pooled harvest by intracerebral injection and 0.5 ml by intraperitoneal injection. Measure the rectal temperature of each animal on each working day for 6 weeks. At the end of the observation period carry out autopsy on each animal.

In addition, administer to not fewer than five guinea-pigs 0.5 ml by intraperitoneal injection and observe as described above for 2 to 3 weeks. At the end of the observation period, carry out a passage from these animals to not fewer than five guinea-pigs using blood and a suspension of liver or spleen tissue. Measure the rectal temperature of the latter guinea-pigs for 2 to 3 weeks. Examine by autopsy all animals that, after the first day of the test, die or are killed because they show disease or show for three consecutive days a body temperature higher than 39°C; carry out histological examination to detect infection with Marburg virus; in addition, inject a suspension of liver or spleen tissue or of blood intraperitoneally into not fewer than three guinea-pigs. If any signs of infection with Marburg virus are noted, confirmatory serological tests are carried out on the blood of the affected animals. The monovalent pooled harvest complies with the test if not fewer than 80.0 per cent of the guinea-pigs survive to the end of the observation period and remain in good health and no animal shows signs of infection with filoviruses virus.

**FINAL BULK VACCINE**

The final bulk vaccine is prepared from one or more satisfactory monovalent pooled harvests and may contain more than one virus type. Suitable flavouring substances and stabilisers may be added.

Only a final bulk vaccine that complies with the following requirement may be used in the preparation of the final lot.

**Sterility (2.2.11).** Complies with the test for sterility.

**FINAL LOT**

Only a final lot that complies with the following requirement for thermal stability and is satisfactory with respect to each of the requirements given below under Identification, Tests and Assay may be released for use.

**Thermal stability.** Expose samples of the final lot at 37°C for 48 hours. Determine the total virus concentration as described under Assay in parallel for the heated vaccine and for unheated vaccine. The estimated difference between the total virus concentration of the unheated and heated vaccines is not greater than 0.5 log₁₀ infectious virus units (CCID₅₀) per single human dose.

**Identification**

The vaccine is shown to contain poliovirus of each type stated on the label, using specific antibodies.

**Tests**

**Sterility (2.2.11).** Complies with the test for sterility.

**Assay**

Titrate for infectious virus at least in triplicate using the method described below. Use an appropriate virus reference preparation to validate each assay. If the vaccine contains more than one poliovirus type, titrate each type separately, using appropriate type-specific antiserum (or preferably a monoclonal antibody) to neutralise each of the other types present.

For a trivalent vaccine, the estimated mean virus titres must be: not less than 1 × 10⁶.0 infectious virus units (CCID₅₀) per single human dose for type 1; not less than 1 × 10⁵.8 infectious virus units (CCID₅₀) for type 2; and not less than 1 × 10⁵.8 infectious virus units (CCID₅₀) for type 3.

For monovalent or divalent vaccine, the minimum virus titres are decided by the competent authority.

**Method.** Groups of eight to twelve flat-bottomed wells in a microtitre plate are inoculated with 0.05 ml of each of the selected dilutions of virus followed by a suitable cell suspension of the Hep-2 (Cincinnati) line. The plates are incubated at a suitable temperature. Examine the cultures on days 7 to 9.

The assay is not valid if (a) the confidence interval (P = 0.95) of the logarithm of the virus concentration is greater than ±0.3; (b) the virus concentration of the reference preparation differs by more than 0.5 log CCID₅₀ from the assigned value.

**Labelling.** The label states (1) the types of poliovirus contained in the vaccine; (2) the minimum amount of virus of each type contained in one single human dose; (3) the cell substrate used for the preparation of the vaccine; (4) that the vaccine is not to be injected.
Rabies Vaccine, Human

Rabies Vaccine for Human use is a freeze-dried or liquid (adsorbed) preparation of a suitable approved, strain of fixed rabies virus grown in an approved cell culture/embryos of duck/chicken and inactivated by a validated method.

The freeze-dried vaccine is reconstituted immediately before use as stated on the label to give a clear or slightly opalescent solution/suspension. It may be coloured owing to the presence of a pH indicator.

The vaccine complies with the General Requirements of Vaccines for Human Use.

Production

General provisions

The vaccine is produced on the basis of virus seed lot system and if a cell line is used for virus propagation, a cell-bank system shall be followed. The production method shall have been shown to yield consistently vaccines that comply with the requirements for immunogenicity, safety and stability. Unless otherwise justified and authorized, the virus in the final vaccine shall not have undergone more passages from the master seed lot than was used to prepare the vaccine shown in clinical studies to be satisfactory with respect to safety and efficacy.

The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy.

Substrate for virus propagation

The virus is propagated in any suitable approved cell substrate like a human diploid cell line (2.7.2), a continuous cell line, or in duck embryos or in cultures of chicken embryos derived from a flock certified as free from specified pathogens (2.7.7).

SEED LOT

The strain of rabies virus used shall be identified by historical records that include information on the origin of the strain and its subsequent manipulation.

Working seed lots are prepared by not more than five passages from the master seed lot.

Only a working seed lot that complies with the following requirements may be used for virus propagation.

Identification

Each working seed lot is identified as rabies virus using specific antibodies by an approved method.

Virus concentration. The virus concentration of each working seed lot is determined by a cell culture method using immunofluorescence or any other approved method.

Extraneous agents (2.7.3). The working seed lot complies with the requirements for the virus seed lots.

PROPAGATION AND HARVEST

All processing of the cell bank and subsequent cell cultures are done under aseptic conditions in an area where no other cells are handled. Approved animal (but not human) serum may be used in the media, but the final medium for maintaining cell growth during virus multiplication does not contain animal serum; the media may contain human albumin. Serum proteins, if present, are reduced to an acceptable level by a suitable method of purification. Serum and trypsin used in the preparation of cell suspension and media are shown to be free from infectious extraneous agents. The cell culture media may contain a pH indicator such as phenol red and approved antibiotics at the lowest effective concentration. Not less than 500 ml of the cell cultures employed for vaccine production are set aside as uninfected cell cultures (control cells). The virus suspension is harvested on one or more occasions during incubation. Multiple harvests from the same production cell culture may be pooled and considered as a single harvest.

When vaccine is prepared in embryonated eggs, the egg proteins are minimized by an appropriate method of purification. The eggs are inoculated with virus seed by the yolk sac route. The infected sterile living embryos are harvested, minced and emulsified in suitable diluent, and stabilizer with aseptic precautions. Emulsions are centrifuged, supernatants are collected and stored as raw virus harvest at a suitable temperature.

Viral harvests that comply with the following requirements are pooled in the preparation of the inactivated viral harvest.

Identification

The single harvest contains virus that is identified as rabies virus using specific antibodies by an approved method.

Virus concentration. Titrate for infective virus in cell cultures or by any other approved method. The titre is used to monitor consistency of production.

Control cells. The control cells of the production cell culture from which the single harvest is derived should comply with a test for identification and with the requirements for extraneous agents (2.7.3).

Control eggs. Control eggs shall be tested for freedom from haemagglutinating agents, and other extraneous agents.

PURIFICATION AND INACTIVATION

The virus harvests may be concentrated and/or purified by suitable methods; the virus harvest is inactivated by a validated method at a fixed, well defined stage of the process which may
be before, during or after any concentration or purification. The method shall have been shown to be capable of inactivating rabies virus without destruction of the immunogenic activity. If betapropiolactone is used, the concentration shall at no time exceed 1:3500.

**Cell culture vaccines**

Only an inactivated viral suspension that complies with the following requirements may be used in the preparation of the final bulk vaccine.

**Inactivation.** Inactivation is confirmed by carrying out an amplification test for residual infectious rabies virus, not more than 4 days after inactivation or on the sample frozen after inactivation and stored at -70°. Inoculate a quantity of inactivated viral suspension equivalent to not less than 25 vaccine doses into cell cultures of the same type as those used for production of the vaccine. Make a passage after 7 days. Maintain the cultures for a further period of 14 days and then examine the cell cultures for rabies virus using an immune fluorescence test. No rabies virus is detected. Alternatively, 5 ml of each culture fluid is pooled on days 14 and 21 and 0.03 ml is inoculated intracerebrally into each of the 10 mice weighing 12 to 15 g. The mice are observed for 14 days for symptoms caused by rabies virus, and mice showing symptoms of rabies are sacrificed and virus presence is confirmed by an immunofluorescence test or method of equal sensitivity. No rabies virus should be detected.

**Residual host-cell DNA (2.2.15).** If a continuous cell line is used for virus propagation, the content of residual host-cell DNA, determined using a suitable method, should not be greater than 10 ng per single human dose.

**Embryonated egg vaccine**

Only concentrated viral suspensions that comply with the test for sterility, antigen content and endotoxin requirements may be used for preparation of bulk for inactivation. Inactivation is confirmed by carrying out Mice Inoculation Test for residual infectious rabies virus, not more than four days after inactivation or on the sample frozen 4 days after inactivation are stored at -70°. Inoculate 0.03 ml into each of 20 mice weighing between 12 and 15 g. The mice are observed for 14 days for symptoms caused by rabies virus and mice showing symptoms of rabies are sacrificed and virus presence is confirmed by an immunofluorescence test or tested for live virus in cell culture by immunofluorescence test or method of equal sensitivity. No rabies virus should be detected.

**FINAL BULK VACCINE**

The final bulk vaccine is prepared from one or more inactivated viral suspensions. An approved stabilizer may be added to maintain the activity of the product during and after freeze-drying. Thiomersal can be used as preservative.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Antigen content.** Determine the antigen content by a suitable approved in vitro or in vivo method. The content should be within the limits approved for the particular product.

**Sterility (2.2.11).** Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

The final bulk vaccine is distributed aseptically into sterile containers and can be freeze-dried in case of lyophilized products. The containers are then sealed so as to prevent contamination and the introduction of moisture.

Only a final lot that complies with each of the requirements given below under Identification, Tests and Assay may be released for use. Provided that the test for inactivation has been carried out with satisfactory results on the inactivated virus suspension and the test for bovine serum albumin has been carried out with satisfactory results on the final bulk vaccine, these tests may be omitted on the final lot.

**Identification**

The vaccine is shown to contain rabies virus antigen by a suitable immunochemical method using specific antibodies, alternatively, the Assay also serves to identify the vaccine.

**Tests**

**Inactivation.** Inoculate a quantity equivalent to not less than 25 human doses of vaccine into cell cultures of the same type as those used for production of the vaccine. Make a passage after 7 days. Maintain the culture for a further 14 days and then examine the cell culture for rabies virus using an immunofluorescence test. No rabies virus is detected. Alternatively, inject 0.03 ml of the vaccine intracerebrally into each of the 10 mice weighing between 12 and 15 g. Neither symptoms of disease in the central nervous system nor death occurs in any of the animal within 14 days. If the inactivation test is already performed on inactivated virus used for final lot, it may be omitted from the test on final lot.

**Sterility (2.2.11).** Complies with the test for sterility.

**Bacterial endotoxins (2.2.3).** Less than 25 IU per single human dose.

**Pyrogens (2.2.8).** Complies with the test for pyrogens. Unless otherwise justified and authorized, inject into each rabbit a single human dose of the vaccine diluted to ten times its volume.

**Water (2.3.43).** Not more than 3.0 per cent determined by an approved method.
Abnormal toxicity (2.2.1). Complies with the test for abnormal toxicity.

Accelerated degradation. The potency determined by method described under “Assay” of a sample of the preparation under examination after storage at 37°C for 4 weeks is not less than 2.5 units per single human dose. This may not be mandatory for lot release, once the consistency of the product is approved by National Regulatory Authority.

Bovine serum albumin (for cell culture vaccine). Not more than 50 ng per single human dose, determined by a suitable immunochemical method (2.2.14).

Aluminium content (for gel absorbed vaccine) (2.3.9). Not more than 1.25 mg per single human dose.

Ovalbumin (for egg based vaccines). Not more than 1 µg of ovalbumin per human dose, determined by a suitable technique using a suitable reference preparation of ovalbumin.

Residual host-cell DNA (for continuous cell line vaccines) (2.2.15). Should not be greater than 10 ng per single human dose.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

Assay

The Standard preparation is the international standard or another suitable preparation, the potency of which has been determined in relation to the International standard. The potency of rabies vaccine is determined by comparing the dose necessary to protect mice against a lethal intracerebral dose of rabies vaccine necessary to provide the same protection. For this comparison, a reference preparation of rabies vaccine, calibrated in international units, and a suitable preparation of rabies virus for use as the challenge preparation are necessary.

The international unit is the activity contained in a stated quantity of the international standard. The equivalence in international units of the international standard is stated by the World Health Organization.

The test described below uses a parallel-line model with at least three points for the vaccine under examination and the reference preparation.

Test animals. Use mice of a suitable strain, drawn from a uniform stock three to four weeks old, weighing between 11 and 15 g. Distribute the mice into six groups of at least 16 mice each and four groups of 10 mice each and must be of the same sex or the sexes must be equally distributed among the groups.

Throughout the test all mice that die before the fifth day after challenge are excluded from the test and all mice that die with signs of rabies between the fifth and fourteenth day after challenge are counted as failing to resist the challenge.

The strain of mice suitable for the test is such that when 0.03 ml containing 5 to 50 LD₅₀ of the challenge virus suspension is injected intracerebrally per mouse there is 100 per cent mortality.

Standard challenge virus suspension. A working pool of the challenge virus strain is prepared by injecting intracerebrally 0.03 ml of a 10 fold dilution of the CVS strain of rabies virus in 2 per cent v/v sterile inactivated normal horse serum in water for injection or another suitable diluent approved by the competent authority into a suitable number of test animals. The animals when moribund after showing characteristic signs of rabies are sacrificed and their brains harvested aseptically. They are then washed in chilled saline solution to remove blood clots. A 10 per cent suspension of the brains is prepared in a suitable diluent approved by the competent authority and thoroughly homogenised. After centrifuging lightly, the supernatant liquid is distributed into sterile vials and freeze dried. The sealed and freeze-dried supernatant liquid containing vials are stored at -20°C. When stored under prescribed conditions the virus titre of the freeze-dried preparation may be expected to be maintained for not less than 3 years. Alternatively, the washed brains are homogenised in a suitable diluent approved by the competent authority to give 10 per cent suspension. It is then centrifuged lightly, distributed into sterile ampoules or sterile plastic vials and sealed. The sealed ampoules or plastic vials can be stored at -60°C or below. When stored under prescribed conditions, the virus titre may be expected to be maintained for not less than one year. Storage time needs to be validated by the manufacturer.

Virus titre of the challenge virus. Prepare ten fold serial dilutions of the standard challenge virus suspension. Using the four groups of 10 mice each, inject 0.03 ml of the virus suspension intracerebrally into each mouse, using a different group for each suspension. Observe the mice for 14 days. Calculate the virus titre of the standard challenge virus suspension in LD₅₀ per dose of 0.03 ml by standard statistical methods.

Determination of potency of the vaccine. Reconstitute the standard preparation with a suitable diluent. Prepare at least three 5-fold serial dilutions of the solution of the standard preparation and three 5-fold serial dilutions of the vaccine under examination. For both, the standard preparation and the preparation under examination, the serial dilutions should be prepared in such a way that the lowest dilution protects more than 50 per cent of the injected mice. Allocate one dilution to each of the six groups of 16 mice each. Inject intraperitoneally each mouse in each group with dilutions of the vaccine and reference preparation and repeat the injections. After 7 days, prepare identical dilutions of the vaccine and
reference preparation and repeat the injections.

After a further 7 days, inject each vaccinated mouse intracerebrally with 0.03 ml of the standard challenge virus suspension such that on the basis of preliminary titration, 0.03 ml contains between 5 to 50 LD$_{50}$. Observe the mice for 14 days and record the number of mice surviving the challenge in each group. Calculate the potency of the preparation under examination by standard statistical methods.

The vaccine complies with the test if the estimated potency is not less than 2.5 IU per single human dose.

The test is not valid unless (a) for both the preparation under examination and the standard preparation, the 50 per cent protective dose lies between the largest and smallest doses given to the mice; (b) there is not deviation from linearity or parallelism of the dose response lines, the confidence limit (P = 0.95) are not less than 25.0 per cent and not more than 400 per cent of the estimated potency; (c) the titre of the challenge virus suspension lies between 5 to 50 LD$_{50}$.

**Labelling.** The label states the biological origin of the cells used for the preparation of the vaccine.

---

**Rubella Vaccine (Live)**

Rubella Vaccine (Live) is a freeze-dried preparation of a suitable attenuated strain of rubella virus. The vaccine is reconstituted immediately before use to give a clear liquid or may be coloured owing to the presence of a pH indicator.

**Production**

**General provisions**

The production of vaccine is based on a virus seed-lot system and a cell-bank system. The production method shall have been shown to yield consistently live rubella vaccines of adequate immunogenicity and safety in man. Unless otherwise justified and authorised, the virus in the final vaccine shall have undergone no more passages from the master seed lot than were used to prepare the vaccine shown in clinical studies to be satisfactory with respect to safety and efficacy.

The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy.

**Substrate for virus propagation**

The virus is propagated in human diploid cells (2.7.2).

**SEED LOT**

The strain of rubella virus used in the production of rubella vaccine shall be identified by historical records that include information on the origin of the strain and its subsequent manipulation.

To avoid unnecessary use of monkeys in the test for neurovirulence virus seed lots are prepared in large quantities and stored at temperatures below -20° if freeze-dried, or below -60° if not freeze-dried.

Only a seed lot that complies with the following tests may be used for virus propagation.

**Identification**

The master and working seed lots are identified as rubella virus by serum neutralisation in cell culture, using specific antibodies.

**Virus concentration.** The virus concentration of the master and working seed lots is determined to ensure consistency of production.

**Extraneous agents** (2.7.3). The working seed lot complies with the tests for seed lots.

**Neurovirulence** (2.7.5). The master/working seed lot complies with the test for neurovirulence of live virus vaccines. *Macaca* and *Cercopithecus* monkeys are suitable for the test.

**PROPAGATION AND HARVEST**

All processing of the cell bank and subsequent cell cultures is done under aseptic conditions in an area where no other cells are handled. Suitable animal (but not human) serum may be used in the growth medium, but the final medium for maintaining cell growth during virus multiplication does not contain animal serum. Serum and trypsin used in the preparation of cell suspensions and culture media are shown to be free from extraneous agents. The cell culture medium may contain a pH indicator such as phenol red and suitable antibiotics at the lowest effective concentration. It is preferable to have a substrate free from antibiotics during production. Not less than 500 ml of the production cell culture is set aside as uninfected cell culture (control cells). The temperature of incubation is controlled during the growth of the virus. The virus suspension is harvested, on one or more occasions, within 28 days of inoculation. Multiple harvests from the same production cell culture may be pooled and considered as a single harvest.

Only a single harvest that complies with the following requirements may be used in the preparation of the final bulk vaccine.

**Identification**

The single harvest contains virus that is identified as rubella virus by serum neutralization in cell culture, using specific antibodies.

**Virus concentration.** The virus concentration in the single harvest is determined as prescribed under Assay to monitor
consistency of production and to determine the dilution to be used for the final bulk vaccine.

**Extraneous agents (2.7.3).** The single harvest complies with the tests for extraneous agents.

**Control cells.** The control cells comply with a test for identification and with the tests for extraneous agents (2.7.3).

**FINAL BULK VACCINE**

Single harvests that comply with the above tests are pooled and clarified to remove cells. A suitable stabilizer may be added and the pooled harvests diluted as appropriate.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Sterility (2.2.11).** Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

A minimum virus concentration for release of the product is established such as to ensure, in the light of stability data, that the minimum concentration stated on the label will be present at the end of the period of validity.

Only a final lot that complies with the tests for minimum virus concentration for release, with the following requirement for thermal stability and with each of the requirements given below under Identification and Tests may be released for use. Provided that the test for bovine serum albumin has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

**Thermal stability.** Maintain samples of the final lot of freeze-dried vaccine in the dry state at 37° for 7 days. Determine the virus concentration as described under Assay in parallel for the vaccine held at 37° for 7 days and for vaccine stored at 2° to 8°. The virus concentration of the heated vaccine is not more than 1.0 log10 lower than that of the unheated vaccine.

**Identification**

When the vaccine reconstituted as stated on the label is mixed with specific rubella antibodies, it is no longer able to infect susceptible cell cultures.

**Tests**

**Sterility (2.2.11).** The reconstituted vaccine complies with the test for sterility.

**Water (2.3.43).** Not more than 3.0 per cent, determined by Karl Fischer, semi-micro determination of water or by any suitable validated method.

**Bovine serum albumin.** Not more than 50 ng per single human dose, determined by a suitable immunochemical method (2.2.14).

**Abnormal toxicity (2.2.1).** Complies with the test for abnormal toxicity.

**Assay**

Titrates the vaccine for infective virus at least in triplicate, using at least five cell cultures for each 0.5 log10 dilution step or by a method of equal precision. Use an appropriate virus reference preparation to validate each assay. The estimated virus concentration is not less than that stated on the label; the minimum virus concentration stated on the label is not less than 1 × 103 CCID50 per human dose. The assay is not valid if the confidence limits (P=0.95) of the logarithm of the virus concentration is greater than ± 0.3.

**Rubella vaccine (Live) RS** is suitable for use as a reference preparation.

**Labelling.** The label states (1) the strain of virus used for the preparation of the vaccine; (2) the type and origin of the cells used for the preparation of the vaccine; (3) the minimum virus concentration; (4) the time within which the vaccine must be used after reconstitution; (5) that the vaccine must not be given to a pregnant woman and that a woman must not become pregnant within two months.

**Tetanus Vaccine (Adsorbed)**

Tetanus Vaccine (Adsorbed) is a preparation of tetanus formol toxoid adsorbed on mineral carrier. The formol toxoid is prepared from the toxin produced by the growth of Clostridium tetani.

**Production**

**General provisions**

The maximum number of Lf per single human dose of tetanus vaccine is 25.

The production method is validated to demonstrate that the product, if tested, would comply with the following test.

**BULK PURIFIED TOXOID**

For the production of tetanus toxin, from which toxoid is prepared, seed cultures are managed in a defined seed-lot system in which toxigenicity is conserved and, where necessary, restored by deliberate reselection. A highly toxigenic strain of Clostridium tetani with known origin and history is grown in a suitable liquid medium. At the end of cultivation, the purity of each culture is tested and contaminated cultures are discarded. Toxin-containing culture medium is collected aseptically. The toxin content (Lf per ml) is checked to monitor consistency of production. Single harvests may be pooled to prepare the bulk purified toxoid.
The toxin is purified to remove components likely to cause adverse reactions in humans. The purified toxin is detoxified with formaldehyde by a method that avoids destruction of the immunogenic potency of the toxoid and reversion of toxoid to toxin, particularly on exposure to heat. Alternatively, purification may be carried out after detoxification.

Only bulk purified toxoid that complies with the following requirements may be used in the preparation of the final bulk vaccine.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**Absence of tetanus toxin.** Inject subcutaneously at least 500 Lf of purified toxoid in a volume of 1 ml into each of five healthy guinea-pigs, each weighing 250 to 350 g, that have not previously been treated with any material that will interfere with the test. If within 21 days of the injection any of the animals shows signs of or dies from tetanus, the toxoid does not comply with the test. If more than one animal dies from non-specific causes, repeat the test once; if more than one animal dies in the second test, the toxoid does not comply with the test.

**Irreversibility of toxoid.** Using the buffer for the final vaccine, prepare a dilution of the bulk purified toxoid containing the same toxoid concentration as the final vaccine. Divide the dilution into two equal parts. Keep one of them at 2° to 8° and the other at 37° for 6 weeks. Test both dilutions by a suitable sensitive assay for active tetanus toxin, such as inoculation into mice or guinea-pigs. The toxoid complies with the test if neither sample produces any sign of a toxic reaction attributable to tetanus toxin.

**Antigenic purity.** Not less than 1,000 Lf per mg of protein nitrogen.

**FINAL BULK VACCINE**

The final bulk vaccine is prepared by adsorption of a suitable quantity of bulk purified toxoid onto a mineral carrier such as hydrated aluminium phosphate or aluminium hydroxide; the resulting mixture is approximately isotonic with blood. Suitable antimicrobial preservatives may be added. Certain antimicrobial preservatives, particularly those of the phenolic type, adversely affect the antigenic activity and must not be used.

Only final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Specific toxicity.** Inject five times the dose stated on the label subcutaneously or intraperitoneally into each of five guinea-pigs. None of the guinea-pigs shows any symptoms of, or dies from, tetanus within 21 days. If more than one animal dies from non-specific causes within this period repeat the test. None of the second group of animals shows symptoms of tetanus or dies from tetanus or any other cause within 21 days.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Free formaldehyde** (2.3.20). Maximum 0.2 g/l.

**pH** (2.4.24). 6.0 and 7.0

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity for antisera and vaccine.

**FINAL LOT**

The final bulk vaccine is distributed aseptically into sterile, tamper-proof containers. The containers are closed so as to prevent contamination.

Only a final lot that is satisfactory with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided the tests for antimicrobial preservative and the assay have been carried out with satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

**Identification**

Tetanus toxoid is identified by a suitable immunochemical method (2.2.14). The following method, applicable to certain vaccines, is given as an example. Dissolve in the vaccine under examination sufficient sodium citrate to give a 10 per cent solution. Maintain at 37° for about 16 hours and centrifuge until a clear supernatant liquid is obtained. The clear supernatant liquid reacts with a suitable tetanus antitoxin, giving a precipitate.

**Tests**

**Aluminium** (2.3.9). Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

**Free formaldehyde** (2.3.20). Maximum 0.2 g/l.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

**Sterility** (2.2.11). Complies with the test for sterility.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity for antisera and vaccine.
Potency of tetanus component

Assay. Determine by either of the following methods.

(1) Inject subcutaneously on each of two occasions separated by an interval of not more than 4 weeks, one-tenth of the stated human dose diluted to 1 ml with saline solution into each of 9 normal, healthy guinea-pigs weighing between 250 and 350 g. Not more than 2 weeks after the second injection, collect the serum from each animal and carry out the biological test for tetanus antitoxin, described under Tetanus antitoxin or any other method approved by National Regulatory Authority.

Sera of at least 6 guinea-pigs out of 9 should contain not less than 0.5 Unit of tetanus antitoxin per ml.

(2) Carry out the biological assay of adsorbed Tetanus Vaccine (Adsorbed) described below.

If the lower limit of the 95.0 per cent confidence interval of estimated potency is less than 40 IU per single human dose then the limits of the 95.0 per cent confidence interval of the estimator of potency shall be within 50 to 200 per cent of the estimated potency unless the lower limit of the 95.0 per cent confidence interval of the estimated potency is greater than 40 IU per single human dose.

Biological assay of adsorbed tetanus vaccine

The potency of adsorbed tetanus vaccine is determined by comparing the dose of the vaccine required to protect guinea-pigs or mice from the paralytic effects of a subcutaneous injection of tetanus toxin with the dose of the Standard preparation needed to give the same protection. For this comparison, the Standard preparation of adsorbed tetanus toxoid and a suitable preparation of tetanus toxin, for use as a challenge toxin, are necessary.

Standard preparation

The Standard preparation is International standard for Tetanus toxoid, adsorbed or another suitable preparation, the potency of which has been determined in relation to the International standard.

Suggested method

(a) Test on guinea-pigs

Test animals. Use healthy guinea-pigs from the same stock and weighing between 250 and 350 g. Distribute them into six groups of sixteen each. The guinea-pigs should all be of the same sex or the males and females should be distributed equally between the groups. If the challenge toxin to be used has not been shown to be stable or has not been adequately standardised, include four further groups of five guinea-pigs to serve as unvaccinated controls.

Challenge toxin. Select a preparation of tetanus toxin containing not less than 50 times the 50 per cent paralytic dose per ml. If the challenge toxin preparation has been shown to be stable, it is not necessary to verify the paralytic dose for every assay.

Preparation of the challenge toxin solution. Immediately prior to use, prepare from the challenge toxin by dilution with phosphate buffered saline pH 7.4 a challenge toxin solution containing fifty times the 50 per cent paralytic dose per ml. If necessary, dilute portions of this challenge toxin solution 16-, 50- and 160-fold with the same buffer solution.

Determination of potency. Prepare in saline solution three dilutions of the vaccine under examination and three dilutions of a solution of the Standard preparation such that, for each, the dilutions form a series differing by not more than 2.5-fold steps and in which the dilutions of intermediate concentration, when injected subcutaneously in 1-ml volumes into guinea-pigs, protect approximately 50 per cent of the animals from the paralytic effects of the subcutaneous injection of the quantity of tetanus toxin prescribed for this test. Allocate the six dilutions one to each of the six groups of sixteen guinea-pigs and inject subcutaneously 1.0 ml of each dilution into each guinea-pig in the group to which that dilution is allocated. After 28 days inject each animal subcutaneously with 1.0 ml of the challenge toxin solution containing fifty times the 50 per cent paralytic dose. If necessary, allocate the challenge toxin solution and the three dilutions made from it one to each of the four groups of five guinea-pigs and inject subcutaneously 1.0 ml of each toxin solution into each guinea-pig in the group to which that toxin solution is allocated. Examine the guinea-pigs twice daily, remove and kill all animals showing definite signs of tetanus paralysis. Count the number of guinea-pigs without paralysis 5 days after injection of the challenge toxin and calculate the potency of the vaccine under examination relative to the potency of the Standard preparation on the basis of the number of animals without paralysis in each of the six groups of sixteen, using standard statistical methods.

The test is not valid unless (a) for both the vaccine under examination and the Standard preparation, the 50 per cent protective doses lie between the largest and smallest doses of the preparations given to the guinea-pigs; (b) if applicable, the number of paralysed animals among the four groups of five injected with the challenge toxin solution and its dilutions indicate that the challenge was approximately 50 times the 50 per cent paralytic dose; (c) the fiducial limits of assay lie between 50.0 per cent and 200.0 per cent of the estimated potency; (d) the statistical analysis shows no deviations from linearity or parallelism. The test may be repeated any number of times but when more than one test is performed the results of all valid tests must be combined in the estimate of potency.

(b) Test on mice

Test animals. Use healthy mice from the same stock, weighing
between 14 and 20 g. Distribute them into six groups of sixteen each. If the challenge toxin to be used has not been shown to be stable or has not been adequately standardised, include four further groups of six mice to serve as unvaccinated controls. The mice should all be of the same sex or the males and females should be distributed equally among the groups.

**Challenge toxin.** Select a preparation of tetanus toxin containing not less than 100 times the 50 per cent paralytic dose per ml.

**Preparation of the challenge toxin solutions.** Immediately prior to use prepare from the challenge toxin by dilution with *phosphate buffered saline pH 7.4* a challenge toxin solution containing fifty times the 50 per cent paralytic dose in each 0.5 ml. If necessary, dilute portions of this challenge toxin solution 16-, 50- and 160-fold with the same buffer solution.

**Determination of potency.** Prepare in *saline solution* three dilutions of the vaccine under examination and three dilutions of a solution of the Standard preparation such that, for each, the dilutions form a series differing by not more than 2.5-fold steps and in which the dilutions of intermediate concentration, when injected subcutaneously in 0.5 ml volumes into mice, protect approximately 50 per cent of the animals from the paralytic effects of the subcutaneous injection of the quantity of tetanus toxin prescribed for this test. Allocate the six dilutions one to each of the six groups of sixteen mice and inject subcutaneously 0.5 ml of each dilution into each mouse in the group to which the dilution is allocated. After 28 days inject each animal subcutaneously with 0.5 ml of the *challenge toxin solution* containing fifty times the 50 per cent paralytic dose. If necessary, allocate the challenge toxin solution and the three dilutions made from it one to each of the four groups of six mice and inject subcutaneously 0.5 ml of each *toxin solution* into each mouse in the group to which that toxin solution is allocated. Count the number of mice without paralysis 4 days after injection of the challenge toxin and calculate the potency of the vaccine under examination relative to the potency of the Standard preparation on the basis of the numbers of animals without paralysis in each of the six groups of sixteen, using standard statistical methods.

The test is not valid unless (a) for both the vaccine under examination and the Standard preparation, the 50 per cent protective doses lie between the largest and smallest doses of the preparations given to the mice; (b) if applicable, the number of paralysed animals among the four groups of six injected with the challenge toxin solution and its dilutions indicate that the challenge was approximately 50 times the 50 per cent paralytic dose; (c) the fiducial limits of the assay lie between 50.0 per cent and 200.0 per cent of the estimated potency; (d) the statistical analysis shows no deviation from linearity or parallelism. The test may be repeated any number of times but when more than one test is performed the results of all valid tests must be combined in the estimate of potency.

(c) **Determination of antibodies in guinea-pigs**

**Preparation of serum samples.** For preparation of serum samples, the following technique has been found suitable. Invert the tubes containing blood samples 6 times and allow to stand at 37° for 2 h, then at 4° for 2 hours, centrifuge at room temperature at 800 g for 20 min. Transfer the serum to sterile tubes and store at a temperature below -20°. At least 40.0 per cent yield of serum is obtained by this procedure.

**Determination of antibody titre.** The ELISA and ToBI tests shown below are given as examples of immunochemical methods that have been found suitable for the determination of antibody titre.

**Determination of antibody titre in guinea-pig serum by enzyme-linked immunosorbent assay (ELISA).** Dilutions of test and reference sera are made on ELISA plates coated with tetanus toxoid. A positive guinea-pig serum control and a negative guinea-pig serum control are included on each plate to monitor the assay performance. Peroxidase-conjugated rabbit or goat antibody directed against guinea-pig-IgG is added followed by a peroxidase substrate. Optical density is measured and the relative antibody titre is calculated using the usual statistical methods.

**Reagents and equipment**

ELISA plates: 96 wells, columns 1-12, rows A-H.

Clostridium tetani guinea-pig antiserum (for vaccines-human use) reference preparation (positive control serum).

Peroxidase conjugate. Peroxidase-conjugated rabbit or goat antibody directed against guinea-pig IgG.

Tetanus toxoid.

Carbonate coating buffer pH 9.6. Dissolve 1.59 g of anhydrous sodium carbonate and 2.93 g of sodium hydrogen carbonate in 1000 ml of water. Distribute into 150 ml bottles and sterilise by autoclaving at 121° for 15 min.

Phosphate buffered saline pH 7.4 (PBS). Dissolve with stirring 80.0 g of sodium chloride, 2.0 g of potassium dihydrogen phosphate, 14.3 g of disodium hydrogen phosphate dihydrate and 2.0 g of potassium chloride in 1000 ml of water. Store at room temperature to prevent crystallisation. Dilute to 10 times its volume with water before use.

Citric acid solution. Dissolve 10.51 g of citric acid in 1000 ml of water and adjust the solution to pH 4.0 with a 400 g/l solution of sodium hydroxide.

Washing buffer. PBS containing 0.5 g/l of polysorbate 20.

Diluent block buffer. PBS containing 0.5 g/l of polysorbate 20 and 25 g/l of dried skimmed milk.

Peroxidase substrate. Shortly before use, dissolve 10 mg of
diammonium 2,2'-azinobis(3-ethylbenzothiazoline-6-sulphonate) (ABTS) in 20 ml of citric acid solution. Immediately before use add 5 µl of strong hydrogen peroxide solution.

**Method**

The description below is given as an example of a suitable plate lay-out but others may be used. Wells 1A-H are for negative control serum and wells 2A-H and 3A-H are for positive control serum for assay monitoring. Wells 4-12A-H are for negative control serum and wells 2A-H and 3A-H are for test samples. Wells 1A-H are for test sera. Allocate the negative control serum to column 12, the positive control to column 11, and a negative control to column 10. The wells of row 11 are a reference guinea-pig tetanus antitoxin in the first well of a row. Place 100 µl of undiluted test sera in the first well of the required number of rows. Using a multichannel micropipette, make two fold serial dilutions of positive control serum to column 1, positive control serum to columns 2 and 3 and test sera to columns 4-12 and add 100 µl of each serum to the first 2 wells of the column to which it is allocated. Using a multi channel micropipette, make twofold serial dilutions from row B down the plate to row H by transferring 100 µl to the following well. Discard 100 µl from the last row so that all wells contain 100 µl. Incubate at 37° for 2 h. Wash thoroughly with washing buffer. Prepare a suitable dilution of peroxidase conjugate in diluent block buffer and add 100 µl to each well. Incubate at 37° in a humid atmosphere for 1 h. Wash the plates thoroughly with washing buffer. Add 100 µl of peroxidase substrate to each well. Allow to stand at room temperature, protected from light, for 30 min. Read the plates at 405 nm in the same order as addition of substrate was made.

**Determination of antibody titre in guinea-pig serum by toxin- or toxoid-binding inhibition (ToBI).** Tetanus toxin or toxoid is added to serial dilutions of test and reference sera; the serum/antigen mixtures are incubated overnight. To determine unbound toxin or toxoid, the mixtures are transferred to an ELISA plate coated with tetanus antitoxin. Peroxidase-conjugated equine anti-tetanus IgG is added followed by a peroxidase substrate. Optical density is measured and the antibody titre is calculated using the usual statistical methods. A positive control serum and a negative control serum are included on each plate to monitor assay performance.

**Reagents and equipment**

Round-bottomed, rigid polystyrene microtitre plates.

Flatt-bottomed ELISA plates.

Tetanus toxin or tetanus toxoid.

Clostridium tetani guinea-pig antiserum (for vaccines-human use) reference preparation.

Equine anti-tetanus IgG.

Peroxidase-conjugated equine anti-tetanus IgG.

Carbonate buffer pH 9.6. Dissolve 1.5 g of anhydrous sodium carbonate, 2.39 g of sodium hydroxide carbonate and 0.2 g of sodium azide in 1000 ml of water; adjust to pH 9.6 and autoclave at 121° for 20 min.

Sodium acetate buffer pH 5.5. Dissolve 90.2 g of anhydrous sodium acetate in 900 ml of water; adjust to pH 5.5 using a saturated solution of citric acid monohydrate and dilute to 1000 ml with water.

Phosphate buffered saline pH 7.2 (PBS). Dissolve 135.0 g of sodium chloride, 20.55 g of disodium hydrogen phosphate dihydrate and 4.80 g of sodium dihydrogen phosphate monohydrate in water and dilute to 15 litres with the same solvent. Autoclave at 100° for 60 min.

Diluent buffer. PBS containing 5 g/l of bovine albumin and 0.5 g/l of polysorbate 80.

Block buffer. PBS containing 5 g/l of bovine albumin.

Tetramethylbenzidine solution. 6 g/l solution of tetramethylbenzidine in alcohol. The substance dissolves within 30-40 min at room temperature.

Peroxidase substrate. Mix 90 ml of water, 10 ml of sodium acetate buffer pH 5.5, 1.67 ml of tetramethylbenzidine solution and 20 µl of strong hydrogen peroxide solution.

Washing solution. Tap water containing 0.5 g/l of polysorbate 80.

**Method**

Block the round-bottomed polystyrene microtitre plates by placing in each well 150 µl of block buffer. Cover the plates with a lid or sealer. Incubate in a humid atmosphere at 37° for 1 h. Wash the plates thoroughly with washing solution. Place 100 µl of PBS in each well. Place 100 µl of reference guinea-pig tetanus antitoxin in the first well of a row. Place 100 µl of undiluted test sera in the first well of the required number of rows. Using a multichannel micropipette, make it two fold serial dilutions across the plate (up to column 10), by transfer of 100 µl to the following well. Discard 100 µl from the last column so that all wells contain 100 µl. Prepare 0.1 Lf/ml solution of tetanus toxin or toxoid using PBS a diluent. Add 40 µl of this solution to all wells except those column 12. The wells of row 11 are a positive control. Add 40 µl of PBS to the wells of column 12 (negative control). Shake the plates gently and cover them with lids. Coat the ELISA plates: immediately before use make
a suitable dilution of equine anti-tetanus IgG in carbonate buffer pH 9.6 and add 100 µl to all wells. Incubate the 2 series of plates overnight in a humid atmosphere at 37°. To avoid temperature gradient effects, do not stack more than 4 plate high. Cover the plates with lids. On the following day, wash the ELISA plates thoroughly with washing solution. Block the plates by placing in each well 125 µl of block buffer. Incubate at 37° in a humid atmosphere for 1 h. Wash the plates thoroughly with washing solution. Transfer 100 µl of the pre-incubation mixture from the polystyrene plates to the corresponding wells of the ELISA plates, starting with column 12 and then from 1 to 11. Cover the plates with a lid. Incubate at 37° in a humid atmosphere for 2 h. Wash the ELISA plates thoroughly with washing solution. Make a suitable dilution (a 1 in 4000 dilution has been found suitable) of the peroxidase-conjugated equine anti-tetanus IgG in diluent buffer. Add 100 µl of the dilution to each well and cover the plates with a lid. Incubate at 37° in a humid atmosphere for 1.5 h. Wash the ELISA plates thoroughly with washing solution. Add 100 µl of peroxidase substrate to each well. A blue colour develops. Incubate the plates at room temperature. Stop the reaction at a given time (within 10 min) by the addition of 100 µl of 2 M sulphuric acid to each well in the same order as the addition of substrate. The colour changes from blue to yellow. Measure the absorbance (2.4.7) at 450 nm immediately after addition of sulphuric acid or maintain the plates in the dark until reading.

(d) Any other validated serological assay in guinea-pigs/mice approved by National Regulatory Authority.

Labelling. The label states (1) the human dose (ml); (2) the minimum units per single human dose or the minimum International Units per single human dose if potency test done by challenge method or both; (3) the name and the amount of the adsorbent and preservative; (4) that the vaccine must be shaken before use; (5) that the vaccine is not to be frozen.

**Tick-borne Encephalitis Vaccine (Inactivated)**

Tick-borne Encephalitis Vaccine (Inactivated) is a liquid preparation of a suitable strain of tick-borne encephalitis virus grown in cultures of chick-embryo cells or other suitable cell cultures and inactivated by a suitable, validated method.

**Production**

**General provisions**

The vaccine complies with the General Requirements of Vaccines for Human Use.

Production of the vaccine is based on a virus seed lot system. The production method shall have been shown to yield consistently vaccines comparable with the vaccine of proven clinical efficacy and safety in man. The virus in the final vaccine shall not have undergone more passages from the master seed lot than the virus in the vaccine used in clinical trials.

The production method is validated to demonstrate that the product, if tested, would comply with the test for abnormal toxicity and immunogenicity.

**Substrate for virus propagation**

The virus is propagated in chick embryo cells prepared from eggs derived from a chicken flock free from specified pathogens (2.7.7) or in other suitable cell cultures.

**SEED LOT**

The strain of virus used is identified by historical records that include information on the origin of the strain and its subsequent manipulation. Virus seed lots are stored at or below -60°.

Only a seed lot that complies with the following requirements may be used for virus propagation.

**Identification**

Each seed lot is identified as containing the vaccine strain of tick-borne encephalitis virus by a suitable immunochemical method, preferably using monoclonal antibodies.

**Virus concentration.** The virus concentration of each seed lot is determined by titration in suitable cell cultures to monitor consistency of production.

**Extraneous agents** (2.7.3). Each seed lot complies with the requirements for extraneous agents in viral vaccines for human use; the tests in cell cultures are carried out in human and simian cells only.

**PROPAGATION AND HARVEST**

All processing of the cell cultures if performed under aseptic conditions in an area where no other cells are being handled. Serum and trypsin used in the preparation of cell suspensions and media used must be shown to be free from extraneous agents. The cell culture media may contain a pH indicator such as phenol red and approved antibiotics at the lowest effective concentration. At least 500 ml of the cell cultures employed for vaccine production is set aside as uninfected cell cultures (control cells).

Only a single harvest that complies with the following requirements may be used in the preparation of the inactivated harvest.

**Identification**

The single harvest is shown to contain tick-borne encephalitis virus by a suitable immunochemical method, preferably using
monoclonal antibodies, or by virus neutralization in cell cultures.

**Sterility** (2.2.11). Complies with the test for sterility carried out using 10 ml for each medium.

**Mycoplasma** (2.7.4). Complies with the test for mycoplasmas carried out using 1 ml for each medium.

**Control cells**. The control cells comply with the tests for extraneous agents (2.7.3). If the vaccine is produced using a cell-bank system, the control cells comply with a test for identification.

**Virus concentration**. Determine the virus concentration by titration in suitable cell culture to monitor consistency of production.

**Inactivation**

To avoid interference, viral aggregates are removed by filtration immediately before the inactivation process. The virus suspension is inactivated by a validated method; the method shall have been shown to be consistently capable of inactivating tick-borne encephalitis virus without destroying the antigenic and immunogenic activity; as part of the validation studies, an inactivation curve is plotted representing residual live virus concentration measured on not fewer than three occasions. If formaldehyde is used for inactivation, the presence of an excess of free formaldehyde is verified at the end of the inactivation process.

Only an inactivated harvest that complies with the following requirements may be used in the preparation of the final bulk vaccine.

**Residual infective virus**. Inoculate a quantity of the inactivated harvest equivalent to not less than ten human doses of vaccine in the final lot into primary chicken fibroblast cell cultures, or other cells shown to be at least as sensitive to tick-borne encephalitis virus with not less than 3 cm² of cell sheet per ml of inoculum. Incubate at 37 ± 1° for 14 days. No cytopathic effect is detected at the end of the incubation period. Collect the culture fluid and inoculate 0.03 ml intracerebrally into each of not fewer than ten mice about 4 weeks old. Observe the mice for 14 days. They show no evidence of tick-borne encephalitis virus infection.

**Purification**

Several inactivated single harvests may be pooled before concentration and purification by suitable methods, preferably by continuous-flow, sucrose density-gradient centrifugation. Only a purified, inactivated harvest that complies with the following requirements may be used in the preparation of final bulk vaccine.

**Sterility** (2.2.11). Complies with the test for sterility, carried out using 10 ml for each medium.

**Specific activity**. Determine the antigen content of the purified, inactivated harvest by a suitable immunochemical method (2.2.14). Determine the total protein content by a suitable method. The specific activity, calculated as the antigen content per unit mass of protein, is within the limits approved for the specific product.

**FINAL BULK VACCINE**

The final bulk vaccine is prepared from one or more purified, inactivated harvests.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

Only a final lot that is satisfactory with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided that the tests for free formaldehyde, bovine serum albumin (where applicable) and pyrogens and the assay have been carried out satisfactory results on the final bulk vaccine, they may be omitted on the final lot.

**Identification**

The vaccine is shown to contain tick-borne encephalitis virus antigen by a suitable immunochemical method using specific antibodies or by the mouse immunogenicity test described under Assay.

**Tests**

**Aluminium** (2.3.9). Maximum 1.25 mg per single human dose, if aluminium hydroxide or hydrated aluminium phosphate is used as the adsorbent.

**Free formaldehyde** (2.3.20). Maximum 0.1 g/l.

**Bovine serum albumin**. If bovine serum albumin has been used during production, the vaccine contains not more than 50 ng per single human dose, determined by a suitable immunochemical method (2.2.14).

**Sterility** (2.2.11). Complies with the test for sterility.

**Pyrogens** (2.2.8). Complies with the test for pyrogens. Inject into each rabbit, per kg of body mass, one dose of vaccine.

**Assay**

The potency is determined by comparing the dose necessary to protect a given proportion of mice against the effects of a lethal dose of tick-borne encephalitis virus, administered intraperitoneally, with the quantity of a reference preparation...
of tick-borne encephalitis vaccine necessary to provide the same protection. For this comparison an approved reference preparation and a suitable preparation of tick-borne encephalitis virus from an approved strain for use as the challenge preparation are necessary.

The following is cited as an example of a method that has been found suitable for a given vaccine.

Selection and distribution of test animals. Use healthy mice weighing between 11 and 17 g derived from the same stock. Distribute the mice into not less than six groups of a suitable size to meet the requirements for validity of the test; for titration of the challenge suspension, use not fewer than four groups of ten mice. Use mice of the same sex or distribute males and females equally between groups.

Determination of potency of the vaccine. Prepare not less than three suitable dilutions of the vaccine under examination and of the reference preparation; in order to comply with validity criteria four to five dilutions will usually be necessary. Prepare dilutions such that the most concentrated suspension is expected to protect more than 50 per cent of the animals and the least concentrated suspension less than 50.0 per cent. Allocate each dilution to a different group of mice and inject subcutaneously into each mouse 0.2 ml of the dilution allocated to its group. Seven days later make a second injection using the same dilution scale. 14 days after the second injection prepare a suspension of the challenge virus containing not less than 100 LD₅₀ in 0.2 ml. Inject 0.2 ml of this virus suspension intraperitoneally into each vaccinated mouse. To verify the challenge dose, prepare a series of not fewer than three dilutions of the challenge virus suspension at not greater than one-hundredfold intervals. Allocate the challenge suspension and the four dilutions, one to each of the five groups of ten mice, and inject intraperitoneally into each mouse 0.2 ml of the challenge suspension or the dilution allocated to its group. Observe the animals for 21 days after the challenge and record the number of mice that die in the period between 7 and 21 days after the challenge.

Calculations. Calculate the results by the usual statistical methods for an assay with quantal responses (5.7).

Validity criteria. The test is not valid unless (1) the concentration of the challenge virus is not less than 100 LD₅₀; (2) for both the vaccine under examination and the reference preparation the 50.0 per cent protective dose (PD₅₀) lies between the largest and smallest doses given to the mice; (3) the statistical analysis shows a significant slope and no significant deviation from linearity and parallelism of the dose-response lines; (4) the fiducial limits (P = 0.95) are not less than 33.0 per cent and not more than 300.0 per cent of the estimated potency.

Potency requirement. Include all valid tests to estimate the mean potency and the fiducial limits (P = 0.95) for the mean potency; compute weighed means with the inverse of the squared standard error as weights. The vaccine complies with the test if the estimated potency is not less than that approved by the competent authority, based on data from clinical efficacy trials.

Labelling. The label states (1) the strain of virus used in preparation; (2) the type of cells used for production of the vaccine.

Tuberculin Purified Protein Derivative

Tuberculin PPD; Tuberculin Purified Protein Derivative for Human Use

Tuberculin Purified Protein Derivative is a preparation made from the heat-treated products of growth and lysis of one or more strains of Mycobacterium tuberculosis that reveal delayed hypersensitivity in animals sensitised by a micro-organism of the same species.

Production

It is prepared from the water-soluble fraction obtained by heating in free-flowing steam or in an autoclave and subsequently filtering cultures of the mycobacteria grown in a suitable liquid medium. The active fraction in the filtrate, which is predominantly protein, is separated by precipitation, washed and redissolved. The preparation is free from mycobacteria. An antimicrobial preservative that does not give rise to false positive reactions, such as 0.5 per cent w/v of phenol, and a suitable stabiliser may be added. Phenol is not added to preparations that are to be freeze-dried. The final sterile product is distributed into sterile glass containers which are then sealed so as to prevent microbial contamination or alternatively it is freeze-dried and the containers subsequently sealed.*

* To ensure availability of a preparation of uniform potency, Tuberculin Purified Protein Derivative is produced and issued by the Statens Serum Institute, Denmark as a powder to be reconstituted as stated on the label.

The preparation may be issued either as a sterile liquid or as a freeze-dried product. If issued as a liquid, it is in a ready-to-use form and 0.1 ml constitutes one intradermal dose containing appropriate number of Units. If issued as a freeze-dried product, it should yield a ready-to-use preparation when reconstituted as per manufacturer’s instructions.

Description. A colourless or pale, straw-coloured liquid, or dry cream-coloured powder, or pellet.

The preparation, reconstituted if necessary as stated on the label, complies with the following requirements.
Identification

A. When progressively increasing doses are injected intradermally into specifically sensitised guinea-pigs, reactions occur at the points of injection, varying from erythema to necrosis. When similar injections are administered to non-sensitised guinea-pigs no such reactions occur.

B. The potency test described below serves as a test for identity if it is performed on material from the final containers.

Tests

pH (2.4.24). 6.5 to 7.5.
Phenol (if present) (2.3.36). Not more than 0.5 per cent w/v.
Sterility (2.2.11). Complies with the tests for sterility.

Potency. Carry out the biological assay of tuberculin purified protein derivative described below.

Tuberculin Purified Protein Derivative in freeze-dried form complies with the following additional requirements.

Live mycobacteria

A. Inject 5.0 ml intraperitoneally or subcutaneously into each of two guinea-pigs weighing between 300 and 400 g. Observe the animals for not less than 42 days. Kill the animals and carry out an autopsy. No guinea-pig shows signs of infection with mycobacteria.

B. Carry out tests for live mycobacteria in the preparation under examination using suitable culture media. No growth of mycobacteria should occur.

Sensitising effect. Inject intradermally into each of three guinea-pigs three times, at intervals of 5 days, a dose of the preparation under examination containing about 500 Units in a volume of 0.1 ml. Two to three weeks after the third injection inoculate the same dose intradermally into these animals and into a control group of three guinea-pigs of the same weight but that have not had any previous injections of tuberculin. The reactions of the two groups are not significantly different after 48 to 72 hours.

Toxicity. Inject subcutaneously into 2 healthy guinea-pigs, weighing not less than 250 g and which have not previously been treated with any material which will interfere with the test, 0.5 ml of a solution containing 1,00,000 Units per ml. No harmful effects are produced within 7 days.

Biological assay

The potency of tuberculin purified protein derivative is determined by comparing the dose necessary to reveal delayed hypersensitivity in guinea-pigs or other animals hypersensitised with mycobacteria of the same type as that used in the preparation of the tuberculin purified protein derivative with the dose of the appropriate Standard Preparation necessary to give the same effect. The estimated potency is not less 80 per cent and not more than 125 per cent of the stated potency. The fiducial limits of error are not less than 64 per cent and not more than 156 per cent of the stated potency.

Standard Preparation

The Standard Preparation is the 1st International Standard for Tuberculin, purified protein derivative (PPD), mammalian, established in 1951, consisting of PPD derived from cultures of M. tuberculosis (supplied in ampoules containing 5,00,000 Units) or another suitable preparation the potency of which has been determined in relation to the International Standard.

Method

Sensitise 12 guinea-pigs each weighing not less than 400 g by the intramuscular injection of a total of about 0.5 ml of a suspension in a suitable mineral oil with or without emulsifier and containing 0.1 mg per ml of heat-inactivated, dried mycobacteria of the same type as that used in the preparation of tuberculin. Use phosphate-buffered saline pH 7.4 containing 0.005 per cent w/v of polysorbate 80 to prepare the dilutions of the Standard preparation and of the preparation under examination and to reconstitute freeze-dried preparations containing no stabiliser. Not less than 1 month and not more than 6 months later carry out the following test:

Shave the flanks to provide space for at least three reactions on each side, but not more than a total of 12 injection sites per animal. Use at least three doses of the Standard preparation and at least three doses of the preparation under examination, the highest dose being about 10 times as strong as the lowest. Dilute the preparations so that the lesions produced are 8 to 25 mm in diameter. Allocate the doses to the available sites in a random manner, in a Latin square design. Inject each dose intradermally in the same volume (0.1 or 0.2 ml) at the sites to which it has been allocated. Measure the diameters of the lesions after 24 to 48 hours and calculate the result of the test using standard statistical methods on the basis that the lesion diameters are directly proportional to the logarithm of the concentration of the tuberculin.

Storage. Store in light-resistant containers at a temperature between 2° and 8°. It should not be allowed to freeze.

Labelling. The label states (1) the number of Units per dose of 0.1 ml or per ml or per mg; (2) the total volume in the container (for liquid preparation); (3) the nature and quantity of the reconstituting liquid (for the freeze-dried preparation); (4) the name and proportion of any added substances; (5) the species or strain used; (6) the storage conditions; (7) the date after which the contents are not intended to be used; (8) that care
should be taken to avoid inhaling the powder (for the freeze-dried preparation).

**Typhoid (Strain Ty 21a) Vaccine, Live (Oral)**

Typhoid Vaccine (Live, Oral, strain Ty 21a) is a freeze-dried preparation of the live *Salmonella typhi* strain Ty 21a grown in a suitable medium. When presented in capsules, the vaccine complies with the tests stated under Capsules.

**Production**

**Choice of vaccine strain**

The main characteristic of the strains is the defect of the enzyme uridine diphosphate-galactose-4 epimerase. The activities of galactopermease, galactokinase and galactose-1-phosphate uridyl-transferase are reduced by 50 to 90 per cent. Whatever the growth conditions, the strain does not contain Vi antigen. The strain agglutinates to anti-O:9 antiserum only if grown in medium containing galactose. It contains the flagellar H:d antigen and does not produce hydrogen sulphide on Kligler iron agar. The strain is nonvirulent for mice. Cells of strain Ty 21a lyse if grown in the presence of 1.0 per cent of galactose.

**SEED LOT**

The vaccine is prepared using a seed-lot system. The working seed lots represent not more than one subculture from the master seed lot. The final vaccine represents not more than four subcultures from the original vaccine on which were made the laboratory and clinical tests showing the strain to be suitable.

Only a master seed lot that complies with the following requirements may be used in the preparation of working seed lots.

**Galactose metabolism**

In a spectrophotometric assay, no activity of the enzyme uridine diphosphate-galactose-4 epimerase is found in the cytoplasm of strain Ty 21a compared to strain Ty 2.

**Biosynthesis of lipopolysaccharide**

Lipopolysaccharides are extracted by the hot-phenol method and examined by size-exclusion chromatography (2.4.16). Strain Ty 21a grown in medium free of galactose shows only the rough (R) type of lipopolysaccharide.

**Serological characteristics**

Strain Ty 21a grown in a synthetic medium without galactose does not agglutinate to specific anti-O:9 antiserum. Whatever the growth conditions, strain Ty 21a does not agglutinate to Vi antiserum. Strain Ty 21a agglutinates to H:d flagellar antiserum.

**Biochemical markers**

Strain Ty 21a does not produce hydrogen sulphide on Kligler iron agar. This property serves to distinguish Ty 21a from other galactose-epimerase-negative *S. typhi* strains.

**Cell growth**

Strain Ty 21a cells lyse when grown in the presence of 1.0 per cent of galactose.

**PROPAGATION AND HARVEST**

The bacteria from the working seed lot are multiplied in a preculture, subcultured once and are then grown in a suitable medium containing 0.001 per cent of galactose at 30° for 13 to 15 hours. The bacteria are harvested. The harvest must be free from contaminating micro-organisms.

Only a single harvest that complies with the following requirements may be used for the preparation of the freeze-dried harvest.

**pH** (2.4.24). 6.8 to 7.5.

**Optical density**

The optical density of the culture, measured at 546 nm, is 6.5 to 11.0. Before carrying out the measurement, dilute the culture so that a reading in the range 0.1 to 0.5 is obtained and correct the reading to take account of the dilution.

**Identification**

Culture bacteria on an agar medium containing 1.0 per cent of galactose and bromothymol blue. Light blue, concave colonies, transparent due to lysis of cells, should be found. No yellow colonies (galactose-fermenting) should be found.

**FREEZE-DRIED HARVEST**

The harvest is mixed with a suitable stabilizer and freeze-dried by a process that ensures the survival of at least 10.0 per cent of the bacteria and to a water content shown to be favourable to the stability of the vaccine. No antimicrobial preservative is added to the vaccine.

Only a freeze-dried harvest that complies with the following tests may be used for the preparation of the final bulk.

**Identification**

Culture bacteria are examined on an agar medium containing 1.0 per cent of galactose and bromothymol blue. Light blue, concave colonies, transparent due to lysis of cells, should be found. No yellow colonies (galactose-fermenting) should be found.
Number of live bacteria
Not less than $1 \times 10^{11}$ live S. typhi strain Ty 21a per gram.

**Water** (2.4.43). 1.5 to 4.0 per cent, determined by the semi-micro determination of water or any other validated method.

**FINAL BULK VACCINE**
The final bulk vaccine is prepared by aseptically mixing one or more freeze-dried harvests with a suitable sterile excipient.

Only a final bulk that complies with the following requirement may be used in the preparation of the final lot.

**Number of live bacteria.** Not less than $40 \times 10^9$ live S. typhi strain Ty 21a per gram.

**FINAL LOT**
The final bulk vaccine is distributed under aseptic conditions into capsules with a gastro-resistant shell or into suitable containers.

Only a final lot that is satisfactory with respect to Identification, Tests and Number of live bacteria will be released for use, except that in the determination of number of live bacteria each dosage unit must contain not less than $4 \times 10^9$ live bacteria.

**Identification**
Culture bacteria from the vaccine under examination on an agar medium containing 1.0 per cent of galactose and bromothymol blue. Light blue, concave colonies transparent due to lysis of cells, should be found. No yellow colonies (galactose-fermenting) should be found.

**Tests**

**Microbial contamination** (2.2.9). Carry out the test using suitable selective media. Determine the total viable count using the plate-count method. The number of contaminating microorganisms per dosage unit is not greater than $10^2$ bacteria and 20 fungi. No pathogenic bacterium, particularly Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and no Salmonella other than strain Ty 21a are found.

**Water** (2.4.43). 1.5 to 4.0 per cent.

**Number of live bacteria**
Carry out the test using not less than five dosage units. Homogenise the contents of the dosage units in a 0.9 per cent w/v solution of sodium chloride at 4°C using a mixer in a cold room with sufficient glass beads to emerge from the liquid. Immediately after homogenization prepare a suitable dilution of the suspension using cooled diluent and inoculate brain heart infusion agar, incubate at $36 \pm 1^\circ$ for 20 to 36 hours. The vaccine contains not less than $2 \times 10^9$ live S. typhi Ty 21a bacteria per dosage unit.

**Labelling.** The label states (1) the minimum number of live bacteria per dosage unit; (2) that the vaccine is for oral use only.

**Typhoid Polysaccharide Vaccine**
Typhoid Polysaccharide Vaccine is a preparation of purified Vi capsular polysaccharide obtained from Salmonella typhi Ty2 strain or some other suitable strain of known origin and history that has the capacity to produce Vi polysaccharide, and which have been characterized by suitable biochemical, physicochemical, serological or molecular methods.

Capsular polysaccharide is a partly 3-O-acetylated repeated units of 2-acetylamino-2-deoxy-D-galactopyranuronic acid with â-(1\(^\rightarrow\)4)-linkages.

**Production**

**General provisions**
The production of Vi polysaccharide is based on a defined seed-lot system. The method of production shall have been shown to yield consistently Vi-polysaccharide typhoid vaccines of adequate immunogenicity and safety in man. The production method is validated to demonstrate that the product, if tested, would comply with the tests for abnormal toxicity.

**SEED LOT**
The strain of S. typhi used for the master seed lot shall be identified by historical records that include information on its origin and by its biochemical and serological characteristics. Cultures from the working seed lot shall have the same characteristics as the strain that was used to prepare the master seed lot, shall be demonstrated along with adequate documentation.

Only a strain that has the following characteristics may be used in the preparation of the vaccine: (a) stained smears from a culture are typical of S. typhi; (b) the culture utilises glucose without production of gas; (c) colonies on agar are oxidase-negative; (d) a suspension of the culture agglutinates specifically with an appropriate Vi antiserum or colonies form haloes on an agar plate containing a suitable Vi antiserum.

**PROPAGATION AND HARVEST**
The working seed lot is cultured on a solid medium, which may contain blood-group substances, or a liquid medium; the inoculum obtained is transferred to a liquid medium, which is used to inoculate the final medium. The liquid medium used and the final medium are semi-synthetic, free from substances that are precipitated by cetrimonium bromide and do not contain blood-group substances or high-molecular-mass
polysaccharides, unless it has been demonstrated that they are removed by the purification process. The bacterial purity of the culture is verified by microscopic examination of Gram-stained smears and by inoculation into appropriate media. The culture is then inactivated at the beginning of the stationary phase by the addition of formaldehyde. Bacterial cells are eliminated by centrifugation; the polysaccharide is precipitated from the culture medium by addition of hexadecyltrimethylammonium bromide (cetrimonium bromide). The precipitate is harvested and may be stored at or below -20° before purification.

**Purified Vi Polysaccharide**

The polysaccharide is purified, after dissociation of the polysaccharide/cetrimonium bromide complex, using suitable procedures to eliminate successively nucleic acids, proteins and lipopolysaccharides. The polysaccharide is precipitated in its salt form and dried at 5 ± 3°; the powder obtained constitutes the purified Vi polysaccharide. The loss on drying is determined by thermogravimetry, Karl Fischer or any other suitable method and is used to calculate the results of the chemical tests shown below with reference to the dried substance.

Only those pools of purified Vi polysaccharide that comply with the following requirements may be used in the preparation of the final bulk:

**Protein** (2.7.1). Not more than 10 mg per gram of polysaccharide, calculated with reference to the dried substance.

**Nucleic acids** (2.7.1). Not more than 20 mg per gram of polysaccharide, calculated with reference to the dried substance.

**O-Acetyl groups** (2.7.1). Not less than 2 mmol per gram of polysaccharide, calculated with reference to the dried substance.

**Molecular size.** Examine by gel filtration or size-exclusion chromatography (2.4.16) using cross-linked agarose for chromatography. Use a column 0.9 m long and 16 mm in internal diameter equilibrated with a solvent having an ionic strength of 0.2 mol per kg and a pH of 7.0 to 7.5. Apply about 5 mg of polysaccharide in a volume of 1 ml to the column and elute at about 20 ml/h. Collect fractions of about 2.5 ml. Determine the point corresponding to \( K_0 = 0.25 \) and make two pools consisting of fractions eluted before and after this point. Determine O-acetyl groups on the two pools. Not less than 50 per cent of the polysaccharide is found in the pool containing fractions eluted before \( K_0 = 0.25 \).

**Identification**

Carry out an identification test using a suitable immunochemical method (2.2.14).

**Bacterial endotoxins** (2.2.3). Determine by a suitable method, the content should not be more than 150 IU per mg of polysaccharide.

**FINAL BULK VACCINE**

One or more batches of purified Vi polysaccharide are dissolved in a suitable solvent, which may contain an antimicrobial preservative, so that the volume corresponding to one dose contains 25 µg of polysaccharide and the solution is isotonic with blood (250 mosm/kg to 350 mosm/kg).

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot:

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**Antimicrobial preservative.** Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount. If phenol has been used in the preparation, the content is not more than 2.5 g/l.

**FINAL LOT**

The final bulk vaccine is distributed and filled aseptically into sterile containers. The containers are closed so as to prevent contamination.

Only a final lot that is satisfactory with respect to each of the requirements prescribed below under Identification, Tests and Assay and with the requirements for Bacterial endotoxins may be released for use. Provided the tests for free formaldehyde and antimicrobial preservative have been carried out on the final bulk vaccine, they may be omitted on the final lot.

The vaccine contains minimum of 25 µg purified Vi-Polysaccharide per dose of 0.5 ml.

**Identification**

Carry out an identification test using a suitable immunochemical method (2.2.14).

**Tests**

**Sterility** (2.2.11). Complies with the tests for sterility.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity.

**pH** (2.4.24). 6.5 to 7.5.

**O-Acetyl groups** (2.7.1). 0.085 (± 25 per cent) µmol per dose (25 µg of polysaccharide).

**Test solution.** Place 3 ml of the vaccine in each of three tubes (two reaction solutions and one correction solution).
Reference solutions. Dissolve 0.150 g of acetylcholine chloride in 10 ml of water (stock solution containing 15 g/l of acetylcholine chloride). Immediately before use, dilute 0.5 ml of the stock solution to 50 ml with water (working dilution containing 150 µg/ml of acetylcholine chloride). In ten tubes, place in duplicate (reaction and correction solutions) 0.1 ml, 0.2 ml, 0.5 ml, 1.0 ml and 1.5 ml of the working dilution. Prepare a blank using 3 ml of purified water.

Make up the volume in each tube to 3 ml with water. Add 0.5 ml of a mixture of 1 volume of water and 2 volumes of dilute hydrochloric acid to each of the correction tubes and to the blank. Add 1.0 ml of alkaline hydroxylamine solution to each tube. Allow the reaction to proceed for exactly 2 min and add 0.5 ml of a mixture of 1 volume of water and 2 volumes of dilute hydrochloric acid to each of the reaction tubes. Add 0.5 ml of a 20 per cent w/v solution of ferric chloride in 0.2 M hydrochloric acid to each tube, stopper the tubes and shake vigorously to remove bubbles.

Measure the absorbance of each solution at 540 nm using the blank as the compensation liquid. For each reaction solution, subtract the absorbance of the corresponding correction solution. Draw a calibration curve from the corrected absorbance for the five reference solutions and the corresponding content of acetylcholine chloride and read from the curve the content of acetylcholine chloride in the test solution for each volume tested. Calculate the mean of the two values.

1 mol of acetylcholine chloride (181.7 g) is equivalent to 1 mol of O-acetyl (43.05 g).

Free formaldehyde (2.3.20). Maximum 0.2 g/l.

Antimicrobial preservative. Where applicable, determine the amount of antimicrobial preservative by a suitable chemical method. The content is not less than 85.0 per cent and not greater than 115.0 per cent of the intended amount.

If phenol has been used in the preparation, the content is not more than 2.5 g/l.

Assay

Determine Vi polysaccharide content by a suitable immunochemical method (2.2.14) using a reference purified polysaccharide. The estimated amount of polysaccharide per dose is 80.0 per cent to 120.0 per cent of the content stated on the label. The fiducial limits of error (P = 0.95) of the estimated amount of polysaccharide are not less than 80.0 per cent and not more than 120.0 per cent.

Labelling. The label states (1) the number of micrograms of polysaccharide per human dose (25 µg); (2) the total quantity of polysaccharide in the container.

Typhoid Vaccine

Typhoid Vaccine is a sterile suspension of inactivated Salmonella typhi containing not less than 5 x 10⁸ and not more than 1 x 10⁹ bacteria per human dose. The human dose does not exceed 1.0 ml.

Production

The vaccine is prepared using a seed-lot system from a suitable strain of S. typhi such as, Ty 2. The final vaccine represents not more than 3 subcultures from the strain on which were made the laboratory and clinical tests that showed it to be suitable. The bacteria are inactivated by acetone, by formaldehyde, by phenol or by heating or by a combination of the last two methods.

The production method is validated to demonstrate that the product, if tested, would comply with the test for abnormal toxicity (2.2.1) modified to the extent that 0.5 ml of the vaccine is injected subcutaneously or intramuscularly or intraperitoneally into each mouse and 1.0 ml into each guinea-pig.

Identification

It is identified by specific agglutination.

Phenol (2.3.36). If phenol has been used in the preparation, the concentration is not more than 0.5 per cent w/v.

Antigenic power. When injected into susceptible laboratory animals, it elicits anti-O, anti-H and, to a lesser extent, anti-Vi agglutinins.

Sterility (2.2.11). Complies with the test for sterility.

Labelling. The label states (1) the method used to inactivate the bacteria; (2) the number of bacteria per human dose.

Typhoid Vaccine (Freeze Dried)

Freeze Dried Typhoid Vaccine is a freeze-dried preparation of inactivated Salmonella typhi. The vaccine is reconstituted as stated on the label to give a uniform suspension containing not less than 5 x 10⁸ and not more than 1 x 10⁹ bacteria per human dose. The human dose does not exceed 1.0 ml of the reconstituted vaccine.

Production

The vaccine is prepared from a seed-lot system from a suitable strain of S. typhi, such as Ty 2. The final vaccine represents not more than 3 subcultures from the strain on which were made the laboratory and clinical tests that showed it to be suitable. The bacteria are inactivated either by acetone or by
formaldehyde or by heat. Phenol is not used in the preparation. The vaccine is distributed into sterile containers and freeze-dried to a moisture content favourable to the stability of the vaccine.

The production method is validated to demonstrate that the product, if tested, would comply with test for abnormal toxicity (2.2.1), modified to the extent that 0.5 ml of the vaccine is injected subcutaneously or intramuscularly or intraperitoneally into each mouse and 1.0 ml into each guinea-pig.

Identification

The vaccine reconstituted as stated on the label is identified by specific agglutination.

Antigenic power. When injected into susceptible laboratory animals, the reconstituted vaccine elicits anti-O, anti-H and, to a lesser extent, anti-Vi agglutinins.

Sterility (2.2.11). The reconstituted vaccine complies with the tests for sterility.

Water. Not more than 5.0 percent.

Labelling. The label states (1) the method used to inactivate the bacteria; (2) the number of bacteria per human dose; (3) that the vaccine should be used within 8 hours of reconstitution.

Varicella Vaccine, Live

Varicella Vaccine (Live) is a freeze-dried preparation of a suitable attenuated strain of Herpesvirus varicellae.

Production

General provisions

The production of vaccine is based on a virus seed-lot system and a cell-bank system. The production method shall have been shown to yield consistently live varicella vaccines of adequate immunogenicity and safety in man. The virus in the final vaccine shall not have been passaged in cell cultures beyond the 38th passage from the original isolated virus.

The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy.

Substrate for virus propagation

The virus is propagated in human diploid cells (2.7.2).

SEED LOT

The strain of varicella virus shall be identified as being suitable by historical records which shall include information on the origin of the strain and its subsequent manipulation. The virus shall at no time have been passaged in continuous cell lines. Seed lots are prepared in the same kind of cells as those used for the production of the final vaccine. To avoid the unnecessary use of monkeys in the test for neurovirulence, virus seed lots are prepared in large quantities and stored at temperatures below -20°, if freeze-dried, or below -60°, if not freeze-dried.

Only a virus seed lot that complies with the following requirements may be used for virus propagation.

Identification

The master and working seed lots are identified as varicella virus by serum neutralisation in cell culture, using specific antibodies.

Virus concentration. The virus concentration of the master and working seed lots is determined as prescribed under Assay to monitor consistency of production.

Extraneous agents (2.7.3). Complies with the requirements for seed lots for live virus vaccines; a sample of 50 ml is taken for the test in cell cultures.

Neurovirulence (2.7.5). Complies with the test for neurovirulence of live virus vaccines.

PROPAGATION AND HARVEST

All processing of the cell bank and subsequent cell cultures is done under aseptic conditions in an area where no other cells are handled. Approved animal (but not human) serum may be used in the media. Serum and trypsin used in the preparation of cell suspensions and media are shown to be free from extraneous agents. The cell culture medium may contain a pH indicator such as phenol red and approved antibiotics at the lowest effective concentration. It is preferable to have a substrate free from antibiotics during production. 5.0 per cent, but not less than 50.0 ml, of the cell cultures employed for vaccine production is set aside as uninfected cell cultures (control cells). The infected cells constituting a single harvest are washed, released from the support surface and pooled. The cell suspension is disrupted by sonication.

Only a virus harvest that complies with the following requirements may be used in the preparation of the final bulk vaccine.

Identification

The virus harvest contains virus that is identified as varicella virus by serum neutralisation in cell culture, using specific antibodies.

Virus concentration. The concentration of infective virus in virus harvests is determined as prescribed under assay to monitor consistency of production and to determine the
dilution to be used for the final bulk vaccine.

**Extraneous agents** (2.7.3). Use 50 ml for the test in cell cultures.

**Control cells.** The control cells of the production cell culture from which the single harvest is derived comply with a test for identity and with the requirements for extraneous agents (2.7.3).

**FINAL BULK VACCINE**

Virus harvests that comply with the above tests are pooled and clarified to remove cells. A suitable stabiliser may be added and the pooled harvests diluted as appropriate.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

**Sterility** (2.2.11). Carry out test for sterility using 10 ml of bulk for each sterility medium.

**FINAL LOT**

The final bulk vaccine is distributed aseptically into sterile, tamper-proof containers and freeze-dried to a moisture content shown to be favourable to the stability of the vaccine. The containers are then closed so as to prevent contamination and the introduction of moisture.

Only a final lot that is satisfactory with respect to each of the requirements given below under Identification, Tests and Assay may be released for use. Provided that the test for bovine serum albumin has been carried out with satisfactory results on the final bulk vaccine, it may be omitted on the final lot.

**Identification**

When the vaccine reconstituted as stated on the label is mixed with specific *Herpesvirus varicellae* antibodies, it is no longer able to infect susceptible cell cultures.

**Tests**

**Sterility** (2.2.11) Complies with the test for sterility.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity.

**Bovine serum albumin.** Not more than 0.5 µg per human dose, determined by a suitable immunochemical method (2.2.14).

**Water** (2.3.43). Not more than 3.0 per cent, determined by the semi-micro determination of water.

**Assay**

Titratre for infective virus, using at least ten cell cultures for each fourfold dilution or by a technique of equal precision. Use a suitable virus reference preparation to validate each assay. The virus concentration is not less than the minimum stated on the label.

**Labelling.** The label states (1) the strain of virus used for the preparation of the vaccine; (2) the type and origin of the cells used for the preparation of the vaccine; (3) that contact with disinfectants is to be avoided; (4) the minimum virus concentration; (5) that the vaccine is not to be administered to pregnant women; (6) the time within which the vaccine must be used after reconstitution.

**Viper Venom**

Daboia Venom

Viper Venom is the dried secretion obtained from the poison glands of *Vipera russelli* and other species of *Viperae* (Fam. Viperidae).

Viper Venom contains not less than 50 Mouse Units per mg.

**Production**

Immediately after extraction, the poisonous secretion is dried from the frozen state. The dried venom is pooled, mixed, dissolved in ice-cold *water for injection* and then filtered through a bacteria-proof filter to give a stock solution. Further dilutions of the stock solution are made with *water for injection* under aseptic conditions to give solutions with the required number of Mouse Units per ml. These solutions are then distributed in single dose sterile glass containers, dried from the frozen state and sealed at a pressure not exceeding 2.75 kPa.

**Description.** An almost white or very light yellow, dry powder which when mixed with *water* yields a clear solution with some insoluble residue.

**Identification**

A. Produces almost immediate coagulation of blood and citrated human plasma.

B. Mix the soluble fraction from at least 0.6 mg with 1 ml of *polyvalent antivenom serum* and incubate the mixture at 37° for 30 minutes. Inject 0.5 ml of the mixture intravenously into a group of mice weighing between 18 and 20 g. Observe the animals for 24 hours; no animal dies.

**Tests**

**Sterility** (2.2.11). Complies with tests for sterility.

**Assay.** Carry out the biological assay of snake venom described below:

**Biological assay of snake venom**

Dissolve a quantity of the freeze-dried venom equivalent to 50 Mouse Units in 25 ml of *saline solution*. Inject 0.5 ml
in intravenously into each of 10 mice weighing between 18 and 20 g and observe the animals for 24 hours. Not less than 3 and not more than 8 of the mice die in 2 to 24 hours. If the number of deaths is not within this range, change the dilution of the venom suitably.

Express the result in terms of number of Mouse Units per mg.

NOTE — The quantity in mg of the venom which will kill in 2 to 24 hours not less than 3 and not more than 8 mice represents one Mouse Unit.

Storage. Store in single dose, light-resistant containers.

Labelling. The label states (1) the number of Mouse Units per container; (2) the volume of water for injection to be used for reconstitution.

Yellow Fever Vaccine (Live)

Yellow Fever Vaccine (Live) is a freeze-dried preparation of the 17D strain of yellow fever virus grown in fertilised hen eggs.

Production

General provisions

The production of vaccine is based on a virus seed-lot system. The production method shall have been shown to yield consistently the yellow fever vaccine (live) of acceptable immunogenicity and safety for man.

The production method is validated to demonstrate that the product, if tested, would comply with the test for safety and efficacy.

Reference preparation. In the test for neurotropism, a suitable batch of vaccine known to have satisfactory properties in man is used as the reference preparation.

Substrate for virus propagation

Virus for the preparation of master and working seed lots and for all vaccine batches is grown in the tissues of chick embryos from a flock free from specified pathogens (2.7.7).

SEED LOT

The 17D strain shall be identified by historical records that include information on the origin of the strain and its subsequent manipulation. Virus seed lots are prepared in large quantities and stored at a temperature below -60°. Master and working seed lots shall not contain any human protein or added serum.

Unless otherwise justified and authorised, the virus in the final vaccine shall be between passage levels 204 and 239 from the original isolate of strain 17D. A working seed lot shall be only one passage from a master seed lot. A working seed lot shall be used without intervening passage as the inoculum for infecting the tissues used in the production of a vaccine lot, so that no vaccine virus is more than one passage from a seed lot that has passed all the safety tests.

Only a virus seed lot that complies with the following requirements may be used for virus propagation.

Identification

The master and working seed lots are identified as containing yellow fever virus by serum neutralisation in cell culture, using specific antibodies.

Extraneous agents (2.7.3). Each working seed lot complies with the test for extraneous agents.

PROPAGATION AND HARVEST

All processing of the fertilised eggs is done under aseptic conditions in an area where no other infectious agents or cells are handled at the same time. Two per cent but not less than twenty and not more than fifty eggs are set aside as uninfected control eggs. After inoculation and incubation at a controlled temperature, only living and typical chick embryos are harvested. The age of the embryo at the time of virus harvest is reckoned from the initial introduction of the egg into the incubator and shall not be more than 12 days. After homogenisation and clarification by centrifugation, the extract of embryonic pulp is tested as described below and kept at -70° or colder until further processing. Virus harvests that comply with the prescribed tests may be pooled. No human protein is added to the virus suspension at any stage during production. If stabilisers are added, they shall have been shown to have no antigenic or sensitising properties for man.

Only a single harvest that complies with the following tests may be used in the preparation of the final bulk vaccine.

Identification

The single harvest contains virus that is identified as yellow fever virus by serum neutralisation in cell culture, using specific antibodies.

Extraneous agents (2.7.3). Complies with the tests for extraneous agents.

Control eggs. Complies with the tests for extraneous agents (2.7.3).

Virus concentration. In order to calculate the dilution for formulation of the final bulk, each single harvest is titrated as described under Assay.

FINAL BULK VACCINE

Single harvests that comply with the tests prescribed above are pooled and clarified again. A test for protein nitrogen
content is carried out. A suitable stabiliser may be added and
the pooled harvests diluted as appropriate.

Only a final bulk vaccine that complies with the following
tests may be used in the preparation of the final lot.
Sterility (2.2.11). Carry out test for sterility using 10 ml of bulk
for each sterility medium.

Protein nitrogen content (2.3.30). The protein nitrogen
content, before the addition of any stabiliser, is not more than
0.25 mg per human dose.

FINAL LOT

The final bulk vaccine is distributed aseptically into sterile,
tamper-proof containers and freeze-dried to a moisture content
shown to be favourable to the stability of the vaccine. The
containers are then closed so as to prevent contamination
and the introduction of moisture.

Only a final lot that is satisfactory with respect to thermal
stability and each of the tests given under Identification, Tests
and Assay may be released for use. Provided that the test for
ovalbumin has been performed with satisfactory results on
the final bulk vaccine, it may be omitted on the final lot.

Thermal stability. Maintain samples of the final lot of freeze-
dried vaccine in the dry state at 37° for 14 days. Determine the
virus concentration as described under Assay in parallel for
the heated vaccine and for unheated vaccine. The difference
in the virus concentration between unheated and heated
vaccine does not exceed $10 \log_{10}$, and the virus concentration
of the heated vaccine is not less than the number of TCID$_{50}$
or plaque-forming units (PFU) equivalent to $1 \times 10^3$ mouse LD$_{50}$
per human dose.

Identification

When the vaccine reconstituted as stated on the label is mixed
with specific yellow fever virus antibodies, there is a significant
reduction in its ability to infect susceptible cell cultures.

Tests

Sterility (2.2.11). Complies with the test for sterility.

Ovalbumin. Not more than 5 µg of ovalbumin per human dose,
determined by a suitable immunochemical method (2.2.14).

Abnormal toxicity (2.2.1). Complies with the test for abnormal
toxicity.

Bacterial endotoxins (2.2.3). Not more than 5 IU of bacterial
endotoxin per human dose.

Water (2.3.43). Not more than 3.0 per cent, determined by the
semi-micro determination of water.

Assay

Titrate for infective virus in cell cultures. Use an appropriate
virus reference preparation to validate each assay.

The virus concentration is not less than the equivalent in
TCID$_{50}$ or PFU of $1 \times 10^3$ mouse LD$_{50}$ per human dose. The
relationship between mouse LD$_{50}$ and TCID$_{50}$ or PFU is
established by each laboratory and approved by the competent
authority.

The method shown below, or another suitable technique, may
be used to determine the mouse LD$_{50}$.

Mouse LD$_{50}$. The statistically calculated quantity of virus
suspension that is expected to produce fatal specific
encephalitis in 50 per cent of mice of a highly susceptible
strain, 4 to 6 weeks of age, after intracerebral inoculation.

Appropriate serial dilutions of the reconstituted vaccine are
made in diluent for yellow fever virus (0.75 per cent solution
of bovine albumin in phosphate-buffered saline pH 7.4, or
any other diluent that has been shown to be equivalent for
maintaining the infectivity of the virus).

Mice of a highly susceptible strain, 4 to 6 weeks of age,
are injected intracerebrally under anaesthesia with 0.03 ml of the
vaccine dilution. Groups of not less than eight mice are used
for each dilution; the series of dilutions is chosen so as to
cover the range 0 to 100.0 per cent mortality of the mice.
Injection of the mice is performed immediately after the
dilutions have been made. The mice are observed for 21 days
and all deaths are recorded. Only survivors and deaths caused
by typical yellow fever infections are counted in the
computations. Mice paralysed on the twenty-first day of
observation are counted as survivors.

Tests in monkeys for Yellow Fever Vaccine

Each master and working seed lot complies with the following
tests in monkeys for viraemia (viscerotropism),
immunogenicity and neurotropism.

The monkeys shall be Macaca spp. susceptible to yellow
fever virus and shall have been shown to be non-immune to
yellow fever at the time of injecting the seed virus. They shall
be healthy and shall not have received previously intracerebral
or intraspinal inoculation. Furthermore, they shall not have
been inoculated by other routes with neurotropic viruses or
with antigens related to yellow fever virus. Not fewer than ten
monkeys are used for each test.

Use a test dose of 0.25 ml containing the equivalent of not
less than 5000 mouse LD$_{50}$ and not more than 50,000 mouse
LD$_{50}$, determined by a titration for infectious virus and using
the established equivalence between virus concentration and
mouse LD$_{50}$ (see under Assay). Inject the test dose into one
frontal lobe of each monkey under anaesthesia and observe
the monkeys for not less than 30 days.

Viraemia (Viscerotropism). Viscerotropism is indicated by the
amount of virus present in serum. Take blood from each of the
test monkeys on the second, fourth and sixth days after
inoculation and prepare serum from each sample. Prepare 1:10, 1:100 and 1:1000 dilutions from each serum and inoculate each dilution into a group of at least six cell culture vessels used for the determination of the virus concentration. The seed lot complies with the test if none of the sera contains more than the equivalent of 500 mouse LD_{50} in 0.03 ml and at most one serum contains more than the equivalent of 100 mouse LD_{50} in 0.03 ml.

**Immunogenicity.** Take blood from each monkey 30 days after the injection of the test dose and prepare serum from each sample. The seed lot complies with the test if at least 90.0 per cent of the test monkeys are shown to be immune, as determined by examining their sera in the test for neutralisation of yellow fever virus described below.

It has been shown that a low dilution of serum (for example, 1:10) may contain non-specific inhibitors that influence this test; such serum shall be treated to remove inhibitors. Mix dilutions of at least 1:10, 1:40 and 1:160 of serum from each monkey with an equal volume of 17D vaccine virus at a dilution that will yield an optimum number of plaques with the titration method used. Incubate the serum-virus mixtures in a water-bath at 37° for 1 h and then cool in iced water; add 0.2 ml of each serum-virus mixture to each of four cell-culture plates and proceed as for the determination of virus concentration. Inoculate similarly ten plates with the same amount of virus plus an equal volume of a 1:10 dilution of monkey serum known to contain no neutralising antibodies to yellow fever virus. At the end of the observation period, compare the mean number of plaques in the plates receiving virus plus non-immune serum with the mean number of plaques in the plates receiving virus plus dilutions of each monkey serum. Not more than 10 per cent of the test monkeys have serum that fails to reduce the number of plaques by 50.0 per cent at the 1:10 dilution.

**Neurotropism.** Neurotropism is assessed from clinical evidence of encephalitis, from incidence of clinical manifestations and by evaluation of histological lesions, in comparison with ten monkeys injected with the reference preparation. The seed lot is not acceptable if either the onset and duration of the febrile reaction or the clinical signs of encephalitis and pathological findings are such as to indicate a change in the properties of the virus.

**Clinical evaluation.** The monkeys are examined daily for 30 days by personnel familiar with clinical signs of encephalitis in primates (if necessary, the monkeys are removed from their cage and examined for signs of motor weakness or spasticity). The seed lot is not acceptable if in the monkeys injected with it the incidence of severe signs of encephalitis, such as paralysis or inability to stand when stimulated, or mortality is greater than for the reference vaccine. These and other signs of encephalitis, such as paresis, in-coordination, lethargy, tremors or spasticity are assigned numerical values for the severity of symptoms by a grading method. Each day each monkey in the test is given a score based on the scale:

- Grade 1 — rough coat, not eating,
- Grade 2 — high-pitched voice, inactive, slow moving,
- Grade 3 — shaky, tremors, unco-ordinated, limb weakness,
- Grade 4 — inability to stand, limb paralysis or death (a dead monkey receives a daily score of 4 from the day of death until day 30).

A clinical score for a particular monkey is the average of its daily scores; the clinical score for the seed lot is the mean of the individual monkey scores. The seed lot is not acceptable if the mean of the clinical severity scores for the group of monkeys inoculated with it is significantly greater (P = 0.95) than the mean for the group of monkeys injected with the reference preparation. In addition, special consideration is given to any animal showing unusually severe signs when deciding on the acceptability of the seed lot.

**Histological evaluation.** Five levels of the brain are examined including:

- Block I — the corpus striatum at the level of the optic chiasma,
- Block II — the thalamus at the level of the mamillary bodies,
- Block III — the mesencephalon at the level of the superior colliculi,
- Block IV — the pons and cerebellum at the level of the superior olives,
- Block V — the medulla oblongata and cerebellum at the level of the mid-inferior olivary nuclei.

Cervical and lumbar enlargements of the spinal cord are each divided equally into six blocks; 15 µm sections are cut from the tissue blocks embedded in paraffin wax and stained with gallocyanin. Numerical scores are given to each hemisection of the cord and to structures in each hemisection of the brain as listed below. Lesions are scored as follows:

- Grade 1. Minimal: 1 to 3 small focal inflammatory infiltrates. Degeneration or loss of a few neurons.
- Grade 2. Moderate: 4 or more focal inflammatory infiltrates. Degeneration or loss of neurons affecting not more than one third of cells.
- Grade 3. Severe: moderate focal or diffuse inflammatory infiltration. Degeneration or loss of up to two third of the neurons.
- Grade 4. Overwhelming: variable but often severe inflammatory reaction. Degeneration or loss of more than 90.0 per cent of neurons.

It has been found that inoculation of yellow fever vaccine into the monkey brain causes histological lesions in different
anatomical formations of the central nervous system with varying frequency and severity (I.S. Levenbook et al., *Journal of Biological Standardization*, 1987, 15, 305-313). Based on these two indicators, the anatomical structures can be divided into target, spared and discriminator areas. Target areas are those which show more severe specific lesions in a majority of monkeys irrespective of the degree of neurovirulence of the seed lot. Spared areas are those which show only minimal specific lesions and in a minority of monkeys. Discriminator areas are those where there is a significant increase in the frequency of more severe specific lesions with seed lots having a higher degree of neurovirulence. Discriminator and target areas for *Macaca cynomolgus* and *Macaca rhesus* monkeys are shown in the table below:

Table 1. The discriminator and target areas for monkey.

<table>
<thead>
<tr>
<th>Type of monkey</th>
<th>Discriminator areas</th>
<th>Target areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macaca cynomolgus</td>
<td>globus pallidus</td>
<td>substantia nigra</td>
</tr>
<tr>
<td></td>
<td>putamen anterior/median thalamic nucleus lateral thalamic nucleus</td>
<td></td>
</tr>
<tr>
<td>Macaca rhesus</td>
<td>caudate nucleus</td>
<td>substantia nigra</td>
</tr>
<tr>
<td></td>
<td>globus pallidus</td>
<td>cervical</td>
</tr>
<tr>
<td></td>
<td>putamen anterior/median thalamic nucleus lateral thalamic nucleus</td>
<td>lumbar enlargement</td>
</tr>
<tr>
<td></td>
<td>cervical enlargement</td>
<td></td>
</tr>
<tr>
<td></td>
<td>lumbar enlargement</td>
<td></td>
</tr>
<tr>
<td></td>
<td>enlargement</td>
<td></td>
</tr>
</tbody>
</table>

Scores for discriminator and target areas are used for the final evaluation of the seed lot. The individual monkey score is calculated from the sum of individual target area scores in each hemisection divided by the number of areas examined. A separate score is calculated similarly for the discriminator areas.

Mean scores for the test group are calculated in two ways: (1) by dividing the sum of the individual monkey discriminator scores by the number of monkeys and (2) by dividing the sum of the individual monkey target and discriminator scores by the number of monkeys. These two mean scores are taken into account when deciding on the acceptability of the seed lot. The seed lot is not acceptable if either of the mean lesion scores is significantly greater (P = 0.95) than for the reference preparation.

**Labelling.** The label states (1) the strain of virus used in preparation; (2) that the vaccine has been prepared in chick embryos; (3) the minimum virus concentration; (4) that contact
# HERBS AND HERBAL PRODUCTS

**General Requirements**

<table>
<thead>
<tr>
<th>Monographs</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acacia</td>
<td></td>
</tr>
<tr>
<td>Amalaki</td>
<td></td>
</tr>
<tr>
<td>Amra</td>
<td></td>
</tr>
<tr>
<td>Arachis Oil</td>
<td></td>
</tr>
<tr>
<td>Arjuna</td>
<td></td>
</tr>
<tr>
<td>Artemisia</td>
<td></td>
</tr>
<tr>
<td>Ashwagandha</td>
<td></td>
</tr>
<tr>
<td>Belladonna Dtry Extract</td>
<td></td>
</tr>
<tr>
<td>Belladonna Leaves</td>
<td></td>
</tr>
<tr>
<td>Bhibhitaki</td>
<td></td>
</tr>
<tr>
<td>Bhringraj</td>
<td></td>
</tr>
<tr>
<td>Bhuimla</td>
<td></td>
</tr>
<tr>
<td>Brahmi</td>
<td></td>
</tr>
<tr>
<td>Castor Oil</td>
<td></td>
</tr>
<tr>
<td>Clove Oil</td>
<td></td>
</tr>
<tr>
<td>Coleus</td>
<td></td>
</tr>
<tr>
<td>Eucalyptus Oil</td>
<td></td>
</tr>
<tr>
<td>Garcinia</td>
<td></td>
</tr>
<tr>
<td>Gokhru</td>
<td></td>
</tr>
<tr>
<td>Guar Gum</td>
<td></td>
</tr>
<tr>
<td>Gudmar</td>
<td></td>
</tr>
<tr>
<td>Guduchi</td>
<td></td>
</tr>
<tr>
<td>Guggul resin</td>
<td></td>
</tr>
<tr>
<td>Gugulipid</td>
<td></td>
</tr>
<tr>
<td>Gugulipid Tablets</td>
<td></td>
</tr>
<tr>
<td>Haridra</td>
<td></td>
</tr>
<tr>
<td>Haritaki</td>
<td></td>
</tr>
<tr>
<td>Hydrogenated Castor Oil</td>
<td></td>
</tr>
</tbody>
</table>
Isapgol Husk  
Kalmegh  
Kunduru  
Kutki  
Lausna  
Malt Extract  
Mendukaparni  
Manjistha  
Maricha  
Mentha Oil  
Opium  
Opium Powder  
Papain  
Peppermint Oil  
Pippali Large  
Pippali Small  
Punarnava  
Sarpagandha  
Senna Pods  
Senna Leaf  
Shatavari  
Shati  
Shellac  
Shunti  
Starch  
Tolu Blasam  
Tragacanth  
Tulasi  
Vasaka  
Yasti
Herbs and Herbal Products

Herbs and products containing herb(s) have been in trade and commerce and are currently used for a variety of purposes. As a country, India has a rich history of use of herbs, processed herbs and formulations containing herbs both from traditional wisdom as well as cultural usage. Herbs and herbal products are also regulated by various laws. For the purposes of pharmacopoeial standards various considerations have been given. This monograph provides a general outline and policies towards the same.

Crude Herbs

This term means, unless specified otherwise, mainly whole, fragmented or cut, plants, parts of plants, algae, fungi, and lichen in a form which is not processed. Herbs are usually in dried form, but sometimes, when specified, may also be in a fresh form. In specific cases exudates which have not been processed further also are covered under the term herbs. Processing, does not include, normally expected value addition steps like grading, sizing, removal of weeds or parts of plants other than those specified herb and removal of adulterants. The term herbs, though botanically generally refer to plants of specified height and nature, for the purposes of pharmacopoeial reference, shall mean and include plants and parts of plants not necessarily from herbs and shrubs, but cover the entire range namely creepers, climbers, trees etc.

Each monograph of a herb in the pharmacopoeia shall specify the botanical scientific name according the binomial system specifying the genus, species, variety and author. In cases where there are controversial botanical identity, as seen with mainly herbs known in the Indian traditional system, the monograph shall specify the official name of the herb along with its botanical scientific name and guidance is taken from Ayurvedic Pharmacopoeia of India to decide the same. In cases where, the same herb is available in different grades or sizes, if found appropriate and necessary, separate monographs may be introduced in the pharmacopoeia to cover each of them with appropriate standards. For example- Pippali (large) and Pippali (small).

While deciding to introduce a monograph for a herb in the pharmacopoeia, the criteria that would be kept in mind, but not limited to are – herbs with specific name and a definitive botanical identity up to species, availability and usage in trade and commerce, regulatory interest, knowledge of and availability of a specific chemical compound of well characterised structure either responsible for the biological activity of the herb (bio-marker) or a chemical compound known to be present in the herb even if not responsible for biological activity (chemical/analytical marker), availability of a quantitative method for estimation of such a compound, knowledge of safety of the herb, and its sustainability. Herbs which may figure in a regulated list under appropriate forest and other laws, may still be taken up for a monograph for inclusion in pharmacopoeia, if there is knowledge of efforts to cultivate or take care of sustainability issues and/or specific permission is available under law for use of the herb. As already specified under “General Notices” in the pharmacopoeia, appearance of a monograph does not mean its approval as a drug under the law. Monograph of a herb in the pharmacopoeia is to provide qualitative and quantitative standards of quality for the herb for its use either as a food item or food ingredient or food supplement/ nutraceuticals, as a drug, and/or as an ingredient in cosmetics. Each such use would need to comply with applicable regulations. Each herb is regarded as one active substance, irrespective of the knowledge about the active constituents of the herb is available of not.

Processed Herbs

Processed herbs means preparations obtained by subjecting herbs to treatment such as extraction, distillation, expression, fractionation, purification, concentration and partial or full fermentation. Processing may also be done by way of powdering herbs, preparing tincture, preparing extract, distilling to get essential oils, fatty oils (either expressed or solvent extracted or a blend of both) expressed juices, extracted exudates, gums and oleo resins, liquid extract where the solvent is evaporated to yield concentrated semi solid mass or dried mass. Extraction may be performed by means of appropriate technology such as infusion, maceration, soxhleting, boiling under ambient or higher pressure, with or without specified enzymes, with or without agitation and combination thereof. Drying of liquid extracts for removal of the solvent may be done by using various appropriate technologies like air drying, sun drying, drying under vacuum or with forced air circulation, drying at low temperature with air circulation, by way of lyophilization or freeze drying. Extracts of herbs may also be prepared by using carbon dioxide as a solvent-super critical fluid extraction.

Extracts may be liquid extracts and tinctures, semi solid (soft extracts) or solid dry extracts of known consistency obtained from herbs. Standardized extract, a term commonly employed, would for pharmacopoeial purposes, mean an extract adjusted with in an acceptable tolerance to a given content of biomarker or chemical/analytical marker. Standardization may be achieved by adjusting the extracts with approved inert material or by blending one or more batches of extracts. Wherever
possible, extracts shall specify the defined range of the constituents (bio-marker or chemical/analytical marker). Extracts not covered in the above description would be defined by the process of production of the herb to the extract, solvent used and technology applied. The difference between extracts and tinctures would be, in the type of solvent used for extracting a herb, and tincture would normally mean an extract where aqueous-ethanol is used as a solvent for extraction. Dry extracts usually have a loss on drying or water content not greater than 5 per cent w/w, unless specified otherwise in any monograph. It is normal to extrapolate safety aspects and history of use information for extracts as long as the process, solvents, extraction ratios are comparable to the processes used in documented traditional knowledge. All extracts should specify the extractive ratios for example 15:1 meaning 15 parts of the herb provides one part of the extracts, either as w/w or w/v as the case may be. Additionally in cases of standardized extracts the inert excipients(s), if any used for standardization or adjustment of the content of constituents should also be declared on the label of such extracts. Extracts shall be free from solvent used for extraction and shall comply with a limit of not more than 10 ppm in cases where the solvent is either acetone, iso-propyl alcohol, methanol and not more than 100 ppm of hexane, if hexane is the solvent used, in the final extract. Harmful and carcinogenic solvents shall not be used for extraction purposes. Solvents and solvent systems may include use of propylene glycol, glycerin, sorbitol and such other polyhydroxy alcohols, as long as the content of such polyhydroxy alcohol are within safe limit in the final product.

In cases where extraction and fractionation process leads to preparation of an extract, which consists of a single chemical compound of more than 70 per cent purity, such extracts shall be treated as an active pharmaceutical ingredient or a food additive or a cosmetic ingredient and would be required to meet relevant laws.

Extracts may also be offered as purified or enriched extracts. Such extract of a herb is processed in such a way to provide higher than normal proportion of the active constituent(s) of the herb as long as the active constituent(s) is/are known. Such purified or enriched extracts may contain additional valuable components which may provide specific properties like enhanced efficacy or stability or solubility and availability of the active constituent(s). Purified and enriched extracts may also be prepared to reduce or remove other specific compound or group of compounds that is scientifically considered undesirable in the herb extracts. Pharmacological, toxicological, pharmaceutical considerations need to be applied while preparing such purified or enriched extracts. Mixed extracts may also be offered which would cover combination of more than one herb extract for purposes of providing simplification or economical way to manufacture herbal formulations.

Herbs may also be extracted using vegetable oils (approved by Food Law) for extraction purposes and such extracts shall specify the oil used for processing.

Approved preservatives or preservatives system may be used during preparation of extracts. The names of such preservatives used which would remain in the final extract shall be listed on the label of such extract, and the proportion of preservatives used shall not exceed normally accepted safe limits of their usage as per relevant laws or pharmacopeial standards. No artificial colours may be used in extracts of herbs.

Extracts may be exposed to ethylene oxide fumigation or low dose gamma radiation for purposes of reducing their microbial contamination. In cases where they are fumigated, the final extracts exposed shall meet residual levels of ethylene oxide limits as applicable. Herbs treated with low dose gamma radiation shall meet national laws related to such treatment and shall be labelled as per law.

Appearance of a monograph of an extract in the pharmacopeia does not mean its approval as a drug under the law. Monograph of an extract in the pharmacopeia is to provide qualitative and quantitative standards of quality for the extract for its use either as a food item or food ingredient or food supplement/nutraceuticals, as a drug and/or as an ingredient in cosmetics. Each such use would need to comply with applicable regulations. Each extract is regarded as one active substance irrespective of the knowledge about the active constituents of the herb is available or not.

**Herbal Formulations**

Herbal formulation shall mean a dosage form consisting of one or more herbs or processed herb(s) in specified quantities to provide specific nutritional, cosmetic benefits, and/or other benefits meant for use to diagnose, treat, mitigate diseases of human beings or animals and/or to alter the structure or physiology of human beings or animals. Dosage forms commonly employed for food or cosmetic or pharmaceuticals may be employed to formulate one or more herb or processed herbs. Dosage forms known in traditional medicines may also be adopted for preparing herbal formulations, either for external use or for internal administration. Adequate consideration for uniform distribution of herb or processed herbs as well as stability of the same in the dosage form shall be provided during formulation development.

Herbal formulation shall be labeled to comply with relevant labelling requirements under food or drug or cosmetics laws as applicable. Additionally, adequate information shall be provided on label of such formulations to include the name of the herb, parts used, nature and type of extract or processed herb used, extraction ratios, quantity per unit dose or per serving, name(s) of inert excipients used and any preservatives added shall be provided on the label.
Appearance of a monograph of a herbal formulation in the pharmacopoeia does not mean its approval as a drug under the law. Monograph of a herbal formulation in the pharmacopoeia is to provide qualitative and quantitative standards of quality for the formulation for its use either as a food item or food ingredient or food supplement/nutraceuticals, as a drug and/or as a cosmetic. Each such use would need to comply with applicable regulations.

Acacia

Gum Acacia; Indian Gum

Acacia is the air-hardened, gummy exudation from the stem and branches of *Acacia nilotica* (Linn.) Del. subsp. *indica* (Benth.) Brenan (syn. *A. arabica* Willd. var. *indica* Benth.) (Fam. Leguminosae), or other species of *Acacia*. It is available as pieces (tears) or in the form of a powder.

**Description**

Tears — Irregular and broken pieces of varying size, yellowish-white, yellow or amber in colour, with numerous minute fissures; brittle fractured surface, glassy and occasionally iridescent; odourless.

Powder — A white or yellowish-white powder; odourless; on treatment with *water* it dissolves to give a mucilaginous liquid which is colourless or yellowish, dense, viscous, adhesive and translucent.

**Identification**

A. An aqueous solution is gelatinised by the addition of lead subacetate solution either dextro-rotatory or slightly laevo-rotatory.

B. To 5 ml of a 10 per cent w/v solution add gradually, while shaking, 10 ml of *ethanol* (95 per cent). The cloudy liquid, on addition of 0.5 ml of *acetic acid*, gives a white precipitate. Filter and add to the clear filtrate 50 ml of *ammonium oxalate solution*; the filtrate becomes cloudy.

C. A 10 per cent w/v solution is either dextro-rotatory or slightly laevo-rotatory.

**Tests**

- **Sterculia gum and agar.** To 50 mg of the powdered substance under examination add 0.2 ml of freshly prepared *ruthenium red solution* and examine microscopically; the particles do not acquire a red colour after irrigation with *water*.

- **Agar and tragacanth.** To 10 ml of a 10 per cent w/v solution add 0.2 ml of *lead acetate solution*; no precipitate is produced.

- **Starch and dextrin.** Boil 10 ml of a 10 per cent w/v solution and cool, add 0.1 ml of *0.05 M iodine*; no blue or brown colour is produced.

- **Tannins.** To 10 ml of a 10 per cent w/v solution add 0.1 ml of *ferric chloride test solution*; a gelatinous precipitate is formed, but neither the precipitate nor the liquid shows a dark blue colour.

- **Sucrose and fructose.** To 1 ml of a 10 per cent w/v solution add 4 ml of *water*, 0.1 g of *resorcinol* and 2 ml of *hydrochloric acid* and heat on a water-bath; no yellow or pink colour develops.

- **Water-insoluble matter.** Dissolve 5 g, in fine powder, in 100 ml of *water* in a 250-ml flask, add 10 ml of *dilute hydrochloric acid* and boil gently for 15 minutes. Filter by suction while hot through a sintered-glass crucible, previously tared, wash thoroughly with hot *water*, dry at 105º and weigh; the residue does not exceed 50 mg.

- **Microbial contamination** (2.2.9). 1.0 g is free from *Escherichia coli*.

- **Sulphated ash** (2.3.18). Not more than 5.0 per cent.

- **Acid-insoluble ash** (2.3.19). Not more than 1.0 per cent, determined on 1.0 g by Method C.

- **Loss on drying** (2.4.19). Not more than 15.0 per cent, determined on 1.0 g by drying in an oven at 105º.

**Storage.** Store protected from heat, moisture and against attack by insects and rodents.
Amalaki

Emblic Myrobalan; Indian Gooseberry

Amalaki consists of the dried fruit pericarp of Emblica officinalis Gaertn. (Phyllanthus emblica Linn.) (Fam. Euphorbiaceae).

Amalaki contains not less than 1.0 per cent w/w gallic acid calculated on the dried basis.

Description. The dried fruit has a highly shriveled and wrinkled external surface. The taste is sour and astringent followed by delicately sweet tinge.

Identification

A. Macroscopic — The dried fruit shows a broad, highly shriveled and wrinkled external convex surface, lateral surface transversely wrinkled, external surface exhibits few whitish specks, occasionally some pieces show a portion of stony testa.

B. Microscopic — The epicarpic cells are rectangular in shape and their walls are highly cuticularized. Anomocytic type of stomata is found rarely. Collateral fibrovascular bundles are scattered throughout the inner mesocarp. Pitted and helical tracheids with tapering ends are seen. At places in the phloem, large cavities filled with crystal mass are present.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel.

Mobile phase. A mixture of 20 volumes of toluene, 45 volumes of ethyl acetate, 20 volumes of glacial acetic acid and 5 volumes of formic acid.

Test solution. Reflux 2 g of the coarsely powdered substance under examination with 50-75 ml of methanol for 15 minutes, cool and filter. Reflux the residue further for two times with 75 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 10 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air, spray with anisaldehyde sulphuric acid reagent. Heat at 100º for 5-10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

Tests

Foreign organic matter (2.6.1). Not more than 3 per cent.

Ethanol-soluble extractive (2.6.2). Not less than 30 per cent.

Water-soluble extractive (2.6.3). Not less than 40 per cent by Method 1.

Ash (2.3.19). Not more than 5.0 per cent.

Acid-insoluble ash (2.3.19). Not more than 2.0 per cent.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Loss on drying (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105º.

Microbial contamination (2.2.9). Complies with the microbial contamination tests.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh accurately about 0.5 g of coarsely powdered substance under examination, add 50 ml of water, sonicate for 3 minutes and heat on a boiling water bath for 15 minutes, cool and dilute to 100.0 ml with water and filter.

Reference solution. A 0.01 per cent w/v solution of gallic acid RS in water.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a gradient mixtures of acetonitrile and a buffer solution prepared by dissolving 0.136 g of potassium di-hydrogen orthophosphate in 500 ml of water, add 0.5 ml of orthophosphoric acid and make up to 1000 ml with water,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 270 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Buffer solution (per cent v/v)</th>
<th>Acetonitrile (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>18</td>
<td>55</td>
<td>45</td>
</tr>
<tr>
<td>25</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>30</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>
Inject the reference solution. The relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution. Calculate the content of gallic acid.

**Storage**. Store protected from light, heat, moisture and against attack by insects and rodents.

---

**Amra**

**Mango; Mangifera**

Amra consists of dried stem bark of *Mangifera indica* L. (Fam. Anacardiaceae).

Amra contains not less than 1.5 per cent of mangiferin calculated on the dried basis.

**Description**. The dried stem bark occurs in pieces of variable size and thickness, surface rough. Odour pleasant and taste astringent.

**Identification**

A. *Macroscopic* — The surface is rough due to longitudinal cracks, fissures and scattered, raised lenticels, greyish to dark brown externally and yellowish-white to reddish internally.

B. *Microscopic* — The mature bark shows a wide cork which has tangentially elongated cells a few outer layers are brown and inner lighter in colour, resin canals and yellow coloured tannin sacs are found in the phloem region, stone cells are thick walled and lignified, prismatic calcium oxalate crystals are present.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel*.

**Mobile phase**. A mixture of 100 volumes of *ethyl acetate*, 11 volumes of *formic acid*, 11 volumes of *acetic acid* and 25 volumes of *water*.

**Test solution**. To 5 g of the coarsely powdered substance under examination, add 50 ml of *methanol* and reflux for 15 minutes, cool and filter. Reflux the residue further for three times with 50 ml of *methanol*, cool and filter. Combine all the filtrates and concentrate under vacuum to 10 ml.

**Reference solution**. Weigh about 2 g of *amra RS*, add 50 ml of *methanol* and reflux for 15 minutes, cool and filter. Reflux the residue further three times with 50 ml of *methanol*, cool and filter. Combine all the filtrates and concentrate under vacuum to 4 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cms. Dry the plate in air, spray with *vanilin sulphuric acid reagent*. Heat at 100º for 5-10 minutes and examine the plate in daylight. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter** (2.6.1). Not more than 2.0 per cent.

**Ethanol-soluble extractive** (2.6.2). Not less than 10.0 per cent.

**Water-soluble extractive** (2.6.3). Not less than 10.0 per cent by method I.

**Ash** (2.3.19). Not more than 16.0 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 5.0 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105º.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay**. Determine by liquid chromatography (2.4.14).

**Test solution**. Weigh 2 g of coarsely powdered substance under examination, add 10 ml of *dimethylformamide*, sonicate for 5 minutes and add 50 ml of *methanol* and boil on a water bath for 10 minutes, cool and dilute to 100.0 ml with *methanol* and filter. Dilute 5.0 ml of this solution to 50.0 ml in *methanol*.

**Reference solution**. Dissolve 10 mg of *mangiferin RS* in 10 ml of *dimethylformamide* and dilute to 100.0 ml with *methanol*.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: filtered and degassed mixture of 15 volumes of *acetonitrile* and 85 volumes of buffer pH 2.8 prepared by dissolving 1.36 g of *potassium dihydrogen orthophosphate* in 950 ml of *water*, adjust the pH 2.8 with *orthophosphoric acid* and make up to 1000 ml,
- flow rate. 1 ml per minute,
Tests

Weight per ml (2.4.29). 0.908 g to 0.920 g.

Refractive index (2.4.27). 1.467 to 1.470.

Alkaline impurities. Mix 10 ml of recently distilled acetone and 0.3 ml of water in a test-tube, add 0.05 ml of a 0.04 per cent w/v solution of bromophenol blue in ethanol (95 per cent) and neutralise the solution, if necessary, with 0.01 M hydrochloric acid or 0.01 M sodium hydroxide. Add 10 ml of the substance under examination, shake and allow to stand. Not more than 0.1 ml of 0.01 M hydrochloric acid is required to change the colour of the upper layer to yellow.

Semi-drying oils. Boil 1 g in a flask under a reflux condenser for 5 minutes with 5 ml of a mixture of 3 volumes of 2 M ethanolic potassium hydroxide and 1 volume of ethanol (95 per cent), add 1.5 ml of 6 M acetic acid and 50 ml of ethanol (70 per cent), warm until the solution is clear. Cool slowly with a thermometer in the liquid; the temperature at which the solution becomes turbid is not lower than 36º.

Peroxide value (2.3.35). Not more than 5.0.

Acid value (2.3.23). Not more than 0.5.

Iodine value (2.3.28). 85 to 105.

Saponification value (2.3.37). 185 to 196.

Rancidity. Shake 1 ml of a 10 per cent v/v solution in ether with 1 ml of hydrochloric acid, add 1 ml of a 0.1 per cent w/v solution of phloroglucinol in ether; no red or pink colour is produced.

Unsaponifiable matter (2.3.39). Not more than 1.0 per cent.

Cottonseed oil. In the Identification test, the chromatogram obtained with the test solution does not correspond to that obtained with reference solution (b).

Sesame oil. In the Identification test, the chromatogram obtained with the test solution does not correspond to that obtained with reference solution (c).

Heavy metals (2.3.13). 2.0 g complies with the limit test for heavy metals, Method B (10 ppm).

Arachis Oil intended for use in the manufacture of parenteral preparations complies with the following additional requirement.

Water (2.3.43). Not more than 0.3 per cent, determined on 3.0 g.

Storage. Store protected from light and moisture, in a well-filled container. Arachis Oil intended for use in the manufacture of parenteral preparations should be stored in a glass container.

Labelling. The label states (1) whether the contents are suitable for use in the manufacture of parenteral preparations; (2) when the addition of antioxidants is authorised, the name and quantity of the added antioxidants.
**Arjuna**
Terminalia Bark

Arjuna consists of dried stem bark of *Terminalia arjuna* (Roxb) Wight & Arn (Fam. Combretaceae)

Arjuna contains not less than 0.02 per cent of arjungenin calculated on the dried basis.

**Description.** A flat or minutely curved thick pieces of bark with reddish gray colour and astringent taste.

**Identification.**

A. **Macroscopic** — Stem bark pieces, flat or minutely curved, with reddish gray external surface and darker inner surface. Internal surface has longitudinal minute ridges. Fractures longitudinal.

B. **Microscopic** — Cork consisting of 6-10 layers of elongated cells, phloem broad, medullary rays uniseriate. Calcium oxalate clusters abundant. Few of the parenchyma cells contain colouring matter.

C. **Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.**

**Mobile phase.** A mixture of 5 volumes of toluene, 5 volumes of ethyl acetate and 0.5 volume of acetic acid.

**Test solution.** Reflux 2 g of coarsely powdered substance under examination with 50 ml of chloroform for 15 minutes, cool and filter. Reflux the residue further with 50 ml of chloroform. Combine the filtrate and concentrate under vacuum to dryness. Dissolve the residue in 10 ml of ethanol at 50° for 10 minutes and filter.

**Reference solution.** Reflux 1 g of arjuna RS with 50 ml of chloroform for 15 minutes, cool and filter. Reflux the residue further with 50 ml of chloroform. Combine the filtrate and concentrate under vacuum to dryness. Dissolve the residue in 5 ml of ethanol at 50° for 10 minutes and filter.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (10 µm),
- mobile phase (A). acetonitrile (70 per cent) in water,
- mobile phase (B). acetonitrile (30 per cent) in water;
- flow rate. 1.2 ml per minute,
- spectrophotometer set at 210 nm,
- a 20 µl loop injector.

**Time**  | **Mobile phase A (per cent v/v)** | **Mobile phase B (per cent v/v)**
---|---|---
0  | 30 | 70
10 | 50 | 50
30 | 70 | 30
50 | 30 | 70

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injection for the analyte peak corresponding to arjungenin is not more than 2.0 per cent.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air, spray with 10 per cent w/v solution of sulphuric acid in methanol and heat at 110° for 5 minutes. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter (2.6.1).** Not more than 2.0 per cent.

**Ethanol-soluble extractive (2.6.2).** Not less than 20.0 per cent.

**Water-soluble extractive (2.6.3).** Not less than 20 per cent by method I.

**Ash (2.3.19).** Not more than 30.0 per cent.

**Acid-insoluble ash (2.3.19).** Not more than 2 per cent.

**Heavy metals (2.3.13).** 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying (2.4.19).** Not more than 10.0 per cent, determined on 5 g by drying in an oven at 105°.

**Microbial contamination (2.2.9).** Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Reflux 5 g of coarsely powdered substance under examination with 50 ml of chloroform for 15 minutes, cool and filter. Reflux the residue further with 50 ml of chloroform, cool and filter. Combine the filtrates and concentrate under vacuum to dryness, then extract dried residue with 10 ml of ethanol at 50° for 10 minutes and filter.

**Reference solution.** A 0.1 per cent w/v solution of arjungenin RS in ethanol.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (10 µm),
- mobile phase (A). acetonitrile (70 per cent) in water,
- mobile phase (B). acetonitrile (30 per cent) in water;
- flow rate. 1.2 ml per minute,
- spectrophotometer set at 210 nm,
- a 20 µl loop injector.

**Time**  | **Mobile phase A (per cent v/v)** | **Mobile phase B (per cent v/v)**
---|---|---
0  | 30 | 70
10 | 50 | 50
30 | 70 | 30
50 | 30 | 70

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injection for the analyte peak corresponding to arjungenin is not more than 2.0 per cent.
Artemisia consists of dried leaves or the dried leaf and flowering tops of *Artemisia annua* L. (Fam. Asteraceae), known as *Qinghao*.

Artemisia contains not less than 0.8 per cent of artemisinin, calculated on the dried basis.

**Description.** Slightly camphoraceous odour and bitter taste.

**Identification**

A. The leaves grayish green, slightly darker upper surface, glabrous to sparsely hairy, break easily into small fragments, 3-pinnatifid, petiolate and much variable in size (2.5-10.0 cm long). Leaf lobes narrow, oblong to elliptical with acuminate tip, about 1.0 mm wide. Petioles up to 1.0 cm long, base amplexicaul. Inflorescence panicked raceme. Dry capitula yellowish brown, pedicellate, heterogamous globose to subglobose or disc shaped, 2.0 mm in diameter, flower heads arranged in lax or drooping, involucral bracts 3-seriate, greenish yellow, glabrous and oblong in shape, measure 1.0-1.2 x 0.5 mm in size. Inner involucral bracts elliptic having a median greenish streak on its outer surface. Ray florets pistillate, 6-8 in number per capitulum and 1.0-1.2 mm long. Disc florets hermaphrodite, 20-36 florets per capitulum and 0.8-1.0 mm long. All florets possess capitulate oil glands on the middle of the outer surface that are 54-83 µm in diameter. Stamens 0.7 mm long attached to the corolla base, anther appendages lanceolate to triangular with acuminate tip. Anthers oblong and introrse. Pollen grains tricolpate, rounded 21-33 µm in diameter. In dry condition, capitula become empty because florets / achenes come out of it. Receptacle globular to oblong. Achenes minute; possess striated surface, yellowish brown in colour, 0.7-1.0 mm long, and oval to elliptic in shape. Stomatal index: 8-10-12.

B. The powder of the herb is grayish green to greenish yellow. Examined under a microscope using chloral hydrate solution. The powder shows the following diagnostic characteristics: T-shaped and globular trichomes, epidermal cells with wavy walls, anomocytic to anisocytic stomata, minute druse crystals, tricolpate rounded pollen grains, stone cells, annular vessels, rod shaped palisade cells and stigma with small and club shaped papillae.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel GF254*.

**Mobile phase.** A mixture of 1 volume of *hexane* and 1 volume of *diethyl ether*.

**Test solution.** Boil 0.1 g of the coarsely powdered substance under examination with 10 ml of *hexane* for 10 minutes and filter. Evaporate the filtrate to 1 ml.

**Reference solution.** A 0.1 per cent w/v solution of *artemisia RS* in *hexane*.

Apply to the plate 5 µl of each solution. Allow the mobile phase to rise 5 cm. Dry the plate in air and spray with a mixture of 50 volumes of *glacial acetic acid*, 1 volume of *sulphuric acid* and 0.5 volume of *anisaldehyde*. Heat the plate at 100º for 15 minutes. The chromatogram having pink colour spot obtained with the test solution corresponds to the reference solution.

**Tests**

**Foreign organic matter** (2.6.1). Not more than 2.0 per cent.

**Ash** (2.3.19). Not more than 11.0 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 3.0 per cent.

**Assay.** Determine by high performance thin-layer chromatography (2.4.17), coating the plate with *silica gel GF254*.

**Mobile phase.** A mixture of 1 volume of *hexane* and 1 volume of *diethyl ether*.

**Test solution.** To 0.1 g of the coarsely powdered substance under examination, add 10 ml of *hexane* and keep for 12 hours, filter. Repeat the process of extraction 3 times. Combine the extracts, evaporate and dissolve in 1.0 ml of *hexane*.

**Reference solution.** A 0.1 per cent w/v solution of *artemisinin RS* in *hexane*.

Apply to the plate 5 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air and spray with a mixture of 50 volumes of *glacial acetic acid*, 1 volume of *sulphuric acid*.
1 volume of sulphuric acid and 0.5 volume of anisaldehyde. Heat the plate at 100º for 15 minutes, scan the plate in absorbance mode at 540 nm. Record the chromatograms and measure the responses for the analyte peak.

Calculate the content of artemisinin.

Storage. Store protected from light and moisture and against attack by insects and rodents.

Ashwagandha
Indian Ginseng; Withania

Ashwagandha consists of the dried mature roots of Withania somnifera Dunal (Fam. Solanaceae).

Ashwagandha contains not less than 0.02 per cent of total withanolide A and withaferin A, calculated on the dried basis.


Identification
A. Macroscopic — Primary roots are straight, conical or finger like in shape, variable in thickness with the age. Secondary roots are thin and fibrous. Surface buff to greyish-yellow with longitudinal wrinkles.


Mobile phase. A mixture of 9 volumes of chloroform and 1 volume of methanol.

Test solution. Reflux 3 g of coarsely powdered substance under examination with 50 ml methanol for 15 minutes, cool and filter.

Reference solution. Reflux 0.6 g of coarsely powdered ashwagandha RS with 10 ml methanol for 15 minutes, cool and filter.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cms above the line of application. Dry the plate in air, spray with solution of anisaldehyde reagent. Heat at 100º for 5-10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

Tests
Foreign organic matter (2.6.1). Not more than 2.0 per cent.

Ethanol-soluble extractive (2.6.2). Not less than 10.0 per cent.

Water-soluble extractive (2.6.3). Not less than 15 per cent by Method I.

Ash (2.3.19). Not more than 7.0 per cent.

Acid-insoluble ash (2.3.19). Not more than 1.2 per cent.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Loss on drying (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105º.

Microbial contamination (2.2.9). Complies with the microbial contamination tests.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Reflux about 5 g of the coarsely powdered substance under examination with 50 ml of methanol on a water bath for 15 minutes, cool and filter. Reflux the residue further with methanol till the last extract turns colorless, cool and filter. Combine all the filtrates and concentrate to 50.0 ml.

Reference solution (a). A solution containing 0.02 per cent w/v each of withanolide A RS and withaferin A RS in methanol, prepared by heating gently on a water bath.

Reference solution (b). A 0.02 per cent w/v solution of withanolide A RS in methanol, prepared by heating gently on a water bath, for peak identification.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (10 µm),
- mobile phase: a gradient mixtures of acetonitrile and a buffer solution prepared by dissolving 1.36 g of potassium dihydrogen phosphate in 900 ml water, adjust pH to 2.8 with dilute phosphoric acid and diluting it to 1000 ml with water,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 227nm,
- a 20 µl loop injector.
Belladonna Dry Extract

Belladonna Dry Extract is a dried and powdered ethanolic extract of Belladonna Herb.

Belladonna Dry Extract contains not less than 0.95 per cent and not more than 1.05 per cent w/w of alkaloids, calculated as hyoscyamine.

Tests

Loss on drying (2.4.19). Not more than 5.0 per cent, determined on 0.5 g by drying in an oven at 105°C.

Assay. Weigh accurately about 3 g and wash into a separating funnel with 12 ml of a mixture of equal volumes of ethanol (95 per cent) and water, shake-well and frequently for 30 minutes, add 2 ml of dilute ammonia solution and 25 ml of chloroform. Shake well, allow to separate and filter the chloroform layer into a second separating funnel through a plug of cotton wool moistened with chloroform. Continue the extraction with further quantities, each of 25 ml, of chloroform until complete extraction of the alkaloids is effected (2.6.4), running each chloroform solution through the same plug of absorbent cotton and filtering into a flask through a plug of cotton wool previously moistened with chloroform. Distil most of the chloroform from the combined extracts and transfer the remainder of the chloroform to a shallow open dish. Evaporate the remainder of the chloroform without the aid of a current of air, heat the residue in an oven at 100°C for 15 minutes, dissolve in a little chloroform, evaporate to dryness without the aid of a current of air and again heat in an oven at 100°C for 15 minutes. Dissolve the residue in 2 ml of chloroform, add 5.0 ml of 0.025 M sulphuric acid, warm to remove the chloroform, cool and titrate the excess of acid with 0.05 M sodium hydroxide using methyl red solution as indicator.

1 ml of 0.025 M sulphuric acid is equivalent to 0.01447 g of alkaloids, calculated as hyoscyamine.

Storage. Store protected from heat, moisture and against attack by insects and rodents.

Belladonna Leaf

Belladonna Leaf consists of the dried leaf and flowering tops of Atropa belladonna Linn. or of A. acuminata Royle ex Lindley (Fam. Solanaceae) or a mixture of both species.

Belladonna Herb contains not less than 0.30 per cent of total alkaloids, calculated as hyoscyamine with reference to the material dried at 100°C to 105°C.

Description. Green to greenish-brown leaves, slightly darker on the upper surface, often crumpled and rolled and partly matted together in the drug. When whole, the lamina is 5 to 25 cm long and 3 to 12 cm wide, elliptical to ovate; margin entire. Petiole 0.5 to 4 cm in length. The young leaves are highly pubescent, the older leaves are slightly pubescent along the veins. In the flowering tops, the stems are hollow and flattened, with leaves in pairs of unequal size, in the axils of which are single flowers with campanulate corolla, about 2 cm long and 1.5 cm wide, purple or yellow-brown in colour, with five short, reflexed lobes, five epipetalous stamens and one bilocular ovary with numerous ovules.

Identification

A. When examined under a microscope it shows epidermal cells with sinuate anticlinal walls and cuticle which is often striated and furrowed. Covering and glandular hairs infrequent, though more frequent in the young leaves and around the veins; covering hairs, multicellular, uniseriate, with thin smooth
walls; glandular hairs; short clavate glands with multicellular heads and glands with a long uniseriate stalk and ovoid unicellular head. Stomata, anisocytic, more frequent on the lower epidermis. The midrib is characterised by an open arc of vascular bundles with isolated groups of perimedullary phloem. Mesophyll dorsiventral with a single palisade layer. Throughout the parenchyma and particularly just below the palisade layer are cells containing microsphenoidal crystals of calcium oxalate or, very rarely, cluster crystals. The stems show pericyclic fibres and perimedullary bundles of phloem, few trichomes; the cortical parenchymatous cells and the pith cells contain microsphenoidal crystals of calcium oxalate.

B. Powder 1 g and shake for 2 minutes with 10 ml of 0.05 M sulphuric acid. Filter and add to the filtrate 1 ml of strong ammonia solution and 5 ml of water. Extract with 15 ml of ether; taking care to prevent the formation of an emulsion. Dry the ether extract over anhydrous sodium sulphate and filter. Evaporate the filtrate to dryness, add 0.5 ml of fuming nitric acid and evaporate to dryness. Add 10 ml of acetone and, dropwise, a 3 per cent w/v solution of potassium hydroxide in ethanol (95 per cent); a deep violet colour develops.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 90 volumes of acetone, 7 volumes of water and 3 volumes of strong ammonia solution.

Test solution. Add 15 ml of 0.05 M sulphuric acid to 0.6 g of the material under examination, in fine powder, shake for 15 minutes, filter and wash the filter with 0.05 M sulphuric acid until 20 ml of filtrate is obtained; add 1 ml of strong ammonia solution to the filtrate, extract with two quantities, each of 10 ml, of peroxide-free ether, separate the ether layer, by centrifugation if necessary, dry the combined ether extracts over anhydrous sodium sulphate, filter, evaporate to dryness on a water-bath and dissolve the residue in 0.5 ml of methanol.

Reference solution. Dissolve 50 mg of hyoscyamine sulphate in 9 ml of methanol (solution A) and dissolve 15 mg of hyoscine hydrobromide in 10 ml of methanol (solution B); mix 8 ml of solution A with 1.8 ml of solution B.

Apply to the plate 10 µl and 20 µl of each solution as bands. After development, dry the plate at 105° for 15 minutes, allow to cool and spray with 10 ml of modified potassium iodobismuthate solution until the bands become visible as orange or brown on a yellow background. The bands in the chromatogram obtained with test solution have similar Rf values to those in the chromatograms obtained with reference solution (hyoscyamine in the lower third of the chromatogram; hyoscine in the upper third) and are similar in colour and atleast equal in size. Faint secondary bands may appear, particularly in the middle of the chromatogram obtained with 20 µl of the test solution or near the line of application in the chromatogram obtained with 10 µl of test solution. Spray the plate with a freshly prepared 10 per cent w/v solution of sodium nitrite until transparent and examine after 15 minutes. The colours due to hyoscyamine in the chromatogram change from brown to reddish-brown but not to greyish-blue (atropine); any secondary bands are no longer visible.

Foreign organic matter (2.6.1). Not more than 3 per cent.

Acid-insoluble ash (2.3.19). Not more than 3 per cent.

Assay. Powder 50 g and determine the loss on drying (2.4.19), by drying 2 g, accurately weighed, in an oven at 105°. From the remaining sample, weigh accurately about 10 g, moisten with a mixture of 5 ml of dilute ammonia solution, 10 ml of ethanol (95 per cent) and 30 ml of ether and mix thoroughly. Transfer the mixture to a percolator with the aid of an extracting solvent mixture consisting of 3 volumes of ether and 1 volume of chloroform. Allow to macerate for 4 hours and percolate with the solvent mixture until complete extraction of the alkaloids is effected, (2.6.4).

Concentrate the percolate to about 50 ml by distilling off the solvent mixture on a water-bath, and transfer to a separator, previously rinsed with ether. Add a quantity of ether at least equal to 2.1 times the volume of the percolate and extract with three quantities, each of 20 ml, of 0.5 M sulphuric acid. Transfer each acid extract to another separating funnel. Combine the acid extracts, make the solution alkaline with dilute ammonia solution and extract with chloroform until complete extraction of the alkaloids has been effected. Wash the combined chloroform extracts with 10 ml water, discard the water, evaporate the chloroform layer to dryness and heat the residue for 15 minutes on a water-bath. Redissolve the residue in successive small quantities of chloroform, evaporating to dryness on a water-bath each time before adding the solvent. Heat for 15 minutes on a water-bath and dissolve the residue in 5 ml of chloroform. Add 20.0 ml of 0.01 M sulphuric acid, remove the chloroform by evaporation on a water-bath and titrate the excess of acid with 0.02 M sodium hydroxide using methyl red solution as indicator.

1 ml of 0.01 M sulphuric acid is equivalent to 0.005788 g of total alkaloids calculated as hyoscyamine. Calculate the content of total alkaloids with reference to the dried material.

Storage. Store protected from light and moisture.
Bhibhitaki
Belliric Myrobalan; Terminalia

Bhibhitaki consists of the dried fruit pericarp of *Terminalia belerica* Roxb. (Fam. Combretaceae).

Bhibhitaki contains not less than 0.3 per cent w/w of ellagic acid and 0.75 per cent w/w of gallic acid, calculated on the dried basis.

**Description.** The dried pericarp appears as curved pieces of irregular shapes, the external surface is velvety, wrinkled grey to brown in colour and has astringent taste.

**Identification**

A. *Macroscopic* – The dried pericarp of the ripe fruit occurs as curved pieces of irregular shapes with convex external surface. The external surface appears velvety, slightly wrinkled grey to brown in colour. Internal surface is pale yellow. The cut surface is with occasional projecting threads, representing the vascular bundles.

B. *Microscopic* – The cells of the epidermis has a characteristic and a slightly bulged based with a hair like prolongation. Several vascular strands traverse the mesocarp in various directions. Peripheral layers of mesocarp have tangentially elongated cells, devoid of starch grains, containing rosettes of calcium oxalate crystals and few small stone cells.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel.

**Mobile phase.** A mixture of 20 volumes of toluene, 45 volumes of ethyl acetate and 20 volumes of glacial acetic acid and 5 volumes of formic acid.

**Test solution.** Reflux 2 g of the coarsely powdered substance under examination with 50-75 ml of methanol for 15 minutes, cool and filter. Reflux the residue further for two times with 75 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 50 ml.

**Reference solution.** Reflux 0.4 g of the coarsely powdered *bhibhitaki* RS with 50-75 ml of methanol for 15 minutes, cool and filter. Reflux the residue further for two times with 75 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 10 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air, spray with anisaldehyde sulphuric acid reagent. Heat at 100º for 5-10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter** (2.6.1). Not more than 2 per cent.

**Ethanol-soluble extractive** (2.6.2). Not less than 25 per cent.

**Water-soluble extractive** (2.6.3). Not less than 35 per cent by Method 1.

**Ash** (2.3.19). Not more than 8 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 2 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105º.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh 0.5 g of coarsely powdered substance under examination, add 50 ml of water, sonicate for 3 minutes and heat on a boiling water bath for 15 minutes, cool and dilute to 100.0 ml with water and filter.

**Reference solution.** A solution containing 0.01 per cent w/v each of gallic acid RS and ellagic RS in water.

**NOTE — Use freshly prepared solution and protected from light.**

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a gradient mixtures of acetonitrile and a buffer solution prepared by dissolving 0.136 g of potassium di-hydrogen orthophosphate in 500 ml of water, add 0.5 ml of orthophosphoric acid and make upto 1000 ml with water,
- flow rate. 1.5 ml per minutes,
- spectrophotometer set at 270 nm,
- a 20 µl loop injector.
<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Buffer solution (per cent v/v)</th>
<th>Acetonitrile (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>18</td>
<td>65</td>
<td>35</td>
</tr>
<tr>
<td>25</td>
<td>45</td>
<td>55</td>
</tr>
<tr>
<td>30</td>
<td>95</td>
<td>5</td>
</tr>
</tbody>
</table>

Inject the reference solution. The relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of gallic acid and ellagic acid.

Storage. Store protected from light, heat, moisture and against attack by insects and rodents.

Bhringraj

Eclipta

Bhringraj consists of the dried whole plant of *Eclipta alba* (L.) Hassk. (Fam. Asteraceae).

Bhringraj contains not less than 0.1 per cent of wedelolcatone, calculated on the dried basis.

Description. A green to greenish brown colour when completely dry.

Identification

A. Macroscopic — Root. Well developed, a number of secondary branches arise from main root up to about 7 mm in dia, cylindrical, greyish.

Stem. Herbaceous, branched occasionally rooting at nodes, cylindrical or flat, rough due to oppressed white hairs, node distinct, greenish, occasionally brownish.

Leaf. Opposite, sessile to sub sessile, usually oblong, lanceolate, sub-entire, sub -acute or acute, strigose with oppressed hairs on both surfaces.

Flower. Solitary or 2, together on unequal axillary peduncles, involucral bracts about 8, ovate, obtuse or acute, herbaceous, strigose with oppressed hairs; ray flowers ligulate, ligule small, spreading, scarcely as long as bracts, not toothed; white disc flowers tubular, corolla often 4 toothed; pappus absent, except occasionally very minute teeth on the top of achene; stamen 5, filaments epipetalous, free, anthers united into a tube with base obtuse; pistill bicarpellary; ovary inferior; unilocular with one basal ovule.

Fruit. Achenial cypsella, one seeded, cuneate, with a narrow wing, covered with warty excrescences, brown.

Seed. Dark brown, hairy and non endospermic.

B. Microscopic — Powder. Dark green; shows vessels in large groups or single broken pieces with pitted walls, numerous fibres entire or in pieces, trichomes entire or in pieces, warty, a few attached with epidermal and subsidiary cells, anomocytic and anisocytic stomata.

Root. The cells of outer one or two rows of secondary cortex, elongated or rounded with air cavities, while cells of inner secondary cortex, elongated to irregular in shape. Stone cells scattered in secondary cortex. Phloem rays broader towards the periphery, cells rounded. Xylem rays distinct, run straight in tangential section, rarely uniseriate and biseriate, cells pitted.

Stem. A few epidermal cells elongate to form characteristic non-glandular trichomes. Secondary cortex composed of large, rounded parenchymatous cells having wide air space. Vascular bundle in a ring, collateral, endarch, of varying size. Vessels barrel-shaped, some elongated with simple perforations, pitted with spiral thickening. A few xylem fibres bifurcate. Xylem rays uniseriate or biseriate.

Leaf. Anomocytic and anisocytic stomata and non-glandular hairs are present on both surface, more abundant on lower side. Vascular bundle, fine in mid rib, central one largest while four other small flanking either side of central bundle.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel F254.

Mobile phase. A mixture of 9 volumes of toluene, 6 volumes of acetone and 1 volume of formic acid.

Test solution. Reflux 1g of the coarsely powdered substance under examination with 25 ml of methanol for 30 minutes, cool and filter. Reflux the residue further with 3 × 25 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 10 ml.

Reference solution. Reflux 0.5 g bhringraj RS with 25 ml of methanol for 30 minutes, cool and filter. Reflux the residue
further with $3 \times 25$ ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 5 ml.

Apply to the plate 10 µl of each solution. Allow the mobile phase to rise 8 cm. Dry the plate in air and examine in ultraviolet light at 254 nm. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter** (2.6.1). Not more than 2.0 per cent.

**Ethanol-soluble extractive** (2.6.2). Not less than 5.0 per cent.

**Water-soluble extractive** (2.6.3). Not less than 15.0 per cent by Method I.

**Ash** (2.3.19). Not more than 22 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 11 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 15.0 per cent, determined on 5 g by drying in an oven at 105°C.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay**. Determine by liquid chromatography (2.4.14).

**Test solution**. Reflux 5 g of the coarsely powdered substance under examination with 30 ml of methanol on a water-bath for 30 minutes, cool and filter. Reflux the residue further with methanol till the last extract turns colourless, cool and filter. Combine all the filtrates and concentrate to 100 ml.

**Reference solution**. 0.01 per cent w/v solution of wedelolactone RS in methanol.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 35 volumes of acetonitrile and 60 volumes of 0.1 per cent v/v phosphoric acid prepared by diluting 1 ml of phosphoric acid to 1000 ml with water,
- flow rate. 1 ml per minute,
- spectrophotometer set at 249 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of wedelolactone.

**Storage**. Store protected from heat, moisture and against attack by insects and rodents.

---

**Bhuiamla**

**Phyllanthus**

Bhuiamla consists of the dried aerial parts of Phyllanthus amarus Schum. & Thom. (Fam. Euphorbiaceae).

Bhuiamla contains not less than 0.25 per cent of total phyllanthin and hypophyllanthin, calculated on the dried basis.

**Description**. A green to greenish yellow in colour, taste, slightly bitter.

**Identification**

A. **Macroscopic** — Stem teret, 1-4 mm in diameter. Leaves oblong 5 × 3 mm, short stalked, greenish brown in colour.

B. **Microscopic** — Stem, inner cortex chlorenchymatous; xylem rays 1-2-seriate. Leaf stomata mostly paracytic; epidermal cell wall markedly sinuous; rosette and prismatic crystals of calcium oxalate along the veins and midrib.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF 254.

**Mobile phase**. A mixture of 6 volumes of toluene, 2 volumes of ethyl acetate, 1 volume of formic acid and 0.2 volume of methanol.

**Test solution**. Reflux 2 g of coarsely powdered substance under examination with 50 ml methanol on a boiling water-bath for 30 minutes, cool and filter. Reflux the residue further with 2 × 50 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 10 ml.

**Reference solution**. Reflux 1 g of bhuiamla RS with 50 ml methanol on a boiling water-bath for 30 minutes, cool and filter. Reflux the residue further with 2 × 50 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 5 ml.
Apply to the plate 10µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cms above the line of application. Dry the plate in air and spray with methanolic sulphuric acid (10 per cent). Heat at 120°C for 5-10 minutes and examine the plate in daylight. The chromatographic profile of the test solution is similar to that of the reference solution.

Tests

Foreign organic matter (2.6.1). Not more than 2.0 per cent.

Ethanol-soluble extractive (2.6.2). Not less than 6.0 per cent.

Water-soluble extractive (2.6.3). Not less than 15.0 per cent by Method I.

Ash (2.3.19). Not more than 8.0 per cent.

Acid-insoluble ash (2.3.19). Not more than 5.0 per cent.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Loss on drying (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105°C.

Microbial contamination (2.2.9). Complies with the microbial contamination tests.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Reflux about 2 g of the coarsely powdered substance under examination with 50 ml of methanol on a water bath for 15 minutes, cool and filter. Reflux the residue further with methanol till the last extract turns colorless, cool and filter. Combine all the filtrates and concentrate to 10.0 ml.

Reference solution (a). A 0.020 per cent w/v solution of phyllanthin RS in methanol.

Reference solution (b). A 0.020 per cent w/v solution of hypophyllanthin RS in methanol.

Chromatographic system – a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5µm), – mobile phase: a mixture of 65 volumes of methanol and 35 volumes of water, – flow rate. 1.5 ml per minute, – spectrophotometer set at 230 nm, – a 20 µl loop injector.

Inject the reference solution (a) and (b). The test is not valid unless the relative standard deviation for the replicate injections for both the analyte peaks corresponding to phyllanthin and hypophyllanthin is not more than 2.0 per cent.

Inject the test solution, reference solutions (a) and (b).

Calculate the contents of phyllanthin and hypophyllanthin.

Storage. Store protected from heat, moisture and against attack by insects and rodents.

Brahmi

Bacopa

Brahmi consists of the dried whole plant, preferably leaves and stem of Bacopa monnieri (Linn.) Pennell (Fam. Scrophulariaceae).

Brahmi contains not less than 2.5 per cent of bacoside A, calculated on the dried basis.

Description. A brown to reddish brown colour when completely dried or green colour when partially dried with slightly bitter taste.

Identification

A. Macroscopic — Herbaceous comprising of stems, runner stems and leaves. Stems glabrous, leafless towards the base; internodes long. Leaves spatulate-ovate, sessile, and glabrous.

B. Microscopic — Cortex in stem composed of parenchyma cells enclosing large air spaces; xylem vessels radially arranged xylem rays uniseriate; pith parenchyma collapsed. In leaf, midrib indistinct, mesophyll isobilateral of spongy cells, a few prismatic crystals of calcium oxalate in mesophyll; stomata anomocytic on both the surfaces of leaf.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 70 volumes of chloroform and 30 volumes of methanol.

Test solution. Reflux 2 g of coarsely powdered substance under examination with 25 ml methanol for 15 minutes, cool and filter. Reflux the residue further with 2 x 25 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 25 ml.

Reference solution. Reflux 0.4 g of coarsely powdered brahmi RS with 5 ml methanol for 15 minutes, cool and filter.
Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cms above the line of application. Dry the plate in air, spray with 20 per cent v/v sulphuric acid in methanol. Heat at 100º for 5-10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

D. In the Assay, the chromatogram obtained with test solution corresponds to the chromatogram obtained with reference solution.

Tests

Foreign organic matter (2.6.1). Not more than 2.0 per cent.

Ethanol-soluble extractive (2.6.2). Not less than 6.0 per cent.

Water-soluble extractive (2.6.3). Not less than 22 per cent by Method I.

Ash (2.3.19). Not more than 18 per cent.

Acid-insoluble ash (2.3.19). Not more than 6.0 per cent.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Loss on drying (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105º.

Microbial contamination (2.2.9). Complies with the microbial contamination tests.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Reflux about 2 g of the coarsely powdered substance under examination with 50 ml of methanol on a water bath for 15 minutes, cool and filter. Reflux the residue further with methanol till the last extract turns colorless, cool and filter. Combine all the filtrates and concentrate to 100.0 ml.

Reference solution. A 0.2 per cent w/v solution of bacoside A RS in methanol, prepared by heating gently on a water bath.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a gradient mixtures of acetonitrile and a buffer solution prepared by dissolving 0.5 g phosphoric acid in 800 ml of water, adjust pH to 2.8 with dilute phosphoric acid and dilute to 1000 ml with water,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 205 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Buffer (pH 2.8) (per cent v/v)</th>
<th>Acetonitrile (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>25</td>
<td>60</td>
<td>40</td>
</tr>
<tr>
<td>35</td>
<td>40</td>
<td>60</td>
</tr>
<tr>
<td>36</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>45</td>
<td>70</td>
<td>30</td>
</tr>
</tbody>
</table>

Inject the reference solution. The relative retention times are 1.00 for bacoside A3, about 1.04 for bacopasaponine II, 1.13 for jujubogenin isomer of bacopasaponine C and 1.19 for bacopasaponine C as bacoside A. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution. Calculate the content of bacoside A.

Storage. Store protected from heat, moisture and against attack by insects and rodents.

Castor Oil

Castor Oil is the fixed oil obtained by cold expression from the seeds of Ricinus communis Linn. (Fam. Euphorbiaceae). It may contain suitable antioxidants.

Description. A pale yellowish or almost colourless, transparent, viscid liquid; odour, slight and characteristic.

Tests

Light absorption (2.4.7). Absorbance of a 1.0 per cent w/v solution in ethanol (95 per cent) at the maximum at about 269 nm, not more than 1.0.

Weight per ml (2.4.29). 0.945 g to 0.965 g.

Refractive index (2.4.27). 1.4758 to 1.4798.

Optical rotation (2.4.22). +3.5º to +6.0º.

Peroxide value (2.3.35). Not more than 5.0.

Acid value (2.3.23). Not more than 2.0.

Acetyl value (2.3.22). Not less than 143.

Hydroxyl value (2.3.27). Not less than 150.

Saponification value (2.3.37). 176 to 187.

Iodine value (2.3.28). 82 to 90.

Foreign fatty substances. A mixture of 2 ml of the substance under examination and 8 ml of ethanol (95 per cent) is clear.

B. Shake 10.0 ml with 20.0 ml of light petroleum (60º to 80º) and allow to separate; the volume of the lower layer is not less than 16.0 ml.

Storage. Store protected from light and moisture at a temperature not exceeding 15º.

Labelling. The label states (1) the name and quantity of any added antioxidant; (2) whether the contents are suitable for use in the manufacture of parenteral preparations.
Clove Oil

Clove oil is the oil distilled from the dried flower buds of Syzygium aromaticum (Linn.) Merrill and Perry [Eugenia caryophyllus (Spreng.) Bull. and Harr.]

**Description.** A clear, colourless or pale yellow liquid when freshly distilled, becoming darker and thicker by ageing or exposure to air; odour as of clove.

Clove Oil contains not less than 85.0 per cent w/w and not more than 95.0 per cent w/w of phenolic substances, chiefly eugenol, C_{10}H_{12}O_{2}.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** Toluene

**Test solution.** Dissolve 20 µl of the substance under examination in 2 ml of toluene.

**Reference solution.** Dissolve 20 µl of eugenol RS in 2 ml of toluene.

Apply to the plate 20 µl of the test solution and 10 µl of the reference solution as bands 20 mm by 3 mm. Use an unlined tank, develop the chromatogram immediately after pouring the mobile phase into the tank and allow the mobile phase to rise 10 cm under the same conditions. Following the second development, dry the plate in air, examine in ultraviolet light at 254 nm and mark the quenching bands. In the chromatogram obtained with the test solution there is a quenching band in the middle of the plate corresponding to the quenching band due to eugenol in the chromatogram obtained with the reference solution. A weak quenching band may also be seen in the chromatogram obtained with the test solution with an Rf value slightly lower than that of the band corresponding to eugenol (acetyleneugenol). Spray the plate with about 10 ml of anisaldehyde solution, heat at 100º to 105º for 10 minutes and examine in daylight. In the chromatogram obtained with the test and reference solutions the bands corresponding to eugenol are strongly coloured brownish-violet and any band corresponding to acetyleneugenol in the chromatogram obtained with the test solution is faintly violet-blue. Other coloured bands may be visible in the chromatogram obtained with the test solution, in particular a faint red band in the lower part of the chromatogram and a reddish-violet band in the upper part (caryophyllene).

**Tests**

**Optical rotation** (2.4.22). 0º to –1.50º.

**Weight per ml** (2.4.29). 1.038 g to 1.060 g.

**Refractive index** (2.4.27). 1.527 to 1.535, determined at 20º.

**Heavy metals** (2.3.13). 0.5 g complies with the limit test for heavy metals, Method B (40 ppm).

**Phenol.** Shake 1 ml with 20 ml of hot water; the mixture shows not more than a scarcely perceptible acid reaction with blue litmus paper. Cool the mixture, pass the aqueous layer through a wetted filter and treat the clear filtrate with 1 drop of ferric chloride test solution. The mixture has only a transient greyish-green colour but not a blue or violet colour.

**Alkali-soluble matter.** Place 80 ml of a 5 per cent w/v solution of potassium hydroxide in a 150-ml flask with a long neck which is graduated in tenths of a ml and is of such a diameter that not less than 15 cm in length has a capacity of 10 ml. Clean the flask with sulphuric acid and rinse well with water before use. Add 10 ml of the oil and shake thoroughly at 5 minute intervals for 30 minutes at ambient temperature. Raise the undissolved portion of the oil into the graduated part of the neck of the flask by the gradual addition of more of the potassium hydroxide solution; allow to stand for not less than 24 hours and read off the volume of the undissolved portion of the oil which measures between 1.0 and 1.5 ml.

**Assay.** Determine by gas chromatography (2.4.14).

**Test solution (a).** A 0.2 per cent w/v solution of the oil under examination in ethanol (95 per cent).

**Test solution (b).** A 0.2 per cent w/v solution of the oil under examination and 0.15 w/v of l-decanol (internal standard) in ethanol (95 per cent).

**Reference solution.** A solution containing 0.2 per cent w/v solution of eugenol RS and 0.15 per cent w/v of the internal standard in ethanol (95 per cent).

**Chromatographic system**

- a glass column 1.5 m x 4 mm, packed with 3 per cent w/w of dimethyl silicone fluid on acid-washed diatomaceous support (120 mesh),
- temperature: column, 110º for 18 minutes, then increased to 170º at a rate of 12º per minute and maintained at this temperature for 2 minutes, inlet port, 220º, detector, 300º,
- flow rate 40 ml per minute of the carrier gas.

Calculate the eugenol content in the oil under examination using the ratios of the area of the peak corresponding to eugenol to the area of the peak due to the internal standard in the chromatogram obtained with test solutions (b) and the reference solution.

**Storage.** Store protected from light in well-filled containers at a temperature not exceeding 30º.
Coleus

Coleus consists of the whole or cut dried roots of *Coleus forskohlii* Briq. (Fam. Lamiaceae).

Coleus contains not less than 0.4 per cent w/w of forskolin, calculated on the dried basis.

**Description.** The roots are light brown in color, generally long and radially spread. They have an aromatic characteristic odor and the taste is slightly pungent.

**Identification**

A. **Macroscopic** — Roots are brown, longitudinally wrinkled, fracture short, cut surface yellowish white.

B. **Microscopic** — The outermost layer consists of rectangular cork cells, cork cambium, rectangular parenchymatous region containing sclereids and calcium oxalate crystals. Vascular cambium is present in the form of a continuous ring. The tracheids and tracheidal fibres have bordered pits.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel*.

**Mobile phase.** A mixture of 75 volumes of *benzene*, and 25 volumes of *ethyl acetate*.

**Test solution.** To 5 g of the coarsely powdered substance under examination, add 50 ml of *methanol* and reflux for 15 minutes, cool and filter. Reflux the residue further for two times with 50 ml of *methanol*, cool and filter. Combine all the filtrates and concentrate under vacuum to 100 ml.

**Reference solution.** To 1 g of *coleus RS* add 50 ml of *methanol* and reflux for 15 minutes, cool and filter. Reflux the residue further for two times with 50 ml of *methanol*, cool and filter. Combine all the filtrates and concentrate under vacuum to 20 ml.

Apply to the plate 20 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cms. Dry the plate in air, spray with *vanillin sulphuric acid reagent*. Heat at 100° for 10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter** (2.6.1). Not more than 2.0 per cent.

**Ethanol-soluble extractive** (2.6.2). Not less than 15.0 per cent.

**Water-soluble extractive** (2.6.3). Not less than 18.0 per cent by method I.

**Ash** (2.3.19). Not more than 15.0 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 5.0 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105°.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh 3 g of coarsely powdered substance under examination, add 50 ml of *methanol* and reflux on a water bath for 15 minutes, cool and filter. Reflux the residue two times with 75 ml of *methanol*, cool and filter, Concentrate the filtrate to 100.0 ml.

**Reference solution.** A 0.1 per cent w/v solution of *forskolin RS* in *methanol*.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: filtered and degassed mixture of 45 volumes of *acetonitrile* and 55 volumes of *water*,
- flow rate. 1.8 ml per minute,
- spectrophotometer set at 220 nm,
- a 20 µl loop injector.

Inject the reference solution. The relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of forskolin.

**Storage.** Store protected from moisture and against attack by insects and rodents.

**Eucalyptus Oil**

**Nilgiri Oil**

Eucalyptus Oil is the essential oil obtained by steam distillation and rectification from the fresh leaves or the fresh terminal
branches of various species of eucalyptus like *Eucalyptus globulus* Labill., *E. fruticetorum* F. von Muell., and *E. smithii* (R. T. Baker) (Fam. Myrtaceae).

Eucalyptus Oil contains not less than 60 per cent w/w of cineole, C_{10}H_{18}O.

**Description.** A colourless or pale yellow liquid; odour, aromatic and camphoraceous; taste, pungent and camphoraceous, followed by a sensation of cold.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 90 volumes of *toluene* and 10 volumes of *ethyl acetate*.

**Test solution.** Dissolve 1 g of the substance under examination in 100 ml of *toluene*.

**Reference solution.** A 1 per cent w/v solution of cineole RS in *toluene*.

Apply to the plate 2 µl of each solution. After development, dry the plate in air, spray with *anisaldehyde solution*, using about 10 ml for a 200 mm x 200 mm plate, heat at 105º for 10 minutes and examine in daylight and in ultraviolet light at 365 nm. In the chromatogram obtained with the reference solution a dark brown spot due to cineole is visible in daylight in the middle part; when examined in ultraviolet light at 365 nm, the spot shows a brown fluorescence. The principal spot in the chromatogram obtained with the test solution corresponds to that of cineole; no carmine-brown spot appears in daylight in the upper third of the chromatogram and when examined in ultraviolet light at 365 nm no spot showing a greenish brown fluorescence appears in the upper third (citronellal). Other spots may be visible in the upper and lower thirds of the chromatogram.

**Tests**

- **Optical rotation** (2.4.22). 0º to +10º.
- **Refractive index** (2.4.27). 1.457 to 1.469.
- **Weight per ml** (2.4.29). 0.897 g to 0.924 g.

**Aldehydes.** Place 10 ml in a glass-stoppered tube (150 mm x 25 mm) add 5 ml of *toluene* and 4 ml of *ethanolic hydroxylamine solution*, shake vigorously and titrate immediately with 0.5 M potassium hydroxide in ethanol (60 per cent) until the red colour changes to yellow. Continue the shaking and neutralising until the pure yellow colour of the indicator is permanent in the lower layer after shaking vigorously for 2 minutes and allowing separation to take place; the reaction is complete in about 15 minutes. Repeat the operation using a further 10 ml of the substance under examination, and as the standard for the end-point, the titrated liquid of the first determination with the addition of 0.5 ml of 0.5 M potassium hydroxide in ethanol (60 per cent). Not more than 2.0 ml of 0.5 M potassium hydroxide in ethanol (60 per cent) is required in the second determination.

**Phellandrene.** Mix 1 ml with 2 ml of *glacial acetic acid* and 5 ml of *light petroleum (40º to 60º)*, add 2 ml of a saturated solution of *sodium nitrite* and shake gently; no crystalline precipitate is produced in the upper layer within 1 hour.

**Assay** (2.3.24) Determine the content of cineole in the oil.

**Storage.** Store in well-filled, tightly-closed containers at a temperature not exceeding 30º.

---

**Garcinia**

**Vilayati Imli**

Garcinia is the dried deseased fruit of *Garcinia cambogia* Desr. (Fam. Guttiferae).

Garcinia contains not less than 12.0 per cent of total hydroxycitric acid and hydroxycitric acid lactone, calculated on the dried basis.

**Description.** Dark brown to blackish brown fruits. Taste, acidic.

**Identification**

- **A. Macroscopic.** Dark brown to blackish brown fruits, ovoid, longitudinally grooved.
- **B. Microscopic.** Mesocarp very wide composed of parenchymatous cells of various sizes and shapes. Compound starch grains and prismatic crystals of calcium oxalate traverse throughout the parenchymatous cells of the mesocarp.
- **C. In the Assay.** The principal peak in the chromatogram obtained with test solution has a retention time similar to that of the peak due to hydroxycitric acid in the chromatogram obtained with reference solution.
Tests

Citric Acid. Not more than 2.0 per cent.
Determine by liquid chromatography (2.4.14).
Test solution, reference solutions (a), (b) and chromatographic system as described under Assay.
Inject test solution and reference solution (b).
Calculate the content of citric acid.

Foreign organic matter (2.6.1). Not more than 5.0 per cent.

Water-soluble extractive (2.6.3). Not less than 40.0 per cent by Method I.

Ash (2.3.19). Not more than 8.0 per cent.

Acid-insoluble ash (2.3.19). Not more than 1.5 per cent.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Loss on drying (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105°.

Microbial contamination (2.2.9). Complies with the microbial contamination tests.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh about 5 g of the coarsely powdered substance under examination and transfer to a 250-ml beaker.
Add 5 ml of dilute phosphoric acid and 100 ml of water, concentrate to half the volume by heating, cool and filter.
Extract the residue further with water till the last extract turns colorless, cool and filter. Combine all the filtrates and concentrate under vacuum to 250.0 ml.

Reference solution (a). A 0.8 per cent w/v solution of hydroxycitric acid calcium salt RS in dilute phosphoric acid.

Reference solution (b). A 0.1 per cent w/v solution of citric acid in dilute phosphoric acid.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a buffer solution prepared by dissolving 1.36 g of potassium dihydrogen phosphate in 900 ml of water, adjusting the pH to 2.5 with dilute phosphoric acid and diluting to 1000.0 ml with water,
- flow rate. 1 ml per minute,
- spectrophotometer set at 215 nm,
- a 20 µl loop injector.

Inject the reference solution (a). The test is not valid unless the relative retention times are about 0.8 for hydroxycitric acid lactone, 1.0 for hydroxycitric acid and 2.0 for citric acid, the resolution factor between hydroxycitric acid lactone and hydroxycitric acid is not less than 1.8, the tailing factor is not more than 1.5 and the relative standard deviation for the replicate injections is not more than 2.0 per cent.
Inject the test solution and reference solution (a).
Calculate the sum of the contents of hydroxycitric acid and hydroxycitric acid lactone.

Storage. Store protected from heat, moisture and against attack by insects and rodents.

Gokhru

Tribulus

Gokhru consists of dried fruits of Tribulus terrestris L.
Gokhru contains not less than 0.5 per cent of diosgenin, calculated on the dried basis.

Description. Pedicellate and globose fruits, having wedge-shaped cocci, covered with short and stiff spines. Possesses faintly aromatic smell and acrid taste.

Identification
A. Macroscopic — Fruit is pedicellate, having wedge-shaped cocci, covered with spines. Surface of schizocarp is rough.
B. Microscopic — Pericarp is differentiated into epicarp, mesocarp and endocarp. Epicarp is surrounded by nonglandular trichomes.
C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 8 volumes of toluene and 2 volumes of ethyl acetate.

Test solution. Reflux 5 g of coarsely powdered substance under examination with 50 ml of methanol for 15 minutes, cool and filter. Reflux the residue further with 50 ml of methanol, cool and filter. Combine both the filtrates and concentrate under vacuum to dryness. Extract the dried residue with 10 ml of methanol at 50° for 10 minutes, filter the solution and use filtrates for analysis.
Reference solution. Reflux 2.5 g of gokhru RS with 50 ml of methanol for 15 minutes, cool and filter. Reflux the residue further with 50 ml of methanol, cool and filter. Combine both the filtrates and concentrate under vacuum to dryness. Extract the dried residue with 5 ml of methanol at 50° for 10 minutes, filter the solution and use the filtrates for analysis.

Apply to the plate 20 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air, spray with anisaldehyde sulphuric acid. The chromatographic profile of the test solution is similar to that of the reference solution.

Tests

Foreign organic matter (2.6.1). Not more than 2 per cent.

Ethanol-soluble extractive (2.6.2). Not less than 3 per cent.

Water-soluble extractive (2.6.3). Not less than 15 per cent by method I.

Ash (2.3.19). Not more than 11 per cent.

Acid-insoluble ash (2.3.19). Not more than 1 per cent.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Loss on drying (2.4.19). Not more than 5 per cent, determined on 5 g by drying in an oven at 105°.

Microbial contamination (2.2.9). Complies with the microbial contamination tests.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Reflux 5.0 g of the substance under examination with 50 ml of sulphuric acid (10 per cent) for 4 hours. Cool and transfer to separating funnel. Extract with 50 ml of ethyl acetate. Repeat the extraction 3 times. Pass the ethyl acetate layer through sodium sulphate and evaporate. Dissolve the residue with 50 ml of methanol.

Reference solution. A 0.1 per cent w/v solution of diosgenin RS in methanol.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm packed with octadeylsilane bonded to porous silica (5 µm),
- mobile phase: 80 volumes of acetonitrile and 20 volumes of methanol,
- flow rate. 1 ml per minute,
- spectrophotometer set at 210 nm,
- a 20 µl loop injector.

Inject the reference solution. The relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution.

Calculate the content of diosgenin.

Storage. Store protected from heat, moisture and against attack by insects and rodents.

Guar Gum

Guar Gum is a gum obtained from the ground endosperms of the seeds of Cyamopsis tetragonolobus (Linn.) Taub or other species of Cyamopsis (Fam. Leguminosae). It consists mainly of a high molecular weight hydrocolloidal polysaccharide, composed of galactan and mannan units combined through glycosidic linkages.

Description. An almost white to pale yellowish white powder; odour, characteristic.

Identification

A. When mounted in lactophenol and examined under a microscope, irregular, angular particles of various sizes and shapes are seen.

B. To 0.1 g add 1 ml of 0.2 M iodine; the mixture does not acquire an olive-green colour.

C. Dissolve 0.1 g in 20 ml of water by shaking and add 0.5 ml of hydrogen peroxide solution (20 vol) and 0.5 ml of a 1 per cent w/v solution of benzidine in ethanol (90 per cent), shake and allow to stand; no blue colour is produced (distinction from acacia).

D. Mount a small quantity in ruthenium red solution and examine under a microscope; the particles do not acquire a pink colour (distinction from sterculia gum and agar).

E. To 2 ml of a 0.5 per cent w/v solution add 2 ml of a 20 per cent w/v solution of lead acetate; a flocculent precipitate is produced (distinction from acacia, ghatti gum and sterculia).

Tests

Acidity or alkalinity. A 0.5 per cent w/v solution is neutral to litmus paper.

Tannin. To 5 ml of a 0.5 per cent w/v solution add 0.1 ml of ferric chloride test solution; no bluish black colour is produced.

Arsenic (2.3.10). Mix 3.3 g with 3 g of anhydrous sodium carbonate, add 10 ml of bromine solution and mix thoroughly. Evaporate to dryness on a water-bath, gently ignite and dissolve the cooled residue in a mixture of 16 ml of brominated hydrochloric acid and 45 ml of water. Remove the excess of bromine with 2 ml of stannous chloride solution AsT. The resulting solution complies with the limit test for arsenic (3 ppm).

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).
Protein. Not more than 5.0 per cent, determined by the following method. Carry out the determination of nitrogen (2.3.30), using about 3.5 g, accurately weighed, and multiplying the percentage of nitrogen determined by 6.25 to obtain the percentage of protein.

Acid-insoluble matter. Not more than 3.0 per cent, determined by the following method. Weigh accurately about 1.5 g and disperse in 150 ml of water and 1.5 ml of sulphuric acid. Warm on a water-bath for 6 hours, replacing the water lost by evaporation. Add about 0.5 g of a suitable filter-aid, accurately weighed, and filter through a suitable ashless filter paper. Wash the residue several times with hot water, dry the filter and its contents at 105° for 3 hours. Cool in a desiccator, weigh and subtract the weight of the filter aid.

Microbial contamination (2.2.9). Total bacterial count: Not more than 5000 per g. 1 g is free from Escherichia coli and 10 g is free from Salmonellae.

Ash (2.3.19). Not more than 2.0 per cent, determined on 1.0 g.

Loss on drying (2.4.19). Not more than 13.0 per cent, determined on 0.5 g by drying in an oven at 105°.

Gudmar

Gymnema

Gudmar consists of the dried mature leaves of Gymnema sylvestre R.Br. (Fam. Asclepiadaceae).

Gudmar contains not less than 1.0 per cent of gymnemic acids (calculated as gymnemagenin), calculated on dried basis.

Description. Greenish-yellow in colour, surface pubescent on both sides and characteristic odour with extremely bitter and acrid taste.

Identification

A. Macroscopic — Leaves, simple, petiolate about 2 to 6 cm long and 1 to 4 cm broad, yellowish brown on adaxial and dark green on abaxial side.

B. Microscopic — Upper and lower epidermis covered with cuticle having uni to tri cellular covering trichomes which are slightly curved at the bulbous base. Below the epidermis is single layer of palisade cells followed by 2-3 layered spongy parenchyma. Starch gains are simple and present in spongy parenchyma. Midrib region shows 2-7 layers of collenchymatous cells. Stomata are of paracytic type, mostly on lower the surface. There is a fan shaped vascular bundle in the centre. Each vascular bundle is collateral, closed and surrounded by parenchymatous sheath. Rosette crystal of calcium oxalate present in the spongy parenchyma.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 5 volumes of chloroforms, 1 volume of methanol and 1 volume of ethyl acetate.

Test solution. Reflux 5 g of the coarsely powdered substance under examination with 50 ml of ethanol (50 per cent v/v) for 15 minutes, cool and filter. Reflux the residue further with 2 x 50 ml of ethanol (50 per cent v/v), cool and filter. Combine all the filtrates and concentrate under vacuum to 25 ml. Take 5 ml of resulting solution, add 5 ml ethanol and 2 ml of potassium hydroxide and reflux for 1 hour. Cool and add 1.8 ml of 12 M hydrochloric acid and heat on water bath. Cool and adjust the pH to 7.5-8.5 with 11 per cent potassium hydroxide. Dilute the solution with ethanol (50 per cent v/v) to 100 ml and filter.

Reference Solution. Reflux 1 g of gudmar RS with 50 ml of ethanol (50 per cent v/v) for 15 minutes, cool and filter. Reflux the residue further with 2 x 50 ml of ethanol (50 per cent v/v), cool and filter. Combine all the filtrates and concentrate under vacuum to 10 ml. Take 5 ml of resulting solution, add 5 ml ethanol and 2 ml of potassium hydroxide and reflux for 1 hour. Cool and add 1.8 ml of 12 M hydrochloric acid and heat on water bath. Cool and adjust the pH to 7.5-8.5 with 11 per cent potassium hydroxide. Dilute the solution with ethanol (50 per cent v/v) to 50 ml and filter.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air, spray with anisaldehyde sulphuric acid solution. Heat at 100° for 10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

Tests

Foreign organic matter (2.6.1). Not more than 2.0 per cent.

Ethanol-soluble extractive (2.6.2). Not less than 5.0 per cent.
**Water-soluble extractive** (2.6.3). Not less than 20.0 per cent by method I.

**Ash** (2.3.19). Not more than 15.0 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 6.0 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 14.0 per cent, determined on 5 g by drying in an oven at 105°C.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay**. Determine by liquid chromatography (2.4.14).

**Test solution**. Reflux 5 g of the coarsely powdered substance under examination with 50 ml of ethanol (50 per cent v/v) for 15 minutes, cool and filter. Reflux the residue further with 2 × 50 ml of ethanol (50 per cent v/v), cool and filter. Combine all the filtrates and concentrate under vacuum to 25 ml. Take 5 ml of resulting solution, add 5 ml ethanol and 2 ml of potassium hydroxide and reflux for 1 hour. Cool and add 1.8 ml of 12 M hydrochloric acid and heat on water bath. Cool and adjust the pH to 7.5-8.5 with 11 per cent potassium hydroxide. Dilute the solution with ethanol (50 per cent v/v) to 100 ml and filter.

**Reference solution**. A 0.01 per cent w/v solution of gymnemagenin RS in methanol.

**Guduchi**

**Tinospora, Giloe, Amrita**

Guduchi consists of the dried, mature pieces of stem of *Tinospora cordifolia* (Willd.) Miers (Fam. Menispermaceae).

Guduchi contains not less than 0.02 per cent w/w of cordifolioside A, calculated on the dried basis.

**Description**. A greyish-black in colour, fibrous fracture and no distinct odour with bitter taste.

**Identification**

A. **Macroscopic** — Stem-pieces glabrous, cylindrical, solid, lenticillate, 5-15 mm in diameter having light brown surface marked with warty protuberances due to circular lenticels. Transversely smoothened surface shows a radial structure with conspicuous medullary rays traversing porous tissues.

B. **Microscopic** — Transverse section of stem shows outermost layer of cork which is differentiated in to outer zone of thick walled, compressed cells and inner zone of thin walled, tangential cells. Cork broken at some places due to lenticels. Cortex consists of 3-5 rows of irregularly arranged tangential, chlorenchymatous cells with numerous intercellular spaces. Inner cortex filled with plenty of starch gains. Vascular zone consists of 10-12 wedge-shaped strips of xylem externally surrounded by semi-circular strips of phloem. Cambium composed of one to two layers of tangentially elongated cells. Primary phloem appears crushed and obliterated; secondary phloem groups are massive. Pith composed of large, thin walled cells mostly containing starch gains.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase**. A mixture of 85 volumes of chloroform and 15 volumes of methanol.

**Test solution**. Reflux 2 g of the coarsely powdered substance...
under examination with 25 ml of methanol for 15 minutes, cool and filter. Reflux the residue further with 2 × 25 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 5 ml.

Reference solution. Reflux 2 g of the guduchi RS with 25 ml of methanol for 15 minutes, cool and filter. Reflux the residue further with 2 × 25 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 5 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air, spray with an anisaldehyde solution. Heat at 110° for 10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

Tests

Foreign organic matter (2.6.1). Not more than 2.0 per cent.

Ethanol-soluble extractive (2.6.2). Not less than 1.5 per cent.

Water-soluble extractive (2.6.3). Not less than 9.0 per cent by method I.

Ash (2.3.19). Not more than 10.0 per cent.

Acid-insoluble ash (2.3.19). Not more than 3.0 per cent.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Loss on drying (2.4.19). Not more than 10.0 per cent, determined on 5 g by drying in an oven at 105°.

Microbial contamination (2.2.9). Complies with the microbial contamination tests.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Reflux 2 g of the coarsely powdered substance under examination with 50 ml of methanol on a water-bath for 15 minutes, cool and filter. Reflux the residue further with methanol till the extract turns colourless, cool and filter. Combine all the filtrates and concentrate to a volume slightly less than 25 ml. Dilute with methanol to 25.0 ml.

Reference solution. A 0.004 per cent w/v solution of cordifolioside A RS in methanol.

Chromatographic system

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Water (per cent v/v)</th>
<th>Acetonitrile (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>80</td>
<td>20</td>
</tr>
<tr>
<td>25</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>30</td>
<td>80</td>
<td>20</td>
</tr>
</tbody>
</table>

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution. Calculate the content of cordifolioside A.

Storage. Store protected from heat, moisture and against attack by insects and rodents.

Guggul Resin

Guggul, Commiphora

Guggul Resin is the oleoresin exudation from Commiphora wightii (Arnott) Bhandari (Commiphora mukul (Arn.) Bhandari, Balsamodendron mukul Hook. ex Stocks) (Fam. Burseraceae).

Guggul Resin contains not less than 1.0 per cent and not more than 1.5 per cent of gugulsterones (Z and E).

Description. Light to dark-brown conglomerates of tears, rounded or irregular, slightly sticky to touch; odour, faintly balsamic.

Identification

A. Prepare a 0.005 per cent w/v solution in ethanol (95 per cent) of the residue obtained in the test for Ethanol-soluble extractive.

When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows absorption maxima at about 245 nm and 327 nm.
B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 3 volumes of light petroleum (60º to 80º) and 1 volume of ethyl acetate.

**Test solution.** Dissolve 0.5 g of the residue obtained in the test for Ethanol-soluble extractive in 100 ml of ethanol (95 per cent).

**Reference solution.** A 0.25 per cent w/v solution of the residue obtained similarly from guggul resin RS in ethanol (95 per cent).

Apply to the plate 20 µl of each solution. After development, dry the plate in air until the odour of the solvent is no longer detectable and spray with a 50 per cent w/v solution of sulphuric acid. The principal spots in the chromatogram obtained with the test solution correspond to the spots in the chromatogram obtained with the reference solution.

**Tests**

**Ethyl acetate-soluble extractive.** Not less than 25.0 per cent, determined by the following method. Crush the substance under examination to a coarse powder. Shake 5.0 g of the powder with 25 ml of light petroleum (60º to 80º) for 1 hour and separate the liquid by filtration. Repeat the extraction twice and dry the defatted material over phosphorus pentoxide at room temperature at a pressure not exceeding 2.75 kPa for 8 hours. Crush the dried material and extract with four quantities, each of 25 ml, of ethyl acetate by shaking each time for 1 hour followed by filtration through a sintered-glass funnel (porosity No. 3) and combining the filtrates. Evaporate the combined filtrates, dry over phosphorus pentoxide at room temperature at a pressure not exceeding 2.75 kPa for 12 hours and weigh.

**Ethanol-soluble extractive** (2.3.46). Not less than 35.0 per cent, determined by the following method. Crush the substance under examination to a coarse powder. Macerate 5.0 g of the powder with 100 ml of ethanol (95 per cent) in a closed flask for 24 hours, shaking frequently during the first 6 hours and allowing to stand for 18 hours. Filter rapidly taking care to avoid loss of ethanol, evaporate 25 ml of the filtrate to dryness, dry at 105º and weigh.

**Sulphated ash** (2.3.18). Not more than 10.0 per cent, determined on 0.5 g.

**Assay.** Determine by liquid chromatography (2.3.14).

**Test solution.** Weigh accurately about 3.0 g of the substance under examination, add 50 ml of acetonitrile, reflux on a water-bath for 30 minutes, cool and filter. Reflux the residue further with three portions, each of 30 ml, of acetonitrile, cool and filter. Combine the filtrates and concentrate to 100.0 ml.

**Reference solution.** A 0.02 per cent w/v solution of gugulsterones (Z and E) RS in acetonitrile.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilyl silica gel (5 µm),
- mobile phase: a filtered and degassed mixture of 45 volumes of acetonitrile and 55 volumes of water,
- flow rate. 2 ml per minute,
- spectrophotometer set at 242 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative retention times are about 0.69 for gugulsterone E and 1.0 for gugulsterone Z and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution. Calculate the contents of gugulsterones (Z and E).

**Storage.** Store protected from light at a temperature not exceeding 30º.

**Gugulipid**

Gugulipid is the ethyl acetate extractive of Guggul Resin.

Gugulipid contains not less than 4.0 per cent and not more than 6.0 per cent of gugulsterones (Z and E).

**Description.** A brown, viscous liquid.

**Identification**

A. When examined in the range 230 nm to 360 nm (2.4.7), a 0.005 per cent w/v solution in chloroform shows absorption maxima at about 245 nm and 327 nm; absorbance at about 245 nm, about 0.87 and at about 327 nm, about 0.52.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 3 volumes of light petroleum (60º to 80º) and 1 volume of ethyl acetate.

**Test solution.** Dissolve 0.25 g of the substance under examination in 100 ml of ethanol (95 per cent).

**Reference solution.** A 0.25 per cent w/v solution of gugulipid RS in ethanol (95 per cent).

Apply to the plate 5 µl of each solution. After development, dry the plate in air until the odour of the solvent is no longer detectable and spray with a 50 per cent w/v solution of sulphuric acid. The principal spots in the chromatogram obtained with the test solution correspond to those in the chromatogram obtained with the reference solution.

**Tests**

**Assay.** Determine by liquid chromatography (2.4.14).
**Test solution.** Weigh accurately about 0.75 g of the substance under examination, add 50 ml of acetonitrile and warm on a boiling water-bath for 10 minutes. Cool and add sufficient acetonitrile to produce 100.0 ml.

**Reference solution.** A solution containing 0.02 per cent w/v of gugulsterones (Z and E) in acetonitrile.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilyl silica gel (5 µm),
- mobile phase: a filtered and degassed mixture of 45 volumes of acetonitrile and 55 volumes of water,
- flow rate. 2 ml per minute,
- spectrophotometer set at 242 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative retention times are about 0.69 for gugulsterone E and 1.0 for gugulsterone Z and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject alternately the test solution and the reference solution. Calculate the contents of gugulsterones (Z and E).

**Storage.** Store protected from light at a temperature not exceeding 30º.

---

**Gugulipid Tablets**

Gugulipid Tablets contain not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of gugulsterones (Z and E). The tablets may be coated.

**Identification**

Extract a quantity of the powdered tablets containing about 20 mg of gugulsterones (Z and E) with two quantities, each of 15 ml, of ethyl acetate, combine the extracts, filter and evaporate to dryness. The residue complies with the following tests.

A. When examined in the range 230 nm to 360 nm (2.4.7), a 0.005 per cent w/v solution in chloroform shows absorption maxima at about 245 nm and 327 nm; absorbance at about 245 nm, about 0.87 and at about 327 nm, about 0.52.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 3 volumes of light petroleum (60º to 80º) and 1 volume of ethyl acetate.

**Test solution.** A 0.25 per cent w/v solution of the substance under examination in ethanol (95 per cent).

**Reference solution.** A 0.25 per cent w/v solution of gugulipid RS in ethanol (95 per cent).

---

Apply to the plate 5 µl of each solution. After development, dry the plate in air until the odour of the solvent is no longer detectable and spray with a 50 per cent w/v solution of sulphuric acid. The principal spots in the chromatogram obtained with the test solution correspond to those in the chromatogram obtained with the reference solution.

**Tests**

**Disintegration (2.5.1).** 60 minutes.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Determine by liquid chromatography (2.4.13).

**Test solution.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing about 10 mg of gugulsterones (Z and E) and extract with five quantities, each of 20 ml, of acetonitrile, with the aid of heat. Combine the extracts and concentrate to 50.0 ml. Filter the solution through a membrane filter disc with an average pore diameter not greater than 1.0 µm and use the filtrate.

**Reference solution.** A solution containing 0.02 per cent w/v of gugulsterones (Z and E) in acetonitrile.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilyl silica gel (5 µm),
- mobile phase: a filtered and degassed mixture of 45 volumes of acetonitrile and 55 volumes of water,
- flow rate. 2 ml per minute,
- spectrophotometer set at 242 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative retention times are about 0.69 for gugulsterone E and 1.0 for gugulsterone Z and the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution. Calculate the contents of gugulsterones (Z and E) in the tablets.

**Storage.** Store protected from light at a temperature not exceeding 30º.

**Labelling.** The label states the strength in terms of the equivalent amount of gugulsterones (Z and E).
Haridra

Haldi; Turmeric; Curcuma

Haridra consists of the dried rhizomes of Curcuma longa Linn. (Fam. Zingiberaceae).

Haridra contains not less than 1.5 per cent of curcumin, calculated on the dried basis.

**Description.** Externally yellowish to yellowish brown with root scars and annulations. Odour, aromatic; taste, warmly aromatic and bitter.

**Tests**

- **Foreign organic matter** (2.6.1). Not more than 2.0 per cent.
- **Ethanol-soluble extractive** (2.6.2). Not less than 6.0 per cent.
- **Water-soluble extractive** (2.6.3). Not less than 12 per cent by Method I.
- **Ash** (2.3.19). Not more than 10 per cent.
- **Acid-insoluble ash** (2.3.19). Not more than 2.0 per cent.
- **Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).
- **Water** (2.3.43). Not more than 12.0 per cent, determined on 0.2 g.
- **Microbial contamination** (2.2.9). Complies with the microbial contamination tests.
- **Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Reflux about 1 g of the coarsely powdered substance under examination with 50 ml of methanol on a water bath for 15 minutes cool and filter. Reflux the residue further with 5 x 25 ml of methanol, cool and filter. Combine all the filtrates and concentrate to 100.0 ml.

**Reference solution.** A 0.01 per cent w/v solution of curcumin RS in methanol.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm packed with silicagel consisting of porous spherical particles with chemically bonded nitrile group,
- mobile phase: 35 volumes of tetrahydrofuran and 65 volumes of a buffer solution prepared by dissolving 10 g of citric acid in 1000 ml of water, adjusting the pH to 3.0 with dilute ammonia solution,
- flow rate. 1.2 ml per minute,
- spectrophotometer set at 430 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of curcumin.

**Storage.** Store protected from moisture.
Haritaki consists of pericarp of the dried fruit of *Terminalia chebula* Retz. (Fam. Combretaceae).

Haritaki contains not less than 5 per cent and not more than 12.5 per cent of chebulinic acid, calculated on the dried basis.

**Description.** It has a shine on its external part and has longitudinal ridges. The colour varies from yellowish brown to light black. It has a astringent taste and is also slightly bitter

**Identification**

*Test C may be omitted if tests A, B and D are carried out and test D may be omitted if tests A, B and C are carried out.*

A. *Macroscopic* — The fruit is 2 to 3 cm in length and 1 to 2 cm in diameter with hard stony appearance. Externally it is shining and is adorned with longitudinal ridges. Color of the fruit rind varies from yellowish brown, uniform brown to light black. Internally the fruit is light yellow.

B. *Microscopic* — Epicarp has thick walls covered with cuticle. The mesocarp has many stone cells of various sizes and shapes which forms a reticulum. Large quantity of tannin is present in the mesocarp. Simple starch granules are present in plenty.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel 60.

*Mobile phase.* A mixture of 35 volumes of toluene, 50 volumes of acetone, 15 volumes of glacial acetic acid and 5 volumes of formic acid.

*Test solution.* To 1 g of the coarsely powdered substance being examined, add 50-75 ml of methanol and reflux for 15 minutes, cool and filter. Reflux the residue further for two times with 75 ml of methanol, cool and filter. Combined all the filtrates and concentrate under vacuum to 10 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cms above the line of application. Dry the plate in air, spray with solution of 10 per cent w/v ferric chloride solution in water. Examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

D. In the Assay, the chromatogram obtained with the test solution corresponds to the chromatogram obtained with reference solution (a).

**Tests**

*Foreign organic matter* (2.6.1). Not more than 2.0 per cent.

*Ethanol-soluble extractive* (2.6.2). Not less than 35.0 per cent.

*Water-soluble extractive* (2.6.3). Not less than 50 per cent by Method I.

*Ash* (2.3.19). Not more than 6.0 per cent.

*Acid-insoluble ash* (2.3.19). Not more than 3.0 per cent.

*Heavy metals* (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm)

*Loss on drying* (2.4.19). Not more than 12 per cent, determined on 5 g by drying in an oven at 105º.

*Microbial contamination* (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

*Test solution.* Weigh 0.5 g of coarsely powdered sample, add 50 ml of water, sonicate for 3 minutes and heat on a boiling water bath for 15 minutes, cool and dilute to 100.0 ml with water and filter. Dilute 10.0 ml of the solution to 25.0 ml with water.

*Reference solution (a).* Weigh 0.5 g of *haritaki RS*, add 50 ml of water, sonicate for 3 minutes and heat on a boiling water bath for 15 minutes, cool and dilute to 100.0 ml with water and filter. Dilute 10.0 ml of the solution to 25.0 ml with water.

*Reference solution (b).* A 0.01 per cent w/v solution of chebulagic acid RS in water.

*Reference solution (c).* A 0.01 per cent w/v solution of chebulinic acid RS in water.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm packed with octadecysilane bonded to porous silica (5 µm).
- mobile phase: filtered and degassed gradient mixtures
of acetonitrile and a buffer solution pH 2.5 prepared by dissolving 0.136 g of potassium di-hydrogen orthophosphate in 500 ml of water, add 0.5 ml of orthophosphoric acid and make up to 1000 ml with water, — flow rate. 1.5 ml per min., — spectrophotometer set at 270 nm, — a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>Buffer solution (per cent v/v)</th>
<th>Acetonitrile (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>18</td>
<td>65</td>
<td>35</td>
</tr>
<tr>
<td>25</td>
<td>45</td>
<td>55</td>
</tr>
<tr>
<td>28</td>
<td>45</td>
<td>55</td>
</tr>
<tr>
<td>35</td>
<td>95</td>
<td>5</td>
</tr>
</tbody>
</table>

Inject the reference solution (b) and (c). The relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution (a).

Calculate the content of Chebulagic acid and Chebulinic acid.

Storage. Store protected from heat, moisture and against attack by insects and rodents.

Ispaghula Husk

Isapgo Husk; Plantago

Acetyl value (2.3.22). Not less than 143.

Hydrogenated Castor Oil

Castor Wax; Opalwax

Hydrogenated Castor Oil is refined, bleached, hydrogenated and deodorised castor oil. It consists mainly of the triglyceride of hydroxystearic acid.

Description. A white to yellow powder of uniform consistency and texture. It may have a hard, waxy consistency.

Tests

Melting range (2.4.21). 85 º to 88º, determined by Method II.

Free fatty acids. Weigh accurately about 20 g, melt on a water-bath, add 75 ml of hot ethanol (95 per cent), previously neutralised to phenolphthalein solution with 0.1 M sodium hydroxide, swirl, add 1 ml of phenolphthalein solution and titrate with 0.1 M sodium hydroxide, swirling vigorously until the solution remains faintly pink after being shaken for 60 seconds; not more than 11.0 ml of 0.1 M sodium hydroxide is required.

Heavy metals (2.3.13). 2.0 g complies with the limit test for heavy metals, Method B (10 ppm).

Acetyl value (2.3.22). Not less than 143.

Ispaghula Husk consists of the epidermis and collapsed adjacent layers removed from the dried ripe seeds of Plantago ovata Forsk.

Description. Pale buff, brittle flakes, more or less lanceolate, up to 2 mm long and 1 mm wide at the centre, much broken into smaller fragments; many of the flakes having a small, brownish, oval spot, about 0.8 to 1.0 mm long, in the centre; the material swells rapidly in water, forming a stiff mucilage.

Identification

When mounted in cresol and examined under a microscope, the particles are found to be transparent and angular, the edges straight or curved and sometimes rolled. They are composed of polygonal prismatic cells with four to six straight or slightly curved walls; the cells vary in size in different parts of the seed coat, from about 25 mm to 60 mm at the summit of the seed, that is, near and over the brown spot, to 25 mm to 100 mm for the remainder of the epidermis except at the edges of the seed, where the cells are smaller, about 45 mm to 70 mm. When mounted in ethanol (95 per cent) and irrigated with
water, the mucilage in the outer part of the epidermal cells swells rapidly and goes into solution, while the two inner layers of mucilage are more resistant and swell to form rounded papillae. When mounted in 0.005 M iodine, occasional simple and two- to four-compound starch granules, about 2 mm to 10 mm, can be seen in some of the cells. Occasional fragments of thick-walled, reddish brown endosperm, cells with pitted walls and elongated fragments of grey embryo may be present.

**Swelling power.** Transfer 1 g to a 100-ml stoppered cylinder containing 90 ml of water; shake well for 30 seconds and allow to stand 24 hours, shaking gently on three occasions during this period. Add sufficient water to produce 100 ml, mix gently for 30 seconds, avoiding the entrapment of air, allow to stand for 5 hours and measure the volume of mucilage. Repeat the determination three times. The average of four determinations is not less than 40 ml.

**Ash** (2.3.19). Not more than 4.5 per cent, determined on 1 g.

**Acid-insoluble ash** (2.3.19). Not more than 0.45 per cent.

**Loss on drying** (2.4.19). Not more than 12.0 per cent, determined on 0.5 g by drying in an oven at 105º for 5 hours.

**Storage.** Store protected from moisture and from attack by insects and rodents.

**Kalmegh**

Andrographis paniculata Nees. (Fam. Acanthaceae).

Kalmegh consists of the dried aerial parts, mainly stems and leaves, of Andrographis paniculata Nees. (Fam. Acanthaceae).

Kalmegh contains not less than 1.0 per cent of andrographolide, calculated on the dried basis.

**Description.** Taste, intensely bitter.

**Identification**

A. **Macroscopic** — Mixture of crisp, dark green-coloured broken leaves and quadrangular stems; leaves brittle. Stem fracture short, fibrous.

B. **Microscopic** — Stems quadrangular with collenchyma strands at angles and on side; small acicular crystals of calcium oxalate present in pith and cortex. Trichomes 1-3 celled, glandular hair disc-shaped and multicellular.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 7 volumes of chloroform and 1 volume of methanol.

**Test solution.** Reflux 1 g of coarsely powdered substance under examination with 50 ml methanol for 15 minutes, cool and filter. Reflux the residue further with 2 × 50 ml of methanol, cool and filter. Combine all the filtrates and concentrate to 10 ml.

**Reference solution.** Reflux 0.5 g of kalmegh RS with 50 ml methanol for 15 minutes, cool and filter. Reflux the residue further with 2 × 50 ml of methanol, cool and filter. Combine all the filtrates and concentrate to 5 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cms. Dry the plate in air and spray with methanolic sulphuric acid (20 per cent). Heat at 120º for 5-10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter** (2.6.1). Not more than 2.0 per cent.

**Ethanol-soluble extractive** (2.6.2). Not less than 3.0 per cent.

**Water-soluble extractive** (2.6.3). Not less than 12.0 per cent by Method I.

**Ash** (2.3.19). Not more than 15 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 3.0 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105º.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Reflux about 2.5 g of the coarsely powdered substance under examination with 50 ml of methanol on a water bath for 15 minutes, cool and filter. Reflux the residue
further with methanol till the last extract turns colorless, cool and filter. Combine all the filtrates and concentrate to 50.0 ml.

**Reference solution.** A 0.01 per cent w/v solution of andrographolide RS in methanol.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 65 volumes of methanol and 35 volumes of water,
- flow rate. 1 ml per minute,
- spectrophotometer set at 223 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of andrographolide.

**Storage.** Store protected from heat, moisture and against attack by insects and rodents.

### Kunduru

Sallaki Gum; Gum of Boswellia Serrata

Kunduru is the gum-resin from *Boswellia serrata* Roxb. (Fam. Burseraceae).

Kunduru contains not less than 1.0 per cent of total 11-keto-β-boswellic acid and acetyl-11-keto-β-boswellic acid, calculated on the dried basis.

**Description.** Translucent, brittle, whitish yellow substance, in roundish, club-shaped, pear-shaped, or irregular tears.

**Identification**

A. *Macroscopic* — Fracture dull. Slightly sticky to touch; odour, balsamic; taste slightly mucilaginous, bitter and aromatic.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF 254.

Mobile phase. A mixture of 7 volumes of hexane and 3 volumes of ethyl acetate.

**Test solution.** Reflux 1 g of coarsely powdered substance under examination with 50 ml methanol on a boiling water-bath for 30 minutes, cool and filter. Evaporate the filtrate to dryness and dissolve the residue in 5 ml of methanol.

**Reference solution.** Reflux 1 g of coarsely powdered kunduru RS with 50 ml methanol on a boiling water-bath for 30 minutes, cool and filter. Evaporate the filtrate to dryness and dissolve the residue in 5 ml of methanol.

Apply to the plate 10µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cms above the line of application. Dry the plate in air and spray with methanolic sulphuric acid (10 per cent) and heat at 110º for 5-10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter** (2.6.1). Not more than 2.0 per cent.

**Ethanol-soluble extractive** (2.6.2). Not less than 35 per cent.

**Ash** (2.3.19). Not more than 10.0 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 2.0 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Water** (2.3.43). Not more than 12.0 per cent, determined on 0.2 g.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Reflux about 2 g of the coarsely powdered substance under examination with 50 ml of methanol on a water bath for 15 minutes, cool and filter. Reflux the residue further with methanol till the last extract turns colorless, cool and filter. Combine all the filtrates and concentrate to 100.0 ml.

**Reference solution (a).** A 0.01 per cent w/v solution of 11-keto-β-boswellic acid RS in methanol.

**Reference solution (b).** A 0.05 per cent w/v solution of acetyl-11-keto-β-boswellic acid RS in methanol.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 90 volumes of methanol and 10 volumes of a mixture containing 5 ml of acetonitrile and 95 ml of acetonitrile.
water, adjusting the pH to 2.8 with *dilute orthophosphoric acid*,

- flow rate. 1.5 ml per minute,
- spectrophotometer set at 247 nm,
- a 20 µl loop injector.

Inject the reference solution (a) and (b). The test is not valid unless the relative retention times are about 0.65 for 11-keto-β-boswellic acid and 1.0 for acetyl-11-keto-β-boswellic acid and the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution.

Calculate the sum of the contents of 11-keto-β-boswellic acid and acetyl-11-keto-β-boswellic acid.

**Storage.** Store protected from heat, moisture and against attack by insects and rodents.

---

**Kutki**

*Picrorhiza*

Kutki consists of dried roots of *Picrorhiza kurroa* Royle ex Benth. (Fam. Scrophulariaceae)

Kutki contains not less than 5 per cent of kutkin, calculated on the dried basis.

**Description.** Rhizomes are sub cylindrical, straight or slightly curved, externally greyish with wrinkled surfaces, circular scars of roots and bud scales, with cork exposed at places.

**Identification**

A. *Macroscopic* — 3-6 cm long and about 1 cm thick, sub-cylindrical, straight, greyish brown, wrinkled roots. Odour is pleasant and tastes bitter.

B. *Microscopic* — There is well-developed periderm. About 7-10 layers of cork cells are seen. Cells of phelloderm loosely arranged.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel G*.

**Mobile phase.** A mixture of 7.5 volumes of *ethyl acetate*, 2.2 volumes of *methanol* and 0.1 volume *glacial acetic acid*.

**Test solution.** Reflux 5 g of coarsely powdered substance under examination with 50 ml of *methanol* for 15 minutes, cool and filter. Reflux the residue further with 50 ml of *methanol*, cool and filter. Combine both the filtrates and concentrate under vacuum to dryness. Extract the dried residue with 10 ml of *methanol* at 50º for 10 minutes, filter the solution and use the filtrate for analysis.

**Reference solution.** Reflux 5 g of *kutki RS* with 50 ml of *methanol* for 15 minutes, cool and filter. Reflux the residue further with 50 ml of *methanol*, cool and filter. Combine both the filtrates and concentrate under vacuum to dryness. Extract the dried residue with 10 ml of *methanol* at 50º for 10 minutes, filter the solution and use the filtrate for analysis.

Apply to the plate 20 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air, spray with *anisaldehyde sulphuric acid*. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter** (2.6.1). Not more than 2 per cent.

**Ethanol-soluble extractive** (2.6.2). Not less than 15 per cent.

**Water-soluble extractive** (2.6.3). Not less than 25 per cent by method I.

**Ash** (2.3.19). Not more than 6 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 1 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 5 per cent, determined on 5 g by drying in an oven at 105º.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 100 mg of the substance under examination in 25.0 ml of *methanol*, filter.

**Reference solution.** A 0.1 per cent w/v solution of *kutkin RS* in *methanol*.

**Chromatographic system**

- a stainless steel column 15 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 83 volumes of 1 per cent v/v *orthophosphoric acid* in *water* and 17 volumes of *acetonitrile,*
Institute of Microbiology

Lasuna contains not less than 0.2 per cent of alliin, calculated on the dried basis.

Description. Bulbs made up of cloves and is wrapped in a white papery sheath with pungent taste and odour.

Identification

A. Microscopic — Each bulb has several cloves which are arranged in concentric rings and enclosed in a shining white or pinkish papery envelope. The cloves are attached to a flat, circular hard disc with numerous thin wiry roots from its underside and short, cylindrical outgrowth from the upper surface. Each clove is ovoid and further covered by papery sheath with a tail like structure at one and opposite to its attachment. The cloves in the outer ring are loose and white in colour where as cloves in the inner ring are adherent and pale pinkish in colour. Each clove covered with a white scale leaf and a pinkish white epidermis, easily separated from the solid portion. In the middle of the bulb a hollow, cylindrical, linear remnant of the scape is seen.

B. Microscopic — The protective leaf contains an epidermis enclosing a mesophyll free from chlorophyll. The outer epidermis consists of lignified sclereid cells of thick, pitted walls, elongated, covered with thin cuticle. The cortical cells are thick walled, non lignified, tending to collapse on maturity, isodiametric and contain purple pigments. The vascular bundles consist of lignified spiral and annular vessels. The storage leaves show an outer epidermis of thin, delicate cells of variable shape. Stomata are present on the outer epidermis only at extreme tip near the base of the foliage leaves. The mesophyll consists of swollen storage parenchyma cells filled with fine granular reserve material.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel F254.

Mobile phase. A mixture of 3 volumes of butyl alcohol, 1 volume of n-propyl alcohol, 1 volume of glacial acetic acid and 1 volume of water.

Test solution. Reflux 1 g of substance under examination with 20 ml of methanol (50 per cent) for 10 minutes, cool and filter. Reflux the residue with another 20 ml of methanol (50 per cent), cool and filter. Combine all the filtrates and concentrate under vacuum to 5 ml.

Reference solution. Reflux 1 g of lasuna RS with 20 ml of methanol (50 per cent) for 10 minutes, cool and filter. Reflux the residue with another 20 ml of methanol (50 per cent), cool and filter. Combine all the filtrates and concentrate under vacuum to 5 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air, spray with 0.2 per cent w/v solution of ninhydrin in mixture of 95 volumes of butyl alcohol and 5 volumes of 2 M acetic acid. Heat at 100º to 105º for about 10 minutes and examine the plate in daylight. The chromatographic profile of the test solution is similar to that of the reference solution.

D. Transfer about 10 g of garlic bulbs that have been cut into small pieces to a beaker, add 10 ml of 1 M sodium hydroxide and 10 ml of water, heat the beaker in a boiling water for 10 minutes, cool and filter. To 2 ml of this filtrate add few drops of freshly prepared solution of sodium nitroprusside. Appearance of a red or orange red colour indicates the presence of sulphur containing compounds in the sample.

Tests

Foreign organic matter (2.6.1). Not more than 2.0 per cent.

Ash (2.3.19). Not more than 5 per cent.

Acid-insoluble ash (2.3.19). Not more than 1.0 per cent.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).
**Loss on drying** (2.4.19). Not more than 65.0 per cent for fresh bulbs, determined on 5 g by drying in an oven at 105º.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh accurately about 2 g of the freshly peeled substance under examination. Add 15 ml of hot water and grind in a porcelain mortar and filter. Grind the residue further with 2 × 15 ml of hot water and filter. Combine all the filtrates and make up to volume 50 ml with distilled water.

**Reference solution.** A 0.004 per cent w/v solution of alliin RS in water.

**Chromatographic system**
- a stainless steel column 25 cm × 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 0.1 per cent v/v phosphoric acid prepared by diluting 1 ml of phosphoric acid to 1000 ml with water,
- flow rate. 0.5 ml per minute,
- spectrophotometer set at 210 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test and reference solution.

Calculate the content of alliin.

**Storage.** Store protected from heat, moisture and against attack by insects and rodents.

---

**Malt Extract**

Malt Extract is a product obtained by extracting malted grains of cereals (barley, cholam or wheat) with water at a suitable temperature and evaporation of the strained liquid until a viscous product is obtained. It may be mixed with 10 per cent by weight of Glycerin.

Malt Extract contains nitrogen equivalent to not less than 4.0 per cent w/w of protein.

**Description.** A sweet, viscous, light brown liquid; odour, pleasant and characteristic.

**Tests**

**Refractive index** (2.4.27). 1.489 to 1.498, determined at 20º.

**Arsenic** (2.3.10). Dissolve 10.0 g in 10 ml of water, add 10 ml of brominated hydrochloric acid, allow to stand for 5 minutes and remove the excess of bromine with a few drops of stannous chloride solution AST. The resulting solution complies with the limit test for arsenic (1 ppm).

**Assay.** Weigh accurately about 5.0 g into a 200-ml long-necked flask and carry out the determination of nitrogen, Method A (2.3.30), using 0.05 M sulphuric acid instead of 0.1 M sulphuric acid.

1 ml of 0.05 M sulphuric acid is equivalent to 0.001401 g of N and multiply the result by 6.25 to obtain the protein content.

**Storage.** Store protected from moisture.

---

**Mandukaparni**

Centella, Gotu Kola

Mandukaparni consists of the dried aerial parts of *Centella asiatica* (Linn.) Urban. (Fam. Umbelliferae).

Mandukaparni contains not less than 0.5 per cent of asiaticoside, calculated on the dried basis.

**Description.** A green to greenish yellow in colour, taste, slightly bitter and sweet.
Identify

A. **Macroscopic** — A slender trailing herb with rooted nodes and internodes. Leaves with elongated petioles and sheathing leaf bases; lamina reniform with crenate margin.

B. **Microscopic** — Animocytic stomata on both surfaces, more on lower surface; petiole epidermis has calcium oxalate prisms; vascular bundles seven arranged in ‘U’ shape, parenchyma cells contain simple and compound starch granules.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel G*.

**Mobile phase.** A mixture of 60 volumes of *chloroform*, 32 volumes of *glacial acetic acid*, 12 volumes of *methanol* and 8 volumes of *water*.

**Test solution.** Reflux 2 g of coarsely powdered substance under examination with 50 ml of *methanol* for 15 minutes, cool and filter. Reflux the residue further with 2 × 50 ml of *methanol*, cool and filter. Combine all the filtrates and concentrate to 10 ml under reduced pressure.

**Reference solution.** Reflux 1 g of *mandukaparni RS* with 50 ml of *methanol* for 15 minutes, cool and filter. Reflux the residue further with 2 × 50 ml of *methanol*, cool and filter. Combine all the filtrates and concentrate to 5 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cms above the line of application. Dry the plate in air, spray with *anisaldehyde* solution. Heat at 100º for 5-10 minutes and examine the plate in daylight. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

- **Foreign organic matter** (2.6.1). Not more than 2.0 per cent.
- **Ethanol-soluble extractive** (2.6.2). Not less than 6.0 per cent.
- **Water-soluble extractive** (2.6.3). Not less than 15.0 per cent by Method I.
- **Ash** (2.3.19). Not more than 24 per cent.
- **Acid-insoluble ash** (2.3.19). Not more than 5.0 per cent.
- **Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).
- **Loss on drying** (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105º.
- **Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Reflux about 3 g of the coarsely powdered substance under examination with 50 ml of *methanol* on a water bath for 15 minutes, cool and filter. Reflux the residue further with *methanol* till the last extract turns colorless, cool and filter. Combine all the filtrates and concentrate to 100.0 ml.

**Reference solution.** A 0.1 per cent w/v solution of *asiaticoside RS* in *methanol*.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm packed with octysilane bonded to porous silica (10 µm),
- mobile phase: 25 volumes of *acetonitrile* and 75 volumes of *water*,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 210 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of *asiaticoside*.

**Storage.** Store protected from heat, moisture and against attack by insects and rodents.

**Manjistha**

**Indian Madder; Rubia Cordifolia**

**Manjistha consists of dried stem of *Rubia cordifolia* Linn. *sensu* Hook. (Fam. Rubiaceae).**

**Description.** A cylindrical, slightly flattened, wiry pieces of brown to purple coloured root with mild bitter taste.

**Identification**

A. **Microscopic** — Exfoliating cork, consisting of 4-12 or more layered radially arranged, thin walled cells.

**Acid-insoluble ash** (2.3.19). Not more than 5.0 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105º.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Reflux about 3 g of the coarsely powdered substance under examination with 50 ml of *methanol* on a
B. Macroscopic — Stem, slender, cylindrical, wiry and about 0.5 cm thick. It is brown to purple coloured and with longitudinal cracks.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 7 volumes of toluene, 25 volumes of ethyl acetate and 0.5 volumes glacial acetic acid.

Test solution. To 4 g of coarsely powdered substance under examination, add 100 ml of methanol, reflux for 15 minutes, cool and filter. Reflux the residue further for two times with 50 ml methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 100 ml.

Reference solution. To 1 g of coarsely powdered manjistha, add 100 ml of methanol, reflux for 15 minutes, cool and filter. Reflux the residue further for two times with 50 ml methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 25 ml.

Apply to the plate 20 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air and examine in the 254 nm, 366 nm and spray the plate with anisaldehyde sulphuric acid. The chromatographic profile of the test solution is similar to that of the reference solution.

Tests

Foreign organic matter (2.6.1). Not more than 2 per cent.

Ethanol-soluble extractive (2.6.2). Not less than 4 per cent.

Water-soluble extractive (2.6.3). Not less than 20 per cent by method I.

Ash (2.3.19). Not more than 10 per cent.

Acid-insoluble ash (2.3.19). Not more than 0.5 per cent.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Loss on drying (2.4.19). Not more than 5 per cent, determined on 5 g by drying in an oven at 105°C.

Microbial contamination (2.2.9). Complies with the microbial contamination tests.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh 4 g of coarsely powdered substance under examination, add 100 ml of methanol, reflux on a water-bath 15 minutes, cool and filter. Reflux the residue 2 x 50 ml methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 100.0 ml.

Reference solution. A 0.002 per cent w/v solution of rubiadin RS in methanol.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm packed with octadecysilane bonded to porous silica (5 µm),
- mobile phase: filtered and degassed gradient mixtures of acetonitrile and a buffer solution pH 2.5 prepared by dissolving 0.136 g of potassium di-hydrogen orthophosphate in 900 ml of water, add 0.5 ml of orthophosphoric acid and dilute to 1000 ml with water,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 278 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>Buffer solution (per cent v/v)</th>
<th>Acetonitrile (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>65</td>
<td>35</td>
</tr>
<tr>
<td>5</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>15</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>30</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>35</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>40</td>
<td>65</td>
<td>35</td>
</tr>
</tbody>
</table>

Inject the reference solution. The relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of rubiadin.

Storage. Store protected from heat, moisture and against attack by insects and rodents.

Maricha

Black pepper; pepper; Piper nigrum

Maricha consists of the unripe fruits of _Piper nigrum_ Linn. (Fam. Piperaceae).

Maricha contains not less than 2.5 per cent w/w of piperine, calculated on the dried basis.

Description. Fruits are globular or oblong. They have a blackish brown cover, with raised reticulated wrinkles. The odor is aromatic and the taste is strong and pungent.
Identification

A. Macroscopic — The fruits are globular or oblong, 4-6 mm in diameter. The outer cover is blackish brown, with raised reticulated wrinkles. One seeded, seeds are white and hollow.

B. Microscopic — The fruit has a well differentiated pericarp, testa and perisperm. Isolated, tangentially elongated oil cells are in the outer region of the mesocarp. Endocarp has beaker shaped stone cells and numerous polyhedral masses of starch grains. Testa has a single layer of yellow colored cells.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 60 volumes of benzene, 30 volumes of ethyl acetate and 10 volumes of diethyl ether.

Test solution. To 2 g of the coarsely powdered substance under examination, add 50 ml of methanol and reflux for 15 minutes, cool and filter. Reflux the residue further for two times with 75 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 50 ml.

Reference solution. To 2 g of the maricha RS, add 50 ml of methanol and reflux for 15 minutes, cool and filter. Reflux the residue further for two times with 75 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 50 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cms. Dry the plate in air and examine in ultraviolet light at 254 nm. The chromatogram obtained with test solution corresponds to the band in the chromatogram obtained with reference solution. Spray with vanilin sulphuric acid reagent. Heat at 100º for 5-10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

Tests

Foreign organic matter (2.6.1). Not more than 2.0 per cent.

Ethanol-soluble extractive (2.6.2). Not less than 6.0 per cent.

Water-soluble extractive (2.6.3). Not less than 6.0 per cent by method I.

Ash (2.3.19). Not more than 7.0 per cent.

Acid-insoluble ash (2.3.19). Not more than 2.0 per cent.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Loss on drying (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105º.

Microbial contamination (2.2.9). Complies with the microbial contamination tests.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh 2 g of coarsely powdered substance under examination, add 50 ml of methanol, sonicate for 3 minutes and heat on a boiling water bath for 15 minutes, cool and dilute to 100.0 ml with methanol and filter. Dilute further if necessary.

Reference solution. A 0.01 per cent w/v solution of piperine RS in methanol.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase. filtered and degassed gradient mixtures of acetonitrile and a buffer solution pH 2.5 prepared by dissolving 0.136 g of potassium di-hydrogen orthophosphate in 500 ml of water, add 0.5 ml of orthophosphoric acid and dilute to 1000 ml with water,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 345 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (in min.)</th>
<th>Buffer solution. (per cent v/v)</th>
<th>Acetonitrile (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>18</td>
<td>55</td>
<td>45</td>
</tr>
<tr>
<td>25</td>
<td>20</td>
<td>80</td>
</tr>
</tbody>
</table>

Inject the reference solution. The relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution. The relative retention time of piperine is 1.

Calculate the content of piperine.

Storage. Store protected from moisture and against attack by insects and rodents.

Mentha Oil

Mentha Oil is the volatile oil distilled with steam from various species of Mentha (Fam. Labiatae) and rectified if necessary.

Mentha Oil contains not less than 50.0 per cent w/w of total menthol, C_{10}H_{20}O.

Description. A colourless or yellowish, clear liquid; odour, characteristic and pleasant.

Tests

Acidity or alkalinity. A solution of 1 ml in 3.5 ml of ethanol (70 per cent) is neutral to litmus.

Weight per ml (2.4.29). 0.892 g to 0.910 g.

Specific optical rotation (2.4.22). –18.0º to –33.0º.
**Assay.** Place about 10.0 g in an acetylation flask, add 10 ml of acetic anhydride and 1 g of anhydrous sodium acetate, attach a reflux condenser and boil for 2 hours. Cool, add 30 ml of water and warm on a water-bath for 15 minutes with occasional shaking. Transfer the contents of the flask to a separating funnel, reject the water layer and wash the remaining oil with water until the last washing no longer shows acid reaction. Dry the resulting oil by shaking with 2 g of anhydrous sodium sulphate, allow to stand for 30 minutes and filter through a dry filter paper. Weigh accurately about 1.5 g of the dry acetylated oil, add 3 ml of ethanol (95 per cent) and 0.1 ml of phenolphthalein solution and dropwise, 0.5 M ethanolic potassium hydroxide until the solution acquires a faint pink colour. Add a further 20.0 ml of the alkali, attach a reflux condenser and boil for 1 hour on a water-bath. Cool, add 1 ml of phenolphthalein solution and titrate the excess of alkali with 0.5 M hydrochloric acid. Repeat the operation with the same quantities of the same reagents in the same manner without the oil and calculate the amount of total menthol from the following expression.

\[
\text{where, } S = \text{the amount, in g, of the acetylated sample taken, } a = \text{the amount, in ml, of 0.5 M hydrochloric acid consumed in the blank test, and } b = \text{the amount, in ml, of 0.5 M hydrochloric acid consumed in saponification of the acetylated oil.}
\]

**Storage.** Store protected from light and moisture.

---

**Opium**

Raw Opium; Papaver

Opium is the air-dried latex obtained by incision from the unripe capsules of Papaver somniferum Linn.

Opium contains not less than 10.0 per cent of morphine, \(C_{17}H_{19}NO_3\), and not less than 2.0 per cent of codeine, \(C_{18}H_{21}NO_3\), both calculated on the dried basis.

**Description.** Masses of various sizes which tend to be soft and shiny and, after drying, hard and brittle; usually in somewhat irregularly shaped masses (natural opium) or moulded into masses of more uniform size and shape (manipulated opium); colour, blackish brown; odour, strong and characteristic.

**Identification**

Strip off any covering, cut the substance under examination into thin slices, if necessary, dry at about 60º for 48 hours and reduce to a powder.

A. When examined under a microscope, a suspension in a 2 per cent w/v solution of potassium hydroxide appears as granules of latex agglomerated in irregular masses and light brown elongated filaments. Some fragments of vessels and rather elongated, refringent crystals are also visible, as well as a smaller number of round pollen grains and fragments of elongated fibres. Hairs of various lengths with sharp points and a few grains of starch introduced during the handling of the latex may be present. Fragments of epicarp consisting of polygonal cells with thick walls defining a stellate lumen may also be present.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A freshly prepared mixture of 20 volumes of acetone, 20 volumes of toluene, 3 volumes of ethanol (95 per cent) and 1 volume of strong ammonia solution.

**Test solution.** Triturate 0.1 g of the powdered substance with 5 ml of ethanol (70 per cent), add 3 ml of ethanol (70 per cent), transfer to a 25-ml conical flask and heat in a water-bath at 50º to 60º for 30 minutes, with stirring. Cool, filter, wash the filter with ethanol (70 per cent) and dilute the filtrate to 10 ml with the same solvent.

**Reference solution.** Dissolve 2 mg of papaverine hydrochloride RS, 12 mg of codeine phosphate RS, 12 mg of noscapine hydrochloride RS, and 25 mg of morphine hydrochloride RS in ethanol (70 per cent) and dilute to 25 ml with the same solvent.

Apply to the plate 20 µl of each solution as 20 mm bands. After development, dry the plate at 100º to 105º for 15 minutes, allow to cool and spray with potassium iodobismuthate solution and then with a 0.4 per cent w/v solution of sulphuric acid. The chromatogram obtained with the reference solution shows in the lower part an orange-red or red band (morphine), above it a similarly coloured band (codeine) and in the upper part an orange-red or red band (papaverine) and above it a similarly coloured band (noscapine). The chromatogram
obtained with the test solution shows orange-red or red bands corresponding to those in the chromatogram obtained with the reference solution. The chromatogram obtained with the test solution may also show a dark red band (thebaine) situated between those due to codeine and to papaverine.

C. To 1 g of the powdered substance add 5 ml of water, shake for 5 minutes, filter and add to the filtrate 0.25 ml of ferric chloride solution; a red colour develops which does not disappear on the addition of 0.5 ml of 2 M hydrochloric acid.

Tests

Thebaine. Not more than 3 per cent, calculated on the dried basis.

Determine by liquid chromatography (2.4.14).

Test solution. Use the test solution prepared in the assay.

Reference solution. Dissolve 25 mg of thebaine in sufficient mobile phase to produce 25.0 ml and dilute 10.0 ml of this solution to 100.0 ml with the mobile phase.

Chromatographic system as described in the Assay.

The test is not valid unless the capacity factor for thebaine is at least 3.0 and the number of theoretical plates is at least 3000. Calculate the percentage content of thebaine from the expression given in the assay.

Ash (2.3.19). Not more than 6.0 per cent, determined on 0.5 g.

Loss on drying (2.4.19). Not more than 15.0 per cent, determined on 0.25 g cut into thin slices, by drying in an oven at 105º for 4 hours.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Suspend about 1.0 g, accurately weighed substance under examination, cut into thin slices, in 50 ml of ethanol (50 per cent), mix with the aid of ultrasound for 1 hour, allow to cool, dilute to 100.0 ml with the same solvent and allow to stand. To 10.0 ml of the supernatant liquid add 5 ml of ammonia buffer pH 9.5, dilute to 25.0 ml with water, mix, transfer 20.0 ml of the solution to a column (about 15 cm x 30 mm) containing 15 g of kieselguhr for column chromatography and allow to stand for 15 minutes. Elute with two quantities, each of 40 ml, of a mixture of 85 volumes of dichloromethane and 15 volumes of 2-propanol, evaporate the eluate to dryness at 40ºat a pressure of 2 kPa, transfer the residue to a 25-ml volumetric flask with the aid of the mobile phase and dilute to volume with the same solvent.

Reference solution. Weigh accurately 0.1 g of morphine hydrochloride and 25 mg of codeine, dissolve in sufficient of the mobile phase to produce 25.0 ml and dilute 10.0 ml of this solution to 100.0 ml with the same solvent.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm), fitted with a guard column 4 cm x 4.6 mm packed with octylsilane bonded to porous silica (5 µm),
- mobile phase: 1.0 g of sodium heptanesulphonate in 420 ml of water, adjusting to pH 3.2 with phosphoric acid that has been diluted to contain 0.49 per cent w/v solution of H₃PO₄ (about 5 ml) and adding 180 ml of acetonitrile,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 280 nm.

Inject suitable volumes of each solution. The assay is not valid unless the resolution between the peaks corresponding to morphine and codeine is at least 2.5. If necessary, adjust the volume of acetonitrile in the mobile phase. Inject the reference solution six times. The assay is not valid unless the relative standard deviation of the peak area for morphine is not more than 1.0 per cent.

Inject the test solution and the reference solution.

Calculate the percentage content of each alkaloid from the expression

\[
\frac{w_1 \times A_2 \times 625 \times 10^4}{w_2 \times A_1 \times 5(100-h)}
\]

where, \( w_1 \) = weight, in g, of the alkaloid used to prepare the reference solution, \( w_2 \) = weight, in g, of the substance under examination used to prepare the test solution, \( A_1 \) = area of the peak corresponding to the alkaloid in the chromatogram obtained with the reference solution, \( A_2 \) = area of the peak corresponding to the alkaloid in the chromatogram obtained with the test solution, \( h \) = percentage loss on drying.

For calculation, 1 mg of morphine hydrochloride may be taken as equivalent to 0.759 mg of morphine and 1 mg of codeine phosphate may be taken as equivalent to 0.943 mg of codeine.

Storage. Store protected from light and moisture.

Opium Powder

Opium Powder is Opium dried at a temperature not exceeding 70º, reduced to a fine or moderately fine powder and adjusted by the addition of Lactose, suitably coloured with Caramel, or other suitable diluent to contain about 10 per cent of morphine and 2 per cent of codeine.

Opium Powder contains not less than 9.5 per cent and not more than 10.5 per cent of morphine, C₁₇H₁₉NO₃, and not less
than 1.9 per cent and not more than 2.1 per cent of codeine, C_{18}H_{21}NO_3, both calculated on the dried basis.

**Description.** A light brown powder consisting of yellowish brown or brownish red particles; odour, characteristic.

**Identification**

A. When examined under a microscope, the residue obtained after extraction with water, appears as granules of latex agglomerated in irregular masses and light brown elongated filaments. Some fragments of vessels and rather elongated, refringent crystals are also visible, as well as a smaller number of round pollen grains and fragments of elongated fibres. Hairs of various lengths with sharp points and a few grains of starch introduced during the handling of the latex may be present. Fragments of epicarp consisting of polygonal cells with thick walls defining a stellate lumen may also be present and if powdered cocoa husk is present, the following: brown colour of the fragments; narrow spiral vessels about 10 to 20 mm wide, in groups of from one to six, traversing a spongy parenchyma of thin-walled cells about 40 to 60 mm in either direction and united by arm-like projections enclosing almost circular intercellular spaces; fragments of the sclerenchymatous layer, consisting of thick-walled lignified brown, rectangular to polyhedral cells in a single layer, individual cells about 5 to 10 µm wide and 10 to 30 µm long; fragments of mucilage staining in ruthenium red solution.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 20 volumes of acetone, 20 volumes of toluene, 3 volumes of ethanol (95 per cent) and 1 volume of strong ammonia solution.

**Test solution.** Triturate 0.10 g of the powdered substance with 5 ml of ethanol (70 per cent), add 3 ml of ethanol (70 per cent), transfer to a 25-ml conical flask and heat in a water-bath at 50º to 60º for 30 minutes, with stirring. Cool, filter, wash the filter with ethanol (70 per cent) and dilute the filtrate to 10 ml with the same solvent.

**Reference solution.** Dissolve 2 mg of papaverine hydrochloride RS, 12 mg of codeine phosphate RS, 12 mg of noscapine hydrochloride RS, and 25 mg of morphine hydrochloride RS in ethanol (70 per cent) and dilute to 25 ml with the same solvent.

Apply to the plate 20 µl of each solution as 20 mm bands. After development, dry the plate at 100º to 105º for 15 minutes, allow to cool and spray with potassium iodosibismuthate solution and then with a 0.4 per cent w/v solution of sulphuric acid. The chromatogram obtained with the reference solution shows in the lower part an orange-red or red band (morphine), above it a similarly coloured band (codeine) and in the upper part an orange-red or red band (papaverine) and above it a similarly coloured band (noscapine). The chromatogram obtained with the test solution shows orange-red or red bands corresponding to those in the chromatogram obtained with the reference solution. The chromatogram obtained with the test solution may also show a dark red band (thebaine) situated between those due to codeine and to papaverine.

C. To 1 g of the powdered substance add 5 ml of water, shake for 5 minutes, filter and add to the filtrate 0.25 ml of ferric chloride solution; a red colour develops which does not disappear on the addition of 0.5 ml of 2 M hydrochloric acid.

**Tests**

**Thebaine.** Not more than 3 per cent, calculated on the dried basis.

Determine by liquid chromatography (2.4.14).

**Test solution.** Use the test solution prepared in the Assay.

**Reference solution.** Dissolve 25 mg of thebaine in sufficient mobile phase to produce 25.0 ml and dilute 10.0 ml of this solution to 100.0 ml with the mobile phase.

Chromatographic condition as described in the Assay.

The test is not valid unless the capacity factor for thebaine is at least 3.0 and the number of theoretical plates is at least 3000. Calculate the percentage content of thebaine from the expression given in the Assay.

**Ash** (2.3.19). Not more than 6.0 per cent, determined on 0.5 g.

**Loss on drying** (2.4.19). Not more than 15.0 per cent, determined on 0.25 g by drying in an oven at 105º for 4 hours.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Suspend about 1.0 g, accurately weighed, of the substance under examination, cut into thin slices, in 50 ml of ethanol (50 per cent), mix with the aid of ultrasound for 1 hour, allow to cool, dilute to 100.0 ml with the same solvent and allow to stand. To 10.0 ml of the supernatant liquid add 5 ml of ammonia buffer pH 9.5, dilute to 25.0 ml with water, mix, transfer 20.0 ml of the solution to a column (about 15 cm x 30 mm) containing 15 g of kieselguhr for column chromatography and allow to stand for 15 minutes. Elute with two quantities, each of 40 ml, of a mixture of 85 volumes of dichloromethane and 15 volumes of 2-propanol, evaporate the eluate to dryness at 40º at a pressure of 2 kPa, transfer the residue to a 25-ml volumetric flask with the aid of the mobile phase and dilute to volume with the same solvent.

**Reference solution.** Weigh accurately 0.1 g of morphine hydrochloride RS and 25 mg of codeine phosphate RS, dissolve in sufficient of the mobile phase to produce 25.0 ml and dilute 10.0 ml of this solution to 100.0 ml with the same solvent.
Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octylsilane bonded to porous silica (5 µm), fitted with a guard column 4 cm x 4.6 mm packed with octylsilane bonded to porous silica (5 µm),
- mobile phase: 1.0 g of sodium heptanesulphonate in 420 ml of water, adjusting to pH 3.2 with phosphoric acid that has been diluted to contain 0.49 per cent w/v solution of H₃PO₄ (about 5 ml) and adding 180 ml of acetonitrile,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 280 nm.

Inject suitable volume of reference solution. The test is not valid unless the resolution between the peaks corresponding to morphine and codeine is at least 2.5. If necessary, adjust the volume of acetonitrile in the mobile phase. The relative standard deviation of the peak area for morphine is not more than 1.0 per cent.

Inject the test solution and the reference solution. Calculate the percentage content of each alkaloid from the expression

\[
\frac{w_1 \times A_2 \times 625 \times 100}{w_2 \times A_1 \times 5(100-h)}
\]

where, \(w_1\) = weight, in g, of the alkaloid used to prepare the reference solution,

\(w_2\) = weight, in g, of the substance under examination used to prepare the test solution,

\(A_1\) = area of the peak corresponding to the alkaloid in the chromatogram obtained with the reference solution,

\(A_2\) = area of the peak corresponding to the alkaloid in the chromatogram obtained with the test solution,

\(h\) = percentage loss on drying.

For calculation, 1 mg of morphine hydrochloride may be taken as equivalent to 0.759 mg of morphine and 1 mg of codeine phosphate may be taken as equivalent to 0.943 mg of codeine.

Storage. Store protected from light and moisture.

Papain

Papain is an enzyme or a mixture of enzymes obtained from the juice of the unripe fruit of *Carica papaya* Linn. (Fam. Caricaceae). It may contain a suitable diluent such as Lactose.

Papain contains not less than the minimum protease activity determined under the conditions of the Assay.

Description. A white to light brown, amorphous or slightly granular powder; odour, characteristic.

Tests

Microbial contamination (2.2.9). 1.0 g is free from *Escherichia coli* and 10.0 g is free from *salmonellae*.

Loss on drying (2.4.19). Not more than 7.0 per cent, determined on 1 g by drying in an oven at 60° at a pressure not exceeding 0.7 kPa for 4 hours.

Assay. Weigh accurately about 0.5 g, triturate with 10 ml of cysteine hydrochloride solution and dilute to 100.0 ml with water. To 30 ml of water in each of two flasks add 15.0 ml of casein solution and maintain at 60° by heating on a water-bath. To the first flask add 5.0 ml of the solution of the substance under examination, and to the second flask add 5.0 ml of the same solution, previously boiled for 2 minutes and cooled. Maintain the solutions at 60° for 30 minutes, cool rapidly to room temperature and add to each flask 0.75 ml of phenolphthalein solution and 10 ml of formaldehyde solution, previously neutralised to phenolphthalein solution. Titrate both solutions with 0.1 M sodium hydroxide to the same definite pink colour; the difference between the two titrations is not less than 4.5 ml.

Storage. Store protected from light and moisture.

Labelling. The label states the name of any added substance.

Peppermint Oil

Peppermint Oil is obtained by steam distillation from the aerial parts of the flowering plant of *Mentha piperita* L. and *M. arvensis* var. *piperascens*.

Peppermint Oil contains not less than 4.5 per cent w/w and not more than 10.0 per cent w/w of esters, calculated as menthyl acetate, C₁₅H₂₂O₂, not less than 44.0 per cent w/w of free alcohols, calculated as menthol, C₁₀H₂₀O, and not less than 15.0 per cent w/w and not more than 32.0 per cent w/w of ketones, calculated as menthone, C₁₀H₁₈O.

Description. A colourless, pale yellow or pale greenish yellow liquid; odour, characteristic; taste, characteristic followed by sensation of cold.

Identification

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G F254.

Mobile phase. A mixture of 95 volumes of toluene and 5 volumes of ethyl acetate.

Test solution. Dissolve 1 g of the oil under examination in 100 ml of toluene.
Reference solution. Dissolve 50 mg of (-)-menthol RS, 20 µl of cineole RS, 10 mg of thymol RS and 10 µl of menthyl acetate RS in sufficient toluene to produce 10 ml.

Apply to the plate 20 µl of test solution and 10 µl of reference solution as bands 20 mm by 3 mm. After development, dry the plate in air until the odour of solvent is no longer detectable and examine in ultraviolet light at 254 nm. In the chromatogram obtained with test solution there are no quenching bands at Rf values slightly lower than that of the faint band due to thymol in the chromatogram obtained with reference solution (carvone and pulegone). Spray the plate with anisaldehyde solution and examine in daylight after heating at 105° for 5 minutes. The chromatogram obtained with reference solution shows, in order of increasing Rf value, an intense blue to violet band (menthol) in the lower third, a violet-blue to brown band (cineole), a pink band (thymol) and a violet-blue band (menthone). The chromatogram obtained with test solution shows an intense greyish green or faint bluish grey bands at Rf values slightly lower than that of the faint band due to thymol in the chromatogram obtained with reference solution (carvone and pulegone). Spectral bands corresponding to cineole, a violet-blue band corresponding to menthol acetate in the middle of the chromatogram and at a slightly lower Rf value a greenish band (menthofuran) at a slightly lower Rf value; other less intensely coloured bands may also be seen.

Tests

Acidity. To 2 g add 0.25 ml of phenolphthalein solution; not more than 0.1 ml of 0.5 M ethanolic potassium hydroxide is required to change the colour of the solution.

Optical rotation (2.4.22). –10° to –30°.

Refractive index (2.4.27). 1.460 to 1.467.

Weight per ml (2.4.29). 0.900 g to 0.916 g.

Dimethyl sulphide. Distil 25 ml, collect the first 1 ml of the distillate and carefully superimpose it on 5 ml of a 6.5 per cent w/v solution of mercuric chloride; no white film is produced within 1 minute at the interface of the two liquids.

Fixed oils and resinified volatile oils. Allow 0.05 ml to fall on a filter paper. The oil evaporates completely within 24 hours without leaving a translucent or greasy mark.

Assay. For esters — To 2 g in a borosilicate glass flask add 2 ml of ethanol (90 per cent) and 0.25 ml of phenolphthalein solution, neutralise with 0.5 M ethanolic potassium hydroxide, add an additional 25.0 ml and a little pumice powder or a few pieces of porous pot and heat under a reflux condenser on a water-bath for 30 minutes. Add 1 ml of phenolphthalein solution and immediately titrate with 0.5 M hydrochloric acid. Repeat the operation without the substance under examination. The difference between the titrations represents the volume of alkali required to saponify the esters.

1 ml of 0.5 M ethanolic potassium hydroxide is equivalent to 0.09915 g of esters, calculated as menthyl acetate, C₈H₁₆O₂.

For free alcohols — To 1 g in a dry, 150-ml acetylation flask, add 3 ml of a mixture of 3 volumes of pyridine and 1 volume of acetic anhydride. Determine the weight of the acetylation mixture to the nearest mg, keeping the flask closed while weighing. Boil under a reflux condenser in a water-bath for 3 hours, maintaining the water level 2 to 3 cm above the level of the liquid in the flask throughout. Remove the flask from the water-bath and add 50 ml of water through the condenser, remove the condenser and wash the walls of the flask with 10 ml of water. Allow to stand for 15 minutes and titrate with 0.5 M sodium hydroxide using 1 ml of phenolphthalein solution as indicator. Repeat the operation without the substance under examination. The difference between the titrations represents the volume of sodium hydroxide required.

1 ml of 0.5 M sodium hydroxide is equivalent to 0.07815 g of free alcohols, calculated as menthol, C₁₀H₂₀O. If the quantities of acetic anhydride in pyridine used in the two determinations differ by more than 5 mg, adjust the volume of alkali used in the second titration by multiplying with a/b where a is the weight, in g, of acetic anhydride in pyridine used in the first determination and b is the weight, in g, of acetic anhydride in pyridine used in the second test.

For ketones — To 2 g add 25 ml of a 5.0 per cent w/v solution of hydroxylamine hydrochloride in ethanol (95 per cent), heat on a water-bath for 1 hour, allow to cool, add about 1 mg of methyl orange and titrate with 0.5 M ethanolic potassium hydroxide until an orange-yellow colour is obtained. Repeat the heating for further periods of 1 hour until, after cooling, not more than 0.1 ml of 0.5 M ethanolic potassium hydroxide is required to neutralise the solution.

1 ml of 0.5 M ethanolic potassium hydroxide is equivalent to 0.07710 g of ketones, calculated as menthone, C₁₀H₁₈O.

Storage. Store protected from light and moisture, in well-filled containers.
Pippali, Large
Long pepper; Catkins (Big)

Pippali, Large consists of the fruiting spikes of *Piper longum* Linn. (Syn. *P. sarmentosum* Wall., *P. latifolium* Hunter, *Chavica roxburghii* Miq., *C. sarmentosa* Miq.) (Fam. Piperaceae)
Pippali, Large contains not less than 1 per cent w/w of piperine, calculated on the dried basis.

**Description.** The spikes are blacking green to green in colour, cylindrical, erect and blunt. It has pungent taste and the odour is aromatic and characteristic. The spikes are 2 to 4 cm long and 0.4-0.7 cm in diameter.

**Identification**

A. **Macroscopic** — The spikes are blackish green to green in colour, surface rough. The spikes bear bracts and numerous small fruits sunk in solid spike.

B. **Microscopic** — Epidermis is a single layer of tangentially elongated cells. Cells are packed with abundant starch grains which are small. Crystals are present in some of the cells, they appear unequal in size. The epicarp is a single layer of thick walled cells having greenish content. Endocarp is wavy in outline. Mostly, endocarp and seed coat are fused together to form a deep zone with hyaline content in outer layer and orange red (brown) inner region.

C Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel GF254*.

**Mobile phase.** A mixture of 60 volumes of benzene, 30 volumes of *ethyl acetate* and 10 volumes of *diethyl ether*.

**Test solution.** Reflux 2 g of the coarsely powdered substance under examination with 50-75 ml of *methanol* for 15 minutes, cool and filter. Reflux the residue further for two times with 75 ml of *methanol*, cool and filter. Combine all the filtrates and concentrate under vacuum to 50 ml.

**Reference solution.** Reflux 0.4 g of the coarsely powdered *pippali, Big RS* with 50-75 ml of *methanol* for 15 minutes, cool and filter. Reflux the residue further for two times with 75 ml of *methanol*, cool and filter. Combine all the filtrates and concentrate under vacuum to 10 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air and examine in ultra violet light at 254 nm. The chromatographic profile of the test solution corresponds to that in the chromatogram obtained with reference solution. Spray with solution of *vanillin sulphuric acid reagent*. Heat at 100º for 5-10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter** (2.6.1). Not more than 2 per cent.

**Ethanol-soluble extractive** (2.6.2). Not less than 8 per cent.

**Water-soluble extractive** (2.6.3). Not less than 10 per cent by Method I.

**Ash** (2.3.19). Not more than 8 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 3 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105º.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh 2 g of coarsely powdered substance under examination, add 50 ml of *methanol*, sonicate for 3 minutes and heat on a boiling water bath for 15 minutes, cool and dilute to 100.0 ml with *methanol* and filter. Dilute further if necessary.

**Reference solution.** A 0.01 per cent w/v solution of *piperine RS* in *methanol*.

**Chromatographic system**

- a stainless steel column 25 cm × 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a gradient mixture of *acetonitrile* and a buffer solution prepared by dissolving 0.136 g of *potassium di-hydrogen orthophosphate* in 900 ml of *water*, adjust the pH to 2.5 with *orthophosphoric acid* and dilute to 1000 ml with *water*,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 270 nm,
- a 20 µl loop injector.


### Pippali, Small

Small pepper; Catkins (small)

Pippali, small consists of the fruiting spike of *Piper longum* Linn. (Fam. Piperaceae)

Pippali, small contains not less than 0.4 per cent w/w of piperine, calculated on the dried basis.

**Description.** The spikes are greenish black to black in colour, cylindrical, erect and blunt. It has pungent taste and the odour is aromatic and characteristic. The spikes are 1.0 to 1.9 cm long and 0.2 to 0.3 cm in diameter.

**Identification**

A. **Macroscopic** — The spikes are greenish black to black in colour, surface rough. The spikes bear bracts and numerous small fruits sunk in solid spike.

B. **Microscopic** — Epidermis is a single layer of tangentially elongated cells. Cells are packed with abundant starch grains which are small. Crystals are present in some of the cells, they appear unequal in size. The epicarp is a single layer of thick walled cells having greenish content. Endocarp is wavy in outline. Mostly, endocarp and seed coat are fused together to form a deep zone with hyaline content in outer layer and orange red (brown) inner region.

C Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel $\text{GF}_254$.

**Test solution.** Reflux 2 g of the coarsely powdered substance under examination with 50-75 ml of methanol for 15 minutes, cool and filter. Reflux the residue further for two times with 75 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 50 ml.

**Reference solution.** Reflux 0.4 g of the coarsely powdered *pippali, small RS* with 50-75 ml of methanol for 15 minutes, cool and filter. Reflux the residue further for two times with 75 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 10 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air and examine in ultra violet light at 254 nm. The chromatographic profile of the test solution corresponds to that in the chromatogram obtained with reference solution. Spray with vanillin sulphuric acid reagent. Heat at 100º for 5-10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter** (2.6.1). Not more than 2 per cent.

**Ethanol-soluble extractive** (2.6.2). Not less than 8 per cent.

**Water-soluble extractive** (2.6.3). Not less than 10 per cent by Method I.

**Ash** (2.3.19). Not more than 8 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 3 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105º.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Weigh 2 g of coarsely powdered substance under examination, add 50 ml of methanol, sonicate for 3 minutes and heat on a boiling water bath for 15 minutes, cool and dilute to 100.0 ml with methanol and filter. Dilute further if
necessary.

Reference solution. A 0.01 per cent w/v solution of piperine RS in methanol.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a gradient mixtures of acetonitrile and a buffer solution prepared by dissolving 0.136 g of potassium di-hydrogen orthophosphate in 900 ml of water, adjust the pH to 2.5 with orthophosphoric acid and dilute to 1000 ml with water,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 270 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Buffer solution (per cent v/v)</th>
<th>Acetonitrile (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>95</td>
<td>5</td>
</tr>
<tr>
<td>18</td>
<td>55</td>
<td>45</td>
</tr>
<tr>
<td>25</td>
<td>20</td>
<td>80</td>
</tr>
<tr>
<td>30</td>
<td>95</td>
<td>5</td>
</tr>
</tbody>
</table>

Inject the reference solution. The relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution. The relative retention time of ninerine is 1.

Punarnava consists of the dried root of Boerhaavia diffusa Linn. (syn. B. reperis Linn) (Fam. Nyctaginaceae).

Punarnava contains not less than 0.005 per cent of boeravinone B, calculated on the dried basis.

Description. A greyish-brown in colour, short and fibrous fracture and no distinct odour with bitter taste.

Identification
A. Macroscopic — Stout, tapering, somewhat knotty and twisted roots upto 30 cm or more long and 0.5-1.5 cm thick often crowned with stem bases, greyish-brown, surface is rough due to minute, irregular, longitudinal striations and root scars.

B. Microscopic — Transverse section of root shows outermost layer of cork which consists of thin walled tangentially elongated cells with brownish walls followed by thin walled 1-2 layered cork cambium. Cortex many layered and composed of thin walled cells. Secondary cortex 2-4 layered and parenchymatous. Concentric bands of xylem tissues alternating with parenchymatous tissues. Vessels are radial with reticulate thickening. Simple and compound starch grains with centric hilum and raphide crystals of calcium oxalate in cortex region. Fibres are aseptate and spindle shaped with pointed ends.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 35 volumes of chloroform, 6 volumes of methanol and 1 volume of glacial acetic acid.

Test solution. Reflux 2 g of the coarsely powdered substance under examination with 25 ml of methanol for 15 minutes, cool and filter. Reflux the residue further with 2 x 25 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 5 ml.

Reference solution. Reflux 2 g of the punarnava RS with 25 ml of methanol for 15 minutes, cool and filter. Reflux the residue further with 2 x 25 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 5 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air, spray with a anisaldehyde solution. Heat at 110° for 10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

Tests

Foreign organic matter (2.6.1). Not more than 2.0 per cent.

Ethanol-soluble extractive (2.6.2). Not less than 0.5 per cent.

Water-soluble extractive (2.6.3). Not less than 9.0 per cent by method I.

Ash (2.3.19). Not more than 10.0 per cent.

Acid-insoluble ash (2.3.19). Not more than 3.0 per cent.
**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 10.0 per cent, determined on 5 g by drying in an oven at 105°.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Reflux 2 g of the coarsely powdered substance under examination with 50 ml of methanol on a water-bath for 15 minutes, cool and filter. Reflux the residue further with methanol till the extract turns colourless, cool and filter. Combine all the filtrates and concentrate to a volume slightly less than 25 ml. Dilute to 25.0 ml with methanol.

**Reference solution.** A 0.002 per cent w/v solution of boeravinone B RS in methanol.

**Chromatographic system**
- a stainless steel column 25 cm × 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a gradient mixtures of water and acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 272 nm,
- a 20 µl loop injector.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Water (per cent v/v)</th>
<th>Acetonitrile (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>90</td>
<td>10</td>
</tr>
<tr>
<td>25</td>
<td>10</td>
<td>90</td>
</tr>
<tr>
<td>35</td>
<td>90</td>
<td>10</td>
</tr>
</tbody>
</table>

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of boeravinone B.

**Storage.** Store protected from heat, moisture and against attack by insects and rodents.

---

**Serpgandha**

**Rauwolfia Root**

Serpgandha consists of the dried roots of *Rauwolfia Serpentina Bentham* ex Kurz (Fam Apocynaceae).

Serpgandha contains not less than 0.15 per cent of reserpine and ajmalicine, calculated on the dried basis.

**Description.** Taste bitter, odour indistinct.

---

**Identification**

A. **Macroscopic** — Roots are sub cylindrical to tapering, tortuous or curved, rarely branched. Occurs as segments usually from 5 to 15 cms in length and 3 to 20 mm in diameter. Externally grayish yellow to brown, wood pale yellow. Roots tough with longitudinal marking & slightly wrinkled surface.

When scraped, bark separates readily from the wood. Fracture is short and irregular.

B. **Microscopic** — In transverse section, cork cells in 2 to 8 alternating bands of radically narrow and broader cells, thin, lignified up to 75 µm in tangential width, broader cells up to about 90 µm in radial length, phelloderm, tangentially elongated to isodimetric parenchyma cells containing starch and short latex cells with brown resinous matter; secondary cortex consists of parenchyma cells, heavily packed with starch grains secondary phloem contains phloem parenchyma and sieve elements, parenchyma contains starch and angular crystals of calcium oxalate 3 to 20 µm in length. Xylem is about 4/5 of the diameter of the root, wood is transversed by medullary rays 1 to 5 cells in width. Xylem consists of vessels, tracheids, wood parenchyma & wood fibers. Xylem vessels are elongated up to 350 µm in length and 50 µm in width and contains simple or bordered pits; tracheids lignified, pitted; wood parenchyma with moderately thick, lignified and pitted walls containing starch; wood fibres highly thickened with pointed ends, stone cells absent.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 70 volumes of chloroform and 30 volumes of acetone.

**Test solution.** To 250 mg of the coarsely powdered substance under examination, add 5 ml methanol, shake for 10 minutes, and filter. Wash the residue with 5 ml of methanol and add the washing to the filtrate.
Reference solution. To 250 mg of sepgandha RS, add 5 ml methanol, shake for 10 minutes, and filter. Wash the residue with 5 ml of methanol and add the washing to the filtrate.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 12 cm. Dry the plate in air, spray with anisaldehyde solution and heat at 100° for 5 minutes and examine the plate in day light. The chromatogram obtained with test solution shows two pinkish-violet bands corresponding to the bands in the chromatogram obtained with reference solution. A dark brown band may also appear at the line of application in the chromatogram obtained with test solution.

Tests

Foreign organic matter (2.6.1). Not more than 2.0 per cent

Ethanol-soluble extractive (2.6.2). Not less than 2.0 per cent.

Water-soluble extractive (2.6.3). Not less than 5.0 per cent.

Ash (2.3.19). Not more than 8.0 per cent.

Acid-insoluble ash (2.3.19): Not more than 2.0 per cent.

Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

Loss on drying (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105°.

Senna Pods

Senna Fruit; Pods of cassia

Senna pods consist of the dried compound Pods of Cassia angustifolia or Cassia senna Vhal. (Family: Leguminosae).

Senna Pods contains not less than 1 per cent of sennosides A and B, calculated on the dried basis.

Description. Pale yellowish green coloured pods with slight odour. Leaflets with mucilaginous and faint odour.

Identification

A. Macroscopic — Flattened reniform pods, brownish yellow at the edges, dark brown in the central area about 40 to 50 mm long and about at least 20 mm wide. At one end is a stylar point and at the other a short stalk. The pods contains 5 to 7 flattened and obovate seeds, green to pale brown, with a continuous network of prominent ridges on the tests and incomplete wavy transverse ridges on the testa. Leaflets, 2.5 to 8 cm long and 5-15 mm wide at centre, pale yellowish green, elongated lanceolate, slightly asymmetric at base; margins entire, flat, apex acute with a sharp spine; both surface smooth with sparse trichomes; odour, faint but distinctive; taste, mucilaginous and disagreeable but not distinctly bitter.
B. **Microscopic** — The pods present an epicarp with strongly cuticularised isodiametric cells, occasional anomocytic or paracytic stomata, and very few conical, unicellular and warty trichomes. Hypodermis with collenchymatous cells, mesocarp with parenchymatous tissue, a layer of prisms of calcium oxalate and containing vascular bundles incompletely surrounded by fibres with crystals sheath of calcium oxalate prisms, endocarp consisting of thick-walled and inter lacing fibres. The seeds present a sub epidermal layers of palisade cells with thick outer walls, endosperm composed of polyhedral cells with mucilaginous wall.

Reduce to moderately fine powder examine microscopically using chloral hydrate solution. The powder consists of epicarp with polygonal cells and a small number of warty trichomes and occasional anomocytic stomata, fibres in two crossed layers, accompanied by a crystal sheath of calcium oxalate prism, characteristic palisade cells in the seeds and stratified cells in the endosperm, cluster and prisms of calcium oxalate prisms.

C. In the Assay, the chromatogram obtained with test solution corresponds to the chromatogram obtained with reference solution.

D. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel F254.

**Mobile phase.** A mixture of 40 volumes of *n*-propyl alcohol, 40 volumes of ethyl acetate, 29 volumes of water and 1 volume of glacial acetic acid.

**Test solution.** Take 1 g of the dried leaves powder substance under examination. Add 25 ml of methanol, reflux for 10 minutes, cool and filter. Reflux the residue with another 20 ml of methanol, cool and filter. Combine all the filtrates and concentrate to 10 ml.

**Reference solution.** A solution containing 0.01 per cent w/v of sennoside A and B RS in methanol.

Apply to the plate 10 µl of each solution as bands 10 mm by 6 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air, spray with 20 per cent v/v of *nitric acid solution*. Heat at 100° to 105° for about 10 minutes and immediately examine the plate. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter** (2.6.1). Not more than 1.0 per cent.

**Ash** (2.3.19). Not more than 14.0 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 2.5 per cent.

**Loss on drying** (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105°.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

Senna leaf consists of the dried compound leaves of *Cassia angustifolia* or *Cassia senna* Vhal. (Family: Leguminosae).

**Description.** Pale yellowish green coloured leaflets with mucilaginous and faint odour.

**Identification**

A. **Macroscopic** — Leaflets, 2.5 to 8 cm long and 5-15 mm wide at centre, pale yellowish green, elongated lanceolate,
sennosides RS in methanol.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 82 volumes of 1 per cent v/v acetic acid in water and 18 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 350 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of sennoside A and B.

Storage. Store protected from light and moisture.

Shatavari
Asparagus racemosus root

Reference solution. A 0.004 per cent w/v solution of sennosides RS in methanol.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 82 volumes of 1 per cent v/v acetic acid in water and 18 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 350 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of sennoside A and B.

Storage. Store protected from light and moisture.

Shatavari
Asparagus racemosus root

Reference solution. A 0.004 per cent w/v solution of sennosides RS in methanol.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 82 volumes of 1 per cent v/v acetic acid in water and 18 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 350 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of sennoside A and B.

Storage. Store protected from light and moisture.

Shatavari
Asparagus racemosus root

Reference solution. A 0.004 per cent w/v solution of sennosides RS in methanol.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 82 volumes of 1 per cent v/v acetic acid in water and 18 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 350 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the content of sennoside A and B.

Storage. Store protected from light and moisture.

Shatavari
Asparagus racemosus root

Reference solution. A 0.004 per cent w/v solution of sennosides RS in methanol.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 82 volumes of 1 per cent v/v acetic acid in water and 18 volumes of acetonitrile,
more or less smooth when fresh, developing longitudinal wrinkles when dry.

B. Microscopic — The inner parenchymatous zone of cortex is composed of 18-24 layers in upper and 42-47 layers in the middle tuberous portion of the roots. The cells are thin-walled cellulosic, with circular to oral outlines and distinct inter cellular spaces. In some roots 3-4 layers of cortex immediately adjacent to the endodermis are modified into a sheath of stone cells round the endodermis. The number of vascular bundles is 30-35 in the upper levels and 35-45 in the middle tuberous portions of the roots.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel F254.

**Mobile phase.** A mixture of 13 volumes of chloroform, 10 volumes of methanol and 2 volumes of water.

**Test solution.** Reflux 1 g of the coarsely powdered substance under examination with 30 ml of methanol for 30 minutes, cool and filter. Reflux the residue further with 2 × 30 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 10.0 ml.

**Reference solution.** Reflux 1 g of shatavari RS with 30 ml of methanol for 30 minutes, cool and filter. Reflux the residue further with 2 × 30 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 10.0 ml.

Apply to the plate 5 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air and spray with 10 per cent v/v sulphuric acid in methanol. Heat the plate at 100º for 5 minutes, scan the plate in absorbance mode at 500 nm. Record the chromatograms and measure the responses for the analyte peak.

Calculate the content of shatavarin IV.

**Method I**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF 254.

**Mobile phase.** A mixture of 6.5 volumes of chloroform and 3.5 volumes of methanol.

**Test solution.** Reflux 4 g of the coarsely powdered substance under examination with 50 ml of methanol on a water-bath for 30 minutes, cool and filter. Reflux the residue further with methanol till the last extract turns colourless, cool and filter. Combine all the filtrates and concentrate to 50 ml.

**Reference solution.** A 0.008 per cent w/v solution of shatavarin IV RS in methanol.

Apply to the plate 5 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air and spray with 10 per cent v/v sulphuric acid in methanol. Heat the plate at 100º for 5 minutes, scan the plate in absorbance mode at 500 nm. Record the chromatograms and measure the responses for the analyte peak.

Calculate the content of shatavarin IV.

**Method II**

Determine by liquid chromatography (2.4.14).

**Test solution.** Reflux 5 g of the coarsely powdered substance under examination with 50 ml of methanol on a water-bath for 30 minutes, cool and filter. Reflux the residue further with methanol till the last extract turns colourless, cool and filter. Combine all the filtrates and concentrate to 50.0 ml.

**Reference solution.** A 0.01 per cent w/v solution of shatavarin IV RS in methanol. Dilute suitably to prepare 0.0075-0.075 per cent w/v solution.

**Chromatographic system**

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 60 volumes of acetonitrile and 40 volumes of water,
- flow rate. 1 ml per minute,
- use evaporative light scattering detector,
- temperature evaporator 110º, nebulizer 90º,
- nebulizer gas nitrogen and gas flow 1 SLM,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the regression coefficient is not more than 0.9.

Inject the test solution and reference solution.

Calculate the content of shatavarin IV.

**Storage.** Store protected from heat, moisture and against attack by insects and rodents.
Shati
Hedychium

Shati consists of the dried rhizomes of *Hedychium spicatum* Buch.-Ham.ex Smith (Fam. Zingiberaceae).

Shati contains not less than 0.80 per cent of p-methoxy cinnamic acid ethyl ester, calculated on the dried basis.

**Description.** A reddish-brown outer surface and white in side, short and uneven fracture and camphoraceous odour with aromatic and pungent taste.

**Identification**

<table>
<thead>
<tr>
<th>A. Macroscopic</th>
<th>B. Microscopic</th>
<th>C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tubercle rhizome having reddish brown, rough outer surface with white root scars or rootlets which remain attached at margins of coalescence. Traversable pieces of dried rhizome are spherical, flat 1 cm in thickness and 2-3 cm in diameter having white and starchy surface.</td>
<td>Transverse section of rhizome shows outermost layer of cortex having 2-6 layers of isodiametric, lignified and suberised cells which are radially arranged. Proximal rhizome, the cork cells are isolated or crushed. Cortex is a broad zone with 20-25 layers of thin walled parenchymatous cells. Cortex region is filled with abundant starch grains and numerous oleo-resin cells. Vascular bundles are closed and collateral and scattered throughout the ground tissues. Cambium has 4-5 rows of tangentially elongated cells. It forms a complete ring between the xylem and phloem groups. Starch grains tissue are simple, circular or oval in shape, found in ground cells.</td>
<td>Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.</td>
</tr>
</tbody>
</table>

**Mobile phase.** A mixture of 80 volumes of *n*-hexane and 20 volumes of acetone.

**Test solution.** Reflux 1 g of the coarsely powdered substance under examination with 25 ml of *methanol* for 15 minutes, cool and filter. Reflux the residue further with 2 \(\times\) 25 ml of *methanol*, cool and filter. Combine all the filtrates and concentrate under vacuum to 25 ml.

**Reference solution.** Reflux 0.5 g of the *shati RS* with 25 ml of *methanol* for 15 minutes, cool and filter. Reflux the residue further with 2 \(\times\) 25 ml of *methanol*, cool and filter. Combine all the filtrates and concentrate under vacuum to 12.5 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air, spray with a *anisaldehyde solution*. Heat at 110° for 10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter** (2.6.1). Not more than 2.0 per cent.

**Ethanol-soluble extractive** (2.6.2). Not less than 0.7 per cent.

**Water-soluble extractive** (2.6.3). Not less than 12 per cent by method I.

**Ash** (2.3.19). Not more than 8 per cent.

**Acid-insoluble ash** (2.3.19). Not more than 3.0 per cent.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying** (2.4.19). Not more than 14.0 per cent, determined on 5 g by drying in an oven at 105°.

**Microbial contamination** (2.2.9). Complies with the microbial contamination tests.

**Assay.** Determine by liquid chromatography (2.4.14).

**Test solution.** Reflux 2 g of the coarsely powdered substance under examination with 50 ml of *methanol* on a water-bath for 15 minutes, cool and filter. Reflux the residue further with *methanol* till the extract turns colourless, cool and filter. Combine all the filtrates and concentrate to a volume slightly less than 100 ml. Dilute to 100.0 ml with *methanol*.

**Reference solution.** A 0.01 per cent w/v solution of *p*-methoxy cinnamic acid ethyl ester RS in *methanol*.

**Chromatographic system**

- a stainless steel column 25 cm \(\times\) 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 40 volumes of *water* and 60 volumes of *acetonitrile*.
- flow rate. 1 ml per minute,
- spectrophotometer set at 310 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.
Calculate the content of p-methoxy cinnamic acid ethyl ester.

**Storage.** Store protected from heat, moisture and against attack by insects and rodents.

### Shellac

Lac

Shellac consists of a resinous substance prepared from a secretion that encrusts the bodies of a scale insect, *Laccifer lacca* Kerr (Fam. Coccidae).

**Description.** Lemon-yellow to brownish orange thin scales or hard, brittle masses; odourless or with a faint odour.

**Identification**

To 50 mg add a few drops of a mixture of 1 g of ammonium molybdate and 3 ml of sulphuric acid; a green colour is produced and it becomes lilac on standing for 5 minutes.

**Tests**

**Acid value** (2.3.23). 50 to 70, determined by the following method. Weigh accurately about 2.0 g and dissolve with the aid of gentle heat, in 50 ml of ethanol (95 per cent) previously neutralised to ethanolic thymol blue solution. Titrate with 0.1 M ethanolic potassium hydroxide using ethanolic thymol blue solution as an external indicator. Calculate the acid value from the expression

\[
5.61 \times \frac{a}{w}
\]

where, \(a\) = number of ml of 0.1 M ethanolic potassium hydroxide and \(w\) = weight, in g, of the sample.

**Ethanol-insoluble matter.** Not more than 2.0 per cent, determined by the following method. Weigh accurately about 5.0 g in an extraction thimble, cover with ethanol (95 per cent) and allow to stand for 16 hours. Place in an apparatus for the continuous extraction of drugs, extract with ethanol (95 per cent) for 4 hours, dry the residue at 100º for 3 hours and weigh.

**Colophony.** Dissolve 2.0 g by shaking with 10 ml of ethanol, add slowly, with shaking 50 ml of light petroleum (40º to 60º), wash with two successive portions, each of 50 ml, of water, filter the washed light petroleum solution, and evaporate to dryness; to the residue add 2 ml of a mixture of 1 volume of liquified phenol and 2 volumes of carbon tetrachloride and transfer to a cavity of a colour-reaction porcelain tile; fill an adjacent cavity with a mixture of 1 volume of bromine and 4 volumes of carbon tetrachloride, and cover both cavities with an inverted watch-glass; no purple or deep indigo-blue colour is produced in the liquid containing the residue.

**Starch**

Starch consists of polysaccharide granules obtained from the caryopsis of maize or corn, *Zea mays* Linn., or of rice, *Oryza sativa* Linn., or of wheat, *Triticum aestivum* Linn., or of rice, *Oryza sativa* Linn., or from the rhizomes of tapioca, *Manihot utilissima* Pohl.

**Description.** A very fine, white or slightly yellowish powder or irregular white masses which are readily reducible to powder, creaks when pressed between the fingers; odourless and tasteless. The presence of granules showing cracks or edge irregularities is exceptional in starches other than wheat starch; wheat starch may contain granules with cracks on the edges.

**Identification**

**A. Corn or maize starch** — Polyhedral granules, 2 to 23 µm in size, or rounded granules, 25 to 32 µm in diameter. The central hilum consists of a distinct cavity or two- to five-rayed cleft; no concentric striations. Viewed between crossed nicip prisms, a distinct black cross is seen intersecting at the hilum.

**Potato starch** — Single granules, either irregular, ovoid or pear-shaped, 30 to 100 µm in size, or rounded, 10 to 35 µm in size; compound granules consisting of groups of two to four elements are rare. Eccentric hilum; clearly visible concentric striations. Viewed between crossed nicip prisms, a distinct black cross is seen intersecting at the hilum.

**Rice starch** — Polyhedral granules, 2 to 5 µm in size, either isolated or aggregated in ovoid masses, 10 to 20 µm in size. Central hilum poorly visible; no concentric striations. Viewed
between crossed nicol prisms, a distinct black cross is seen intersecting at the hilum.

Tapioca starch — Principally simple granules, sub-spherical, muller-shaped or rounded polyhedral; smaller granules 5 to 10 µm, larger granules 20 to 35 µm in diameter; hilum, central, punctate, linear or triradiate; striations, faint, concentric; compound granules, few, of two to three unequal components.

Wheat starch — Large discoid or, more rarely, reniform granules, 10 to 45 µm in size; profile, elliptical and fusiform, slit along the main axis. Small rounded or polyhedral granules, 2 to 10 µm in size. Granules of intermediate size very rarely occur. Hilum and striations invisible or barely visible. Viewed between crossed nicol prisms, a distinct black cross is seen intersecting at the hilum.

B. Heat to boiling for 1 minute a suspension of 1 g in 50 ml of water and cool; a thin and cloudy mucilage is produced with all starches except potato starch which gives a thick and more transparent mucilage.

C. To 10 ml of the mucilage obtained in test B add 0.05 ml of 0.01 M iodine; a dark blue colour is produced, which disappears on heating and reappears on cooling.

## Tests

**Acidity.** Add 10.0 g to 100 ml of ethanol (70 per cent) in solution, shake filtrate with 0.1 M required to change

Sunthi is the whole or cut scraped or unscraped, dried rhizomes of Zingiber officinale Rosc. (Fam. Zingiberaceae).

Sunthi contains not less than 0.8 per cent of total gingerols, calculated on the dried basis.

**Description.** Odour, agreeable and aromatic; taste, agreeable and pungent.

**Identification**

A. **Macroscopic** — Rhizome laterally compressed, bearing short, flattened, oblique branches; outer surface buff-coloured, longitudinally striate; inner surface pale yellow, starchy and fibrous. Fracture short with projecting fibers.

B. **Microscopic** — Fibro-vascular bundles and oleoresin cells with yellow pigment scattered in ground tissue. Starch grains abundant in parenchyma cells, mostly simple, sack shaped, spherical; hilum eccentric.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 30 volumes of hexane and 70 volumes of diethyl ether.

**Test solution.** Reflux 1 g of the coarsely powdered substance under examination with 25 ml of methanol for 15 minutes, cool and filter. Wash the residue with 10 ml of methanol. Combine all the filtrates and concentrate to 10 ml.

**Reference solution.** Reflux 0.5 g of coarsely powdered sunthi RS with 5 ml methanol for 15 minutes, cool and filter.
Tolu Balsam
Balsam of Tolu

Tolu Balsam is a solid or semi-solid, balsam obtained by incision from the trunk of *Myroxylon balsamum* (Linn.) Harms (Fam. Leguminosae).

Tolu Balsam contains not less than 35.0 per cent and not more than 50.0 per cent of total balsamic acids, calculated as cinnamic acid, C\(_9\)H\(_8\)O\(_2\), on the dry, ethanol-soluble matter.

**Description.** A soft, tenacious, brownish yellow or brown mass, when first collected; subsequently, becoming harder and finally brittle. Transparent in thin films; odour, aromatic and vanilla-like. Warmed and pressed between pieces of glass and examined with a lens, it exhibits crystals of cinnamic acid.

**Identification.**

A. To a solution in ethanol (90 per cent) add ferric chloride test solution; a green colour is produced.

B. To 1 g add to 5 ml of water, heat to boiling, filter, add 30 mg of potassium permanganate and continue heating; the odour of benzaldehyde is produced.

**Tests**

**Acidity.** A solution in ethanol (90 per cent) is acidic to litmus solution.

**Acid value** (2.3.23). 97 to 160, calculated on the dry, ethanol-soluble basis, determined by the following method. Dissolve 5.0 g in 50 ml of boiling ethanol (90 per cent), add 3 ml of phenolphthalein solution and titrate the hot solution with 1 M ethanolic potassium hydroxide. When the colour becomes dark brown, attach to a reflux condenser, boil for a few minutes to break up the precipitate and complete the titration.

**Ethanol-insoluble matter.** Not more than 5 per cent, determined by the following method. Digest 2.5 g with 50 ml of methanol (90 per cent), filter through a sintered glass crucible, wash with hot methanol (90 per cent) until all soluble matter is removed and dry to constant weight at 100º.

**Colophony.** Add 5 g to 25 ml of carbon disulphide, warm gently on a water-bath under a reflux condenser, filter, evaporate the solution to dryness, dissolve the residue in 6 ml of light petroleum (40º to 60º) and shake with 10 ml of a 0.5 per cent w/v solution of cupric acetate; the light petroleum layer is not coloured green.

**Assay.** Determine by liquid chromatography (2.4.14).

Test solution. Reflux about 3 g of the coarsely powdered substance under examination with 100 ml of methanol on a water–bath for 15 minutes cool and filter. Reflux the residue further with methanol till the last extract turns colorless, cool and filter. Combine all the filtrates and concentrate to 50.0 ml

Reference solution. A 0.1 per cent w/v solution of 6-gingerol RS in methanol.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: 55 volumes of acetonitrile and 45 volumes of water,
- flow rate. 1.3 ml per minute,
- spectrophotometer set at 278 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution.

Calculate the contents of total gingerols by summing the peak areas of 6-gingerol with all other peaks, which elute after 6-gingerol and have a peak area of at least 5 per cent of the peak area of 6-gingerol.

Storage. Store protected from heat, moisture and against attack by insects and rodents.
Loss on drying (2.4.19). Not more than 4 per cent, determined on 2.0 g by drying in a thin layer in an oven at 60° over phosphorus pentoxide at a pressure not exceeding 2.7 kPa.

Assay. Weigh accurately about 2.0 g and boil with 25 ml of dilute ethanolic potassium hydroxide solution under a reflux condenser for 1 hour. Remove the ethanol and digest the residue with 50 ml of hot water until diffused. Cool the liquid, add 150 ml of water and 1.5 g of magnesium sulphate dissolved in 50 ml of water. Mix thoroughly and set aside for 10 minutes. Filter, wash the residue on the filter with 20 ml of water, acidify the combined filtrate and washings with hydrochloric acid and extract with successive quantities of 50, 40, 30, 30 and 30 ml of ether. Combine the ether extracts and discard the aqueous portion. Extract with successive quantities of 20, 20, 10, 10, 10 and 10 ml of sodium bicarbonate solution, washing each aqueous extract with the same 20 ml of ether. Discard the ether layers, acidify the combined aqueous extracts with hydrochloric acid and extract with successive quantities of 20, 20, 10, 10 and 10 ml of chloroform, filtering each chloroform extract through a plug of cotton wool on which a layer of anhydrous sodium sulphate is placed. Evaporate the chloroform on a water-bath until about 10 ml remains and remove the remainder in a current of air stopping immediately when the last trace of solvent is removed. Dissolve the residue by warming with 10 ml of ethanol (95 per cent), previously neutralised to phenol red solution, cool and titrate with 0.1 M sodium hydroxide using phenol red solution as indicator.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.01482 g of total balsamic acids, calculated as cinnamic acid, C9H8O2.

Storage. Store protected from light and moisture. Avoid exposure to excessive heat.

Tragacanth
Tragacanth is the air-hardened gummy exudate, flowing naturally or obtained by incision, from the trunk and branches of Astragalus gummifer Labill. and certain other species of Astragalus.

Description. Pale yellow, thin, flattened ribbons or brittle pieces; odourless and almost tasteless. On the addition of about 10 times its weight of water; it forms a mucilaginous gel.

It has the macroscopic and microscopic characteristics described under Identification tests A and B.

Identification
A. Macroscopic — Occurs as thin, flattened pieces, 30 mm long, 10 mm wide and up to 1 mm in thickness, more or less curved, marked on the surface by fine longitudinal striae and concentric transverse ridges; white, translucent, horny; fracture, short. May also be in the form of thicker, less brittle pieces, white to pale yellow and more opaque.

B. Microscopic — Reduce to powder. Examine under a microscope; the powder shows in the gummy mass numerous stratified cellular membranes which turn violet on the addition of iodinated zinc chloride solution. The mass includes starch granules, isolated or in small clusters, rounded or occasionally deformed, diameter 4 to 10 µm, and up to 20 µm, with a central hilum, visible in polarised light.

C. Moisten 0.5 g of the powdered material with 1 ml of ethanol (95 per cent) and add gradually, while shaking, 50 ml of water until a homogeneous mucilage is obtained. To 5 ml of the mucilage add 5 ml of water and 2 ml of barium hydroxide solution. A slightly flocculent precipitate is formed which, when heated for 10 minutes on a water-bath, gives an intense yellow colour.

D. Add 4 ml of a 0.5 per cent w/v dispersion in water to 0.5 ml of hydrochloric acid and heat on a water-bath for 30 minutes. To one half of the resulting liquid add 1.5 ml of sodium hydroxide solution and 3 ml of alkaline cupric-tartrate solution and heat on a water-bath; a reddish brown precipitate is formed. To the other half of the liquid, add a few drops of barium chloride solution; no precipitate is formed (freedom from agar).

Tests
Acacia and other soluble gums. To 20 ml of a 2.5 per cent w/v suspension of the powdered material prepared with freshly boiled water add 10 ml of lead acetate solution; a flocculent precipitate is formed. Filter and add to the filtrate 10 ml of lead subacetate solution; a slight cloudiness may appear, but there is no precipitate.

Karaya gum. Boil 1 g with 20 ml of water until a mucilage is formed, add 5 ml of hydrochloric acid and again boil for 5 minutes; no pink or red colour develops.

Sterculia. A. Shake 0.2 g of the powdered material with 10 ml of ethanol (60 per cent) in a 10-ml stoppered cylinder; any gel formed occupies not more than 1.5 ml.

B. Shake 1 g of the powdered material with 100 ml of water and titrate with 0.01 M sodium hydroxide, using methyl red solution as indicator. Not more than 5.0 ml is required to change the colour of the solution.

Foreign matter. Not more than 1.0 per cent, determined by the following method. To 2.0 g of the powdered material in a 250-ml round-bottomed flask add 95 ml of methanol, swirl to moisten the powder and add 60 ml of 7 M hydrochloric acid. Add a few glass beads and heat under a reflux condenser in a water-bath for 3 hours, shaking occasionally. Remove the glass beads and filter the hot suspension under reduced pressure.
through a sintered-glass crucible (porosity No. 1). Rinse the flask with a small quantity of water, passing the rinsings through the filter. Wash the residue on the filter with about 40 ml of methanol and dry to constant weight at 110º.

**Arsenic (2.3.10).** Mix 3.3 g with 3 g of anhydrous sodium carbonate, add 10 ml of bromine solution and mix thoroughly. Evaporate to dryness on a water-bath, gently ignite, and dissolve the cooled residue in 16 ml of brominated hydrochloric acid and 45 ml of water. Remove the excess of bromine with 2 ml of stannous chloride. The resulting solution complies with the limit test for arsenic (3 ppm).

**Heavy metals (2.3.13).** 0.5 g complies with the limit test for heavy metals, Method B (40 ppm).

**Ash (2.3.19).** Not more than 4.0 per cent, determined on 1.0 g.

**Microbial contamination (2.2.9).** 1 g is free from Escherichia coli and 10 g is free from salmonellae.

**Storage.** Store protected from moisture.

---

**Tulasi**

Ocimum, Basil

Tulasi consists of leaves of *Ocimum sanctum* Linn (Fam. Lamiaceae).

Tulasi contains not less than 0.40 per cent of eugenol, calculated on the dried basis.

**Description.** Greyish-black in colour having characteristic odour with slightly pungent and aromatic taste.

**Identification**

A. **Macroscopic** — Leaves simple, elliptic, 2.7-7.5 cm long, 1-3 cm wide, with acute top, cuneate, obtuse to rounded base, margin entire, undulate or serrate, both surfaces thinly pubescent and dotted; petiole 0.2-3.0 cm long. Flowers are 5-7 mm in length. It has both male and female parts. Calyx: There are 5 sepals and it is greenish in colour. Corolla: There are 5 petals, bilabiate in shape and covered with scattered hairs. Petals whitish-purple.

B. **Microscopic** — Transverse section of leaf shows a pot shaped midrib. Upper epidermis consists of a layer of small, quadrangular transparent cells with thin walls and thin smooth cuticle. On tangential view, these cells are polygonal with straight or wavy walls. Lower epidermis consists of a layer of small, quadrangular transparent cells with thin walls and thin and thin smooth cuticle. Trichomes bent, consisting of 2-6 of 1 stalk cell and 2-4 cells with rounded heads. Palisade parenchyma consists of layer of long cylindrical cells containing chlorophyll; spongy parenchyma consists of polygonal cells with thin, straight or slightly wavy side walls. Vascular bundles collateral type. Stomata diacytic.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel *G*.

**Mobile phase.** A mixture of 97 volumes of toluene and 3 volumes of ethyl acetate.

**Test solution.** Reflux 2 g of the coarsely powdered substance under examination with 25 ml of methanol for 15 minutes, cool and filter. Reflux the residue further with 2 × 25 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 10 ml.

**Reference solution.** Reflux 1 g of tulasi RS with 25 ml of methanol for 15 minutes, cool and filter. Reflux the residue further with 2 × 25 ml of methanol, cool and filter. Combine all the filtrates and concentrate under vacuum to 5 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cm. Dry the plate in air, spray with anisaldehyde solution. Heat at 110º for 10 minutes and examine the plate in day light. The chromatographic profile of the test solution is similar to that of the reference solution.

**Tests**

**Foreign organic matter (2.6.1).** Not more than 2.0 per cent.

**Ethanol-soluble extractive (2.6.2).** Not less than 3.0 per cent.

**Water-soluble extractive (2.6.3).** Not less than 10.0 per cent by method I.

**Ash (2.3.19).** Not more than 15.0 per cent.

**Acid-insoluble ash (2.3.19).** Not more than 5.0 per cent.

**Heavy metals (2.3.13).** 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).

**Loss on drying (2.4.19).** Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105º.
Microbial contamination (2.2.9). Complies with the microbial contamination tests.

Assay. Determine by gas chromatography (2.4.13).

Test solution. Reflux 0.5 g of the coarsely powdered substance under examination with 50 ml of methanol on a water-bath for 15 minutes, cool and filter. Reflux the residue further with methanol till the extract turns colourless, cool and filter. Combine all the filtrates and concentrate to a volume slightly less than 100 ml. Dilute to 100.0 ml with methanol.

Reference solution. A 0.004 per cent w/v solution of eugenol RS in methanol.

Chromatographic system
- a capillary column 30 m x 0.25 x 0.25 mm coated with 100 per cent dimethylpolysiloxane
- temperature: oven 60° to 260° @10° per minute, (Initially and finally hold for 5 minutes respectively)
  Injector 240°,
  detector 280°,
- flow rate. 0.8 ml per minute,
- split flow 20 ml per minute.

Inject 1 µl of the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Vasaka contains not less than 0.6 per cent of vasicine, calculated on the dried basis.

Description. Taste, bitter.

Identification
A. Macroscopic — Leaf pieces membranous, brittle, greyish-brown, a few pieces green coloured. Floral bracts leaf-like.
B. Microscopic — Stomata diacytic, more on the lower epidermis; glandular and non-glandular hair on both surfaces of leaf; elongated cystoliths present in palisade cells.
C. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 8 volumes of ethyl acetate, 2 volumes of methanol and 0.2 volume of strong ammonia solution.

Test solution. Reflux 1 g of coarsely powdered substance under examination with 50 ml methanol for 15 minutes, cool and filter. Reflux the residue further with 2 × 50 ml of methanol, cool and filter. Combine all the filtrates and concentrate to 10 ml.

Reference solution. Reflux 0.5 g of vasaka RS with 50 ml methanol for 15 minutes, cool and filter. Reflux the residue further with 2 × 50 ml of methanol, cool and filter. Combine all the filtrates and concentrate to 5 ml.

Apply to the plate 10 µl of each solution as bands 10 mm by 2 mm. Allow the mobile phase to rise 8 cms. Dry the plate in air and spray with Dragendorf’s reagent. The chromatographic profile of the test solution is similar to that of the reference solution.

Tests
Foreign organic matter (2.6.1). Not more than 2.0 per cent.
Ethanol-soluble extractive (2.6.2). Not less than 3.0 per cent.
Water-soluble extractive (2.6.3). Not less than 22 per cent by Method I.
Ash (2.3.19). Not more than 21 per cent.
Acid-insoluble ash (2.3.19). Not more than 2.0 per cent.
Heavy metals (2.3.13). 1.0 g complies with the limit test for heavy metals, Method B (20 ppm).
Loss on drying (2.4.19). Not more than 12.0 per cent, determined on 5 g by drying in an oven at 105°.
Microbial contamination (2.2.9). Complies with the microbial contamination tests.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Reflux about 2 g of the coarsely powdered substance under examination with 50 ml of methanol on a water-bath for 15 minutes, cool and filter.

Vasaka consists of the dried mature leaves of Adhatoda vasica Nees. (Fam. Acanthaceae).
water bath for 15 minutes, cool and filter. Reflux the residue further with methanol till the last extract turns colorless, cool and filter. Combine all the filtrates and concentrate to 100.0 ml.

**Reference solution.** Dissolve 25 mg of vasicine hydrochloride RS in 50 ml of methanol. Dilute 5.0 ml of this solution to 50.0 ml with methanol.

**Chromatographic system**
- a stainless steel column 25 cm x 4.6 mm packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 3 volumes of the solution prepared by dissolving 1 g of sodium hexane-sulphonate in 1000 ml of water, 1 volume of acetonitrile and 20 volumes of glacial acetic acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 300 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for the replicate injections is not more than 2.0 per cent.

Inject the test solution and reference solution. Calculate the content of vasicine.

**Storage.** Store protected from heat, moisture and against attack by insects and rodents.

**Yasti**

Liquorice root; Mulethi; Glycyrrhiza

Yasti consists of the dried, unpeeled roots and stolons of Glycyrrhiza glabra Linn. (Fam. Leguminoseae).

Yasti contains not less than 3.0 per cent of glycyrrhizinic acid.

**Description.** Odour, characteristic and slightly aromatic; taste, very sweet and faintly astringent; the bark is not bitter.

**Identification**

**A. Macroscopic.** — Root with few branches, up to 1 m long and 0.5 to 3 cm in diameter. Bark, brownish-grey to brown with longitudinal striations, bearing traces of lateral roots. Stolons, cylindrical, 1 to 2 cm in diameter and up to several metres long, but may be cut into lengths of 10 to 15 cm; similar in external appearance to the root but with occasional small buds. Fracture of the root and stolon, granular and fibrous. Cork layer, thin; secondary phloem region, wide, light yellow with radial striations; xylem, compact, yellow, with radiate structure. The stolon has a central pith which is absent from the root.

**B. Microscopic.** — Cork and phelloderm are narrow. Phloem consisting of bundles of thick-walled, yellow fibres with narrow lumina surrounded by cells each containing a calcium oxalate prism, alternating in the external layers with areas of strongly hyaline keratenchyma; functional sieve tissue near the cambium. Medullary rays parenchymatous, widening towards the exterior, 3 to 12 cells wide. Xylem composed of radial rows of tracheids and vessels alternating with bundles of lignified fibres with crystal sheaths similar to those of the secondary phloem; vessels 30 µm to 150 µm in diameter with thick walls (5 µm to 10 µm) having reticulate thickenings or numerous bordered pits with slit-shaped openings associated with lignified xylem parenchyma. Medullary rays, 2 to 5 cells wide. Parenchymatous cells throughout containing simple, round, oval or fusiform starch granules 2 µm to 20 µm, mostly 5 µm to 12 µm, in diameter; parenchymatous pith present solely in the stolon.

**C.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** The upper layer, even if turbid, of a mixture of 60 volumes of ethyl acetate, 27 volumes of 1 M ammonia and 13 volumes of ethanol, shaken together and allowed to stand for 5 minutes.

**Test solution.** Shake 1 g, in No. 180 powder, with 20 ml of chloroform for 15 minutes, filter and reserve the extracted powder for the preparation of reference solution (a). Evaporate the filtrate to dryness and dissolve the residue in 2 ml of a mixture of equal volumes of chloroform and methanol.

**Reference solution (a).** Add to the extracted powder 30 ml of 0.5 M sulphuric acid and heat under a reflux condenser for 1 hour, allow to cool and extract with two quantities, each of 20 ml, of chloroform; dry the combined chloroform extracts with anhydrous sodium sulphate, filter, evaporate to dryness and dissolve the residue in 2 ml of a mixture of equal volumes of chloroform and methanol.

**Reference solution (b).** Dissolve 10 mg of glycyrrhetinic acid in 2 ml of a mixture of equal volumes of chloroform and methanol.
Apply to the plate 10 µl of test solution, reference solution (a) and 20 µl of reference solution (b) as bands 20 mm by 3 mm. After development, dry the plate in air for 5 minutes and examine in ultraviolet light at 254 nm. The chromatogram obtained with reference solution (b) exhibits a band corresponding to b-glycyrhretinic acid with an R<sub>f</sub> value of about 0.1. The chromatogram obtained with reference solution (a) exhibits a corresponding band but this is not seen in the chromatogram obtained with the test solution. Spray the plate with anisaldehyde solution, using about 10 ml for a plate, 20 cm × 20 cm in size, heat at 105º for 10 minutes and examine in daylight. The b-glycyrhretinic acid bands become violet-blue. One or two bands with an R<sub>f</sub> value of about 0.6, visible in daylight before spraying, become orange-yellow and several other violet-blue bands appear in the chromatograms obtained with the test solution and reference solution (a). The band corresponding to b-glycyrhretinic acid in the chromatogram obtained with reference solution (a) is at least equal in size to the band in the chromatogram obtained with reference solution (b).

D. Mix a small quantity, in powder, with 0.05 ml of sulphuric acid; the powder particles become orange-yellow and some fragments change, more slowly, to pinkish red.

Tests

Curcuma. When examined under a microscope, none of the fragments of the powder in sulphuric acid (see Identification test D) should immediately take on a carmine-red colour.

Water-soluble extractive (2.6.3). Not less than 20 per cent, determined by the following method. Mix 2.5 g of the finely powdered drug with 50 ml of water and allow to stand for 2 hours, shaking frequently. Filter, evaporate 10.0 g of the filtrate to dryness on a water-bath, dry the residue at 105º and weigh.

Acid-insoluble ash (2.3.19). Not more than 2.0 per cent.

Sulphated ash (2.3.18). Not more than 10.0 per cent.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Weigh accurately about 1.0 g of the coarsely powdered substance under examination in a 250-ml conical flask, add 100 ml of 0.1 M ammonia and mix with the aid of ultrasound for 30 minutes. Centrifuge a part of the supernatant liquid and dilute 1.0 ml to 5.0 ml with 0.1 M ammonia. Filter the solution through a membrane filter disc with an average pore diameter not greater than 1.0 µm and use the filtrate.

Reference solution. A 0.005 per cent w/v solution of glycyrrhizinic acid RS in 0.1 M ammonia.

Chromatographic system
- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 6 volumes of glacial acetic acid, 30 volumes of acetonitrile and 64 volumes of water,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject the reference solution. The test is not valid unless the relative standard deviation for replicate injections is not more than 2.0 per cent.

Inject the test solution and the reference solution and measure the responses for the analyte peak.

Calculate the content of glycyrrhizinic acid.

Storage. Store protected from light and moisture.
BLOOD AND BLOOD-RELATED PRODUCTS

Anti-A Blood Grouping Serum
Anti-B Blood Grouping Serum
Anti-D (Rh.) Immunoglobulin
Anti-D Immunoglobulin Human for Intravenous Use
Anti-Human Globulin Serum
Blood Grouping Serums Anti-D, Anti-C, Anti-E, Anti-c, Anti-e
Concentrated Human Red Blood Cells
Cryoprecipitated Antihemophilic Factor
Dried Human Antihaemophilic Fraction
Fibrin Sealant Kit
Human Albumin
Human Coagulation Factor IX
Human Coagulation Factor VII
Human Coagulation Factor VIII (rDNA)
Human Normal Immunoglobulin
Human Plasma Protein Fraction
Human Prothrombin Complex
Normal Immunoglobulin for Intravenous Use
Plasma for Fractionation
Platelet Concentrate
Whole Human Blood
**Anti-A Blood Grouping Serum**

Anti-A Blood Grouping Serum is a sterile, liquid or dried preparation containing the particular blood group antibodies derived from high-titered blood plasma or serum of human subjects, with or without stimulation by the injection of Blood Group Specific Substance A (or AB). It contains a suitable antimicrobial preservative. It is of two types polyclonal & monoclonal.

**Production**

The monoclonal antibody technique devised by Kohler and Milsten has proved useful in producing high titre and specific antibodies. Laboratory animals, usually mice are immunized for the production of monoclonal antibodies. After suitable immune response, mouse spleen cells containing antibody secreting lymphocytes are fused to neoplastic plasma cells of infinite reproductive capacity from a mouse (that is myeloma cells). The resulting hybridomas are screened for antibody with the required specificity and affinity. The antibody secreting clones may then be propagated in tissue culture or by inoculation into mice in which case the antibodies are collected as ascites. The clonal line produces a single antibody, there is no need for absorption or to remove heterospecific antibodies. All antibody molecules produced by a clone of hybridoma cells are identical in terms of antibody structure and antigen specificity. Once one antibody secreting clone of cells has been established, antibody with same specificity and reaction characteristics will be available indefinitely.

**Identification**

It agglutinates human red cells containing A-antigens, are blood groups A and AB (including subgroups A₁, A₂, A₁B, and A₂B but not necessarily weaker subgroups).

**Tests**

It meets the requirements to the test for potency, in parallel with, and not less than equivalent to, the Reference Blood Grouping Serum Anti-A, in agglutinating red blood cells from Group A, and Group A₁B donors. It complies with the tests for specificity with Group A, A₁, A₂, B, and O cells and confirms the absence of contaminating antibodies reactive with M⁺, Wr⁻ antigens as well as other antigens having an incidence of 1 per cent or greater in the general population (see under Blood Grouping Serums Anti-D, Anti-C, Anti-E, Anti-c, rAnti-e). It complies with the tests for avidity with Group A₁ and A₂B cells. All fresh or frozen red blood cell suspensions used for these tests are prepared under specified conditions and meet specified criteria. Anti-A Blood Grouping Serum may be artificially coloured blue.

**Expiration date.** The expiration date for liquid serum is not later than 1 year, and for dried serum not later than 5 years after date of issue from manufacturer’s cold storage (5°, 1 year; or 0°, 2 years), provided that the expiration date for dried serum is not later than 1 year after constitution.

**Storage.** Store at a temperature between 2° and 8°.

**Labelling.** Label states that the source material was not reactive for hepatitis B surface antigen, but that no known test method offers assurance that products derived from human blood will not transmit hepatitis in case of polyclonal. Label also states that it is for in vitro diagnostic use.

**NOTE—The labeling is in black lettering imprinted on paper that is white or is coloured completely or in part to match the specified blue colour standard.**

---

**Anti-B Blood Grouping Serum**

Anti-B Blood Grouping Serum is a sterile, liquid or dried preparation containing the particular blood group antibodies derived from high-titered blood plasma or serum of human subjects, with or without stimulation by the injection of Blood Group Specific Substance B (or AB). It contains a suitable antimicrobial preservative.

**Production**

The monoclonal antibody technique devised by Kohler and Milsten has proved useful in producing high titre and specific antibodies. Laboratory animals, usually mice are immunized for the production of monoclonal antibodies. After suitable immune response, mouse spleen cells containing antibody secreting lymphocytes are fused to neoplastic plasma cells of infinite reproductive capacity from a mouse (that is myeloma cells). The resulting hybridomas are screened for antibody with the required specificity and affinity. The antibody secreting clones may then be propagated in tissue culture or by inoculation into mice in which case the antibodies are collected as ascites. The clonal line produces a single antibody, there is no need for absorption or to remove heterospecific antibodies. All antibody molecules produced by a clone of hybridoma cells are identical in terms of antibody structure and antigen specificity. Once one antibody secreting clone of cells has been established, antibody with same specificity and reaction characteristics will be available indefinitely.

**Identification**

It agglutinates human red cells containing B-antigens, i.e., blood groups B and AB (including subgroups A₁B and A₂B).

**Tests**

It complies with the test for potency, in parallel with, and not less than equivalent to, the Reference Blood Grouping Serum Anti-B, in agglutinating red blood cells from Group B donors. It complies with the tests for specificity with Group A₁, B, and O cells and confirms the absence of contaminating antibodies reactive with M⁺, Wr⁻ antigens as well as other antigens having an incidence of 1.0 per cent or greater in the general population (see under Blood Grouping Serums Anti-D, Anti-C, Anti-E,
**Anti-D (Rh<sub>o</sub>) Immunoglobulin**

**Human Anti-D Immunoglobulin**

Human anti-D immunoglobulin is a liquid or freeze-dried preparation containing immunoglobulins, mainly immunoglobulin G. The preparation is intended for intramuscular administration. It contains specific antibodies against erythrocyte D-antigen and may also contain small quantities of other blood-group antibodies. Human normal immunoglobulin may be added.

It complies with the monograph on Human Normal Immunoglobulin, except for the minimum number of donors and the minimum total protein content. For products prepared by a method that eliminates immunoglobulins with specificities other than anti-D, where authorised, the test for antibodies to hepatitis B surface antigen is not required.

**Production**

Human anti-D immunoglobulin is preferably obtained from the plasma of donors with a sufficient titre of previously acquired anti-D antibodies. Where necessary, in order to ensure an adequate supply of human anti-D immunoglobulin, it is obtained from plasma derived from donors immunised with D-positive erythrocytes that are compatible in relevant blood group systems in order to avoid formation of undesirable antibodies.

**Erythrocyte donors**

Erythrocyte donors comply with the requirements for donors prescribed in the monograph on Human Plasma for Fractionation.

**Immunisation**

Immunisation of the plasma donor is carried out under proper medical supervision. Recommendations concerning donor immunisation, including testing of erythrocyte donors, have been formulated by the World Health Organisation (Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives, WHO Technical Report Series, No. 840, 1994 or subsequent revision).

**Pooled plasma**

To limit the potential B19 virus burden in plasma pools used for the manufacture of anti-D immunoglobulin, the plasma pool is tested for B19 virus using validated nucleic acid amplification techniques (2.8.1).

**B19 virus DNA.** Maximum 10<sup>4</sup> IU per ml.

A positive control with 10<sup>4</sup> IU of B19 virus DNA per ml and, to test for inhibitors, an internal control prepared by addition of a suitable marker to a sample of the plasma pool are included in the test. The test is invalid if the positive control is non-reactive or if the result obtained with the internal control indicates the presence of inhibitors.

**B19 virus DNA for NAT testing reference preparation** is suitable for use as a positive control.

If Human Normal Immunoglobulin is added to the preparation, the plasma pool from which it is derived complies with the above requirement for B19 virus DNA.

**Tests**

**Potency.** Determine the assay of human anti-D immunoglobulin by Method A (2.8.2). The estimated potency is not less than 90.0 per cent of the stated potency. The confidence limits (P = 0.95) are not less than 80.0 per cent and not more than 120.0 per cent of the estimated potency.

Method B or C (2.8.3) may be used for potency determination if a satisfactory correlation with the results obtained by Method A has been established for the particular product.

**Storage.** For the liquid preparation, store protected from light, in a plastic container. For the freeze-dried preparation, store protected from light, in a plastic container.

**Labelling.** The label states (1) for liquid preparations, the volume of the preparation in the container and the protein content expressed in grams per litre; (2) for freeze-dried preparations, the quantity of protein in the container; (3) the route of administration; (4) for freeze-dried preparations, the name or composition and the volume of the reconstituting liquid to be added; (5) where applicable, that the preparation is suitable for use in the prophylaxis of hepatitis A infection; (6) where applicable, the anti-hepatitis A virus activity in International Units per ml; (7) where applicable, the name and amount of antimicrobial preservative in the preparation.

The label also states the number of International Units per container.
Anti-D Immunoglobulin for Intravenous Use

Anti-D Immunoglobulin Human for Intravenous Use

Anti-D Immunoglobulin for intravenous administration is a liquid or freeze-dried preparation containing immunoglobulins, mainly immunoglobulin G. It contains specific antibodies against erythrocyte D-antigen and may also contain small quantities of other blood-group antibodies. Human normal immunoglobulin for intravenous use may be added.

It complies with the monograph on Human Normal Immunoglobulin for Intravenous Administration, except for the minimum number of donors, the minimum total protein content, the limit for osmolality and the limit for prekallikrein activator. For products prepared by a method that eliminates immunoglobulins with specificities other than anti-D: where authorised, the test for antibodies to hepatitis B surface antigen is not required; a suitable test for Fc function is carried out.

Production

Polyclonal (human) anti Rh (D) serum

Human anti-D immunoglobulin is preferably obtained from the plasma of donors with a sufficient titre of previously acquired anti-D antibodies. Where necessary, in order to ensure an adequate supply of human anti-D immunoglobulin, it is obtained from plasma derived from donors immunised with D-positive erythrocytes that are compatible in relevant blood group systems in order to avoid formation of undesirable antibodies.

Erythrocyte donors

Laboratory tests are carried out for each donation to detect the following viral markers:

1. Antibodies against human immunodeficiency virus 1 (anti-HIV-1),
2. Antibodies against human immunodeficiency virus 2 (anti-HIV-2),
3. Antibodies against hepatitis C virus (anti-HCV),
4. Hepatitis B surface antigen (HBsAg),

Pending complete harmonisation of the laboratory tests to be carried out, the competent authority may require that a test for alanine aminotransferase (ALT) also be carried out.

The test methods used are of suitable sensitivity and specificity and comply with the regulations in force. If a repeat-reactive result is found in any of these tests, the donation is not accepted.

Immunisation

Immunisation of the plasma donor is carried out under proper medical supervision. Recommendations concerning donor immunisation, including testing of erythrocyte donors, have been formulated by the World Health Organisation (Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives, WHO Technical Report Series, No. 840, 1994 or subsequent revision).

Pooled plasma

To limit the potential B19 virus burden in plasma pools used for the manufacture of anti-D immunoglobulin, the plasma pool is tested for B19 virus using validated nucleic acid amplification techniques (2.8.1).

Identification

Examine by a suitable immunoelectrophoresis technique. Using antiserum to normal human serum, compare normal human serum and sample under examination in a dilution of 10 g per litre of protein. The main component of the sample corresponds to the IgG component of normal human serum.

Tests

B19 virus DNA. Maximum 10^4 IU per ml.

A positive control with 10^4 IU of B19 virus DNA per ml and, to test for inhibitors, an internal control prepared by addition of a suitable marker to a sample of the plasma pool are included in the test. The test is invalid if the positive control is non-reactive or if the result obtained with the internal control indicates the presence of inhibitors.

B19 virus DNA for NAT testing RP is suitable for use as a positive control.

If Human normal immunoglobulin for intravenous administration is added to the preparation, the plasma pool from which it is derived complies with the above test for B19 virus DNA.

Assay. Determine by method A of human anti-D immunoglobulin (2.8.2). The estimated potency is not less than 90.0 per cent of the stated potency. The confidence limits (P = 0.95) are not less than 80.0 per cent and not more than 120.0 per cent of the estimated potency.

Method B or C (2.8.3) may be used for potency determination if a satisfactory correlation with the results obtained by Method A has been established for the particular product.

Storage. For the liquid preparation, store protected from light, in a colourless glass container, at the temperature stated on the label. For the freeze-dried preparation, store protected from light, in colourless glass container, at a temperature not exceeding 25°.

Labelling. The label states (1) for liquid preparations, the volume of the preparation in the container and the protein content expressed in gram per litre; (2) for freeze-dried preparations, the quantity of protein in the container; (3) the amount of immunoglobulin in the container; (4) the route of
administration, (5) for freeze-dried preparations, the name or composition and the volume of the reconstituting liquid to be added; (6) the distribution of subclasses of immunoglobulin G present in the preparation; (7) where applicable, the amount of albumin added as a stabilizer; (8) the maximum content of immunoglobulin A.

The label states the number of International Units per container.

**Anti-Human Globulin Serum**

Anti-Human Globulin Serum is a sterile, liquid preparation of serum produced by immunizing lower animals such as rabbits or goats with human serum or plasma, or with selected human plasma proteins. It is free from agglutinins and from hemolysins to nonsensitized human red cells of all blood groups. It contains a suitable antimicrobial preservative.

Three varieties of Anti-Human Globulin Serum are recognized:

1. A general-purpose polyspecific reagent which, as a minimum, contains antibodies specific for immunoglobulin IgG, and at least the C3d component of human complement (for use in the direct antiglobulin test, it contains this Anti-C3d and Anti-IgG activity) and which may be artificially coloured green;
2. A reagent containing antibodies only against immunoglobulin IgG (not heavy chain specific) intended for use in the indirect antiglobulin test, and which may be artificially coloured green; and
3. Reagents containing antibodies specific for individual or selected components of human complement, such as Anti-C3, and Anti-C3b-C3d-C4, or a single class of immunoglobulins, such as Anti-IgG (heavy chain specific), used only to identify plasma components coated on the surface of red blood cells. Anti-Human Globulin Serum containing Anti-IgG complies with the test for potency, in parallel with the Reference Anti-Human Globulin (Anti-IgG) Serum (at a 1:4 dilution) when tested with red cells suspended in isotonic saline sensitized with decreasing amounts of nonagglutinating Anti-D (Anti-Rh) serum, and with cells sensitized in the same manner with an immunoglobulin IgG Anti-Fy' serum of similar potency. Anti-Human Globulin Serum containing one or more Anti-complement components complies with the tests for potency in giving a 2+ agglutination reaction (i.e., agglutinated cells dislodged into many small clumps of equal size) by the low-ionic sucrose or sucrose–trypsin procedures when tested as recommended in the labelling. Anti-Human Globulin Serum containing Anti-3Cd activity meets the requirements for stability, by potency testing of representative lots every 3 months during the dating period.

**Expiration date.** Its expiration date is not later than 1 year after the date of issue from manufacturer’s cold storage (5°, 1 year; or 0°, 2 years).

**Storage.** Store at a temperature between 2° and 8°.

**Labelling.** Label states the animal source of the product. Label also states the specific antibody activities present; the application for which the reagent is intended; a cautionary statement that it does not contain antibodies to immunoglobulins or that it does not contain antibodies to complement components, wherever and whichever is applicable; and states that it is for in vitro diagnostic use.

**NOTE—**The lettering on the label of the general-purpose polyspecific reagent is black on a white background. The label of all other Anti-Human Globulin Serum containers is in white lettering on a black background.

**Blood Grouping Serums Anti-D, Anti-C, Anti-E, Anti-c, Anti-e**

Anti-Rh Blood Grouping Serums

Blood Grouping Serums Anti-D, Anti-C, Anti-E, Anti-c, Anti-e (Anti-Rh Group) are sterile, liquid or dried preparations derived from the blood plasma or serum of human subjects who have developed specific Rh antibodies. They are free from agglutinins for the A or B antigens and from alloantibodies other than those for which claims are made in the labelling. They contain a suitable antimicrobial preservative. Liquid serums are not artificially coloured. Two varieties of Anti-Rh Blood Grouping Serums are recognized, i.e., (1) saline agglutinating “complete” antiseraums, which specifically agglutinate human red blood cells suspended in saline and (2) “blocking or incomplete” antiseraums, which contain protein or other macromolecular substances, usually require the cells to be suspended in serum or plasma, and generally are for slide or rapid tube tests. The most commonly used of these blood grouping serums are listed in Table 1 each reacting with the antigen(s) designated by the corresponding letter(s) with the alternative nomenclature indicated parenthetically.

<table>
<thead>
<tr>
<th>Serum</th>
<th>Antigen(s) Reacting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-D (Anti-Rh)</td>
<td>D (Rh)</td>
</tr>
<tr>
<td>Anti-C (Anti-rh')</td>
<td>C (rh')</td>
</tr>
<tr>
<td>Anti-E (Anti-rh‘‘)</td>
<td>E (rh‘‘)</td>
</tr>
<tr>
<td>Anti-CD (Anti-Rh o)</td>
<td>D (Rh o) and C (rh')</td>
</tr>
<tr>
<td>Anti-DE (Anti-Rh o‘‘)</td>
<td>D (Rh o) and E (rh‘‘)</td>
</tr>
<tr>
<td>Anti-CDE (Anti-Rh o‘‘‘)</td>
<td>D (Rh o), C (rh'), and E (rh‘‘) c (hr')</td>
</tr>
<tr>
<td>Anti-c (Anti-hr')</td>
<td>e (hr‘‘)</td>
</tr>
</tbody>
</table>

Each serum meets the requirements of the test for potency in the case of serums for saline tube test in parallel with, and not less than equivalent to, the Reference Blood Grouping Serum.
for Anti-D, Anti-C, or Anti-E, whichever is applicable, or, in the case of Anti-c and Anti-e for saline tube test which have no reference preparations, the test for minimum agglutination reactivity at a specified dilution; and in the case of sera for slide or rapid tube test in parallel with, and not less than equivalent to, the Reference Blood Grouping Serum for Anti-D, Anti-C, Anti-E, Anti-c, or Anti-e, whichever is applicable, in agglutinating as a minimum red blood cells from the donors indicated in Table 2 (which may be from Group A, B, AB, or O). Each serum for slide or rapid tube test complies with the tests for avidity with the cells as indicated under tests for potency above.

<table>
<thead>
<tr>
<th>Serum</th>
<th>Phenotype of Cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-D</td>
<td>cDe</td>
</tr>
<tr>
<td>Anti-C</td>
<td>Ccde</td>
</tr>
<tr>
<td>Anti-E</td>
<td>cdEe</td>
</tr>
<tr>
<td>Anti-CD</td>
<td>cDe, Ccde</td>
</tr>
<tr>
<td>Anti-DE</td>
<td>cDe, Ccde, cdEe</td>
</tr>
<tr>
<td>Anti-CDE</td>
<td>cDe, Ccde, cdEe, A, cde, B cde, O cde, and where recommended for detection of the G antigen, r^r</td>
</tr>
<tr>
<td>Anti-c</td>
<td>Ccde, A, CDe, B CDe, O CDe, and CDEe or CDE or CdE</td>
</tr>
<tr>
<td>Anti-e</td>
<td>cdEe, A, CDE, B cDE, O cDE, and CcDE or CDE or CdE</td>
</tr>
</tbody>
</table>

All fresh or frozen red blood cell suspensions used for these tests are prepared under specified conditions and meet specified criteria.

**Monoclonal Rh (D) antibodies.** Monoclonal antibodies are derived from hybridoma cell lines produced by fusing mouse antibody produced by B lymphocyte with mouse myeloma cells or are derived from a human B cell line through Epstein-Barr Virus (EBV) transformation. Each hybridoma cell line produces homogenous antibodies of only one immunoglobulin class, which are identical in their chemical structure and immunological activity.

The type of monoclonal anti-D reagents are:

1. IgM anti-D monoclonal reagent,
2. Blend of IgM and IgG monoclonal antibodies reagent,
3. Blend of monoclonal IgM and polyclonal (human) IgG anti-D.

IgM anti-D monoclonal antibodies are highly specific and saline reacting equally well at room temperature and at 37°. They are good for slide test or immediate spin tube tests as well as routine Rh(D) typing in tube. IgM anti D are unreliable for detection of weak D (Du) by AHG test. Blend of IgM and IgG (monoclonal) anti-D or blend of IgM (monoclonal) and polyclonal (human) IgG anti-D can be used for testing weak D (Du) antigen by AHG test. Mostly blended IgM and IgG (monoclonal) anti-Rh(D) or blended monoclonal IgM and polyclonal (human) IgG anti Rh (D) antibodies are used now in routine.

**Expiration date.** The expiration date for liquid sera is not later than 1 year and for dried sera not later than 5 years after date of issue from manufacturer’s cold storage (5°, 1 year; or 0°, 2 years), provided that the expiration date for dried sera is not later than 1 year after constitution.

**Storage.** Store at a temperature between 2° and 8°.

**Labelling.** Label each to state that the source material was not reactive for hepatitis B surface antigen, but that no known test method offers assurance that products derived from human blood will not transmit hepatitis. Label each to state that it is for in vitro diagnostic use.
Concentrated Human Red Blood Corpuscles

Concentrate of Human Red Blood Cells; Packed Red Cells

Concentrated Red Blood Cells (RBCs) are units of whole blood with most of the plasma removed. Additive red cell preservative systems consist of a primary collection bag containing an anticoagulant preservative with at least two satellite bags integrally attached, one is empty and one contains an additive solution (AS).

Each 100 ml citrate phosphate dextrose (CPD) contains

<table>
<thead>
<tr>
<th>Substance</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citric acid (monohydrate)</td>
<td>0.327 g</td>
</tr>
<tr>
<td>Sodium citrate (dihydrate)</td>
<td>2.63 g</td>
</tr>
<tr>
<td>Sodium acid phosphate (dihydrate)</td>
<td>0.251 g</td>
</tr>
<tr>
<td>Dextrose (monohydrate)</td>
<td>2.55 g</td>
</tr>
<tr>
<td>Water for injection</td>
<td>100 ml</td>
</tr>
</tbody>
</table>

AS contains sodium chloride, dextrose, adenine and other substances that support red cell survival and function up to 42 days. The volume of AS in 350 ml is 49 ml and in 450 ml is 63 ml. AS is added to the red cells remaining in the primary bag after most of the plasma has been removed. This allows blood centres to use or recover a maximum amount of plasma, yet still prepare a red cell component with a final hematocrit between 55.0 per cent and 65.0 per cent, a level that facilitates excellent flow rates and allows easy administration.

Production

It may be prepared by centrifugation or undisturbed sedimentation for the separation of plasma and anticoagulant solution equivalent to not less than 40.0 per cent of the total volume of Whole Human Blood. A portion of the plasma, sufficiently to ensure optimal cell preservation, shall be left. All surfaces that come in contact with the red cells and plasma shall be sterile and pyrogen-free and the entire processing of the blood shall be conducted in a sterile system or in a closed system by use of satellite bags. The final containers used for the Concentrated Human Red Blood Corpuscles shall be the original blood containers unless the method of processing requires a different container. Immediately after processing, the containers are stored at a temperature between 2° and 8° and not opened until immediately before transfusion. Human Red Blood Corpuscles may be stored for a period not longer than that for which the Whole Human Blood from which it is prepared. However, if the hermetic seal is broken during processing, the product must be used within 24 hours. From the tube of the blood bag sample is taken for compatibility and infections markers testing.

Concentrated Human Red Blood Corpuscles should be administered only with suitable equipment meant for the transfusion of blood and blood components.

Concentrated Human Red Blood Corpuscles contains not less than 15.5 per cent w/v of haemoglobin.

Description. A dark red fluid when prepared; after standing, the red corpuscles may form a sediment, leaving a small supernatant layer of yellowish plasma.

Tests

Sterility (2.2.11). Complies with the tests for sterility, determined by Method B.

Assay. Determine the haemoglobin content by photometric haemoglobinometry (2.8.12).

Storage. Store in containers which are made of colourless and transparent glass, or of a suitable plastic material, are sterile and sealed so as to exclude micro-organisms. Store at a temperature between 2° and 8°.

Labelling. The label states (1) the reference number of the Whole Human Blood from which the preparation was made; (2) the ABO and Rh groups of the Whole Human Blood; (3) the date of collection of the Whole Human Blood from which the preparation was made; (4) the storage conditions; (5) the date after which the preparation is not suitable for transfusion; (6) that the preparation should not be used if there is any visible evidence of haemolysis or other deterioration.

Cryoprecipitated Antihaemophilic Factor

Cryoprecipitated Antihaemophilic Factor is a sterile, frozen concentrate of human antihaemophilic factor prepared from the Factor VIII-rich cryoprotein fraction of human venous plasma obtained from suitable whole-blood donors from a single unit of plasma derived from whole blood or by plasmapheresis, collected and processed in a closed system. It contains no preservative. It complies with the test for potency by comparison with the Standard Antihaemophilic Factor (Factor VIII) or with a working reference that has been calibrated with it, in having an average potency of not less than 80 Antihaemophilic Factor Units per container, made at intervals of not more than 1 month during the dating period.

Expiration date. The expiration date is not later than 1 year from the date of collection of source material.

Storage. Store in hermetic containers at a temperature of -18° or lower.

Labelling. Label it to indicate (1) the ABO blood group designation and the identification number of the donor from whom the source material was obtained; (2) with the type and result of a serologic test for syphilis, or to indicate that it was non-reactive in such test; with the type and result of a test for hepatitis B surface antigen, or to indicate that it was non-reactive in such test; with a warning not to use it if there is evidence of breakage or thawing; with instructions to thaw it before use to a temperature between 20° and 37°, after which it is to be stored at room temperature and used as soon as possible but within 6 hours after thawing; (3) to state that it is...
to be used within 4 hours after the container is entered; (4) to state that it is for intravenous administration; (5) that a filter is to be used in the administration equipment.

Dried Human Antihaemophilic Fraction

Dried Factor VIII Fraction; Freeze-dried Human Coagulation Factor VIII

Dried Human Antihaemophilic Fraction is a preparation of antihaemophilic factor which is obtained from human plasma. It is rich in clotting factor VIII.

When the contents of a sealed container of Dried Human Antihaemophilic Fraction are dissolved in a volume of water equal to the volume of water for injection stated on the label, the resulting solution contains not less than 3.0 Units per ml, not less than 0.1 Unit per mg of protein, not more than 80.0 per cent of which is fibrinogen, and not more than 200 millimoles of sodium ions per litre.

Production

The plasma to be used for preparing Dried Human Antihaemophilic Fraction is obtained from blood of healthy human donors who are, as far as can be ascertained after clinical examination, laboratory tests on their blood and consideration of their medical history, free from detectable agents of infection transmissible by blood transfusion. The examinations and tests to be carried out are decided by the National Regulatory Authority. In particular, the blood must be tested with negative results for (a) evidence of syphilitic infection; (b) hepatitis B surface antigen and (c) HIV antibodies by suitably sensitive methods. The haemoglobin value of the donor’s blood is not less than 12.5 per cent w/v.

The blood is withdrawn aseptically through a closed system of sterile tubing into a sterile container in which a suitable anticoagulant solution has been placed before sterilisation. During the withdrawal there is no interruption in the flow from the donor, and the container is gently agitated. Immediately after the withdrawal is completed, the blood is cooled to 4°C; if the plasma is to be stored frozen it is separated from the cellular components by centrifugation and frozen to –30°C or below, preferably within 12 hours of collection; if the plasma is not to be frozen it is separated from the cellular components by centrifugation as soon as possible and not later than 18 hours after collection, and fractionation begun without delay.

Dried Human Antihaemophilic Fraction may be prepared from human plasma so obtained by precipitation under controlled conditions of pH, ionic strength and temperature with organic solvents, or by freezing and thawing. The precipitate may be washed by extraction with suitable solvents, dissolved in a solution of sodium citrate adjusted to a pH of 6.8 to 7.2, which may also contain sodium chloride. The solution is sterilised by filtration through a membrane filter, distributed in sterile containers and dried from the frozen state. The air is removed or replaced by oxygen-free nitrogen and the containers are sealed so as to exclude micro-organisms. No antimicrobial preservative is added but an antiviral agent may be added provided that it can be demonstrated to have no deleterious effect on the final product in the amount present and to cause no adverse reaction in man. Heparin may be used.

For the following tests, where it is directed that a solution is to be used, dissolve the contents of a sealed container in a volume of the appropriate solvent equal to the volume of water for injection stated on the label.

Description. A white or pale yellow powder or friable solid.

Identification

A. Precipitation tests with a suitable range of species specific antisera give positive results for the presence of plasma proteins of human origin and negative results with antisera specific to plasma proteins of the other species.

B. A freshly prepared solution in water causes a reduction in clotting time when treated as directed under Assay.

Tests

pH (2.4.24). 6.8 to 7.4, determined on the reconstituted solution.

Loss on drying (2.4.19). Not more than 2.0 per cent, determined by drying 0.5 g over phosphorus pentoxide at a pressure not exceeding 3 kPa for 24 hours.

Haemagglutinins, anti-A and anti-B. Dissolve in water. Dilute the solution with saline solution to produce a solution containing 3 Units per ml. Carry out the test for haemagglutinins anti-A and anti-B using a suitable indirect method such as that described below.

Prepare in duplicate serial dilutions of the preparation under examination in saline solution. To each dilution of one series add an equal volume of a 5.0 per cent v/v suspension of group A, red blood cells previously washed three times with saline solution. To each dilution of the other series add an equal volume of a 5.0 per cent v/v suspension of group B red blood cells previously washed three times with saline solution. Incubate the suspensions at 37°C for 30 minutes and then wash the cells three times with saline solution. Leave the cells in contact with a polyvalent anti-human globulin reagent for 30 minutes. Without centrifuging, examine each suspension for agglutination under a microscope. The 1 in 64 dilutions do not show agglutination.

Hepatitis B surface antigen. Dissolve in water. Examine the solution by a suitably sensitive method such as radioimmunoassay. Hepatitis B surface antigen is not detected.

Abnormal toxicity (2.2.1). When dissolved in water for injection, complies with the test for abnormal toxicity, Method B, injecting into each mouse a volume containing 1.5 Units and into each guinea-pig a volume containing 15 Units.

Pyrogens (2.2.8). When dissolved in water for injection, complies with the test for pyrogens, using a volume containing
10 Units per kg of the rabbit’s weight in rabbits that have not previously received blood products.

**Sterility (2.2.11).** Complies with the tests for sterility.

**Assay**

For *potency* — Carry out the biological assay of human antihaemophilic fraction described below. The estimated potency is not less than 80.0 per cent and not more than 125.0 per cent of the stated potency. The fiducial limits of error are not less than 64.0 per cent and not more than 156.0 per cent of the stated potency.

**Biological assay**

The potency of human antihaemophilic fraction is determined by comparing the amount necessary to reduce the clotting time of a test mixture containing substances that cause clotting of blood with the amount of the Standard Preparation necessary to produce the same effect under the conditions of the following method of assay.

**Standard preparation**

The Standard preparation is the 4th International Standard for Blood coagulation factor VIII:C, concentrate, human, established in 1989, consisting of an intermediate purity concentrate of human blood clotting factor VIII (supplied in ampoules containing 6.3 Units of clotting factor VIII), or another suitable preparation the potency of which has been determined in relation to the International Standard.

The Unit is the specific antihaemophilic factor contained in such an amount of the Standard Preparation as the Ministry of Health & Family Welfare, Govt. of India may from time to time indicate as the quantity exactly equivalent to the Unit accepted for international use.

**Special reagents**

**Normal serum reagent.** Collect normal human blood in a dry, sterile, glass bottle, shake continuously until coagulation is complete, incubate at 37º for 3 hours, maintain at 4º overnight, remove the serum, store at –20º, dry from the frozen state and keep in a vacuum desiccator over phosphorus pentoxide. Dissolve a quantity of the dried serum calculated to have been obtained from 1 ml of the serum in sufficient imidazole buffer pH 7.4 to produce 10 ml and allow to stand at 4º for 16 to 24 hours.

**Phospholipid.** Wash a quantity of normal human or bovine blood from meninges and blood vessels and macerate in a suitable blender. Weigh 1,000 to 1,300 g of the macerate and measure its volume (V). Extract with three quantities, each of 4V ml, of acetone, filter by suction and dry the precipitate at 37º for 18 hours. Extract the dried precipitate with two quantities, each of 2V ml, of a mixture of two volumes of light petroleum (boiling range 30º to 40º) and 3 volumes of light petroleum (boiling range 40º to 60º), filtering each extract through a filter paper previously washed with the light petroleum mixture. Combine the extracts and evaporate to dryness at 45º at a pressure not exceeding 0.7 kPa. Dissolve the residue in 0.2Y ml of ether and allow to stand at 4º until a deposit forms. Centrifuge and evaporate the clear supernatant liquid under reduced pressure until the volume is about 100 ml per kg of the original macerate. Allow to stand at 4º until a precipitate forms (12 to 24 hours) and centrifuge. To the clear supernatant liquid add 5 times its volume of acetone, centrifuge, discard the supernatant liquid, dry the precipitate and store protected from light in a vacuum desiccator.

**Phospholipid reagent.** Suspend 0.125 g of phospholipid in 5 ml of water, shake and stir until a uniform suspension is obtained. Prepare a dilution with saline solution that will give minimum clotting times consistent with the largest clotting time differences between consecutive dilutions of the Standard preparation and the preparation under examination. The concentration usually lies between 50 and 250 µg per ml. The diluted suspension may be kept at –20º for 6 weeks.

**Clotting factor V solution.** Prepare from fresh oxalated bovine plasma by fractionation at 4º with a saturated solution of ammonium sulphate prepared at 4º. Use the fraction precipitating between 38 per cent and 50 per cent saturation (which contains clotting factor V not significantly contaminated with clotting factor VIII), dialysed to remove ammonium sulphate and diluted with saline solution to give a solution containing between 10 per cent and 20 per cent of the amount of clotting factor V present in fresh normal human plasma.

Determine the clotting factor V content of the solution as follows. Prepare two dilutions in imidazole buffer pH 7.4 to contain 1 volume of the solution under examination in 10 volumes and 20 volumes respectively. Test each dilution as follows. Mix 0.1 ml each of substrate plasma deficient in clotting factor V, the dilution under test, thrombokinase extract and 0.025M calcium chloride. Record as the clotting time the interval between the addition of the calcium chloride solution and the first indication of fibrin formation, which may be observed visually or by mechanical means.

Similarly determine the clotting times, in duplicate, for four dilutions of pooled normal human plasma in imidazole buffer pH 7.4 containing 1 volume in 10 volumes (equivalent to 100 per cent of clotting factor V), in 50 volumes (20 per cent), in 100 volumes (10 per cent), and in 1,000 volumes (1 per cent), respectively.

To calculate the result, plot the mean of the clotting times for each dilution of human plasma on double cycle log/log paper against the equivalent percentage of clotting factor V and read the percentage of clotting factor V for the two dilutions of clotting factor V solution by interpolation from the curve. The mean of the two results is taken as the percentage of clotting factor V in the solution.

**Substrate plasma.** Separate the plasma from 9 volumes of human or bovine blood collected in 1 volume of a 3.8 per cent w/v solution of sodium citrate or from 3.5 volumes of human or bovine blood collected in 1 volume of a solution containing 2.0 per cent w/v of sodium acid citrate and 2.5 per cent w/v of
dextrose. In the former case, prepare the substrate plasma on the day of collection of the blood. In the latter case, the substrate plasma may be prepared up to 2 days after collection of the blood. Store at −20°.

**Substrate plasma deficient in clotting factor V.** Preferably use congenitally deficient plasma or, alternatively, prepare as follows. Separate the plasma from human blood collected in one-tenth its volume of a 1.34 per cent w/v solution of sodium citrate and incubate at 37° for 24 to 36 hours. This plasma should have a clotting time, when tested by the assay method given under *clotting factor V solution*, of 70 to 100 seconds; if the clotting time is less than 70 seconds, incubate the plasma for a further 12 to 24 hours.

**Storage.** Store in small amounts, at −20° or below.

**Suggested method.**

Dissolve the contents of the sealed container of the substance under examination in the volume of the liquid stated on the label and use immediately. Reconstitute the entire contents of one ampoule of the Standard preparation as stated on the label and use immediately.

To the reconstituted Standard preparation and the preparation under examination, add sufficient imidazole buffer pH 7.4 to produce solutions containing between 0.5 and 2 Units per ml; these solutions are stable for 15 minutes at 20°. Using a mixture of 1 volume of a 3.8 per cent w/v solution of sodium citrate and 5 volumes of saline solution as the diluent, make from the solutions three successive 2-fold dilutions in the range 1 in 16 to 1 in 256 so that all the clotting times are between 17 and 35 seconds; the dilutions must be accurately made and used immediately.

Introduce into each of six glass incubation tubes (75 mm 100 mm) 0.1 ml each of *clotting factor V solution*, phospholipid reagent and normal serum reagent. To the first tube add 0.1 ml of the highest dilution of the Standard Preparation, place the tube in a water-bath at 37°, add 0.1 ml of 0.05M calcium chloride and start a stop-watch. During the next minute add 0.1 ml of the second highest dilution of the standard to a second tube, place it in the water-bath, and add 0.1 ml of 0.05M calcium chloride at exactly 1 minute by the stop-watch. Repeat the procedure with the lowest dilution of the standard and the highest to lowest dilutions of the preparation under examination so that the calcium chloride solution is added at 2, 3, 4 and 5 minutes by the stop-watch, respectively.

Place in a water-bath at 37° twelve glass tubes each containing 0.2 ml of 0.025M calcium chloride and a further tube containing about 3 ml of substrate plasma. At 14 minutes, 40 seconds by the stop-watch, transfer 0.1 ml of the mixture from the first incubation tube to one of the tubes containing 0.2 ml of 0.025M calcium chloride solution and mix. At 15 minutes add 0.2 ml of the warmed substrate plasma and, using a second stop-watch, record as the clotting time the interval between the addition of the substrate plasma and the first indication of fibrin formation, which may be observed visually or by mechanical means. Repeat the procedure with the other incubation tubes at 1-minute intervals and carry out a second series of determinations at 21 to 26 minutes. The period of incubation should, if necessary, be adjusted so that the clotting times recorded in the corresponding tests in the two series of determinations do not differ by more than 5.0 per cent, showing that a stable plateau of prothrombin activator formation has been reached.

Carry out a blank determination using in place of the preparation under examination, an equal quantity of a mixture of 1 volume of a 3.8 per cent w/v solution of sodium citrate and 5 volumes of saline solution. The result of the assay is not valid unless the clotting time in the blank determination is more than 40 seconds. Calculate the result of the assay by standard statistical methods.

*For total protein. Dilute 1.0 ml to 10.0 ml with saline solution.* Determine the assay described under Human Plasma using 5.0 ml of the dilution and beginning at the words “add 0.2 ml of a 7.5 per cent w/v solution....”.

*For fibrinogen. Dilute 1.0 ml of the solution to 10.0 ml with a phosphate-saline buffer pH 6.5 and ionic strength 0.15. Clot 5.0 ml of the dilution with the minimum amount of thrombin, collect the clot and add three drops of a 30 per cent w/v solution of copper sulphate and 1 ml of nitrogen-free sulphuric acid and boil gently for 10 minutes; cool, add 1 g of anhydrous sodium sulphate and 10 mg of selenium, boil gently for 1 hour and cool. Transfer to an ammonia distillation apparatus, add 6 ml of a saturated solution of sodium hydroxide and pass steam through the flask; distil for seven minutes, collecting the distillate in a mixture of five ml of a saturated solution of boric acid, 5 ml of water, and 1 drop of a saturated solution of methyl red in alcohol containing 0.1 per cent of methylene blue, and titrate with 0.02 M hydrochloric acid.*

1 ml of 0.02M hydrochloric acid is equivalent to 0.00175 g of fibrinogen.

*For sodium ions. To 10.0 ml of the solution add sufficient water to produce 100 ml, dilute 10.0 ml to 500 ml with water and determine the content of sodium ions by Method B for flame photometry (2.4.4), measuring at about 589 nm and using sodium solution FP suitably diluted with water as the standard solution.*

**Storage.** Store protected from light, in an atmosphere of nitrogen at a temperature below 8°. The containers are sterile and sealed so as to exclude micro-organisms.

**Labelling.** The label states (1) the ABO blood group designation of the source of blood; (2) the number of Units in the container; (3) that 1 Unit is approximately equivalent to the antihae thrompholic activity of 1 ml of average normal plasma; (4) the concentration of protein in g per litre and of sodium ions in millimoles per litre of the solution constituted as directed; (5) the maximum fibrinogen content; (6) where applicable, the number of Units of heparin in the container; (7) the name and amount of any other added substance contained in it; (8) the volume of Water for Injections necessary to constitute the solution; (9) the instructions for constitution
and that reconstitution may take up to 30 minutes; (10) that if the solution is not complete or if a gel forms on constitution, the preparation should not be used; (11) that the solution should be used as soon as possible and in any case within 3 hours of constitution and any unused solution should be discarded; (12) that the solution should be administered only with equipment that includes a filter; (13) the storage conditions.

Fibrin Sealant Kit

Fibrin Sealant Kit is essentially composed of two components, namely fibrinogen concentrate (component 1), a protein fraction containing human fibrinogen and a preparation containing human thrombin (component 2). A fibrin clot is rapidly formed when the two thawed or reconstituted components are mixed. Other ingredients (for example, human coagulation factor XIII, a fibrinolysis inhibitor or calcium ions) and stabilizers (for example, Human albumin solution) may be added. No antimicrobial preservative is added.

Human constituents are obtained from plasma that complies with the requirements of the monograph on Human Plasma for Fractionation. No antibiotic is added to the plasma used.

When thawed or reconstituted as stated on the label, component 1 contains not less than 4.0 per cent of clottable protein; the thrombin activity of component 2 varies over a wide range (approximately 4-1000 IU per ml).

Production

The method of preparation includes a step or steps that have been shown to remove or to inactivate known agents of infection; if substances are used for inactivation of viruses during production, the subsequent purification procedure must be validated to demonstrate that the concentration of these substances is reduced to a suitable level and any residues are such as not to compromise the safety of the preparation for patients.

Constituents or mixtures of constituents are passed through a bacteria-retentive filter and distributed aseptically into sterile containers. Containers of freeze-dried constituents are closed under vacuum or filled with oxygen-free nitrogen or other suitable inert gas before being closed. In either case, they are closed so as to exclude micro-organisms.

If the human coagulation factor XIII content in component 1 is greater than 10 Units per ml, the assay of coagulation factor XIII is carried out.

Description. Freeze-dried constituents are hygroscopic, white or pale yellow powders or friable solids. Frozen constituents are colourless or pale yellow, opaque solids. Liquid constituents are colourless or pale yellow.

For the freeze-dried or frozen constituents, reconstitute or thaw as stated on the label immediately before carrying out the Identification and the Tests, except those for solubility and water.

Component 1 (Fibrinogen Concentrate)

Identification

A. Complies with the limits of the assay of fibrinogen.
B. Complies with the limits of the assay of factor XIII (where applicable).

Tests

pH (2.4.24). 6.5 to 8.0.

Stability of solution. No gel formation appears at room temperature during 120 min following thawing or reconstitution.

Water. Determine by semi-microdetermination (2.3.43), loss on drying (2.4.19) or near infrared spectrophotometry (2.4.6), the water content is within the limits approved by the competent authority.

Sterility (2.2.11). Complies with the test for sterility.

Assay

Fibrinogen (Clottable Protein)

The estimated content in mg of clottable protein is not less than 70.0 per cent and not more than 130.0 per cent of the content stated on the label.

Mix 0.2 ml of the reconstituted preparation with 2 ml of a suitable buffer solution pH 6.6 to 7.4 containing sufficient human thrombin (approximately 3 IU per ml) and calcium (0.05 mol per l). Maintain at 37°C for 20 minutes, separate the precipitate by centrifugation (5000 g, 20 minutes), wash thoroughly with a 0.9 per cent solution of sodium chloride and determine the protein as nitrogen by sulphuric acid digestion (2.3.30). Calculate the protein content by multiplying the result by 6.0. If for a particular preparation this method cannot be applied, use another validated method for determination of fibrinogen.

Factor XIII

Where the label indicates that the human coagulation factor XIII activity is greater than 10 Units per ml, the estimated activity is not less than 80.0 per cent and not more than 120.0 per cent of the activity stated on the label.

Make at least 3 suitable dilutions of thawed or reconstituted component 1 and of human normal plasma (reference preparation) using as diluent coagulation factor XIII deficient plasma or another suitable diluent. Add to each dilution a. activator reagent, containing bovine or human thrombin, a suitable buffer, calcium chloride and a suitable inhibitor such as Gly-Pro-Arg-Pro-Ala-NH₂, which inhibits clotting of the sample but does not prevent coagulation factor XIII
activation by thrombin,
b. detection reagent, containing a suitable factor XIIIa-specific peptide substrate, such as Leu-Gly-Pro-Gly-Glu-Ser-Lys-Val-Ile-Gly-NH₂ and glycine ethyl ester as 2nd substrate in a suitable buffer solution,
c. NADH reagent, containing glutamate dehydrogenase, a-ketoglutarate and NADH in a suitable buffer solution.

After mixing, the absorbance changes (ΔA per min) are measured at a wavelength of 340 nm, after the linear phase of the reaction is reached.

1 Unit of factor XIII is equal to the activity of 1 ml of human normal plasma.

Calculate the activity of the test preparation by the usual statistical methods. The confidence limits (P = 0.95) are not less than 80.0 per cent and not more than 125.0 per cent of the estimated activity.

Component 2 (Thrombin Preparation)

Identification

Complies with the limits of the assay of thrombin.

Tests

pH (2.4.24). 5.0 to 8.0.

Water. Determine by semi-microdetermination of water (2.3.43), loss on drying (2.4.19) or near infrared spectrophotometry (2.4.6), the water content is within the limits approved by the competent authority.

Sterility (2.2.11). Complies with the test for sterility.

Assay

Thrombin

The estimated activity is not less than 80.0 per cent and not more than 125.0 per cent of the activity stated on the label.

If necessary, dilute the reconstituted preparation under examination to approximately 2-20 IU of thrombin per ml using as diluent a suitable buffer pH 7.3 to 7.5, such as imidazole buffer solution pH 7.3 containing 1.0 per cent of human albumin or bovine albumin. To a suitable volume of the dilution, add a suitable volume of fibrinogen solution (0.1 per cent of clottable protein) warmed to 37°C and start measurement of the clotting time immediately. Repeat the procedure with each of at least 3 dilutions, in the range stated above, of a reference preparation of thrombin, calibrated in International Units. Calculate the activity of the test preparation by the usual statistical methods. The confidence limits (P = 0.95) are not less than 80.0 per cent and not more than 125.0 per cent of the estimated activity.

Storage. Store protected from light.

Labelling. The label states (1) the amount of fibrinogen (mg of clottable protein), thrombin (International Units) per container, and coagulation factor XIII, if this is greater than 10 Units per ml; (2) where applicable, the name and volume of solvent to be used to reconstitute the components.

Human Albumin

Human Normal Albumin; Human Albumin Solution

Human Albumin is a sterile non-pyrogenic solution of the albumin component obtained from pooled human blood or from normal placentae frozen immediately after collection. It is obtained by fractionating source material such as blood, plasma, serum or placentae from healthy human donors and tested individually for the absence of hepatitis B surface antigen, HCV antibodies and HIV antibodies and complies with other tests and requirements prescribed by the appropriate national control authority. Source material obtained from donors who do not meet all the requirements stated may be used provided that it has been demonstrated to the national control authority that the process of fractionation will remove any known agent capable of adversely affecting the health of subjects treated with the preparation. It may be prepared from pooled source materials by precipitation with organic solvents under controlled conditions of pH, ionic strength and temperature or by chromatography or by any other method which does not affect the integrity of the product and has been shown to yield consistently a product containing not less than 95.0 per cent w/v of the total protein as albumin which is safe for intravenous injection. Residual organic solvent, if present, is removed by freeze-drying or other suitable treatment. The product is dissolved in sufficient water to obtain a suitable concentration, and a suitable stabilising agent is added to stabilise it to heat. It is prepared as a solution containing 15.0 to 25.0 per cent w/v of total protein or as an isotonic solution containing 4.0 to 5.0 per cent w/v of total protein. No antimicrobial agent is added at any stage during preparation and all processing steps are conducted in a manner to minimise risk of contamination from either micro-organisms or other deleterious matter. The solution is sterilised by filtration and distributed aseptically into containers which are then sealed so as to exclude micro-organisms. The solution is then heated to and maintained at 60°C ± 0.5°C for 10 hours so as to prevent the transmission of agents of infection transmissible by transfusion of blood or blood derivatives. Finally, the containers are stored for not less than 14 days at 30°C to 32°C or for not less than 4 weeks at 20°C and examined visually. Those showing abnormalities such as abnormal colour, turbidity, microbial contamination, or presence of atypical particles must be discarded.

Albumin Solution should be tested in accordance with the requirements decided by the National Regulatory Authority; in particular, tests for the absence of hepatitis B surface antigen and HIV antibodies are carried out by suitably sensitive methods.
Human Albumin contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of protein. It contains not less than 95.0 per cent and not more than 105.0 per cent of the contents of Na and K stated on the label which are, in any case, not more than 160 millimoles of Na per litre and 2 millimoles of K per litre.

**Description.** A clear, slightly viscous liquid, ranging in colour from almost colourless to greenish-yellow or amber depending on protein concentration and the method of fractionation used.

**Identification**

A. It contains plasma proteins of human origin only as determined by precipitation tests with specific antisera.

B. Determine the cellulose acetate by electrophoresis (2.4.12), using barbitone buffer pH 8.6, ionic strength 0.1 and human albumin for electrophoresis RS; 96.0 per cent of the protein has the mobility of human albumin.

**Tests**

**Acidity or alkalinity** (2.4.24). Dilute with sufficient saline solution to produce a solution containing 1.0 per cent w/v of protein; pH of the resulting solution, 6.7 to 7.3.

**Alkaline phosphatase.** Not more than 0.1 Unit per g of protein, determined by the following method. Transfer a mixture of 0.5 ml of the substance under examination and 0.5 ml of diethanolamine buffer pH 10.0 to a spectrophotometer cell maintained at a temperature of 37° ± 0.2° and add 0.1 ml of nitrophenyl phosphate solution. Using a continuously recording spectrophotometer record the absorbance of the solution at about 405 nm (2.4.7), over a period of at least 30 seconds from the time of addition of the nitrophenyl phosphate solution. Calculate the alkaline phosphatase activity at 37° in Units per g of protein from the expression 118.3x/P, where x is the rate of increase of absorbance per minute and P is the content of total protein in g per litre, as determined in the Assay.

**Haem content.** Dilute with sufficient saline solution to produce a solution containing 1.0 per cent w/v of protein; absorbance of the resulting solution at about 403 nm, not more than 0.15 (2.4.7).

**Denatured protein.** Equilibrate a column (60 to 75 cm x 2.5 to 3.0 cm) of a gel of a cross-linked dextran suitable for fractionation of proteins in the range of molecular weight from 5,000 to 3,50,000, with a lower molecular weight for complete exclusion of globulin proteins of molecular weight between 4,00,000 and 5,00,000 (Sephadex G 150 is suitable) at 20° to 25° with a saline-phosphate solution prepared by mixing 2 volumes of saline solution and 1 volume of mixed phosphate buffer pH 7.0 with azide. Apply to the column 2.5 ml of normal human serum, previously clarified by centrifuging, and elute with the saline-phosphate solution at a rate of 20 ml per hour. Prepare a chromatogram by recording the absorbance (2.4.7), of the eluate at about 280 nm in relation to its volume. The chromatogram exhibits three well-defined peaks. Determine the volume, V, of the eluate from the entry of the sample into the column to the apex of the first peak.

Dilute the substance under examination with the saline-phosphate solution to contain about 5.0 per cent w/v of protein, apply 2.5 ml to the column and elute under the above conditions, collecting the eluate in 5-ml portions. Three peaks may appear in similar positions to those in the chromatogram obtained from the normal human serum but the relative peak heights may be different. To the fraction eluted between volume 0.85 V and 1.15 V, add for each 10 ml, 0.4 ml of a 7.5 per cent w/v solution of sodium molybdate and 0.4 ml of a mixture of 1 part of nitrogen-free sulphuric acid and 30 parts of water, shake, centrifuge for 5 minutes and complete the Assay described under Human Plasma beginning at the words “decant the supernatant...”. The weight of protein in the fraction of the eluate is not more than 3.5 per cent of the weight of protein in the volume of the substance under examination applied to the column.

Heat the substance under examination for 50 hours at 56.5° to 57.5° and repeat the chromatographic separation and the determination of the weight of protein in the fraction eluted between 0.85 V and 1.15 V. When expressed as a percentage of the weight of protein in the volume of the substance under examination applied to the column, it exceeds the percentage obtained before heating by not more than 1.5 per cent w/v.

**Protein composition.** Not less than 95.0 per cent w/v of the total protein as albumin, when determined by the following method. Carry out Method II for cellulose acetate electrophoresis (2.4.12), using one strip of cellulose for each solution.

**Test solution.** Dilute the substance under examination with saline solution to contain 2.0 per cent w/v of total protein.

**Reference solution.** Dilute human albumin for electrophoresis RS with saline solution to obtain a solution containing 2.0 per cent w/v of total protein.

Not more than 5.0 per cent of total protein is contained in bands other than the principal band in the strip obtained with test solution. The test is not valid if the proportion of the protein in the principal band is not within the limits stated in the leaflet supplied with human albumin for electrophoresis RS.

**Stability.** The contents of the final container remain unchanged, as determined by visual inspection, after heating at 57° for 50 hours, when compared to its control consisting of a sample from the same lot which has not undergone this heating.

**Pyrogens** (2.2.8). Complies with the test for pyrogens, using 3 ml per kg of the rabbit’s weight, irrespective of the protein content, in rabbits that have not previously received blood products.

**Sterility** (2.2.11). Complies with the tests for sterility.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity, using Method B and 0.5 ml of the solution for each mouse and 5 ml for each guinea-pig irrespective of the protein.
content.

Assay

For protein. Dilute to about 0.75 per cent w/v of total protein with saline solution. Take 2 ml of this solution in a round-bottomed centrifuge tube, add 2 ml of a 7.5 per cent w/v solution of sodium molybdate and 2 ml of a mixture of 30 volumes of water and 1 volume of nitrogen-free sulphuric acid. Shake, centrifuge for 5 minutes, decant the supernatant liquid and let the inverted tube stand on a filter paper to drain the fluid. Carry out Method E for determination of nitrogen (2.3.30), on the residue thus obtained and multiply the result by 6.25 to obtain the protein content.

For sodium. Dilute to 0.01 per cent w/v of protein with water and determine by Method A for atomic absorption spectrophotometry (2.4.2), or by Method B for flame photometry (2.4.4), measuring at about 589 nm and using sodium solution FP suitably diluted with water as the standard solution.

For potassium. Dilute to 0.25 per cent w/v of protein with water and determine by Method A for atomic absorption spectrophotometry (2.4.2), or by Method B for flame photometry (2.4.4), measuring at about 767 nm and using potassium solution FP suitably diluted with water as the standard solution.

Human Albumin intended for administration to patients undergoing dialysis or to premature infants complies with the following additional test.

Aluminium (2.3.8). Not more than 200 µg of Al per litre. Determine by atomic absorption spectrophotometry (2.4.2), with a furnace as atomic generator and measuring at 309.3 nm and using as standard solutions a suitable range of dilutions in water of aluminium standard solution (10 ppm Al) further diluted, as necessary, with a solution containing 0.17 per cent w/v of magnesium nitrate and 0.05 per cent w/v of octoxinol 10 in a solution of nitric acid containing 1 per cent w/v of nitric acid. Prepare suitable dilutions of the preparation under examination and human albumin for aluminium validation RS with water. Dilute the solutions, as necessary, with the magnesium nitrate-octoxinol 10-nitric acid solution used for dilution of the standard solution. The test is valid only if the aluminium content determined for human albumin for aluminium validation RS is within 20 per cent of the stated value.

NOTE — Wash all equipments with a solution containing 20.0 per cent w/v of nitric acid before use and use plastic containers only to prepare all solutions.

Storage. Store protected from light, at a temperature between 2° and 25°. HumanAlbumin stored at 2° to 8° may be expected to continue to meet the requirements of the monograph for 5 years from the date on which it was heated at 60° for 10 hours. Human Albumin stored at a temperature not exceeding 25° may be expected to continue to meet the requirements of the monograph for 3 years from the date on which it was heated at 60° for 10 hours.

Labelling. The label states (1) the volume in the container; (2) the total amount of protein in the container expressed in g per litre or as percentage; (3) the concentration of sodium and potassium ions expressed in millimoles per litre; (4) the names and concentrations of any stabilising agents and any other additives in the final solution; (5) the type of source material used to manufacture the product; (6) the words “Do not use if turbid”; (7) that the contents must not be used more than 4 hours after the container has been penetrated and any remnant portion must be discarded; (8) the storage conditions; (9) the date after which the solution is not intended to be used; (10) either that the preparation is suitable for administration to patients undergoing dialysis and to premature infants or that it is not intended for such purpose.

Human Coagulation Factor IX

Human Coagulation Factor IX is a plasma protein fraction containing coagulation factor IX, prepared by a method that effectively separates factor IX from other prothrombin complex factors (factors II, VII and X). It is obtained from human plasma that complies with the monograph on Human Plasma for Fractionation.

The potency of the preparation, reconstituted as stated on the label, is not less than 20 IU of factor IX per ml.

Production

The method of preparation is designed to maintain functional integrity of factor IX, to minimise activation of any coagulation factor (to minimise potential thrombogenicity) and includes a step or steps that have been shown to remove or to inactivate known agents of infection; if substances are used for inactivation of viruses during production, the subsequent purification procedure must be validated to demonstrate that the concentration of these substances is reduced to a suitable level and that any residues are such as not to compromise the safety of the preparation for patients.

The specific activity is not less than 50 IU of factor IX per mg of total protein, before the addition of any protein stabiliser.

The factor IX fraction is dissolved in a suitable liquid. Heparin, antithrombin and other auxiliary substances such as a stabiliser may be included. No antimicrobial preservative is added. The solution is passed through a bacteria-retentive filter, distributed aseptically into the final containers and immediately frozen. It is subsequently freeze-dried and the containers are closed under vacuum or under an inert gas.

Consistency of the method

The consistency of the method of production is evaluated by suitable analytical procedures that are determined during process development and which normally include (1) assay of factor IX; (2) determination of activated coagulation factors;
(3) determination of activities of factors II, VII and X which shall be shown to be not more than 5.0 per cent of the activity of factor IX.

**Description.** A white or pale yellow, hygroscopic powder or friable solid.

Reconstitute the preparation under examination as stated on the label, immediately before carrying out the Identification, Tests (except those for solubility and water) and Assay.

**Identification**

It complies with the limits of the Assay.

**Tests**

pH (2.4.24). 6.5 to 7.5.

Osmolality (2.4.23). Minimum 240 mosmol per kg.

**Total protein.** If necessary, dilute an accurately measured volume of the preparation under examination with a 0.9 per cent solution of sodium chloride, to obtain a solution which may be expected to contain about 15 mg of protein in 2 ml. To 2.0 ml of that solution, in a round-bottomed centrifuge tube, add 2 ml of a 7.5 per cent solution of sodium molybdate and 2 ml of a mixture of 1 volume of nitrogen-free sulphuric acid and 30 volumes of water. Shake, centrifuge for 5 minutes decant the supernatant liquid and allow the inverted tube to drain on filter paper. Determine the nitrogen in the residue by the method of sulphuric acid digestion (2.3.30) and calculate the amount of protein by multiplying the result by 6.25.

For some products, especially those without a protein stabiliser such as albumin, this method may not be applicable. Another validated method for protein determination must therefore be performed.

**Activated coagulation factors (2.8.4).** If necessary, dilute the preparation under examination to contain 20 IU of factor IX per ml. For each of the dilutions the coagulation time is not less than 150 seconds.

**Heparin.** If heparin has been added during preparation, determine the amount by the assay of heparin in coagulation factor concentrates (2.8.10). The preparation under examination contains not more than the amount of heparin stated on the label and in any case not more than 0.5 IU of heparin per International Unit of factor IX.

**Water.** Determine by semi-micro determination of water (2.3.43), loss on drying (2.4.19) or near infrared spectrophotometry (2.4.6), the water content is within the limits approved by the competent authority.

**Sterility (2.2.11).** Complies with the test for sterility.

**Pyrogens (2.2.8).** Complies with the test for pyrogens. Inject per kg of the rabbit’s mass a volume equivalent to not less than 50 IU of factor IX.

**Assay.** Determine the assay of human blood coagulation factor IX (2.8.8).

The estimated potency is not less than 80.0 per cent and not more than 125.0 per cent of the stated potency. The confidence limits (P = 0.95) are not less than 80.0 per cent and not more than 125.0 per cent of the estimated potency.

**Storage.** Store protected from light.

**Labelling.** The label states (1) the number of International Units of factor IX per container; (2) the amount of protein per container; (3) the name and quantity of any added substances including, where applicable, heparin; (4) the name and volume of the liquid to be used for reconstitution; (5) that the transmission of infectious agents cannot be totally excluded when medicinal products prepared from human blood or plasma are administered.

**Human Coagulation Factor VII**

Human Coagulation Factor VII is a plasma protein fraction that contains the single-chain glycoprotein factor VII and may also contain small amounts of the activated form, the two-chain derivative factor VIIa. It may also contain coagulation factors II, IX and X and protein C and protein seconds. It is obtained from human plasma that complies with the monograph on Human Plasma for Fractionation.

The potency of the preparation, reconstituted as stated on the label, is not less than 15 IU of factor VII per ml.

**Production**

The method of preparation is designed to minimise activation of any coagulation factor (to minimise potential thrombogenicity) and includes a step or steps that have been shown to remove or to inactivate known agents of infection; if substances are used for inactivation of viruses during production, the subsequent purification procedure must be validated to demonstrate that the concentration of these substances is reduced to a suitable level and that any residues are such as not to compromise the safety of the preparation for patients.

The specific activity is not less than 2 IU of factor VII per mg of total protein, before the addition of any protein stabiliser.

The factor VII fraction is dissolved in a suitable liquid. Heparin, antithrombin and other auxiliary substances such as a stabiliser may be added. No antimicrobial preservative is added. The solution is passed through a bacteria-retentive filter, distributed aseptically into the final containers and immediately frozen. It is subsequently freeze-dried and the containers are closed under vacuum or under an inert gas.

**Consistency of the method**

The consistency of the method of production with respect to
the activities of factors II, IX and X of the preparation, expressed in International Units relative to the activity of factor VII, shall be demonstrated.

The consistency of the method of production with respect to the activity of factor VIIa of the preparation shall be demonstrated. The activity of factor VIIa may be determined, for example, using a recombinant soluble tissue factor that does not activate factor VII but possesses a cofactor function specific for factor VIIa; after incubation of a mixture of the recombinant soluble tissue factor with phospholipids reagent and the dilution of the test sample in factor VII-deficient plasma, calcium chloride is added and the clotting time determined; the clotting time is inversely related to the factor VIIa activity of the test sample.

**Description.** A hygroscopic powder or friable solid that may be white, pale yellow, green or blue.

Reconstitute the preparation under examination as stated on the label immediately before carrying out the Identification, Tests (except those for solubility and water) and Assay.

**Identification**

It complies with the limits of the assay.

**Tests**

**pH** (2.4.24). 6.5 to 7.5.

**Osmolality** (2.4.23). Minimum 240 mosmol per kg.

**Total protein.** If necessary, dilute an accurately measured volume of the reconstituted preparation with a 0.9 per cent solution of sodium chloride to obtain a solution expected to contain about 15 mg of protein in 2 ml. To 2.0 ml of the solution in a round-bottomed centrifuge tube add 2 ml of a 7.5 per cent solution of sodium molybdate and 2 ml of a mixture of 1 volume of nitrogen-free sulphuric acid and 30 volumes of water. Shake, centrifuge for 5 minutes, decant the supernatant liquid and allow the inverted tube to drain on filter paper. Determine the nitrogen in the residue by the method of sulphuric acid digestion (2.3.30) and calculate the amount of protein by multiplying the result by 6.25.

**Activated coagulation factors** (2.8.4). For each of the dilutions, the coagulation time is not less than 150 seconds.

**Heparin.** If heparin has been added during preparation, determine the amount present by the assay of heparin in coagulation factor concentrates (2.8.10). The preparation under examination contains not more than the amount of heparin stated on the label and in any case not more than 0.5 IU of heparin per International Unit of factor VII.

**Thrombin.** If the preparation under examination contains heparin, determine the amount present as described in the test for heparin and neutralise the heparin by addition of protamine sulphate (10 µg of protamine sulphate neutralises 1 IU of heparin). In each of 2 test-tubes, mix equal volumes of the reconstituted preparation and a 0.3 per cent solution of fibrinogen. Keep one of the tubes at 37° for 6 hours and the other at room temperature for 24 hours. In a third tube, mix a volume of the fibrinogen solution with an equal volume of a solution of human thrombin (1 IU per ml) and place the tube in a water-bath at 37°. No coagulation occurs in the tubes containing the preparation under examination. Coagulation occurs within 30 seconds in the tube containing thrombin.

**Factor II**

Determine the assay of human coagulation factor II (2.8.5).

The estimated content is not more than 125.0 per cent of the stated content. The confidence limits (P = 0.95) are not less than 90.0 per cent and not more than 111.0 per cent of the estimated potency.

**Factor IX**

Determine the assay of human coagulation factor IX (2.8.8).

The estimated content is not more than 125.0 per cent of the stated content. The confidence limits (P = 0.95) are not less than 80.0 per cent and not more than 125.0 per cent of the estimated potency.

**Factor X**

Determine the assay of human coagulation factor X (2.8.9).

The estimated content is not more than 125.0 per cent of the stated content. The confidence limits (P = 0.95) are not less than 90.0 per cent and not more than 111.0 per cent of the estimated potency.

**Water.** Determine by semi-micro determination of water (2.3.43), loss on drying (2.4.19) or near-infrared spectrophotometry (2.4.6), the water content is within the limits approved by the competent authority.

**Sterility** (2.2.11). Complies with the test for sterility.

**Pyrogens** (2.2.8). Complies with the test for pyrogens. Inject per kg of the rabbit’s mass a volume equivalent to not less than 30 IU of factor VII.

**Assay**

Determine the assay of human coagulation factor VII (2.8.6).

The estimated potency is not less than 80.0 per cent and not more than 125.0 per cent of the stated potency. The confidence limits (P = 0.95) are not less than 80.0 per cent and not more than 125.0 per cent of the estimated potency.

**Storage.** Store protected from light.

**Labelling.** The label states (1) the number of International Units of factor VII per container; (2) the maximum content of International Units of factor II, factor IX and factor X per
container; (3) the amount of protein per container; (4) the
name and quantity of any added substances, including where
applicable, heparin; (5) the name and volume of the liquid to
be used for reconstitution; (6) that the transmission of
infectious agents cannot be totally excluded when medicinal
products prepared from human blood or plasma are
administered.

Human Coagulation Factor VIII
(rDNA)

Human Coagulation Factor VIII (rDNA) is a freeze-dried
preparation of glycoproteins having the same activity as
coaulation factor VIII in human plasma. It acts as a cofactor
of the activation of factor X in the presence of factor IXa,
phospholipids and calcium ions. It circulates in plasma
mainly as a two-chain glycosylated protein with 1 heavy
(relative molecular mass of about 2,00,000) and 1 light (relative
molecular mass 80,000) chain held together by divalent metal
ions. Human coagulation factor VIII (rDNA) is prepared as
full-length factor VIII (octocog alfa), or as a shortened two-
chain structure (relative molecular mass 90,000 and 80,000), in
which the B-domain has been deleted from the heavy chain
(morocctocog alfa).

Full-length human rDNA coagulation factor VIII contains 25
potential N-glycosylation sites, 19 in the B domain of the
heavy chain, 3 in the remaining part of the heavy chain (relative
molecular mass 90,000) and 3 in the light chain (relative
molecular mass 80,000). The different products are
characterised by their molecular size and post-translational
modification and/or other modifications.

Production

Human coagulation factor VIII (rDNA) is produced by
recombinant DNA technology in mammalian cell culture. It is
produced under conditions designed to minimise microbial
contamination.

Purified bulk factor VIII (rDNA) may contain added human
albumin and/or other stabilising agents, as well as other
auxiliary substances to provide, for example, correct pH and
osmolarity.

The specific activity is not less than 2,000 IU of factor VIII:C
per mg of total protein before the addition of any protein
stabiliser, and varies depending on purity and the type of
modification of molecular structure of factor VIII.

The quality of the bulk preparation is controlled using
reference preparations.

Reference preparations

During development, reference preparations are established
for subsequent verification of batch consistency during
production, and for control of bulk and final preparation. They
are derived from representative batches of purified bulk factor
VIII (rDNA) that are extensively characterised by tests
including those described below and whose procoagulant
and other relevant functional properties have been
ascertained and compared, wherever possible, with the
International Standard for factor VIII concentrate. The
reference preparations are suitably characterised for their
intended purpose and are stored in suitably sized aliquots
under conditions ensuring their stability.

Purified bulk factor VIII (rDNA)
The purified bulk complies with a suitable combination of
the following tests for characterisation of integrity of the
factor VIII (rDNA). Where any substance added during
preparation of the purified bulk interferes with a test, the
test is carried out before addition of that substance. Where
applicable, the characterisation tests may alternatively be
carried out on the finished product.

Specific biological activity or ratio of factor VIII activity to
factor VIII antigen

Determine the assay of human coagulation factor VIII (2.8.7).
The protein content, or where a protein stabiliser is present,
the factor VIII antigen content, is determined by a suitable
method and the specific biological activity or the ratio of factor
VIII activity to factor VIII antigen is calculated.

Protein composition

The protein composition is determined by a selection of
appropriate characterisation techniques which may include
peptide mapping, Western blots, HPLC, gel electrophoresis,
capillary electrophoresis, mass spectrometry or other
techniques to monitor integrity and purity. The protein
composition is comparable to that of the reference preparation.

Molecular size. Using size-exclusion chromatography (2.4.16),
the molecular size distribution is comparable to that of the
reference preparation.

Peptide mapping (2.3.47). There is no significant difference
between the test protein and the reference preparation.

Carbohydrates/sialic acid. To monitor batch-to-batch
consistency, the monosaccharide content and the degree of
sialylation or the oligosaccharide profile are monitored and
correspond to those of the reference preparation.

Final lot

It complies with the tests under Identification, Tests and Assay.

Excipients. 80.0 per cent to 120.0 per cent of the stated content,
determined by a suitable method, where applicable.

Description. A white or slightly yellow powder or friable mass.

Identification
A. It complies with the limits of the Assay.

B. The distribution of characteristic peptide bands corresponds with that of the reference preparation (SDS-PAGE or Western blot).

Tests

Reconstitute the preparation as stated on the label immediately before carrying out the Tests (except those for solubility and water) and Assay.

pH (2.4.24). 6.5 to 7.5.

Osmolality (2.4.23). Minimum 240 mosmol per kg.

Water. Determine by semi-micro determination of water (2.3.43), loss on drying (2.4.19) or near infrared spectrophotometry (2.4.6), the water content is within the limits approved by the competent authority.

Sterility (2.2.11). Complies with the test for sterility.

Bacterial endotoxins (2.2.3). Less than 3 IU in the volume that contains 100 IU of factor VIII activity.

Assay

Determine the assay of human coagulation factor VIII (2.8.7).

The estimated potency is not less than 80.0 per cent and not more than 125.0 per cent of the stated potency. The confidence limits (P = 0.95) are not less than 80.0 per cent and not more than 120.0 per cent of the estimated potency.

Storage. Store protected from light.

Labelling. The label states (1) the factor VIII content in International Units; (2) the name and amount of any excipient; (3) the composition and volume of the liquid to be used for reconstitution.

Human Normal Immunoglobulin

Normal Immunoglobulin; Immune Human Serum Globulin; Human Gamma Globulin

Human Normal Immunoglobulin is a sterile solution or freeze-dried preparation containing immunoglobulins, mainly immunoglobulin G (IgG), together with smaller amounts of other plasma proteins.

Production

It is obtained from source materials such as the blood, plasma, serum or placenta frozen immediately after collection from healthy donors who must as far as can be ascertained after clinical examination, laboratory tests on their blood and a study of their medical history, be free from disease transmissible by transfusion of blood or blood products. The examinations and tests to be carried out are decided by the National Regulatory Authority; in particular, tests for hepatitis B surface antigen, HCV antibodies and for HIV antibodies must be carried out by suitable sensitive methods and must show negative results in both cases. Plasma, serum or placenta obtained from donors who do not meet all the requirements stated above may be used as source material provided that it has been demonstrated to the national authority that process of fractionation and production removes any known agent capable of adversely affecting the health of subjects treated with the preparation. No antibiotic is added to the source materials used for the preparation of immunoglobulin.

It is prepared from pooled material of a minimum volume of 25 litres by a method which has been shown (a) to be capable of concentrating tenfold from source material at least two different antibodies, one viral and one bacterial, for which an International Standard or Reference Preparation is available; (b) not to affect the integrity of the globulins; (c) to consistently yield a product which is safe for intramuscular injection and; (d) to yield a product that does not transmit viral hepatitis or any other infection.

The liquid preparation is prepared as a stabilised solution in saline solution or a 2.25 per cent w/v solution of glycine or other suitable agent and is sterilised by filtration and distributed into previously sterilised containers which are then sealed so as to exclude micro-organisms. An antimicrobial preservative may be added except when the preparation is to be freeze-dried. Any antimicrobial preservative or stabilising agent added must be such that neither deleterious effect on the final product in the amounts present nor capability to cause untoward reactions in human beings is demonstrated.

An accelerated degradation test is carried out on the final liquid or freeze-dried preparation by heating at 37° for 4 weeks. The difference between the percentages of protein eluted in the fractions following the main peak as determined by size-exclusion chromatography (2.4.16), before and after exposure at 37° does not exceed 5.0 per cent.

Human Normal Immunoglobulin contains not less than 90.0 per cent and not more than 110.0 per cent of the quantity of protein stated on the label and in any case, not less than 10.0 per cent w/v and not more than 18.0 per cent w/v of protein.

Description. The liquid preparation is clear pale yellow or brownish in colour; on storage it may show turbidity or a small amount of particulate matter. The freeze-dried preparation is a white to slightly yellow powder or solid, friable mass.

Identification

A. Precipitation tests with a suitable range of species-specific antisera which give positive results for the presence of proteins of human origin and negative results with antisera specific to plasma proteins of the other species.

B. Examine by electrophoresis (2.4.12), using the moving boundary technique and a 1.0 per cent w/v solution in barbitone buffer solution pH 8.6 of ionic strength 0.1. At
least 90.0 per cent w/v of the protein has a mobility not greater than \(-2.8 \times 10^{-5} \text{ cm}^2\text{V}^{-1}\text{S}^{-1}\).

**Tests**

**pH** (2.4.24). 6.4 to 7.2, determined in a solution prepared by dilution of a quantity with saline solution so as to contain 1.0 per cent w/v of protein.

**Protein composition.** Determine by cellulose acetate electrophoresis (2.4.12), but applying an electric field such that the albumin band of normal human serum applied in a control strip migrates at least 30 mm and using one strip of cellulose acetate for each of the following solutions:

*Test solution.* Dilute the preparation under examination with saline solution to produce a solution containing 5 per cent w/v of protein.

*Reference solution.* Reconstitute human immunoglobulin for electrophoresis RS with saline solution to produce a solution containing 5 per cent w/v of protein.

Calculate the result as the mean of three measurements of the absorbance of each strip. In the electrophoretogram obtained with test solution not more than 10.0 per cent of the protein is contained in bands other than the principal band. The test is not valid unless the proportion of protein in the principal band in the electrophoretogram obtained with reference solution is within the limits stated in the leaflet supplied with human immunoglobulin for electrophoresis RS.

**Molecular size.** Determine by size-exclusion chromatography (2.4.16), applying 2 ml of the preparation under examination diluted with mixed phosphate buffer pH 7.0 with azide to produce a solution containing 4.0 to 5.0 per cent w/v of protein.

**Chromatographic system**

- a column 1 m x 25 mm packed with agarose trapped within a cross-linked polyacrylamide network and having a linear fraction range suitable for fractionation of globular proteins in the range of molecular weights from 20,000 to 350,000,
- mobile phase: mixed phosphate buffer pH 7.0 with azide,
- flow rate 20 ml per hour (4 ml per cm² of column cross-sectional area),
- spectrophotometer set at 280 nm.

Collect the eluate in fractions of about 4 ml. Examine the chromatogram in comparison with that in Fig.1. The sum of the areas of the peaks containing IgG monomer, dimer, albumin and other proteins of similar molecular size (area B) is not less than 85.0 per cent of the total area of the chromatogram. Not more than 10.0 per cent of the total area of the chromatogram represents proteins eluted ahead of IgG monomer and albumin (area C).

![Fig.1 Typical Chromatogram for Human Normal Immunoglobulin](image)

**Stability.** Heat approximately 2 ml at 57°C for 4 hours in a stoppered glass tube (75 mm x 12 mm); no gelation or flocculation occurs.

**Pyrogens** (2.2.8). Complies with the test for pyrogens, using 1 ml of the preparation under examination per kg of the rabbit’s weight.

**Sterility** (2.2.11). Complies with the tests for sterility.

**Abnormal toxicity** (2.2.1). Complies with the test for abnormal toxicity, Method A, injecting 0.5 ml into each mouse and 5 ml into each guinea-pig.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Dilute a suitable volume with water to produce a solution containing 1.0 per cent w/v of protein. Take 1.5 ml of the dilution in a round-bottomed centrifuge tube. Add 5 ml of water, mix, add 0.2 ml of 7.5 per cent w/v solution of sodium molybdate and 2 ml of a mixture consisting of 1 volume nitrogen free sulphuric acid and 30 volumes of water. Shake, centrifuge for five minutes, decant the supernatant liquid and allow the inverted tube to drain on filter paper. To the residue in the tube add three drops of a 30 per cent w/v solution of copper sulphate and 1 ml of nitrogen-free sulphuric acid and boil gently for 10 minutes; cool, add 1 g of anhydrous sodium sulphate and 10 mg of selenium, boil gently for 1 hour and cool. Transfer to an ammonia distillation apparatus, add 6 ml of a saturated solution of sodium hydroxide and pass steam through the flask; distil for seven minutes, collecting the distillate in a mixture of 5 ml of a saturated solution of boric acid, 5 ml of water, and 1 drop saturated solution of...
methyl red in alcohol containing 0.1 per cent of methylene blue, and titrate with 0.02 M hydrochloric acid.

1ml of 0.02 M hydrochloric acid is equivalent to 0.00175 g of protein.

Freeze-dried Human Normal Immunoglobulin complies with the following additional requirements.

**Solubility rate.** Add the volume of the liquid stated on the label and allow it to stand for 15 minutes at a temperature of 20° to 25°; it dissolves completely.

**Loss on drying** (2.4.19). Not more than 2.0 per cent, determined on 0.5 g, by drying over phosphorus pentoxide at a pressure not exceeding 3 Pa for 24 hours.

Human Normal Immunoglobulin intended for use in the prevention of infective hepatitis (hepatitis A) complies with the following additional requirement.

**Anti-hepatitis A activity.** Determine the anti-hepatitis A activity by comparison with the activity of the Standard preparation, using an immunoassay of suitable sensitivity and specificity. The stated potency is not less than 100 Units per ml. The estimated potency is not less than the stated potency. The fiducial limits of error are not less than 80.0 per cent and not more than 125.0 per cent.

**Standard Preparation.** The Standard Preparation is the 1st International Reference Preparation for Hepatitis A immunoglobulin, established in 1981, consisting of freeze-dried material derived from fractionated plasma (supplied in ampoules containing 100 Units), or another suitable preparation the antigen binding of which has been determined in relation to the International Reference Preparation.

**Storage.** Store protected from light, the liquid preparation in sealed, colourless, glass containers, at a temperature between 2° and 8°. Store the freeze-dried preparation under vacuum or under an inert gas.

**Labelling.** The label states (1) the volume and the protein concentration expressed in g per litre or, for freeze-dried preparations, the total amount of protein in the container; (2) the type of source material; (3) the name and quantity of any added preservative or stabilising agent; (4) the recommended human dose; (5) that it is meant for intramuscular injection only; (6) the storage conditions.

**Human Plasma Protein Fraction**

Plasma Protein Solution; Human Albumin Fraction (Saline); Plasma Protein Fraction; PPF

Human Plasma Protein Fraction is a sterile isotonic aqueous solution of proteins of plasma or serum containing albumin and globulins. It is prepared as an isotonic solution containing 4.0 to 5.0 per cent w/v of total protein. It contains no fibrinogen or antibodies.

**Production**

The plasma or serum is obtained from healthy human donors who must, after clinical examination, laboratory tests on their blood and a study of their medical history, be free from detectable agents of infection transmissible by transfusion of blood or blood derivatives. The examinations and tests to be carried out are decided by the National Regulatory Authority; in particular tests for hepatitis B surface antigen and for HIV antibodies are carried out by suitable sensitive methods and must give negative results in both cases. Other disease-causing agents that are not destroyed or removed by the processing method must not be present. Plasma or serum obtained from donors who do not meet all the stated requirements may be used as source material provided that it has been demonstrated to the national authority that the process of fractionation will remove any known agent capable of adversely affecting the health of recipients of the Human Plasma Protein Fraction.

The separation of the protein may be done by precipitation with suitable organic solvents under controlled conditions, particularly of pH, ionic strength and temperature, so that in the final product not less than 85.0 per cent of the total protein is albumin. Residual solvent, if present, may be removed by freeze-drying or other suitable treatment. Alternative methods of preparation which shall not affect the integrity of the product and shall have been shown to yield consistently a product which is safe for intravenous injection may be adopted.

The product is dissolved in water and sufficient quantities of a suitable stabiliser against the effect of heat, like sodium caprylate in a suitable concentration, and sufficient sodium chloride to adjust the sodium ions to between 130 and 160 millimoles per litre may be added but no antibiotic or antimicrobial preservative is added at any stage during preparation. The solution is sterilised by filtration through a bacteria-retentive filter and distributed aseptically into sterile containers which are then closed so as to prevent microbial contamination. The solution in its final container is heated at 60° ± 0.5° and maintained at this temperature for 10 hours. The containers are then incubated at 30° to 32° for not less than 14 days or at 20° to 25° for not less than 4 weeks and examined visually for evidence of microbial contamination. Those showing abnormalities such as abnormal colour, turbidity, presence of atypical particles or microbial contamination are discarded.

Human Plasma Protein Fraction contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of total protein.

**Description.** A clear, almost colourless or pale yellow liquid; almost odourless. On storage a dust-like precipitate may develop but it disappears on shaking.

**Identification**

A. Precipitation tests with specific antisera show that the preparation consists only of plasma proteins of human origin only and gives negative results with antisera specific to plasma...
proteins of other species.

B. Examine by a suitable immunoelectrophoresis technique. Using antiserum to normal human serum, compare normal human serum and the preparation under examination, both diluted to contain 1.0 per cent w/v of protein. The main component of the preparation under examination corresponds to the main component of the normal human serum. The solution may show the presence of small quantities of other plasma proteins.

Tests

pH (2.4.24). 6.7 to 7.3, determined in a solution prepared by diluting with sufficient of saline solution to produce a solution containing 1.0 per cent w/v of protein.

Polymers and aggregates. Determine by size-exclusion chromatography (2.4.16), applying 2 ml of the preparation under examination.

Chromatographic system

- a column 1 m x 25 mm packed with a cross-linked dextran suitable for fractionation of globular proteins in the range of molecular weights from 5,000 to 3,50,000 (such as Sephadex G-150),
- mobile phase. mixed phosphate buffer pH 7.0 with azide,
- flow rate 20 ml per hour (4 ml per square centimeter of column cross-sectional area),
- spectrophotometer set at 280 nm.

Collect the eluate in fractions of about 4 ml and combine the fractions corresponding to each peak. For each combined fraction, determine by Method E for determination of nitrogen (2.3.30).

1 ml of 0.02M hydrochloric acid is equivalent to 0.00028 g of nitrogen. Not more than 10.0 per cent of the total nitrogen is present in the combined fraction associated with non-retained proteins.

Protein composition. Carry out by cellulose acetate electrophoresis (2.4.12), Method II using one strip for each solution.

Test solution. Dilute the preparation under examination with saline solution to obtain a solution containing 2.0 per cent w/v of protein.

Reference solution. Dilute human plasma protein fraction for electrophoresis RS with saline solution to obtain a solution containing 2.0 per cent w/v of protein.

Calculate the result as the mean of three measurements of the absorbance of each of the 10 strips. In the electrophoretogram obtained with test solution not more than 15.0 per cent of the protein is contained in bands other than the principal band. The test is not valid unless the proportion of protein in the principal band in the electrophoretogram obtained with reference solution is within the limits stated in the leaflet supplied with human plasma protein fraction for electrophoresis RS.

Sodium. Not less than 95.0 per cent and not more than 105.0 per cent of the stated amount and, in any case not more than 160 millimoles of Na per litre, determined by Method A for atomic absorption spectrophotometry (2.4.2), measuring at 589 nm and using sodium solution AAS suitably diluted with water to prepare the standard solutions.

Potassium. Not more than 50 µmol of K per g of protein, determined by atomic absorption spectrophotometry (2.4.2), measuring at 766 nm and using potassium solution AAS, suitably diluted with water to prepare the standard solutions.

Alkaline phosphatase. Not more than 0.1 Unit per g of protein, determined by the following method. Transfer a mixture of 0.5 ml of the substance under examination and 0.5 ml of diethanolamine buffer pH 10.0 to a spectrophotometer cell maintained at a temperature of 37°C ± 0.2°C and add 0.1 ml of nitrophenyl phosphate solution. Record the absorbance of the solution at about 405 nm (2.4.7), over a period of at least 30 seconds from the time of addition of the nitrophenyl phosphate solution. Calculate the alkaline phosphatase activity at 37°C in Units per g of protein from the expression 118.3x/P, where x is the rate of increase of absorbance per minute and P is the content of total protein in g per litre, as determined in the Assay.

Haem content. Dilute with sufficient saline solution to produce a solution containing 1.0 per cent w/v of protein; absorbance of the resulting solution at about 403 nm, not more than 0.15 (2.4.7).

Sterility (2.2.11). Complies with the tests for sterility.

Abnormal toxicity (2.2.1). Complies with the test for abnormal toxicity, using Method B and 0.5 ml of the solution for each mouse and 5 ml for each guinea-pig irrespective of the protein content.

Pyrogens (2.2.8). Complies with the test for pyrogens, using 3 ml per kg of the rabbit’s weight in rabbits that have not previously received blood products.

Assay

For protein. Dilute to about 0.75 per cent w/v of total protein with saline solution. Take 2 ml of this solution in a round-bottomed centrifuge tube, add 2 ml of a 7.5 per cent w/v solution of sodium molybdate and 2 ml of a mixture of 30 volumes of water and 1 volume of nitrogen-free sulphuric acid. Shake, centrifuge for 5 minutes, decant the supernatant liquid and let the inverted tube stand on a filter paper to drain the fluid. Carry out Method E for determination of nitrogen (2.3.30), on the residue thus obtained and multiply the result by 6.25 to obtain the protein content.

Storage. Store protected from light at a temperature between 2°C and 25°C.

Labelling. The label states (1) the volume in the container; (2) the total amount of protein in the container expressed as a percentage or in grams per litre; (3) the concentration of sodium
ions in millimoles per litre; (4) the names and concentrations of stabilising agents and of any other added substances present in the final solution; (5) that the solution should not be used if the solution is cloudy or shows a deposit which does not disappear on shaking; (6) that, once the container has been penetrated, the contents must be used within 4 hours and any unused solution discarded; (7) the storage conditions.

Human Prothrombin Complex

Human Prothrombin Complex is a plasma protein fraction containing blood coagulation factor IX together with variable amounts of coagulation factors II, VII and X; the presence and proportion of these additional factors depends on the method of fractionation. It is obtained from human plasma that complies with the monograph on Human Plasma for Fractionation. The potency of the preparation, reconstituted as stated on the label, is not less than 20 IU of factor IX per ml.

Production

The method of preparation is designed to minimise activation of any coagulation factor (to minimise potential thrombogenicity) and includes a step or steps that have been shown to remove or to inactivate known agents of infection; if substances are used for inactivation of viruses during production, the subsequent purification procedure must be validated to demonstrate that the concentration of these substances is reduced to a suitable level and that any residues are such as not to compromise the safety of the preparation for patients.

The specific activity is not less than 0.6 IU of factor IX per mg of total protein, before the addition of any protein stabiliser. The prothrombin complex fraction is dissolved in a suitable liquid. Heparin, antithrombin and other auxiliary substances such as a stabiliser may be added. No antimicrobial preservative is added. The solution is passed through a bacteria-retentive filter, distributed aseptically into the final containers and immediately frozen. It is subsequently freeze-dried and the containers are closed under vacuum or under an inert gas.

Description. A white or slightly coloured powder or friable solid, very hygroscopic.

Reconstitute the preparation under examination as stated on the label immediately before carrying out the Identification, Tests (except those for solubility and water) and Assay.

Identification

It complies with the limits of the assay for coagulation factor IX activity and, where applicable, those for factors II, VII and X.

Tests

pH (2.4.24). 6.5 to 7.5.

Osmolality (2.4.23). Minimum 240 mosmol per kg.

Total protein. If necessary, dilute an accurately measured volume of the reconstituted preparation with a 0.9 per cent w/v solution of sodium chloride to obtain a solution expected to contain about 15 mg of protein in 2 ml. To 2.0 ml of the solution in a round-bottomed centrifuge tube add 2 ml of a 7.5 per cent w/v solution of sodium molybdate and 2 ml of a mixture of 1 volume of nitrogen-free sulphuric acid and 30 volumes of water. Shake, centrifuge for 5 minutes, decant the supernatant liquid and allow the inverted tube to drain on filter paper. Determine the nitrogen in the residue by the method of sulphuric acid digestion (2.3.30) and calculate the amount of protein by multiplying the result by 6.25.

Activated coagulation factors (2.8.4). If necessary, dilute the preparation under examination to contain 20 IU of factor IX per ml. For each of the dilutions, the coagulation time is not less than 150 seconds.

Heparin. If heparin has been added during preparation, determine the amount present by the assay of heparin in coagulation factor concentrates (2.8.10). The preparation under examination contains not more than the amount of heparin stated on the label and in any case not more than 0.5 IU of heparin per International Unit of factor IX.

Thrombin. If the preparation under examination contains heparin, determine the amount present as described in the test for heparin and neutralise it by addition of protamine sulphate (10 µg of protamine sulphate neutralises 1 IU of heparin). In each of 2 test-tubes, mix equal volumes of the reconstituted preparation and a 0.3 per cent w/v solution of fibrinogen. Keep one of the tubes at 37° for 6 hours and the other at room temperature for 24 hours. In a third tube, mix a volume of the fibrinogen solution with an equal volume of a solution of human thrombin (1 IU/ml) and place the tube in a water-bath at 37°. No coagulation occurs in the tubes containing the preparation under examination. Coagulation occurs within 30 seconds in the tube containing thrombin.

Water. Determine by semi-micro determination of water (2.3.43), loss on drying (2.4.19) or near-infrared spectrometry (2.4.6), the water content is within the limits approved by the competent authority.

Sterility (2.2.11). Complies with the test for sterility.

Pyrogens (2.2.8). Complies with the test for pyrogens. Inject per kg of the rabbit’s mass a volume of the reconstituted preparation equivalent to not less than 30 IU of factor IX.

Assay

Factor IX

Determine the assay of human coagulation factor IX (2.8.8). The estimated potency is not less than 80.0 per cent and not
more than 125.0 per cent of the stated potency. The confidence interval (P = 0.95) of the estimated potency is not greater than 80.0 per cent to 125.0 per cent.

**Factor II**

Determine the assay of human coagulation factor II (2.8.5).
The estimated potency is not less than 80.0 per cent and not more than 125.0 per cent of the stated potency. The confidence interval (P = 0.95) of the estimated potency is not greater than 90.0 per cent to 111.0 per cent.

**Factor VII**

If the label states that the preparation contains factor VII, Determine the assay of human coagulation factor VII (2.8.6).
The estimated potency is not less than 80.0 per cent and not more than 125.0 per cent of the stated potency. The confidence interval (P = 0.95) of the estimated potency is not greater than 80.0 per cent to 125.0 per cent.

**Factor X**

Determine the assay of human coagulation factor X (2.8.9).
The estimated potency is not less than 80.0 per cent and not more than 125.0 per cent of the stated potency. The confidence interval (P = 0.95) of the estimated potency is not greater than 90.0 per cent to 111.0 per cent.

**Storage.** Store protected from light.

**Labelling.** The label states (1) the number of International Units of factor IX, factor II and factor X per container; (2) where applicable, the number of International Units of factor VII per container; (3) where applicable, that the preparation contains protein C and/or protein S; (4) the amount of protein per container; (5) the name and quantity of any added substances, including where applicable, heparin; (6) the name and quantity of the liquid to be used for reconstitution; (7) that the transmission of infectious agents cannot be totally excluded when medicinal products prepared from human blood or plasma are administered.

**Normal Immunoglobulin for Intravenous Use**

Human Normal Immunoglobulin for Intravenous Administration

Human Normal Immunoglobulin for Intravenous Administration is a liquid or freeze-dried preparation containing immunoglobulins, mainly immunoglobulin G (IgG). Other proteins may be present. Human normal immunoglobulin for intravenous administration contains the IgG antibodies of normal subjects. This monograph does not apply to products intentionally prepared to contain fragments or chemically modified IgG.

Human normal immunoglobulin for intravenous administration is obtained from plasma that complies with the requirements of the monograph on Human plasma for fractionation. No antibiotic is added to the plasma used.

**Production**

The method of preparation includes a step or steps that have been shown to remove or to inactivate known agents of infection; if substances are used for inactivation of viruses, it shall have been shown that any residues present in the final product have no adverse effects on the patients treated with the immunoglobulin.

The product shall have been shown, by suitable tests in animals and evaluation during clinical trials, to be well tolerated when administered intravenously.

Human normal immunoglobulin for intravenous administration is prepared from pooled material from not fewer than 1,000 donors by a method that has been shown to yield a product that (a) does not transmit infection; (b) at an immunoglobulin concentration of 50 g per litre, contains antibodies for at least 2 of which (one viral and one bacterial) an International Standard or Reference Preparation is available, the concentration of such antibodies being at least 3 times that in the initial pooled material; (c) has a defined distribution of immunoglobulin G subclasses; (d) complies with the test for Fc function of immunoglobulin.

**Test for Fc function of immunoglobulin**

**Stabilised human blood.** Collect group O human red blood into ACD anticoagulant solution. Store the stabilised blood at 4° for not more than 3 weeks.

**Phosphate buffered saline pH 7.2.** Dissolve 1.022 g of anhydrous disodium hydrogen phosphate, 0.336 g of anhydrous sodium dihydrogen phosphate and 8.766 g of sodium chloride in 800 ml of water and dilute to 1,000 ml with the same solvent.

**Magnesium and calcium stock solution.** Dissolve 1.103 g of calcium chloride and 5.083 g of magnesium chloride in water and dilute to 25 ml with the same solvent.

**Barbital buffer stock solution.** Dissolve 207.5 g of sodium chloride and 25.48 g of barbital sodium in 4,000 ml of water and adjust to pH 7.3 using 1 M hydrochloric acid. Add 12.5 ml of magnesium and calcium stock solution and dilute to 5,000 ml with water. Filter through a membrane filter (pore size 0.22 µm). Store at 4° in glass containers.

**Albumin barbital buffer solution.** Dissolve 0.150 g of bovine albumin in 20 ml of barbital buffer stock solution and dilute to 100 ml with water.

**Tannic acid solution.** Dissolve 10 mg of tannic acid in 100 ml of phosphate-buffered saline pH 7.2. Prepare immediately before use.

**Guinea-pig complement.** Prepare a pool of serum from the blood of not fewer than 10 guinea-pigs. Separate the serum
from the clotted blood by centrifugation at about 4°. Store the serum in small amounts below -70°. Immediately before starting complement-initiated haemolysis, dilute to 125 to 200 CH₅₀ per ml with albumin barbital buffer solution and store in an ice-bath during the test.

Rubella antigen. Suitable rubella antigen for haemagglutination-inhibition titre (HIT). Titre > 256 HA units.

Preparation of tanned human red blood cells. Separate human red blood cells by centrifuging an appropriate volume of stabilised human blood and wash the cells at least 3 times with phosphate-buffered saline pH 7.2 and suspend at 2 per cent v/v in phosphate-buffered saline pH 7.2. Dilute 0.1 ml of tannic acid solution to 7.5 ml with phosphate-buffered saline pH 7.2 (final concentration 1.3 mg per litre). Mix 1 volume of the freshly prepared dilution with 1 volume of human red blood cell suspension and incubate at 37° for 10 minutes. Collect the cells by centrifugation (400 to 800 g for 10 minutes), discard the supernatant and wash the cells once with phosphate-buffered saline pH 7.2. Resuspend the tanned cells at 1.0 per cent v/v in phosphate-buffered saline pH 7.2.

Antigen coating of tanned human red blood cells. Take a suitable volume (\( V_s \)) of tanned cells, add 0.2 ml of rubella antigen per 1.0 ml of tanned cells and incubate at 37° for 30 minutes. Collect the cells by centrifugation (400 to 800 g for 10 minutes) and discard the supernatant, leaving a volume of 200 µl. Add a volume of albumin barbital buffer solution equivalent to the discarded supernatant, resuspend and collect the cells as described and repeat the washing procedure. Make up the remaining 200 µl to three-quarters of \( V_s \), thereby obtaining the initial volume (\( V_i \)). Mix 900 µl of albumin barbital buffer solution with 100 µl of \( V_i \), which is thereby reduced to the residual volume (\( V_s \)), and determine the initial absorbance at 541 nm (\( A_i \)). Dilute \( V_i \) by a factor equal to \( A \) using albumin barbital buffer solution, thereby obtaining the final adjusted volume \( V' = V_i \times A \) of sensitised human red blood cells and adjusting \( A \) to 1.0 ± 0.1 for a tenfold dilution.

Antibody binding of antigen-coated tanned human red blood cells. Prepare the following solutions in succession and in duplicate, using for each solution a separate half-micro cuvette (for example, disposable type) or test-tube:

* **Test solutions.** If necessary, adjust the immunoglobulin under examination to pH 7, for example by addition of 1 M sodium hydroxide. Dilute volumes of the preparation under examination containing 30 mg and 40 mg of immunoglobulin with albumin barbital buffer solution and adjust the volume to 900 µl.

* **Reference solutions.** Prepare as for the test solutions using human immunoglobulin RS.

* **Complement control.** 900 µl of albumin barbital buffer solution.

Add to each cuvette/test-tube 100 µl of sensitised human red blood cells and mix well.

Incubate at room temperature for 15 minutes, add 1,000 µl of albumin barbital buffer solution, collect the cells by centrifugation (1,000 g for 10 min) of the cuvette/test-tube and remove 1,900 µl of the supernatant. Replace the 1,900 µl with albumin barbital buffer solution and repeat the whole of the washing procedure, finally leaving a volume of 200 µl. Test samples may be stored in sealed cuvette/test-tubes at 4° for 24 hours.

Complement-initiated haemolysis. To measure haemolysis, add 600 µl of albumin barbital buffer solution warmed to 37° to the test sample, re-suspend the cells carefully by repeated pipetting (not fewer than 5 times) and place the cuvette in the thermostatted cuvette holder of a spectrophotometer. After 2 minutes, add 200 µl of diluted guinea-pig complement (125 to 200 CH₅₀/ml), mix thoroughly by pipetting twice and start immediately after the second pipetting the time-dependent recording of absorbance at 541 nm, using albumin barbital buffer solution as the compensation liquid. Stop the measurement if absorbance as a function of time has clearly passed the inflexion point.

Evaluation. Determine the slope (S) of the haemolysis curve at the approximate inflexion point by segmenting the steepest section in suitable time intervals \( \Delta t \) (for example, \( \Delta t = 1 \) minute) and calculate \( S \) between adjacent intersection points, expressed as \( \Delta A \) per minute. The largest value for \( S \) serves as \( S' \). In addition, determine the absorbance at the start of measurement (\( A \)) by extrapolating the curve, which is almost linear and parallel to the time axis within the first few minutes. Correct (\( S' \)) using the expression:

\[
S' = \frac{S'_{\exp}}{A_S}
\]

Calculate the arithmetic mean of the values of \( S' \) for each preparation. Calculate the index of Fc function (\( I_{Fc} \)) from the expression:

\[
I_{Fc} = \frac{100 \times (S' - S'_{c})}{S' - S'_{s}}
\]

\( S' = \) arithmetic mean of the corrected slope for the preparation under examination,

\( S'_{s} = \) arithmetic mean of the corrected slope for the reference preparation,

\( S'_{c} = \) arithmetic mean of the corrected slope for the complement control.

Calculate the index of Fc function for the preparation under examination; the value is not less than that stated in the leaflet accompanying the reference preparation.

Human normal immunoglobulin for intravenous administration is prepared as a stabilised solution or as a freeze-dried...
preparation. A stabiliser may be added. In both cases the preparation is passed through a bacteria-retentive filter. The preparation may subsequently be freeze-dried and the containers closed under vacuum or under an inert gas. No antimicrobial preservative is added either during fractionation or at the stage of the final bulk solution.

The stability of the preparation is demonstrated by suitable tests carried out during development studies.

**Description.** The liquid preparation is clear or slightly opalescent and colourless or pale yellow. The freeze-dried preparation is a hygroscopic, white or slightly yellow powder or solid friable mass.

For the freeze-dried preparation, reconstitute as stated on the label immediately before carrying out the identification and the tests, except those for solubility and water.

**Identification**

Examine by a suitable immunoelectrophoresis technique. Using antisera to normal human serum, compare normal human serum and the preparation under examination, both diluted to contain 1.0 per cent w/v of protein. The main component of the preparation under examination corresponds to the IgG component of normal human serum. The preparation under examination may show the presence of small quantities of other plasma proteins; if human albumin has been added as a stabiliser, it may be seen as a major component.

**Tests**

**pH** (2.4.24). 4.0 to 7.4.

Dilute the preparation under examination with a 0.9 per cent solution of sodium chloride to obtain a solution containing 1.0 per cent of protein.

**Osmolality** (2.4.23). Minimum 240 mosmol per kg.

**Total protein.** Minimum 3.0 per cent w/v and between 90.0 to 110.0 per cent of the quantity of protein stated on the label.

Dilute the preparation under examination with a 0.9 per cent solution of sodium chloride to obtain a solution containing about 15 mg of protein in 2 ml. To 2.0 ml of this solution add 2 ml of 0.75 per cent w/v solution of sodium molybdate and 2 ml of a mixture of 1 volume of nitrogen-free sulphuric acid and 30 volumes of water. Shake, centrifuge for 5 minutes, decant the supernatant liquid and allow the inverted tube to drain on filter paper. Determine the nitrogen in the centrifugation residue by the method of sulphuric acid digestion (2.3.30) and calculate the content of protein by multiplying the result by 6.25.

**Protein composition.** Determine by zone electrophoresis (2.4.12).

Use strips of suitable cellulose acetate gel as the supporting medium and barbital buffer solution pH 8.6 as the electrolyte solution.

**Test solution.** Dilute the preparation under examination with a 0.9 per cent w/v solution of sodium chloride to an immunoglobulin concentration of 3.0 per cent w/v.

**Reference solution.** Reconstitute human immunoglobulin for electrophoresis reference preparation and dilute with a 0.9 per cent w/v solution of sodium chloride to a protein concentration of 3.0 per cent w/v.

To a strip apply 4 µl of the test solution as a 10 mm band or apply 0.4 µl per mm if a narrower strip is used. To another strip apply in the same manner the same volume of the reference solution. Apply a suitable electric field such that the albumin band of normal human serum applied on a control strip migrates at least 30 mm. Stain the strips with amido black 10B solution for 5 minutes. Decolourise with a mixture of 10 volumes of glacial acetic acid and 90 volumes of methanol so that the background is just free of colour. Develop the transparency of the strips with a mixture of 19 volumes of glacial acetic acid and 81 volumes of methanol. Measure the absorbance of the bands at 600 nm in an instrument having a linear response over the range of measurement. Calculate the result as the mean of 3 measurements of each strip.

**System suitability.** In the electropherogram obtained with the reference preparation, the proportion of protein in the principal band is within the limits stated in the leaflet accompanying the reference preparation.

**Results.** In the electropherogram obtained with the test solution, not more than 5.0 per cent of protein has a mobility different from that of the principal band. This limit is not applicable if albumin has been added to the preparation as a stabiliser; for such preparations, a test for protein composition is carried out during manufacture before addition of the stabiliser.

**Molecular size.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dilute the preparation under examination with a 0.9 per cent w/v solution of sodium chloride to obtain a concentration in the range of 0.4 to 1.2 per cent w/v and injection of 50 to 600 µg of protein are usually suitable.

**Reference solution.** Dilute human immunoglobulin RS with a 0.9 per cent w/v solution of sodium chloride to the same protein concentration as the test solution.

**Chromatographic system**

- a stainless steel column 60 cm x 7.5 mm or 30 cm x 7.8 mm packed with hydrophilic silica gel,
- mobile phase. dissolve 4.873 g of disodium hydrogen phosphate dihydrate, 1.741 g of sodium dihydrogen phosphate monohydrate, 11.688 g of sodium chloride and 50 mg of sodium azide in 1000 ml of water.
- flow rate 0.5 ml per minute,
- spectrophotometer set at 280 nm.

In the chromatogram obtained with the reference solution, the principal peak corresponds to IgG monomer and there is a peak corresponding to dimer with a relative retention to the principal peak of about 0.85. Identify the peaks in the chromatogram obtained with the test solution by comparison.
with the chromatogram obtained with the reference solution; any peak with a retention time shorter than that of dimer corresponds to polymers and aggregates.

Results. In the chromatogram obtained with the test solution:

a. relative retention: for monomer and dimer, the relative retention to the corresponding peak in the chromatogram obtained with the reference solution is 1 ± 0.2;

b. peak area: the sum of the peak areas of monomer and dimer represent not less than 90.0 per cent of the total area of the chromatogram and the sum of the peak areas of polymers and aggregates represents not more than 3.0 per cent of the total area of the chromatogram. This requirement does not apply to products where albumin has been added as a stabiliser; for products stabilised with albumin, a test for distribution of molecular size is carried out during manufacture before addition of the stabiliser.

Anticomplementary activity. The consumption of complement is not greater than 50.0 per cent (1 CH50/mg of immunoglobulin).

Test for anticomplementary activity of immunoglobulin

For the measurement of anticomplementary activity (ACA) of immunoglobulin, a defined amount of test material (10 mg of immunoglobulin) is incubated with a defined amount of guinea-pig complement (20 CH50) and the remaining complement is titrated; the anticomplementary activity is expressed as the percentage consumption of complement relative to the complement control considered as 100.0 per cent.

The haemolytic unit of complement activity (CH50) is the amount of complement that, in the given reaction conditions, will produce the lysis of 2.5 × 10^8 out of a total of 5 × 10^8 optimally sensitised red blood cells.

Magnesium and calcium stock solution. Prepare as stated earlier.

Barbital buffer stock solution. Prepare as stated earlier.

Gelatin solution. Dissolve 12.5 g of gelatin in about 800 ml of water and heat to boiling in a water-bath. Cool to 20° and dilute to 10 litres with water. Filter through a membrane filter (pore size: 0.22 μm). Store at 4°. Use clear solutions only.

Citrate solution. Dissolve 8.0 g of sodium citrate, 4.2 g of sodium chloride and 20.5 g of glucose in 750 ml of water. Adjust to pH 6.1 using a 10.0 per cent w/v solution of citric acid and dilute to 1,000 ml with water.

Gelatin barbital buffer solution. Add 4 volumes of gelatin solution to 1 volume of barbital buffer stock solution and mix. Adjust to pH 7.3, if necessary, using 1 M sodium hydroxide or 1 M hydrochloric acid. Maintain at 4°. Prepare fresh solutions daily.

Stabilised sheep blood. Collect one volume of sheep blood into one volume of citrate solution and mix. Store at 4° for not less than 7 days and not more than 28 days. (Stabilised sheep blood and sheep red blood cells are available from a number of commercial sources.)

Haemolysin. Antiserum against sheep red blood cells prepared in rabbits.

Guinea-pig complement. Prepare a pool of serum from the blood of not fewer than ten guinea-pigs. Separate the serum from the clotted blood by centrifugation at about 4°. Store the serum in small amounts below -70°.

Method

Preparation of standardised 5 per cent sheep red blood cell suspension. Separate sheep red blood cells by centrifuging an appropriate volume of stabilised sheep blood and wash the cells at least three times with gelatin barbital buffer solution and prepare as a 5.0 per cent v/v suspension in the same solution. Measure the cell density of the suspension as follows: add 0.2 to 2.8 ml of water and centrifuge the lysed solution for 5 minutes at 1,000 g; the cell density is suitable if the absorbance (2.4.7) of the supernatant liquid at 541 nm is 0.62 ± 0.01. Correct the cell density by adding gelatin barbital buffer solution according to the formula:

\[ V \times A \]

\[ V_f \]

\[ V_f = \frac{V_i}{0.62} \]

\[ V_f = \text{final adjusted volume}, \]

\[ V_i = \text{initial volume}, \]

\[ A = \text{absorbance of the original suspension at 541 nm}. \]

The adjusted suspension contains about 1 × 10^9 cells per ml.

Haemolysin titration

Prepare haemolysin dilutions as shown in Table 1.

Add 1.0 ml of 5.0 per cent sheep red blood cell suspension to each tube of the haemolysin dilution series, starting at the 1:75 dilution, and mix. Incubate at 37° for 30 minutes.

Transfer 0.2 ml of each of these incubated mixtures to new tubes and add 1.1 ml of gelatin barbital buffer solution and 0.2 ml of diluted guinea-pig complement (for example, 1:150). Perform this in duplicate.

As the unhaemolysed cell control, prepare three tubes with 1.4 ml of gelatin barbital buffer solution and 0.1 ml of 5.0 per cent sheep red blood cell suspension.

As the fully haemolysed control, prepare three tubes with 1.4 ml of water and 0.1 ml of 5.0 per cent sheep red cell suspension.

Incubate all tubes at 37° for 60 minutes and centrifuge at 1,000 g for 5 minutes. Measure the absorbance (2.4.7) of the supernatants at 541 nm and calculate the percentage degree of haemolysis in each tube using the expression:

\[ \frac{A_a - A_1}{A_b - A_1} \times 100 \]

\[ A_a = \text{absorbance of tubes with haemolysin dilution}, \]

\[ A_b = \text{absorbance of tubes with no haemolysin}, \]

\[ A_1 = \text{absorbance of unhaemolysed control}, \]

\[ A_2 = \text{absorbance of fully haemolysed control}. \]
\(A_b = \text{mean absorbance of the three tubes with full haemolysis,}\)
\(A_1 = \text{mean absorbance of the three tubes with no haemolysis.}\)

Plot the percentage degree of haemolysis as the ordinate against the corresponding reciprocal value of the haemolysin dilution as the abscissa on linear graph paper. Determine the optimal dilution of the haemolysin from the graph by inspection. Select a dilution such that further increase in the amount of haemolysin does not cause appreciable change in the degree of haemolysis. This dilution is defined as one minimal haemolytic unit (1 MHU) in 1.0 ml. The optimal haemolytic haemolysin dilution for preparation of sensitised sheep red blood cells contains 2 MHU per ml.

The haemolysin titration is not valid unless the maximum degree of haemolysis is 50.0 per cent to 70.0 per cent. If the maximum degree of haemolysis is not in this range, repeat the titration with more or less diluted complement solution.

### Table - 1

<table>
<thead>
<tr>
<th>Required dilution of haemolysin</th>
<th>Prepared using</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gelatin barbital buffer solution</strong></td>
<td><strong>Volume</strong></td>
<td><strong>Dilution (1 : …)</strong></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>7.5</td>
<td>0.65</td>
<td>undiluted</td>
</tr>
<tr>
<td>10</td>
<td>0.90</td>
<td>undiluted</td>
</tr>
<tr>
<td>75</td>
<td>1.80</td>
<td>7.5</td>
</tr>
<tr>
<td>100</td>
<td>1.80</td>
<td>10</td>
</tr>
<tr>
<td>150</td>
<td>1.00</td>
<td>75</td>
</tr>
<tr>
<td>200</td>
<td>1.00</td>
<td>100</td>
</tr>
<tr>
<td>300</td>
<td>1.00</td>
<td>150</td>
</tr>
<tr>
<td>400</td>
<td>1.00</td>
<td>200</td>
</tr>
<tr>
<td>600</td>
<td>1.00</td>
<td>300</td>
</tr>
<tr>
<td>800</td>
<td>1.00</td>
<td>400</td>
</tr>
<tr>
<td>1200</td>
<td>1.00</td>
<td>600</td>
</tr>
<tr>
<td>1600</td>
<td>1.00</td>
<td>800</td>
</tr>
<tr>
<td>2400</td>
<td>1.00</td>
<td>1200</td>
</tr>
<tr>
<td>3200*</td>
<td>1.00</td>
<td>1600</td>
</tr>
<tr>
<td>4800*</td>
<td>1.00</td>
<td>2400</td>
</tr>
</tbody>
</table>

* discard 1.0 ml of the mixture

**Preparation of optimised sensitised sheep red blood cells (haemolytic system)**

Prepare an appropriate volume of diluted haemolysin containing 2 MHU/ml and an equal volume of standardised 5.0 per cent sheep red blood cell suspension. Add the haemolysin dilution to the standardised cell suspension and mix. Incubate at 37° for 15 minutes, store at 2° to 8° and use within 6 hours.

**Titration of complement.** Prepare an appropriate dilution of complement (for example, 1:250) with gelatin barbital buffer solution and perform the titration in duplicate as shown in Table 2.

Add 0.2 ml of sensitised sheep red blood cells to each tube, mix well and incubate at 37° for 60 minutes. Cool the tubes in an ice-bath and centrifuge at 1,000 g for 5 minutes. Measure the absorbance of the supernatant liquid at 541 nm and calculate the degree of haemolysis \(Y\) using the expression:

\[
\frac{A_c - A_1}{A_b - A_1}
\]

Plot \(Y/(1 - Y)\) as the abscissa against the amount of diluted complement in ml as the ordinate on log–log graph paper. Fit the best line to the points and determine the ordinate for the 50.0 per cent haemolytic complement dose where \(Y/(1 - Y) = 1.0\). Calculate the activity in haemolytic units (CH50/ml) from the expression:

\[
\frac{C_d}{C_a \times 5}
\]

\(C_d = \text{reciprocal value of the complement dilution,}\)
\(C_a = \text{volume of diluted complement in ml resulting in 50.0 per cent haemolysis,}\)
\(S = \text{scaling factor to take account of the number of red blood cells.}\)

The test is not valid unless the plot is a straight line between 15.0 per cent and 85.0 per cent haemolysis and the slope is 0.15 to 0.40, and preferably 0.18 to 0.30.

### Table - 2

<table>
<thead>
<tr>
<th>Tube Number</th>
<th>Volume of diluted</th>
<th>Volume of gelatin</th>
</tr>
</thead>
</table>
IP 2007

<table>
<thead>
<tr>
<th>Immunoglobulin (50 mg per ml)</th>
<th>0.2 ml</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gelatin barbital buffer</td>
<td>0.6 ml</td>
<td>0.8 ml</td>
</tr>
<tr>
<td>Complement</td>
<td>0.2 ml</td>
<td>0.2 ml</td>
</tr>
</tbody>
</table>

Table - 3

Carry out the test on the immunoglobulin under examination and prepare ACA negative and positive controls using human immunoglobulin RS, as indicated in the leaflet accompanying the reference preparation. Higher or lower volumes of sample and of gelatin barbital buffer solution are added if the immunoglobulin concentration varies from 50 mg per ml; for example, 0.47 ml of gelatin barbital buffer solution is added to 0.33 ml of immunoglobulin containing 30 mg per ml to give 0.8 ml. Close the tubes and incubate at 37°C for 60 minutes. Add 0.2 ml of each incubation mixture to 9.8 ml of gelatin barbital buffer solution to dilute the complement. Perform complement titrations as described above on each tube to determine the remaining complement activity (Table 2). Calculate the anticomplementary activity of the preparation under examination relative to the complement control considered as 100.0 per cent, from the expression:

\[
a - \frac{b}{a} \times 100
\]

\(a\) = mean complement activity (CH\textsubscript{50}/ml) of complement control,

\(b\) = complement activity (CH\textsubscript{50}/ml) of tested sample.

The test is not valid unless:

a. the anticomplementary activities found for ACA negative control and ACA positive control are within the limits stated in the leaflet accompanying the reference preparation,

b. the complement activity of the complement control \((a)\) is in the range 80 to 120 CH\textsubscript{50} per ml.

Prekallikrein activator. Maximum 35 IU per ml, calculated with reference to a dilution of the preparation under examination containing 3.0 per cent w/v of immunoglobulin.

Test for prekallikrein activator

Prekallikrein activator (PKA) activates prekallikrein to kallikrein and may be assayed by its ability to cleave a chromophore from a synthetic peptide substrate so that the rate of cleavage can be measured spectrophotometrically and the concentration of PKA calculated by comparison with a reference preparation calibrated in International Units.

The International Unit is the activity of a stated amount of the International Standard which consists of freeze-dried prekallikrein activator. The equivalence in International Units of the International Standard is stated by the World Health Organisation.

Reagents. Prekallikrein activator in albumin RS is calibrated in International Units by comparison with the International Standard.

Buffer A. Dissolve 6.055 g of tris(hydroxymethyl)-aminomethane, 1.17 g of sodium chloride, 50 mg of hexadimethrine bromide and 0.100 g of sodium azide in water. Adjust to pH 8.0 with 2 M hydrochloric acid and dilute to 1,000 ml with water.

Buffer B. Dissolve 6.055 g of tris(hydroxymethyl)-aminomethane and 8.77 g of sodium chloride in water. Adjust to pH 8.0 with 2 M hydrochloric acid and dilute to 1,000 ml.
with water.

**Preparation of prekallikrein substrate**

To avoid coagulation activation, blood or plasma used for the preparation of prekallikrein must come into contact only with plastics or silicone-treated glass surfaces.

Draw 9 volumes of human blood into 1 volume of anticoagulant solution (ACD, CPD or 3.8 per cent w/v solution of sodium citrate) to which 1 mg per ml of hexadimethrine bromide has been added. Centrifuge the mixture at 3,600 g for 5 minutes. Separate the plasma and centrifuge again at 6,000 g for 20 minutes to sediment platelets. Separate the platelet-poor plasma and dialyse against 10 volumes of buffer A for 20 hours. Apply the dialysed plasma to a chromatography column containing agarose-DEAE for ion exchange chromatography which has been equilibrated in buffer A and is equal to twice the volume of the plasma. Elute from the column with buffer A at 20 ml per cm² per hour. Collect the eluate in fractions and record the absorbance (2.4.7) at 280 nm. Pool the fractions containing the first protein peak so that the volume of the pool is about 1.2 times the volume of the platelet-poor plasma.

Test the substrate pool for absence of kallikrein activity by mixing 1 part with 20 parts of the pre-warmed chromogenic substrate solution to be used in the assay and incubate at 37° for 2 minutes. The substrate is suitable if the increase in absorbance is less than 0.001 per minute. Add to the pooled solution 0.7 per cent w/v of sodium chloride and filter using a membrane filter (porosity 0.45 µm). Freeze the filtrate in portions and store at -25°; the substrate may be freeze-dried before storage.

Carry out all procedures from the beginning of the chromatography to freezing in portions during a single working day.

**Method.** The assay may be carried out using an automated enzyme analyser or a suitable microtitre plate system allowing kinetic measurements, with appropriate software for calculation of results. Standards, samples and prekallikrein substrate may be diluted as necessary using buffer B.

Incubate diluted standards or samples with prekallikrein substrate for 10 minutes such that the volume of the undiluted sample does not exceed 1/10 of the total volume of the incubation mixture to avoid errors caused by variation in ionic strength and pH in the incubation mixture. Incubate the mixture or a part thereof with at least an equal volume of a solution of a suitable synthetic chromogenic substrate, known to be specific for kallikrein (for example, N-benzoyl-L-prolyl-L-phenylalanyl-L-arginine 4-nitroanilide acetate or D-prolyl-L-phenylalanyl-L-arginine 4-nitroanilide-dihydrochloride), dissolved in buffer B. Record the rate of change in absorbance per minute for 2 to 10 minutes at the wavelength specific for the substrate used. Prepare a blank for each mixture of sample or standard using buffer B instead of prekallikrein substrate.

Depending on the method used, ΔA per minutes has to be corrected by subtracting the value obtained for the corresponding blank without the prekallikrein substrate. The results may be calculated using a standard curve, a parallel-line or a slope ratio assay or any other suitable statistical method. Plot a calibration curve using the values thus obtained for the reference preparation and the respective concentrations; use the curve to determine the PKA activity of the preparation under examination.

**Anti-A and anti-B haemagglutinins.** Carry out the tests for anti-A and anti-B haemagglutinins as stated under Dried human haemophilic fraction If the preparation under examination contains more than 3.0 per cent of immunoglobulin, dilute to this concentration before preparing the dilutions to be used in the test. The 1 to 64 dilutions do not show agglutination.

**Anti-D antibodies.** It complies with the test for anti-D antibodies in human immunoglobulin for intravenous administration.

**Test for anti-D antibodies in human immunoglobulin for intravenous administration**

**Materials**

**Phosphate-buffered saline (PBS).** Dissolve 8.0 g of sodium chloride, 0.76 g of anhydrous disodium hydrogen phosphate, 0.2 g of potassium chloride, 0.2 g of potassium dihydrogen phosphate and 0.2 g of sodium azide in water and dilute to 1,000 ml with the same solvent.

**Papain solution.** Use serological grade papain from a commercial source, the activity of which has been validated.

**Red blood cells.** Use pooled red blood cells from not fewer than 3 donors of group OR, 2 and 3 donors of group Orr respectively. Wash the cells 4 times with PBS or until the supernatant is clear. Centrifuge the cells at 1, 800 g for 5 minutes to pack. Treat the packed red cells with papain solution according to the manufacturer’s instructions. Store in Alsever’s solution for not more than 1 week.

**Microtitre plates.** Use V-bottomed rigid micro-titre plates.

**Reference standards.** Immunoglobulin (anti-D antibodies test) reference preparation and Immunoglobulin (anti-D antibodies test negative control) reference preparation are suitable for use as the reference preparation and negative control, respectively.

**Method**

**Reference preparation and negative control solutions.** Reconstitute the reference preparation and the negative control according to instructions. Dilute the reconstituted preparations with an equal volume of PBS containing 0.2 per cent w/v of bovine albumin and then prepare a further 7 serial two-fold dilutions using PBS containing 0.2 per cent w/v of bovine albumin to give a total dilution range from 1/2 to 1/256. Make 2 independent sets of dilutions for each preparation. Add 20 µl of each dilution to the microtitre plate.
Test solutions. Initially dilute the test samples to give a starting immunoglobulin G (IgG) concentration of 2.5 per cent w/v using PBS containing 0.2 per cent w/v of bovine albumin and then prepare a further 7 serial two-fold dilutions using PBS containing 0.2 per cent w/v of bovine albumin to give a total dilution range from 1/2 to 1/256. Make 2 independent sets of dilutions for each test sample. Add 20 µl of each dilution to the microtitre plate.

Prepare 3.0 per cent v/v suspensions of papain-treated D-positive (OR,R₂) and D-negative (Orr) red cells in PBS containing 0.2 per cent w/v of bovine albumin. Add 20 µl of D-positive cells to one dilution series of each of the test sample, the reference preparation and the negative control, and 20 µl of D-negative cells to the other dilution series of each of the test samples, the reference preparation and the negative control. Mix by shaking the plate on a shaker for 10 seconds. Centrifuge the plate at 80 g for 1 minutes to pellet the cells.

Place the plate at an angle of approximately 70°. Read after 4 to 5 minutes (or until the cells have streamed in the wells containing the negative control and the wells where the D-negative cells have been added). A cell button at the bottom of the well indicates a positive result. A stream of cells represents a negative result.

Record the endpoint titre as the reciprocal of the highest dilution that gives rise to a positive result.

The titre of the preparation under examination is not greater than the titre of the reference preparation.

Water. Determine by semi-micro determination of water (2.3.43), loss on drying (2.4.19) or near infrared spectrophotometry (2.4.6), the water content is within the limits approved by the competent authority.

Sterility (2.2.11). Complies with the test for sterility.

Pyrogens (2.2.8). Complies with the test for pyrogens. Inject per kg of the rabbit’s mass a volume equivalent to 0.5 g of immunoglobulin but not more than 10 ml per kg of body mass.

Antibody to hepatitis B surface antigen
Minimum 0.5 IU per g of immunoglobulin, determined by a suitable immunochemical method.

Storage. For the liquid preparation, store in a colourless glass container, protected from light, at the temperature stated on the label. For the freeze-dried preparation, store in an airtight colourless glass container, protected from light, at a temperature not exceeding 25°.

Labelling. The label states (1) for liquid preparations, the volume of the preparation in the container and the protein content expressed in grams per litre; (2) for freeze-dried preparations, the quantity of protein in the container; (3) the amount of immunoglobulin in the container; (4) the route of administration; (5) for freeze-dried preparations, the name or composition and the volume of the reconstituting liquid to be added; (6) the distribution of subclasses of immunoglobulin G present in the preparation; (7) where applicable, the amount of albumin added as a stabilizer; (8) the maximum content of immunoglobulin A.

Plasma for Fractionation

Human Plasma for Fractionation

Human Plasma for Fractionation is the liquid part of human blood remaining after separation of the cellular elements from blood collected in a receptacle containing an anticoagulant, or separated by continuous filtration or centrifugation of anticoagulated blood in an apheresis procedure; it is intended for the manufacture of plasma-derived products.

Production

Donors

Only a carefully selected, healthy donor who, as far as can be ascertained after medical examination, laboratory blood tests and a study of the donor’s medical history, is free from detectable agents of infection transmissible by plasma-derived products may be used.

Immunisation of donors

Immunisation of donors to obtain immunoglobulins with specific activities may be carried out when sufficient supplies of material of suitable quality can not be obtained from naturally immunised donors. Recommendations for such immunisations are formulated by the World Health Organisation (Requirements for the collection, processing and quality control of blood, blood components and plasma derivatives, WHO Technical Report Series, No. 840, 1994 or subsequent revision).

Records

Records of donors and donations made are kept in such a way that, while maintaining the required degree of confidentiality concerning the donor’s identity, the origin of each donation in a plasma pool and the results of the corresponding acceptance procedures and laboratory tests can be traced.

Laboratory tests

Laboratory tests are carried out for each donation to detect the following viral markers:
1. Antibodies against human immunodeficiency virus 1 (anti-HIV-1),
2. Antibodies against human immunodeficiency virus 2 (anti-HIV-2),
3. Antibodies against hepatitis C virus (anti-HCV),
4. Hepatitis B surface antigen (HBsAg).

Pending complete harmonisation of the laboratory tests to be carried out, the competent authority may require that a test for
alanine aminotransferase (ALT) also be carried out. The test methods used are of suitable sensitivity and specificity and comply with the regulations in force. If a repeat-reactive result is found in any of these tests, the donation is not accepted.

**Individual plasma units**

The plasma is prepared by a method that removes cells and cell debris as completely as possible. Whether prepared from whole blood or by plasmapheresis, the plasma is separated from the cells by a method designed to prevent the introduction of micro-organisms. No antibacterial or antifungal agent is added to the plasma. The containers comply with the requirements for plastic containers for blood and blood components (6.2). The containers are closed so as to prevent any possibility of contamination.

If 2 or more units are pooled prior to freezing, the operations are carried out using sterile connecting devices or under aseptic conditions and using containers that have not previously been used.

When obtained by plasmapheresis, plasma intended for the recovery of proteins that are labile in plasma is frozen by cooling rapidly in a chamber at -30° or below as soon as possible and at the latest within 24 hours of collection.

When obtained from whole blood, plasma intended for the recovery of proteins that are labile in plasma is separated from cellular elements and is frozen by cooling rapidly in a chamber at -30° or below as soon as possible and at the latest within 24 hours of collection.

When obtained from whole blood, plasma intended solely for the recovery of proteins that are not labile in plasma is separated from cellular elements and is frozen in a chamber at -20° or below as soon as possible and at the latest within 24 hours of collection.

It is not intended that the determination of total protein and factor VIII shown below be carried out on each unit of plasma. They are rather given as guidelines for good manufacturing practice, the test for factor VIII being relevant for plasma intended for use in the preparation of concentrates of labile proteins.

The total protein content of a unit of plasma depends on the serum protein content of the donor and the degree of dilution inherent in the donation procedure. When plasma is obtained from a suitable donor and using the intended proportion of anticoagulant solution, a total protein content complying with the limit of 5 per cent is obtained. If a volume of blood or plasma smaller than intended is collected into the anticoagulant solution, the resulting plasma is not necessarily unsuitable for pooling for fractionation. The aim of good manufacturing practice must be to achieve the prescribed limit for all normal donations.

Preservation of factor VIII in the donation depends on the collection procedure and the subsequent handling of the blood and plasma. With good practice, 0.7 IU/ml can usually be achieved, but units of plasma with a lower activity may still be suitable for use in the production of coagulation factor concentrates. The aim of good manufacturing practice is to conserve labile proteins as much as possible.

**Total protein.** Carry out the test using a pool of not less than 10 units. Dilute the pool with a 0.9 per cent solution of sodium chloride to obtain a solution containing about 15 mg of protein in 2 ml. To 2.0 ml of this solution in a round-bottomed centrifuge tube add 2 ml of a 7.5 per cent solution of sodium molybdate and 2 ml of a mixture of 1 volume of nitrogen-free sulphuric acid and 30 volumes of water. Shake, centrifuge for 5 minutes, decant the supernatant liquid and allow the inverted tube to drain on filter paper. Determine the nitrogen in the residue by the method of sulphuric acid digestion (2.3.30) and calculate the protein content by multiplying the quantity of nitrogen by 6.25. The total protein content is not less than 5.0 per cent.

**Factor VIII**

Carry out the test using a pool of not less than 10 units. Thaw the samples under examination, if necessary, at 37°. Determine the assay of factor VIII (2.8.7), using a reference plasma calibrated against the International Standard for human coagulation factor VIII in plasma. The activity is not less than 0.7 IU per ml.

**Pooled plasma**

During the manufacture of plasma products, the first homogeneous pool of plasma (for example, after removal of cryoprecipitate) is tested for HBsAg, HCV antibodies and for HIV antibodies using test methods of suitable sensitivity and specificity; the pool must give negative results in these tests.

The plasma pool is also tested for hepatitis C virus RNA using a validated nucleic acid amplification technique (2.8.1). A positive control with 100 IU per ml of hepatitis C virus RNA and, to test for inhibitors, an internal control prepared by addition of a suitable marker to a sample of the plasma pool are included in the test. The test is invalid if the positive control is non-reactive or if the result obtained with the internal control indicates the presence of inhibitors. The plasma pool complies with the test if it is found non-reactive for hepatitis C virus RNA.

**Description.** Before freezing, a clear to slightly turbid liquid without visible signs of haemolysis; it may vary in colour from light yellow to green.

**Storage.** Frozen plasma is stored in conditions designed to maintain the temperature at or below -20°; for accidental reasons, the storage temperature may rise above -20° on one or more occasions during storage but the plasma is nevertheless considered suitable for fractionation if all the following conditions are fulfilled (1) the total period of time during which the temperature exceeds -20° does not exceed 72 hours; (2) the temperature does not exceed -15° on more than one occasion; (3) the temperature at no time exceeds -5°.

**Labelling.** The label enables each individual unit to be traced to a specific donor.


Platelet Concentrate

Platelets separated from whole blood within 4 to 6 hours of collection and suspended in 40 to 50 ml of plasma are designated as platelet concentrate.

Production

Platelet Concentrate is prepared from units of whole blood that have not been allowed to cool below 20°. Platelet rich plasma (PRP) is separated within 4-6 hours after completion of the phlebotomy. The final component should contain resuspended platelets in an amount of plasma adequate to maintain an acceptable pH - generally 40 to 70 ml is used.

Tests

Four PC per month should be assayed for pH and for platelet, RBC and leucocyte counts.

PRP

- **Counts**: 3.0 - 4.5 x 10⁷ per µl (approximately)
- **Volume**: 170 - 250 ml (approximately)
- **Total Count**: 9 x 10⁹ per bag (approximately)

PRC

- **Counts**: 8 - 10 x 10⁷ per µl 350 ml bag (approximately)
  10 - 12 x 10⁷ per µl 450 ml bag (approximately)
- **Volume**: 40 - 50 ml per bag

**Platelet counts**: > 5.5 x 10¹⁰ per bag in 75 per cent of bags
  (if prepared from 450 ml bags)
  > 4.2 x 10¹⁰ per bag in 75 per cent of bags
  (if prepared from 350 ml bags)

Leucocyte count < 0.12 x 10⁹ per bag.

RBC counts < 1.2 x 10⁹ per bag.

pH < 6.3 at the end of 5 days storage.

Expiration time. The expiration time is not more than 72 hours from the time of collection of the source material.

Storage. Store at 20° to 22° in polyvinylchloride plastic bags. Preserve at the temperature relevant to the volume of resuspension plasma, either between 20° and 22° or between 1° and 6°, the latter except during shipment, when the temperature may be between 1° and 10°.

Labelling. In addition to the labelling requirements of Whole Blood applicable to this product, label it to state the volume of original plasma present, the kind and volume of anticoagulant solution present in the original plasma, the blood group designation of the source blood, and the hour of expiration on the stated expiration date. Where labelled for storage at 20° to 22°, label it also to state that a continuous gentle agitation shall be maintained, or where labelled for storage at 1° to 6°, to state that such agitation is optional. Label it also with the type and result of a serologic test for syphilis, or to indicate that it was nonreactive in such test; with the type and result of a test for hepatitis B surface antigen, or to indicate that it was nonreactive in such test; with a warning that it is to be used as soon as possible but not more than 6 hours after entering the container; to state that a filter is to be used in the administration equipment; and to state that the instruction circular provided is to be consulted for directions for use.

Whole Human Blood

Whole Blood (Human)

Whole Human Blood is blood drawn aseptically from selected human donors and mixed with a suitable anticoagulant.

Whole Human Blood is the final mixture of blood and anticoagulant solution contains not less than 9.7 per cent w/v of haemoglobin, calculated from the haemoglobin content of the donor’s blood and the dilution due to the anticoagulant solution. It is obtained from healthy donors who must:

(a) be in the age range of 18 to 60 years and be in good health as indicated in part by normal temperature and blood pressure within normal limits;
(b) not be pregnant, if females;
(c) not have undergone major surgery within 6 months of donation;
(d) as far as can be ascertained after clinical and laboratory examination and the study of medical history of the donor be free from disease transmissible by blood transfusion;
(e) have blood containing not less than 12.5 per cent w/v of haemoglobin;
(f) be free from acute respiratory diseases;
(g) be free from any infectious skin disease at the site of phlebotomy;
(h) have no history of malarial fever within 12 months of donation;
(i) have no history of viral hepatitis or of close contact with an individual having viral hepatitis within 12 months of donation and have blood that has given negative results in tests for the presence of hepatitis-B antigen;
(j) have blood that has been tested with negative results for evidence of syphilitic infection, HCV antibodies, HIV antibodies and malarial parasites.

The examinations and tests to be carried out are decided by the National Regulatory Authority.

The frequency of donations of whole blood shall not exceed once every 3 months with a maximum volume of 1.5 litres in any consecutive 12 month period.
The blood is drawn aseptically through a closed system into a suitable sterile container containing a specific amount of Anticoagulant Citrate Dextrose Solution (ACD Solution) or Anticoagulant Citrate Phosphate Dextrose Solution (CPD Solution) which is placed before the container is sterilised. The quantity of anticoagulant solution should not exceed 22.0 per cent v/v of the final volume of the mixture. No antimicrobial preservative is added.

During the withdrawal of blood the container is gently agitated to ensure thorough mixing. When withdrawal is complete the container is immediately sealed and cooled to 2° to 8°. It is not opened until immediately before transfusion. With every container of blood, a separate sample mixed with the appropriate quantity of anticoagulant solution, is collected for compatibility and other tests; this small container is firmly attached to the main container.

Whole Human Blood in containers from which samples have been removed for tests should not be used for transfusion. Consequently, it is not intended that the Tests and the Assay should be carried out on the contents of the container. The Blood Bank or the service collecting the blood is responsible for ensuring that the conditions in which the blood is collected and stored are such that, if and when tested, the blood will comply with the requirements of the monograph.

Blood group. Determine the blood group (in the sample accompanying each donation) under the ABO system (2.8.11), by examination of both corpuscles and serum, and under the Rh system (2.8.11), by examination of the corpuscles.

Description. Deep red fluid which, on standing separates into a lower layer of sedimented-red cells and a yellowish, almost clear upper layer of plasma, free from visible signs of haemolysis, with a greyish layer between the two consisting of leucocytes and thrombocytes. A layer containing emulsified fat may form on the surface.

Tests

Sterility (2.2.11). Complies with the tests for sterility, determined by Method B.

Assay. Determine the haemoglobin content by photometric haemoglobinometry (2.8.12).

Storage. Store in colourless, transparent and sterile containers into which it was originally drawn. The containers should be provided with a hermetic, contamination-proof closure. Store at a temperature between 2° to 8°.

Labelling. The label states (1) the distinctive code number by reference to which the details of the donor are available; (2) the ABO group with the approved colour scheme for different groups as specified by the National Regulatory Authority; (3) the Rh group; (4) the total volume of fluid, the proportion of blood, and the nature and volume of anticoagulant solution; (5) the date on which the blood was withdrawn; (6) the expiry date which should not exceed 21 days from the date of withdrawal of blood; (7) the storage conditions; (8) that the blood must not be used for transfusion if there is any visible evidence of haemolysis or other deterioration; (9) for blood of group O whether haemolysins are present or not and if they are, that the blood must be administered only to recipients of blood group O; (10) that the blood has given negative results in the tests for the presence of malarial parasites, hepatitis-B antigen, syphilis and HIV antibodies and any other tests prescribed by the National Regulatory Authority.
BIOTECHNOLOGY PRODUCTS

General Monographs

r-DNA Biotechnology Products of Therapeutic Value  ....

Monographs

Erythropoietin concentrated solution  ....
Granulocyte Colony Stimulating Factor, Human (Filgrastim)  ....
Interferon alfa-2 concentrated solution  ....
Sereptokinase  ....
r-DNA Biotechnology Products of Therapeutic Value

This monograph states the general requirements for the manufacture of products of recombinant DNA technology that are produced by genetic modification in which the DNA coding for the required product is introduced into a suitable cell line or microorganism by means of a plasmid or viral vector. The DNA is expressed and translated into protein of interest in the genetically modified organism.

Therapeutic proteins are derived from several processes. One of them is the recombinant DNA technology, the products of which are often referred to as r-DNA products. The process involves isolation of a specific active gene and inserting into a host cell. The host cell expresses the protein encoded in the transferred gene. The host cell could be a microorganism or an animal cell. Large-scale propagation yields large quantities of crude protein. Purification of the crude protein using multiple techniques derives a safe, pure and biologically active product.

The product being a protein may cause immunological sensitization in the recipients and therefore needs a high degree of characterization. Testing of the product for safety, identity, strength, quality and purity are similar to those applied to other pharmaceutical products, although the tests themselves may require some modification due to the pretentious nature of the active compound.

Recombinant DNA technology products are produced by genetic manipulation of a cell line or microorganism usually through a plasmid transfer or viral vector. The recovery of the desired product expressed by such genetically modified organisms is by multistage purification. Monoclonal antibodies too fall under this category.

The cell or microorganism used for expressing the protein is referred to as the host cell and the transformed cell after the gene insertion is referred to as the host-vector system. The host cells could be Prokaryotic or Eukaryotic cells. The differences in their metabolic pathway result in differences in the type proteins expressed by them. Prokaryotic cells do not have the ability to do glycosylation. Therefore, proteins expressed by the Prokaryotic cells may require post translation modification to make them biologically active.

Monoclonal antibodies are derived from a single clone of B lymphocyte. They differs from polyclonal antibodies that are a mixture of antibodies of several antigenic epitopes. B-lymphocytes have a short life span and hence need to be immortalized if they are to be used for production for a long period. Fusion with myeloma cells make them immortal. Such fused hybridoma cells inherit the property of producing the desired antibody from the B lymphocyte and immortal property from the Myeloma cells. Large scale culturing of these hybridoma cells using various techniques yield monoclonal antibodies.

r-DNA derived products suffer from a danger of microheterogeneity in the expressed protein and therefore require extensive process validation. In addition, the concern of adventitious viruses, presence of host cell DNA, presence of oncogenic genes, residual host proteins, endotoxins, residual media proteins etc calls for stringent methods of testing to ensure their removal to acceptable levels.

r-DNA derived products are not significantly different from other therapeutic proteins derived from natural sources after the final purification step and therefore basic requirements of validation of the process, environmental conditions, and aseptic techniques during manufacturing, quality assurance and quality control do not differ in approach from conventional pharmaceutical products. Handling of genetically modified organisms in the production process require adherence to the rules governing environmental safety.

r-DNA products are produced in Prokaryotic or Eukaryotic systems. The choice of the system primarily depends upon the size of the protein and the extent of glycosylation required to make them biologically active. The choice of bacteria in the Prokaryotic system is E.Coli due to the extensive information available of this bacterium.

The disadvantages in use of the organism are:

1) The proteins are produced in the reduced state.
2) Need to remove the N formyl methionine sequence.
3) Product degradation during the production process due to the presence of protease enzyme.
4) Need for endotoxin removal step.

Eukaryotic cells including yeasts on the other hand have the ability to produce proteins that are properly folded due to its glycosylation ability. Primary cell lines have a short life span. Cloning, selection, amplification, master cell bank creation, scaling up requires several passages. Primary Cell lines do not last these many passages. Use of immortal cell lines has helped overcome the problem but brought in new challenges in the form of oncogenes, potential viral and retroviral contamination, and presence of animal derived growth promoters etc., which are required to be removed by various purification steps.

Exhaustive analysis, validation of the process and safety tests are done on the Master Banks are done to rule out presence of adventitious agents. Cells are used only after this for large-scale production.

Yeast offers an advantage against the complexities of using animal cell lines but have the disadvantage that they maintain plasmids extra chromosomally creating a danger of losing the inserted gene. However, their ability to produce glycosylated protein makes them a better choice than Escherichia coli.
Monoclonal antibodies are produced in two ways depending on the source of the lymphocyte – murine or Human. Antibodies of Murine origin are produced by selecting the lymphocytes from the spleen of previously inoculated mice or rats and fusing them with an immortal cell line like myeloma cells. Such hybridoma cells are cloned, propagated in large scale and used for antibody production. Antibody produced is as per the chromosomal information acquired during the hybridoma formation process.

Large-scale propagation of bacteria and Yeast are often referred to as Fermentation. During the process the growth rate, purity of the culture and yields are monitored. Nucleotide sequence analysis or DNA restriction mapping checks the genetic stability of the plasmid. Peptide mapping of the expressed protein is carried out for confirmation. Proteolytic degradation of the expressed protein is a concern and therefore optimization of the fermentation process is essential to minimize it. Recovery of the protein often requires lysis of the cells. Proteases released during the process of cell lysis calls for rapid processing to minimize the damage caused by it.

Large-scale cell culture is quite well established but poses its own challenges like genetic stability, protein folding and culture conditions. Genetic stability cannot be rapidly checked as in the case of Prokaryotic as the gene is incorporated in the cell genome. Peptide mapping of the expressed protein is the only check but lacks sensitivity to detect minor genetic mutations. Manufacturers are required to demonstrate the purity of the cultures against contaminating organisms including mycoplasma and adventitious viruses, at the end of purification. The advantage of cell culture is that the protein is directly secreted into the medium and therefore cell separation is sufficient to achieve a significant level of purification.

Production

Production is based on a validated stable host –vector combination using a seed-lot system. The seed-lot system uses a master cell bank and a working cell bank derived from the master seed lot of the host-vector combination. The validation to determine the suitability shall include the following.

Characterization of the Host-Vector System

Characterization of the host-vector system is used for establishing its suitability for production. Characterization of the host-vector system involves several tests that are performed to establish the purity.

Characterization includes documentation of:

i. The origin of the nucleotide sequence coding for the protein.

Validation of the cell banks

Validation of the cell banks shall include:

i. Stability by measuring viability and the retention of the vector.

Validation of the purification process

The ability of the different steps of the extraction and purification process to remove and/or inactivate contaminating substances derived from the host cell or culture medium,
including, virus particles, proteins, nucleic acids and added substances, must be validated. Validation studies should demonstrate that the production process routinely meets the following criteria:

i. Removal of extraneous agents from the product.
ii. Removal of vector, host-cell, culture medium and reagent-derived contaminants below the acceptable levels.
iii. Capability to reduce the DNA below acceptable levels.
iv. Adequate stability of any partially purified product if stored during the process.
v. Minimum yields in the process.

Characterization of the substance
The identity, purity, potency and stability of the final bulk product are established initially by carrying out a wide range of chemical, physical, immunochemical and biological tests. Prior to release, each batch of the product is tested by the manufacturer for identity and purity and an appropriate assay is carried out.

Production Consistency
Suitable tests for demonstrating the consistency of the production and purification are performed. The tests include, especially characterization tests, in-process controls and final-product tests, for example:

Amino-acid composition
Partial amino acid sequence analysis test for confirmation of the correct N-terminal processing and detect loss of the C-terminal amino acids.

Peptide mapping
Peptide mapping using chemical and/or enzymatic cleavage of the protein product must be done that no significant difference between the test protein and reference preparation is found. Two-dimensional gel electrophoresis, capillary electrophoresis or liquid chromatography may be used for analysis. Peptide mapping can also be used to demonstrate correct disulphide bonding.

Determination of molecular mass

Cloned-gene Retention
The relevant authority approves the minimum amount in percentage of the cells containing the vector or the cloned gene after cultivation.

Total Protein. The yield of protein is determined.

Chemical Purity
The purity of the protein product is analyzed in comparison with a reference preparation by a suitable method such as liquid chromatography, capillary electrophoresis or sodium dodecyl sulphate polyacrylamide gel electrophoresis.

Host-cell-derived proteins
Host-cell-derived proteins are detected by immunochemical methods, using, polyclonal antisera rose against protein components of the host-vector system. Liquid-phase displacement assays (radioimmunoassay), liquid-phase direct-binding assays and direct-binding assays using antigens immobilized on nitrocellulose (or similar) membranes (for example, dot-immunoblot assays, Western blots) may be used for the assay.

The Antisera are raised against a preparation of antigens derived from the host organism, into which has been inserted the vector used in the manufacturing process that lacks the specific gene coding for the product. This host cell is cultured, and proteins are extracted, using conditions identical to those used for culture and extraction in the manufacturing process. Partly purified preparations of antigens, using some of the purification steps in the manufacturing process, may also be used for the preparation of antisera.

Host-cell- and vector-derived DNA
Residual DNA is detected by hybridization analysis, using suitably sensitive, sequence-independent analytical techniques or other suitably sensitive analytical techniques. However, the method used must be validated to ensure parallelism with the DNA standard used, linearity of response and non-interference of either the drug substance or excipients of the formulation at the dilutions used in the assay.

The limits for the presence of these are as currently prescribed by W.H.O. or competent authorities.

Erythropoietin Concentrated Solution

<table>
<thead>
<tr>
<th>APPRLICDSR</th>
<th>VLERYLLEAK</th>
<th>EAENITTGCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>EHCSLNENIT</td>
<td>VPDTKVNFYA</td>
<td>WKRMEVGQQA</td>
</tr>
<tr>
<td>VEVVWQGLALL</td>
<td>SEAVLRGQAL</td>
<td>LVNSSQPWEPE</td>
</tr>
<tr>
<td>LQLHVDKAVS</td>
<td>GLRSLLTTLR</td>
<td>ALGAQKEAIS</td>
</tr>
<tr>
<td>PPDAASAAPL</td>
<td>RTITADTFRK</td>
<td>LFRVYNFLR</td>
</tr>
<tr>
<td>GKLKLYTGEA</td>
<td>CRTGD</td>
<td></td>
</tr>
</tbody>
</table>

Mol. Wt. 30,600 (approx)

Erythropoietin Concentrated Solution contains a family of closely-related glycoproteins which are not different from the
naturally occurring human erythropoietin (urinary erythropoietin) in terms of the amino acid sequence (165 amino acids) and average glycosylation pattern, at a concentration of 0.5 mg per ml to 10 mg per ml. It has a potency of not less than 100000 IU per mg of active substance.

**Production**

Erythropoietin is produced in rodent cells *in vitro* by a method based on recombinant DNA technology. All batches are tested as described below, prior to release.

**Host cell-derived proteins**

The limit is as prescribed by WHO.

**Host cell-derived proteins (HCP).** This must be routinely monitored using a scientifically accepted method that demonstrates that:

1. the assay is sensitive (a useful target for the limit of detection is 1 to 100 ppm)
2. the assay is specific for the HCP (defined by proprietary detection reagents such as antibodies elicited against process-specific contaminating HCP) consistently found in the product from a specific manufacturing / purification process.

Acceptable limits should be set empirically based on the above by the manufacturer.

**Host cell- and vector-derived DNA**

The limit is as prescribed by the regulatory authority.

**Description.** A clear and colourless solution.

**Identification**

A. It gives the appropriate response when examined using the conditions described under Assay.

B. Determine by capillary electrophoresis (capillary isoelectric focusing) (2.4.32).

**Test solution.** Dilute if necessary the preparation in water and desalt the preparation. Using a membrane filtration system suitable for desalting proteins, desalt the sample. Make up the volume to the original volume with water.

**Reference solution.** Dissolve erythropoietin RS in water to produce a solution containing 1 mg per ml and desalt as above. The isoelectric focusing procedure may be carried out using a 0.5mm thick polyacrylamide slab gel containing ampholytes covering the pH of range 3 to 10, prepared as follows.

Mix 9 g of urea, 6.0 ml of 30 per cent acrylamide / bisacrylamide solution, 1.05 ml of pH 3 to 5 amphotolyte, 0.45 ml pH 3 to 10 amphotolyte and 13.5 ml of water. Degas. Add 15 µl of tetramethylethylene diamine and 0.3 ml of a 100 g per litre freshly prepared solution of ammonium persulphate. Pour into a suitable gel cassette, with approximate dimensions of 15 cm x 15 cm x 0.05 cm. Insert a suitable sample well comb and allow to polymerize.

Use as the anode solution the anolyte for isoelectric focusing pH 3 to 5 and as the cathode solution the catholyte for isoelectric focusing pH 3 to 5. Allow prefocusing to take place for 1 hour at a constant power of 10 W, with maximum voltage and current settings of 2000 V and 100 mA respectively.

Dilate the test solution to 0.5 mg per ml with water. Apply to the gel 10 µl of each solution. Carry out focusing for a further 30 minutes at the same power supply settings. Take the gel out of the focusing chamber, and transfer the proteins onto a membrane suitable for immobilization of proteins (such as Polyvinylidene Fluoride), using commercially available electrotransfer equipment and following the manufacturer’s instructions. After electrotransfer, incubate the membrane in a neutral isotonic buffer containing a suitable blocking agent (for example, 50 g per litre of dried milk), for 1 hour, followed by incubation in the same blocking solution with a suitable dilution of a polyclonal anti-erythropoietin antibody. Detect the erythropoietin-bound antibody using a suitable enzyme- or radiolabelled antibody (for example, an alkaline phosphatase-conjugated second antibody). The precise details of blocking details of blocking agents, concentrations and incubation times should be optimized using the principles set out in Immunochemical methods.

The test is not valid unless the distribution of bands in the electrophoretogram obtained with the reference solution contains at least 6 well separated bands. If necessary, the voltage settings and duration may be altered to optimize the separation of the isoforms.

In the electrophoretogram obtained with the test solution, the pH range of the bands observed corresponds to that of the electrophoretogram obtained with the reference solution. The predominant bands correspond to isoforms 4, 5, 6 and 7. Additional, fainter bands corresponding to isoforms 1, 2, 3 and 8 may also be present. Other bands are present in no more than trace amounts.

C. Determine by capillary electrophoresis (capillary zone electrophoresis) (2.4.32).

All the solutions should be filtered through a 0.45 µm membrane filter before use.

**Test solution.** Dilute the substance under examination with water or concentrate it to obtain a concentration of 1 mg per ml. Desalt 0.25 ml of the solution by passage through a micro-concentrator cartridge provided with a membrane with a molecular mass cut-off of not more than 10000. Add 0.2 ml of water to the sample and desalt again. Repeat the desalting procedure once more. Dilute the sample with water, determine its protein concentration as described under Tests and adjust...
to a concentration of approximately 1 mg per ml with water.

**Reference solution.** Dissolve erythropoietin RS in water to produce a solution containing 1 mg per ml. Desalt the sample as described for the test solution.

**Capillary system**
- material. uncoated fused silica,
- size. effective length = about 100 cm, Ø = 50 µm,
- temperature. 35°,
- spectrophotometer set at 214 nm,
- injection. under pressure or vacuum.

**CZE buffer concentrate (0.1 M sodium chloride, 0.1 M tricine, 0.1 M sodium acetate).** Dissolve 0.584 g of sodium chloride, 1.792 g of tricine and 0.820 g of anhydrous sodium acetate in water and dilute to 100.0 ml with the same solvent.

**1 M putrescine solution.** Dissolve 0.882 g of putrescine in 10 ml of water. Distribute in 0.5 ml aliquots.

**CZE buffer. (0.01 M tricine, 0.01 M sodium chloride, 0.01 M sodium acetate, 7 M urea, 2.5 mM putrescine).** Dissolve 21.0 g of urea in 25 ml of water by warming in a water-bath at 30°. Add 5.0 ml of **CZE buffer concentrate** and 125 ml of 1 M putrescine solution. Dilute to 50.0 ml with water. Using **dilute acetic acid**, adjust the pH to 5.55 at room temperature and filter through a 0.45 µm membrane filter.

Set the auto sampler to store the samples at 4° during analysis.

**Preconditioning of the capillary.** Rinse the capillary for 60 minutes with 0.1 M sodium hydroxide filtered through a 0.45 µm membrane filter and for 60 minutes with **CZE buffer**. Apply voltage for 12 hours (20 kV).

**Between-run rinsing.** Rinse the capillary for 10 minutes with water, for 5 minutes with 0.1 M sodium hydroxide filtered through a 0.45 µm membrane filter and for 10 minutes with **CZE buffer**.

**Migration.** Apply a field strength of 143 V/cm (15.4 kV for capillaries of 107 cm total length) for 80 min, using **CZE buffer** as the electrolyte in both buffer reservoirs.

**System suitability.** In the electropherogram obtained with the reference solution, a pattern of well- separated peaks corresponding to the peaks in the reference electropherogram of erythropoietin RS is seen, and the largest peak is at least 50 times greater than the baseline noise. If necessary, adjust the sample load to give peaks of sufficient height. Identify the peaks corresponding to isoforms 1 to 8. The peak corresponding to isoform 1 is detected; the resolution between the peaks corresponding to isoforms 5 and 6 is not less than 1. Repeat the separation at least 3 times. The baseline is stable, showing little drift, and the distribution of peaks is qualitatively and quantitatively similar to the distribution of peaks in the reference electropherogram of erythropoietin RS. The relative standard deviation of the migration time of the peak corresponding to isoform 2 is less than 2 per cent.

Reference electropherogram of Erythropoietin
Identify the peaks corresponding to isoforms 1 to 8 in the electropherogram obtained with the test solution by comparison with the electropherogram obtained with the reference solution. Calculate the percentage content of each isoform from the corresponding peak area. The percentages are within the following ranges:

<table>
<thead>
<tr>
<th>Isoform Number</th>
<th>Content (per cent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0 – 15</td>
</tr>
<tr>
<td>2</td>
<td>0 – 15</td>
</tr>
<tr>
<td>3</td>
<td>0 – 20</td>
</tr>
<tr>
<td>4</td>
<td>10 – 35</td>
</tr>
<tr>
<td>5</td>
<td>15 – 40</td>
</tr>
<tr>
<td>6</td>
<td>10 – 35</td>
</tr>
<tr>
<td>7</td>
<td>0 – 20</td>
</tr>
<tr>
<td>8</td>
<td>0 – 15</td>
</tr>
</tbody>
</table>

D. Immunoblotting. Determine by electrophoresis (sodium dodecyl sulphate polyacrylamide gel electrophoresis) (SDS-PAGE)(2.4.12).

Use a 1-mm thick spacer with six-well comb, a well capacity of 45 l and plate size of 100 x 120 mm

Assemble the gel casting as recommended by the manufacturer.

Use the composition of gel given below:

— Separating gel. 12 per cent
— Add the reagents into a clean glass/plastic container in the same sequence as given in the table below:

<table>
<thead>
<tr>
<th>Solutions</th>
<th>For 5 ml (1 gel)</th>
<th>For 10 ml (2 gels)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>1.8 ml</td>
<td>3.6 ml</td>
</tr>
<tr>
<td>Acrylamide (30 per cent)</td>
<td>0.6 ml</td>
<td>1.2 ml</td>
</tr>
<tr>
<td>0.5 M Tris Cl pH. 6.8</td>
<td>2.5 ml</td>
<td>5.0 ml</td>
</tr>
<tr>
<td>20 per cent SDS</td>
<td>25 µl</td>
<td>50 µl</td>
</tr>
<tr>
<td>Ammonium persulphate (10 per cent w/v) (APS)</td>
<td>50 µl</td>
<td>100 µl</td>
</tr>
<tr>
<td>TEMED</td>
<td>5 µl</td>
<td>10 µl</td>
</tr>
</tbody>
</table>

Mix the above ingredients by swirling gently and pour over the separating gel. Avoid bubbles. Keep aside for at least 45 minutes for polymerization at room temperature.

Preparation of samples and loading

Samples include:

1. Test sample 1.0 µg
2. Reference standard RS 1.0 µg
3. Prestained Marker 20 µl

Test solution. Take X µl of the test sample and add an equal volume of 2X non-reducing sample buffer where,

\[ X (\mu l) = 1 \mu g \text{per (concentration of the test sample in mg per ml)} \]

Reference solution. Dilute a part of 1mg per ml reference standard RS stock 10 times to get a final concentration of 0.1 mg per ml with water as follows:

10 µl of 1 mg per ml reference standard RS + 90 ml water.

To 10 µl of 0.1 mg per ml reference standard RS solution add 10 ml of 2X non-reducing sample buffer.

Prestained marker: Take 20 µl of prestained marker, reconstituted as recommended by the manufacturer.

Loading of samples

Boil the samples for two minutes, centrifuge, bring to room temperature and load the entire volume on the gel.
Running the gel

1. Fix the gel apparatus in the running unit according to the manufacturer’s instructions.
2. Chill the 1X running buffer to 4º for at least 1 hour.
3. Pour 1X running buffer in the upper as well as lower chambers of the running unit.
4. Set parameters on the Power pack as follows:
   — Constant Voltage: 130 V
   — Max Current: 200 mA.
5. Run until dye front just goes out at the gel bottom (usually about 1.5 hrs)

Transfer, blotting and development of membrane:

1. Disassemble the running unit according to the manufacturer’s instructions.
2. Cut Nitrocellulose Membrane (NCM) having the same dimensions as of the gel.
3. Equilibrate the membrane in chilled transfer buffer for 15 – 20 minutes.
4. Equilibrate the gel in chilled transfer buffer for 15 – 20 minutes.
5. Soak the nylon pads in transfer buffer and place on the pad on the cathode.
6. Take 5 sheets of a suitable filter paper, cut to the size of the gel and soak in chilled transfer buffer. Place them on the nylon pad placed on cathode plate.
7. Carefully place the equilibrated gel on the filter papers.
8. Place the equilibrated membrane onto the gel.
9. Roll a clean glass rod dipped in transfer buffer on top of the membrane to get rid of any air bubbles trapped between the gel and the membrane.
10. Place 5 sheets of a suitable filter paper soaked in chilled transfer buffer over the membrane. Once again roll the glass rod to remove any air bubbles.
11. Close the cassette.
12. Place the cassette in the running unit.
13. Connect the electrodes with the Power pack and set following parameters for transfer:
   — Current: 200 mA
   — Voltage: 100 V
   — Time: 1 hour.
14. After the transfer is over, disassemble the cassette.
15. Transfer the membrane to the blocking solution. Incubate the membrane in the blocking buffer for 1 hour with gentle shaking at room temperature.
16. Discard the blocking buffer. Add 25 ml of rabbit anti r-Hu EPO antibody (Primary antibody) solution.
17. Incubate for 1 hour with gentle agitation at room temperature.
18. Wash the membrane with 1X transfer buffer saline with change of buffer in-between at room temperature with gentle agitation. (3 times X 5 minutes)
19. Discard the transfer buffer saline. Add 25 ml of goat anti-rabbit ALP conjugated antibody (secondary antibody) solution. Incubate for 1 hour with gentle shaking at room temperature.
20. Wash the membrane with 1X transfer buffer saline (3 times X 5 minutes)
21. Develop the color by adding 5 ml of the substrate solution. (Usually it takes 15 – 20 minutes).
22. Stop the reaction by pouring off the substrate solution and washing it with water before the color of the background gets dark.
23. Scan the blot while it is wet.
24. Air dry the blot and preserve it.

The molecular mass markers are resolved on the membrane into discrete bands with a linear relationship between distance migrated and log_{10} of the molecular mass.

To evaluate the linear relationship between the distance migrated and log_{10} of the molecular mass, calculate
   a) log molecular weights corresponding to marker bands
   b) migration distance of protein band
   c) plot (a) vs (b) and perform linear regression analysis

The graph should be linear

The single broad band of the test solution and of reference standard RS match in position and intensity.

E. Peptide mapping (2.3.47).

Test solution. Dilute the substance under examination in tris-acetate buffer solution pH 8.5 to a concentration of 1.0 mg per ml. Equilibrate the solution in tris-acetate buffer solution pH 8.5 using a suitable procedure (such as dialysis against tris-acetate buffer solution pH 8.5, or membrane filtration using the procedure described under Identification C, but reconstituting the desalted sample with tris-acetate buffer solution pH 8.5). Transfer the dialyzed solution to a polypropylene centrifuge tube. Freshly prepare a solution of trypsin for peptide mapping at a concentration of 1 mg per ml in water, and add 5 ml to 0.25 ml of the dialysed solution. Cap the tube and place in a water-bath at 37º for 18 hours. Remove the sample from the water-bath and stop the reaction immediately by freezing.

Reference solution. Dissolve the contents of a vial of erythropoietin RS in 0.25 ml of water. Prepare as for the test solution, ensuring that all procedures are carried out simultaneously, and under identical conditions.
Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with butylsilyl silica gel (5-10 µm),
- mobile phase: A. 0.06 per cent v/v solution of trifluoroacetic acid,
  B. to 100 ml of water add 0.6 ml of trifluoroacetic acid and dilute to 1000 ml with acetonitrile,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 214 nm,
- a 50 µl loop injector.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Flow rate (ml/min)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 – 10</td>
<td>0.75</td>
<td>100</td>
<td>0</td>
</tr>
<tr>
<td>10 – 125</td>
<td>0.75</td>
<td>100 → 39</td>
<td>0 → 61</td>
</tr>
<tr>
<td>125 – 135</td>
<td>1.25</td>
<td>39 → 17</td>
<td>61 → 83</td>
</tr>
<tr>
<td>135 – 145</td>
<td>1.25</td>
<td>17 → 0</td>
<td>83 → 100</td>
</tr>
<tr>
<td>145 – 150</td>
<td>1.25</td>
<td>100</td>
<td>0</td>
</tr>
</tbody>
</table>

Equilibrate at initial conditions for at least 15 minutes. Carry out a blank run using the above-mentioned gradient.

The chromatogram obtained with each solution is qualitatively similar to the reference chromatogram of erythropoietin RS digest.

The profile of the chromatogram obtained with the test solution corresponds to that of the chromatogram obtained with the reference solution.

F. Determine by N-terminal sequence analysis

The first 15 amino acids are: Alanine - Proline - Proline - Arginine - Leucine - Isoleucine - (no recovered peak) - Aspartic acid - Serine - Arginine - Valine - Leucine - Glutamic acid - Arginine - Tyrosine.

Perform the Edman degradation using an automated solid-phase sequencer, operated in accordance with the manufacturer’s instructions.

Desalt the equivalent of 50 µg of erythropoietin. For example, dilute a volume of the substance under examination containing 50 µg of the active substance in 1 ml of a 0.1 per cent v/v solution of trifluoroacetic acid. Pre-wash a C18 reverse-phase sample preparation cartridge according to the instructions supplied by the manufacturer and equilibrate the cartridge in a 0.1 per cent v/v solution of trifluoroacetic acid. Apply the sample to the cartridge, and wash successively with a 0.1 per cent v/v solution of trifluoroacetic acid containing 0 per cent, 10 per cent and 50 per cent v/v of acetonitrile according to the manufacturer’s instructions. Lyophilise the 50 per cent v/v acetonitrile eluate.

Redissolve the desalted sample in 50 µl of a 0.1 per cent v/v solution of trifluoroacetic acid and couple to a sequencing cartridge using the protocol provided by the manufacturer. Run 15 sequencing cycles, using the reaction conditions for proline when running the second and third cycles.

Identify the phenylthiohydantoin (PTH)-amino acids released at each sequencing cycle by reverse-phase liquid chromatography. The procedure may be carried out using the column and reagents recommended by the manufacturer of the sequencing equipment for the separation of PTH-amino acids.

The separation procedure is calibrated using:
- the mixture of PTH-amino acids provided by the manufacturer of the sequencer, with the gradient conditions adjusted as indicated to achieve optimum resolution of all amino acids,
- a sample obtained from a blank sequencing cycle obtained as recommended by the equipment manufacturer.

If a sample does not comply with the limits set for the n-1 and n-2 sequences repeat the analysis.

Tests

Protein. 80 per cent to 120 per cent of the stated amount.

Test solution. Dilute the substance under examination in a 0.4 per cent w/v solution of ammonium hydrogen carbonate or the appropriate blank solution.

When examined in the range 250 nm to 400 nm (2.4.7), the solution shows an absorption maximum between 276 nm and 282 nm. Calculate the content of erythropoietin taking the specific absorbance to be 7.43.

Dimers and related substances of higher molecular mass

A. Determine by size-exclusion chromatography (2.4.16).

Test solution. Dilute the substance under examination in the mobile phase to obtain a concentration of 0.2 mg per ml.

Reference solution. To 0.02 ml of the test solution add 0.98 ml of the mobile phase (2 per cent).

Chromatographic system

- a stainless steel column 6 cm x 7.5 mm, packed with hydrophilic silica gel, of a grade suitable for fractionation of globular proteins in the molecular mass range of 20 000 to 200 000,
- mobile phase: Dissolve 1.15 g of anhydrous disodium hydrogen phosphate, 0.2 g of potassium dihydrogen phosphate and 23.4 g of sodium chloride in 1 litre of water (1.5 mM potassium dihydrogen phosphate, 8.1 mM disodium hydrogen phosphate, 0.4M sodium chloride, pH 7.4); adjust the pH to 7.4 if necessary,
- flow rate. 0.5 ml per minute,
- spectrophotometer at 214 nm,
Inject the test solution and the reference solution. Continue the chromatography for 1 hour. The area of the principal peak in the chromatogram obtained with the reference solution is 1.5 to 2.5 per cent of the area of the principal peak in the chromatogram obtained with the test solution. The total area of any peaks eluted before the principal peak is not more than the area of the principal peak in the chromatogram obtained with the reference solution (2 per cent).

B. Determine by electrophoresis (sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) (2.4.12).

Casting the Gels
— Use a 1-mm thick spacer with eight-well comb.
— The well capacity is 65 µl.
— Assemble the gel - casting unit according to the manufacturer’s instructions.
— Use the assembly of plate size, 160 x 160 mm.

a) Casting the separating gel: 12 per cent

Add the reagents into a clean glass/plastic container in the same sequence as given in the table below:

<table>
<thead>
<tr>
<th>Solutions</th>
<th>For 20 ml (1 gel)</th>
<th>For 40 ml (2 gels)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>6.17 ml</td>
<td>12.34 ml</td>
</tr>
<tr>
<td>Acrylamide (30 per cent)</td>
<td>8.0 ml</td>
<td>16.0 ml</td>
</tr>
<tr>
<td>1.5 M Tris Cl pH. 8.8</td>
<td>5.0 ml</td>
<td>10.0 ml</td>
</tr>
<tr>
<td>20 per cent SDS</td>
<td>100 µl</td>
<td>200 µl</td>
</tr>
<tr>
<td>Ammonium persulphate</td>
<td>200 µl</td>
<td>400 µl</td>
</tr>
<tr>
<td>(10 per cent w/v) (APS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEMED</td>
<td>8 µl</td>
<td>16 µl</td>
</tr>
</tbody>
</table>

Mix the above ingredients by swirling gently and pour into the casting unit using a 1-ml pipette till 1 - 1.5 cm from the top edge of the plate. After addition of ammonium persulphate and TEMED, the solution should be mixed and poured quickly (less than 1 minute) or it will begin to polymerize.

Pour 200 – 1000 µl of water-saturated butanol on the top of the separation gel.

Keep aside for at least 45 minutes for polymerization at room temperature (RT).

b) Casting the Stacking gel: 4 per cent

Decant the water-saturated butanol and rinse the separating gel with water. (If the gel has not polymerized and flows out, discard and prepare fresh)

Add the reagents into a clean glass/plastic container in the same sequence as given in the table below:

<table>
<thead>
<tr>
<th>Solutions</th>
<th>For 5 ml (1 gel)</th>
<th>For 10 ml (2 gels)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>1.8 ml</td>
<td>3.6 ml</td>
</tr>
<tr>
<td>Acrylamide (30 per cent)</td>
<td>0.6 ml</td>
<td>1.2 ml</td>
</tr>
<tr>
<td>0.5 M Tris Cl pH. 6.8</td>
<td>2.5 ml</td>
<td>5.0 ml</td>
</tr>
<tr>
<td>20 per cent SDS</td>
<td>25 µl</td>
<td>50 µl</td>
</tr>
<tr>
<td>Ammonium persulphate</td>
<td>50 µl</td>
<td>100 µl</td>
</tr>
<tr>
<td>(10 per cent w/v) (APS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEMED</td>
<td>5 µl</td>
<td>10 µl</td>
</tr>
</tbody>
</table>

Mix the above contents by swirling gently and pour over the separating gel. Avoid bubbles.

Keep aside for at least 45 minutes for polymerization at room temperature.

Preparation of samples

Samples include:
1. Test sample
2. Reference standard RS
3. Marker for non-reducing gel

Test solution. To a volume containing 10 µg of protein add an equal volume of 2X non-reducing sample buffer.

Reference solution. Take 10 µl of the reference standard RS from 1mg per ml stock in a micro-centrifuge tube and add 10 µl of 2X non-reducing sample buffer.

Molecular weight marker. Take 20 µl of low molecular weight markers for SDS-PAGE, which is reconstituted according to the manufacturer’s instruction:

Sample loading

Keep all the samples in a boiling water-bath for 2 minutes. Centrifuge, bring to room temperature and load the entire volume on to the gel.

<table>
<thead>
<tr>
<th>Sample No.</th>
<th>Samples</th>
<th>Amount of protein loaded/well (µg)</th>
<th>Total Vol. to be loaded (µl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Test Sample</td>
<td>1</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>Reference</td>
<td>1</td>
<td>20</td>
</tr>
<tr>
<td>3</td>
<td>Marker</td>
<td>–</td>
<td>20</td>
</tr>
</tbody>
</table>

Running the gel

Fix the gel apparatus in the running unit as given in the instruction manual of the manufacturer.
Chill the 1X running buffer to 4° for at least 1 hour.

Pour 1X running buffer in the upper as well as lower chambers of the running unit.

Set parameters on the Power pack as follows:
- Constant Voltage: 130 V
- Max Current: 200 mA.

Run until the dye front reaches the bottom of the gel (usually about 5.0 hrs. The dye front should have run at least 80 per cent of the gel).

**Staining of Gel**

Stop the run. Disassemble the casting unit and transfer the gel carefully into a staining tray. Do not touch the gel with naked hands; wear gloves while handling the gel.

Detect proteins in the gel by silver staining.

**Scanning**

Scan and save the image of the stained gel.

**Gel drying**

The stained gel is placed in between two cellophane sheets and clamped with the gel dryer frames (taking care that no air bubbles are present in between the two cellophane sheets). The set up is placed in the gel dryer apparatus and left at least 2 hrs for drying.

The dye front is run for at least 80 per cent of the total gel length. Molecular weight markers are resolved on the gel into discrete bands, with a linear relationship between distance migrated and logarithm of the molecular mass.

To evaluate the linear relationship between distance migrated and logarithm of the molecular mass, calculate

a) log molecular weights corresponding to marker bands
b) migration distance of protein bands
c) plot (a) vs (b) and perform linear regression analysis.

The graph should be linear.

The single diffuse band of the test solution and of the reference solution match in position and intensity.

**Sialic acids.** Not less than 10 mol of Sialic acids (calculated as N-acetylneuraminic acid) per mole of erythropoietin, determined in the following manner.

**Test solution (a).** Dilute the preparation under examination in the mobile phase used in the test for dimers and related substances of higher molecular mass to obtain a concentration of 0.3 mg/ml.

**Test solution (b).** To 0.5 ml of test solution (a) add 0.5 ml of the mobile phase used in the test for dimers and related substances of higher molecular mass.

**Reference solution (a).** Dissolve a suitable amount of N-acetylneuraminic acid in water to produce a solution containing 0.1 mg per ml.

**Reference solution (b).** To 0.8 ml of reference solution (a) add 0.2 ml of water.

**Reference solution (c).** To 0.6 ml of reference solution (a) add 0.4 ml of water.

**Reference solution (d).** To 0.4 ml of reference solution (a) add 0.6 ml of water.

**Reference solution (e).** To 0.2 ml of reference solution (a) add 0.8 ml of water.

**Reference solution (f).** Use water

Carry out the test in triplicate. Transfer 100 ml each of the test and reference solutions to 10-ml glass test tubes. To each tube add 1.0 ml of resorcinol reagent. Stopper the tubes and incubate at 100° for 30 minutes. Cool on ice. To each tube, add 2.0 ml of a mixture of 12 volumes of butanol and 48 volumes of butyl acetate. Mix vigorously, and allow the 2 phases to separate. Ensuring that the upper phase is completely clear, remove the upper phase, taking care to exclude completely any of the lower phases. Measure the absorbance of all samples at 580 nm (2.4.7).

Using the calibration curve generated by the reference solutions, determine the content of sialic acids in each of the two test solutions and calculate the mean. Calculate the number of moles of sialic acids per mole of erythropoietin assuming that the relative molecular mass of erythropoietin is 30 600 and that the relative molecular mass of N-acetylneuraminic acid is 309.

**System suitability.** The individual replicates agree to within ±10 per cent of each other; the value obtained from reference solution (a) is between 1.5 and 2.5 times that obtained with test solution (a).

**Bacterial endotoxins (2.2.3).** Not more than 20 Endotoxin Units in the volume that contains 100 000 IU of erythropoietin.

**Assay.** The activity of the preparation is compared with that of erythropoietin RS and expressed in International Units (IU).

The estimated potency is not less than 80 per cent and not more than 125 per cent of the stated potency. The fiducial limits of error of the estimated potency ($P = 0.95$) are not less than 64 per cent and not more than 156 per cent of the stated potency.

Determine by Method A or Method B.

A. In polycythaemic mice

The activity of the preparation is estimated by examining, under given conditions, its effect in stimulating the
incorporation of $^{59}$Fe into circulating red blood cells of mice made polycythaemic by exposure to reduced atmospheric pressure.

The following schedule, using treatment in a hypobaric chamber, has been found to be suitable.

Induce polycythaemia in female mice of the same strain, weighing 16 to 18 g. Place the mice in a hypoxic chamber and reduce the pressure to 0.6 atmospheres. After 3 days at 0.6 atmospheres, further reduce the pressure to 0.4-0.5 atmospheres and maintain the animals at this pressure for a further 11 days (the partial vacuum is interrupted daily for a maximum of 1 h at about 11:00 a.m., in order to clean the cages and feed the animals). At the end of the specified period, return the mice to normal atmospheric conditions. Randomly distribute the mice into cages, each containing 6 animals, and mark them.

*Test solution (a).* Dilute the substance under examination in phosphate-albumin buffered saline pH 7.2 to obtain a concentration of 0.2 IU per ml.

*Test solution (b).* Mix equal volumes of test solution (a) and phosphate-albumin buffered saline pH 7.2.

*Test solution (c).* Mix equal volumes of test solution (b) and phosphate-albumin buffered saline pH 7.2.

*Reference solution (a).* Dissolve erythropoietin RS in phosphate-albumin buffered saline pH 7.2 to obtain a concentration of 0.2 IU per ml.

*Reference solution (b).* Mix equal volumes of reference solution (a) and phosphate-albumin buffered saline pH 7.2.

*Reference solution (c).* Mix equal volumes of reference solution (b) and phosphate-albumin buffered saline pH 7.2.

**Radiolabelled ferric $^{59}$Fe chloride solution, concentrated.** Use a commercially available solution of $^{59}$Fe ferric chloride (approximate specific activity: 100-1000 MBq per mg of Fe).

**Radiolabelled $^{59}$Fe ferric chloride solution.** Dilute the concentrated radiolabelled $^{59}$Fe ferric chloride solution in sodium citrate buffer solution pH 7.8 to obtain a solution with an activity of $3.7 \times 10^4$ Bq per ml.

The concentrations of the test solutions and reference solutions may need to be modified, based on the response range of the animals used.

3 days after returning the animals to atmospheric pressure, inject each animal subcutaneously with 0.2 ml of one of the solutions. The 6 animals in each cage must each receive one of the 6 different treatments (3 test solutions and 3 reference solutions), and the order of injection must be separately randomised for each cage. A minimum of 8 cages is recommended. 2 days after injection of the test or reference solution, inject each animal intraperitoneally with 0.2 ml of radiolabelled $^{59}$Fe ferric chloride solution. The order of the injections must be the same as that of the erythropoietin injections, and the time interval between administration of the erythropoietin and the radiolabelled ferric chloride solution must be the same for each animal. After a further 48 h, anaesthetise each animal by injection of a suitable anaesthetic, record body weights and withdraw blood samples (0.65 ml) into haematocrit capillaries from the bifurcation of the aorta. After determining the packed cell volume for each sample, measure the radioactivity.

Calculate the response (percentage of iron-59 in total circulating blood) for each mouse using the expression:

$$\frac{A_s \times M \times 7.5}{A_t \times V_s}$$

Where, $A_s$ = radioactivity in the sample,

$A_t$ = total radioactivity injected,

$7.5$ = total blood volume as per cent body weight,

$M$ = body weight, in grams,

$V_s$ = sample volume.

Calculate the potency by the usual statistical methods for a parallel line assay. Eliminate from the calculation any animal where the packed cell volume is less than 54 per cent, or where the body weight is more than 24 g.

**B. In normocythaemic mice**

The assay is based on the measurement of stimulation of reticulocyte production in normocythaemic mice.

**Test solution (a).** Dilute the substance under examination in phosphate-albumin buffered saline pH 7.2 to obtain a concentration of 80 IU per ml.

**Test solution (b).** Mix equal volumes of test solution (a) and phosphate-albumin buffered saline pH 7.2.

**Test solution (c).** Mix equal volumes of test solution (b) and phosphate-albumin buffered saline pH 7.2.

**Reference solution (a).** Dissolve erythropoietin RS in phosphate-albumin buffered saline pH 7.2 to produce a solution containing 80 IU per ml.

**Reference solution (b).** Mix equal volumes of reference solution (a) and phosphate-albumin buffered saline pH 7.2.

**Reference solution (c).** Mix equal volumes of reference solution (b) and phosphate-albumin buffered saline pH 7.2.

The exact concentrations of the test solutions and reference solutions may need to be modified, based on the response range of the animals used.

At the beginning of the assay procedure, randomly distribute mice of a suitable age and strain (8-week old B6D2F1 mice are
suitable. Other strains like Swiss Albino, Balb/C of suitable age can also be used) into 6 cages. A minimum of 8 mice per cage is recommended. Inject each animal subcutaneously with 0.5 ml of the appropriate treatment (one solution per cage) and put the animal in a new cage. Combine the mice in such a way that each cage housing the treated mice contains one mouse out of the 6 different treatments (3 test solutions and 3 reference solutions, 6 mice per cage). 4 days after the injections, collect blood samples from the animals and determine the number of reticulocytes using the following procedure.

The volume of blood, dilution procedure and fluorescent reagent may need to be modified to ensure maximum development and stability of fluorescence.

Colorant solution, concentrated. Use a solution of thiazole orange suitable for the determination of reticulocytes. Prepare at a concentration twice that necessary for the analysis.

Proceed with the following dilution steps. Dilute whole blood 500-fold in the buffer used to prepare the colorant solution. Dilute this solution 2-fold in the concentrated colorant solution. After staining for 3-10 min, determine the reticulocyte count microfluorometrically in a flow cytometer. The percentage of reticulocytes is determined using a biparametric histogram: number of cells/red fluorescence (620 nm).

Calculate the potency by the usual statistical methods for a parallel line assay.

Storage. Store in an airtight container at a temperature below -20º. Avoid repeated freezing and thawing.

Labelling. The label states (1) the erythropoietin content in mg per ml; (2) the activity in International Units per ml; (3) the name and the concentration of any other excipients.

Filgrastim Concentrated Solution

Granulocyte Colony Stimulating Factor Solution

Filgrastim Concentrated Solution contains not less than 1.5 mg of protein per ml, and not less than 1.0 x 10⁶ IU of filgrastim per mg of protein.

Prior to release, the following tests are carried out on each batch of the final bulk product, unless the regulatory authority has granted exemption.

Description. A clear, colourless to slightly yellowish liquid.

Identification

A. It shows the biological activity as described under Assay.
B. Determine by capillary electrophoresis (capillary isoelectric focusing) (2.4.32).

In the test for impurities with charges different from that of filgrastim, the principal band in the electropherogram obtained with the test solution is similar in position to the principal band in the electropherogram obtained with the reference solution.

C. In the test for impurities of molecular masses higher than that of filgrastim, the retention time, of the principal peak obtained with the test solution is similar to that of the principal peak obtained with the reference solution.

D. In the test for impurities with molecular masses differing from that of rG-CSF under both reducing and non-reducing conditions, the principal band in the electropherogram obtained with test solution (a) is similar in position to the principle band in the electropherogram obtained with reference solution (a).

E. Determine by peptide mapping (2.3.47).

Test solution. Introduce 50 µl of a 0.05 M sodium phosphate buffer pH 8.0 into a polypropylene tube. Add a volume of the substance under examination corresponding to 25 µg of protein, and 25 µl of a 0.1 mg per ml solution of Glu-C2 protease; dilute to 1 ml with water, stopper the tube and incubate at about 37º for 18 hours. Add 125 µl of a 7.64 per cent w/v solution of guanidine hydrochloride and mix well. Add 10 µl of a 1.542 per cent w/v solution of dithiothreitol and mix well. Place the capped tube in boiling water for 1 minute. Allow to cool to room temperature.

Reference solution. Prepare at the same time and in the same manner as for the test solution but use G-CSF RS instead of the test preparation under examination.

Chromatographic system

- a stainless steel column 10 cm x 2 mm, packed with octadecysilsyl silica gel (5 µm) with a pore size of 20 nm,
- mobile phase: A. Dilute 0.5 ml of trifluoroacetic acid to 950 ml with water; add 50 ml of acetonitrile and mix, B. Dilute 0.5 ml of trifluoroacetic acid to 50 ml with water; add 950 ml of acetonitrile,
- flow rate. 0.2 ml per minute,
A linear gradient programme using the conditions given below,
- spectrophotometer set at 215 nm,
- a 10 µl loop injector.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 – 8.0</td>
<td>3 – 6</td>
<td>97 – 94</td>
</tr>
<tr>
<td>8 – 25</td>
<td>6 – 34</td>
<td>94 – 66</td>
</tr>
<tr>
<td>25 – 40</td>
<td>34 – 90</td>
<td>66 – 100</td>
</tr>
<tr>
<td>40 – 45</td>
<td>90</td>
<td>10</td>
</tr>
<tr>
<td>45 – 46</td>
<td>90 – 3</td>
<td>10 – 97</td>
</tr>
<tr>
<td>46 – 65</td>
<td>3</td>
<td>97</td>
</tr>
</tbody>
</table>

Equilibrate the column at the initial conditions for at least 30 minutes.

Inject the test solution and the reference solution.
The chromatograms obtained with the reference solution and the test solutions are qualitatively similar.
The profile of chromatogram obtained with the reference solution and the test solution corresponds to that of the chromatogram obtained with the reference solution.

F. Determine by N-Terminal Sequencing.
Perform the Edman degradation using an automated solid-phase sequencer, operated in accordance with the manufacturer’s instructions.
Load about 1 ml of the test preparation to a sequencing cartridge using the protocol provided by the manufacturer. Run 16 sequencing cycles, noting, if appropriate the presence of praline at positions 3, 6 and 111.
Identify PTH-amino acids released at each sequencing cycle by RP-HPLC. The procedure may be carried out using the column and reagents recommended by the manufacturer of the sequencing equipment for the separation of PTH-amino acids.
The separation procedure is calibrated using:
a) the mixture of PTH-amino acids provided by the manufacturer of the sequencer, with the gradient conditions adjusted as indicated to achieve optimum resolution of all amino acids;
b) a sample obtained from a blank sequencing cycle obtained as recommended by the equipment manufacturer.
The first 16 amino acids should match the sequence given in the beginning starting with Met.

Tests
Impurities with molecular masses differing from that of Filgrastim. Determine by electrophoresis (sodium dodecyl sulphate polyacrylamide gel electrophoresis) (2.4.12) under both reducing and non-reducing conditions.
Gel dimensions. 1.0 mm thick. 160 X 160 mm
Resolving gel. 13 per cent Acrylamide
Sample buffer A.
Sample buffer B (reducing conditions).

Test solution (a). Dilute the preparation under examination with water to produce a solution containing 0.1 mg per ml. To 50 volumes of this solution, add 13 volumes of concentrated SDS-PAGE sample buffer.

Test solution (b). Prepare in the same manner as test solution (a) but using concentrated SDS-PAGE sample buffer for reducing conditions.

Reference solution (a). Dilute the preparation under examination with water to obtain a concentration of 0.1 mg per ml. To 50 volumes of this solution, add 13 volumes of concentrated SDS-PAGE sample buffer.

Reference solution (b). Prepare as for reference solution (a), but using concentrated SDS-PAGE sample buffer for reducing conditions.

Reference solution (c). Use a solution of molecular mass marker suitable for calibrating SDS-PAGE gels in the range of 14 400 to 94 000. Dissolve in sample buffer of sample buffer (reducing conditions), as appropriate.

<table>
<thead>
<tr>
<th>Reference solution</th>
<th>Protein amount (µg)</th>
<th>Sample Volume (µl)</th>
<th>SDS-PAGE Sample Buffer</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a)</td>
<td>100</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>(b)</td>
<td>50</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>(c)</td>
<td>20</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>(d)</td>
<td>10</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>(e)</td>
<td>5</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>(f)</td>
<td>2</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>(g)</td>
<td>1</td>
<td>20</td>
<td>20</td>
</tr>
</tbody>
</table>

Sample treatment: boil for 5 minutes.
Apply 20 µl of each reduced and non-reduced solutions to separate gels.
Detection: Silver staining as described below.
Immerse the gel for 30 minutes in a mixture of 10 volumes of acetic acid, 40 volumes of water and 50 volumes of methanol. Transfer the gel to 5 per cent methanol and shake for 5 minutes.
Repeat this washing step thrice. Replace the 5 per cent v/v solution of methanol with 0.2 g per litre sodium thiosulphate. Wash the gel thrice in water for 30 seconds each. Transfer the gel to a 0.2 per cent w/v solution of silver nitrate.
This solution is prepared immediately before use. Place the gel on shaker for 25 minutes. Wash the gel for 1 minute. Repeat this washing step thrice. Transfer the gel into a mixture containing 30 g per litre solution of sodium carbonate, 0.05 per cent v/v solution of formaldehyde and 0.2 g per litre solution of sodium thiosulphate in water. Protein bands become visible during this step. Keep the gel in the solution until sufficiently stained and then stop the staining by soaking the gel in a 14 g per litre solution of disodium edetate.

The test is not valid unless the proteins of the molecular weight marker are distributed along 80 per cent of the gel and over the required separation range (the range covering the product and its dimer or the product and its related impurities).

In the electropherogram obtained with test solution (a) no band is more intense that the principal band in the electropherogram obtained with reference solution (f).

Impurities with charges differing from that of Filgrastim. Determine by capillary electrophoresis (capillary isoelectric focusing) (2.4.32).

Test solution. Dilute the preparation under examination to produce a solution containing 0.3 mg per ml.

Reference solution (a). A solution of filgrastim RS containing 0.3 mg per ml.

Reference solution (b). A solution of filgrastim RS containing 0.06 mg per ml.

Reference solution (c). Use an isoelectric point (pI) calibration solution, in the pI range of 2.5-6.5, prepared according to manufacturer’s instructions.

Focusing:
- pH gradient. 4.5 - 8.0,
- catholyte. 1 M sodium hydroxide,
- anolyte: 0.04 M glutamic acid in a 0.0025 per cent v/v solution of phosphoric acid,
- Application 20 µl.

Detection. Proceed as described in Isoelectric Focusing (2.4.33).

Detect the product and its dimer or the product and its related impurities.

In the electropherogram obtained with reference solution (c), relevant isoelectric point markers are distributed along the entire length of the gel.

In the electropherogram obtained with reference solution (a), the pI of the principal band is 5.7-6.3.

No band is more intense that the principal band in the electropherogram obtained with reference solution (b).

Related Proteins. Determine by liquid chromatography (2.4.14).

Test solution. Dilute the preparation under examination with mobile phase A to obtain a concentration of 0.3 mg per ml.

Reference solution (a). Dilute G-CSFRS with the same mobile phase to obtain a concentration of 0.3 mg per ml.

Reference solution (b). To 570 µl of reference solution (a), add 6.8 µl of a 0.45 per cent v/v solution of hydrogen peroxide; mix and incubate at 25° for 1 hour, then add 2.5 mg of methionine RS.

Chromatographic system
- a stainless steel column 15 cm x 4.6 mm, packed with octadeacylsilyl silica gel (5 µm) with a pore size of 20 nm and a guard column 7.5 cm x 7.5mm packed with octadeacylsilyl silica gel,
- column temperature. 65º,
- mobile phase: A. dilute 1 ml of trifluoroacetic acid to 500 ml with water and add 499 ml of acetonitrile, B. dilute 1 ml of trifluoroacetic acid to 950 ml with acetonitrile and add 49 ml of water,
- flow rate. 1 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 215 nm,
- a 50 µl loop injector.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 – 4</td>
<td>92 → 72</td>
<td>8 → 28</td>
</tr>
<tr>
<td>4 – 19</td>
<td>92 → 0</td>
<td>28 → 100</td>
</tr>
<tr>
<td>19 – 19.1</td>
<td>0 → 92</td>
<td>100 → 8</td>
</tr>
<tr>
<td>21 – 25</td>
<td>92 → 8</td>
<td>8</td>
</tr>
</tbody>
</table>

Inject the test solution and reference solutions (a) and (b).

Relative retention with reference to filgrastim (retention time=about 12 minutes): oxidized filgrastim 2= about 0.95

The profile of the chromatogram obtained with reference solution (b) is similar to that of the chromatogram of oxidized filgrastim supplied with filgrastim RS. Two peaks corresponding respectively to oxidized filgrastim 2 elute before the principal peak, the second peak not being completely separated form the principal peak.

In the chromatogram obtained with the test solution, the area of any peak other than the principal peak is not greater than 2.0 per cent of the total area of all the peaks. The sum of the areas of any peaks other than the principal peak is not greater than 3.5 per cent of the total area of all of the peaks.

Dimers and Related Substance of Higher Molecular Mass. Determine by size exclusion chromatography (2.4.14).
**Solution A.** Dissolve 4.1 g of sodium acetate in 400 ml of water, adjust to pH 4.0 with acetic acid and dilute to 500 ml with water.

**Test solution.** Dilute the preparation under examination with solution A to obtain a concentration of 0.4 mg per ml.

**Reference solution.** Dilute filgrastim RS with solution A to obtain a concentration of 0.4 mg per ml.

**Resolution solution.** Mix a sample of the reference solution for about 30 seconds using a vortex mixer.

Chromatographic system
- a stainless steel column 30 cm x 7.8 mm, packed with hydrophilic silica gel
- column temperature: 30°C
- mobile phase: dissolve 7.9 g of ammonium hydrogen carbonate in 1000 ml of water and adjust to pH 7.0 with phosphoric acid; dilute to 2000 ml with water,
- flow rate: 0.5 ml per minute,
- spectrophotometer set at 215 nm,
- a 200 µl loop injector.

Relative retention times with reference to filgrastim monomer (retention time=about 19 minutes): aggregates = about 0.60; filgrastim oligomer 1= about 0.75; filgrastim oligomer 2= about 0.80; filgrastim dimer=about 0.85.

Inject the resolution solution. The retention time of filgrastim monomer is 17 minutes to 20 minutes. The resolution between the peaks due to filgrastim dimer and filgrastim monomer is not less than 4.0.

Calculate the content of dimer, oligomers and aggregates. The sum of the peaks with retention times less that of the principal peak is not more than 2.5 per cent.

**Bacterial Endotoxins.** Not more than 2 Endotoxin Unit per mg of protein.

**Assay.** A. **Protein -** Determine by liquid chromatography (2.4.14) as described under the test for Related proteins.

Inject the test solution and reference solution (a).

Calculate the content of filgrastim.

B. **Potency-** Determination of the biological activity of rG-CSF concentrated solution is based on the stimulation of NFS60 cells (murine myeloblastic cell line) by rG-CSF.

The following method uses the conversion of tetrazolium bromide (MTS) as a staining method. Alternative methods of quantifying cell proliferation, such as measurement of intracellular ATP by luciferase bioluminescence have also been found suitable, and may be used as the assay readout, subject to appropriate validation.

NFS-60 cells are incubated with varying dilution of test and reference preparations of rG-CSF. They are then incubated with a solution of MTT. This cytochemical stain is converted by cellular dehydrogenases to a purple formazan product. The formazan is then measured spectrophotometrically. The potency of the test preparation is determined by comparison of the dilutions of the test preparation with the dilutions of the appropriate International Standard of rG-CSF or with a reference preparation calibrated in International Units, which yield the same response (50 per cent maximal stimulation).

The International Unit is the activity contained in a stated amount of the appropriate International Standard. The equivalence in International Units of the International standard is stated by the World Health Organization.

Add 50 µl of the dilution medium to all wells of a 96 –well microtitre plate. Add an additional 50 µl of this solution to the wells designed for blanks. Add 50 µl of each solution to be tested in triplicate (test preparation and reference preparation at a concentration of about 800 IU per ml, plus a series of 10 twofold dilutions to obtain a standard curve). Prepare a suspension of NFS-60 cells containing 7x10⁵ cells per ml. Immediately before use, add 2-mercaptoethanol to a final concentration of 0.1 mM, and add 50 µl of the prepared cell suspension to each well, maintaining the cells in a uniform suspension during addition.

Incubate the plate at 36.0º- 38.0º for a minimum of 24 hours in a humidified incubator using 6 ± 1 per cent CO₂. Add 20 ml of a 5.0 g per litre sterile solution of tetrazolium bromide to each well and re-incubate 4 hours. Estimate the quantity of formazan produced using a microtitre well plate reader at 490 nm.

Analyze the data by fitting a sigmoidal dose-response curve to the data obtained and by using a suitable stastical method, for example the 4-parameter or parallel line models.

The estimated potency is not less than 80 per cent and not more than 125 per cent of the stated potency. The confidence limits (P=0.95) of the estimated potency are not less than 74 per cent and not more than 136 per cent of the stated potency.

**Storage.** Store protected from light in a refrigerator (2º to 8º).

**Labeling.** The label states the content, in mg of protein per ml; the potency, in IU per mg of protein.

### Interferon Alfa-2 Concentrated Solution

<table>
<thead>
<tr>
<th>CDLPQTHSLG</th>
<th>CDLPQTHSLG</th>
<th>CDLPQTHSLG</th>
<th>CDLPQTHSLG</th>
<th>CDLPQTHSLG</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRTTLMLIAQ</td>
<td>SRTTLMLIAQ</td>
<td>SRTTLMLIAQ</td>
<td>SRTTLMLIAQ</td>
<td>SRTTLMLIAQ</td>
</tr>
<tr>
<td>CDLPQTHSLG</td>
<td>CDLPQTHSLG</td>
<td>CDLPQTHSLG</td>
<td>CDLPQTHSLG</td>
<td>CDLPQTHSLG</td>
</tr>
</tbody>
</table>

**alfa-2a:** C₈₆₀H₁₃₅₁N₂₂₇O₂₅₅S₉  Mol. Wt. 19,241

**alfa-2b:** C₈₆₀H₁₃₅₁N₂₂₇O₂₅₅S₉  Mol. Wt. 19,269
Interferon alfa-2 concentrated solution is a solution of an r-DNA derived therapeutic protein which exhibits non-specific antiviral activity, at least in homologous cells. Interferon alfa-2 concentrated solution also exerts antiproliferative and immunomodulator activity. Two different types of alfa-2 interferon, varying in the amino acid residue at position 23, are found and are named as alfa-2a and alfa-2b.

<table>
<thead>
<tr>
<th>Designation</th>
<th>Residue at position 23 (X₁)</th>
</tr>
</thead>
<tbody>
<tr>
<td>alfa-2a</td>
<td>Lys</td>
</tr>
<tr>
<td>alfa-2b</td>
<td>Arg</td>
</tr>
</tbody>
</table>

This monograph applies to interferon alfa-2a and 2b concentrated solutions.

Interferon alfa-2 concentrated solution contains not less than $1.4 \times 10^8$ IU per mg of protein and not less than 0.5 mg of interferon alfa-2 per ml.

**Production**

Interferon alfa-2 concentrated solution is produced by a method based on recombinant DNA (rDNA) technology. It is produced under controlled conditions designed to ensure sterility of the product.

Interferon alfa-2 concentrated solution complies with the following additional requirements.

**Host-cell-derived proteins**

The limit is approved by WHO guidelines.

**Host-cell- or vector-derived DNA**

The limit is approved by WHO guidelines.

**Description**. A clear, colourless or slightly yellowish liquid.

**Identification**

A. It shows the expected biological activity as described under Assay for potency.

B. Determine by isoelectric focusing.

**Test solution**. Dilute the preparation under examination with water to obtain a solution containing 0.5 mg protein per ml.

**Reference solution**. A 0.5 mg per ml solution of interferon alfa-2 RS in water.

Isoelectric point calibration solution pl range 3.0 to 10.0. Prepare and use according to the manufacturer’s instructions.

Isoelectric focusing is carried out using either horizontal electrophoresis system or by vertical electrophoresis system as per the procedure described below or by any appropriate validated method.

**Horizontal Electrophoresis**

Select and use a suitable horizontal isoelectric focusing apparatus with facility for connecting a circulating bath chiller capable of maintaining 10°. Select gels for isoelectric focusing with a pH gradient from 3.5 to 9.5.

Use phosphoric acid as anode solution (98 g per litre phosphoric acid) and 1 M sodium hydroxide as the cathode solution. Using filter paper apply 15 µl of the test solution and the reference solution to the gel close to the cathode.

Start the isoelectric focusing at 1500 V and 50 mA. Turn off the power after 30 minutes. Remove the application filters and reconnect the power supply for 1 hour. Keep the power constant during the focusing process.

Immerse the gel in a solution containing 115 g per litre of trichloroacetic acid and 34.5 g per litre of sulphosalicylic acid in water and agitate the container gently for 60 minutes.

Prepare a mixture of 32 volumes of glacial acetic acid, 100 volumes of ethanol and 268 volumes of water. Transfer the gel to the mixture and soak for 5 minutes.

Immerse the gel for 10 minutes in a staining solution prewarmed to 60°. The staining solution is prepared by adding 1.2 g per litre of acid blue 83 to the mixture of glacial acetic acid, ethanol and water.

Wash the gel several times to destain with the mixture of glacial acetic acid, ethanol and water and keep the gel in this mixture for about 12-24 hours until the background is clear.

Add glycerol 10 per cent v/v to the mixture of glacial acetic acid, ethanol and water. Soak the gel for 1 hour in the solution.

The principal bands of the electropherogram obtained with the test solution correspond in position to the principal bands of the electropherogram obtained with the reference solution. Plot the migration distances of the isoelectric point markers versus their isoelectric points and determine the isoelectric points of the principal components of the test solution and the reference solution. They do not differ by more than 0.2 pl unit. The test is not valid unless the isoelectric point markers are distributed along the entire length of the gel and the isoelectric points of the principal bands in the electropherogram obtained with the reference solution are between 5.8 and 6.3.

C. Examine the electropherograms obtained under reducing conditions in the test for impurities of molecular masses differing from that of interferon alfa-2. The principal band in the electropherogram obtained with test solution (a) corresponds in position to the principal band in the electropherogram obtained with reference solution (a).

D. Determine by peptide mapping (2.3.47).

**Test solution**. Dilute the preparation under examination with water to produce a solution containing 0.5 mg protein per ml.
Transfer 25 µl to a microfuge tube of 1.5 ml capacity. Add 1.6 µl of 1 M phosphate buffer solution pH 8.0, 2.8 µl of a freshly prepared 1.0 mg per ml solution of trypsin in water (suitable for peptide mapping) and 3.6 µl of water and mix vigorously. Cap the tube and place it in a water-bath at 37º for 18 hours. Add 100 µl of a 573 g per litre solution of guanidine hydrochloride and mix well. Add 7 µl of 154.2 g per litre solution of dithiothreitol and mix well. Place the capped tube in boiling water for 1 minute and cool to room temperature.

**Reference solution.** A 0.5 mg per ml solution of the appropriate interferon alfa-2 RS prepared at the same time and in the same manner as the test solution.

**Chromatographic system**
- a stainless steel column 100 cm x 4.6 mm, packed with octadeylsilil silica gel (5 µm) with a pore size of 30 nm,
- mobile phase A.1 ml of trifluoroacetic acid dilute to 1000 ml with water,
  - B. Add 1 ml of trifluoroacetic acid to 100 ml of water and dilute to 1000 ml with acetonitrile,
- flow rate. 1 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 214 nm,
- a 100 µl loop injector.

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.8</td>
<td>100</td>
<td>0</td>
<td>isocratic</td>
</tr>
<tr>
<td>8.68</td>
<td>100 → 04</td>
<td>0 → 60</td>
<td>linear gradient</td>
</tr>
<tr>
<td>68.72</td>
<td>40</td>
<td>60</td>
<td>isocratic</td>
</tr>
<tr>
<td>72.75</td>
<td>40 → 100</td>
<td>60 → 0</td>
<td>linear gradient</td>
</tr>
<tr>
<td>75.08</td>
<td>100</td>
<td>0</td>
<td>re-equilibration</td>
</tr>
</tbody>
</table>

Equilibrate the column with mobile phase A for at least 15 minutes maintaining the temperature of the column at 30º.

Inject the test solution and the reference solution. The chromatogram obtained with each solution should be qualitatively similar to the chromatogram of interferon alfa-2. The profile of the chromatogram obtained with the test solution should also correspond to that of the chromatogram obtained with the reference solution.

**Tests**

**Impurities of molecular masses differing from that of interferon alfa-2.** Determine by electrophoresis (sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) (2.4.12). The test is performed under both reducing and non-reducing conditions, using resolving gels of 14 per cent acrylamide and silver staining as the detection method.

**Sample buffer (non-reducing conditions).** Mix equal volumes of water and concentrated SDS PAGE sample buffer.

**Sample buffer (reducing conditions).** Mix equal volumes of water and concentrated SDS PAGE sample buffer for reducing conditions containing 2-mercaptoethanol as the reducing agent.

**Test solution (a).** Dilute the preparation under examination in the sample buffer to obtain a solution containing a concentration of 0.5 mg protein per ml.

**Test solution (b).** Dilute 0.2 ml of test solution (a) to 1 ml with the sample buffer.

**Reference solution (a).** Prepare a 0.625 mg per ml solution of the appropriate interferon alfa-2 RS in the sample buffer.

**Reference solution (b).** Dilute 0.2 ml of reference solution (a) to 1 ml with the sample buffer.

**Reference solution (c).** Dilute 0.2 ml of reference solution (b) to 1 ml with the sample buffer.

**Reference solution (d).** Dilute 0.2 ml of reference solution (c) to 1 ml with the sample buffer.

**Reference solution (e).** Dilute 0.2 ml of reference solution (d) to 1 ml with the sample buffer.

**Reference solution (f).** Use a solution of molecular mass standards suitable for calibrating SDS-PAGE gels in the range 15 kDa to 67 kDa.

Place the test and reference solutions, contained in covered test-tubes, on a water-bath for 2 minutes.

Apply 10 µl of reference solution (f) and 50 µl of each of the other solutions to the stacking gel wells. Perform the electrophoresis under the conditions recommended by the manufacturer of the equipment. Detect proteins in the gel by silver staining.

The test is not valid unless (1) the validation criteria are met; (2) a band is seen in the electropherogram obtained with reference solution (e); (3) a gradation of intensity of staining is seen in the electropherograms obtained, respectively, with test solution (a) and test solution (b) and with reference solutions (a) to (e).

The electropherogram obtained with test solution (a) under reducing conditions may show, additional bands but no such band should be more intense than the band obtained with reference solution (d). Further, not more than 3 such bands should be more intense than the principal band obtained with reference solution (e).

The electropherogram obtained with test solution (a) under non-reducing conditions may show, in addition to the principal band, less intense bands with molecular masses higher than the principal band. No such band is more intense than the principal band in the electropherogram obtained with reference solution (d) and not more than three such bands are more
intense than the principal band in the electropherogram obtained with reference solution (e).

**Related proteins.** Determine by liquid chromatography (2.4.14).

0.25 per cent w/w hydrogen peroxide solution. Dilute hydrogen peroxide solution with water to obtain 0.25 per cent w/w solution.

Test solution. Dilute the preparation under examination with water to obtain a solution containing 0.5 mg protein per ml.

Reference solution. To a volume of the test solution, add a suitable volume of the 0.25 per cent hydrogen peroxide solution to give a final hydrogen peroxide concentration of 0.005 per cent, and allow to stand at room temperature for 1 hour, to generate about 5 per cent oxidised interferon. Add 12.5 mg of L-methionine per ml of the solution. Allow to stand at room temperature for 1 hour. Store the solutions for not longer than 24 hours at a temperature of 2º to 8º.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilil silica gel (5 μm) with a pore size of 30 nm,
- mobile phase: A. To 700 ml of water add 2 ml of trifluoroacetic acid and 300 ml of acetonitrile,
  B. To 200 ml of water add 2 ml of trifluoroacetic acid and 800 ml of acetonitrile,
- flow rate. 1 ml per minute,
- a linear gradient programme using the conditions given below,
- spectrophotometer set at 210 nm, and
- a 100 µl loop injector

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Mobile phase A (per cent v/v)</th>
<th>Mobile phase B (per cent v/v)</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1</td>
<td>72</td>
<td>280</td>
<td>isocratic</td>
</tr>
<tr>
<td>1.5</td>
<td>72→67</td>
<td>28→33</td>
<td>linear gradient</td>
</tr>
<tr>
<td>5–20</td>
<td>67→63</td>
<td>33→37</td>
<td>linear gradient</td>
</tr>
<tr>
<td>20–30</td>
<td>63→57</td>
<td>37→43</td>
<td>linear gradient</td>
</tr>
<tr>
<td>30–40</td>
<td>57→40</td>
<td>43→60</td>
<td>linear gradient</td>
</tr>
<tr>
<td>40–42</td>
<td>40</td>
<td>60</td>
<td>isocratic</td>
</tr>
<tr>
<td>42–50</td>
<td>40→72</td>
<td>60→28</td>
<td>linear gradient</td>
</tr>
<tr>
<td>50–60</td>
<td>72</td>
<td>28</td>
<td>re-equilibration</td>
</tr>
</tbody>
</table>

Equilibrate the column with the mobile phases in the initial gradient ratio for at least 15 minutes.

Inject alternatively the test solution and the reference solution.

Interferon alfa-2 elutes at a retention time of about 20 minutes in the chromatogram. With the reference solution a peak related to oxidized interferon appears at a retention time of about 0.9 relative to the principal peak.

The test is not valid unless the resolution between the peaks corresponding to oxidised interferon and interferon is at least 1.0. Consider only the peaks whose retention time is 0.7 to 1.4 relative to that of the principal peak.

In the chromatogram obtained with the test solution, the area of any peak, apart from the principal peak, is not greater than 3.0 per cent of the total area of all of the peaks. The sum of the areas of any peaks other than the principal peak is not greater than 5.0 per cent of the total area of all of the peaks.

**Bacterial endotoxins (2.2.3).** Not more than 100 Endotoxin Units per mg of protein.

**Assay**

**Protein**

Test solution. Dilute the preparation under examination with water to obtain a concentration of about 0.5 mg of interferon alfa-2 per ml.

Reference solutions. Prepare a stock solution of 0.5 mg per ml of bovine albumin. Prepare eight dilutions of the stock solution containing between 3 µg per ml and 30 µg per ml of bovine albumin.

Prepare 30-fold and 50-fold dilutions of the test solution.

Prepare a mixture of 2.0 ml of a 2.0 per cent w/v solution of copper sulphate in water, 2.0 ml of a 4.0 per cent w/v solution of sodium tartrate in water and 96.0 ml of a 4.0 per cent w/v solution of sodium carbonate in 0.2 M sodium hydroxide.

Add 1.25 ml of the above mixture to the test-tube containing 1.5 ml of water to prepare the blank, 1.25 ml to the test tube containing different dilutions of the sample and 1.25 ml to the test tube with the reference solution.

Mix after each addition and after approximately 10 minutes, add to each test-tube 0.25 ml of a mixture of equal volumes of water and phosphomolybdotungstic reagent. Mix after each addition. After 30 minutes, measure the absorbance of each solution at 750 nm (2.4.7) using the blank as the compensation liquid.

Draw a calibration curve from the absorbances of the eight reference solutions and the corresponding protein contents and read from the curve the content of protein in the test solution.

**Potency**

The potency of interferon alfa-2 is estimated based on its ability to protect cells against a viral cytopathic effect compared to the protection accorded by an appropriate International Standard of human recombinant interferon alfa-2 or of a reference preparation calibrated in International Units.

The International Unit is the activity contained in a stated amount of the appropriate International Standard. The equivalence in International Units of the International Standard is stated by the World Health Organisation.
Carry out the assay by a suitable method, based on the following design.

Use, an established cell line sensitive to the cytopathic effect of a suitable virus, responsive to interferon.

The following cell cultures and virus have shown to be suitable: MDBK cells (ATCC No. CCL22), or Mouse L cells (NCTC clone 929; ATCC No.CCL 1) as the cell culture and vesicular stomatitis virus VSV, Indiana strain (ATCC No. VR-158) as the infective agent; or human diploid fibroblast FS-71 cells responsive to interferon as the cell culture, and encephalomyocarditis virus (ATCC No.VR-129B) as the infective agent.

Incubate in at least three groups, cells with three or more different concentrations of the preparation under examination and one with the reference preparation in a microtitre plate. Include appropriate controls of untreated cells in each group.

Choose the concentrations of the preparations such that the lowest concentration produces some protection and the largest concentration produces less than maximal protection against the viral cytopathic effect.

Add the cytopathic virus after the cells have established to all wells except the control wells.

Determine the cytopathic effect of virus quantitatively and calculate the potency of the preparation to be examined by the usual statistical methods for a parallel line assay.

The estimated potency is not less than 80 per cent and not more than 125 per cent of the stated potency. The confidence limits of the estimated potency (P= 0.95) are not less than 64 per cent and not more than 156 per cent of the stated potency.

Storage. Store protected from light, at or below –20º.

Labelling. The label states (1) The type of interferon (alfa-2a or alfa-2b); (2) the type of production.

Streptokinase Bulk Solution

Streptokinase Bulk Solution is a fibrinolytic enzyme present in certain strains of haemolytic Streptococcus group C. It has the property of combining with human plasminogen to form plasminogen activator. Streptokinase is also produced by a method based on recombinant DNA technology using bacteria or suitable genetically engineered host cells.

Streptokinase Bulk Solution has a potency of not less than 96,000 IU per mg of protein.

Production

If intended for use in the manufacture of parenteral preparations, the method of manufacture is validated to demonstrate that the product, if tested, would comply with the following test.

Abnormal toxicity

Inject into each mouse a quantity of the preparation under examination (diluted, if necessary, with water for injections) containing 50,000 IU of streptokinase activity in 0.5 ml, the injection lasting 15-20 seconds.

Description. A clear, colourless liquid.

Identification

A. Place 0.5 ml of *citrated human plasma* in a haemolysis tube maintained in a water-bath at 37º. Add 0.1 ml of a dilution of the preparation under examination containing 10,000 IU of streptokinase activity per ml in *phosphate buffer pH 7.2* and 0.1 ml of a solution of *human thrombin RS* containing 20 IU per ml in *phosphate buffer pH 7.2*. Mix immediately. A clot forms and lysed within 30 minutes. Repeat the procedure using *citrated bovine plasma*. The clot does not lyse within 60 minutes.

B. Dissolve 0.6 g of *agar* in 50.0 ml of *barbitone buffer pH 8.6*, heating until a clear solution is obtained. Use glass plates 50 mm square (transparency mounts) free from traces of grease. Using a pipette, apply to each plate 4 ml of the agar solution. Maintain the plates horizontal. Allow to cool. Pierce a cavity 6 mm in diameter in the centre of the agar and an appropriate number of cavities (not exceeding 6) at distances of 11 mm from the central cavity. Remove the residual agar from the cavities using a cannula connected to a vacuum pump. Using pipettes graduated in microlitres, place in the central cavity about 80 µl of goat or rabbit antistreptokinase serum containing 10,000 units of antistreptokinase activity per ml; place in each of the surrounding cavities about 80 µl of a dilution of the preparation under examination containing 125,000 IU of streptokinase activity per ml. Allow the plates to stand in a humidified tank for 24 hours. Only one precipitation arc appears and it is well defined and localised between the application point of the serum and each cavity containing the solution of the preparation under examination.

Tests

pH (2.4.24). 6.8 to 7.5, determined in a solution prepared by diluting the preparation under examination in *carbon dioxide-free water* to produce a solution containing 5000 IU of streptokinase activity per ml.

Streptodornase. Not more than 10 IU of streptodornase activity per 100,000 IU of streptokinase activity.

Test solution. Dilute the preparation under examination in *imidazole buffer pH 6.5* to obtain a solution containing 150,000 IU of streptokinase activity per ml.
**Reference solution.** Dissolve in imidazole buffer pH 6.5 a reference preparation of streptodornase, calibrated in International Units against the International Standard of streptodornase, to obtain a solution containing 20 IU of streptodornase activity per ml. The equivalence in International Units of the International Standard is stated by the regulatory authority.

To each of 8 numbered centrifuge tubes, add 0.5 ml of a 0.1 per cent solution of sodium deoxyribonuclease in imidazole buffer pH 6.5. To tube number 1 and tube number 2 add 0.25 ml of imidazole buffer pH 6.5, 0.25 ml of the test solution and, immediately, 3.0 ml of 2.5 per cent w/v of perchloric acid. Mix, centrifuge at about 3000 rpm for 5 minutes and measure the absorbances of the supernatant liquids at 260 nm (2.4.7), using as the compensation liquid a mixture of 1.0 ml of imidazole buffer pH 6.5 and 3.0 ml of 2.5 per cent w/v solution of perchloric acid (absorbances A1 and A2). To the other 6 tubes (numbers 3 to 8) add 0.25 ml, 0.25 ml, 0.125 ml, 0.125 ml, 0 ml and 0 ml respectively of imidazole buffer solution pH 6.5; add to each tube 0.25 ml of the test solution and 0 ml, 0 ml, 0.125 ml, 0.125 ml, 0.25 ml and 0.25 ml respectively of the reference solution. Mix the contents of each tube and heat at 37º for 15 minutes. To each tube add 3.0 ml of 2.5 per cent w/v of perchloric acid, mix and centrifuge. Measure the absorbances of the supernatant liquids at 260 nm (2.4.7), using the compensation liquid described above (absorbances A3 to A8). The absorbances comply with the following test.

\[
(A3 + A4) - (A1 + A2) < \frac{(A5 + A6 + A7 + A8)}{2} - (A3 + A4)
\]

**Streptolysin**

In a haemolysis tube, use a quantity of the preparation under examination containing 500,000 IU of streptokinase activity and dilute to 0.5 ml with a mixture of 1 volume of phosphate buffer pH 7.2 and 9 volumes of a 0.9 per cent w/v solution of sodium chloride. Add 0.4 ml of a 2.3 per cent w/v solution of sodium thioglycollate. Heat in a water-bath at 37º for 10 minutes. Add 0.1 ml of a solution of a reference preparation of human antistreptolysin O containing 5 IU per ml. Heat at 37º for 5 minutes. Add 1 ml of rabbit erythrocyte suspension. Heat at 37º for 30 minutes. Centrifuge at about 1000 rpm. In the same manner, prepare a haemolysis tube in which the solution of the preparation under examination has been replaced by 0.5 ml of a mixture of 1 volume of phosphate buffer pH 7.2 and 9 volumes of a 0.9 per cent w/v solution of sodium chloride. Measure the absorbances of the supernatant liquids at 550 nm (2.4.7). The absorbance of the test solution is not more than 50 per cent than that of the reference solution.

**Protein.** Determine the nitrogen content (2.3.30).

1 mg of N is equivalent to 6.25 mg of protein.

**Potency**

The potency of streptokinase is determined by comparing its capacity to activate plasminogen to form plasmin with the same capacity of a reference preparation of streptokinase calibrated in International Units; the formation of plasmin is determined using a suitable chromogenic substrate.

The International Unit is the activity of a stated amount of the International Standard for streptokinase. The equivalence in International Units of the International Standard is stated by the regulatory authority.

**Reference and test solutions.** Prepare 2 independent series of 4 dilutions of each of the substance under examination and of the reference preparation of streptokinase in tris (hydroxymethyl) aminomethane sodium chloride buffer pH 7.4, in the range of 0.5-4.0 IU per ml. Prepare and maintain all solutions at 37º.

**Substrate solution.** Mix 1.0 ml of tris (hydroxymethyl) aminomethane buffer pH 7.4 with 1.0 ml of chromophore substrate. Add 5 μl of a 10 per cent w/v solution of polysorbate 20. Keep at 37º in a water-bath. Immediately before commencing the activation assay, add 45 μl of a 1 mg per ml solution of human plasminogen.

Analyse each streptokinase dilution, maintained at 37º, in duplicate. Initiate the activation reaction by adding 60 μl of each dilution to 40 μl of substrate solution. For blank wells, use 60 μl of tris (hydroxymethyl) aminomethane sodium chloride buffer solution pH 7.4 instead of the reference and test solutions. Allow the reaction to proceed at 37º for 20 minutes and read the absorbance at 405 nm (2.4.7). If a suitable thermostated plate reader is available, this may be used to monitor the reaction. Alternatively, it may be necessary to stop the reaction after 20 minutes using 50 µl of a 50 per cent v/v solution of glacial acetic acid. Best results are obtained when the absorbance for the highest streptokinase concentration is between 0.1 and 0.2 (after blank subtraction). If necessary, adjust the time of incubation in order to reach this range of absorbances.

Calculate the regression of the absorbance on log concentrations of the solutions of the substance under examination and of the reference preparation of streptokinase and calculate the potency of the substance under examination using the usual statistical methods for parallel-line assays.

The estimated potency is not less than 90 per cent and not more than 111 per cent of the stated potency. The confidence limits (P = 0.95) of the estimated potency are not less than 80 per cent and not more than 125 per cent of the stated potency.

**Streptokinase Bulk Solution intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial
endotoxins complies with the following additional requirement.

**Bacterial endotoxins** (2.2.3). Less than 0.02 Endotoxin Unit per 100 IU of streptokinase activity.

**Storage.** Store protected from light and at a temperature of about -20°C. If it is intended for the manufacture of parenteral preparations, the container should be sterile and sealed so as to exclude micro-organisms.

**Labelling.** The label states (1) the number of International Units of streptokinase activity per mg, calculated on the dried basis; (2) the name and quantity of any added substance; (3) where applicable, that the substance is free from bacterial endotoxins; (4) where applicable, that the substance is suitable for use in the manufacture of parenteral preparations.
VETERINARY PRODUCTS

General Monographs

Dip Concentrates
Intramammary Infusions
Premixes
Veterinary Aerosols
Veterinary Diagnostics
Veterinary Oral Liquids
Veterinary Oral Powders
Veterinary Parenteral Preparations
Veterinary Tablets

Monographs

Non Biological
Biological
Veterinary Vaccines
Veterinary Preparations

General Requirements

The general requirements relating to a specific type of dosage form of an active pharmaceutical ingredient or ingredients, that have been given in the chapter on General Monographs on Dosage Forms of Active Pharmaceutical Ingredients apply to all veterinary dosage forms or preparations of the type defined. However, a valid interpretation of the appropriateness of a test or requirement should be done in the context of the monograph as a whole and of the relevant General Notices.

The requirement for compliance with the tests given under each dosage form or preparation is indicated in each monograph of a drug product or preparation under the heading ‘Other tests’. These tests are mandatory and are additional to the tests given in the individual monograph.

Dip Concentrates

Dip concentrates are preparations for the prevention and treatment of ectoparasitic infestations of animals. They contain one or more medicaments, usually in the form of wettable powders, pastes or solutions from which diluted suspensions or emulsions are prepared by appropriate dilution with the recommended liquid. The diluted preparations are applied by complete immersion of the animal or by spraying, as appropriate. They contain suitable antimicrobial preservatives.

Labelling. The label states (1) the name(s) and proportion(s) of medicament(s); (2) the name and proportion of any added antimicrobial preservative; (3) the name and quantity of the diluent and the manner of preparing the diluted dip solution or spray; (4) any special precautions to be taken for use of the preparation; (6) the storage conditions; (6) the date after which the preparation is not intended to be used.

If the preparation contains an organophosphorus compound the label also states (1) that the preparation contains an organophosphorus compound; (2) and special precautions on the use of the preparation.

Intramammary Infusions

Intramammary Infusions for Veterinary Use; Intramammary Injections.

Intramammary Infusions are sterile products intended for injection into the mammary gland through the teat canal. They are solutions, emulsions or suspensions or semi-solid preparations containing one or more active ingredients in a suitable vehicle. They may contain stabilizing, emulsifying, suspending and thickening agents. If a sediment is formed in a suspension, it is readily dispersible on shaking. In emulsions, phase separation may occur but this is readily miscible on shaking.

There are two main types of Intramammary Infusions. One is intended for administration to lactating animals as qualified by the term Lactating Cow/Buffalo and the other, qualified as Non-lactating or Dry Cow/Buffalo, is intended for administration to animals at the end of lactation or during the non-lactating period for the prevention or treatment of infection during the dry period.

Intramammary Infusions are prepared by dissolving or suspending the sterile medicaments in the sterilized vehicle using aseptic precautions, unless a process of terminal sterilisation is employed.

Containers. Intramammary Infusions are usually supplied in single dose containers for administration into a single teat canal of an animal. If supplied in multiple dose containers, aqueous preparations contain an antimicrobial preservative in adequate concentration except when the preparation itself has antimicrobial properties. The containers are made as far as possible from materials that meet the requirements for Parenteral Preparations intended for use in human beings.

The containers are sealed so as to exclude micro-organisms and each container is fitted with a smooth, tapered nozzle to facilitate the introduction of the infusion into the teat canal. The containers are sterilised and filled aseptically unless the preparation is subjected to a process of terminal sterilisation.

Tests

Sterility. Intramammary Infusions comply with the test for sterility (2.2.11), using Method A or B, as appropriate, using the contents of 10 containers mixed thoroughly before use in the test. Use for each medium 0.5 to 1.0 g or 0.5 to 1.0 ml, as appropriate, of the mixed sample.

Storage. Store in sterile, single dose or multiple dose, tamper-evident containers.

Labelling. The label states (1) the strength in terms of the weight or the number of Units of activity of the active ingredient(s) or that may be expressed from the container using normal techniques; (2) whether the preparation is intended for use in lactating cow/buffalo or in dry or non-lactating cow/buffalo; (3) for Intramammary Infusions (Non-lactating or Dry Cow/Buffalo), that the preparation is not intended for use in lactating animals; (4) in the case of infusions in multiple dose containers, the name of any added antimicrobial preservative.
Premixes

Premixes are mixtures of one or more active ingredients with suitable bases intended for mixing with feedstuffs before administration to the animals. They are used to dilute medicament(s) with the feed and are usually issued as pellets, granules or powders. If issued as granules, these are free-flowing and free from aggregates. Suitable precautions are taken during manufacture for ensuring that the premix is homogeneous.

Unless otherwise stated in the individual monograph, the concentration of the premix in medicated feedstuffs is not less than 0.5 per cent.

Tests

Loss on drying (2.4.19). Not more than 15.0 per cent, determined on 3 g by drying in an oven at 105º for 2 hours.

Labelling. The label states (1) the strength in terms of the amount of active ingredient(s) as a percentage; (2) the category of animal for which the premix is intended to be used; (3) the directions for the preparation of the medicated feed; (4) where applicable, the minimum interval between the stoppage of feeding of the diluted premix and the slaughter of the animal for human consumption; (5) any special precautions to be taken for use of the premix; (6) the storage conditions; (7) the date after which the preparation is not intended to be used.

Veterinary Aerosols

Veterinary Aerosols are solutions, suspensions or emulsions of one or more active ingredients intended for use by external application. They may contain auxiliary substances such as solvents, solubilising agents, emulsifying agents and suspending agents. They are delivered in the form of an aerosol by the actuation of an appropriate valve or by means of a suitable atomizing device that is either an integral part of the container or is supplied separately.

They may be presented in special containers under pressure of a gas and contain propellants or mixtures of propellants. The medicaments are released from the container in the form of an aerosol upon actuation of an appropriate valve.

Veterinary Aerosols supplied in special pressurized containers comply with the appropriate requirements for Inhalation Preparations. The following requirements also apply for any veterinary aerosol that is the subject of an individual monograph.

Containers. A suitable atomizing device may form part of the container or is supplied separately.

Labelling. The label states (1) that the aerosol is intended for external use only; (2) the instructions for use; (3) any special precautions in the use of the preparation.

Veterinary Diagnostics

Veterinary Diagnostics are antigenic materials of bacterial or viral origin employed for various tests. These will also include polyclonal or monoclonal antibodies. The preparations are examined for their purity at various critical stages of production. The diagnostic kits may be prepared using bacterial or viral antigens and antisera.

Tests

Veterinary Diagnostics, reconstituted where necessary, comply with the following tests unless otherwise stated in the individual monograph.

Identification

Unless otherwise stated in the individual monograph, Veterinary Diagnostics give specific reaction when injected into the skin of a healthy white guinea-pig or rabbit that has not been previously treated with any material that will interfere with the test but fails to produce this reaction when mixed with a sufficient quantity of the specific antitoxin or antiserum.

Sterility. Unless otherwise stated, Veterinary Diagnostics comply with the test for sterility (2.2.11), except that in the case of preparations containing living bacteria there may be growth of the organism from which the diagnostic was prepared.

Use suitable solid media for streaking the preparation under examination and incubate at 32º to 37º for 72 hours for detecting bacteria and at 20º to 25º for 72 hours for detecting fungi. The media selected will depend upon the nature of the product to be tested. The contents of each randomly selected sealed container of the preparation under examination or portions or dilutions thereof, as appropriate, are used for the test.

Other tests to determine the nature and identity of contaminating microorganisms, if any, detected during the test include examination for mobility of the organisms, fermentation reactions, thermo-agglutination tests and dye inhibitor tests (in the case of Brucella cultures).

Unless otherwise stated in the monograph, the preparation passes the test if no growth of microorganisms, other than those from which the veterinary diagnostic was prepared, is observed in any of the media during the incubation period. Repeat the tests if growth of organisms, other than those from which the veterinary diagnostic was prepared, is observed. The vaccine passes the test if no growth of microorganisms,
other than those from which the diagnostic was prepared, is observed in any of the media. The preparation fails the test if growth of a microorganism that was seen after the first test, other than those from which the veterinary diagnostic was prepared, is observed. If growth of a different microorganism is observed, the test may be repeated a second time. The preparation passes the test if no growth of a microorganism, other than those from which the veterinary diagnostic was prepared, is observed in any of the media.

The number of containers recommended to be drawn by the manufacturer for performing the test for sterility depends on the environmental conditions of manufacture, the volume of preparation per container and any other special considerations applicable to the preparation concerned. For preparations intended for veterinary use, 1 per cent of the containers in a batch, with a minimum of three and a maximum of ten, is considered a suitable number assuming that the preparation has been manufactured under appropriately validated conditions designed to exclude contamination.

Storage. Store protected from light in a refrigerator (2º to 8º) unless otherwise stated in the individual monograph.

Labelling. The label states (1) the name and quantity of any antibacterial substance added; (2) for a dried preparation, the nature and quantity of the liquid to be used for reconstitution.

Veterinary Oral Liquids
Veterinary oral liquids intended for administration in large animals may also be called Drenches.

Veterinary Oral Powders
Veterinary Oral Powders are intended for oral administration, usually after dilution in drinking water or the feed. They may be in the form of soluble or wettable powders.

Labelling. The label states (1) for single dose containers, the name and quantity of active medicament(s) per container; (2) for multiple dose containers, the name and quantity of active medicament(s) by weight; (3) the name of any added antimicrobial preservative(s); (4) the directions for use of the preparation.

Veterinary Parenteral Preparations
Veterinary Parenteral Preparations prepared with oily vehicles are not meant for intravenous administration but are suitable for intramuscular or subcutaneous use.

Veterinary Parenteral Preparations comply with the appropriate requirements for Parenteral Preparations (Injections) that are given in the chapter on General Monographs on Dosage Forms of Active Pharmaceutical Ingredients.

Veterinary Tablets
Veterinary tablets are usually solid, circular cylinders the end surfaces of which are flat or biconvex and the edges of which are bevelled except that those weighing 5 g of more may be elongated or biconical.

Tests
Disintegration (2.5.1). The test may have to be suitably modified in the case of large tablets; the discs may have to be omitted because they would otherwise be dislodged from the disintegration tubes. It may also be necessary to adjust the volume of the disintegration medium so that the tablet does not break the surface of the medium at the top of the up-stroke, care being taken to apply the minimum practical volume of liquid for this purpose. For certain tablets where the diameter of the tablet may not permit adequate movement of the disintegration medium, the apparatus and the method should be suitably modified.

Veterinary Vaccines
Veterinary Vaccines
Vaccines for Veterinary Use
Vaccines are a heterogeneous class of medicinal products containing immunogenic substances capable of inducing specific, active and protective host immunity against infectious diseases. They may be prepared from bacteria, viruses, parasites or other organisms or their toxins. Vaccines may contain live attenuated or avirulent microorganisms or these may consist of killed or inactivated microorganisms. Some vaccines consist of antigenic fractions or substances produced by the same pathogenic organisms but rendered harmless whilst retaining their immunogenicity. Vaccines may be prepared from one species or from two or more species of microorganisms.

Vaccines may be prepared by the method described in the individual monograph or by any other appropriate method provided the identity of the antigens is maintained and the preparations are free from microbial contamination and extraneous agents. Suitable adjuvants may be added during the preparation of the vaccines. The addition of antibiotics during the manufacturing process is normally restricted to cell culture fluids and other media, egg inocula and material harvested from skin or other tissues. A suitable bactericide may be added to sterile and inactivated vaccines. The final products are distributed aseptically into sterile containers that
are then sealed to exclude extraneous microorganisms. Unless otherwise indicated in the monograph, the final vaccine may be filled into single dose or multiple dose containers; however, inactivated vaccines in multiple dose containers must invariably contain a bactericide.

**Bacterial vaccines.** Bacterial vaccines are either suspensions of live or killed bacteria or sterile antigenic extracts or derivatives of bacteria pathogenic to animals. They may be simple vaccines prepared from one species or may be combined or polyvalent vaccines prepared by blending two or more simple vaccines from different species or strains. Bacterial vaccines may be prepared from cultures grown on suitable solid or liquid media. The identity, antigenic potency and purity of each bacterial culture must be carefully controlled.

Bacterial vaccines are suspensions of varying degrees of opacity in colourless or slightly coloured liquids or they may be freeze-dried so that the water content is not more than 3.0 per cent w/w unless otherwise stated in the individual monograph. They may be standardised in terms of international opacity units or, where appropriate, by numbers of live or killed bacteria determined by viable count or by direct cell count.

**Live bacterial vaccines.** Live bacterial vaccines are prepared from avirulent or attenuated strains of the specific bacteria that are capable of stimulating immune response against pathogenic strains of the same or of antigenically related species of bacteria.

**Inactivated bacterial vaccines.** Inactivated bacterial vaccines are either prepared from bacteria or their immunogenic components that have been inactivated in a suitable way that they retain adequate immunogenicity.

**Bacterial toxoids.** Bacterial toxoids are prepared from toxins by diminishing their toxicity to a very low level or by completely eliminating it by physical or chemical means whilst retaining adequate immunising potency. The toxins are obtained from selected strains of specific microorganisms, grown in suitable media devoid of agents capable of inducing undesirable immunological reactions in animals. Bacterial toxoids may be liquid or may be prepared by adsorbing on suitable agents such as aluminium phosphate, aluminium hydroxide or any other suitable adsorbents. Bacterial toxoids are clear or slightly opalescent liquids, colourless or slightly yellow. Adsorbed toxoids may be white or greyish-white suspensions or paleyellow liquids with sediment at the bottom of the container. Freeze-dried preparations are greyish-white or yellowish-white powders or pellets.

**Viral vaccines.** Viral vaccines are suspensions of viruses or preparations obtained from tissues or blood of animals artificially infected with viruses pathogenic to animals or from cultures in fertile eggs, or from cell or tissue cultures, they may be live, inactivated / killed and may be freeze-dried.

**Live viral vaccines.** Live viral vaccines are prepared using avirulent or attenuated strains of the specific viruses that are capable of stimulating immunogenic response against pathogenic strains of the same or of antigenically related viruses.

**Inactivated viral vaccines.** Inactivated viral vaccines contain viruses that have been inactivated by suitable chemical or physical means in such a way that the preparations retain adequate immunogenicity or they are suspensions of immunogenic components of such viruses.

**Combined vaccines.** Combined vaccines consist of two or more antigens, combined by the manufacturer at the final formulation stage or mixed immediately before administration. Such vaccines are intended to protect against either more than one disease, or against one disease caused by different strains or serotypes of the same organism.

**Stability.** Stability is the ability of a vaccine to retain its chemical, physical, microbiological and biological properties within specified limits throughout its shelf life.

**Adjuvants.** Substances that are intended to enhance relevant immune response and subsequent clinical efficacy of the vaccine.

**Tests**

Vaccines comply with the tests prescribed in the individual monographs including, where applicable, the following:

- **Aluminium** (2.3.9). Where an aluminium adsorbent has been used in the vaccine, not more than 1.25 mg of aluminium (Al) per single dose, unless otherwise stated.
- **Calcium** (2.3.11). Where a calcium adsorbent has been used in the vaccine, not more than 1.3 mg of calcium (Ca) per single dose, unless otherwise stated.
- **Formaldehyde** (2.3.20). Where formaldehyde has been used in the preparation of the vaccine, not more than 0.2 g/l of free formaldehyde is present in the final product, unless otherwise stated.
- **Phenol** (2.3.36). Where phenol has been used in the preparation of the vaccine, not more than 2.5 g/l is present in the final product, unless otherwise stated.
- **Water** (2.3.43). For freeze-dried vaccines, not more than 3.0 per cent, unless otherwise stated.
- **Thiomersal** (2.3.12) (2.3.48). Where thiomersal has been used in the preparation of the vaccine, not more than 0.02 per cent w/v.

**Extraneous pathogens.** Unless otherwise stated in the individual monograph, live viral vaccines other than those intended for poultry comply with the following test. The mixture obtained after neutralisation of the vaccine with specific
antiserum does not cause cytopathic effects in cell cultures known to be sensitive to agents pathogenic for the species in which the vaccine is intended to be used.

**Sterility (2.2.11).** Unless otherwise stated in the individual monograph, use method A. Incubate the media for not less than 14 days at 30° to 37° in the test for detecting bacteria and at 20° to 25° in the test for detecting fungi. However, for live bacterial vaccines growth of the organism from which the vaccine was prepared is permitted.

The number of containers to be drawn for the test should be 1 per cent of the containers in a batch, with a minimum of 3 and a maximum of 10, assuming that the preparation has been manufactured under appropriately validated conditions designed to exclude contamination.

**Safety Test.** Unless otherwise stated in the individual monograph, vaccines other than live viral vaccines intended for poultry comply with the following test.

Inject at least 2 healthy, susceptible animals of one of the species in which the vaccine is intended to be used by the route recommended by the manufacturer for field use. The quantity to be injected in each animal is twice the appropriate vaccinating dose. Observe the animals for not less than 7 days. No animal exhibits an abnormal reaction.

**Abnormal toxicity.** Where stated in the individual monograph vaccines comply with the following test.

Inject 0.5 ml subcutaneously into each of five mice and 2 ml intraperitoneally into each of two guinea pigs. If the vaccine being examined contains an adjuvant, inject 2 ml of the vaccine subcutaneously into each guinea pig. Observe the animals for 7 days. None of the animals shows significant local or systemic reaction. If one animal dies or shows signs of ill health during the observation period repeat the test. None of the animals of the second group dies or shows signs of ill health. This test may be omitted if a safety test is carried out on animals of the species for which the vaccine is intended.

**Potency.** Determine the potency of the vaccine using the method described in the individual monograph. The vaccine complies with the level of immune response specified in the monograph. A combined vaccine complies with the level specified in the respective monographs for each individual component. If the immunogenicity test (potency test) has been performed with satisfactory results on representative batch of live vaccine from the same seed lot, it may be omitted as a routine control test during production of other batches of the vaccine prepared from the same seed lot.

**Storage.** Store protected from light in a refrigerator (2° to 8°), unless otherwise directed. Do not freeze. Store freeze-dried vaccines at a temperature not exceeding 20°.

**Labelling.** The label states (1) the potency of the preparation; (2) the route of administration and dose; (3) the date up to which the product is expected to remain within specifications; (4) the storage conditions.
Acepromazine Maleate

Acepromazine Maleate is 2-acetyl-10-(3-dimethylaminopropyl)phenothiazine maleate.

Description. A yellow, crystalline powder.

Acepromazine Maleate contains not less than 98.5 per cent and not more than 101.0 per cent of C₁₉H₂₂N₂OS,C₄H₄O₄, calculated on the dried basis.

Identification

Tests B and D may be omitted if tests A, C, E and F are carried out. Tests A and E may be omitted if tests B, C, D and F are carried out.

NOTE — Carry out the tests in subdued light.

A. Dissolve 20 mg in 2 ml of water, add 3 ml of 2 M sodium hydroxide, extract with 5 ml of cyclohexane and remove the solvent under reduced pressure. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with acepromazine RS or with the reference spectrum of acepromazine.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in 0.1 M hydrochloric acid, exhibits maxima at about 244 nm and 280 nm; absorbance at about 244 nm, about 1.1 and at about 280 nm, about 0.82.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with kieselguhr G.

Mobile phase. A mixture of 100 volumes of light petroleum (40° to 60°), 2 volumes of diethylamine and 6 to 8 volumes of 2-phenoxethanol. Shake and use the supernatant liquid.

Test solution. Dissolve 0.2 g of the substance under examination in 100 ml of dichloromethane.

Reference solution. A 0.2 per cent w/v solution of acepromazine maleate RS in dichloromethane.

Impregnate the dry plate by placing it in a tank containing a shallow layer of a mixture of 85 volumes of acetone, 10 volumes of 2-phenoxethanol and 5 volumes of polyethylene glycol 300 so that the plate dips about 5 mm below the surface of the liquid and allow the impregnating solvent to ascend almost to the top. Use the plate immediately after removing it from the tank. Apply to the plate 1 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with the reference solution. A secondary spot due to maleic acid is also observed in both chromatograms. Spray the plate with ethanolic sulphuric acid (10 per cent v/v). The spot in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with the reference solution.

D. Dissolve 5 mg in 2 ml of sulphuric acid; a yellow colour is produced which changes to deep orange on warming for 2 minutes.

E. Dissolve 0.2 g in a mixture of 3 ml of water and 2 ml of 5 M sodium hydroxide and shake with three quantities, each of 3 ml, of ether. Discard the ether extracts. Add 2 ml of bromine solution to the aqueous solution, warm in a water-bath for 10 minutes, heat to boiling, cool and add 0.25 ml to a solution of 10 mg of resorcinol in 3 ml of sulphuric acid; a bluish-black colour is produced on heating for 15 minutes in a water-bath.

F. Melting range (2.4.21). 136° to 139°.

Tests

pH (2.4.24). 4.0 to 4.5, determined in a 1.0 per cent w/v solution.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Solvent mixture. A mixture of 95 volumes of methanol and 5 volumes of diethylaniline.

Mobile phase. A mixture of 75 volumes of hexane, 17 volumes of 2-butanol and 8 volumes of diethylamine.

Test solution. Dissolve 0.2 g of the substance under examination in 10 ml of the solvent mixture.

Reference solution. A 0.010 per cent w/v solution of the substance under examination in the solvent mixture.

Sulphated ash (2.3.18) Not more than 0.2 per cent.

Loss on drying (2.4.19). Not more than 0.1 per cent, determined on 1.0 g by drying in an oven at 105°.

Assay. Weigh accurately about 0.4 g, dissolve in 50 ml of acetic anhydride. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

C₁₀H₁₉N₂OS, C₄H₄O₄ Mol. Wt. 442.5
1 ml of 0.1 M perchloric acid is equivalent to 0.04425 g of 
C_{19}H_{22}N_{2}O_{5}C_{4}H_{4}O_{4}.

Storage. Store protected from moisture.

**Acepromazine Injection**

Acepromazine Maleate Injection

Acepromazine Injection is a sterile solution of Acepromazine Maleate in Water for Injections.

Acepromazine Injection contains not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of acepromazine, C_{19}H_{22}N_{2}O_{5}.

**Identification**

NOTE — Carry out the tests in subdued light.

A. To a volume containing 20 mg of acepromazine, add 2 ml of water and 3 ml of 2 M sodium hydroxide, extract with two quantities, each of 5 ml, of cyclohexane and remove the solvent under reduced pressure. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with acepromazine RS or with the reference spectrum of acepromazine.

B. To 5 mg of the residue obtained in test A, add 2 ml of sulphuric acid; a yellow colour is produced which changes to deep orange on warming for 2 minutes.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with kieselguhr G.

Mobile phase. A mixture of 100 volumes of light petroleum (40° to 60°), 2 volumes of diethyamine and 6 to 8 volumes of 2-phenoxyethanol. Shake and use the supernatant liquid.

Test solution. Extract a volume containing 20 mg of acepromazine with two quantities, each of 5 ml, of dichloromethane and use the combined extracts.

Reference solution. A 0.2 per cent w/v solution of acepromazine maleate RS in dichloromethane.

Impregnate the dry plate by placing it in a tank containing a shallow layer of a mixture of 85 volumes of acetone, 10 volumes of 2-phenoxyethanol and 5 volumes of polyethylenglycol 300 so that the plate dips about 5 mm below the surface of the liquid and allow the impregnating solvent to ascend almost to the top. Use the plate immediately after removing it from the tank. Apply to the plate 1 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with the reference solution. A secondary spot due to maleic acid is also observed in both chromatograms. Spray the plate with ethanolic sulphuric acid (10 per cent v/v). The spot in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with the reference solution.

D. To a volume containing 25 mg of acepromazine add 2 ml of 5 M sodium hydroxide and shake with three quantities, each of 3 ml, of ether. Discard the ether extracts. Add 2 ml of bromine solution to the aqueous solution, warm in a water-bath for 10 minutes, heat to boiling, cool and add 0.25 ml to a solution of 10 mg of resorcinol in 3 ml of sulphuric acid; a bluish-black colour is produced on heating for 15 minutes in a water-bath.

**Tests**

pH (2.4.24). 4.5 to 5.5.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. To an accurately measured volume containing 40 mg of acepromazine add 5 ml of 1 M sodium hydroxide and extract with three or more quantities, each of 50 ml, of dichloromethane until the dichloromethane extract is colourless. Wash the extracts with the same 10 ml of water and filter through a plug of absorbent cotton previously moistened with dichloromethane. Evaporate the combined extracts to dryness, dissolve the residue in 15 ml of acetic anhydride. Titrate with 0.02 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.02 M perchloric acid is equivalent to 0.006529 g of C_{19}H_{22}N_{2}O_{5}.

Storage. Store protected from light.

**Labelling.** The label states the strength in terms of the equivalent amount of acepromazine.

**Acepromazine Tablets**

Acepromazine Maleate Tablets

Acepromazine Tablets contain not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of acepromazine, C_{19}H_{22}N_{2}O_{5}.

**Identification**

NOTE — Carry out the tests in subdued light.

A. To a quantity of the powdered tablets containing 20 mg of acepromazine add 2 ml of water and 3 ml of 2 M sodium hydroxide. Extract with two quantities, each of 5 ml, of cyclohexane and remove the solvent under reduced pressure. The residue complies with the following test.
Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with acepromazine RS or with the reference spectrum of acepromazine.

B. To 5 mg of the residue obtained in test A add 2 ml of sulphuric acid; a yellow colour is produced which changes to deep orange on warming for 2 minutes.

C. Determine by thin-layer chromatography (2.4.17), coating the plate with kieselguhr G.

Mobile phase. A mixture of 100 volumes of light petroleum (40° to 60°), 2 volumes of diethylamine and 6 to 8 volumes of 2-phenoxyethanol. Shake and use the supernatant liquid.

Test solution. Extract a quantity of powdered tablets containing 20 mg of acepromazine with two quantities, each of 5 ml, of dichloromethane and use the combined extracts.

Reference solution. A 0.2 per cent w/v solution of acepromazine maleate RS in dichloromethane.

Impregnate the dry plate by placing it in a tank containing a shallow layer of a mixture of 85 volumes of acetone, 10 volumes of 2-phenoxyethanol and 5 volumes of polyethylene glycol 300 so that the plate dips about 5 mm below the surface of the liquid and allow the impregnating solvent to ascend almost to the top. Use the plate immediately after removing it from the tank. Apply to the plate 1 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with the reference solution. A secondary spot due to maleic acid is also observed in both chromatograms. Spray the plate with ethanolic sulphuric acid (10 per cent v/v). The spot in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with the reference solution.

D. Dissolve a quantity of the powdered tablets containing 25 mg of acepromazine as completely as possible in a mixture of 3 ml of water and 2 ml of 5 M sodium hydroxide and shake with three quantities, each of 3 ml, of ether. Discard the ether extracts. Add 2 ml of bromine solution to the aqueous solution, warm in a water-bath for 10 minutes, heat to boiling, cool and add 0.25 ml of a solution of 10 mg of resorcinol in 3 ml of sulphuric acid; a bluish-black colour is produced on heating for 15 minutes in a water-bath.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Solvent mixture. A mixture of 95 volumes of methanol and 5 volumes of diethylamine.

Mobile phase. A mixture of 75 volumes of hexane, 17 volumes of 2-butanol and 8 volumes of diethylamine.

Test solution. Shake a quantity of the powdered tablets containing 50 mg of acepromazine with 10 ml of dichloromethane, filter, evaporate to dryness and dissolve the residue in 5 ml of methanol containing 0.5 per cent v/v of strong ammonia solution.

Reference solution. Dilute 1 ml of the test solution to 100 ml with methanol containing 0.5 per cent v/v of strong ammonia solution.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Other tests. Comply with the tests stated under Tablets.

Assay. Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 60 mg of acepromazine, add 5 ml of water and extract with three or more quantities, each of 50 ml, of dichloromethane until the dichloromethane extract is colourless. Wash the extracts with the same 10 ml of water and filter through a plug of absorbent cotton previously moistened with dichloromethane. Evaporate the combined extracts to dryness, dissolve the residue in 15 ml of acetic anhydride. Titrate with 0.02 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.02 M perchloric acid is equivalent to 0.006529 g of C₁₉H₂₂N₂O₅S.

Labelling. The label states the strength in terms of the equivalent amount of acepromazine.

Amitraz

\[
\text{C}_{19}\text{H}_{23}\text{N}_3 \quad \text{Mol. Wt. 293.41}
\]

Amitraz is \(N,N\)-di-(2,4-xylyliminomethyl)methylamine.

Description. A white to buff powder.

Amitraz contains not less than 95.0 per cent and not more than 101.5 per cent of \(C_{19}H_{22}N_3\), calculated on the anhydrous basis.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with amitraz RS or with the reference spectrum of amitraz.
B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).

C. In the Assay, the principal peak in the chromatogram obtained with the test solution (b) corresponds to the peak in the chromatogram obtained with the reference solution.

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

**Mobile phase.** A mixture of 50 volumes of cyclohexane, 30 volumes of ethyl acetate and 20 volumes of triethylamine.

**Test solution (a).** Dissolve 1 g of the substance under examination in 10 ml of toluene.

**Test solution (b).** Dissolve 20 mg of the substance under examination in 10 ml of toluene.

**Reference solution (a).** A 0.20 per cent w/v solution of amitraz RS in toluene.

**Reference solution (b).** A 0.030 per cent w/v of 2,4-dimethylaniline in toluene.

Impregnate the plate to a depth of about 3.5 cm with a solution prepared by dissolving 35 g of acetamide in 100 ml of methanol, adding 100 ml of triethylamine and diluting to 250 ml with methanol, before standing it in a stream of cold air for about 30 seconds. Immediately apply to the plate, at a level 1 cm below the top of the impregnated zone, 2 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with test solution (a) is not more intense than the spot in the chromatogram obtained with reference solution (a). Expose to the vapours of hydrochloric acid until the plate smells strongly of acid. Expose to the vapours of nitrogen dioxide (prepared by the action of nitric acid on granulated zinc) for 10 minutes, remove the excess of nitrogen dioxide with air and spray with a 0.5 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride in a 50 per cent v/v solution of methanol. Any secondary spot corresponding to 2,4-dimethylaniline in the chromatogram obtained with test solution (a) is not more intense than the corresponding spot in the chromatogram obtained with reference solution (b).

**Water (2.3.43).** Not more than 0.1 per cent, determined on 5 g and using anhydrous pyridine in place of anhydrous methanol.

**Sulphated ash (2.3.18).** Not more than 0.2 per cent.

**Assay.** Determine by gas chromatography (2.4.13).

**Internal Standard Solution.** A 1.0 per cent v/v solution of squalane in methyl acetate.

**Liquid Amitraz Dip Concentrate**

Liquid Amitraz Dip Concentrate contains Amitraz in a suitable emulsifiable vehicle. It may contain a suitable stabilising agent. Liquid Amitraz Dip Concentrate contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of amitraz, C₁₉H₂₃N₃.

**Identification**

A. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).

B. In the Assay, the principal peak in the chromatogram obtained with the test solution (b) corresponds to the peak in the chromatogram obtained with reference solution (b).

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

**Mobile phase.** A mixture of 50 volumes of cyclohexane, 30 volumes of ethyl acetate and 20 volumes of triethylamine.

**Test solution (a).** Dilute the dip concentrate with toluene to obtain 5.0 per cent w/v of Amitraz.

**Test solution (b).** Dilute the dip concentrate with toluene to obtain 0.2 per cent w/v of Amitraz.

**Reference solution (a).** A 0.20 per cent w/v solution of amitraz RS in toluene.
AMITRAZ DIP CONCENTRATE POWDER

Amitraz Dip Concentrate Powder consists of Amitraz mixed with suitable wetting, dispersing and suspending agents. It may contain a suitable stabilising agent.

Amitraz Dip Concentrate Powder contains not less than 92.0 per cent and not more than 108.0 per cent of the stated amount of amitraz, C₁₉H₂₃N₃.

Identification

A. Shake a quantity of the powder containing 0.1 g of Amitraz with 10 ml of acetone for 5 minutes, filter and evaporate the filtrate to dryness. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with amitraz RS or with the reference spectrum of amitraz.

B. In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (a).

C. In the Assay, the principal peak in the chromatogram obtained with the test solution (b) corresponds to the peak in the chromatogram obtained with the reference solution.

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel HF254.

Mobile phase. A mixture of 50 volumes of cyclohexane, 30 volumes of ethyl acetate and 20 volumes of triethylamine.

Test solution (a). The supernatant liquid obtained by shaking a quantity of the powder containing 0.5 g of Amitraz with 10 ml of toluene for 5 minutes and centrifuging the suspension.

Test solution (b). The supernatant liquid obtained by shaking a quantity of the powder containing 20 mg of Amitraz with 10 ml of toluene for 5 minutes and centrifuging the suspension.

Reference solution (a). A 0.20 per cent w/v solution of amitraz RS in toluene.

Reference solution (b). A 0.030 per cent w/v of 2,4-dimethylaniline in toluene.

Impregnate the plate to a depth of about 3.5 cm in a solution prepared by dissolving 35 g of acetamide in 100 ml of methanol, adding 100 ml of triethylamine and diluting to 250 ml with methanol, before standing it in a stream of cold air for about 30 seconds. Immediately apply to the plate, at a level 1 cm below the top of the impregnated zone, 2 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution (a) is not more intense than the spot in the chromatogram obtained with the reference solution (a). Expose the plate to the vapours of hydrochloric acid until the plate smells strongly of acid. Expose to the vapours of nitrogen dioxide (prepared by the action of nitric acid on granulated zinc) for 10 minutes, remove the excess of nitrogen dioxide with air and spray with a 0.5 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride in a 50 per cent v/v solution of methanol.

Any secondary spot corresponding to 2,4-dimethylaniline in the chromatogram obtained with test solution (a) is not more intense than the corresponding spot in the chromatogram obtained with reference solution (b).

Water (2.3.43). Not more than 0.15 per cent w/v, determined in 5 ml of the dip concentrate and using anhydrous pyridine in place of anhydrous methanol.

Other tests. Complies with the tests stated under Dip Concentrates.

Assay. Determine by gas chromatography (2.4.13).

Internal Standard Solution. A 1.0 per cent v/v solution of squalane in methyl acetate.

Test solution (a). Dissolve an accurately measured volume of the dip concentrate containing 80 mg of Amitraz in 10 ml of methyl acetate.

Test solution (b). Dissolve an accurately measured volume of the dip concentrate containing 80 mg of Amitraz in 10 ml of the internal standard solution.

Reference solution. A 0.8 per cent w/v solution of amitraz RS in the internal standard solution.

Chromatographic system

- a glass column 1.5 m x 4 mm, packed with acid-washed, silanised diatomaceous support (80 to 100 mesh) coated with 3 per cent w/w methyl silicone gum or fluid (such as OV-1 or OV-101),
- temperature: column 250°C, inlet port and detector 280°C,
- flow rate. 30 ml per minute of the carrier gas.

Calculate the content of C₁₉H₂₃N₃.
intense than the spot in the chromatogram obtained with the reference solution (a). Expose the plate to the vapours of hydrochloric acid until the plate smells strongly of acid. Expose to the vapours of nitrogen dioxide (prepared by the action of nitric acid on granulated zinc) for 10 minutes, remove the excess of nitrogen dioxide with air and spray with a 0.5 per cent w/v solution of \( N-(1\text{-naphthyl}) \text{ethylenediamine dihydrochloride} \) in a 50 per cent v/v solution of methanol. Any secondary spot corresponding to 2,4-dimethylaniline in the chromatogram obtained with test solution (a) is not more intense than the corresponding spot in the chromatogram obtained with reference solution (b).

**Other tests.** Complies with the tests stated under Dip Concentrates.

**Assay.** Determine by gas chromatography (2.4.13).

**Internal Standard Solution.** A 1.0 per cent v/v solution of squalane in methyl acetate.

**Test solution (a).** Shake a quantity of the powder containing 80 mg of Amitraz with 10 ml of methyl acetate, centrifuge and use the supernatant liquid.

**Test solution (b).** Shake a quantity of the powder containing 80 mg of Amitraz with 10 ml of the internal standard solution, centrifuge and use the supernatant liquid.

**Reference solution.** A 0.8 per cent w/v solution of amitraz RS in the internal standard solution.

**Chromatographic system**
- a glass column 1.5 m x 4 mm, packed with acid-washed, silanised diatomaceous support (80 to 100 mesh) coated with 3 per cent w/w methyl silicone gum or fluid (such as OV-1 or OV-101),
- temperature: column 250°, inlet port and detector 280°,
- flow rate: 30 ml per minute of the carrier gas.

Calculate the content of \( \text{C}_{19}\text{H}_{23}\text{N}_3 \).

Ampicillin and Cloxacillin Intramammary Infusion (Lactating Cow/Buffalo)

Ampicillin Sodium and Cloxacillin Sodium Intramammary Infusion (LC/B)

Ampicillin and Cloxacillin Intramammary Infusion (Lactating Cow/Buffalo) is a sterile suspension of Ampicillin Sodium and Cloxacillin Sodium in a suitable vehicle containing suitable suspending agents.
volumes of glacial acetic acid and 2 volumes of a 1 per cent w/v solution of iodine in a 4 per cent w/v solution of potassium iodide. The principal spot in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with the reference solution.

C. Extract a quantity containing 50 mg of ampicillin with three successive quantities, each of 15 ml, of light petroleum (120° to 160°). Discard the extracts, wash the residue with 10 ml of ether and dry the residue at 55°. The residue produces an intense, persistent yellowish orange colour when introduced into a non-luminous flame on a platinum wire moistened with hydrochloric acid.

Tests

Water (2.3.43). Not more than 1.0 per cent, determined on 1.5 g using a mixture of 70 volumes of dichloromethane and 30 volumes of anhydrous methanol as the solvent.

Other tests. Complies with the tests stated under Intramammary Infusions.

Assay. Weigh and mix the contents of 10 containers. Weigh accurately a quantity of the mixed contents containing 50 mg of ampicillin and extract with three successive quantities, each of 15 ml, of light petroleum (120° to 160°) previously saturated with ampicillin sodium and cloxacillin sodium. Discard the extracts, wash the residue with ether previously saturated with ampicillin sodium and cloxacillin sodium, dry in a current of air, dissolve in water and dilute to 100.0 ml with water. Centrifuge and use the clear supernatant liquid (solution B).

For ampicillin — Dilute 2.0 ml of solution B to 50.0 ml with buffered cupric sulphate solution pH 5.2, transfer 10.0 ml of the resulting solution to a stoppered test-tube and heat in a water-bath at 75° for 30 minutes. Cool to room temperature rapidly, dilute to 20.0 ml with buffered cupric sulphate solution pH 5.2 and measure the absorbance of the resulting solution at the maximum at about 320 nm (2.4.7), using as the blank a solution prepared by diluting 2.0 ml of solution B to 100.0 ml with buffered cupric sulphate solution pH 5.2.

Calculate the content of C₁₆H₁₉N₃O₄S in a container of average content from the absorbance obtained by carrying out the procedure simultaneously using 2.0 ml of a solution prepared by dissolving 0.14 g of cloxacillin sodium RS in 100.0 ml of water.

Labelling. The label states the quantity of Ampicillin Sodium in terms of the equivalent amount of ampicillin and the quantity of Cloxacillin Sodium in terms of the equivalent amount of cloxacillin.

Ampicillin and Cloxacillin Benzathine Intramammary Infusion (Dry Cow/Buffalo)

Ampicillin and Cloxacillin Benzathine Intramammary Infusion (Dry Cow/Buffalo) is a sterile suspension of Ampicillin Trihydrate and Cloxacillin Benzathine in a suitable vehicle containing suitable suspending agents.

Ampicillin and Cloxacillin Benzathine Intramammary Infusion (Dry Cow/Buffalo) contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of ampicillin, C₁₆H₁₉N₃O₄S, and cloxacillin, C₁₉H₁₈ClN₃O₅S.

Identification

A. Extract a quantity containing 250 mg of ampicillin with three quantities, each of 15 ml, of light petroleum (120° to 160°). Discard the extracts, wash the residue with 10 ml of ether and dry in a current of air. Shake with 10 ml of dichloromethane and filter. Keep both the residue and the filtrate.

Wash the residue with two quantities, each of 5 ml, of dichloromethane and dry in a vacuum desiccator.

On the residue determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ampicillin trihydrate RS or with the reference spectrum of ampicillin trihydrate.

B. Wash the filtrate with two quantities, each of 5 ml, of water, dry the dichloromethane layer with anhydrous sodium sulphate, filter and dilute the filtrate to 20 ml with dichloromethane.

On the filtrate determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with cloxacillin benzathine RS or with the reference spectrum of cloxacillin benzathine.

Tests

Water (2.3.43). Not more than 3.0 per cent, determined on 1.5 g using a mixture of 70 volumes of dichloromethane and 30 volumes of anhydrous methanol as the solvent.
Other tests. Complies with the tests stated under Intramammary Infusions.

Assay. Weigh and mix the contents of 10 containers. Weigh accurately a quantity of the mixed contents containing 60 mg of ampicillin and extract with three quantities, each of 15 ml, of light petroleum (120° to 160°) previously saturated with ampicillin trihydrate and cloxacillin benzathine. Discard the extracts, wash the residue with ether previously saturated with ampicillin trihydrate and cloxacillin benzathine, dry in a current of air, dissolve in 50 ml of methanol and dilute to 100.0 ml with water. Centrifuge and use the clear supernatant liquid (solution A).

For ampicillin — Dilute 2.0 ml of solution A to 50.0 ml with buffered cupric sulphate solution pH 5.2, transfer 10.0 ml to a stoppered test-tube and heat in a water-bath at 75° for 30 minutes. Cool to room temperature rapidly, dilute to 20.0 ml with buffered cupric sulphate solution pH 5.2 and measure the absorbance of the resulting solution at the maximum at about 320 nm (2.4.7), using as the blank the unheated buffered solution of the infusion.

Calculate the content of C_{16}H_{19}N_{3}O_{4}S in a container of average content from the absorbance obtained by carrying out the procedure simultaneously using 2.0 ml of a solution prepared by dissolving 70 mg of ampicillin trihydrate RS in 100.0 ml of a 50 per cent v/v solution of methanol, diluting to 50.0 ml with buffered cupric sulphate solution pH 5.2, and beginning at the words “transfer 10.0 ml ....”.

For cloxacillin — Dilute 2.0 ml of solution A to 100.0 ml with 1 M hydrochloric acid and measure the absorbance of the resulting solution at 20° after exactly 12 minutes at the maximum at about 350 nm, (2.4.7), using 1 M hydrochloric acid as the blank. Calculate the content of C_{19}H_{18}ClN_{3}O_{5}S in a container of average content from the absorbance obtained by carrying out the procedure simultaneously using 2.0 ml of a solution prepared by dissolving 0.165 g of cloxacillin benzathine RS in 100.0 ml of a 50 per cent v/v solution of methanol, diluting to 100.0 ml with a 1 per cent w/v solution of disodium edetate in mixed phosphate buffer pH 4.0 and 1 volume of 1-butanol.

Labelling. The label states the strength of Ampicillin Trihydrate in terms of the equivalent amount of ampicillin and that of Cloxacillin Benzathine in terms of the equivalent amount of cloxacillin.

Ampicillin Veterinary Oral Powder

Ampicillin TrihydrateVeterinary Oral Powder

Ampicillin Veterinary Oral Powder is a mixture of Ampicillin Trihydrate and Lactose or other suitable diluent.

Ampicillin Veterinary Oral Powder contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of ampicillin, C_{16}H_{19}N_{3}O_{4}S.

Description. A fine granular powder.

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

NOTE — Prepare the solutions immediately before use.

Mobile phase. A mixture of 10 volumes of butyl acetate, 6 volumes of glacial acetic acid, 2 volumes of a 0.1 per cent w/v solution of disodium edetate in mixed phosphate buffer pH 4.0 and 1 volume of 1-butanol.

Test solution. Shake a quantity of the powder containing 0.1 g of ampicillin with 50 ml of phosphate buffer pH 7.0 for 15 minutes, filter and use the filtrate.

Reference solution. A 0.2 per cent w/v solution of ampicillin trihydrate RS in phosphate buffer pH 7.0.

Impregnate the dry plate by placing it in a tank containing a shallow layer of a 0.1 per cent w/v solution of disodium edetate in mixed phosphate buffer pH 4.0, allowing the solvent to ascend to the top, removing the plate from the tank and allowing the solvent to evaporate. Use the plate with the flow of the mobile phase in the direction in which impregnation was carried out. Before use heat the plate at 100° for 1 hour and allow to cool. Apply to the plate 1 µl of each solution. After development, dry the plate in air and spray with a mixture of 100 volumes of a 1 per cent w/v solution of starch, 6 volumes of glacial acetic acid and 2 volumes of a 1 per cent w/v solution of iodine in a 4 per cent w/v solution of potassium iodide. The principal spot in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with the reference solution.

B. To a quantity of the powder containing 10 mg of ampicillin add sufficient water to produce 10 ml, shake for 15 minutes and filter. Place 0.1 ml of a 0.1 per cent w/v solution of ninhydrin on a filter paper, dry at 105°, superimpose 0.1 ml of the solution of the preparation under examination, heat for 5 minutes at 105° and allow to cool; a mauve colour is produced.

C. Suspend a quantity of the powder containing 10 mg of ampicillin in 1 ml of water and add 2 ml of a mixture of 2 ml of potassium cupri-tartrate solution and 6 ml of water; a magenta-violet colour is immediately produced.

Tests

Uniformity of weight. When supplied in containers intended for use on one occasion, complies with the test for Uniformity of weight described under Parenteral Preparations (Powders for Injection).

Other tests. Complies with the tests stated under Veterinary Oral Powders.
Assay. Weigh accurately a quantity of the powder containing 0.1 g of ampicillin, add sufficient water to produce 100.0 ml, shake for 15 minutes and filter. Dilute 2.0 ml to 100.0 ml with buffered cupric sulphate solution pH 5.2, transfer 10.0 ml of the resulting solution to a stoppered test-tube and heat in a water-bath at 75° for 30 minutes. Cool to room temperature rapidly, adjust the volume if necessary to 10.0 ml with water and measure the absorbance at the maximum at about 320 nm (2.4.7), using as the blank the unheated buffered solution of the powder under examination. Calculate the content of C16H19N3O4S from the absorbance obtained by carrying out the procedure simultaneously using 0.12 g of ampicillin trihydrate RS. When the powder is supplied in containers intended for use on more than one occasion, take the quantity of powder without previous mixing.

Storage. Store protected from moisture, at a temperature not exceeding 30°.

Labelling. The label states the strength in terms of the equivalent concentration of ampicillin.

**Amprolium Hydrochloride**

C14H19ClN4.HCl

Mol. Wt. 315.2

Amprolium Hydrochloride is hydrochloride salt of 1-[4-amino-2-propyl-5-pyrimidinyl)methyl]-2-methylpyridinium chloride.

Amprolium Hydrochloride contains not less than 97.5 per cent and not more than 101.0 per cent of C14H19ClN4.HCl, calculated on the dried basis.

Description. A white or almost white powder.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with amprolium hydrochloride RS or with the reference spectrum of amprolium hydrochloride.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in 0.1 M hydrochloric acid exhibits maxima at about 246 nm and 262 nm; absorbance at about 246 nm, about 0.84 and at about 262 nm, about 0.80.

C. To 1 mg add 5 ml of naphthalenediol reagent; a deep violet colour is produced.

D. Gives the reactions of chlorides (2.3.1).

Tests

Picoline. Dissolve 1.5 g in 30 ml of water in a distillation flask, add 20 ml of a saturated solution of potassium carbonate sesquihydrate, connect the flask to a ground-glass aerator extending to the bottom of a 100-ml graduated cylinder containing 50 ml of 0.05 M hydrochloric acid and pass air, which has previously been passed through sulphuric acid and glass wool, through the system for 60 minutes. To 5 ml of the hydrochloric acid solution add sufficient 0.05 M hydrochloric acid to produce 200 ml. Absorbance of the resulting solution at about 262 nm (2.4.7), not more than 0.52.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying to constant weight at 100° at a pressure not exceeding 0.7 kPa.

Assay. Weigh accurately about 0.3 g, dissolve in 20 ml of anhydrous glacial acetic acid, add 10 ml of mercuric acetate solution. Titrate with 0.1 M perchloric acid, using 1-naphtholbenzein solution as indicator. Carry out a blank titration. 1 ml of 0.1 M perchloric acid is equivalent to 0.01577 g of C14H19ClN4.HCl.

**Amprolium Hydrochloride and Ethopabate Premix**

Amprolium Hydrochloride and Ethopabate Premix contains Amprolium Hydrochloride and Ethopabate.

Amprolium Hydrochloride and Ethopabate Premix contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of amprolium hydrochloride, C14H19ClN4.HCl and of ethopabate, C12H15NO4.

Identification

A. Shake a quantity containing 20 mg of Amprolium Hydrochloride with 90 ml of methanol and filter. Add 5 ml of the filtrate to 5 ml of naphthalenediol reagent; a deep violet colour is produced.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

 NOTE — Prepare the solution immediately before use.

Mobile phase. A mixture of 90 volumes of dichloromethane and 10 volumes of methanol.
Test solution. Shake continuously for 10 minutes a quantity containing 10 mg of Ethopabate with 25 ml of acetone that has been warmed to 50°, filter and use the filtrate.

Reference solution. A 0.04 per cent w/v solution of ethopabate RS in acetone.

Apply to the plate 2 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to the spot in the chromatogram obtained with the reference solution.

Tests

pH (2.4.24). 2.5 to 4.0, determined in a 25 per cent w/v slurry in carbon dioxide-free water.

Other tests. Complies with the tests stated under Premixes.

Assay. For amprolium hydrochloride — Weigh accurately a quantity containing 50 mg of Amprolium Hydrochloride, shake continuously for 20 minutes with 100.0 ml of a mixture of 2 volumes of methanol and 1 volume of water and filter. Dilute 5.0 ml of the filtrate to 100.0 ml with the methanol-water mixture. To 4.0 ml of the resulting solution add 10.0 ml of naphthalenediol reagent, allow to stand for 20 minutes and measure the absorbance of the resulting solution at the maximum at about 520 nm (2.4.7), using as the blank a solution obtained by mixing 4.0 ml of a mixture of 2 volumes of methanol and 1 volume of water with 10.0 ml of naphthalenediol reagent and allowing to stand for 20 minutes. Calculate the content of C_{14}H_{19}ClN_{4}HCl, of ethopabate, C_{12}H_{15}NO_{4}, and of sulphaquinoxaline, C_{12}H_{12}N_{4}O_{5}S.

For ethopabate — Weigh accurately a quantity containing 6 mg of Ethopabate, add 75 ml of methanol, shake continuously for 20 minutes, dilute to 100.0 ml with methanol and filter. To 10.0 ml of the filtrate add 10 ml of 1 M sodium hydroxide and evaporate to dryness. Dissolve the residue in 10.0 ml of water, heat on a water-bath for 15 minutes, add 10 ml of 2 M hydrochloric acid, dilute to 100.0 ml with water and filter. To 25.0 ml of the filtrate, add 2.5 ml of 2 M hydrochloric acid and 5 ml of a 0.1 per cent w/v solution of sodium nitrite prepared immediately before use. Allow to stand for 3 minutes and add 2.0 ml of a freshly prepared 0.5 per cent w/v solution of ammonium sulphamate. Allow to stand for 2 minutes, add 5.0 ml of a freshly prepared 0.1 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride, allow to stand for 10 minutes and dilute to 50.0 ml with water. Measure the absorbance of the resulting solution at the maximum at about 540 nm (2.4.7), using as the blank a solution obtained by repeating the procedure with 25 ml of water and beginning at the words “add 2.5 ml of 2 M hydrochloric acid......”.

Calculate the content of C_{14}H_{19}NO_{4} from the absorbance obtained by carrying out the procedure simultaneously, using 10.0 ml of a 0.006 per cent w/v solution of ethopabate RS in methanol and beginning at the words “add 10 ml of 1 M sodium hydroxide and evaporate to dryness......”.

Amprolium, Ethopabate and Sulphaquinoxaline Premix

Amprolium, Ethopabate and Sulphaquinoxaline Premix contains Amprolium Hydrochloride, Ethopabate and Sulphaquinoxaline.

Amprolium, Ethopabate and Sulphaquinoxaline Premix contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of amprolium hydrochloride, C_{14}H_{19}ClN_{4}HCl, of ethopabate, C_{12}H_{15}NO_{4}, and of sulphaquinoxaline, C_{12}H_{12}N_{4}O_{5}S.

Identification

A. Shake a quantity containing 20 mg of Amprolium Hydrochloride with 90 ml of methanol and filter. Add 5 ml of the filtrate to 5 ml of naphthalenediol reagent; a deep violet colour is produced.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

NOTE — Prepare the solution immediately before use.

Mobile phase. A mixture of 90 volumes of dichloromethane and 10 volumes of methanol.

For ethopabate — Weigh accurately a quantity containing 6 mg of Ethopabate, add 75 ml of methanol, shake continuously for 20 minutes, dilute to 100.0 ml with methanol and filter. To 10.0 ml of the filtrate add 10 ml of 1 M sodium hydroxide and evaporate to dryness. Dissolve the residue in 10.0 ml of water, heat on a water-bath for 15 minutes, add 10 ml of 2 M hydrochloric acid, dilute to 100.0 ml with water and filter. To 25.0 ml of the filtrate, add 2.5 ml of 2 M hydrochloric acid and 5 ml of a 0.1 per cent w/v solution of sodium nitrite prepared immediately before use. Allow to stand for 3 minutes and add 2.0 ml of a freshly prepared 0.5 per cent w/v solution of ammonium sulphamate. Allow to stand for 2 minutes, add 5.0 ml of a freshly prepared 0.1 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride, allow to stand for 10 minutes and dilute to 50.0 ml with water. Measure the absorbance of the resulting solution at the maximum at about 540 nm (2.4.7), using as the blank a solution obtained by repeating the procedure with 25 ml of water and beginning at the words “add 2.5 ml of 2 M hydrochloric acid......”.

Calculate the content of C_{14}H_{19}NO_{4} from the absorbance obtained by carrying out the procedure simultaneously, using 10.0 ml of a 0.006 per cent w/v solution of ethopabate RS in methanol and beginning at the words “add 10 ml of 1 M sodium hydroxide and evaporate to dryness......”.

Tests

pH (2.4.24). 2.5 to 4.0, determined in a 25 per cent w/v slurry in carbon dioxide-free water.

NOTE — Weigh accurately a quantity containing 50 mg of Amprolium Hydrochloride, shake continuously for 20 minutes with 100.0 ml of a mixture of 2 volumes of methanol and 1 volume of water and filter. Dilute 5.0 ml of the filtrate to 100.0 ml with the methanol-water mixture. To 4.0 ml of the resulting solution add 10.0 ml of naphthalenediol reagent, allow to stand for 20 minutes and measure the absorbance of the resulting solution at the maximum at about 520 nm (2.4.7), using as the blank a solution obtained by mixing 4.0 ml of a mixture of 2 volumes of methanol and 1 volume of water with 10.0 ml of naphthalenediol reagent and allowing to stand for 20 minutes. Calculate the content of C_{14}H_{19}ClN_{4}HCl from the absorbance obtained by carrying out the procedure simultaneously, using 4.0 ml of a 0.0025 per cent w/v solution of amprolium hydrochloride RS in a mixture of 2 volumes of methanol and 1 volume of water and beginning at the words, “To 4.0 ml of the resulting solution add 10.0 ml of......”.

For ethopabate — Weigh accurately a quantity containing 6 mg of Ethopabate, add 75 ml of methanol, shake continuously for 20 minutes, dilute to 100.0 ml with methanol and filter. To 10.0 ml of the filtrate add 10 ml of 1 M sodium hydroxide and evaporate to dryness. Dissolve the residue in 10.0 ml of water, heat on a water-bath for 15 minutes, add 10 ml of 2 M hydrochloric acid, dilute to 100.0 ml with water and filter. To 25.0 ml of the filtrate, add 2.5 ml of 2 M hydrochloric acid and 5 ml of a 0.1 per cent w/v solution of sodium nitrite prepared immediately before use. Allow to stand for 3 minutes and add 2.0 ml of a freshly prepared 0.5 per cent w/v solution of ammonium sulphamate. Allow to stand for 2 minutes, add 5.0 ml of a freshly prepared 0.1 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride, allow to stand for 10 minutes and dilute to 50.0 ml with water. Measure the absorbance of the resulting solution at the maximum at about 540 nm (2.4.7), using as the blank a solution obtained by repeating the procedure with 25 ml of water and beginning at the words “add 2.5 ml of 2 M hydrochloric acid......”. Calculate the content of C_{14}H_{19}NO_{4} from the absorbance obtained by carrying out the procedure simultaneously, using 10.0 ml of a 0.006 per cent w/v solution of ethopabate RS in methanol and beginning at the words “add 10 ml of 1 M sodium hydroxide and evaporate to dryness......”.

Amprolium, Ethopabate and Sulphaquinoxaline Premix

Amprolium, Ethopabate and Sulphaquinoxaline Premix contains Amprolium Hydrochloride, Ethopabate and Sulphaquinoxaline.

Amprolium, Ethopabate and Sulphaquinoxaline Premix contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of amprolium hydrochloride, C_{14}H_{19}ClN_{4}HCl, of ethopabate, C_{12}H_{15}NO_{4}, and of sulphaquinoxaline, C_{12}H_{12}N_{4}O_{5}S.
Other tests. Complies with the tests stated under Premixes.

Assay. For amprolium hydrochloride — Weigh accurately a quantity containing 50 mg of Amprolium Hydrochloride, shake continuously for 20 minutes with 100.0 ml of a mixture of 2 volumes of methanol and 1 volume of water and filter. Dilute 5.0 ml of the filtrate to 100.0 ml with the methanol-water mixture. To 4.0 ml of the resulting solution add 10.0 ml of naphthalenediol reagent, allow to stand for 20 minutes and measure the absorbance of the resulting solution at the maximum at about 520 nm (2.4.7), using as the blank the solution obtained by mixing 4.0 ml of a mixture of 2 volumes of methanol and 1 volume of water with 10.0 ml of naphthalenediol reagent and allowing to stand for 20 minutes. Calculate the content of C₁₅H₁₉ClN₄.HCl from the absorbance obtained by carrying out the procedure simultaneously, using 4.0 ml of a 0.0025 per cent w/v solution of amprolium hydrochloride RS in a mixture of 2 volumes of methanol and 1 volume of water and beginning at the words, “To 4.0 ml of the resulting solution add 10.0 ml of.....”.

For ethopabate — Weigh accurately a quantity containing 6 mg of Ethopabate, add 75 ml of methanol, shake continuously for 20 minutes, dilute to 100.0 ml with methanol and filter. To 10.0 ml of the filtrate add 10 ml of 1 M sodium hydroxide and evaporate to dryness. Dissolve the residue in 10.0 ml of water, heat on a water-bath for 15 minutes, add 10 ml of 2 M hydrochloric acid, dilute to 100.0 ml with water and filter. To 25.0 ml of the filtrate, add 2.5 ml of 2 M hydrochloric acid and 5 ml of a 0.1 per cent w/v solution of sodium nitrite prepared immediately before use. Allow to stand for 3 minutes and add 2.0 ml of a freshly prepared 0.5 per cent w/v solution of ammonium sulphamate. Allow to stand for 2 minutes, add 5.0 ml of a freshly prepared 0.1 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride, allow to stand for 10 minutes and dilute to 50.0 ml with water. Measure the absorbance of the resulting solution at the maximum at about 540 nm (2.4.7), using as the blank the solution obtained by repeating the procedure with 10 ml of water and beginning at the words “add 2.5 ml of 2 M hydrochloric acid.....”. Calculate the content of C₁₅H₁₉N₄.HCl from the absorbance obtained by carrying out the procedure simultaneously, using 10.0 ml of a 0.0008 per cent w/v solution of sulphaquinoxaline RS in 0.001 M sodium hydroxide and beginning at the words “To 10.0 ml of the diluted solution add 2.5 ml of 2 M hydrochloric acid.....”.

Calcium Borogluconate Injection

Calcium Borogluconate Injection is a sterile solution of Calcium Gluconate and Boric Acid in Water for Injections. The solution may contain up to 0.2 per cent w/v of Chlorocresol.

Calcium Borogluconate Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of calcium, Ca, and boric acid, H₃BO₃, equivalent to not more than 2.3 times the stated content of calcium.

Identification

A. Dilute 1 ml with sufficient water to produce a solution containing about 0.75 per cent w/v of calcium and add 0.05 ml of ferric chloride test solution; an intense yellow or yellowish green colour is produced.

B. Gives the reactions of calcium salts (2.3.1).

C. To 1 ml add 0.15 ml of sulphuric acid and 5 ml of methanol and ignite; the mixture burns with a flame tinged with green.

Tests

pH (2.4.24). 3.0 to 4.0, determined in a solution diluted if necessary with carbon dioxide-free water to produce a solution containing 1.5 per cent w/v of calcium.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. For calcium — Dilute an accurately measured volume containing 45 mg of calcium to about 50 ml with water. Titrate with 0.05 M disodium edetate to within a few ml of the expected end-point, add 4 ml of a 40 per cent w/v solution of sodium hydroxide and 10 mg of calcon mixture and continue the titration until the colour changes from pink to blue. 1 ml of 0.05 M disodium edetate is equivalent to 0.002004 g of Ca.
For boric acid — Dilute an accurately measured volume containing 0.1 g of Boric Acid to 50 ml with water, add 3 g of mannitol and titrate with 0.1 M sodium hydroxide using phenolphthalein solution as indicator.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.006183 g of H₃BO₃.

**Storage.** Store protected from light, at a temperature not exceeding 30°.

**Labelling.** The label states (1) the strength in terms of the equivalent amount of calcium in a suitable dose-volume; (2) the proportion of boric acid present; (3) the proportion of chlorocresol, if present.

### Calcium Magnesium Borogluconate Injection

Calcium Magnesium Borogluconate Injection is a sterile solution of Calcium Glucoconate, Boric Acid, Magnesium Hypophosphite and Dextrose in Water for Injections. It may contain up to 0.2 per cent w/v of Chlorocresol.

Calcium Magnesium Borogluconate Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amounts of calcium, Ca, of magnesium, calculated as magnesium hypophosphite, Mg(H₂PO₂)₂·6H₂O, and of dextrose, C₆H₁₂O₆, and the content of boric acid, H₃BO₃, is not more than 2.3 times the stated content of calcium.

**Identification**

A. Dilute 1 ml with sufficient water to produce a solution containing about 0.75 per cent w/v of calcium and add 0.05 ml of feric chloride test solution; an intense yellow or yellowish green colour is produced.

B. Gives the reactions of calcium salts (2.3.1).

C. Gives the reactions of magnesium salts (2.3.1).

D. To 1 ml add 5 ml of water, neutralise to pH 7.0 with dilute ammonia solution and add 5 ml of silver nitrate solution. A yellow precipitate is produced which does not change colour on boiling but dissolves on addition of dilute ammonia solution.

E. To 1 ml add 0.15 ml of sulphuric acid and 5 ml of methanol and ignite; the mixture burns with a flame tinged with green.

F. To 1 ml add 2 ml of 2 M sodium hydroxide solution and 0.05 ml of copper sulphate solution. The solution is blue and clear. Heat to boiling. A copious red precipitate is produced.

**Tests**

**pH** (2.4.24). 3.0 to 4.0, determined in a solution diluted, if necessary, with carbon dioxide-free water so as to contain 1.5 per cent w/v of calcium.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Bacterial endotoxins** (2.2.3). Not more than 0.5 Endotoxin Unit per ml.

**Sterility** (2.2.11). Complies with the test for sterility.

**Assay.** For calcium — Dilute a volume containing 45 mg of calcium to about 50 ml with water. Add 1 ml of 1 M sodium hydroxide solution. Titrinate with 0.05 M disodium edetate to within a few ml of the expected end-point, add 5 ml of strong ammonia-ammonium chloride solution and 10 mg of calcon mixture as indicator and continue the titration until the colour changes from pink to blue. Calculate the volume of 0.05 M disodium edetate consumed by subtracting the volume of 0.05 M disodium edetate consumed in the assay for magnesium.

1 ml of 0.05 M disodium edetate is equivalent to 0.002004 g of Ca.

For magnesium — Dilute a volume containing 10 mg of magnesium to about 50 ml with water. Add 1 g of ammonium chloride and 1 g of ammonium oxalate. Neutralise to litmus paper with dilute ammonia solution and add 5 ml in excess. Boil for 5 minutes and allow to stand for 1 hour. Filter and wash the residue with hot water. Collect the filtrate and washings and add 5 ml of strong ammonia-ammonium chloride solution. Titrate with 0.05 M disodium edetate using eriochrome black T mixture as indicator.

1 ml of disodium edetate is equivalent to 0.001216 g of magnesium or 0.0107894 g of magnesium hypophosphite, Mg(H₂PO₂)₂·6H₂O.

For boric acid — Dilute a volume containing 0.1 g of boric acid to 50 ml with water; add 3 g of mannitol and titrate with 0.1 M sodium hydroxide using phenolphthalein solution as indicator.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.006183 g of H₃BO₃.

For dextrose — Dilute a volume containing 200 mg of dextrose to 50 ml with water; add 30 ml of 0.1 M iodine solution and 10 ml of a 5 per cent w/v solution of sodium carbonate and allow to stand for 20 minutes. Add 15 ml of 1 M hydrochloric acid and titrate the excess of iodine with 0.1 M sodium thiosulphate solution using starch solution as indicator. Carry out a blank titration.

1 ml of 0.1 M iodine solution is equivalent to 0.009008 g of dextrose, C₆H₁₂O₆.

**Storage.** Store protected from light.

**Labelling.** The label states (1) the strength in terms of the equivalent amount of calcium and magnesium in a suitable dose-volume; (2) the proportion of boric acid to calcium; (3) the percentage of any added stabilising agent.
**Chloral Hydrate**

![Chemical Structure of Chloral Hydrate](image)

\[ \text{C}_2\text{H}_3\text{Cl}_3\text{O}_2 \quad \text{Mol. Wt. 165.4} \]

Chloral Hydrate is 2,2,2-trichloro-1,1-ethane-diol.

**Description.** A colourless, transparent crystals; odour, pungent.

Chloral Hydrate contains not less than 98.5 per cent and not more than 101.0 per cent of the stated amount of chloral hydrate, \( \text{C}_2\text{H}_3\text{Cl}_3\text{O}_2 \).

**Identification**

A. To 10 ml of a 10 per cent w/v solution in carbon dioxide-free water (solution A) add 2 ml of 2 M sodium hydroxide. The mixture becomes cloudy and when heated gives an odour of chloroform.

B. To 1 ml of solution A add 2 ml of sodium sulphide solution; a yellow colour develops which quickly turns reddish brown and may yield a red precipitate on standing.

**Tests**

**pH** (2.4.24). 3.5 to 5.5, determined in solution A.

**Appearance of solution.** Solution A is clear (2.4.1) and colourless (2.4.1).

**Heavy metals** (2.3.13). 12 ml of a 5 per cent w/v solution in water; complies with the limit test for heavy metals, Method D (20 ppm).

**Chlorides** (2.3.12). Dissolve 2.5 g in 15 ml with water; the resulting solution complies with the limit test for chlorides (100 ppm).

**Chloral alcololate.** Warm 1 g with 10 ml of 2 M sodium hydroxide, filter the upper layer and add 0.05 M iodine dropwise until a yellow colour is produced. Set aside for 1 hour; no yellow precipitate is produced and no smell of iodoform is perceptible.

**Assay.** Weigh accurately about 4 g, dissolve in 10 ml of water and add 40 ml of 1 M sodium hydroxide. Allow the mixture to stand for exactly 2 minutes and titrate the residual alkali immediately with 0.5 M sulphuric acid using phenolphthalein solution as indicator.

1 ml of 1 M sodium hydroxide is equivalent to 0.1654 g of \( \text{C}_2\text{H}_3\text{Cl}_3\text{O}_2 \).

**Storage.** Store protected from moisture.

---

**Chloramphenicol Injection**

Chloramphenicol Injection is a sterile suspension of Chloramphenicol in Water for Injections containing suitable suspending and stabilising agents.

Chloramphenicol Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of chloramphenicol, \( \text{C}_{11}\text{H}_{12}\text{Cl}_2\text{N}_2\text{O}_5 \).

**Identification**

Centrifuge a volume containing 0.15 g of Chloramphenicol; wash the residue with water and dry over self-indicating silica gel and then for 1 hour at 105°. The dried residue complies with the following tests.

A. Wash 75 mg of the residue with two quantities, each of 10 ml, of light petroleum ( 60° to 80°) and allow to dry. The residue complies with the following test.

B. In the test for Related substances, the principal spot in the chromatogram obtained with 1 µl of test solution corresponds to that in the chromatogram obtained with reference solution (a).

C. To 5 ml of a 0.1 per cent w/v solution add a few drops of silver nitrate solution; no precipitate is produced. Heat about 50 mg with 3 ml of ethanolic potassium hydroxide solution on a water-bath for 15 minutes, add 15 mg of decolorising charcoal, shake and filter. The filtrate gives the reactions of chlorides (2.3.1).

**Tests**

**pH** (2.4.24). 3.5 to 6.5.

**Consistence.** Chloramphenicol Injection containing 150 mg per ml passes readily through a 23G hypodermic needle.

**2-Amino-1-(4-nitrophenyl)propane-1,3-diol** Determine by liquid chromatography (2.4.14).

**Test solution.** Dilute the injection with sufficient of the mobile phase to produce a solution containing 0.030 per cent w/v of Chloramphenicol.

**Reference solution.** A 0.00225 per cent w/v of 2-amino-1-(4-nitrophenyl)propane-1,3-diol RS in the mobile phase.

**Chromatographic system**

- a stainless steel column 10 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 μm),
- mobile phase: a filtered and degassed mixture of 85 volumes of 0.012 M sodium pentane-sulphonate, 15 volumes of acetonitrile and 1 volume of glacial acetic acid,
– flow rate. 2 ml per minute,
– spectrophotometer set at 272 nm,
– a 20 µl loop injector.

Inject alternatively the test solution and the reference solution. In the chromatogram obtained with test solution the area of any peak corresponding to 2-amino-1-(4-nitrophenyl)-propane-1,3-diol is not more than the area of the peak obtained with the reference solution.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 90 volumes of dichloromethane, 10 volumes of methanol and 1 volume of water.

**Test solution.** A 1.0 per cent w/v solution of the dried residue obtained in the test for Identification in acetone.

**Reference solution (a).** A 1.0 per cent w/v solution of chloramphenicol RS in acetone.

**Reference solution (b).** Dilute 1 ml of reference solution (a) to 200 ml with acetone.

Apply to the plate 1 µl and 20 µl of the test solution, 1 µl of reference solution (a) and 20 µl of reference solution (b). After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (b).

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** To an accurately measured volume containing 0.75 g of Chloramphenicol add sufficient water to produce 1000.0 ml and shake until a clear solution is obtained. Dilute 5.0 ml of this solution to 200.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 278 nm (2.4.7). Calculate the content of \( C_{11}H_{12}Cl_{2}N_{2}O_{5} \) in the injection taking 297 as the specific absorbance at 278 nm.

**Storage.** Store protected from light. Do not freeze.

**Labelling.** The label states (1) the name of any added suspending agent; (2) that the injection is for intramuscular injection only; (3) the date after which the contents are not intended to be used.

### Chlortetracycline Hydrochloride

Chlortetracycline Hydrochloride is \([4S-(4\alpha,4a,5\alpha,6\beta,12\alpha\alpha)]-7\text{-chloro-}4\text{-dimethylamino-}
1,4,4a,5,5a,6,11,12a\text{-octahydro-3,6,10,12,12a-pentahydroxy-6-
methyl-1,11-dioxo-2-naphthacenecarboxamide hydrochloride.} \)

Chlortetracycline Hydrochloride contains not less than 89.5 per cent of chlortetracycline hydrochloride and the sum of the contents of chlortetracycline hydrochloride and tetracycline hydrochloride is not less than 94.5 per cent and not more than 100.5 per cent, calculated on the anhydrous basis.

**Description.** Yellow powder.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H.

**NOTE — Use freshly prepared solution.**

**Mobile phase.** A mixture of 59 volumes of dichloromethane, 35 volumes of methanol and 6 volumes of water.

**Test solution.** Dissolve 50 mg of the substance under examination in 100 ml of methanol.

**Reference solution (a).** A 0.05 per cent w/v of chlortetracycline hydrochloride RS in methanol.

**Reference solution (b).** A solution containing 0.05 per cent w/v each of chlortetracycline hydrochloride RS, tetracycline hydrochloride RS and metacycline hydrochloride RS in methanol.

Adjust the pH of a 10 per cent w/v solution of disodium edetate to 8.0 with 10 M sodium hydroxide and spray this solution evenly on the plate (about 10 ml for a plate of 100 mm x 200 mm size). Allow the plate to dry in a horizontal position for at least 1 hour. Dry the plate in an oven at 100° for 1 hour before use. Apply to the plate 1 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

B. To about 2 mg add 5 ml of sulphuric acid; a deep blue colour develops which becomes bluish green. Add the solution to 2.5 ml of water; the colour changes to brownish.

C. Gives reaction A of chlorides (2.3.1).

**Tests**

**pH (2.4.24).** 2.3 to 3.3, determined in a 1 per cent w/v solution in carbon dioxide-free water prepared by slight heating, if necessary.
Specific optical rotation (2.4.22). –235° to –250°, determined at 20° in a 0.25 per cent w/v solution in water, calculated on the anhydrous basis.

Light absorption. When examined in the range 430 nm to 460 nm of a 0.5 per cent w/v solution in water is not greater than 0.40.

Related substances. Carry out the method described under Assay injecting test solution, reference solutions (e) and (f). The test is not valid unless the peak in the chromatogram obtained with reference solution (f) is properly integrated. In the chromatogram obtained with test solution the area of the peak corresponding to 4-epichlortetracycline is not more than the area of the peak corresponding to 4-epichlortetracycline in the chromatogram obtained with reference solution (e) (4 per cent) and the total area of any secondary peaks, other than the peaks due to tetracycline and 4-epichlortetracycline, is not more than 25 per cent of the area of the peak corresponding to 4-epichlortetracycline in the chromatogram obtained with reference solution (e) (1 per cent). Ignore any peak with an area smaller than that of the principal peak in the chromatogram obtained with reference solution (f) (0.1 per cent).

Tetracycline hydrochloride. Not more than 8.0 per cent, calculated on the anhydrous basis and determined as described under the Assay, injecting separately test solution and reference solution (e).

Heavy metals (2.3.13). 0.5 g complies with the limit test for heavy metals, Method D (50 ppm), using 2.5 ml of lead standard solution to 100 ml with 0.01 M hydrochloric acid.

Sulphated ash (2.3.18). Not more than 0.5 per cent.

Water (2.3.43). Not more than 2.0 per cent, determined on 0.3 g.

Assay. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 100 mg of the substance under examination in 0.01 M hydrochloric acid.

Reference solution (a). A 0.1 per cent w/v solution of chlortetracycline hydrochloride RS in 0.01 M hydrochloric acid.

Reference solution (b). A 0.04 per cent w/v of 4-epichlortetracycline hydrochloride RS in 0.01 M hydrochloric acid.

Reference solution (c). A 0.08 per cent w/v of tetracycline hydrochloride RS in 0.01 M hydrochloric acid.

Reference solution (d). Mix 5 ml of reference solution (a) and 10 ml of reference solution (b) and dilute to 25 ml with 0.01 M hydrochloric acid.

Reference solution (e). Mix 5 ml of reference solution (b) and 5 ml of reference solution (c) and dilute to 50 ml with 0.01 M hydrochloric acid.

Reference solution (f). Dilute 1 ml of reference solution (c) to 20 ml with 0.01 M hydrochloric acid and dilute 2.5 ml of this solution to 100 ml with 0.01 M hydrochloric acid.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with octylsilyl groups (5 µm),
- column temperature 35°,
- mobile phase: a filtered and degassed mixture of 450 ml of dimethyl sulphoxide, 50 ml of 1 M perchloric acid and 500 ml of water,
- flow rate. 1 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 µl loop injector.

Inject reference solution (d) and adjust the instrument so that the peak heights correspond to at least 50 per cent of the full scale deflection of the recorder. If necessary, adjust the dimethyl sulphoxide content in the mobile phase. The test is not valid unless the resolution factor between the first peak (4-epichlor-tetracycline) and the second (chlortetracycline) is not less than 2.0 and the symmetry factor for the second peak is not more than 1.3.

Inject reference solution (a). The test is not valid unless the relative standard deviation of the peak area for chlortetracycline hydrochloride is not more than 1.0 per cent. If necessary, adjust the integrator parameters.

Inject alternately the test solution and reference solution (a).

Calculate the content of C_{22}H_{23}ClN_{2}O_{8},HCl.

Chlortetracycline Hydrochloride intended for use in the manufacture of Parenteral Preparations without a further appropriate procedure for removal of bacterial endotoxins complies with the following additional requirement.

Bacterial endotoxins (2.2.3). Not more than 1.1 EU per mg.

Chlortetracycline Hydrochloride intended for use in the manufacture of Parenteral Preparations without a further appropriate sterilisation procedure complies with the following additional requirement.

Sterility (2.2.11). Complies with the test for sterility.

Storage. Store protected from light. If it is intended for use in the manufacture of Parenteral Preparations, the container should be sterile, tamper-evident and sealed so as to exclude micro-organisms.

Labelling. The label states (1) the date after which the material is not intended to be used; (2) the storage conditions; (3) where applicable, that the material is sterile and free from Bacterial endotoxins.
Chlortetracycline Veterinary Oral Powder

Chlortetracycline Hydrochloride Veterinary Oral Powder; Chlortetracycline Soluble Powder

Chlortetracycline Veterinary Oral Powder is a mixture of Chlortetracycline Hydrochloride and Lactose or other suitable diluent.

Chlortetracycline Veterinary Oral Powder contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of chlortetracycline hydrochloride, C_{22}H_{23}ClN_{2}O_{8}.HCl

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H.

NOTE — Use freshly prepared solutions.

Mobile phase. A mixture of 59 volumes of dichloromethane, 35 volumes of methanol and 6 volumes of water.

Test solution. The supernatant liquid obtained by extracting a quantity containing 5 mg of Chlortetracycline Hydrochloride with 10 ml of methanol and centrifuging.

Reference solution (a). A 0.05 per cent w/v of chlortetracycline hydrochloride RS in methanol.

Reference solution (b). A solution containing 0.05 per cent w/v each of chlortetracycline hydrochloride RS, tetracycline hydrochloride RS and metacycline hydrochloride RS in methanol.

Adjust the pH of a 10 per cent w/v solution of disodium edetate to 8.0 with 10 M sodium hydroxide and spray this solution evenly on the plate (about 10 ml for a plate of 100 mm x 200 mm size). Allow the plate to dry in a horizontal position for at least 1 hour. Dry the plate in an oven at 100° for 1 hour before use. Apply to the plate 1 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

B. To a quantity containing 10 mg of Chlortetracycline Hydrochloride, add 20 ml of warm ethanol (95 per cent), allow to stand for 20 minutes, filter and evaporate to dryness on a water-bath. Dissolve the residue in sufficient phosphate buffer pH 7.6 to produce a 0.1 per cent w/v solution and heat at 100° for 1 minute; it exhibits a strong blue fluorescence in ultra-violet light.

Tests

Other tests. Complies with the tests stated under Veterinary Oral Powders.

Assay. Weigh accurately a quantity containing 0.25 g of Chlortetracycline Hydrochloride, add 500 ml of water, mix thoroughly and carry out the microbiological assay of antibiotics (2.2.10).

Calculate the content of chlortetracycline hydrochloride taking each 1000 Units found to be equivalent to 1 mg of chlortetracycline hydrochloride.

Storage. Store protected from moisture, at a temperature not exceeding 30°.

Labelling. The label states the strength in terms of the concentration of Chlortetracycline Hydrochloride.

Cloxacillin Benzathine

Cloxacillin Benzathine is \( N,N' \)-dibenzylethylene-diammonium bis-[(6R)-6-\{-3-(2-chlorophenyl)-5-methyl-isoxazole-4-carboxamido\}penicillanate].

Cloxacillin Benzathine contains not less than 92.0 per cent of \((C_{19}H_{18}ClN_{3}O_{5}S)_{2}C_{16}H_{20}N_{2}\) and not less than 20.0 per cent and not more than 22.0 per cent of benzathine, \( C_{16}H_{20}N_{2}\), both calculated on the anhydrous basis.

Description. A white or almost white powder.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with cloxacillin benzathine RS or with the reference spectrum of cloxacillin benzathine.

B. Shake 0.1 g with 1 ml of 1 M sodium hydroxide for 2 minutes, add 2 ml of ether, shake for 1 minute and allow to separate. Evaporate 1 ml of the ether layer to dryness, dissolve the residue in 2 ml of glacial acetic acid and add 1 ml of dilute potassium dichromate solution; a golden yellow precipitate is produced.

C. Shake 50 mg with 10 ml of water and filter. To 5 ml of the filtrate add a few drops of silver nitrate solution; no precipitate is produced. Heat 50 mg with 2 ml of ethanolic potassium
hydroxide solution on a water-bath for 15 minutes, add 15 mg of decolorising charcoal, shake and filter. Acidify the filtrate with 2 M nitric acid; the solution gives reaction A of chlorides (2.3.1).

Tests

Water (2.3.43). Not more than 5.0 per cent w/w, determined on 0.5 g.

Assay. For cloxacillin benzathine — Weigh accurately about 60 mg, add 40 ml of methanol, shake to dissolve, add 25 ml of 1 M sodium hydroxide and allow to stand for 30 minutes. Add 27.5 ml of 1 M hydrochloric acid and sufficient water to produce 100.0 ml, mix, transfer 20.0 ml of the solution to a stoppered conical flask, add 30.0 ml of 0.01 M iodine, close the flask with a wet stopper and allow to stand for 15 minutes protected from light. Titrate the excess of iodine with 0.02 M sodium thiosulphate, using starch mucilage, added towards the end of the titration, as indicator. Add a further 12 mg of the substance under examination to 10 ml of water, swirl to disperse, add 30 ml of 0.01 M iodine and titrate immediately with 0.02 M sodium thiosulphate, using starch mucilage, added towards the end of the titration, as indicator. The difference between the titrations represents the volume of 0.01 M iodine equivalent to the total penicillins present.

Calculate the content of (C₁₉H₁₈ClN₃O₅S)₂C₁₆H₂₀N₂ from the difference obtained by carrying out the procedure simultaneously using cloxacillin benzathine RS.

For benzathine — Weigh accurately about 1 g, add 30 ml of a saturated solution of sodium chloride and 10 ml of 5 M sodium hydroxide, shake well and extract with four quantities, each of 50 ml of ether. Wash the combined extracts with three quantities, each of 10 ml of water, extract the combined washings with 25 ml of ether and add the extract to the main ether solution. Evaporate the ether solution to low volume, add 2 ml of ethanol and evaporate to dryness. To the residue add 50 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, using 0.1 ml of 1-naphtholbenzein solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01202 g of C₁₉H₁₈N₂O₄S₂.

Cloxacillin Benzathine intended for use in the manufacture of either parenteral preparations or intramammary infusions without a further appropriate sterilisation procedure complies with the following additional requirement.

Sterility (2.2.11). Complies with the test for sterility.

Storage. Store protected from moisture. If it is intended for use in the manufacture of parenteral preparations or intramammary infusions, the container should be sterile, tamper-evident and sealed so as to exclude micro-organisms.

Cloxacillin Benzathine Intramammary Infusion (Dry Cow/ Buffalo)

Cloxacillin Benzathine Intramammary Injection; Cloxacillin Intramammary Infusion (Dry Cow/Buffalo); Cloxacillin Intramammary Infusion (DC/B)

Cloxacillin Benzathine Intramammary Infusion (Dry Cow/ Buffalo) is a sterile suspension of Cloxacillin Benzathine in a suitable non-aqueous suspension of Cloxacillin Benzathine in a suitable non-aqueous vehicle containing suitable suspending agents.

Cloxacillin Benzathine Intramammary Infusion (Dry Cow/ Buffalo) contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of cloxacillin, C₁₉H₁₈ClN₃O₅S.

Identification

Extract a quantity containing 75 mg of cloxacillin with three quantities, each of 15 ml, of light petroleum (120° to 160°). Discard the extracts, wash the residue with 10 ml of ether and dry in a current of air. The residue complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with cloxacillin benzathine RS or with the reference spectrum of cloxacillin benzathine.

B. Shake 50 mg with 1 ml of 1 M sodium hydroxide for 2 minutes, add 2 ml of ether, shake for 1 minute and allow to separate. Evaporate 1 ml of the ether layer to dryness, dissolve the residue in 2 ml of glacial acetic acid and add 1 ml of dilute potassium dichromate solution; a golden yellow precipitate is produced.

Tests

Water (2.3.43). Not more than 2.0 per cent, determined on 3 g and using a mixture of 70 volumes of dichloromethane and 30 volumes of anhydrous methanol as the solvent.

Other tests. Complies with the tests stated under Intramammary Infusions.

Assay. Weigh and mix the contents of 10 containers. Weigh accurately a quantity of the mixed contents containing 80 mg of cloxacillin and extract with three quantities, each of 15 ml, of light petroleum (120° to 160°) previously saturated with cloxacillin benzathine. Discard the extracts, wash the residue with ether previously saturated with cloxacillin benzathine. Dry in a current of air, dissolve in 25 ml of methanol and dilute to 50.0 ml with water. Dilute 2.0 ml to 100.0 ml with buffered cupric sulphate solution pH 2.0, transfer 10.0 ml to a stoppered test-tube and heat in a water-bath at 70° for 20 minutes. Cool to room temperature rapidly, dilute to 20.0 ml with ethanol and measure the absorbance of the resulting solution at the
maximum at about 338 nm (2.4.7), using as the blank 10.0 ml of the unheated buffered solution of the substance under examination after dilution to 20.0 ml with ethanol.

Calculate the content of C₁₉H₁₈ClN₃O₅S in a container of average weight from the absorbance obtained by carrying out the procedure simultaneously using 2.0 ml of a solution prepared by dissolving 105 mg of cloxacillin benzathine RS in 50.0 ml of a mixture of equal volumes of methanol and water.

**Labelling.** The label states the strength in terms of the equivalent amount of cloxacillin in the sealed container.

**Cloxacillin Sodium Intramammary Infusion (Lactating Cow/Buffalo)**

Cloxacillin Intramammary Injection; Cloxacillin Intramammary Infusion (Lactating Cow/Buffalo); Cloxacillin Intramammary Infusion (LC/B)

Cloxacillin Sodium Intramammary Infusion (Lactating Cow/Buffalo) is a sterile suspension of Cloxacillin Sodium in a suitable non-aqueous vehicle containing suitable suspending and dispersing agents.

Cloxacillin Sodium Intramammary Infusion (Lactating Cow/Buffalo) contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of cloxacillin, C₁₉H₁₈ClN₃O₅S.

**Identification**

Extract a quantity containing 75 mg of cloxacillin with three quantities, each of 15 ml, of light petroleum (120° to 160°). Discard the extracts, wash the residue with 10 ml of ether and dry in a current of air. The residue complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with cloxacillin sodium RS or with the reference spectrum of cloxacillin sodium.

B. Gives reaction A of sodium salts (2.3.1).

**Tests**

**Water** (2.3.43). Not more than 1.0 per cent, determined on 3 g using a mixture of 70 volumes of dichloromethane and 30 volumes of anhydrous methanol as the solvent.

**Other tests.** Complies with the tests stated under Intramammary Infusions.

**Assay.** Weigh and mix the contents of 10 containers. Weigh accurately a quantity of the mixed contents containing 80 mg of cloxacillin and extract with three quantities, each of 15 ml, of light petroleum (120° to 160°) previously saturated with cloxacillin sodium. Discard the extracts, wash the residue with ether previously saturated with cloxacillin sodium. Dry in a current of air, dissolve in water and dilute to 50.0 ml with the same solvent. Dilute 2.0 ml to 100.0 ml with buffered cupric sulphate solution pH 2.0, transfer 10.0 ml to a stoppered test-tube and heat in a water-bath at 70° for 20 minutes. Cool to room temperature rapidly, dilute to 20.0 ml with ethanol and measure the absorbance of the resulting solution at the maximum at about 338 nm (2.4.7), using as the blank 10.0 ml of the unheated buffered solution of the substance under examination after dilution to 20.0 ml with ethanol.

Calculate the content of C₁₉H₁₈ClN₃O₅S in a container of average weight from the absorbance obtained by carrying out the procedure simultaneously using 2.0 ml of a solution prepared by dissolving 85 mg of cloxacillin sodium RS in 50.0 ml of water, diluting to 100 ml with buffered cupric sulphate solution pH 2.0, and beginning at the words “transfer 10.0 ml...”.

**Labelling.** The label states the strength in terms of the equivalent amount of cloxacillin.

**Dichlofenthion**

C₁₀H₁₃Cl₂O₃ Mol. Wt. 315.2

Dichlofenthion is O-2,4-dichlorophenyl-O,O-diethyl phosphorothioate.

Dichlofenthion contains not less than 95.0 per cent and not more than 100.5 per cent of C₁₀H₁₃Cl₂O₃PS.

**Description.** A colourless or pale yellow, oily substance.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with dichlofenthion RS or with the reference spectrum of dichlofenthion.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 95 volumes of hexane and 5 volumes of 2-butanone.

**Test solution.** Dissolve 0.5 g of the substance under examination in 100 ml of methanol.

**Reference solution.** A 0.5 per cent w/v solution of dichlofenthion RS in methanol.
Apply to the plate 2 µl of each solution. After development, dry the plate in air and spray with a 2 per cent w/v solution of 4-(4-nitrobenzyl)pyridine in ethyl acetate. Heat the plate at 130°C for 10 minutes, allow to cool and spray with a 2 per cent w/v solution of lithium hydroxide in a mixture of 8 volumes of methanol, 1 volume of diethylene glycol and 1 volume of water. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

C. Burn 50 mg by the oxygen-flask method (2.3.34), using 20 ml of 1 M sodium hydroxide as the absorbing liquid. The solution obtained, after acidification with 2 M nitric acid gives reaction A of chlorides and reaction C of phosphates (2.3.1).

Tests

Refractive index (2.4.27). 1.530 to 1.533.

Weight per ml (2.4.29). 1.296 to 1.316 g.

Assay. Determine by gas chromatography (2.4.13).

Test solution (a). Dissolve 0.3 g of the substance under examination in 100 ml of dichloromethane.

Test solution (b). A solution containing 0.3 per cent w/v of the substance under examination and 0.2 per cent w/v of methyl stearate (internal standard) in dichloromethane.

Reference solution. A solution containing 0.3 per cent w/w of dichlofenthion RS and 0.2 per cent w/v of methyl stearate (internal standard) in dichloromethane.

Chromatographic system

- a glass column 1.5 m x 4 mm, packed with 3 per cent w/w of phenyl methyl silicone fluid (50 per cent phenyl) on acid-washed, silanised diatomaceous support (80 to 100 mesh) (such as OV-17),
- temperature: column 190°C, inlet port and detector. 280°C,
- flow rate. 30 ml per minute of the carrier gas.

Calculate the content of C_{10}H_{13}Cl_{2}O_{3}PS.

Dichlorophen contains not less than 97.0 per cent and not more than 101.0 per cent of C_{13}H_{10}Cl_{2}O_{2}, calculated on the dried basis.

Description. A white or almost white powder; odour, slightly phenolic.

Identification

A. When examined in the range 220 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in 0.1 M sodium hydroxide shows absorption maxima at about 245 nm and 304 nm. The absorbances of the solution after further dilution with an equal volume of 0.1 M sodium hydroxide at these maxima are about 0.65 and 0.27 respectively.

B. Dissolve 0.2 g in 10 ml of 2.5 M sodium hydroxide, cool in ice and add a solution prepared by mixing 1 ml of sodium nitrite solution with a cold solution containing 0.15 ml of aniline in a mixture of 4 ml of water and 1 ml of hydrochloric acid; a reddish-brown precipitate is produced.

C. Fuse 0.5 g with 2 g of anhydrous sodium carbonate, cool, extract the residue with water and filter. The filtrate gives reaction A of chlorides (2.3.1).

D. Melting point (2.4.21). about 175°C.

Tests

Chlorides (2.3.12). Shake 3.0 g with 6 ml of ethanol (95 per cent), dilute with water to 100 ml, allow to stand for 5 minutes and filter. 25 ml of the filtrate complies with the limit test for chlorides (330 ppm).

Sulphates (2.3.17). Shake 1.0 g with 20 ml of water for 2 minutes and filter. 5 ml of the filtrate complies with the limit test for sulphates (600 ppm).

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. Dissolve 100 mg of the substance under examination in 10 ml of the mobile phase.

Reference solution (a). A 1.0 per cent w/v solution of dichlorophen impurity standard RS in the mobile phase.

Reference solution (b). A 0.0010 per cent w/v solution of 4-chlorophenol in the mobile phase.

Chromatographic system

- a stainless steel column 20 cm x 5 mm, packed with octadecylsilane bonded to porous silica (10 µm) (such as Spherisorb ODS 1),
- mobile phase: a filtered and degassed mixture of 75 volumes of methanol, 25 volumes of water and 1 volume of glacial acetic acid,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 280 nm,
— a 20 µl loop injector.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution the area of the peak corresponding to 4-dichlorophenol is not more than the area of the principal peak in the chromatogram obtained with reference solution (b). The content of 4,4'-di- chloro-2,2'-(2-hydroxy-4-chloro-m-xylene-a,a¢-diyl) diphenol in the substance under examination does not exceed 8.0 per cent w/w and the sum of the contents of any other impurities, excluding 4-chlorophenol, is not more than 2.0 per cent w/w.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 3 per cent, determined on 1.0 g by drying in an oven at 105°.

Assay. Weigh accurately about 0.5 g, dissolve in 20 ml of 2-propanol. Titrate with 0.1 M tetrabutylammonium hydroxide, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M tetrabutylammonium hydroxide is equivalent to 0.02691 g of C₁₃H₁₀Cl₂O₂.

Labelling. The label states that the substance is intended for animal treatment only.

**Dichlorophen Veterinary Aerosol**

Dichlorophen Veterinary Aerosol Spray; Dichlorophen Veterinary Spray

Dichlorophen Veterinary Aerosol is a solution of Dichlorophen in a suitable solvent to which suitable propellants have been added. It may contain a suitable dye as a marker.

Dichlorophen Veterinary Aerosol contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of dichlorophen, C₁₃H₁₀Cl₂O₂.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

*Mobile phase.* A mixture of 60 volumes of hexane and 40 volumes of acetone.

*Test solution.* Solution A obtained in the Assay diluted with methanol to contain the equivalent of 1 per cent w/v of Dichlorophen.

*Reference solution.* A 1 per cent w/v solution of dichlorophen RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and spray with a freshly prepared solution containing 3.5 per cent w/v of ferric chloride and 0.25 per cent w/v of potassium ferricyanide. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

**Tests**

**Other tests.** Complies with the tests stated under Veterinary Aerosols.

**Assay.** Weigh the intact container. Place the container in an ice-bath for 15 minutes. Make a small hole about 1 cm from the top of the body of the container and let the propellant escape. When the flow of propellant stops, enlarge the hole. Transfer the contents of the container to a tared vessel capable of being fitted with a reflux condenser. Remove the top of the container carefully retaining all fragments. Wash the container with suitable solvents and add the washings to the tared vessel. Dry the container and reweigh to obtain the net weight of the contents. Heat the contents of the tared vessel under reflux for 30 minutes, cool and weigh (solution A). Dilute an accurately measured volume of the resulting solution containing about 0.25 g of Dichlorophen to 100.0 ml with acetone. Dilute 2.0 ml of this solution to 200.0 ml with ammonia buffer pH 10.9 and mix. To 10.0 ml of the resulting solution add 20 ml of ammonia buffer pH 10.9 and 2 ml of a freshly prepared 2 per cent w/v solution of 4-aminophenazone, mix, and add 2 ml of a freshly prepared 8 per cent w/v solution of potassium ferricyanide. Dilute to 50.0 ml with ammonia buffer pH 10.9 and allow to stand for 15 minutes. Measure the absorbance of the resulting solution at the maximum at about 510 nm (2.4.7), using as the blank a solution obtained in a similar manner by carrying out the procedure simultaneously, beginning at the words “To 10.0 ml of the resulting solution.....” but omitting the 4-aminophenazone solution. Calculate the weight of C₁₃H₁₀Cl₂O₂ in the container from the absorbance obtained by repeating the operation using a 0.25 per cent w/v solution of dichlorophen in acetone beginning at the words “Dilute 2.0 ml.....”.

**Labelling.** The label states (1) the weight of Dichlorophen present in the container; (2) the total weight of contents; (3) the name and proportion of any added dye.

**Dichlorophen Tablets**

Dichlorophen Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of dichlorophen, C₁₃H₁₀Cl₂O₂.

**Identification**

A. Shake a quantity of the powdered tablets containing 0.1 g of Dichlorophen with 50 ml of 0.1 M sodium hydroxide for 15
minutes, add sufficient 0.1 M sodium hydroxide to produce 100 ml, centrifuge and dilute a suitable volume of the supernatant liquid with 0.1 M sodium hydroxide to produce a solution containing 0.002 per cent w/v of Dichlorophen.

When examined in the range 220 to 360 nm (2.4.7), the resulting solution shows absorption maxima at about 245 nm and 304 nm; absorbances at about 245 nm and 304 nm, about 1.3 and 0.54 respectively.

B. Shake a quantity of the powdered tablets containing 0.2 g of Dichlorophen with a mixture of 5 ml of water and 5 ml of 5 M sodium hydroxide, filter, cool in ice and add a solution prepared by mixing 1 ml of sodium nitrite solution with a cold solution containing 0.15 ml of aniline in a mixture of 4 ml of water and 1 ml of hydrochloric acid; a reddish-brown precipitate is produced.

C. Fuse a quantity of the powdered tablets containing 0.5 g of Dichlorophen with 2 g of anhydrous sodium carbonate, cool, extract the residue with water and filter. The filtrate gives reaction A of chlorides (2.3.1).

**Tests**

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Shake a quantity of the powdered tablets containing 0.50 g of Dichlorophen with 20 ml of methanol for 10 minutes, filter, add 7 ml of water and dilute to 50 ml with the mobile phase.

**Reference solution (a).** A 1.0 per cent w/v solution of dichlorophen impurity standard RS in the mobile phase.

**Reference solution (b).** A 0.0010 per cent w/v solution of 4-chlorophenol in the mobile phase.

**Chromatographic system**

- a stainless steel column 20 cm x 5 mm, packed with octadecylsilane bonded to porous silica (10 μm) (such as Spherisorb ODS 1),
- mobile phase: a filtered and degassed mixture of 75 volumes of methanol, 25 volumes of water and 1 volume of glacial acetic acid,
- flow rate. 1.5 ml per minute,
- spectrophotometer set at 280 nm,
- a 20 μl loop injector.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution the area of the peak corresponding to 4-dichlorophenol is not more than the area of the principal peak in the chromatogram obtained with reference solution (b). The content of 4,4’-dichloro-2,2’-(2-hydroxy-4-chloro-m-xylene-a,a’-diyl) diphenol in the substance under examination does not exceed 8.0 per cent w/w and the sum of the contents of any other impurities, excluding 4-chlorophenol, is not more than 2.0 per cent w/w.

**Other tests.** Comply with the tests stated under Tablets.

**Assay.** Weigh and powder 20 tablets. Weigh accurately a quantity of the powder containing 0.1 g of Dichlorophen, shake with 50 ml of 0.1 M sodium hydroxide for 15 minutes and add sufficient 0.1 M sodium hydroxide to produce 100.0 ml. Centrifuge and dilute 10.0 ml of the clear supernatant liquid to 100.0 ml with 0.1 M sodium hydroxide. Dilute 20.0 ml of this solution to 100.0 ml with 0.1 M sodium hydroxide and measure the absorbance of the resulting solution at the maximum at about 304 nm (2.4.7). Calculate the content of C_{13}H_{10}Cl_{2}O_{2} taking 275 as the specific absorbance at 304 nm.

**Diethylcarbamazine Injection**

Diethylcarbamazine Citrate Injection.

Diethylcarbamazine Injection is a sterile solution of Diethylcarbamazine Citrate in Water for Injections.

Diethylcarbamazine Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of diethylcarbamazine citrate, C_{10}H_{21}N_{3}O\cdot C_{6}H_{8}O_{7}.

**Identification**

A. To a volume containing 0.5 g of Diethylcarbamazine Citrate add 2 ml of water and make alkaline with 5 M sodium hydroxide. Extract with four quantities, each of 5 ml, of dichloromethane, reserve the aqueous solution for test B, wash the combined dichloromethane extracts with water and remove the dichloromethane by evaporation. Add 0.5 ml of iodoethane to the residue and heat gently under a reflux condenser for 5 minutes. Remove the excess iodoethane with a current of air, dissolve the viscous yellow oil in 2 ml of ethanol (95 per cent) and add, with continuous stirring, sufficient ether to precipitate the quaternary ammonium salt. Decant off the ether, dissolve the residue in 2 ml of ethanol (95 per cent), reprecipitate with ether and dry at 105°; the residue melts at about 152° (2.4.21).

B. Neutralise the aqueous solution obtained in test A with 1 M sulphuric acid, add an excess of mercuric sulphate solution, boil and add a few drops of potassium permanganate solution; a white precipitate is produced.

**Tests**

**pH (2.4.24).** 6.0 to 7.0.

**N,N’-Dimethylpiperazine and N-methylpiperazine.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 65 volumes of methanol, 30 volumes of 2-butanone and 5 volumes of strong ammonia solution.
Test solution. Dilute a volume of the injection with sufficient methanol to produce a solution containing the equivalent of 5.0 per cent w/v of Diethylcarbamazine Citrate.

Reference solution (a). A 5.0 per cent w/v solution of diethylcarbamazine citrate RS in methanol.

Reference solution (b). A 0.010 per cent w/v solution of N,N'-dimethylpiperazine in methanol.

Reference solution (c). A 0.010 per cent w/v solution N-methylpiperazine in methanol.

Apply to the plate 10 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate at 105° and expose it to iodine vapours for 30 minutes. Any spots corresponding to N,N'-dimethylpiperazine and N-methylpiperazine in the chromatogram obtained with the test solution are not more intense than the spots in the chromatograms obtained with reference solutions (b) and (c) respectively.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. To an accurately measured volume containing 8 g of Diethylcarbamazine Citrate add sufficient water to produce 100.0 ml. To 10.0 ml of this solution add 2 ml of 5 M sodium hydroxide and extract with four quantities, each of 25 ml, of dichloromethane. Wash each extract with the same two quantities, each of 20 ml, of water and with a third quantity if the second becomes alkaline to phenolphthalein solution. Extract the combined dichloromethane extracts in succession with 25.0 ml of 0.05 M sulphuric acid and 15 ml and 10 ml of water. Combine the acid and water extracts, remove the dichloromethane, by warming, cool and titrate the excess of acid with 0.1 M sodium hydroxide using bromocresol green solution as indicator.

1 ml of 0.05 M sulphuric acid is equivalent to 0.03914 g of C_{10}H_{21}N_{3}O.C_{6}H_{8}O_{7}.

Storage. Store protected from light.

Dihydrostreptomycin Sulphate

Dihydrostreptomycin sulphate is O-2-deoxy-2-methylamino-D-l-lyxofuranosyl-(1→4)-N^1,N^3-diamidino-D-streptamine sulphate.

Dihydrostreptomycin Sulphate has a potency equivalent to not less than 730 Units per mg, calculated on the dried basis.

Description. A white or almost white powder; may be hygroscopic.

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate in the following manner. Mix 0.3 g of carbomer with 240 ml of water, allow to stand with moderate stirring for 1 hour, adjust to pH 7.0 by the gradual addition with constant shaking of 2 M sodium hydroxide and add 30 g of silica gel H. Spread a uniform layer of the resulting suspension 0.75 mm thick. Heat the plate at 110° for 1 hour, allow to cool and use immediately.

Mobile phase. A 7 per cent w/v solution of potassium dihydrogen phosphate.

Test solution. Dissolve 100 mg of the substance under examination in 100 ml of water.

Reference solution (a). A 0.10 per cent w/v of dihydrostreptomycin sulphate RS in water.

Reference solution (b). A solution containing 0.10 per cent w/v of dihydrostreptomycin sulphate RS, 0.10 per cent w/v of neomycin sulphate RS and 0.10 per cent w/v of kanamycin sulphate RS in water.
Apply to the plate 10 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air, spray it with a mixture of equal volumes of a 0.2 per cent w/v solution of naphthalene-1,3-diol in ethanol (95 per cent) and a 46 per cent w/v solution of sulphuric acid and heat at 150°C for 5 to 10 minutes. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

B. Dissolve 0.1 g in 5 ml of water and add 1 ml of dilute 1-naphthol solution and 2 ml of a mixture of equal volumes of sodium hypochlorite solution (3 per cent Cl) and water; a red colour is produced.

C. Dissolve 10 mg in 5 ml of water and add 1 ml of 1 M hydrochloric acid. Heat in a water-bath for 2 minutes. Add 2 ml of a 0.5 per cent w/v solution of 1-naphthol in 1 M sodium hydroxide and heat in a water-bath for 1 minute; a violet-pink colour is produced (distinction from streptomycin).

D. Gives the reactions of sulphates (2.3.1).

Tests

Appearance of solution. A 25 per cent w/v solution in carbon dioxide-free water is not more intensely coloured than degree 4 of the appropriate range of reference solutions (2.4.1). The solution, after standing protected from light at a temperature of about 20°C for 24 hours, is not more opalescent than opalescence standard OS2 (2.4.1).

pH (2.4.24). 5.0 to 7.0, determined in a 25 per cent w/v solution.

Specific optical rotation (2.4.22). –83° to –91°, calculated on the dried basis, determined in a 2 per cent w/v solution in water.

Sulphate. 18.0 per cent to 21.5 per cent, calculated on the dried basis.

Dissolve 0.25 g in 100 ml of water, adjust the pH to 11 with strong ammonia solution and add 10.0 ml of 0.1 M barium chloride and 0.5 mg of metalthalaein. Titrate the excess of barium chloride with 0.1 M disodium edetate, adding 50 ml of ethanol (95 per cent) when the colour of the solution begins to change and continuing the titration until the violet-blue colour disappears.

1 ml of 0.1 M barium chloride is equivalent to 0.009606 g of sulphate, SO4.

Streptomycin. Weigh accurately about 0.10 g and dissolve in sufficient water to produce 5.0 ml. Add 5.0 ml of 0.2 M sodium hydroxide and heat for exactly 10 minutes in a water-bath. Cool in ice for exactly 5 minutes, add 3 ml of a 1.5 per cent w/v solution of ferric ammonium sulphate in 0.25 M sulphuric acid and sufficient water to produce 25.0 ml, and mix. Exactly 20 minutes after the addition of the ferric ammonium sulphate solution, measure the absorbance of a 2-cm layer at the maximum at about 525 nm (2.4.7), using as the blank a solution prepared in the same manner, omitting the substance under examination. The absorbance is not more than that obtained by carrying out the procedure simultaneously using 5.0 ml of a solution prepared by dissolving 10 mg, accurately weighed, of streptomycin sulphate RS in sufficient water to produce 50 ml and beginning at the words “Add 5.0 ml...”, both absorbances being calculated on the dried basis.

Methanol. Determine by gas chromatography (2.4.13).

Test solution. Dissolve 4.0 g of the substance under examination in 100 ml of water.

Reference solution. A 0.008 per cent w/v of methanol.

Chromatographic system
- a glass column 1.5 to 2.0 m x 2 to 4 mm, packed with ethylnivinylbenzene-divinylenzene copolymer (150 to 180 mm) porous polymer beads (such as Porapak Q),
- temperature: column 50°C, inlet port and detector. 280°C,
- flow rate, 30 to 40 ml per minute of the carrier gas.

The area of any peak corresponding to methanol in the chromatogram obtained with test solution is not more than that of the peak in the chromatogram obtained with reference solution (0.2 per cent).

Sulphated ash (2.3.18). Not more than 1.0 per cent.

Loss on drying (2.4.19). Not more than 5 per cent, determined on 1 g by drying over phosphorus pentoxide at 60°C at a pressure not exceeding 0.1 kPa for 4 hours.

Assay. Carry out the microbiological assay of antibiotics, Method A or B (2.2.10), and express the result in Units of dihydrostreptomycin per mg.

Dihydrostreptomycin Sulphate intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins complies with the following additional requirement.

Bacterial endotoxins (2.2.3). Not more than 0.5 Endotoxin Unit per mg of dihydrostreptomycin sulphate.

Dihydrostreptomycin Sulphate intended for use in the manufacture of parenteral preparations without a further appropriate sterilization procedure complies with the following additional requirement.

Sterility (2.2.11). Complies with the test for sterility.

Storage. Store protected from light, at a temperature not exceeding 30°C. If it is intended for use in the manufacture of parenteral preparations or intramammary infusions, the
container should be sterile and sealed so as to exclude micro-organisms.

**Labelling**. The label states (1) the number of Units per mg; (2) the name and quantity of any added stabiliser; (3) whether or not the contents are intended for use in the manufacture of Parenteral Preparations or intramammary infusions; (4) that the substance is meant for veterinary use only; (5) the storage conditions; (6) the date after which the contents are not intended to be used.

**Dihydrostreptomycin Injection**

Dihydrostreptomycin Sulphate Injection.

Dihydrostreptomycin Injection is a sterile solution of Dihydrostreptomycin Sulphate in Water for Injections. It is prepared by dissolving the contents of a sealed container in the requisite amount of Water for Injections immediately before use.

Dihydrostreptomycin Injection contains not less than 90.0 per cent and not more than 115.0 per cent of the stated amount of dihydrostreptomycin, C$_{21}$H$_{41}$N$_{7}$O$_{12}$, calculated on the dried basis.

**Description**. A white or almost white powder which yields a clear, colourless or faintly yellow solution when dissolved in water.

The injection complies with the tests stated under Parenteral Preparations (Powders for Injection).

The contents of the sealed container comply with the following requirements.

**Identification**

A. Determine by thin-layer chromatography (2.4.17), prepared by mixing 0.3 g of carboxem with 240 ml of water, allow to stand with moderate stirring for 1 hour, adjust to pH 7.0 by the gradual addition with constant shaking of 2 M sodium hydroxide and add 30 g of silica gel H. Spread a uniform layer of the resulting suspension 0.75 mm thick. Heat the plate at 110° for 1 hour, allow to cool and use immediately.

**Mobile phase.** A 7 per cent w/v solution of potassium dihydrogen phosphate.

**Test solution.** Dissolve 100 mg of the substance under examination in 100 ml of water.

**Reference solution (a).** A 0.10 per cent w/v of dihydrostreptomycin sulphate RS in water.

**Reference solution (b).** A solution containing 0.10 per cent w/v of dihydrostreptomycin sulphate RS; 0.10 per cent w/v of neomycin sulphate RS and 0.10 per cent w/v of kanamycin sulphate RS in water.

Apply to the plate 10 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air, spray it with a mixture of equal volumes of a 0.2 per cent w/v solution of naphtalene-1,3-diol in ethanol (95 per cent) and a 46 per cent w/v solution of sulphuric acid and heat at 150° for 5 to 10 minutes. The principal spot in the chromatogram obtained with test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

B. Dissolve 0.1 g in 2 ml of water and add 1 ml of *dilute l-naphthol solution* and 2 ml of a mixture of equal volume of *sodium hypochlorite solution* (3 per cent Cl) and water; a red colour is produced.

C. Dissolve 10 mg in 5 ml of water and add 1 ml of 1 M hydrochloric acid. Heat in a water-bath for 2 minutes. Add 2 ml of a 0.5 per cent w/v solution of *l-naphthol in 1 M sodium hydroxide* and heat in a water-bath for 1 minute; a violet-pink colour is produced (distinction from streptomycin).

D. Gives the reactions of sulphates (2.3.1).

**Tests**

**Appearance of solution.** A 25 per cent w/v solution in carbon dioxide-free water is not more intensely coloured than degree 4 of the appropriate range of reference solutions (2.4.1). The solution, after standing protected from light at a temperature of about 20° for 24 hours, is not more opalescent than opalescence standard OS2 (2.4.1).

**pH** (2.4.24). 5.0 to 7.0, determined in a 25 per cent w/v solution.

**Specific optical rotation** (2.4.22). –83° to –91°, calculated on the dried basis, determined in a 2 per cent w/v solution in water.

**Sulphate.** 18.0 per cent to 21.5 per cent, calculated on the dried basis.

Dissolve 0.25 g in 100 ml of water, adjust the pH to 11 with strong ammonium solution and add 10.0 ml of 0.1 M barium chloride and 0.5 mg of methalpine. Titrate the excess of barium chloride with 0.1 M disodium edetate, adding 50 ml of ethanol (95 per cent) when the colour of the solution begins to change and continuing the titration until the violet-blue colour disappears.

1 ml of 0.1 M barium chloride is equivalent to 0.009606 g of sulphate, SO$_{4}$.

**Streptomycin.** Weigh accurately about 0.10 g and dissolve in sufficient water to produce 5.0 ml. Add 5.0 ml of 0.2 M sodium hydroxide and heat for exactly 10 minutes in a water-bath. 1530
Cool in ice for exactly 5 minutes, add 3 ml of a 1.5 per cent w/v solution of ferric ammonium sulphate in 0.25 M sulphuric acid and sufficient water to produce 25.0 ml, and mix. Exactly 20 minutes after the addition of the ferric ammonium sulphate solution, measure the absorbance of a 2-cm layer at the maximum at about 525 nm (2.4.7), using as the blank a solution prepared in the same manner, omitting the substance under examination. The absorbance is not more than that obtained by carrying out the procedure simultaneously using 5.0 ml of a solution prepared by dissolving 10 mg, accurately weighed, of streptomycin sulphate RS in sufficient water to produce 50 ml and beginning at the words “Add 5.0 ml....”, both absorbances being calculated on the dried basis.

**Methanol.** Determine by gas chromatography (2.4.13).

**Test solution.** Dissolve 4.0 g of the substance under examination in 100 ml of water.

**Reference solution.** A 0.008 per cent w/v of methanol.

**Chromatographic system**
- a glass column 1.5 to 2.0 m x 2 to 4 mm, packed with ethylvinyldivinylbenzene copolymer (150 to 180 mm) and glass beads (such as Porapak Q),
- temperature: column 50°, inlet port and detector, 280°,
- flow rate, 30 to 40 ml per minute of the carrier gas.

The area of any peak corresponding to methanol in the chromatogram obtained with test solution is not more than that of the peak in the chromatogram obtained with reference solution (0.2 per cent).

**Sulphated ash** (2.3.18). Not more than 1.0 per cent.

**Loss on drying** (2.4.19). Not more than 5 per cent, determined on 1 g by drying over phosphorus pentoxide at 60° at a pressure not exceeding 0.1 kPa for 4 hours.

**Assay.** On the mixed contents of ten containers carry out the microbiological assay, Method A or B (2.2.10), and express the result in Units of dihydrostreptomycin per mg.

**Dihydrostreptomycin Sulphate intended for use in the manufacture of Parenteral Preparations without a further appropriate procedure for the removal of bacterial endotoxins complies with the following additional requirement.**

**Bacterial endotoxins** (2.2.3). Not more than 0.5 Endotoxin Unit per mg of dihydrostreptomycin sulphate.

**Dihydrostreptomycin Sulphate intended for use in the manufacture of Parenteral Preparations without a further appropriate sterilization procedure complies with the following additional requirement.**

**Sterility** (2.2.11). Complies with the test for sterility.

**Storage.** Store protected from light. Use the injection within 7 days of the preparation of the solution when stored in a cool place or within 1 month when stored in a cold place.

**Labelling.** The label states (1) the strength in terms of the equivalent amount of dihydrostreptomycin in a suitable dose-volume; (2) that the contents are meant for veterinary use only; (3) the storage conditions; (4) the date after which the contents are not intended to be used.

### Dimetridazole

![Dimetridazole Structure](image)

**C$_4$H$_8$N$_3$O**

Mol. Wt. 141.1

Dimetridazole is 1,2-dimethyl-5-nitro-1H-imidazole.

Dimetridazole contains not less than 98.0 per cent and not more than 101.0 per cent of the stated amount of dimetridazole, C$_4$H$_8$N$_3$O$_2$, calculated on the anhydrous basis.

**Description.** An almost white to brownish yellow powder; darkens on exposure to light, odourless or almost odourless.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with dimetridazole RS or with the reference spectrum of dimetridazole.

B. When examined in the range of 230 to 360 nm (2.4.7), a 0.002 per cent w/v solution in methanol shows a well-defined absorption maximum only at about 309 nm; absorbance at about 309 nm, about 1.3.

C. Dissolve 0.1 g in 20 ml of ether, add 10 ml of a 1 per cent w/v solution of picric acid in ether, induce crystallisation by scratching the sides of the vessel and allow to stand. Wash the precipitate obtained with ether and dry at 105°; the residue melts at about 160° (2.4.21).

**Tests**

**2-Methyl-5-nitroimidazole.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 90 volumes of dichloromethane and 10 volumes of 2-propanol.

**Test solution.** Dissolve 2 g of the substance under examination in 100 ml of dichloromethane.
Reference solution. A 0.010 per cent w/v of 2-methyl-5-nitroimidazole RS in dichloromethane.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any spot corresponding to 2-methyl-5-nitroimidazole in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Water (2.3.43). Not more than 1.0 per cent, determined on 1 g.

Assay. Weigh accurately about 0.3 g, dissolve in 30 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01411 g of C₅H₇N₃O₂.

Storage. Store protected from light.

Dimetridazole Premix

Dimetridazole Premix contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of dimetridazole, C₅H₇N₃O₂.

Identification

Mix a quantity containing 0.1 g of Dimetridazole with 20 ml of ether, shake and filter. To the filtrate add 10 ml of a 1 per cent w/v solution of picric acid in ether, stir to induce crystallisation and allow to stand. Wash the precipitate obtained with ether and dry at 105°C; the residue melts at about 160°C (2.4.21).

Tests

Other tests. Complies with the tests stated under Premixes.

Assay. Weigh accurately a quantity containing 0.45 g of Dimetridazole, transfer to a sintered glass funnel (porosity No. 4), add 10 ml of dichloromethane, stir for 1 minute, and apply gentle suction. Repeat the extraction with four further quantities, each of 10 ml, of dichloromethane. To the combined dichloromethane extracts add 50 ml of anhydrous glacial acetic acid previously neutralised to crystal violet solution by the dropwise addition of 0.1 M perchloric acid. Titrate with 0.1 M perchloric acid, using crystal violet solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.01411 g of C₅H₇N₃O₂.

Storage. Store protected from light.

Dinitolmide

Dinitolmide is 3,5-dinitro-2-methylbenzamide.

Dinitolmide contains not less than 98.0 per cent and not more than 100.5 per cent of C₈H₇N₃O₅, calculated on the dried basis.

Description. A cream to light tan powder.
Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with dinitolmide RS or with the reference spectrum of dinitolmide.

B. Heat 1 g with 20 ml of 9 M sulphuric acid under a reflux condenser for 1 hour, cool, add 50 ml of water and filter. The residue after washing with water and drying at 105° melts at about 205° (2.4.21).

Tests

Acid value (2.3.23). Not more than 5.0, determined on 0.5 g and using 50 ml of ethanol (95 per cent) as the solvent.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 85 volumes of dichloromethane, 10 volumes of methanol and 5 volumes of glacial acetic acid.

Test solution. Dissolve 2.5 g of the substance under examination in 100 ml of acetone.

Reference solution (a). A 0.0125 per cent w/v of the substance under examination in acetone.

Reference solution (b). A 0.0125 per cent w/v of o-toluic acid in acetone.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Spray with titanium trichloride solution, diluted 5 times with water, heat at 100° for 5 minutes and spray with ethanolic dimethylaminobenzaldehyde solution. When viewed under ultraviolet light at 354 nm the spot in the chromatogram obtained with reference solution (b) is more intense than any corresponding spot in the chromatogram obtained with the test solution. By both methods of visualisation any secondary spot in the chromatogram obtained with the test solution is not more intense than any spot in the chromatogram obtained with reference solution (a).

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105°.

Assay. Weigh accurately about 0.15 g, dissolve in acetone and dilute to 50.0 ml. To 10.0 ml of the solution add 10 ml of glacial acetic acid and 15 ml of a 40 per cent w/v solution of sodium acetate. Maintain a stream of carbon dioxide through the flask throughout the determination. Add 25.0 ml of 0.1 M titanium trichloride and allow to stand for 5 minutes. Add 10 ml of hydrochloric acid, 10 ml of water and 1 ml of potassium thiocyanate solution. Titrate with 0.1 M ferric ammonium sulphate until the solution becomes first colourless and then orange. Repeat the operation without the substance under examination. The difference between the titrations represents the amount of titanium trichloride required.

1 ml of 0.1 M titanium trichloride is equivalent to 0.001876 g of C8H7N3O5.

Ethopabate

C12H15NO4  Mol. Wt. 237.3

Ethopabate is methyl 4-acetamide-2-ethoxybenzoate.

Ethopabate contains not less than 96.0 per cent and not more than 104.0 per cent of ethopabate, C12H15NO4, calculated on the dried basis.

Description. A white or pinkish white powder, odourless or almost odourless.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ethopabate RS or with the reference spectrum of ethopabate.

B. When examined in the range 230 to 360 nm (2.4.7), a 0.0016 per cent w/v solution in methanol shows absorption maxima at about 268 nm and at about 299 nm; absorbance at about 268 nm, about 1.3 and at about 299 nm, about 0.58.

C. Melts at about 148° (2.4.21).

Tests

Diazotisable substances. Dissolve 0.2 g in 10 ml of dichloromethane and extract in succession with 100 ml and 90 ml of 0.1 M hydrochloric acid, combine the acid extracts, wash with 5 ml of dichloromethane, dilute to 200 ml with 0.1 M hydrochloric acid and filter. To 5 ml, add 6 ml of 1 M hydrochloric acid and 1 ml of a 0.1 per cent w/v solution of sodium nitrite, mix, and allow to stand for 4 minutes. Add 1 ml of a 0.5 per cent w/v solution of ammonium sulphamate, mix and allow to stand for 3 minutes. Add 1.0 ml of a 0.1 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride, mix, and allow to stand for 30 minutes. Absorbance of the resulting solution at about 545 nm (2.4.7), not more than 0.70.

Phenolic substances. Dissolve 0.25 g in 15 ml of methanol and add sufficient methanol to produce 25 ml. To 5 ml add 5 ml of a 3 per cent w/v solution of anhydrous ferric chloride, mix and allow to stand for 10 minutes. Absorbance of the resulting solution at about 525 nm (2.4.7), not more than 0.70.
using as the blank a solution prepared by adding 5 ml of a 3 per cent w/v solution of anhydrous ferric chloride to 5 ml of methanol.

**Sulphated ash** (2.3.18). Not more than 0.5 per cent.

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1.0 g, by drying in an oven at 105° at a pressure not exceeding 0.7 kPa.

**Assay.** Weigh accurately about 75 mg and dissolve in sufficient methanol to produce 250.0 ml. Dilute 10.0 ml to 100.0 ml with water, transfer 10.0 ml of this solution to an evaporating dish, add 10 ml of 1 M sodium hydroxide and evaporate to dryness on a water-bath. Moisten the dish with 10 ml of water, evaporate to dryness, again moisten with 10 ml of water and heat on a water-bath for 15 minutes. Add 20 ml of 1 M hydrochloric acid, transfer to a flask and add sufficient water to produce 100.0 ml. To 25.0 ml add 5.0 ml of 1 M hydrochloric acid and 5.0 ml of a 0.1 per cent w/v solution of sodium nitrite, mix and allow to stand for 2 minutes. Add 5.0 ml of 0.5 per cent w/v solution of ammonia sulphamate, mix and allow to stand for 2 minutes. Add 5.0 ml of a 0.1 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride, mix and allow to stand for 10 minutes. Add sufficient water to produce 50.0 ml and measure the absorbance of the resulting solution at the maximum at about 545 nm (2.4.7). Calculate the content of C₁₂H₁₅NO₄ from the absorbance obtained by carrying out the procedure simultaneously, using ethopabate RS in place of the substance under examination.

**Furazolidone Veterinary Oral Suspension**

*Furazolidone Veterinary Mixture; Furazolidone Mixture; Furazolidone Drench*

Furazolidone Veterinary Oral Suspension is an aqueous suspension of Furazolidone.

Furazolidone Veterinary Oral Suspension contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of furazolidone, C₈H₇N₃O₅.

**Identification**

A. Add 0.2 ml to a mixture of 15 ml of dimethylformamide and 1 ml of 0.5 M ethanolic potassium hydroxide; a blue colour is produced.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 50 volumes of dichloromethane and 40 volumes of nitromethane and 10 volumes of methanol.

**Test solution.** Shake a quantity of the suspension containing 5 mg of Furazolidone with 1 ml of acetone, allow to stand, and use the supernatant liquid.

**Reference solution.** A 0.5 per cent w/v solution of furazolidone RS in acetone.

Apply to the plate 10 μl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

**Tests**

**Other tests.** Complies with the tests stated under Veterinary Oral Liquids.

**Assay.** Protect the solutions from light throughout the assay.

Weigh accurately a quantity of the well-shaken suspension containing 35 mg of Furazolidone, add slowly and with stirring, 50 ml of dimethylformamide. Warm on a water-bath, with occasional stirring, until most of the solid is dissolved. Decant the supernatant liquid and extract the residue further with two quantities, each of 50 ml, of dimethylformamide, decanting the supernatant solution. No yellow colour should be visible in the third extract. Cool the combined dimethylformamide extracts, add sufficient water to produce 500.0 ml and filter. To 10.0 ml of the filtrate add sufficient water to produce 100.0 ml and measure the absorbance of the resulting solution at the maximum at about 367 nm (2.4.7). Calculate the content of C₈H₇N₃O₅ taking 754 as the specific absorbance at 367 nm.

Determine the weight per ml of the suspension (2.4.29), and calculate the content of furazolidone, weight in volume.

**Storage.** Store protected from light.

**Labelling.** The label states that the oral suspension should be administered undiluted.

**Furazolidone Premix**

Furazolidone Premix contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of furazolidone, C₈H₇N₃O₅.

**Identification**

A. To a mixture of 15 ml of dimethylformamide and 1 ml of 0.5 M ethanolic potassium hydroxide add 5 mg of the premix; a blue colour is produced.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.
**Mobile phase.** A mixture of 50 volumes of dichloromethane and 40 volumes of nitromethane and 10 volumes of methanol.

**Test solution.** The supernatant liquid obtained by shaking a quantity of the premix containing 5 mg of furazolidone with 1 ml of acetone.

**Reference solution.** A 0.5 per cent w/v solution of furazolidone RS in acetone.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

**Tests**

**Other tests.** Complies with the tests stated under Premixes.

**Assay.** Protect the solutions from light throughout the assay.

Weigh accurately a quantity of the premix containing 35 mg of Furazolidone, add 50 ml of dimethylformamide and shake for 20 minutes. Add sufficient water to produce 500.0 ml and filter. To 10.0 ml of the filtrate add sufficient water to produce 100.0 ml and measure the absorbance of the resulting solution at the maximum at about 367 nm (2.4.7). Calculate the content of C₈H₇N₃O₅ taking 754 as the specific absorbance at 367 nm.

Determine the weight per ml, (2.4.29), and calculate the content of furazolidone, weight in volume.

**Storage.** Store protected from light.

---

**Haloxon**

![Haloxon Structural Formula]

C₁₄H₁₄Cl₃O₆P  
Mol. Wt. 415.6

Haloxone is phosphoric acid bis(2-chloroethyl) 3-chloro-4-methyl-2-oxo-2H-1-benzopyran-7-yl ester.

Haloxon contains not less than 95.0 per cent and not more than 100.5 per cent of C₁₄H₁₄Cl₃O₆P, calculated on the dried basis.

**Description.** A white or almost white powder.

**Identification**

A. Dissolve about 20 mg in 10 ml of dioxan, add 0.5 ml of 0.1 M hydrochloric acid and dilute to 25 ml with methanol. Dilute 1 ml to 25 ml with methanol.

When examined in the range 230 to 360 nm (2.4.7), the resulting solution exhibits a maximum at about 290 nm and a less well defined maximum at about 312 nm. Ratio of the absorbance at about 312 nm to that at about 290 nm, about 1.08.

B. Dissolve 0.1 g in 5 ml of 5 M sodium hydroxide with the aid of warming, cool, acidify 1 ml of the solution by the addition of 2 M nitric acid and add 1 ml of silver nitrate solution, a white precipitate is formed. The precipitate is soluble in 5 M ammonia giving a brown solution which exhibits a green fluorescence when viewed under screened ultraviolet light.

C. Melting range (2.4.21). 88° to 93°.

**Tests**

**Acidity.** Dissolve 0.1 g in 10 ml of ethanol (95 per cent) previously neutralised to methyl red solution; the solution requires for neutralisation not more than 0.1 ml of 0.1 M sodium hydroxide.

**3-Chloro-4-methylumbelliferone.** Not more than 2.0 per cent.

**NOTE – Prepare the solutions immediately before use and protected from light.**

Dissolve 0.20 g in 50 ml of 0.01 M methanolic hydrochloric acid and dilute 5 ml to 100 ml with 0.01 M methanolic hydrochloric acid. Measure the fluorescence of the resulting solution (2.4.5), using an excitation wavelength of about 345 nm and an emission wavelength of about 400 nm and setting the spectrofluorimeter to zero with 0.01 M methanolic hydrochloric acid and to 100 with a standard solution prepared by dissolving 25 mg of 3-chloro-4-methyl-umbelliferone RS in sufficient 0.01 M methanolic hydrochloric acid to produce 250 ml (solution A) and diluting 5 ml to 100 ml with 0.01 M methanolic hydrochloric acid. Calculate the content of 3-chloro-4-methylumbelliferone from a calibration curve prepared by measuring the fluorescence of suitable dilutions of solution A.

**Loss on drying (2.4.19).** Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 80° at a pressure not exceeding 0.7 kPa.

**Assay.** Weigh accurately about 0.25 g and dissolve in sufficient acetonitrile to produce 10 ml and record the infrared absorption of a 0.2 mm layer of the solution at the maximum at about 1155 cm⁻¹(2.4.6). Construct a base line between the minima at about 1125 cm⁻¹ and 1180 cm⁻¹. Calculate the content of C₁₄H₁₄Cl₃O₆P from the absorption obtained by repeating the procedure using haloxon RS in place of the substance under examination.

**Storage.** Avoid contact with metals.
Ivermectin contains not less than 95.0 per cent and not more than 102.0 per cent of $H_2B_{1a}$ + $H_2B_{1b}$, calculated on the dried basis.

The ratio $H_2B_{1a}/(H_2B_{1a} + H_2B_{1b})$, determined by liquid chromatography is not less than 90.0 per cent.

**Description.** A white crystalline powder, slightly hygroscopic.

**Identification**

A. Determine by infrared absorption spectrophotometery (2.4.6). Compare the spectrum with that obtained with ivermectin RS.

B. In the Assay, the principal peak in the chromatogram obtained with the test solution corresponds to the peak in the chromatogram obtained with reference solution (a).

**Tests**

**Appearance of solution.** A 2.0 per cent w/v solution in toluene is clear (2.4.1) and not more intensely colored than reference solution BY57 (2.4.1).

**Specific optical rotation** (2.4.22)-17.0 to -20.0, determined on a 2.5 per cent w/v solution in methanol.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 40 mg of the substance under examination in 50 ml of methanol.

**Reference solution (a).** A 0.08 per cent w/v solution of ivermectin RS in methanol.

**Reference solution (b).** Dilute 1.0 ml of reference solution (a) to 100 ml with methanol.

**Reference solution (c).** Dilute 5 ml of reference solution (b) to 100 ml with methanol.

Chromatographic system

- a stainless steel column 25 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm),
- mobile phase: a mixture of 15 volumes of water, 34 volumes of methanol and 51 volumes of acetonitrile,
- flow rate. 1 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject reference solution (a). This test is not valid unless resolution between the component $H_2B_{1a}$ (first peak) and component $H_2B_{1b}$ (second peak) is not less than 3.0.

Inject the test solution and reference solution (b). In the chromatogram obtained with the test solution the impurity with a relative retention of 1.3 to 1.5 with reference to the principal peak is not more than 2.5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (2.5 per cent). The area of any other peak is not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent) and the sum of all the secondary peaks is not more than 5 times the area of the principal peak in the chromatogram obtained with reference solution (b) (5.0 per cent).

**Ethanol and formamide.** Determine by gas chromatography (2.4.13).

**Internal standard solution.** Dilute 0.5 ml of propanol to 100 ml with water.

**Test solution.** Dissolve 0.120 g of the substance under examination in 2.0 ml of m-xylene by heating on a water-bath at 40 to 50°, add 2.0 ml of water, mix thoroughly and centrifuge. Remove the upper layer and extract it with 2.0 ml of water. Discard the upper layer and combine the aqueous layers. Add 1.0 ml of the internal standard solution. Centrifuge and discard any remaining m-xylene.

**Reference solution (a).** Dilute 3.0 g of ethanol to 100 ml with water.

**Reference solution (b).** Dilute 1.0 g of formamide to 100 ml with water.

**Reference solution (c).** Dilute 5.0 ml of reference solution (a) and 5 ml of reference solution (b) to 50.0 ml with water. Transfer 2.0 ml of this solution to a centrifuge tube, add 2 ml of m-xylene, mix thoroughly and centrifuge. Remove the upper layer and extract it with 2.0 ml of water. Discard the upper layer and combine the aqueous layers. Add 1.0 ml of the internal standard solution. Centrifuge and discard any remaining m-xylene.

**Reference solution (d).** Dilute 10.0 ml of reference solution (a) and 10.0 ml of reference solution (b) to 50.0 ml with water. Transfer 2.0 ml of this solution to a centrifuge tube, add 2 ml of m-xylene, mix thoroughly and centrifuge. Remove the upper layer and extract it with 2.0 ml of water. Discard the upper layer and combine the aqueous layers. Add 1.0 ml of the internal
standard solution. Centrifuge and discard any remaining m-xylene.

Chromatographic system
- a glass column 30 m x 0.53 mm, packed with fused silica with macrogl 20,000 with film thickness 1 mm,
- temperature
  column 80° increase @ 60° per minute to 240°,
  injection port 220° and detector 280°,
- flow rate. 7.5 ml per minute of helium as carrier gas.

Inject 1 µl of the test solution and reference solutions (c) and (d).

Calculate the content of ethanol is not more than 5 per cent and formamide not more than 1 per cent.

Heavy metals (2.3.13). 1 g complies with the limit test for heavy metals, Method C (20 ppm).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Water (2.3.43). Not more 0.1 per cent, determined on 0.5 gm.

Assay. Determine by liquid chromatography (2.4.14), as described under Related substances.

Inject the test solution and reference solution (a).

Calculate the percentage contents of ivermectin (H2B1a + H2B1b) and the ratio H2B1a/(H2B1a + H2B1b).

Storage. Store protected from light.

Ivermectin Injection

Ivermectin Injection is a sterile solution of Ivermectin with or with one or more anaesthetics, preservatives and solvents.

Ivermectin Injection contains not less than 90 per cent and not more than 110 per cent of H2B1a, and not more than 5 per cent of H2B1b.

The content of H2B1a + H2B1b is not less than 95 per cent and not more than 110 per cent of the stated amount of Ivermectin.

Description. A clear, colourless to yellow colour solution.

Identification

When examined in the range 220 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in methanol shows an absorption maximum at about 245 nm.

Tests

pH (2.4.24). 5.5 to 7.0.

Pyrogens (2.2.8). Complies with the test for pyrogens, by injecting 0.2 mg of Ivermectin per kg body weight of rabbit.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Kaolin Veterinary Oral Suspension

Kaolin Veterinary Mixture; Kaolin Mixture

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Light Kaolin</td>
<td>200 g</td>
</tr>
<tr>
<td>Light Magnesium Carbonate</td>
<td>50 g</td>
</tr>
<tr>
<td>Sodium Bicarbonate</td>
<td>50 g</td>
</tr>
<tr>
<td>Water to produce</td>
<td>1000 ml</td>
</tr>
</tbody>
</table>

Kaolin Veterinary Oral Suspension should be freshly prepared, unless the Light Kaolin has been sterilised.

Kaolin Veterinary Oral Suspension contains not less than 1.04 per cent w/w and not more than 1.25 per cent w/w of the stated amount of magnesium, Mg and not less than 4.05 per cent w/w and not more than 4.65 per cent w/w of the stated amount of sodium bicarbonate, NaHCO3.

Tests

Acid-insoluble matter. 13.8 to 18.4 per cent w/w, determined by the following method. Weigh accurately about 3 g, add 15 ml of water and make acid to litmus paper by the cautious addition of 2 M hydrochloric acid; boil for 5 minutes, replacing water lost by evaporation, cool and decant the supernatant layer through a filter. Boil the residue with 20 ml of water and 10 ml of 2 M hydrochloric acid, cool, filter through the same filter, and wash the residue with water until the washings are...
free from chloride, reserving the filtrate and washings for the Assay for magnesium. Dry and ignite the residue to constant weight at red heat.

Other tests. Complies with the tests stated under Veterinary Oral Liquids.

Assay. For magnesium — Dilute the combined filtrate and washings reserved in the determination of acid-insoluble matter to 100.0 ml with water. To 20.0 ml add 0.1 g of ascorbic acid, make slightly alkaline to litmus paper with 5 M ammonia and add 10 ml of triethanolamine, 10 ml of ammonia buffer pH 10.9 and 1 ml of potassium cyanide solution. Titrate with 0.05 M disodium edetate using eriochrome black T solution as indicator.

1 ml of 0.05 M disodium edetate is equivalent to 0.001215 g of Mg.

For sodium bicarbonate — Weigh accurately about 10 g, boil with 100 ml of water for 5 minutes and filter. Boil the residue with 100 ml of water for 5 minutes and filter. Cool the combined filtrates and titrate with 0.5 M hydrochloric acid using methyl orange-xylene cyanol FF solution as indicator. Add 10 ml of ammonia buffer pH 10.9 and titrate with 0.05 M disodium edetate using eriochrome black T solution as indicator.

1 ml of 0.5 M hydrochloric acid after subtracting one fifth of the volume of 0.05 M disodium edetate is equivalent to 0.0420 g of NaHCO₃.

**Levamisole Injection**

Levamisole Hydrochloride Injection

Levamisole Injection is a sterile solution of Levamisole Hydrochloride in Water for Injections. It may contain suitable colouring agents.

Levamisole Injection contains not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of levamisole hydrochloride, C₁₁H₁₂N₂S.HCl.

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 100 volumes of ethyl acetate, 10 volumes of methanol and 1 volume of strong ammonia solution.

**Test solution.** Dilute a volume of the injection to produce a solution containing 1.0 per cent w/v of Levamisole Hydrochloride in methanol.

**Reference solution.** A 1.0 per cent w/v of levamisole hydrochloride RS in methanol.

Apply to the plate 1 µl of each solution. After development, dry the plate in air and spray with potassium iodoplatinate solution. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

B. Dilute a volume of the injection containing 0.75 g of Levamisole Hydrochloride to 20 ml with water and add 6 ml of 1 M sodium hydroxide. Extract with 20 ml of dichloromethane, discard the aqueous layer and wash the dichloromethane layer with 10 ml of water. Dry by shaking with anhydrous sodium sulphate, filter and evaporate the solvent at room temperature. The residue, after drying over phosphorus pentoxide at a pressure of 1.5 to 2.5 kPa at a temperature not exceeding 40°, melts at about 59° (2.4.21).

C. The injection is laevorotatory.

D. Gives reaction B of chlorides (2.3.1).

Tests

pH (2.4.24). 3.3 to 3.7.

2,3-Dihydro-6-phenylimidazo[2,1-b]thiazole hydrochloride. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 45 volumes of toluene, 8 volumes of methanol and 4 volumes of anhydrous glacial acetic acid.

**Test solution.** Dilute a volume of the injection with methanol to produce a solution containing 5.0 per cent w/v of Levamisole Hydrochloride.

**Reference solution.** A 0.025 per cent w/v of 2,3-dihydro-6-phenylimidazo[2,1-b]thiazole hydrochloride RS in methanol.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and spray with potassium iodoplatinate solution. Any spot corresponding to 2,3-dihydro-6-phenylimidazo[2,1-b]thiazole hydrochloride in the chromatogram obtained with test solution is not more intense than the spot in the chromatogram obtained with reference solution.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. To an accurately measured volume containing 0.75 g of Levamisole Hydrochloride add 50 ml of water and 15 ml of 2 M sodium hydroxide, extract with three quantities, each of 25 ml, 20 ml and 15 ml of dichloromethane, wash the combined extracts with two quantities, each of 10 ml, of water and discard the washings. To the clear dichloromethane solution, after drying with anhydrous sodium sulphate, add 50 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, using 1-naphtholbenzenesulphonic acid solution as indicator. Carry out a blank titration.
1 ml of 0.1 M perchloric acid is equivalent to 0.02408 g of C11H12N2S,HCl.

Storage. Store protected from light.

Levamisole Hydrochloride Veterinary Oral Solution

Levamisole Hydrochloride Veterinary Mixture; Levamisole Veterinary Oral Solution; Levamisole Veterinary Mixture

Levamisole Hydrochloride Veterinary Oral Solution is an aqueous solution of Levamisole Hydrochloride containing suitable stabilising agents.

Levamisole Hydrochloride Veterinary Oral Solution contains not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of levamisole hydrochloride, C11H12N2S,HCl.

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 100 volumes of ethyl acetate, 10 volumes of methanol and 1 volume of strong ammonia solution.

Test solution. Dilute a volume of the preparation under examination with methanol to produce a solution containing 1.0 per cent w/v of Levamisole Hydrochloride.

Reference solution. A 1.0 per cent w/v of levamisole hydrochloride RS in methanol.

Apply to the plate 1 µl of each solution. After development, dry the plate in air and spray with potassium iodoplatinate solution. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

B. To a quantity containing 0.3 g of Levamisole Hydrochloride add 10 ml of water and 6 ml of 1 M sodium hydroxide. Extract with three quantities each of 25 ml, 20 ml and 15 ml of dichloromethane, wash the combined extracts with two quantities, each of 10 ml, of water and discard the washings. To the clear dichloromethane solution, after drying with anhydrous sodium sulphate, add 50 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, using 1-naphtholbenzein solution as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02408 g of C11H12N2S,HCl.

Lincomycin Premix

Lincomycin Hydrochloride Premix.

Lincomycin Premix contains Lincomycin Hydrochloride.

Lincomycin Premix contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of lincomycin, C18H34N2O6S.

Identification

In the Assay, the chromatogram obtained with the test solution (b) corresponds to the chromatogram obtained with the reference solution.

Tests

Lincomycin B. Examine test solution (a) as described in the Assay but increasing the sensitivity by 8 to 10 times while recording the peak due to the trimethylsilyl derivative of lincomycin B, which is eluted immediately before the
trimethylsilyl derivative of lincomycin. The area of the peak due to the trimethylsilyl derivative of lincomycin B, after correction for the sensitivity factor, is not more than 5 per cent of the area of the peak due to the trimethylsilyl derivative of lincomycin.

Other tests. Complies with the tests stated under Premixes.

Assay. Determine by gas chromatography (2.4.13).

Solution A. Weigh accurately a quantity of the premix containing about 90 mg of lincomycin, shake with 10.0 ml of dimethylformamide and filter.

Test solution (a). Add 1 ml of a 1 per cent w/v solution of tetraphenylcyclopentadienone (internal standard) in dimethylformamide and 0.4 ml of a mixture of 9 volumes of N₂O-bis(trimethylsilyl) acetamide and 1 volume of trimethylchlorosilane to 1 ml of solution A, mix and allow to stand for 15 minutes.

Test solution (b). Add 1 ml of dimethylformamide and 0.4 ml of a mixture of 9 volumes of N₂O-bis(trimethylsilyl) acetamide and 1 volume of trimethylchlorosilane to 1 ml of solution A, mix and allow to stand for 15 minutes.

Reference solution. Add 1 ml of a 1 per cent w/v solution of tetraphenylcyclopentadienone (internal standard) in dimethylformamide and 0.4 ml of a mixture of 9 volumes of N₂O-bis(trimethylsilyl) acetamide and 1 volume of trimethylchlorosilane to 1 ml of a per cent w/v solution of lincomycin hydrochloride RS in dimethylformamide, mix and allow to stand for 15 minutes.

Chromatographic system
- a glass column 1.5 m x 3 mm, packed with silanised diatomaceous support (100 to 120 mesh) coated with 3 per cent w/w of methyl silicone gum (such as SE 30),
- temperature: column 260°C,
- inlet port and detector, 260°C to 290°C,
- flow rate, 30 ml per minute of the carrier gas.

Calculate the content of C₁₂H₁₇N₂O₆S.

Labelling. The label states the strength in terms of the equivalent amount of lincomycin.

Lithium Antimony Thiomalate

\[
\left(\text{LiOOC} - \text{C} - \text{CH}_2\text{COOLi}\right)_3, 9\text{H}_2\text{O}
\]

C₁₂H₁₇Li₂O₂Sb₂,9H₂O

Mol. Wt. 766.9

Lithium Antimony Thiomalate contains not less than 15.5 per cent and not more than 16.5 per cent of Sb and not less than 5.1 per cent and not more than 5.7 per cent of Li, calculated on the dried, solvent-free basis.

Description. A pinkish white or creamy powder; hygroscopic.

Identification
A. To 0.2 g dissolved in 5 ml of water add 2 ml of hydrochloric acid and 5 ml of sodium sulphide solution; a yellowish-orange precipitate is produced which does not dissolve on addition of dilute ammonia solution.

B. When moistened with hydrochloric acid and introduced on a platinum wire it imparts a red colour to a non-luminous flame.

Tests

Appearance of solution. A 6 per cent w/v solution in carbon dioxide-free water is clear (2.4.1), and not more intensely coloured than reference solution RS3 (2.4.1).

pH (2.4.24). 9.0 to 10.5, determined in a 6 per cent w/v solution in carbon dioxide-free water.

Assay. For antimony — Weigh accurately about 0.50 g, add 35 ml of water and swirl to dissolve. Add 5 g of ammonium persulphate, 10 ml of sodium hydroxide solution and 3 or 4 glass beads (approximately 0.5 cm diameter). Place a small funnel in the neck of the flask and boil gently for 20 minutes at such a rate that the volume is not reduced appreciably. Cool, add through the funnel 0.25 ml of phenolphthalein solution and sufficient 0.1 M hydrochloric acid until the last trace of pink colour disappears. Add 25 ml of a 10 per cent w/v solution of oxalic acid through the funnel and boil vigorously for 3 minutes. Rinse the funnel, with a small quantity of water, remove it and add 5 ml of hydrochloric acid and 2 g of potassium iodide. Allow to stand for 10 minutes and boil until the solution becomes yellow and shows no further decrease in colour, but taking care to see that the volume is not reduced to less than about 30 ml. Cool and remove a small drop of the solution with a sealed capillary melting point tube and add to starch iodide paper. If a bluish colour is produced, add 1 drop of 0.1 M sodium thiosulphate while swirling and again test with starch iodide paper. Repeat if necessary until a bluish colour is no longer produced.

Add 5 g of sodium potassium tartrate, cool to about 15°C to 20°C and cautiously add small portions of sodium bicarbonate until no further effervescence is produced. Add 2 to 4 g more of sodium bicarbonate and titrate with 0.1 M iodine until the first permanent light yellow colour is produced.

1 ml of 0.1 M iodine is equivalent to 0.006088 g of Sb.

For lithium — Weigh accurately about 0.2 g, dissolve in 50 ml of glacial acetic acid. Titrate with 0.1 M perchloric acid, using 1 ml of crystal violet solution as indicator. Carry out a blank titration.
1 ml of 0.1 M perchloric acid is equivalent to 0.000694 g of Li.  

**Storage.** Store protected from light and moisture.

### Lithium Antimony Thiomalate Injection

Lithium Antimony Thiomalate Injection is a sterile solution of Lithium Antimony Thiomalate in Water for Injection containing a suitable antimicrobial preservative.

Lithium Antimony Thiomalate Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of lithium antimony thiomalate, C_{12}H_{9}Li_{6}O_{12}S_{3}Sb_{9}H_{2}O.

#### Identification

A. Dilute a volume containing 0.2 g of Lithium Antimony Thiomalate to 5 ml with water. Add 2 ml of hydrochloric acid and 5 ml of sodium sulphide solution; a yellowish orange precipitate is produced which does not dissolve on addition of dilute ammonia solution.

B. Dilute 0.2 ml of the injection under examination to 10 ml with a 5 per cent w/v solution of sodium potassium tartrate. To 2 ml of the solution add sodium sulphide solution dropwise; a reddish orange precipitate is produced. The precipitate dissolves on adding dilute sodium hydroxide solution.

#### Tests

**Appearance of solution.** The solution is clear (2.4.1), and not more intensely coloured than reference solution RS3 (2.4.1).

**pH.** (2.4.24). 9.0 to 10.5.

**Pyrogens.** Complies with the test for pyrogens (2.2.8), using per 1.5 kg of the rabbit’s weight, a volume containing 0.012 g of Lithium Antimony Thiomalate.

**Sterility (2.2.11).** Complies with the test for sterility.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Dilute 10.0 ml with 25 ml of water, add 7.5 g of ammonium persulphate and 16 ml of sodium hydroxide solution, boil gently for 20 minutes, cool and add 0.5 ml of phenolphthalein solution. Neutralise the solution with dilute hydrochloric acid and boil for 3 minutes. Add 50 ml of a 10 per cent w/v solution of oxalic acid, 7.5 ml of hydrochloric acid and sufficient water to make up the volume, if necessary. Add 2 g of potassium iodide to the hot solution, allow to stand for 10 minutes and boil until it acquires a pale yellow colour (about 10 minutes). Cool and remove the colour by adding 0.1 M sodium thiosulphate using starch iodide solution as an external indicator. Add 7.5 g of sodium potassium tartrate and dilute to 200 ml. Add sodium bicarbonate carefully (avoiding loss by spurring due to effervescence) till alkaline to litmus paper and titrate with 0.05 M iodine using 1 ml of starch solution, added towards the end of the titration, as indicator.

1 ml of 0.05 M iodine is equivalent to 0.03834 g of C_{12}H_{9}Li_{6}O_{12}S_{3}Sb_{9}H_{2}O.

**Storage.** Store protected from light.

### Magnesium Hypophosphite

\[
\text{HO—P—Mg—P—OH, 6H}_{2}\text{O}
\]

\[
\text{Mg(H}_{2}\text{PO}_{2})_{2},6\text{H}_{2}\text{O}
\]

Mol. Wt. 262.4

Magnesium Hypophosphite contains not less than 98.5 per cent and not more than 101.0 per cent of Mg(H_{2}PO_{2})_{2},6H_{2}O.

**Description.** Colourless crystals or white crystalline powder.

#### Identification

A. Gives the reactions of magnesium salts (2.3.1).

B. Dissolve about 50 mg in 5 ml of water and add 0.5 ml of mercuric chloride solution; a white precipitate is produced.

C. Dissolve about 50 mg in 5 ml of water and acidify with sulphuric acid. Add 0.5 ml of cupric sulphate solution and warm; a red precipitate is produced.

#### Tests

**Appearance of solution.** A 5 per cent w/v solution is clear (2.4.1) and colourless (2.4.1).

**Heavy metals (2.3.13).** Dissolve 1.0 g in 20 ml of water, add 2 ml of dilute hydrochloric acid and sufficient water to produce 25 ml. The resulting solution complies with the limit test for heavy metals, Method A (20 ppm).

**Chlorides (2.3.12).** To 1 g add 200 ml of water and filter. 10 ml of the filtrate complies with the limit test for chlorides (0.1 per cent).

**Sulphates (2.3.17).** 1 g complies with the limit test for sulphates (0.015 per cent).

**Assay.** Weigh accurately about 0.2 g, dissolve in 50 ml of water, add 5 ml of strong ammonia-ammonium chloride solution and titrate with 0.05 M disodium edetate using 0.1 g of mordant black II mixture as indicator, until a blue colour is obtained.

1 ml of 0.05 M disodium edetate is equivalent to 0.01312 g of Mg(H_{2}PO_{2})_{2},6H_{2}O.

**Storage.** Store protected from moisture.
Meclofenamic Acid

C₁₄H₁₁Cl₂NO₂  Mol. Wt. 296.2

Meclofenamic acid is N-(2,6-dichloro-3-methylphenyl) anthranilic acid.

Meclofenamic Acid contains not less than 98.5 per cent and not more than 100.5 per cent of the stated amount of C₁₄H₁₁Cl₂NO₂, calculated on the dried basis.

**Description.** A white or almost white, crystalline powder.

**Identification.**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with meclofenamic acid RS or with the reference spectrum of meclofenamic acid.

B. When examined in the range 220 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in 0.1 M sodium hydroxide shows absorption maxima at about 279 nm, and 371 nm; absorbance at about 279 nm, about 0.45, and at about 317 nm, about 0.33.

C. Dissolve 25 mg in 15 ml of dichloromethane; the solution exhibits a strong blue fluorescene when examined under ultraviolet light.

D. Dissolve 1 mg in 2 ml of sulphuric acid and add 0.05 ml of 0.02 M potassium dichromate; an intense purple colour is produced, which rapidly fades to purple brown.

**Tests**

**Appearance of solution.** A 5.0 per cent w/v solution in 1 M sodium hydroxide is not more opalescent than reference suspension OS2 (2.4.1) and is not more intensely coloured than reference solution BYS5 (2.4.1).

**Light absorption** (2.4.7). Absorbance of a 0.002 per cent w/v solution in 0.01 M methanolic hydrochloric acid at the maximum at about 279 nm, not less than 0.400 and not more than 0.445, and at the maximum at about 335 nm, not less than 0.440 and not more than 0.490.

**Related substances.** Determine by liquid chromatography (2.4.14).

**Test solution.** Dissolve 1.0 g of the substance under examination in 100 ml of ethanol.

**Reference solution (a).** A 0.0035 per cent w/v solution of ethyl meclofenamate RS (internal standard) in ethanol.

**Reference solution (b).** A solution containing 1.0 per cent w/v of the substance under examination and 0.0035 per cent w/v of ethyl meclofenamate RS (internal standard) in ethanol.

**Chromatographic system**
- a stainless steel column 20 cm x 4 mm, packed with particles of silica gel (10 µm) the surface of which has been modified with chemically-bonded octadecasilyl groups (such as Spherisorb ODS),
- mobile phase: a mixture of 75 volumes of methanol, 25 volumes of water and 1 volume of glacial acetic acid,
- flow rate. 2 ml per minute,
- spectrophotometer set at 254 nm,
- a 20 µl loop injector.

Inject reference solution (a). The test is not valid unless the column efficiency is not less than 4500 theoretical plates.

Inject reference solution (b). The area of the peak immediately preceding the peak due to meclofenamic acid is not more than one-seventh of the area of the peak due to the internal standard. The area of any other peak is not more than the area of the peak due to the internal standard.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method D (20 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°C.

**Assay.** Weigh accurately about 0.6 g, dissolve in 100 ml of warm ethanol previously neutralised to phenol red solution and titrate with 0.1 M sodium hydroxide, using phenol red solution as indicator.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.02962 g of C₁₄H₁₁Cl₂NO₂.

**Storage.** Store protected from moisture.

Mepyramine Injection

Mepyramine Maleate Injection; Pyrilamine Maleate Injection; Pyrilamine Injection

Mepyramine Injection is a sterile solution of Mepyramine Maleate in Water for Injections.

Mepyramine Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of mepyramine maleate, C₁₇H₂₃N₃O.C₄H₄O₄.

**Description.** Colourless or almost colourless solution.

**Identification.**

A. To a volume containing 0.1 g of Mepyramine Maleate add 2 ml of 5 M sodium hydroxide and shake with three quantities, each of 3 ml, of ether. Warm the aqueous layer in a water-bath for 10 minutes with 2 ml of bromine solution, heat to boiling, cool, and add 0.2 ml to a solution of 10 mg of resorcinol in 3 ml
of sulphuric acid; a blue-black colour develops on heating for 15 minutes in a water-bath.

B. Dilute a volume containing 20 mg of mepyramine maleate to 2 ml with water, add 1 ml of cyanogen bromide solution and 5 ml of a 2 per cent w/v solution of potassium hydrogen phthalate, mix, allow to stand for 15 minutes and add 1 ml of a 4 per cent solution of aniline in ethanol (95 per cent); a yellow colour is produced.

Tests

pH (2.4.24). 5.5 to 6.5.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. To an accurately measured volume containing about 25 mg of mepyramine maleate add sufficient 0.01 M hydrochloric acid to produce 100.0 ml. Dilute 10.0 ml of this solution to 100.0 ml with 0.01 M hydrochloric acid and measure the absorbance of the resulting solution at the maximum at about 316 nm (2.4.7). Calculate the content of C_{17}H_{23}N_{3}O,C_{4}H_{4}O_{4}, taking 206 as the specific absorbance at 316 nm.

Monosulfiram

Sulfiniram

\[
\begin{align*}
\text{H}_3\text{C} & \quad \text{CH}_3 \\
\text{H}_3\text{C} & \quad \text{N} \quad \text{S} \quad \text{N} \quad \text{CH}_3
\end{align*}
\]

C_{10}H_{20}N_{2}S_{3}  
Mol. Wt. 264.5

Monosulfiram is bis(diethylthiocarbamoyl)sulphide.

Monosulfiram contains not less than 98.0 per cent and not more than 101.0 per cent of C_{10}H_{20}N_{2}S_{3}, calculated on the anhydrous basis.

Description. A yellow or yellowish-brown soft solid; odour, sulphurous.

Identification

A. When examined in the range 230 nm to 360 nm (2.4.7), a 2-cm layer of a 0.001 per cent w/v solution in methanol shows a well-defined absorption maximum only at about 281 nm; absorbance at about 281 nm, about 1.3.

B. Dissolve 0.1 g in a mixture of 0.15 ml of a 1 per cent w/v solution of cupric sulphate and 5 ml of ethanol (95 per cent), evaporate on a water-bath and dissolve the residue in dichloromethane; a deep yellowish brown colour is produced.

C. Boil 0.1 g with 2 M hydrochloric acid; hydrogen sulphide is evolved which has a characteristic odour and turns filter paper treated with lead acetate solution, black.

Tests

Freezing point (2.4.11). 28.5° to 32.0°.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

NOTE – Carry out the test in subdued light.

Mobile phase. A mixture of 70 volumes of n-hexane and 30 volumes of butyl acetate.

Test solution. Dissolve 2.5 g of the substance under examination in 100 ml of ethyl acetate.

Reference solution (a). A 0.125 per cent w/v solution of disulfiram RS in ethyl acetate.

Reference solution (b). A 0.050 per cent w/v solution of the substance under examination in ethyl acetate.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. In the chromatogram obtained with the test solution any secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (a) and any other spot, apart from the principal spot, is not more intense than the spot in the chromatogram obtained with reference solution (b).

Water (2.3.43). Not more than 1.0 per cent, determined on 1 g.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Assay. Weigh accurately about 0.35 g, dissolve in 8 ml of nitrogen-free sulphuric acid and carry out the method for the determination of nitrogen (2.3.30).

1 ml of 0.05 M sulphuric acid is equivalent to 0.01322 g of C_{10}H_{20}N_{2}S_{3}.

Storage. Store protected from light.

Monosulfiram Soap

Monosulfiram Soap contains not less than 5 per cent w/w of monosulfiram in a toilet soap basis which may be perfumed.

Monosulfiram Soap contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of monosulfiram, C_{10}H_{20}N_{2}S_{3}.

Identification

In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (c).
Tests

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel* GF254.

**NOTE —** Carry out the test in subdued light.

**Mobile phase.** A mixture of 70 volumes of n-*hexane* and 30 volumes of *butyl acetate*.

**Test solution (a).** Shake a quantity of the finely shredded soap containing 20 mg of Monosulfiram with 10 ml of *dichloromethane*, filter and wash the filtrate with *dichloromethane*. Evaporate the combined filtrate and washings just to dryness at room temperature in a current of *nitrogen* and dissolve the residue in 1 ml of *ethanol* (95 per cent).

**Test solution (b).** Dilute 0.5 ml of test solution (a) to 10 ml with *ethanol* (95 per cent).

**Reference solution (a).** A 0.10 per cent w/v solution of *disulfiram RS* in *ethanol* (95 per cent).

**Reference solution (b).** A 0.040 per cent w/v solution of *monosulfiram RS* in *ethanol* (95 per cent).

**Reference solution (c).** A 0.10 per cent w/v solution of *monosulfiram RS* in *ethanol* (95 per cent).

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. In the chromatogram obtained with test solution any spot running ahead of the principal spot and corresponding in position to disulfiram is not more intense than the spot in the chromatogram obtained with reference solution (a) and any spot running behind the principal spot is not more intense than the spot in the chromatogram obtained with reference solution (b). Ignore any subsidiary spots due to the soap basis which may also be observed ahead of the principal spot in the chromatogram obtained with test solution (a).

**Assay.** Protect the solutions from light throughout the assay. Determine by gas chromatography (2.4.13).

**Test solution (a).** Weigh accurately a quantity of the finely shredded soap containing about 0.25 g of Monosulfiram, shake for 10 minutes with 50 ml of *dimethylformamide*, centrifuge and use the supernatant liquid.

**Test solution (b).** Weigh accurately a quantity of the finely shredded soap containing about 0.25 g of Monosulfiram, shake for 10 minutes with 50 ml of *dimethylformamide* containing 0.125 g of N-*phenylcarbazole* (internal standard), centrifuge and use the supernatant liquid.

**Reference solution.** A solution containing 0.5 per cent w/v of *monosulfiram RS* and 0.25 per cent w/v of N-*phenylcarbazole* (internal standard) in *dimethylformamide*.

**Chromatographic system**
- a glass column 1.5 m x 4 mm, packed with 2 per cent w/w of methyl silicone gum on acid-washed, silanised diatomaceous support (80 to 100 mesh) (such as SE 30),
- temperature: column 180°, inlet port 180° and detector 280°,
- flow rate. 30 ml per minute of the carrier gas.

Calculate the content of C₁₀H₂₀N₂S₃.

**Labelling.** The label states (1) the proportion of Monosulfiram in the preparation; (2) the method of use of the preparation.

Monosulfiram Solution

Monosulfiram Solution is a solution of Monosulfiram in Ethanol (95 per cent) containing a suitable dispersing agent. In making Monosulfiram Solution the ethanol (95 per cent) may be replaced by Industrial Methylated Spirit provided that the statutory requirements governing the use of Industrial Methylated Spirit are observed. Monosulfiram Solution contains not less than 94.0 per cent and not more than 106.0 per cent of the stated amount of monosulfiram, C₁₀H₂₀N₂S₃.

**Description.** Clear, bright, deep reddish-brown liquid; crystals from which may deposit slowly at low temperatures but dissolve on warming. Yields a pale yellow dispersion on dilution with *water*.

**Identification**

In the test for Related substances, the principal spot in the chromatogram obtained with test solution (b) corresponds to that in the chromatogram obtained with reference solution (c).

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with *silica gel* GF254.

**NOTE —** Carry out the test in subdued light.

**Mobile phase.** A mixture of 70 volumes of n-*hexane* and 30 volumes of *butyl acetate*.

**Test solution (a).** Dilute a quantity of the solution under examination with *ethanol* (95 per cent) so as to contain of 2.0 per cent w/v of Monosulfiram.

**Test solution (b).** Dilute 0.5 ml of test solution (a) to 10 ml with *ethanol* (95 per cent).

**Reference solution (a).** A 0.10 per cent w/v solution of *disulfiram RS* in *ethanol* (95 per cent).

**Reference solution (b).** A 0.040 per cent w/v solution of *monosulfiram RS* in *ethanol* (95 per cent).
Reference solution (c). A 0.10 per cent w/v solution of monosulfiram RS in ethanol (95 per cent).

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. In the chromatogram obtained with the test solution any spot running ahead of the principal spot and corresponding in position to disulfiram is not more intense than the spot in the chromatogram obtained with reference solution (a) and any spot running behind the principal spot is not more intense than the spot in the chromatogram obtained with reference solution (b).

Assay. Protect the solutions from light throughout the assay.

Determine by gas chromatography (2.4.13).

Test solution (a). Dilute the solution under examination in dimethylformamide containing the equivalent of 0.5 per cent w/v of Monosulfiram.

Test solution (b). Weigh accurately a quantity of the finely shredded soap containing about 0.25 g of Monosulfiram, shake for 10 minutes with 50 ml of dimethylformamide containing 0.125 g of N-phenylcarbazole (internal standard), centrifuge and use the supernatant liquid.

Reference solution. A solution containing 0.5 per cent w/v of monosulfiram RS and 0.25 per cent w/v of N-phenylcarbazole (internal standard) in dimethylformamide.

Chromatographic system
- a glass column 1.5 m x 4 mm, packed with 2 per cent w/w of methyl silicone gum on acid-washed, silanised diatomaceous support (80 to 100 mesh) (such as SE 30),
- temperature: column 180°, inlet port 180° and detector 280°,
- flow rate. 30 ml per minute of the carrier gas.

Calculate the content of C₁₀H₂₀N₂S₃.

Labelling. The label states (1) the percentage w/w of monosulfiram; (2) the method of use of the preparation.

Nandrolone Laurate

Nandrolone Laurate is 3-oxoestr-4-en-17β-yl-dodecanoate. Nandrolone Laurate contains not less than 97.0 per cent and not more than 103.0 per cent of C₃₀H₄₈O₃, calculated on the dried basis.

Description. A white to creamy white, crystalline powder; odour, faint and characteristic.

Identification
A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nandrolone laurate RS or with the reference spectrum of nandrolone laurate.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254, surface of which has been modified by chemically bonded octadecylsilyl groups (such as Whatman KC 18F plates).

Mobile phase. A mixture of 60 volumes of 2-propanol, 40 volumes of acetonitrile and 20 volumes of water.

Test solution. Dissolve 0.5 g of the substance under examination in dichloromethane.

Reference solution (a). A 0.5 per cent w/v of nandrolone laurate RS in dichloromethane.

Reference solution (b). A mixture of equal volumes of the test solution and reference solution (a).

Apply to the plate 5 µl of each solution. After development, dry the plate in air until the odour of the solvent is no longer detectable and heat at 100° for 10 minutes. Allow to cool and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution (a). The test is not valid unless the principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

C. Melts at about 47° (2.4.21).

Tests
Specific optical rotation (2.4.22). +31.0° to +35.0°, determined in a freshly prepared 2 per cent w/v solution in dioxan.

Nandrolone. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 70 volumes of n-heptane and 30 volumes of acetone.

Test solution. Dissolve 1.5 g of the substance under examination in dichloromethane.

Reference solution. A 0.030 per cent w/v of nandrolone RS in dichloromethane.
Apply to the plate 1 µl of each solution. After development, dry the plate in air until the odour of the solvent is no longer detectable, spray with a 10 per cent v/v solution of sulphuric acid in ethanol (95 per cent), heat at 105°C for 30 minutes and examine in ultraviolet light at 365 nm. Any spot in the chromatogram obtained with the test solution corresponding to nandrolone is not more intense than the spot in the chromatogram obtained with the reference solution.

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 24 hours.

**Assay.** Weigh accurately about 0.1 g, dissolve in sufficient ethanol to produce 100.0 ml and dilute 10.0 ml to 100.0 ml with ethanol. Dilute 10.0 ml of this solution to 100.0 ml with ethanol and measure the absorbance of the resulting solution at the maximum at about 240 nm (2.4.7). Calculate the content of C₃₀H₄₈O₃ taking 380 as the specific absorbance at 240 nm.

**Storage.** Store protected from light.

---

**Nandrolone Laurate Injection**

Nandrolone Laurate Injection is a sterile solution of Nandrolone Laurate in Ethyl Oleate or other suitable ester, in a suitable fixed oil, or in any mixture of these.

Nandrolone Laurate Injection contains not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of nandrolone laurate, C₃₀H₄₈O₃.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254, surface of which has been modified by chemically bonded octadecylsilyl groups (such as Whatman KC 18F plates).

**Mobile phase.** A mixture of 60 volumes of 2-propanol, 40 volumes of acetonitrile and 20 volumes of water.

**Test solution.** Dilute a suitable volume with dichloromethane to produce 0.5 per cent w/v of Nandrolone Laurate.

**Reference solution (a).** A 0.5 per cent w/v of nandrolone laurate RS in dichloromethane.

**Reference solution (b).** A mixture of equal volumes of the test solution and reference solution (a)

Apply to the plate 5 µl of each solution. After development, dry the plate in air until the odour of the solvent is no longer detectable and heat at 100°C for 10 minutes. Allow to cool and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution (a). The test is not valid unless the principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

---

**Tests**

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** To an accurately measured volume containing about 0.1 g of Nandrolone Laurate add sufficient dichloromethane to produce 100.0 ml. Dilute 3.0 ml of the resulting solution to 50.0 ml with dichloromethane. To 5.0 ml of this solution add 10 ml of isoniazid solution and sufficient methanol to produce 20.0 ml. Allow to stand for 45 minutes and measure the absorbance of the resulting solution at the maximum at about 380 nm (2.4.7), using as the blank 5 ml of dichloromethane treated in a similar manner. Calculate the content of C₃₀H₄₈O₃ from the absorbance obtained by repeating the procedure using a suitable quantity of nandrolone RS. 1 mg of C₃₀H₄₈O₃ is equivalent to 0.001664 g of C₃₀H₄₈O₃.

**Storage.** Store protected from light.

---

**Niclosamide Veterinary Oral Powder**

Niclosamide Dispersible Powder for Veterinary Use

Niclosamide Veterinary Oral Powder contains Niclosamide with suitable auxiliary substances.

Niclosamide Veterinary Oral Powder contains not less than 97.0 per cent and not more than 103.0 per cent of the stated amount of niclosamide, C₁₃H₈Cl₂N₂O₄.

**Identification**

Heat 50 mg with 5 ml of 1 M hydrochloric acid and 0.1 g of zinc powder in a water-bath for 10 minutes, cool and filter. To the filtrate add 0.5 ml of a 1 per cent w/v solution of sodium nitrite and allow to stand for 10 minutes. Add 2 ml of a 2 per cent w/v solution of ammonium sulphamate, shake, allow to stand for 10 minutes and add 2 ml of a 0.5 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride; a deep red colour is produced.

**Tests**

**2-Chloro-4-nitroaniline.** Boil a quantity containing 0.10 g of Niclosamide with 20 ml of methanol for 2 minutes, cool, add sufficient 1 M hydrochloric acid to produce 50 ml and filter. To 10 ml of the filtrate add 0.5 ml of a 0.5 per cent w/v solution of sodium nitrite and allow to stand for 10 minutes. Add 1 ml
IP 2007

**Nitroxynil**

![Nitroxynil structure](image)

C₇H₃IN₂O₃  
Mol. Wt. 290.0  
Nitroxynil is 4-hydroxy-3-iodo-5-nitrobenzonitrile.

Nitroxynil contains not less than 98.0 per cent and not more than 101.0 per cent of C₇H₃IN₂O₃, calculated on the dried basis.

**Description.** A yellow to yellowish brown powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with nitroxynil RS or with the reference spectrum of nandrolone nitroxynil.

B. When examined in the range 220 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in 0.01 M sodium hydroxide exhibits maxima at about 225 nm and at about 271 nm; absorbance at about 271 nm, about 1.3.

C. When heated with sulphuric acid, iodine vapours are evolved.

D. Melting range (2.4.21). 136° to 139°.

**Tests**

**Inorganic iodide.** To 0.40 g add 0.35 g of N-methylglucamine and 10 ml of water. Shake to dissolve and add sufficient water to produce 50 ml. To 10 ml of the resulting solution add 4 ml of 1 M sulphuric acid and extract with three quantities, each of 10 ml, of dichloromethane. Add to the aqueous extract 1 ml of hydrogen peroxide solution (100 vol) and 1 ml of dichloromethane, shake for 2 minutes and allow to separate. Any purple colour in the dichloromethane layer is not more intense than that obtained by adding 2 ml of a 0.0026 per cent w/v solution of potassium iodide to a mixture of 4 ml of 1 M sulphuric acid and 8 ml of water, adding 10 ml of dichloromethane, shaking for 2 minutes, adding to the aqueous layer 1 ml of hydrogen peroxide solution (100 vol) and 1 ml of dichloromethane, shaking for 2 minutes and allowing to separate (500 ppm).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent.

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1 g by drying in an oven at 105° for 4 hours.

**Assay.** Carry out the oxygen flask method for iodine (2.3.34), using 25 mg.

1 ml of 0.02 M sodium thiosulphate is equivalent to 0.0009667 g of C₇H₃IN₂O₃.

**Storage.** Store protected from light.

---

**Nitroxynil Injection**

Nitroxynil Injection is a sterile solution of the N-ethylglucamine salt of Nitroxynil in Water for Injections.

Nitroxynil Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of nitroxynil, C₇H₃IN₂O₃.

**Identification**

A. When examined in the range 230 nm to 360 nm (2.4.7), of the final solution obtained in the Assay exhibits a maximum at about 271 nm.

B. Heat 0.5 ml with 3 ml of sulphuric acid; iodine vapours are evolved.

**Tests**

**pH** (2.4.24). 5.0 to 7.0, determined by using a 20 per cent w/v solution of N-ethylglucamine hydrochloride instead of a
saturated solution of potassium chloride as the liquid junction solution.

**Inorganic iodide.** To a volume containing 0.4 g of Nitroxynil add 0.35 g of N-methylglucamine and dilute to 100 ml with water. To 10 ml of the diluted solution add 4 ml of 1 M sulphuric acid and extract with three quantities, each of 10 ml, of dichloromethane. Add to the aqueous extract 1 ml of hydrogen peroxide solution (100 vol) and 1 ml of dichloromethane, shake for 2 minutes and allow to separate. Any purple colour in the dichloromethane layer is not more intense than that obtained by adding 2 ml of a 0.0026 per cent w/v solution of potassium iodide to a mixture of 4 ml of 1 M sulphuric acid and 8 ml of water, adding 10 ml of dichloromethane, shaking for 2 minutes, adding to the aqueous layer 1 ml of hydrogen peroxide solution (100 vol) and 1 ml of dichloromethane, shaking for 2 minutes and allowing to separate (500 ppm) (0.1 per cent w/v of iodide).

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** To an accurately measured volume containing about 1.7 g of Nitroxynil add sufficient 0.01 M sodium hydroxide to produce 500.0 ml. Dilute 20.0 ml of this solution to 500.0 ml with 0.01 M sodium hydroxide. To 5.0 ml of this solution add sufficient 0.01 M sodium hydroxide to produce 100.0 ml and measure the absorbance of the resulting solution at the maximum at about 271 nm (2.4.7). Calculate the content of C7H3IN2O3 taking 660 as the specific absorbance at 271 nm.

**Storage.** Store protected from light.

---

**Oxfendazole**

C₁₅H₁₃N₃O₃S  
Mol. Wt. 315.4

Oxfendazole is methyl 5-(phenylsulphinyl)-2-benzimidazolecarbamate.

Oxfendazole contains not less than 97.0 per cent and not more than 100.5 per cent of C₁₅H₁₃N₃O₃S, calculated on the dried basis.

**Description.** A white or almost white powder; odour, slight and characteristic.

**Identification**

A. Dissolve 0.1 g in 50 ml of methanol, evaporate to a volume of about 2 ml, cool, filter, wash the residue with 2 ml of water and dry at 105° at a pressure not exceeding 2.7 kPa. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with oxfendazole RS or with the reference spectrum of oxfendazole.

B. When examined in the range 220 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in methanol exhibits two maxima at about 228 nm and about 297 nm; absorbances at about 228 nm, about 1.4 and at about 297 nm, about 0.55.

**Tests**

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Solvent mixture.** 40 volumes of ethyl acetate and 10 volumes of glacial acetic acid.

**Mobile phase.** A mixture of 95 volumes of ethyl acetate and 5 volumes of glacial acetic acid.

**Test solution.** Dissolve 0.5 g of the substance under examination in 100 ml of solvent mixture.

**Reference solution (a).** A 0.010 per cent w/v solution of the substance under examination in solvent mixture.

**Reference solution (b).** A 0.0050 per cent w/v solution of methyl 5-phenylthio-1H-benzimidazol-2-yl carbamate RS in solvent mixture.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any spot corresponding to methyl 5-phenylthio-1H-benzimidazol-2-yl carbamate in the chromatogram obtained with test solution is not more intense than the spot in the chromatogram obtained with reference solution (b). Any other secondary spot in the chromatogram obtained with test solution is not more intense than the spot in the chromatogram obtained with reference solution (a).

**Sulphated ash** (2.3.18). Not more than 0.2 per cent.

**Loss on drying** (2.4.19). Not more than 1.0 per cent, determined on 1 g by drying in an oven at 105° for 2 hours at a pressure not exceeding 0.7 kPa.

**Assay.** Weigh accurately about 0.3 g, dissolve in 20 ml of glacial acetic acid, add 3 g of potassium iodide and 1 ml of acetyl chloride and stir for 10 minutes. Add 50 ml of 1 M hydrochloric acid and 10 ml of dichloromethane and titrate immediately with 0.1 M sodium thiosulphate, shaking after each addition, until the dichloromethane layer is colourless. Repeat the operation omitting the substance under examination; the difference between the titrations represents the amount of sodium thiosulphate required.

1 ml of 0.1 M sodium thiosulphate is equivalent to 0.01577 g of C₁₅H₁₃N₃O₃S.
Storage. Store protected from light.

Oxfendazole Veterinary Oral Suspension

Oxfendazole Veterinary Mixture; Oxfendazole Mixture; Oxfendazole Oral Suspension

Oxfendazole Veterinary Oral Suspension is an aqueous suspension of Oxfendazole containing suitable suspending or dispersing agents.

Oxfendazole Veterinary Oral Suspension contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of oxfendazole, C₁₅H₁₃N₃O₃S.

Identification

Shake a quantity containing 0.1 g of Oxfendazole with 50 ml of methanol for 15 minutes, centrifuge, evaporate the supernatant liquid to a volume of about 2 ml, cool, filter and wash the residue with 2 ml of water and dry at 105° for 1 hour at a pressure not exceeding 2.7 kPa. The residue complies with the following tests.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with oxfendazole RS or with the reference spectrum of oxfendazole.

B. When examined in the range 220 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 1 M hydrochloric acid exhibits three maxima, at about 226, 284 and 291 nm.

Tests

pH (2.4.24). 4.3 to 5.3.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Solvent mixture. 40 volumes of ethyl acetate and 10 volumes of glacial acetic acid.

Mobile phase. A mixture of 95 volumes of ethyl acetate and 5 volumes of glacial acetic acid.

Test solution. Shake a quantity containing 0.1 g of Oxfendazole with 20 ml of solvent mixture and filter.

Reference solution (a). Dilute 1 volume of test solution to 50 volumes with the solvent mixture.

Reference solution (b). A 0.0050 per cent w/v solution of methyl 5-phenylthio-1H-benzimidazol-2-yl carbamate RS in solvent mixture.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any spot corresponding to methyl 5-phenylthio-1H-benzimidazol-2-yl carbamate in the chromatogram obtained with test solution is not more intense than the spot in the chromatogram obtained with reference solution (b). Any other secondary spot in the chromatogram obtained with test solution is not more intense than the spot in the chromatogram obtained with reference solution (a).

Other tests. Complies with the tests stated under Veterinary Oral Liquids.

Assay. Weigh accurately a quantity of the well-mixed suspension containing about 0.1 g of Oxfendazole and disperse in 15 ml of water. Add 200 ml of methanol and mix in an ultrasonic bath for 15 minutes, cool, add sufficient methanol to produce 500.0 ml and filter. Dilute 4.0 ml of the filtrate to 100.0 ml with methanol and measure the absorbance of the resulting solution at the maximum at about 296 nm (2.4.7).

Calculate the content of C₁₅H₁₃N₃O₃S taking 550 as the specific absorbance at 296 nm.

Determine the weight per ml of the suspension (2.4.29), and calculate the content of oxfendazole, weight in volume.

Oxyclozanide

C₁₃H₆Cl₅NO₃  Mol. Wt. 401.5

Oxyclozanide is 2,3,5-trichloro-N-(3,5-dichloro-2-hydroxyphenyl)-6-hydroxybenzamide.

Oxyclozanide contains not less than 98.0 per cent and not more than 101.0 per cent of C₁₃H₆Cl₅NO₃, calculated on the dried basis.

Description. A pale cream to cream-coloured powder.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with oxyclozanide RS or with the reference spectrum of oxyclozanide.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.003 per cent w/v solution in 1 M methanolic hydrochloric acid exhibits a maximum only at about 300 nm; absorbance at about 300 nm, about 0.76.

C. Melting range (2.4.21). 208° to 211°.
Tests

Ionisable chlorine. Dissolve 2 g in 100 ml of methanol, add 10 ml of 1.5 M nitric acid and titrate with 0.1 M silver nitrate, determining the end-point potentiometrically (2.4.25). Not more than 1.4 ml is required (0.25 per cent).

Related substances. Determine by liquid chromatography (2.4.14).

Test solution. A 0.1 per cent w/v solution of the substance under examination prepared by dissolving it in a suitable volume of methanol and slowly diluting with water containing 0.1 per cent v/v of phosphoric acid to give a solution containing about the same proportion of methanol to water as in the mobile phase.

Reference solution. Dilute 1 ml of test solution to 100 ml with the mobile phase.

Chromatographic system
- a stainless steel column 20 cm x 5 mm, packed with octadecylsilane bonded to porous silica (5 µm) (such as Hypersil ODS),
- mobile phase: a filtered and degassed mixture of 62 volumes of methanol and 38 volumes of water containing 0.1 per cent v/v of phosphoric acid,
- flow rate. 2 ml per minute,
- spectrophotometer set at 300 nm,
- a 20 µl loop injector.

Inject alternatively test solution and the reference solution. In the chromatogram obtained with test solution the area of any secondary peak with a retention time less than that of the principal peak is not more than one-third of the area of the principal peak in the chromatogram obtained with reference solution and the area of any secondary peak with a retention time greater than that of the principal peak is not more than the area of the principal peak in the chromatogram obtained with reference solution.

Sulphated ash (2.3.18). Not more than 0.2 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1 g by drying in an oven at 60° at a pressure not exceeding 0.7 kPa.

Assay. Weigh accurately about 0.25 g, dissolve in 75 ml of anhydrous pyridine and pass a stream of nitrogen through the solution for 5 minutes. Titrate with 0.1 M tetrabutylammonium hydroxide, maintaining a stream of nitrogen through the solution throughout the titration, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M tetrabutylammonium hydroxide is equivalent to 0.02007 g of $C_{13}H_6Cl_5NO_3$.

## OxyClozanide Veterinary Oral Suspension

OxyClozanide Veterinary Oral Suspension; OxyClozanide Suspension; OxyClozanide Mixture; OxyClozanide Drench

OxyClozanide Veterinary Oral Suspension is an aqueous suspension of OxyClozanide containing suitable suspending or dispersing agents.

OxyClozanide Veterinary Oral Suspension contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of ocyClozanide, $C_{13}H_6Cl_5NO_3$.

Identification

In test A for Related substances, the principal spot in the chromatogram obtained with 10 ml of test solution corresponds to that in the chromatogram obtained with reference solution (b).

Tests

Related substances. A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 60 volumes of light petroleum (60° to 80°), 20 volumes of acetone and 5 volumes of glacial acetic acid.

Test solution. Dilute a quantity with acetone to contain 1.0 per cent w/v of OxyClozanide, centrifuge and use the supernatant liquid.

Reference solution (a). A 0.050 per cent w/v solution of 3,5,6-trichloro-2-hydroxybenzoic acid RS in acetone.

Reference solution (b). A 1.0 per cent w/v solution of ocyClozanide RS in acetone.

Apply to the plate 40 µl and 10 µl of test solution, 4 µl of reference solution (a) and 10 µl of reference solution (b). After development, dry the plate in air and spray with a 3 per cent w/v solution of ferric chloride in methanol. In the chromatogram obtained with 40 µl of test solution any spot corresponding to 3,5,6-trichloro-2-hydroxybenzoic acid RS is not more intense than that in the chromatogram obtained with reference solution (a).

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 100 volumes of ethyl acetate, 10 volumes of methanol and 1 volume of strong ammonia solution.

Test solution. Dilute a quantity with acetone to contain 1.0 per cent w/v of OxyClozanide, centrifuge and use the supernatant liquid.
Reference solution. A 0.040 per cent w/v of 2-amino-4,6-dichlorophenol RS in acetone.

Apply to the plate 40 µl of test solution and 4 µl of reference solution. After development, dry the plate in air and spray with lithium and sodium molybdotungstophosphate solution. In the chromatogram obtained with test solution any spot corresponding to 2-amino-4,6-dichlorophenol is not more intense than that in the chromatogram obtained with reference solution.

Other tests. Complies with the tests stated under Veterinary Oral Liquids.

Assay. Protect the solutions from light throughout the procedure. Weigh accurately a quantity containing about 60 mg of Oxyclozanide, add 60 ml of acidified methanol and boil gently on a water-bath. Shake continuously for 20 minutes, cool to 2° and dilute to 100.0 ml with acidified methanol. Filter, dilute 5.0 ml of the filtrate to 100.0 ml with acidified methanol and measure the absorbance of the resulting solution at the maximum at about 300 nm (2.4.7). Calculate the content of C13H6Cl5NO3 taking 254 as the specific absorbance at 300 nm.

Determine the weight per ml of the suspension (2.4.29), and calculate the content of oxyclozanide, weight in volume.

Oxyclozanide Premix

Oxyclozanide Granules

Oxyclozanide Premix contains Oxyclozanide.

Oxyclozanide Premix contains not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of oxyclozanide, C13H6Cl5NO3.

Identification

In test A for Related substances, the principal spot in the chromatogram obtained with 10 ml of test solution corresponds to that in the chromatogram obtained with reference solution (b).

Tests

Related substances. A. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 60 volumes of light petroleum (60° to 80°), 20 volumes of acetone and 5 volumes of glacial acetic acid.

Test solution. Extract the finely powdered preparation under examination with sufficient acetone to produce a mixture containing 1.0 per cent w/v of Oxyclozanide, centrifuge and use the supernatant liquid.

Reference solution (a). A 0.050 per cent w/v solution of 3,5,6-trichloro-2-hydroxybenzoic acid RS in acetone.

Reference solution (b). A 1.0 per cent w/v solution of oxyclozanide RS in acetone.

Apply to the plate 40 µl and 10 µl of test solution, 4 µl of reference solution (a) and 10 µl of reference solution (b). After development, dry the plate in air and spray with a 3 per cent w/v solution of ferric chloride in methanol. In the chromatogram obtained with 40 µl of test solution any spot corresponding to 3,5,6-trichloro-2-hydroxybenzoic acid RS is not more intense than that in the chromatogram obtained with reference solution (a).

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

Mobile phase. A mixture of 100 volumes of ethyl acetate, 10 volumes of methanol and 1 volume of strong ammonia solution.

Test solution. Extract the finely powdered preparation under examination with sufficient acetone to produce a mixture containing 1.0 per cent w/v of Oxyclozanide, centrifuge and use the supernatant liquid.

Reference solution. A 0.040 per cent w/v of 2-amino-4,6-dichlorophenol RS in acetone.

Apply to the plate 40 µl of test solution and 4 µl of reference solution. After development, dry the plate in air and spray with lithium and sodium molybdotungstophosphate solution. In the chromatogram obtained with test solution any spot corresponding to 2-amino-4,6-dichlorophenol is not more intense than that in the chromatogram obtained with reference solution.

Other tests. Complies with the tests stated under Premixes.

Assay. Protect the solutions from light throughout the procedure. Weigh accurately a quantity of the finely powdered preparation under examination containing 60 mg of Oxyclozanide, add 60 ml of acidified methanol and boil gently on a water-bath. Shake continuously for 20 minutes, cool to 2° and dilute to 100.0 ml with acidified methanol. Filter, dilute 5.0 ml of the filtrate to 100.0 ml with acidified methanol and measure the absorbance of the resulting solution at the maximum at about 300 nm (2.4.7). Calculate the content of C13H6Cl5NO3 taking 254 as the specific absorbance at 300 nm.

Labelling. The label states (1) the proportion of oxyclozanide in the premix and (2) the method of use of the preparation.
Oxytetracycline Veterinary Oral Powder

Oxytetracycline Hydrochloride Veterinary Oral Powder; Oxytetracycline Hydrochloride Soluble Powder; Oxytetracycline Soluble Powder

Oxytetracycline Veterinary Oral Powder is a mixture of Oxytetracycline Hydrochloride and Lactose or other suitable diluent.

Oxytetracycline Veterinary Oral Powder contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of oxytetracycline hydrochloride, $C_{22}H_{24}N_2O_9.HCl$.

Identification

A. Determine by thin-layer chromatography (2.4.17), coating the plate with a substance prepared by mixing 25 g of silica gel G with 50 ml of a mixture of 2.5 ml of glycerin and 47.5 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution. After spreading the plate, allow it to stand at room temperature till it is dry (70 to 90 minutes).

Mobile phase. The lower layer formed after shaking 200 ml of a mixture of 2 volumes of ethyl acetate, 2 volumes of dichloromethane and 1 volume of acetone with 25 ml of 0.1 M disodium edetate previously adjusted to pH 7.0 with dilute ammonia solution.

Test solution. Extract a quantity of the oral powder containing 10 mg of Oxytetracycline Hydrochloride with 20 ml of methanol, centrifuge and use the supernatant liquid.

Reference solution (a). A 0.05 per cent w/v solution of oxytetracycline hydrochloride RS in methanol.

Reference solution (b). A solution containing 0.05 per cent w/v each of demethylchlortetracycline hydrochloride RS, oxytetracycline hydrochloride RS and tetracycline hydrochloride RS in methanol.

Apply to the plate 1 µl of each solution. After development, dry the plate in air, expose to the vapours of ammonia and examine in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The test is not valid unless the chromatogram obtained with reference solution (b) shows three clearly separated spots.

C. Shake a quantity of the powder containing 100 mg of Oxytetracyline Hydrochloride with 10 ml of 2 M nitric acid and filter. To the filtrate add activated charcoal to decolorise it and filter again. The filtrate gives the reactions of chlorides (2.3.1).

Tests

Assay. To a quantity of the powder containing 0.25 g of Oxytetracycline Hydrochloride, add 250.0 ml of water, shake, filter and carry out the microbiological assay (2.2.10), Method A or B.

Storage. Store at a temperature not exceeding 15°.

Pentobarbitone Injection

Pentobarbitone Sodium Injection; Pentobarbital Sodium Injection

Pentobarbitone Injection is a sterile solution of Pentobarbitone Sodium in a suitable vehicle.

Solutions containing 20 per cent w/v of Pentobarbitone Sodium in 100-ml and 500-ml containers are also available for use other than for injection. Such solutions may be coloured and need not be sterile but must comply with all other requirements of this monograph.

Pentobarbitone Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of pentobarbitone sodium, $C_{11}H_{17}N_2NaO_3$.

Description. A clear, colourless or almost colourless solution.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with pentobarbitone RS or with the reference spectrum of pentobarbitone.

B. The residue obtained in the Assay melts at about 128° (2.4.21).

C. When introduced on a platinum wire into a Bunsen burner flame, a golden yellow colour is imparted to the flame.

Tests

pH (2.4.24). 10.0 to 11.5.

Isomer. To a volume of the injection containing 0.3 g of Pentobarbitone Sodium diluted, if necessary, to 5 ml with water add 0.3 g of 4-nitrobenzyl bromide dissolved in 10 ml of ethanol (95 per cent). Heat under a reflux condenser for 30 minutes, cool to 25°, scratch the sides of the vessel with a glass rod if necessary to induce crystallisation, filter and wash the residue with five quantities, each of 5 ml, of water. Transfer the residue as completely as possible to a small flask, add 25 ml of ethanol (95 per cent) and heat under a reflux condenser for 10 minutes. Filter the hot solution, cool to 25° and scratch the sides of the vessel with a glass rod to induce
crystallisation. Filter and wash the residue with two quantities, each of 5 ml, of water and dry at 105° for 30 minutes. The dried residue melts completely between 136° and 148° (2.4.21).

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** To an accurately measured volume containing about 0.5 g of Pentobarbitone Sodium diluted to 15 ml with water add 5 ml of 2 M hydrochloric acid, extract with 50 ml of ether and then with successive quantities, each of 25 ml, of ether until complete extraction is effected. Wash the combined extracts with two quantities, each of 5 ml, of water and wash the combined aqueous extracts with 10 ml of ether. Add the ether washings to the main ethereal extract, filter and wash the filter with ether. Evaporate the solvent and dry the residue to constant weight at 105°.

1 g of the residue is equivalent to 1.097 g of C₁₁H₁₇N₂NaO₃.

**Progesterone**

![Diagram of Progesterone](image)

C₂₁H₃₀O₂  Mol. Wt. 314.5

Progesterone is pregn-4-en-3,20-dione.

Progesterone contains not less than 97.0 per cent and not more than 103.0 per cent of C₂₁H₃₀O₂, calculated on the dried basis.

**Description.** Colourless crystals or a white or almost white crystalline powder.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with progesterone RS or with the reference spectrum of progesterone. If the spectra are not concordant, prepare spectra using 5 per cent w/v solutions in chloroform IR.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Solvent mixture.** A mixture of 90 volumes of acetone and 10 volumes of 1,2-propanediol.

**Mobile phase.** A mixture of equal volumes of cyclohexane and light petroleum (40° to 60°).

**Test solution.** Dissolve 25 mg of the substance under examination in 10 ml of the solvent mixture.

**Reference solution (a).** A 0.25 per cent w/v solution of progesterone RS in the solvent mixture.

**Reference solution (b).** Mix equal volumes of the test solution and reference solution (a).

**Place the dry plate in a tank containing a shallow layer of the solvent mixture, allow the solvent mixture to ascend to the top, remove the plate from the tank and allow the solvent to evaporate. Use within 2 hours, with the flow of the mobile phase in the direction in which the aforementioned treatment was done.**

**Apply to the plate 2 µl of each solution. Allow the mobile phase to rise 12 cm. Dry the plate in a current of warm air, allow the solvent to evaporate, heat at 120° for 15 minutes and spray**
the hot plate with ethanolic sulphuric acid (20 per cent v/v). Heat at 120° for a further 10 minutes, allow to cool and examine in daylight and in ultraviolet light at 365 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). The principal spot in the chromatogram obtained with reference solution (b) appears as a single, compact spot.

Tests

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. To an accurately measured volume containing about 50 mg of Progesterone add sufficient dichloromethane to produce 100.0 ml. Dilute 3.0 ml to 50.0 ml with dichloromethane. To 5.0 ml of the solution add 10 ml of isoniazid solution and sufficient methanol to produce 20.0 ml. Allow to stand for 45 minutes and measure the absorbance of the resulting solution at the maximum at about 380 nm (2.4.7), using as the blank 5 ml of dichloromethane treated in the same manner. Calculate the content of C$_{17}$H$_{20}$O$_{2}$ from the absorbance obtained by repeating the procedure using a 0.003 per cent w/v solution of progesterone RS in dichloromethane and beginning at the words “To 5.0 ml of the solution.....”.

Storage. Store protected from light. If solid matter separates on standing, it should be redissolved by heating before use.

Labelling. The label states (1) the composition of the solvent; (2) that the preparation is intended for veterinary use by subcutaneous or intramuscular injection only.

Promazine Hydrochloride

\[
\begin{array}{c}
\text{N} \\
\text{CH}_3 \\
\text{CH}_3 \\
\text{S} \\
\end{array}
\text{HCl}
\]

C$_{17}$H$_{20}$N$_2$S.HCl

Mol. Wt. 320.9

Promazine Hydrochloride is 10-(3-dimethylaminopropyl) phenothiazine hydrochloride.

Promazine Hydrochloride contains not less than 99.0 per cent and not more than 101.0 per cent of C$_{17}$H$_{20}$N$_2$S.HCl, calculated on the dried basis.

Description. A white or almost white, crystalline powder; slightly hygroscopic.

Identification

Test A may be omitted if tests B, C, D and E are carried out. Tests B, C and D may be omitted if tests A and E are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with promazine hydrochloride RS or with the reference spectrum of promazine hydrochloride.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.01 M hydrochloric acid shows an absorption maximum at about 252 nm and a less well-defined maximum at about 302 nm; absorbance at about 252 nm, about 0.93.

C. Dissolve 5 mg in 2 ml of sulphuric acid and allow to stand for 5 minutes; an orange colour is produced.

D. Melting range (2.4.21). 177° to 181°.

E. Gives reaction A of chlorides (2.3.1).

Tests

pH (2.4.24). 4.2 to 5.4, determined in a 5 per cent w/v solution.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 105°.

Assay. Weigh accurately about 0.6 g, dissolve in 100 ml of acetone. Titrate with 0.1 M perchloric acid, using 3 ml of a saturated solution of methyl orange in acetone as indicator. Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.03209 g of C$_{17}$H$_{20}$N$_2$S.HCl.

Storage. Store protected from light.

Promazine Injection

Promazine Hydrochloride Injection

Promazine Injection is a sterile solution of Promazine Hydrochloride in Water for Injections free from dissolved air and containing suitable buffering and stabilising agents. The solution is distributed in containers, the air in which is replaced by nitrogen or other suitable gas.

Promazine Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of promazine hydrochloride, C$_{17}$H$_{20}$N$_2$S.HCl.

Description. A colourless or almost colourless liquid.

Identification

A. To a volume containing 0.1 g of Promazine Hydrochloride add 20 ml of water and 2 ml of 10 M sodium hydroxide. Shake
and extract the mixture with 25 ml of ether. Wash the ether extract with two quantities, each of 5 ml, of water, dry with anhydrous sodium sulphate and evaporate the ether. A 10 per cent w/v solution of the oily residue in chloroform complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with promazine hydrochloride RS, treated in the same manner.

B. To a volume containing 5 mg of Promazine Hydrochloride add carefully 2 ml of sulphuric acid and allow to stand for 5 minutes; an orange colour is produced.

C. To a volume containing 0.2 g of Promazine Hydrochloride add 1 ml of 1 M sodium hydroxide and extract with four quantities, each of 10 ml, of ether. Wash the combined extracts with 10 ml of water, remove the ether and dissolve the residue in 4 ml of methanol. Heat on a water-bath almost to boiling, immediately add 2 ml of a boiling 3.5 per cent w/v solution of picric acid in methanol and boil for 2 minutes. Cool in ice, filter, wash the crystals thrice with methanol, dissolve in 10 ml of hot methanol and repeat the crystallisation and washing. The rust-red crystals so obtained, after drying at 105° for 1 hour, melt at about 144° (2.4.21).

Tests

pH (2.4.24). 4.4 to 5.2.

Related substances. Carry out the test for identification of related substances in phenothiazines (2.3.5), using mobile phase A and applying separately to the plate 10 µl of each of the following freshly-prepared solutions.

Test solution. Dilute a volume of the injection with sufficient methanol to produce a solution containing the equivalent of 1.0 per cent w/v of Promazine Hydrochloride.

Reference wsolution (a). Dilute 1 volume of the test solution to 40 volumes with methanol.

Reference wsolution (b). Dilute 1 volume of the test solution to 200 volumes with methanol.

Any secondary spot in the chromatogram obtained with the test solution is more intense than the spot in the chromatogram obtained with reference solution (a) and not more than one such spot is more intense than the spot in the chromatogram obtained with reference solution (b).

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. Protect the solutions from light throughout the procedure.

To an accurately measured volume containing about 50 mg of Promazine Hydrochloride, add 5 ml of 2 M hydrochloric acid and sufficient water to produce 1000.0 ml. To 10.0 ml add 10 ml of 0.1 M hydrochloric acid, dilute to 100.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 251 nm (2.4.7). Calculate the content of C₁₇H₂₀N₂S,HCl taking 935 as the specific absorbance at 251 nm.

Storage. Store protected from light.

Rafoxanide

\[
\text{C}_{10}\text{H}_{15}\text{Cl}_{2}\text{I}_{2}\text{NO}_{3}\quad \text{Mol. Wt. 626.0}
\]

Rafoxanide is \(N\)-[3-chloro-4-(4-chlorophenoxy)phenyl]-2-hydroxy-3,5-diiodobenzamide.

Rafoxanide contains not less than 98.0 per cent and not more than 101.0 per cent of C₁₀H₁₅Cl₂I₂NO₃, calculated on the dried basis.

Description. A greyish-white to brown powder.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with rafoxanide RS or with the reference spectrum of rafoxanide.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.004 per cent w/v solution in 0.1 M methanolic hydrochloric acid shows absorption maxima at about 280 nm and at 335 nm; absorbance at about 280 nm, about 0.97 and at about 335 nm, about 0.59.

C. Burn 20 mg by the oxygen-flask method (2.3.34), using 5 ml of 2 M sodium hydroxide as the absorbing liquid, and dilute to 25 ml with water. To 5 ml add 1 ml of silver nitrate solution; a yellow precipitate is produced; add 5 ml of 5 M ammonia, shake, filter, and acidify the filtrate with nitric acid; a white precipitate is produced.

D. Shake 10 mg with 10 ml of ethanol (80 per cent) and add 0.1 ml of ferric chloride test solution; a violet colour is produced.

E. Melts at about 175° (2.4.21).

Tests

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.
NOTE – Carry out the test in subdued light and use freshly prepared solution.

Mobile phase. A mixture of 170 volumes of dichloromethane, 30 volumes of methanol and 2 volumes of strong ammonia solution.

Test solution. Dissolve 2 g of the substance under examination in 100 ml of dichloromethane.

Reference solution. A 0.010 per cent w/v of rafoxanide RS in dichloromethane.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 0.5 per cent, determined on 1.0 g by drying in an oven at 90° at a pressure not exceeding 0.7 kPa for 2 hours.

Assay. To 50 ml of dioxan add 1 ml of phenolphthalein solution, replace the air in the flask with nitrogen and titrate with 0.1 M sodium hydroxide. Weigh accurately about 1.25 g, dissolve it in the mixture and again titrate with 0.1 M sodium hydroxide. The difference between the titrations represents the amount of 0.1 M sodium hydroxide required.

1 ml of 0.1 M sodium hydroxide is equivalent to 0.06260 g of C_{19}H_{11}Cl_{2}I_{2}NO_{3}.

Storage. Store protected from light.

Rafoxanide Veterinary Oral Suspension

Rafoxanide Suspension; Rafoxanide Veterinary Mixture; Rafoxanide Mixture

Rafoxanide Veterinary Oral Suspension is an aqueous suspension of Rafoxanide containing suitable suspending and dispersing agents and antimicrobial preservatives.

Rafoxanide Veterinary Oral Suspension contains not less than 90.0 per cent and not more than 110.0 per cent of rafoxanide, C_{19}H_{11}Cl_{2}I_{2}NO_{3}.

Identification

A. Evaporate a volume containing 0.2 g of Rafoxanide to dryness on a water-bath and heat the residue over a Bunsen burner flame; the vapours turn moistened starch-iodide paper blue.

B. In addition to the absorbance at about 335 nm, measure the absorbance at about 280 nm (2.4.7), of the final solution obtained in the Assay. The ratio of the absorbance at about 280 nm to that at about 335 nm is 1.59 to 1.69.

Tests

Other tests. Complies with requirements stated under Veterinary Oral Liquids.

Assay. Weigh accurately a quantity of the well-mixed suspension containing about 0.12 g of Rafoxanide in a stoppered 50-ml test tube and add 15 ml of 0.1 M sodium hydroxide and 15 ml of ether. Shake for 5 minutes and centrifuge. Remove the ether layer and repeat the extraction with three further quantities, each of 15 ml, of ether. Dilute the combined ether solutions to 250.0 ml with ether and mix. Dilute 5.0 ml of this solution to 100.0 ml with 0.1 M methanolic hydrochloric acid, mix and measure the absorbance of the resulting solution at about 335 nm (2.4.7). Calculate the content of C_{19}H_{11}Cl_{2}I_{2}NO_{3} taking 149 as the specific absorbance at 335 nm.

Determine the weight per ml of the suspension (2.4.29), and calculate the content of rafoxanide, weight in volume.

Ronidazole

Ronidazole is 1-methyl-2-[(carbamoyloxy)methyl]-5-nitroimidazole.

Ronidazole contains not less than 98.5 per cent and not more than 101.0 per cent of C_{6}H_{8}N_{4}O_{4}, calculated on the anhydrous basis.

Description. A white to yellowish-brown powder; odourless or almost odourless.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ronidazole RS or with the reference spectrum of ronidazole.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.002 per cent w/v solution in 0.1 M methanolic hydrochloric acid shows an absorption maximum only at about 270 nm; absorbance at about 270 nm, about 0.64.

C. Melts at about 167° (2.4.21).
Tests

Appearance of solution. A 0.5 per cent w/v solution in methanol is not more intensely coloured than reference solution YS6 (2.4.1).

(1-Methyl-5-nitroimidazol-2-yl)methanol. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 80 volumes of toluene, 5 volumes of methanol and 5 volumes of glacial acetic acid.

Test solution. Dissolve 1 g of the substance under examination in 100 ml of acetone.

Reference solution. A 0.0050 per cent w/v of (1-methyl-5-nitroimidazol-2-yl)methanol RS in acetone.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution corresponding to (1-methyl-5-nitroimidazol-2-yl)methanol RS is not more intense than the spot in the chromatogram obtained with the reference solution.

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Water (2.3.43). Not more than 0.5 per cent, determined on 5 g.

Assay. Weigh accurately about 0.3 g, dissolve in 50 ml of anhydrous glacial acetic acid. Titrate with 0.1 M perchloric acid, determining the end-point potentiometrically (2.4.25). Carry out a blank titration.

1 ml of 0.1 M perchloric acid is equivalent to 0.02002 g of C₆H₈N₄O₄.

Storage. Store protected from light.

Ronidazole Veterinary Oral Powder

Ronidazole Veterinary Oral Powder is a mixture of Ronidazole with suitable diluents.

Ronidazole Veterinary Oral Powder contains not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of ronidazole, C₆H₈N₄O₄.

Identification

A. Shake a quantity of the powder containing 0.1 g of Ronidazole with 10 ml of acetone for 15 minutes, filter and evaporate the filtrate to dryness. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with ronidazole RS or with the reference spectrum of ronidazole.

B. When examined in the range 230 nm to 360 nm (2.4.7), the final solution obtained in the Assay shows an absorption maximum only at about 281 nm.

Tests

(1-Methyl-5-nitroimidazol-2-yl)methanol. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 80 volumes of toluene, 5 volumes of methanol and 5 volumes of glacial acetic acid.

Test solution. Shake a quantity of the powder containing 0.1 g of Ronidazole with 10 ml of acetone for 15 minutes and filter.

Reference solution. A 0.0050 per cent w/v of (1-methyl-5-nitroimidazol-2-yl)methanol RS in acetone.

Apply to the plate 20 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. Any secondary spot in the chromatogram obtained with the test solution corresponding to (1-methyl-5-nitroimidazol-2-yl)methanol RS is not more intense than the spot in the chromatogram obtained with the reference solution.

Other tests. Complies with the tests stated under Veterinary Oral Powders.

Assay. Weigh accurately a quantity of powder containing 2 g of Ronidazole, dissolve in 450 ml of water and add sufficient water to produce 500.0 ml. Dilute 5.0 ml of this solution to 100.0 ml with 0.1 M hydrochloric acid and measure the absorbance of the resulting solution at the maximum at about 281 nm (2.4.7). Calculate the content of C₆H₈N₄O₄ taking 279 as the specific absorbance at 281 nm.

Storage. Store protected from light.

Serum Gonadotrophin for Veterinary Use

Equine Serum Gonadotrophin for Veterinary Use

Serum Gonadotrophin for Veterinary Use is a dry preparation of a glycoprotein fraction, obtained from the serum or plasma of pregnant mares in their 60th to 75th day of pregnancy, which stimulates the formation of follicles and induces luteinising activity.

Serum Gonadotrophin for Veterinary Use contains not less than 1000 Units per mg, calculated on the anhydrous basis.

Description. A white or pale grey, amorphous powder.

Identification

Causes enlargement of the ovaries of immature female rats when administered as directed in the Assay.
Tests

Water (2.3.43). Not more than 10.0 per cent, determined on 80 mg.

Assay. Carry out the biological assay of serum gonadotrophin described below.

The potency of serum gonadotrophin for veterinary use is determined by comparing its effect in increasing the weight of the ovaries of immature rats with that of the Standard Preparation of serum gonadotrophin under the conditions of the following method of assay.

Standard Preparation

The Standard Preparation is the 2nd International Standard for serum gonadotrophin, equine, for bioassay, established in 1966, consisting of the freeze-dried active principle from the serum of pregnant mares, with lactose (supplied in ampoules containing 1600 Units), or other suitable preparation the potency of which has been determined in relation to the International Standard.

Method

Test animals. Use immature female rats of the same strain, 21 to 28 days old, differing in age by not more than 3 days and of approximately equal weights such that the difference between the heaviest and the lightest rat is not more than 10 g. Assign the rats at random to six equal groups of not less than five animals. If sets of six litter-mates are available, allot one litter-mate from each set at random to each group and mark according to the litter.

Procedure. Choose three doses of the Standard Preparation and three doses of the preparation under examination such that the smallest dose is sufficient to produce a positive response in some of the rats and the largest dose does not produce a maximal response in all of the rats. Use doses in geometric progression. As an initial approximation total doses of 8, 12 and 18 Units may be tried although the dose will depend on the sensitivity of the animals used, which may vary widely. Dissolve separately the total quantities of the preparation under examination and of the Standard Preparation corresponding to the doses to be used in sufficient of a sterile saline solution containing 1 mg of bovine albumin per ml such that each single dose may be administered by the injection of 6 equally-divided portions, in the same volume of about 0.2 ml. Store the solutions at a temperature 2° to 8°. Inject subcutaneously into each rat the dose allocated to its group. Repeat the injections 18, 21, 24, 42 and 48 hours after the first injection. Kill the rats between 40 hours and 72 hours after the last injection and remove the ovaries. Remove any extraneous fluid and tissue and immediately weigh the two ovaries from each rat.

Calculate the result of the assay by standard statistical methods using the combined weight of the two ovaries of each animal as the response.

Limits of error - The estimated potency is not less than 80 per cent and not more than 125 per cent of the stated potency. The fiducial limits of error \( (P = 0.95) \) of the estimated potency are not less than 64 per cent and not more than 156 per cent of the stated potency.

Serum Gonadotrophin for Veterinary Use intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of pyrogens complies with the following additional requirement.

Pyrogens. Complies with the test for pyrogens (2.2.8), using per kg of the rabbit’s weight 1 ml of a solution in sodium chloride injection containing 500 Units per ml.

Serum Gonadotrophin for Veterinary Use intended for use in the manufacture of parenteral preparations without a further appropriate sterilisation procedure complies with the following additional requirement.

Sterility (2.2.11). Complies with the test for sterility.

Storage. Store protected from moisture and light in a refrigerator (2 to 8). If the contents are sterile, the containers should be sterile, tamper-evident and sealed so as to exclude micro-organisms.

Labelling. The label states (1) the number of Units per mg; (2) the total number of Units in the container; (3) the date after which the material is not intended to be used; (4) the storage conditions; (5) whether or not it is intended for use in the manufacture of parenteral preparations.

Serum Gonadotrophin Injection for Veterinary Use

Serum Gonadotrophin Injection for Veterinary Use is a sterile material consisting of Serum Gonadotrophin for Veterinary Use with or without buffering agents and other excipients. It is filled in a sealed container.

The injection is constituted by dissolving the contents of the sealed container in the requisite amount of sterile Water for Injections, immediately before use.

The constituted solution complies with the requirements for Clarity of solution and Particulate matter stated under Parenteral Preparations (Injections).

Storage. The constituted solution should be used immediately after preparation but, in any case, within the period recommended by the manufacturer.
Serum Gonadotrophin Injection for veterinary Use contains not less than 80.0 per cent and not more than 125.0 per cent of the stated potency.

The contents of the sealed container comply with the requirements stated under Parenteral Preparations (Powders for Injection) and with the following requirements.

**Identification**
Causes enlargement of the ovaries of immature female rats when administered as directed in the Assay.

**Tests**
**Appearance of solution.** A solution containing 5000 Units per ml (solution A) is clear (2.4.1), and colourless (2.4.1).

**pH** (2.4.24). 6.0 to 8.0, determined on solution A.

**Water** (2.3.43). Not more than 10.0 per cent, determined on 80 mg.

**Assay.** Carry out the biological assay of serum gonadotrophin described below.

The potency of serum gonadotrophin for veterinary use is determined by comparing its effect in increasing the weight of the ovaries of immature rats with that of the Standard Preparation of serum gonadotrophin under the conditions of the following method of assay.

**Standard Preparation**
The Standard Preparation is the 2nd International Standard for serum gonadotrophin, equine, for bioassay, established in 1966, consisting of the freeze-dried active principle from the serum of pregnant mares, with lactose (supplied in ampoules containing 1600 Units), or other suitable preparation the potency of which has been determined in relation to the International Standard.

**Test animals.** Use immature female rats of the same strain, 21 to 28 days old, differing in age by not more than 3 days and of approximately equal weights such that the difference between the heaviest and the lightest rat is not more than 10 g. Assign the rats at random to six equal groups of not less than five animals. If sets of six litter-mates are available, allot one litter-mate from each set at random to each group and mark according to the litter.

**Procedure.** Choose three doses of the Standard Preparation and three doses of the preparation under examination such that the smallest dose is sufficient to produce a positive response in some of the rats and the largest dose does not produce a maximal response in all of the rats. Use doses in geometric progression. As an initial approximation total doses of 8, 12 and 18 Units may be tried although the dose will depend on the sensitivity of the animals used, which may vary widely. Dissolve separately the total quantities of the preparation under examination and of the Standard Preparation corresponding to the doses to be used in sufficient of a sterile saline solution containing 1 mg of bovine albumin per ml such that each single dose may be administered by the injection of 6 equally-divided portions, in the same volume of about 0.2 ml. Store the solutions at a temperature 2° to 8°. Inject subcutaneously into each rat the dose allocated to its group. Repeat the injections 18, 21, 24, 42 and 48 hours after the first injection. Kill the rats between 40 hours and 72 hours after the last injection and remove the ovaries. Remove any extraneous fluid and tissue and immediately weigh the two ovaries from each rat.

Calculate the result of the assay by standard statistical methods using the combined weight of the two ovaries of each animal as the response.

**Limits of error -** The estimated potency is not less than 80 per cent and not more than 125 per cent of the stated potency. The fiducial limits of error ($\alpha = 0.95$) of the estimated potency are not less than 64 per cent and not more than 156 per cent of the stated potency.

**Pyrogens.** Complies with the test for pyrogens (2.2.8), using per kg of the rabbit’s weight 1 ml of a solution in sodium chloride injection containing 500 Units per ml.

**Storage.** Store protected from light in a refrigerator (2° to 8°).

**Labelling.** The label states the number of Units contained in the sealed container.

### Spectinomycin Hydrochloride

![Spectinomycin Hydrochloride](image)

C_{14}H_{24}N_{2}O_{7}.2HCl, 5H_2O

Mol. Wt. 495.4

Spectinomycin Hydrochloride is [2R-(2\alpha,4\alpha,5\alpha,6\beta,7β,8β,9α,9α,10αβ)-decahydro-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)-4H-pyran[2,3-b][1,4]benzodioxin-4-one dihydrochloride pentahydrate.

Spectinomycin Hydrochloride contains not less than 95.0 per cent and not more than 100.5 per cent of C_{14}H_{24}N_{2}O_{7}.2HCl, calculated on the anhydrous basis.

**Description.** A white or almost white, crystalline powder.
Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with spectinomycin hydrochloride RS or with the reference spectrum of spectinomycin hydrochloride.

B. Gives reaction A of chlorides (2.3.1).

Tests

**Appearance of solution.** A 10 per cent w/v solution is clear (2.4.1), and colourless (2.4.1).

**pH** (2.4.24). 3.8 to 5.6, determined in a 10 per cent w/v solution.

**Specific optical rotation** (2.4.22). +15.0° to +21.0°, determined in a 10 per cent w/v solution within 20 minutes of preparation, on the anhydrous basis.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 50 volumes of 1-propanol, 40 volumes of water, 5 volumes of glacial acetic acid and 5 volumes of pyridine.

**Test solution.** Dissolve 2 g of the substance under examination in 100 ml water.

**Reference solution.** A 0.020 per cent w/v solution of the substance under examination in water.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and spray with a 5 per cent w/v solution of potassium permanganate. Allow the plate to stand for 2 to 3 minutes. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with the reference solution (1 per cent).

**Sulphated ash** (2.3.18). Not more than 1.0 per cent w/v.

**Water** (2.3.43). 16.0 to 20.0 per cent, determined on 0.2 g.

**Assay.** Determine by gas chromatography (2.4.13).

**NOTE – Use the solutions within 1 hour after preparation.**

**Test solution (a).** Take 60 mg of the substance under examination in a glass-stoppered conical flask, add 10.0 ml of dimethylformamide and 2.0 ml of hexamethyl-disilazane, shake intermittently for 1 hour and dilute to 20.0 ml with dimethylformamide.

**Test solution (b).** Take 60 mg of the substance under examination in a glass-stoppered conical flask, add 10.0 ml of a solution containing 0.15 per cent w/v of phenazone (internal standard) in dimethylformamide and 2.0 ml of hexamethyl-disilazane, shake intermittently for 1 hour and dilute to 20.0 ml with dimethylformamide.

**Reference solution.** Take 60 mg of the spectinomycin hydrochloride RS in a glass-stoppered conical flask, add 10.0 ml of a solution containing 0.15 per cent w/v of phenazone (internal standard) in dimethylformamide and 2.0 ml of hexamethyl-disilazane, shake intermittently for 1 hour and dilute to 20.0 ml with dimethylformamide.

**Chromatographic system.**
- a glass column 1.5 m x 4 mm, packed with acid-washed, silanised diatomaceous support (100 to 120 mesh) coated with 3 per cent w/v of phenylmethysilicone fluid (50 per cent phenyl),
- temperature: column 200°, inlet port 200° and detector 230°,
- flow rate. 45 ml per minute of the carrier gas.

Inject the chosen volumes of test solutions (a) and (b). The test is not valid unless the resolution factor between the peak due to the internal standard and the principal peak in the chromatogram obtained with test solution (a) is not less than 8.0.

Inject alternately test solution (b) and the reference solution.

Calculate the content of C_{14}H_{24}N_{2}O_{7}.2HCl.

**Spectinomycin Hydrochloride intended for use in the manufacture of parenteral preparations without a further appropriate procedure for the removal of bacterial endotoxins complies with the following additional requirement.**

**Bacterial endotoxins** (2.2.3). Not more than 0.09 Endotoxin Unit per mg determined in a 0.42 per cent w/v solution of sodium bicarbonate.

Spectinomycin Hydrochloride intended for use in the manufacture of parenteral preparations without a further appropriate sterilisation procedure complies with the following additional requirement.

**Spectinomycin Injection**

Spectinomycin Hydrochloride Injection

Spectinomycin Injection is a sterile material consisting of Spectinomycin Hydrochloride with or without auxiliary substances. It is filled in a sealed container.
The injection is constituted by suspending the contents of the sealed container in the requisite amount of sterile Water for Injections, immediately before use.

**Storage.** The constituted suspension should be used immediately after preparation but, in any case, within the period recommended by the manufacturer.

Spectinomycin Injection contains not less than 90.0 per cent and not more than 110.0 per cent the stated amount of spectinomycin, C_{14}H_{24}N_{2}O_{7}.

The contents of the sealed container comply with the requirements stated under Parenteral Preparations (Powders for Injection) and with the following requirements.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with spectinomycin hydrochloride RS or with the reference spectrum of spectinomycin hydrochloride.

B. Gives reaction A of chlorides (2.3.1).

**Tests**

**pH** (2.4.24). 4.0 to 7.0, determined in a suspension of the contents of a sealed container in the volume of the liquid stated on the label.

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 50 volumes of 1-propanol, 40 volumes of water, 5 volumes of glacial acetic acid and 5 volumes of pyridine.

**Test solution.** Prepare a solution containing the equivalent of 1.4 per cent w/v of spectinomycin in water.

**Reference solution.** Prepare a solution containing the equivalent of 0.014 per cent w/v of spectinomycin hydrochloride RS in water.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and spray with a 5 per cent w/v solution of potassium permanganate. Allow the plate to stand for 2 to 3 minutes. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution.

**Water** (2.3.43). Not more than 20.0 per cent, determined on 0.2 g.

**Bacterial endotoxins** (2.2.3). Not more than 0.09 Endotoxin Unit per ml, determined on a solution prepared by dissolving the contents in a solution containing 0.05 M sodium bicarbonate in water BET to give a solution containing the equivalent of 1 mg of spectinomycin per ml (solution A), and using the maximum valid dilution of solution A calculated from the declared sensitivity of the lysate used in the test.

**Assay.** Determine by gas chromatography (2.4.13).

**NOTE – Use the solutions within 1 hour after preparation.**

**Test solution (a).** Weigh and mix the contents of the 10 containers. To an accurately weighed quantity containing about 60 mg of Spectinomycin Hydrochloride in a glass-stoppered conical flask, add 10.0 ml of dimethylformamide and 2.0 ml of hexamethyl-disilazane, shake intermittently for 1 hour and dilute to 20.0 ml with dimethylformamide.

**Test solution (b).** To an accurately weighed quantity containing about 60 mg of Spectinomycin Hydrochloride in a glass-stoppered conical flask, add 10.0 ml of a solution containing 0.15 per cent w/v of phenazone (internal standard) in dimethylformamide and 2.0 ml of hexamethyl-disilazane, shake intermittently for 1 hour and dilute to 20.0 ml with dimethylformamide.

**Reference solution.** To about 60 mg, accurately weighed, of spectinomycin hydrochloride RS in a glass-stoppered conical flask, add 10.0 ml of a solution containing 0.15 per cent w/v of phenazone (internal standard) in water.

**Chromatographic system**

- a glass column 1.5 m x 4 mm, packed with acid-washed, silanised diatomaceous support (100 to 120 mesh) coated with 3 per cent w/w of phenylmethylsilicone fluid (50 per cent phenyl),
- temperature: column 200°, inlet port 200° and detector 230°,
- flow rate. 45 ml per minute of the carrier gas.

Inject the chosen volumes of test solutions (a) and (b). The test is not valid unless the resolution factor between the peak due to the internal standard and the principal peak in the chromatogram obtained with test solution (a) is not less than 8.0.

Inject alternately test solution (b) and the reference solution. Calculate the content of C_{14}H_{24}N_{2}O_{7}\cdot2HCl.

**Storage.** Use the injection immediately after preparation but, in any case, within the period recommended by the manufacturer provided it is prepared and stored in accordance with the manufacturer’s instructions.

**Labelling.** The label states the strength in terms of the equivalent amount of spectinomycin.
Spiramycin

Spiramycin is a mixture comprised primarily of spiramycin I produced by *Streptomyces ambrofacien* from soil of northern France.

Spiramycin contains not less than 3900 Units per mg, calculated on the dried basis.

**Description.** A white or slightly yellowish powder; odour, slight; slightly hygroscopic.

**Identification**

A. When examined in the range 220 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in methanol shows an absorption maximum only at about 232 nm; absorbance at about 232 nm, about 0.34.

B. In the test for Related substances the principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution (a). If in the chromatogram obtained with the test solution one or two additional spots appear with Rf values slightly higher than that of the principal spot, these spots correspond to the secondary spots in the chromatogram obtained with reference solution (a) but differ from the spots in the chromatogram obtained with reference solution (e).

C. Dissolve 0.5 g in a mixture of 10 ml of 0.05 M sulphuric acid and 25 ml of water. Adjust the pH to about 8 by addition of 0.1 M sodium hydroxide and dilute to 50 ml with water. To 5 ml of the resulting solution add 2 ml of a mixture of 1 volume of water and 2 volumes of sulphuric acid; a brown colour is produced.

**Tests**

**pH** (2.4.24). 8.5 to 10.5, determined in a solution prepared by dissolving 0.5 g in 5 ml of methanol and diluting to 100 ml with carbon dioxide-free water.

**Specific optical rotation** (2.4.22). –80.0° to –85.0°, determined in a 2 per cent w/v solution in 0.2 M acetic acid.

**Heavy metals** (2.3.13). 1.0 g complies with the limit test for heavy metals, Method A (20 ppm).

**Related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel G.

**Mobile phase.** A mixture of 45 volumes of ethyl acetate, 40 volumes of a 15 per cent w/v of ammonium acetate previously adjusted to pH 9.6 with 10 M sodium hydroxide and 20 volumes of 2-propanol. Use the upper layer.

**Test solution.** Dissolve 0.4 g of the substance under examination in 100 ml of methanol.

**Reference solution (a).** A 0.40 per cent w/v solution of spiramycin RS in methanol.

**Reference solution (b).** A 0.040 per cent w/v solution of spiramycin RS in methanol.

**Reference solution (c).** A 0.020 per cent w/v solution of spiramycin RS in methanol.

**Reference solution (d).** A 0.0080 per cent w/v solution of spiramycin RS in methanol.

**Reference solution (e).** A 0.40 per cent w/v of erythromycin RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and spray with ethanolic anisaldehyde solution and heat at 110° for 5 minutes. In the chromatogram obtained with reference solution (a) there are two spots with Rf values slightly higher than that of the principal spot; the spot nearer the principal spot corresponds to the monoacetate ester and the one farther from the principal spot corresponds to the monopropionate ester. In the chromatogram obtained with the test solution any spot corresponding to the monoacetate is not more intense than the spot in the chromatogram obtained with reference solution (c), any spot corresponding to the monopropionate is not more intense than the spot in the chromatogram obtained with reference solution (b) and any other secondary spot is not more intense than the spot in the chromatogram obtained with reference solution (d).

**Sulphated ash** (2.3.18). Not more than 0.1 per cent w/v.

**Loss on drying** (2.4.19). Not more than 3.5 per cent, determined on 0.5 g by drying over phosphorus pentoxide at 80° at a pressure not exceeding 0.7 kPa for 6 hours.

**Assay.** Carry out the microbiological assay of antibiotics (2.2.10), Method A.

**Storage.** Store protected from moisture.

**Sulphadiazine and Trimethoprim Injection**

Trimethoprim and Sulphadiazine Injection; Co-trimazine Injection

Sulphadiazine and Trimethoprim Injection is a sterile suspension in Water for Injections containing Sulphadiazine and Trimethoprim in the proportion of five parts to one part respectively.
Sulphadiazine and Trimethoprim Injection contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of sulphadiazine, C_{10}H_{10}N_{4}O_{2}S and of trimethoprim, C_{14}H_{18}N_{4}O_{3}.

Identification

A. When examined in the range 230 nm to 360 nm (2.4.7), the solution obtained in the Assay for trimethoprim shows an absorption maximum only at about 271 nm.

B. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 75 volumes of ethyl acetate, 15 volumes of dimethylformamide and 5 volumes of water.

Test solution. Add 4 ml of hydrochloric acid to 2.5 ml of the well-mixed contents of the container and dilute to 50 ml with 1.4 M methanolic ammonia.

Reference solution (a). A 2.0 per cent w/v of sulphadiazine RS in 1.4 M methanolic ammonia.

Reference solution (b). A 0.4 per cent w/v of trimethoprim RS in 1.4 M methanolic ammonia.

Apply to the plate 1 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm.

C. To 5 ml of the filtrate obtained in the Assay for sulphadiazine add 10 ml of water and 5 ml of thiobarbituric acid-citrate buffer. Mix and heat on a water-bath for 30 minutes; a pink colour is produced.

Tests

pH (2.4.24). 10.0 to 10.5.

Other tests. Complies with the tests stated under Parenteral Preparations (Injections).

Assay. For sulphadiazine — Disperse the trimethoprim evenly throughout the injection solution by gently inverting the container several times without foam formation. Transfer an accurately measured quantity of the injection containing 2 g of Sulphadiazine to a separating funnel containing 50 ml of 0.1 M sodium hydroxide and extract with two quantities, each of 100 ml and 50 ml of dichloromethane, washing the extract with the same 25-ml quantity of 0.1 M sodium hydroxide. Reserve the combined dichloromethane extracts for the assay for trimethoprim.

Dilute the combined aqueous solutions and washings to 250.0 ml with water and filter, and dilute 5.0 ml of the filtrate to 200.0 ml with water. Dilute 10.0 ml of this solution to 100.0 ml with water. To 3.0 ml of the resulting solution add 1 ml of 2 M hydrochloric acid and 1 ml of a 0.1 per cent w/v solution of sodium nitrite and allow to stand for 2 minutes. Add 1 ml of a 0.5 per cent w/v solution of ammonium sulphamate and allow to stand for 3 minutes. Add 1 ml of a 0.1 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride, allow to stand for 10 minutes, add sufficient water to produce 25.0 ml and measure the absorbance of the resulting solution at the maximum at about 538 nm (2.4.7). Calculate the content of C_{10}H_{10}N_{4}O_{2}S from the absorbance obtained by carrying out the procedure simultaneously, using 3.0 ml of a solution prepared by dissolving 200 mg of sulphadiazine RS in 50 ml of 0.1 M sodium hydroxide, adding sufficient water to produce 200.0 ml, diluting 5.0 ml to 250.0 ml with water and beginning at the words “add 1 ml of 2 M hydrochloric acid........”.

For trimethoprim — Extract the dichloromethane solution reserved in the Assay for sulphadiazine with three quantities, each of 100 ml, 50 ml and 50 ml, of 1 M acetic acid and dilute the combined extracts to 500.0 ml with 1 M acetic acid. To 5.0 ml add 35 ml of 1 M acetic acid and sufficient water to produce 200.0 ml and measure the absorbance of the resulting solution at the maximum at about 271 nm (2.4.7). Calculate the content of C_{14}H_{18}N_{4}O_{3} taking 204 as the specific absorbance at 271 nm.

Labelling. The label states the content of Sulphadiazine and Trimethoprim in a suitable dose-volume.

Sulphadiazine and Trimethoprim Veterinary Oral Powder

Trimethoprim and Sulphadiazine Veterinary Oral Powder; Sulphadiazine and Trimethoprim Dispersible Powder; Co-trimazine Veterinary Oral Powder

Sulphadiazine and Trimethoprim Veterinary Oral Powder consists of Sulphadiazine and Trimethoprim in the proportion of five parts to one part respectively, mixed with suitable wetting, dispersing and suspending agents. Sulphadiazine and Trimethoprim Veterinary Oral Powder contains not less than 92.5 per cent and not more than 107.5 per cent of the stated amounts of sulphadiazine, C_{10}H_{10}N_{4}O_{2}S, and of trimethoprim, C_{14}H_{18}N_{4}O_{3}.

Identification

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 75 volumes of ethyl acetate, 15 volumes of dimethylformamide and 5 volumes of water.

Test solution (a). The supernatant liquid obtained by shaking a quantity of the powder containing 0.2 g of Sulphadiazine
with sufficient 1.4 M methanolic ammonia to produce 100 ml and centrifuging.

**Test solution (b).** The supernatant liquid obtained by shaking a quantity of the powder containing 0.2 g of Trimethoprim with sufficient 1.4 M methanolic ammonia to produce 100 ml and centrifuging.

**Reference solution (a).** A 0.2 per cent w/v solution of sulphadiazine RS in 1.4 M methanolic ammonia.

**Reference solution (b).** A 0.2 per cent w/v solution of trimethoprim RS in 1.4 M methanolic ammonia.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and spray with a 0.1 per cent w/v solution of 4-dimethylaminobenzaldehyde in a mixture of 1 ml of hydrochloric acid and 100 ml of ethanol (95 per cent), allow to dry and spray with dilute potassium iodobismuthate solution. The spot in the chromatogram obtained with test solution (a) having Rf value of about 0.7 corresponds to the principal spot in the chromatogram obtained with reference solution (a). The spot in the chromatogram obtained with test solution (b) having Rf value of about 0.3 corresponds to the principal spot in the chromatogram obtained with reference solution (b).

**Tests**

**Other tests.** Complies with the tests stated under Veterinary Oral Powders.

**Assay.** For sulphadiazine - Weigh accurately a quantity of the powder containing about 0.125 g of Sulphadiazine, transfer into a separator containing 20 ml of 0.1 M sodium hydroxide and extract with four quantities, each of 50 ml, of dichloromethane. Wash each dichloromethane extract with the same two quantities, each of 10 ml, of 0.1 M sodium hydroxide. Combine the aqueous washings and the aqueous layer from the separator and reserve the combined dichloromethane extracts for the Assay for trimethoprim.

Dilute the combined aqueous solutions to 250.0 ml with water, filter and dilute 10.0 ml of the filtrate to 200.0 ml with water. To 2.0 ml of the resulting solution add 0.5 ml of 4 M hydrochloric acid and 1 ml of a 0.1 per cent w/v solution of sodium nitrite and allow to stand for 2 minutes. Add 1 ml of a 0.5 per cent w/v solution of ammonium sulphamate and allow to stand for 3 minutes. Add 1 ml of a 0.1 per cent w/v solution of N-(-naphthyl)ethylenediamine dihydrochloride, allow to stand for 10 minutes. Dilute the solution to 25.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 538 nm (2.4.7), using as the blank a solution prepared in the same manner using 2 ml of water and beginning at the words “add 0.5 ml of 4 M hydrochloric acid........”.

Calculate the content of C_{10}H_{10}N_4O_2S from the absorbance obtained by carrying out the procedure simultaneously, with 2.0 ml of a 0.0025 per cent w/v solution of sulphadiazine RS in 0.0005 M sodium hydroxide and beginning at the words “add 0.5 ml of 4 M hydrochloric acid.......”.

For trimethoprim - Extract the combined dichloromethane extracts from the Assay for sulphadiazine with four quantities, each of 50 ml, of a 5 per cent v/v solution of 6 M acetic acid; wash the combined aqueous extracts with 5 ml of dichloromethane, discard the dichloromethane layer and dilute to 250.0 ml with a 5 per cent v/v solution of 6 M acetic acid. Dilute 20.0 ml to 100.0 ml with water and determine the absorbance of the resulting solution at the maximum at about 271 nm (2.4.7). Calculate the content of C_{14}H_{18}N_4O_3 taking 204 as the specific absorbance at 271 nm.

**Sulphadiazine and Trimethoprim Veterinary Oral Suspension**

Sulphadiazine and Trimethoprim Mixture; Trimethoprim and Sulphadiazine Veterinary Oral Suspension; Co-trimazine Oral Suspension; Co-trimazine Mixture

Sulphadiazine and Trimethoprim Veterinary Oral Suspension is a suspension of Sulphadiazine and Trimethoprim in the proportion of five parts to one part respectively, containing suitable suspending and dispersing agents. It may contain suitable antimicrobial preservatives.

Sulphadiazine and Trimethoprim Veterinary Oral Suspension contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of sulphadiazine, C_{10}H_{10}N_4O_2S, and of trimethoprim, C_{14}H_{18}N_4O_3.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 75 volumes of ethyl acetate, 15 volumes of dimethylformamide and 5 volumes of water.

**Test solution (a).** A dilution of the oral suspension in 1.4 M methanolic ammonia containing the equivalent of 0.2 per cent w/v of Sulphadiazine.

**Test solution (b).** A dilution of the oral suspension in 1.4 M methanolic ammonia containing the equivalent of 0.2 per cent w/v of Trimethoprim.

**Reference solution (a).** A 0.2 per cent w/v solution of sulphadiazine RS in 1.4 M methanolic ammonia.

**Reference solution (b).** A 0.2 per cent w/v solution of trimethoprim RS in 1.4 M methanolic ammonia.

Apply to the plate 5 µl of each solution. After development, dry the plate in air and spray with a 0.1 per cent w/v solution of 4-dimethylaminobenzaldehyde in a mixture of 1 ml of hydrochloric acid and 100 ml of ethanol (95 per cent), allow to dry and spray with dilute potassium iodobismuthate solution. The spot in the chromatogram obtained with test solution (a) having Rf value of about 0.7 corresponds to the principal spot in the chromatogram obtained with reference solution (a). The spot in the chromatogram obtained with test solution (b) having Rf value of about 0.3 corresponds to the principal spot in the chromatogram obtained with reference solution (b).
of 4-dimethylaminobenzaldehyde in a mixture of 1 ml of hydrochloric acid and 100 ml of ethanol (95 per cent), allow to dry and spray with dilute potassium iodobismuthate solution. The spot in the chromatogram obtained with test solution (a) having Rf value of about 0.7 corresponds to the principal spot in the chromatogram obtained with reference solution (a). The spot in the chromatogram obtained with test solution (b) having Rf value of about 0.3 corresponds to the principal spot in the chromatogram obtained with reference solution (b).

Tests

Other tests. Complies with the tests stated under Veterinary Oral Liquids.

Assay. For sulphadiazine - Transfer an accurately weighed quantity of the oral suspension containing about 0.125 g of Sulphadiazine, into a separator containing 20 ml of 0.1 M sodium hydroxide and extract with four quantities, each of 50 ml, of dichloromethane. Wash each dichloromethane extract with the same two quantities, each of 10 ml, of 0.1 M sodium hydroxide. Combine the aqueous washings and the aqueous layer from the separator and reserve the combined dichloromethane extracts for the Assay for trimethoprim.

Dilute the combined aqueous solutions to 250.0 ml with water, filter and dilute 10.0 ml of the filtrate to 200.0 ml with water. To 2.0 ml of the resulting solution add 0.5 ml of 4 M hydrochloric acid and 1 ml of a 0.1 per cent w/v solution of sodium nitrite and allow to stand for 2 minutes. Add 1 ml of a 0.5 per cent w/v solution of ammonium sulphamate and allow to stand for 3 minutes. Add 1 ml of a 0.1 per cent w/v solution of N-(1-naphthyl)ethylenediamine dihydrochloride, allow to stand for 10 minutes. Dilute the solution to 25.0 ml with water and measure the absorbance of the resulting solution at the maximum at about 538 nm (2.4.7), using as the blank a solution prepared in the same manner using 2 ml of water and beginning at the words “add 0.5 ml of 4 M hydrochloric acid.......”.

Calculate the content of C_{10}H_{12}N_{4}O_{2}S from the absorbance obtained by carrying out the procedure simultaneously, with 2.0 ml of a 0.0025 per cent w/v solution of sulphadiazine RS in 0.0005 M sodium hydroxide and beginning at the words “add 0.5 ml of 4 M hydrochloric acid.......”.

For trimethoprim - Extract the combined dichloromethane extracts from the Assay for sulphadiazine with four quantities, each of 50 ml, of a 5 per cent v/v solution of 6 M acetic acid; wash the combined aqueous extracts with 5 ml of dichloromethane, discard the dichloromethane layer and dilute to 250.0 ml with a 5 per cent v/v solution of 6 M acetic acid. Dilute 20.0 ml to 100.0 ml with water and determine the absorbance of the resulting solution at about 271 nm (2.4.7). Calculate the content of C_{14}H_{18}N_{4}O_{3} taking 204 as the specific absorbance at 271 nm.

Determine the weight per ml of the suspension (2.4.29), and calculate the contents of sulphadiazine and trimethoprim, weight in volume.

Labelling. The label states the strength in terms of the amounts of Sulphadiazine and Trimethoprim.

Sulphaquinoxaline

\[
\text{C}_{14}\text{H}_{12}\text{N}_{4}\text{O}_{2}\text{S} \quad \text{Mol. Wt. 300.3}
\]

Sulphaquinoxaline is 4-amino-\text{N}-2-quinoxalinylbenzene-sulphonamide.

Sulphaquinoxaline contains not less than 98.0 per cent and not more than 101.0 per cent of C_{14}H_{12}N_{4}O_{2}S, calculated on the dried basis.

Description. A yellow colour powder.

Identification

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphaquinoxaline RS or with the reference spectrum of sulphaquinoxaline.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.001 per cent w/v solution in 0.01 M sodium hydroxide shows an absorption maximum only at about 252 nm; absorbance at about 252 nm, about 1.1.

C. Dissolve 4 mg in 2 ml of warm 2 M hydrochloric acid. The solution gives the reaction of primary aromatic amines (2.3.1).

Tests

Acidity. To 2 g add 100 ml of water, heat at 70° for 5 minutes, cool to 20°, and filter. Titrate 50 ml of the filtrate to pH 7.0 with 0.1 M sodium hydroxide; not more than 0.2 ml of 0.1 M sodium hydroxide is required.

Heavy metals. Dissolve the residue obtained in the test for Sulphated ash in 1 ml of 2 M hydrochloric acid and dilute to 14 ml with water. 12 ml of the solution complies with limit test for heavy metals, Method D (2.3.13) (20 ppm).

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 60 volumes of dichloromethane, 40 volumes of methanol and 20 volumes of strong ammonia solution.
Test solution. Dissolve 0.20 g of the substance under examination in 2 ml of 1 M sodium hydroxide and add sufficient methanol to produce 50 ml.

Reference solution (a). A 0.012 per cent w/v solution of N\textsubscript{1},N\textsubscript{2}-diquinoxalin-2-ylsulphanilamide RS in methanol.

Reference solution (b). A 0.0040 per cent w/v solution of sulphanilamide RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air until the odour of the solvent is no longer detectable and examine in ultraviolet light at 254 nm. Any spot corresponding to N\textsubscript{1},N\textsubscript{2}-diquinoxalin-2-ylsulphanilamide in the chromatogram obtained with the test solution not more intense than that of the spot in the chromatogram obtained with reference solution (a). Any other secondary spot in the chromatogram obtained with the test solution is not more intense than that in the chromatogram obtained by reference solution (b).

Sulphated ash (2.3.18). Not more than 0.1 per cent.

Loss on drying (2.4.19). Not more than 1.0 per cent, determined on 1.0 g by drying in an oven at 105°.

Assay. Weigh accurately about 0.65 g and dissolve in 10 ml of a mixture of equal volumes of 1 M sodium hydroxide and water. Add 20 ml of glycerin, 20 ml of 9 M sulphuric acid and 5 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.03003 g of C\textsubscript{14}H\textsubscript{12}N\textsubscript{4}O\textsubscript{2}S.

Storage. Store protected from light.

Sulphaquinoxaline Sodium Solution

Sulphaquinoxaline Sodium Solution is an aqueous solution of sulphaquinoxaline sodium prepared by the interaction of Sulphaquinoxaline and Sodium Hydroxide.

Sulphaquinoxaline Sodium Solution contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of sulphaquinoxaline, C\textsubscript{14}H\textsubscript{12}N\textsubscript{4}O\textsubscript{2}S.

Description. A clear, yellow to brown solution.

Identification

A. To a volume containing 1 g of Sulphaquinoxaline add 10 ml of water and 3 ml of 2 M hydrochloric acid, filter, wash the precipitate with water and dry for 2 hours at 105°. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphaquinoxaline RS or with the reference spectrum of sulphaquinoxaline.

B. Dissolve 4 mg of the residue obtained in test A in 2 ml of warm 2 M hydrochloric acid. The solution gives the reaction of primary aromatic amines (2.3.1).

C. Acidify with 6 M acetic acid, filter and evaporate the filtrate to dryness. The incinerated residue, when moistened with hydrochloric acid and introduced on a platinum wire into a Bunsen burner flame, gives a yellow colour to the flame.

Tests

pH (2.4.24). 12.2 to 12.8, determined in a 9.6 per cent w/v solution in carbon dioxide-free water.

Related substances. Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

Mobile phase. A mixture of 60 volumes of dichloromethane, 40 volumes of methanol and 20 volumes of strong ammonia solution.

Test solution. Dilute a solution containing 0.20 g of Sulphaquinoxaline to 50 ml with methanol.

Reference solution (a). A 0.012 per cent w/v solution of N\textsubscript{1},N\textsubscript{2}-diquinoxalin-2-ylsulphanilamide RS in methanol.

Reference solution (b). A 0.0040 per cent w/v solution of sulphanilamide RS in methanol.

Apply to the plate 5 µl of each solution. After development, dry the plate in air until the odour of the solvent is no longer detectable and examine in ultraviolet light at 254 nm. Any spot corresponding to N\textsubscript{1},N\textsubscript{2}-diquinoxalin-2-ylsulphanilamide in the chromatogram obtained with the test solution not more intense than that of the spot in the chromatogram obtained with reference solution (a). Any other secondary spot in the chromatogram obtained with the test solution is not more intense than that in the chromatogram obtained by reference solution (b).

Other tests. Complies with the tests stated under Veterinary Oral Liquids.

Assay. To an accurately measured volume containing about 0.48 g of Sulphaquinoxaline add 30 ml water, 20 ml of glycerin, 20 ml of 9 M sulphuric acid and 5 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.03003 g of C\textsubscript{14}H\textsubscript{12}N\textsubscript{4}O\textsubscript{2}S.

Storage. Store protected from light.

Labelling. The label states the strength in terms of the equivalent amount of Sulphaquinoxaline in a suitable dose-volume.
**Sulphathiazole Sodium**

C₉H₈N₃NaO₂S₂,H₂O  
Mol. Wt. 304.3

C₉H₈N₃NaO₂S₂,5H₂O  
Mol. Wt. 367.4

Sulphathiazole Sodium is sodium salt of 4-amino-N-2-thiazolylbenzenesulphonamide with five or one and half molecules of water.

Sulphathiazole Sodium contains not less than 99.0 per cent and not more than 101.0 per cent of C₉H₈N₃NaO₂S₂, calculated on the dried basis.

**Description.** A white or yellowish white, crystalline powder or granules.

**Identification**

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphathiazole sodium RS or with the reference spectrum of sulphathiazole sodium.

B. Dissolve 1 g in 25 ml of water and add 2 ml of 6 M acetic acid. Wash the precipitate formed with water and dry for 4 hours at 105°C. The residue melts at about 201°C (2.4.21).

C. The precipitate obtained in test B gives the reaction of primary aromatic amines (2.3.1).

**Tests**

**pH** (2.4.24). 9.0 to 10.0, determined in a 1 per cent w/v solution.

**Heavy metals.** Dissolve 2.5 g of the substance under examination in 10 ml of water, add 15 ml of 2 M acetic acid, shake for 30 minutes and filter.

12 ml of this solution complies with the limit test for heavy metals, Method D (2.3.13) (20 ppm).

**Related substances.** Complies with test A for related substances in sulphonamides (2.3.7).

**Loss on drying** (2.4.19). Not less than 6.0 per cent and not more than 10.0 per cent (sesquihydrate) or not less than 22.0 per cent and not more than 27.0 per cent (pentahydrate), determined on 1.0 g by drying in an oven at 105°C.

**Assay.** Weigh accurately about 0.5 g, dissolve in a mixture of 75 ml of water and 10 ml of hydrochloric acid, add 3 g of potassium bromide, cool in ice and carry out the nitrite titration (2.3.31).

1 ml of 0.1 M sodium nitrite is equivalent to 0.02773 g of C₉H₈N₃NaO₂S₂.

**Storage.** Store protected from light.

**Labelling.** The label states whether the substance is the sesquihydrate or the pentahydrate.

---

**Thiabendazole Veterinary Oral Suspension**

Thiabendazole Oral Suspension; Thiabendazole Mixture; Thiabendazole Drench

Thiabendazole Veterinary Oral Suspension is an aqueous suspension of Thiabendazole containing suitable suspending agents and antimicrobial preservatives.

Thiabendazole Veterinary Oral Suspension contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of thiabendazole, C₁₀H₇N₃S.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 50 volumes of toluene, 20 volumes of glacial acetic acid, 8 volumes of acetone and 2 volumes of water.

**Test solution.** Add 50 ml of ethyl acetate and 2 ml of glacial acetic acid to a volume of the well-mixed oral suspension containing about 0.25 g of Thiabendazole. Shake for 5 minutes, heat to boiling, cool, shake for a further 15 minutes and filter.

**Reference solution.** Dissolve 0.25 g of thiabendazole RS in 50 ml of ethyl acetate and add 2 ml of glacial acetic acid.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with reference solution.

**Tests**

**Other tests.** Complies with the tests stated under Veterinary Oral Liquids.

**Assay.** Weigh accurately a quantity of the well-mixed oral suspension containing about 1 g of Thiabendazole, add to 700 ml of 0.1 M hydrochloric acid, shake for 30 minutes, add sufficient 0.1 M hydrochloric acid to produce 1000.0 ml, mix and filter. Dilute 10.0 ml of the filtrate to 100.0 ml with 0.1 M hydrochloric acid. Dilute 5.0 ml to 100.0 ml with 0.1 M hydrochloric acid and measure the absorbance of the resulting
solution at the maximum at about 302 nm (2.4.7). Calculate the content of C_{10}H_{7}N_{3}S taking 1230 as the specific absorbance at 302 nm.

Determine the weight per ml of the suspension (2.4.29), and calculate the content of thiabendazole, weight in volume.

**Labelling.** The label states that the suspension should be administered undiluted.

---

**Thiabendazole and Rafoxanide Veterinary Oral Suspension**

Thiabendazole and Rafoxanide Suspension; Thiabendazole and Rafoxanide Mixture

Thiabendazole and Rafoxanide Veterinary Oral Suspension is an aqueous suspension of Thiabendazole and Rafoxanide containing suitable suspending and dispersing agents.

Thiabendazole and Rafoxanide Veterinary Oral Suspension contains not less than 92.5 per cent and not more than 107.5 per cent of the stated amount of thiabendazole, C_{10}H_{7}N_{3}S, and not less than 90.0 per cent and not more than 110.0 per cent of the stated amount of rafoxanide, C_{19}H_{11}Cl_{2}I_{2}NO_{3}.

**Identification**

A. Mix a volume containing 20 mg of Thiabendazole with 5 ml of 0.1 M hydrochloric acid, add 3 mg of 4-phenylenediamine dihydrochloride, mix, add 0.1 g of zinc powder and allow to stand for 2 minutes. Add 10 ml of ferric ammonium sulphate solution; a deep blue or blue violet colour is produced.

B. In addition to the absorbance at about 335 nm, measure the absorbance at about 280 nm (2.4.7), of the final solution obtained in the Assay. The ratio of the absorbance at about 280 nm to that at about 335 nm is 1.59 to 1.69.

**Tests**

**Other tests.** Complies with the tests stated under Veterinary Oral Liquids.

**Assay.** For thiabendazole - Weigh accurately a volume of the well-mixed suspension containing about 85 mg of Thiabendazole, add 20 ml of water and 9 ml of 0.1 M hydrochloric acid and warm on a water-bath for 30 minutes with occasional stirring. Transfer the suspension to a flask, rinse the vessel with water and add the washings to the flask. Cool, add sufficient water to produce 1000.0 ml and filter. Dilute 5.0 ml of the filtrate to 100.0 ml with 0.1 M hydrochloric acid and measure the absorbance of the resulting solution at the maximum at about 302 nm (2.4.7). Calculate the content of C_{10}H_{7}N_{3}S taking 1230 as the specific absorbance at 302 nm.

For rafoxanide - Protect the solutions from light throughout the determination.

Weigh accurately a volume of the well-mixed suspension containing about 0.1 g of Rafoxanide in a 500-ml stoppered flask and add sufficient water to produce 100 ml. Swirl to disperse, add 20 ml of 1 M hydrochloric acid, mix well and add 300 ml of ethyl acetate. Shake the mixture for 1 hour, set aside for separation of the immiscible layers and centrifuge a portion of the ethyl acetate layer. Transfer 15.0 ml of the clear solution to a 50-ml centrifuge tube, add 20 ml of 0.1 M hydrochloric acid, stopper the tube, shake for 15 minutes, and centrifuge. Remove and discard the aqueous layer. Repeat the washing with two quantities, each of 20 ml, of 0.1 M hydrochloric acid. Evaporate the ethyl acetate solution almost to dryness in a warm water-bath, passing a stream of nitrogen over the surface of the liquid. Add 10 ml of water, warm on a water-bath for 10 minutes, add 5 ml of 1 M sodium hydroxide and mix. Add 15 ml of ether, shake for 15 minutes, centrifuge, and remove the ether layer. Repeat the extraction with two quantities, each of 15 ml, of ether. Evaporate the combined ether extracts almost to dryness on a warm water-bath, passing a stream of nitrogen over the surface of the liquid. Dissolve the residue in sufficient 0.1 M methanolic hydrochloric acid to produce 200.0 ml and measure the absorbance of the resulting solution at the maximum at about 335 nm (2.4.7).

Calculate the content of C_{19}H_{11}Cl_{2}I_{2}NO_{3} from the absorbance obtained by carrying out the procedure simultaneously, using 0.1 g of rafoxanide RS and beginning at the words, “add sufficient water to produce 100 ml. .....”.

Determine the weight per ml of the suspension (2.4.29), and calculate the content of thiabendazole and rafoxanide, weight in volume.

**Thiabendazole Premix**

Thiabendazole Premix contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of thiabendazole, C_{10}H_{7}N_{3}S.

**Identification**

Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel GF254.

**Mobile phase.** A mixture of 50 volumes of toluene, 20 volumes of glacial acetic acid, 8 volumes of acetone and 2 volumes of water.

**Test solution.** To a quantity of the premix containing 0.25 g of Thiabendazole, finely powdered if necessary, add 50 ml of ethyl acetate and 2 ml of glacial acetic acid, shake for 5 minutes, heat to boiling, cool, shake for a further 15 minutes and filter.

1568
Reference solution. Dissolve 0.25 g of thiabendazole RS in 50 ml of ethyl acetate and add 2 ml of glacial acetic acid.

Apply to the plate 10 µl of each solution. After development, dry the plate in air and examine in ultraviolet light at 254 nm. The principal spot in the chromatogram obtained with the test solution corresponds to that in the chromatogram obtained with the reference solution.

Tests

Other tests. Complies with the tests stated under Premixes.

Assay. Weigh accurately a quantity containing about 0.1 g of Thiabendazole, add 700 ml of 0.1 M hydrochloric acid, shake for 30 minutes, dilute to 1000.0 ml with 0.1 M hydrochloric acid and filter. Dilute 5.0 ml of the filtrate to 100.0 ml with 0.1 M hydrochloric acid and measure the absorbance of the resulting solution at the maximum at about 302 nm (2.4.7). Calculate the content of C_{10}H_{7}N_{3}S, taking 1230 as the specific absorbance at 302 nm.

Tylosin

\[ \text{C}_{46}\text{H}_{77}\text{NO}_{17} \quad \text{Mol. Wt. 916.1} \]

Tylosin is a macrolide antibiotic isolated from a strain of Streptomycetes fradiae found in soil from Thailand.

Tylosin has a potency of not less than 900 Units per mg, calculated on the dried basis. The content of tylosin A is not less than 80.0 per cent and the sum of the contents of tylosin A, tylosin B, tylosin C and tylosin D is not less than 95.0 per cent.

Description. Almost white or slightly yellow powder.

Identification

Tests B and C may be omitted if tests A, D and E are carried out. Tests D and E may be omitted if tests A, B and C are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tylosin RS or with the reference spectrum of tylosin.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.004 per cent w/v solution in 0.1 M hydrochloric acid (solution A) shows an absorption maximum only at about 290 nm; absorbance at about 290 nm, about 0.94.

C. To 10 ml of solution A add 1 ml of 2 M sodium hydroxide, heat on a water-bath for 20 minutes and cool. When examined in the range 250 nm to 430 nm (2.4.7), of the resulting solution shows an absorption maximum only at about 332 nm.

D. In the test for Tylosin A and other tylosins, the retention time and size of the principal peak in the chromatogram obtained with the test solution are approximately the same as those of the principal peak in the chromatogram obtained with reference solution (a).

E. Dissolve about 30 mg in a mixture of 0.15 ml of water, 2.5 ml of acetic anhydride and 7.5 ml of pyridine. Allow to stand for 10 minutes; no green colour develops.

Tests

pH (2.4.24). 8.5 to 10.5, determined in a 2.5 per cent w/v suspension in carbon dioxide-free water.

Heavy metals. To the residue obtained in the test for Sulphated ash add 2 ml of hydrochloric acid and evaporate slowly to dryness on a water-bath. Moisten the residue with 0.05 ml of hydrochloric acid, add 10 ml of boiling water and heat for 10 minutes on a water-bath. Cool and dilute to 25 ml with water. 12 ml of the solution complies with the limit test for heavy metals, Method D (2.3.13) (20 ppm).

Tyramine. Dissolve 50 mg in 5 ml of 0.03 M phosphoric acid in a 25-ml volumetric flask, add 1 ml of pyridine and 2 ml of a saturated solution of ninhydrin in water (approximately 4 per cent w/v). Close the flask by covering with a piece of aluminium foil and heat in a water-bath at 85° for at least 20 minutes. Cool rapidly and add sufficient water to produce 25 ml. Mix and measure without delay the absorbance of the solution at about 570 nm (2.4.7), using as the blank a solution prepared in a similar manner but omitting the substance under examination. The absorbance is not more than that obtained by carrying out the procedure simultaneously, using 5 ml of a solution in 0.03 M phosphoric acid containing 35 mg of tyramine per ml and beginning at the words “add 1 ml of pyridine......” (0.35 per cent).

Sulphated ash (2.3.18). Not more than 3.0 per cent.

Loss on drying (2.4.19). Not more than 5.0 per cent, determined on 1.0 g by drying at 60° at a pressure not exceeding 0.7 kPa for 3 hours.

Tylosin A and other tylosins. Determine by liquid chromatography (2.4.14).

NOTE. Use freshly prepared solutions.

Test solution. Dissolve 20 mg of the substance under examination in 100 ml of a mixture of equal volumes of acetonitrile and water.
**Reference solution (a).** A 0.02 per cent w/v solution of tylosin RS in a mixture of equal volumes of acetonitrile and water.

**Reference solution (b).** A solution containing 0.02 per cent w/v each of tylosin A RS and tylosin D RS in a mixture of equal volumes of acetonitrile and water.

**Chromatographic system**
- a stainless steel column 20 cm \( \times \) 4.6 mm, packed with octadecylsilane bonded to porous silica (5 \( \mu \)m) (such as Nucleosil C18),
- column temperature 35\(^{\circ}\),
- mobile phase: a filtered and degassed mixture of 60 volumes of 0.85 \( \text{M sodium perchlorate} \) and 40 volumes of acetonitrile adjusted to pH 2.5 with \( 1 \text{M hydrochloric acid} \),
- flow rate. 1 ml per minute,
- spectrophotometer set at 290 nm,
- a 20 \( \mu \)l loop injector.

Inject reference solution (b). If necessary, adjust the molarity of the sodium perchlorate or increase the temperature of the column to a maximum of 50\(^{\circ}\) so as to obtain a retention time of about 12 minutes for tylosin A. The test is not valid unless the resolution between the peaks due to tylosin A and tylosin D is at least 2.0.

Inject reference solution (a). The column efficiency, determined using the peak due to tylosin A, should be not less than 22,000 theoretical plates per metre.

Inject alternatively the test solution and reference solution (a). The order of elution of the major components of the substance under examination is desmycinosyltylosin, tylosin C, tylosin B, tylosin D, tylosin A aldol and tylosin A.

Calculate the percentage content of components from the areas of the peaks in the chromatogram obtained with the test solution by normalisation.

**Assay.** Carry out the microbiological assay of antibiotics (2.2.10).

**Tylosin intended for use in the manufacture of Parenteral Preparations without a further appropriate sterilisation procedure complies with the following additional requirement.**

**Sterility (2.2.11).** Complies with the test for sterility.

**Storage.** Store protected from light. If it is intended for use in the manufacture of Parenteral Preparations, the container should be sterile, tamper-evident and sealed so as to exclude micro-organisms.

**Labelling.** The label states (1) the number of Units per mg; (2) the date after which the material is not intended to be used; (3) the storage conditions; (4) where applicable, that it is suitable for use in the manufacture of Parenteral Preparations; (5) that the preparation is intended for veterinary use.

**Tylosin Injection**

Tylosin Injection is a sterile solution of Tylosin in a mixture of equal volumes of Propylene Glycol and Water for Injections.

Tylosin Injection contains not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of tylosin. The content of tylosin A is not less than 80.0 per cent and the sum of the contents of tylosin A, tylosin B, tylosin C and tylosin D is not less than 90.0 per cent.

**Description.** A pale yellow to amber-coloured solution.

**Identification**

A. To a volume containing 0.1 g of Tylosin add sufficient water to obtain a solution containing 0.02 per cent w/v of Tylosin. To 5 ml of this solution add 10 ml of 0.1 \( \text{M sodium hydroxide} \) and extract with 10 ml of dichloromethane. Separate the dichloromethane layer and extract it with 25 ml of 0.1 \( \text{M hydrochloric acid} \). Discard the dichloromethane layer, wash the aqueous layer with 3 ml of dichloromethane, discard the washings and filter. When examined in the range 230 nm to 360 nm (2.4.7), of the resulting solution exhibits a maximum only at about 290 nm; absorbance at about 290 nm, about 0.94.

B. To 10 ml of the filtrate obtained in test A add 1 ml of 2 \( \text{M sodium hydroxide} \), heat in a water-bath for 20 minutes and cool. When examined in the range 250 nm to 430 nm (2.4.7), exhibits a maximum only at about 332 nm.

**Tests**

**Tyramine.** Dilute a volume containing 100 mg of Tylosin with 5 ml of 0.03 \( \text{M phosphoric acid} \) in a 25-ml volumetric flask, add 1 ml of pyridine and 2 ml of a saturated solution of ninhydrin in water (approximately 4 per cent w/v). Close the flask by covering with a piece of aluminium foil and heat in a water-bath at 85\(^{\circ}\) for at least 20 minutes. Cool rapidly and add sufficient water to produce 25 ml. Mix and measure without delay the absorbance of the resulting solution at about 570 nm (2.4.7), using as the blank a solution prepared in a similar manner but omitting the preparation under examination. The absorbance is not more than that obtained by carrying out the procedure simultaneously, using 5 ml of a solution in 0.03 \( \text{M phosphoric acid} \) containing 30 mg of tyramine per ml and beginning at the words “add 1 ml of pyridine…..” (0.15 per cent).

**Tylosin A and other tylosins.** Determine by liquid chromatography (2.4.14).

**NOTE - Use freshly prepared solutions.**

**Test solution.** Dilute the injection with sufficient of a mixture of equal volumes of acetonitrile and water to produce a solution containing 0.02 per cent w/v of Tylosin.
*Reference solution (a).* A 0.02 per cent w/v solution of tylosin RS in a mixture of equal volumes of acetonitrile and water.

*Reference solution (b).* A solution containing 0.02 per cent w/v each of tylosin A RS and tylosin D RS in a mixture of equal volumes of acetonitrile and water.

**Chromatographic system**
- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm) (such as Nucleosil C18),
- column temperature 35°,
- mobile phase: a filtered and degassed mixture of 60 volumes of 0.85 M sodium perchlorate and 40 volumes of acetonitrile adjusted to pH 2.5 with 1 M hydrochloric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 290 nm,
- a 20 µl loop injector.

Inject reference solution (b). If necessary, adjust the molarity of the sodium perchlorate or increase the temperature of the column to a maximum of 50° so as to obtain a retention time of about 12 minutes for tylosin A. The test is not valid unless the resolution between the peaks due to tylosin A and tylosin D is at least 2.0.

Inject reference solution (a). The column efficiency, determined using the peak due to tylosin A, should be not less than 22,000 theoretical plates per metre.

Inject alternatively test solution and reference solution (a). The order of elution of the major components of the substance under examination is desmycinosyltylosin, tylosin C, tylosin B, tylosin D, tylosin A aldol and tylosin A.

Calculate the percentage content of components from the areas of the peaks in the chromatogram obtained with the test solution.

**Other tests.** Complies with the tests stated under Parenteral Preparations (Injections).

**Assay.** Carry out the microbiological assay of antibiotics (2.2.10). Calculate the content of tylosin in the injection, taking each 1000 Units found to be equivalent to 1 mg of tylosin.

**Storage.** Store protected from moisture.

**Labelling.** The label states that the preparation is intended for veterinary use by intramuscular injection only.

## Tylosin Tablets

Tylosin Tablets contain not less than 95.0 per cent and not more than 105.0 per cent of the stated amount of tylosin. The content of tylosin A is not less than 80.0 per cent and the sum of the contents of tylosin A, tylosin B, tylosin C and tylosin D is not less than 90.0 per cent.

**Identification**

A. Triturate a quantity of the powdered tablets containing 0.2 g of Tylosin with 20 ml of dichloromethane and filter. Dry the dichloromethane extract by shaking with anhydrous sodium sulphate, filter and evaporate the filtrate to dryness. Dry the residue over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 1 hour.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tylosin RS or with the reference spectrum of tylosin.

B. Triturate a quantity of the powdered tablets containing 0.2 g of Tylosin with two quantities, each of 10 ml, of 0.1 M hydrochloric acid, filter and dilute the filtrate to 100 ml with 0.1 M hydrochloric acid. Dilute 10 ml of the resulting solution to 50 ml with the same solvent. Dilute 5 ml of this solution further to 50 ml with the same solvent.

When examined in the range 230 nm to 360 nm (2.4.7), the resulting solution shows an absorption maximum only at about 290 nm; absorbance at about 290 nm, about 0.94.

C. To 10 ml of the final solution obtained in test B add 1 ml of 2 M sodium hydroxide, heat in a water-bath for 20 minutes and cool. When examined in the range 250 nm to 430 nm (2.4.7), exhibits a maximum only at about 332 nm.

**Tests**

**Tyrmine.** Shake a quantity of the powdered tablets containing 50 mg of Tylosin with 5 ml of 0.03 M phosphoric acid. Filter into a 25-ml volumetric flask, add 1 ml of pyridine and 2 ml of a saturated solution of ninhydrin in water (approximately 4 per cent w/v). Close the flask by covering with a piece of aluminium foil and heat in a water-bath at 85° for at least 20 minutes. Cool rapidly and add sufficient water to produce 25 ml. Mix and measure without delay the absorbance of the solution at about 570 nm (2.4.7), using as the blank a solution prepared in a similar manner but omitting the substance under examination. The absorbance is not more than that obtained by carrying out the procedure simultaneously, using 5 ml of a solution in 0.03 M phosphoric acid containing 35 mg of tyrmine per ml and beginning at the words “add 1 ml of pyridine......” (0.35 per cent).

**Tylosin A and other tylosins.** Determine by liquid chromatography (2.4.14).

**NOTE – Use freshly prepared solutions.**

**Test solution.** Shake a quantity of the powdered tablets containing 0.2 g of Tylosin with 50 ml of methanol, filter and dilute 5 ml of the filtrate to 100 ml with a mixture of equal volumes of acetonitrile and water.

*Reference solution (a).* A 0.02 per cent w/v solution of tylosin RS in a mixture of equal volumes of acetonitrile and water.
Reference solution (b). A solution containing 0.02 per cent w/v each of tylosin A RS and tylosin D RS in a mixture of equal volumes of acetonitrile and water.

Chromatographic system

- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm) (such as Nucleosil C18),
- column temperature 35°,
- mobile phase: a filtered and degassed mixture of 60 volumes of 0.85 M sodium perchlorate and 40 volumes of acetonitrile adjusted to pH 2.5 with 1 M hydrochloric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 290 nm,
- a 20 µl loop injector.

Inject reference solution (b). If necessary, adjust the molarity of the sodium perchlorate or increase the temperature of the column to a maximum of 50° so as to obtain a retention time of about 12 minutes for tylosin A. The test is not valid unless the resolution between the peaks due to tylosin A and tylosin D is at least 2.0.

Inject reference solution (a). The column efficiency, determined using the peak due to tylosin A, should be not less than 22,000 theoretical plates per metre.

Inject alternatively the test solution and reference solution (a). The order of elution of the major components of the substance under examination is desmycinosyltylosin, tylosin C, tylosin B, tylosin D, tylosin A aldol and tylosin A.

Calculate the percentage content of components from the areas of the peaks in the chromatogram obtained with test solution.

Other tests. Comply with the tests stated under Tablets.

Assay. Carry out the microbiological assay of antibiotics (2.2.10). Calculate the content of tylosin in the tablets, taking each 1000 Units found to be equivalent to 1 mg of tylosin.

Tylosin Tartrate

Tylosin Tartrate is the tartrate of Tylosin, which is a mixture of antimicrobial macrolides produced by the growth of certain strains of Streptomyces fradiae or by any other means. It consists largely of tylosin A tartrate but tartrates of tylosin B (desmycosin), tylosin C (macrocin) and tylosin D (relomycin) may also be present.

Tylosin Tartrate contains not less than 800 Units per mg, calculated on the dried basis. The content of tylosin A is not less than 80.0 per cent and the sum of the contents of tylosin A, tylosin B, tylosin C and tylosin D is not less than 95.0 per cent.

Description. An almost white or slightly yellow, hygroscopic powder.

Identification

Tests B and C may be omitted if tests A, D and E are carried out. Tests D and E may be omitted if tests A, B and C are carried out.

A. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tylosin tartrate RS or with the reference spectrum of tylosin tartrate.

B. When examined in the range 230 nm to 360 nm (2.4.7), a 0.004 per cent w/v solution in 0.1 M hydrochloric acid (solution A) shows an absorption maximum only at about 290 nm; absorbance at about 290 nm, about 0.88.

C. To 10 ml of solution A add 1 ml of 2 M sodium hydroxide, heat on a water-bath for 20 minutes and cool. When examined in the range 250 nm to 430 nm (2.4.7), the resulting solution shows an absorption maximum only at about 332 nm.

D. In the test for Tylosin A and other tylosins, the retention time and size of the principal peak in the chromatogram obtained with the test solution are approximately the same as those of the principal peak in the chromatogram obtained with the reference solution.

E. Dissolve about 30 mg in a mixture of 0.15 ml of water, 2.5 ml of acetic anhydride and 7.5 ml of pyridine. Allow to stand for 10 minutes; a green colour develops.

Tests

pH (2.4.24). 5.0 to 7.2, determined in a 2.5 per cent w/v solution in carbon dioxide-free water.

Tyramine. Dissolve 50 mg in 5 ml of 0.03 M phosphoric acid in a 25-ml volumetric flask, add 1 ml of pyridine and 2 ml of a saturated solution of ninhydrin in water (approximately 4 per cent w/v). Close the flask by covering with a piece of aluminium foil and heat in a water-bath at 85° for at least 20 minutes. Cool rapidly and add sufficient water to produce 25 ml. Mix and measure without delay the absorbance of the solution at about 570 nm (2.4.7), using as the blank a solution prepared in a
similar manner but omitting the substance under examination. The absorbance is not more than that obtained by carrying out the procedure simultaneously, using 5 ml of a solution in 0.03 M phosphoric acid containing 35 mg of tyramine per ml and beginning at the words “add 1 ml of pyridine......” (0.35 per cent).

**Sulphated ash** (2.3.18). Not more than 2.5 per cent.

**Loss on drying** (2.4.19). Not more than 4.5 per cent, determined on 1.0 g by drying at 60° at a pressure not exceeding 0.7 kPa for 3 hours.

**Tylosin A and other tylosins.** Determine by liquid chromatography (2.4.14).

**NOTE - Use freshly prepared solutions.**

**Test solution.** Dissolve a quantity containing 20 mg of tylosin in 100 ml of a mixture of equal volumes of acetonitrile and water.

**Reference solution (a).** A 0.02 per cent w/v solution of tylosin RS in a mixture of equal volumes of acetonitrile and water.

**Reference solution (b).** A solution containing 0.02 per cent w/v each of tylosin A RS and tylosin D RS in a mixture of equal volumes of acetonitrile and water.

**Chromatographic system**
- a stainless steel column 20 cm x 4.6 mm, packed with octadecylsilane bonded to porous silica (5 µm) (such as Nucleosil C18),
- column temperature 35°,
- mobile phase: a filtered and degassed mixture of 60 volumes of 0.85 M sodium perchlorate and 40 volumes of acetonitrile adjusted to pH 2.5 with 1 M hydrochloric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 290 nm,
- a 20 µl loop injector.

Inject reference solution (b). If necessary, adjust the molarity of the sodium perchlorate or increase the temperature of the column to a maximum of 50° so as to obtain a retention time of about 12 minutes for tylosin A. The test is not valid unless the resolution between the peaks due to tylosin A and tylosin D is at least 2.0.

Inject reference solution (a). The column efficiency, determined using the peak due to tylosin A, should be not less than 22,000 theoretical plates per metre.

Inject alternatively the test solution and the reference solution (a). The order of elution of the major components of the substance under examination is desmycinosyltylosin, tylosin C, tylosin B, tylosin D, tylosin A aldol and tylosin A.

Calculate the percentage content of components from the areas of the peaks in the chromatogram obtained with test solution.

**Assay.** Carry out the microbiological assay of antibiotics (2.2.10).

**Tylosin Tartrate intended for use in the manufacture of parenteral preparations complies with the above requirements with the following modification.**

**Tyramine.** Carry out the procedure described in the test for Tyramine but using 100 mg in 5 ml of 0.03 M phosphoric acid. Measure the absorbance of the solution under the conditions described in the test. The absorbance is not more than that obtained by simultaneously carrying out the procedure using 5 ml of a solution in 0.03 M phosphoric acid containing 30 mg of tyramine per ml and beginning at the words “add 1 ml of pyridine......” (0.15 per cent).

**Tyrosin Tartrate intended for use in the manufacture of parenteral preparations without a further appropriate sterilisation procedure complies with the following additional requirement.**

**Sterility** (2.2.11). Complies with the test for sterility.

**Storage.** Store protected from light. If it is intended to be used in the manufacture of parenteral preparations, the container should be sterile, tamper-evident and sealed so as to exclude micro-organisms.

**Labelling.** The label states (1) the number of Units per mg; (2) the quantity of Tylosin Tartrate in terms of equivalent amount of tylosin; (3) the date after which the material is not intended to be used; (4) the storage conditions; (5) where applicable, that it is suitable for use in the manufacture of parenteral preparations; (6) that the preparation is intended for veterinary use.

**Tylosin Tartrate and Sulphathiazole Sodium Veterinary Oral Powder**

Tylosin Tartrate and Sulphathiazole Sodium Veterinary Oral Powder is a mixture of Tylosin Tartrate and Sulphathiazole Sodium. It contains 3 parts of Sulphathiazole Sodium for 1 part, by weight, of Tylosin.

Tylosin Tartrate and Sulphathiazole Sodium Veterinary Oral Powder contains not less than 90.0 per cent and not more than 110.0 per cent of the stated amounts of tylosin and sulphathiazole sodium sesquihydrate, C_{9}H_{8}NaO_{2}S_{2}·11/2H_{2}O.

**Identification**

A. Triturate a quantity of the powder containing 0.25 g of Tylosin with two quantities, each of 25 ml, of dichloromethane and filter. Reserve the dichloromethane-insoluble matter for test B. Wash the combined filtrates by shaking for 1 minute with 20 ml of 0.1 M sodium hydroxide and dry the dichloromethane layer by the addition of anhydrous sodium...
sulphate. Evaporate the filtrate to dryness and dry the residue over phosphorus pentoxide at a pressure not exceeding 0.7 kPa for 1 hour. The residue complies with the following test. Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with tylosin RS or with the reference spectrum of tylosin.

B. Dry the dichloromethane-insoluble matter reserved in test A at 105° for 1 hour. The residue complies with the following test.

Determine by infrared absorption spectrophotometry (2.4.6). Compare the spectrum with that obtained with sulphathiazole sodium RS or with the reference spectrum of sulphathiazole sodium.

Tests

**Sulphonamide-related substances.** Determine by thin-layer chromatography (2.4.17), coating the plate with silica gel H. **Solvent mixture.** A mixture of 9 volumes of ethanol (95 per cent) and 1 volume of strong ammonia solution. **Mobile phase.** A mixture of 90 volumes of 1-butanol and 18 volumes of 10 M ammonia. **Test solution.** Shake a quantity of the powder containing 0.1 g of sulphathiazole sodium sesquihydrate with 10 ml of the solvent mixture. **Reference solution.** A 0.0050 per cent w/v solution of sulphanilamide in the solvent mixture.

Apply to the plate 10 µl of each solution. After development, dry the plate by heating it at 105° for 10 minutes and spray with a 0.1 per cent solution of 4-dimethylaminobenzaldehyde in a mixture of 99 volumes of ethanol (95 per cent) and 1 volume of hydrochloric acid. Any secondary spot in the chromatogram obtained with the test solution is not more intense than the spot in the chromatogram obtained with reference solution (0.5 per cent).

**Tylosin A and other tylosins.** Determine by liquid chromatography (2.4.14).

**NOTE - Use freshly prepared solutions.**

**Test solution.** Dissolve a quantity containing 20 mg of tylosin in 100 ml of a mixture of equal volumes of acetonitrile and water.

**Reference solution (a).** A 0.02 per cent w/v solution of tylosin RS in a mixture of equal volumes of acetonitrile and water.

**Reference solution (b).** A solution containing 0.02 per cent w/v each of tylosin A RS and tylosin D RS in a mixture of equal volumes of acetonitrile and water.

**Chromatographic system**
- a stainless steel column 20 cm x 4.6 mm, packed with octadeysilsilane bonded to porous silica (5 µm) (such as Nucleosil C18),
- column temperature 35°,
- mobile phase: a filtered and degassed mixture of 60 volumes of 0.85 M sodium perchlorate and 40 volumes of acetonitrile adjusted to pH 2.5 with 1 M hydrochloric acid,
- flow rate. 1 ml per minute,
- spectrophotometer set at 290 nm,
- a 20 µl loop injector.

Inject reference solution (b). If necessary, adjust the molarity of the sodium perchlorate or increase the temperature of the column to a maximum of 50° so as to obtain a retention time of about 12 minutes for tylosin A. The test is not valid unless the resolution between the peaks due to tylosin A and tylosin D is at least 2.0.

Inject reference solution (a). The column efficiency, determined using the peak due to tylosin A, should be not less than 22,000 theoretical plates per metre.

Inject alternatively the test solution and the reference solution (a). The order of elution of the major components of the substance under examination is desmycinosyltylosin, tylosin C, tylosin B, tylosin D, tylosin A aldol and tylosin A.

Calculate the percentage content of components from the areas of the peaks in the chromatogram obtained with the test solution by normalisation. In the chromatogram obtained with the test solution the content of tylosin A is not less than 80.0 per cent and the sum of the contents of tylosin A, tylosin B, tylosin C and tylosin D is not less than 95.0 per cent.

**Other tests.** Complies with the tests stated under Veterinary Oral Powders.

**Assay.** For tylosin activity - Weigh accurately a quantity of the powder containing about 0.2 g of Tylosin, transfer to a 100-ml volumetric flask with three quantities, each of 10 ml, of methanol, swirl to dissolve and add sufficient sterile phosphate buffer pH 7.0 to produce 100.0 ml. Filter and dilute 5.0 ml of the filtrate to 100.0 ml with sterile phosphate buffer pH 7.0. Carry out the microbiological assay of antibiotics (2.2.10). Calculate the content of tylosin taking each 1000 Units found to be equivalent to 1 mg of tylosin.

For sulphathiazole sodium - Weigh accurately a quantity of the powder containing about 0.4 g of sulphathiazole sodium sesquihydrate, dissolve in a mixture of 75 ml of water and 10 ml of hydrochloric acid, add 3 g of potassium bromide, cool in ice and titrate slowly with 0.1 M sodium nitrite, stirring constantly and determine the end-point potentiometrically (2.4.25).

1 ml of 0.1 M sodium nitrite is equivalent to 0.03043 g of C9H8N3NaO2S2.11/2H2O.

**Storage.** Store protected from moisture.
Labelling. The label states the strength of Tylosin Tartrate in terms of the equivalent amount of tylosin and that of Sulphathiazole Sodium in terms of the equivalent amount of sulphathiazole sodium sesquihydrate.
Anthrax Spore Vaccine, Live

Anthrax Spore Vaccine, Live consists of a suspension of live spores of an attenuated, non-capsulated strain of *Bacillus anthracis*.

**Production**

The strain used may either be not lethal to guinea pigs or the mouse or lethal to guinea pigs but not to the rabbit or lethal to some rabbits. At the end of growth the spores are suspended in 50 per cent glycerin saline and counted. The vaccine may contain an adjuvant.

**Identification**

*B. anthracis* present in the vaccine is identified by means of morphological, serological test, culture and biochemical test.

**Tests**

**Safety.** Carry out the test on one of the species for which the vaccine is intended. If the vaccine is intended for several species including the goat, carry out the test on sheep and goats. Administer subcutaneously or intramuscularly to each of two animals having no antibodies against *B. anthracis*, twice the dose (example, 2 million spores) stated on the label for the species used and observe the animals for 10 days. No abnormal systemic reaction is produced but a mild local reaction may occur at the site of injection. The severity of the local reaction may vary according to the strain of the spores and the adjuvants used in the preparation, but necrosis does not occur.

**Sterility (2.2.11).** Complies with the test for sterility.

**Spore count.** Determine the number of viable spores by plate count. The number of live spores is not less than 80 per cent of that stated on the label.

**Potency.** For a strain of *B. anthracis* which is not lethal to the guinea pig or the mouse, the test may be carried out in the guinea pigs. For a strain which is lethal to the guinea pig but not to the rabbit, the test may be carried out in rabbits. For a strain which is lethal to some rabbits, carry out the test in sheep.

If the test is carried out in guinea pigs or rabbits. Inject into animals (each guinea pig weighing not less than 500 g and each rabbit weighing not less than 4.5 kg) subcutaneously or intramuscularly, 1/10th of the smallest dose of the vaccine stated on the label for sheep and observe the animal for 21 days. None of the sheep shows any untoward reaction. If more than 2 animals die from non-specific causes, repeat the test.

Inject subcutaneously into each vaccinated guinea pig or rabbit or sheep at least 100 MLD and to each of these control animals 10 MLD of a strain of *B. anthracis* pathogenic for the species of animal used in the test. Observe all the animals for 10 days, all vaccinates animals survive and all the controls die from anthrax during the observation period. If a vaccinated animal dies after the challenge, repeat the test. If in the second test, a vaccinated animal dies, the vaccine fails the test.

**Labelling.** The label states (1) the strain used for the preparation of the vaccine; (2) the number of viable spores per ml.

Avian Infectious Bronchitis Vaccine, Inactivated

Avian Infectious Bronchitis Vaccine, Inactivated consists of an emulsion or a suspension of one or more serotypes of avian infectious bronchitis virus which have been inactivated in such a manner that the immunogenic activity is retained. The vaccine may contain one or more suitable adjuvants. These vaccines intended to protect against a drop in egg production or quality; for vaccines also intended to protect against respiratory symptoms, a demonstration of efficacy (2.7.12) additional to that described under Potency is required.

**Production**

The virus is propagated in fertilised hen eggs (2.7.7) from SPF flock or in suitable cell cultures. The master seed lot complies with the tests for extreneous agents in seed lot (2.7.10).

**Inactivation**

An amplification test for residual live avian infectious bronchitis virus is carried out on each batch of antigen immediately after inactivation and on the final bulk vaccine or, if the vaccine contains an adjuvant, on the bulk antigen or mixture of bulk antigens immediately before the addition of adjuvant; the test is carried out in fertilised hen eggs from flocks free from specified pathogens (SPF) or in suitable cell cultures and the quantity of inactivated virus used is equivalent to not less than 10 doses of vaccine. No live virus is detected.

**Identification**

In susceptible birds, the vaccine stimulates the production of specific antibodies against each of the virus serotypes in the vaccine, detectable by virus neutralisation and protects chicken against infectious bronchitis.
Tests

Sterility (2.2.11). Complies with the test for sterility.

Safety. Inject intramuscularly a quantity equivalent to 2 doses into each of twenty healthy chickens, 2 to 4 weeks old, free from specific antibodies (2.7.7). Observe the chickens for 14 days. No abnormal systemic or local reaction is seen.

Inactivation

A. For vaccine prepared with embryo-adapted strains of virus, inject 2/5 of a dose into the allantoic cavity of ten 9 to 11-day-old fertilised hen eggs from an SPF flock and incubate. Observe for 5 to 6 days and pool separately the allantoic fluid from eggs containing live embryos and that from eggs containing dead embryos, excluding those that die within the first 24 hours after injection. Examine for abnormalities all embryos which die after 24 hours of injection or which survive 5 to 6 days. No death or abnormality attributable to the vaccine virus occurs.

Inject into the allantoic cavity of each of ten 9 to 11-day-old fertilised hen eggs from an SPF flock, 0.2 ml of the pooled allantoic fluid from the live embryos and into each of 10 similar eggs 0.2 ml of the pooled liquid from the dead embryos and incubate for 5 to 6 days. Examine for abnormalities all embryos which die after 24 hours of injection or which survive 5 to 6 days. No death or abnormality attributable to the vaccine virus occurs.

If more than 20 per cent of the embryos die at either stage repeat the test from that stage. The vaccine complies with the test if there is no death or abnormality attributable to the vaccine virus.

B. For vaccine prepared with cell-culture-adapted strains of virus, inoculate 10 doses of the vaccine into suitable cell cultures. If the vaccine contains an oil adjuvant, eliminate it by suitable means. Incubate at 37 ± 1° for 7 days. Make a passage on another set of cell cultures and incubate at 37 ± 1° for 7 days. None of the cultures shows signs of infection.

Extraneous agents. Use the chickens from the test for safety. 21 days after injection of the double dose of vaccine, inject 1 dose by the same route into each chicken. Collect serum samples from each chicken 2 weeks later and carry out tests for antibodies to the following agents: avian encephalomyelitis virus, avian leucosis viruses, haemagglutinating avian adenovirus, infectious bursal disease virus, infectious laryngotracheitis virus, influenza A virus, Marek’s disease virus, Newcastle disease virus. The vaccine does not stimulate the formation of antibodies against these agents.

Potency. Inject one dose by the route stated on the label into each of twenty chickens, 3 to 4 weeks old, complying with the requirements stated under Test on chickens flocks free from pathogens for the production and quality control of vaccines (2.7.7 ). Use ten similar chickens as controls and house them together with the vaccinated chickens. After 28 days, collect serum samples from each of the vaccinated and control chickens and perform haemagglutination inhibition (HI) test on each serum using 8 haemagglutinating (HA) units of antigen and chicken erythrocytes, testing all serum samples at the same time. The vaccine passes the test if the mean antibody titre of the vaccinated group is not less than 1:64 and no specific antibody is detected in the control chickens. Alternatively, serum neutralization test may be carried out in SPF eggs. Serum neutralization titer should not be less than 10² neutralization units.

If the immunogenicity test (potency test) has been performed with satisfactory results on representative batch of the vaccine from the same seed lot, it may be omitted as a routine control test during production of other batches of the vaccine prepared from the same seed lot.

Labelling. The label states (1) the strain of virus used in preparing the vaccine; (2) the name of any added adjuvant.

Avian Infectious Bronchitis Vaccine, Live

Avian Infectious Bronchitis Vaccine, live is a preparation of one or more suitable strains of different types of avian infectious bronchitis virus.

Production

The vaccine virus is grown in embryonated hens’ eggs or in cell cultures.

Substrate for virus propagation

Embryonated hens’ eggs. If the vaccine virus is grown in embryonated hens’ eggs, they are obtained from SPF (2.7.7).

Identification

Carry out either the test A or B.

A. Inoculate 0.2 ml undiluted vaccine in the allantoic sac of SPF embryonated eggs and incubate at 37° for 7 days. Lesions typical of infectious bronchitis are observed in the embryos and the allantoic fluid does not agglutinate chicken erythrocytes.

B. Specific antisera against the strain or each of the strains of the avian infectious bronchitis virus used in the vaccine are neutralised by the vaccine.

Tests

Water (2.3.43). Not more than 3.0 per cent.
**Black Quarter Vaccine**

Black Quarter Vaccine is a culture of suitable strain or strains of *Clostridium chauvoei* grown in a suitable anaerobic fluid medium and rendered sterile and non-toxic by addition of solution of *formaldehyde* in such a manner that it retains its immunizing properties. The vaccine may contain a suitable adjuvant.

**Identification**

Protects susceptible animals against infection with *Cl. chauvoei*.

---

**Mycoplasmas (2.7.9).** Complies with the test for mycoplasmas.

**Safety.** Inject 10 times the dose by the route stated on the label into each of 10 healthy chickens free from specific antibodies (2.7.7) to 10 days old. Use five healthy chickens from the same source and stock as controls. Observe the birds for 21 days. Not more than one of the vaccinated chickens shows symptoms of or dies from infectious bronchitis. The test is not valid unless all the control chickens are free of clinical symptoms of infectious bronchitis. If during the period of observation more than 2 of the vaccinated chickens die from causes not attributable to the vaccine, repeat the test.

**Sterility (2.2.11).** Complies with the test for sterility.

**Virus titre.** Titrate the vaccine in cell cultures derived from SPF embryos by inoculating into the allantoic sac of SPF embryonated eggs, 9 to 11 days old. One dose of the vaccine contains not less than \(10^{3.5}\) TCID\(_{50}\)/EID\(_{50}\).

**Immunogenicity.** Carry out a test for each route of administration recommended on the label and for each serotype against which protection is claimed. Administer to each of 20 healthy chickens, free from specific antibodies (2.7.7) 3 to 4 weeks old, for each of the stated routes a volume of reconstituted vaccine containing a quantity of virus equivalent to the minimum titre stated on the label. Ten additional healthy chickens of same flock for each serotype against which protection is claimed are used as unvaccinated controls. Three to four weeks later, administer by eye drop a virulent strain of bronchitis virus with a titre of at least \(10^{3.5}\) EID\(_{50}\)/ml to all the vaccinated and control birds. Between the fourth and seventh day after the challenge, take tracheal swabs from each of the vaccinated and control birds. Place each swab in a sterile test tube containing 3 ml of tryptose phosphate broth and antibiotics. Swirl thoroughly the tubes and swabs and store at 70° pending inoculation into eggs. For each chicken swab, inoculate at least 5 chicken embryos, 9 to 11 days old, with 0.2 ml of the broth from each tube into the allantoic cavity. All the embryos surviving on the third day after inoculation are used in the evaluation. A tracheal swab is considered positive for recovery of the virus if any of the embryos shows typical infectious bronchitis lesions such as stunting, curling, kidney urates, clubbing down or death between the fourth and seventh day after inoculation. The vaccine complies with the test if not less than 80 per cent of the controls and not more than 20 per cent of the vaccinated chickens are positive for virus recovery. If less than 80 per cent of the vaccinated chickens are negative for virus recovery the stock seed is unsatisfactory. The stock seed virus may be tested for immunogenicity once in 5 years provided it is maintained under standard conditions of storage of the bronchitis virus.

**Labelling.** The label states (1) strain of virus used; (2) recommended age for vaccination.

---

**Avian Spirochaetosis Vaccine**

Avian Spirochaetosis Vaccine is a suspension prepared from viscera and membranes of developing chicken embryos of SPF eggs infected with antigenic strains of *Borrelia anserina* which has been inactivated in such a manner that its immunogenic activity is retained.

**Production**

The organism is grown in embryonated eggs derived from SPF flocks (2.7.7).

**Identification**

Protects chickens against infection with *B. anserina*.

**Tests**

**Safety.** Complies with the requirement stated under Veterinary Vaccine.

**Sterility (2.2.11).** Complies with the test for sterility.

**Potency.** Inject at least twelve healthy chicken, free from antibodies, 8 to 12 weeks old, with the minimum dose of the vaccine by the route stated on the label. Use five chickens of the same stock as controls. Ten days later challenge all the chickens intraperitoneally with an adequate dose of a virulent culture of *B. anserina* used to prepare the vaccine or with a suspension of liver or kidney tissue obtained from infected chicken. Observe the chickens for 10 days. The vaccinated chickens do not show any symptoms of the disease. The test is not valid unless the control chickens show typical symptoms of spirochaetosis.

If the potency test has been performed with satisfactory results on representative batch of the vaccine from the same seed lot, it may be omitted as a routine control test during production of other batches of the vaccine prepared from the same seed lot.

**Labelling.** The label states (1) strain of virus used; (2) recommended age for vaccination.

---

**Blackquarter Vaccine**

Blackquarter Vaccine is a culture of suitable strain or strains of *Clostridium chauvoei* grown in a suitable anaerobic fluid medium and rendered sterile and non-toxic by addition of solution of *formaldehyde* in such a manner that it retains its immunizing properties. The vaccine may contain a suitable adjuvant.

**Identification**

Protects susceptible animals against infection with *Cl. chauvoei*. 
**Tests**

**Safety.** Use two healthy susceptible animals of one of the species for which the vaccine is intended. Inject into each animal by the recommended route twice the maximum dose stated on the label. Observe the animals for 7 days. No significant local or systemic reaction is produced.

**Sterility (2.2.11).** Complies with the test for sterility.

**Potency.** Inject ten healthy adult guinea pigs weighing between 350 and 450 g with a quantity of the product not greater than the minimum dose and route as stated on the label. Repeat the inoculation with the same dose of the vaccine after 28 days. None of the vaccinated guinea pigs shows any systemic reaction. However a minimal local reaction may be observed in the animal.

Fourteen days after the second vaccination, inoculate intramuscularly into each of 10 vaccinated and into each of 5 control guinea pigs with a suitable quantity of virulent culture or spore suspension of Cl. Chauvoei, activated if necessary, with the solution of calcium chloride.

The vaccine complies with the test, if not more than 10 per cent of the vaccinated guinea pigs die from Cl. chauvoei infection within 5 days and all the control animals die from Cl. chauvoei infection within 48 hours of challenge if virulent culture was used or within 72 hours if a spore suspension was used for the challenge. Repeat the test if 20 per cent of the vaccinated animals die.

On repetition, the vaccine complies with the test if not more than 10 per cent of the vaccinated animals die from Cl. chauvoei infection within 5 days and all of the control animals die within 21 days after the second injection collect serum from each dog separately and examine each sample as described below.

Inactivate the serum by heating at 56° for 30 min and prepare serial dilutions in a suitable medium. Add to each dilution an equal volume of serum-virus suspension containing approximately $10^2$ TCID$_{50}$. Incubate the mixtures for 1 hour at 37°. Add suitable cell culture with minimum of four replicates for each dilution and incubate at 37° for 4 to 8 days. Examine each culture for evidence of specific cytopathic effect. Calculate the antibody titre. The serum from each dog contains not less than 80 SN$_{50}$ per ml.

**Labelling.** The label states (1) the strain used for the preparation; (2) the name of any added adjuvant.

**Identification**

When injected into a susceptible dog, the animal develops specific neutralizing antibodies.

**Tests**

**Water (2.3.43).** Not more than 3.0 per cent (for freeze dried vaccine only).

**Safety.** Inject each of two healthy dogs, between 8 and 14 weeks old, that have been previously tested and shown to be free from canine adenovirus neutralizing antibodies, with twice the dose and by the route stated on the label. Observe the animals for 14 days. No abnormal systemic or local reaction occurs.

**Sterility (2.2.11).** Complies with the test for sterility.

**Potency.** Inject each of two healthy susceptible dogs, between 8 and 14 weeks old, that have been previously tested and shown to be free from canine adenovirus neutralizing antibodies, with the minimum dose and by the route stated on the label. After 14 days inject a second dose. Between 14 and 21 days after the second injection collect serum from each dog separately and examine each sample as described below.

Inactivate the serum by heating at 56° for 30 min and prepare serial dilutions in a suitable medium. Add to each dilution an equal volume of serum-virus suspension containing approximately $10^2$ TCID$_{50}$. Incubate the mixtures for 1 hour at 37°. Add suitable cell culture with minimum of four replicates for each dilution and incubate at 37° for 4 to 8 days. Examine each culture for evidence of specific cytopathic effect. Calculate the antibody titre. The serum from each dog contains not less than 80 SN$_{50}$ per ml.

**Labelling.** The label states (1) the strain used for the preparation; (2) the name of any added adjuvant.

**Canine Contagious Hepatitis Vaccine, Inactivated**

Canine Contagious Hepatitis Vaccine, Inactivated is a preparation containing canine contagious hepatitis virus inactivated in such a manner that its immunogenic activity is retained. It may be a freeze-dried preparation or a liquid preparation containing a suitable adjuvant.

**Production**

The virus is propagated in suitable cell culture systems, the viral suspension is harvested, titrated and may contain a suitable stabilizing solution.

**Canine Contagious Hepatitis Vaccine, Live**

Canine Contagious Hepatitis/Canine Adenovirus Vaccine is a freeze dried preparation containing one or more attenuated strains of canine adenovirus.

**Production**

The virus is propagated in a suitable cell cultures, harvested, titrated and may be mixed with a suitable stabilizing solution. The stock seed virus should be tested for immunogenicity at least once in 5 years, if maintained under suitable conditions of storage.
Identification

The vaccine, mixed with one or more specific antisera of canine adenovirus(s), does not produce specific cytopathic effects in susceptible cell cultures.

Tests

Water (2.3.43). Not more than 3.0 per cent.

Virus titre. Not less than $10^3$ TCID$_{50}$ virus per dose, determining the titre of the vaccine in a suitable cell culture.

Safety. Inject each of two susceptible dogs, between 8 and 14 weeks old, that have been previously tested and shown to be free from canine adenovirus neutralising antibodies, with twice the dose and by the route stated on the label. Observe the animals for 21 days. No abnormal systemic or local reaction occurs.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Inject five healthy susceptible dogs, between 8 and 14 weeks old, that have been previously tested and shown to be free from canine adenovirus neutralizing antibodies, with a quantity of the vaccine equivalent to the minimum titre and by the route stated on the label. Observe the animals for 21 days. Inject intravenously each of the five vaccinated animals and each of two control animals of the same stock and weight range with a quantity of a virulent strain of canine contagious hepatitis virus sufficient to cause death or typical signs of the disease in a susceptible dog. Observe the animals for a further period of 21 days. The vaccinated animals remain in normal health and the controls die from hepatitis or show typical signs of serious infection. If one of the controls does not show any signs of the disease, repeat the test. The vaccinated animals of the second group remain in normal health and the control animals die from hepatitis or show typical signs of serious infection.

If the potency test has been performed with satisfactory results on a representative batch of the vaccine from the seed lot, it may be omitted as a routine control test during production on other batches of the vaccine prepared from the same seed lot.

Labelling. The label states (1) the minimum virus titre; (2) the species of the animals in which use of the vaccine is recommended.

Canine Corona Virus Vaccine, Inactivated

Canine Corona Virus Vaccine, Inactivated is a preparation containing canine corona virus inactivated in such a manner that its immunogenic activity is retained. It may be issued as a liquid or as a freeze-dried preparation to be reconstituted with a suitable liquid immediately before use. The liquid vaccine may contain a suitable adjuvant.

Production

The virus is grown in suitable cell cultures systems. The vaccine may contain a suitable adjuvant. Only an inactivated viral suspension that complies with the requirements mentioned under final bulk vaccine of each batch is used in the preparation of the final vaccine.

Identification

When inoculated into dogs, the vaccine stimulates the production of specific neutralizing antibodies against canine corona virus as determined by suitable serological tests.

Tests

Water (2.3.43). Not more than 3.0 per cent (for freeze dried vaccine only).

Safety. Inject each of two healthy susceptible dogs, between 8 and 14 weeks old, free from canine corona virus antibodies with a quantity equivalent to 2 doses by the route stated on the label. Observe the animals for 14 days. No abnormal systemic or local reaction occurs.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Either of the test A or B may be carried out.

A. Inject each of five healthy susceptible guinea pigs, each weighing between 350 and 400 g, with half the minimum dose and by the route stated on the label. Repeat the injection after 14 days. Fourteen days after the second injection collect blood samples and obtain the serum from each guinea pig separately. Inactivate each serum by heating at 56° for 30 min. Examine the serum samples for antibodies by the following method. Prepare 2-fold serial dilutions of serum in a medium suitable for canine cells. Add to each dilution an equal volume of a virus suspension containing approximately $10^2$ TCID$_{50}$ and incubate the mixtures at 37° for 1 hour. Inoculate a suitable volume of canine cells into at least 4 replicates of serum virus mixtures and incubate at 37° for 4 days. Examine for evidence of specific cytopathic effects and calculate the antibody titre. The vaccine complies with the test if the mean antibody titre is not less than 32 SN$_{50}$ per 0.05 ml of serum.

B. Inject each of two healthy susceptible dogs, between 8 and 14 weeks old, having antibody titre less than 4 SN$_{50}$ per 0.05 ml of serum, with the dose and by the route recommended on the label. Fourteen days later collect the serum samples from each dog separately. Inactivate each serum by heating at 56° for 30 min. Examine the serum samples for antibodies by the following method. Prepare 2-fold serial dilutions of serum in a medium suitable for canine cells. Add to each dilution an equal volume of a virus suspension containing approximately $10^2$ TCID$_{50}$ and incubate the mixtures at 37° for 1 hour. Inoculate a suitable volume of canine cells into at least 4 replicates of serum virus mixtures and incubate at 37° for 4 days. Examine for evidence of specific cytopathic effects and calculate the antibody titre. The vaccine complies with the test if the mean antibody titre is not less than 32 SN$_{50}$ per 0.05 ml of serum.
for 30 min. Examine the serum samples individually for neutralizing antibodies by the method described in test A.
If one dog fails to respond, i.e., the antibody titre is less than 4 SN_{50} per 0.05 ml of serum, repeat the test with two more dogs and calculate the mean titres of the three dogs that have responded. The vaccine complies with the test if the median antibody titre of the sera is not less than 32 SN_{50} per 0.05 ml.

Labelling. The label states (1) the recommended routes of administration; (2) that the preparation should be shaken well before use; (3) that the liquid preparation should not be allowed to freeze; (4) that the vaccine should be used immediately after reconstitution.

Canine Distemper Vaccine, Live

Canine Distemper Vaccine, Live is a freeze-dried preparation of a strain of canine distemper virus that has been attenuated for dogs and is grown either in SPF embryonated eggs or in suitable cell cultures.

Production

The virus is propagated in suitable cell culture systems, the viral suspension is harvested, titrated and may contain a suitable stabilizing solution. The stock seed virus should be tested for potency at least once in 5 years, if maintained under suitable conditions of storage.

Identification

A. The vaccine infects the chorio-allantoic membranes of SPF embryonated eggs or suitable cell cultures. This effect is neutralized by canine distemper antiserum.

B. An injection into susceptible ferrets or dogs does not cause distemper but immunizes them against the disease. The vaccine strain is satisfactory with respect to absence of increase in virulence.

Tests

Water (2.3.43). Not more than 3.0 per cent.

Virus titre. Not less than 10^6 EID_{50}/TCID_{50} of the virus per dose, determining the titre of the vaccine in a suitable cell culture or SPF eggs (2.7.7).

Extraneous pathogens

A. Mix the vaccine under examination with a mono specific distemper antiserum. It no longer provokes cytopathic effects in susceptible cell cultures and shows no evidence of haemagglutinating or haemadsorbing agents.

B. Use a sufficient number of mice, not less than ten, each weighing between 11 and 15 g, such that a total of three-tenths of the dose of the vaccine is injected. Inject each mouse intracerebrally with 0.03 ml of the vaccine. Observe for 21 days. Not more than two mice die within the first 48 hours. If more than two mice die within the first 48 hours, repeat the test. From the third day to 21 days after the injection, the mice do not show any abnormalities attributable to the vaccine.

Mycoplasmas (2.7.8). Complies with the test for freedom from mycoplasmas.

Safety. Reconstitute the vaccine as recommended on the label and carry out the following tests.

A. For chicken embryo-adapted vaccine only. Inject 0.3 ml intracerebrally into each of a group of eight mice, between 3 and 4 weeks old, and 0.5 ml intraperitoneally into each of another eight mice of the same age group.

Observe both the groups for 7 days. Not more than one mouse in either group shows any abnormal local or systemic reaction attributable to the vaccine.

B. Inject each of two susceptible dogs, between 8 and 14 weeks old which do not have antibodies against canine distemper virus with twice the dose and by the route stated on the label. Observe the animals for 21 days. None of the dogs shows any abnormal local or systemic reaction.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Inject each of five susceptible dogs, between 8 and 14 weeks old, that have been previously tested and shown to be free from distemper virus neutralizing antibodies with a volume of the reconstituted vaccine containing a quantity of the virus equivalent to the minimum titre and by the route stated on the label. Use another two dogs of the same stock and age group as unvaccinated controls. Observe the animals for 21 days. Inject intravenously each of the seven animals with a quantity of virulent strain of canine distemper virus sufficient to cause death or produce typical signs of the disease in a susceptible dog. Observe the animals for a further 21 days. The vaccinated animals survive and show no clinical signs of canine distemper. The test is not valid unless the control dogs die or show symptoms typical of canine distemper.

If the potency test has been performed with satisfactory results on a representative batch of the vaccine from the seed lot, it may be omitted as a routine control test during production on other batches of the vaccine prepared from the same seed lot.

Labelling. The label states (1) the strain used for the preparation; (2) virus titre per dose.
Canine Parainfluenza Virus Vaccine, Live

Canine Parainfluenza Virus Vaccine, Live is a freeze-dried preparation of tissue culture fluid containing the cell culture-adapted attenuated canine parainfluenza virus of stock seed which has been established as pure, safe and immunogenic.

Production

The virus is propagated in suitable cell culture systems, the viral suspension is harvested, titrated and may contain a suitable stabilizing solution.

Identification

When inoculated into dogs, the vaccine stimulates the production of specific neutralizing antibodies against canine parainfluenza virus as determined by suitable serological tests.

Tests

Water (2.3.43). Not more than 3.0 per cent.

Virus titre. Not less than $10^3$ TCID$_{50}$ per dose, determining the titre of the vaccine in a suitable cell culture.

Safety. Inject each of two susceptible dogs, between 8 and 14 weeks old, free from canine parainfluenza virus haemagglutinating antibodies with a dose of the vaccine reconstituted with the sterile diluent equivalent to 10 times the dose and by the route stated on the label. Observe the animals for 14 days. None of the dogs shows any systemic or local reactions.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Use two healthy susceptible dogs, between 8 and 14 weeks old, having haemagglutination inhibition antibody titres less than 1:4 per 0.1 ml of serum. Keep equal number of dogs as unvaccinated controls. Vaccinate each test group dog with the vaccine as per schedule stated on the label. After 21 days, collect the serum from each dog separately and examine each sample as described below. Heat the serum of each animal at $56^\circ$ for 30 minutes and prepare serial dilutions with saline solution. To 0.025 ml of each dilution add 0.025 ml of a canine parainfluenza virus suspension containing 4 haemagglutinating units. Allow the mixture to stand at room temperature for 30 minutes and add 0.05 ml of a suspension of chicken erythrocytes containing $2 \times 10^8$ erythrocytes per ml. Allow to stand for 1 hour and note the last dilution of serum that completely inhibits haemagglutination. Calculate the median antibody titre of the sera which should not be less than 1:32 per 0.1 ml of the serum. If one dog fails to respond, repeat the test using two more dogs and calculate the result as the mean of titres obtained from all of three dogs that have responded which is not less than 1 :32 per 0.1 ml of the serum.

If the potency test has been performed with satisfactory results on a representative batch of the vaccine it may be omitted as a routine test during production on the other batches of vaccine prepared from the same seed lot.

Labelling. The label states (1) the strain used for the preparation; (2) the virus titre per dose.

Canine Parvovirus Vaccine, Inactivated

Canine Parvovirus Vaccine, Inactivated is a liquid or freeze dried preparation of canine parvovirus inactivated by a suitable method so that its immunogenic activity is retained.

Production

The virus is grown in suitable cell culture systems. The virus may be cloned, purified and concentrated. The vaccine may contain a suitable adjuvant.

Identification

When inoculated into dogs, the development of specific neutralizing antibodies against canine parvovirus can be demonstrated by suitable serological tests.

Tests

Safety. Inject into each of two healthy susceptible dogs, between 8 and 14 weeks old, preferably sero negative ones with a quantity equivalent to 2 doses by the route stated on the label. Observe the animals for 14 days. No abnormal systemic or local reaction occurs.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Either of the test A or B may be carried out.

A. Inject subcutaneously each of five healthy susceptible guinea-pigs, each weighing between 350 and 400g, with half of the dose stated on the label. After 14 days, inject again half of the dose stated on the label. Fourteen days after the second injection collect blood samples and obtain the serum from each guinea pig separately. Inactivate each serum by heating at $56^\circ$ for 30 min. To 1 volume of each serum add 9 volumes of a 20 per cent suspension of light kaolin in phosphate buffered saline pH 7.4. Shake the mixture for 20 minutes and centrifuge at 2,000 rpm for 10 minutes. Collect the supernatant liquid and mix with 1 volume of a concentrated suspension of Rhesus monkey/pig erythrocytes. Allow the mixture to stand at 4$^\circ$ for 60 minutes and centrifuge at 2,000 rpm for 10 minutes and collect the supernatant serum obtained in 10-fold dilution. Using each serum, prepare a series of 2-fold dilutions. To 0.025 ml of each of the latter dilutions add 0.025 ml of a
suspension of canine parvovirus antigen containing approximately 8 haemagglutinating (HA) units and allow to stand at 37° for 30 minutes. Add 0.05 ml or other suitable quantity of a 1 per cent suspension of Rhesus monkey/pig erythrocytes containing 30 x 10⁶ cells per ml to at least four replicates of each dilution. Allow to stand at 4° for 90 minutes and note the last dilution of the serum that completely inhibits haemagglutination. The vaccine complies with the test if the median antibody titre of the sera is not less than 1:80.

B. Inject each of two healthy susceptible dogs, between 8 and 14 weeks old, having antibody titres less than 4 ND₅₀ (50 percent neutralizing dose) per 0.1 ml of serum, with the dose and by the route recommended on the label. Fourteen days later collect the blood/serum samples from each dog separately. Inactivate each serum by heating at 56° for 30 min. Examine the serum samples individually for neutralizing antibodies as follows:

Prepare 2-fold serial dilutions of serum in a medium suitable for canine cells. Add to each dilution an equal volume of virus suspension containing approximately 10⁴ TCID₅₀ and incubate the mixtures at 37° for one hour. Inoculate a suitable volume of canine cells into at least four replicates of serum virus mixtures and incubate at 37° for 7 days. Examine for evidence of specific cytopathic effects and calculate the antibody titre. The vaccine complies with the test if the mean antibody titre is not less than 32 ND₅₀ per 0.1 ml of serum. If one dog fails to respond repeat the test using two more dogs and calculate the mean titres of the three dogs that have responded.

Labelling. The label states (1) the method of preparation; (2) the types and strains of virus used to prepare the vaccine.

Canine Parvovirus Vaccine, Live

Canine Parvovirus Vaccine, Live is a freeze-dried preparation of a strain of canine parvovirus that is attenuated for the target species of dogs.

Production

The attenuated virus is grown in suitable cell culture systems. The viral harvest is titrated and mixed with a suitable stabilizing solution. The stock seed virus should be tested for immunogenicity at least once in 5 years, if maintained under suitable conditions of storage.

Identification

When inoculated into dogs, the development of specific neutralizing antibodies against canine parvovirus can be demonstrated by suitable serological tests.

Tests

Water (2.3.43). Not more than 3.0 per cent.

Virus titre. Not less than 10⁶ TCID₅₀ per dose, determining the titre of the vaccine in a suitable cell culture.

Safety. Inject each of two susceptible dogs, between 8 and 14 weeks old, free from canine parvovirus haemagglutinating antibodies, a quantity of the vaccine reconstituted with the sterile diluent equivalent to 10 times the dose and by the route stated on the label. Observe the animals for 21 days. No abnormal systemic or local reaction occurs.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Inject each of seven dogs, between 8 and 14 weeks old, free from canine parvovirus haemagglutinating antibodies, subcutaneously with the minimum dose stated on the label. Use two dogs of the same stock, weight and age range as controls. Not less than 21 days after injection of the vaccine, challenge the vaccinated and control animals through the oronasal route with a virulent strain of infectious canine parvovirus. Observe the animals for 14 days. Not less than five of the vaccinated dogs survive. The test is not valid unless the control dogs die or show clinical signs of canine parvovirus infection.

If the potency test has been performed with satisfactory results on a representative batch of the vaccine it may be omitted as a routine test during production of the other batches of vaccine prepared from the same seed lot.

Labelling. The label states (1) the strain used for the preparation; (2) virus titre per dose.

Clostridium Multicomponent Vaccine, Inactivated

Clostridium Multicomponent Vaccine, Inactivated consists of five highly antigenic components containing the toxoids of *C. perfringens* type ‘B’, *C. perfringens* type ‘C’, *C. perfringens* type ‘D’, *C. oedematiens* and *C. septicum* which are prepared in double strength and then combined in such a proportion that would invoke adequate anti-toxin response in the vaccinated sheep against each antigen incorporated in the vaccine.

Identification

When injected into susceptible animals, it stimulates the production of epsilon and beta antitoxin against *C. perfringens* types ‘B’, ‘C’ and ‘D’ and also antitoxins against *C. septicum* and toxin of *C. oedematiens*.

Tests

Safety. Four sheep each are inoculated with two times the dose of vaccine subcutaneously and are observed for 7 days.
during which period the animals do not show any local or systemic reaction.

**Sterility** (2.2.11). Complies with the test for sterility.

**Potency.** Eight sheep each are inoculated with 2 doses of vaccine subcutaneously at an interval of 21 to 28 days and bled on 10th day after second inoculation for collection of serum for assessing the antitoxin titre against each antigen incorporated in the vaccine. The post-inoculation serum contains not less than 2 IU of epsilon antitoxin and 10 units of beta antitoxins of C. perfringens types ‘B’ and ‘C’ and 2.5 IU of C. septicum antitoxin and 3.5 IU of C. oedematiens antitoxin.

**Labelling.** The label states (1) the types of Clostridia contained in the vaccine; (2) the preparation should be shaken before use.

### CLOSTRIDIUM NOVYI (TYPE B) VACCINE FOR VETERINARY USE

*Clostridium novyi* (Type B) Vaccine for Veterinary Use is prepared from a liquid culture of a suitable strain of *Clostridium novyi* type B.

**Production**

The whole culture or its filtrate or a mixture of the two is inactivated in such a manner that toxicity is eliminated and immunogenic activity is retained. Toxoids and/or inactivated cultures may be treated with a suitable adjuvant, after concentration if necessary.

**Choice of vaccine composition.** The vaccine is shown to be satisfactory with respect to safety and efficacy (2.7.12). For the latter, it shall be demonstrated that for each target species the vaccine, when administered according to the recommended schedule, stimulates an immune response (for example, induction of antibodies) consistent with the claims made for the product.

**Batch testing**

**Safety.** Administer by a recommended route, to each of 2 sheep that have not been vaccinated against *C. novyi* type B twice the maximum dose of the vaccine stated on the label. Observe the animals for not less than 14 days. No abnormal local or systemic reaction occurs.

**Residual toxicity.** Inject 0.5 ml of the vaccine subcutaneously into each of 5 mice, each weighing between 17 and 22 g. Observe the animals for 7 days. No abnormal local or systemic reaction occurs.

**Identification**

The vaccine stimulates the formation of *C. novyi* type ‘B’ alpha antitoxin when injected into animals.

**Tests**

**Sterility** (2.2.11). Complies with the test for sterility.

**Potency.** Inject subcutaneously into each of not less than 10 healthy rabbits, 3 to 6 months old, a quantity of vaccine not exceeding the minimum dose stated on the label as the first dose. After 21 to 28 days, inject into the same animals a quantity of the vaccine not exceeding the minimum dose stated on the label as the second dose. 10 to 14 days after the second injection, bleed the rabbits and pool the sera. The alpha antitoxin titre of the pooled sera is not less than 3.5 IU per ml.

The International Unit is the specific neutralising activity for *C. novyi* alpha antitoxin contained in a stated amount of the International standard, which consists of a quantity of dried immune horse serum. The equivalence in International Units of the International standard is stated by the World Health Organisation.

The potency of the pooled sera obtained from the rabbits is determined by comparing the quantity necessary to protect mice or other suitable animals against the toxic effects of a fixed dose of *C. novyi* alpha antitoxin with the quantity of a reference preparation of *Clostridium novyi* alpha antitoxin, calibrated in International Units, necessary to give the same protection. For this comparison, a suitable preparation of *C. novyi* alpha antitoxin for use as a test toxin is required. The dose of the test toxin is determined in relation to the reference preparation; the potency of the serum under examination is determined in relation to the reference preparation using the test toxin.

**Preparation of test toxin.** Prepare the test toxin from a sterile filtrate of an approximately 3 to 5 day culture in liquid medium of *C. novyi* type B and dry by a suitable method. Select the test dose of the toxin in mice by determining the L+10 dose and the LD50 of the observation period being 72 hours. A suitable alpha toxin contains not less than one L+/10 dose in 0.05 mg and not less than 10 LD50 in each L+/10 dose.

**Determination of test dose of toxin.** Prepare a solution of the reference preparation in a suitable liquid so that it contains 1 IU per ml. Prepare a solution of the test toxin in a suitable liquid so that 1 ml contains a precisely known amount such as 1 mg. Prepare mixtures of the solution of the reference preparation and the solution of the test toxin such that each mixture contains 1.0 ml of the solution of the reference preparation (1 IU), one of a series of graded volumes of the solution of the test toxin and sufficient of a suitable liquid to bring the total volume to 2.0 ml. Allow the mixtures to stand at room temperature for 60 min. Using not less than 2 mice, each weighing between 17 and 22 g, for each mixture, inject a dose of 0.2 ml subcutaneously into each mouse. Observe the mice for 72 hours. If all the mice die, the amount of toxin present in
0.2 ml of the mixture is in excess of the test dose. If none of the
mice dies, the amount of toxin present in 0.2 ml of the mixture
is less than the test dose. Prepare fresh mixtures such that
2.0 ml of each mixture contains 1.0 ml of the solution of the
reference preparation (1 IU) and one of a series of graded
volumes of the solution of the test toxin separated from each
other by steps of not more than 20 per cent and covering the
expected end-point. Allow the mixtures to stand at room
temperature for 60 min. Using not less than two mice for each
mixture, inject a dose of 0.2 ml subcutaneously into each mouse.
Observe the mice for 72 hours. Repeat the determination at
least once and combine the results of the separate tests that
have been made with mixtures of the same composition so
that a series of totals is obtained, each total representing the
mortality due to a mixture of a given composition.

The test dose of toxin is the amount present in 0.2 ml of that
mixture which causes the death of one half of the total number
of mice injected with it.

**Determination of the potency of the serum obtained from
rabbits**

*Preliminary test.* Dissolve a quantity of the test toxin in a
suitable liquid so that 1 ml contains 10 times the test dose
(solution of the test toxin). Prepare a series of mixtures of the
solution of the test toxin and of the serum under examination
such that each mixture contains 1.0 ml of the solution of the
test toxin, one of a series of graded volumes of the serum
under examination and sufficient of a suitable liquid to bring
the final volume to 2.0 ml. Allow the mixtures to stand at room
temperature for 60 min. Using not less than 2 mice for each
mixture, inject a dose of 0.2 ml subcutaneously into each mouse.
Observe the mice for 72 h. If none of the mice dies, 0.2 ml of
the mixture contains more than 0.1 IU. If all the mice die, 0.2 ml
of the mixture contains less than 0.1 IU.

*Final test.* Prepare a series of mixtures of the solution of the
test toxin and of the serum under examination such that 2.0 ml
of each mixture contains 1.0 ml of the solution of the test toxin
and one of a series of graded volumes of the serum under
examination, separated from each other by steps of not more
than 20 per cent and covering the expected end-point as
determined by the preliminary test. Prepare further mixtures of
the solution of the test toxin and of the solution of the reference
preparation such that 2.0 ml of each mixture contains 1.0 ml of
the solution of the test toxin and one of a series of graded
volumes of the solution of the reference preparation, in order
to confirm the test dose of the toxin. Allow the mixtures to
stand at room temperature for 60 min. Using not less than 2
mice for each mixture, proceed as described in the preliminary
test. The test mixture which contains 0.1 IU in 0.2 ml is that
mixture which kills the same or almost the same number of
mice as the reference mixture containing 0.1 IU in 0.2 ml. Repeat
the determination at least once and calculate the average of all
valid estimates. The test is valid only if the reference
preparation gives a result within 20 per cent of the expected
value.

The confidence limits (P = 0.95) have been estimated to be (a)
85 per cent and 114 per cent when 2 animals per dose are used;
b) 91.5 per cent and 109 per cent when 4 animals per dose are
used; (c) 93 per cent and 108 per cent when 6 animals per
dose are used.

**Labelling.** The label states (1) whether the product is a toxoid,
a vaccine prepared from a whole inactivated culture or a
mixture of the two; (2) that the preparation is to be shaken
before use; (3) for each target species, the immunising effect
produced (for example, antibody production, protection
against signs of disease or infection).

**Clostridium Perfringens Vaccine, Inactivated**

The vaccines contain cultures strains of *C. perfringens* type
B (Lamb Dysentery Vaccine), type C (Struck Vaccine) or type
D (Enterotoxaemia Vaccine; Pulpy Kidney Vaccine) or any
combination of these types.

**Production**

The organisms grown in an anaerobic medium, the whole
culture or their filtrates or a mixture of the two are inactivated
in such a manner that toxicity is eliminated and immunogenic
activity is retained. Toxoid and or inactivated cultures may
contain a suitable adjuvant.

**Batch testing**

**Safety.** Inject subcutaneously two healthy susceptible sheep
weighing about 18 kg each or two healthy susceptible rabbits
weighing between 1.5 and 2.0 kg each with twice the dose
stated on the label and observe for 7 days. No systemic or
local reaction is observed.

Observe the animals for 14 days. No abnormal local or systemic
reaction occurs.

**Residual toxicity.** Inject 0.5 ml of the vaccine subcutaneously
into each of 5 mice, each weighing 17 to 22 g. Observe the
animals for 7 days. No abnormal local or systemic reaction
occurs.

**Sterility (2.2.11).** Complies with the test for sterility.

**Potency**

*C. perfringens* Type B Vaccine. Inject subcutaneously into
each of six healthy susceptible sheep weighing about 18 kg or
ten healthy susceptible rabbits weighing between 1.5 and 2.0
The potency of \textit{Biological assay of C. perfringens antitoxins} separately and estimated for the antitoxin levels. The rabbits are inoculated with the same dose after one month. Repeat the dose after an interval of 21 to 28 days. Bleed the animals 10 to 14 days after the second dose of the vaccine and determine beta antitoxin titres in the pooled serum sample by testing in mice as per the method described for \textit{C. perfringens Type D Vaccine}. Product passes the test if the post-inoculation pooled serum contains not less than 10 IU of beta antitoxins, and not less than 5 IU of epsilon toxin per milliliter.

\textit{C. perfringens Type C Vaccine}. Carry out the test for potency as described for \textit{C. perfringens Type B Vaccine}.

1 ml of serum contains not less than 10 IU of beta antitoxin per ml.

\textit{C. perfringens Type D (Enterotoxaemia) Vaccine}. Carry out the test as described below.

1 ml of serum contains not less than 5 IU of \textit{C. perfringens} epsilon toxin per ml.

**Identification**

A. When injected into susceptible animals, the \textit{C. perfringens} Type B Vaccine stimulates the production of \textit{C. perfringens} beta and epsilon antitoxins.

B. When injected into susceptible animals, the \textit{C. perfringens} Type C Vaccine stimulates the production of \textit{C. perfringens} beta antitoxin.

C. When injected into susceptible animals, the \textit{C. perfringens} Type D Vaccine stimulates the production of \textit{C. perfringens} epsilon antitoxin.

**Tests**

**Potency test.** Inject subcutaneously into each of at least six healthy susceptible sheep weighing about 18 kg or ten healthy susceptible rabbits weighing between 2.0 and 2.5 kg with the minimum dose of the vaccine stated on the label. Repeat the dose in each sheep/rabbit after an interval of 21 to 28 days. The rabbits are inoculated with the same dose after one month of the first inoculation. Bleed the animals 10 to 14 days after the second inoculation. The sera of sheep or rabbits are pooled separately and estimated for the antitoxin levels.

**Biological assay of \textit{C. perfringens} antitoxins**

The potency of \textit{C. perfringens} beta and epsilon antitoxins is determined by comparing the dose of antitoxin necessary to protect mice or other suitable animals against the toxic effects of \textit{C. perfringens} beta toxin or epsilon toxin with the dose of a standard preparation of the respective antitoxin necessary to give the same protection. For this comparison, the Standard preparations of \textit{C. perfringens} beta antitoxin and \textit{C. perfringens} epsilon antitoxin and suitable preparations of \textit{C. perfringens} beta and epsilon toxins are required.

The test dose of each toxin is established in relation to the appropriate Standard preparation of antitoxin and the potency of antitoxin under examination is then determined in relation to the appropriate Standard preparation using the appropriate test toxin.

**International standard for the standard preparations**

The International units of the antitoxin is the specific neutralizing activity of \textit{C. perfringens} epsilon toxin contained in the stated amount in relation to International standards in the dried Horse serum.

The International units of the antitoxins is the specific neutralizing activity for the \textit{C. perfringens} beta toxin contained in the stated amount in relation to International standards in the dried Horse serum.

**Test animals**

Use healthy mice having body weights such that the difference between the lightest and heaviest is not more than 5 g.

**Suggested method for preparation of test toxin.** Prepare \textit{C. perfringens} toxins from sterile supernatants/filtrates of early cultures of \textit{C. perfringens} type B, type C or type D. The supernatants may be purified by precipitation with \textit{ammonium sulphate} and the resulting precipitate collected. This may then be dried over \textit{phosphorus pentoxide} at a pressure of 1.5 to 2.5 kPa, powdered and kept dry or re-dissolved and freeze-dried.

**Selection of test toxin.** Select toxin for use as the test toxin by determining the following quantities.

**\textit{L+} and \textit{L+}/10 doses.** These are the smallest quantities of toxin that when mixed respectively with 1 Unit of antitoxin and with 0.1 Unit of antitoxin and injected intravenously into mice cause the death of the animals within 72 hours.

**\textit{LD}_{50}.** This is the quantity of toxin that when injected intravenously into mice causes the death of one-half of the mice injected within 72 hours.

A suitable \textit{C. perfringens} beta toxin is one that has an \textit{L+} dose in 0.2 mg or less and contains not less than 25 \textit{LD}_{50} in an \textit{L+} dose.

A suitable \textit{Clostridium perfringens} epsilon toxin is one that has an \textit{L+}/10 dose in 0.005 mg or less and contains not less than 20 \textit{LD}_{50} in an \textit{L+}/10 dose.

**Determination of test dose of \textit{C. perfringens} beta toxin.** Dissolve a quantity of dried toxin in a suitable liquid such that 1.0 ml contains a precise amount such as 10 mg. Reconstitute the Standard preparation of \textit{C. perfringens} beta antitoxin with a suitable liquid to give a solution containing 5 Units of \textit{C. perfringens} beta antitoxin in 1 ml.
Prepare mixtures such that 5.0 ml of each mixture contains 2.0 ml of the solution of the Standard preparation (10 Units) and one of a series of graded volumes of the solution of the toxin. Dilute each mixture to the same final volume with a suitable liquid. Allow the mixtures to stand at room temperature, protected from light, for 30 minutes and then inject a dose of 0.5 ml of each mixture intravenously into each of not less than two mice. Observe the mice for 72 hours. If all the mice die, the amount of toxin present in 0.5 ml of the mixture is in excess of the test dose. If none of the mice dies, the amount of toxin present in 0.5 ml of the mixture is less than the test dose. Prepare similar fresh mixtures such that 5.0 ml of each mixture contains 2.0 ml of the solution of the Standard preparation (10 Units) and one of a series of graded volumes of the solution of the toxin, separated from each other by steps of not more than 20 per cent and covering the expected end-point.

Allow the mixtures to stand at room temperature, protected from light, for 30 minutes. Inject a dose of 0.5 ml of each mixture intravenously into each of not less than two mice. Observe the mice for 72 hours. Repeat the determinations at least once and add together the results of the separate tests that have been made with mixtures of the same composition such that a series of totals is obtained, each total representing the mortality due to a mixture of a given composition.

The test dose of toxin is the amount present in 0.5 ml of that mixture that causes the death of one-half of the total number of mice injected with it within 72 hours.

**Determination of test dose of C. perfringens epsilon toxin.**

Carry out the method described for the determination of test dose of C. perfringens beta toxin with the following modification. Dissolve a quantity of dried toxin in a suitable liquid such that 1.0 ml contains a precise amount such as 1 mg.

Reconstitute the Standard preparation of C. perfringens epsilon antitoxin with a suitable liquid to give a solution containing 0.5 Unit in 1 ml (the prepared mixtures will therefore contain 1 Unit of the Standard preparation in 5 ml).

The test dose of toxin is the amount present in 0.5 ml of that mixture that causes the death of one-half of the total number of mice injected with it within 72 hours.

**Determination of potency of C. perfringens beta antitoxin**

*Preliminary test.* Dilute the test toxin with a suitable liquid such that 2.0 ml contains 10 times the test dose. Prepare mixtures such that 5.0 ml of each mixture contains 2.0 ml of the solution of the toxin and one of a series of graded volumes of the preparation under examination. Adjust each mixture to the same final volume with a suitable liquid. Allow the mixtures to stand at room temperature, protected from light, for 30 minutes. Inject a dose of 0.5 ml of each mixture intravenously into each of not less than two mice and observe the mice for 72 hours. If all the mice die, 0.5 ml of the mixture contains less than 1 Unit of antitoxin. If none of the mice dies 0.5 ml of the mixture contains more than 1 Unit of antitoxin.

*Final test.* Prepare similar fresh mixtures such that 5.0 ml of each mixture contains 2.0 ml of the solution of the toxin and one of a series of graded volumes of the preparation under examination, separated from each other by steps of not more than 20 per cent and covering the expected end-point. Prepare further mixtures of 5.0 ml containing 2.0 ml of the solution of the toxin and graded volumes of the Standard preparation of C. perfringens beta antitoxin to confirm the test dose of the toxin. Allow the mixtures to stand at room temperature, protected from light, for 30 minutes. Inject a dose of 0.5 ml of each mixture intravenously into each of not less than two mice and observe the mice for 72 hours. The mixture of the antitoxin under examination which contains 1 Unit of C. perfringens beta antitoxin in 0.5 ml is that mixture which causes the death of the same or almost the same number of mice as the mixture containing 1 Unit of the Standard preparation of C. perfringens beta antitoxin in 0.5 ml. Repeat the determinations at least once and calculate the average of all valid estimates. Estimates are not valid unless the Standard preparation gives a result within 20 per cent of the expected value.

**Determination of potency of C. perfringens epsilon antitoxin.**

Carry out the preliminary test and final test as described for the determination of potency of C. perfringens beta antitoxin with the following amendments.

Dilute a quantity of the test toxin in a suitable liquid such that 2.0 ml contains 10 times the test dose. The Standard preparation used in these tests is that of C. perfringens epsilon antitoxin.

The mixture of the antitoxin under examination which contains 0.1 Unit of C. perfringens epsilon antitoxin in 0.5 ml is that mixture which causes the death of the same or almost the same number of mice as the mixture containing 0.1 Unit of the Standard preparation of C. perfringens epsilon antitoxin in 0.5 ml.

**Limits of error.** For the suggested method, the limits of error (P = 0.95) have been estimated to be 85 to 114 per cent when two mice are used per dose, 91.5 to 109 per cent when four mice are used per dose, and 93 to 108 per cent when six mice are used per dose.

**Labelling.** The label states (a) the type or types of C. perfringens from which the vaccine has been prepared; (b) whether the preparation is a toxoid or a vaccine prepared from a whole inactivated culture or a mixture of the two; (c) that the preparation is to be shaken before use; (d) for each target species, the immunising effect produced (for example, antibody production, protection against signs of disease or infection).
**Clostridium Septicum Vaccine**

Clostridium Septicum Vaccine is a suspension of a culture of a highly toxigenic strain of *C. septicum* grown in an anaerobic medium, or a filtrate from such a culture.

**Production**

The whole culture or its filtrate or a mixture of the two is inactivated in such a manner that toxicity is eliminated and immunogenic activity is retained. Toxoid and/or inactivated cultures may be treated with a suitable adjuvant.

**Batch testing**

**Residual toxicity.** Inject 0.5 ml of the vaccine subcutaneously into each of 5 mice, each weighing between 17 and 22 g. Observe the animals for 7 days. No abnormal local or systemic reaction occurs.

**Sterility** (2.2.11). Complies with the test for sterility.

**Potency.** Inject subcutaneously each of eight healthy susceptible sheep, between 8 and 12 months old, or ten rabbits, between 3 and 6 months old, with the minimum dose of the vaccine stated on the label. Repeat the dose after an interval of 21 to 28 days. Ten days after the second inoculation, bleed the animals. Pool the sera samples from individual animals and determine the antitoxin titre by the biological assay of *C. septicum* antitoxin described below.

1 ml of serum contains not less than 2.5 Units of *C. septicum* antitoxin by biological assay of *C. septicum* antitoxin.

The potency of *Clostridium septicum* antitoxin is determined by comparing the dose of antitoxin necessary to protect mice or other suitable animals against the lethal effects of *Clostridium septicum* toxin with the dose of a Standard preparation of *Clostridium septicum* antitoxin necessary to give the same protection. For this purpose, the Standard preparation of *C. septicum* antitoxin and a suitable preparation of *C. septicum* toxin for use as a test toxin are required.

**Identification**

When injected into healthy susceptible animals, it stimulates the production of antitoxins to *C. septicum*.

**Tests**

The test dose of the toxin is determined in relation to the Standard preparation of antitoxin and the potency of antitoxin under examination is then determined in relation to the Standard preparation using the test toxin.

**Assay**

**Standard preparation**

The Standard preparation is the 3rd International standard, established in 1957, consisting of dried hyperimmune horse serum (supplied in ampoules containing 500 Units) or another suitable preparation the potency of which has been determined in relation to the International standard.

**Safety.** Inject subcutaneously each of two healthy susceptible sheep, between 8 and 12 months old, with twice the dose stated on the label. Observe the animals for 7 days; none of the animals shows any systemic or local reaction. Observe the animals for 14 days.

**Test animals.** Use healthy mice having body weights such that the difference between the lightest and heaviest is not more than 5 g.

**Preparation of test toxin.** Prepare *C. septicum* toxin by growing *C. septicum* in a liquid culture medium, filtering the supernatant aseptically and precipitating with *ammonium sulphate*. The resulting precipitate, which contains the toxin, is collected, dried over *phosphorus pentoxide* at a pressure of 1.5 to 2.5 kPa, powdered and kept dry.

**Selection of test toxin.** Select toxin for use as the test toxin by determining the following quantities.

**L+1/5 dose.** This is the smallest quantity of the toxin which when mixed with 0.2 Unit of antitoxin and injected intravenously into mice causes the death of the animals within 72 hours.

**LD50.** This is the quantity of toxin which when injected intravenously into mice causes the death of one-half of the animals within 72 hours.

A suitable *C. septicum* toxin is one that has an L+1/5 dose in 1 mg or less and contains not less than 10 LD50 in an L+1/5 dose.

**Determination of test dose of toxin.** Weigh accurately a quantity of the dried toxin and dissolve it in a suitable liquid so that 1.0 ml contains a precise known amount, such as 4 mg.

Prepare a solution of the Standard preparation in a suitable liquid such that 1.0 ml contains 1 Unit.

Prepare mixtures such that 5.0 ml of each mixture contains 2.0 ml of the solution of the Standard preparation (2 Units) and one of a series of graded volumes of the solution of the toxin. Dilute each mixture with a suitable liquid to the same final volume (5.0 ml). Allow the mixtures to stand at room temperature, protected from light, for 60 minutes and then inject a dose of 0.5 ml of each mixture intravenously into each of not less than 2 mice. Observe the mice for 72 hours. If all the mice die the amount of toxin present in 0.5 ml of the mixture is in excess of the test dose. If none of the mice dies, the amount of toxin present in 0.5 ml of the mixture is less than the test dose. Prepare similar fresh mixtures such that 5.0 ml of each mixture contains 2.0 ml of the solution of the Standard preparation (2 Units) and one of a series of graded volumes of the solution of the toxin separated from each other by steps of not more than 20 per cent and covering the expected endpoint.
Allow the mixtures to stand at room temperature, protected from light, for 60 minutes. Inject a dose of 0.5 ml of each mixture intravenously into each of not less than two mice. Observe the mice for 72 hours. Repeat the determinations at least once and add together the results of the separate tests that have been made with mixtures of the same composition such that a series of totals is obtained, each total representing the mortality due to a mixture of a given composition.

The test dose of toxin is the amount present in 0.5 ml of that mixture that causes the death of one-half of the total number of mice injected within 72 hours.

**Determination of potency of the antitoxin**

**Preliminary test.** Dilute the test toxin with a suitable liquid such that 2.0 ml contains 10 times the test dose. Prepare mixtures such that 5.0 ml of each mixture contains 2.0 ml of the solution of the toxin and one of a series of graded volumes of the preparation under examination. Adjust each mixture to the same final volume with a suitable liquid.

Allow the mixtures to stand at room temperature, protected from light, for 60 minutes. Inject a dose of 0.5 ml of each mixture intravenously into each of not less than two mice and observe the mice for 72 hours. If all the mice die, 0.5 ml of the mixture contains less than 0.2 Unit of antitoxin. If none of the mice dies, 0.5 ml of the mixture contains more than 0.2 Unit of antitoxin.

**Final test.** Prepare similar fresh mixtures such that 5.0 ml of each mixture contains 2.0 ml of the solution of the toxin and one of a series of graded volumes of the preparation under examination, separated from each other by steps of not more than 20 per cent and covering the expected end-point. Prepare further mixtures of 5.0 ml containing 2.0 ml of the solution of the toxin and graded volumes of the Standard preparation to confirm the test dose of the toxin.

Allow the mixtures to stand at room temperature, protected from light, for 60 minutes. Inject a dose of 0.5 ml of each mixture intravenously into each of not less than two mice and observe the mice for 72 hours. The mixture of the antitoxin under examination which contains 0.2 Unit in 0.5 ml is that mixture which causes the death of the same or almost the same number of mice as the mixture containing 0.2 Unit of the Standard preparation in 0.5 ml. Repeat the determinations at least once and calculate the average of all valid estimates. Estimates are not valid unless the Standard preparation gives a result within 20 per cent of the expected value.

**Limits of error.** For the suggested method, the limits of error (P = 0.95) have been estimated to be (a) 85 per cent and 114 per cent when 2 animals per dose are used; (b) 91.5 per cent and 109 per cent when 4 animals per dose are used; (c) 93 per cent and 108 per cent when 6 animals per dose are used.

The vaccine passes the test if the pooled serum contains 2.5 IU of *C. septicum* antitoxins.

**Labelling.** The label states (1) whether the preparation is a toxoid or a vaccine prepared from a whole inactivated culture, or a mixture of the two; (2) that the preparation is to be shaken before use; (3) for each target species, the immunising effect produced (for example, antibody production, protection against signs of disease or infection).

**Duck Pasteurella Vaccine, Inactivated**

Duck Pasteurella Vaccine, Inactivated consists of an emulsion or suspension of a virulent strain of *Pasteurella multocida* which has been inactivated in such a manner that the toxicity is eliminated and the immunogenic activity is retained.

**Identification**

Protects susceptible ducks against infection with *P. multocida*.

**Tests**

**Safety.** Either test A or test B may be carried out.

A. Inject 5 ml subcutaneously into each of four healthy rabbits, weighing between 1.0 and 1.5 kg. Observe the animals for 7 days. No untoward reaction except slight and transient local swelling occurs.

B. Inject 5 ml subcutaneously into each of two healthy rabbits, each weighing between 1.0 and 1.5 kg, and 0.5 ml subcutaneously into each of six mice, each weighing between 25 and 30 g. Observe the animals for 7 days. No untoward reaction except slight and transient local swelling occurs in both species of animals.

**Sterility** (2.2.11). Complies with the test for sterility.

**Potency.** Either test A or test B may be carried out.

A. Inject subcutaneously with the minimum dose of the vaccine stated on the label three healthy susceptible ducks, between 4 and 6 weeks old. Use another two ducks of the same stock and age as unvaccinated controls. Three weeks later, challenge each of the vaccinated and control ducks, subcutaneously with 10^2 mouse LD₅₀ viable organisms in 0.2 ml of a suitably diluted 18-hour broth culture of the homologous virulent strain of *P. multocida*. Observe the ducks for 7 days. Not less than two of the vaccinated ducks remain in normal health and both the controls die of pasteurellosis.

B. Inject subcutaneously each of six mice, each weighing between 25 and 30 g, with 0.2 ml of the vaccine under examination. Use another six mice of the same stock and weight range as unvaccinated controls. Three weeks later, challenge each of the vaccinated and control mice subcutaneously with...
0.2 ml of a suitably diluted 18-hour broth culture of the homologous virulent strain of P. multocida containing 50 mouse LD₅₀ viable organisms. Observe the animals for 7 days. All the vaccinated mice survive. The test is not valid unless all the control mice die of pasteurellosis during the observation period.

**Labelling.** The label states (1) type of strain; (2) the recommended age for vaccination.

### Duck Plague Vaccine, Live

Duck Plague Vaccine, Live is a preparation of attenuated strain of duck plague virus. This monograph applies to vaccines intended for administration to duck for active immunisation against duck plague disease.

**Production**

The vaccine virus is grown in SPF eggs (2.7.7) or in cell cultures. The master seed lot complies with the tests for extreneous agents in seed lot (2.7.10).

**Substrate for virus propagation**

The vaccine virus is grown in embryonated hens’ eggs or in cell cultures obtained from flocks free from specified pathogens SPF (2.7.7). If the vaccine virus is grown in cell cultures, they comply with the requirements for cell cultures for production of veterinary vaccines. The vaccine virus is filled with suitable stabilizing agent and freeze dried.

**Identification**

Protects ducks against duck plague.

**Tests**

**Water** (2.3.43). Not more than 3.0 per cent.

**Safety:** Inject subcutaneously each of four healthy susceptible ducks, between 8 and 12 weeks old and each weighing not less than 600 g, with 1 ml of a 1 : 10 dilution of the reconstituted vaccine. Observe the ducks for 14 days. None of the ducks shows any untoward reaction.

**Sterility** (2.2.11). Complies with the test for sterility.

**Potency.** Inject subcutaneously each of four healthy susceptible ducks, between 8 and 12 weeks old and each weighing not less than 600 g, with a volume of the reconstituted vaccine containing a quantity of the virus equivalent to the minimum dose stated on the label. Fourteen days later, challenge each of the vaccinated ducks and each of two control ducks of the same stock and weight range, subcutaneously with 10² ID₅₀ of virulent duck plague virus. Observe the ducks for 14 days. None of the vaccinated ducks dies or shows any clinical symptoms of plague. The test is not valid unless the control ducks die from duck plague or show typical signs of serious infection during the observation period.

If potency test has been performed with satisfactory results on a representative batch of the vaccine, it may be omitted as a vaccine test during production on the other batches of vaccine prepared from the same seed lot.

**Labelling.** The label states (1) the minimum virus titre per dose; (2) the recommended age of the birds in which the vaccine is to be used.

### Egg Drop Syndrome 76 (Adenovirus) Vaccine, Inactivated

Egg Drop Syndrome 76 (Adenovirus) Vaccine, Inactivated consists of an emulsion or a suspension of a suitable strain of egg drop syndrome ‘76 virus (haemagglutinating avian adenovirus) which has been inactivated in such a manner that immunogenic activity is retained.

**Production**

The vaccine strain is propagated in fertilized SPF hen or duck eggs from healthy flocks (2.7.7) or in suitable cell cultures.

**Test for inactivation.**

The test for inactivation is carried out in fertilized duck eggs from a flock free from egg drop syndrome ‘76 virus infection or hen eggs from a flock free from specified pathogens, or in suitable cell cultures, whichever is the most sensitive for the vaccine strain; the quantity of virus used in the test is equivalent to not less than ten doses of the vaccine. No live virus is detected.

The vaccine may contain adjuvant

**Identification**

When inoculated into chicken, the development of specific neutralizing antibodies against egg drop syndrome ‘76 (adenovirus) can be demonstrated by suitable serological tests.

**Tests**

**Safety.** Inject each of ten chickens between 2 and 4 weeks old, with two doses and by the route stated on the label. Observe the chicken for 14 days. None of the chicken shows any abnormal local or systemic reaction.

**Sterility** (2.2.11). Complies with the test for sterility.

**Potency.** Inject each of twenty healthy chickens free of antibodies (2.7.7) between 3 to 4 weeks old, with the dose and by the route stated on the label. After 21 days, collect serum
samples from each of the birds as well as ten-control chickens of the same stock and perform haemagglutination inhibition test on each serum using 4 haemagglutinating units of antigen and chicken erythrocytes. The vaccine passes the potency test if the mean antibody titre of the vaccinated group is greater than 1:128. The test is valid only if no specific antibody is found in the control chicken.

If the potency has been performed with satisfactory results on representative batch of the vaccine from the same seed lot, it may be omitted as a routine control test during production of other batches of the vaccine prepared from the same seed lot.

Labelling: The label states (1) the strain used for the preparation; (2) the name of any added adjuvant; (3) the route of administration.

Foot-and-Mouth Disease Vaccine, Inactivated

Foot-and-Mouth Disease Vaccine, Inactivated is a liquid preparation containing one or more types of foot-and-mouth disease virus that have been inactivated in such a manner that its immunogenic activity is retained. Depending on the number of types of virus incorporated, the vaccine is described as monovalent, bivalent, trivalent or polyvalent.

Production

The virus is grown in suitable cell cultures. The virus is separated from cellular material by filtration or other suitable procedures and the virus is inactivated using binary ethylenimine (BEI) in suitable conditions. The antigen may be concentrated and purified. The antigen is used for the preparation of vaccine. The vaccine contains a suitable adjuvant.

Only an inactivated antigen suspension that complies with the requirements mentioned under final bulk vaccine may be used in the preparation of the final lot.

FINAL BULK VACCINE

The final bulk vaccine is prepared from one or more inactivated antigen suspensions.

During inactivation of the virus, samples should be taken at regular intervals for the purpose of monitoring the rate and linearity of the inactivation process. Virus titres in the samples are determined by inoculation into sensitive cell culture. The infectivities of the timed samples are plotted against time, and the inactivation procedure is not considered to be satisfactory unless the extrapolation indicates that there would be less than one infectious particle per 10^4 litres of liquid preparation at the end of the inactivation period.

Only a final bulk vaccine that complies with the following requirements may be used in the preparation of the final lot.

Tests

Inactivation. A proportion of each batch of bulk inactivated antigen representing at least 200 doses are tested for freedom from infectious virus by inoculation into sensitive cell culture. A sample of inactivated antigen is concentrated to volumes adequate for inoculation into cell cultures and it must show that the concentrated antigen does not interfere with the sensitivity or reading of the assay. The sample is passaged 3 times at an interval of 24 to 48 hours and inoculated cell cultures are examined for the presence of foot-and-mouth disease virus by suitable tests. No cytopathic changes attributable to foot-and-mouth disease virus replication should be detected. If infectious foot-and-mouth disease virus is detected, the bulk antigen is rejected.

FINAL LOT

The final bulk vaccine is distributed aseptically into sterile containers. The containers are closed so as to avoid contamination.

Only a final lot that complies with each of the requirements given below under Identification, Tests and Assay may be released for use.

Identification

The serum of a foot-and-mouth disease susceptible animal that has been immunized with the vaccine neutralizes the types of virus used to prepare the vaccine, when tested by a suitable method.

Tests

Safety. Use two non-vaccinated cattle not less than 6 months old free from foot-and-mouth disease antibodies. Inoculate each animal with whole vaccine in case of gel adjuvant vaccine and the final bulk in case of oil adjuvant vaccine intradermally into the tongue at not less than twenty sites with 0.1 ml per site. Observe the animals for 4 days. No lesions or signs of foot-and-mouth disease infection should occur. At the end of the observation period, inject into the same animals three times the dose by the prescribed route as stated on the label. Observe the animals for a further period of 6 days. No lesions or clinical signs due to foot-and-mouth disease infection should occur on the feet or tongue and no evidence of toxicity shall be noticed.

Sterility (2.2.11). Complies with the test for sterility.

Assay. Use three groups of not less than five cattle per group, not less than 6 months old, which have never been vaccinated and are free from antibodies neutralizing the different types of foot-and-mouth disease virus in the vaccine. Vaccinate the 3
groups by the route stated on the label. Use different doses of the vaccine for each group without diluting the vaccine. For example, if 3 ml is one dose, a 1/3 dose of vaccine would be obtained by injecting 1 ml, and a 1/10 dose would be obtained by injecting 0.3 ml. Three weeks later, challenge all the vaccinated animals and a control group of two, susceptible to foot-and-mouth disease with a suspension of virus that is fully virulent and of the same type as that used for preparation of the vaccine by inoculating 10,000 ID$_{50}$ (50 per cent bovine infectious dose) intradermally into two sites into the tongue (0.1 ml per site). The challenge of oil adjuvanted vaccines is effected 28 days post vaccination. Observe the animals for 8 days and then sacrifice them. Unprotected animals show lesions at sites other than the tongue. Protected animals may display lingual lesions. The test is not valid unless control animals show lesions on at least three feet. From the number of animals protected in each group, calculate the PD$_{50}$ content of the vaccine. The potency of the vaccine is expressed as the number of 50 per cent cattle protective doses (PD$_{50}$) contained in the dose stated on the label. The vaccine must contain at least 3 PD$_{50}$ per dose for cattle.

Indirect tests, including post vaccination measurement of virus neutralizing antibodies in cell culture, or ELISA, may be used to assess the potency of a vaccine provided that a statistical evaluation has established a satisfactory correlation between the results obtained by the test on the relevant vaccine serotype and the potency test in cattle.

The description applies to the testing of a monovalent vaccine. Polyvalent vaccines may be potency tested by challenging each valency as described above.

**Labelling.** The label states (1) the method of preparation; (2) the types and strains of virus used to prepare the vaccine.

### Fowl Cholera Vaccine, Inactivated

Fowl Cholera Vaccine, Inactivated is a preparation of 1 or more suitable strains of 1 or more serovars of *Pasteurella multocida*. This monograph applies to vaccines intended for the active immunisation of chickens, turkeys, ducks and geese against acute fowl cholera.

**Production**

The seed material is inoculated in a suitable medium. If the vaccine contains more than 1 strain of bacterium, the different strains are grown and harvested separately. The bacterial harvests are inactivated with suitable agent. The vaccine may contain suitable adjuvant.

**Identification**

Protects susceptible chicken against infection with *P. multocida*.

### Tests

**Safety.** Administer double dose of vaccine subcutaneously into each of ten healthy chickens, free of antibodies (2.7.7) of 4 to 6 weeks age. Observe the chickens for 7 days; none of the chicken shows untoward reaction other than slight transient local swelling.

**Sterility (2.2.11).** Complies with the test for sterility.

**Potency.** Inject subcutaneously each of ten healthy chickens free from antibodies (2.7.7) between 4 to 6 weeks old, with the minimum dose stated on the label. Use five healthy chickens of the same age group and from the same stock as controls. Three weeks later challenge the vaccinated and control chickens by injecting subcutaneously with 0.2 ml of an 18-hour broth culture of the homologous virulent strain of *P. multocida* diluted suitably so as to contain 10$^2$ mouse LD$_{50}$ or 200 to 300 CFU in the injected dose in each chicken. Observe the chickens for 14 days; not less than eight out of ten of the vaccinated chickens survive. The test is not valid unless 100 per cent of the control chickens die of pasteurellosis within the observation period.

**Labelling.** The label states (1) the serovar(s) used to prepare the vaccine, the serovar(s) against which protection is claimed; (2) the method of preparation.

### Fowl Pox Vaccine, Live

Fowl Pox Vaccine, Live is a preparation of a suitable strain of avian pox virus. This monograph applies to vaccines intended for administration to chickens for active immunization.

**Production**

The vaccine virus is grown in embryonated hens’ eggs or in cell cultures.

**Substrate for virus propagation**

The vaccine virus is grown either in embryonated hens’ eggs or in avian cell cultures obtained from flocks free from specified pathogens SPF (2.7.7). The master seed lot complies with the test for extreneous agents in seed lot (2.7.10).

**Identification**

The vaccine protects susceptible chicken against fowl pox. Carry out an immunostaining test in cell cultures to demonstrate the presence of the vaccine virus. For egg adapted strains, inoculate the vaccine into eggs and notice the characteristic lesions.

**Tests**

**Water (2.3.43).** Not more than 3.0 per cent.
Mycoplasmas (2.7.4). The vaccine complies with the test for mycoplasmas.

Extraneous agents (2.7.11). The vaccine complies with the tests for extraneous agents in batches of finished product.

Safety. Administer 10 doses of the vaccine to each of ten chickens 6 to 8 weeks old complying with the requirements of test B of the test for freedom from specified pathogens and antibodies (2.7.7), SPF chicks and by the route stated on the label. Observe the birds for 21 days. No chicken dies from causes attributable to the vaccine or shows signs of toxicity other than mild, transient, local reactions. If during the observation period more than two chickens die from causes not attributable to the vaccine, repeat the test.

Virus titre. Not less than 10⁴ EID₅₀/TCID₅₀ of the virus per dose, determining the titre by inoculation into the chorio-allantoic membrane of SPF embryonated eggs, between 9 and 11 days old, or in a cell culture derived from SPF embryos (2.7.7).

Sterility (2.2.11). Complies with the test for sterility.

Potency. Carry out a separate potency test for each of the routes of administration stated on the label. Use not less than ten susceptible chickens, 6 to 8 weeks old, complying with the requirements of test B of the test for freedom from specific pathogens and antibodies (2.7.7), and of the minimum age for vaccination stated on the label. Use ten birds from the same flock and weight range as controls. Administer to each chicken a volmne of the reconstituted vaccine containing a quantity of the virus equivalent to the minimum titre stated on the label. After 21 days, challenge each chicken by intradermal injection into the chorio-allantoic membrane of SPF embryonated eggs, between 9 and 11 days old, or in a cell culture derived from SPF embryos (2.7.7).

If the potency test has been performed with satisfactory results on a representative batch of the vaccine it may be omitted as a routine test during production of the other batches of the vaccine prepared from the same seed lot.

Labelling. The label states (1) the minimum virus titre; (2) the age of vaccination; (3) the types and strains of virus used to prepare the vaccine.

Goat Pox Vaccine, Live

Goat Pox Vaccine, Live is a freeze-dried preparation of an attenuated strain of goat poxvirus propagated in a suitable cell culture. It is reconstituted immediately before use by a suitable diluent.

Production

The virus is propagated in suitable cell culture. The viral suspension is harvested, titrated and may be mixed with a suitable stabilizing agent. The vaccine is then freeze-dried.

Identification

The vaccine protects susceptible animals against goat pox.

Tests

Water (2.3.43). Not more than 3.0 per cent.

Safety

A. Inoculate 10 doses of the reconstituted vaccine in each animal of the three species mentioned below by the route stated against each. Administer 0.2 ml intraperitoneally to each of six mice and 0.5 ml and 1.0 ml subcutaneously to each of three guinea pigs and three rabbits respectively. Observe the animals for 10 days. None of the animals shows an abnormal reaction.

B. Inject 100 doses of the vaccine contained in 1 ml of the reconstituted vaccine subcutaneously into each of two susceptible goats, 6 to 8 months old. Observe the goats for 10 days. None of the animals shows abnormalities other than local erythema of not more than 3 cm in diameter around the site of injection.

Virus titre. Not less than 10³ TCID₅₀ of the virus per dose, determining the titre in a suitable cell culture or by inoculation into the chorio-allantoic membrane of SPF embryonated eggs (2.7.7), 9 to 11 days old.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Use nine susceptible goats, 8 to 10 months old. Divide them into three groups of three goats each. Inject subcutaneously 1/20th of the dose of the vaccine stated on the label into each goat of one group. Administer a quantity equivalent to the dose of the vaccine stated on the label into each goat of the second group. Use the third group as unvaccinated controls which should be kept along with the inoculated goats. Observe the animals for 14 days and record the rectal temperature daily of each goat during the observation period. None of the vaccinated goats shows any thermal reaction or local or generalised lesion. After 21 days, challenge the vaccinated and control animals with sufficient quantity of a virulent goat pox virus by intradermal injection. Observe the animals for 14 days and record the rectal temperature daily of each goat during the observation period. None of the vaccinated goats shows any thermal reaction or local or generalised lesions. The test is valid only if the control animals develop high fever or show local or generalised lesions. If the test for potency has been carried out with satisfactory results on a representative batch of vaccine, this test may be omitted.
as a routine control on other batches of vaccine prepared from the same seed lot, subject to agreement by the competent authority.

**Labelling.** The label states (1) the strain used for the preparation; (2) virus titer; (3) dose and age of vaccination.

---

**Haemorrhagic Septicaemia Vaccine**

Haemorrhagic Septicaemia Vaccine (Inactivated) is a preparation of *Pasteurella multocida*. The whole culture is inactivated which may be heated with a suitable adjuvant.

**Identification**

The vaccine protects susceptible animals against infection with *P. multocida*.

**Tests**

**Safety.** Inject intraperitoneally or intramuscularly into each of six mice, weighing not less than 18 g, with 0.2 ml of the vaccine under examination. Observe the animals for 5 days; no abnormal systemic reaction occurs.

Inject two seronegative cattle with twice the maximum dose stated on the label and observe for 10 days for adverse effects.

**Sterility** (2.2.11). Complies with the test for sterility.

**Potency.** Carry out any of the following three tests.

(a) **Test on mice.** Inject intramuscularly each of fifty mice, weighing not less than 18 g, with 0.2 ml of the preparation under examination. Repeat the dose 14 days later. After 7 days, divide the mice into ten groups of five each. Use another fifty mice of the same weight and from the same stock as controls. Divide the controls also into ten groups of five each. Challenge the vaccinated and the control mice with an 8 to 12-hour old broth culture of a virulent strain of *P. multocida* in the range of 10^{-1} to 10^{-10}. Observe the mice for 5 days and record the number of vaccinated and control mice found dead in each group. Calculate the median lethal dose (LD$_{50}$) for the vaccinated and control mice by standard methods. The protection provided by the vaccine is calculated as number of protection units using following formula:

\[
\text{Number of protection units} = \text{LD}_{50} \text{ in control animals} - \text{LD}_{50} \text{ in vaccinated animals.}
\]

The vaccine passes the test if it provides minimum protection of 10^4 units.

(b) **Test on rabbits.** Inject intramuscularly each of not less than six rabbits, each weighing not less than 2.0 kg, with 2 ml of the vaccine under examination. Use two rabbits of the same weight and of the same stock as controls. After 21 days, challenge each of the vaccinated rabbits as well as the control rabbits with an 18 hour old culture of *P. multocida* containing not less than 10 LD$_{50}$ of virulent organisms. Observe the animals for 7 days; none of the vaccinated animals dies of pasteurellosis. The test is not valid unless both the control rabbits die of pasteurellosis.

(c) **Test on calves.** Inject each of not less than 3 healthy susceptible calves, weighing not less than 140 kg each with 2 ml of vaccine. Three weeks later, these animals along with two healthy animals of the same type are challenged subcutaneously with 18-hours old broth culture of *P. multocida* equivalent to at least 50 million mouse minimum infective. Observe the animals for 7 days. Both the controls should die of pasteurellosis and at least two out of three vaccinated animals should survive.

Potency is conducted on each seed lot or for every fifth batch produced from the seed lot.

**Labelling.** The label states (1) the type and strains of bacteria used to prepare the vaccine; (2) adjuvant used.

---

**Inclusion Body Hepatitis (IBH) Vaccine Inactivated**

Inclusion Body Hepatitis (IBH)/Hydropericardium Syndrome (HPS) Vaccine (Inactivated) consists of an emulsion or a suspension of avian adenovirus type 4 virus which have been inactivated in such a manner that the immunogenic activity is retained. The vaccine may contain one or more suitable adjuvants.

**Production**

**Substrate for virus propagation**

Vaccine virus is grown in SPF chicks (2.7.7).

**Inactivation**

An amplification test for residual live IBH/HPS disease virus is carried out on each batch of antigen immediately after inactivation and on the final bulk vaccine or, if the vaccine contains an adjuvant, on the bulk antigen or the mixture of bulk antigens immediately before the addition of any adjuvant, to confirm inactivation; the test is carried out on chickens from a flock free from specified pathogens. The quantity of inactivated virus used in the test is equivalent to not less than ten doses of the vaccine. No live virus is detected.

**Identification**

Protects chickens against infection of IBH/HPS.
Tests

Safety. Inject subcutaneously a quantity equivalent to 2 doses into each of 20 healthy chickens free from specific antibodies, of the recommended age at which vaccine is to be used. Observe the chickens for 14 days, no abnormal systemic or local reaction is seen.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Inject one dose by the route stated on the label into each of 20 healthy chickens free from specific antibodies at the minimum recommended age at which vaccine is to be used. Use 10 similar chickens from same source as controls. Challenge chickens after 21 days by intraperitoneal route with $10^4$ Chick Infective Dose (CID$_{50}$) of virulent strain of IBH/HPS. Observe the chickens of both groups for 14 days. Vaccine complies with the test if not more than 2 of vaccinated chickens die or show signs of disease. At the end of observation period sacrifice all the chickens. The test is valid only if at least 80 per cent of control chicks either die or show symptoms or show post-mortem lesions on sacrifice at the end of observation period post challenge.

If the potency test has been performed with satisfactory results on representative batch of the vaccine from the same seed lot, it may be omitted as a routine control test during production of other batches of the vaccine prepared from the same seed lot.

Labelling. The label states (1) strain used for vaccine production; (2) recommended age for vaccination.

Infectious Avian Encephalomyelitis Vaccine, Live

Infectious Avian Encephalomyelitis Vaccine, Live is a freeze-dried preparation of an attenuated strain of infectious avian encephalomyelitis virus.

Production

The virus is grown in SPF embryonated eggs (2.7.7) or in suitable cell cultures. The master seed lot complies with the test for extraneous agents in seed lot (2.7.10).

Identification

Inoculate 0.1 ml of the undiluted reconstituted vaccine into the yolk sac of SPF embryonated eggs, between 5 and 6 days old. Keep them in an incubator and transfer to the brooder for hatching. Observe the hatched chickens for 7 days. Not less than 50 per cent of the chickens show the typical symptoms characteristic of infectious avian encephalomyelitis-like weakness or paralysis of legs and tremors.
Inactivation

An amplification test for residual live infectious avian bursal disease virus is carried out on each batch of antigen immediately after inactivation and on the final bulk vaccine or, if the vaccine contains an adjuvant, on the bulk antigen or the mixture of bulk antigens immediately before the addition of any adjuvant, to confirm inactivation; the test is carried out in fertilized hen eggs or in suitable cell culture or, where chickens have been used for production of the vaccine, in chickens from a flock free from specified pathogens the quantity of inactivated virus used in the test is equivalent to not less than ten doses of the vaccine. No live virus is detected.

Identification

Protects susceptible chickens against infectious bursal disease by producing specific antibodies on inoculation.

Tests

Inactivation

For vaccine prepared with embryo-adapted strains of the virus. Inject two-fifths of a dose into the allantoic cavity or onto the chorio-allantoic membrane of the SPF embryonated hen eggs, between 9 and 10 days old, and incubate at 37°. Observe for 6 days and pool separately the allantoic fluid from eggs containing live embryos, and that from eggs containing dead embryos, excluding those dying from non-specific causes within the first 24 hours after inoculation.

Inject into the allantoic cavity of each of the SPF embryonated hen eggs, between 9 and 10 days old, 0.2 ml of the pooled allantoic fluid from the live embryos or membrane from the dead embryos and incubate at 37° for 6 days. Examine each embryo for lesions of infectious bursal disease. The vaccine complies with the test if there is no evidence of lesions of infectious bursal disease.

The test is valid only if not more than 20 per cent of the embryos die at either stage of the test. If more than 20 per cent of the embryos die at either one of the stages of the test, repeat that stage. In any repeat test, not more than 20 per cent of the embryos die from non-specific causes. Antibiotics may be used to control extraneous bacterial infection.

For vaccine prepared with strains of virus not adapted to embryos. Inject two doses intramuscularly into each of twenty chickens, between 14 and 28 days old, complying with the requirements stated under Test on chicken flocks free from pathogens for the production and quality control vaccines (2.7.7). Four day later, kill ten of the chickens and remove bursa of fabricius from each chicken, pool the bursa and homogenise in an equal volume of a suitable liquid. Inject 1 ml of the homogenate into each of a further ten chickens of the same flock and age. After 21 days, examine microscopically the bursa of each chicken from the first group and the second group. No evidence of infectious bursal disease is seen and no abnormal local reaction develops.

Safety. Inject each of twenty healthy chickens free from specific antibodies (2.7.7) between 14 and 28 days old with twice the minimum vaccinating dose and by one of the routes stated on the label. Observe the chickens for 14 days. No abnormal local or systemic reaction is seen.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Inject each of twenty healthy chickens free from specific antibodies (2.7.7) between 3 and 4 weeks old, with the minimum dose and by the route stated on the label. Use ten chickens of the same flock and age as controls. After 21 days, collect serum samples from each bird including the ten-control chickens and perform quantitative agar gel precipitation test on each serum sample. The mean antibody titre of sera in vaccinated group shall be 8.0 and there are no specific antibodies in the sera of control chicken.

If the potency test has carried out been with satisfactory results on representative batch of the vaccine from the same seed lot, it may be omitted as a routine control test during production of other batches of the vaccine prepared from the same seed lot.

Labelling. The label states (1) the type of strain; (2) the recommended age for vaccination.

Infectious Coryza Vaccine

Infectious Coryza Vaccine for chickens is a suspension of inactivated culture of one or more virulent strain of Haemophilus paragallinarum. A suitable adjuvant may be added.

Identification

Protects susceptible chicken against infection with H. paragallinarum organism.

Tests

Safety. Inject 1.0 ml subcutaneously into each of 10 healthy chickens free from antibodies (2.7.7) at the minimum age group at which vaccine is intended. Observe these birds for 7 days; no bird shows untoward reactions other than slight transient local swelling.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Inject subcutaneously each of 10 healthy chickens free from antibodies (2.7.7) of the minimum age group at which vaccine is used, with minimum dose stated on the label. Repeat the vaccination after 2 weeks. Use 10 healthy chickens of
same age group and of same stock as controls. Three weeks later, challenge vaccinated and control chickens by instillation with 0.2 ml of 18-hour broth culture of homologous virulent strain of *H. paragallinarium* diluted suitably so as to contain \(1 \times 10^6\) Chick ID\(_{50}\) by infra-orbital sinus inoculation. Observe the chickens for 7 days for unilateral eye swelling, nasal discharge, isolation of the virulent organisms from infra-orbital sinus in a suitable medium. Not less than 7 vaccinated chickens show prevention from lesions and isolation of homologous virulent organisms. The test is not valid unless 70 per cent of control chickens exhibit typical symptoms of eye swelling and nasal discharge typical of infectious coryza.

**Labelling.** The label states (1) strains used for preparation; (2) route of administration.

### Laryngotracheitis Vaccine, Live

Laryngotracheitis Vaccine, Live is a preparation of a suitable strain of Avian infectious laryngotracheitis virus (gallid herpes virus 1). This monograph applies to vaccines intended for administration to chickens for active immunization against laryngotracheitis disease in chickens.

#### Production

The vaccine virus is grown in embryonated hens’ eggs or in cell cultures.

If the vaccine virus is grown in embryonated hens’ eggs, they are obtained from flocks free from specified pathogens (SPF) (2.7.7). If the vaccine virus is grown in cell cultures, they comply with the requirements for cell cultures for production of veterinary vaccines. The vaccine virus is filled with suitable stabilizing agent and freeze dried. The master seed lot complies with the tests for extraneous agents in seed lot (2.7.10).

#### Identification

When mixed with mono specific laryngotracheitis disease virus antiserum the vaccine no longer infects susceptible cell cultures or embryonated hen eggs, 9 to 11 days old.

#### Tests

**Water** (2.3.43). Not more than 3.0 per cent.

**Virus titre.** Titrature the vaccine virus by inoculation into embryonated hens’ eggs from an SPF flock or into suitable cell cultures. The vaccine complies with the test if 1 dose contains not less than the minimum titre stated on the label.

**Safety.** Use not less than 10 chickens from a healthy flock and of the youngest age recommended for vaccination. Administer by eye-drop to each chicken 10 doses of the vaccine. Observe the chickens at least daily for 21 days. The test is not valid if more than 20 per cent of the chickens show abnormal clinical signs or die from causes not attributable to the vaccine. The vaccine complies with the test if no chicken shows notable clinical signs of disease or dies from causes attributable to the vaccine.

**Sterility** (2.2.11). Complies with the test for sterility.

**Potency.** A test is carried out for each route and method of administration to be recommended using in each case chickens not older than the youngest age to be recommended for vaccination. The quantity of the vaccine virus administered to each of 20 chickens is not greater than the minimum virus titre to be stated on the label and the virus is at the most attenuated passage level that will be present in a batch of the vaccine. Vaccinate by a recommended route not less than 20 chickens. Maintain not less than 10 chickens as controls. Challenge each chicken after 21 days by the intratracheal route with a sufficient quantity of virulent infectious laryngotracheitis virus. Observe the chickens at least daily for 7 days after challenge. Record the deaths and the number of surviving chickens that show clinical signs of disease. At the end of the observation period kill all the surviving chickens and carry out examination for macroscopic lesions: mucoid, hemorrhagic and pseudomembranous inflammation of the trachea and orbital sinuses. The test is not valid if during the observation period after challenge less than 90 per cent of the control chickens die or show severe clinical signs of avian infectious laryngotracheitis or notable macroscopic lesions of the trachea and orbital sinuses, or if during the period between the vaccination and challenge more than 10 per cent of the vaccinated or control chickens show notable clinical signs of disease or die from causes not attributable to the vaccine. The vaccine virus complies with the test if during the observation period after challenge not less than 90 per cent of the vaccinated chickens survive and show no notable clinical signs of disease and/or macroscopically lesions of the trachea and orbital sinuses.

If the potency test has been performed with satisfactory results on a representative batch of the vaccine from the seed lot, it may be omitted as a routine control test during production on other batches of the vaccine prepared from the same seed lot.

**Labelling.** The label states (1) strain of virus used; (2) recommended age for vaccination.

### Leptospira Veterinary Vaccine, Inactivated

Canine Leptospirosis Vaccine (Inactivated) is a suspension of inactivated whole organisms and/or antigenic extract(s) of one or more suitable strains of one or more of *Leptospira*
interrogans serovar canicola, serovar icterohaemorrhagiae or any other epidemiologically appropriate serovar, inactivated and prepared in such a way that adequate immunogenicity is maintained.

**Production**

The seed material is cultured in a suitable medium; each strain is cultivated separately. During production, various parameters such as growth rate are monitored by suitable methods; the values are within the limits approved for the particular product. Purity and identity are verified on the harvest using suitable methods. After cultivation, the bacterial harvests are collected separately and inactivated by a suitable method. The antigen may be concentrated. The vaccine may contain an adjuvant.

**Inactivation**

Carry out a test for inactivation by inoculation on to a specific medium. Inoculate 1 ml of the vaccine into 100 ml of the medium. Incubate at 30° for 14 days, subculture into a further quantity of the medium and incubate both media at 30° for 14 days: no growth occurs in either medium. At the same time, carry out a control test by inoculating a further quantity of the medium with the vaccine together with a quantity of a culture containing approximately 100 leptospirae and incubating at 30° Growth of leptospirae occurs within 14 days.

**Identification**

When administered to experimental animals causes the appearance of agglutinating antibodies against the serotype or serotypes used to prepare the vaccine.

**Tests**

**Safety.** Use 2 dogs of the minimum age recommended for vaccination and which do not have antibodies to the leptospira serovar(s) present in the vaccine. Administer 2 doses of the vaccine to each dog by a recommended route. Observe the animals for 14 days. The animals remain in good health and no abnormal local or systemic reaction occurs.

**Sterility** (2.2.11). Complies with the test for sterility.

**Potency.** Carry out a separate potency test for each serotype if the vaccine is prepared with different serotypes. Inject each of five hamsters not more than 3 months old, the animals being drawn from the same stock, subcutaneously with 1/40 of the dose of the vaccine stated on the label for dogs. Use an equal number of animals of the species used for the test as controls. After 15 to 20 days inject intraperitoneally into each of the vaccinated and control animals an adequate dose of a virulent culture of leptospirae of the serotype used to prepare the vaccine or a suspension of liver or kidney tissue obtained from animals infected with the serotype used to prepare the vaccine. Observe the animals for 14 days after the injection. Not less than four of the control animals die showing typical leptospira infection. Not less than four of the vaccinated animals remain in good health for not less than 14 days after the death of the four control animals.

**Labelling.** The label states (1) the strain used for the preparation; (2) the name of any added adjuvant.

**Peste Des Petitis Ruminants Vaccine, Live**

Peste Des Petitis Ruminants Vaccine, Live is a preparation of a suitable strain of PPR virus that is attenuated for sheep and goats.

**Production**

The vaccine strain is grown in suitable cell cultures. The viral suspension is harvested, mixed with a suitable stabilizing liquid and freeze-dried.

**Batch testing**

If the test for potency has been carried out with satisfactory results on the representative batch of vaccine, this test may be omitted as a routine control on other batches of vaccine prepared from the same seed lot, subject to agreement by a National Regulatory Authority.

**Identification**

When injected into the target animals, the vaccine stimulates the production specific neutralizing antibodies.

**Tests**

**Safety.** Administer 0.5 ml of vaccine equivalent to 5 doses intramuscularly into each of two healthy guinea pigs weighing between 200 and 250 g and 0.5 ml each into two healthy guinea pigs weighing between 200 and 250 g intraperitoneally and 0.1 ml of vaccine equivalent to one dose intraperitoneally in each of six healthy mice weighing between 17 and 22 g. Keep two guinea pigs and two mice as uninoculated controls. Observe the animals for 3 weeks. At the end of 3 weeks of observation, all animals are killed for post-mortem examination. The vaccine is considered safe if during the first or second test at least 80 per cent of animals remain in good health during the period of observation, and no significant post-mortem lesion is found.

Inject two susceptible goats of one year old free from antibodies to rinderpest or PPR by subcutaneous route with a 100 times the dose of vaccine stated on the label. Observe the animals for 21 days. No sign of illness attributable to PPR is noticed.
Water (2.3.43). Not more than 3 per cent.

Virus titer. Virus titer not less than \(10^5\) TCID\(_{50}\) per dose.

Extraneous viruses. The reconstituted vaccine when mixed with specific anti-PPR serum should not produce cytopathic effects in susceptible cell cultures and the cells should show no evidence of the presence of haemadsorbing agents.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Use not less than six healthy goats and six healthy sheep of 1 year old free from antibodies to rinderpest or PPR. Collect sera from the animals before the time of vaccination and 3 weeks after vaccination and just before challenge. Vaccinate two goats and two sheep subcutaneously with 100 doses per ml; vaccinate two goats and two sheep subcutaneously with 1 dose per ml. Keep the remaining animals as the in-contact controls. Monitor each animal for clinical signs, in particular respiratory symptoms and record temperature measurements daily for three weeks. Three weeks after vaccination challenge the vaccinated animals and in-contact controls group with a suspension of virus containing \(10^3\) LD\(_{50}\) pathogenic PPRV by subcutaneous route. The animals are observed for clinical signs and the body temperatures are recorded daily for two weeks. The vaccine passes the test if all vaccinated animals resist challenge infection and all the in-contact controls develop signs of PPR. The serum neutralization test must be positive for PPR antibody in vaccinated animal only, in samples taken three weeks after vaccination.

If the potency test has been performed with satisfactory results on a representative batch of the vaccine from the seed lot, it may be omitted as a routine control test during production on other batches of the vaccine prepared from the same seed lot.

Labelling. The label states (1) cell line used for vaccine manufacture; (2) virus titer per dose; (3) recommended age for vaccination.

Rabies Veterinary Vaccine, Inactivated (Cell Culture)

Rabies Vaccine for Veterinary Use is a preparation of rabies fixed virus adapted to and propagated in cell culture and inactivated by a suitable method. It may be issued as a liquid containing a suitable adjuvant or as a freeze-dried preparation to be reconstituted with a suitable liquid immediately before use.

Production

The vaccine is prepared from virus grown either in suitable cell lines or in primary cell cultures from healthy animals. The virus suspension is harvested on one or more occasions within 28 days of inoculation. Multiple harvests from a single production cell culture may be pooled and considered as a single harvest. The rabies virus is inactivated by a suitable method. The vaccine may contain one or more adjuvants.

Inactivation

A. The test for residual live rabies virus is carried out by inoculation of the inactivated virus into the same type of cell culture as that used in the production of the vaccine or a cell culture shown to be at least as sensitive. The quantity of inactivated virus used in the test is equivalent to not less than 25 doses of the vaccine. After incubation for 4 days, a subculture is made using trypsinised cells; after incubation for a further 4 days, the cultures are examined for residual live rabies virus by an immunofluorescence test. No live virus is detected.

B. Inject each of twenty suckling mice, each weighing between 12 and 16 g, intracerebrally with not less than 0.03 ml of the vaccine under examination. Observe the animals for 21 days. None of the mice dies or shows any abnormalities attributable to the vaccine. If more than two mice die within 48 hours, repeat the test.

Identification

When injected into animals, the vaccine stimulates production of specific neutralising antibodies.

Tests

Water (2.3.43). Not more than 3.0 per cent (for freeze dried vaccine only).

Safety. Inject each of twenty mice, each weighing between 12 and 16 g, intracerebrally with not less than 0.03 ml of the vaccine under examination. Observe the animals for 21 days. None of the mice dies or shows any abnormalities attributable to the vaccine. If more than two mice die within 48 hours repeat the test. If the vaccine is intended for more than one species including one belonging to the order of Carnivore, carry out the test in dogs. Otherwise use one of the species for which the vaccine is intended. Administer, by a recommended route, a double dose of vaccine to each of 2 animals having no antibodies against rabies virus. Observe the animals for 14 days. No abnormal local or systemic reaction occurs.

Sterility (2.2.11). Complies with the test for sterility.

Potency. The potency of rabies vaccine is determined by comparing the dose necessary to protect mice against the clinical effects of the dose of rabies virus defined below, administered intracerebrally, with the quantity of a reference preparation, calibrated in International Units, necessary to provide the same protection.
**Preparation of the challenge suspension.** Inoculate a group of mice intracerebrally with the CVS strain of rabies virus and when the mice show signs of rabies, but before they die, kill the mice and remove the brains and prepare a homogenate of the brain tissue in a suitable diluent. Separate gross particulate matter by centrifugation and use the supernatant liquid as challenge suspension. Distribute the suspension in small volumes in ampoules, seal and store at a temperature below -60°. Thaw one ampoule of the suspension and make serial dilutions in a suitable diluent. Allocate each dilution to a group of 10 mice and inject intracerebrally into each mouse 0.03 ml of the dilution allocated to its group. Observe the animals for 14 days and record the number in each group that, between the fifth and the fourteenth day, develop signs of rabies. Calculate the ID₅₀ of the undiluted suspension.

**Determination of potency of the vaccine**

Use in the test healthy mice about 4 weeks old and from the same stock. Distribute the mice into at least 10 groups of not less than 10 mice. Prepare at least three serial dilutions of the vaccine under examination and three similar dilutions of the reference preparation. Prepare the dilutions such that those containing the largest quantity of vaccine may be expected to protect more than 50 per cent of the animals into which they are injected and those containing the smallest quantities of vaccine may be expected to protect less than 50 per cent of the animals into which they are injected. Allocate each dilution to a different group of mice and inject intraperitoneally into each mouse 0.5 ml of the dilution allocated to its group. Fourteen days after the injection prepare a suspension of the challenge virus such that, on the basis of the preliminary titration, it contains about 50 ID₅₀ in each 0.03 ml. Inject intracerebrally into each vaccinated mouse 0.03 ml of this suspension. Prepare 3 suitable serial dilutions of the challenge suspension. Allocate the challenge suspension and the 3 dilutions one to each of 4 groups of 10 unvaccinated mice and inject intracerebrally into each mouse 0.03 ml of the suspension or one of the dilutions allocated to its group. Observe the animals in each group for 14 days. The test is not valid if more than 2 mice of any group die within the first 4 days after challenge. Record the numbers in each group that show signs of rabies in the period 5 days to 14 days after challenge.

The test is not valid unless (a) for both the vaccine under examination and the reference preparation the 50 per cent protective dose lies between the smallest and the largest dose given to the mice; (b) the titration of the challenge suspension shows that 0.03 ml of the suspension contained at least 10 ID₅₀ and not more than 50 ID₅₀; (c) the confidence limits (P = 0.95) are not less than 25 per cent and not more than 400 per cent of the estimated potency; (d) the statistical analysis shows a significant slope and no significant deviations from linearity or parallelism of the dose-response lines.

The vaccine complies with the test if the estimated potency is not less than 1 IU in the smallest prescribed dose.

**Labelling.** The label states (1) the strain used for the preparation; (2) the name of any added adjuvant.

**Ranikhet Disease Vaccine, Inactivated**

Newcastle Disease Vaccine, Inactivated

Ranikhet Disease Vaccine, Inactivated consists of an emulsion or a suspension of a suitable strain of Newcastle disease virus (avian paramyxovirus 1) that has been inactivated in such a manner that immunogenic activity is retained.

**Production**

**Preparation of the vaccine**

The vaccine virus is grown either in embryonated hens’ eggs or in avian cell cultures obtained from flocks free from specified pathogens (SPF) (2.7.7).

**Inactivation.** Inject 2/5 of a dose into the allantoic cavity of each of 10 embryonated hen eggs that are 9 to 11 days old SPF eggs, and incubate. Observe for 6 days and pool separately the allantoic fluid from eggs containing live embryos and from eggs containing dead embryos, excluding those dying within 24 hours of the injection. Examine embryos that die within 24 hours of injection for the presence of Newcastle disease virus: the vaccine does not comply with the test if Newcastle disease virus is found.

Inject into the allantoic cavity of each of 10 SPF eggs, 9 to 11 days old, 0.2 ml of the pooled allantoic fluid from the live embryos and, into each of 10 similar eggs, 0.2 ml of the pooled fluid from the dead embryos and incubate for 5 to 6 days. Test the allantoic fluid from each egg for the presence of haemagglutinins using chicken erythrocytes.

The vaccine complies with the test if there is no evidence of haemagglutinating activity and if not more than 20 per cent of the embryos die at either stage. If more than 20 per cent of the embryos die at one of the stages, repeat that stage; the vaccine complies with the test if there is no evidence of haemagglutinating activity and not more than 20 per cent of the embryos die at that stage.

Antibiotics may be used in the test to control extraneous bacterial infection.

**Identification**

When injected into susceptible healthy chicken, free of antibodies (2.7.7) the vaccine stimulates the production of specific antibodies against Newcastle disease virus.
Tests

Safety. Inject ten healthy chickens, free of antibodies (2.7.7) between 2 and 4 weeks old, with twice the dose and by the route stated on the label. Observe the birds for 21 days. No abnormal local or systemic reaction is observed.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Either test A or test B may be carried out.

A. Inject intramuscularly each of ten healthy chickens, free from antibodies (2.7.7) between 3 and 4 weeks old, with a volume of the vaccine equivalent to one-fiftieth of a dose. Use ten chickens of the same stock and age group as controls. After 21 days, collect serum samples from each of the vaccinated and unvaccinated chicken. Perform haemagglutination inhibition test using the method described below. Use the positive control serum calibrated against a Standard preparation of anti-Newcastle disease serum. The vaccine passes the test if a mean HI titre of the vaccinated group is equal to or greater than 1:16 and that of the unvaccinated controls is equal to or less than 1:4.

Standard preparation

The Standard preparation is the 1st International reference preparation, established in 1966, consisting of freeze-dried chicken serum (supplied in ampoules containing 320 Units), or another suitable preparation, the potency of which has been determined in relation to the International reference preparation.

Suggested method of haemagglutination inhibition test. Inactivate the serum samples by heating at 56° for 30 minutes. Add 0.05 ml of saline solution to all the wells in a microtitre plate and 0.05 ml of the test sera to the first row of wells. Prepare two-fold dilutions of the serum samples across the plate. Add 0.05 ml of a suspension of Newcastle disease virus containing 4 haemagglutinating units of inactivated Newcastle disease virus. Incubate the plate at 4° for one hour. Add 0.05 ml of a 1 per cent suspension of erythrocytes collected from chicken, between 3 and 4 weeks old, susceptible to Newcastle disease.

Incubate the plate at 4° for one hour. It must be ensured that negative and positive control sera are included in the test. The positive control serum must show a titre of 300 to 400 Units determined by calibration against the Standard reference preparation.

B. Inject intramuscularly each of three groups of twenty healthy chickens, free from antibodies (2.7.7) between 3 and 4 weeks old, with five fold dilution of vaccine. Use minimum three dilutions. Allocate a different volume to each vaccination group. Vaccinate each chicken by the intramuscular route with the volume of vaccine allocated to its group. Maintain not less than 10 chickens as controls. Challenge each chicken after 21 days by the intramuscular route with 6 log_{10} chick LD_{50} of the virulent strain of avian paramyxovirus 1. Observe the chickens at least daily for 7 days after challenge. At the end of the observation period, calculate the PD_{50} by standard statistical methods from the number of chickens that survive in each vaccinated group without showing any signs of Newcastle disease during the 7 days. The vaccine complies with the test if the smallest dose stated on the label corresponds to not less than 50 PD_{50} and the lower confidence limit is not less than 35 PD_{50} per dose. If the lower confidence limit is less than 35 PD_{50} per dose, repeat the test; the vaccine must be shown to contain not less than 50 PD_{50} in the repeat test. The test is not valid unless all the control birds die within 6 days of challenge.

Labelling. The label states (1) strain of virus used; (2) recommended age for vaccination of vaccines for veterinary use.

Ranikhet Disease Vaccine, Live (Lentogenic Strain)

Newcastle Disease Vaccine, Live (Lentogenic strain)

Ranikhet Disease Vaccine Live (Lentogenic Strain) is a preparation of a suitable strain of Newcastle disease/Ranikhet disease virus (avian paramyxovirus 1). This monograph applies to vaccines intended for administration to chickens and/or other avian species for active immunization.

Production

Preparation of the vaccine

The vaccine virus is grown in embryonated hens’ eggs or in cell cultures derived from SPF flocks (2.7.7). The master seed lot complies with the tests for extraneous agents in seed lot (2.7.10).

Identification

The vaccine, diluted if necessary and mixed with a monospecific Newcastle disease virus antiserum, no longer provokes haemagglutination of chicken red blood cells or infects embryonated hens’ eggs from an SPF flock or susceptible cell cultures into which it is inoculated.

Tests

Water (2.3.43). Not more than 3.0 per cent.

For vaccines recommended for use in healthy chickens, free of antibodies (2.7.7) use not less than 10 chickens from an SPF flock and of the youngest age recommended for vaccination.
For vaccines recommended for use only in avian species other than the chicken, use not fewer than 10 birds of the species likely to be most sensitive to Newcastle disease, that do not have antibodies against Newcastle disease virus and of the minimum age recommended for vaccination. Administer to each bird by eye-drop, or parenterally if only parenteral administration is recommended, 10 doses of the vaccine in a volume suitable for the test. Observe the birds at least daily for 21 days. The test is not valid if more than 20 per cent of the birds show abnormal clinical signs or die from causes not attributable to the vaccine. The vaccine complies with the test if no bird shows notable clinical signs of disease or dies from causes attributable to the vaccine.

Virus titre. Not less than $10^6$ TCID$_{50}$/EID$_{50}$ of the virus per dose, determining the titre in suitable cell culture or by inoculation into the allantoic cavity of SPF embryonated eggs, 9 to 11 days old.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Carry out a potency test for each of the routes of administration stated on the label. For each of the stated routes, use at least twenty susceptible chickens and of the minimum age recommended for vaccination.

Administer each chicken with a volume of the reconstituted vaccine containing a quantity of the virus equivalent to the minimum titre stated on the label. Use eight chicken of the same flock and age as controls. After 14 to 21 days, challenge each chicken by intramuscular injection with $10^5$ LD$_{50}$ of a virulent strain of Newcastle disease virus. Observe the animals for 14 days. The vaccine complies with the test if not more than two of the vaccinated chickens die or show signs of disease. The test is valid only if all the control chickens die within 6 days of inoculation of the virulent challenge strain.

If the potency test has been performed with satisfactory results on a representative batch of the vaccine from the seed lot, it may be omitted as a routine control test during production on other batches of the vaccine prepared from the same seed lot.

Labelling. The label states (1) strain of virus used; (2) recommended age for vaccination of vaccines for veterinary use.

Ranikhet Disease Vaccine, Live (Mesogenic Strain)

Ranikhet Disease Vaccine, Live (Mesogenic strain) is a preparation of a suitable strain of Newcastle disease virus (naturally modified avian paramyxovirus 1). This monograph applies to vaccines intended for administration to chickens for active immunization.

Identification

The vaccine, diluted if necessary and mixed with a monospecific Newcastle disease virus antiserum, no longer provokes haemagglutination of chicken red blood cells or infects embryonated hens' eggs from an SPF flock (2.7.7) or susceptible cell cultures into which it is inoculated. The master seed lot complies with the tests for extraneous agents in seed lot (2.7.10).

Tests

Water (2.3.43). Not more than 3.0 per cent.

Safety. Administer fifteen healthy chickens free from antibodies (2.7.7), 8 to 9 weeks old, with the minimum ten dose and by the route stated on the label. Observe the chickens for 21 days. None of them shows abnormal clinical signs or dies due to causes attributable to the vaccine. If more than two chickens die during the period of observation due to causes other than those attributable to the vaccine, repeat the test.

Virus titre. Not less than $10^5$ TCID$_{50}$/EID$_{50}$ of the virus per dose, determining the titre in suitable cell culture or by inoculation into the allantoic cavity of SPF embryonated eggs, (2.7.7) between 9 and 11 days old.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Carry out a potency test for each of the routes of administration stated on the label. For each of the stated routes, use not less than twenty susceptible healthy chickens free of antibodies (2.7.7) and of the minimum age recommended for vaccination. Administer each chicken with a volume of the reconstituted vaccine containing a quantity of the virus equivalent to the minimum titre stated on the label. Use eight chickens of the same flock and age as controls. After 14 to 21 days, challenge each chicken by intramuscular injection with $10^5$ LD$_{50}$ of a virulent strain of Newcastle disease virus. Observe the animals for 14 days. The vaccine complies with the test if not more than two of the vaccinated chickens die or show signs of disease. The test is valid only if all the control chickens die within 6 days of inoculation of the virulent challenge strain.

If the potency test has been performed with satisfactory results on a representative batch of the vaccine from the seed lot, it may be omitted as a routine control test during production on other batches of the vaccine prepared from the same seed lot.

Labelling. The label states (1) strain of virus used; (2) recommended age for vaccination.
Rinderpest Vaccine, Live

Rinderpest Vaccine, Live is a freeze-dried preparation of a live attenuated strain of rinderpest virus that has been modified by adaptation to and propagation in suitable cell cultures in such a manner that it remains avirulent but retains its immunogenicity in cattle. It is reconstituted immediately before use with a suitable diluent.

Production

SEED LOT

The seed lots should be validated for the following tests:

a) Purity. It should be free from contaminations with viruses, bacteria, fungi and mycoplasmas;

b) Should not induce any abnormal clinical reaction on inoculation into rinderpest susceptible cattle;

c) Efficacy. It should induce an immunity to rinderpest in the susceptible cattle.

CELLS. The primary cells/subcultured cells/continuous cell lines when used should be free from BVD and other contaminating viruses.

Identification

A. The vaccine protects cattle against virulent rinderpest virus.

B. The seed and the vaccine must be titrated in a suitable cell culture system capable of supporting the multiplication of the rinderpest virus.

C. When neutralised with a specific rinderpest antiserum, the vaccine is no longer capable of protecting cattle against rinderpest infection.

Tests

Water (2.3.43). Not more than 3.0 per cent.

Mycoplasmas (2.7.4). Complies with the test for absence of mycoplasmas.

Extraneous pathogens. Complies with the requirements stated under Veterinary Vaccines.

Safety

A. Use four healthy guinea-pigs, each weighing not less than 400 g. Inject two of them intramuscularly and two intraperitoneally with 0.5 ml of the vaccine under examination. In addition, inject intraperitoneally each of six mice, each weighing between 18 and 25 g, with 0.1 ml of the vaccine. Observe the animals for 21 days. All the animals remain healthy during the observation period. At the end of the observation period sacrifice the animals and perform autopsy on each. None of the animals shows any unusual changes.

B. Inject subcutaneously each of two susceptible cattle, free from specific antibodies, with a quantity of the vaccine containing not less than 100 times the minimum dose stated on the label, using pooled reconstituted contents of not less than ten containers taken at random. Observe the animals for 21 days. No sign of disease attributable to the vaccine other than mild transient pyrexia is seen.

Virus titer. Not less than $10^3$ TCID$_{50}$ per dose of cell culture vaccine determining the virus content of the reconstituted vaccine in a suitable cell culture system.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Inject subcutaneously each of two susceptible cattle, free from rinderpest specific antibodies, with a field dose and 1/10th of the minimum dose respectively stated on the label, considering $10^3$ TCID$_{50}$ of cell culture vaccine. Use two animals of the same stock and age as controls. Observe the animals for 21 days. Challenge intramuscularly each animal with a dose of not less than $10^4$ ID$_{50}$ of virulent rinderpest virus. Observe the animals for 14 days. None of the vaccinated animals shows any clinical signs suggestive of rinderpest. The test is not valid unless both the control animals develop signs of rinderpest.

If the potency test has been performed with satisfactory results on a representative batch of the vaccine from the seed lot, it may be omitted as a routine control test during production on other batches of the vaccine prepared from the same seed lot, provided the National Regulatory Authority permits.

Labelling. The label states (1) the strain of the virus used; (2) the number of doses in the container; (3) that the vaccine should be used immediately after reconstitution.

Salmonella Abortus Equi Vaccine

Salmonella Abortus Equi Vaccine is a suspension of killed mixture of equal parts of pure formalized cultures of smooth laboratory strains of Salmonella abortus equi.

Production

The whole culture or its filtrate or a mixture is inactivated in such a manner that pathogenicity is eliminated and immunogenic activity is retained. The inactivated cultures may be treated with a suitable adjuvant.

Identification

It protects susceptible animals against infection with Salmonella abortus equi.

Tests

Safety. Inject 0.5 ml of the vaccine intraperitoneally to each of six mice, each weighing not less than 18 g. Observe the mice for 96 hours, none of the mice dies of salmonellosis.
Sterility (2.2.11). Complies with the test for sterility.

Potency. Inject each of twelve mice, each weighing not less than 18 g, subcutaneously with 0.5 ml of the preparation under examination. Use another twelve mice of the same weight range and from the same stock as controls. Three weeks later, challenge the mice from both groups by injecting intraperitoneally each animal with 0.5 ml of a suspension of an 18-hour old culture containing 10 LD50 virulent organisms of S. abortus equi. Observe the mice for 7 days. The vaccine passes the test if not less than nine mice of the vaccinated group survive. The test is not valid unless not less than nine of the control mice succumb to the challenge.

Labelling. The label states (1) the method of preparation; (2) the strains of bacteria used to prepare the vaccine.

Sheep Pox Vaccine, Live Attenuated
Sheep Pox Vaccine, Live Attenuated is a freeze dried preparation obtained by producing attenuated sheep pox virus in a suitable cell culture and mixed with a suitable stabilizer and freeze dried. The freeze dried vial is reconstituted with a suitable diluent and used immediately.

Production
The vaccine reconstituted with a suitable liquid and diluted if necessary to provide a concentration appropriate to the particular test, complies with the requirements stated under Veterinary Vaccines with the following modifications.

The seed lots used for vaccine preparation must be free from extraneous pathogens.

Identification
The vaccine specifically protects sheep against sheep pox.

Tests
Water (2.3.43). Not more than 3.0 per cent.

Safety. Inoculate not less than 2 sheep of 8 to 12 months old, free from neutralizing antibodies against sheep pox virus, with ten times the field dose of the vaccine contained in 1 ml by subcutaneous route. Observe the animals for 14 days. The vaccine complies the test if none of the vaccinated animals show deep necrotic lesion and generalization.

Virus titre. Not less than 10^2.5TCID₅₀ of the virus per dose as determined by the titre of the vaccine in a suitable cell culture system.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Administer each of three sheep, between 8 and 12 months old, free from sheep pox neutralizing antibodies, with the dose of the vaccine and by the route stated on the label. Use two sheep of the same stock and age as un-vaccinated controls. Shave the animals closely on the flank from the shoulder to the proctodal area. Challenge each animal after 21 days post-vaccination by inoculating intradermally with 0.1 ml of a suspension six ten fold dilution of the sheep pox challenge virus. Make five separate inoculations in a vertical line for each serial dilution from the anterior to the posterior of the animals. The titer of the challenge virus is calculated using a standard statistical method for the vaccinated and control sheep by the number of pox lesions observed in each dilution. The titer of the challenge virus is calculated for the vaccinated and control animals. The vaccine passes the test if there is a difference of log titer of more than log₁₀ 2.5.

Labelling. The label states (1) the strain of virus used in preparing the vaccine; (2) the virus titre; (3) the minimum dose and the routes of administration; (4) the volume of the liquid to be used for reconstitution of the vaccine.

Swine Fever Vaccine, Live
Swine Fever Vaccine, Live is a preparation of a modified strain of classical swine fever virus, which is devoid of pathogenicity for the pig by adaptation either to cell cultures or to the rabbit. It is prepared immediately before use by reconstitution from the dried vaccine with a suitable diluent.

Production
The virus is propagated in suitable cell culture. The viral suspension is harvested, titrated and may be mixed with a suitable stabilizing agents. The vaccine is then freeze-dried.

Identification
LAPINISED VACCINE. Administer 0.5 ml intravenously into one or more non-immunised rabbits, immunized either with an identical dose of a vaccine of the same type injected by the same route between 10 and 60 days before hand or with a sufficient dose of antiseraum administered a few hours before the injection of the vaccine. Twenty-four hours after the injection, start recording the temperature of the rabbits in the mornings and the evenings until the fifth day after the injection. The immunised rabbits do not exhibit a rise in temperature of more than 1.5°. The test is not valid unless the nonimmunised rabbits exhibit a rise in temperature of not less than 1.5°.

CELL CULTURE VACCINE. For non-lapinised vaccines prepared in cell cultures, on administration to pigs immunised with the vaccine specific neutralizing antibodies develop.

Tests
Test for extraneous pathogens. The vaccine mixed with a mono specific antiserum does not cause cytopathic effects in
susceptible cell cultures. The cells also show no evidence of the presence of haemadsorbing agents and the cell-culture fluids are free of haemagglutinating agents when tested with chicken erythrocytes.

**Water** (2.3.43) Not more than 3.0 per cent.

**Safety.** Inject intramuscularly 10 times the minimum dose stated on the label into each of three healthy piglets, between 6 and 7 weeks old, free from swine fever virus antibodies. Observe the animals for 21 days. Temperature curve should be normal and animals remain in apparent good health and display normal growth.

Inject intracerebrally 0.03 ml of the vaccine, reconstituted in a manner that 1.0 ml contains 1 ml dose, into each of ten mice, weighing between 11g and 15g. Observe the mice for 21 days. If more than two mice die within the first 48 hours repeat the test. The mice show no abnormalities attributable to the vaccine within the third and twenty-first day after the injection.

**Virus titre.** Not less than minimum virus titre per dose stated on the label, determining the titre in a suitable cell culture.

**Sterility** (2.2.11). Complies with the test for sterility.

**Potency.** All the animals are healthy and must have had no contact with swine fever virus and serologically must be free from CSF and BVDV antibodies. Use four healthy piglets, between 6 and 7 weeks old, for each of the 1:50, 1:200 and 1:400 dilutions of the vaccine prepared in a suitable diluent or buffer. Inject intramuscularly 1 ml of these dilutions into each of the piglets in respective groups. Use two healthy susceptible piglets of the same stock and age as control animal group. After 21 days, inoculate intramuscularly with a sufficient quantity of the challenge virus in each vaccinated piglet and in each of the two unvaccinated control animals so that at least one of the two unvaccinated control animals die within 7 to 14 days. Observe the vaccinated animals for 14 days. Calculate the number of PD$_{50}$ contained in the vaccine by standard statistical methods from the number of animals, which survive without showing any signs of swine fever. The vaccine contains not less than 100 PD$_{50}$ per dose. The test is not valid unless the control animals die within 7 to 14 days after inoculation. PD$_{50}$ correlation studies with virus titres can replace the potency test on routine basis.

If the test for potency has been carried out with satisfactory results on a representative batch of vaccine, this test may be omitted as a routine control on other batches of vaccine prepared from the same seed lot, subject-to agreement by the competent authority.

**Labelling.** The label states (1) the minimum dose; (2) the recommended routes of administration; (3) the name of any added adjuvant.

---

**Tetanus Veterinary Vaccine**

Tetanus Vaccine for Veterinary Use is a preparation of the neurotoxin of *Clostridium tetani* treated in a manner that eliminates toxicity while maintaining adequate immunogenic properties.

**Production**

The *C. tetani* strain used for production is cultured in a suitable medium. The toxin is purified and then detoxified or it may be detoxified before purification. The antigenic purity is determined in Lf units of tetanus toxoid per milligram of protein and shown to be not less than the value approved for the particular product.

**Choice of vaccine composition**

The *C. tetani* strain used in the preparation of the vaccine is shown to be satisfactory with respect to the production of the neurotoxin. The vaccine is shown to be satisfactory with respect to safety and immunogenicity for each species of animal for which it is intended. As part of the studies to demonstrate these characteristics, the tests described below may be used.

**Production of antigens.** The production of the neurotoxin of *C. tetani* is verified by a suitable immunochemical method carried out on the neurotoxin obtained from the vaccine strain under the conditions used for the production of the vaccine.

**Safety.** Carry out the test for each recommended route of administration and species of animal for which the vaccine is intended; use animals of the minimum age recommended for vaccination and of the most sensitive category for the species.

Use not less than 15 animals, free from antitoxic antibodies for each test. Administer a double dose of vaccine to each animal. Administer a single dose of vaccine to each animal after the interval stated on the label. Observe the animals until 14 days after the last administration. The vaccine complies with the test if no animal shows abnormal local or systemic signs of disease or dies from causes attributable to the vaccine.

**DETOXIFIED HARVEST**

*Absence of toxin and irreversibility of toxoid.* Carry out a test for reversion to toxicity on the detoxified harvest using 2 groups of 5 guinea-pigs, each weighing between 350 to 450 g; if the vaccine is adsorbed, carry out the test with the shortest practical time interval before adsorption. Prepare a dilution of the detoxified harvest so that the guinea-pigs each receive 10 times the amount of toxoid (measured in Lf units) that will be present in a dose of vaccine. Divide the dilution into 2 equal parts. Keep one part at 5 ± 3° and the other at 37° for 6 weeks. Attribute each dilution to a separate group of guinea-pigs and inject into each guinea-pig the dilution attributed to its
group. Observe the animals for 21 days. The toxoid complies with the test if no guinea-pig shows clinical signs of disease or dies from causes attributable to the neurotoxin of \textit{C. tetani}.

\textbf{FINAL LOT}

The final bulk vaccine is distributed aseptically into sterile containers. The containers are closed so as to avoid contamination.

\textbf{Identification}

Carry out test A if permitted by the nature of the adjuvant. Otherwise carry out test B.

A. Separate the toxoid from the adjuvant. For vaccines adsorbed on aluminium hydroxide, the following treatment is suitable. Dissolve sufficient sodium citrate in the vaccine under examination to give a 10 per cent w/v concentration. Maintain at 37° for about 16 hours and centrifuge. The clear supernatant liquid reacts with a suitable tetanus antitoxin and yields a precipitate.

B. When inoculated into healthy susceptible animals, the vaccine stimulates the formation of antitoxin to the neurotoxin of \textit{Clostridium tetani} or protects the animals against the paralytic effects of the toxin.

\textbf{Tests}

\textbf{Safety.} Inject 5 ml of the vaccine subcutaneously as two equally divided doses at separate sites into each of five guinea pigs, each weighing between 350 and 450 g. Observe the guinea pigs for 21 days. None of the animals shows any symptoms of tetanus or dies from tetanus. If more than one animal dies of non-specific causes, repeat the test. No animal dies in the second test.

\textbf{Sterility (2.2.11).} Complies with the test for sterility.

\textbf{Potency.} Test A may be omitted if test B is carried out. Test B may be omitted if test A is carried out.

A. Inject subcutaneously each of ten guinea pigs, each weighing between 350 and 450 g, with a quantity of the vaccine not more than the minimum dose stated on the label as the primary dose, and 28 days later with a quantity of the vaccine not more than the minimum dose stated on the label as the secondary dose. Fourteen days after the second dose, collect the blood from each guinea pig, pool the sera and determine the antitoxin titre by the biological assay of \textit{Cl. tetani} antitoxin described below.

1 ml of serum contains not less than 7.5 IU per ml or, for vaccine intended for use in equine, not less than 30 IU per ml.

When \textit{Cl. tetani} vaccine is presented as a component of a mixed vaccine intended for use in animals other than equine and the potency test of the other component or components normally uses rabbits, the potency test described above may be carried out using ten healthy rabbits, between 3 and 6 months old.

1 ml of serum contains not less than 2.5 Units.

\textbf{Biological assay of \textit{Cl. tetani} antitoxin}

The potency of \textit{Cl. tetani} antitoxin is determined by comparing the dose necessary to protect mice or other suitable animals against the toxic effects of a fixed dose of \textit{Cl. tetani} toxin with the quantity of a Standard preparation of \textit{Cl. tetani} antitoxin necessary to give the same protection. For this purpose, the Standard preparation of \textit{Cl. tetani} antitoxin and a suitable preparation of \textit{Cl. tetani} toxin are required.

The test dose of the toxin is determined in relation to the Standard preparation of antitoxin and the potency of the preparation under examination is then determined in relation to the Standard preparation using the test toxin.

\textbf{Standard preparation}

The Standard preparation is the 2nd International standard, established in 1969, consisting of freeze-dried hyperimmune horse serum (supplied in ampoules containing 1400 Units) or another suitable preparation, the potency of which has been determined in relation to the International standard.

\textbf{Suggested method}

\textit{NOTE} - The severity of tetanic paralysis to be regarded as the end-point is such that the paralysis is readily recognised but not sufficiently extensive to cause significant suffering. For humane reasons the animals should be examined at least twice a day and should be killed as soon as the end-point is reached.

In practice, when using high levels of toxin to determine the test dose, or when using low levels of antitoxin in the preliminary and final tests, the development of paralysis is so rapid that the defined end-point is usually synchronous with death. Where death occurs, the combined totals of animals dying or reaching the paralytic end-point are used in the calculations.

\textbf{Preparation of test toxin.} Prepare \textit{Cl. tetani} toxin by growing \textit{Cl. tetani} in liquid culture for 8 to 10 days and then adding 1 volume of a sterile filtrate of the culture to 1 or 2 volumes of glycerine. Store at 0° or at temperatures slightly below it. The toxin may be dried by a suitable method.

\textbf{Selection of test toxin.} Select toxin for use as the test toxin by determining the following quantities:

\textbf{LP/10 dose (\textit{Limes paralyticum}).} This is the smallest quantity of toxin that when mixed with 0.1 Unit of antitoxin and injected subcutaneously into mice (or guinea-pigs) causes tetanic paralysis in the animals on or by the fourth day after injection.
Paralytic dose 50. This is the quantity of toxin that when injected subcutaneously into mice (or guinea-pigs) causes tetanic paralysis in one-half of the animals injected on or by the fourth day after injection. A suitable toxin is one that contains not less than 1000 paralytic dose 50 in an LP/10 dose.

Determination of test dose of toxin. Measure or weigh a quantity of the test toxin and dilute with or dissolve in a suitable liquid. Reconstitute or dilute the Standard preparation with a suitable liquid to give a solution containing 0.5 Unit in 1 ml.

Prepare mixtures of the solution of the Standard preparation and the solution of the test toxin such that each mixture contains 0.1 Unit of antitoxin in the volume selected for injection and one of a series of graded volumes of the solution of the toxin, separated from each other by steps of not more than 20 per cent and covering the expected end-point. Adjust each mixture to the same final volume (0.4 to 0.6 ml if mice are used or 4.0 ml if guinea-pigs are used) with a suitable liquid. Allow the mixtures to stand at room temperature, protected from light, for 60 minutes and then inject a dose of the selected volume of each mixture subcutaneously into each of not less than 2 animals of the group to which each mixture has been allocated. Observe the animals for 4 days and record daily the degree of tetanus developing in each group of animals. Repeat the determination at least once, add together the results of the separate tests that have been made with mixtures of the same composition such that a series of totals is obtained and determine the mean values. The test dose of the toxin is the amount present in that mixture that causes tetanic paralysis in one-half of the total number of animals injected with it. When the test dose of the test toxin has been determined, a concentrated solution of the test toxin may be prepared in a mixture consisting of 1 volume of saline solution and 1 or 2 volumes of glycerine. This concentrated solution may be stored frozen and diluted as required. The specific activity of such a solution must be determined at frequent intervals.

Determination of potency of the antitoxin.

Preliminary test. Measure or weigh a quantity of the test toxin and dilute with or dissolve in a suitable liquid such that the solution contains 5 test doses per ml. Prepare mixtures of the solution of the test toxin and the preparation under examination such that for each mixture the volume selected for injection contains the test dose of toxin and one of a series of graded volumes of the preparation under examination. Adjust each mixture to the same final volume with a suitable liquid. Allow the mixtures to stand at room temperature, protected from light, for 60 minutes. Inject a dose of the selected volumes of each mixture subcutaneously into each of not less than two animals of the group to which each mixture has been allocated. Observe the animals for 4 days and record daily the degree of tetanus developing in each group of animals. From the results select suitable mixtures for the final test.

Final test. Prepare similar fresh mixtures of the test toxin and the preparation under examination such that for each mixture the volume selected for injection contains the test dose of toxin and one of a series of graded volumes of the preparation under examination, separated from each other by steps of not more than 20 per cent and covering the expected end-point as determined in the preliminary test. Prepare further mixtures with the same amount of test toxin and graded volumes of the Standard preparation, centered on 0.1 Unit in the volume selected for injection to confirm the test dose of the toxin. Adjust each mixture to the same final volume with a suitable liquid. Allow the mixture to stand at room temperature, protected from light, for 6 minutes. Inject a dose of the selected volume of each mixture subcutaneously into each of not less than two animals of the group to which each mixture has been allocated. Observe the animals for 4 days and record daily the degree of tetanus developing in each group of animals. The mixture of antitoxin under examination that contains 0.1 Unit in the volume injected is that mixture which causes tetanic paralysis in the same, or almost the same number of animals as the mixture containing 0.1 Unit of the Standard preparation in the volume injected. Repeat the determination at least once and calculate the average of all valid estimates. Estimates are not valid unless the Standard preparation gives a result within 20 per cent of the expected value.

Limits of error. For the suggested method, the limits of error (P = 0.95) have been estimated to be 85 to 114 per cent when two animals are used per dose, 91.5 to 109 per cent when three animals are used per dose, and 93 to 108 per cent when six animals are used per dose.

B. Carry out the biological assay of adsorbed tetanus vaccine as stated under Tetanus Vaccine (Adsorbed).

This method may only be used for those preparations for which it has been shown to be suitable and in particular may not be suitable for vaccine with an oil adjuvant. Where this alternative method is used the estimated potency is not less than 150 units in the smallest dose stated on the label.

Labelling. The label states (1) the name of the adjuvant used; (2) the preparation should be shaken before use.

Theileriosis Vaccine, Live

Theileriosis Vaccine, Live is a lymphoblast cell culture containing Theileria annulata macroschizonts attenuated by passage in such a manner that it remains avirulent while it retains its immunogenicity. The concentrate of the vaccine may be diluted with a suitable diluent after thawing.
Production

Production is based on approved seed lot system. The working seeds are prepared from the master seeds. The production seed may be prepared by propagating a large number of cells either in suspension/monolayer cultures.

Identification

Protects susceptible cattle against theileriosis.

Tests

Safety. Inject each of two healthy susceptible cattle not less than 9 months old with twice the dose as recommended on the label. Observe the animals for 30 days. None of the animals shows systemic reactions other than mild pyrexia and mild swelling of superficial lymph nodes. No schizonts/piroplasms should be seen in the blood smears/lymph node smear.

Cell count. Contains not less than 2 million live lymphoblast cells in each dose.

Sterility (2.2.11). Complies with the test for sterility.

Potency. Inject each of three susceptible cattle not less than 9 months old with the minimum dose by the route stated on the label. Use two cattle of the same stock and age as controls. After 30 days, challenge each of the vaccinated as well as the control animals with a preparation of gut homogenate of ticks containing suitable quantity of sporozoites to infect adult cattle. Observe the animals for 30 days; none of the vaccinated animals shows any abnormal signs. The test is not valid unless both the control animals show typical signs of theileriosis. If these tests have been performed with satisfactory results on a representative batch of the vaccine from the seed lot, they may be omitted by the manufacturer as a routine control on other batches of the vaccine prepared from the same seed lot.

Labelling. The label states (1) the number of doses in the container; (2) the recommended dose; (3) the method of thawing and reconstitution; (4) that the reconstituted vaccine should be used within 3 hours after thawing and reconstitution.